<SEC-DOCUMENT>0001193125-22-037414.txt : 20220211
<SEC-HEADER>0001193125-22-037414.hdr.sgml : 20220211
<ACCEPTANCE-DATETIME>20220211171929
ACCESSION NUMBER:		0001193125-22-037414
CONFORMED SUBMISSION TYPE:	424B4
PUBLIC DOCUMENT COUNT:		39
FILED AS OF DATE:		20220211
DATE AS OF CHANGE:		20220211

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001831828
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				812744449
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B4
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-262569
		FILM NUMBER:		22622776

	BUSINESS ADDRESS:	
		STREET 1:		8000 MARINA BOULEVARD, SUITE 120
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		650-770-0077

	MAIL ADDRESS:	
		STREET 1:		8000 MARINA BOULEVARD, SUITE 120
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B4
<SEQUENCE>1
<FILENAME>d210084d424b4.htm
<DESCRIPTION>424B4
<TEXT>
<HTML><HEAD>
<TITLE>424B4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(4)<BR>Registration Nos. 333-262569 and<BR> 333-262618 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>Prospectus </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>4,993,067 shares </I></B></P> <P STYLE="font-size:16pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g210084g01o02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:arial"><B><I>Class&nbsp;A common stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
offering 4,993,067 shares of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Class&nbsp;A common stock is listed on the Nasdaq Global Market under the symbol &#147;VERA.&#148;
On February 9, 2022, the last reported sale price of our Class&nbsp;A common stock on the Nasdaq Global Market was $19.05 per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company&#148; as defined under the federal securities laws and, as such, have elected to comply with certain reduced reporting requirements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have two classes of common stock: Class&nbsp;A common stock and Class&nbsp;B common stock. The rights of the holders of Class&nbsp;A common stock and Class&nbsp;B
common stock are identical, except with respect to voting and conversion. Each share of Class&nbsp;A common stock is entitled to one vote and shares of Class&nbsp;B common stock are <FONT STYLE="white-space:nowrap">non-voting,</FONT> except as may
be required by law. Each share of Class&nbsp;B common stock may be converted at any time into one share of Class&nbsp;A common stock at the option of its holder, subject to the ownership limitations provided for in our amended and restated
certificate of incorporation. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Per&nbsp;share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">74,896,005.00</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Underwriting discounts and commissions(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top">$</TD>
<TD VALIGN="top" ALIGN="right">4,493,760.30</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="10"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD>
<TD HEIGHT="10" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Proceeds to Vera Therapeutics, Inc., before expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">14.10</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">70,402,244.70</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See the section titled &#147;Underwriting&#148; beginning on page 209 for a description of the compensation payable to the underwriters. </TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have granted the underwriters an option to purchase up to 748,959 additional shares of Class&nbsp;A common stock from us at the public offering price, less
underwriting discounts and commissions, within 30 days from the date of this prospectus. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Investing in our Class&nbsp;A common stock involves a high degree of
risk. See the section titled &#147;<A HREF="#toc210084_4">Risk factors</A>&#148; beginning on page&nbsp;16 of this prospectus. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Neither the Securities and
Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters expect to deliver the shares to purchasers on or about February&nbsp;14, 2022. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:16pt" ALIGN="center">


<TR>

<TD WIDTH="41%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="18%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:16pt">
<TD VALIGN="bottom"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:16pt; font-family:arial"><B>Cowen</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore&nbsp;ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:11pt; font-family:arial"><B>February 10, 2022. </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc"></A>Table of contents </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_1">Prospectus summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_2">The offering</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_3">Summary financial data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_4">Risk factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_5">Special note regarding forward-looking statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">88</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_6">Market, industry and other data</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">91</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_7">Use of proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">92</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_8">Dividend policy</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">93</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_9">Capitalization</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_10">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">96</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_11">Management&#146;s discussion and analysis of financial condition and results of operations
</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">98</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_12">Business</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">115</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_13">Management</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">175</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_14">Executive compensation</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">185</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_15">Certain relationships and related person transactions</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">200</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_16">Principal stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">205</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_17">Description of capital stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">208</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_18">Certain material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">213</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_19">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">218</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_20">Legal matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_21">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_22">Where you can find additional information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">228</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><A HREF="#toc210084_23">Index to financial statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">F-1</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither we nor the underwriters have authorized anyone to provide you any information or make any representations other than those
contained in this prospectus or in any free writing prospectuses prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to the reliability of, any other
information that others may give you. We and the underwriters are not making an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information appearing in this prospectus or in
any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our securities. Our business, financial condition, results of operations and prospects may have changed since that date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of
this prospectus in any jurisdiction where action for that purpose is required, other than the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions
relating to, the offering of our securities and the distribution of this prospectus outside of the United States. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_1"></A>Prospectus summary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>This summary highlights selected information contained elsewhere in this prospectus. This summary does not contain all of the information you should consider before
investing in our securities. You should read this entire prospectus carefully, including the sections in this prospectus titled &#147;Risk factors&#148; and &#147;Management&#146;s discussion and analysis of financial condition and results of
operations,&#148; and our financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. Unless otherwise indicated, all references in this prospectus to &#147;Vera,&#148; the
&#147;company,&#148; &#147;we,&#148; &#147;our,&#148; &#147;us&#148; or similar terms refer to Vera Therapeutics, Inc. </I></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Our lead
product candidate, atacicept, a self-administered fusion protein that blocks both B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL), is currently being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) in
the Phase 2b ORIGIN trial, which we expect will complete enrollment in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and report topline results in the fourth quarter of 2022. If the data from this trial are positive, we plan to initiate a pivotal
Phase 3 clinical trial in 2023. We plan to initiate a Phase 3 clinical trial of atacicept in lupus nephritis (LN), a severe renal manifestation of systemic lupus erythematosus (SLE), based on positive feedback from the U.S. Food and Drug
Administration&#146;s (FDA) review of promising clinical results in a Phase 2 clinical trial of atacicept in high disease activity patients with SLE. In December 2021, we obtained worldwide, exclusive development and commercial rights from Amplyx
Pharmaceuticals, Inc. (Amplyx), a wholly owned subsidiary of Pfizer, for MAU868, a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody to treat BK virus (BKV) infections. We
believe MAU868 is the only clinical-stage neutralizing monoclonal antibody that is directed against BKV, a polyoma virus that can have devastating consequences in certain settings such as kidney transplant and hematopoietic stem cell transplant. In
an interim analysis of Phase 2 data in BK viremia among kidney transplant recipients, MAU868 was shown to be well tolerated and demonstrated a clinically significant reduction of virologic activity. We expect to share full results from the interim
analysis in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and expect to initiate a Phase 2b or Phase 3 clinical trial in 2023. We believe that our current pipeline programs, shown in Figure A, leverage the deep expertise of the Vera Therapeutics
team and have strong commercial synergies. We currently hold global rights to all of our pipeline programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021, we also entered into a Loan and
Security Agreement (Loan Agreement) with Oxford Finance LLC, a Delaware limited liability company, as lender (Oxford) and collateral agent. The Loan Agreement provides for a term loan in an aggregate maximum principal amount of $50.0&nbsp;million
(Loan). Of this amount, $5.0&nbsp;million was funded at closing on December&nbsp;17, 2021 and the balance of which is available to be drawn between January&nbsp;3, 2022 and December&nbsp;31, 2022. The Loan is available in minimum draws of
$5.0&nbsp;million, entirely at our option and not contingent upon the completion of clinical, regulatory, financial or other related milestones. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure A: Vera therapeutics pipeline </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g55o74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Financial update </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31,
2021, we estimate that we had approximately $79.7&nbsp;million of cash, cash equivalents and investments. This amount has not been audited, reviewed, or compiled by our independent registered public accounting firm. Our actual total cash, cash
equivalents and investments as of December&nbsp;31, 2021 may differ from this amount after we complete our comprehensive accounting procedures for the period ended December&nbsp;31, 2021. Our audited financial statements for the year ended
December&nbsp;31, 2021 will not be available until after this offering is completed and, consequently, will not be available to you prior to investing in this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Atacicept </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is a fully humanized fusion protein that impacts the <FONT
STYLE="white-space:nowrap">B-cell</FONT> pathway, which has well characterized implications in immunologic diseases. Specifically, atacicept contains the soluble transmembrane activator and calcium-modulating cyclophilin ligand interactor (TACI)
receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote <FONT STYLE="white-space:nowrap">B-cell</FONT> survival and autoantibody production associated with IgAN and other
immunologic diseases. Dual blockade of BlyS and APRIL has been shown to be more potent than blocking BLyS alone or APRIL alone and has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing autoantibody production,
including <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> IgA, IgG and IgM. Therefore, atacicept&#146;s mechanism acts directly on the source of certain immunologic diseases, including IgAN and LN. Through an integrated analysis of randomized,
double-blind, placebo-controlled clinical trials in over 1,500 patients to date, atacicept has a well-characterized clinical safety profile. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in
IgAN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union (EU), and 130,000 in
Japan. Up to 50% of patients diagnosed with IgAN develop <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease (ESRD) within 20 years from initial diagnosis, requiring dialysis or kidney transplant. ESRD causes considerable morbidity and
impact on patients&#146; lives and represents a significant health economic burden, which was estimated to be $49.2&nbsp;billion in the United States in 2018. Despite this high level of morbidity, the
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
current standard of care consists of <FONT STYLE="white-space:nowrap">off-label</FONT> use of renin-angiotensin-aldosterone system (RAAS) inhibitors, including angiotensin-converting enzyme (ACE)
inhibitors and angiotensin II receptor blockers (ARBs), and potentially steroids. We estimate the U.S. market opportunity for novel therapeutics in IgAN is approximately $4.0&nbsp;billion to $8.0&nbsp;billion annually, based on the disease
prevalence and the segment of IgAN patients at high risk of progressing to ESRD. In Europe and Japan, we estimate the annual market opportunity for novel IgAN therapeutics to be $1.0&nbsp;billion and $600&nbsp;million, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept has been shown in a clinical trial to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> which is central to the pathogenesis of IgAN, and therefore has
the potential to be the first disease modifying therapy for IgAN due to its ability to act on core pathophysiology processes. Clinical trials of patients with IgAN have correlated higher serum levels of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> with greater severity of IgAN disease, suggesting that reduction in serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> may slow disease progression. As published in Kidney International,
in a prospective study of 275 patients with IgAN, higher serum levels of aberrantly glycosylated IgA1 demonstrated correlation with a higher likelihood of developing progressive renal failure, as shown in Figure B below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure B: Renal survival in IgAN patients with four quartile serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g210084g02b10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that atacicept&#146;s mechanism has the potential to drive clinical success by measures designed to assess efficacy in IgAN
and other immunologic diseases. BLyS inhibition has been clinically and commercially validated through the approval of Benlysta (belimumab) in both SLE and LN. Preclinical and clinical evidence supports that atacicept&#146;s mechanism of dual
inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;29, 2020, we entered into a worldwide, exclusive license to atacicept from Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany,
which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several autoimmune diseases in over 1,500 patients. We believe the large and well-characterized clinical data set for atacicept provides a competitive
advantage for us versus other approved and emerging therapies in development, many of which are either earlier in development and have clinical profiles that are not as well characterized or are characterized by the well-known acute and chronic side
effects of corticosteroids that limit their medical use. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In IgAN, Merck KGaA, Darmstadt, Germany, conducted a randomized, double-blind, placebo-controlled Phase 2a
clinical trial that enrolled 16 patients, known as JANUS. A clinically meaningful reduction in proteinuria was </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
observed at week 24 in the atacicept group versus an increase in the placebo group, as shown in Figure C below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure C: Proteinuria at week 24 in the phase 2a JANUS trial </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g210084g03c19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept 75 mg also showed a 60% reduction of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> at 24 weeks (as shown in Figure D
below), the largest magnitude in reduction of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients by any molecule in a randomized controlled trial for IgAN. Clear dose-dependent reductions of serum
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> were observed over the <FONT STYLE="white-space:nowrap">72-week</FONT> period studied, with atacicept 75 mg reducing <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> significantly (60%) and durably.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure D: Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels over time in the phase 2a JANUS trial </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt; margin-left:2%; text-indent:-2%" ALIGN="center">


<IMG SRC="g210084g04d28.jpg" ALT="LOGO">
 </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are conducting a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in IgAN, which we
refer to as ORIGIN. The ORIGIN trial is evaluating three subcutaneous weekly doses of atacicept (25 mg, 75 mg and 150 mg) and their impact on the reduction of proteinuria as the primary endpoint. A significant reduction in proteinuria, as measured
by urine protein to creatinine ratio (UPCR) in a <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, is associated with improved renal outcomes in patients with IgAN. UPCR is a surrogate endpoint endorsed by the FDA for primary
glomerular diseases associated with significant proteinuria, including IgAN. The ORIGIN trial is powered to demonstrate a statistically significant difference between atacicept and placebo in decrease of proteinuria. Given the FDA&#146;s recent
approval of TARPEYO (developed by Calliditas Therapeutics AB under the name Nefecon), we believe this provides validation for the use of proteinuria as a surrogate for accelerated approval. Secondary endpoints include the difference in kidney
function between treated and placebo patients as measured by estimated glomerular filtration rate (eGFR) and reduction in <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> We are currently enrolling the Phase 2b ORIGIN trial and expect to enroll a
total of 105 patients at multiple global sites and to report topline results in the fourth quarter of 2022. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in LN </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on positive feedback from the FDA&#146;s review of promising clinical results in a Phase 2 clinical trial of atacicept in high disease activity patients with SLE,
we are planning to initiate a Phase 3 clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there are approximately 110,000 LN patients in the United States, 69,000 in the
European Union, and 22,000 in Japan. We estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million and $200&nbsp;million in the United States, Europe and Japan, respectively. Significant
unmet need for improved efficacy persists for these patients despite the recent approval of the first two <FONT STYLE="white-space:nowrap">LN-specific</FONT> therapies. Fewer than half of patients treated for LN have a complete response to therapy,
and among patients without a complete response, over half will have <FONT STYLE="white-space:nowrap">non-functioning</FONT> kidneys within five years. Benlysta (belimumab), a BlyS-only inhibitor, is one of the two therapies approved for patients
with LN. Both BlyS and APRIL levels are increased in patients with SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BLyS alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA,
Darmstadt, Germany previously initiated a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the <FONT STYLE="white-space:nowrap">APRIL-LN</FONT> trial, aimed to evaluate the efficacy and safety of atacicept at
150 mg twice weekly for four weeks&#151;then weekly&#151;in patients with active LN. However, this trial was terminated early due to three subjects developing hypogammaglobulinemia with induction therapy (mycophenolate mofetil (MMF) and
corticosteroids (CS)) which continued to worsen when initiating atacicept and subsequently two subjects developed pneumonia. In prior Phase 2 clinical trials of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its
primary endpoint in the broader SLE study population, atacicept achieved positive clinical data on multiple measures within the <FONT STYLE="white-space:nowrap">pre-specified</FONT> High Disease Activity patient segment (defined as Systemic Lupus
Erythematosus Disease Activity Index 2000 <FONT STYLE="white-space:nowrap">(SLEDAI-2K)</FONT> <FONT STYLE="font-family:Times New Roman">&#8805;</FONT> 10 at screening), including reduction of renal flares, which we believe supports atacicept&#146;s
applicability in LN. Because both preclinical and clinical evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either
signal alone, we believe there is a strong rationale to conduct a clinical trial of atacicept in LN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 3 randomized, double-blinded, placebo-controlled
trial will evaluate the efficacy and safety of atacicept in subjects with LN. The clinical trial consists of a <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind treatment period, followed by a
<FONT STYLE="white-space:nowrap">104-week</FONT> open-label treatment period and a <FONT STYLE="white-space:nowrap">26-week</FONT> safety <FONT STYLE="white-space:nowrap">follow-up</FONT> period. The trial will assess 150 mg of once weekly
subcutaneous injections of atacicept versus placebo. The primary endpoint is complete renal response at 52 weeks. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MAU868 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021,
we obtained worldwide, exclusive development and commercial rights from Amplyx, a wholly owned subsidiary of Pfizer, for MAU868, a potentially <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal
antibody to treat BKV infections. We believe MAU868 is the only clinical-stage neutralizing monoclonal antibody that is directed against BKV, a polyoma virus that can have devastating consequences in certain settings such as kidney transplant and
hematopoietic stem cell transplant (HSCT). In an interim analysis of Phase 2 data in BK viremia among kidney transplant recipients, MAU868 was shown to be well tolerated and demonstrated a clinically significant reduction of virologic activity. We
expect to share full results from the interim analysis in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and expect to initiate a Phase 2b or Phase 3 clinical trial in 2023. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MAU868 in BK viremia among kidney transplant recipients </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
developing MAU868 as a potential treatment for BK viremia in kidney transplant recipients. While up to 90% of healthy adults have been infected with the BKV at some point in their lives, it remains latent in everyone except severely
immunocompromised populations such as kidney transplant recipients. There are approximately 80,000 kidney transplants annually worldwide, with approximately 20,000 in the United States. Approximately 225,000 kidney allograft recipients are living in
the United States. Waitlists to receive kidneys are long: approximately <FONT STYLE="white-space:nowrap">3-5</FONT> years and 75,000 people long in the United States. Up to 12% of transplants per year are
<FONT STYLE="white-space:nowrap">re-transplants,</FONT> which further limits organ availability for new patients. BKV is a polyoma virus that is tropic to the kidney and bladder tissue and can reactivate with the immunosuppression required for
kidney </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">transplant. This reactivation can cause BKV Nephropathy (BKVN), a condition in which BK infection, typically first identified as BK viremia, triggers
inflammation, which then progresses to renal fibrosis and tubular injury; as shown in Figure E, BKVN is a leading cause of allograft loss, a devastating outcome for kidney transplant recipients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure E: Graft survival (%) in kidney transplant patients is worse with BKVN </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center"><B>


<IMG SRC="g210084g15d15.jpg" ALT="LOGO">
 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Currently, there are no approved treatment options for BK viremia or BKVN. In <FONT STYLE="white-space:nowrap">mid-2022,</FONT> we
expect to share full Cohort 1 and Cohort 2 results from the Phase 2 trial conducted by Amplyx, and initiate a Phase 2b or Phase 3 clinical trial in 2023. We believe that MAU868 has the potential to become standard of care for the treatment of BK
viremia in order to prevent devastating consequences such as BKVN. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our patent portfolio; potential market exclusivity </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, our licensed patent portfolio related to atacicept contains approximately 15 issued U.S. patents, as well as foreign counterparts of a
subset of these patents in several foreign countries, including countries within the European Patent Convention and the Eurasian Patent Organization. Our licensed patent portfolio related to atacicept also includes a pending Patent Cooperation
Treaty (PCT) application and a counterpart Taiwanese application. Because atacicept is a biologic, marketing approval would also provide 12 years of market exclusivity from the approval date of a Biologics License Application (BLA) in the United
States. Additionally, we plan to seek orphan drug designation for atacicept in IgAN from the FDA and European Medicines Agency (EMA), which would allow us to obtain regulatory exclusivity protection from the approval date for seven years in the
United States and 10 years in the European Union. Our licensed patent portfolio covering MAU868 includes three issued U.S. patents, a pending US application, as well as certain foreign counterparts of a subset of these patents granted in Australia,
China, and Taiwan, and pending applications in other jurisdictions such as Canada, Mexico, Europe and Japan.&nbsp;In addition, there is a pending PCT application, and a counterpart application in Taiwan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our business principles and strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is to develop and
commercialize transformative treatments for patients suffering from severe immunological diseases. We believe the successful translation of biomedical science into innovative therapeutic products for patients with immunological diseases will enable
outsized growth over the next decade and beyond. Specifically, our strategy is based on the following business principles: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Develop disease modifying medicines to improve patients&#146; lives. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Establish clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> to successful
products. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Build a leading biotech company that delivers innovative medicines to patients. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These principles have guided us to the successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> of atacicept from Ares and obtaining the rights to MAU868 from
Amplyx, in each case with worldwide rights for development and commercialization in all indications. We take a gated-capital raise approach and scale product candidate investment and exposure in close step with key development milestones to ensure
high return on development costs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The near-term objectives to achieve our goal include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Complete global development of atacicept in IgAN. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Complete global development of atacicept in LN. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Complete global development of MAU868 in BK viremia in kidney transplant recipients and explore treatment of BK cystitis in
HSCT patients. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Build and scale organizational capabilities to support commercialization of atacicept and MAU868. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Explore additional disease areas where atacicept holds significant therapeutic promise. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expand our pipeline by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates for immunologic
diseases with unmet needs. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our team </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were founded
and are led by a team of experienced drug development professionals who have proven track records in clinical and commercial development and have led or been involved in the approvals of 10 medicines
</P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from Gilead Sciences. Inc. (Gilead) and Genentech, Inc. (Genentech), including numerous drugs within Gilead&#146;s multi-billion blockbuster HIV and HCV franchises. Our President and Chief
Executive Officer, Marshall Fordyce, M.D., brings more than 15 years of experience leading teams in clinical translation, development, and commercialization of new treatments. Earlier in his career, Dr.&nbsp;Fordyce served as Gilead&#146;s Senior
Director of Clinical Research where he contributed to seven new drug approvals and served as project lead for Gilead&#146;s tenofovir alafenamide development program that led to five commercial products, including Genvoya and Descovy, which
collectively generated over $12.0&nbsp;billion in worldwide sales in 2019. Our senior management team also includes: Chief Financial Officer, Sean Grant, who was previously Vice President, Corporate Strategy and Business Development at CareDx, Inc.
and Vice President in the Global Healthcare Investment Banking Division at Citigroup where he specialized in public and private capital raising as well as M&amp;A, and executed a broad range of transactions for many of the world&#146;s leading life
sciences companies; Chief Medical Officer, Celia Lin, M.D., who joined from Genentech and was previously at Amgen Inc., where she led Phase 3 global trial execution in various therapeutic areas, as well as a regulatory filing in an orphan disease;
Chief Development Officer, Joanne Curley, Ph.D., who was formerly head of Portfolio Management at Gilead; Chief Business Officer, Lauren Frenz, who held positions of increasing responsibility within Gilead&#146;s commercial organization; Senior Vice
President, Development Operations, Tom Doan, who was formerly Executive Director of Clinical Operations and Therapeutic Area Head of Inflammation and Respiratory at Gilead; Senior Vice President and Head of Product Development and Manufacturing, Tad
Thomas, Ph.D., who was formerly Associate Vice President, Technical Operations at Codexis, Inc. and held previous manufacturing leadership roles at Bayer HealthCare LLC and other biopharmaceutical companies; and Senior Vice President, Finance and
Chief Accounting Officer, Joseph Young, who was formerly Senior Vice President, Finance and Treasurer at Plexxikon Inc. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Investing in our securities involves substantial risk. The risks, described under the section titled &#147;Risk factors&#148; immediately following this prospectus
summary, may cause us to not realize the full benefits of our strengths or may cause us to be unable to successfully execute all or part of our strategy. Some of the more significant risks and challenges include, without limitation, the following:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for
commercial sale, which may make it difficult to evaluate our current business and predict our future success and viability. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We will require substantial additional capital to finance our operations. If we are unable to raise such capital when
needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In
addition, we may be unable to continue as a going concern over the long-term. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are substantially dependent on the success of our product candidates, atacicept and MAU868, which are currently in the
clinical development stage. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of
operations and prospects will be significantly harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more
difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with IgAN, the availability of competitive products, and significant competition for recruiting patients in clinical trials.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The incidence and prevalence for target patient populations of atacicept in specific indications are based on estimates and
third-party sources. If the market opportunities for atacicept, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient
population, our revenue and ability to achieve profitability might be materially and adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Interim, initial, <FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical
trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We face significant competition, which may result in others discovering, developing or commercializing products before or
more successfully than us. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone
or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative
consequences. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Even if any product candidate we develop receives regulatory approval, it could be subject to significant post-marketing
regulatory requirements and will be subject to continued regulatory oversight. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Biosimilars to our product candidates may provide competition sooner than anticipated. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The outbreak of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our
business, including our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our success depends on our ability to protect our intellectual property and our proprietary technologies. If we or our
potential licensors, licensees, or collaborators are unable to obtain or maintain patent protection with respect to our product candidates, proprietary technologies and their uses, our business, financial condition, results of operations and
prospects could be significantly harmed. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional
capital through debt financing, the terms of any new debt could further restrict our ability to operate our business. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and
key consultants. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have never commercialized a product candidate before and may lack the necessary expertise, personnel and resources to
successfully commercialize any products on our own or together with suitable collaborators. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we breach our license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the
license agreement with Novartis International Pharmaceutical AG (Novartis) related to MAU868, we could lose the ability to continue the development and commercialization of atacicept or MAU868, respectively. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may be required to make significant payments under our license agreements related to atacicept and MAU868.
</P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our
ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Patent terms may be inadequate to protect our competitive position on atacicept, MAU868 or any future product candidates we
may develop for an adequate amount of time. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We rely, and expect to continue to rely, on third parties, including independent clinical investigators and contract
research organizations (CROs), to conduct certain aspects of our nonclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected
deadlines, we may not be able to obtain regulatory approval for or commercialize atacicept, MAU868 or future product candidates we may develop and our business, financial condition, results of operations and prospects could be significantly harmed.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production. If any of
our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our product for patients, if approved, could be delayed or prevented. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our
stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The price of our Class&nbsp;A common stock may be volatile, and you could lose all or part of your investment.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have identified a material weakness in our internal control over financial reporting. If our remediation of this
material weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our
financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our Class&nbsp;A common stock. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Our principal stockholders and management own a significant percentage of our outstanding voting stock and will be able to
exert significant control over matters subject to stockholder approval. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws and Delaware law could
make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We may be subject to securities litigation, which is expensive and could divert management attention.
</P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Corporate information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were initially incorporated
in Delaware in May 2016 under the name CDF Therapeutics, Inc. In October 2017, we changed our name to Trucode Gene Repair, Inc., and in April 2020, we changed our name to Vera Therapeutics, Inc. Our principal executive offices are located at 8000
Marina Boulevard, Suite 120, Brisbane, California 94005, and our telephone number is (650) <FONT STYLE="white-space:nowrap">770-0077.</FONT> Our website address is www.veratx.com. Information contained in, or accessible through, our website is not a
part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive textual reference. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use the VERA THERAPEUTICS word mark,
Vera Therapeutics logo and other marks as trademarks in the United States and other countries. This prospectus contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and
trade names referred to in this </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prospectus, including logos, artwork and other visual displays, may appear without the <SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> or
<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to
these trademarks and trade names. We do not intend our use or display of other entities&#146; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Implications of being an emerging growth company and smaller reporting company </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company&#148; as defined in the Jumpstart Our Business Startups Act of 2012 (JOBS Act). We may take advantage of certain exemptions from
various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm under Section&nbsp;404 of the Sarbanes-Oxley Act of 2002
(the Sarbanes-Oxley Act), reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and any
golden parachute payments. In particular, in this prospectus, we have provided only two years of audited financial statements and have not included all of the executive compensation related information that would be required if we were not an
emerging growth company. Accordingly, the information contained herein may be different than the information you receive from other public companies in which you hold stock. We will remain an emerging growth company until the earliest of
(i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenues of $1.07&nbsp;billion or more; (ii)&nbsp;December&nbsp;31, 2026; (iii) the date on which we are deemed to be a &#147;large accelerated filer,&#148; under the
rules of the SEC, which means the market value of equity securities that is held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> exceeds $700.0&nbsp;million as of the prior June 30th; and (iv)&nbsp;the date on which we have issued more
than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the JOBS Act
provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. This provision allows an emerging growth company to delay the adoption of accounting standards that
have different effective dates for public and private companies until those standards would otherwise apply to private companies. We have elected to avail ourselves of this exemption and, therefore, we will not be subject to the same requirements to
adopt new or revised accounting standards as other public companies that are not &#147;emerging growth companies.&#148; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are also a &#147;smaller reporting
company&#148; as defined in the Securities Exchange Act of 1934, as amended (Exchange Act). We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled
disclosures available to smaller reporting companies and will be able to take advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by
<FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250.0&nbsp;million measured on the last business day of our second fiscal quarter, or our annual revenue is less than $100.0&nbsp;million during the most recently completed fiscal
year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700.0&nbsp;million measured on the last business day of our second fiscal quarter.
Specifically, as a smaller reporting company, we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and have reduced disclosure
obligations regarding executive compensation, and, similar to emerging growth companies, if we are a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, we would not be required to obtain an attestation report on internal control over
financial reporting issued by our independent registered public accounting firm. </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_2"></A>The offering </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Class&nbsp;A common stock offered </B></P></TD>
<TD>4,993,067 shares. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Underwriters&#146; option to purchase additional shares of Class&nbsp;A common stock </B></P></TD>
<TD>We have granted the underwriters an option for a period of 30 days to purchase up to 748,959 additional shares of our Class&nbsp;A common stock at the public offering price, less underwriting discounts and commissions. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Total Class&nbsp;A and Class&nbsp;B common stock to be outstanding after this offering </B></P></TD>
<TD>26,270,681 shares (or 27,019,640 shares if the underwriters exercise their option to purchase additional shares in full). </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Use of proceeds </B></P></TD>
<TD>We estimate that the net proceeds from this offering will be approximately $69.7&nbsp;million (or approximately $80.2&nbsp;million if the underwriters&#146; option to purchase additional shares is exercised in full), after deducting underwriting
discounts and commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We currently intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund: a Phase 3 clinical trial of atacicept in LN; clinical development of MAU868 for the
treatment of BKV in kidney transplant patients and potential additional indications; and the remainder for general corporate purposes, including working capital, operating expenses and capital expenditures. See the section titled &#147;Use of
proceeds&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Voting rights </B></P></TD>
<TD>We have two classes of common stock: Class&nbsp;A common stock and Class&nbsp;B common stock. The rights of the holders of Class&nbsp;A common stock and Class&nbsp;B common stock are identical, except with respect to voting and conversion.
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="28%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Each share of Class&nbsp;A common stock is entitled to one vote and shares of Class&nbsp;B common stock are <FONT STYLE="white-space:nowrap">non-voting,</FONT> except as may be required by law. Each share of
Class&nbsp;B common stock may be converted into one share of Class&nbsp;A common stock at the option of its holder, subject to the ownership limitations provided for in our amended and restated certificate of incorporation. See the section titled
&#147;Description of capital stock&#148; for additional information. </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Risk factors </B></P></TD>
<TD>See the section titled &#147;Risk factors&#148; beginning on page 17 and other information included in this prospectus for a discussion of factors you should consider carefully before deciding to invest in our securities. </TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="28%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:arial"><B>Nasdaq Global Market trading symbol </B></P></TD>
<TD>&#147;VERA&#148; </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The number of shares of our Class&nbsp;A common stock and Class&nbsp;B common stock to be outstanding after this offering is
based on 20,968,376 shares of Class&nbsp;A common stock and 309,238 shares of Class&nbsp;B common stock </P>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
outstanding as of September&nbsp;30, 2021, including<B> </B>4,137 shares of our unvested restricted Class&nbsp;A common stock subject to repurchase as of such date, and excludes, as of
September&nbsp;30, 2021: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,894,671 shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding stock options as of
September&nbsp;30, 2021, with a weighted-average exercise price of $5.43 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1,510,665 shares of our Class&nbsp;A common stock available for future issuance under the 2021 Equity Incentive Plan (2021
Plan) as of September&nbsp;30, 2021, an additional 1,048,419 shares of our Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the 2021 Plan, as well as any future automatic annual
increases in the number of shares of Class&nbsp;A common stock reserved for issuance under our 2021 Plan and any shares of Class&nbsp;A common stock underlying outstanding stock awards granted under our 2017 Equity Incentive Plan (2017 Plan) that
expire or are repurchased, forfeited, cancelled or withheld, as more fully described in the section titled &#147;Executive compensation&#151;Equity benefit plans&#148;; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">220,251 shares of our Class&nbsp;A common stock reserved for issuance under our 2021 Employee Stock Purchase Plan (ESPP),
an additional 209,684 shares of our Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the ESPP, and any future automatic annual increases in the number of shares of Class&nbsp;A
common stock reserved for future issuance under our ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise indicated, this prospectus assumes or gives effect to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">11.5869-for-one</FONT></FONT> reverse stock split of
our common stock effected on May&nbsp;7, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the automatic conversion of all outstanding shares of our redeemable convertible preferred stock into an aggregate of
15,464,776 shares of our Class A common stock and 309,238 shares of our Class B common stock that was effected upon the closing of our initial public offering (IPO) in May 2021; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise of the outstanding options described above; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">no exercise by the underwriters of their option to purchase 748,959 additional shares of Class&nbsp;A common stock from us
in this offering. </P></TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_3"></A>Summary financial data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables set forth a summary of our financial data as of, and for the periods ended on, the dates indicated. We have derived the summary statements of
operations and comprehensive loss data for the years ended December&nbsp;31, 2019 and 2020, from our audited financial statements included elsewhere in this prospectus. The summary statement of operations and comprehensive loss data for the nine
months ended September&nbsp;30, 2021 and the balance sheet data as of September&nbsp;30, 2021, are derived from our unaudited condensed financial statements and notes included elsewhere in this prospectus. We have prepared the unaudited condensed
financial statements in accordance with accounting principles generally accepted in the United States, and on the same basis as the audited financial statements and have included all adjustments, consisting of only normal recurring adjustments that,
in our opinion, we consider necessary for a fair statement of the financial information set forth in those statements. Our historical results are not necessarily indicative of the results that may be expected for any period in the future. You should
read the following summary financial data together with the section titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and our financial statements and the related notes included elsewhere
in this prospectus. The summary financial data included in this section are not intended to replace the financial statements and are qualified in their entirety by our financial statements and the related notes included elsewhere in this prospectus.
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="67%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months<BR>ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands, except share and per share data)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on the issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income(expense), net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per common share, basic and diluted(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(166.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1.46</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares used to compute net loss per common share, basic and diluted<SUP
STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">295,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">319,963</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,793,436</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">See Note 2 to our audited financial statements and Note 2 to our unaudited condensed financial statements, each included elsewhere in this prospectus, for a description of how we compute basic and diluted net loss per
share attributable to common stockholders. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1px solid #000000;BORDER-LEFT:1px solid #000000;BORDER-RIGHT:1px solid #000000;BORDER-TOP:1px solid #000000; MARGIN-LEFT:0px; MARGIN-RIGHT:0px; max-width:100%"><div style="width:97%; margin-top:1.5%; margin-bottom:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(unaudited, in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>As&nbsp;adjusted(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="8"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Balance Sheet Data:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD COLSPAN="5" VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Working capital(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">160,819</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">85,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">155,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The as adjusted column reflects our issuance and sale of 4,993,067 shares of our Class&nbsp;A common stock in this offering at the public offering price of $15.00 per share and after deducting underwriting discounts and
commissions and estimated offering expenses payable by us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We define working capital as current assets less current liabilities. See our unaudited condensed financial statements and related notes included elsewhere in this prospectus for further details regarding our current
assets and current liabilities. </TD></TR></TABLE>
</div></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_4"></A>Risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Investing in our Class&nbsp;A common stock involves a high degree of risk. You should carefully consider the risks described below, as well as the other information
in this prospectus, including our financial statements and the related notes and the section titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; before deciding whether to invest in our
Class&nbsp;A common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and growth prospects. In such an event, the market price of our Class&nbsp;A common
stock could decline, and you may lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial also may impair our business operations. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our financial position and need for additional capital </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have not completed any clinical trials for our lead product candidate, atacicept, and have no products approved for commercial sale, which may make it difficult
to evaluate our current business and predict our future success and viability. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a late-stage biotechnology company and we have no products approved
for commercial sale, have not generated any revenue from product sales and have incurred losses since inception. To date, we have devoted substantially all of our resources and efforts to organizing and staffing our company, business planning,
executing partnerships, raising capital, acquiring, developing and securing our technology and product candidates, and completing the Phase 2b clinical trial to further evaluate atacicept in patients with IgAN. We have not yet demonstrated our
ability to successfully complete any clinical trials with respect to our product candidates, obtain marketing approvals, manufacture a commercial-scale product or arrange for a third party to do so on our behalf, or conduct sales and marketing
activities necessary for successful product commercialization. As a result, it may be more difficult to accurately predict our future success or viability than it could be if we had a longer operating history. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors and risks frequently experienced by late-stage
biotechnology companies in rapidly evolving fields. We may face difficulty transitioning from a company with a research focus to a company capable of successfully executing drug development activities and supporting commercial operations. If we do
not adequately address these risks and difficulties or successfully make such a transition, our business, financial condition, results of operations and prospects will be significantly harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if this offering is successful, we will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed,
or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs of our product candidates or future commercialization efforts. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Developing treatments for immunological and inflammatory diseases, including conducting nonclinical studies and clinical trials, is a very time-consuming, expensive and
uncertain process that takes years to complete. Our operations have consumed substantial amounts of cash since inception, and we expect our expenses will increase in connection with our ongoing activities, particularly as we continue to conduct
clinical trials of, and seek marketing approval for, our product candidates. We anticipate incurring significant costs associated with the development of our product candidates. Our expenses could increase beyond expectations if we are required by
the FDA, or any comparable foreign regulatory authority to perform clinical trials or nonclinical studies in addition to those that we currently anticipate. Other unanticipated costs may also arise. In addition, if we obtain marketing approval for
atacicept or MAU868, we expect to incur significant commercialization expenses related to drug sales, marketing, manufacturing and distribution. Because the design and outcome of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development and commercialization of any
product candidate we develop. We also will continue to incur costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in order to maintain our continuing operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2021, we had $86.2&nbsp;million in cash and cash equivalents. In December 2021, we entered into the Loan Agreement with Oxford, providing us
with up to $50.0&nbsp;million of borrowing capacity. Of this amount, $5.0&nbsp;million was funded at closing of the Loan Agreement in December 2021. We believe, based on our current operating plan, that the net proceeds from this offering, together
with our existing cash and cash equivalents and the funds available under the Loan Agreement with Oxford, will be sufficient to fund our operations at least into the second quarter of 2024. Our estimate as to how long we expect the net proceeds from
this offering together with our existing cash and cash equivalents to be able to continue to fund our operating expenses and capital expenditures requirements is based on assumptions that may prove to be wrong, and we could use our available capital
resources sooner than we currently expect. Changing circumstances, some of which may be beyond our control, could cause us to consume capital significantly faster than we currently anticipate, and we may need to seek additional funds sooner than
planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic nature of our business, the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and the macro-economic environment
generally. We anticipate that our expenses will increase substantially if, and as, we: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue our ongoing and planned research and development of atacicept for the treatment of IgAN and other indications;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">initiate or continue nonclinical studies and clinical trials for atacicept, MAU868 and any additional product candidates
that we may pursue in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue our ongoing and planned research and development of MAU868 for the treatment of BKV disease in kidney transplant
recipients and other indications; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity
requirements for clinical trials and potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related
additional commercial manufacturing costs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets, and <FONT
STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">acquire, develop or <FONT STYLE="white-space:nowrap">in-license</FONT> other product candidates and technologies and
further expand our clinical product pipeline; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain additional clinical, scientific, quality control, and manufacturing management and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We plan to use the net proceeds from this offering to advance and expand our clinical and nonclinical development programs and for working capital
and other general corporate purposes. Advancing the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
development of atacicept, MAU868 and any future product candidates we may develop will require a significant amount of capital. The net proceeds from this offering and our existing cash and cash
equivalents will not be sufficient to fund all of the activities that are necessary to complete the development of our product candidates through approval and commercial launch. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will be required to obtain further funding through public or private equity offerings, debt financings, collaborations and licensing arrangements or other sources,
which may dilute our stockholders or restrict our operating activities. Adequate additional financing may not be available to us on acceptable terms, or at all. Market volatility, including as a result of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, could also adversely impact our ability to access capital as and when needed. Our failure to raise capital as and when needed or on acceptable terms would have a negative impact on our
financial condition and our ability to pursue our business strategy, and we may have to delay, reduce the scope of, suspend or eliminate one or more of our research-stage programs, clinical trials or future commercialization efforts. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have incurred net losses since inception, and we expect to continue to incur net losses for the foreseeable future. In addition, we may be unable to continue as
a going concern over the long-term. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred net losses in each reporting period since the commencement of our operations and have not generated any
revenue from product sales to date. We had net losses of $15.8&nbsp;million and $53.4&nbsp;million for the nine months ended September&nbsp;30, 2021 and year ended December&nbsp;31, 2020, respectively. We had an accumulated deficit of
$107.2&nbsp;million as of September&nbsp;30, 2021. Our losses have resulted principally from expenses incurred in research and development and from management and administrative costs and other expenses that we have incurred while building our
business infrastructure, a significant portion of which were incurred resulting from our efforts to develop <FONT STYLE="white-space:nowrap">gamma-PNA</FONT> chemistry and triplex gene editing for therapeutic use, which we discontinued in September
2020. Our lead product candidate, atacicept, is in clinical trials and MAU868 is in a Phase 2 clinical trial. As a result, we expect that it will be several years, if ever, before we have a commercialized product and generate revenue from product
sales. Even if we succeed in receiving marketing approval for and commercializing our product candidates in one of our lead indications, we expect that we will continue to incur substantial research and development and other expenses as we continue
the clinical development programs for our product candidates in other indications. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to continue to incur increased expenses and operating losses for the
foreseeable future as we continue our research and development efforts and seek to obtain regulatory approval for our product candidates. The net losses we incur may fluctuate significantly from quarter to quarter such that a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">period-to-period</FONT></FONT> comparison of our results of operations may not be a good indication of our future performance. The size of our future net losses will depend, in part, on the
rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had, and will continue to have, an adverse effect on our working capital. In any particular period, our operating results
could be below the expectations of securities analysts or investors, which could cause our stock price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our audited financial statements for
the year ended December&nbsp;31, 2020 included elsewhere in this prospectus have been prepared assuming we will continue as a going concern. However, we have incurred losses and negative cash flows from operations. As a development stage company, we
expect to incur significant and increasing losses until regulatory approval is granted for our product candidates. Regulatory approval is not guaranteed and may never be obtained. As a result, these conditions raise substantial doubt about our
ability to continue as a going concern over the long-term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have never generated revenue from product sales and may never be profitable. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with our collaboration partners, to successfully complete
the development of, and obtain the regulatory </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approvals necessary to commercialize, atacicept, MAU868 and any future product candidates we may develop. We do not anticipate generating revenue from product sales for the next several years, if
ever. Our ability to generate revenue from product sales depends heavily on our and our current and potential future collaborators&#146; success in: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completing clinical development of product candidates and programs and identifying and developing new product candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seeking and obtaining marketing approvals for any product candidates that we develop; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">launching and commercializing product candidates for which we obtain marketing approval by establishing a sales force,
marketing, medical affairs and distribution infrastructure or, alternatively, collaborating with a commercialization partner; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">achieving adequate access and reimbursement by government and third-party payors for product candidates that we develop;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establishing and maintaining supply and manufacturing relationships with third parties that can provide adequate, in both
amount and quality, products and services to support clinical development and the market demand for product candidates that we develop, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining market acceptance of product candidates that we develop as viable treatment options; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">addressing any competing technological and market developments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintaining our rights under our existing license agreement with Ares, Novartis and any similar agreements we may enter
into in the future; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing
our obligations in such collaborations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">maintaining, protecting, enforcing and expanding our portfolio of intellectual property rights, including patents, trade
secrets and <FONT STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">defending against third-party interference, infringement or other intellectual property-related claims, if any; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attracting, hiring and retaining qualified personnel. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if atacicept, MAU868, or any future product candidate that we may develop is approved for commercial sale, we anticipate incurring significant costs associated with
commercializing any approved product candidate. Our expenses could increase beyond expectations if we are required by the FDA or comparable foreign regulatory authorities to perform clinical trials or nonclinical studies in addition to those that we
currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not be able to reach or sustain profitability, and may need to obtain additional funding to continue operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The terms of our loan agreement place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of
any new debt could further restrict our ability to operate our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021, we entered into the Loan Agreement with Oxford, providing us with
up to $50.0&nbsp;million of borrowing capacity. Of this amount, $5.0&nbsp;million was funded at closing of the Loan Agreement in December 2021. Our overall leverage and certain obligations and affirmative and negative covenants contained in the
related documentation could adversely affect our financial health and business and future operations by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
limiting our ability to, among other things, satisfy our obligations under the Loan Agreement, refinance our debt on terms acceptable to us or at all, plan for and adjust to changing business,
industry and market conditions, use our available cash flow to fund future acquisitions and make dividend payments, and obtain additional financing for working capital, to fund growth or for general corporate purposes, even when necessary to
maintain adequate liquidity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we default under the Loan Agreement, Oxford may accelerate all of our repayment obligations and exercise all of their rights and
remedies under the Loan Agreement and applicable law, potentially requiring us to renegotiate our agreement on terms less favorable to us. Further, if we are liquidated, the lenders&#146; right to repayment would be senior to the rights of the
holders of our Class&nbsp;A common stock to receive any proceeds from the liquidation. Oxford could declare a default upon the occurrence of customary events of default, including events that they interpret as a material adverse change as delineated
in the Loan Agreement, payment defaults or breaches of certain affirmative or negative covenants, thereby requiring us to repay the loan immediately. Any declaration by the lender of an event of default could significantly harm our business and
prospects and could cause the price of our Class&nbsp;A common stock to decline. Additionally, if we raise any additional debt financing, the terms of such additional debt could further restrict our operating and financial flexibility. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to the discovery, development and commercialization of our product candidates </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are substantially dependent on the success of our product candidates, atacicept and MAU868, which are currently in the clinical development stage. If we are
unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or more indications and in a timely manner, our business, financial condition, results of operations and prospects will be
significantly harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our future success is heavily dependent on our ability to timely complete clinical trials, obtain marketing approval for and
successfully commercialize our product candidates. We expect that a substantial portion of our efforts and expenses over the next several years will be devoted to the development of atacicept in our ongoing clinical trials in patients with IgAN, as
well as our efforts to evaluate atacicept in LN and MAU868 in kidney transplant recipients. We are investing significant efforts and financial resources in the research and development of our product candidates, which will require additional
clinical development, evaluation of clinical, nonclinical and manufacturing activities, marketing approval from government regulators, and significant marketing efforts before we can generate any revenues from product sales. We are not permitted to
market or promote our product candidates before we receive marketing approval from the FDA and comparable foreign regulatory authorities, and we may never receive such marketing approvals. Should our planned clinical development of atacicept in
patients with IgAN or MAU868 in kidney transplant recipients fail to be completed in a timely manner or at all, we will need to rely on clinical development of atacicept or MAU868 in additional indications, which will require more time and resources
to obtain regulatory approval and proceed with commercialization, and may ultimately be unsuccessful. We cannot assure you that our planned clinical development programs for our product candidates will be completed in a timely manner, or at all, or
that we will be able to obtain approval for atacicept or MAU868 from the FDA or comparable foreign regulatory authorities. If we are unable to complete development of, obtain regulatory approval for and commercialize our product candidates in one or
more indications and in a timely manner, our business, financial condition, results of operations and prospects will be significantly harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical development is a lengthy and expensive process with an uncertain outcome, and results of earlier
studies and trials may not be predictive of future trial results. Failure can occur at any stage of clinical development. We have never completed a clinical trial or submitted a BLA to the FDA or similar drug approval filings to comparable foreign
authorities. If we are ultimately unable to obtain regulatory approval for our product candidates, we will be unable to generate product revenue and our business, financial condition, results of operations and prospects will be significantly harmed.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the
clinical trial process. The results of nonclinical studies and early clinical trials may not be predictive of the results of subsequent clinical trials. We have a limited operating history and to date have not demonstrated our ability to complete
large scale clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed
through nonclinical studies and initial clinical trials. For example, atacicept has been the subject of clinical trials by prior sponsors, including a Phase 2 trial in SLE, that missed its primary endpoint in the overall study population. In the
future, clinical trial failures may result from a multitude of factors including flaws in trial design, dose selection, placebo effect and patient enrollment criteria. A number of companies in the biotechnology industry have suffered significant
setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. Based upon negative or inconclusive results, we or any potential future collaborator may decide, or
regulators may require us, to conduct additional clinical trials or nonclinical studies. In addition, data obtained from trials and studies are susceptible to varying interpretations, and regulators may not interpret our data as favorably as we do,
which may delay, limit or prevent regulatory approval. Any future delays or abandonment could harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if our clinical trials are completed as planned, we cannot be certain that their results will support our proposed indications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our future clinical trials may not be successful. If any product candidate is found to be unsafe or lack efficacy, we will not be able to obtain regulatory approval for
it and our business, financial condition, results of operations and prospects may be significantly harmed. In some instances, there can be significant variability in safety and/or efficacy results between different trials of the same product
candidate due to numerous factors, including changes in trial protocols, differences in composition of the patient populations, adherence to the dosing regimen and other trial protocols and the dropout rate among clinical trial participants.
Patients treated with our product candidates may also be undergoing surgical, radiation and chemotherapy treatments and may be using other approved products or investigational new drugs, which can cause side effects or adverse events that are
unrelated to our product candidates. As a result, assessments of efficacy can vary widely for a particular patient, and from patient to patient and site to site within a clinical trial. This subjectivity can increase the uncertainty of, and
adversely impact, our clinical trial outcomes. We do not know whether any clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety sufficient to obtain marketing approval to market our product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not know whether our clinical trials will demonstrate consistent or adequate efficacy and safety to obtain regulatory approval to market our product candidates.
Most product candidates that begin clinical trials are never approved by regulatory authorities for commercialization. If we are unable to bring our product candidates to market, our ability to create long-term shareholder value will be limited.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may rely in part on nonclinical, clinical and quality data generated by CROs and other third parties for regulatory submissions. While we have or
will have agreements governing these third parties&#146; services, we have limited influence over their actual performance. If these third parties do not make data </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
available to us, or, if applicable, make regulatory submissions in a timely manner, our development programs may be significantly delayed, and we may need to conduct additional studies or collect
additional data independently. In either case, our development costs would increase. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, nonclinical and clinical data are often susceptible to varying
interpretations and analyses and many companies that believed their product candidates performed satisfactorily in nonclinical studies and clinical trials nonetheless failed to obtain FDA or comparable foreign regulatory authority approval. We
cannot guarantee that the FDA or foreign regulatory authorities will interpret trial results as we do, and more trials could be required before we are able to submit an application seeking approval of our product candidates. To the extent that the
results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, we may be required to expend significant resources, which may not be available to us, to conduct additional trials in
support of potential approval of our product candidates. Even if regulatory approval is secured, the terms of such approval may limit the scope and use, which may also limit commercial potential. Furthermore, the approval policies or regulations of
the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval, which may lead to the FDA or comparable foreign regulatory authorities delaying, limiting or denying
approval of a product candidate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize
or delay our ability to obtain regulatory approval and commence product sales. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may experience delays in clinical trials of our product candidates. Our
planned clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients, or be completed on schedule, if at all. Our clinical trials can be delayed for a variety of reasons, including delays related to: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining regulatory authorizations to commence a trial or reaching a consensus with regulatory authorities on trial
design; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any failure or delay in reaching an agreement with CROs and clinical trial sites, the terms of which can be subject to
extensive negotiation and may vary significantly among different CROs and trial sites; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining approval from one or more institutional review boards (IRBs); </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">IRBs refusing to approve, suspending or terminating the trial at an investigational site, precluding enrollment of
additional subjects, or withdrawing their approval of the trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes to clinical trial protocol; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical sites deviating from trial protocol or dropping out of a trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">study conduct issues, which could confound the clinical endpoints and/or data; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">manufacturing sufficient quantities of clinical trial material to supply the clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subjects failing to enroll or remain in our trial at the rate we expect, or failing to return for post-treatment <FONT
STYLE="white-space:nowrap">follow-up;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in enrollment due to low prevalence or incidence rates of subjects with the applicable disease;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in enrollment by subjects, or completion of the trial by subjects, due to the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subjects choosing an alternative treatment or participating in competing clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">lack of adequate funding to continue the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subjects experiencing severe or unexpected drug-related adverse effects; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory authorities imposing a clinical hold; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">occurrence of serious adverse events in trials of the same class of agents conducted by other companies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">shutdowns, either temporarily or permanently, of any facility manufacturing our product candidates or any of their
components, including by order from the FDA or comparable foreign regulatory authorities due to violations of current good manufacturing practice (cGMP), regulations or other applicable requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">third-party clinical investigators losing the licenses or permits necessary to perform our clinical trials, not performing
our clinical trials on our anticipated schedule or consistent with the clinical trial protocol, good clinical practices (GCP) or other regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">third-party contractors not performing data collection or analysis in a timely or accurate manner; or
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory
authorities for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to use some or all of the data produced by such contractors in support of our marketing applications.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, disruptions caused by the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may increase the likelihood that we encounter
such difficulties or delays in initiating, enrolling, conducting or completing our planned and ongoing clinical trials. For example, some hospitals delayed initiating clinical trials due to their focus on treating
<FONT STYLE="white-space:nowrap">COVID-19</FONT> patients. Manufacturing timelines for drug product could be delayed, for example, due to a global shortage of syringes. We could also encounter delays if a clinical trial is suspended or terminated by
us, by the IRBs of the institutions in which such trials are being conducted, by a Data Safety Monitoring Board for such trial or by the FDA or comparable foreign regulatory authorities. Such authorities may impose such a suspension or termination
due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or comparable foreign regulatory
authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate
funding to continue the clinical trial. In addition, changes in regulatory requirements and policies may occur, and we may need to amend clinical trial protocols to comply with these changes. Amendments may require us to resubmit our clinical trial
protocols to IRBs for reexamination, which may impact the costs, timing or successful completion of a clinical trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, conducting clinical trials in foreign
countries, as we may do for our product candidates, presents additional risks that may delay completion of our clinical trials. These risks include the failure of enrolled patients in foreign countries to adhere to clinical protocol as a result of
differences in healthcare services or cultural customs, managing additional administrative burdens associated with foreign regulatory schemes, as well as political and economic risks relevant to such foreign countries. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we experience delays in the completion of, or termination of, any clinical trial, the commercial prospects of our product candidates will be harmed, and our ability
to generate product revenues will be delayed. Moreover, any delays in completing our clinical trials will increase our costs, slow down development and approval processes and jeopardize our ability to commence product sales and generate revenues.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, many of the factors that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical trials may also
ultimately lead to the denial of regulatory approval. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Any delays in our clinical trials that occur as a result could shorten any period during which we may have the exclusive right to commercialize atacicept, MAU868 or any other product candidates
and our competitors may be able to bring products to market before we do, and the commercial viability of atacicept, MAU868 or other product candidates could be significantly reduced. Any of these occurrences may significantly harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Enrollment and retention of patients in clinical trials is an expensive and time-consuming process
and could be made more difficult or rendered impossible by multiple factors outside our control, including difficulties in identifying patients with IgAN, the availability of competitive products, and significant competition for recruiting patients
in clinical trials. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We may encounter delays in
enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled we may be unable to retain a sufficient number of patients to complete any of our trials. In particular, as a result of
the inherent difficulties in diagnosing IgAN, the availability of competitive products such as TARPEYO, and the significant competition for recruiting the limited number of patients who have the diseases for which our product candidates are being
developed, there may be delays in enrolling the patients we need to complete clinical trials on a timely basis, or at all. Although we have engaged certain third-party investigators to assist with patient enrollment, there can be no assurance that
we will be able to maintain our relationships with such third parties or that such third parties will be successful in helping us identify patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Factors that
may generally affect patient enrollment include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size and nature of the patient population; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the number and location of clinical sites we enroll; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competition with other companies for clinical sites or patients; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the drug background and clinical experience (e.g., safety profile, risk/benefit assessment, mechanism of action, known
proof of concept); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the eligibility and exclusion criteria for the trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the design of the clinical trial; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inability to obtain and maintain patient consents; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risk that enrolled participants will drop out before completion; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">competing clinical trials and clinicians&#146; and patients&#146; perceptions as to the potential advantages of the drug
being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
addition, if any significant adverse events or other side effects are observed in any of our future clinical trials or other sponsor development programs of similar mechanism of action that may result in a drug class effect, it may make it more
difficult for us to recruit patients to our clinical trials and patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of one or more product candidates altogether. Our inability to enroll a
sufficient number of patients for our clinical trials would result in significant delays, which would increase our costs and have an adverse effect on our company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may develop atacicept, MAU868 and potentially future product candidates, in combination with other therapies, which exposes us to additional risks. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may develop atacicept, MAU868 and future product candidates in combination with one or more currently approved therapies. Even if atacicept, MAU868 or any product
candidate we develop, were to receive marketing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the
United States could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed
from the market or being less successful commercially. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may also evaluate atacicept, MAU868 or any other future product candidates in combination with one or more
other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market and sell atacicept, MAU868 or any product candidate we develop in combination with
any such unapproved therapies that do not ultimately obtain marketing approval. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy,
manufacturing, or supply issues arise with, the drugs we choose to evaluate in combination with atacicept, MAU868 or any other product candidate we develop, we may be unable to obtain approval of or market atacicept, MAU868 or any other product
candidate we develop. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The incidence and prevalence for target patient populations of our product candidates in specific indications are based on estimates and
third-party sources. If the market opportunities for atacicept, MAU868 or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the
patient population, our revenue and ability to achieve profitability might be materially and adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Periodically, we make estimates regarding
the incidence and prevalence of target patient populations for particular diseases based on various third-party sources and internally generated analysis and use such estimates in making decisions regarding our drug development strategy, including
acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates and determining indications on which to focus in nonclinical or clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The incidence and prevalence for target patient populations of our product candidates in specific indications are based on estimates and third-party sources.<B><I>
</I></B>These estimates may be inaccurate or based on imprecise data. For example, the total addressable market opportunity will depend on, among other things, acceptance of our drugs by the medical community and patient access, drug pricing and
reimbursement. The number of patients in the addressable markets may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our drugs, or new patients may become increasingly difficult to identify or gain access
to. If the market opportunities for atacicept, MAU868, or any future product candidate we may develop, if and when approved, are smaller than we estimate or if any approval that we obtain is based on a narrower definition of the patient population,
our revenue and ability to achieve and sustain profitability might be materially and adversely affected. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Interim, initial,
<FONT STYLE="white-space:nowrap">&#147;top-line&#148;</FONT> and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification
procedures that could result in material changes in the final data. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may publicly disclose preliminary or <FONT
STYLE="white-space:nowrap">top-line</FONT> data from our nonclinical studies and clinical trials, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a
more comprehensive review of the data related to the particular study or trial. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and
carefully evaluate all data. As a result, the <FONT STYLE="white-space:nowrap">top-line</FONT> or preliminary results that we report may differ from future results of the same studies, or different conclusions or considerations may qualify such
results, once additional data have been received and fully evaluated. <FONT STYLE="white-space:nowrap">Top-line</FONT> data also remain subject to audit and verification procedures that may result in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the final data being materially different from the preliminary data we previously published. As a result, <FONT STYLE="white-space:nowrap">top-line</FONT> data should be viewed with caution until
the final data are available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may also disclose interim data from our clinical trials. Interim data from clinical trials that we may complete
are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available or as patients from our clinical trials continue other treatments for their disease.
Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our Class&nbsp;A
common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, others, including regulatory agencies, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may
interpret or weigh the importance of data differently, which could impact the value of our particular program, the approvability or commercialization of our particular product candidate or product and our company in general. In addition, the
information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to
include in our disclosure. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the interim, <FONT STYLE="white-space:nowrap">top-line,</FONT> or preliminary data that we report differ from actual results, or if
others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, our product candidates may be harmed, which could significantly harm our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We face significant competition, which may result in others discovering, developing or commercializing products before or more
successfully than us. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our competitors include
multinational pharmaceutical companies, specialized biotechnology companies and universities and other research institutions. The current <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> for IgAN
consists of treatment with RAAS inhibitors, including ACE inhibitors or ARBs, to control blood pressure, or steroids with or without other immunosuppressive agents to non-specifically reduce inflammation. Among emerging therapies, we consider our
most direct competitors with respect to atacicept in IgAN to be the recently approved reformulated steroid from Calliditas Therapeutics AB, and programs in Phase 3 clinical development: Novartis Pharmaceuticals Corporation, Omeros Corporation,
Travere Therapeutics, Inc., and Chinook Therapeutics Inc., and the following companies with programs in Phase 2 of clinical development: Chinook Therapeutics Inc., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Reata Pharmaceuticals,
Inc., RemeGen Co., Ltd., Visterra, Inc., Ionis Pharmaceuticals, Inc., Alexion Pharmaceuticals Inc. (Alexion), and DiaMedica Therapeutics, Inc. There is also a potential that SGLT2 inhibitors, including AstraZeneca plc&#146;s (AstraZeneca) Farxiga,
which has completed Phase 3 clinical development, and C.H. Boehringer Sohn AG&nbsp;&amp; Ko. KG&#146;s (Boehringer) jardiance, which is undergoing Phase 3 clinical development, will be approved broadly for chronic kidney disease and used in IgAN.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In LN, prior to December 2020, there had been no approved therapies, and the
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> has consisted of a number of <FONT STYLE="white-space:nowrap">non-specific</FONT> therapies, including MMF, steroids, cyclophosphamide, rituximab,
calcineurin inhibitors, azathioprine, and hydroxychloroquine, dependent on class of disease and whether a patient was cycling through the induction or maintenance phase of therapy. We expect that these paradigms will evolve with the recent FDA
approvals of GlaxoSmithKline plc&#146;s Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.&#146;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include: Roche Holding AG and Novartis Pharmaceuticals
Corporation, each of which have programs in Phase 3 clinical development; and BeiGene Ltd., Janssen Pharmaceuticals, Inc., AstraZeneca, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Alexion, Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, and Novartis Pharmaceuticals Corporation, each of which have programs in Phase 2 clinical development. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the kidney transplant or HSCT setting, there are currently no <FONT STYLE="white-space:nowrap">anti-BKV</FONT> therapies approved. The standard of care in both
settings is to reduce immunosuppression as a first line, and potentially to offer intravenous immune globulin (IVIG) in kidney transplant recipients or antivirals with limited clinical evidence, including leflunomide and cidofovir, in either
setting. There are few industry sponsored programs in development for these indications; we consider our most direct competitor to be Allovir&#146;s multi-virus specific <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy, Posoleucel, which is in
a Phase 2 clinical trial for BK viremia in kidney transplant recipients, a Phase 3 clinical trial for treatment of virus-associated cystitis, and a Phase 2 clinical trial in multi-virus prevention following allogeneic HSCT. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may be better equipped to develop, manufacture and
market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new pharmaceutical products and in obtaining
regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our competitors have established distribution channels for the commercialization of their products,
whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in
even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or other intellectual property rights that
limit our ability to develop or commercialize our product candidates or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less costly or have a better safety profile
than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be able to commercialize our product
candidates or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and retaining qualified scientific,
management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Changes in methods of manufacturing or formulation of our product candidates may result in additional costs or delays. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As our product candidates progress through preclinical to late-stage clinical trials to marketing approval and commercialization, it is common that various aspects of
the development program, such as manufacturing methods and formulation, and manufacturing sites are altered along the way in an effort to optimize yield, manufacturing batch size, minimize costs and achieve consistent quality and results. Such
changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted
with the altered materials. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and
jeopardize our ability to commercialize our product candidates, if approved, and generate revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to regulatory approval and other legal compliance matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately
unable to obtain regulatory approval for our product candidates, our business, financial condition, results of operations and prospects will be significantly harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The time required to obtain approval by the FDA and comparable foreign authorities typically takes many years following the commencement of clinical trials. In addition,
approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#146;s clinical development and may vary among jurisdictions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Applications for atacicept or MAU868 could fail to receive regulatory approval for many reasons, including the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with the design, implementation or results of our
clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may determine that our product candidate is not safe and effective,
only moderately effective or have undesirable or unintended side effects, toxicities or other characteristics that preclude our obtaining marketing approval or prevent or limit commercial use; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the population studied in the clinical trial may not be sufficiently broad or representative to assure efficacy and safety
in the full population for which we seek approval, resulting in a restrictive label and limiting commercial use; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from nonclinical studies
or clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the data collected from clinical trials may not be sufficient to support the submission of a BLA, or other submission or to
obtain regulatory approval in the United States or elsewhere; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may be unable to demonstrate to the FDA or comparable foreign regulatory authorities that the risk-benefit ratio for our
proposed indication is acceptable; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes, test procedures and
specifications or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a
manner rendering our clinical data insufficient for approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This lengthy approval process, as well as the unpredictability of the results of
clinical trials, may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, even if we obtain approval of our product candidates for a lead indication, regulatory authorities may not approve them for other indications, may impose
significant limitations in the form of narrow indications, warnings, or a Risk Evaluation and Mitigation Strategy (REMS). Certain regulatory authorities may grant approval contingent on the performance of costly post-marketing clinical trials or may
approve them with a label that does not include the labeling claims necessary or desirable for successful commercialization of our product candidates. In addition, if we are unable to obtain regulatory approval, or if regulatory approval results in
a limited label, our business, financial condition, results of operation and prospects will be significantly harmed. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if approved, our product candidates may not achieve adequate market acceptance among physicians, patients,
healthcare payors and others in the medical community necessary for commercial success. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if our product candidates receive regulatory approval, they may
not gain adequate market acceptance among physicians, patients, healthcare payors and others in the medical community. The degree of market acceptance of any of our product candidates would depend on a number of factors, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the efficacy and safety profile as demonstrated in clinical trials compared to alternative treatments;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing of market introduction of the product candidate as well as competitive products, such as TARPEYO;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the clinical indications for which the product candidate is approved; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on use, such as boxed warnings or contraindications in labeling, or a REMS, if any, which may not be required
of alternative treatments and competitor products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the potential and perceived advantages of product candidates over alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the cost of treatment in relation to alternative treatments; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our pricing and the availability of coverage and adequate reimbursement by third-party payors, including government
authorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the availability of atacicept or MAU868 for use as a combination therapy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">relative convenience and ease of administration; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the effectiveness of sales and marketing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">inclusion or exclusion of our product candidates from treatment guidelines established by various physician groups;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unfavorable publicity relating to our product candidates or similar approved products or product candidates in development
by third parties; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the approval of other new therapies for the same indications. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sales of medical products also depend on the willingness of physicians to prescribe the treatment, which is likely to be based on a determination by these physicians
that the products are safe, therapeutically effective and accessible to patients. In addition, the inclusion or exclusion of products from treatment guidelines established by various physician groups and the viewpoints of influential physicians can
affect the willingness of other physicians to prescribe the treatment. We cannot predict whether physicians, physicians&#146; organizations, hospitals, other healthcare providers, government agencies or private insurers will determine that our
product is safe, therapeutically effective and cost effective as compared with competing treatments. If any product candidate is approved but does not achieve an adequate level of acceptance by such parties, we may not generate or derive sufficient
revenue from such product candidate and may not be able to achieve or sustain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our business entails a significant risk of product liability and
if we are unable to obtain sufficient insurance coverage, such inability could significantly harm our business, financial condition, results of operations and prospects. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business exposes us to significant product liability risks inherent in the development, testing, manufacturing and marketing of therapeutic treatments. Product
liability claims could delay or prevent </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
completion of our development programs. If we succeed in marketing products, such claims could result in an FDA or other regulatory authority investigation of the safety and effectiveness of our
product, our manufacturing processes and facilities or our marketing programs. FDA or other regulatory authority investigations could potentially lead to a recall of our product or more serious enforcement action, limitations on the approved
indications for which it may be used or suspension or withdrawal of approvals. Regardless of the merits or eventual outcome, liability claims may also result in decreased demand for our product, injury to our reputation, costs to defend the related
litigation, a diversion of management&#146;s time and our resources and substantial monetary awards to trial participants or patients. We currently have product liability insurance that we believe is appropriate for our stage of development and may
need to obtain higher levels prior to marketing any product candidate, if approved. Any insurance we have or may obtain may not provide sufficient coverage against potential liabilities. Furthermore, clinical trial and product liability insurance is
becoming increasingly expensive. As a result, we may be unable to obtain sufficient insurance at a reasonable cost to protect us against losses caused by product liability claims that could significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our product candidates may cause significant adverse events, toxicities or other undesirable side effects when used alone
or in combination with other approved products or investigational new drugs that may result in a safety profile that could inhibit regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative
consequences. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is the case with pharmaceuticals generally, it is likely that there may be side effects and adverse events associated with the use of
atacicept, MAU868 or any future product candidates we may develop. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Undesirable side effects caused by our
product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or comparable foreign regulatory
authorities. For example, Merck KGaA, Darmstadt, Germany previously conducted <FONT STYLE="white-space:nowrap">APRIL-LN,</FONT> a study aimed to evaluate the efficacy and safety of atacicept in patients with active LN, receiving newly initiated CS
and MMF. Two weeks before the initiation of atacicept, significant decreases in immunoglobulin G (igG) levels began unexpectedly with initiation of MMF and high-dose CS, and persisted upon initiation of atacicept, which led to trial termination. The
drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. Any of these occurrences may significantly harm our business, financial condition,
results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If product candidates we develop are associated with undesirable side effects or have unexpected characteristics in nonclinical
studies or clinical trials when used alone or in combination with other approved products or investigational new drugs, we may need to interrupt, delay or abandon their development or limit development to more narrow uses or subpopulations in which
the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to
complete a trial, or result in potential product liability claims. Any of these occurrences may prevent us from achieving or maintaining market acceptance of the affected product candidate and may significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients in our ongoing and planned clinical trials may in the future suffer significant adverse events or other
side effects not observed in our nonclinical studies or previous clinical trials. Our product candidates may be used as chronic therapies or be used in pediatric populations, for which safety concerns may be particularly scrutinized by regulatory
agencies. In addition, if atacicept, MAU868 or any future product candidates we may develop, are used in combination with other therapies, atacicept, MAU868 or any future product candidates we may develop may exacerbate adverse events associated
with the therapy and it may not be possible to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
determine whether it was caused by our product or the one with which it was combined. Patients treated with our product candidates may also be undergoing surgical, radiation, chemotherapy or
other treatments, which can cause side effects or adverse events that are unrelated to our product candidates, but may still impact the success of our clinical trials. The inclusion of patients with advanced disease in our clinical trials may result
in deaths or other adverse medical events due to other therapies or medications that such patients may be using or due to the gravity of such patients&#146; illnesses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If significant adverse events or other side effects are observed in any of our current or future clinical trials, we may have difficulty recruiting patients to the
clinical trials, patients may drop out of our trials, or we may be required to abandon the trials or our development efforts of that product candidate altogether. We, the FDA, other comparable regulatory authorities or an IRB may suspend clinical
trials of a product candidate at any time for various reasons, including a belief that subjects in such trials are being exposed to unacceptable health risks or adverse side effects. Some potential therapeutics developed in the biotechnology
industry that initially showed therapeutic promise in early-stage trials have later been found to cause side effects that prevented their further development. Even if the side effects do not preclude the product candidate from obtaining or
maintaining marketing approval, undesirable side effects may inhibit market acceptance due to its tolerability versus other therapies. Any of these developments could significantly harm our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, toxicities associated with our products not seen during clinical testing may also develop after any approval, if obtained, and lead to a
requirement to conduct additional clinical safety trials, additional contraindications, warnings and precautions being added to the drug label, significant restrictions on the use of the product or the withdrawal of the product from the market. We
cannot predict whether our product candidates will cause toxicities in humans that would preclude or lead to the revocation of regulatory approval based on nonclinical studies or early-stage clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory
approval in other jurisdictions. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will
be able to obtain or maintain regulatory approval in any other jurisdiction. For example, even if the FDA or other foreign regulatory authority grants marketing approval of a product candidate, comparable regulatory authorities in foreign
jurisdictions must also approve the marketing approval of the product candidate in their countries. However, a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in
others. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from those in the United States, including additional nonclinical studies or clinical trials as clinical trials conducted
in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that
jurisdiction. In some cases, the price that we intend to charge for our product is also subject to approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining foreign regulatory approvals and establishing
and maintaining compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product in certain countries. If we or any future collaborator fail
to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even if any product candidate we develop receives regulatory approval, it could be subject to significant
post-marketing regulatory requirements and will be subject to continued regulatory oversight. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any regulatory approvals that we may receive for our product
candidates will require the submission of reports to regulatory authorities and surveillance to monitor the safety and efficacy of the marketed product, may contain significant limitations related to use restrictions for specified age groups,
warnings, precautions or contraindications, and may include burdensome post-approval study or risk management requirements. For example, the FDA may require a REMS in order to approve atacicept or MAU868, which could entail requirements for a
medication guide, physician training and communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or applicable foreign
regulatory authorities approve atacicept, MAU868 or any product candidate we develop in the future, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and
recordkeeping will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as
<FONT STYLE="white-space:nowrap">on-going</FONT> compliance with cGMPs and GCP for any clinical trials that we conduct post-approval. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic,
unannounced inspections by the FDA and other regulatory authorities for compliance with cGMP regulations and standards. If we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated
severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the
market or suspension of manufacturing. In addition, failure to comply with FDA and other comparable foreign regulatory requirements may subject our company to administrative or judicially imposed sanctions, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays in or the rejection of product approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on our ability to conduct clinical trials, including full or partial clinical holds on ongoing or planned
trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the products, manufacturers or manufacturing process; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">warning letters; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">civil and criminal penalties; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">suspension or withdrawal of regulatory approvals; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizures, detentions or import bans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">voluntary or mandatory product recalls and publicity requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">total or partial suspension of production; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">imposition of restrictions on operations, including costly new manufacturing requirements. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The occurrence of any event or penalty described above may inhibit our ability to commercialize atacicept, MAU868, or any product candidate we may develop in the future,
and generate revenue and could require us to expend significant time and resources in response and could generate negative publicity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA&#146;s and other
regulatory authorities&#146; policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept, MAU868 or any product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidate we may develop in the future. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain
regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not be able to achieve or sustain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also cannot
predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If these actions impose constraints on FDA&#146;s or foreign
regulatory authorities&#146; ability to engage in oversight and implementation activities in the normal course, it may significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are currently seeking orphan drug designation for atacicept for the treatment of IgAN, but even if designated we may not ultimately realize the potential
benefits of orphan drug designation. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently seeking orphan drug designation from the FDA and European Medicines Agency for atacicept for the
treatment of IgAN. Under the Orphan Drug Act, the FDA may designate a drug product as an orphan drug if it is intended to treat a rare disease or condition, defined as a patient population of fewer than 200,000 in the United States, or a patient
population greater than 200,000 in the United States but where there is no reasonable expectation to recover the costs of developing and marketing a treatment drug in the United States. In the United States, orphan drug designation entitles a party
to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and application fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use
are disclosed publicly by the FDA. However, orphan drug designation neither shortens the development time nor regulatory review time of a product candidate nor gives the candidate any advantage in the regulatory review or approval process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity,
which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan
exclusivity or where the manufacturer is unable to assure sufficient product quantity for the orphan patient population. Exclusive marketing rights in the United States may also be unavailable if we or our collaborators seek approval for an
indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective. Even if we obtain orphan drug designation, we may not be the first to obtain marketing
approval for any particular orphan indication due to the uncertainties associated with developing pharmaceutical products. Further, even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the
product from competition because different drugs can be approved for the same condition. Even after an orphan drug is approved, the FDA can subsequently approve the same drug for the same condition if the FDA concludes that the later drug is
clinically superior in that it is safer, more effective, or makes a major contribution to patient care. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, in Europe, a medicinal product may receive orphan
designation under Article 3 of Regulation (EC) 141/2000. This applies to products that are intended for a life-threatening or chronically debilitating condition and either (1)&nbsp;such condition affects no more than five in 10,000 persons in the EU
when the application is made, or (2)&nbsp;the product, without the benefits derived from orphan status, would be unlikely to generate sufficient returns in the EU to justify the necessary investment in its development. Moreover, in order to obtain
orphan designation in the EU it is necessary to demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU or, if such a method exists, the product will be of
significant benefit to those affected by the condition. In the EU, orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and applicants can benefit from specific regulatory assistance and scientific
advice. Products receiving orphan designation in the EU can </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
receive 10 years of market exclusivity, during which time no &#147;similar medicinal product&#148; for the same indication may be placed on the market. A &#147;similar medicinal product&#148; is
defined as a medicinal product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two
years of market exclusivity in the EU for pediatric studies. However, the <FONT STYLE="white-space:nowrap">10-year</FONT> market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer
meets the criteria for orphan designation&#151;for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Additionally, marketing authorization may be granted to a similar medicinal product for the same
indication at any time if: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically
superior; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the first marketing authorization holder for the authorized product consents to a second orphan medicinal product
application; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the marketing authorization holder for the authorized product cannot supply enough orphan medicinal product.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we do not receive or maintain orphan drug designation for atacicept for the treatment of IgAN, it could limit our ability to realize revenues.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Even though MAU868 has Fast Track designation from FDA for the prevention of BK virus disease in renal transplant and hematopoietic stem cell transplant, it
may not lead to a faster development or regulatory review or approval process, and will not increase the likelihood that MAU868 will receive marketing approval. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a drug or biologic is intended for the treatment of a serious or life-threatening condition or disease, and nonclinical or clinical data demonstrate the potential to
address an unmet medical need, the product may qualify for FDA Fast Track designation, for which sponsors must apply. The FDA has broad discretion whether or not to grant this designation. Although we have received Fast Track designation for the
investigation of MAU868 for the prevention of BK virus disease in renal transplant and hematopoietic stem cell transplant recipients, we may not experience a faster development process, review or approval compared to conventional FDA procedures. In
addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may attempt to secure approval from the FDA or comparable foreign regulatory authorities through the use of accelerated approval pathways. If we are unable to
obtain such approval, we may be required to conduct additional nonclinical studies or clinical trials beyond those that we contemplate, which could increase the expense of obtaining, and delay the receipt of, necessary marketing approvals. Even if
we receive accelerated approval from the FDA or comparable foreign regulatory authorities, if our confirmatory trials do not verify clinical benefit, or if we do not comply with rigorous post-marketing requirements, the FDA or comparable foreign
regulatory authorities may seek to withdraw any accelerated approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may in the future seek an accelerated approval for atacicept, MAU868 or future
product candidates we may develop. For example, if the results from our Phase 2b trial of atacicept in patients with IgAN are positive, we may seek accelerated approval with the FDA based on this trial, which we may not be granted. Under the
accelerated approval program, the FDA may grant accelerated approval to a product candidate designed to treat a serious or life-threatening condition that provides meaningful therapeutic benefit over available therapies upon a determination that the
product candidate has an effect on a surrogate endpoint or intermediate clinical endpoint that is reasonably likely to predict clinical benefit. The FDA considers a clinical benefit to be a positive therapeutic effect that is clinically meaningful
in the context of a given disease, such as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
irreversible morbidity or mortality. For the purposes of accelerated approval, a surrogate endpoint is a marker, such as a laboratory measurement, radiographic image, physical sign, or other
measure that is thought to predict clinical benefit, but is not itself a measure of clinical benefit. For example, UPCR is an accepted surrogate primary endpoint for clinical trials in IgAN, which could allow for a faster path to commercialization
than rate of change/slope in glomerular filtration rate (GFR). We may seek accelerated approval based on the UPCR endpoint. An intermediate clinical endpoint is a clinical endpoint that can be measured earlier than an effect on irreversible
morbidity or mortality that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit. The accelerated approval pathway may be used in cases in which the advantage of a new drug over available therapy
may not be a direct therapeutic advantage, but is a clinically important improvement from a patient and public health perspective. Use of the accelerated approval pathway would entail submission of a BLA under Subpart E of the FDA regulations with
the UPCR surrogate endpoint data while conducting the Phase 3 trial to collect change/slope in GFR data. If granted, accelerated approval is usually contingent on the sponsor&#146;s agreement to complete ongoing trials and/or conduct, in a diligent
manner, additional post-approval confirmatory studies to verity and describe the drug&#146;s clinical benefit. Additionally, unless and until converted to full approval at the time of satisfying the conditions of any accelerated approval letter, the
sponsor must submit any promotional materials for the accelerated approval drug to FDA at least 30 days prior to use. Third-party payors may refuse to provide coverage or reimbursement for the drug until the confirmatory studies are complete.
Additionally, if such post-approval studies fail to confirm the drug&#146;s clinical benefit, the FDA may withdraw its approval of the drug. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to seeking
accelerated approval for atacicept or MAU868, we intend to seek feedback from the FDA and will otherwise evaluate our ability to seek and receive accelerated approval. There can be no assurance that after our evaluation of the feedback and other
factors we will decide to pursue or submit a BLA, for accelerated approval or any other form of expedited development, review or approval. Similarly, there can be no assurance that after subsequent FDA feedback we will continue to pursue or apply
for accelerated approval or any other form of expedited development, review or approval, even if we initially decide to do so. Furthermore, if we decide to submit an application for accelerated approval or receive an expedited regulatory designation
(e.g., breakthrough therapy designation) for atacicept, there can be no assurance that such submission or application will be accepted or that any expedited development, review or approval will be granted on a timely basis, or at all. The FDA or
comparable foreign regulatory authorities could also require us to conduct further studies prior to considering our application or granting approval of any type. A failure to obtain accelerated approval or any other form of expedited development,
review or approval for atacicept or MAU868 would result in a longer time period to commercialization of such product candidate, could increase the cost of development of atacicept or MAU868 and could harm our competitive position in the marketplace.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Biosimilars to our product candidates may provide competition sooner than anticipated. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, ACA), signed into law on
March&nbsp;23, 2010, includes a subtitle called the Biologics Price Competition and Innovation Act of 2009 (BPCIA), which created an abbreviated approval pathway for biological products that are biosimilar to or interchangeable with an <FONT
STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Under the BPCIA, an application for a biosimilar product may not be submitted to the FDA until four years following the date that the reference product was first licensed
by the FDA. In addition, the approval of a biosimilar product may not be made effective by the FDA until 12 years from the date on which the reference product was first licensed. During this <FONT STYLE="white-space:nowrap">12-year</FONT> period of
exclusivity, another company may still market a competing version of the reference product if the FDA approves a full BLA for the competing product containing the sponsor&#146;s own preclinical data and data from adequate and well-controlled
clinical trials to demonstrate the safety, purity and potency of their product. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that any of our product candidates approved as a biological product under a BLA should qualify for the <FONT
STYLE="white-space:nowrap">12-year</FONT> period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, or that the FDA will not consider our product candidates to be reference
products for competing<I> </I>products, potentially creating the opportunity for generic competition sooner than anticipated. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have also been the subject of recent
litigation. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of our reference products in a way that is similar to traditional generic substitution for <FONT STYLE="white-space:nowrap">non-biological</FONT>
products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any approved products are subject to
biosimilar competition sooner than we expect, we will face significant pricing pressure and our commercial opportunity will be limited. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Any product candidate
we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to seek approval to
market atacicept and MAU868 in both the United States, in the EU and in certain foreign jurisdictions. If we obtain approval in one or more foreign jurisdictions for atacicept or MAU868, we will be subject to rules and regulations in those
jurisdictions. In some foreign countries, particularly those in the EU, the pricing of drugs is subject to governmental control and other market regulations which could put pressure on the pricing and usage of atacicept or MAU868. In these
countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. In addition, market acceptance and sales of a product candidate will depend significantly on the
availability of adequate coverage and reimbursement from third-party payors for the product candidate and may be affected by existing and future healthcare reform measures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The availability and extent of coverage and adequate reimbursement by third-party payors, including government health administration authorities, private health coverage
insurers, managed care organizations and other third-party payors is essential for most patients to be able to afford expensive treatments. If we obtain marketing approval of a product candidate, sales of such product will depend substantially, both
in the United States and internationally, on the extent to which the costs of the product will be covered and reimbursed by third-party payors. If reimbursement is not available, or is available only at inadequate levels, we may not be able to
successfully commercialize any product candidates we develop. Even if coverage is provided, the approved reimbursement amount may not be high enough to allow us to establish or maintain pricing sufficient to realize an adequate return on our
investment. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If coverage and reimbursement are not available or reimbursement is available only to limited levels, we
may not successfully commercialize any product candidate for which we obtain marketing approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is significant uncertainty related to third-party payor
coverage and reimbursement of newly approved products. In the United States, for example, principal decisions about reimbursement for new products are typically made by the Centers for Medicare&nbsp;&amp; Medicaid Services (CMS) an agency within the
U.S. Department of Health and Human Services (HHS). CMS decides whether and to what extent a new product will be covered and reimbursed under Medicare, and private third-party payors often follow CMS&#146;s decisions regarding coverage and
reimbursement to a substantial degree. However, one third-party payor&#146;s determination to provide coverage for a product candidate does not assure that other payors will also provide coverage for the product candidate. Moreover, eligibility for
reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not
be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. As a result, the coverage determination
process is often time-consuming and costly. This process will require us to provide scientific and clinical support for the use of our product to each third-party payor separately, with no assurance that coverage and adequate reimbursement will be
applied consistently or obtained in the first instance. Factors payors consider in determining reimbursement are based on whether the product is: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Governmental payors, as well as other third-party payors, including pharmacy benefit
managers, have attempted to control costs by limiting coverage and the amount of reimbursement for particular products and requiring substitutions of generic products and/or biosimilars. Increasingly, third-party payors are requiring that drug
companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Further, such payors are increasingly examining the medical necessity and reviewing the cost effectiveness of medical
product candidates. There may be especially significant delays in obtaining coverage and reimbursement for newly approved drugs. Third-party payors may limit coverage to specific product candidates on an approved list, known as a formulary, which
might not include all <FONT STYLE="white-space:nowrap">FDA-approved</FONT> drugs for a particular indication. We may need to conduct expensive pharmaco-economic studies to demonstrate the medical necessity and cost effectiveness of our product.
Nonetheless, atacicept, MAU868 or any future product candidates we may develop may not be considered medically necessary or cost effective. We cannot be sure that coverage and reimbursement will be available for any product that we commercialize
and, if reimbursement is available, what the level of reimbursement will be. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Outside the United States, international operations are generally subject to extensive
governmental price controls and other market regulations, and we believe the increasing emphasis on cost containment initiatives in Europe, Canada and other countries has and will continue to put pressure on the pricing and usage of therapeutics
such as atacicept, MAU868 or any future product candidates we may develop. In many countries, particularly the countries of the EU, medical product prices are subject to varying price control mechanisms as part of national health systems. In these
countries, pricing negotiations with governmental authorities can take considerable time after a product receives marketing approval. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that
compares the cost-effectiveness of atacicept, MAU868 or any future product candidates we may develop to other available therapies. In general, product prices under such systems are substantially lower than in the United States. Other countries allow
companies to fix their own prices for products, but monitor and control company profits. Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for atacicept, MAU868 or any
future product candidates we may develop. Accordingly, in markets outside the United States, the reimbursement for any product that we commercialize may be reduced compared with the United States and may be insufficient to generate commercially
reasonable revenue and profits. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are unable to establish or sustain coverage and adequate reimbursement for any product candidates that we commercialize from
third-party payors, the adoption of those products and potential sales revenue would be adversely affected, which, in turn, could adversely affect the ability to market or sell those product candidates, if approved. Coverage policies and third-party
payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for a product for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in
the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may face difficulties from changes to current regulations and future legislation. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Existing regulatory policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of atacicept, MAU868
or any future product candidates we may develop. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or
unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not be able to
achieve or sustain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, the ACA was passed in March 2010, which, among other things, subjected biologic products to potential competition by
lower-cost biosimilars; addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted or injected; increased the minimum Medicaid
rebates owed by most manufacturers under the Medicaid Drug Rebate Program; extended the Medicaid Drug Rebate program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations; subjected manufacturers to new
annual fees and taxes for certain branded prescription drugs; created a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% (increased to 70% pursuant to the Bipartisan Budget Act of 2018, effective as
of January&nbsp;1, 2019) <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a
condition for the manufacturer&#146;s outpatient drugs to be covered under<I> </I>Medicare Part D; and provided incentives to programs that increase the federal government&#146;s comparative effectiveness research. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the ACA. For example, on
June&nbsp;17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect
in its current form. Moreover, prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order that initiated a special enrollment period coverage through the ACA marketplace, which began on
February&nbsp;15, 2021 and remained open through August&nbsp;15, 2021. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among
others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is possible that
the ACA will be subject to judicial or Congressional challenges in the future. It is also unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the ACA and our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. These changes include aggregate reductions to
Medicare payments to providers of 2% per fiscal year pursuant to the Budget Control Act of 2011, which began in 2013, and due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect
through 2031, unless additional congressional action is taken. <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic relief legislation suspended the 2% Medicare sequester from May&nbsp;1, 2020 through March&nbsp;31, 2022. Under current
legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which
eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. The American Taxpayer Relief Act of 2012, among
other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. These laws may result in additional reductions in
Medicare and other healthcare funding, which could have an adverse </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
effect on customers for our product candidates, if approved, and, accordingly, our financial operations. In addition, Congress is considering additional health reform measures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, there has been heightened governmental scrutiny in the United States of pharmaceutical pricing practices in light of the rising cost of prescription drugs and
biologics. Such scrutiny has resulted in several recent congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between
pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through
federal budget proposals, executive orders and policy initiatives. For example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to
implement several of the administration&#146;s proposals. In response, the FDA concurrently released a final rule and guidance in September 2020, which went into effect on November&nbsp;30, 2020, providing pathways for states to build and submit
importation plans for drugs from Canada. Further, on November&nbsp;20, 2020 CMS issued an interim final rule implementing the Most Favored Nation (MFN) Model under which Medicare Part B reimbursement rates will be calculated for certain drugs and
biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita. As a result of litigation challenging the MFN Model, on December
27, 2021, CMS published a final rule that rescinded the Most Favored Nation model interim final rule. Additionally, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical
manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to an order entered by the U.S.
District Court for the District of Columbia, the portion of the rule eliminating safe harbor protection for certain rebates related to the sale or purchase of a pharmaceutical product from a manufacturer to a plan sponsor under Medicare Part D has
been delayed to January&nbsp;1, 2023. Further, implementation of this change and new safe harbors for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> reductions in price for prescription pharmaceutical
products and pharmacy benefit manager service fees have also been delayed until January&nbsp;1, 2023. In July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple
provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety
of potential legislative policies that Congress could pursue as well as potential administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. At the
state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement-constraints, discounts, restrictions on certain
product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that the ACA, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional
downward pressure on the price that we receive for any approved product. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost
containment measures or other healthcare reforms may prevent us from being able to generate revenue, achieve and sustain profitability or commercialize atacicept, MAU868 or any future product candidates we may develop. It is possible that additional
governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Legislative and regulatory proposals have been made to
expand post-approval requirements and restrict sales and promotional activities for biotechnology products. We cannot be sure whether additional legislative </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
changes will be enacted, or whether FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of any product candidates we
develop, may be. In addition, increased scrutiny by Congress of the FDA&#146;s approval process may significantly delay or prevent marketing approval, as well as subject us to more stringent product labeling and post-marketing testing and other
requirements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, FDA regulations and guidance may be revised or reinterpreted by the FDA in ways that may significantly affect our business and our
products. Any new regulations or guidance, or revisions or reinterpretations of existing regulations or guidance, may impose additional costs or lengthen FDA review times for atacicept, MAU868 or future product candidates we may develop. We cannot
determine how changes in regulations, statutes, policies, or interpretations when and if issued, enacted or adopted, may affect our business in the future. Such changes could, among other things, require: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">additional clinical trials to be conducted prior to obtaining approval; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes to manufacturing methods; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">recalls, replacements, or discontinuance of one or more of our products; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">additional recordkeeping. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Such changes would likely require substantial time and impose significant costs, or could reduce the potential commercial value of atacicept, MAU868 or future product
candidates we may develop, and could materially harm our business and our financial results. In addition, delays in receipt of or failure to receive regulatory clearances or approvals for any other products would harm our business, financial
condition, and results of operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our relationships with healthcare professionals, clinical investigators, CROs and third party payors in connection with
our current and future business activities may be subject to federal and state healthcare fraud and abuse laws, false claims laws, transparency laws, government price reporting, and health information privacy and security laws, which could expose us
to, among other things, criminal sanctions, civil penalties, contractual damages, exclusion from governmental healthcare programs, reputational harm, administrative burdens and diminished profits and future earnings. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Healthcare providers and third-party payors play a primary role in the recommendation and prescription of our product candidates for which we obtain marketing approval.
Our current and future arrangements with healthcare professionals, clinical investigators, CROs, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the
business or financial arrangements and relationships through which we research, market, sell and distribute our product for which we obtain marketing approval. Restrictions under applicable federal and state healthcare laws and regulations include
the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully
soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service,
for which payment may be made under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have
committed a violation. In addition, the government may assert that a claim including items or services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False
Claims Act; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal false claims laws, including the civil False Claims Act, which can be enforced by private citizens through
civil whistleblower or qui tam actions, and civil monetary penalties laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or
fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Health Insurance Portability and Accountability Act of 1996 (HIPAA) prohibits, among other things, executing or
attempting to execute a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the
statute or specific intent to violate it in order to have committed a violation; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (HITECH) and their
implementing regulations, also imposes obligations, including mandatory contractual terms, certain covered healthcare providers, health plans, and healthcare clearinghouses as well as their respective business associates and subcontractors that
perform services for them that involve the use, or disclosure of, individually identifiable health information with respect to safeguarding the privacy, security and transmission of individually identifiable health information;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the federal Physician Payments Sunshine Act requires applicable manufacturers of covered drugs, devices, biologics and
medical supplies for which payment is available under Medicare, Medicaid or the Children&#146;s Health Insurance Program, with specific exceptions, to annually report to CMS information regarding payments and other transfers of value to physicians
(defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching hospitals, as well as information regarding ownership and
investment interests held by physicians and their immediate family members; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or
marketing arrangements and claims involving healthcare items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some state laws require biotechnology companies to comply with the biotechnology industry&#146;s voluntary compliance guidelines and the relevant compliance guidance
promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures. Some state laws require
biotechnology companies to report information on the pricing of certain drug products. Some state and local laws require the registration of pharmaceutical sales representatives. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Much like the federal Anti-Kickback Statute prohibition in the United States, the provision of benefits or advantages to physicians to induce or encourage the
prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to induce or reward improper performance generally is governed by the national
anti-bribery laws of EU Member States, and the<I> </I>Bribery Act 2010 in the United Kingdom (UK). Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal
products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons
unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification
and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional
codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable
healthcare laws and regulations will involve <FONT STYLE="white-space:nowrap">on-going</FONT> substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes,
regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject
to significant penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government funded healthcare programs, such as Medicare and Medicaid, integrity oversight
and reporting obligations, contractual damages, reputational harm, diminished profits and future earnings and the curtailment or restructuring of our operations. Defending against any such actions can be costly, time-consuming and may require
significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. Further, if any of the physicians or other healthcare providers
or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, and policies related to data privacy and security, and
our actual or perceived failure to comply with such obligations could harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business is subject to stringent and evolving U.S. and foreign
laws, rules, and regulations and contractual obligations relating to data privacy and security, including the collection, use, processing, disclosure, retention and security of personal information. The regulatory frameworks for data privacy and
security are evolving and may result in increasing regulatory and public scrutiny and escalating levels of enforcement and sanctions, including monetary penalties and prohibitions on processing personal information that could require us to change
our business practices. Interpretation of these frameworks is likely to remain uncertain and potentially inconsistent for the foreseeable future. This evolution may create uncertainty in our business, affect our ability (or the ability of our
collaborators, service providers, and contractors) to operate in certain jurisdictions or to collect, store, process, transfer, use or share personal information. This evolution could also necessitate the acceptance of more onerous obligations in
our contracts and impose additional costs on us. Our efforts to bring our practices (and those of our collaborators, service providers, and contractors) into compliance with these obligations may not succeed for a variety of reasons, including due
to internal or external factors such as resource allocation limitations or a lack of vendor cooperation. Noncompliance could result in the commencement of legal proceedings against us by governmental and regulatory entities, collaborators, data
subjects or others. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Among the most stringent of these laws is the General Data Protection Regulation ((EU) 2016/679) (GDPR), which applies to the processing of
personal information about clinical trials participants and other individuals in the EU and the UK. Companies that violate the GDPR can face private litigation, prohibitions on data processing and fines of up to the greater of 20&nbsp;million Euros
or 4% of their worldwide annual revenue. The GDPR requires us to give detailed disclosures about how we collect, use and share personal information; ensure any consents relied on to process personal information (including special categories of
personal data, such as health data) meet the stricter GDPR requirements; contractually impose data protection requirements on vendors entrusted with personal information; maintain adequate data security measures; notify regulators and affected
individuals of certain data breaches; meet extensive privacy governance and documentation requirements; and honor individuals&#146; data protection rights, including their rights to access, correct and delete their personal information. European
data protection authorities may interpret the GDPR and national laws implementing it differently and impose additional requirements or obligations on us, which further contribute to the complexity of processing personal information in or from
Europe. Guidance on implementation and compliance with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
GDPR is often updated or otherwise revised. The GDPR may increase our responsibility and liability in relation to personal information that we process, and we may be required to implement
additional mechanisms to comply with the GDPR. These mechanisms may be onerous and, if our efforts to comply with the GDPR or other applicable European data protection laws and regulations are not successful, our business in Europe could be
adversely affected. In addition, further to the UK&#146;s exit from the EU on January&nbsp;31, 2020, the GDPR ceased to apply in the UK at the end of the transition period on December&nbsp;31, 2020. However, as of January&nbsp;1, 2021, the UK&#146;s
European Union (Withdrawal) Act 2018 incorporated the GDPR (as it existed on December&nbsp;31, 2020 but subject to certain UK specific amendments) into UK law (referred to as the UK GDPR). The UK GDPR and the UK Data Protection Act 2018 set out the
UK&#146;s data protection regime, which is independent from but aligned to the European&#146;s data protection regime. <FONT STYLE="white-space:nowrap">Non-compliance</FONT> with the UK GDPR may result in monetary penalties of up to
&pound;17.5&nbsp;million or 4% of worldwide revenue, whichever is higher. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">European data protection laws also generally prohibit the transfer of personal information
from Europe to the United States and most other countries unless the parties to the transfer have implemented specific safeguards to protect the transferred personal information. One of the primary safeguards used for transfers of personal
information from the EU and Switzerland to the United States until recently was the Privacy Shield framework administered by the U.S. Department of Commerce, which was invalidated by a decision of the EU&#146;s highest court in July 2020. The same
decision also cast doubt on the viability of one of the primary alternatives to the Privacy Shield, namely, the European Commission&#146;s Standard Contractual Clauses, as a vehicle for such transfers. Similarly, the Swiss Federal Data Protection
and Information Commissioner has opined that the Privacy Shield is inadequate for transfers of data from Switzerland to the U.S. and raised similar questions regarding the Standard Contractual Clauses. At present, there are few, if any, viable
alternatives to the Standard Contractual Clauses and, therefore, there is uncertainty regarding how to lawfully transfer personal information from Europe or the UK to the U.S. and other third countries. Failure to comply with the GDPR&#146;s
cross-border data restrictions may increase our exposure to its heightened sanctions, restrict our clinical trial activities in Europe, and limit our ability to collaborate with CROs, service providers and other companies subject to European and UK
data protection laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, it is unclear whether the transfer of personal information from the EU to the UK will continue to remain lawful under the GDPR in
light of Brexit. Pursuant to a post-Brexit trade deal between the UK and the EU, transfers of personal information from the European Economic Area to the UK are not considered restricted transfers under the GDPR for a period of up to six months from
January&nbsp;1, 2021. However, unless the EU Commission makes an adequacy finding with respect to the UK before the end of that period, the UK will be considered a &#147;third country&#148; under the GDPR and transfers of European personal
information to the UK will require an approved compliance mechanism to render such transfers lawful under the GDPR. Although the UK&#146;s primary data protection legislation is designed to be consistent with the GDPR, uncertainty remains regarding
how data transfers to and from the UK will be regulated after Brexit. This uncertainty and any restrictions on data transfers between the UK and the EU may further limit our ability to do business in the region. Additionally, other countries outside
of Europe have enacted or are considering enacting similar cross-border data transfer restrictions and laws requiring local data residency, which could increase the cost and complexity of delivering our services and operating our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Privacy and data security laws in the United States are also increasingly complex and changing rapidly. Just over a month after the GDPR took effect, the California
legislature passed the California Consumer Privacy Act of 2018 (CCPA), which took effect on January&nbsp;1, 2020. The CCPA gives California residents certain rights similar to the individual rights given under the GDPR (including the right to access
and delete their personal information, <FONT STYLE="white-space:nowrap">opt-out</FONT> of certain personal information sharing, and receive detailed information about how their personal information is used), and provides for civil penalties for
violations. Since the enactment of the CCPA, new privacy and data security laws have been proposed in more than half of the states and in United States </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Congress, reflecting a trend toward more stringent privacy legislation in the United States that may increase our compliance costs and our exposure to<I> </I>liability. Further, a new California
privacy law, the California Privacy Rights Act (CPRA) was passed by California voters on November&nbsp;3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect
on January&nbsp;1, 2023 (with certain provisions having retroactive effect to January&nbsp;1, 2022). While certain clinical trials activities are exempt from the CCPA&#146;s requirements, other personal information that we handle may be subject to
the CCPA, which may increase our compliance costs, exposure to regulatory enforcement action and other liabilities. All of these evolving compliance and operational requirements impose significant costs that are likely to increase over time, may
require us to modify our data processing practices and policies, divert resources from other initiatives and projects, including increased costs related to insurance, cybersecurity and information technology, and could restrict the way products and
services involving data are offered, all of which could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we fail
to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business, financial condition, results of operations or prospects. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage,
treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract
with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held
liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Although we maintain workers&#146; compensation insurance to cover us for costs and expenses we may incur due to injuries to our employees resulting from the use of
hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or
disposal of hazardous and flammable materials, including chemicals and biological materials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we may incur substantial costs in order to comply with
current or future environmental, health and safety laws and regulations. These current or future laws and regulations may impair our research, development or commercialization efforts. Failure to comply with these laws and regulations also may
result in substantial fines, penalties or other sanctions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our business activities may be subject to the U.S. Foreign Corrupt Practices Act (FCPA) and similar
anti-bribery and anti-corruption laws of other countries in which we operate, as well as U.S. and certain foreign export controls, trade sanctions, and import laws and regulations. Compliance with these legal requirements could limit our ability to
compete in foreign markets and subject us to liability if we violate them. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we expand our operations outside of the United States, we must dedicate
additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. Our business activities may be subject to the FCPA and similar anti-bribery or anti-corruption laws, regulations or rules of other
countries in which we operate. The FCPA generally prohibits companies and their employees and third party intermediaries from offering, promising, giving or authorizing the provision of anything of value, either directly or indirectly, to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> government official in order to influence official action or otherwise obtain or retain business. The FCPA also requires public companies to make and keep books and records that accurately and fairly
reflect the transactions of the corporation and to devise and maintain an adequate system of internal accounting controls. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Our business is heavily regulated and therefore involves significant interaction with public officials, including officials of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> governments.
Additionally, in many other countries, hospitals owned and operated by the government, and doctors and other hospital employees would be considered foreign officials under the FCPA. Recently the SEC and Department of Justice have increased their
FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents or contractors, or those of our affiliates, will comply with all applicable laws and regulations,
particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers or our employees, disgorgement, and other sanctions and remedial measures, and
prohibitions on the conduct of our<I> </I>business. Any such violations could include prohibitions on our ability to offer our product in one or more countries and could materially damage our reputation, our brand, our international activities, our
ability to attract and retain employees and our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, our product and activities may be subject to U.S. and foreign export controls, trade
sanctions and import laws and regulations. Governmental regulation of the import or export of our product, or our failure to obtain any required import or export authorization for our product, when applicable, could harm our international sales and
adversely affect our revenue. Compliance with applicable regulatory requirements regarding the export of our product may create delays in the introduction of our product in international markets or, in some cases, prevent the export of our product
to some countries altogether. Furthermore, U.S. export control laws and economic sanctions prohibit the shipment of certain products and services to countries, governments, and persons targeted by U.S. sanctions. If we fail to comply with export and
import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. Moreover, any new export or import restrictions, new legislation or shifting approaches in the enforcement or
scope of existing regulations, or in the countries, persons, or product targeted by such regulations, could result in decreased use of our product by, or in our decreased ability to export our product to existing or potential customers with
international operations. Any decreased use of our product or limitation on our ability to export or sell access to our product would likely significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are subject to various laws relating to foreign investment and the export of certain technologies, and our failure to comply with these laws or adequately
monitor the compliance of our suppliers and others we do business with could subject us to substantial fines, penalties and even injunctions, the imposition of which on us could have a material adverse effect on the success of our business.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are subject to U.S. laws that regulate foreign investments in U.S. businesses and access by foreign persons to technology developed and produced in the
United States. These laws include Section&nbsp;721 of the Defense Production Act of 1950, as amended by the Foreign Investment Risk Review Modernization Act of 2018, and the regulations at 31 C.F.R. Parts 800 and 801, as amended, administered by the
Committee on Foreign Investment in the United States; and the Export Control Reform Act of 2018, which is being implemented in part through Commerce Department rulemakings to impose new export control restrictions on &#147;emerging and foundational
technologies&#148; yet to be fully identified. Application of these laws, including as they are implemented through regulations being developed, may negatively impact our business in various ways, including by restricting our access to capital and
markets; limiting the collaborations we may pursue; regulating the export our products, services, and technology from the United States and abroad; increasing our costs and the time necessary to obtain required authorizations and to ensure
compliance; and threatening monetary fines and other penalties if we do not. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to employee matters, managing our growth and other risks related to our business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The outbreak of the novel coronavirus disease, <FONT STYLE="white-space:nowrap">COVID-19,</FONT> could adversely impact our business, including our clinical
trials. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2020, the World Health Organization declared the <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak a pandemic, and since such time,
actions taken around the world to help mitigate the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have included varying restrictions on travel, quarantines in certain areas, and forced closures for several types of public places and
businesses The outbreak and government measures taken in response have had a significant impact, both direct and indirect, on businesses and commerce, as worker shortages have occurred; supply chains have been disrupted; facilities and production
have been suspended; and demand for certain goods and services, such as medical services and supplies, has spiked, while demand for other goods and services, such as travel, has fallen. The effects of government orders and our work-from-home could
slow our productivity or disrupt our business in the future, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In response
to the spread of <FONT STYLE="white-space:nowrap">COVID-19,</FONT> we have closed our executive offices with our administrative employees continuing their work outside of our offices and limited the number of staff in any given research and
development laboratory. As a result of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we may experience additional disruptions that could severely impact our business, preclinical studies and clinical trials, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or difficulties in enrolling and retaining patients in our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">delays or difficulties in clinical site initiation, including difficulties in recruiting clinical site investigators and
clinical site staff; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">diversion of healthcare resources away from the conduct of clinical trials, including the diversion of hospitals serving as
our clinical trial sites and hospital staff supporting the conduct of our clinical trials; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of key clinical trial activities, such as clinical trial site data monitoring, due to limitations on travel
imposed or recommended by federal or state governments, employers and others or interruption of clinical trial subject visits and study procedures, which may impact the integrity of subject data and clinical trial endpoints; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption or delays in the operations of the FDA or other regulatory authorities, which may impact review and approval
timelines; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on our business operations by the local, state, or federal government that could impact our ability to sell or
deliver our instruments and consumables; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of, or delays in receiving, supplies of atacicept or MAU868 from our contract manufacturing organizations
(CMO) due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of or delays in receiving products and supplies from the third parties we rely on to, among other things,
manufacture components of our instruments, due to staffing shortages, production slowdowns or stoppages and disruptions in delivery systems, which may impair our ability to sell our products and consumables; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruptions in nonclinical studies due to restricted or limited operations at our laboratory facility;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working
from home, travel limitations, cyber security and data accessibility limits, or communication or mass transit disruptions; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on employee resources that would otherwise be focused on the conduct of our nonclinical studies and clinical
trials, including because of sickness of employees or their families or the desire of employees to avoid contact with large groups of people; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption or delays to our sourced discovery and clinical activities. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Three vaccines for <FONT STYLE="white-space:nowrap">COVID-19</FONT> were granted Emergency Use Authorization by the FDA in late 2020 and early 2021, one received full
approval in August 2021 and more, including boosters, are likely to be authorized in the coming months. The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of
1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the products needed for our clinical trials, which could lead to delays in these trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is uncertain when restrictions will be fully lifted, and if so, when we will be able to resume <FONT STYLE="white-space:nowrap">pre-pandemic</FONT> work routines.
Imposition of government orders, including quarantine and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">shelter-in-place</FONT></FONT> orders related to <FONT STYLE="white-space:nowrap">COVID-19</FONT> or other infectious
diseases, is expected to continue to impact personnel at our and our third-party manufacturing facilities for the foreseeable future. The ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to evolve. The extent to which the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to impact our business, clinical development, including our ongoing and planned preclinical studies and clinical trials, will depend on future developments, which are highly uncertain and
cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the pandemic, travel restrictions and social distancing in the United States and other countries, business closures or business disruptions
and the effectiveness of actions taken in the United States and other countries to contain and treat the disease, including the effectiveness and timing of vaccination programs in the United States and worldwide. Accordingly, we do not yet know the
full extent of potential delays or impacts on our business, our clinical and regulatory activities, healthcare systems or the global economy as a whole. However, these effects could have negative impacts on our business, financial condition and
results of operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, to the extent the evolving <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to adversely affect our business
and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described in this &#147;Risk factors&#148; section. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees and key consultants. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To succeed, we must recruit, retain, manage and motivate qualified clinical, scientific, technical and management personnel, and we face significant competition for
experienced personnel. We are highly dependent on the management, research and development, clinical, financial and business development expertise of our executive officers, as well as the other members of our scientific and clinical teams,
including certain key consultants. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, although we have employment offer letters with each of our executive officers, each of them may terminate their
employment with us at any time. We do not maintain &#147;key person&#148; insurance for all of our executives or employees. If we do not succeed in attracting and retaining qualified personnel, particularly at the management level, it could
adversely affect our ability to execute our business plan and harm our operating results. In particular, the loss of one or more of our executive officers could be detrimental to us if we cannot recruit suitable replacements in a timely manner. The
competition for qualified personnel in the biotechnology field is intense and as a result, we may be unable to continue to attract and retain qualified personnel necessary for the future success of our business. We could in the future have
difficulty attracting experienced personnel to our company and may be required to expend significant financial resources in our employee recruitment and retention efforts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of the other biotechnology companies that we compete against for qualified personnel have greater financial and
other resources, different risk profiles and a longer history in the industry than we do. They also may provide more diverse opportunities and better prospects for career advancement. Some of these characteristics may be more appealing to
high-quality candidates than what we have to offer. If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can discover, develop and commercialize atacicept, MAU868 or any other product candidate
will be limited and the potential for successfully growing our business will be harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to establish sales or marketing capabilities or enter
into agreements with third parties to sell or market atacicept, MAU868 or any product candidate we may develop in the future, we may not be able to successfully sell or market atacicept, MAU868 or any future product candidate we may develop in the
future that obtained regulatory approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently do not have, and have never had, a marketing or sales team. In order to commercialize any product
candidates, if approved, we must build marketing, sales, distribution, managerial and other <FONT STYLE="white-space:nowrap">non-technical</FONT> capabilities or make arrangements with third parties to perform these services for each of the
territories in which we may have approval to sell or market atacicept, MAU868 or any future product candidate we may develop. We may not be successful in accomplishing these required tasks. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Establishing an internal sales or marketing team with technical expertise and supporting distribution capabilities to commercialize atacicept, MAU868 or any product
candidate we may develop in the future will be expensive and time-consuming, and will require significant attention of our executive officers to manage. Any failure or delay in the development of our internal sales, marketing and distribution
capabilities could adversely impact the commercialization of atacicept, MAU868 or any product candidate we may develop in the future that we obtain approval to market, if we do not have arrangements in place with third parties to provide such
services on our behalf. Alternatively, if we choose to collaborate, either globally or on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">territory-by-territory</FONT></FONT> basis, with third parties that have direct sales
forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems, we will be required to negotiate and enter into arrangements with such third
parties relating to the proposed collaboration. If we are unable to enter into such arrangements when needed, on acceptable terms, or at all, we may not be able to successfully commercialize atacicept, MAU868 or any product candidate we may develop
in the future which may receive regulatory approval or any such commercialization may experience delays or limitations. If we are unable to successfully commercialize our approved product candidates, either on our own or through collaborations with
one or more third parties, our future product revenue will suffer and we may incur significant additional losses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have never commercialized a product
candidate before and may lack the necessary expertise, personnel and resources to successfully commercialize any products on our own or together with suitable collaborators. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never commercialized a product candidate, and we currently have no sales force, marketing or distribution capabilities. To achieve commercial success for a
product candidate, which we may license to others, we will rely on the assistance and guidance of those collaborators. For any product candidates for which we retain commercialization rights, we will have to develop our own sales, marketing and
supply organization or outsource these activities to a third party. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As an organization, we have never commercialized a product candidate. Factors that may affect
our ability to commercialize our current or any future product candidate we may develop, on our own include recruiting and retaining adequate numbers of effective sales and marketing personnel, obtaining access to or persuading adequate numbers of
physicians to prescribe our current or any future product candidates we may develop and other unforeseen costs associated with creating an independent sales and marketing organization. Developing </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
a sales and marketing organization will be expensive and time-consuming and could delay the launch of atacicept, MAU868 or any future product candidate we may develop. We may not be able to build
an effective sales and marketing organization. If we are unable to build our own distribution and marketing capabilities or to find suitable partners for the commercialization of our current or any future product candidate we may develop, we may not
generate revenues from such product candidate or be able to achieve or sustain profitability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>In order to successfully implement our plans and strategies, we
will need to grow the size of our organization, and we may experience difficulties in managing this growth. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, we had 17
full-time employees, including 11 employees engaged in research and development. In order to successfully implement our development and commercialization plans and strategies, and as we continue to operate as a public company, we expect to need
additional managerial, operational, sales, marketing, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying, recruiting, integrating, maintaining and motivating additional employees; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">managing our internal development efforts effectively, including the clinical, FDA and other comparable foreign regulatory
agencies&#146; review process for atacicept, MAU868 and any other future product candidates we may develop, while complying with any contractual obligations to contractors and other third parties we may have; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">improving our operational, financial and management controls, reporting systems and procedures. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we expect to be conducting multiple clinical trials of atacicept for several different indications concurrently, as well as MAU868 for the treatment of BKV
disease in kidney transplant recipients. Given the small size of our organization, we may encounter difficulties managing multiple clinical trials at the same time, which could negatively affect our ability to manage growth of our organization,
particularly as we take on additional responsibility associated with being a public company. Our future financial performance and our ability to successfully develop and, if approved, commercialize, atacicept, MAU868 and any other future product
candidates will depend, in part, on our ability to effectively manage any future growth, and our management may also have to divert a disproportionate amount of its attention away from
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities in order to devote a substantial amount of time to managing these growth activities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide
certain services, including key aspects of clinical development and manufacturing. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or
that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by third party service providers is compromised for any reason, our
clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of atacicept, MAU868 and any other future product candidates we may develop or otherwise advance our business. We cannot assure you that we
will be able to manage our existing third party service providers or find other competent outside contractors and consultants on economically reasonable terms, or at all. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we are not able to effectively expand our organization by hiring new employees and/or engaging additional third party service providers, we may not be able to
successfully implement the tasks necessary to further develop and commercialize atacicept, MAU868 and any other future product candidates we may develop and, accordingly, may not achieve our research, development and commercialization goals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We or the third parties upon whom we depend may be adversely affected by earthquakes, fires or other natural
disasters and our business continuity and disaster recovery plans may not adequately protect us from a serious disaster. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our headquarters is located in
Brisbane, California, which in the past has experienced severe earthquakes and fires. If these earthquakes, fires, other natural disasters, terrorism and similar unforeseen events beyond our control prevented us from using all or a significant
portion of our research facility, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. We do not have a disaster recovery or business continuity plan in place and may incur
substantial expenses as a result of the absence or limited nature of our internal or third-party service provider disaster recovery and business continuity plans, which, particularly when taken together with our lack of earthquake insurance, could
have a material adverse effect on our business. Furthermore, integral parties in our supply chain are operating from single sites, increasing their vulnerability to natural disasters or other sudden, unforeseen and severe adverse events. If such an
event were to affect our supply chain, it could have an adverse effect on our ability to conduct our clinical trials, our development plans and business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive tax reform legislation could adversely affect our business and financial condition. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">New income, sales, use or other tax laws, statutes, rules, regulations or ordinances could be enacted at any time, which could adversely affect our business operations
and financial performance. Further, existing tax laws, statutes, rules, regulations or ordinances could be interpreted, changed, modified or applied adversely to us. For example, the Tax Cuts and Jobs Act of 2017 (Tax Act) enacted many significant
changes to the U.S. tax laws. Future guidance from the Internal Revenue Service and other tax authorities with respect to the Tax Act may affect us, and certain aspects of the Tax Act could be repealed or modified in future legislation. For example,
the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) signed into law on March&nbsp;27, 2020, modified certain provisions of the Tax Act. In addition, it is uncertain if and to what extent various states will conform to the Tax Act or
any newly enacted federal tax legislation. Changes in corporate tax rates, the realization of net deferred tax assets relating to our operations, the taxation of foreign earnings, and the deductibility of expenses under the Tax Act or future reform
legislation could have a material impact on the value of our deferred tax assets, could result in significant <FONT STYLE="white-space:nowrap">one-time</FONT> charges, and could increase our future U.S. tax expense. For example, proposals have
recently been made in Congress to make various changes to the federal corporate income tax rules, although these have not yet been enacted. Among the changes made by the Tax Act were a reduction of the business tax credit for certain clinical
testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#147;orphan drugs&#148;. We continue to examine the impact this tax reform legislation may have on our business. We urge investors to
consult with their legal and tax advisers regarding the implications of the Tax Act and potential changes in U.S. tax laws on an investment in our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred losses during our history, we expect to continue to incur significant losses for the foreseeable future, and we may never achieve profitability. As of
December&nbsp;31, 2020, we had federal and state net operating loss (NOL) carryforwards of $10.2&nbsp;million and $3.5&nbsp;million, respectively, that will begin expiring in the year 2032 and 2036, respectively, if not utilized. We also have
$33.8&nbsp;million of federal NOL carryforwards as of December&nbsp;31, 2020, that do not expire as a result of recent tax law changes. Our NOL carryforwards are subject to review and possible adjustment by the U.S. and state tax authorities. Our
NOL carryforwards could expire unused and be unavailable to offset future income tax liabilities because of their limited duration or because of restrictions under U.S. tax law. NOLs generated in tax years ending on or prior to December&nbsp;31,
2017 are only permitted to be carried forward for 20 taxable years under applicable U.S. federal tax law. Under the Tax Act, as modified by the CARES Act, NOLs arising in tax years beginning after December&nbsp;31, 2017, and before
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
January&nbsp;1, 2021 may be carried back to each of the five tax years preceding the tax year of such loss, and NOLs arising in tax years beginning after December&nbsp;31, 2020 may not be carried
back. Moreover, under the Tax Act as modified by the CARES Act, federal NOLs generated in tax years ending after December&nbsp;31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current
year taxable income for tax years beginning after December&nbsp;31, 2020. In addition, at the state level, there may be periods during which the use of NOLs is suspended or otherwise limited, which could accelerate or permanently increase state
taxes owed. For example, California recently imposed limits on the usability of California state NOL carryforwards and certain tax credits to offset taxable income and tax, respectively, in taxable years beginning after 2019 and before 2023. It is
generally uncertain if and to what extent various states will conform to the Tax Act or the CARES Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, under Sections 382 and 383 of the Internal
Revenue Code of 1986, as amended, if a corporation undergoes an &#147;ownership change&#148; (generally defined as a cumulative change in our ownership by <FONT STYLE="white-space:nowrap">&#147;5-percent</FONT> shareholders&#148; that exceeds 50
percentage points over a rolling three-year period), the corporation&#146;s ability to use its <FONT STYLE="white-space:nowrap">pre-change</FONT> NOLs and certain other <FONT STYLE="white-space:nowrap">pre-change</FONT> tax attributes to offset its
post-change income and taxes may be limited. Similar rules may apply under state tax laws. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our
stock ownership, some of which are outside our control. We have not conducted any studies to determine annual limitations, if any, that could result from such changes in the ownership. Our ability to utilize those NOLs could be limited by an
&#147;ownership change&#148; as described above and consequently, we may not be able to utilize a material portion of our NOLs and certain other tax attributes, which could have an adverse effect on our cash flows and results of operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>A variety of risks associated with marketing our current or any future product candidate we may develop internationally could significantly harm our business,
financial condition, results of operations and prospects. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We plan to seek regulatory approval of our current or any future product candidates we may develop
outside of the United States and, accordingly, we expect that we will be subject to additional risks related to operating in foreign countries if we obtain the necessary approvals, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">differing regulatory requirements and reimbursement regimes in foreign countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">economic weakness, including inflation, or political instability in particular foreign economies and markets;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">foreign taxes, including withholding of payroll taxes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other
obligations incident to doing business in another country; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">difficulties staffing and managing foreign operations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">workforce uncertainty in countries where labor unrest is more common than in the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential liability under the FCPA or comparable foreign regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not
respect and protect intellectual property rights to the same extent as the United States; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">51 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business interruptions resulting from <FONT STYLE="white-space:nowrap">geo-political</FONT> actions, including war and
terrorism. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These and other risks associated with our international operations may significantly harm our business, financial condition, results of
operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our intellectual property </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our success depends on our ability to protect our intellectual property and our proprietary technologies. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends in part on our and our current or future licensors&#146;, licensees&#146; or collaborators&#146; ability to obtain and maintain
proprietary or intellectual property protection in the United States and other countries for atacicept, MAU868, and any future product candidates that we may develop and technologies related to their various uses. We generally seek to protect our
proprietary position by, among other things, filing patent applications in the United States and abroad related to our proprietary technologies, and their manufacture and uses that are important to our business, as well as inventions and
improvements that are important to the development and implementation of our business. Our owned and <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications in both United States and certain foreign jurisdictions relate
to atacicept, MAU868, and other products. There can be no assurance that the claims of our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, or any patent application that issues as a patent, will exclude others from making,
using or selling our product candidates or any future product candidates or products that are substantially similar to our product candidates or any future product candidates. We also rely on trade secrets,
<FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our proprietary and intellectual property position. We may seek to<I> </I>protect our proprietary position by acquiring or <FONT
STYLE="white-space:nowrap">in-licensing</FONT> additional relevant issued patents or pending applications from third parties. If we or our potential licensors, licensees or collaborators are unable to obtain or maintain patent protection with
respect to atacicept, MAU868, and our other products, proprietary technologies and their uses, our business, financial condition, results of operations and prospects could be significantly harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pending patent applications cannot be enforced against third parties practicing the technology claimed in such applications unless, and until, patents issue from such
applications, and then only to the extent the issued claims cover the technology. There can be no assurance that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patent applications or our current or future licensors&#146;,
licensees&#146; or collaborators&#146; patent applications will result in additional patents being issued or that issued patents will afford sufficient protection against competitors with similar technology, nor can there be any assurance that the
patents issued will not be infringed, designed around or invalidated by third parties. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, in the future, some of our owned or
<FONT STYLE="white-space:nowrap">in-licensed</FONT> patents and patent applications may be <FONT STYLE="white-space:nowrap">co-owned</FONT> with third parties. If we are unable to obtain exclusive licenses to any such
<FONT STYLE="white-space:nowrap">co-owners&#146;</FONT> interest in such patents or patent applications, then such <FONT STYLE="white-space:nowrap">co-owners</FONT> may be able to license their rights to other third parties, including our
competitors, and our competitors could market competing products and technology. In addition, we may need the cooperation of any such <FONT STYLE="white-space:nowrap">co-owners</FONT> in order to enforce such patents against third parties, and such
cooperation may not be provided to us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even issued patents may later be found invalid or unenforceable or may be modified or revoked in proceedings instituted by
third parties before various patent offices or in courts. Thus, the degree of future protection for our proprietary rights is uncertain. Only limited protection may be available and may not adequately protect our rights or permit us to gain or keep
any competitive advantage. These uncertainties and/or limitations in our ability to properly protect the intellectual property rights relating to atacicept, MAU868, or any future product </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">52 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
candidates we may develop could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot be certain that the claims in our U.S. pending patent applications and corresponding international applications will be considered patentable by the United
States Patent and Trademark Office (USPTO) courts in the United States or by the patent offices and courts in foreign countries, nor can we be certain that the claims in our issued patent(s) will not be found invalid or unenforceable if challenged.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent application process is subject to numerous risks and uncertainties, and there can be no assurance that we or any of our potential future collaborators
will be successful in protecting atacicept, MAU868, or any future product candidates we may develop by obtaining and defending patents. These risks and uncertainties include the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications must be filed in advance of certain events (e.g., third party filings, certain sales or offers for
sale, or other activities that might be legally deemed to be public disclosures) and we might not be aware of such events or otherwise might not succeed in filing applications before they occur; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee
payment and other provisions during the patent process, the noncompliance with which can result in abandonment or lapse of a patent or patent application, and partial or complete loss of patent rights in the relevant jurisdiction;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patent applications may not result in any patents being issued; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">patents may be challenged, invalidated, modified, revoked, circumvented, found to be unenforceable or otherwise may not
provide any competitive advantage; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">there may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent
protection both inside and outside the United States; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">countries other than the United States may have patent laws less favorable to patentees than those upheld by U.S. courts,
allowing foreign competitors a better opportunity to create, develop and market competing product candidates. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent prosecution process is
also expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner or in all jurisdictions where protection
may be commercially advantageous. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection, for example, if patentable aspects are publicly
disclosed, by us or a third party, such as by public use, sale or offer for sale, or publication. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, although we enter into
<FONT STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, outside scientific collaborators,
CROs, third-party manufacturers, consultants, advisors and other third parties, any of these parties may breach such agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent
protection. Further, although we require our employees, commercial contractors, and certain consultants and investigators to enter into invention assignment agreements that grant us ownership of any discoveries or inventions made by them while in
our employ, we cannot guarantee that we have entered into such agreements with each party, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach such agreements and claim ownership in
intellectual property that we believe is owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by us. In addition, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in
the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">53 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we were the first to make the
inventions claimed in our owned or any licensed patents or pending patent applications, or that we were the first to file for patent protection of such inventions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or
shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. Should any of the above events occur, it
could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we breach our license agreement with Ares, an affiliate of
Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis related to MAU868, we could lose the ability to continue the development and commercialization of atacicept or MAU868, respectively. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are dependent on patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology licensed or sublicensed to us from Ares and Novartis. Our
commercial success depends upon our ability to develop, manufacture, market and sell our product candidates and use our and our licensor&#146;s proprietary technologies without infringing the proprietary rights of third parties. Either Ares or
Novartis may have the right to terminate the applicable license agreement in full in the event we materially breach or default in the performance of any of the obligations under the applicable license agreement. A termination of either license
agreement could result in the loss of significant rights and could harm our ability to commercialize our product candidates. Additionally, certain patents, <FONT STYLE="white-space:nowrap">know-how</FONT> and proprietary technology of third parties,
including certain composition of matter patents, are sublicensed to us and in the event the applicable license agreement terminates, expires or is in dispute, it could result in the loss of significant rights and could harm our ability to
commercialize our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may also arise between us and Ares, an affiliate of Merck KGaA, Darmstadt, Germany, Novartis, or any future potential
licensors, regarding intellectual property subject to a license agreement, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patent and other rights to third parties under collaborative development relationships;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations with respect to the use of the licensed technology in relation to our development and
commercialization of our product candidates and what activities satisfy those diligence obligations; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint creation or use
of intellectual property by our licensors and us and our partners. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If disputes over intellectual property that we have licensed prevent or impair
our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we acquired worldwide, exclusive rights to atacicept pursuant to our license agreement (Ares Agreement) with Ares, and worldwide, exclusive rights to
develop, manufacture and commercialize MAU868 pursuant to our asset purchase agreement with Amplyx (Amplyx Agreement) pursuant to which we acquired Amplyx&#146;s right, title and interest in the license agreement between Amplyx and Novartis related
to MAU868 (the Novartis Agreement). The Ares Agreement and Novartis Agreement are complex, and certain provisions </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">54 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the
relevant intellectual property, or increase what we believe to be our financial or other obligations under such agreement, either of which could have an adverse effect on our business, financial condition, results of operations, and prospects.
Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangement on commercially acceptable terms, we may be unable to successfully develop and commercialize the
affected product candidates, which could have an adverse effect on our business, financial conditions, results of operations, and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are generally also
subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual
property, our ability to commercialize products could suffer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be required to make significant payments under our license agreements related to
atacicept and MAU868. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Ares Agreement, in consideration for the license, we issued 22,171,553 shares of our Series C redeemable convertible
preferred stock to Ares at the time of the initial closing of our Series C redeemable convertible preferred stock financing in October 2020, which automatically converted into 1,913,501 shares of our Class&nbsp;A common stock upon the closing of our
IPO. As additional consideration for the license, we paid Ares $25.0&nbsp;million upon delivery and initiation of the transfer of specified information and materials and we are required to pay Ares aggregate milestone payments of up to
$176.5&nbsp;million upon the achievement of specified BLA filing or regulatory approval and aggregate milestone payments of up to $515.0&nbsp;million upon the achievement of specified commercial milestones. Commencing on the first commercial sale of
licensed products, we are obligated to pay tiered royalties of low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net sales of the products covered by the license. In the event we sublicense our rights under
the Ares Agreement, we are obligated to pay Ares a percentage ranging from the <FONT STYLE="white-space:nowrap">mid-single-digit</FONT> to the low double-digits of specified sublicensing income received. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Amplyx Agreement, we made an upfront initial payment of $5.0&nbsp;million. We are also obligated to make certain milestone payments in an aggregate amount of
up to $7.0&nbsp;million based on the achievement of certain regulatory milestones. Further, we are required to pay Amplyx low single digit percentage royalties on net sales of MAU868 on a <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis. In addition, pursuant to the Novartis Agreement, we are obligated to make
certain milestone payments in an aggregate amount of up to $69.0&nbsp;million based on the achievement of certain clinical development, regulatory and sales milestones. Further, we are required to pay Novartis mid-to high-single digit percentage
royalties based on net sales of MAU868 on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT>
basis. If milestone or other <FONT STYLE="white-space:nowrap">non-royalty</FONT> obligations become due, we may not have sufficient funds available to meet our obligations, which will adversely affect our business operations and financial condition.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors
from commercializing similar or identical product candidates would be adversely affected. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The patent positions of biotechnology companies generally are
highly uncertain, involve complex legal and factual questions for which important legal principles remain unsolved and have been the subject of much litigation in recent years. As a result, the issuance, scope, validity, enforceability and
commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect atacicept or MAU868 or which effectively prevent others from commercializing competitive
technologies and product candidates. In addition, the laws of foreign countries may not protect our </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">55 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
rights to the same extent as the laws of the United States. For example, many countries restrict the patentability of methods of treatment of the human body. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted after issuance. Legal
standards relating to valid and enforceable claim scope are unsettled in the United States and elsewhere and disputes challenging or <FONT STYLE="white-space:nowrap">re-defining</FONT> scope are common in the biopharmaceutical industry. Even if
patent applications we own or <FONT STYLE="white-space:nowrap">in-license</FONT> currently or in the future issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third
parties from competing with us, or otherwise provide us with any competitive advantage. Any patents that we own or <FONT STYLE="white-space:nowrap">in-license</FONT> may be challenged or circumvented by third parties or may be narrowed or
invalidated as a result of challenges by third parties. Consequently, we do not know whether atacicept, or MAU868, or any future product candidates we may develop will be protectable or remain protected by valid and enforceable patents. Our
competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products in a <FONT STYLE="white-space:nowrap">non-infringing</FONT> manner which could significantly harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and
our patents may be challenged in the courts or patent offices in the United States and abroad. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process by which patent applications are examined and considered
for issuance as patents involves consideration by the relevant patent office of &#147;prior art&#148; relative to the invented technology. Different countries have different rules about what information or events can be considered &#147;prior
art,&#148; and different requirements regarding when a patent application must be filed relative to any particular piece of potential prior art. Moreover, legal decisions can <FONT STYLE="white-space:nowrap">re-interpret</FONT> or change whether
particular information or events are considered to be &#147;prior art.&#148; Still further, in the United States, patent applicants are required to notify the USPTO of any material &#147;prior art&#148; of which they are aware for the patent
examiner to consider in addition to independent searches that the patent examiner is required to do. Also, in the United States and certain other jurisdictions, third parties are entitled to submit prior art to patent offices for consideration
during examination. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not be aware of certain relevant prior art, may fail to identify or timely cite certain prior art, or may not be able to convince a
patent examiner that our patent(s) should issue in light of the art. Also, we cannot be certain that all relevant art will be or was identified during examination of a patent application so that, even if a patent issues, it may be susceptible to
challenge that it is not valid over art that was not considered during its examination. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be subject to a third-party
<FONT STYLE="white-space:nowrap">pre-issuance</FONT> submission of prior art to the USPTO or other jurisdictions, or become involved in post-grant challenges such as opposition, derivation, revocation, reexamination, post-grant review (PGR) and<I>
inter partes</I> review (IPR), or other similar proceedings, or in litigation, challenging our patent rights, including by challenging the validity or the claim of priority of our patents. An adverse determination in any such submission, proceeding
or litigation could reduce the scope of, or invalidate or render unenforceable, our patent rights, allow third parties to commercialize atacicept, MAU868, or any future product candidates we may develop and compete directly with us, without payment
to us. Such challenges may result in loss of patent rights, loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical
technology and products, or limit the duration of the patent protection of atacicept, MAU868, or any future product candidates we may develop. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect
to the validity question, for example, we cannot be certain that there is no invalidating prior art, including art of which we were unaware, and art which was not raised during prosecution of any of our patents or patent applications. If a third
party were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our technology or platform, or any product candidates
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">56 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
that we may develop. Such a loss of patent protection would significantly impact our business, financial condition, results of operations and prospects. Such proceedings also may result in
substantial cost and require significant time from our scientists and management, even if the eventual outcome is favorable to us. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened,
regardless of the outcome, it could dissuade companies from collaborating with us to license, develop, or commercialize current or future product candidates or could embolden competitors to launch products or take other steps that could disadvantage
us in the marketplace or draw us into additional expensive and time consuming disputes. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property rights do not necessarily address all potential threats to our competitive advantage. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately
protect our business or permit us to maintain our competitive advantage. For example: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not be able to detect infringement of our issued patents; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may be able to develop products that are similar to atacicept, MAU868, or any future product candidates we may
develop, but that are not covered by the claims of the patents that we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors may seek or may have already obtained patents that will limit, interfere with or eliminate our ability to
make, use and sell atacicept, MAU868, or any future product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or our current or future collaborators or license partners, might not have been the first to make the inventions
covered by the issued patents or patent applications that we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we, or our current or future collaborators or license partners, might be found not have been the first to file patent
applications covering certain of our or their inventions; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">others may independently develop similar or alternative technologies or duplicate any of our technologies without
infringing our intellectual property rights; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that the pending patent applications we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future
or own will not lead to issued patents; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">it is possible that there are prior public disclosures that could invalidate our patents, or parts of our patents, for
which we are not aware; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents that we hold rights to may be held invalid or unenforceable, as a result of legal challenges by our
competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">issued patents may not have sufficient term or geographic scope to provide meaningful protection; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our competitors might conduct research and development activities in countries where we do not have patent rights and then
use the information learned from such activities to develop competitive products for sale in our major commercial markets; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may not develop additional proprietary technologies that are patentable; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the patents of others may have an adverse effect on our business; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">we may choose not to file a patent in order to maintain certain trade secrets, and a third party may subsequently file a
patent covering such intellectual property. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">57 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these events occur, it could significantly harm our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our commercial success depends significantly on our ability to operate without infringing, misappropriating or otherwise violating the patents
and other proprietary rights of third parties. Claims by third parties that we infringe, misappropriate or otherwise violate their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization
efforts. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our commercial success depends in part on avoiding infringement, misappropriation or other violations of the patents and proprietary rights of
third parties. However, our research, development and commercialization activities may be subject to claims that we infringe, misappropriate or otherwise violate patents or other intellectual property rights owned or controlled by third parties. A
finding by a court or administrative body that we infringe the claims of issued patents owned by third parties could preclude us from commercializing atacicept, MAU868, or any future product candidates we may develop. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other entities may have or obtain patents or proprietary rights that could limit our ability to make, use, sell, offer for sale or import atacicept, MAU868, or any
future product candidates we may develop and products that may be approved in the future, or impair our competitive position. There is a substantial amount of litigation, both within and outside the United States, involving patent and other
intellectual property rights in the biotechnology industry, including patent infringement lawsuits, and proceedings, such as oppositions, reexaminations, IPR proceedings and PGR proceedings, before the USPTO and/or corresponding foreign patent
offices. In addition, many companies in intellectual property-dependent industries, including the biotechnology industry, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous third-party
U.S. and foreign issued patents and pending patent applications may exist in the fields in which we are developing atacicept, MAU868, or any future product candidates we may develop. There may be third-party patents or patent applications with
claims to compositions, formulations, methods of manufacture or methods for treatment related to the use or manufacture of atacicept, MAU868, or any future product candidates we may develop. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is possible that one or more organizations will hold patent rights to which we will need a license. If those organizations refuse to grant us a license to such patent
rights on reasonable terms, we may be unable to develop, manufacture, market, sell and commercialize products or services or perform research and development or other activities covered by these patents. In the event that any of these patents were
to issue and be asserted against us, we believe that we would have defenses against any such assertion, including that such patents are not valid. However, if such defenses to such assertion were unsuccessful, we could be liable for damages, which
could be significant and include treble damages and attorneys&#146; fees if we are found to willfully infringe such patents. We could also be required to obtain a license to such patents, which may not be available on commercially reasonable terms
or at all. If we are unable to obtain such a license, we could be precluded from commercializing any product candidates that were ultimately held to infringe such patents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As the biotechnology industry expands and more patents are issued, the risk increases that atacicept, MAU868, or any future product candidates we may develop, may be
subject to claims of infringement of the patent rights of third parties. Because patent applications are maintained as confidential for a certain period of time, until the relevant application is published, we may be unaware of third-party patents
that may be infringed by commercialization of atacicept, MAU868, or any future product candidates we may develop, and we cannot be certain that we were the first to file a patent application related to a product candidate or technology. Moreover,
because patent applications can take many years to issue, there may be currently-pending patent applications that may later result in issued patents that atacicept, MAU868, or any future product candidates we may develop may infringe. In addition,
identification of third-party patent rights that may be relevant to our technology is difficult because patent searching is imperfect due to differences in terminology among patents, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">58 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
incomplete databases and the difficulty in assessing the meaning of patent claims. There is also no assurance that there is not prior art of which we are aware, but which we do not believe is
relevant to our business, which may, nonetheless, ultimately be found to limit our ability to make, use, sell, offer for sale or import our products that may be approved in the future, or impair our competitive position. In addition, third parties
may obtain patents in the future and claim that use of our technologies infringes upon these patents. Still further, we cannot rely on our experience that third parties have not so far alleged that we infringe their patent rights, as provisions of
U.S. patent laws provide a safe harbor from patent infringement for therapeutic products under clinical development. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any claims of patent infringement,
misappropriation or other violations asserted by third parties would be time consuming and could: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">result in costly litigation that may cause negative publicity; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">divert the time and attention of our technical personnel and management; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cause development delays; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prevent us from commercializing atacicept, MAU868, or any future product candidates we may develop; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require us to develop <FONT STYLE="white-space:nowrap">non-infringing</FONT> technology, which may not be possible on a
cost-effective basis; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">subject us to significant liability to third parties; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require us to enter into royalty or licensing agreements, which may not be available on commercially reasonable terms, or
at all, or which might be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> which could result in our competitors gaining access to the same technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any patent-related legal action against us claiming damages or seeking to enjoin commercial activities relating to our products, or processes could subject us to
significant liability for damages, including treble damages if we were determined to willfully infringe, and require us to obtain a license to manufacture or market atacicept, MAU868, or any future product candidates we may develop. Defense of these
claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions or that any license required
under any of these patents would be made available on commercially acceptable terms, if at all. Moreover, even if we or a future strategic partner were able to obtain a license, the rights may be nonexclusive, which could result in our competitors
gaining access to the same intellectual property. In addition, we cannot be certain that we could redesign atacicept, MAU868, or any future product candidates we may develop processes to avoid infringement, if necessary. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An adverse determination in a judicial or administrative proceeding, or the failure to obtain necessary licenses, could prevent us from developing and commercializing
atacicept, MAU868, or any future product candidates we may develop, which could significantly harm our business, financial condition and operating results. In addition, intellectual property litigation, regardless of its outcome, may cause negative
publicity and could prohibit us from marketing or otherwise commercializing atacicept, MAU868, and future product candidates and technologies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Parties making claims
against us may be able to sustain the costs of complex patent litigation more effectively than we can. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or administrative
proceedings, there is a risk that some of our confidential information could be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to
raise additional funds or otherwise significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">59 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may not be successful in obtaining or maintaining necessary rights from third parties that we identify as
necessary for future product candidates we may develop through acquisitions and <FONT STYLE="white-space:nowrap">in-licenses.</FONT> </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because our development
programs may in the future require the use of proprietary rights held by third parties, the growth of our business may depend in part on our ability to acquire, <FONT STYLE="white-space:nowrap">in-license,</FONT> or use these third-party proprietary
rights. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we may have <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents that cover atacicept and MAU868, it is possible that third parties may have
blocking patents that prevent us from marketing, manufacturing or commercializing our patented products and practicing our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patented technology. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may be unsuccessful in acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> compositions, methods of use, processes, or other intellectual property
rights from third parties that we identify as necessary for practicing inventions claimed by our patents, including the manufacture, sale and use of atacicept, MAU868, and any future product candidates we may develop. The licensing and acquisition
of third-party intellectual property rights is a competitive area, and a number of more established companies may pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These
established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to
assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain
rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could significantly harm our business,
financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be involved in lawsuits to protect or enforce our patents, which could be expensive, time
consuming and unsuccessful. Further, our issued patents could be found invalid or unenforceable if challenged in court. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Competitors or other third parties
may infringe, misappropriate or otherwise violate our intellectual property rights. To prevent infringement or unauthorized use, we may be required to file infringement or other intellectual property claims, which can be expensive and
time-consuming. In addition, in a patent infringement proceeding, a court may decide that a patent we may <FONT STYLE="white-space:nowrap">in-license</FONT> in the future or own is not valid, is unenforceable, and/or is not infringed, or may refuse
to stop the other party from using the technology at issue on the grounds that our owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents do not cover the technology in question. If we or any of our potential future collaborators were
to initiate legal proceedings against a third party to enforce a patent directed at atacicept, MAU868, or any future product candidates we may develop, the defendant could counterclaim that our patent is invalid and/or unenforceable in whole or in
part. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge include an alleged failure to meet any of several statutory requirements,
including lack of novelty, obviousness, written description, <FONT STYLE="white-space:nowrap">non-enablement,</FONT> or obviousness-type double patenting. Grounds for an unenforceability assertion could include an allegation that someone connected
with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a defendant were to prevail on a
legal assertion of invalidity and/or unenforceability, we may lose at least part, and perhaps all, of the patent protection on such product candidate. In addition, if the breadth or strength of protection provided by our patents and patent
applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. Such a loss of patent protection would significantly harm our business, financial
condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">60 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights,
particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license on commercially reasonable terms. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if resolved in our favor, litigation or other legal proceedings relating to our intellectual property rights may cause us to incur significant expenses, and could
distract our technical and management personnel from their normal responsibilities. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales,
marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Our competitors may be able to sustain the costs of such litigation or proceedings more effectively
than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other legal proceedings relating to our
intellectual property rights, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the course of any intellectual property litigation, there could be public announcements of the initiation of the litigation as well as results of
hearings, rulings on motions, and other interim proceedings in the litigation. If securities analysts or investors regard these announcements as negative, the perceived value of our existing products, programs or intellectual property could be
diminished. Accordingly, the market price of shares of our Class&nbsp;A common stock may decline. Such announcements could also harm our reputation or the market for our future products, which could significantly harm our business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may
require us to cease using the related technology or to attempt to license rights from the prevailing party. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Derivation proceedings provoked by third parties
or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to
license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of derivation proceedings may fail and, even if successful, may result in
substantial costs and distract our management and other employees. In addition, the uncertainties associated with such proceedings could have an adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our
research programs, license necessary technology from third parties or enter into development or manufacturing partnerships that would help us bring atacicept, MAU868, or any future product candidates to market. Should any of these events occur, it
could significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">61 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent
applications and the enforcement or defense of our patents. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As is the case with other biotechnology companies, our success is heavily dependent on
intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve a high degree of technological and legal complexity. Therefore, obtaining and enforcing biopharmaceutical patents is costly, time
consuming and inherently uncertain. Our ability to obtain patents is highly uncertain because, to date, some legal principles remain unresolved, and there has not been a consistent policy regarding the breadth or interpretation of claims allowed in
patents in the United States. Furthermore, the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific, and factual
issues. Changes in either patent laws or interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, the United States has enacted and implemented wide-ranging patent reform legislation and the U.S. Supreme Court has ruled on several patent cases in recent
years, either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the
future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the U.S. federal courts, the USPTO, or similar authorities in foreign jurisdictions, the
laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patent and the patents we might obtain or license in the future. An inability to obtain,
enforce, and defend patents covering our proprietary technologies (including atacicept and MAU868) would adversely affect our business prospects and financial condition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, changes in patent laws and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the
relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we may obtain in the future. Further, the laws of some foreign countries do not protect proprietary rights to
the same extent or in the same manner as the laws of the United States and Europe. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. For example, if the
issuance in a given country of a patent covering an invention is not followed by the issuance in other countries of patents covering the same invention, or if any judicial interpretation of the validity, enforceability or scope of the claims or the
written description or enablement, in a patent issued in one country is not similar to the interpretation given to the corresponding patent issued in another country, our ability to protect our intellectual property in those countries may be
limited. Changes in either patent laws or in interpretations of patent laws in the United States and other countries may materially diminish the value of our intellectual property or narrow the scope of our patent protection. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">It is possible that we do not transfer or perfect ownership of all patents, patent applications or other intellectual property. This possibility includes the risk that
we do not identify all inventors, or identify incorrect inventors, which may lead to claims disputing inventorship or ownership of our patents, patent applications or other intellectual property by former employees or other third parties. There is
also a risk that we do not establish an unbroken chain of title from inventors to us. Errors in inventorship or ownership can sometimes also impact priority claims. If we were to lose ability to claim priority for certain patent filings, intervening
art or other events may preclude us from issuing patents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">62 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail
in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights. Such an outcome could significantly harm our business, financial condition, results of operations and prospects. Even if we are
successful in defending against such claims, litigation could result in substantial costs and distraction to management and other employees. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may
be inadequate to protect our competitive position on atacicept, MAU868, or any future product candidates we may develop for an adequate amount of time. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patents have a limited lifespan. Generally, issued patents are granted a term of 20 years from the earliest claimed
<FONT STYLE="white-space:nowrap">non-provisional</FONT> filing date. Various extensions may be available, but there can be no assurance that any such extensions will be obtained, and the life of a patent, and the protection it affords, is limited.
In certain instances, patent term can be adjusted to recapture a portion of delay by the USPTO in examining the patent application (patent term adjustment) or extended to account for term effectively lost as a result of the FDA regulatory review
period (patent term extension), or both. There is a risk that we may take action that detracts from any accrued patent term adjustment. Even if patents covering atacicept, MAU868, or any future product candidates we may develop are obtained, once
the patent life has expired, we may be open to competition from competitive products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire
before or shortly after such candidates are commercialized. As a result, our patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our earliest <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents may expire before, or soon after, our first product achieves marketing approval in the United
States or foreign jurisdictions. Upon the expiration of our current patents, we may lose the right to exclude others from practicing these inventions. The expiration of these patents could also have a similar material adverse effect on our business,
financial condition, prospects and results of operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Any of the foregoing could significantly harm our business, financial condition, results of operations and
prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time, and if we do not obtain
protection under the Hatch-Waxman Amendments and similar <FONT STYLE="white-space:nowrap">non-United</FONT> States legislation for extending the term of patents covering each of our product candidates, our business may be significantly harmed.
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might
expire before or shortly after such candidates are commercialized. Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, one or more of our United States patents may be eligible for limited patent
term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments, and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years
for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. A patent term extension cannot extend the remaining term of a patent beyond a total of 14
years from the date of product approval. Only one patent may be extended per approved drug product, and only those claims covering the approved drug product, a method for using it, or a method for manufacturing it may be extended. However, we may
not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we
request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be impacted and our
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">63 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
competitors may obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced and could have a material adverse effect on our business.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We will not be able to protect our intellectual property rights throughout the world. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Filing, prosecuting and defending patents in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries
outside the United States may be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States.
Consequently, we will not be able to prevent third parties from practicing our inventions in all countries outside the United States or from selling or importing products made using our inventions in and into the United States or other
jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection,
but enforcement is not as strong as that in the United States. These infringing products may compete with atacicept, MAU868, or any future product candidates we may develop, without any available recourse. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The laws of some other countries do not protect intellectual property rights to the same extent as the laws of the United States. Patent protection must ultimately be
sought on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis, which is an expensive and time-consuming process with uncertain outcomes. Accordingly, we may choose not to seek patent protection
in certain countries, and we will not have the benefit of patent protection in such countries. In addition, the legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual
property protection, especially those relating to biopharmaceuticals. As a result, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. Because the legal systems of
many foreign countries do not favor the enforcement of patents and other intellectual property protection, particularly those relating to biopharmaceutical products, it could be difficult for us to stop the infringement, misappropriation or
violation of our patents or our licensors&#146; patents or marketing of competing products in violation of our proprietary rights. Proceedings to enforce our intellectual property and other proprietary rights in foreign jurisdictions could result in
substantial costs and divert our efforts and attention from other aspects of our business, could put our patents or the patents of our licensors at risk of being invalidated or interpreted narrowly, could put our patent applications or the patent
applications of our licensors at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially
meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the
enforceability of patents against government agencies or<I> </I>government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we are forced to grant a license to
third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be significantly harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, recordation of licenses with respect to exclusively licensed patent rights outside of the United States is potentially costly and we might fail to record
such rights timely. If we fail to timely record our patent rights, third parties may try to seek licenses from the patent owners, or we may not be able to recover full damages for patent infringement in jurisdictions where we have no such
recordations, any of which could significantly harm our business, financial condition, results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">64 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee
payment, and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these requirements. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to the USPTO and various foreign
patent offices at various points over the lifetime of our patents and/or patent applications. We have systems in place to remind us to pay these fees, and we rely on our outside patent annuity service to pay these fees when due. Additionally, the
USPTO and various foreign patent offices require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us
comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with rules applicable to the particular jurisdiction. However, there are situations in which noncompliance can result in
abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If such an event were to occur, potential competitors might be able to enter the market with similar or
identical products or technology, which could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If our trademarks and
trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business, financial condition, results of operations and prospects could be significantly harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to use registered or unregistered trademarks or trade names to brand and market ourselves and our products. Our trademarks or trade names may be challenged,
infringed, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in
our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or
trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition
based on our trademarks and trade names, then we may not be able to compete effectively, and our business, financial condition, results of operations and prospects may be significantly harmed. Our efforts to enforce or protect our proprietary rights
related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could significantly harm our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, any proprietary name we propose to use with our current or future products in the United States must be approved by the
FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA
objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the
existing rights of third parties and be acceptable to the FDA. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we are unable to protect the confidentiality of our trade secrets, our business, financial
condition, results of operations, prospects and competitive position would be significantly harmed. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, we rely on the protection of our trade
secrets, including unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> technology and other proprietary information to maintain our competitive position. Although we have taken steps to protect
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">65 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
our trade secrets and unpatented <FONT STYLE="white-space:nowrap">know-how,</FONT> including entering into confidentiality agreements with third parties, and confidential information and
inventions agreements with employees, consultants and advisors, we cannot guarantee<I> </I>that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology or processes.
Further, we cannot provide any assurances that all such agreements have been duly executed, and any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, or claim ownership in intellectual
property that we believe is owned or <FONT STYLE="white-space:nowrap">in-licensed</FONT> by us. Monitoring unauthorized uses and disclosures of our intellectual property is difficult, and we do not know whether the steps we have taken to protect our
intellectual property will be effective. In addition, we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming,
and the outcome is unpredictable. In addition, some courts inside and outside the United States are less willing or unwilling to protect trade secrets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, if
any of our trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them from using that technology or information to compete with us. If any of these events occurs
or if we otherwise lose protection for our trade secrets, the value of this information may be greatly reduced, and our competitive position would be harmed. If we do not apply for patent protection prior to such publication or if we cannot
otherwise maintain the confidentiality of our proprietary technology and other confidential information, then our ability to obtain patent protection or to protect our trade secret information may be jeopardized. Any of the foregoing could
significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to claims that we or our employees have
wrongfully used or disclosed alleged confidential information or trade secrets. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into and may enter in the future into <FONT
STYLE="white-space:nowrap">non-disclosure</FONT> and confidentiality agreements to protect the proprietary positions of third parties, such as outside scientific collaborators, CROs, third-party manufacturers, consultants, advisors, potential
partners, lessees of shared multi-company property and other third parties. Many of our employees and consultants were previously employed at, or may have previously provided or may be currently providing consulting services to, other biotechnology
companies, including our competitors or potential competitors. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, collaborators and other third parties with whom we do
business include provisions requiring such parties to assign rights in inventions to us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential
information of our employees&#146; former employers or other third parties. We may also be subject to claims that former employers or other third parties have an ownership interest in our future patents or patent applications. Defense of such
matters, regardless of their merit, could involve substantial litigation expense and be a substantial diversion of employee resources from our business. We cannot predict whether we would prevail in any such actions. Moreover, intellectual property
litigation, regardless of its outcome, may cause negative publicity and could prohibit us from marketing or otherwise commercializing atacicept, MAU868, or any future product candidates or technologies we may develop. Failure to defend against any
such claim could subject us to significant liability for monetary damages or prevent or delay our developmental and commercialization efforts, and cause us to lose valuable intellectual property rights or personnel, which could significantly harm
our business, financial condition, results of operations and prospects. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to our management team and other employees. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Parties making claims against us may be able to sustain the costs of complex intellectual property litigation more effectively than we can. Furthermore, because of the
substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">66 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
be compromised by disclosure. In addition, any uncertainties resulting from the initiation and continuation of any litigation could have an adverse effect on our ability to raise additional funds
or otherwise significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our rights to develop and commercialize our technology
and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may enter into license agreements in the
future with others to advance our research or allow commercialization of our product candidates. These and other licenses may not provide exclusive rights to use such intellectual property and technology in all relevant fields of use and in all
territories in which we may wish to develop or commercialize our technology and products in the future. As a result, we may not be able to<I> </I>prevent competitors from developing and commercializing competitive products in territories included in
our licenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we fail to comply with our obligations under any such license agreements, including obligations to make various milestone payments and royalty
payments and other obligations, the licensor may have the right to terminate the license. If these agreements are terminated, we could lose intellectual property rights that are important to our business, be liable for any damages to such licensors
or be prevented from developing and commercializing our product candidates, and competitors could have the freedom to seek regulatory approval of, and to market, products identical to ours. Termination of these agreements or reduction or elimination
of our rights under these agreements may also result in our being required to negotiate new or reinstated agreements with less favorable terms, cause us to lose our rights under these agreements, including our rights to important intellectual
property or technology, or impede, delay or prohibit the further development or commercialization of one or more product candidates that rely on such agreements. It is possible that we may be unable to obtain any additional licenses at a reasonable
cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to redesign our product candidates or the methods for manufacturing them or to develop or license replacement technology, all of which
may not be feasible on a technical or commercial basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, subject to the terms of any such license agreements, we may not have the right to control the
preparation, filing, prosecution, maintenance, enforcement and defense of patents and patent applications covering the technology that we license from third parties. In such an event, we cannot be certain that these patents and patent applications
will be prepared, filed, prosecuted, maintained, enforced and defended in a manner consistent with the best interests of our business, including the payment of all applicable fees for patents covering our product candidates. If our licensors fail to
prosecute, maintain, enforce and defend such patents, or lose rights to those patents or patent applications, the rights we have licensed may be reduced or eliminated, and our right to develop and commercialize any of our products that are subject
of such licensed rights could be adversely affected. Further, we may not be able to prevent competitors from making, using and selling competing products. In addition, even where we have the right to control the prosecution of patents and patent
applications we have licensed to and from third parties, we may still be adversely affected or prejudiced by the actions or inactions of our licensees, our licensors and their counsel that took place prior to the date upon which we assumed control
over patent prosecution. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our licensors may have relied on third party consultants or collaborators or on funds from third parties such that our licensors are not
the sole and exclusive owners of the patents we <FONT STYLE="white-space:nowrap">in-licensed.</FONT> If other third parties have ownership rights to our <FONT STYLE="white-space:nowrap">in-licensed</FONT> patents, they may be able to license such
patents to our competitors, and our competitors could market competing products and technology. This could have an adverse effect on our competitive position, business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may need to obtain additional licenses from existing licensors and others to advance our research or allow commercialization of product candidates we develop. It is
possible that we may be unable to obtain additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">67 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
licenses at a reasonable cost or on reasonable terms, if at all. Even if we are able to obtain a license, it may be <FONT STYLE="white-space:nowrap">non-exclusive,</FONT> thereby giving our
competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to redesign our technology, product candidates, or the methods for manufacturing them or to develop or license
replacement technology, all of which may not be feasible on a technical or commercial basis. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could significantly harm our business,
financial condition, results of operations and prospects significantly. We cannot provide any assurances that third party patents do not exist which might be enforced against our current technology, manufacturing methods, product candidates, or
future methods or products resulting in either an injunction prohibiting our manufacture or future sales, or, with respect to our future sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties, which
could be significant. Should any of these events occur, it could significantly harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If
we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that
are important to our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Disputes may arise between us and our past, current or future licensors regarding intellectual property subject to a license
agreement, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of rights granted under the license agreement and other interpretation-related issues; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not
subject to the licensing agreement; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to sublicense patents and other rights to third parties; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our diligence obligations under the license agreement and what activities satisfy those diligence obligations;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our right to transfer or assign the license; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the inventorship and ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> resulting from the joint
creation or use of intellectual property by our licensors and us and our partners; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the priority of invention of patented technology. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the agreements under which we license intellectual property or technology from third parties are complex, and certain provisions in such agreements may be
susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could narrow what we believe to be the scope of our rights to the relevant intellectual property or technology, or increase what we
believe to be our financial or other obligations under the relevant agreement, either of which could significantly harm our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we
have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates, which could significantly harm
our business, financial condition and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In spite of our best efforts, our licensors might conclude that we have materially breached our license agreements
and might therefore terminate the license agreements, thereby removing our ability to develop and commercialize products and technology covered by these license agreements. If these <FONT STYLE="white-space:nowrap">in-licenses</FONT> are terminated,
or if the underlying patents fail to provide the intended exclusivity, competitors would have the freedom to seek regulatory approval of, and to market, products identical to ours. This could significantly harm our competitive position, business,
financial condition and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">68 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Intellectual property discovered through government funded programs may be subject to federal regulations such
as <FONT STYLE="white-space:nowrap">&#147;march-in&#148;</FONT> rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> manufacturers. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may develop, acquire, or license intellectual property rights that have been generated through
the use of U.S. government funding or grants. Pursuant to the Bayh-Dole Act of 1980, the U.S. government has certain rights in inventions developed with government funding. These U.S. government rights include a
<FONT STYLE="white-space:nowrap">non-exclusive,</FONT> <FONT STYLE="white-space:nowrap">non-transferable,</FONT> irrevocable worldwide license to use inventions for any governmental purpose. In addition, the U.S. government has the right, under
certain limited circumstances, to require us to grant exclusive, partially exclusive, or <FONT STYLE="white-space:nowrap">non-exclusive</FONT> licenses to any of these inventions to a third party if it determines that: (1)&nbsp;adequate steps have
not been taken to commercialize the invention; (2)&nbsp;government action is necessary to meet public health or safety needs; or (3)&nbsp;government action is necessary to meet requirements for public use under federal regulations (also referred to
as <FONT STYLE="white-space:nowrap">&#147;march-in</FONT> rights&#148;). If the U.S. government exercised its <FONT STYLE="white-space:nowrap">march-in</FONT> rights in our future intellectual property rights that are generated through the use of
U.S. government funding or grants, we could be forced to license or sublicense intellectual property developed by us or that we license on terms unfavorable to us, and there can be no assurance that we would receive compensation from the U.S.
government for the exercise of such rights. The U.S. government also has the right to take title to these inventions if the grant recipient fails to disclose the invention to the government or fails to file an application to register the
intellectual property within specified time limits. Intellectual property generated under a government funded program is also subject to certain reporting requirements, compliance with which may require us to expend substantial resources. In
addition, the U.S. government requires that any products embodying any of these inventions or produced through the use of any of these inventions be manufactured substantially in the United States. This preference for U.S. industry may be waived by
the federal agency that<I> </I>provided the funding if the owner or assignee of the intellectual property can show that reasonable but unsuccessful efforts have been made to grant licenses on similar terms to potential licensees that would be likely
to manufacture substantially in the United States or that under the circumstances domestic manufacture is not commercially feasible. This preference for U.S. industry may limit our ability to contract with
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> product manufacturers for products covered by such intellectual property. Any exercise by the government of any of the foregoing rights could harm our competitive position, business, financial
condition, results of operations and prospects. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to our dependence on third parties </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We rely, and expect to continue to rely, on third parties, including independent clinical investigators and CROs, to conduct certain aspects of our nonclinical
studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlines, we may not be able to obtain regulatory approval for or
commercialize atacicept, MAU868 or future product candidates we may develop and our business, financial condition, results of operations and prospects could be significantly harmed. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have relied upon and plan to continue to rely upon third parties, including independent clinical investigators and third-party CROs, to conduct certain aspects of our
nonclinical studies and clinical trials and to monitor and manage data for our ongoing nonclinical and clinical programs. We rely on these parties for execution of our nonclinical studies and clinical trials, and control only certain aspects of
their activities. Nevertheless, we are responsible for ensuring that each of our studies and trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not
relieve us of our regulatory responsibilities. We and our third-party contractors and CROs are required to comply with GCP requirements, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">69 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
authorities for atacicept and MAU868 in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If
we or any of these third parties or our CROs fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform
additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP regulations.
In addition, our clinical trials must be conducted with product produced under cGMP regulations. Failure to comply and maintain adequate documentation with these regulations may require us to repeat clinical trials, which would delay the regulatory
approval process. Moreover, our business may be adversely affected if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, these investigators and CROs are not our employees and we will not be able to control, other than by contract, the amount of resources, including time, which
they devote to atacicept or MAU868 and clinical trials. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development
activities, which could affect their performance on our behalf. If independent investigators or CROs fail to devote sufficient resources to the development of atacicept or MAU868, or if CROs do not successfully carry out their contractual duties or
obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons,
our clinical trials may be extended, delayed or terminated and we may not be able to obtain regulatory approval for or successfully commercialize atacicept or MAU868. As a result, our results of operations and the commercial prospects for atacicept
and MAU868 would be harmed, our costs could increase and our ability to generate revenues could be delayed or precluded entirely, and our business, financial condition, results of operations and prospects could be significantly harmed. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our CROs have the right to terminate their agreements with us in the event of an uncured material breach. In addition, some of our CROs have an ability to terminate
their respective agreements with us if it can be reasonably demonstrated that the safety of the subjects participating in our clinical trials warrants such termination, if we make a general assignment for the benefit of our creditors or if we are
liquidated. In addition, our CROs could fail to perform, we could terminate their agreements or they could go out of business. If our relationships with our CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so
on commercially reasonable terms. Switching or adding CROs involves substantial cost and requires management time and focus, and could delay development and commercialization of atacicept, MAU868 or any future product candidate we may develop. In
addition,<I> </I>there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our
relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business and financial condition. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and government measures taken in response have also had a significant impact on our CROs, and we expect
that they will face further disruption which may affect our ability to initiate and complete our nonclinical studies and clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If any of our
relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves additional cost and requires management
time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Additionally, CROs may lack the
capacity to absorb higher workloads or take on additional capacity to support our needs. There can be no assurance that we will </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">70 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
not encounter challenges or delays with CROs in the future or that these delays or challenges will not significantly harm our business, financial condition, results of operations and prospects.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to obtaining the rights to MAU868 from Amplyx, third parties had been responsible for all development activities. Although we believe the historical
development activities were conducted in accordance with applicable rules and regulations in material respects, we cannot assure you that we will not discover inaccuracies or noncompliance in prior development activities that have an adverse effect
on the future development of MAU868. For example, a regulatory authority may choose to inspect an investigational site and/or vendor such as a CRO for an MAU868 study that was previously conducted by Amplyx. Findings from such inspections could have
an impact on the review of any future marketing applications by the FDA or foreign regulatory authorities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with our acquisition of MAU868, we have
assumed the responsibility for ongoing clinical studies with MAU868, including related expenses and manufacturing and regulatory activities, which were previously managed and funded by Amplyx. This includes responsibility for the ongoing Phase 2
clinical trial of MAU868 for the treatment of BKV infection in kidney transplant recipients previously conducted by Amplyx. Any adverse events or reactions experienced by subjects in the trial may be attributed to MAU868 and may limit our ability to
obtain regulatory approval with labeling that we consider desirable, or at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We contract with third parties for the manufacture of atacicept for our
ongoing clinical trials, and expect to continue to do so for additional clinical trials of our product candidates and ultimately for commercialization. This reliance on third parties increases the risk that we will not have sufficient quantities of
atacicept, MAU868 or other product candidates necessary for the development or commercialization of atacicept, MAU868 or such other product candidates or such quantities at an acceptable cost, which could delay, prevent or impair our development or
commercialization efforts. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not currently have the infrastructure or internal capability to manufacture supplies of our product candidates for use in
development and commercialization. We rely, and expect to continue to rely, on third-party manufacturers for the production of our product candidates for clinical trials under the guidance of members of our organization. We do not have long-term
supply agreements for atacicept or MAU868. Furthermore, the raw materials for our product candidates are sourced, in some cases, from a single-source supplier. If we were to experience an unexpected loss of supply of our product candidates for any
reason, whether as a result of manufacturing, supply or storage issues or otherwise, we could experience delays, disruptions, suspensions or terminations of, or be required to restart or repeat, any pending or ongoing clinical trials. For example,
the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic impacts our ability to procure sufficient supplies for the development of our product candidates in the future will depend on the severity and duration of the spread
of the virus, and the actions undertaken to contain <FONT STYLE="white-space:nowrap">COVID-19</FONT> or treat its effects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to continue to rely on
third-party manufacturers for the commercial supply of our product candidates, if we obtain marketing approval. We may be unable to maintain or establish required agreements with third-party manufacturers or to do so on acceptable terms. Even if we
are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of the third party to manufacture our product candidates according to our schedule, or at all, including if our
third-party contractors give greater priority to the supply of other products over our product candidates or otherwise do not satisfactorily perform according to the terms of the agreements between us and them; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disruptions resulting from the impact of public health pandemics or epidemics (including, for example, the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic); </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">71 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the reduction or termination of production or deliveries by suppliers, or the raising of prices or renegotiation of terms;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the termination or nonrenewal of arrangements or agreements by our third-party contractors at a time that is costly or
inconvenient for us; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the breach by the third-party contractors of our agreements with them; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of third-party contractors to comply with applicable regulatory requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the failure of the third party to manufacture our product candidates according to our specifications;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the mislabeling of clinical supplies, potentially resulting in the wrong dose amounts being supplied or active drug or
placebo not being properly identified; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">clinical supplies not being delivered to clinical sites on time, leading to clinical trial interruptions, or of drug
supplies not being distributed to commercial vendors in a timely manner, resulting in lost sales; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the misappropriation of our proprietary information, including our trade secrets and
<FONT STYLE="white-space:nowrap">know-how.</FONT> </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not have control over all aspects of the manufacturing process of, and are dependent on,
our contract manufacturing partners for compliance with cGMP regulations for manufacturing both active drug substances and finished drug products. Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory
requirements outside of the United States. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or
maintain marketing approval for their manufacturing facilities. In addition, we do not have control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a
comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates, or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would
significantly impact our ability to develop, obtain marketing approval for or market our product candidates, if approved. Our failure, or the failure of our third-party manufacturers, to comply with applicable regulations could result in sanctions
being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or drugs, operating restrictions and criminal prosecutions, any of which
could significantly and adversely affect supplies of our product candidates or other drugs necessary for the development or commercialization of our product candidates and significantly harm our business, financial condition, results of operations
and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, if the third-party providers of therapies or therapies in development used in combination with our product candidates are unable to
produce sufficient quantities for clinical trials or for commercialization of our product candidates, or if the cost of combination therapies are prohibitive, our development and commercialization efforts would be impaired, which would significantly
harm our business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our current and anticipated future dependence upon others for the manufacture of our
product candidates or other drugs necessary for the development or commercialization of our product candidates may adversely affect our future profit margins and our ability to commercialize any product candidates that receive marketing approval on
a timely and competitive basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">72 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The manufacture of drugs is complex and our third-party manufacturers may encounter difficulties in production.
If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our product for patients, if approved, could be delayed or prevented. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturing drugs, especially in large quantities, is complex and may require the use of innovative technologies. Each lot of an approved drug product must undergo
thorough testing for identity, strength, quality, purity and potency. Manufacturing drugs requires facilities specifically designed for and validated for this purpose, and sophisticated quality assurance and quality control procedures are necessary.
Slight deviations anywhere in the manufacturing process, including filling, labeling, packaging, storage and shipping and quality control and testing, may result in lot failures, product recalls or spoilage. When changes are made to the
manufacturing process, we may be required to provide nonclinical and clinical data showing the comparable identity, strength, quality, purity or potency of the products before and after such changes. If microbial, viral or other contaminations are
discovered at the facilities of our manufacturer, such facilities may need to be closed for an extended period of time to investigate and remedy the contamination, which could delay clinical trials and significantly harm our business, financial
condition, results of operations and prospects. The use of biologically derived ingredients can also lead to allegations of harm, including infections or allergic reactions, or closure of product facilities due to possible contamination. If our
manufacturers are unable to produce sufficient quantities for clinical trials or for commercialization as a result of these challenges, or otherwise, our development and commercialization efforts would be impaired, which would significantly harm our
business, financial condition, results of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we engage in future acquisitions or strategic partnerships, this may increase our
capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we
may evaluate various acquisition opportunities and strategic partnerships, including licensing or acquiring complementary products, intellectual property rights, technologies or businesses. Any potential acquisition or strategic partnership may
entail numerous risks, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased operating expenses and cash requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the assumption of contingent liabilities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the issuance of our equity securities; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">assimilation of operations, intellectual property and products of an acquired company, including difficulties associated
with integrating new personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the diversion of our management&#146;s attention from our existing programs and initiatives in pursuing such a strategic
merger or acquisition; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">retention of key employees, the loss of key personnel and uncertainties in our ability to maintain key business
relationships; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">risks and uncertainties associated with the other party to such a transaction, including the prospects of that party and
their existing products or product candidates and marketing approvals; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our inability to generate revenue from acquired technology and/or products sufficient to meet our objectives in undertaking
the acquisition or even to offset the associated acquisition and maintenance costs. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, if we undertake acquisitions or pursue
partnerships in the future, we may issue dilutive securities, assume or incur debt obligations, incur large <FONT STYLE="white-space:nowrap">one-time</FONT> expenses and acquire intangible assets that could result
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">73 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
in significant future amortization expense. Moreover, we may not be able to locate suitable acquisition opportunities, and this inability could impair our ability to grow or obtain access to
technology or products that may be important to the development of our business. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may enter into collaborations with third parties for the development and
commercialization of our product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of atacicept or MAU868. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the future, we may partner with third-party collaborators for the development and commercialization of our product candidates. Our likely collaborators for any future
collaboration arrangements would likely include large and <FONT STYLE="white-space:nowrap">mid-size</FONT> pharmaceutical companies, regional and national pharmaceutical companies and biotechnology companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will likely have limited control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of our product
candidates. Our ability to generate revenues from these arrangements will depend on our collaborators&#146; abilities and efforts to successfully perform the functions assigned to them in these arrangements. Collaborations involving our product
candidates could pose numerous risks to us, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators have significant discretion in determining the efforts and resources that they will apply to these
collaborations and may not perform their obligations as expected; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may deemphasize or not pursue development and commercialization of our product candidates or may elect not to
continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators&#146; strategic focus, including as a result of a sale or disposition of a business unit or development function, or available
funding or external factors such as an acquisition that diverts resources or creates competing priorities; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial
or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with
our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a collaborator with marketing and distribution rights to multiple products may not commit sufficient resources to the
marketing and distribution of our product relative to other products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborators may not properly obtain, maintain, defend or enforce our intellectual property rights or may use our
proprietary information and intellectual property in such a way as to invite litigation or other intellectual property related proceedings that could jeopardize or invalidate our proprietary information and intellectual property or expose us to
potential litigation or other intellectual property related proceedings; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">disputes may arise between the collaborators and us that result in the delay or termination of the research, development or
commercialization of our product candidates or that result in costly litigation or arbitration that diverts management attention and resources; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaborations may be terminated and, if terminated, may result in a need for additional capital to pursue further
development or commercialization of the applicable product candidates; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">74 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">collaboration agreements may not lead to development or commercialization of product candidates in the most efficient
manner or at all; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our drug
development or commercialization program could be delayed, diminished or terminated. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If we decide to establish collaborations in the future,
but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
drug development programs and the potential commercialization of our current or any future product candidates we may develop will require substantial additional cash to fund expenses. We may continue to seek to selectively form collaborations to
expand our capabilities, potentially accelerate research and development activities and provide for commercialization activities by third parties. Any of these relationships may require us to incur
<FONT STYLE="white-space:nowrap">non-recurring</FONT> and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If we seek collaborations in the future, we will face significant competition in seeking appropriate collaborators and the negotiation process is time-consuming and
complex. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#146;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed
collaborator&#146;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or comparable foreign regulatory authorities, the potential market for the subject
product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing drugs, the existence of uncertainty with respect to our ownership of intellectual property and industry and
market conditions generally. The potential collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such collaboration could be more attractive than the
one with us for our product candidates. Further, we may not be successful in our efforts to establish a collaboration or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of
development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, there
have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators. Even if we are successful in entering into a collaboration, the terms and
conditions of that collaboration may restrict us from entering into future agreements on certain terms with potential collaborators. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If and when we seek to enter
into additional collaborations, we may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of a product candidate, reduce or delay its
development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization
activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we
do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">75 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Risks related to this offering and the ownership of our Class&nbsp;A common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>An active, liquid and orderly trading market for our Class&nbsp;A common stock may not be developed or sustained. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to the closing of our IPO in May 2021, no public market for shares of our Class&nbsp;A common stock existed. The trading market for our Class&nbsp;A common stock
on the Nasdaq Global Market has been limited and an active trading market for our Class&nbsp;A common stock may never develop or be sustained. The lack of an active market may impair your ability to sell your shares at the time you wish to sell them
or at a price that you consider reasonable. The lack of an active market may also reduce the fair market value of your shares. Furthermore, an inactive market may also impair our ability to raise capital by selling shares of our Class&nbsp;A common
stock and may impair our ability to enter into strategic collaborations or acquire companies, technologies or other assets by using our shares of Class&nbsp;A common stock as consideration. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The price of our Class&nbsp;A common stock may be volatile, and you could lose all or part of your investment. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading price of our Class&nbsp;A common stock has been, and is likely to be, highly volatile and subject to wide fluctuations in response to various factors, some
of which we cannot control. For example, the closing price of our Class&nbsp;A common stock since its trading began on May&nbsp;14, 2021, to December&nbsp;31, 2021, has ranged from a low of $11.30 to a high of $37.11. The stock market in general,
and pharmaceutical and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Broad market and industry factors may negatively affect the market price of our Class&nbsp;A common stock, regardless of our actual operating performance. In addition to
the factors discussed in this &#147;Risk factors&#148; section and elsewhere in this prospectus, these factors include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and results of nonclinical studies and clinical trials of our current or any future product candidates we may
develop or those of our competitors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory actions with respect to our product candidate or our competitors&#146; products; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures,
collaborations or capital commitments; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of competitive products or announcements by potential competitors of their product development efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments associated with our license with Ares, an affiliate of Merck KGaA, Darmstadt, Germany, including any
termination or other change in our relationship with Ares or Merck KGaA, Darmstadt, Germany; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments associated with our license with Novartis, including any termination or other change in our relationship with
Novartis or Amplyx; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in our growth rate relative to our competitors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory or legal developments in the United States and other countries; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the recruitment or departure of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the results of our efforts to <FONT STYLE="white-space:nowrap">in-license</FONT> or acquire additional product candidates
or products; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities
analysts; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">76 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fluctuations in the valuation of companies perceived by investors to be comparable to us; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">market conditions in the pharmaceutical and biotechnology sector; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in the structure of healthcare payment systems; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">announcement or expectation of additional financing efforts; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">sales of our securities by us, our insiders or our other stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expiration of market <FONT STYLE="white-space:nowrap">stand-off</FONT> or <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general economic, industry and market conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, the trading prices for common stock of other biotechnology companies have been highly volatile as a result of factors unrelated to the specific company or
its technology, as well as due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. The <FONT STYLE="white-space:nowrap">COVID-19</FONT> outbreak continues to evolve. The extent to which the outbreak may impact our business, nonclinical
studies and clinical trials will depend on future developments, which are highly uncertain and cannot be predicted with confidence. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The realization of any of the
above risks or any of a broad range of other risks, including those described in this &#147;Risk factors&#148; section, could have a dramatic and adverse impact on the market price of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We have identified a material weakness in our internal control over financial reporting. If our remediation of this material weakness is not effective, or if we
experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which
may adversely affect investor confidence in us and, as a result, the value of our Class&nbsp;A common stock. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to our IPO, we were a private company
with limited accounting personnel to adequately execute our accounting processes and other supervisory resources with which to address our internal control over financial reporting. In connection with the audit of our financial statements as of and
for the years ended December&nbsp;31, 2019 and 2020, we identified a material weakness in our internal control over financial reporting. A material weakness is a deficiency, or combination of deficiencies, in internal control over financial
reporting such that there is a reasonable possibility that a material misstatement of our financial statements will not be prevented or detected on a timely basis. The material weakness related to a lack of sufficient number of qualified personnel
within our accounting function to adequately segregate duties, to perform sufficient reviews and approval of manual journal entries posted to the general ledger and to consistently execute review procedures over general ledger account
reconciliations, financial statement preparation and accounting for <FONT STYLE="white-space:nowrap">non-routine</FONT> transactions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are implementing measures
designed to improve our internal control over financial reporting to remediate this material weakness, including the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We are formalizing our internal control documentation and strengthening supervisory reviews by our management; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">We have added additional accounting personnel and are segregating duties amongst accounting personnel.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">77 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot assure you that the measures we have taken to date, and are continuing to implement, will be sufficient to
remediate the material weakness we have identified or avoid potential future material weaknesses. If the steps we take do not correct the material weakness in a timely manner, we will be unable to conclude that we maintain effective internal control
over financial reporting. Accordingly, there could continue to be a reasonable possibility that a material misstatement of our financial statements would not be prevented or detected on a timely basis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, we are required to maintain internal control over financial reporting and to report any material weaknesses in such internal controls.
Section&nbsp;404 of the Sarbanes-Oxley Act (Section 404) requires that we evaluate and determine the effectiveness of our internal control over financial reporting and, beginning with our annual report for our fiscal year ending December&nbsp;31,
2021, provide a management report on internal control over financial reporting. The Sarbanes-Oxley Act also requires that our management report on internal control over financial reporting be attested to by our independent registered public
accounting firm, to the extent we are no longer an &#147;emerging growth company,&#148; as defined in the JOBS Act, and are not a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer. We do not expect our independent registered public
accounting firm to attest to our management report on internal control over financial reporting for so long as we are an emerging growth company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are in the
process of designing and implementing the internal control over financial reporting required to comply with this obligation, which process will be time consuming, costly and complicated. If we identify any additional material weaknesses in our
internal control over financial reporting, if we are unable to comply with the requirements of Section&nbsp;404 in a timely manner, if we are unable to assert that our internal control over financial reporting is effective, or when required in the
future, if our independent registered public accounting firm is unable to express an opinion as to the effectiveness of our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial
reports and the market price of our Class&nbsp;A common stock could be adversely affected, and we could become subject to investigations by the stock exchange on which our securities are listed, the SEC, or other regulatory authorities, which could
require additional financial and management resources. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our quarterly operating results may fluctuate significantly or may fall below the expectations of
investors or securities analysts, each of which may cause our stock price to fluctuate or decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect our operating results to be subject to
quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timing and variations in the level of expense related to the ongoing development of our product candidates or future
development programs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">timing and status of enrollment for our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">impacts from the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on us or third parties with which we engage;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">results of clinical trials, or the addition or termination of clinical trials or funding support by us or potential future
partners; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our execution of any collaboration, licensing or similar arrangements, and the timing of payments we may make or receive
under potential future arrangements or the termination or modification of any such potential future arrangements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any intellectual property infringement, misappropriation or violation lawsuit or opposition, interference or cancellation
proceeding in which we may become involved; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">78 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">additions and departures of key personnel; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">strategic decisions by us or our competitors, such as acquisitions, divestitures, spin-offs, joint ventures, strategic
investments or changes in business strategy; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">if our current or any future product candidates we may develop receive regulatory approval, the timing and terms of such
approval and market acceptance and demand for such product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and cost to establish a sales, marketing and distribution infrastructure to commercialize any products for which
we may obtain marketing approval and intend to commercialize on our own or jointly with current or future collaborators; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">regulatory developments affecting atacicept, MAU868 or any future product candidate we may develop or those of our
competitors; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">changes in general market and economic conditions. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our Class&nbsp;A common stock could decline
substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially. We believe that quarterly comparisons of our financial results are not necessarily meaningful and
should not be relied upon as an indication of our future performance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our principal stockholders and management own a significant percentage of our
outstanding voting stock and will be able to exert significant control over matters subject to stockholder approval. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our executive officers and directors,
combined with our stockholders who own more than 5% of our outstanding capital stock, beneficially own a significant percentage of our outstanding voting stock. Therefore, these stockholders are able to significantly influence us through this
ownership position. These stockholders may be able to determine all matters requiring stockholder approval. For example, these stockholders may be able to control elections of directors, amendments of our organizational documents or approval of any
merger, sale of assets or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our Class&nbsp;A common stock that you may feel are in your best interest as one of our stockholders. The
interests of this group of stockholders may not always coincide with your interests or the interests of other stockholders and they may act in a manner that advances their best interests and not necessarily those of other stockholders, including
seeking a premium value for their shares, and might affect the prevailing market price for our Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If you purchase shares of our
Class&nbsp;A common stock in this offering, you will experience substantial and immediate dilution. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The public offering price is substantially higher than
the net tangible book value per share of our outstanding Class&nbsp;A common stock immediately following the closing of this offering. Based on the public offering price of $15.00 per share, if you purchase shares of our Class&nbsp;A common stock in
this offering, you will experience substantial and immediate dilution in the as adjusted net tangible book value per share of $9.09 per share as of September&nbsp;30, 2021. That is because the price that you pay will be substantially greater than
the as adjusted net tangible book value per share of the Class&nbsp;A common stock that you acquire. This dilution is due in large part to the fact that our earlier investors paid substantially less than the public offering price when they purchased
their shares of our capital stock. You will experience additional dilution when those holding stock options exercise their right to purchase Class&nbsp;A common stock under our equity incentive plans or when we otherwise issue additional shares of
Class&nbsp;A common stock. See the section titled &#147;Dilution.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">79 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sales of a substantial number of shares of our Class&nbsp;A common stock in the public market could cause our
stock price to fall. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Class&nbsp;A common stock price could decline as a result of sales of a large number of shares of Class&nbsp;A common stock after
this offering or the perception that these sales could occur. These sales, or the possibility that these sales may occur, might also make it more difficult for us to sell equity securities in the future at a time and price that we deem appropriate.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, there were 20,968,376 shares of Class&nbsp;A common stock outstanding and held of record by 34 stockholders and 309,238 shares of
Class&nbsp;B common stock outstanding and held of record by one stockholder. The number of record holders of our Class&nbsp;A common stock does not include DTC participants or beneficial owners holding shares through nominee names. The resale of
shares of Class&nbsp;A common stock following this offering held by our officers and directors is currently prohibited or otherwise restricted as a result of <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into by our officers and
directors with the underwriters in connection with this offering. However, subject to applicable securities law restrictions, these shares will be able to be sold in the public market beginning 91 days after the date of this prospectus. The
representatives of the underwriters may release some or all of the shares of common stock subject to <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements at any time in their sole discretion and without notice, which would allow for earlier
sales of shares in the public market. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Further, certain holders of our Class&nbsp;A and Class&nbsp;B common stock have rights, subject to certain conditions, to
require us to file registration statements covering the sale of their shares or to include their shares in registration statements that we may file for ourselves or our other stockholders. We have also registered all shares of common stock that we
may issue under our equity compensation plans. Such shares can be freely sold in the public market upon issuance, subject to volume limitations applicable to affiliates and the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements entered into
with the representatives in connection with our IPO. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in the future, we may issue additional shares of common stock, or other equity or debt securities
convertible into Class&nbsp;A common stock, in connection with a financing, acquisition, employee arrangement or otherwise. Any such issuance could result in substantial dilution to our existing stockholders and could cause the price of our
Class&nbsp;A common stock to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Raising additional capital may cause dilution to our existing stockholders, restrict our operations or require us to
relinquish rights to atacicept, MAU868 or future product candidates we may develop on unfavorable terms to us. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We may seek additional capital through a
variety of means, including through public or private equity, debt financings or other sources, including <FONT STYLE="white-space:nowrap">up-front</FONT> payments and milestone payments from strategic collaborations. To the extent that we raise
additional capital through the sale of equity or convertible debt or equity securities, your ownership interest will be diluted, and the terms may include liquidation or other preferences that adversely affect your rights as a stockholder. Such
financing may result in dilution to stockholders, imposition of debt covenants, increased fixed payment obligations or other restrictions that may affect our business. If we raise additional funds through
<FONT STYLE="white-space:nowrap">up-front</FONT> payments or milestone payments pursuant to strategic collaborations with third parties, we may have to relinquish valuable rights to atacicept, MAU868 or future product candidates we may develop, or
grant licenses on terms that are not favorable to us. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">80 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We are an &#147;emerging growth company,&#148; and a &#147;smaller reporting company&#148; and we cannot be
certain if the reduced reporting requirements applicable to emerging growth companies and smaller reporting companies will make our Class&nbsp;A common stock less attractive to investors. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth company,&#148; as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we intend to take advantage of
exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">being permitted to provide only two years of audited financial statements, in addition to any required unaudited interim
financial statements, with correspondingly reduced &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; disclosure in this prospectus; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to comply with the auditor attestation requirements of Section&nbsp;404 of the Sarbanes-Oxley Act;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">not being required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board
regarding mandatory audit firm rotation or a supplement to the auditor&#146;s report providing additional information about the audit and the financial statements; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reduced disclosure obligations regarding executive compensation in this prospectus and our periodic reports and proxy
statements; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">exemptions from the requirements of holding nonbinding advisory stockholder votes on executive compensation and stockholder
approval of any golden parachute payments not previously approved. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We cannot predict if investors will find our Class&nbsp;A common stock less
attractive because we may rely on these exemptions. If some investors find our Class&nbsp;A common stock less attractive as a result, there may be a less active trading market for our Class&nbsp;A common stock and our stock price may be more
volatile. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will remain an emerging growth company until the earliest to occur of: (1)&nbsp;the last day of the fiscal year in which we have more than
$1.07&nbsp;billion in annual revenue; (2)&nbsp;the date we qualify as a &#147;large accelerated filer,&#148; with at least $700&nbsp;million of equity securities held by <FONT STYLE="white-space:nowrap">non-affiliates;</FONT> (3)&nbsp;the date on
which we have issued more than $1.0&nbsp;billion in <FONT STYLE="white-space:nowrap">non-convertible</FONT> debt securities during the prior three-year period; and (4)&nbsp;December&nbsp;31, 2026. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies.
We have taken advantage of the extended transition period for adopting new or revised accounting standards under the JOBS Act as an emerging growth company. As a result of this election, our financial statements may not be comparable to companies
that comply with public company effective dates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to Section&nbsp;404 we will be required to furnish a report by our management on our internal control over
financial reporting, including, if required by our filing status, an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. However, while we remain an emerging growth company or
a <FONT STYLE="white-space:nowrap">non-accelerated</FONT> filer, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. To achieve compliance
with Section&nbsp;404 within the prescribed period, we will be engaged in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we will need to continue to dedicate
internal resources, potentially engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through
testing that controls are functioning as </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">81 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that neither we nor our independent
registered public accounting firm will be able to conclude within the prescribed timeframe that our internal control over financial reporting is effective as required by Section&nbsp;404. This could result in an adverse reaction in the financial
markets due to a loss of confidence in the reliability of our financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, we are also a &#147;smaller reporting company,&#148; as defined in
the Exchange Act. We may continue to be a smaller reporting company even after we are no longer an emerging growth company. We may take advantage of certain of the scaled disclosures available to smaller reporting companies and will be able to take
advantage of these scaled disclosures for so long as our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than $250&nbsp;million measured on the last
business day of our second fiscal quarter, or our annual revenue is less than $100&nbsp;million during the most recently completed fiscal year and our voting and <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Investors may find
our Class&nbsp;A common stock less attractive as a result of our reliance on these exemptions. If some investors find our Class&nbsp;A common stock less attractive as a result, there may be a less active trading market for our Class&nbsp;A common
stock and our stock price may be more volatile. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our management team has broad discretion to use the net proceeds from this offering and its investment of
these proceeds may not yield a favorable return. They may invest the net proceeds from this offering in ways with which investors disagree. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to use
a portion of the net proceeds from this offering to fund a Phase 3 clinical trial of atacicept in LN, fund clinical development of MAU868 for treatment of BKV in kidney transplant patients and potential additional indications, and for other general
corporate purposes, including working capital, operating expenses and capital expenditures. See the section titled &#147;Use of proceeds.&#148; However, within the scope of our plan, and in light of the various risks to our business, including those
discussed in this &#147;Risk factors&#148; section and elsewhere in this prospectus, our management will have broad discretion over the use of net proceeds from this offering, and could spend the net proceeds in ways our stockholders may not agree
with or that do not yield a favorable return, if at all. If we do not invest or apply the net proceeds from this offering in ways that improve our operating results, we may fail to achieve expected financial results, which could cause our stock
price to decline. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We do not currently intend to pay dividends on our Class&nbsp;A common stock and, consequently, your ability to achieve a return on your
investment will depend on appreciation of the value of our Class&nbsp;A common stock. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have never declared or paid any cash dividends on our equity
securities. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, the terms of
the Loan Agreement between us and Oxford, dated December&nbsp;17, 2021, restrict our ability to declare and pay dividends without the prior written consent of Oxford. Any return to stockholders will therefore be limited to any appreciation in the
value of our Class&nbsp;A common stock, which is not certain. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Provisions in our amended and restated certificate of incorporation and amended and restated
bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation and amended and restated bylaws may discourage, delay or prevent a merger, acquisition or other change in control
of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">82 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
provisions also could limit the price that investors might be willing to pay in the future for shares of our Class&nbsp;A common stock, thereby depressing the market price of our Class&nbsp;A
common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by
making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a classified board of directors such that not all members of the board are elected at one time;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">allow the authorized number of our directors to be changed only by resolution of our board of directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limit the manner in which stockholders can remove directors from the board; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and
nominations to our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our
stockholders by written consent; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit our stockholders from calling a special meeting of our stockholders; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">prohibit cumulative voting; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">authorize our board of directors to issue preferred stock without stockholder approval, which could be used to institute a
stockholder rights plan, or <FONT STYLE="white-space:nowrap">so-called</FONT> &#147;poison pill,&#148; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by
our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">require the approval of the holders of at least 66 2/3% of the votes that all our stockholders would be entitled to cast to
amend or repeal certain provisions of our amended and restated certificate of incorporations or amended and restated bylaws. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moreover, because we
are incorporated in Delaware, we are governed by the provisions of Section&nbsp;203 of the Delaware General Corporation Law (DGCL), which prohibits a person who owns 15% or more of our outstanding voting stock from merging or combining with us for a
period of three years after the date of the transaction in which the person acquired 15% or more of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. These provisions could discourage potential
acquisition proposals and could delay or prevent a change in control transaction. They could also have the effect of discouraging others from making tender offers for our Class&nbsp;A common stock, including transactions that may be in your best
interests. These provisions may also prevent changes in our management or limit the price that investors are willing to pay for our stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our amended and
restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States are the exclusive forums for substantially all disputes between us and our stockholders, which
could limit our stockholders&#146; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended
and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of
Delaware or, if and only if all such state courts lack subject matter </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">83 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
jurisdiction, the federal district court for the District of Delaware) and any appellate court therefrom is the sole and exclusive forum for the following claims or causes of action under the
Delaware statutory or common law: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any derivative claim or cause of action brought on our behalf; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any claim or cause of action for a breach of fiduciary duty owed by any of our current or former directors, officers, or
other employees to us or our stockholders; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any claim or cause of action against us or any of our current or former directors, officers or other employees arising out
of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time to time); </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any claim or cause of action seeking to interpret, apply, enforce or determine the validity of our amended and restated
certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any claim or cause of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware;
and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any claim or cause of action against us or any of our current or former directors, officers, or other employees governed by
the internal-affairs doctrine, in all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This choice of forum provision would not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or
any other claim for which the federal courts have exclusive jurisdiction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To prevent having to litigate claims in multiple jurisdictions and the threat of
inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving
any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be
enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or
certified any part of the documents underlying such offering. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those
designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require
significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These exclusive forum provisions may limit a stockholder&#146;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our
directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive forum provision contained in our amended and restated certificate of
incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving the dispute in other jurisdictions, all of which could seriously harm our business, financial condition,
results of operations and prospects. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">84 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General risk factors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our information technology systems, or those of any of our CROs, manufacturers, other contractors, consultants, third party vendors, collaborators, or potential
future collaborators, may fail or suffer cybersecurity incidents, breaches or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal information, which could result in
additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations, or otherwise harm our business. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
the course of our business, we collect, store and transmit proprietary, confidential and sensitive information, including personal information. The information and data processed and stored in our technology systems, and those of our research
collaborators, CROs, contractors, consultants, and other third parties on which we depend to operate our business, may be vulnerable to security breaches, loss, damage, corruption, unauthorized access, use or disclosure, or misappropriation. Such
incidents may also result from errors or malfeasance by our personnel or the personnel of the third parties we work with, malware, viruses, software vulnerabilities, hacking, denial of service attacks, social engineering (including phishing),
ransomware, credential stuffing or other cyberattacks, including attacks by state-sponsored organizations or sophisticated groups of hackers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While we have
developed systems and processes designed to protect the integrity, confidentiality and security of the confidential and personal information under our control, we cannot assure you that any security measures that we or our third party service
providers have implemented will be effective in preventing cybersecurity incidents. There are many different cybercrime and hacking techniques and as such techniques continue to evolve, we may be unable to anticipate attempted security breaches,
identify them before our information is exploited, or react in a timely manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, as a result of the ongoing
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, certain functional areas of our workforce remain in a remote work environment and outside of our corporate network security protection boundaries, which imposes additional risks to our
business, including increased risk of industrial espionage, phishing and other cybersecurity attacks, and unauthorized dissemination of proprietary or confidential information, any of which could have a material adverse effect on our business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite our efforts to strengthen security and authentication measures, we have experienced an overall increase in cybersecurity incidents, none of which have caused
material disruption to our business, or to our knowledge, involved a material security breach. However, we or the third parties we rely on could experience a material system failure, security breach or other cybersecurity incident in the future,
which could interrupt our operations disrupt our development programs and have a material adverse effect on our business, financial condition and results of operations. For example, the loss of clinical trial data from completed or future clinical
trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties for the manufacture of our product candidates, to analyze clinical trial
samples and to conduct clinical trials, and cybersecurity incidents experienced by these third parties could have a material adverse effect on our business. Security breaches and other cybersecurity incidents affecting us or the third parties we
rely on could also result in substantial remediation costs and expose us to litigation, regulatory enforcement action, fines, penalties, and other liabilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
cannot be certain that our insurance coverage will be adequate for data security liabilities actually incurred, will continue to be available to us on economically reasonable terms, or at all, or that any insurer will not deny coverage as to any
future claim. The successful assertion of one or more large claims against us that exceed available insurance coverage, or the occurrence of changes in our insurance policies, including premium increases or the imposition of large deductible or <FONT
STYLE="white-space:nowrap">co-insurance</FONT> requirements, could adversely affect our reputation, business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">85 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is
accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and
procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These
inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by
collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Future changes in financial accounting standards or practices may cause adverse and unexpected revenue fluctuations and adversely affect our reported results of
operations. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Future changes in financial accounting standards may cause adverse, unexpected revenue fluctuations and affect our reported financial position
or results of operations. Financial accounting standards in the United States are constantly under review and new pronouncements and varying interpretations of pronouncements have occurred with frequency in the past and are expected to occur again
in the future. As a result, we may be required to make changes in our accounting policies. Those changes could affect our financial condition and results of operations or the way in which such financial condition and results of operations are
reported. We intend to invest resources to comply with evolving standards, and this investment may result in increased general and administrative expenses and a diversion of management time and attention from business activities to compliance
activities. See the section titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#151; Recent accounting pronouncements.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>The requirements of being a public company may strain our resources, result in more litigation and divert management&#146;s attention. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a public company, we are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection
Act the listing requirements of the Nasdaq Stock Market LLC and other applicable securities rules and regulations. Complying with these rules and regulations has increased and will increase our legal and financial compliance costs, make some
activities more difficult, time consuming or costly and increase demand on our systems and resources. The Exchange Act requires, among other things, that we file annual, quarterly and current reports with respect to our business and operating
results. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We are required to disclose changes made in our internal control and
procedures on a quarterly basis. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be
required. As a result, management&#146;s attention may be diverted from other business concerns, which could significantly harm our business, financial condition, results of operations and prospects. We may also need to hire additional employees or
engage outside consultants to comply with these requirements, which will increase our costs and expenses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, changing laws, regulations and standards
relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject
to varying interpretations, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">86 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
many cases due to their lack of specificity and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result
in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this
investment may result in increased general and administrative expenses and a diversion of management&#146;s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and
standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to their application and practice, regulatory authorities may initiate legal proceedings against us and our business, financial condition,
results of operations and prospects may be harmed. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These rules and regulations may make it more expensive for us to obtain director and officer liability insurance
and, in the future, we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These factors could also make it more difficult for us to attract and retain qualified members of our board of directors,
particularly to serve on our audit committee and compensation committee, and qualified executive officers. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">By disclosing information in SEC filings required of a
public company, our business and financial condition will become more visible, which we believe may result in threatened or actual litigation, including by competitors and other third parties. If those claims are successful, our business could be
seriously harmed. Even if the claims do not result in litigation or are resolved in our favor, the time and resources needed to resolve them could divert our management&#146;s resources and seriously harm our business, financial condition, results
of operations and prospects. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>We may be subject to securities litigation, which is expensive and could divert management attention. </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The market price of our Class&nbsp;A common stock may be volatile and, in the past, companies that have experienced volatility in the market price of their stock have
been subject to securities class action litigation and shareholder derivative actions. We may be the target of these types of litigation and claims in the future. These claims and litigation against us could result in substantial costs and divert
our management&#146;s attention from other business concerns, which could seriously harm our business, financial condition, results of operations and prospects. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>If securities or industry analysts do not publish research or reports, or if they publish adverse or misleading research or reports, regarding us, our business or
our market, our stock price and trading volume could decline. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The trading market for our Class&nbsp;A common stock is influenced by the research and reports
that securities or industry analysts publish about us, our business or our market. If few securities or industry analysts commence coverage of us, the stock price would be negatively impacted. If any of the analysts who cover us issue adverse or
misleading research or reports regarding us, our business model, our intellectual property, our stock performance or our market, or if our operating results fail to meet the expectations of analysts, our stock price would likely decline. If one or
more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">87 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_5"></A>Special note regarding forward-looking statements </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus contains &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act, Section&nbsp;21E of the Exchange Act and
the safe harbor provisions for the U.S. Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this prospectus, including statements regarding our future results of operations and
financial position, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies, clinical trials, research and development costs, regulatory approvals, timing and likelihood of success, as
well as plans and objectives of management for future operations, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our
actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, you can identify forward-looking statements by terms such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;would,&#148; &#147;expect,&#148;
&#147;plan,&#148; &#147;anticipate,&#148; &#147;could,&#148; &#147;intend,&#148; &#147;target,&#148; &#147;project,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative
of these terms or other similar expressions. Forward-looking statements contained in this prospectus include, but are not limited to, statements about: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our financial performance; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the accuracy of our estimates regarding expenses, future revenue, capital requirements, and needs for additional financing;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope, progress, results and costs of developing our product candidates and conducting nonclinical studies and clinical
trials, including our atacicept Phase 2b clinical trial and MAU868 Phase 2 clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the timing and costs involved in obtaining and maintaining regulatory approval of our product candidates and the timing or
likelihood of regulatory filings and approvals, including our expectation to seek special designations for our product candidates for various diseases; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our plans relating to commercializing our product candidates, if approved, including the geographic areas of focus and our
ability to grow a sales team; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability to license additional intellectual property relating to any future product candidates and to comply with our
existing license agreements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the impact of the ongoing <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and operations,
including enrollment in our clinical trial; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the implementation of our strategic plans for our business and current product candidates or any other product candidates
we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the size of the market opportunity for our product candidates in each of the diseases we target; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our reliance on third parties to conduct nonclinical research activities, and for the manufacture of our product
candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the beneficial characteristics, safety, efficacy and therapeutic effects of our product candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our estimates of the number of patients in the United States who suffer from the diseases we target and the number of
subjects that will enroll in our clinical trials; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">88 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress and focus of our current and future clinical trials, and the reporting of data from those trials;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to advance product candidates into and successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the ability of our clinical trials to demonstrate the safety and efficacy of our product candidates, and other positive
results; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the success of competing therapies that are or may become available; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developments relating to our competitors and our industry, including competing product candidates and therapies;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our plans relating to the further development and manufacturing of our product candidates, including additional indications
that we may pursue; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">existing regulations and regulatory developments in the United States and other jurisdictions; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our potential and ability to successfully manufacture and supply our product candidates for clinical trials and for
commercial use, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rate and degree of market acceptance of our product candidates, as well as the pricing and reimbursement of our product
candidates, if approved; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our continued reliance on third parties to conduct additional clinical trials of our product candidates, and for the
manufacture of our product candidates; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our plans and ability to obtain and protect intellectual property rights; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the scope of protection we are able to establish and maintain for intellectual property rights, including atacicept, MAU868
and any other product candidates we may develop; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our ability to retain the continued service of our key personnel and to identify, hire, and then retain additional
qualified personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our business and
operations, including clinical trials, manufacturing suppliers, collaborators, use of CROs and employees; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our expectations regarding the period during which we will qualify as an emerging growth company under the JOBS Act and as
a smaller reporting company under the Exchange Act; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our anticipated use of our existing cash and cash equivalents and the net proceeds from this offering.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have based these forward-looking statements largely on our current expectations and projections about our business, the industry in which we
operate and financial trends that we believe may affect our business, financial condition, results of operations and prospects, and these forward-looking statements are not guarantees of future performance or development. These forward-looking
statements speak only as of the date of this prospectus and are subject to a number of risks, uncertainties and assumptions described in the section titled &#147;Risk factors&#148; and elsewhere in this prospectus. Because forward-looking statements
are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our
forward-looking statements may not be achieved or occur and actual results could differ materially from those projected in the forward-looking statements. Except as required by applicable law, we do not plan to publicly update or revise any
forward-looking statements contained herein until after we distribute this prospectus, whether as a result of any new information, future events or otherwise. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">89 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, statements that &#147;we believe&#148; and similar statements reflect our beliefs and opinions on the
relevant subject. These statements are based upon information available to us as of the date of this prospectus, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and
our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon
these statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">90 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_6"></A>Market, industry and other data </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We obtained the industry, market and competitive position data used throughout this prospectus from our own internal estimates and research, as well as from independent
market research, industry and general publications and surveys, governmental agencies and publicly available information in addition to research, surveys and studies conducted by third parties. Internal estimates are derived from publicly available
information released by industry analysts and third-party sources, our internal research and our industry experience, and are based on assumptions made by us based on such data and our knowledge of our industry and market, which we believe to be
reasonable. In some cases, we do not expressly refer to the sources from which this data is derived. In that regard, when we refer to one or more sources of this type of data in any paragraph, you should assume that other data of this type appearing
in the same paragraph is derived from the same sources, unless otherwise expressly stated or the context otherwise requires. In addition, while we believe the industry, market and competitive position data included in this prospectus is reliable and
based on reasonable assumptions, such data involve risks and uncertainties and are subject to change based on various factors, including those discussed in the section titled &#147;Risk factors.&#148; These and other factors could cause results to
differ materially from those expressed in the estimates made by the independent parties or by us. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">91 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_7"></A>Use of proceeds </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that we will receive net proceeds from this offering of approximately $69.7&nbsp;million (or approximately $80.2&nbsp;million if the underwriters&#146;
option to purchase 748,959 additional shares of our Class&nbsp;A common stock is exercised in full) based on the public offering price of $15.00 per share and after deducting underwriting discounts and commissions and estimated offering expenses
payable by us. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We currently intend to use the net proceeds we receive from this offering, together with our existing cash and cash equivalents, as follows: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $60.0 million to fund a Phase 3 clinical trial of atacicept in LN; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approximately $15.0 million to fund clinical development of MAU868 for the treatment of BKV in kidney transplant patients
and potential additional indications; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the remainder for general corporate purposes, including working capital, operating expenses and capital expenditures.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe, based on our current operating plan, that the net proceeds from this offering, together with our existing cash and cash equivalents
and the funds available under the Loan Agreement with Oxford, will be sufficient to fund our operations at least into the second quarter of 2024. However, our expected use of proceeds from this offering described above represents our current
intentions based on our present plans and business condition. As of the date of this prospectus, we cannot predict with certainty all of the particular uses for the proceeds to be received upon the closing of this offering or the actual amounts that
we will spend on the uses set forth above. The net proceeds from this offering, together with our cash and cash equivalents, will not be sufficient for us to fund atacicept in IgAN or LN or MAU868 in kidney transplant recipients with BK viremia
through regulatory approval, and we will need to raise additional capital to complete the development and commercialization of atacicept in IgAN, LN, and MAU868 in kidney transplant patients with BK viremia, and any future product candidates we may
develop. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The amounts and timing of our actual expenditures will depend on numerous factors, including the time and cost necessary to conduct our planned clinical
trials, the results of our planned clinical trials and other factors described in the section titled &#147;Risk factors&#148; in this prospectus, as well as the amount of cash used in our operations and any unforeseen cash needs. Therefore, our
actual expenditures may differ materially from the estimates described above. We may find it necessary or advisable to use the net proceeds for other purposes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
will have broad discretion over how to use the net proceeds to us from this offering. We intend to invest the net proceeds to us from the offering that are not used as described above in short-term, investment-grade, interest-bearing instruments.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">92 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_8"></A>Dividend policy </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not anticipate declaring or paying, in the foreseeable future, any cash dividends on our capital stock. We intend to retain all available funds and future
earnings, if any, to fund the development and expansion of our business. Any future determination regarding the declaration and payment of dividends, if any, will be at the discretion of our board of directors, subject to applicable laws, and will
depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our board of directors may deem relevant. In addition, the terms of the
Loan Agreement with Oxford restrict our ability to declare and pay dividends without the prior written consent of Oxford. Our ability to pay cash dividends on our capital stock in the future may be limited by the terms of any future debt or
preferred securities we issue or any credit facilities we enter into. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">93 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_9"></A>Capitalization </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth our cash and cash equivalents and capitalization as of September&nbsp;30, 2021 on: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an actual basis; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">on an adjusted basis to give effect to our issuance and sale of 4,993,067 shares of our Class&nbsp;A common stock in this
offering at the public offering price of $15.00 per share and after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </P></TD></TR></TABLE>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">You should read this table together with the sections titled &#147;Management&#146;s discussion and analysis of financial condition and results of operations&#148; and
&#147;Description of capital stock&#148; and our financial statements and related notes included elsewhere in this prospectus. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>As of September&nbsp;30, 2021</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(In thousands, except share amounts)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Actual</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>As</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>adjusted</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">86,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">155,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit (equity)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Preferred stock, $0.001 par value; 10,000,000 shares authorized; no shares issued and outstanding as of
September&nbsp;30, 2021, actual; 10,000,000 shares authorized and no shares issued and outstanding as of September 30, 2021, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;A common stock, $0.001 par value; 500,000,000 shares authorized and 20,968,376 issued and
outstanding as of September&nbsp;30, 2021, actual; 500,000,000 shares authorized and 25,961,443 issued and outstanding as of September 30, 2021, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;B Common stock, $0.001 par value; 14,600,000 shares authorized and 309,238 shares issued and
outstanding as of September&nbsp;30, 2021, actual; 14,600,000 shares authorized and 309,238 shares issued and outstanding as of September 30, 2021, as adjusted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">262,312</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">155,129</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total capitalization</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">85,477</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">155,129</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The foregoing discussion and table above assume no issuance of Class&nbsp;B common stock in connection with this offering and exclude, as
of September&nbsp;30, 2021: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,894,671 shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding stock options as of
September&nbsp;30, 2021, with a weighted-average exercise price of $5.43 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1,510,665 shares of our Class&nbsp;A common stock available for future issuance under the 2021 Plan as of
September&nbsp;30, 2021, an additional 1,048,419 shares of our Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the 2021 Plan, as well as any future automatic annual increases
in the number of shares of Class&nbsp;A common stock reserved for issuance under our 2021 Plan and any shares of Class&nbsp;A common stock underlying outstanding stock awards granted under our 2017 Plan that expire or are repurchased, forfeited,
cancelled or withheld, as more fully described in the section titled &#147;Executive compensation&#151;Equity benefit plans&#148;; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">94 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">220,251 shares of our Class&nbsp;A common stock reserved for issuance under our ESPP, an additional 209,684 shares of our
Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the ESPP, and any future automatic annual increases in the number of shares of Class&nbsp;A common stock reserved for future
issuance under our ESPP. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">95 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_10"></A>Dilution </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If you invest in our Class&nbsp;A common stock in this offering, your interest will be diluted to the extent of the difference between the public offering price per
share of Class&nbsp;A common stock and the as adjusted net tangible book value per share immediately after this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2021, we had a
historical net tangible book value of $85.5&nbsp;million, or $4.02 per share of common stock, based on the 20,968,376 shares of Class&nbsp;A and 309,238 shares of Class B common stock outstanding as of such date, including 4,137 shares subject to
repurchase as of such date. Our historical net tangible book value per share represents total tangible assets less total liabilities, divided by the number of shares of Class&nbsp;A and Class B common stock outstanding as of September&nbsp;30, 2021,
including 4,137 shares of Class&nbsp;A common stock subject to repurchase as of such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After giving effect to our issuance and sale of 4,993,067 shares of
Class&nbsp;A common stock in this offering at the public offering price of $15.00 per share, and after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our as adjusted net tangible book value as of
September&nbsp;30, 2021 would have been $155.1 million, or $5.91 per share. This amount represents an immediate increase in our as adjusted net tangible book value of $1.89 per share to our existing stockholders and an immediate dilution in our as
adjusted net tangible book value of $9.09 per share to investors purchasing Class&nbsp;A common stock in this offering. We determine dilution by subtracting the as adjusted net tangible book value per share after this offering from the amount of
cash paid by an investor for a share of Class&nbsp;A common stock in this offering. The following table illustrates this dilution on a per share basis: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-TOP:2.00pt solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Public offering price per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-TOP:2.00pt solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000" ALIGN="right">15.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Historical net tangible book value per share as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.02</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Increase in net tangible book value per share attributable to investors purchasing shares in this
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.89</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">As adjusted net tangible book value per share after this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dilution in as adjusted net tangible book value per share to
investors purchasing shares in this offering</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9.09</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the underwriters exercise their option to purchase additional shares of Class&nbsp;A common stock in full, the net tangible book value
per share, as adjusted to give effect to this offering, would be $6.13 per share, and the dilution in pro forma net tangible book value per share to investors in this offering would be $8.87 per share, in each case based on the public offering price
of $15.00 per share. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The foregoing discussion and tables above exclude, as of September&nbsp;30, 2021: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">2,894,671 shares of our Class&nbsp;A common stock issuable upon the exercise of outstanding stock options as of
September&nbsp;30, 2021, with a weighted-average exercise price of $5.43 per share; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">1,510,665 shares of our Class&nbsp;A common stock available for future issuance under the 2021 Plan as of
September&nbsp;30, 2021, an additional 1,048,419 shares of our Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the 2021 Plan, as well as any future automatic annual increases
in the number of shares of Class&nbsp;A common stock reserved for issuance under our 2021 Plan and any shares of Class&nbsp;A common stock underlying outstanding stock awards granted under our 2017 Plan that expire or are repurchased, forfeited,
cancelled or withheld, as more fully described in the section titled &#147;Executive compensation&#151;Equity benefit plans&#148;; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">96 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">220,251 shares of our Class&nbsp;A common stock reserved for issuance under our ESPP, an additional 209,684 shares of our
Class&nbsp;A common stock that were reserved for future issuance on January&nbsp;1, 2022 in accordance with the terms of the ESPP, and any future automatic annual increases in the number of shares of Class&nbsp;A common stock reserved for future
issuance under our ESPP. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that any outstanding options are exercised or new options or other convertible securities are issued under
our stock-based compensation plans, or we issue additional shares of Class&nbsp;A common stock and Class&nbsp;B common stock in the future, there will be further dilution to investors participating in this offering. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">97 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_11"></A>Management&#146;s discussion and analysis of financial condition and results of
operations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>The following discussion should be read in conjunction with our financial statements and related notes thereto included elsewhere in this
prospectus. In addition to historical information, this discussion contains forward-looking statements that involve risks, uncertainties and assumptions that could cause actual results to differ materially from management&#146;s expectations.
Factors that could cause such differences are discussed in the sections titled &#147;Special note regarding forward-looking statements&#148; and &#147;Risk factors.&#148; We are not undertaking any obligation to update any forward-looking statements
or other statements we may make in the following discussion or elsewhere in this document even though these statements may be affected by events or circumstances occurring after the forward-looking statements or other statements were made.
Therefore, no reader of this document should rely on these statements being current as of any time other than the time at which this document is declared effective by the SEC. </I></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a late-stage biotechnology company focused on developing and
commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate atacicept is currently being evaluated for the treatment of IgAN in the Phase 2b ORIGIN trial which we expect will complete
enrollment in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and report topline results in the fourth quarter of 2022. If the data from this trial are positive, we plan to initiate a pivotal Phase 3 clinical trial in 2023. In addition, based on
positive feedback from the FDA&#146;s review of promising clinical results in a Phase 2 clinical trial of atacicept in high disease activity patients with SLE, we plan to initiate a Phase 3 study of atacicept in LN, a severe renal manifestation of
SLE. In December 2021, we obtained from Amplyx, a wholly owned subsidiary of Pfizer, development and commercial rights to MAU868, which, we believe, is the only clinical-stage neutralizing monoclonal antibody that is directed against BK virus, a
polyoma virus that can have devastating consequences in certain settings such as kidney transplant and hematopoietic stem cell transplant. In an interim analysis of Phase 2 data in BK viremia among kidney transplant recipients, MAU868 was shown to
be well tolerated and demonstrated a clinically significant reduction of virologic activity. We expect to share full results from the interim analysis in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and expect to initiate a Phase 2b or Phase 3
clinical trial in 2023. We believe that our current pipeline programs leverage the deep expertise of the Vera Therapeutics team and have strong commercial synergies. We currently hold global rights to all of our pipeline programs. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since our inception, we have devoted substantially all of our resources to our research and development efforts, <FONT STYLE="white-space:nowrap">pre-clinical</FONT>
studies and clinical trials, establishing and maintaining our intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We do not have any product candidates approved for commercial sale, and we have not generated any revenue from product sales. Our ability to generate revenue sufficient
to achieve profitability, if ever, will depend on the successful development and eventual commercialization of one or more of our product candidates, which we expect will take a number of years, if ever. We also do not own or operate, and currently
have no plans to establish, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for nonclinical and clinical testing, as well as for commercial manufacturing if any of
our product candidates obtain marketing approval. We believe that this strategy allows us to maintain a more efficient infrastructure by eliminating the need for us to invest in our own manufacturing facilities, equipment, and personnel while also
enabling us to focus our expertise and resources on the development of our product candidates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">98 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have funded our operations primarily through proceeds from the sale of shares of our Class&nbsp;A common
stock, redeemable convertible preferred stock, debt financing and convertible promissory notes. As of September&nbsp;30, 2021, we had $86.2&nbsp;million in unrestricted cash and cash equivalents. Based on our current operating plan, we believe that
the net proceeds from this offering, together with our existing cash and cash equivalents and proceeds from the $50.0&nbsp;million Loan Agreement with Oxford, will be sufficient to fund our planned operating expenses and capital expenditure
requirements at least into the second quarter of 2024. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have incurred significant operating losses since the commencement of our operations. Our net losses were
$15.8&nbsp;million and $10.5&nbsp;million for the nine months ended September&nbsp;30, 2021 and 2020, respectively, and we expect to incur significant and increasing losses for the foreseeable future as we continue to advance our product candidates,
atacicept and MAU868, to commercialization. Our net losses may fluctuate significantly from period to period, depending on the timing of expenditures on our research and development activities. As of September&nbsp;30, 2021, we had an accumulated
deficit of $107.2&nbsp;million. Our primary use of cash is to fund operating expenses, which consist primarily of research and development expenditures and general and administrative expenditures. Cash used to fund operating expenses depends on the
timing of when we pay these expenses, as reflected in the changes in our prepaid expense, accounts payable and other current liabilities balances. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect to
continue to incur net operating losses for at least the next several years, and we expect our research and development expenses, general and administrative expenses, and capital expenditures will continue to increase. We expect our expenses and
capital requirements will increase significantly in connection with our ongoing activities as we: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue our ongoing and planned research and development of our product candidates, atacicept for the treatment of IgAN
and LN, and MAU868 for the treatment of BK viremia; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">conduct clinical trials and nonclinical studies for atacicept and MAU868; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">seek regulatory approvals for any product candidates that successfully complete clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">continue to scale up external manufacturing capacity with the aim of securing sufficient quantities to meet our capacity
requirements for clinical trials and potential commercialization; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">establish a sales, marketing and distribution infrastructure to commercialize any approved product candidates and related
additional commercial manufacturing costs; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">develop, maintain, expand, protect and enforce our intellectual property portfolio, including patents, trade secrets and <FONT
STYLE="white-space:nowrap">know-how;</FONT> </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">attract, hire and retain additional clinical, scientific, quality control, manufacturing management and administrative
personnel; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">add clinical, operational, financial and management information systems and personnel, including personnel to support our
product development and planned future commercialization efforts; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">incur additional legal, accounting, investor relations and other expenses associated with operating as a public company.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate
significantly from <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">quarter-to-quarter</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">year-to-year,</FONT></FONT> depending on the timing of our
clinical trials and our expenditures on other research and development activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will require substantial additional funding to develop our product candidates
and support our continuing operations. Until such time that we can generate significant revenue from product sales or other sources, if </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">99 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ever, we expect to finance our operations through the sale of equity, debt financings, or other capital sources, which could include income from collaborations, strategic partnerships, or
marketing, distribution, licensing or other strategic arrangements with third parties, or from grants. We may be unable to raise additional funds or to enter into such agreements or arrangements on favorable terms, or at all. Our ability to raise
additional funds may be adversely impacted by potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from the ongoing <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and otherwise. Our failure to obtain sufficient funds on acceptable terms when needed could have a material adverse effect on our business, results of operations or financial condition, including
requiring us to have to delay, reduce or eliminate our product development or future commercialization efforts. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less
favorable terms than we would otherwise choose. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our development efforts. We cannot provide assurance that we will ever be
profitable or generate positive cash flow from operating activities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since it was reported to have surfaced in December 2019, a novel strain of <FONT STYLE="white-space:nowrap">coronavirus&nbsp;(COVID-19)&nbsp;has</FONT> spread across the
world and has been declared a pandemic by the World Health Organization. Efforts to contain the spread of <FONT STYLE="white-space:nowrap">COVID-19</FONT> have intensified and governments around the world, including in the United States, Europe and
Asia, have implemented travel restrictions, social distancing requirements, <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">stay-at-home</FONT></FONT> orders and have delayed the commencement of <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">non-COVID-19-related</FONT></FONT></FONT> clinical trials, among other restrictions. As a result, the current <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has presented a
substantial public health and economic challenge around the world and is affecting our employees, patients, communities and business operations, as well as contributing to significant volatility and negative pressure on the U.S. economy and in
financial markets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result of the outbreak, many companies have experienced disruptions in their operations and in markets served. To date, we have initiated
some and may take additional, temporary precautionary measures intended to help ensure our employees&#146; well-being and minimize business disruption. For the safety of our employees and their families, we have reduced the amount of time we expect
our employees to spend onsite in our facilities. Certain of our third-party service providers have also experienced shutdowns or other business disruptions. We are continuing to assess the impact of the
<FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our current and future business and operations, including our expenses and clinical trials and other development timelines, as well as on our industry and the healthcare system. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, we have and may in the future experience severe disruptions, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">interruption of or delays in receiving products and supplies from the third parties on which we rely, due to staffing
shortages, production slowdowns or stoppages and disruptions in delivery systems; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on our business operations by the local, state, or federal government; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">business disruptions caused by workplace, laboratory and office closures and an increased reliance on employees working
from home, travel limitations, cybersecurity and data accessibility limits, or communication or mass transit disruptions; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">limitations on employee resources that would otherwise be focused on the conduct of our activities, including because of
sickness of employees or their families or the desire of employees to avoid contact with large groups of people. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">100 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Results of operations </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparisons of the nine months ended September&nbsp;30, 2021 and 2020 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the periods presented. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="66%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">81%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,183</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">179%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,416</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8,136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,912</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(10,538</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(5,224</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">50%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses represent a substantial portion of our operating expenses. Our research and development expenses consist primarily of direct and
indirect expenses incurred in connection with the discovery and development of our product candidates. Since October 2020, we have been engaged in the development of atacicept. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses are recorded as expense in the period they are incurred, and payments we make prior to the receipt of goods or services to be used in
research and development efforts are deferred as prepaid expenses until the goods or services are received and used. The cost incurred in obtaining technology licenses, including initial and subsequent milestone payments incurred under our licensing
agreements, are recorded as expense in the period in which they are incurred, as the licensed technology, method or process has no alternative future uses other than for our research and development activities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">101 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses incurred during the respective periods. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consulting and contract research</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">6,687</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,315</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">387%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Internal laboratory expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect research and development expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,029</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,702</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">128%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities, depreciation and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,359</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development expenses</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9,731</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5,362</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,369</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">81%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $4.4&nbsp;million, or 81%, to $9.7&nbsp;million in the
nine months ended September&nbsp;30, 2021, from $5.4&nbsp;million in the nine months ended September&nbsp;30, 2020. The increase was primarily due to an increase of $5.3&nbsp;million in consulting and contract research expense resulting from the
Phase 2b clinical trial of atacicept initiating and enrolling during the current period, and an increase of $1.7&nbsp;million of employee compensation and related expenses resulting from the increased headcount to support clinical development of
atacicept during the current period. These were partially offset by decreases of $1.3&nbsp;million of internal research and development expenses resulting from our ceasing of internal research in September 2020 and $1.4&nbsp;million for facilities,
depreciation and other expenses, as a result of the vacating and sublease of our leased facilities in South San Francisco in November 2020. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General and
administrative </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses consist primarily of compensation and personnel-related expenses, including stock-based compensation, for
our personnel in executive management, legal, finance, human resources, and other administrative functions. General and administrative expenses also include professional fees paid for accounting, auditing, legal, tax and consulting services, and
other general overhead costs to support our operations. General and administrative expenses are recorded as expense in the period they are incurred, and payments we make prior to the receipt of goods or services to be used for general and
administrative purposes efforts are deferred as prepaid expenses until the goods or services are received and used. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">8,086</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5,183</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">179%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses increased by $5.2&nbsp;million, or 179%, to $8.1&nbsp;million in the nine months ended
September&nbsp;30, 2021, from $2.9&nbsp;million in the nine months ended September&nbsp;30, 2020, due primarily to increases of $2.0&nbsp;million of payroll and related expenses including stock-based compensation, an increase of $1.1&nbsp;million in
insurance premium expense, an increase of $0.8&nbsp;million in legal expenses, an increase of $0.5&nbsp;million in accounting and auditing expenses, and an increase of $0.5 million in cash and stock-based compensation to non-employee directors, all
as a result of being a public company during the current period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">102 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restructuring costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restructuring costs primarily consist of contract termination costs related to leases and employee termination costs. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="75%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring Costs</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(1,416</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We restructured in September 2020, resulting in the termination of certain employees and vacating of
leased facilities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Total other income (expense) </I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Three&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(857</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,912</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Total other income increased by $2.9&nbsp;million to $2.1&nbsp;million in the nine months ended
September&nbsp;30, 2021, from $(0.9) million (expense) in the nine months ended September&nbsp;30, 2020, due to other income of $2.7&nbsp;million recognized in the current period from the sale of assets to NeuBase Therapeutics, Inc. (NeuBase),
partially offset by $0.7&nbsp;million of other expense recognized in the current period due to unrealized losses from <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities. We recorded $0.8&nbsp;million of other expense due to the
change in fair value of convertible notes during the period in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">103 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comparisons of the years ended December&nbsp;31, 2019 and 2020 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our results of operations for the periods presented. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="62%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">37,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">520%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(371</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(8)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,735</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,048</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,280</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(40,280</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">337%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(95)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(115</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">225%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,279</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,184)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(41,559</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">351%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(41,559</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">351%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development expenses </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our research and development expenses incurred during the respective periods. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Direct preclinical and clinical expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Consulting and outside services</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,706</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">417</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,426</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">622</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(56)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">License</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">38,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&#151;*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Indirect preclinical and clinical expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Compensation and related benefits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,052</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,902</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(150</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7)%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Facilities, depreciation and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,855</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">37,916</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">520%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Not meaningful </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development expenses increased by $37.9&nbsp;million, or 520%, to $45.2&nbsp;million in 2020
from $7.3&nbsp;million in 2019. The increase was primarily due to payments made to Ares pursuant to our exclusive license of atacicept, consisting of an initial payment of $13.1&nbsp;million payable in shares of our Series C redeemable convertible
preferred stock and subsequent cash milestone payments of $25.0&nbsp;million, and an increase of $0.4&nbsp;million in consulting and outside services expense resulting primarily from services commenced by clinical research organizations to initiate
the Phase 2b clinical trial of atacicept, which were partially offset by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">104 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
decreases of $0.8&nbsp;million of equipment expense, as we recorded such expense through September 2020 at which time we ceased using our laboratory equipment for preclinical activities, and
$0.2&nbsp;million of compensation and benefits expense, resulting from our ceasing use of laboratory equipment and reducing our preclinical workforce in September 2020. Facilities, depreciation and other expenses of $2.9&nbsp;million in 2020 include
an impairment charge of $1.0&nbsp;million resulting from our disposal of furniture and laboratory equipment associated with the preclinical activities that we ceased in September 2020. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>General and administrative </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our general
and administrative expenses incurred during the respective periods. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(371</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(8)%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">General and administrative expenses decreased by $0.4&nbsp;million, or 8%, to $4.0&nbsp;million in 2020 from $4.4&nbsp;million in 2019,
due primarily to lower rent expense of $0.7&nbsp;million and lower compensation and benefits of $0.1&nbsp;million resulting from our ceasing preclinical activities during the year. These decreases were partially offset by an increase in professional
services of $0.3&nbsp;million and an impairment charge of $0.1&nbsp;million associated with the disposal of office equipment. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restructuring costs
</I></B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="72%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,735</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,048%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restructuring costs increased by $2.7&nbsp;million, or 1,048%, to $3.0&nbsp;million in 2020 from $0.3&nbsp;million in 2019, due primarily
due to our restructuring in September 2020, which resulted in our termination of certain of our employees, vacating leased facilities, and ceasing use of leased equipment that had been focused on our preclinical research and development activities.
Restructuring costs in 2019 resulted from vacating our lab and office facilities in Massachusetts. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Total other income (expense) </I></B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="68%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Change</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(dollars in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>%</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(1,279</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(1,184)%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The decrease of $1.3&nbsp;million in total other income (expense) to $1.2&nbsp;million other expense in 2020 from $0.1&nbsp;million other
income in 2019 resulted from a loss due to an increase of $1.1&nbsp;million in the fair value of our convertible notes for which we elected to account for at fair value, a $0.1&nbsp;million increase in interest expense attributable to the issuance
of such notes, which converted into shares of our Series C redeemable convertible preferred stock during 2020, and a $0.2&nbsp;million decrease in interest income due a lower level of available cash invested in 2020. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">105 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity and capital resources </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To date, we have funded our operations primarily through the issuance and sale of redeemable convertible preferred stock and convertible notes, net proceeds from our IPO
and net proceeds from our Loan and Security Agreement (Loan Agreement) with Oxford Finance LLC (Oxford). From our inception through September&nbsp;30, 2021, we have raised aggregate net cash proceeds of $190.0&nbsp;million from the issuance and sale
of redeemable convertible preferred stock, convertible notes and our IPO. Since the date of our incorporation, we have not generated any revenue from product sales and have incurred substantial operating losses and negative cash flows from
operations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We use our cash to fund operations, primarily to fund our research and development efforts, clinical trials, establishing and maintaining our
intellectual property portfolio, hiring personnel, raising capital, and providing general and administrative support for these operations. Cash used to fund operating expenses is affected by the timing of when we pay these expenses, as reflected in
the change in our outstanding accounts payable, accrued expenses and prepaid assets. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We anticipate that we will continue to incur net losses for the foreseeable
future as we continue research and development activities of atacicept and MAU868, hire additional staff, including clinical, operational, financial and management personnel, and incur additional expenses associated with operating as a public
company. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our clinical development activities and our product candidate portfolio. We expect that our research and development and general and
administrative costs will increase substantially as a result of our acquisition of MAU868, including in connection with conducting additional clinical trials and clinical trials for our research programs and product candidates, contracting with
third parties to support nonclinical studies and clinical trials, expanding our intellectual property portfolio, and providing general and administrative support for our operations. As a result, we will need additional capital to fund our
operations, which we may obtain from additional equity or debt financings, collaborations, licensing arrangements, or other sources. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On May&nbsp;18, 2021, we
completed our IPO. In connection with our IPO, we issued and sold 5,002,500 shares of Class&nbsp;A common stock, including 652,500 shares associated with the full exercise on May&nbsp;20, 2021, of the underwriters&#146; option to purchase additional
shares, at a price to the public of $11.00 per share, resulting in net proceeds to us of approximately $48.4&nbsp;million, after deducting underwriting discounts and commissions and offering related expenses payable by us. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2021, we had unrestricted cash and cash equivalents balance of $86.2&nbsp;million, as compared to $53.7&nbsp;million and $3.2&nbsp;million as of
December&nbsp;31, 2020 and 2019, respectively. We expect that our existing cash and cash equivalents, together with the proceeds from our Loan Agreement with Oxford and net proceeds from this offering, will be sufficient to fund our operations at
least into the second quarter of 2024. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash flows </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following
table summarizes our cash flows for the periods indicated. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended<BR>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(in thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(34,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net cash provided by (used in) financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net increase (decrease) in cash and cash equivalents and restricted
cash</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(10,551</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">50,439</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(2,037</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">32,487</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">106 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Operating activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2021, we used $17.3&nbsp;million of cash in operating activities, attributable to a net loss of $15.8&nbsp;million, a
$2.7&nbsp;million <FONT STYLE="white-space:nowrap">non-cash</FONT> gain on sale of assets to NeuBase, and a $3.0&nbsp;million increase in prepaid expenses and other current assets resulting mostly from prepaid insurance premiums, partially offset by
a $2.2&nbsp;million increase in accrued and other current liabilities resulting mostly from accrued expenses for research and development activities, and $2.0&nbsp;million of <FONT STYLE="white-space:nowrap">non-cash</FONT> stock-based compensation
expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2020, we used $7.4&nbsp;million of cash in operating activities, attributable to a net loss of
$10.5&nbsp;million, partially offset by the <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $1.2&nbsp;million resulting from an impairment loss on property, equipment and intangible assets resulting from our restructuring,
$0.9&nbsp;million from depreciation, amortization and accretion, and a $0.8&nbsp;million decrease in the fair value of convertible notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2020, we used
$34.8&nbsp;million of cash used in operating activities, attributable to a net loss of $53.4&nbsp;million, partially offset by <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $13.1&nbsp;million resulting from a license payment made in
shares of redeemable convertible preferred stock, an increase of $2.4&nbsp;million in the liability for restructuring, net of cash paid, a net change of $0.1&nbsp;million in our net operating assets and liabilities, and $2.9&nbsp;million of other <FONT
STYLE="white-space:nowrap">non-cash</FONT> expenses, of which $1.2&nbsp;million was an impairment charge associated with the disposal of property, equipment and intangible assets, $1.1&nbsp;million was attributable to the change in fair value on
convertible notes payable, $0.3&nbsp;million of stock-based compensation and $0.3&nbsp;million of depreciation and amortization. The net change of $0.1&nbsp;million in our net operating assets and liabilities resulted primarily from a
$0.5&nbsp;million decrease in other liabilities, a $0.6&nbsp;million increase in accounts payable and a $0.1&nbsp;million decrease in other assets, which were partially offset by a $0.1&nbsp;million increase in prepaid expense and other assets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2019, we used $10.3&nbsp;million of cash in operating activities, attributable to a net loss of $11.9&nbsp;million, partially offset by a net change in our net
operating assets and liabilities of $0.5&nbsp;million, the accrual for restructuring costs, net of cash paid, of $0.2&nbsp;million, and <FONT STYLE="white-space:nowrap">non-cash</FONT> expenses of $0.9&nbsp;million, of which $0.5&nbsp;million was
for depreciation and amortization, $0.3&nbsp;million was for stock-based compensation and $0.1&nbsp;million was for the loss on disposal of property and equipment. The change in our net operating assets and liabilities resulted primarily from a
decrease in prepaid expenses and other current assets of $0.3&nbsp;million, a decrease in grants receivable of $0.2&nbsp;million, an increase in accrued and other current liabilities of $0.1&nbsp;million, and an increase in other liabilities of
$0.3&nbsp;million, which were partially offset by a decrease in accounts payable of $0.3&nbsp;million. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Investing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2021, our investing activities provided $0.8&nbsp;million of cash resulting from the sale of assets to NeuBase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2020, our investing activities used $0.1&nbsp;million of cash in the purchase of property and equipment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2020, we used $42,000 of cash for investing activities as a result of the purchase of $0.1&nbsp;million of equipment, partially offset by our receipt of proceeds in
the amount of $57,000 from the sale of equipment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2019, we used $0.1&nbsp;million of cash for investing activities, resulting from the purchase of property and
equipment used for research and development activities and for general and administrative operations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Financing activities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2021, our financing activities provided $49.0&nbsp;million of cash resulting from $51.2&nbsp;million proceeds from our IPO,
net of underwriting discounts and commissions, partially offset by the payment of $2.8&nbsp;million of related offering costs during the period. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">107 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the nine months ended September&nbsp;30, 2020, our financing activities provided $5.5&nbsp;million of cash
resulting from $5.6 million in proceeds from the issuance of convertible notes payable that were subsequently converted into Series C redeemable convertible preferred stock later in 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2020, our financing activities provided $85.3&nbsp;million of cash resulting from $79.6&nbsp;million in proceeds from our issuance of Series C redeemable convertible
preferred stock, net of issuance costs, proceeds of $5.6&nbsp;million from our issuance of convertible notes payable that were converted into Series C redeemable convertible preferred stock, and proceeds of $0.2&nbsp;million from the exercise of
stock options to purchase Class&nbsp;A common stock, partially offset by the payment of $0.1&nbsp;million of capital lease obligations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2019, cash used in
financing activities was $0.1&nbsp;million. This was attributable to the payment of capital lease obligations totaling $0.2&nbsp;million, partially offset by the proceeds from the exercise of stock options totaling $0.1&nbsp;million. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Contractual obligations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes our
contractual obligations as of December&nbsp;31, 2020. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="20" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Payments due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>(In thousands)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Less&nbsp;than</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>1 year</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">1-3&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B><FONT STYLE="white-space:nowrap">3-5&nbsp;years</FONT></B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>More&nbsp;than</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>5&nbsp;years</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating leases</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">11,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,838</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,646</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into agreements in the normal course of business with various third parties for preclinical, clinical and other services. These
contracts are generally cancellable without material penalty upon written notice. Payments associated with these agreements are not included in this table of contractual obligations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our operating lease obligations reflect our lease obligations for our office and laboratory space in Woburn, Massachusetts and our office and life science research space
in South San Francisco, California. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During 2019, we vacated our leased facilities in Woburn, Massachusetts and recorded a discounted lease-related restructuring
liability, which was calculated as the present value of the estimated future facility costs for which we would obtain no future economic benefit over the remaining term of the lease, which ended in July 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During 2020, we vacated the leased facilities in South San Francisco. Our total future minimum commitment due pursuant to this lease is $11.1&nbsp;million. In November
2020, we entered into a non-cancellable sublease agreement for the facility, under the terms of which we are entitled to receive $8.8&nbsp;million in lease payments over the term of the sublease, which ends concurrently with the original lease in
September 2025. As tenant, we remain responsible for the $11.1&nbsp;million minimum lease commitment on the facilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021, we entered into a lease
agreement for approximately 5,000 square feet of office space in Brisbane, California. The term of the lease is three years, and rent will be approximately $0.3&nbsp;million for the first year, with scheduled annual 3% increases. The lease includes
renewal options. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to the office leases, we have future minimum lease payments of $0.6&nbsp;million for leases on research and laboratory equipment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Loan and security agreement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On December&nbsp;17, 2021, we entered
into the Loan Agreement with Oxford, a Delaware limited liability company, as lender (Lender) and collateral agent. The Loan Agreement provides for a term loan in an aggregate </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">108 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
maximum principal amount of $50.0&nbsp;million, of which $5.0&nbsp;million was funded on December&nbsp;17, 2021 and the balance of which is available to be drawn between January&nbsp;3, 2022 and
December&nbsp;31, 2022. The Loan is available in minimum draws of $5.0&nbsp;million, entirely at our option and not contingent upon the completion of clinical, regulatory, financial or other related milestones. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The final maturity date of the Loan is December&nbsp;17, 2026, which may, upon achieving either (i)&nbsp;positive Phase 2b clinical trial data of atacicept in IgAN or
(ii)&nbsp;positive pivotal trial data of atacicept in LN, at our option, be extended by 12 months (the Maturity Date Extension). We are required to make monthly interest-only payments for 48 months (extended to 60 months if the Maturity Date
Extension is exercised) followed by full amortization through maturity. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Initially, through December&nbsp;30, 2021, the Loan bears interest at a per annum rate of
8.254%. Thereafter, the Loan will bear interest at a floating per annum rate (based on the actual number of days elapsed divided by a year of 360 days) equal to the greater of (i) 8.25% and (ii)&nbsp;the sum of (a)&nbsp;the greater of (x)&nbsp;the <FONT
STYLE="white-space:nowrap">30-day</FONT> U.S. LIBOR rate reported in the Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (y) 0.09%, plus (b) 8.16%. The Loan
Agreement also provides for the selection of an alternative benchmark rate in the event of the discontinuance of LIBOR or any subsequent benchmark rate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are
permitted to prepay the Loan in full or in part at any time upon 10 business days&#146; written notice to the Lender, subject to the applicable Prepayment Fee (as defined below). Upon the earliest to occur of the maturity date, acceleration of the
Loan or prepayment of the Loan, we are required to make a final payment equal to 5.0% (7.0% if the Maturity Date Extension is exercised) of the aggregate principal amount of the Loan (the Final Fee). Any prepayments of the Loan, whether mandatory or
voluntary, must include an amount equal to the sum of (a)&nbsp;the portion of the outstanding principal of the Loan being prepaid plus accrued and unpaid interest thereon through the prepayment date, (b)&nbsp;the Final Fee, (c)&nbsp;the
Lender&#146;s expenses and all other obligations that are due and payable to the Lender, and (d)&nbsp;a prepayment fee of (i) 3.0% of the portion of the Loan being prepaid if the repayment is on or before the first anniversary of the funding date of
such term loan or (ii) 2.0% of the portion of the Loan being prepaid if the repayment is after the first anniversary of the funding date but on or before the second anniversary of the funding date of such term loan (the Prepayment Fee). There is no
Prepayment Fee for any prepayments occurring after the second anniversary of the funding date of such term loan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our obligations under the Loan Agreement are
secured by a security interest in all of our assets, other than our intellectual property, which is subject to a negative pledge. The Loan Agreement does not contain any financial related covenants. Included in the Loan Agreement are customary
representations and covenants that, subject to exceptions, restrict our ability to, among other things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness;
engage in mergers, acquisitions and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are not related to our existing business. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon the occurrence of an event of default, a default interest rate of an additional 5.0% may be applied to the outstanding loan balances, and the Lender may declare all
outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Events of default under the Loan Agreement include customary events of default, including, but not limited to: (i)&nbsp;failure to
(a)&nbsp;make any payment of principal or interest on its due date, or (b)&nbsp;pay any other obligations within three business days after such obligations are due and payable; (ii)&nbsp;failure to perform any obligation under specified covenants;
(iii)&nbsp;the occurrence of a material adverse change; (iv)&nbsp;we or any of our subsidiaries being or becoming insolvent, beginning an insolvency proceeding, or becoming subject to an insolvency proceeding that is not dismissed or stayed within
45 days; (v)&nbsp;a default under any agreement with a third party resulting in a right by such third </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">109 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
party to accelerate the maturity of any indebtedness in an amount in excess of $500,000 or that could reasonably be expected to have a material adverse change; (vi)&nbsp;the rendering of
judgments, orders, or decrees for the payment of money in an amount, individually or in the aggregate, of at least $500,000 that remain unsatisfied, unvacated, or unstayed for a period of 10 days after the entry thereof; (vii)&nbsp;revocation,
rescission, suspension or adverse modification of any governmental approval, or <FONT STYLE="white-space:nowrap">non-renewal</FONT> of a governmental approval in the ordinary course for a full term, that could reasonably be expected to result in a
material adverse change; and (viii)&nbsp;failure of a lien created under the Loan Agreement or any other loan document to constitute a valid and perfected lien on any of the collateral purported to be secured thereby, subject to no prior or equal
lien, other than permitted liens. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Internal control over financial reporting </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the preparation of our financial statements for 2020, we determined a material weakness in our internal control over financial reporting existed during 2019, which
material weakness remained unremediated as of December&nbsp;31, 2020. See the section titled &#147;Risk factors&#151;We have identified a material weakness in our internal control over financial reporting. If our remediation of this material
weakness is not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial
condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our Class&nbsp;A common stock.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT
STYLE="white-space:nowrap">Off-balance</FONT> sheet arrangements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since the date of our incorporation, we have not engaged in any <FONT
STYLE="white-space:nowrap">off-balance</FONT> sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Critical
accounting policies, significant judgments and use of estimates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The discussion and analysis of our financial condition and results of operations is based on
our financial statements, which have been prepared in accordance with United States generally accepted accounting principles. The preparation of these financial statements requires us to make estimates and assumptions that affect the reported
amounts of assets and liabilities, and the disclosure of contingent assets and liabilities, at the date of the financial statements, as well as revenue and expenses incurred during the reporting periods. Our estimates are based on our historical
experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other
sources. Actual results may differ from these estimates under different assumptions or conditions. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate
to the more significant areas involving management&#146;s judgments and estimates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">While our significant accounting policies are described in the notes to our
financial statements, we believe that the following critical accounting policies and estimates are most important to understanding and evaluating our reported financial results. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research contract costs and accruals </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We enter into various research
and development and other agreements with commercial firms, researchers and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are recorded as research and development
expenses as incurred. We record accruals for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">110 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies or clinical trials, including the phase or completion
of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ materially from our estimates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain a stock-based compensation plan
as a long-term incentive for employees, <FONT STYLE="white-space:nowrap">non-employee</FONT> directors, consultants and advisors. The plan allows for the issuance of a variety of equity incentive awards, including incentive stock options, <FONT
STYLE="white-space:nowrap">non-qualified</FONT> stock options and restricted stock awards. We account for stock-based compensation by measuring and recognizing compensation expense for all share-based awards made to employees and <FONT
STYLE="white-space:nowrap">non-employees</FONT> based on estimated grant-date fair values. We use the straight-line method to allocate compensation cost to reporting periods over the requisite service period, which is generally the vesting period.
We recognize actual forfeitures by reducing the stock-based compensation expense in the same period as the forfeitures occur. We estimate the fair value of share-based awards to employees and <FONT STYLE="white-space:nowrap">non-employees</FONT>
using the Black-Scholes model. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Estimating the fair value of equity-settled awards as of the grant date using the Black-Scholes option pricing model is affected by
assumptions regarding a number of complex variables. Changes in the assumptions can materially affect the fair value and ultimately how much stock-based compensation is recognized. These inputs are subjective and generally require significant
analysis and judgment to develop. These inputs are as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Fair value of common stock&#151;See the subsection titled &#147;Fair value of common stock&#148; below.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expected term&#151;The expected term represents the average period that our options granted are expected to be outstanding
and is determined using the simplified method (based on the <FONT STYLE="white-space:nowrap">mid-point</FONT> between the weighted-average vesting date and the end of the contractual term). We have very limited historical information to develop
reasonable expectations about future exercise patterns and post-vesting employment termination behavior for our stock option grants. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expected volatility&#151;Since we were a privately-held company until our IPO in May 2021 and have only a limited trading
history for our common stock, the expected volatility was estimated based on the historical average volatility for comparable publicly traded biopharmaceutical companies over a period equal to the expected term of the stock option grants. The
comparable companies were chosen based on their similar size, life cycle stage, or area of specialty. We will continue to apply this process until enough historical information regarding the volatility of our own stock price becomes available.
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Risk-free interest rate&#151;The risk-free interest rate is based on the U.S. Treasury zero coupon issues in effect at the
time of grant for periods corresponding with the expected term of the options. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Expected dividend yield&#151;We have never paid dividends on our common stock and have no plans to pay dividends on our
common stock. Therefore, we used an expected dividend yield of zero. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will continue to use judgment in evaluating the expected volatility,
expected terms, and interest rates utilized for our stock-based compensation calculations on a prospective basis. Assumptions we used in applying the Black-Scholes option-pricing model to determine the estimated fair value of our stock options
granted involve inherent uncertainties and the application of significant judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or estimates, our equity-based compensation could be materially
different. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">111 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value of common stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Historically, for all periods prior to our IPO, the fair values of the shares of our common stock underlying our share-based awards were determined on each grant date by
our board of directors with input from management and the assistance of an independent third-party valuation specialist. Given the absence of a public trading market of our common stock, and in accordance with the American Institute of Certified
Public Accountants Practice Aid, <I>Valuation of Privately-Held-Company Equity Securities Issued as Compensation</I> (Practice Aid), our board of directors exercised reasonable judgment and considered numerous objective and subjective factors to
determine the best estimate of the fair value of our common stock at each grant date. These factors include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">external market conditions affecting the proteomics and genomics biotechnology industry and trends within the industry;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our stage of development; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the rights, preferences and privileges of our redeemable convertible preferred stock relative to those of our common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the prices at which we sold shares of our redeemable convertible preferred stock; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">actual operating results and projected financial performance, including our levels of available capital resources;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the progress of our research and development efforts and business strategy; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">equity market conditions affecting comparable public companies; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">general U.S. market conditions; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the lack of marketability of our common stock. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In valuing our common stock, the fair value of our business, or enterprise value, was determined using various valuation methods, including combinations of income,
market and asset approaches with input from management. The income approach determines value by using one or more methods that convert anticipated economic benefits into a present single amount. The application of the income approach establishes
value by methods that discount or capitalize earnings or cash flow, by a discount or capitalization rate that reflects investors&#146; rate of return expectations, market conditions, and the relative risk of the subject investment. The market
approach involves identifying and evaluating comparable public companies and acquisition targets that operate in the same industry or which have similar operating characteristics as the subject company. From the comparable companies, publicly
available information is used to extrapolate market-based valuation multiples that are applied to historical or prospective financial information in order to derive an indication of value. The asset approach determines the value of the underlying
assets and liabilities of a business as a means of determining the value of the business in aggregate. This approach can include the value of both tangible and intangible assets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Practice Aid identifies various available methods for allocating enterprise value across classes and series of capital stock to determine the estimated fair value of
common stock at each valuation date. In accordance with the Practice Aid, we considered the following methods: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Option Pricing Method (OPM)</B>.&nbsp;&nbsp;&nbsp;&nbsp;Under the OPM, shares are valued by creating a series of call
options with exercise prices based on the liquidation preferences and conversion terms of each equity class. The estimated fair values of the redeemable convertible preferred stock and common stock are inferred by
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">112 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
analyzing these options. This method is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Probability-Weighted Expected Return Method (PWERM)</B>.&nbsp;&nbsp;&nbsp;&nbsp;The PWERM is a scenario-based analysis
that estimates value per share based on the probability-weighted present value of expected future investment returns, considering each of the possible outcomes available to us, as well as the economic and control rights of each share class. This
method is generally most appropriate to use when the time to a liquidity event is short, making the range of possible future outcomes relatively easy to predict. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on our early stage of development and other relevant factors, we determined that the OPM was the most appropriate method for allocating our enterprise value to
determine the estimated fair value of our common stock for valuations during 2019 and early 2020. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Beginning in March 2020, we used a hybrid method to determine the
estimated fair value of our common stock, which included both the OPM and PWERM models. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Application of these approaches involves the use of estimates, judgment, and
assumptions that are highly complex and subjective, such as those regarding our expected future revenue, expenses, and cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of future events. Changes
in any or all of these estimates and assumptions, or the relationships between those assumptions, impact our valuations as of each valuation date and may have a material impact on the valuation of common stock. The assumptions underlying these
valuations represent our management&#146;s best estimate, which involve inherent uncertainties and the application of management judgment. As a result, if factors or expected outcomes change and we use significantly different assumptions or
estimates, our stock-based compensation could be materially different. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the completion of our IPO, the fair value of each share of the underlying common stock
has been determined based on the closing price as reported on the date of grant on the primary stock exchange on which our Class&nbsp;A common stock is traded. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging growth company status </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an emerging growth company, as
defined in the JOBS Act. Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. Other
exemptions and reduced reporting requirements under the JOBS Act for emerging growth companies include presentation of only two years audited financial statements in this prospectus, an exemption from the requirement to provide an auditor&#146;s
report on internal controls over financial reporting pursuant to the Sarbanes-Oxley Act, an exemption from any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation, and less
extensive disclosure about our executive compensation arrangements. We have elected to use the extended transition period for complying with new or revised accounting standards that have different effective dates for public and private companies
until the earlier of the date that (i)&nbsp;we are no longer an emerging growth company or (ii)&nbsp;we affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not
be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We will remain an emerging growth
company under the JOBS Act until the earliest of (i)&nbsp;the last day of our first fiscal year in which we have total annual gross revenue of $1.07&nbsp;billion or more, (ii)&nbsp;the date on which we have issued more than $1.0&nbsp;billion of <FONT
STYLE="white-space:nowrap">non-convertible</FONT> debt instruments during the previous three fiscal years, (iii)&nbsp;the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">113 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
date on which we are deemed a &#147;large accelerated filer&#148; under the rules of the SEC with at least $700.0&nbsp;million of outstanding equity securities held by <FONT
STYLE="white-space:nowrap">non-affiliates,</FONT> or (iv)&nbsp;December 31, 2026. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recent accounting pronouncements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See Note 2 to our audited financial statements included elsewhere in this prospectus for more information about recent accounting pronouncements, the timing of their
adoption, and our assessment, to the extent we have made one yet, of their potential impact on our financial condition of results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">114 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_12"></A>Business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Overview </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are a late-stage biotechnology company focused on developing and
commercializing transformative treatments for patients with serious immunological diseases. Our lead product candidate, atacicept, a self-administered fusion protein that blocks both BLyS and APRIL, is currently being evaluated for the treatment of
IgAN in the Phase 2b ORIGIN trial, which we expect will complete enrollment in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and report topline results in the fourth quarter of 2022. If the data from this trial are positive, we plan to initiate a
pivotal Phase 3 clinical trial in 2023. We plan to initiate a Phase 3 clinical trial of atacicept in LN, a severe renal manifestation of SLE, based on positive feedback from the FDA&#146;s review of promising clinical results in a Phase 2 clinical
trial of atacicept in high disease activity patients with SLE. In December 2021, we obtained worldwide, exclusive development and commercial rights from Amplyx, a wholly owned subsidiary of Pfizer, for MAU868, a potentially <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> monoclonal antibody to treat BKV infections. We believe MAU868 is the only clinical-stage neutralizing monoclonal antibody that is directed against BKV, a
polyoma virus that can have devastating consequences in certain settings such as kidney transplant and hematopoietic stem cell transplant. In an interim analysis of Phase 2 data in BK viremia among kidney transplant recipients, MAU868 was shown to
be well tolerated and demonstrated a clinically significant reduction of virologic activity. We expect to share full results from the interim analysis in <FONT STYLE="white-space:nowrap">mid-2022</FONT> and expect to initiate a Phase 2b or Phase 3
clinical trial in 2023. We believe that our current pipeline programs, shown in Figure 1, leverage the deep expertise of the Vera Therapeutics team and have strong commercial synergies. We currently hold global rights to all of our pipeline
programs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 1: Vera therapeutics pipeline </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g55o74.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in IgAN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">IgAN is a
serious and progressive autoimmune disease of the kidney that is driven by the production of immunogenic galactose-deficient IgA1 <FONT STYLE="white-space:nowrap">(Gd-IgA1)</FONT> which is associated with increased risk of kidney-related morbidity
and mortality. We estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union, and 130,000 in Japan. Up to 50% of patients diagnosed with IgAN develop ESRD within 20 years from initial
diagnosis, requiring dialysis or kidney transplant. ESRD causes considerable morbidity and impact on patients&#146; lives and represents a significant health economic burden, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">115 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
which was estimated to be $49.2&nbsp;billion in the United States in 2018. Despite this high level of morbidity, only one treatment, TARPEYO (developed by Calliditas Therapeutics AB under the
name Nefecon), a recently-approved reformulated steroid, has been approved for this indication, and the current standard of care continues to consist of <FONT STYLE="white-space:nowrap">off-label</FONT> use of RAAS inhibitors, including ACE
inhibitors and ARBs, and potentially steroids. We estimate the U.S. market opportunity for novel therapeutics in IgAN is approximately $4.0&nbsp;billion to $8.0&nbsp;billion annually, based on the disease prevalence and the segment of IgAN patients
at high risk of progressing to ESRD. In Europe and Japan, we estimate the annual market opportunity for novel IgAN therapeutics to be $1.0&nbsp;billion and $600&nbsp;million, respectively. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is a fusion protein self-administered as a subcutaneous injection once weekly that blocks both BLyS and APRIL, which stimulate B cells and plasma cells to
produce autoantibodies contributing to certain autoimmune diseases. We believe that atacicept&#146;s mechanism has the potential to drive clinical success by measures designed to assess efficacy in IgAN and other immunologic diseases. BLyS
inhibition has been clinically and commercially validated through the approval of Benlysta (belimumab) in both SLE and LN. Preclinical and clinical evidence supports that atacicept&#146;s mechanism of dual inhibition of BLyS and APRIL may provide
improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone. Atacicept has been shown in a clinical trial to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> which is central to
the pathogenesis of IgAN, and therefore has the potential to be the first disease modifying therapy for IgAN due to its ability to act on core pathophysiology processes. As reported in a Phase 2a clinical trial of 16 patients conducted by Merck
KGaA, Darmstadt, Germany, atacicept is the first and only molecule in development to demonstrate a 60% reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in a randomized controlled study in IgAN patients (75 mg dose, n&#061;4 at 24
weeks), which we believe can be disease modifying. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have worldwide, exclusive rights to atacicept from Ares, an affiliate of Merck KGaA, Darmstadt, Germany,
pursuant to the Ares Agreement, which advanced atacicept in randomized, double-blind, placebo-controlled clinical trials for several autoimmune diseases in over 1,500 patients, in which it was well tolerated. In IgAN, Merck KGaA, Darmstadt, Germany,
conducted a randomized, double-blind, placebo-controlled Phase 2a trial, known as JANUS. Results from the JANUS trial showed a dose-dependent effect of atacicept 25mg and 75mg weekly on serum <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT>
proteinuria and key biomarkers, including serum immunoglobulin levels. Atacicept was observed to be generally well tolerated. Specifically, the atacicept 75 mg dose arm demonstrated a 60% reduction in serum
<FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are conducting a global, randomized, double-blind, placebo-controlled Phase 2b clinical trial in IgAN, which we
refer to as ORIGIN. The ORIGIN trial is evaluating three subcutaneous weekly doses of atacicept (25 mg, 75 mg and 150 mg) and their impact on the reduction of proteinuria as the primary endpoint. A significant reduction in proteinuria, as measured
by UPCR in a <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, is associated with improved renal outcomes in patients with IgAN. UPCR is a surrogate endpoint endorsed by the FDA for primary glomerular diseases associated with
significant proteinuria, including IgAN. The ORIGIN trial is powered to demonstrate a statistically significant difference between atacicept and placebo in decrease of proteinuria. Given the FDA&#146;s recent approval of TARPEYO, we believe this
provides validation for the use of proteinuria as a surrogate for accelerated approval. Secondary endpoints include the difference in kidney function between treated and placebo patients as measured by estimated eGFR and reduction in <FONT
STYLE="white-space:nowrap">Gd-IgA1.</FONT> We are currently enrolling the Phase 2b ORIGIN trial and expect to enroll a total of 105 patients at multiple global sites and to report topline results in the fourth quarter of 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in LN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on positive feedback from the FDA&#146;s review
of promising clinical results in a Phase 2 clinical trial of atacicept in high disease activity patients with SLE, we are planning to initiate a Phase 3 clinical trial of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">116 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that there are approximately 110,000 LN patients in the United States, 69,000 in the
European Union, and 22,000 in Japan. We estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million and $200&nbsp;million in United States, Europe and Japan, respectively. Significant unmet
need for improved efficacy persists for these patients despite the recent approval of the first two <FONT STYLE="white-space:nowrap">LN-specific</FONT> therapies. Fewer than half of patients treated for LN have a complete response to therapy, and
among patients without a complete response, over half will have non-functioning kidneys within five years. Benlysta (belimumab), a BlyS-only inhibitor, is one of the two therapies approved for patients with LN. Both BlyS and APRIL levels are
increased in patients with SLE, suggesting that dual inhibition by atacicept may be more potent than blocking BLyS alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously initiated a
randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the <FONT STYLE="white-space:nowrap">APRIL-LN</FONT> trial, aimed to evaluate the efficacy and safety of atacicept at 150 mg twice weekly for four
weeks&#151;then weekly&#151;in patients with active LN. However, this trial was terminated early due to three subjects developing hypogammaglobulinemia with induction therapy (MMF and CS) which continued to worsen when initiating atacicept and
subsequently two subjects developed pneumonia. In prior Phase 2 clinical trials of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint in the broader SLE study population, atacicept achieved
positive clinical data on multiple measures within the <FONT STYLE="white-space:nowrap">pre-specified</FONT> High Disease Activity patient segment (defined as Systemic Lupus Erythematosus Disease Activity Index 2000
<FONT STYLE="white-space:nowrap">(SLEDAI-2K)</FONT> <FONT STYLE="font-family:Times New Roman">&#8805;</FONT> 10 at screening), including reduction of renal flares, which we believe supports atacicept&#146;s applicability in LN. Because both
preclinical and clinical evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone, we believe there is
a strong rationale to conduct a clinical trial of atacicept in LN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 3 randomized, double-blinded, placebo-controlled trial will evaluate the efficacy and
safety of atacicept in subjects with LN. The clinical trial consists of a <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind treatment period, followed by a <FONT STYLE="white-space:nowrap">104-week</FONT> open-label treatment period and a
<FONT STYLE="white-space:nowrap">26-week</FONT> safety <FONT STYLE="white-space:nowrap">follow-up</FONT> period. The trial will assess 150 mg of once weekly subcutaneous injections of atacicept versus placebo. The primary endpoint is complete renal
response at 52 weeks. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MAU868 in BK viremia among kidney transplant recipients </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are developing MAU868 as a potential treatment for BK viremia in kidney transplant recipients. While up to 90% of healthy adults have been infected with the BKV at
some point in their lives, it remains latent in everyone except severely immunocompromised populations such as kidney transplant recipients. BKV is a polyoma virus that can cause BKVN, a condition in which BK infection, typically first identified as
BK viremia, triggers inflammation, which then progresses to fibrosis and tubular injury; BKVN is a leading cause of allograft loss. Currently, there are no approved treatment options for BK viremia or BKVN. We estimate that there are approximately
80,000 kidney transplants are conducted globally each year, with approximately 20,000 in the United States, 20,000 in Europe, 1,500 in Japan, and 10,000 in China. Approximately 15% of kidney transplant recipients develop BK viremia; <FONT
STYLE="white-space:nowrap">3-4%</FONT> of kidney transplant recipients develop BKVN. We estimate the market for a novel agent to treat BK viremia in kidney transplant recipients to be approximately $700&nbsp;million annually worldwide, with
$350&nbsp;million, $120&nbsp;million, $18&nbsp;million, and $50&nbsp;million in peak sales generated in the United States, Europe, Japan, and China, respectively. We believe that MAU868 has the potential to become standard of care for the treatment
of BK viremia in order to prevent devastating consequences such as BKVN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MAU868 has been shown in an interim analysis of week 12 data from Cohort 1 and 2 of a Phase
2 clinical trial to be well tolerated and have reduction of virologic activity. We expect to share full Cohort 1 and Cohort 2 interim </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">117 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
analysis results in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> Given the overlap of patients with IgAN and BKV, we obtained worldwide, exclusive rights to develop, manufacture and
commercialize MAU868 from Amplyx, a wholly owned subsidiary of Pfizer in December 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MAU868 in BK cystitis among HSCT patients </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are exploring the development of MAU868 to treat BKV cystitis in HSCT patients. Patients undergoing HSCT are at risk for BKV reactivation due to immunodeficiency; in
this setting, BK reactivation and subsequent viruria and viremia can lead to cystitis, including hemorrhagic cystitis. Cystitis is characterized by dysuria, urgency, and/or frequency, while hemorrhagic cystitis indicates the presence of microscopic
or gross hematuria. Both BKV cystitis and hemorrhagic cystitis are associated with high patient morbidity and prolonged hospitalization, yet there are no approved treatment options. An estimated 44,000 allogeneic HSCTs are conducted globally each
year, with approximately 10,000 in the United States, 16,000 in Europe, 3,500 in Japan, and 2,500 in China. An estimated 57,000 autologous HSCTs are conducted globally each year, with approximately 17,000 in the United States, 27,000 in Europe,
2,500 in Japan, and 1,800 in China. Approximately 15% of allogeneic recipients and 5% of autologous recipients develop BK cystitis, including hemorrhagic cystitis. Based on primary market research with physicians and extensive secondary research, we
estimate the market for a novel agent to treat BKV cystitis to be approximately $550&nbsp;million annually worldwide, with $230&nbsp;million, $230&nbsp;million, $50&nbsp;million, and $7&nbsp;million in peak sales generated in the United States,
Europe, Japan, and China, respectively. We believe that MAU868 may represent an important future treatment option for these patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Our business principles
and strategy </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our goal is to develop and commercialize transformative treatments for patients suffering from severe immunological diseases. We believe the
successful translation of biomedical science into innovative therapeutic products for patients with immunological diseases will enable outsized growth over the next decade and beyond. Specifically, our strategy is based on the following business
principles: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Develop disease modifying medicines to improve patients&#146; lives.&nbsp;&nbsp;&nbsp;&nbsp;</B>Our team seeks to bring
transformative medical products to patients with severe immunological diseases, who often receive steroids for treatment. The <FONT STYLE="white-space:nowrap">non-specific</FONT> immunologic effect of steroids, with known acute and chronic side
effects, presents an important opportunity for innovation. We aim to develop and commercialize disease modifying drugs that target the source of disease, minimize side effects, and have high potential to meaningfully change standard medical care and
improve patients&#146; lives. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Establish clear <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> to
successful products.&nbsp;&nbsp;&nbsp;&nbsp;</B>We apply our deep drug development experience, scientific rigor, and disciplined decision making to establish clear
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">line-of-sight</FONT></FONT> along the full spectrum of drug development. We pursue biologic targets, product candidates, and disease indications with a
<FONT STYLE="white-space:nowrap">de-risked</FONT> profile and capital efficient development pathway, and optimize for high probability of clinical, regulatory, and commercial success. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Build a leading biotech company that delivers innovative medicines to patients.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe
our team&#146;s expertise and our business culture are fundamental to our success. Our Research and Development team is led by experienced drug development executives with proven track records in clinical and commercial development who have led or
been involved in the approvals of more than 12 medicines from leading companies, including Gilead Sciences and Genentech. We leverage our team&#146;s <FONT STYLE="white-space:nowrap">know-how</FONT> with additional outsourced resources and enable
focused clinical development of our product candidates with the goal of improving patients&#146; lives. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These principles have guided us to the
successful <FONT STYLE="white-space:nowrap">in-licensing</FONT> of atacicept from Ares and obtaining the rights to MAU868 from Amplyx, in each case with worldwide rights for development and commercialization in all
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">118 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
indications. We take a gated-capital raise approach and scale product candidate investment and exposure in close step with key development milestones to ensure high return on development costs.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The near-term objectives to achieve our goal include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Complete global development of atacicept in IgAN.&nbsp;&nbsp;&nbsp;&nbsp;</B>We are currently enrolling patients in the
Phase 2b ORIGIN trial and expect to enroll a total of 105 patients at multiple global sites. We expect to report topline results from ORIGIN in the fourth quarter of 2022. If the data from this trial are positive, we plan to initiate a pivotal Phase
3 clinical trial in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Complete global development of atacicept in LN.</B>&nbsp;&nbsp;&nbsp;&nbsp;We intend to initiate a Phase 3 clinical
trial of atacicept as a potential treatment for patients with LN. LN is a frequent but devastating complication of SLE. The recent FDA approval of the anti-BLyS antibody, Benlysta (belimumab), provides clinical and regulatory precedent upon which to
build our program. We believe that atacicept could offer a significant efficacy advantage for LN patients with its dual anti-APRIL and anti-BlyS mechanism. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Complete global development of MAU868 in BK viremia in kidney transplant recipients and explore treatment of BK cystitis
in HSCT patients</B>.&nbsp;&nbsp;&nbsp;&nbsp;We expect to share full Cohort 1 and Cohort 2 interim analysis results from the ongoing Phase 2 clinical trial in kidney transplant recipients in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> We
intend to initiate a Phase 2b or Phase 3 clinical trial in 2023. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Build and scale organizational capabilities to support commercialization of atacicept and
MAU868.</B>&nbsp;&nbsp;&nbsp;&nbsp;Under the leadership of our experienced management team, we plan to build a specialized commercial organization to launch atacicept and MAU868 in the United States and other key markets, if approved. Within certain
<FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets, we may consider strategic collaborations for commercialization. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Explore additional disease areas where atacicept holds significant therapeutic promise.&nbsp;&nbsp;&nbsp;&nbsp;</B>By
targeting APRIL and BLyS, atacicept&#146;s ability to reduce disease causing autoantibodies may provide clinical benefit. We intend to explore additional immunologic diseases where BLyS and APRIL are abnormally elevated, or where autoantibodies play
an important role. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><B>Expand our pipeline by acquiring or <FONT STYLE="white-space:nowrap">in-licensing</FONT> product candidates for
immunologic diseases with unmet needs.</B>&nbsp;&nbsp;&nbsp;&nbsp;We believe our expertise and track record will enable us to identify and acquire or <FONT STYLE="white-space:nowrap">in-license</FONT> additional product candidates that represent
opportunities to expand the potential value of our pipeline. We will leverage our lean clinical development operation to bring to market additional product candidates to address immunologic diseases. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Management team </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We were founded and are led by a team of experienced drug
development professionals who have proven track records in clinical and commercial development and have led or been involved in the approvals of 10 medicines from Gilead Sciences. Inc. (Gilead) and Genentech, Inc. (Genentech), including numerous
drugs within Gilead&#146;s multi-billion blockbuster HIV and HCV franchises. Our President and Chief Executive Officer, Marshall Fordyce, M.D., brings more than 15 years of experience leading teams in clinical translation, development, and
commercialization of new treatments. Earlier in his career, Dr.&nbsp;Fordyce served as Gilead&#146;s Senior Director of Clinical Research where he contributed to seven new drug approvals and served as project lead for Gilead&#146;s tenofovir
alafenamide development program that led to five commercial products, including Genvoya and Descovy, which collectively generated over $12.0&nbsp;billion in worldwide sales in 2019. Our senior management team also includes: Chief Financial Officer,
Sean Grant, who was previously Vice President, Corporate Strategy </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">119 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and Business Development at CareDx, Inc. and Vice President in the Global Healthcare Investment Banking Division at Citigroup where he specialized in public and private capital raising as well as
M&amp;A, and executed a broad range of transactions for many of the world&#146;s leading life sciences companies; Chief Medical Officer, Celia Lin, M.D., who joined from Genentech and was previously at Amgen Inc., where she led Phase 3 global trial
execution in various therapeutic areas, as well as a regulatory filing in an orphan disease; Chief Development Officer, Joanne Curley, Ph.D., who was formerly head of Portfolio Management at Gilead; Chief Business Officer, Lauren Frenz, who held
positions of increasing responsibility within Gilead&#146;s commercial organization; Senior Vice President, Development Operations, Tom Doan, who was formerly Executive Director of Clinical Operations and Therapeutic Area Head of Inflammation and
Respiratory at Gilead; Senior Vice President and Head of Product Development and Manufacturing, Tad Thomas, Ph.D., who was formerly Associate Vice President, Technical Operations at Codexis, Inc. and held previous manufacturing leadership roles at
Bayer HealthCare LLC and other biopharmaceutical companies; and Senior Vice President, Finance and Chief Accounting Officer, Joseph Young, who was formerly Senior Vice President, Finance and Treasurer at Plexxikon Inc. In conjunction with the Ares
Agreement, we completed an approximately $80.0&nbsp;million Series C redeemable convertible preferred stock financing led by Abingworth LLP. Other investors included Sofinnova Investments, Longitude Capital, Fidelity Management&nbsp;&amp; Research
Company LLC, Surveyor Capital (a Citadel company), Octagon Capital, Kleiner Perkins, GV (formerly Google Ventures), and Alexandria Venture Investments. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of<B> </B>December&nbsp;31, 2021, our licensed
patent portfolio related to atacicept contains approximately 15 issued U.S. patents, as well as foreign counterparts of a subset of these patents in several foreign countries, including countries within the European Patent Convention and the
Eurasian Patent Organization. Our licensed patent portfolio related to atacicept also includes a pending PCT application and a counterpart Taiwanese application. Because atacicept is a biologic, marketing approval would also provide 12 years of
market exclusivity from the approval date of a BLA in the United States. Additionally, we plan to seek orphan drug designation for atacicept in IgAN from the FDA and European Medicines Agency (EMA), which would allow us to obtain regulatory
exclusivity protection from the approval date for seven years in the United States and 10 years in the European Union. Our licensed patent portfolio covering MAU868 includes three issued U.S. patents, a pending US application, as well as certain
foreign counterparts of a subset of these patents granted in Australia, China, and Taiwan, and pending applications in other jurisdictions such as Canada, Mexico, Europe and Japan.&nbsp;In addition, there is a pending PCT application, and a
counterpart application in Taiwan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Atacicept in IgAN </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are developing
atacicept as a potential treatment for patients with IgAN, a disease with a high unmet medical need and limited treatment options available. IgAN is a serious and progressive autoimmune disease of the kidney, that is driven by the production of
pathogenic <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> IgAN patients with elevated <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> are at increased risk of kidney-related morbidity and mortality. As reported in the Phase 2a JANUS trial,
atacicept is the first molecule in development to demonstrate a 60% or greater reduction in plasma <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients, suggesting atacicept targets the source of disease in these patients. Based on these
encouraging results, we are currently conducting the randomized, double-blind, placebo-controlled Phase 2b ORIGIN trial to further evaluate the efficacy and safety of atacicept in patients with IgAN. We expect to report topline results in the fourth
quarter of 2022, and if positive, we plan to initiate a pivotal Phase 3 clinical trial in 2023. We believe that atacicept has the potential to be the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and
the leading B cell-targeted therapy for IgAN. Up to 50% of confirmed IgAN patients progress to ESRD, requiring dialysis or kidney transplant. ESRD causes significant morbidity and impact on patients&#146; lives and represents a significant health
economic burden </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">120 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
estimated to be over $40.0&nbsp;billion annually in the United States. Despite this high level of morbidity, the current standard of care consists of
<FONT STYLE="white-space:nowrap">off-label</FONT> use of RAAS inhibitors, including ACE inhibitors and ARBs, and potentially steroids. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pathophysiology of
IgAN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The IgA antibody plays a key role in the immune system by protecting the body from foreign substances such as bacteria and viruses. Patients with IgAN
produce elevated levels of <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> This abnormal glycosylation pattern of IgA1 is of central importance to the disease etiology. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figure 2 below, a multi-step process leads to the ultimate development of progressive renal injury. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 2: IgAN pathophysiology&#151;overview </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g05e37.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f46.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">B cells, which mature into plasma cells, are abnormally primed in the Peyer&#146;s patch region of the ileum of the intestines, potentially due to a
combination of genetic predisposition and environmental, bacterial or dietary factors. BLyS promotes B cell maturation and survival, increasing the number of disease causing B&nbsp;cells.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f47.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">APRIL, a factor important for plasma cell survival, becomes upregulated, resulting in increased numbers of disease-causing plasma cells.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f48.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">APRIL increases the number of plasma cells and increases antibody class switching, which is a mechanism that changes cells production from one
immunoglobulin to another, causing an increase in the production of immunogenic <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> (See &#147;Hit 1&#148; in Figure 3 below.)</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f49.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> antibodies are immunogenic when found in the systemic circulation, which triggers autoantibodies,
or antibodies created by the body in response to a constituent of its own tissue. (See &#147;Hit&nbsp;2&#148; in Figure 3 below.)</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f50.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Autoantibodies against <FONT STYLE="white-space:nowrap">Gd-IgA</FONT> lead to the formation of pathogenic immune complexes, or clusters of antibodies.
(See &#147;Hit 3&#148; in Figure 3 below.)</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">121 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f51.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pathogenic immune complexes are deposited and become trapped in the kidney&#146;s glomeruli and initiate an inflammatory response that damages the
membranes, resulting in protein and blood leaking into the urine. (See &#147;Hit 4&#148; in Figure 3 below.)</P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f52.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">As the glomeruli are destroyed, the kidney&#146;s ability to remove waste products from the blood is reduced, which can result in potentially life-threatening complications that lead to the need for dialysis or kidney transplant in
many patients.</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Similarly, IgAN has also been described as having a <FONT STYLE="white-space:nowrap">multi-hit</FONT> pathogenesis, as shown in Figure 3
below, and referenced in the steps <FONT STYLE="white-space:nowrap">3-6</FONT> above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 3: IgAN pathophysiology&#151;downstream effects of
elevated <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g07g55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is central to the pathogenesis of IgAN </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is a subclass of IgA antibodies that lack units of galactose, a type of sugar, at the
<FONT STYLE="white-space:nowrap">O-linked</FONT> glycans of their hinge region, as shown in Figure 4 below. The hinge region is a stretch of amino acids in the IgA antibody. Circulating immune complex&#151;containing
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> proteins have been shown to be the target antigens for IgG antibodies with specificity for the hinge region. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">122 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 4: Components of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g07g56.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A histopathological hallmark of IgAN is deposition of Gd&#151;IgA1 in the glomerular mesangium, either alone or in combination with
IgG and/or immunoglobulin M (IgM). Sampling of the serum of subjects with IgAN has confirmed the presence of elevated levels of circulating immune complex&#151;containing <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials of patients with IgAN have correlated higher serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> with greater severity of IgAN disease,
suggesting that reduction in serum levels of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> may slow disease progression. Compared with healthy subjects, patients with IgAN have an increase in the proportion of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> <FONT STYLE="white-space:nowrap">O-glycoforms</FONT> in the serum. As published in Kidney International, in a prospective study of 275 patients with IgAN, higher serum levels of aberrantly glycosylated
IgA1 demonstrated correlation with a higher likelihood of developing progressive renal failure, as shown in Figure 5 below. A separate clinical trial of patients with IgAN of varying severity found that higher titers of autoantibodies specific for <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> corresponded to both absolute renal risk score and risk of <FONT STYLE="white-space:nowrap">end-stage</FONT> renal disease or death. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 5: Renal survival in IgAN patients with four quartile serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g02b10.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">123 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, high serum APRIL levels correlate with increased expression of serum Gd&#151;IgA1 in IgAN patients and
high serum BLyS levels are associated with more severe clinical features, as well as more severe histopathological features. For these reasons, we believe a fusion protein that blocks both BLyS and APRIL, which has the potential to reduce levels of <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> in serum, would address the upstream source of IgAN, and represent the first disease-modifying approach for IgAN. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Disease burden, diagnosis, and predictors of disease progression </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">IgAN
is a rare disease in the United States and European Union and is also the predominant cause of primary glomerulonephritis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients with IgAN are diagnosed
throughout life, but most commonly in the second and third decade. There are three common ways in which patients present: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">40-50%</FONT> present with one or more episodes of gross (visible) hematuria, often linked
to an upper respiratory tract infection. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">30-40%</FONT> present with microscopic hematuria and mild proteinuria, which is detected
in a routine physical or during chronic kidney disease evaluation. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Less than 10% present with either nephrotic syndrome or an acute, rapidly progressive glomerulonephritis with symptoms
including edema, hypertension, renal insufficiency, and hematuria. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once IgAN is suspected based on clinical history and laboratory data, kidney
biopsy, which is the gold standard for IgAN diagnosis, is performed. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>IgAN market opportunity </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate there are approximately 126,000 biopsy-confirmed IgAN patients in the United States, 136,000 in the European Union, and 130,000 in Japan, and that growth in
the diagnosed prevalent population is due to overall population growth. Underlying genetic differences may contribute to the significantly higher rate in Japan. As therapies become commercially available, however, an increase in diagnosis rate or
longer time to progression, due to better treatments, may increase the diagnosed population over time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate the U.S. market opportunity for novel
therapeutics in IgAN is approximately $4.0&nbsp;billion to $8.0&nbsp;billion annually, based on the prevalence of the disease in the United States and the segment of IgAN patients at high risk of progressing to ESRD. In Europe and Japan, we estimate
the annual market opportunity for novel IgAN therapeutics to be $1.0&nbsp;billion and $600&nbsp;million, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Current standard of care for IgAN
patients </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite the high unmet medical need in IgAN, there are limited treatment options available. The following two general approaches are typically
employed for the treatment of patients with IgAN: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">Non-specific</FONT> measures to slow progression, including blood pressure control, and in
patients with proteinuria, RAAS inhibitors, including ACE inhibitors or ARBs. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Steroids with or without other immunosuppressive agents to <FONT STYLE="white-space:nowrap">non-specifically</FONT> reduce
inflammation as a result of immune complex deposition in the glomeruli. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Treatment is selected based on perceived risk of progressive kidney
disease, and clinical measures such as hematuria, proteinuria, and eGFR are used to monitor patients while on treatment. The current standard of care is seen as insufficient by physicians and patients; these treatment approaches have limited
clinical efficacy and are not well tolerated. Approximately 50% of patients fail to achieve controlled UPCR on ACE inhibitors, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">124 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
ARBS, or steroids. The use of steroids may cause significant side effects, including serious infections, high blood pressure, weight gain, diabetes, and osteoporosis. As such, there is a high
unmet medical need for targeted therapies that impact the underlying disease pathophysiology and more tolerable, steroid-sparing treatment options for IgAN patients. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging therapies in development </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is only one agent approved
for the treatment of IgAN, a reformulated steroid, and there are several treatments in clinical development. The multistep IgAN pathogenesis hypothesis offers potential target points and approaches for therapeutic intervention. Most therapeutic
candidates in clinical development have employed various approaches to target inflammation and the downstream effects. Atacicept is the first agent in development that has demonstrated a 60% reduction of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> in IgAN patients, the upstream source of IgAN pathogenesis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These agents can be grouped mechanistically into the
following categories: glucocorticoid receptor agonists, endothelin receptor antagonists (ERAs), complement inhibitors, <FONT STYLE="white-space:nowrap">B-cell</FONT> modulators, and a variety of other approaches that are earlier in development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Glucocorticoid receptor agonists</I>.&nbsp;&nbsp;&nbsp;&nbsp;Glucocorticoid receptor agonists are a well-known class of molecules that have broad anti-inflammatory
effects, and well established acute and chronic side effects. Though reduction in the risk of eGFR decline was shown in clinical trials, there is no consensus on whether glucocorticoid may improve renal survival. The glucocorticoid, budesonide, has
been reformulated to concentrate steroid effects locally on the gut mucosa, theoretically suppressing the abnormal <FONT STYLE="white-space:nowrap">B-cell</FONT> activity reducing systemic steroid toxicity. Currently in a Phase 3 clinical trial in
IgAN, reformulated budesonide has demonstrated statistically meaningful reduction of proteinuria, though systemic steroid side effects have been observed in prior clinical trials and the ongoing Phase 3 clinical trial. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>ERAs</I>.&nbsp;&nbsp;&nbsp;&nbsp;Aberrant endothelin signaling is implicated in structural podocyte changes and increased mesangial proliferation in chronic kidney
diseases, including IgAN. ERAs block endothelin-induced cell proliferation hence may reduce renal perfusion pressure and proteinuria. Since this mechanism of action works downstream of disease related immune activities, it is not expected to reduce <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> or the resulting immune complexes that cause the disease. Several ERAs, which have previously been approved for the treatment of pulmonary arterial hypertension and erectile dysfunction and make use of a
vasodilatory effect, are currently in Phase 3 development and have been shown to reduce proteinuria in patients with IgAN. However, ERAs have been associated with edema, significant liver toxicity and increased risk of heart failure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Complement inhibitors</I>.&nbsp;&nbsp;&nbsp;&nbsp;Increased complement activation is commonly observed in patients with IgAN. It is hypothesized that immune-complex
deposition in glomeruli may contribute to complement activation, though the exact mechanism is not well understood. Several agents that inhibit complement activation are in clinical development for IgAN. Modest reduction of proteinuria has been
observed in early clinical trials. As complement inhibition works downstream of immune complex formation, these agents are not expected to impact the upstream cause of disease and reduce <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> or the
resulting immune complexes that cause inflammation and complement activation in the kidney. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">B-cell</FONT> modulators</I><FONT
STYLE="white-space:nowrap">.&nbsp;&nbsp;&nbsp;&nbsp;B-cell</FONT> modulators, including atacicept, are an important category of emerging therapies for IgAN. The disease causing <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> is predominantly
produced by B cells and plasma cells. Therefore, control of <FONT STYLE="white-space:nowrap">B-cell</FONT> activation may reduce production of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> and the downstream formation of autoantibodies and immune
complex. Interestingly, product candidates that modulate B cells through other single-target mechanisms, such as rituximab (CD20 alone), or blisibimod (BlyS alone), have been studied in patients with IgAN and have not shown a meaningful reduction of
<FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> and/or proteinuria. Preclinical models have shown that dual inhibition of BlyS and APRIL offers improved suppression of B cell activities than blocking BlyS or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">125 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
APRIL alone. Atacicept blocks both BlyS and APRIL, and has shown substantial reduction (60%) in <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT> We believe that dual inhibition may also confer a
potential dosing advantage versus APRIL only inhibition. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our solution: Atacicept </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is a fusion protein that blocks both BLyS and APRIL, which play key roles in the upstream pathway that causes IgAN, and is dosed once weekly via a 1 mL
subcutaneous injection. As a result, we believe atacicept has the potential to be the first disease modifying therapy for IgAN. Through an integrated analysis of randomized, double-blind, placebo-controlled clinical trials in over 1,500 patients to
date, atacicept has a well-characterized clinical safety profile. In a Phase 2a clinical trial in patients with IgAN, atacicept substantially reduced <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> and demonstrated a clinically meaningful reduction
in proteinuria and stable eGFR parameters at week 24. We are currently enrolling patients in the Phase 2b ORIGIN trial, and we expect to report topline results in the fourth quarter of 2022. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our approach to IgAN: Reducing <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> the source of autoantibodies </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is a fully humanized fusion protein that impacts the <FONT STYLE="white-space:nowrap">B-cell</FONT> pathway, which has well characterized implications in
immunologic diseases. Specifically, as shown in Figure 6 below, atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL. These cytokines are members of the tumor necrosis factor family that promote <FONT
STYLE="white-space:nowrap">B-cell</FONT> survival and autoantibody production associated with IgAN and other immunologic diseases. Dual blockade of BlyS and APRIL by TACI has been shown to be more potent than blocking BLyS alone or APRIL alone and
has the benefit of targeting long-lived plasma cells, in addition to B cells, thus reducing autoantibody production, including <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> IgA, IgG and IgM. Therefore, atacicept&#146;s mechanism acts directly on
the source of IgAN, which we believe will significantly mitigate the downstream effects of the disease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 6: Atacicept blocks both BLyS and
APRIL </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g08h64.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">126 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept: Potential to address the core processes underlying IgAN pathogenesis </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept&#146;s specific actions on IgAN disease pathogenesis are shown in Figure 7 below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g08h65.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 7: Atacicept impact on IgAN pathogenesis </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="4%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="95%"></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g210084g09i73.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept blocks BLyS, a factor important for B cell survival and maturation, resulting in reduced numbers of disease-causing B cells.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g09i74.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept blocks APRIL, a factor important for Plasma cell survival, resulting in reduced numbers of disease-causing plasma cells.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g10j82.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Reductions in plasma cells and in antibody class switching to IgA reduces production of immunogenic <FONT STYLE="white-space:nowrap">Gd-IgA.</FONT></P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g10j83.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Reductions in B cells, plasma cells, and <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> work together to cause a reduction in production of
autoantibodies to <FONT STYLE="white-space:nowrap">Gd-IgA1.</FONT></P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f50.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Therefore, formation of pathogenic immune complexes is greatly reduced.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f51.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This in turn, reduces immune complex deposition in glomeruli and reduces complement activation.</P>
<P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:1pt">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt">


<IMG SRC="g210084g06f52.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Ultimately, progressive renal injury is reduced, which we believe will significantly lower the morbidity and mortality associated with IgAN.</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept&#146;s disease modifying mechanism addresses the upstream processes that cause IgAN, while most other molecules in development
act downstream. Therefore, we believe that the clinical outcomes of atacicept, measured by measures designed to assess efficacy and durability will be favorable to competitors, with a demonstrated tolerability profile. Once weekly 1 mL subcutaneous
dosing also provides an attractive target product profile for patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in IgAN: clinical development </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept was the subject of a collaboration agreement between ZymoGenetics, Inc. in 2001 and licensed on an exclusive basis to Ares in 2008. It was advanced by Merck
KGaA, Darmstadt, Germany, in clinical trials for several autoimmune disease, including rheumatoid arthritis (RA), multiple sclerosis, SLE, and IgAN, and in totality studied in double-blind placebo-controlled clinical trials in over 1,500 subjects to
date. Safety, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">127 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
tolerability, pharmacokinetics, pharmacodynamics, and clinical efficacy of the weekly 25 mg, 75 mg and 150 mg doses administered subcutaneously have been studied. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the Phase 2a JANUS trial conducted by Merck KGaA, Darmstadt, Germany in patients with IgAN, atacicept (25&nbsp;mg and 75 mg doses) reduced <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> by 60% in IgAN patients. Atacicept has been the first molecule observed to reduce <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> the presumed upstream source of the disease, by this magnitude in IgAN
patients. The 150 mg dose was not studied in the JANUS trial. A clinically meaningful reduction in proteinuria and stable eGFR parameters was observed at week 24 for both the 25 mg and 75 mg doses. The clinically significant and robust reduction in <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> provides important corroborative evidence of the potential benefit of atacicept for patients with IgAN. Based on this encouraging data, we are conducting the Phase 2b ORIGIN trial in IgAN to test 25 mg, 75
mg and 150 mg of atacicept with endpoints of proteinuria, eGFR and <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> planned from week 12 though week 96. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe
atacicept has the potential to be the first disease modifying therapy for IgAN. We believe the large and established clinical data set for atacicept provides a competitive advantage for us versus other emerging and approved therapies in development,
many of which are either earlier in development and have clinical profiles that are not as well characterized or are characterized by the well-known acute and chronic side effects of corticosteroids that limit their medical use. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 2a JANUS trial of atacicept in patients with IgAN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Phase 2a
JANUS trial was a randomized, double-blind, placebo-controlled trial evaluating the efficacy and safety of atacicept in IgAN. The trial enrolled 16 subjects with IgAN and persistent proteinuria who were on a stable and optimized dose of ACEi and/or
ARB. The JANUS trial design is shown in Figure 8 below and the baseline patient characteristics shown in Figure 9 below. Results showed a dose dependent effect of atacicept 25mg and 75mg weekly on proteinuria as well as key biomarkers including
serum immunoglobulin levels, and <FONT STYLE="white-space:nowrap">Gd-IgA1,</FONT> and atacicept was observed to be generally well tolerated. The JANUS trial was terminated earlier than planned due to Ares&#146; decision to deprioritize the program
and therefore the sample size was truncated to 16&nbsp;subjects, the 150 mg dose arm was not enrolled, and there was limited long-term follow up after week 24. Trial termination was not related to safety or efficacy. Due to the small sample size of
JANUS, the results should be interpreted with caution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">128 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 8: Phase 2a JANUS trial design </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g39a99.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 9: Phase 2a JANUS trial baseline characteristics </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g39b02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept dose-related effects within target weekly dose ranges </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A clinically meaningful reduction in proteinuria parameters was observed at week 24 in the atacicept group. The median percent change for UPCR and total protein by <FONT
STYLE="white-space:nowrap">24-hour</FONT> urine collection decreased from baseline to week 24 for the atacicept 25 mg and 75 mg groups and increased for the placebo group, as shown in Figure 10 below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">129 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 10: Proteinuria at week 24 in the phase 2a JANUS trial </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g03c19.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After week 24, a persistent reduction in UPCR and total protein by <FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection
was observed in the atacicept 25 mg group. The results for the 75 mg group after week 24 were inconclusive, however, because of confounding factors related to low subject numbers and changes in <FONT STYLE="white-space:nowrap">co-morbid</FONT>
disease and treatments, such as diabetes and hypertension, that affected four of the five subjects. All five subjects showed an initial decrease of proteinuria parameters. The one subject without trial management issues after week 24 showed a
persistent reduction in UPCR and total protein at weeks 48 and 72. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As seen in Figure 11 below, atacicept also showed stable eGFR for greater than one year versus
expected 25% decline, as was shown in the placebo arm. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 11: eGFR over time in the phase 2a JANUS trial </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g11k91.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">130 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept 75 mg also showed a 60% reduction of <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> at 24 weeks, the
largest magnitude in reduction of any molecule in a randomized controlled study in IgAN patients, and dose-dependent reduction in serum IgA, IgG and IgM, as shown in Figure 12 below. Clear dose-dependent reductions of serum <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> were observed over the <FONT STYLE="white-space:nowrap">72-week</FONT> period studied (as shown in Figure 13 below), with atacicept 75 mg reducing <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT>
significantly (60%) and durably. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 12: Median change from baseline (%) in immunoglobulin levels at week 24 in the phase 2a JANUS trial
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g14s55.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 13: Serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels over time in the phase 2a JANUS trial
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g04d28.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">New analysis of these results initially divided JANUS trial patients into four equal groups according to the quartiles of serum <FONT
STYLE="white-space:nowrap">Gd-IgA1</FONT> distribution at baseline. Quartile level was then assessed at each timepoint. This additional analysis showed that atacicept decreased serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels by up to
two quartiles. As shown in Figure 14 below, the largest effect was seen in the atacicept 75mg arm where after 24 weeks all study patients had reductions in serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> to the lowest risk quartiles, which is
associated with the most favorable renal survival. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">131 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Additionally, the serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> quartiles determined from a separate cohort of
150 IgAN patients from the University of Leicester were applied to the 16 JANUS patients&#146; quartile level assessment and confirmed that atacicept 75mg reduced serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> to the lowest quartiles at each
measured timepoint. These new analyses were presented at the American Society of Nephrology Kidney Week 2021. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 14: Quartile analysis of
serum <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels from the phase 2a JANUS trial </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g14a81.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As the number of subjects included in the Phase 2a JANUS trial in IgAN for atacicept 25 mg and 75 mg was limited, further
investigation of these doses is warranted in a larger cohort, while also evaluating the safety and efficacy of atacicept 150 mg in IgAN, to ensure the optimal dose of atacicept is selected for a Phase 3 clinical trial. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept safety and tolerability profile in the JANUS trial </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept 25 mg and 75 mg weekly were observed to be generally well tolerated in the Phase 2a JANUS trial, with treatment-emergent adverse events (TEAEs) shown in Figure
15 below. Among the 11 atacicept treated patients, there was no TEAE leading to death and only one patient in the 25 mg weekly cohort discontinued treatment due to injection site pruritus. Most TEAEs were graded as mild and were related to injection
site events such as injection site bruising and erythema. The one severe TEAE event of cervical spinal stenosis was reported by a patient in the 25 mg weekly cohort during the safety <FONT STYLE="white-space:nowrap">follow-up</FONT> period, and was
deemed not drug related. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 15: Overview of treatment-emergent adverse events by severity in the phase 2a JANUS trial </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g14b82.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">132 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Atacicept safety and tolerability profile: Integrated analysis </I></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Though there was a limited number of patients in the JANUS trial, in an integrated safety analysis in clinical trials of over 1,500 patients in a number of indications
atacicept was well tolerated, shown in Figure 16 below. Serious TEAEs reported in the highest proportions were those in infections and infestations (placebo 3.9% versus atacicept 4.4%), musculoskeletal and connective tissue disorders (placebo 1.9%
versus atacicept 1.3%), and nervous system disorders (placebo 2.1% versus atacicept 1.2%). The most frequently reported TEAE was pneumonia (placebo 1.2% versus atacicept 1.3%). We believe that this large and established data set is a competitive
advantage for us versus other approved and emerging therapies in development, many of which lack extensive safety data. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 16. Integrated
safety analysis: Summary of treatment-emergent adverse events &gt; 5% in any arm, by dose </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g51a11.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The safety profile of atacicept 25 mg, 75 mg and 150 mg has been characterized in healthy subjects and subjects with RA, multiple
sclerosis, optic neuritis, SLE, and <FONT STYLE="white-space:nowrap">B-cell</FONT> malignancies, and is considered acceptable in IgAN. Over 1,940 subjects have been enrolled in 22 clinical trials, of which, over 1,425 subjects have received at least
one dose of atacicept. In the three Phase 2/3 clinical trials, 590 subjects with SLE and 11 subjects with IgAN have received at least one dose of atacicept. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the
most recent atacicept Phase 2 SLE clinical trial, ADDRESS II, the frequencies of treatment-emergent adverse events were infections and infestations were similar among atacicept 75 mg, 150 mg and placebo. There was no correlation between infections
and reduced levels of IgG, IgM, or IgA or reduced na&iuml;ve B cell or plasma cell numbers. No association was found between decreases in IgG and risk of serious or severe infection. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe the benefit-risk balance of atacicept to be favorable for further development in IgAN and certain additional autoimmune diseases, and we intend to explore
additional immunologic diseases where BLyS and APRIL are abnormally elevated, or where autoantibodies play an important role. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ongoing phase 2b ORIGIN
clinical trial design </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ORIGIN, our ongoing Phase 2b randomized, double-blinded, placebo-controlled, dose-ranging trial, will evaluate the efficacy and safety
of atacicept in subjects with IgAN. The clinical trial consists of a <FONT STYLE="white-space:nowrap">36-week</FONT> double-blind treatment period, followed by a <FONT STYLE="white-space:nowrap">60-week</FONT> open-label treatment period and a <FONT
STYLE="white-space:nowrap">26-week</FONT> safety <FONT STYLE="white-space:nowrap">follow-up</FONT> period. The trial will assess multiple doses (25 mg, 75 mg and 150 mg) of once weekly 1 mL subcutaneous injections of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">133 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
atacicept versus placebo on impact of renal function as measured by proteinuria. The primary endpoint is change from baseline in UPCR at 24 weeks based on
<FONT STYLE="white-space:nowrap">24-hour</FONT> urine collection, with a secondary endpoint of UPCR at 36 weeks. Other endpoints include change from baseline in UPCR at 12, 48, 96 weeks, change from baseline in eGFR at 12, 24, 36, 48, 96 weeks,
change from baseline in IgA, IgG, IgM, C3, C4, and <FONT STYLE="white-space:nowrap">Gd-IgA1</FONT> levels at 12, 24, 36, 48, and 96 weeks, number of participants with adverse events during the double-blind treatment period through 36 weeks, and the
serum concentration of atacicept through study completion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 17. Phase 2b ORIGIN trial design </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g53a66.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">UPCR is an accepted surrogate primary endpoint for clinical trials in IgAN, which allows for a faster path to commercialization than
rate of change/slope in GFR, which is measured after two years. The recommendation for usage of this surrogate endpoint was put forward by the ASN, partnering with the FDA under the auspices of the Kidney Health Initiative, and the EMA, and has now
been implemented in five Phase 3 clinical trials in IgAN and in the one FDA approval granted. Accelerated and/or conditional approval may be granted on the UPCR endpoint, with full approval to be granted upon longer-term data demonstrating
stabilization of eGFR with treatment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are currently enrolling the Phase 2b ORIGIN trial and expect to enroll a total of 105 patients at multiple global sites. We
expect to complete enrollment by <FONT STYLE="white-space:nowrap">mid-2022</FONT> and report topline results from ORIGIN in the fourth quarter of 2022. If the data from this trial are positive, we plan to initiate a pivotal Phase 3 clinical trial in
2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Atacicept in LN: A severe renal manifestation of SLE </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on
discussions with the FDA following the review of positive Phase 2 data in SLE, we are planning to initiate a Phase 3 clinical trial of atacicept as a potential treatment for patients with LN, a severe renal manifestation of SLE. We estimate that
there are approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan. Significant unmet need for improved efficacy persists for these patients despite the recent approval of the first two <FONT
STYLE="white-space:nowrap">LN-specific</FONT> therapies. Fewer than half of patients treated for LN have a complete response to therapy, and among patients without a complete response, over half will have
<FONT STYLE="white-space:nowrap">non-functioning</FONT> kidneys within five years. Benlysta (belimumab), a BlyS-only inhibitor, is one of the two therapies approved for patients with LN. Both BlyS and APRIL levels are increased in patients with SLE,
suggesting that dual inhibition by atacicept may be more potent than blocking BLyS alone and has the benefit of targeting plasma cells in addition to B cells. Merck KGaA, Darmstadt, Germany previously
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">134 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
initiated a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the <FONT STYLE="white-space:nowrap">APRIL-LN</FONT> trial, aimed to evaluate the efficacy
and safety of atacicept at 150 mg twice weekly for four weeks&#151;then weekly&#151;in patients with active LN. However, this trial was terminated early due to three subjects developing hypogammaglobulinemia with induction therapy (MMF and CS) which
continued to worsen when initiating atacicept and subsequently two subjects developed pneumonia. In a prior Phase 2 clinical trials of atacicept in SLE also conducted by Merck KGaA, Darmstadt, Germany, despite missing its primary endpoint of
improved SLE responder index 4 <FONT STYLE="white-space:nowrap">(SRI-</FONT> 4) at week 24, in the broader SLE study population, atacicept achieved positive clinical data on multiple measures within the prespecified High Disease Activity patient
segment, including reduction of renal flares, which we believe supports atacicept&#146;s applicability in LN. Because both preclinical and clinical evidence suggests atacicept&#146;s dual inhibition of BLyS and APRIL may provide improved clinical
outcomes, measured by endpoints designed to assess efficacy, compared to inhibiting either signal alone, we believe there is a strong rationale to conduct a clinical trial of atacicept in LN. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pathophysiology of LN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">LN is a severe renal manifestation of SLE (also
referred to as lupus). SLE is a chronic and disabling autoimmune disease in which the body&#146;s own immune system attacks itself. SLE predominantly affects women and is more prevalent in women of color. When LN is diagnosed in a patient, mortality
risk dramatically increases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">LN pathogenesis involves a variety of disease-causing mechanisms, including the formation of immune deposits within the kidneys that
are primarily due to anti-double stranded DNA (anti-dsDNA) antibodies, which atacicept has been shown to reduce in a dose-dependent manner. However, there are also instances in which induction of LN by anti-dsDNA may not require immune complex
formation&#151;autoreactive plasma cells in the kidney may be another cause of nephritis. Certain genes and genetic factors may also predispose patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>LN
disease burden and diagnosis </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">LN has a strong influence on morbidity and mortality within SLE, with up to 26% of patients progressing to ESRD within 15 to 20
years from initial diagnosis. LN is characterized by abnormal proteinuria, hematuria, and impaired kidney function. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Diagnosed SLE patients are routinely monitored
by rheumatologists, who will refer to nephrologists upon suspicion of renal manifestations. In the United States and European Union, LN patients without a prior SLE diagnosis will typically first present to a primary care physician (U.S.) or
internist (EU) with hematuria or proteinuria before ultimate referral to a nephrologist. For confirmatory diagnosis, nephrologists perform renal biopsy&#151;of which the results are analyzed to determine histologic class and relevant treatment
course. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">LN patients are segmented in Class&nbsp;I&#151;VI based on histopathology and degree of renal impairment, and this classification drives treatment
decisions. Class&nbsp;I, or Minimal mesangial LN, is rarely diagnosed as these patients have normal urinalysis and therefore biopsy is not typically performed. Class&nbsp;II, Mesangial proliferative LN, refers to microscopic hematuria and/or
proteinuria. Patients with Class&nbsp;III, or Focal LN, tend to have both hematuria and proteinuria, and may have hypertension, decreased eGFR, and nephrotic syndrome. Class&nbsp;IV, or Diffuse LN, is the most commonly diagnosed and severe form of
LN, with patients exhibiting hematuria, proteinuria, nephrotic syndrome, hypertension, and decreased eGFR. Patients with Class&nbsp;V, or lupus membranous nephropathy, tend to have nephrotic syndrome, may have microscopic hematuria and hypertension,
but normal UPCR. Class&nbsp;VI, or advanced sclerosing LN, refers to a slow progression of kidney dysfunction correlated with proteinuria. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As shown in Figure 18
below, LN typically develops early in the disease course, though the rate of SLE patients that develop LN increases over time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">135 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 18: LN progression </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g12l01.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>LN market opportunity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">According to
the Centers for Disease Control and Prevention, there are approximately 322,000 people living with SLE in the United States. Approximately half of individuals living with SLE develop LN within 15 years of their initial diagnosis, as shown in Figure
18 above. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that there are approximately 110,000 LN patients in the United States, 69,000 in the European Union, and 22,000 in Japan at present. In the
United States, higher prevalence rates occur in the heterogeneous population, as both SLE and LN occur more frequently among <FONT STYLE="white-space:nowrap">non-Caucasian</FONT> patients&#151;with the highest frequency of LN occurring in Black and
Hispanic populations after adjustment for socioeconomic factors. In all three geographies, women account for the majority of LN cases. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on primary market
research with physicians and payors and extensive secondary research, we estimate the market for novel LN therapeutics annually to be approximately $2.0 to $5.0&nbsp;billion, $600&nbsp;million and $200&nbsp;million in United States, Europe and
Japan, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Current standard of care for LN patients </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Current LN treatment is largely cyclical, with induction versus maintenance therapy dictated by the severity of disease and frequency of flares. Treatment is driven by
histologic class and can be influenced by the treatments that the patient has been on since SLE diagnosis. Class&nbsp;I and II LN do not generally need <FONT STYLE="white-space:nowrap">LN-specific</FONT> treatment. Within <FONT
STYLE="white-space:nowrap">Class&nbsp;III-V,</FONT> patients tend to receive induction therapy for approximately one year to achieve complete or partial remission. Induction therapy for <FONT STYLE="white-space:nowrap">Class&nbsp;III-IV</FONT>
patients include several immunosuppressive agents, such as MMF &plusmn; corticosteroids or cylophosphamide (CYC) &plusmn; corticosteroids in the first line of treatment, switching to either CYC or MMF in the second line, whichever was not
administered first line. Third line induction therapy has generally consisted of rituximab for <FONT STYLE="white-space:nowrap">Class&nbsp;III-V</FONT> patients. For induction therapy of Class&nbsp;V LN patients, patients typically receive MMF
&plusmn; steroids in the first line, a calcineurin inhibitor in the second line, and rituximab for third line. Maintenance therapy, which typically consists of MMF, azathioprine (AZA), or hydroxychloroquine (HCQ), is typically prescribed to well
controlled patients after any line of induction to reduce flares. Immunosuppressive therapy is unlikely to be beneficial for Class&nbsp;VI, or advanced sclerosing LN. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Patients on maintenance still experience flares approximately every year, resulting in cycling back to induction therapy. Many of the therapies used in the treatment
paradigm today have limited efficacy and poor tolerability profiles&#151;and therefore there is significant unmet need for safe and specific therapies that have a direct impact on LN disease activity without a high risk of infection. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently approved and emerging therapies in development </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Until
recently, there were no approved therapies for the treatment of LN. In December 2020, the FDA approved Benlysta (belimumab), an anti-BLyS antibody, for treatment of adult patients with active LN who are receiving
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">136 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
standard therapy. In January 2021, the FDA approved Lupkynis (voclosporin), a calcineurin inhibitor, to be used in combination with a background immunosuppressive therapy regimen for adult
patients with active LN. Clinical guidelines on how these two medicines may be incorporated into standard of care remain to be updated. In addition to Benlysta (belimumab) and Lupkynis (voclosporin), there are several other cytokine inhibitors and
complement inhibitors in development for LN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">B-cell</FONT> Modulators</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Benlysta (belimumab) is
an anti-BLyS antibody, belonging to the class of <FONT STYLE="white-space:nowrap">B-cell</FONT> modulators. Within the <FONT STYLE="white-space:nowrap">B-cell</FONT> modulator class, there is a desire for different mechanisms to target the complex
pathophysiology of LN. The results shared to date for these agents reveal statistically significant efficacy, but only achieve complete response rates in fewer than 50% of the patients studied. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Calcineurin Inhibition</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Lupkynis (voclosporin) is a calcineurin inhibitor, a mechanism which has been commonly used in generic form
as induction therapy for Class&nbsp;V patients. Calcineurin inhibition has been shown to reduce cytokine activation of <FONT STYLE="white-space:nowrap">T-cells</FONT> and protect against proteinuria, however it may pose serious infection risks and
nephrotoxicity is a known class effect. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cytokine Inhibitors</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;The other cytokine inhibitors under investigation offer blockade
of key <FONT STYLE="white-space:nowrap">pro-inflammatory</FONT> cytokines (IL17A, IL23, Type 1 IFNs) involved in the pathogenesis of LN, however they are early in their development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Complement Pathway Inhibitors</I></B>.&nbsp;&nbsp;&nbsp;&nbsp;Complement pathway inhibitors are also early in their development, but unlikely to be disease
modifying, since complement activation is one result of the inflammation caused by immune-complex deposition in the kidneys, downstream of key steps in disease pathophysiology. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our solution: Atacicept </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Targeting both BLyS and APRIL is key to
reduce autoantibodies produced by B cells and plasma cells in LN.</B>&nbsp;&nbsp;&nbsp;&nbsp; Autoantibodies play a large role in the pathogenesis of LN. Autoantibodies target tissue or form immune complexes, leading to tissue and organ damage. Both
short-lived and long-lived plasma cells are responsible for generating high levels of autoantibodies in LN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Short-lived plasma blasts are the main B cell effector
subset dependent on activation of various of B cell receptors such as TACI, BCMA and BLyS. Therefore, B cell blocking agents such as Rituxan (rituximab; anti-CD20) and Benlysta (belimumab; anti-BLyS) can reduce short-lived plasma cells and the
resulting autoantibody production. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Long-lived plasma cells are in bone marrow and inflammatory tissue niches, and form antibodies in the absence of <FONT
STYLE="white-space:nowrap">B-cell</FONT> activation. Inflammatory tissue has high levels of BLyS and APRIL, which serve to maintain long-lived plasma cells. Inhibiting APRIL blocks long-lived nonproliferating plasma cell activities to further reduce
autoantibody formations in LN. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept contains the soluble TACI receptor that binds to the cytokines BLyS and APRIL and prevents their interaction with TACI,
BCMA and BlyS receptors <FONT STYLE="white-space:nowrap">(BLyS-R</FONT> is also known as <FONT STYLE="white-space:nowrap">BAFF-R).</FONT> Atacicept thus inhibits survival of immature and mature B cells and antibody-producing plasma cells and
prevents immunoglobulin class switching. In contrast to a range of available biologics directed at B cells only, we believe atacicept has a prompt and marked effect on antibody production by inhibiting both short-lived and long-lived plasma cells.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>Preclinical evidence indicates that dual inhibition of BLyS and APRIL is superior to either BLyS or APRIL alone. </B>&nbsp;&nbsp;&nbsp;&nbsp;Animal models of
kidney disease have confirmed that atacicept reduces plasma cell numbers and reduces autoantibodies more effectively than BLyS and APRIL antibodies given individually. In a mouse model of collagen-induced arthritis, soluble atacicept inhibited
development of collagen-specific antibodies and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">137 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
reduced the incidence of the disease better than BLyS (also known as BAFF) agents alone. In a mouse model of SLE, soluble atacicept decreased the number of B cells, increased survival time and
reduced severity of disease symptoms. Furthermore, in a mouse model of SLE, atacicept administered after onset of autoimmunity decreased the number of bone marrow plasma cells and slowed down further formation of autoantibodies. Atacicept prevented
renal damage during a <FONT STYLE="white-space:nowrap">12-week</FONT> treatment period regardless of autoantibody levels, while BLyS-only inhibitor did not. Atacicept also decreased established plasma cells in an immunization model better than
single inhibitors of BLyS or APRIL. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In patients with active SLE, targeting BLyS and APRIL (atacicept) appears to have improved clinical outcomes, measured by
endpoints designed to assess efficacy, compared to BLyS alone (Benlysta (belimumab)). While Atacicept and Benlysta (belimumab) have not been studied <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> in
clinical trials, each has been studied in similar populations of patients with SLE, and results of a Phase 2 clinical trial of 150 mg of atacicept compared favorably to published reports on changes in symptom response index <FONT
STYLE="white-space:nowrap">(SRI-4)</FONT> of belimumab. In a Phase 2 clinical trial of atacicept, the magnitude of efficacy as measured by the difference between treatment and placebo by <FONT STYLE="white-space:nowrap">SRI-4</FONT> at 24 weeks was
approximately 39% (25% placebo, 64% atacicept 75 mg, 65% atacicept 150 mg, both p&#061;0.005). For Benlysta (belimumab), in a Phase 3 clinical trial of SLE patients, a published analysis of patients with HDA and serologically active disease,
clinical efficacy for Benlysta (belimumab) 10 mg/kg showed a difference between treatment and placebo by <FONT STYLE="white-space:nowrap">SRI-4</FONT> at 24 weeks of approximately 12%. However, as this data is based on a cross-trial comparison and
not a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">head-to-head</FONT></FONT> clinical trial, such data may not be directly comparable due to differences in study protocols, conditions and patient populations. Accordingly,
cross-trial comparisons may not be reliable predictors of the relative efficacy or other benefits of atacicept compared to other product candidates that may be approved or that are in development. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In SLE, atacicept consistently demonstrated improved clinical outcomes, measured by endpoints designed to assess efficacy, in SLE patients with HDA <FONT
STYLE="white-space:nowrap">(SLEDAI-2K</FONT> <FONT STYLE="font-family:Times New Roman">&#8805;</FONT>10) versus placebo across additional clinical measures and consistent across all SRI <FONT STYLE="white-space:nowrap">cut-offs,</FONT> as well as
using the separate clinical assessment, BILAG-based Combined Lupus Assessment (BICLA). In the HDA population in ADDRESS II, the BICLA delta at week 24 was 20% (atacicept 150 mg 49%, placebo 29.2%, p&#061;0.035), which compares very favorably to
BICLA data from other late-stage SLE clinical trials, such as anifrolumab (week 24 BICLA in 16%). We believe that based on these results, we believe an improved clinical benefit may be observed in patients with LN. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Prior clinical development of atacicept in LN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Merck KGaA, Darmstadt,
Germany conducted a randomized, double-blind, placebo-controlled Phase 2/3 clinical trial of atacicept in LN, the <FONT STYLE="white-space:nowrap">APRIL-LN</FONT> trial, aimed to evaluate the efficacy and safety of atacicept in patients with active
LN. As per trial protocol, patients initiated high-dose CS (the lesser of 0.8 mg/kg/day or 60 mg/day prednisone) and mycophenolate mofetil MMF (1 g daily, increased by 1 g/day each week to 3 g daily) at the time of screening (day <FONT
STYLE="white-space:nowrap">-14).</FONT> From day 1, atacicept (150 mg, subcutaneously, twice weekly for four weeks, then weekly) was initiated with MMF along with a tapered dose of CS. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Four of the six enrolled LN subjects developed decreases in the serum IgG levels following the initiation of MMF and CS in the setting of significant proteinuria, which
are contributing factors of hypogammaglobulinemia. After initiation of atacicept, serum IgG levels further reduced; two subjects developed severe hypogammaglobulinemia, defined as IgG &lt;3 g/L, and pneumonia. These two subjects recovered after
treatment discontinuation and received antibiotics therapy. This trial was terminated. Based on the detailed assessment of results from this trial, plans to develop atacicept for the treatment of LN will explore alternatives to the induction regimen
studied previously, including not dosing atacicept 150 mg twice weekly; clearly defining the dosing regimen for CS and MMF; and closely monitoring immunoglobulin levels during induction therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">138 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Planned phase 3 clinical trial design </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Phase 3 randomized, double-blinded, placebo-controlled trial will evaluate the efficacy and safety of atacicept in subjects with lupus nephritis. The clinical trial
consists of a <FONT STYLE="white-space:nowrap">52-week</FONT> double-blind treatment period, followed by a <FONT STYLE="white-space:nowrap">104-week</FONT> open-label treatment period and a <FONT STYLE="white-space:nowrap">26-week</FONT> safety <FONT
STYLE="white-space:nowrap">follow-up</FONT> period. The trial, as shown in Figure 19 below, will assess 150 mg of once weekly subcutaneous injections of atacicept versus placebo. The primary endpoint is complete renal response at 52 weeks. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 19: Planned phase 3 clinical trial design </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g60a22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Evaluation of safety and efficacy profile of atacicept In SLE </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept 75 mg and 150 mg, dosed once per week with subcutaneous auto-injection, have demonstrated improved clinical outcomes, measured by endpoints designed to assess
efficacy, in subjects with SLE in the Phase 2 <FONT STYLE="white-space:nowrap">APRIL-SLE</FONT> and ADDRESS II trials. In these trials, autoantibody titers were significantly reduced, and prespecified and post hoc analyses revealed prevention of
flare and reduction of active disease with atacicept treatment, despite the fact that the primary endpoints in these trials were not met. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In ADDRESS II, SLE
subjects with HDA <FONT STYLE="white-space:nowrap">(SLEDAI-2K</FONT> <FONT STYLE="font-family:Times New Roman">&#8805;</FONT> 10) had an increase in SLE Responder Index <FONT STYLE="white-space:nowrap">(SRI)-6</FONT> response, attainment of low
disease activity (LDA), or <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> <FONT STYLE="font-family:Times New Roman">&#8804;</FONT> 2, and a reduction of the risk of a first new severe flare (defined by SLEDAI Flare Index (SFI) or by BILAG A) when
treated with atacicept 150 mg. Furthermore, the 024 long-term extension (LTE) trial showed durability of these effects through a median duration of treatment of 96 weeks. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following the release of the HDA data, Merck KGaA, Darmstadt, Germany pursued the planning and initiation of a global Phase 3 registrational program for atacicept 150 mg
once per week in SLE. This program, including two large Phase 3 randomized placebo-controlled trials of atacicept 150 mg compared to placebo, were reviewed by FDA via
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-phase</FONT></FONT> 2 communication and scientific advice communication with EMA, prior to Merck KGaA, Darmstadt, Germany terminating the SLE program and the IgAN program for
business strategy reasons. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Phase 2 SLE clinical trial in patients with SLE for 24 weeks </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">ADDRESS II, a Phase 2b SLE trial of 306 patients, evaluated the efficacy and safety of atacicept at two subcutaneous doses (150 mg and 75 mg) versus placebo over the
course of 24 weeks, with an LTE arm continuing an additional 96 weeks. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">139 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept demonstrated consistent reductions in IgG, IgA, and IgM serum levels, and reductions in anti-dsDNA
antibodies, as well as improvements in serum C3 and C4 levels, as shown in Figure 20 below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 20: Atacicept impact on key biomarkers in the
phase 2 ADDRESS II trial </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g13m10.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Though atacicept missed its primary endpoint of <FONT STYLE="white-space:nowrap">SRI-6</FONT> reduction versus placebo in all comers,
in a <FONT STYLE="white-space:nowrap">pre-specified</FONT> analysis within HDA patients, which comprised approximately half of those enrolled, atacicept 150 mg showed improved clinical outcomes, measured by multiple endpoints designed to assess
efficacy, including a 26% improvement (p&#061;0.005) by <FONT STYLE="white-space:nowrap">SRI-6</FONT> versus placebo, flare risk reduction, and serologic marker normalization. <FONT STYLE="white-space:nowrap">SRI-6</FONT> response is defined as <FONT
STYLE="font-family:Times New Roman">&#8805;</FONT><FONT STYLE="white-space:nowrap">6-point</FONT> reduction in the SELENA-SLEDAI score, and no new BILAG A organ domain score or two new BILAG B organ domain scores, and no worsening <FONT
STYLE="white-space:nowrap">(&lt;0.30-point</FONT> increase) in Physician&#146;s Global Assessment score. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 21:
<FONT STYLE="white-space:nowrap">SRI-6</FONT> response among HDA patients in the phase 2 ADDRESS II trial </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g11i11.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">140 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Also, among this HDA patient segment, significantly more patients on the atacicept 150 mg arm reached LDA, as measured
by <FONT STYLE="white-space:nowrap">SLEDAI-2K</FONT> &lt;&#061; 2, as shown in Figure 22 below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 22: HDA patients reaching LDA in the phase
2 ADDRESS II trial </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g11i22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, Figure 23 below demonstrates the durable clinical outcomes observed in the HDA segment: more patients reached LDA by
multiple measures at both week 24 and week 48. Significantly more patients treated with atacicept 150 mg once weekly versus placebo demonstrated clinical improvement (as shown by <FONT STYLE="white-space:nowrap">SRI-6),</FONT> achieved LDA, and
remission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 23: Durable clinical outcomes observed in HDA patients in the phase 2 ADDRESS II trial </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g22i44.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">141 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that the clinical outcomes, measured by endpoints designed to assess efficacy, demonstrated on multiple
measures within the HDA segment of the SLE population in the ADDRESS II trial&#151;and a favorable tolerability profile observed in ADDRESS II, as well as the integrated safety analysis in over 1,500 patients&#151;provide the foundation of our
rationale for developing atacicept further in LN, a severe renal manifestation of SLE. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MAU868 in BK viremia among kidney transplant recipients </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are developing MAU868 as a potential treatment for BK viremia in kidney transplant recipients. While up to 90% of healthy adults have been infected with the BKV at
some point in their lives, it remains latent in everyone except severely immunocompromised populations such as kidney transplant recipients. There are approximately 80,000 kidney transplants annually worldwide, with approximately 20,000 in the
United States. Approximately 225,000 kidney allograft recipients are living in the United States. Waitlists to receive kidneys are long: approximately <FONT STYLE="white-space:nowrap">3-5</FONT> years and 75,000 people long in the United States. Up
to 12% of transplants per year are <FONT STYLE="white-space:nowrap">re-transplants,</FONT> which further limits organ availability for new patients. BKV is a polyoma virus that is tropic to the kidney and bladder tissue and can reactivate with the
immunosuppression required for kidney transplant. This reactivation can cause BKVN, a condition in which BK infection, typically first identified as BK viremia, triggers inflammation, which then progresses to renal fibrosis and tubular injury; as
shown in Figure 24, BKVN is a leading cause of allograft loss, a devastating outcome for kidney transplant recipients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 24: Graft survival
(%) in kidney transplant patients is worse with BKVN </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g15d15.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Currently, there are no approved treatment options for BK viremia or BKVN. In <FONT STYLE="white-space:nowrap">mid-2022,</FONT> we
expect to share full Cohort 1 and Cohort 2 results from the Phase 2 trial conducted by Amplyx, and initiate a Phase 2b or Phase 3 clinical trial in 2023. We believe that MAU868 has the potential to become standard of care for the treatment of BK
viremia in order to prevent devastating consequences such as BKVN. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pathophysiology of BK virus in kidney transplant </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">BKV has a worldwide seroprevalence of up to 90%. Primary BK infection is typically acquired during childhood, after which the virus establishes lifelong infection in the
kidney and bladder tissue. Most people do not experience any known adverse effects from either primary or persistent infection. Control of infection is dependent on CD4&#043; and CD8&#043; T cell immunity, which immunosuppressants can displace. In
the setting of kidney transplant and related immunosuppression, latent virus can be reactivated or new virus can be transmitted via the donor kidney. BKV reactivation is marked first by viruria&#151;or detection of virus in the urine, and then
viremia&#151;detection of viral DNA in the blood, and most commonly occurs within the first year of transplant. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">142 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Viremia typically occurs in 15% of kidney transplant recipients, after which BKVN may occur. Approximately <FONT STYLE="white-space:nowrap">3-4%</FONT> of kidney transplant recipients develop
BKVN. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>BKVN disease burden and diagnosis </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">BKVN may lead to
allograft injury and in some cases, allograft loss. Up to <FONT STYLE="white-space:nowrap">24-60%</FONT> of all graft losses are due to <FONT STYLE="white-space:nowrap">BKV-associated</FONT> disease. The average cost of a kidney transplant in the
United States is over $440,000. <FONT STYLE="white-space:nowrap">Pre-transplant,</FONT> recipients are typically on dialysis, for which the cost is approximately $90,000 per year; there is an approximate 450% increase in annual medical cost to treat
transplant recipients who experience graft loss. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Most institutions monitor for BK in both the urine, through PCR and urinalysis, and plasma, via PCR. It is common
practice to screen kidney transplant recipients for BK viremia via PCR test monthly at the first six months post-transplant and then every three months until two years post-transplant, after which patients are typically screened annually. Also, at
any sign of allograft dysfunction, physicians will test for BK viremia. Viral load levels &gt; 1000 copies/mL are considered positive for BK viremia, and levels &gt;10,000 copies/mL are considered presumptive BKVN. Kidney allograft biopsy is
considered gold standard for diagnosing BKVN. Late diagnosis of BKV can lead to irreversible renal function decline and poor treatment outcomes. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Kidney
transplant market opportunity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An estimated 80,000 kidney transplants are conducted globally each year, with approximately 20,000 in the United States,
20,000 in Europe, 1,500 in Japan, and 10,000 in China. Approximately 225,000 kidney allograft recipients are living in the United States. Waitlists to receive kidneys are long: <FONT STYLE="white-space:nowrap">3-5</FONT> years and 75,000 people deep
in the United States. Up to 12% of transplants per year are <FONT STYLE="white-space:nowrap">re-transplants,</FONT> which further limits organ availability for new patients. Approximately 15% of kidney transplant recipients develop BK viremia.
Patients can be risk stratified for BK viremia based on the degree of immunosuppression employed, which is related to the degree of human leukocyte antigen (HLA) match between the graft and recipient; the greater the mismatch, the more intense
immunosuppression required, which increases the risk of BKV reactivation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on primary market research with physicians and extensive secondary research, we
estimate the market for a novel agent to treat BK viremia to be approximately $700&nbsp;million annually worldwide, with $350&nbsp;million, $120&nbsp;million, $18&nbsp;million, and $50&nbsp;million in peak sales generated in the United States,
Europe, Japan, and China, respectively. There may also be potential for usage in additional patient segments, such as prophylaxis in high risk patients. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Current standard of care for kidney transplant patients with BK viremia </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Currently, there is no approved treatment specific to BKV. Upon detection of BK viremia, physicians first line of defense is to reduce immunosuppression with the goal of
restoring CD4&#043; and CD8&#043; T cell immunity without causing acute rejection. Initial modification will typically consist of lowering MMF by 50% followed by a reduction in tacrolimus by 50%. If no improvement is observed, use of MMF and
tacrolimus will be stopped and dose of prednisone will be increased. Other agents such as IVIG, leflunomide, and cidofovir, are occasionally used&#151;but all have limited data and both leflunomide and cidofovir have serious safety concerns. After
development of BKVN, patients have limited options and may continue to receive antivirals or IVIG. Physicians are not satisfied with current treatment options for BKV and highlight that there is a significant unmet need for a viable therapy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">143 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging therapies in development </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite the high level of unmet need in treating BK viremia and preventing devastating consequences, there is limited development in the space. There is only one
alternate industry-sponsored program in clinical development: Allovir&#146;s Posoleucel (formerly known as <FONT STYLE="white-space:nowrap">ALVR-105</FONT> and <FONT STYLE="white-space:nowrap">Viralym-M),</FONT> a multi-virus specific <FONT
STYLE="white-space:nowrap">T-cell</FONT> therapy, which is currently being evaluated in a Phase 2 clinical trial. While this approach may have the potential to treat BKV and other opportunistic infections, logistics and distribution are likely to
render this approach less feasible than a monoclonal antibody, for instance. Therefore, Posoleucel may be reserved for second line of therapy and/or treatment of presumptive BKVN rather than BK viremia. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Our solution: MAU868 / scientific rationale </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MAU868 is a human
monoclonal antibody (IgG1/<FONT STYLE="font-family:Times New Roman"><FONT STYLE="FONT-FAMILY:SYMBOL">&#108;</FONT></FONT> isotype subclass) directed against the major viral capsid protein of BKV, VP1, which is essential for binding to and infection
of new cells, as shown in Figure 25. MAU868 neutralizes all four serotypes of BKV at <FONT STYLE="white-space:nowrap">sub-nanomolar</FONT> concentrations and has a high barrier to resistance <I>in vitro</I> (resistant isolates of BKV were not
selected <I>in vitro</I> at any of the concentrations of MAU868 investigated). MAU868 is being developed for the treatment of BKV disease in kidney transplant recipients (BKV nephropathy) and being considered for hematopoietic cell transplant
recipients <FONT STYLE="white-space:nowrap">(BKV-associated</FONT> hemorrhagic cystitis). MAU868 also has neutralizing activity <I>in vitro</I> against the closely related JC virus, the cause of progressive multifocal leukoencephalopathy. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 25: MAU868 blocks BK virion binding </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g14n19.jpg" ALT="LOGO">
 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">144 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical development of MAU868 </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Phase 1 </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-human,</FONT></FONT> randomized, blinded, placebo-controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics of MAU868 following IV or
SC administration to healthy adult subjects was performed. Administration of up to 100 mg/kg MAU868 IV and 3&nbsp;mg/kg MAU868 SC were safe and well tolerated. No deaths or SAEs were reported, and there were no AEs that led to the discontinuation of
the infusion or the study. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Ongoing phase 2 </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A Phase 2 randomized,
double-blind, placebo-controlled clinical trial designed to assess the safety, tolerability, and efficacy of MAU868 for the treatment of allograft-threatening BKV infection in kidney (or kidney-pancreas) transplant recipients is ongoing. Up to 36
patients with BK viremia will participate in 1 of 3 sequential cohorts. As shown in Figure 26, each cohort was designed to randomize approximately 12 patients (8 to MAU868 and 4 to placebo), for which Cohort 1 (1350 mg IV approximately every 28 days
for a total of 4 doses) and Cohort 2 (6750 mg IV on Day 1, 1350 mg IV every 28 days for 3 additional doses) have completed dosing. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary objective of the
clinical trial is to assess the safety and tolerability of MAU868, with secondary objectives to assess the impact of MAU868 on BKV related outcomes. MAU868 has been shown in an interim analysis of week 12 data from Cohort 1 and 2 of a Phase 2 study
to be well-tolerated and showed a greater proportion of subjects with decrease in BK plasma viral load versus placebo. We expect to share Cohort 1 and Cohort 2 interim analysis results from the ongoing Phase 2 clinical trial in kidney transplant
recipients in <FONT STYLE="white-space:nowrap">mid-2022.</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>Figure 26: MAU868 phase 2 clinical trial design </B></P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g17f77.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Future clinical trials </I></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We intend to
initiate a Phase 2b or Phase 3 clinical trial in 2023. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>MAU868 in BKV cystitis among HSCT recipients </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are exploring development of MAU868 to treat BKV cystitis in HSCT patients. Patients undergoing HSCT are at risk for BKV reactivation due to immunodeficiency; in this
setting, BK reactivation and subsequent viruria and viremia can lead to cystitis, including hemorrhagic cystitis. Cystitis is characterized by dysuria, urgency, and/or frequency, while hemorrhagic cystitis indicates the presence of microscopic or
gross hematuria. Both </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">145 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
BKV cystitis and hemorrhagic cystitis are associated with high patient morbidity and prolonged hospitalization, yet there are no approved treatment options. We believe that MAU868 may represent
and important future treatment option for these patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pathophysiology of BK virus reactivation in HSCT </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">HSCT patients, particularly those who have received allogeneic transplants, are at high risk of various infectious diseases due to immunodeficiency. During the early
post-engraftment period, BKV is a common cause of hemorrhagic cystitis. Patients are at highest risk for BKV cystitis three to six weeks following HSCT. Myeloablative conditioning regimen in the setting of human leukocyte antigen (HLA) mismatch is a
particular risk factor for BK reactivation. Viruria occurs in approximately half of allogeneic and less than 10% of autologous HSCT recipients. BK viremia &gt; 10,000 copies/mL have been shown to be predictive of renal and urologic outcomes in HSCT
patients. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>BKV cystitis disease burden and diagnosis </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Moderate to
severe BKV cystitis may occur prior to discharge and prolong hospital stay and/or result in readmission to the hospital if already discharged. Currently HSCT patients are not routinely monitored for BKV reactivation given the lack of treatments
available. BKV testing and monitoring is initiated only in patients who become symptomatic and present with cystitis symptoms, which may emerge several weeks or months following engraftment. Patients who are symptomatic would then be monitored for
BKV via urine and/or blood testing monthly for six months, and then at longer intervals. BK viruria alone is not concerning unless the viral load is rapidly accelerating; BKV viremia is more concerning and may trigger physicians to actively treat
the cystitis symptoms. In our market research, physicians estimate that 15% of allogeneic HSCT patients and approximately 5% of autologous HSCT patients develop BKV cystitis, including hemorrhagic cystitis. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>HSCT market opportunity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary addressable patient segment
initially is for the treatment of symptomatic BKV cystitis, including hemorrhagic cystitis. Other potential segments may include prophylaxis in high-risk patients and treatment of BK viremia. BK viremia is not screened for currently until symptoms
of cystitis occur, but this is likely to change once physicians have an effective treatment available. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">An estimated 44,000 allogeneic HSCTs are conducted globally
each year, with approximately 10,000 in the United States, 16,000 in Europe, 3,500 in Japan, and 2,500 in China. An estimated 57,000 autologous HSCTs are conducted globally each year, with approximately 17,000 in the United States, 27,000 in Europe,
2,500 in Japan, and 1,800 in China. Approximately 15% of allogeneic recipients and 5% of autologous recipients develop BK cystitis, including hemorrhagic cystitis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Based on primary market research with physicians and extensive secondary research, we estimate the market for a novel agent to treat BKV cystitis to be approximately
$550&nbsp;million annually worldwide, with $230&nbsp;million, $230&nbsp;million, $50&nbsp;million, and $7&nbsp;million in peak sales generated in the United States, Europe, Japan, and China, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Current standard of care for BKV cystitis in HSCT patients </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Upon
diagnosis of BKV associated cystitis, physicians consider reducing immunosuppression &#150; with initial modification typically consisting of lowering MMF by 50% or modifying the tacrolimus dose. This reduction of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">146 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
immunosuppression must be balanced with consideration for increased risk of acute Graft versus Host Disease (GvHD). Antivirals such as <FONT STYLE="white-space:nowrap">low-dose</FONT> cidofovir
and leflunomide as well as IVIG are used in patients whose BKV does not resolve after a reduction of immunosuppression, or in patients where reduction in immunosuppression is viewed as too high risk (I.e., instances of HLA mismatch or prior history
of GvHD). However, there is not robust clinical trial evidence supporting use of these agents in this setting. Symptomatic treatments for severe bleeding due to hematuria include red blood cell transfusions, bladder embolization or cystectomy. For
HSCT patients, physicians&#146; primary concerns are acute GvHD and cytomegalovirus (CMV)&nbsp;reactivation moreso than BKV, though they continue to view BKV cystitis as an area of high unmet need. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging therapies in development </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is limited clinical
development of new agents targeting BKV in the HSCT setting. Allovir&#146;s Posoleucel (formerly known as <FONT STYLE="white-space:nowrap">ALVR-105</FONT> and <FONT STYLE="white-space:nowrap">Viralym-M),</FONT> a multi-virus specific <FONT
STYLE="white-space:nowrap">T-cell</FONT> therapy, is currently in a Phase 3 clinical trial for the treatment of virus-associated hemorrhagic cystitis. This therapy has the potential to treat six viral pathogens: BKV, CMV, adenovirus, Epstein-Barr
virus, human herpesvirus 6 and JC virus, and therefore may have utility when physicians are concerned about multiple viral reactivations. Posoleucel is also in two Phase 2 clinical trials: one in kidney transplant recipients with BK viremia and
another in multi-virus prevention following allogeneic HSCT. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that MAU868 may represent an important future treatment option for HSCT patients with BKV
cystitis and that its relative ease of distribution and administration may provide a competitive advantage over other emerging therapies. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Exclusive license
agreement with Ares Trading S.A. </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;29, 2020, we entered into the Ares Agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany,
pursuant to which Ares granted us an exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize therapeutic products containing atacicept or
any other compound that is covered by a claim of such licensed patents. Pursuant to the Ares Agreement, Ares also transferred inventory of licensed product to us for use in our clinical development of atacicept. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Per the Ares Agreement, we have obligations to use commercially reasonable efforts to develop at least one licensed product, to launch at least one licensed product in a
major market country within a specified time frame after receiving marketing approval for such product and to maintain sufficient resources to manufacture and supply licensed products to meet the market demand in each country for which a licensed
product has received marketing approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In consideration for the rights granted under the Ares Agreement, we issued 22,171,553 shares of our Series C redeemable
convertible preferred stock to Ares at the time of the initial closing of our Series C redeemable convertible preferred stock financing in October 2020, representing ownership of approximately 10% on a fully diluted basis. As additional
consideration under the Ares Agreement, we paid Ares $25.0&nbsp;million upon delivery and initiation of the transfer of specified information and supply of drug product and drug substance and we are required to pay Ares aggregate milestone payments
of up to $176.5&nbsp;million upon the achievement of specified BLA filing or regulatory approvals in the United States, Europe and Japan (the first of which consists of a $15.0&nbsp;million payment upon filing of the BLA), and aggregate milestone
payments of up to $515&nbsp;million upon the achievement of specified commercial milestones. Commencing on the first commercial sale of licensed products, we are obligated to pay tiered royalties of low double-digit to
<FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net sales of the products covered by the license. Our obligation to pay royalties will expire on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis until the latest of (i) 15 years
after the first </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">147 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
commercial sale of such licensed product in such country; (ii)&nbsp;the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its use, importation or
manufacture with respect to, such country; and (iii)&nbsp;expiration of all applicable regulatory exclusivity periods in such country with respect to such licensed product. In the event we sublicense our rights under the Ares Agreement, we are
obligated to pay Ares a percentage ranging from the mid single-digit to the low double-digits of specified sublicensing income received. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The term of the Ares
Agreement will expire on a licensed <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-licensed</FONT></FONT> product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT>
basis upon the expiration of our obligation to pay royalties to Ares with respect to such licensed product in such country. We have the right to terminate the Ares Agreement at will upon a specified notice period, provided that such termination is
not within two years of the effective date of the Ares Agreement. Ares has the right to terminate the Ares Agreement in the event we challenge the validity of the licensed patents. Additionally, either party can terminate the Ares Agreement for the
other party&#146;s uncured material breach or bankruptcy. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Asset purchase agreement with Amplyx and exclusive license with Novartis </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On December&nbsp;16, 2021, we entered into the Amplyx Agreement with Amplyx, a wholly-owned subsidiary of Pfizer Inc. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the terms of the Amplyx Agreement, we acquired all of Amplyx&#146;s right, title and interest in and to certain assets of Amplyx related to MAU868, a
monoclonal antibody that was under development by Amplyx for the treatment of BKV infections (the Purchased Assets). The Purchased Assets include an investigational new drug application filed with the U.S. Food and Drug Administration, patents,
contracts, including the Novartis License, chemical and biological materials, and development and regulatory files, documentation, data, results and other electronic records related to MAU868. We also assumed certain liabilities of Amplyx arising
out of the Purchased Assets. We and Amplyx have made customary representations and warranties and agreed to customary covenants in the Amplyx Agreement. Subject to certain limitations, each of we and Amplyx has also agreed to indemnify the other for
breaches of representations and warranties and other specified matters. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In partial consideration for the Asset Acquisition, we made an upfront initial payment of
$5.0&nbsp;million to Amplyx. In addition, we are also obligated to make certain milestone payments to Amplyx in an aggregate amount of up to $7.0&nbsp;million based on certain regulatory milestones. Further, we are required to pay Amplyx low single
digit percentage royalties based on net sales on a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MAU868 is subject to the Novartis License, which was
assigned to us by Amplyx. Pursuant to the terms of the Novartis License, we obtained a worldwide, exclusive license from Novartis to develop, manufacture and commercialize MAU868, subject to certain retained rights for research and development by
Novartis, provided that Novartis may not develop or sell products incorporating monoclonal antibody targeting BKV and treating BKV disease within a certain period. We will be solely responsible for all research, development, regulatory,
manufacturing and commercialization activities of MAU868. Pursuant to the Novartis License, we are obligated to make certain milestone payments to Novartis in an aggregate amount of up to $69.0&nbsp;million based on certain clinical development,
regulatory and sales milestones. Further, we are required to pay Novartis <FONT STYLE="white-space:nowrap">mid-</FONT> to high-single digit percentage royalties based on net sales on a
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-product</FONT></FONT> basis. Unless terminated earlier, the Novartis
License will remain in effect with respect to each MAU868 product until the expiration of the royalty term for such product. We may terminate the Novartis License for convenience with 60 days&#146; prior written notice. We or Novartis may terminate
the Novartis License for the other party&#146;s uncured material breach. Novartis may terminate the Novartis License for our insolvency. Upon termination, any license granted by Novartis to us will terminate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">148 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Intellectual property </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our
success depends in part upon our ability to protect our core technology and intellectual property. To protect our intellectual property rights, we rely on patents, trademarks, copyrights and trade secret laws, confidentiality procedures, and
employee disclosure and invention assignment agreements. Our intellectual property is critical to our business and we strive to protect it through a variety of approaches, including by obtaining and maintaining patent protection in the United States
and internationally for our product candidate, and other inventions that are important to our business. For our product candidates, we generally intend to pursue patent protection covering compositions of matter, including new formulations, methods
of making and methods of use. As we continue the development of our product candidates, we intend to identify additional means of obtaining patent protection that would potentially enhance commercial success, including through claims covering
additional methods of use. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, we have licensed, including pursuant to sublicenses, from Ares, an affiliate of Merck KGaA, Darmstadt,
Germany, a patent portfolio related to atacicept that contains approximately 15 issued U.S. patents, as well as certain foreign counterparts of a subset of these patents in foreign countries, including Australia, Brazil, Canada, China, Hong Kong,
Israel, India, Japan, Mexico, New Zealand, Ukraine, Singapore, South Korea, South Africa, and countries within the European Patent Convention and the Eurasian Patent Organization. The issued patents are expected to expire between 2022 and 2029, with
patents covering the composition of matter of atacicept expiring in 2022. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In regard to atacicept, we <FONT STYLE="white-space:nowrap">in-license</FONT> a patent
family that includes one issued U.S. patent with claims covering a method of purifying atacicept and over 10 foreign patents granted in various jurisdictions including Australia, China, Europe, Israel, and Mexico. The U.S. patent is expected to
expire in 2028 and the foreign patents are expected to expire in 2027. We also <FONT STYLE="white-space:nowrap">in-license</FONT> a patent family that includes one issued U.S. patent with claims covering a formulation of atacicept and six foreign
patents granted in various jurisdictions such as Australia, Canada, China, and Europe. The U.S. patent is expected to expire in 2029, without taking into account any patent term extension, and the foreign patents are expected to expire in 2028.
There is also a pending PCT application and a counterpart Taiwanese application directed to treatment of IgAN and proteinuria. Once nationalized, patents that issue in this family are expected to expire in 2041. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because atacicept is a biologic, marketing approval would also provide 12 years of market exclusivity from the approval date of a BLA in the United States. We are
currently seeking orphan drug designation for atacicept in IgAN from the FDA and EMA, which, if secured, would provide seven and ten years, in the United States and European Union, respectively, of regulatory exclusivity protection from the approval
date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our patent portfolio covering MAU868 includes three issued U.S. patents with claims covering the composition of matter of MAU868, and methods of neutralizing
BKV or JC virus as well as methods of treating or reducing the likelihood of BKV or JC virus associated disorders. The U.S. patents are expected to expire in 2036. Corresponding foreign counterparts are granted in Australia, China, and Taiwan, and
pending in other jurisdictions such as Canada, Mexico, Europe and Japan.&nbsp;The foreign patents are expected to expire in 2036. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, an application
directed to dosing regimens for MAU868 is pending as a PCT application and is also pending in Taiwan. Once nationalized, patents that issue in this family are expected to expire in 2041.In addition to patents, we may rely upon unpatented trade
secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> and continuing technological innovation to develop and maintain our competitive position. However, trade secrets and <FONT STYLE="white-space:nowrap">know-how</FONT> can be difficult to
protect. We seek to protect our proprietary information, in part, by executing confidentiality agreements with our collaborators and scientific advisors, and <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> confidentiality, and invention
assignment agreements with our employees and consultants. We have also executed agreements requiring assignment of inventions with selected scientific advisors and collaborators. The confidentiality agreements we
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">149 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
enter into are designed to protect our proprietary information and the agreements or clauses requiring assignment of inventions to us are designed to grant us ownership of technologies that are
developed through our relationship with the respective counterparty. We cannot guarantee, however, that we have executed such agreements with all applicable counterparties, such agreements will not be breached, or that these agreements will afford
us adequate protection of our intellectual property and proprietary rights. For more information, see &#147;Risk factors&#151;Risks related to our intellectual property.&#148; </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, we seek trademark protection in the United States and internationally where available and when we deem appropriate. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Manufacturing and supply </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We manage a number of external CMOs to develop and
manufacture our product candidates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is a fully humanized fusion protein that impacts the <FONT STYLE="white-space:nowrap">B-cell</FONT> pathway, which has
well characterized implications in immunologic diseases. The human <FONT STYLE="white-space:nowrap">IgG1-Fc</FONT> was modified to reduce the Fc binding to the C1q component of complement and the interaction with Fc receptors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Atacicept is manufactured following cGMPs using a process that is similar to that used routinely for production of monoclonal antibodies. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The atacicept drug product is available as a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">ready-to-use</FONT></FONT> injection solution in a
prefilled syringe (PFS) at strengths of 25 mg/mL, 75 mg/mL, or 150 mg/mL of trial drug. Each atacicept PFS is designed to deliver a 1 mL solution of drug product. The drug product formulation is composed of atacicept as the active substance, a sugar
as a stabilizing agent, and sodium acetate as a buffer. All formulation components are pharmacopeia grade. An atacicept prefilled syringe/autoinjector combination is in late-stage development and will be introduced into future clinical trials when
appropriate. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Ares Agreement includes the transfer of all existing inventory of atacicept drug substance and drug product, for our use in planned and future
clinical trials. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We acquired approximately 35,000 PFS of atacicept, representing all three strengths, 25 mg, 75 mg and 150 mg, of atacicept and approximately 25,000
PFS of placebo, as part of the Ares Agreement. This drug product will be used to initiate the Phase 2b ORIGIN trial. Additionally, we will acquire 6 kg of atacicept drug substance. As part of the Ares Agreement, in the first quarter of 2022, Ares
will convert the 6 kg of drug substance into drug product to supply both the ongoing Phase 2b ORIGIN trial and to support our future clinical trials through the first quarter in 2026. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">MAU868 is an IgG1 monoclonal antibody that binds to BKV protein VP1. It is manufactured according to cGMP using a high expression CHO cell and a standard antibody
manufacturing process that is completely free from animal or human derived raw materials. The MAU868 manufacturing supply chain is fully established using contract manufacturing organizations with contracts that are assignable to Vera Therapeutics.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fully formulated MAU868 drug product is provided as a 3 mL fill in a 6 mL vial which can be combined with multiple vials to prepare infusions at different
dosage strengths for use in clinical trials. The drug product formulation is composed of MAU868 as the active substance, a buffering agent, and both a sugar and a surfactant as stabilizing agents. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Amplyx Agreement includes the transfer of all existing inventory and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-process</FONT></FONT>
of MAU868 drug product for use in clinical trials. This includes 2777 unlabeled vials and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">work-in-process</FONT></FONT> expected to yield approximately 5300 vials with release
targeted for March 2022. These materials will support both the completion of the ongoing Phase 2 clinical trial and initiation of a future clinical trial. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">150 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Commercialization plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate the market opportunity for novel therapeutics in
IgAN across the United States, Europe and Japan to be approximately $5.6&nbsp;billion to $9.6&nbsp;billion annually, based on our assumptions, secondary research, and primary market research with physicians and payors. In order to capitalize on this
opportunity, we plan to build a specialty commercial infrastructure focused on IgAN, engaging treating physicians, including nephrologists, educating and engaging patients, and ensuring market access for patients. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For novel therapeutics in LN, we estimate the market opportunity across the United States, Europe and Japan to be $2.8&nbsp;billion to $5.8&nbsp;billion annually, based
on a similar methodology. If we receive regulatory approval for atacicept in both IgAN and LN, we plan to assess call point overlap for the two indications and selectively build out our future commercial infrastructure to address any gaps to
optimize our coverage of LN treating physicians. We also plan to build out <FONT STYLE="white-space:nowrap">LN-specific</FONT> patient and market access programs, leveraging synergies where possible. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through the Ares Agreement, we were granted worldwide rights to the development and commercialization of atacicept in all indications. We intend to commercialize
atacicept ourselves in the United States and other key markets, if approved. Within certain <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets, we may consider strategic collaborations to facilitate commercialization. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MAU868 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate the worldwide market opportunity for novel
therapeutics addressing the BKV across both kidney transplant recipients and HSCT patients will be approximately $1&nbsp;billion in annual revenues in 2036, based on our assumptions, secondary research, and primary market research with physicians.
We plan to prioritize the development of MAU868 for the treatment of BK viremia in kidney transplant, which has strong commercial synergies with our plans for atacicept. We believe that the prescribing physicians for MAU868 in renal transplant, if
approved, will be a subset of the IgAN treating physicians, and plan to conduct an assessment of call point overlap. The launch of this indication, if prior to the atacicept launch, would require a smaller specialty commercial infrastructure build
focused on educating and engaging treating physicians, including transplant nephrologists, partnering with kidney transplant organizations, and ensuring market access for patients. If prior to the atacicept launch, we would plan to leverage this
infrastructure for eventual atacicept sales and marketing activities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through the Amplyx Agreement, we obtained worldwide rights to the development and
commercialization of MAU868 in all indications. Similar to our plans with atacicept, we intend to commercialize MAU868 ourselves in the United States and other key markets, if approved. We also may consider strategic collaborations to facilitate
commercialization in certain <FONT STYLE="white-space:nowrap">ex-U.S.</FONT> markets. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Competition </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The biotechnology and pharmaceutical industries are characterized by rapidly changing technologies, significant competition and a strong emphasis on intellectual
property. This is also true for the development and commercialization of treatments for immunologic diseases. Though we believe that our focus, experienced team, scientific knowledge, and intellectual property provide us with competitive advantages,
we face competition from a number of sources, including large and small biopharmaceutical companies, universities, and other research institutions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">151 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Many of our competitors have significantly greater financial, technical, human and other resources than we do and may
be better equipped to develop, manufacture and market technologically superior products. In addition, many of these competitors have significantly greater experience than we have in undertaking nonclinical studies and human clinical trials of new
pharmaceutical products and in obtaining regulatory approvals of human therapeutic products. Accordingly, our competitors may succeed in obtaining FDA approval for superior products. Many of our competitors have established distribution channels for
the commercialization of their products, whereas we have no such channel or capabilities. In addition, many competitors have greater name recognition and more extensive collaborative relationships. Mergers and acquisitions in the pharmaceutical and
biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements
with large and established companies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our competitors may obtain regulatory approval of their products more rapidly than we do or may obtain patent protection or
other intellectual property rights that limit our ability to develop or commercialize our product candidates or any future product candidates. Our competitors may also develop drugs that are more effective, more convenient, more widely used and less
costly or have a better safety profile than our products and these competitors may also be more successful than we are in manufacturing and marketing their products. If we are unable to compete effectively against these companies, then we may not be
able to commercialize our product candidates or any future product candidates or achieve a competitive position in the market. This would adversely affect our ability to generate revenue. Our competitors also compete with us in recruiting and
retaining qualified scientific, management and commercial personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs.<I> </I> </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in IgAN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Despite a high level of morbidity for IgAN, the
current standard of care consists of <FONT STYLE="white-space:nowrap">off-label</FONT> use of RAAS inhibitors, including ACE inhibitors and ARBs, and potentially steroids. Atacicept, if and when approved and successfully commercialized, may compete
with these existing approaches and with any new therapies that may become available in the future. Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be the recently approved reformulated steroid
from Calliditas Therapeutics AB, programs in Phase 3 clinical development: Novartis, Omeros Corporation, Travere Therapeutics, Inc., and Chinook Therapeutics Inc., and the following companies with programs in Phase 2 of clinical development: Chinook
Therapeutics Inc., Alnylam Pharmaceuticals Inc., Apellis Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., RemeGen Co., Ltd., Visterra, Inc., Ionis Pharmaceuticals, Inc., Alexion, and DiaMedica Therapeutics, Inc. There is also a potential that
SGLT2 inhibitors, including AstraZeneca&#146;s Farxiga, which has been approved for chronic kidney disease in April 2021 and Boehringer&#146;s jardiance, which is undergoing Phase 3 clinical development, will be approved broadly for chronic kidney
disease and used in IgAN. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Atacicept in LN </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In LN, prior to
December 2020, there had been no approved therapies, and the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">standard-of-care</FONT></FONT> has consisted of a number of <FONT STYLE="white-space:nowrap">non-specific</FONT>
therapies, including MMF, steroids, CYC, rituximab, calcineurin inhibitors, AZA, and HCQ, dependent on class of disease and whether a patient was cycling through the induction or maintenance phase of therapy. We expect that these paradigms will
evolve with the recent FDA approvals of GlaxoSmithKline plc&#146;s Benlysta (belimumab) and Aurinia Pharmaceuticals Inc.&#146;s Lupkynis (voclosporin), both of which we consider to be direct competitors. Our competitors include: Roche Holding AG and
Novartis Pharmaceuticals Corporation, each of which have programs in Phase 3 clinical development; and BeiGene Ltd., Janssen </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">152 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
Pharmaceuticals, Inc., AstraZeneca, Alexion, Omeros Corporation, Kezar Life Science Inc., Bristol Myers Squibb, Boehringer, and Novartis Pharmaceuticals Corporation, each of which have programs
in Phase 2 clinical development. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>MAU868 </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are currently no <FONT
STYLE="white-space:nowrap">anti-BKV</FONT> therapies approved, either in the kidney transplant or HSCT setting. The standard of care in both settings is to reduce immunosuppression as a first line, and potentially to offer IVIG in kidney transplant
recipients or antivirals with limited clinical evidence, including leflunomide and cidofovir, in either setting. There are few industry sponsored programs in development for these indications; we consider our most direct competitor to be
Allovir&#146;s multi-virus specific <FONT STYLE="white-space:nowrap">T-cell</FONT> therapy, Posoleucel, which is in a Phase 2 clinical trial for BK viremia in kidney transplant recipients, a Phase 3 clinical trial for treatment of virus-associated
cystitis, and a Phase 2 clinical trial in multi-virus prevention following allogeneic HSCT. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Government regulation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Government authorities in the United States at the federal, state and local level and in other countries and jurisdictions, including the European Union, extensively
regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and
export and import of drug and biological products, such as our investigational medicines and any future investigational medicines. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and
efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulatory approval in the United States </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the United States,
pharmaceutical products are subject to extensive regulation by the FDA. The Federal Food, Drug and Cosmetic Act (FDCA), and other federal and state statutes and regulations, govern, among other things, the research, development, testing,
manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post- approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Biological products used for the prevention,
treatment or cure of a disease or condition of a human being are subject to regulation under the FDCA, except the section of the FDCA that governs the approval of a new drug application (NDA). Biological products are approved, or licensed, for
marketing under provisions of the Public Health Service Act (PHSA) via a BLA. The application process and requirements for approval of BLAs for originator biological products are similar to those for NDAs for new chemical entities, and biologics are
associated with similar approval risks and costs as drugs. Failure to comply with applicable U.S. requirements may subject a company to a variety of administrative or judicial sanctions, such as clinical hold, FDA refusal to approve pending NDAs or
BLAs, warning or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, civil penalties, and criminal prosecution. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our investigational medicines and any future investigational medicines must be approved by the FDA pursuant to a BLA before they may be legally marketed in the United
States. The process generally involves the following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">completion of extensive preclinical laboratory and animal studies in accordance with applicable regulations, including
studies conducted in accordance with good laboratory practices (GLP) requirements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the FDA of an Investigational New Drug Application (IND), which must become effective before human clinical
trials may begin; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">153 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approval of the protocol and related documents by an IRB or independent ethics committee at each clinical trial site before
each clinical trial may be commenced; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well controlled human clinical trials in accordance with applicable IND regulations, GCP
requirements and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preparation of and submission to the FDA of a BLA for marketing approval that includes sufficient evidence of establishing
the safety, purity, and potency of the proposed biological product for its intended indication, including from results of nonclinical testing and clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">payment of any user fees for FDA review of the BLA; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a determination by the FDA within 60 days of its receipt of a BLA to accept the filing for review; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of one or more FDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspections of the
manufacturing facility or facilities where the biologic, or components thereof, will be produced to assess compliance with current cGMP requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#146;s
identity, strength, quality and purity; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of any potential FDA audits of the clinical trial sites that generated the data in support of the
BLA to assure compliance with GCPs and integrity of the clinical data; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">FDA review and approval of the BLA, including consideration of the views of any FDA advisory committee; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">compliance with any post-approval requirements, including a REMS, where applicable, and post- approval studies required by
the FDA as a condition of approval. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preclinical and clinical testing and approval process requires substantial time, effort and financial
resources, and we cannot be certain that any approvals for our product candidates will be granted on a timely basis, or at all. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before testing any biological product candidates in humans, the product candidate must undergo rigorous preclinical testing. Preclinical studies include
laboratory evaluation of product chemistry and formulation, as well as in vitro and animal studies to assess the potential for adverse events and in some cases to establish a rationale for therapeutic use. The conduct of preclinical studies is
subject to federal regulations and requirements, including GLP regulations for safety/toxicology studies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prior to beginning the first clinical trial with a product
candidate in the United States, an IND must be submitted to the FDA and the FDA must allow the IND to proceed. An IND is an exemption from the FDCA that allows an unapproved product candidate to be shipped in interstate commerce for use in an
investigational clinical trial and a request for FDA allowance that such investigational product may be administered to humans in connection with such trial. Such authorization must be secured prior to interstate shipment and administration. In
support of a request for an IND, applicants must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. An IND sponsor must also submit the results of the preclinical tests,
together with manufacturing information, analytical data, any available clinical </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">154 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
data or literature and plans for clinical trials, among other things, to the FDA as part of an IND. Some long-term preclinical testing may continue after the IND is submitted. An IND
automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the trial on clinical hold. In such a case, the IND sponsor and
the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to commence. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical trials </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The clinical stage of development involves the
administration of the investigational product to healthy volunteers or patients under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor&#146;s control. Clinical trials must be conducted:
(i)&nbsp;in compliance with federal regulations; (ii)&nbsp;in compliance with GCPs, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators and monitors; as well
as (iii)&nbsp;under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated in the trial. Each protocol involving testing on U.S. patients
and subsequent protocol amendments must be submitted to the FDA as part of the IND. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, each clinical trial must be reviewed and approved by an IRB for
each institution at which the clinical trial will be conducted to ensure that the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the informed
consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate
approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the product candidate has been associated with unexpected serious
harm to patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data safety monitoring board or
committee (DSMB). This group provides authorization as to whether or not a trial may move forward at designated check points based on access that only the group maintains to available data from the study. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain
clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website. Information related to the product, patient population, phase of investigation, clinical trial
sites and investigators and other aspects of the clinical trial is then made public as part of the registration. Disclosure of the results of these clinical trials can be delayed in certain circumstances for up to two years after the date of
completion of the trial. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the
clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. The FDA will accept a well- designed and well-conducted foreign clinical
trial not conducted under an IND if the clinical trial was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Clinical trials are generally conducted in three sequential phases, known as Phase 1, Phase 2 and Phase&nbsp;3: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 1 clinical trials generally involve a small number of healthy volunteers or disease-affected patients who are
initially exposed to a single dose and then multiple doses of the product candidate. The primary purpose </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">155 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">
of these clinical trials is to assess the metabolism, pharmacokinetics, pharmacologic action, side effect tolerability, safety of the product candidate, and, if possible, early evidence of
effectiveness. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 2 clinical trials generally involve studies in disease-affected patients to evaluate proof of concept and/or
determine the dosing regimen(s) for subsequent investigations. At the same time, safety and further pharmacokinetic and pharmacodynamic information is collected, possible adverse effects and safety risks are identified, and a preliminary evaluation
of efficacy is conducted. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Phase 3 clinical trials generally involve a large number of patients at multiple sites and are designed to provide the data
necessary to demonstrate the effectiveness of the product for its intended use, its safety in use and to establish the overall benefit/risk relationship of the product and provide an adequate basis for product labeling. In most cases, the FDA
requires two adequate and well-controlled Phase 3 clinical trials to demonstrate the efficacy of the biologic. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These Phases may overlap or be
combined. For example, a Phase 1/2 clinical trial may contain both a dose-escalation stage and a dose-expansion stage, the latter of which may confirm tolerability at the recommended dose for expansion in future clinical trials. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A single Phase 3 or Phase 2 trial with other confirmatory evidence may be sufficient in rare instances to provide substantial evidence of effectiveness (generally
subject to the requirement of additional post-approval studies). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In some cases, FDA may require, or firms may voluntary pursue, post-approval clinical trials,
sometimes referred to as Phase 4 clinical trials, after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety
<FONT STYLE="white-space:nowrap">follow-up.</FONT> </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all
clinical activities, clinical data, and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA and the
investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or <I>in vitro</I> testing that suggest a significant risk for human subjects, or any clinically important increase in the rate of
a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The
sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor&#146;s initial receipt of the information. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Phase 1, Phase 2, Phase 3 and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA, the IRB, or the sponsor
may suspend or terminate a clinical trial at any time on various grounds, including <FONT STYLE="white-space:nowrap">non-compliance</FONT> with regulatory requirements or a finding that the patients are being exposed to an unacceptable health risk.
Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#146;s requirements or if the drug or biologic has been associated with unexpected
serious harm to patients. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Concurrent with clinical trials, companies usually complete additional animal studies and also must develop additional information about
the chemistry and physical characteristics of the drug or biologic as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently
producing quality batches of the product and, among other things, companies must develop methods for testing the identity, strength, quality, potency and purity of the final product. Additionally, appropriate packaging must be selected and tested,
and stability studies must be conducted to demonstrate that the investigational medicines do not undergo unacceptable deterioration over their shelf life. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">156 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>FDA review processes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Following completion of the clinical trials, the results of preclinical studies and clinical trials are submitted to the FDA as part of a BLA, along with proposed
labeling, chemistry and manufacturing information to ensure product quality and other relevant data. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the
investigational product to the satisfaction of the FDA. FDA approval of a BLA must be obtained before a biologic or drug may be marketed in the United States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
cost of preparing and submitting a BLA is substantial. Under the Prescription Drug User Fee Act (PDUFA), each BLA must be accompanied by a substantial user fee. The FDA adjusts the PDUFA user fees on an annual basis. Fee waivers or reductions are
available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also
includes a <FONT STYLE="white-space:nowrap">non-orphan</FONT> indication. The applicant under an approved BLA is also subject to an annual program fee. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Within 60
days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the FDA accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable
at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review to determine if it is substantially complete before
the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an <FONT STYLE="white-space:nowrap">in-depth</FONT> review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product
is safe, pure and potent, for its intended use, and whether the product is being manufactured in accordance with cGMP to ensure its continued safety, purity and potency. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months, from the filing date, in which to complete its initial review of an original BLA
for a new molecular entity and respond to the applicant, and six months from the filing date of an original BLA designated for priority review. The review process for both standard and priority review may be extended by the FDA for three additional
months to consider certain late-submitted information, or information intended to clarify information already provided in the submission. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process can be
extended by FDA requests for additional information or clarification. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Before approving a BLA, the FDA will conduct a
<FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection of the manufacturing facilities for the new product to determine whether they comply with cGMP requirements. The FDA will not approve the product unless it determines that the
manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA also may audit data from clinical trials to ensure compliance with GCP requirements and the integrity of the data supporting safety and efficacy. Additionally,
the FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation
as to whether the application should be approved and under what conditions, if any. The FDA is not bound by recommendations of an advisory committee, but it generally follows such recommendations when making decisions on approval. The FDA likely
will reanalyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the FDA
evaluates a BLA, it will issue either an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A Complete Response Letter
indicates that the review cycle of the application is complete and the application will not be approved in its present form. A Complete Response Letter generally outlines the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">157 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
deficiencies in the BLA and may require additional clinical data, additional pivotal clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials,
preclinical studies or manufacturing in order for FDA to reconsider the application. If a Complete Response Letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the
application or request an opportunity for a hearing. The FDA has committed to reviewing such resubmissions in two or six months, depending on the type of information included. Even if such data and information are submitted, the FDA may decide that
the BLA does not satisfy the criteria for approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a product receives regulatory approval, the approval may be significantly limited to specific diseases and
dosages or the indications for use may otherwise be limited, including to subpopulations of patients, which could restrict the commercial value of the product. Furthermore, as a condition of BLA approval, the FDA may require a REMS to help ensure
that the benefits of the biologic outweigh the potential risks to patients. A REMS can include medication guides, communication plans for healthcare professionals and elements to assure a product&#146;s safe use (ETASU). An ETASU can include, but is
not limited to, special training or certification for prescribing or dispensing the product, dispensing the product only under certain circumstances, special monitoring and the use of patient-specific registries. The requirement for a REMS can
materially affect the potential market and profitability of the product. Moreover, the FDA may require substantial post-approval testing and surveillance to monitor the product&#146;s safety or efficacy. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Orphan drug designation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Orphan Drug Act, the FDA may grant
orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the
United States but for which there is no reasonable expectation that the cost of developing and making the product for this type of disease or condition will be recovered from sales of the product in the United States. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential
orphan use are disclosed publicly by the FDA. Orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is
entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same product for the same indication for seven years from the date of such approval, except in limited circumstances, such as a
showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. A designated orphan drug may not
receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. Orphan drug exclusivity may be lost if the FDA later determines that the request for designation was materially
defective. Further, competitors may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because healthcare professionals are free to prescribe products for <FONT
STYLE="white-space:nowrap">off-label</FONT> uses, the competitor&#146;s product could be used for the orphan indication despite another product&#146;s orphan exclusivity. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Expedited development and review programs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The FDA is authorized to
designate certain products for expedited review if they are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">158 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fast track designation may be granted for products that are intended to treat a serious or life-threatening disease or
condition for which there is no effective treatment and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which
it is being studied. The sponsor of a new biologic candidate can request the FDA to designate the candidate for a specific indication for fast track status concurrent with, or after, the submission of the IND for the candidate. The FDA must
determine if the biologic candidate qualifies for fast track designation within 60 days of receipt of the sponsor&#146;s request. For fast track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of
sections of a fast track product&#146;s BLA before the application is complete. This &#147;rolling review&#148; is available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a fast track product may
be effective. The sponsor must also provide, and the FDA must approve, a schedule for the submission of the remaining information and the sponsor must pay applicable user fees. Any product submitted to the FDA for marketing, including under a fast
track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Breakthrough therapy designation may be granted for products that are intended, alone or in combination with one or more other products, to treat a serious or
life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. Under the breakthrough therapy
program, the sponsor of a new biologic candidate may request that the FDA designate the candidate for a specific indication as a breakthrough therapy concurrent with, or after, the submission of the IND for the biologic candidate. The FDA must
determine if the biological product qualifies for breakthrough therapy designation within 60 days of receipt of the sponsor&#146;s request. The FDA may take certain actions with respect to breakthrough therapies, including holding meetings with the
sponsor throughout the development process, providing timely advice to the product sponsor regarding development and approval, involving more senior staff in the review process, assigning a cross-disciplinary project lead for the review team and
taking other steps to design the clinical trials in an efficient manner. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Priority review may be granted for products that are intended to treat a serious or
life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application designated for
priority review in an effort to facilitate the review. Under priority review, the FDA&#146;s goal is to review an application in six months once it is filed, compared to ten months for a standard review. Priority review designation does not change
the standard for approval or the quality of evidence necessary to support approval. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accelerated approval may be granted for products that are intended to treat a
serious or life-threatening condition and that generally provide a meaningful therapeutic advantage to patients over existing treatments. A product eligible for accelerated approval may be approved on the basis of either a surrogate endpoint that is
reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical
benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. In clinical trials, a surrogate endpoint is a measurement of laboratory or clinical signs of a disease or
condition that substitutes for a direct measurement of how a patient feels, functions or survives. The accelerated approval pathway is most often used in settings in which the course of a disease is long, and an extended period of time is required
to measure the intended clinical benefit of a product, even if the effect on the surrogate or intermediate clinical endpoint occurs rapidly. Use of the accelerated approval pathway entails submission of a BLA with the surrogate or intermediate
clinical endpoint data while continuing to conduct the trial(s) to completion and is contingent on a sponsor&#146;s agreement to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">159 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
complete and/or conduct additional post-approval confirmatory studies to verify and describe the product&#146;s clinical benefit. These confirmatory trials must be completed with due diligence
and, in some cases, the FDA may require that the trial be designed, initiated and/or fully enrolled prior to approval. Failure to conduct required post-approval studies, or to confirm a clinical benefit during post-marketing studies, would allow the
FDA to withdraw the product from the market on an expedited basis. All promotional materials for product candidates approved under accelerated regulations are subject to prior review by the FDA. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time
period for FDA review or approval may not be shortened. Furthermore, fast track designation, breakthrough therapy designation, priority review and accelerated approval do not change the standards for approval, but may expedite the development or
approval process. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Additional controls for biologics </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To help
reduce the increased risk of the introduction of adventitious agents, the PHSA emphasizes the importance of manufacturing controls for products whose attributes cannot be precisely defined. The PHSA also provides authority to the FDA to immediately
suspend licenses in situations where there exists a danger to public health, to prepare or procure products in the event of shortages and critical public health needs, and to authorize the creation and enforcement of regulations to prevent the
introduction or spread of communicable diseases in the United States and between states. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After a BLA is approved, the product may also be subject to official lot
release as a condition of approval. As part of the manufacturing process, the manufacturer is required to perform certain tests on each lot of the product before it is released for distribution. If the product is subject to official release by the
FDA, the manufacturer submits samples of each lot of product to the FDA together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#146;s tests performed on the lot. The FDA
may also perform certain confirmatory tests on lots of some products, such as viral vaccines, before releasing the lots for distribution by the manufacturer. In addition, the FDA conducts laboratory research related to the regulatory standards on
the safety, purity, potency and effectiveness of biological products. As with drugs, after approval of biologics, manufacturers must address any safety issues that arise, are subject to recalls or a halt in manufacturing, and are subject to periodic
inspection after approval. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Combination products </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A combination
product is a product comprised of two or more regulated components, e.g., drug and medical device, that are physically combined and produced as a single entity, packaged together in a single package, or packaged separately but intended to be labeled
for use together. Atacicept in a prefilled autoinjector would be such a combination of therapeutic and delivery device. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">FDA is divided into various branches, or
Centers, by product type. Different Centers typically review drug, biologic, or device applications. In order to review an application for a combination product, FDA must decide which Center should be responsible for the review. FDA regulations
require that FDA determine the combination product&#146;s primary mode of action, or PMOA, which is the single mode of a combination product that provides the most important therapeutic action of the combination product. The Center that regulates
that portion of the product that generates the PMOA becomes the lead evaluator. If there are two independent modes of action, neither of which is subordinate to the other, FDA makes a determination as to which Center to assign the product based on
consistency with other combination products raising similar types of safety and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">160 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
effectiveness questions or to the Center with the most expertise in evaluating the most significant safety and effectiveness questions raised by the combination product. When evaluating an
application, a lead Center may consult other Centers but still retain complete reviewing authority, or it may collaborate with another Center, by which the Center assigns review of a specific section of the application to another Center, delegating
its review authority for that section. Typically, FDA requires a single marketing application submitted to the Center selected to be the lead evaluator, although the agency has the discretion to require separate applications to more than one Center.
We believe that our prefilled autoinjector would have a biologic PMOA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pediatric information </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the Pediatric Research Equity Act (PREA), BLAs or supplements to BLAs must contain data to assess the safety and effectiveness of the biological product for the
claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the biological product is safe and effective. The FDA may grant full or partial waivers, or deferrals,
for submission of data. Unless otherwise required by regulation, PREA generally does not apply to any biological product for an indication for which orphan designation has been granted. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Best Pharmaceuticals for Children Act (BPCA) provides a <FONT STYLE="white-space:nowrap">six-month</FONT> extension of any exclusivity&#151;patent or <FONT
STYLE="white-space:nowrap">non-patent&#151;for</FONT> a biologic if certain conditions are met. Conditions for exclusivity include the FDA&#146;s determination that information relating to the use of a new biologic in the pediatric population may
produce health benefits in that population, FDA making a written request for pediatric studies, and the applicant agreeing to perform, and reporting on, the requested studies within the statutory timeframe. Applications under the BPCA are treated as
priority applications, with all of the benefits that designation confers. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Post-approval requirements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once a BLA is approved, a product will be subject to certain post-approval requirements. For instance, the FDA closely regulates the post-approval marketing and
promotion of biologics, including standards and regulations for <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">direct-to-consumer</FONT></FONT> advertising, <FONT STYLE="white-space:nowrap">off-label</FONT> promotion,
industry-sponsored scientific and educational activities and promotional activities involving the Internet. Biologics may be marketed only for the approved indications and in a manner consistent with the provisions of the approved labeling. Although
physicians may prescribe products for <FONT STYLE="white-space:nowrap">off-label</FONT> uses as the FDA and other regulatory agencies do not regulate a physician&#146;s choice of drug treatment made in the physician&#146;s independent medical
judgment, they do restrict promotional communications from companies or their sales force with respect to <FONT STYLE="white-space:nowrap">off-label</FONT> uses of products for which marketing clearance has not been issued. Companies may only share
truthful and not misleading information that is otherwise consistent with a product&#146;s FDA approved labeling. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Adverse event reporting and submission of periodic
safety summary reports is required following FDA approval of a BLA. The FDA also may require post-marketing testing, known as Phase 4 testing, REMS, and surveillance to monitor the effects of an approved product, or the FDA may place conditions on
an approval that could restrict the distribution or use of the product. In addition, quality control, biological product manufacture, packaging and labeling procedures must continue to conform to cGMPs after approval. Biologic manufacturers and
certain of their subcontractors are required to register their establishments with the FDA and certain state agencies. Registration with the FDA subjects entities to periodic unannounced inspections by the FDA, during which the agency inspects a
biologic product&#146;s manufacturing facilities to assess compliance with cGMPs. Accordingly, manufacturers must continue to expend time, money and effort in the areas of production and quality-control to maintain compliance with cGMPs. Regulatory
authorities may withdraw product approvals or request product recalls if a company fails to comply with required regulatory standards, if it encounters problems following initial marketing, or if previously unrecognized problems are subsequently
discovered. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">161 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and
standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes or
failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information, imposition of post-market studies or clinical trials to assess new safety risks or imposition of distribution or other
restrictions under a REMS program. Other potential consequences include, among other things: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">restrictions on the marketing or manufacturing of the product, suspension of the approval, complete withdrawal of the
product from the market or product recalls; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">fines, warning or other enforcement-related letters or holds on post-approval clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">refusal of the FDA to approve pending BLAs or supplements to approved BLAs, or suspension or revocation of product license
approvals; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">product seizure or detention, or refusal to permit the import or export of products; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">injunctions or the imposition of civil or criminal penalties. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>U.S. marketing exclusivity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The BPCIA created an abbreviated approval
pathway for biological products shown to be biosimilar to, or interchangeable with, an <FONT STYLE="white-space:nowrap">FDA-licensed</FONT> reference biological product. Biosimilarity, which requires that the biological product be highly similar to
the reference product notwithstanding minor differences in clinically inactive components and that there be no clinically meaningful differences between the biological product and the reference product in terms of safety, purity and potency, can be
shown through analytical studies, animal studies and a clinical trial or trials. Interchangeability requires that a biological product be biosimilar to the reference product and that the product can be expected to produce the same clinical results
as the reference product in any given patient and, for products administered multiple times to an individual, that the product and the reference product may be alternated or switched after one has been previously administered without increasing
safety risks or risks of diminished efficacy relative to exclusive use of the reference biological product without such alternation or switch. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A reference
biological product is granted 12 years of data exclusivity from the time of first licensure of the product and the FDA will not accept an application for a biosimilar or interchangeable product based on the reference biological product until four
years after the date of first licensure of the reference product. &#147;First licensure&#148; typically means the initial date the particular product at issue was licensed in the United States. Date of first licensure does not include the date of
licensure of (and a new period of exclusivity is not available for) a biological product if the licensure is for a supplement for the biological product or for a subsequent application by the same sponsor or manufacturer of the biological product
(or licensor, predecessor in interest or other related entity) for a change (not including a modification to the structure of the biological product) that results in a new indication, route of administration, dosing schedule, dosage form, delivery
system, delivery device or strength, or for a modification to the structure of the biological product that does not result in a change in safety, purity or potency. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Regulatory approval in the European Union </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The EMA is a decentralized
scientific agency of the European Union. It coordinates the evaluation and monitoring of centrally authorized medicinal products. It is responsible for the scientific evaluation of applications for EU marketing authorizations, as well as the
development of technical guidance and the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">162 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
provision of scientific advice to sponsors. The EMA decentralizes its scientific assessment of medicines by working through a network of about 4,500 experts throughout the European Union,
nominated by the Member States. The EMA draws on resources of over 40 national competent authorities of European Union Member States. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The process regarding approval
of medicinal products in the European Union follows roughly the same lines as in the United States and likewise generally involves satisfactorily completing each of the following: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">preclinical laboratory tests, animal studies and formulation studies all performed in accordance with the applicable EU
Good Laboratory Practice regulations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the relevant national competent authorities of a clinical trial application (CTA) for each trial in humans,
which must be approved by such national authorities and at least one independent ethics committee before the trial may begin in each country where patient enrollment is planned; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each
proposed indication; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">submission to the relevant competent authorities of a marketing authorization application (MAA) which includes the data
supporting safety and efficacy as well as detailed information on the manufacture and composition of the product in clinical development and proposed labelling; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">satisfactory completion of an inspection by the relevant national authorities of the manufacturing facility or facilities,
including those of third parties, at which the product is produced to assess compliance with strictly enforced cGMP; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">potential audits of the <FONT STYLE="white-space:nowrap">non-clinical</FONT> and clinical trial sites that generated the
data in support of the MAA; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">review and approval by the relevant competent authority of the MAA before any commercial marketing, sale or shipment of the
product. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Preclinical studies </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Preclinical tests
include laboratory evaluations of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animal studies, in order to assess the quality and potential safety and efficacy of the product. The conduct of the
preclinical tests and formulation of the compounds for testing must comply with the relevant international, E.U. and national legislation, regulations and guidelines. The results of the preclinical tests, together with relevant manufacturing
information and analytical data, are submitted as part of the CTA. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Clinical trials </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Clinical Trials Directive 2001/20/EC, as amended (Clinical Trials Directive), a system for the approval of clinical trials in the European Union has been
implemented through national legislation of the member states. Under this system, approval must be obtained from the national competent authority of each European Union Member State in which a clinical trial is planned to be conducted. To this end,
a CTA is submitted, which must be supported by an investigational medicinal product dossier and further supporting information prescribed by the Clinical Trials Directive and other applicable guidance documents including but not being limited to the
clinical trial protocol. Furthermore, a clinical trial may only be started after an independent ethics committee has issued a favorable opinion on the CTA in that country. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2014, the EU adopted a new Clinical Trials Regulation (EU) No 536/2014, which is set to replace the current Clinical Trials Directive. The Regulation introduces
an authorization procedure based on a single </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">163 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
submission via a single E.U. portal, an assessment procedure leading to a single decision, as well as transparency requirements (the proactive publication of clinical trial data in the E.U.
database). It is expected that the new Regulation will apply following confirmation of full functionality of the Clinical Trials Information System (CTIS), the centralized EU portal and database for clinical trials foreseen by the Regulation,
through an independent audit, currently expected to occur in December 2021. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Manufacturing and import into the E.U. of investigational medicinal products for use in
clinical trials is subject to the holding of appropriate authorizations and must be carried out in accordance with cGMP. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Review and approval </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Authorization to market a product in the European Economic Area (EEA), comprising the European Union Member States plus Norway, Iceland and Liechtenstein, proceeds under
one of four procedures: a centralized authorization procedure, a mutual recognition procedure, a decentralized procedure or a national procedure. Since our products by their virtue of being antibody-based biologics fall under the centralized
procedure, only this procedure will be described here. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain drugs, including medicinal products developed by means of biotechnological processes, must be
approved via the centralized authorization procedure for marketing authorization. The centralized procedure is also mandatory for orphan medicinal products, advanced-therapy medicinal products (i.e. gene-therapy, somatic cell-therapy or
tissue-engineered medicines) and medicinal products containing a new active substance indicated for the treatment of HIV, AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and other immune dysfunctions and viral diseases. The
centralized procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public
health. A successful application under the centralized authorization procedure results in a marketing authorization from the European Commission, which is automatically valid throughout the EEA. The other European Economic Area member states (namely
Norway, Iceland and Liechtenstein) are also obligated to recognize the European Commission decision. The EMA and the European Commission administer the centralized authorization procedure. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the centralized authorization procedure, the Committee for Medicinal Products for Human Use (CHMP) serves as the scientific committee that renders opinions about
the safety, efficacy and quality of human medicinal products on behalf of the EMA. The CHMP is composed of experts nominated by each member state&#146;s national drug authority, with one of them appointed to act as Rapporteur for the <FONT
STYLE="white-space:nowrap">co-ordination</FONT> of the evaluation with the possible assistance of a further member of the CHMP acting as a <FONT STYLE="white-space:nowrap">Co-Rapporteur.</FONT> After approval, the Rapporteur(s) continue to monitor
the product throughout its life cycle. The CHMP is required to issue an opinion within 210 days of receipt of a valid application, though the clock is stopped if it is necessary to ask the applicant for clarification or further supporting data.
Clock stops may extend the timeframe of evaluation of a marketing authorization application considerably beyond 210 days. The process is complex and involves extensive consultation with the regulatory authorities of Member States and a number of
experts. Once the procedure is completed, a European Public Assessment Report is produced. If the CHMP concludes that the quality, safety and efficacy of the medicinal product is sufficiently proven, it adopts a positive opinion. The CHMP&#146;s
opinion is sent to the European Commission, which uses the opinion as the basis for its decision whether or not to grant a marketing authorization. The European Commission&#146;s decision is issued within 67 days of receipt of the CHMP&#146;s
recommendation. If the opinion is negative, information is given as to the grounds on which this conclusion was reached. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After a drug has been authorized and
launched, it is a condition of maintaining the marketing authorization that all aspects relating to its quality, safety and efficacy must be kept under review. Sanctions may be imposed for </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">164 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
failure to adhere to the conditions of the marketing authorization. In extreme cases, the authorization may be revoked, resulting in withdrawal of the product from sale. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Now that the UK (which comprises Great Britain and Northern Ireland) has left the EU, Great Britain will no longer be covered by centralized MAs (under the Northern
Irish Protocol, centralized MAs will continue to be recognized in Northern Ireland). All medicinal products with a current centralized MA were automatically converted to Great Britain MAs on January&nbsp;1, 2021. For a period of two years from
January&nbsp;1, 2021, the Medicines and Healthcare products Regulatory Agency (MHRA), the UK medicines regulator, may rely on a decision taken by the European Commission on the approval of a new marketing authorization in the centralized procedure,
in order to more quickly grant a new Great Britain MA. A separate application will, however, still be required. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conditional approval and accelerated
assessment </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As per Article 14(7) of Regulation (EC) 726/2004, a medicine that would fulfill an unmet medical need may, if its immediate availability is in
the interest of public health, be granted a conditional marketing authorization on the basis of less complete clinical data than are normally required, subject to specific obligations with defined timelines being imposed on the authorization holder.
The list of these obligations shall be made publicly accessible. In order for a conditional marketing authorization to be granted, the CHMP must find that all of the following criteria are met: (i)&nbsp;the benefit-risk balance of the medicine is
positive; (ii)&nbsp;it is likely that the applicant will be able to provide comprehensive data post-authorization; (iii)&nbsp;the medicine fulfils an unmet medical need; and (iv)&nbsp;the benefit of the medicine&#146;s immediate availability to
patients is greater than the risk inherent in the fact that additional data are still required. Such an authorization shall be valid for one year, on a renewable basis. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">When an application is submitted for a marketing authorization in respect of a drug for human use which is of major interest from the point of view of public health and
in particular from the viewpoint of therapeutic innovation, the applicant may request an accelerated assessment procedure pursuant to Article 14(9) of Regulation (EC) 726/2004. Under the accelerated assessment procedure, the CHMP is required to
issue an opinion within 150 days of receipt of a valid application, subject to clock stops, but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer
appropriate to conduct an accelerated assessment. We believe that some of the disease indications in which our product candidates are currently being or may be developed in the future qualify for this provision, and we will take advantage of this
provision as appropriate. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Period of authorization and renewals </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A
marketing authorization is initially valid for five years and may then be renewed on the basis of a <FONT STYLE="white-space:nowrap">re-evaluation</FONT> of the risk-benefit balance by the EMA or by the national competent authority of the
authorizing Member State (where the centralized procedure is not used). To this end, the marketing authorization holder shall provide the EMA or the competent authority with a version of the file in respect of quality, safety and efficacy, including
all variants introduced since the marketing authorization was granted, at least six months before expiry of the initial five year period. Once renewed, the marketing authorization shall be valid for an unlimited period, unless the European
Commission or the relevant national competent authority decides, on justified grounds relating to pharmacovigilance, to proceed with one additional five-year renewal. Any authorization which is not followed by the actual placing of the drug on the
EEA market (if the centralized procedure is used) or on the market of the authorizing Member State (if the centralized procedure is not used) within three years after authorization shall cease to be valid (the
<FONT STYLE="white-space:nowrap">so-called</FONT> &#147;sunset clause&#148;). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">165 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Without prejudice to the law on the protection of industrial and commercial property, marketing authorizations for
innovative medicinal products benefit from an 8&#043;2&#043;1 year period of regulatory protection. This regime consists of a regulatory data protection period of eight years plus a concurrent market exclusivity of 10 years plus an additional market
exclusivity of one further year if, during the first eight years of those 10 years, the marketing approval holder obtains an approval for one or more new therapeutic indications which, during the scientific evaluation prior to their approval, are
determined to bring a significant clinical benefit in comparison with existing therapies. Under the current rules, a third party making a generic or biosimilar application may not reference the preclinical and clinical data of the reference product
until the expiry of eight years after first approval of the reference product, and the third party may only market a generic or biosimilar version of the reference product after 10 (or 11) years have lapsed since the first authorization of the
reference product. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Orphan drug designation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulation (EC)
141/2000 states that a drug shall be designated as an orphan drug if its sponsor can establish (i)&nbsp;that it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; (ii)&nbsp;either such
condition affects not more than five in 10,000 persons in the European Union when the application is made, or, without incentives, it is unlikely that the marketing of the drug in the European Union would generate sufficient return to justify the
necessary investment in its development; and (iii)&nbsp;that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the European Union or, if such method exists, the drug
will be of significant benefit to those affected by that condition. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Regulation (EC) 847/2000 sets out provisions for the implementation of the criteria for the
designation of orphan drugs. An application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a <FONT
STYLE="white-space:nowrap">10-year</FONT> period of market exclusivity, which means that no similar medicinal product can be authorized in the same indication. A &#147;similar medicinal product&#148; is defined as a medicinal product containing a
similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. This period may, however, be reduced to six years if, at the end of the fifth year, it is
established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify continued market exclusivity. In addition, derogation from market exclusivity may be
granted on an individual basis in very select cases, such as with consent from the marketing authorization holder, inability to supply sufficient quantities of the authorized product or demonstration of &#147;clinically relevant superiority&#148; by
a similar medicinal product. Medicinal products designated as orphan drugs pursuant to Regulation (EC) 141/2000 are eligible for incentives made available by the European Union and by the Member States to support research into, and the development
and availability of, orphan drugs. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the MAA of a medicinal product designated as an orphan drug pursuant to Regulation (EC) 141/2000 includes the results of all
studies conducted in compliance with an agreed pediatric investigation plan, and a corresponding statement is subsequently included in the marketing authorization granted, the <FONT STYLE="white-space:nowrap">10-year</FONT> period of market
exclusivity will be extended to 12 years. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>European and United Kingdom data collection and processing </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The collection, use, disclosure and other processing of health-related and other personal information about clinical trials participants and other individuals in Europe
is governed by the GDPR (and in the UK, is governed by the European Union (Withdrawal) Act 2018 and the UK Data Protection Act 2018 (UK GDPR)). The GDPR and UK GDPR require companies to give detailed disclosures about how they collect, use and share
personal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">166 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
information; ensure any consents relied on to process personal information (including special categories of personal data, such as health data) meet the stricter GDPR requirements; contractually
impose data protection measures on vendors entrusted with personal information; maintain adequate data security measures; notify regulators and affected individuals of certain data breaches; meet extensive privacy governance and documentation
requirements; honor individuals&#146; data protection rights, including their rights to access, correct and delete their personal information; and refrain from transferring personal information from Europe or the UK to most other countries unless
specific safeguards can be implemented. Companies that violate the GDPR or UK GDPR can face private litigation, prohibitions on data processing and heavy fines. Complying with the GDPR and UK GDPR may be costly and require us to limit our activities
in Europe. If our efforts to comply are not successful, we may face litigation, reputational harm, significant penalties and other liabilities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Marketing
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Much like the Anti-Kickback Statute prohibition in the United States, as described below, the provision of benefits or advantages to physicians to induce or
encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the E.U. The provision of benefits or advantages to induce or reward improper performance generally is governed by
the national anti-bribery laws of European Union member states and the Bribery Act 2010 in the UK. Infringement of these laws could result in substantial fines and imprisonment. EU Directive 2001/83/EC, which is the EU Directive governing medicinal
products for human use, further provides that, where medicinal products are being promoted to persons qualified to prescribe or supply them, no gifts, pecuniary advantages or benefits in kind may be supplied, offered or promised to such persons
unless they are inexpensive and relevant to the practice of medicine or pharmacy. This provision has been transposed into the Human Medicines Regulations 2012 and so remains applicable in the UK despite its departure from the EU. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Payments made to physicians in certain European Union member states must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior
notification and approval by the physician&#146;s employer, his or her competent professional organization and/or the regulatory authorities of the individual European Union member states. These requirements are provided in the national laws,
industry codes or professional codes of conduct, applicable in the European Union member states. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Brexit and the regulatory framework in the United Kingdom </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June
2016, the electorate in the UK voted in favor of leaving the EU (commonly referred to as &#147;Brexit&#148;). Thereafter, in March 2017, the country formally notified the EU of its intention to withdraw pursuant to Article 50 of the Lisbon Treaty
and the UK formally left the EU on January&nbsp;31, 2020. A transition period began on February&nbsp;1, 2020, during which EU pharmaceutical law remained applicable to the UK, which ended on December&nbsp;31, 2020. Since the regulatory framework in
the UK covering the quality, safety and efficacy of medicinal products, clinical trials, marketing authorization, commercial sales and distribution of medicinal products is derived from EU Directives and Regulations, Brexit could materially impact
the future regulatory regime which applies to products and the approval of product candidates in the UK, as UK legislation now has the potential to diverge from EU legislation. It remains to be seen how Brexit will impact regulatory requirements for
product candidates and products in the UK in the long-term. The MHRA, the UK medicines and medical devices regulator, has recently published detailed guidance for industry and organizations to follow from January&nbsp;1, 2021 now the transition
period is over, which will be updated as the UK&#146;s regulatory position on medicinal products evolves over time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">167 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>International regulation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition to regulations in the United States and Europe, a variety of foreign regulations govern clinical trials, commercial sales and distribution of product
candidates. The approval process varies from country to country and the time to approval may be longer or shorter than that required for FDA or European Commission approval. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other healthcare laws and regulations and legislative reform </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Healthcare laws and regulations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Healthcare providers and third-party
payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our operations, including any arrangements with healthcare providers, physicians, third-party payors and
customers may expose us to broadly applicable fraud and abuse and other healthcare laws that may affect the business or financial arrangements and relationships through which we conduct research and would market, sell and distribute our products.
The healthcare laws that may affect our ability to operate include, but are not limited to: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully
soliciting, receiving, offering or paying any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order or recommendation of an item or service
reimbursable, in whole or in part, under a federal healthcare program, such as the Medicare and Medicaid programs. The term &#147;remuneration&#148; has been broadly interpreted to include anything of value. The federal Anti-Kickback Statute has
also been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand. There are a number of statutory exceptions and regulatory safe harbors
protecting some common activities from prosecution, but the exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Additionally, the intent standard under the federal Anti-Kickback Statute was
amended by the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 (collectively, Affordable Care Act), to a stricter standard such that a person or entity does not need to have actual
knowledge of the statute or specific intent to violate it in order to have committed a violation. Further, the Affordable Care Act codified case law that a claim including items or services resulting from a violation of the federal Anti-Kickback
Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Federal civil and criminal false claims laws, such as the False Claims Act, which can be enforced by private citizens
through civil qui tam actions, and civil monetary penalty laws prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, false, fictitious or fraudulent claims for payment of federal funds, and
knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to avoid, decrease or conceal an obligation to pay money to the federal government. For example, pharmaceutical companies have
been prosecuted under the False Claims Act in connection with their alleged <FONT STYLE="white-space:nowrap">off-label</FONT> promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for
government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product. In addition, a claim including items or services resulting from a
violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#147;any request or
demand&#148; for money or property presented to the U.S. government. In addition, manufacturers can be held liable under the False Claims Act even when they do not submit claims directly to government payors if they are deemed to &#147;cause&#148;
the submission of false or fraudulent claims. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">168 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, among other things, imposes criminal liability for executing or attempting to execute a scheme to defraud any
healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and creates federal criminal
laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation, or making or using any false writing or document knowing the same
to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">HIPAA, as amended by HITECH, and their implementing regulations, which impose privacy, security and breach reporting
obligations with respect to individually identifiable health information upon entities subject to the law, such as health plans, healthcare clearinghouses and certain healthcare providers, known as covered entities, and their respective business
associates and subcontractors that perform services for them that involve individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable
to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce HIPAA laws and seek attorneys&#146; fees and costs associated with pursuing federal civil
actions. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Federal and state consumer protection and unfair competition laws, which broadly regulate marketplace activities and
activities that potentially harm consumers. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">The federal transparency requirements under the Physician Payments Sunshine Act, created under the Affordable Care Act,
which requires, among other things, certain manufacturers of drugs, devices, biologics and medical supplies reimbursed under Medicare, Medicaid, or the Children&#146;s Health Insurance Program to report annually to CMS information related to
payments and other transfers of value provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other health care professionals (such as physician assistants and nurse practitioners) and teaching
hospitals, as well as information regarding ownership and investment interests held by physicians and their immediate family members. </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">State and foreign laws that are analogous to each of the above federal laws, such as anti-kickback and false claims laws,
that may impose similar or more prohibitive restrictions, and may apply to items or services reimbursed by <FONT STYLE="white-space:nowrap">non-governmental</FONT> third-party payors, including private insurers. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">State and foreign laws that require pharmaceutical companies to implement compliance programs, comply with the
pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or to track and report gifts, compensation and other remuneration provided to physicians and other healthcare
providers; state laws that require the reporting of marketing expenditures or drug pricing, including information pertaining to and justifying price increases; state and local laws that require the registration of pharmaceutical sales
representatives; state laws that prohibit various marketing-related activities, such as the provision of certain kinds of gifts or meals; state laws that require the posting of information relating to clinical trials and their outcomes; and other
federal, state and foreign laws that govern the privacy and security of health information or personally identifiable information in certain circumstances, including state health information privacy and data breach notification laws which govern the
collection, use, disclosure and protection of health-related and other personal information, many of which differ from each other in significant ways and often are not <FONT STYLE="white-space:nowrap">pre-empted</FONT> by HIPAA, thus requiring
additional compliance efforts. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If our operations are found to be in violation of any of these laws or any other current or future healthcare laws
that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">169 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, diminished profits and future
earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of <FONT STYLE="white-space:nowrap">non-compliance</FONT> with these laws, and the curtailment
or restructuring of our operations, any of which could substantially disrupt our operations. Although effective compliance programs can mitigate the risk of investigation and prosecution for violations of these laws, these risks cannot be entirely
eliminated. Any action against us for an alleged or suspected violation could cause us to incur significant legal expenses and could divert our management&#146;s attention from the operation of our business, even if our defense is successful. In
addition, if any of the physicians or other healthcare providers or entities with whom we expect to do business is found not to be in compliance with applicable laws, they may be subject to significant criminal, civil or administrative sanctions,
including exclusions from government funded healthcare programs. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Legislative reform </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We operate in a highly regulated industry, and new laws, regulations and judicial decisions, or new interpretations of existing laws, regulations and decisions, related
to healthcare availability, the method of delivery and payment for healthcare products and services could negatively affect our business, financial condition and prospects. There is significant interest in promoting healthcare reforms, and it is
likely that federal and state legislatures within the United States and the governments of other countries will continue to consider changes to existing healthcare legislation. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For example, the United States and state governments continue to propose and pass legislation designed to reduce the cost of healthcare. In 2010, the U.S. Congress
enacted the Affordable Care Act, which included changes to the coverage and reimbursement of drug products under government healthcare programs such as: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">established a branded prescription drug fee that pharmaceutical manufacturers of certain branded prescription drugs must
pay to the federal government; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expanded the list of covered entities eligible to participate in the 340B drug pricing program by adding new entities to
the program; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">established a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 70% <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">point-of-sale</FONT></FONT> discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#146;s
outpatient drugs to be covered under Medicare Part D; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">extended manufacturers&#146; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in
Medicaid managed care organizations; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to
additional individuals and by adding new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#146; Medicaid rebate liability; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for
certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">established a new Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative
clinical effectiveness research, along with funding for such research; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">170 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">established a Center for Medicare and Medicaid Innovation at the CMS to test innovative payment and service delivery models
to lower Medicare and Medicaid spending, potentially including prescription drug spending; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">created a licensure framework for <FONT STYLE="white-space:nowrap">follow-on</FONT> biologic products.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There have been executive, judicial and congressional challenges to certain aspects of the Affordable Care Act as well as efforts to repeal or
replace certain aspects of the Affordable Care Act. For example, on June&nbsp;17, 2021 the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the ACA is unconstitutional in its entirety because the &#147;individual
mandate&#148; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January&nbsp;28, 2021, President Biden issued an executive order to initiate a special enrollment period for
purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February&nbsp;15, 2021 and will remain open through August&nbsp;15, 2021. The executive order also instructed certain governmental agencies
to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary
barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the ACA will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges and the
healthcare reform measures of the Biden administration will impact the Affordable Care Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, there have been and continue to be a number of initiatives
at the United States federal and state levels that seek to reduce healthcare costs. In 2011, the U.S. Congress enacted the Budget Control Act, which included provisions intended to reduce the federal deficit. The Budget Control Act resulted in the
imposition of 2% reductions in Medicare payments to providers beginning in 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031 with the exception of a temporary suspension from May&nbsp;1, 2020
through March&nbsp;31, 2022 due to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic, absent additional congressional action. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in
the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#146;s average
manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. If government spending is further reduced, anticipated budgetary shortfalls may also impact the ability of relevant agencies, such as the FDA, to
continue to function at current levels, which may impact the ability of relevant agencies to timely review and approve research and development, manufacturing and marketing activities, which may delay our ability to develop, market and sell any
product candidates we may develop. In addition, any significant spending reductions affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented, or any significant taxes or fees that may be imposed on
us, as part of any broader deficit reduction effort or legislative replacement to the Budget Control Act, could have an adverse impact on our anticipated product revenues. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several
congressional inquiries and proposed legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient assistance programs and reform government program
reimbursement methodologies for drug products. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For
example, on July&nbsp;24, 2020 and September&nbsp;13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that seek to implement several of the administration&#146;s proposals. As a result, the FDA
concurrently released a final rule and guidance in September 2020, providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November&nbsp;20, 2020, HHS finalized a regulation removing safe harbor
protection for price reductions from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">171 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
pharmaceutical manufacturers to plan sponsors under Medicare Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the
rule has been delayed by the Biden administration from January&nbsp;1, 2022 to January&nbsp;1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">point-of-sale,</FONT></FONT> as well as a new safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which have also been delayed until January&nbsp;1,
2023. On November&nbsp;20, 2020, the CMS issued an interim final rule implementing the Trump administration&#146;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest
price paid in other economically advanced countries, effective January&nbsp;1, 2021. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation model
interim final rule. In July 2021, the Biden administration released an executive order, &#147;Promoting Competition in the American Economy,&#148; with multiple provisions aimed at prescription drugs. In response to Biden&#146;s executive order, on
September&nbsp;9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue as well as potential
administrative actions HHS can take to advance these principles. No legislation or administrative actions have been finalized to implement these principles. Individual states in the United States have also become increasingly active in passing
legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency
measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what
pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. It is difficult to predict the future legislative landscape in healthcare and the effect on our business, results of operations,
financial condition and prospects. However, we expect that additional state and federal healthcare reform measures will be adopted in the future, particularly in light of the new presidential administration. Further, it is possible that additional
governmental action is taken in response to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Environmental, health and safety laws and
regulations </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We and our third-party contractors are subject to numerous environmental, health and safety laws and regulations, including those governing
laboratory procedures and the use, generation, manufacture, distribution, storage, handling, treatment, remediation and disposal of hazardous materials and wastes. Hazardous chemicals, including flammable and biological materials, are involved in
certain aspects of our business, and we cannot eliminate the risk of injury or contamination from the use, generation, manufacture, distribution, storage, handling, treatment or disposal of hazardous materials and wastes. In particular, our product
candidates use PBDs, which are highly potent cytotoxins that require special handling by our and our contractors&#146; staff. In the event of contamination or injury, or failure to comply with environmental, health and safety laws and regulations,
we could be held liable for any resulting damages, fines and penalties associated with such liability could exceed our assets and resources. Environmental, health and safety laws and regulations are becoming increasingly more stringent. We may incur
substantial costs in order to comply with current or future environmental, health and safety laws and regulations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Pharmaceutical coverage, pricing and
reimbursement </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The availability and extent of coverage and adequate reimbursement by governmental and private third-party payors are essential for most
patients to be able to afford expensive medical treatments. In both domestic and foreign markets, sales of our product candidates will depend substantially on the extent to which the costs of our product candidates will be covered by third- party
payors, such as government health programs, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">172 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
commercial insurance and managed healthcare organizations. These third-party payors decide which products will be covered and establish reimbursement levels for those products. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Coverage and reimbursement by a third-party payor may depend upon a number of factors, including the third-party payor&#146;s determination that use of a product is:
</P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a covered benefit under its health plan; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">safe, effective and medically necessary; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">appropriate for the specific patient; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">cost-effective; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">neither experimental nor investigational. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Obtaining coverage approval and reimbursement for a product from a government or other third-party payor is a time-consuming and costly process that could require us to
provide supporting scientific, clinical and cost- effectiveness data for the use of our products to the payor. We may not be able to provide data sufficient to gain acceptance with respect to coverage and reimbursement at a satisfactory level. If
coverage and adequate reimbursement of our future products, if any, are unavailable or limited in scope or amount, such as may result where alternative or generic treatments are available, we may be unable to achieve or sustain profitability.
Adverse coverage and reimbursement limitations may hinder our ability to recoup our investment in our product candidates, even if such product candidates obtain regulatory approval. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. There is no uniform policy for coverage and
reimbursement in the United States and, as a result, coverage and reimbursement can differ significantly from payor to payor. In the United States, the principal decisions about reimbursement for new medicines are typically made by the CMS, which
decides whether and to what extent a new medicine will be covered and reimbursed under Medicare. Private payors often, but not always, follow the CMS&#146;s decisions regarding coverage and reimbursement. It is difficult to predict what third-party
payors will decide with respect to coverage and reimbursement for fundamentally novel products such as ours, as there is no body of established practices and precedents for these new products. Further, one payor&#146;s determination to provide
coverage and adequate reimbursement for a product does not assure that other payors will also provide coverage and adequate reimbursement for that product. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the
medical necessity and cost-effectiveness of our product candidates. There can be no assurance that our product candidates will be considered medically necessary or cost-effective. Therefore, it is possible that any of our product candidates, even if
approved, may not be covered by third-party payors or the reimbursement limit may be so restrictive that we cannot commercialize the product candidates profitably. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Reimbursement agencies in Europe may be more restrictive than payors in the United States. In Europe, pricing and reimbursement schemes vary widely from country to
country. For example, some countries provide that products may be marketed only after an agreement on reimbursement price has been reached. Such pricing negotiations with governmental authorities can take considerable time after receipt of marketing
approval for a product. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Other countries require the completion of additional
health technology assessments that compare the cost- effectiveness of a particular product candidate to currently available therapies. In addition, the European Union provides options for its member states to restrict the range of products for which
their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a product, may adopt a system of direct or indirect controls
on the profitability of the company placing the product on the market or monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Reference pricing used by various European Union member states and parallel
distribution, or arbitrage between <FONT STYLE="white-space:nowrap">low-priced</FONT> and high-priced member states, can further reduce </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">173 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
prices. Furthermore, many countries in the European Union have increased the amount of discounts required on pharmaceutical products, and these efforts could continue as countries attempt to
manage healthcare expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the European Union. The downward pressure on healthcare costs in general, and prescription products in particular, has become
increasingly intense. As a result, there are increasingly higher barriers to entry for new products. There can be no assurance that any country that has reimbursement limitations for pharmaceutical products will allow favorable reimbursement and
pricing arrangements for any of our products, if approved in those countries. Accordingly, the reimbursement for any products in Europe may be reduced compared with the United States and may be insufficient to generate commercially reasonable
revenues and profits. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Furthermore, the containment of healthcare costs has become a priority of foreign and domestic governments as well as private third-party
payors. The prices of drugs have been a focus in this effort. Governments and private third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications, which could affect our ability
to sell our product candidates profitably. We also expect to experience pricing pressures due to the trend towards managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. These and other
cost-control initiatives could cause us to decrease the price we might establish for products, which could result in lower-than-anticipated product revenues. In addition, the publication of discounts by third-party payors or authorities may lead to
further pressure on the prices or reimbursement levels within the country of publication and other countries. If pricing is set at unsatisfactory levels or if coverage and adequate reimbursement of our products is unavailable or limited in scope or
amount, our revenues and the potential profitability of our product candidates in those countries would be negatively affected. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employees and human capital
resources </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2021, we had a total of 17 full-time employees and approximately 20 consultants on a part-time basis. We have in the past, and
may in the future, retain additional expert consultants if required in connection with our plans. We are not a party to any collective bargaining agreements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Attracting, hiring, and retaining highly qualified individuals are key to our success. To do so, we believe we offer competitive compensation packages&#151;inclusive of
base salary, bonus, and equity, and benefits. We also sought to establish a values-based culture centered around our core values of <I>teamwork</I>, <I>accountability</I>, and <I>empathy </I>for patients to enhance the working environment for our
current employees and to attract our desired candidates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Facilities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
have recently leased and are occupying 4,945 square feet of office space at 8000 Marina Boulevard in Brisbane, California though November&nbsp;30, 2024. We also have leased 24,606 square feet of office and lab space at 170 Harbor Way in South San
Francisco, California. This space is currently subleased to Vaxart, Inc. through September&nbsp;30, 2025. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I><FONT STYLE="white-space:nowrap">COVID-19</FONT>
impact on facilities </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are operating through a blend of <FONT STYLE="white-space:nowrap">in-person</FONT> and virtual work to align with local <FONT
STYLE="white-space:nowrap">COVID-19</FONT> guidelines, which we believe meets our operational needs as a late-stage biotechnology company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Legal proceedings
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From time to time, we may become involved in legal proceedings or be subject to claims arising in the ordinary course of our business. We are not currently a
party to any material legal proceedings. Regardless of outcome, such proceedings or claims can have an adverse impact on us because of defense and settlement costs, diversion of resources and other factors, and there can be no assurances that
favorable outcomes will be obtained. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">174 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_13"></A>Management </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers, key employees and directors </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets
forth information regarding our executive officers, key employees and directors, including ages as of December&nbsp;31, 2021. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="31%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="63%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="2" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Age</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Position</B></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"><I>Executive Officers:</I></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">President, Chief Executive Officer and Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Celia Lin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Medical Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Joanne Curley, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">53</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Development Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sean Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">37</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I>Other Key Employees</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lauren Frenz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chief Business Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tom Doan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Development Operations</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Joseph Young</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President, Finance and Chief Accounting Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tad Thomas, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">62</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Senior Vice President and Head of Product Development and Manufacturing</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Directors:</I></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kurt von Emster, C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">(2)(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Chairperson of the Board of Directors</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andrew Cheng, M.D., Ph.D.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Beth Seidenberg, M.D.<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maha Katabi, Ph.D., C.F.A.<SUP STYLE="font-size:85%; vertical-align:top">(1)(2)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Enright<SUP STYLE="font-size:85%; vertical-align:top">(1)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Scott Morrison<SUP STYLE="font-size:85%; vertical-align:top">(3)</SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">64</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kimball Hall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Director</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="7" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the compensation committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the nominating and corporate governance committee. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Member of the audit committee. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Marshall Fordyce, M.D.</I></B> is our founder and has served as our President and Chief Executive Officer and as a member of our board of directors since May 2016.
From April 2011 to July 2016, Dr.&nbsp;Fordyce held a number of senior leadership roles at Gilead Sciences, Inc. (Gilead), a biotechnology company, including Director of Clinical Research and Senior Director of Clinical Research, where he was
responsible for leading teams in clinical translation, development and commercialization of new treatments. In April 2012, Dr.&nbsp;Fordyce joined the Albert and Mary Lasker Foundation, a foundation supporting biomedical research, as a <FONT
STYLE="white-space:nowrap">non-executive</FONT> director and continues in that role. Dr.&nbsp;Fordyce received a B.A. in medical anthropology from Harvard University and an M.D. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">175 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
from Harvard Medical School. Our board of directors believes that Dr.&nbsp;Fordyce is qualified to serve on our board of directors due to his extensive experience in the biotechnology industry in
senior leadership roles, as well as the perspective and experience he brings as our President and Chief Executive Officer. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Celia Lin, M.D.</I></B> has served
as our Chief Medical Officer since February 2021. From August 2015 to February 2021, Dr.&nbsp;Lin was Senior Medical Director at Genentech. She was responsible for late stage development and regulatory approval for a novel product in an orphan
disease. She also served as Global Development Lead for a BTK inhibitor in multiple sclerosis, and led other programs including monoclonal antibodies, bispecifics, and complement inhibitors in various therapeutic areas such as respiratory, allergy,
nephrology, infectious disease and inflammation. Dr.&nbsp;Lin previously served as Medical Director in Clinical Development and Medical Affairs at Amgen, from April 2012 to August 2015, leading teams and activities related to the approval and
commercialization of two osteoporosis therapies. Dr.&nbsp;Lin is a board certified physician. Prior to joining industry, she was on faculty at UCSF. She received her B.S. from UCLA and her M.D. from University of Rochester School of Medicine. She
trained in internal medicine at Boston Medical Center and in rheumatology at UCLA and Washington University in St. Louis where she also was a post-doctoral fellow. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Joanne Curley, Ph.D.</I></B> has served as our Chief Development Officer since March 2020. From June 2005 until March 2020, Dr.&nbsp;Curley held a number of senior
leadership roles at Gilead, a biotechnology company, including Senior Director, Project and Portfolio Management and Vice President, Project and Portfolio Management, where she was responsible for developing products from research through regulatory
approval. From 2002 to 2005, Dr.&nbsp;Curley served as a staff scientist at Nektar Therapeutics, a pharmaceutical company. Dr.&nbsp;Curley has served as a member of the board of directors of VistaGen Therapeutics, Inc., a biopharmaceutical company,
since April 2021. Dr.&nbsp;Curley received a B.Sc. in physics and chemistry from Trinity College, Ireland, a Ph.D. in polymer science and engineering from the University of Massachusetts, Amherst, and did a post-doctorate at Massachusetts Institute
of Technology and Harvard Medical School focused on long-acting biodegradable formulations. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Sean Grant</I></B> has served as our Chief Financial Officer since
July 2021. Mr.&nbsp;Grant previously served as Vice President of Corporate Strategy and Business Development for CareDx, Inc., a biotechnology company, from May 2020 to June 2021. His responsibilities included leading mergers and acquisitions,
venture investments and partnerships across diagnostics and therapeutics. Prior to joining CareDx, Mr.&nbsp;Grant served as Vice President in the Investment Banking Healthcare Division at Citigroup Global Capital Markets from July 2015 to March
2020. At Citigroup, Mr.&nbsp;Grant specialized in public and private capital raising as well as mergers and acquisitions for leading life science companies. Mr.&nbsp;Grant received a B.A. in Government and International Politics from George Mason
University and an M.B.A. from the Johns Hopkins University Carey Business School. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other key employees </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Lauren Frenz</I></B> has served as our Chief Business Officer since April 2020. Ms.&nbsp;Frenz previously served as our Senior Vice President of Corporate Strategy
and Finance from August 2017 to April 2020. From June 2012 to July 2017, Ms.&nbsp;Frenz served in positions of increasing responsibility at Gilead, a biotechnology company, in the US Sales&nbsp;&amp; Marketing and Global Commercial
Planning&nbsp;&amp; Operations organizations in multiple therapeutic areas. At Gilead, she most recently led healthcare provider marketing for multiple blockbuster HIV therapies. Prior to Gilead, Ms.&nbsp;Frenz worked at SVB Leerink, an investment
bank specializing in healthcare and life sciences, in their Strategic Advisory Group, devising business development, commercial, and portfolio management strategies for biotech and pharmaceutical companies. Ms.&nbsp;Frenz received an M.B.A. from
Harvard Business School and an A.B. in psychology with a certificate in neuroscience from Princeton University. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">176 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Tom Doan</I></B> has served as our Senior Vice President, Development Operations since March 2020. From April
2007 to March 2020, Mr.&nbsp;Doan held a number of senior leadership roles at Gilead, a biotechnology company, where he was responsible for clinical operations for multiple successful drug market filings and approvals, including most recently
Executive Director, Clinical Operations, Therapeutic Area Head, Inflammation/Respiratory. From October 2003 until April 2007, Mr.&nbsp;Doan served as Clinical Trial Manager and Senior Clinical Trial Manager, BioOncology, at Genentech, a
biotechnology company. From September 1999 until October 2003, Mr.&nbsp;Doan served as Clinical Research Manager and Clinical Research Associate, at Cato Research, LLC, a clinical research organization. Mr.&nbsp;Doan received a B.S. in Fisheries
Biology from Humboldt State University. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Joseph Young</I></B> has served as our Senior Vice President, Finance since March 2021 and our Chief Accounting
Officer since May 2021. From April 2006 to July 2020, Mr.&nbsp;Young held a number of senior leadership roles at Plexxikon Inc., a biotechnology company, and wholly-owned subsidiary of Daiichi-Sankyo Co., Ltd. since its acquisition of Plexxikon in
2011, including most recently Senior Vice President, Finance and Treasurer, where he was responsible for all accounting, finance and treasury operations, in addition to oversight of other business functions. From August 2005 to April 2006,
Mr.&nbsp;Young served as Associate Director, Internal Controls Compliance at VaxGen, Inc., a biotechnology company. From February 1999 to August 2005, Mr.&nbsp;Young held management roles at Cerus Corporation, a biotechnology company, including most
recently Controller. From October 1994 to January 1999, Mr.&nbsp;Young was an auditor at Ernst&nbsp;&amp; Young LLP. Mr.&nbsp;Young received a B.A. in Business-Economics from the University of California, Los Angeles and an M.B.A. from the
University of California, Berkeley&#151;Haas School of Business, and is a Certified Public Accountant (inactive status). </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Tad Thomas, Ph.D.</I></B> has served
as our Senior Vice President and Head of Product Development and Manufacturing since April 2021. From March 2019 to April 2021, Dr.&nbsp;Thomas served as Associate Vice President, Technical Operations at Codexis, Inc., a biotechnology company, where
he was responsible for overseeing preclinical development for biotherapeutic products and management of external contract manufacturing partnerships. From July 2013 to March 2019, Dr.&nbsp;Thomas served as Director and Global Lead, Biologics Process
Transfer and Launch at Bayer HealthCare LLC, a pharmaceutical and life sciences company, where he was responsible for leading manufacturing site process transfers of clinical phase projects and leading the teams that drafted the Quality (CMC)
sections of the successful marketing applications for Kovaltry and Jivi. Dr.&nbsp;Thomas received a B.A. in Biochemistry from the University of California, Berkeley, a Ph.D. in Biochemistry&nbsp;&amp; Biophysics from the University of California,
Davis, and completed a post-doctoral fellowship at the Harvard Medical School and Brigham and Women&#146;s Hospital. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> directors </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Kurt
von Emster, C.F.A.</I></B> has served on our board of directors since October 2020. Mr.&nbsp;von Emster currently serves as Managing Partner at Abingworth LLP, a venture capital firm, where he has been employed as a Partner since January 2015.
Mr.&nbsp;von Emster has served as a member of the board of directors of Tizona Therapeutics, Inc, a biotechnology company, since December 2020, Launch Therapeutics, Inc., a biotechnology company, since August 2021, Orbus Therapeutics, Inc., a
pharmaceutical company, since July 2020, SFJ Pharmaceuticals, Inc., a specialty pharmaceutical company, since April 2020, Jasper Therapeutics, Inc., a biotechnology company, since November 2019, Vaxcyte Inc. (Vaxcyte), a biopharmaceutical vaccine
company, since July 2015, and CymaBay Therapeutics, Inc., a biotechnology company, since April 2009. Mr.&nbsp;von Emster previously served on the board of directors of the following companies: Trishula Therapeutics, Inc. from December 2020 to
December 2021, CRISPR Therapeutics, Inc. from March 2015 to June 2019, Kesios Therapeutics Ltd. from November 2015 to January 2017, Cytos Biotechnology AG from November 2012 to January 2016 (merged and renamed Kuros Biosciences AG in January 2016),
Aurinia Pharmaceuticals Inc. from February 2014 to March 2015, Facet Biotech Corporation (acquired by Abbott Laboratories in April 2010) from </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">177 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
February 2009 to April 2010, and Somaxon Pharmaceuticals, Inc. (acquired by Pernix Therapeutics Holdings, Inc. in March 2013) from August 2005 to March 2013. In addition, Mr.&nbsp;von Emster <FONT
STYLE="white-space:nowrap">co-founded</FONT> venBio LLC, a health-care focused investment firm, in 2009, and served as Partner until 2014. Prior to that, Mr.&nbsp;von Emster was General Partner at MPM Capital, Inc., a biotechnology private equity
firm, from 2000 to 2009. Mr.&nbsp;von Emster was also a Biotechnology and Healthcare Analyst and Portfolio Manager at Franklin Templeton Group from 1989 to 2000. Mr.&nbsp;von Emster received a B.S. in Business and Economics from the University of
California, Santa Barbara and is a Chartered Financial Analyst (C.F.A.). Our board of directors believes that Mr.&nbsp;von Emster&#146;s experience in the biotechnology industry, as well as his experience as a member on the boards of directors of
multiple companies in the industry, qualifies him to serve on our board of directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Andrew Cheng, M.D., Ph.D.</I></B> has served as a member of our board of
directors since May 2017. Dr.&nbsp;Cheng has served as the President and Chief Executive Officer, as well as a director, of Akero Therapeutics, Inc., a biotechnology company, since September 2018. In August 2019, Dr.&nbsp;Cheng joined Arbutus
Biopharma Corporation, a biopharmaceutical company, as a <FONT STYLE="white-space:nowrap">non-executive</FONT> director and continues in that role. Before joining Akero, Dr.&nbsp;Cheng was at Gilead, a biotechnology company, as Chief Medical Officer
from March 2018 to September 2018, Executive Vice President from February 2015 to September 2018, and Senior Vice President from February 2009 to February 2015. From April 2018 to November 2018, Dr.&nbsp;Cheng served on the board of directors of
Syntimmune, Inc., a biotechnology company, which was acquired by Alexion Pharmaceuticals Inc. Dr.&nbsp;Cheng holds a B.A. in biology from the Johns Hopkins University and an M.D. and Ph.D. in cellular and molecular biology from Columbia University
College of Physicians and Surgeons. He completed his internal medicine residency at UCLA and was board certified in internal medicine. Our board of directors believes that Dr.&nbsp;Cheng is qualified to serve as a member of our board of directors
due to his extensive experience in clinical development across multiple therapeutic areas. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Beth Seidenberg, M.D.</I></B> has served as a member of our board
of directors since June 2016. Dr.&nbsp;Seidenberg is a founding Managing Director of Westlake Village BioPartners, a venture capital firm, a position she has held since September 2018. Dr.&nbsp;Seidenberg has been a Partner at Kleiner Perkins, a
venture capital firm, since May 2005, where she primarily focuses on life sciences investing. Prior to joining Kleiner Perkins, Dr.&nbsp;Seidenberg was the Senior Vice President, Head of Global Development and Chief Medical Officer at Amgen, a
biotechnology company. In addition, Dr.&nbsp;Seidenberg was a senior executive in research and development at Bristol Myers Squibb Company, a biopharmaceutical company, and Merck&nbsp;&amp; Co., Inc. Dr.&nbsp;Seidenberg has served on the board of
directors of Atara Biotherapeutics, Inc. since August 2012. Dr.&nbsp;Seidenberg has served on the board of directors of Progyny, Inc. since May 2010. From February 2008 until September 2019 she served on the board of directors of Epizyme, Inc., from
June 2011 to February 2019 she served on the board of directors of Tesaro, Inc., and from December 2012 to June 2018 she served on the board of directors of ARMO BioSciences, Inc. Dr.&nbsp;Seidenberg received a B.S. from Barnard College and an M.D.
from the University of Miami School of Medicine and completed her post-graduate training at the Johns Hopkins University, George Washington University and the National Institutes of Health. Our board of directors believes that Dr.&nbsp;Seidenberg is
qualified to serve on our board of directors because of her extensive experience in the life sciences industry as a senior executive and venture capitalist, as well as her training as a physician. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Maha Katabi, Ph.D.</I></B> has served as a member of our board of directors since October 2020. Dr.&nbsp;Katabi is a General Partner at Sofinnova Investments, a
venture capital firm, since March 2020. She joined Sofinnova as a Partner in April 2019. Prior to joining Sofinnova, Dr.&nbsp;Katabi was a founding Managing Partner at Oxalis Capital, a venture capital firm, from August 2018 until April 2019. From
September 2008 until January 2018, Dr.&nbsp;Katabi was a Partner, Private Equity at Sectoral Asset Management, an investment advisor exclusively focused on the global healthcare sector. She was the portfolio manager of a family of funds investing in
small cap and private biotech companies She held these positions since July 2012, and joined Sectoral in 2008 as Investment Manager. Prior to joining Sectoral in 2008, Dr.&nbsp;Katabi was a Vice President at Ventures West from 2004 to
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">178 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
2008, where she focused on early-stage venture investments in the life sciences industry. She started her venture capital career in 1999 with T2C2 Capital Bio, a seed fund focused on university <FONT
STYLE="white-space:nowrap">start-ups.</FONT> Dr.&nbsp;Katabi has served as a member of the board of directors of several private companies, and currently serves as a director of Aerovate Therapeutics, Inc., Gyroscope Therapeutics Limited, Northsea
Therapeutics B.V., Quanta Therapeutics, Inc., and Sofinnova Investments, Inc. She received a Ph.D. in Pharmacology in 1999 at McGill University and her CFA charter in 2011. Our board of directors believes that Dr.&nbsp;Katabi is qualified to serve
on our board of directors due to her experience as a biopharmaceutical and biotechnology public and private company investor. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Patrick Enright</I></B> has
served on our board of directors since October 2020. Since July 2007, Mr.&nbsp;Enright has served as a Managing Director of Longitude Capital, a venture capital firm, of which he is a co-founder. From 2002 through 2006, Mr.&nbsp;Enright was a
Managing Director of Pequot Ventures, a venture capital investment firm, where he <FONT STYLE="white-space:nowrap">co-led</FONT> the life sciences investment practice. Mr.&nbsp;Enright currently serves on the boards of Aptinyx Inc. (APTX), Jazz
Pharmaceuticals plc (JAZZ) and other private companies as well as the National Venture Capital Association (NVCA). Selected prior board memberships include Aimmune Therapeutics, Inc. (AIMT, acquired by Nestl&eacute;), Esperion Therapeutics, Inc.
(ESPR) and Vaxcyte (PCVX). Mr.&nbsp;Enright received a B.S. in Biological Sciences from Stanford University and an M.B.A. from the Wharton School of the University of Pennsylvania. Our board of directors believes that Mr.&nbsp;Enright is qualified
to serve on our board of directors due to his experience serving on the board of directors of clinical-stage biotechnology companies and his investment experience in the life sciences industry. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Scott Morrison</I></B> has served on our board of directors since April 2020. From 1996 to December 2015, Mr.&nbsp;Morrison was a partner with Ernst&nbsp;&amp;
Young LLP, a public accounting firm, where he also served as U.S. Life Sciences Leader from 2002 to December 2015. Mr.&nbsp;Morrison has served on the board of directors of Corvus Pharmaceuticals Inc., a biopharmaceutical company, since December
2015, IDEAYA Biosciences, Inc., a biotechnology company, since July 2018, Audentes Therapeutics, Inc., a biotechnology company, from December 2015 through its sale to Astellas Pharma Inc. on January&nbsp;15, 2021, Global Blood Therapeutics, Inc., a
biopharmaceutical company, since December 2015, Escape Bio, Inc., a biotechnology company, since October 2020, and Zai Lab Limited, a biotechnology company, since October 2021. Mr.&nbsp;Morrison has also held roles on the boards of directors of
numerous other life sciences industry organizations. Mr.&nbsp;Morrison has previously served on the boards of directors of the Life Sciences Foundation, the California Life Sciences Association, the Biotech Institute and the Emerging Companies
Section of the Biotechnology Innovation Organization. He holds a B.S. in Business Administration from the University of California, Berkeley and is a certified public accountant (inactive). Our board of directors believes that
Mr.&nbsp;Morrison&#146;s 40 years of experience serving life sciences companies and in public accounting as well as many years of governance experience qualifies him to serve on our board of directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Kimball Hall</I></B><B> </B>has served on our board of directors since December 2021. Since December 2020, Ms.&nbsp;Hall has served as President and Chief
Operating Officer of Abzena Holdings (US), LLC, a privately owned Contract Development and Manufacturing Organization. She also serves as a member of Abzena&#146;s board of directors and first joined as Chief Operating Officer in October 2019. Since
January 2016, prior to joining Abzena, Ms.&nbsp;Hall held several executive positions at Genentech, Inc., a member of the Roche family. She served as a member of the Genentech Executive Committee and was Senior Vice President, Global Head of Drug
Substance Manufacturing. Prior to joining Genentech, Ms.&nbsp;Hall spent 16 years at Amgen, a biotechnology company. Ms.&nbsp;Hall received a B.S. in microbiology from the University of Washington. Our board of directors believes that Ms.&nbsp;Hall
is qualified to serve on our board of directors given her extensive experience as an executive in the pharmaceutical and biotechnology sectors. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Family
relationships </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There are no family relationships among any of our executive officers or directors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">179 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Composition of our board of directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our business and affairs are organized under the direction of our board of directors, which currently consists of eight members with no vacancies. The primary
responsibilities of our board of directors are to provide oversight, strategic guidance, counseling and direction to our management. Our board of directors meets on a regular basis and additionally as required. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All members of our board of directors, other than Ms.&nbsp;Hall, were elected under the provisions of our Amended and Restated Voting Agreement entered into in October
2020. Under the terms of this Voting Agreement, the stockholders party to the Voting Agreement agreed how to vote their respective shares in the election of our directors. This Voting Agreement terminated upon the closing of our IPO. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may establish the authorized number of directors from time to time by resolution. In accordance with our amended and restated certificate of
incorporation, our board of directors is divided into three classes with staggered three-year terms. At each annual meeting of stockholders, the successors to directors whose terms then expire will be elected to serve from the time of election and
qualification until the third annual meeting following election. Our directors are divided among the three classes as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;I directors are Dr.&nbsp;Fordyce,&nbsp;M.D., Dr.&nbsp;Seidenberg,&nbsp;M.D., and Ms.&nbsp;Hall, and their
terms will expire at the annual meeting of stockholders to be held in 2022; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;II directors are Mr.&nbsp;von Emster, Dr.&nbsp;Katabi Ph.D., and Mr.&nbsp;Enright, and their terms will
expire at the annual meeting of stockholders to be held in 2023; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the Class&nbsp;III directors are Dr.&nbsp;Cheng&nbsp;M.D., Ph.D. and Mr.&nbsp;Morrison, and their terms will expire at the
annual meeting of stockholders to be held in 2024. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We expect that any additional directorships resulting from an increase in the number of
directors will be distributed among the three classes so that, as nearly as possible, each class will consist of one third of the directors. The division of our board of directors into three classes with staggered three-year terms may delay or
prevent a change of our management or a change in control. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Director independence </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under the listing requirements and rules of the Nasdaq Stock Market LLC (Nasdaq Listing Rules), a majority of our directors must be independent directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has undertaken a review of the independence of each director. Based on information provided by each director concerning her or his background,
employment and affiliations, including family relationships, our board of directors has determined that Dr.&nbsp;Cheng,&nbsp;M.D., Ph.D., Dr.&nbsp;Seidenberg,&nbsp;M.D., Mr.&nbsp;von Emster, Dr.&nbsp;Katabi, Ph.D., Mr.&nbsp;Enright,
Mr.&nbsp;Morrison and Ms.&nbsp;Hall do not have relationships that would interfere with the exercise of independent judgment in carrying out the responsibilities of a director and that each of these directors is &#147;independent&#148; as that term
is defined under the Nasdaq Listing Rules. Our board of directors has determined that Dr.&nbsp;Fordyce, by virtue of his position as our President and Chief Executive Officer, is not independent under applicable rules and regulations of the U.S.
Securities and Exchange Commission (SEC) and the Nasdaq Listing Rules. In making these determinations, our board of directors considered the current and prior relationships that each <FONT STYLE="white-space:nowrap">non-employee</FONT> director has
with our company and all other facts and circumstances our board of directors deemed relevant in determining their independence, including the beneficial ownership of our shares by each <FONT STYLE="white-space:nowrap">non-employee</FONT> director
and the transactions described in the section titled &#147;Certain relationships and related person transactions.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">180 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Committees of our board of directors </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has established an audit committee, a compensation committee and a nominating and corporate governance committee. The composition and
responsibilities of each of the committees of our board of directors are described below. Members serve on these committees until their resignation or until otherwise determined by our board of directors. Each committee has adopted a written charter
that satisfies the application rules and regulation of the SEC and the Nasdaq Listing Rules, which are posted on our website at www.veratx.com. Information contained on, or accessible through, our website is not a part of this prospectus, and the
inclusion of our website address in this prospectus is only an inactive textual reference. Our board of directors may establish other committees as it deems necessary or appropriate from time to time. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Audit committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our audit committee currently consists of
Mr.&nbsp;Morrison, Mr.&nbsp;von Emster and Dr.&nbsp;Seidenberg&nbsp;M.D., each of whom our board of directors has determined satisfies the independence requirements under the Nasdaq Listing Rules and Rule
<FONT STYLE="white-space:nowrap">10A-3(b)(1)</FONT> of the Exchange Act. With respect to Mr.&nbsp;von Emster specifically, our board of directors has determined that he is independent even though he falls outside the &#147;safe harbor&#148;
definition set forth in Rule <FONT STYLE="white-space:nowrap">10A-</FONT> 3(e)(1)(ii) under the Exchange Act. Mr.&nbsp;von Emster has not accepted directly or indirectly any consulting, advisory or other compensatory fee from us, and while he is a
Managing Partner of Abingworth LLP, he shares, but does not control, voting and investment power over the shares held by Abingworth Bioventures 8 LP, which is an affiliate of Abingworth LLP and owns in excess of 10% of our outstanding common stock
prior to this public offering. As a result of this facts and circumstances analysis, our board of directors has determined in good faith that Mr.&nbsp;von Emster is not an &#147;affiliated person&#148; of us who would fail to satisfy the applicable
independence requirements for audit committee members. The chair of our audit committee is Mr.&nbsp;Morrison, who our board of directors has determined is an &#147;audit committee financial expert&#148; within the meaning of SEC regulations. Each
member of our audit committee can read and understand fundamental financial statements in accordance with applicable requirements. In arriving at these determinations, the board of directors has examined each audit committee member&#146;s scope of
experience and the nature of their employment in the corporate finance sector. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary purpose of the audit committee is to discharge the responsibilities of
our board of directors with respect to our corporate accounting and financial reporting processes, systems of internal control and financial-statement audits, and to oversee our independent registered accounting firm. Specific responsibilities of
our audit committee include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">helping our board of directors oversee our corporate accounting and financial reporting processes; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">managing the selection, engagement, qualifications, independence and performance of a qualified firm to serve as the
independent registered public accounting firm to audit our financial statements; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">discussing the scope and results of the audit with the independent registered public accounting firm, and reviewing, with
management and the independent accountants, our interim and <FONT STYLE="white-space:nowrap">year-end</FONT> operating results; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing procedures for employees to submit concerns anonymously about questionable accounting or audit matters;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">monitoring and assessing, and overseeing the reporting of, any material cybersecurity breaches and associated risks;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing related person transactions; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">181 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">obtaining and reviewing a report by the independent registered public accounting firm at least annually, that describes our
internal quality control procedures, any material issues with such procedures, and any steps taken to deal with such issues when required by applicable law; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">approving, or, as permitted, <FONT STYLE="white-space:nowrap">pre-approving,</FONT> audit and permissible <FONT
STYLE="white-space:nowrap">non-audit</FONT> services to be performed by the independent registered public accounting firm. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Compensation
committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our compensation committee currently consists of Mr.&nbsp;Enright, Dr.&nbsp;Katabi, Ph.D., and Dr.&nbsp;Cheng,&nbsp;M.D., Ph.D. The chair of our
compensation committee is Mr.&nbsp;Enright. Our board of directors has determined that each member of the compensation committee is independent under the Nasdaq Listing Rules and as a <FONT STYLE="white-space:nowrap">&#147;non-employee</FONT>
director&#148; as defined in Rule <FONT STYLE="white-space:nowrap">16b-3</FONT> promulgated under the Exchange Act. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The primary purpose of our compensation
committee is to discharge the responsibilities of our board of directors in overseeing our compensation policies, plans and programs and to review and determine the compensation to be paid to our executive officers, directors and other senior
management, as appropriate. Specific responsibilities of our compensation committee include: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation of our chief executive officer, other executive officers and senior management,
and overseeing the development and performance of our officers and our succession planning; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and recommending to our board of directors the compensation paid to our directors; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing employee diversity and inclusion initiatives; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and approving the compensation arrangements with our executive officers and other senior management;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">administering our equity incentive plans and other benefit programs; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing, adopting, amending and terminating, incentive compensation and equity plans, severance agreements, profit
sharing plans, bonus plans and any other compensatory arrangements for our executive officers and other senior management; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing, evaluating and recommending to our board of directors succession plans for our executive officers; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">reviewing and establishing general policies relating to compensation and benefits of our employees. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Nominating and corporate governance committee </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our nominating and
corporate governance committee consists of Mr.&nbsp;von Emster, Dr.&nbsp;Katabi, Ph.D., and Dr.&nbsp;Cheng,&nbsp;M.D., Ph.D. The chair of our nominating and corporate governance committee is Mr.&nbsp;von Emster. Our board of directors has determined
that each member of the nominating and corporate governance committee is independent under the Nasdaq Listing Rules, a <FONT STYLE="white-space:nowrap">non-employee</FONT> director, and free from any relationship that would interfere with the
exercise of his or her independent judgment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Specific responsibilities of our nominating and corporate governance committee include: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">identifying and evaluating candidates, including the nomination of incumbent directors for reelection and nominees
recommended by stockholders, to serve on our board of directors; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">182 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">considering and making recommendations to our board of directors regarding the composition and chairmanship of the
committees of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">instituting plans or programs for the continuing education of our board of directors and orientation of new directors;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">developing and making recommendations to our board of directors regarding corporate governance guidelines and matters; and
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">overseeing periodic evaluations of the board of directors&#146; performance, including committees of the board of directors
and management. </P></TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Code of business conduct and ethics </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain a written Code of Business Conduct and Ethics that applies to all our employees, officers and directors. This includes our principal executive officer,
principal financial officer and principal accounting officer or controller, or persons performing similar functions. The full text of our Code of Business Conduct and Ethics is posted on our website at www.veratx.com. We intend to disclose on our
website any future amendments of our Code of Business Conduct and Ethics or waivers that exempt any principal executive officer, principal financial officer, principal accounting officer or controller, persons performing similar functions or our
directors from provisions in the Code of Business Conduct and Ethics. Information contained on, or accessible through, our website is not a part of this prospectus, and the inclusion of our website address in this prospectus is only an inactive
textual reference. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Compensation committee interlocks and insider participation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">None of the members of our compensation committee is currently, or has been at any time, one of our executive officers or employees. None of our executive officers
currently serves, or has served during the last calendar year, as a member of the board of directors or compensation committee of any entity that has one or more executive officers serving as a member of our board of directors or compensation
committee. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth in summary form information concerning the compensation that we paid or awarded during the year ended December&nbsp;31, 2021 to each of
our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors who served on our board of directors during 2021: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="65%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Fees&nbsp;earned&nbsp;or</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>paid&nbsp;in&nbsp;cash</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option<BR>awards</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)(1)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total ($)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Beth Seidenberg, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26,563</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">93,399</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andrew Cheng, M.D., Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Scott Morrison</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">31,250</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">98,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maha Katabi, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kurt von Emster</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47,813</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,649</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kimball Hall(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">313,120</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">315,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Enright</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28,125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">66,836</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent the aggregate grant date fair value of the stock options granted to our non-employee directors during fiscal year 2021 under our 2021 Plan, computed in accordance with FASB ASC Topic 718.
The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 9 to our unaudited condensed financial statements for the nine months ended September&nbsp;30, 2021, included elsewhere in this prospectus. This
amount does not reflect the actual economic value that may be realized by the named executive officer. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">183 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The aggregate number of shares underlying outstanding options to purchase our Class&nbsp;A common stock held by our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors was 286,529, as follows: 78,968 by
Dr.&nbsp;Seidenberg; 78,968 by Dr.&nbsp;Cheng; 78,968 by Mr.&nbsp;Morrison; 9,925 by Dr.&nbsp;Katabi; 9,925 by Mr.&nbsp;von Emster; 19,850 by Ms.&nbsp;Hall; and 9,925 by Mr.&nbsp;Enright. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ms.&nbsp;Hall was appointed as a member of our board of directors effective as of December&nbsp;10, 2021. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have
reimbursed and will continue to reimburse all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors for their reasonable <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses incurred
in attending board of directors and committee meetings. Marshall Fordyce, M.D., our President and Chief Executive Officer, was also a director as of December&nbsp;31, 2021, but did not receive any additional compensation for his service as a
director. See the section titled &#147;Executive compensation&#148; for more information regarding the compensation earned by Dr.&nbsp;Fordyce. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year
ended December&nbsp;31, 2021, each of the following individuals served on our board of directors as <FONT STYLE="white-space:nowrap">non-employee</FONT> directors: Kurt von Emster, Maha Katabi, Ph.D., Patrick Enright, Andrew Cheng, M.D., Ph.D., Beth
Seidenberg, M.D., Scott Morrison, and Kimball Hall. Other than as set forth above, none of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors earned any compensation in the year ended December&nbsp;31, 2021 or held any equity awards
as of December&nbsp;31, 2021. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors adopted a <FONT STYLE="white-space:nowrap">non-employee</FONT> director compensation policy in May 2021 that is
applicable to all of our <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. This compensation policy provides that each such <FONT STYLE="white-space:nowrap">non-employee</FONT> director will receive the following compensation for
service on our board of directors: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an annual cash retainer of $35,000; and an additional annual cash retainer of $30,000 for services as <FONT
STYLE="white-space:nowrap">non-executive</FONT> chairperson of our board of directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as a member of the audit committee,
compensation committee and the nominating and corporate governance committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an additional annual cash retainer of $7,500, $5,000 and $4,000 for service as chair of the audit committee, compensation
committee and the nominating and corporate governance committee, respectively; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an initial option grant to purchase 19,850 shares of our Class&nbsp;A common stock on the date of each such <FONT
STYLE="white-space:nowrap">non-employee</FONT> director&#146;s appointment to our board of directors; and </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an annual option grant to purchase 9,925 shares of our Class&nbsp;A common stock on the date of each of our annual
stockholder meetings. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each of the option grants described above will be granted under our 2021 Plan, the terms of which are described in more
detail below under the section titled &#147;Executive compensation&#151;Equity benefit plans&#151;2021 Equity incentive plan.&#148; Each such option grant will vest and become exercisable subject to the director&#146;s continuous service to us
through the earlier of the first anniversary of the date of grant or the next annual stockholder meeting. The term of each option will be 10 years, subject to earlier termination as provided in the 2021 Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">184 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_14"></A>Executive compensation </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers for the year ended December&nbsp;31, 2021, consisting of our principal executive officer and the next two most highly compensated executive
officers, were: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Marshall Fordyce, M.D., our President, Chief Executive Officer and Director; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Sean Grant, our Chief Financial Officer; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">Celia Lin, M.D., our Chief Medical Officer. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Summary compensation table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents all of the
compensation awarded to, earned by, or paid to our named executive officers during the fiscal years indicated below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="37%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name&nbsp;and&nbsp;principal&nbsp;position</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Fiscal</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>year</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Salary</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Bonus</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Stock</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>awards</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>awards</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)(3)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap">Non-equity</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>incentive&nbsp;plan<BR>compensation</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)(4)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>All other</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>compensation</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:arial" ALIGN="right"><B>Total</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="top" ALIGN="right"><I>2021</I></TD>
<TD NOWRAP VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">479,099</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">770,343</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">236,259</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,485,701</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>President and Chief Executive Officer</I></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="top" ALIGN="right"><I>2020</I></TD>
<TD NOWRAP VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">360,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">316,323</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,441,982</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">108,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3,226,305</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sean Grant</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="top" ALIGN="right"><I>2021</I></TD>
<TD NOWRAP VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">189,487</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">60,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,765,026</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">67,858</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2,082,371</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>Chief Financial Officer</I>(5)</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="top" ALIGN="right"><I>2020</I></TD>
<TD NOWRAP VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Celia Lin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="top" ALIGN="right"><I>2021</I></TD>
<TD NOWRAP VALIGN="top"><I>&nbsp;</I></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">361,205</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">797,776</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">134,616</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD NOWRAP VALIGN="top" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1,443,597</TD>
<TD NOWRAP VALIGN="top">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; font-size:10pt; font-family:arial"><I>Chief Medical Officer</I>(6)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>&nbsp;</I></TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><I>2020</I></TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"><I>&nbsp;</I></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Grant was paid a lump sum advance of $60,000 that will be earned if he remains continuously employed by us through July&nbsp;12, 2022 or, if earlier, through the date on which his employment terminates for any
reason other than termination for cause or his resignation without good reason (each as defined in his offer letter). Dr.&nbsp;Lin was paid a lump sum hiring bonus of $150,000 subject to the signing of her offer letter. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">In October 2020, in connection with the closing of our Series C redeemable convertible preferred stock financing, 49,636 outstanding shares of our Class&nbsp;A common stock held by Dr.&nbsp;Fordyce were amended to be
subject to a 12 month vesting period. The amounts disclosed represent the value of such amendment, computed in accordance with FASB ASC Topic 718. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent the aggregate grant date fair value of the awards granted to our named executive officers during fiscal years 2020 and 2021 under our 2017 and 2021 Plan, respectively, computed in
accordance with FASB ASC Topic 718. The assumptions used in calculating the grant date fair value of the stock options are set forth in Note 9 to our unaudited condensed financial statements for the nine months ended September&nbsp;30, 2021,
included elsewhere in this prospectus. This amount does not reflect the actual economic value that may be realized by the named executive officer. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The amounts disclosed represent performance bonuses earned in 2020 and 2021, but paid in the beginning of 2021 and 2022, respectively. Mr.&nbsp;Grant&#146;s and Dr.&nbsp;Lin&#146;s bonuses were <FONT
STYLE="white-space:nowrap">pro-rated</FONT> to reflect each of their partial years of service. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Grant has served as our Chief Financial Officer since July 2021. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lin has served as our Chief Medical Officer since February 2021. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Narrative to the summary compensation
table </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors reviews compensation annually for all employees, including our named executive officers. In making compensation determinations, we
consider compensation for comparable positions in the market, the historical compensation levels of our executives, individual performance as compared to our expectations and objectives, our desire to motivate our employees to achieve short- and
long-term results that are in the best interests of our stockholders and a long-term commitment to our company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has historically determined
our named executive officers&#146; compensation and has typically reviewed and discussed management&#146;s proposed compensation with our chief executive officer for all executives other than our chief executive officer. Based on those discussions
and its discretion, our board of directors then </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">185 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
approved the compensation of each named executive officer. The compensation committee determines our executive officers&#146; compensation and follows this process, but generally the compensation
committee itself, rather than our board of directors, approves the compensation of each named executive officer. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Annual base salary </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Base salaries for our named executive officers are initially established through <FONT STYLE="white-space:nowrap">arm&#146;s-length</FONT> negotiations at the time of
the named executive officer&#146;s hiring, taking into account such named executive officer&#146;s qualifications, experience, the scope of his or her responsibilities and competitive market compensation paid by other companies for similar positions
within the industry and geography. Base salaries are reviewed periodically, typically in connection with our annual performance review process, and adjusted from time to time to realign salaries with market levels after taking into account
individual responsibilities, performance and experience. In making decisions regarding salary increases, we may also draw upon the experience of members of our board of directors with executives at other companies. The 2021 annual base salaries for
our named executive officers are set forth in the table below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>2021&nbsp;base</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>salary</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marshall Fordyce, M.D.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">525,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sean Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Celia Lin, M.D.(2)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">429,200</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Fordyce&#146;s base salary increased from $400,000 to $525,000 on May&nbsp;13, 2021. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Lin&#146;s base salary increased from $370,000 to $429,200 on May&nbsp;13, 2021. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Outstanding equity awards
as of December&nbsp;31, 2021 </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table presents the outstanding equity incentive plan awards held by each named executive officer as of
December&nbsp;31, 2021. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="44%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="20" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Option awards(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Grant</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>securities</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercised</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>options</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercisable</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>(#)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>securities</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>underlying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercised</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>options</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>unexercisable</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>(#)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exercise</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>price&nbsp;per</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>share</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>($)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Option</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>expiration</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>date</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marshall Fordyce, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">01-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,319</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,350</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">01-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-16-2020</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">276,803</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">830,409</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">12-15-2030</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">05-13-2021</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110,038</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">05-12-2031</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sean Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">07-13-2021</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.87</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">07-12-2031</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="2"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD>
<TD HEIGHT="2" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Celia Lin, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">02-23-2021</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">02-22-2031</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">05-13-2021</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">(7)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">16,916</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">11.00</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">05-12-2031</FONT></FONT></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">All of the option and stock awards granted prior to May&nbsp;13, 2021 were granted under the 2017 Plan, the terms of which plan is described below under &#147;&#151;Equity benefit plans&#151;2017 Equity incentive
plan.&#148; All of the option and stock awards granted on or subsequent to May&nbsp;13, 2021 were granted under the 2021 Plan, the terms of which plan is described below under &#147;&#151;Equity benefit plans&#151;2021 Equity incentive plan.&#148;
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-third</FONT> of the shares subject to the option award vest on January&nbsp;10, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-thirty-sixth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. Dr.&nbsp;Fordyce exercised this option with respect to 3,607 shares of Class&nbsp;A common stock in April 2021. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on December&nbsp;16, 2021, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. This option was conditioned on the cancellation of an option covering 12,945 shares granted to Dr.&nbsp;Fordyce on March&nbsp;26, 2019 and an option covering
17,260 shares granted to Dr.&nbsp;Fordyce on February&nbsp;7, 2018. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">186 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on May&nbsp;13, 2022, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on July&nbsp;13, 2022, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on February&nbsp;23, 2022, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject
to the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"><FONT STYLE="white-space:nowrap">One-fourth</FONT> of the shares subject to the option award vest on May&nbsp;13, 2022, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to
the option award vest on each monthly anniversary, subject to continuous service to us. </TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Options held by certain of our named executive officers are
eligible for accelerated vesting under specified circumstances. Please see the subsection titled &#147;&#151;Employment, severance and change in control agreements&#148; below for a description of such potential acceleration. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Emerging growth company status </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are an &#147;emerging growth
company,&#148; as defined in the JOBS Act. As an emerging growth company we will be exempt from certain requirements related to executive compensation, including the requirements to hold a nonbinding advisory vote on executive compensation and to
provide information relating to the ratio of total compensation of our chief executive officer to the median of the annual total compensation of all of our employees, each as required by the Investor Protection and Securities Reform Act of 2010,
which is part of the Dodd-Frank Wall Street Reform and Consumer Protection Act. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Pension benefits </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named executive officers did not participate in, or otherwise receive any benefits under, any pension or retirement plan sponsored by us during the fiscal year ended
December&nbsp;31, 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Nonqualified deferred compensation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our named
executive officers did not participate in, or earn any benefits under, a <FONT STYLE="white-space:nowrap">non-qualified</FONT> deferred compensation plan sponsored by us during the fiscal year ended December&nbsp;31, 2021. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employment, severance and change in control agreements </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Offer letters
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Below are descriptions of our offer letters with our named executive officers. For a discussion of the severance pay and other benefits to be provided in
connection with a termination of employment and/or a change in control under the arrangements with our named executive officers, please see the section titled &#147;&#151;Potential payments and benefits upon termination or change in control&#148;
below. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dr.</I><I></I><I>&nbsp;Fordyce</I>.&nbsp;&nbsp;&nbsp;&nbsp;In December 2020, we and Dr.&nbsp;Fordyce entered into an offer letter that governs the current
terms of Dr.&nbsp;Fordyce&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Fordyce is entitled to an initial annual base salary of $400,000, is eligible to receive an annual performance bonus with a target achievement of 40% of his
base salary, as determined by our board of directors, and was granted an option exercisable for 1,141,733 shares of our Class&nbsp;A common stock (in addition to shares of our stock that Dr.&nbsp;Fordyce held at the time we entered into his offer
letter). In May 2021, we and Dr.&nbsp;Fordyce entered into an amended and restated offer letter pursuant to which Dr.&nbsp;Fordyce&#146;s annual base salary increased to $525,000 and his annual performance bonus target achievement increased to 50%
of his base salary, as determined by our board of directors. In addition, Dr.&nbsp;Fordyce received a stock option covering 110,038 shares of our Class&nbsp;A common stock, at $11.00 per share, which vest as follows:
<FONT STYLE="white-space:nowrap">one-fourth</FONT> of the shares subject to the option vest on May&nbsp;13, 2022, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">187 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to the option award vest on each monthly anniversary, subject to continuous service to us.
Dr.&nbsp;Fordyce is also entitled to certain severance benefits, the terms of which are described below under the section titled &#147;&#151;Potential payments and benefits upon termination or change of control.&#148; Dr.&nbsp;Fordyce&#146;s
employment is at will. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Mr.</I><I></I><I>&nbsp;Grant</I>.&nbsp;&nbsp;&nbsp;&nbsp;In July 2021, we and Mr.&nbsp;Grant entered in an offer letter that governs the
current terms of Mr.&nbsp;Grant&#146;s employment with us. Pursuant to the agreement, Mr.&nbsp;Grant is entitled to an initial base salary of $400,000, is eligible to receive an annual performance bonus with a target achievement of 40% of his base
salary, based on our company&#146;s assessment of his performance and our company&#146;s attainment of written targeted goals as set by our company in its sole discretion. Mr.&nbsp;Grant was also paid a lump sum advance of $60,000 that will be
earned if he remains continuously employed by us through July&nbsp;12, 2022 or, if earlier, through the date on which his employment terminates for any reason other than termination for cause or his resignation without good reason (each as defined
below). In addition, Mr.&nbsp;Grant was granted a stock option covering 180,000 shares of our Class&nbsp;A common stock, at $14.87 per share, which vest over a period of four years, with 25% of the shares vesting on July&nbsp;13, 2022, and the
remaining shares vesting in 36 equal monthly installments thereafter, in each case subject to Mr.&nbsp;Grant&#146;s continued employment through the applicable vesting dates. Mr.&nbsp;Grant is also entitled to certain severance benefits, the terms
of which are described below under the section titled &#147;&#151;Potential payments and benefits upon termination or change of control.&#148; Mr.&nbsp;Grant&#146;s employment is at will. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dr.</I><I></I><I>&nbsp;Lin.</I>&nbsp;&nbsp;&nbsp;&nbsp;In February 2021, we and Dr.&nbsp;Lin entered into an offer letter that governs the current terms of
Dr.&nbsp;Lin&#146;s employment with us. Pursuant to the agreement, Dr.&nbsp;Lin is entitled to an initial annual base salary of $370,000, is eligible to receive an annual performance bonus with a target achievement of 30% of her base salary, as
determined by our board of directors, and was granted an option exercisable for 230,821 shares of our Class&nbsp;A common stock. Dr.&nbsp;Lin was also paid a lump sum hiring bonus of $150,000. In May 2021, we and Dr.&nbsp;Lin entered into an amended
and restated offer letter pursuant to which Dr.&nbsp;Lin&#146;s annual base salary increased to $429,200 and her annual performance bonus target achievement increased to 40% of her base salary, as determined by our board of directors. In addition,
Dr.&nbsp;Lin received a stock option covering 16,916 shares of our Class&nbsp;A common stock, at $11.00 per share, which vest as follows: <FONT STYLE="white-space:nowrap">one-fourth</FONT> of the shares subject to the option vest on May&nbsp;13,
2022, and thereafter <FONT STYLE="white-space:nowrap">one-forty-eighth</FONT> of the shares subject to the option award vest on each monthly anniversary, subject to continuous service to us. Dr.&nbsp;Lin is also entitled to certain severance
benefits, the terms of which are described below under the section titled &#147;&#151;Potential payments and benefits upon termination or change of control.&#148; Dr.&nbsp;Lin&#146;s employment is at will. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Potential payments and benefits upon termination or change of control </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dr.</I><I></I><I>&nbsp;Fordyce.</I> &nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Dr.&nbsp;Fordyce&#146;s amended and restated offer letter, if (a)&nbsp;his employment is
terminated without cause (as defined below), and other than as a result of his death or disability, or (b)&nbsp;he resigns for good reason (as defined below), then in addition to any amounts accrued and payable under the terms of our benefit plans
through the date of termination, Dr.&nbsp;Fordyce will be entitled to receive severance in the form of 12 months of his then base salary, such amount to be paid in equal installments over a <FONT STYLE="white-space:nowrap">12-month</FONT> period
after the date of termination, subject to applicable taxes and withholding, as well as up to 12 months of COBRA coverage. These severance benefits are conditioned upon Dr.&nbsp;Fordyce continuing to comply with his obligations under his proprietary
information agreement and his delivery of a general release of claims in favor of the company that becomes effective and irrevocable within 21 days of the date of termination. Further, if within the three-month period immediately prior to or <FONT
STYLE="white-space:nowrap">12-month</FONT> period that immediately follows a change of control (as defined below) Dr.&nbsp;Fordyce&#146;s employment is terminated without cause or for good reason, then (a) 100% of his then-unvested equity grants
shall accelerate and become fully vested as of the termination date, (b)&nbsp;the amount of his cash severance and COBRA severance described above shall be increased from 12 months to 18 months and (c)&nbsp;he
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">188 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
shall receive additional cash severance in an amount equal to his target annual bonus for the year of such termination, to be paid in a single lump sum within 10 business days after the effective
date of his release. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Mr.</I><I></I><I>&nbsp;Grant</I>.&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Mr.&nbsp;Grant&#146;s offer letter, if (a)&nbsp;his employment is
terminated without cause (as defined below), and other than as a result of his death or disability, or (b)&nbsp;he resigns for good reason (as defined below), then in addition to any amounts accrued and payable under the terms of our benefit plans
through the date of termination, Mr.&nbsp;Grant will be entitled to receive severance in the form of nine months of his then base salary, such amount to be paid in installments on the ordinary payroll dates, subject to applicable taxes and
withholding, as well as up to nine months of COBRA coverage. These severance benefits are conditioned upon Mr.&nbsp;Grant continuing to comply with his obligations under his proprietary information agreement and his delivery of a general release of
claims in favor of the company that becomes effective and irrevocable within 21 days of the date of termination. Further, if within the three-month period immediately prior to or <FONT STYLE="white-space:nowrap">12-month</FONT> period that
immediately follows a change of control (as defined below) Mr.&nbsp;Grant&#146;s employment is terminated without cause or for good reason, then (a) 100% of his then-unvested equity grants shall accelerate and become fully vested as of the
termination date, (b)&nbsp;the amount of his cash severance and COBRA severance described above shall be increased from nine months to 12 months and (c)&nbsp;he shall receive additional cash severance in an amount equal to his target annual bonus
for the year of such termination, to be paid in a single lump sum within 10 business days after the effective date of his release. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dr.</I><I></I><I>&nbsp;Lin.</I>&nbsp;&nbsp;&nbsp;&nbsp;Pursuant to Dr.&nbsp;Lin&#146;s amended and restated offer letter, if (a)&nbsp;her employment is terminated
without cause (as defined below), and other than as a result of her death or disability, or (b)&nbsp;she resigns for good reason (as defined below), then in addition to any amounts accrued and payable under the terms of our benefit plans through the
date of termination, Dr.&nbsp;Lin will be entitled to receive severance in the form of nine months of her then base salary, such amount to be paid in installments on the ordinary payroll dates, subject to applicable taxes and withholding, as well as
up to nine months of COBRA coverage. These severance benefits are conditioned upon Dr.&nbsp;Lin continuing to comply with her obligations under her proprietary information agreement and her delivery of a general release of claims in favor of the
company that becomes effective and irrevocable within 21 days of the date of termination. Further, if within the three-month period immediately prior to or <FONT STYLE="white-space:nowrap">12-month</FONT> period that immediately follows a change of
control (as defined below) Dr.&nbsp;Lin&#146;s employment is terminated without cause or for good reason, then (a) 100% of her then-unvested equity grants shall accelerate and become fully vested as of the termination date, (b)&nbsp;the amount of
her cash severance and COBRA severance described above shall be increased from nine months to 12 months and (c)&nbsp;she shall receive additional cash severance in an amount equal to her target annual bonus for the year of such termination, to be
paid in a single lump sum within 10 business days after the effective date of her release. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of Dr.&nbsp;Fordyce&#146;s, Mr.&nbsp;Grant&#146;s, and
Dr.&nbsp;Lin&#146;s severance benefits, the following definitions apply: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;cause&#148; means (a)&nbsp;the officer&#146;s commission or conviction (including a guilty plea or plea of nolo
contendere) of any felony or any other crime involving fraud, dishonesty or moral turpitude; (b)&nbsp;officer&#146;s commission or attempted commission of or participation in a fraud or act of dishonesty or misrepresentation against us;
(c)&nbsp;willful and material breach of officer&#146;s duties to us; (d)&nbsp;willful damage to any of our property; (e)&nbsp;willful misconduct, or other willful violation of our policy that causes harm; or (f)&nbsp;officer&#146;s material
violation of any written and fully executed contract or agreement between us and the officer, including without limitation, material breach of agreements relating to <FONT STYLE="white-space:nowrap">non-solicitation,</FONT> nondisclosure and/or
assignment of inventions, or material breach of any company policy, or of any statutory duty officer owes to us; provided, however, that in the event of subparagraph (f)&nbsp;above, we are required to provide written notice of such alleged violation
and breach, and officer will have 30 days from receipt of such notice to cure. For purposes of this definition of Cause, no act, or failure to act, on officer&#146;s part shall be considered &#147;willful&#148; unless it is done, or omitted to be
done, by officer intentionally and without reasonable belief that officer&#146;s action or omission was in the best interests of the company. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">189 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;change of control&#148; means (a)&nbsp;any consolidation or merger of the company with or into any other corporation
or other entity or person, or any other corporate reorganization, other than any such consolidation, merger or reorganization in which the stockholders of the company immediately prior to such consolidation, merger or reorganization, continue to
hold a majority of the voting power of the surviving entity (or, if the surviving entity is a wholly owned subsidiary, its parent) immediately after such consolidation, merger or reorganization; (b)&nbsp;any transaction or series of related
transactions to which the company is a party in which in excess of 50% of our voting power is transferred; provided that the foregoing shall not include any transaction or series of transactions principally for bona fide equity financing purposes in
which cash is received by us or our indebtedness is cancelled or converted or a combination thereof; or (c)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially all of our assets. </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;good reason&#148; means any of the following actions, if taken by us without officer&#146;s prior written consent:
(a)&nbsp;a material reduction in officer&#146;s base salary, which we and officer agree is a reduction of at least 10% of officer&#146;s base salary (unless pursuant to a salary reduction program applicable generally to our similarly situated
employees); (b) a material reduction in officer&#146;s duties (including responsibilities and/or authorities) (with respect to Dr.&nbsp;Fordyce, as our President and Chief Executive Officer), provided, however, that a change in job position
(including a change in title) shall not be deemed a &#147;material reduction&#148; in and of itself unless officer&#146;s new duties are materially reduced from the prior duties; (c)&nbsp;relocation of officer&#146;s principal place of employment to
a place that increases officer&#146;s <FONT STYLE="white-space:nowrap">one-way</FONT> commute by more than 50 miles as compared to officer&#146;s then-current principal place of employment immediately prior to such relocation, provided that if
officer works remotely during any period in which officer&#146;s regular principal place of business at a company office is closed, then neither officer&#146;s relocation to remote work or back to the office from remote work will be considered a
relocation from officer&#146;s principal place of employment for the purposes of this definition; or, with respect to Dr.&nbsp;Fordyce, (d)&nbsp;prior to a change of control, no longer being a member of our board of directors or reporting to our
board of directors as Chief Executive Officer. In order to resign for good reason, officer must provide written notice to our board of directors, or with respect to Mr.&nbsp;Grant or Dr.&nbsp;Lin, our Chief Executive Officer, within 30 days after
each occurrence of the event giving rise to good reason setting forth the basis for officer&#146;s resignation, allow us at least 30 days from receipt of such written notice to cure such event, and if such event is not reasonably cured within such
period, officer must resign from all positions officer then holds with the company not later than 30 days after the expiration of the cure period. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Other compensation and benefits </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our current named executive officers
are eligible to participate in our employee benefit plans, including our medical, dental and vision, in each case on the same basis as all of our other employees. We pay the premiums for the medical, disability, accidental death and dismemberment
insurance for all of our employees, including our named executive officers. We generally do not provide perquisites or personal benefits to our named executive officers. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Equity benefit plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that our ability to grant equity-based
awards is a valuable and necessary compensation tool that aligns the long-term financial interests of our employees, consultants and directors with the financial interests of our stockholders. In addition, we believe that our ability to grant
options and other equity-based awards helps us to attract, retain and motivate employees, consultants and directors, and encourages them to devote their best efforts to our business and financial success. The principal features of our equity
incentive plans and our 401(k) plan are summarized below. These summaries are qualified in their entirety by reference to the actual text of the plans, which, other than the 401(k) plan, are filed as exhibits to the registration statement of which
this prospectus is a part. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">190 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>2021 Equity incentive plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has adopted, and our stockholders have approved, our 2021 Plan. Our 2021 Plan became effective on May&nbsp;13, 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2021 Plan provides for the grant of incentive stock options (ISOs) within the meaning of Section&nbsp;422 of the Internal
Revenue Code of 1986, as amended (Code), to our employees and our parent and subsidiary corporations&#146; employees, and for the grant of nonstatutory stock options (NSOs), stock appreciation rights, restricted stock awards, restricted stock unit
awards, performance awards and other forms of awards to our employees, directors and consultants and any of our affiliates&#146; employees and consultants. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Authorized shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;Initially, the maximum number of shares of our Class&nbsp;A common stock that may be issued under our 2021 Plan will not
exceed 4,405,336 shares of our Class&nbsp;A common stock, which is the sum of (i) 2,212,335 new shares, plus (ii)&nbsp;an additional number of shares up to a maximum of 2,193,001 shares, which number consists of shares of our Class&nbsp;A common
stock subject to outstanding stock options or other stock awards granted under our 2017 Plan that, on or after our 2021 Plan became effective, terminate or expire prior to exercise or settlement; are not issued because the award is settled in cash;
are forfeited because of the failure to vest; or are reacquired or withheld (or not issued) to satisfy a tax withholding obligation or the purchase or exercise price. In addition, the number of shares of our Class&nbsp;A common stock reserved for
issuance under our 2021 Plan will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year for a period of 10 years, beginning on January&nbsp;1, 2022 and continuing through January&nbsp;1, 2031, in an
amount equal to (1) 5% of the total number of shares of our Class&nbsp;A common stock outstanding on December 31<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of the immediately preceding year, or (2)&nbsp;a lesser number of shares
determined by our board of directors no later than the date of any such increase. The maximum number of shares of our Class&nbsp;A common stock that may be issued on the exercise of ISOs under our 2021 Plan is 13,216,008 shares. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Shares subject to stock awards granted under our 2021 Plan that expire or terminate without being exercised in full or that are paid out in cash rather than in shares
will not reduce the number of shares available for issuance under our 2021 Plan. Shares withheld under a stock award to satisfy the exercise, strike or purchase price of a stock award or to satisfy a tax withholding obligation will not reduce the
number of shares available for issuance under our 2021 Plan. If any shares of our Class&nbsp;A common stock issued pursuant to a stock award are forfeited back to or repurchased or reacquired by us (i)&nbsp;because of a failure to meet a contingency
or condition required for the vesting of such shares; (ii)&nbsp;to satisfy the exercise, strike or purchase price of a stock award; or (iii)&nbsp;to satisfy a tax withholding obligation in connection with a stock award, the shares that are forfeited
or repurchased or reacquired will revert to and again become available for issuance under our 2021 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Plan administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our
board of directors, or a duly authorized committee of our board of directors, administers our 2021 Plan. Our board of directors may delegate to one or more of our officers the authority to (i)&nbsp;designate employees (other than officers) to
receive specified stock awards; and (ii)&nbsp;determine the number of shares subject to such stock awards. Under our 2021 Plan, our board of directors has the authority to determine stock award recipients, the types of stock awards to be granted,
grant dates, the number of shares subject to each stock award, the fair market value of our Class&nbsp;A common stock, and the provisions of each stock award, including the period of exercisability and the vesting schedule applicable to a stock
award. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under our 2021 Plan, our board of directors also generally has the authority to effect, with the consent of any materially adversely affected participant,
(i)&nbsp;the reduction of the exercise, purchase, or strike price of any outstanding option or stock appreciation right; (ii)&nbsp;the cancellation of any outstanding option or stock appreciation right and the grant in substitution therefore of
other awards, cash, or other consideration; or (iii)&nbsp;any other action that is treated as a repricing under generally accepted accounting principles. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">191 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock options</I>.&nbsp;&nbsp;&nbsp;&nbsp;ISOs and NSOs are granted under stock option agreements adopted by the
administrator. The administrator will determine the exercise price for stock options, within the terms and conditions of our 2021 Plan, except the exercise price of a stock option generally will not be less than 100% of the fair market value of our
Class&nbsp;A common stock on the date of grant. Options granted under our 2021 Plan will vest at the rate specified in the stock option agreement as will be determined by the administrator. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The administrator will determine the term of stock options granted under our 2021 Plan, up to a maximum of 10 years. Unless the terms of an optionholder&#146;s stock
option agreement, or other written agreement between us and the recipient, provide otherwise, if an optionholder&#146;s service relationship with us or any of our affiliates ceases for any reason other than disability, death, or cause, the
optionholder may generally exercise any vested options for a period of three months following the cessation of service. This period may be extended in the event that exercise of the option is prohibited by applicable securities laws. If an
optionholder&#146;s service relationship with us or any of our affiliates ceases due to death, or an optionholder dies within a certain period following cessation of service, the optionholder or a beneficiary may generally exercise any vested
options for a period of 18 months following the date of death. If an optionholder&#146;s service relationship with us or any of our affiliates ceases due to disability, the optionholder may generally exercise any vested options for a period of 12
months following the cessation of service. In the event of a termination for cause, options generally terminate upon the termination date. In no event may an option be exercised beyond the expiration of its term. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Acceptable consideration for the purchase of Class&nbsp;A common stock issued upon the exercise of a stock option will be determined by the administrator and may include
(i)&nbsp;cash, check, bank draft or money order; (ii)&nbsp;a broker-assisted cashless exercise; (iii)&nbsp;the tender of shares of our Class&nbsp;A common stock previously owned by the optionholder; (iv)&nbsp;a net exercise of the option if it is an
NSO; or (v)&nbsp;other legal consideration approved by the administrator. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless the administrator provides otherwise, options or stock appreciation rights
generally are not transferable except by will or the laws of descent and distribution. Subject to approval of the administrator or a duly authorized officer, an option may be transferred pursuant to a domestic relations order, official marital
settlement agreement, or other divorce or separation instrument. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Tax limitations on ISOs</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate fair market value, determined
at the time of grant, of our Class&nbsp;A common stock with respect to ISOs that are exercisable for the first time by an award holder during any calendar year under all of our stock plans may not exceed $100,000. Options or portions thereof that
exceed such limit will generally be treated as NSOs. No ISO may be granted to any person who, at the time of the grant, owns or is deemed to own stock possessing more than 10% of our total combined voting power or that of any of our parent or
subsidiary corporations unless (i)&nbsp;the option exercise price is at least 110% of the fair market value of the stock subject to the option on the date of grant; and (ii)&nbsp;the term of the ISO does not exceed five years from the date of grant.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock unit awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock unit awards are granted under restricted stock unit award agreements adopted by the
administrator. Restricted stock unit awards may be granted in consideration for any form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. A restricted stock unit award may be settled by
cash, delivery of stock, a combination of cash and stock as deemed appropriate by the administrator, or in any other form of consideration set forth in the restricted stock unit award agreement. Additionally, dividend equivalents may be credited in
respect of shares covered by a restricted stock unit award. Except as otherwise provided in the applicable award agreement, or other written agreement between us and the recipient, restricted stock unit awards that have not vested will be forfeited
once the participant&#146;s continuous service ends for any reason. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Restricted stock awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Restricted stock awards are granted under
restricted stock award agreements adopted by the administrator. A restricted stock award may be awarded in consideration for cash, check, bank </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">192 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
draft or money order, past or future services to us, or any other form of legal consideration that may be acceptable to our board of directors and permissible under applicable law. The
administrator will determine the terms and conditions of restricted stock awards, including vesting and forfeiture terms. If a participant&#146;s service relationship with us ends for any reason, we may receive any or all of the shares of
Class&nbsp;A common stock held by the participant that have not vested as of the date the participant terminates service with us through a forfeiture condition or a repurchase right. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Stock appreciation rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock appreciation rights are granted under stock appreciation right agreements adopted by the administrator.
The administrator will determine the purchase price or strike price for a stock appreciation right, which generally will not be less than 100% of the fair market value of our Class&nbsp;A common stock on the date of grant. A stock appreciation right
granted under our 2021 Plan will vest at the rate specified in the stock appreciation right agreement as will be determined by the administrator. Stock appreciation rights may be settled in cash or shares of our Class&nbsp;A common stock or in any
other form of payment as determined by our board of directors and specified in the stock appreciation right agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The administrator will determine the term of
stock appreciation rights granted under our 2021 Plan, up to a maximum of 10 years. If a participant&#146;s service relationship with us or any of our affiliates ceases for any reason other than cause, disability, or death, the participant may
generally exercise any vested stock appreciation right for a period of three months following the cessation of service. This period may be further extended in the event that exercise of the stock appreciation right following such a termination of
service is prohibited by applicable securities laws. If a participant&#146;s service relationship with us, or any of our affiliates, ceases due to disability or death, or a participant dies within a certain period following cessation of service, the
participant or a beneficiary may generally exercise any vested stock appreciation right for a period of 12 months in the event of disability and 18 months in the event of death. In the event of a termination for cause, stock appreciation rights
generally terminate upon the termination date. In no event may a stock appreciation right be exercised beyond the expiration of its term. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Performance
awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2021 Plan permits the grant of performance awards that may be settled in stock, cash or other property. Performance awards may be structured so that the stock or cash will be issued or paid only following the
achievement of certain <FONT STYLE="white-space:nowrap">pre-established</FONT> performance goals during a designated performance period. Performance awards that are settled in cash or other property are not required to be valued in whole or in part
by reference to, or otherwise based on, our Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The performance goals may be based on any measure of performance selected by our board of
directors. The performance goals may be based on company-wide performance or performance of one or more business units, divisions, affiliates, or business segments, and may be either absolute or relative to the performance of one or more comparable
companies or the performance of one or more relevant indices. Unless specified otherwise by our board of directors at the time the performance award is granted, our board will appropriately make adjustments in the method of calculating the
attainment of performance goals as follows: (i)&nbsp;to exclude restructuring or other nonrecurring charges; (ii)&nbsp;to exclude exchange rate effects; (iii)&nbsp;to exclude the effects of changes to generally accepted accounting principles;
(iv)&nbsp;to exclude the effects of any statutory adjustments to corporate tax rates; (v)&nbsp;to exclude the effects of items that are &#147;unusual&#148; in nature or occur &#147;infrequently&#148; as determined under generally accepted accounting
principles; (vi)&nbsp;to exclude the dilutive effects of acquisitions or joint ventures; (vii)&nbsp;to assume that any business divested by us achieved performance objectives at targeted levels during the balance of a performance period following
such divestiture; (viii)&nbsp;to exclude the effect of any change in the outstanding shares of our Class&nbsp;A common stock by reason of any stock dividend or split, stock repurchase, reorganization, recapitalization, merger, consolidation, <FONT
STYLE="white-space:nowrap">spin-off,</FONT> combination or exchange of shares or other similar corporate change, or any distributions to Class&nbsp;A common stockholders other than regular cash dividends; (ix)&nbsp;to exclude the effects of stock
based compensation and the award of bonuses under our bonus plans; (x)&nbsp;to exclude costs incurred in connection with potential acquisitions or divestitures that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">193 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
required to be expensed under generally accepted accounting principles; and (xi)&nbsp;to exclude the goodwill and intangible asset impairment charges that are required to be recorded under
generally accepted accounting principles. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Other stock awards</I>.&nbsp;&nbsp;&nbsp;&nbsp;The administrator is permitted to grant other awards based in whole or
in part by reference to our Class&nbsp;A common stock. The administrator will set the number of shares under the stock award (or cash equivalent) and all other terms and conditions of such awards. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I><FONT STYLE="white-space:nowrap">Non-employee</FONT> director compensation limit</I>.&nbsp;&nbsp;&nbsp;&nbsp;The aggregate value of all compensation granted or paid
to any <FONT STYLE="white-space:nowrap">non-employee</FONT> director with respect to any calendar year, including awards granted and cash fees paid by us to such <FONT STYLE="white-space:nowrap">non-employee</FONT> director, will not exceed $750,000
in total value, except such amount will increase to $1,000,000 for the first year for newly appointed or elected <FONT STYLE="white-space:nowrap">non-employee</FONT> directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Changes to capital structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event there is a specified type of change in our capital structure, such as a stock split, reverse
stock split, or recapitalization, appropriate adjustments will be made to (i)&nbsp;the class and maximum number of shares reserved for issuance under our 2021 Plan, (ii)&nbsp;the class and maximum number of shares by which the share reserve may
increase automatically each year, (iii)&nbsp;the class and maximum number of shares that may be issued on the exercise of ISOs, and (iv)&nbsp;the class and number of shares and exercise price, strike price, or purchase price, if applicable, of all
outstanding stock awards. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Corporate transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;In the event of a corporate transaction (as defined below), unless otherwise
provided in a participant&#146;s stock award agreement or other written agreement with us or one of our affiliates or unless otherwise expressly provided by the administrator at the time of grant, any stock awards outstanding under our 2021 Plan may
be assumed, continued or substituted for by any surviving or acquiring corporation (or its parent company), and any reacquisition or repurchase rights held by us with respect to the stock award may be assigned to the successor (or its parent
company). If the surviving or acquiring corporation (or its parent company) does not assume, continue or substitute for such stock awards, then (i)&nbsp;with respect to any such stock awards that are held by participants whose continuous service has
not terminated prior to the effective time of the corporate transaction, or current participants, the vesting (and exercisability, if applicable) of such stock awards will be accelerated in full (or, in the case of performance awards with multiple
vesting levels depending on the level of performance, vesting will accelerate at 100% of the target level if the award is not assumed) to a date prior to the effective time of the corporate transaction (contingent upon the effectiveness of the
corporate transaction), and such stock awards will terminate if not exercised (if applicable) at or prior to the effective time of the corporate transaction, and any reacquisition or repurchase rights held by us with respect to such stock awards
will lapse (contingent upon the effectiveness of the corporate transaction); and (ii)&nbsp;any such stock awards that are held by persons other than current participants will terminate if not exercised (if applicable) prior to the effective time of
the corporate transaction, except that any reacquisition or repurchase rights held by us with respect to such stock awards will not terminate and may continue to be exercised notwithstanding the corporate transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event a stock award will terminate if not exercised prior to the effective time of a corporate transaction, the administrator may provide, in its sole discretion,
that the holder of such stock award may not exercise such stock award but instead will receive a payment equal in value to the excess (if any) of (i)&nbsp;the value of the property the participant would have received upon the exercise of the stock
award, over (ii)&nbsp;any per share exercise price payable by such holder, if applicable. In addition, any escrow, holdback, earn out or similar provisions in the definitive agreement for the corporate transaction may apply to such payment to the
same extent and in the same manner as such provisions apply to the holders of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under our 2021 Plan, a &#147;corporate
transaction&#148; is generally the consummation of (i)&nbsp;a sale or other disposition of all or substantially all of our assets; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">194 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or (iv)&nbsp;a merger, consolidation or similar transaction following
which we are the surviving corporation but the shares of our Class&nbsp;A common stock outstanding immediately prior to such transaction are converted or exchanged into other property by virtue of the transaction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Change in control</I>.&nbsp;&nbsp;&nbsp;&nbsp;Stock awards granted under our 2021 Plan may be subject to acceleration of vesting and exercisability upon or after a
change in control (as defined below) as may be provided in the applicable stock award agreement or in any other written agreement between us or any affiliate and the participant, but in the absence of such provision, no such acceleration will
automatically occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under our 2021 Plan, a &#147;change in control&#148; is generally (i)&nbsp;the acquisition by any person or company of more than 50% of the
combined voting power of our then outstanding stock; (ii)&nbsp;a merger, consolidation or similar transaction in which our stockholders immediately before the transaction do not own, directly or indirectly, more than 50% of the combined voting power
of the surviving entity (or the parent of the surviving entity) in substantially the same proportions as their ownership immediately prior to such transaction; (iii)&nbsp;a sale, lease, exclusive license or other disposition of all or substantially
all of our assets other than to an entity more than 50% of the combined voting power of which is owned by our stockholders in substantially the same proportions as their ownership of our outstanding voting securities immediately prior to such
transaction; or (iv)&nbsp;when a majority of our board of directors becomes comprised of individuals who were not serving on our board of directors on the date of the underwriting agreement related to our initial public offering, or the incumbent
board, or whose nomination, appointment, or election was not approved by a majority of the incumbent board still in office. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Plan amendment or
termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend, suspend, or terminate our 2021 Plan at any time, provided that such action does not materially impair the existing rights of any participant without such
participant&#146;s written consent. Certain material amendments also require the approval of our stockholders. No ISOs may be granted after the tenth anniversary of the date our board of directors adopted our 2021 Plan. No stock awards may be
granted under our 2021 Plan while it is suspended or after it is terminated. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2017 Equity incentive plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors adopted the 2017 Plan and our stockholders approved the 2017 Plan in February 2017. The 2017 Plan is the successor to and continuation of the PNA
Innovations, Inc. 2011 Stock Plan. The 2017 Plan provided for the grant of ISOs, NSOs, stock appreciation rights, restricted stock awards, restricted stock unit awards and other awards to our employees, directors and consultants or our affiliates.
ISOs may be granted only to our employees or employees of our affiliates. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2021, upon the effective date of the 2021 Plan, the 2017 Plan was terminated.
However, any outstanding awards granted under the 2017 Plan remain outstanding, subject to the terms of the 2017 Plan and award agreements, until such outstanding options are exercised or until any awards terminate or expire by their terms. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Authorized shares</I>.&nbsp;&nbsp;&nbsp;&nbsp;We can no longer grant awards under our 2017 Plan. As of December&nbsp;31, 2021, options to purchase 2,191,563 shares
were outstanding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Plan administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board or a duly authorized committee of our board administers our 2017 Plan and the awards
granted under it. The administrator has the power to modify outstanding awards under our 2017 Plan. The administrator has the authority to reprice any outstanding option with the consent of any adversely affected participant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Corporate transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our 2017 Plan provides that in the event of certain specified significant corporate transactions, as defined under
our 2017 Plan, our board may (1)&nbsp;arrange for the assumption, continuation or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">195 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
substitution of an award by a successor corporation, or the acquiring corporation&#146;s parent company; (2)&nbsp;arrange for the assignment of any reacquisition or repurchase rights held by us
to a successor corporation, or the acquiring corporation&#146;s parent company; (3)&nbsp;accelerate the vesting, in whole or in part, of the award and provide for its termination prior to the transaction if not exercised prior to the effective time
of the corporate transaction; (4)&nbsp;arrange for the lapse, in whole or in part, of any reacquisition or repurchase rights held by us; (5)&nbsp;cancel or arrange for the cancellation of the award prior to the transaction in exchange for a cash
payment, if any, determined by the board; or (6)&nbsp;make a payment in such form as determined by the board of directors equal to the excess, if any, of the per share amount (or value of property per share) payable to holders of Class&nbsp;A common
stock over the per share exercise price under the applicable award. The administrator is not obligated to treat all awards or portions of awards, even those that are of the same type, in the same manner. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of a change in control, as defined under our 2017 Plan, awards granted under our 2017 Plan will not receive automatic acceleration of vesting and
exercisability, although this treatment may be provided for in an award agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Transferability</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board may impose limitations
on the transferability of ISOs, NSOs and stock appreciation rights as the board will determine. Absent such limitations, a participant may not transfer awards under our 2017 Plan other than by will, the laws of descent and distribution or as
otherwise provided under our 2017 Plan. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Plan amendment or termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board has the authority to suspend or terminate our 2017
Plan at any time, provided that such action will not impair a participant&#146;s rights under such participant&#146;s outstanding award without his or her written consent. As described above, our 2017 Plan will be terminated upon the effective date
of the 2021 Plan and no future awards will be granted under the 2017 Plan following such termination. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2021 Employee stock purchase plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors has adopted, and our stockholders have approved, our ESPP. Our ESPP became effective on May&nbsp;13, 2021. The purpose of our ESPP is to secure
the services of new employees, to retain the services of existing employees, and to provide incentives for such individuals to exert maximum efforts toward our success and that of our affiliates. Our ESPP includes two components. One component is
designed to allow eligible U.S. employees to purchase our Class&nbsp;A common stock in a manner that may qualify for favorable tax treatment under Section&nbsp;423 of the Code. The other component permits the grant of purchase rights that do not
qualify for such favorable tax treatment in order to allow deviations necessary to permit participation by eligible employees who are foreign nationals or employed outside of the U.S. while complying with applicable foreign laws. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Share reserve</I>.&nbsp;&nbsp;&nbsp;&nbsp;The ESPP authorizes the issuance of 220,251 shares of our Class&nbsp;A common stock under purchase rights granted to our
employees or to employees of any of our designated affiliates. The number of shares of our Class&nbsp;A common stock reserved for issuance will automatically increase on January 1<SUP STYLE="font-size:85%; vertical-align:top">st</SUP> of each year
for a period of 10 years, beginning on January&nbsp;1, 2022 and continuing through January&nbsp;1, 2031, by the lesser of (i) 1% of the total number of shares of our Class&nbsp;A common stock outstanding on December&nbsp;31 of the immediately
preceding year; and (ii) 440,502 shares, except before the date of any such increase, our board of directors may determine that such increase will be less than the amount set forth in clauses (i)&nbsp;and (ii). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Administration</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors administers our ESPP and may delegate its authority to administer our ESPP to our compensation
committee. Our ESPP is implemented through a series of offerings under which eligible employees are granted purchase rights to purchase shares of our Class&nbsp;A common stock on specified dates during such offerings. Under our ESPP, our board of
directors is permitted to specify offerings with durations of not more than 27 months and to specify shorter purchase periods within each offering. Each offering will have one or more purchase dates on which shares of our Class&nbsp;A common stock
will be purchased for employees participating in the offering. An offering under the ESPP may be terminated under certain circumstances. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">196 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Payroll deductions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Generally, all regular employees, including executive officers,
employed by us or by any of our designated affiliates, will be eligible to participate in our ESPP and to contribute, normally through payroll deductions, up to a maximum percentage of their earnings (as defined in our ESPP) for the purchase of our
Class&nbsp;A common stock under our ESPP. Unless otherwise determined by our board of directors, Class&nbsp;A common stock will be purchased for the accounts of employees participating in our ESPP at a price per share equal to the lesser of (i) 85%
of the fair market value of a share of our Class&nbsp;A common stock on the first day of an offering; or (ii) 85% of the fair market value of a share of our Class&nbsp;A common stock on the date of purchase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Limitations</I>.&nbsp;&nbsp;&nbsp;&nbsp;Employees may have to satisfy one or more of the following service requirements before participating in our ESPP, as
determined by our board of directors: (i)&nbsp;being customarily employed for more than 20 hours per week; (ii)&nbsp;being customarily employed for more than five months per calendar year; or (iii)&nbsp;continuous employment with us or one of our
affiliates for a period of time (not to exceed two years). No employee will be permitted to purchase shares under our ESPP at a rate in excess of $25,000 worth of our Class&nbsp;A common stock (based on the fair market value per share of our
Class&nbsp;A common stock at the beginning of an offering) for each calendar year such a purchase right is outstanding. Finally, no employee will be eligible for the grant of any purchase rights under our ESPP if immediately after such rights are
granted, such employee has voting power over 5% or more of our outstanding capital stock measured by vote or value under Section&nbsp;424(d) of the Code. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Changes
to capital structure</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our ESPP provides that in the event there occurs a change in our capital structure through such actions as a stock split, merger, consolidation, reorganization, recapitalization, reincorporation,
stock dividend, dividend in property other than cash, large nonrecurring cash dividend, liquidating dividend, combination of shares, exchange of shares, change in corporate structure, or similar transaction, our board of directors will make
appropriate adjustments to: (i)&nbsp;the class(es) and maximum number of shares reserved under our ESPP; (ii)&nbsp;the class(es) and maximum number of shares by which the share reserve may increase automatically each year; (iii)&nbsp;the class(es)
and number of shares subject to, and purchase price applicable to, outstanding offerings and purchase rights; and (iv)&nbsp;the class(es) and number of shares that are subject to purchase limits under ongoing offerings. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Corporate transactions</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our ESPP provides that in the event of a corporate transaction (as defined below), any then-outstanding rights to
purchase our stock under our ESPP may be assumed, continued, or substituted for by any surviving or acquiring entity (or its parent company). If the surviving or acquiring entity (or its parent company) elects not to assume, continue, or substitute
for such purchase rights, then the participants&#146; accumulated payroll contributions will be used to purchase shares of our Class&nbsp;A common stock within 10 business days before such corporate transaction, and such purchase rights will
terminate immediately after such purchase. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under our ESPP, a &#147;corporate transaction&#148; is generally the consummation of (i)&nbsp;a sale or other disposition
of all or substantially all of our assets; (ii)&nbsp;a sale or other disposition of at least 50% of our outstanding securities; (iii)&nbsp;a merger, consolidation or similar transaction following which we are not the surviving corporation; or
(iv)&nbsp;a merger, consolidation or similar transaction following which we are the surviving corporation but the shares of our Class&nbsp;A common stock outstanding immediately prior to such transaction are converted or exchanged into other
property by virtue of the transaction. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Amendment or termination</I>.&nbsp;&nbsp;&nbsp;&nbsp;Our board of directors has the authority to amend or terminate our
ESPP, except in certain circumstances such amendment or termination may not materially impair any outstanding purchase rights without the holder&#146;s consent. We will obtain stockholder approval of any amendment to our ESPP as required by
applicable law or listing requirements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">197 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>401(k) Plan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We
maintain a 401(k) plan that provides eligible U.S. employees with an opportunity to save for retirement on a tax advantaged basis. Eligible employees are able to defer eligible compensation up to certain Code limits, which are updated annually. We
have the ability to make matching and discretionary contributions to the 401(k) plan. Currently, we do not make matching contributions or discretionary contributions to the 401(k) plan. The 401(k) plan is intended to be qualified under
Section&nbsp;401(a) of the Code, with the related trust intended to be tax exempt under Section&nbsp;501(a) of the Code. As a <FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plan, contributions to the 401(k) plan are deductible by
us when made, and contributions and earnings on those amounts are not generally taxable to the employees until withdrawn or distributed from the 401(k) plan. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated
certificate of incorporation contains provisions that limit the liability of our current and former directors for monetary damages to the fullest extent permitted by Delaware law. Delaware law provides that directors of a corporation will not be
personally liable for monetary damages for any breach of fiduciary duties as directors, except liability for: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any breach of the director&#146;s duty of loyalty to the corporation or its stockholders; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any act or omission not in good faith or that involves intentional misconduct or a knowing violation of law;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">unlawful payments of dividends or unlawful stock repurchases or redemptions; or </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any transaction from which the director derived an improper personal benefit. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as
injunctive relief or rescission. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation authorizes us to indemnify our directors, officers, employees and other
agents to the fullest extent permitted by Delaware law. Our amended and restated bylaws provide that we are required to indemnify our directors and officers to the fullest extent permitted by Delaware law and may indemnify our other employees and
agents. Our amended and restated bylaws also provide that, on satisfaction of certain conditions, we will advance expenses incurred by a director or officer in advance of the final disposition of any action or proceeding, and permit us to secure
insurance on behalf of any officer, director, employee, or other agent for any liability arising out of his or her actions in that capacity regardless of whether we would otherwise be permitted to indemnify him or her under the provisions of
Delaware law. We have entered and expect to continue to enter into agreements to indemnify our directors, executive officers and other employees as determined by the board of directors. With certain exceptions, these agreements provide for
indemnification for related expenses including attorneys&#146; fees, judgments, fines and settlement amounts incurred by any of these individuals in any action or proceeding. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We believe that these amended and restated certificate of incorporation and amended and restated bylaw provisions and indemnification agreements are necessary to attract
and retain qualified persons as directors and officers. We also maintain customary directors&#146; and officers&#146; liability insurance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The limitation of
liability and indemnification provisions in our amended and restated certificate of incorporation and amended and restated bylaws may discourage stockholders from bringing a lawsuit against our directors for breach of their fiduciary duty. They may
also reduce the likelihood of derivative litigation against our directors and officers, even though an action, if successful, might benefit us and other stockholders. Further, a stockholder&#146;s investment may be adversely affected to the extent
that we pay the costs of settlement and damage awards against directors and officers as required by these indemnification provisions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">198 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Insofar as indemnification for liabilities arising under the Securities Act may be permitted for directors, executive
officers, or persons controlling us, we have been informed that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors,
officers and key consultant may adopt written plans, known as Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plans, in which they will contract with a broker to buy or sell shares of our Class&nbsp;A common stock on a periodic basis. Under a
Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT> plan, a broker executes trades under parameters established by the director or officer when entering into the plan, without further direction from them. The director or officer may amend a Rule <FONT
STYLE="white-space:nowrap">10b5-1</FONT> plan in some circumstances and may terminate a plan at any time. Our directors and executive officers may also buy or sell additional shares outside of a Rule <FONT STYLE="white-space:nowrap">10b5-1</FONT>
plan when they do not possess of material nonpublic information, subject to compliance with the terms of our insider trading policy. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">199 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_15"></A>Certain relationships and related person transactions </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than compensation arrangements for our directors and executive officers, which are described elsewhere in this prospectus, below we describe transactions since
January&nbsp;1, 2019 and each currently proposed transaction in which: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the amounts involved exceeded or will exceed $120,000; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">any of our directors, executive officers or holders of more than 5% of our outstanding capital stock, or any immediate
family member of, or person sharing the household with, any of these individuals or entities, had or will have a direct or indirect material interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Participation in our initial public offering </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of our 5% stockholders
and their affiliates purchased an aggregate of 3,883,078 shares of our Class&nbsp;A common stock in our IPO at the public offering price and on the same terms as the other purchasers in such offering and not pursuant to any <FONT
STYLE="white-space:nowrap">pre-existing</FONT> contractual rights or obligations. The following table sets forth the number of shares of our Class&nbsp;A common stock purchased by our then 5% stockholders and their affiliates, and the aggregate
purchase price paid for such shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="73%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>class&nbsp;A&nbsp;common<BR>stock</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchased</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Aggregate&nbsp;cash</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Longitude Venture Partners IV, L.P.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">909,090</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,999,990</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Fidelity Management&nbsp;&amp; Research Company LLC(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">884,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,728,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Abingworth Bioventures 8 LP(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">772,727</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,499,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sofinnova Venture Partners X LP(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">727,272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,999,992</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Surveyor Capital Management(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">589,595</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,485,545</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">42,713,858</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Patrick Enright is a managing member of Longitude Capital Partners IV, LLC, the general partner of Longitude Venture Partners IV, L.P. and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Entities affiliated with Fidelity Management&nbsp;&amp; Research Company LLC collectively beneficially own more than 5% of our outstanding capital stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Kurt von Emster, C.F.A., is a managing partner at Abingworth Bioventures 8 LP and a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Maha Katabi, Ph.D., is a general partner at Sofinnova Venture Partners X, L.P. and a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Surveyor Capital Management is an affiliate of Citadel Multi-Strategy Equities Master Fund Ltd., the beneficial owner of more than 5% of our outstanding capital stock. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2020 convertible promissory note financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">From March 2020 to May 2020, we
issued and sold convertible promissory notes (2020 Notes) in the aggregate principal amount of approximately $5.6&nbsp;million. The 2020 Notes accrued interest at a rate of 4% per annum. The aggregate principal amount and interest on the
then-outstanding 2020 Notes converted into shares of our Series C convertible preferred stock (Series C preferred stock) in October 2020 in connection with our Series C convertible preferred stock financing (Series C preferred stock financing). Upon
the closing of our IPO in May 2021, all shares of our Series C preferred stock converted into 15,774,013 shares of our Class&nbsp;A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">200 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth the principal amount and accrued interest of 2020 Notes purchased by holders of more
than 5% of our capital stock and entities affiliated with our executive officers and members of our board of directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="85%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participants(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Principal<BR>amount and<BR>interest of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>2020 notes</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">KPCB Holdings, Inc.(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,073,314.91</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">GV 2019, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,048,876.44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">10-26-2010(4)</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">101,928.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James W. Fordyce, as Trustee of the James W. Fordyce 2005 Revocable Trust(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,081.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Walton, Mitchell&nbsp;&amp; Co., Inc.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">102,060.21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD
6/29/35 for James M. Walton(7)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,182.74</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are included in this prospectus under the caption &#147;Principal stockholders.&#148; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beth Seidenberg, M.D., a member of our board of directors, is affiliated with KPCB Holdings, Inc. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Krishna Yeshwant, M.D., a member of our board of directors until October 2020, is a managing partner of GV 2019, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Cheng is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fordyce is an immediate family member of Dr.&nbsp;Fordyce, our President, Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with Walton, Mitchell&nbsp;&amp; Co., Inc. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Series C preferred stock financing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, we (1)&nbsp;issued and
sold an aggregate of 168,756,599 shares of our Series C preferred stock at a purchase price of $0.5918 per share, and (2)&nbsp;issued an aggregate of 11,404,246 shares of our Series C preferred stock upon conversion of the aggregate principal amount
and interest on the then-outstanding 2020 Notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">201 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the shares of our Series C preferred stock held by holders of more than 5% of our
capital stock and entities affiliated with our executive officers and members of our board of directors. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="58%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Participants(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of<BR>series C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>preferred<BR>stock</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchased<BR>for cash
(#)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Aggregate cash</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>purchase price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Shares of<BR>series C</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>preferred<BR>stock</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>issued&nbsp;upon</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>conversion&nbsp;of</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>2020 notes<BR>(#)</B></P></TD>

<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Abingworth Bioventures 8 LP(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Fidelity(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Longitude Venture Partners IV, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sofinnova Venture Partners X, L.P.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25,346,400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,999,999.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ares Trading S.A.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,171,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0</TD>
<TD NOWRAP VALIGN="bottom"><SUP STYLE="font-size:85%; vertical-align:top">(14)</SUP>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Citadel Multi-Strategy Equities Master Fund Ltd.(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,897,600</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,999,999.68</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">GV 2019, L.P.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,379,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,073,313</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">KPCB Holdings, Inc., as nominee(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,379,520</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,999,999.94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,109,970</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andrew K. Cheng, as Trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">10-26-2010(10)</FONT></FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,641</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">James W. Fordyce, as Trustee of the James W. Fordyce 2005 Revocable Trust(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">253,464</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">150,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,946</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Walton, Mitchell&nbsp;&amp; Co., Inc.(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">84,488</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">50,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">202,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD
6/29/35 for James M. Walton(13)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">20,244</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Additional details regarding these stockholders and their equity holdings are included in this prospectus under the caption &#147;Principal stockholders.&#148; </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Abingworth Bioventures 8 LP beneficially owns more than 5% of our outstanding capital stock. Kurt von Emster, C.F.A., is a managing partner at Abingworth Bioventures 8 LP and a member of our board of directors.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 631,285 shares of Series C preferred stock purchased by Fidelity Mt. Vernon Street Trust: Fidelity Series Growth Company Fund, (ii) 3,591,850 shares of Series C preferred stock purchased by Fidelity Mt.
Vernon Street Trust: Fidelity Growth Company Fund, (iii) 3,612,515 shares of Series C preferred stock purchased by Fidelity Growth Company Commingled Pool, (iv) 613,150 shares of Series C preferred stock purchased by Fidelity Mt. Vernon Street
Trust: Fidelity Growth Company K6 Fund, (v) 8,448,800 shares of Series C preferred stock purchased by Fidelity Select Portfolios: Biotechnology Portfolio, and (vi) 8,448,800 shares of Series C preferred stock purchased by Fidelity Advisor Series
VII: Fidelity Advisor Biotechnology Fund. These entities beneficially own more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Longitude Venture Partners IV, L.P. beneficially owns more than 5% of our outstanding capital stock. Patrick Enright is a managing member of Longitude Capital Partners IV, LLC, the general partner of Longitude Venture
Partners IV, L.P. and a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Sofinnova Venture Partners X, L.P. beneficially owns more than 5% of our outstanding capital stock. Maha Katabi, Ph.D., is a general partner at Sofinnova Venture Partners X, L.P. and a member of our board of directors.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Ares Trading S.A. beneficially owns more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Citadel Multi-Strategy Equities Master Fund Ltd. beneficially owns more than 5% of our outstanding capital stock. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Krishna Yeshwant, M.D., a member of our board of directors until October 2020, is a managing partner of GV 2019, L.P. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Beth Seidenberg, M.D., a member of our board of directors, is affiliated with KPCB Holdings, Inc. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Dr.&nbsp;Cheng is a member of our board of directors. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Fordyce is an immediate family member of Dr.&nbsp;Fordyce, our President, Chief Executive Officer and a member of our board of directors. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with Walton, Mitchell&nbsp;&amp; Co., Inc. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Walton, a member of our board of directors until October 2020, is affiliated with BNY Mellon N.A., as Trustee of the Trust U/D/T William L. Mellon DTD 6/29/35 for James M. Walton. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(14)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">The shares of Series C preferred stock issued to Ares Trading S.A. were partial consideration for the license agreement entered into simultaneously with the sale and issuance of the Series C convertible preferred stock
</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">202 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Employment agreements and stock option grants to directors and executive officers </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have entered into employment agreements with certain of our named executive officers, and granted stock options to our named executive officers and certain of our
directors, as more fully described in the sections titled &#147;Executive compensation&#148; and <FONT STYLE="white-space:nowrap">&#147;Management&#151;Non-employee</FONT> director compensation.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>License agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On October&nbsp;29, 2020, we entered into the Ares
Agreement, an exclusive worldwide license agreement with Ares, an affiliate of Merck KGaA, Darmstadt, Germany. Under the Ares Agreement, Ares granted us an exclusive license to certain patents and certain related
<FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize throughout the world therapeutic products containing atacicept or any other compound that is covered by a claim of such patents. In
consideration for the rights granted under the Ares Agreement, we issued to Ares an aggregate of 22,171,553 shares of Series C redeemable convertible preferred stock, we paid Ares $25&nbsp;million upon delivery and initiation of the transfer of
specified information and materials and we are obligated to pay Ares certain clinical, regulatory and commercial milestone payments, sublicensing revenue payments and royalty payments on future sales of licensed products. Upon the closing of our IPO
in May 2021, all shares of our Series C preferred stock converted into 15,774,013 shares of our Class&nbsp;A common stock. For more information regarding the license agreement see &#147;Business&#151;Exclusive license agreement with Ares Trading
S.A.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Consulting services agreement with Dr.&nbsp;Kotzin </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In
February 2021, we entered into a consulting services agreement with BLKotzin, Inc., an entity affiliated with our former director, Brian Kotzin, M.D., pursuant to which Dr.&nbsp;Kotzin provides certain consulting services to us. We pay
Dr.&nbsp;Kotzin for his services at a rate of $400 per hour up to a maximum of $40,000 per year. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Consulting services agreement with Dr.&nbsp;Ebens </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2021, we entered into a consulting services agreement with Allen Ebens, Ph.D., our former Chief Scientific Officer, pursuant to which Dr.&nbsp;Ebens provides
certain consulting services to us. We pay Dr.&nbsp;Ebens for his services at a rate of $350 per hour up to a maximum of $300,000 per year. In addition, pursuant to the agreement, we granted Dr.&nbsp;Ebens an option covering 38,405 shares of our
Class&nbsp;A common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Investors&#146; rights agreement </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October
2020, we entered into a Second Amended and Restated Investors&#146; Rights Agreement (Rights Agreement) with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares Trading S.A., entities
affiliated with Fidelity, Citadel Multi-Strategy Equities Master Fund Ltd., GV 2019, L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of our directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Rights Agreement granted to the holders of our outstanding redeemable convertible preferred stock certain rights, including certain registration rights with respect
to the registrable securities held by them. See the section titled &#147;Description of capital stock&#151;Registration rights&#148; for additional information. In addition, the Rights Agreement imposed certain affirmative obligations on us,
including our obligation to, among other things, (i)&nbsp;grant each holder who holds shares of our redeemable convertible preferred stock with an aggregate original issue price of at least $4.6&nbsp;million (Major Investors), a right of first offer
with respect to future sales of our equity, excluding the shares to be offered and sold in this offering, and grant certain information and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">203 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
inspection rights to such Major Investors. Each of these obligations terminated in connection with the closing of our IPO in May 2021, except for the registration rights, as more fully described
below in &#147;Description of capital stock&#151;Registration rights&#148;. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Voting agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, we entered into the Voting Agreement with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares
Trading S.A., entities affiliated with Fidelity, Citadel Multi-Strategy Equities Master Fund Ltd., GV 2019, L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of
our directors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the Voting Agreement, each of Abingworth Bioventures 8 LP, Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P.
formerly had the right to designate one member to be elected to our board of directors. See the section titled &#147;Management&#151;Composition of our board of directors.&#148; The Voting Agreement terminated by its terms in connection with the
closing of our IPO in May 2021 and none of our stockholders have any continuing rights regarding the election or designation of members of our board of directors. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Right of first refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> agreement </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, we entered into a Second Amended and Restated Right of First Refusal and <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement <FONT
STYLE="white-space:nowrap">(Co-Sale</FONT> Agreement) with certain holders of more than 5% of our outstanding capital stock, including Abingworth Bioventures 8 LP, Ares Trading S.A., entities affiliated with Fidelity, Citadel Multi-Strategy Equities
Master Fund Ltd., GV 2019, L.P., KPCB Holdings, Inc., Longitude Venture Partners IV, L.P. and Sofinnova Venture Partners X, L.P., and including certain affiliates of our directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Pursuant to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement, we formerly had a right of first refusal in respect of certain sales of securities by certain
holders of our common stock and redeemable convertible preferred stock. To the extent we do not exercise such right in full, the investors party to the <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement were granted certain rights of first
refusal and <FONT STYLE="white-space:nowrap">co-sale</FONT> in respect of such sale. The <FONT STYLE="white-space:nowrap">Co-Sale</FONT> Agreement terminated in connection with the closing of our IPO in May 2021. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Policies and procedures for transactions with related persons </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We maintain a
written policy that our executive officers, directors, nominees for election as a director, beneficial owners of more than 5% of any class of our common stock and any members of the immediate family of any of the foregoing persons are not permitted
to enter into a related person transaction with us without the approval or ratification of our board of directors or our audit committee. Any request for us to enter into a transaction with an executive officer, director, nominee for election as a
director, beneficial owner of more than 5% of any class of our common stock, or any member of the immediate family of any of the foregoing persons, in which the amount involved exceeds $120,000 (or, if less, 1% of the average of our total assets in
a fiscal year) and such person would have a direct or indirect interest, must be presented to our board of directors or our audit committee for review, consideration and approval. In approving or rejecting any such proposal, our board of directors
or our audit committee is to consider the material facts of the transaction, including whether the transaction is on terms no less favorable than terms generally available to an unaffiliated third party under the same or similar circumstances and
the extent of the related person&#146;s interest in the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">204 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_16"></A>Principal stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table sets forth information regarding beneficial ownership of our capital stock as of December&nbsp;15, 2021 by: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each person, or group of affiliated persons, known by us to beneficially own more than 5% of our Class&nbsp;A common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each of our directors; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">each our of named executive officers; and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">all of our current executive officers and directors as a group. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have determined beneficial ownership in accordance with the rules and regulations of the SEC, and the information is not necessarily indicative of beneficial
ownership for any other purpose. Except as indicated by the footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to all
shares that they beneficially own, subject to applicable community property laws. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Applicable percentage ownership before the offering is based on 20,968,376 shares
of our Class&nbsp;A common stock outstanding and 309,238 shares of our Class&nbsp;B common stock outstanding as of December&nbsp;15, 2021. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Applicable percentage
ownership after the offering is based on 25,961,443 shares of Class&nbsp;A common stock and 309,238 shares of Class&nbsp;B common stock assumed to be outstanding immediately after the closing of this offering, and assuming no exercise by the
underwriters of their option to purchase additional shares and no purchase of any shares of Class&nbsp;A common stock in this offering by the beneficial owners identified in the table below. In computing the number of shares beneficially owned by a
person and the percentage ownership of such person, we deemed to be outstanding all shares subject to options held by the person that are currently exercisable, or exercisable within 60 days of December&nbsp;15, 2021. However, except as described
above, we did not deem such shares outstanding for the purpose of computing the percentage ownership of any other person. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">205 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Unless otherwise indicated, the address for each beneficial owner listed in the table below is c/o Vera Therapeutics,
Inc., 8000 Marina Boulevard, Suite 120, Brisbane, California 94005. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Number of</B><br><B>shares</B><br><B>beneficially</B><br><B>owned before</B><br><B>the offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of</B><br><B>shares</B><br><B>beneficially</B><br><B>owned before</B><br><B>the offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Percentage of</B><br><B>shares</B><br><B>beneficially</B><br><B>owned after</B><br><B>the offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name of beneficial owner</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;A</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Class&nbsp;B</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>common</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>stock</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>5% Stockholders:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Abingworth Bioventures 8 LP(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Entities affiliated with Fidelity(2)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,071,896</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Longitude Venture Partners IV, L.P.(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sofinnova Venture Partners X, L.P.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Ares Trading S.A.(5)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,913,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Citadel Multi-Strategy Equities Master Fund Ltd.(6)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,740,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">KPCB Holdings, Inc., as nominee(7)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,343,152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Directors and Named Executive Officers:</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Marshall Fordyce, M.D.(8)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">440,103</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Sean Grant</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Celia Lin, M.D.<SUP STYLE="font-size:85%; vertical-align:top"> </SUP></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kurt von Emster, C.F.A.(1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,960,231</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.4%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Andrew Cheng, M.D., Ph.D.(9)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,063</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Beth Seidenberg, M.D.(7)(10)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,368,084</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Maha Katabi, Ph.D.(4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,914,776</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.2%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Patrick Enright(3)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,096,594</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14.8%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11.9%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Scott Morrison(11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,932</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Kimball Hall(12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,102</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">*</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">All directors and executive officers as a group (11
persons)(13)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,905,905</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">51.0%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">41.3%</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Represents beneficial ownership of less than 1%. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,960,231 shares of Class&nbsp;A common stock held by Abingworth Bioventures 8, LP (ABV 8) and excludes options to purchase up to 9,925 shares of Class&nbsp;A common stock issued to Mr.&nbsp;von Emster which
vest on the earlier of May&nbsp;13, 2022 or the Company&#146;s 2022 annual meeting of stockholders. Abingworth Bioventures 8 GP LP (Abingworth GP) serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner
of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8.
Mr.&nbsp;Von Emster is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. Each
of ABV 8, Abingworth LLP, Abingworth GP, Abingworth General Partner 8 LLP, and each member of the investment committee disclaims beneficial ownership of the shares held by ABV 8. The address for ABV 8 is c/o Abingworth LLP, 38 Jermyn Street, London,
SW1Y 6DN, UK. The foregoing information was obtained from a Schedule 13D filed on May&nbsp;18, 2021. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(2)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">Consists of 3,071,896 shares of Class&nbsp;A common stock beneficially owned, or that may be deemed to be beneficially
owned, by FMR LLC, certain of its subsidiaries and affiliates, and other companies. Abigail P. Johnson is a Director, the Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the Johnson family, including Abigail P.
Johnson, are the predominant owners, directly or through trusts, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a
shareholders&#146; voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of
the shareholders&#146; voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. Neither FMR LLC nor Abigail P. Johnson has the sole power to vote or
direct the voting of the shares owned directly by the various investment companies registered under the Investment Company Act (Fidelity Funds) advised by Fidelity Management&nbsp;&amp; Research Company (FMR Co), a wholly owned subsidiary of FMR
LLC, which power resides with the Fidelity Funds&#146; Boards of Trustees. Fidelity Management&nbsp;&amp; Research Company carries out the voting of the shares under written guidelines established by the Fidelity
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">206 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="3%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:7.5pt">
Funds&#146; Boards of Trustees. The address of FMR LLC is 245 Summer Street, V13H, Boston, Massachusetts 02110. The foregoing information was obtained from a Schedule 13G filed on June&nbsp;10,
2021. </P></TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(3)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 3,096,594 shares of Class&nbsp;A common stock held by Longitude Venture Partners IV, L.P. (LVP IV). Longitude Capital Partners IV, LLC (LCP IV), is the general partner of LVP IV and may be deemed to have
voting and investment power over the shares held by LVP IV. Patrick Enright and Juliet Tammenoms Bakker are managing members of LCP IV and may be deemed to share voting and investment power over the shares held by LVP IV. Each of LCP IV,
Ms.&nbsp;Bakker and Mr.&nbsp;Enright disclaims beneficial ownership of such shares except to the extent of their respective pecuniary interests therein. The address for this entity is 2740 Sand Hill Road, 2<SUP
STYLE="font-size:85%; vertical-align:top">nd</SUP> Floor, Menlo Park, CA 94025. The foregoing information was obtained from a Schedule 13D filed on May&nbsp;27, 2021. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(4)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 2,914,776 shares of Class&nbsp;A common stock held by Sofinnova Venture Partners X, L.P. (SVP X). Sofinnova Management X, L.L.C. (SM X), is the general partner of SVP X. As such, each of James Healy, Maha
Katabi and Michael Powell, the managing members of SM X, may be deemed to have shared voting and dispositive power over the shares owned by SVP X. The address for this entity is c/o Sofinnova Investments, 3000 Sand Hill Road, Building <FONT
STYLE="white-space:nowrap">4-Suite</FONT> 250, Menlo Park, CA 94025. The foregoing information was obtained from a Schedule 13D filed on May&nbsp;24, 2021. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(5)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,913,501 shares of Class&nbsp;A common stock held by Ares Trading S.A. The address for this entity is c/o Merck KGaA, Frankfurter Stra&szlig;e 250, 64293 Darmstadt, Germany, Attn: Alliance Management.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(6)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,715,149 shares of Class&nbsp;A common stock and 309,238 shares of Class&nbsp;B common stock held by Citadel Multi-Strategy Equities Master Fund Ltd. (Citadel). The Class&nbsp;B common stock is convertible
into Class&nbsp;A common stock in Citadel&#146;s discretion but subject to the limitations described below under &#147;Description of capital stock.&#148; Citadel Advisors LLC (Citadel Advisors) is the portfolio manager of Citadel. Citadel Advisors
Holdings LP (CAH) is the sole member of Citadel Advisors. Citadel GP LLC (CGP) is the general partner of CAH. Kenneth Griffin owns a controlling interest in CGP. Mr.&nbsp;Griffin, as the owner of a controlling interest in CGP, may be deemed to have
shared power to vote or direct the vote of, and/or shared power to dispose or to direct the disposition over, the shares held by Citadel. The foregoing should not be construed as an admission that Mr.&nbsp;Griffin or any of the Citadel related
entities is the beneficial owner of any of our securities other than the securities actually owned by such person (if any). The address for this entity is 131 S Dearborn St, 32nd Floor, Chicago, IL 60603. The foregoing information was obtained from
a Schedule 13G filed on May&nbsp;28, 2021. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(7)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,298,695 shares of Class&nbsp;A common stock held by Kleiner Perkins Caufield&nbsp;&amp; Byers XVI, LLC (KPCB XVI) and 44,457 shares of Class&nbsp;A common stock held by KPCB XVI Founders Fund, LLC (XVI
Founders). All shares are held for convenience in the name of &#147;KPCB Holdings, Inc., as nominee&#148;. The managing member of KPCB XVI is KPCB XVI Associates, LLC (KPCB XVI Associates). L. John Doerr, Beth Seidenberg, Randy Komisar, Theodore E.
Schlein and Wen Hsieh, the managing members of KPCB XVI Associates, exercise shared voting and dispositive control over the shares held by KPCB XVI. Such managing members disclaim beneficial ownership of all shares held by KPCB XVI except to the
extent of their pecuniary interest therein. The address for KPCB Holdings Inc. is c/o Kleiner Perkins Caufield&nbsp;&amp; Byers, LLC, 2750 Sand Hill Road, Menlo Park, CA 94025. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(8)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 133,793 shares of Class&nbsp;A common stock held directly by Dr.&nbsp;Fordyce and (ii) 306,310 shares of Class&nbsp;A common stock subject to options exercisable within 60 days of December&nbsp;15, 2021
held by Dr.&nbsp;Fordyce. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(9)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 17,488 shares of Class&nbsp;A common stock held by Dr.&nbsp;Cheng, as trustee of the Andrew Cheng 2010 Trust UA <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">10-26-2010</FONT></FONT>
and (ii) 28,575 shares of Class&nbsp;A common stock subject to options exercisable within 60 days of December&nbsp;15, 2021 held by Dr.&nbsp;Cheng. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(10)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 24,932 shares of Class&nbsp;A common stock subject to options exercisable within 60 days of December&nbsp;15, 2021 held by Dr.&nbsp;Seidenberg. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(11)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 24,932 shares of Class&nbsp;A common stock subject to options exercisable within 60 days of December&nbsp;15, 2021 held by Mr.&nbsp;Morrison. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(12)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of 1,102 shares of Class&nbsp;A common stock subject to options exercisable within 60 days of December&nbsp;15, 2021 held by Ms.&nbsp;Hall. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(13)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Consists of (i) 10,489,767 shares of Class&nbsp;A common stock beneficially owned by our current executive officers and directors, and (ii) 416,138 shares of Class&nbsp;A common stock subject to options exercisable
within 60 days of December&nbsp;15, 2021. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">207 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_17"></A>Description of capital stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>General </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following description of our capital stock and certain provisions
of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to the amended and restated certificate of incorporation and the amended and restated bylaws. Copies of these
documents have been filed with the SEC as exhibits to our registration statement, of which this prospectus forms a part. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our authorized capital stock consists of
500,000,000 shares of Class&nbsp;A common stock, par value $0.001 per share, 14,600,000 shares of Class&nbsp;B common stock, par value $0.001 per share, and 10,000,000 shares of preferred stock, par value $0.001 per share. All of our authorized
shares of preferred stock are undesignated. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting
rights and conversion rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of our Class&nbsp;A common stock are entitled to one vote per share of Class&nbsp;A common stock on any matter that
is submitted to a vote of our stockholders and holders of our Class&nbsp;B common stock are not entitled to any votes per share of Class&nbsp;B common stock, including for the election of directors. Additionally, holders of our Class&nbsp;A common
stock have no conversion rights, while holders of our Class&nbsp;B common stock shall have the right to convert each share of our Class&nbsp;B common stock into one share of Class&nbsp;A common stock at such holder&#146;s election, provided that as
a result of such conversion, such holder would not beneficially own in excess of 9.9% of any class of our securities registered under the Exchange Act, unless otherwise as expressly provided for in our amended and restated certificate of
incorporation. However, this ownership limitation may be increased to any other percentage designated by such holder of Class&nbsp;B common stock upon 61 days&#146; notice to us or decreased at any time. Holders of our Class&nbsp;B common stock are
also permitted to make certain transfers of Class&nbsp;B common stock to <FONT STYLE="white-space:nowrap">non-affiliates</FONT> upon which, such transferred shares could be immediately converted into shares of our Class&nbsp;A common stock. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation does not provide for cumulative voting for the election of directors for our Class&nbsp;A common stock. Our amended
and restated certificate of incorporation establishes a classified board of directors that is divided into three classes with staggered three-year terms. Only the directors in one class will be subject to election by a plurality of the votes cast at
each annual meeting of our stockholders holding shares of Class&nbsp;A common stock, with the directors in the other classes continuing for the remainder of their respective three-year terms. The affirmative vote of holders of at least 66<SUP
STYLE="font-size:85%; vertical-align:top">2</SUP>/<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>% of the voting power of all of the then-outstanding shares of capital stock, voting as a single class, will be required to amend certain
provisions of our amended and restated certificate of incorporation, including provisions relating to amending our amended and restated bylaws, the classified structure of our board of directors, the size of our board of directors, removal of
directors, director liability, vacancies on our board of directors, special meetings, stockholder notices, actions by written consent and exclusive jurisdiction. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Economic rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Except as otherwise expressly provided in our amended
and restated certificate of incorporation or required by applicable law, and other than the voting rights and conversion rights stated above, all shares of Class&nbsp;A common stock and Class&nbsp;B common stock will have the same rights and
privileges and rank equally, share ratably, and be identical in all respects for all matters, including those described below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Dividends</I>.&nbsp;&nbsp;&nbsp;&nbsp;Subject to preferences that may apply to any shares of preferred stock outstanding at the time, the holders of our Class&nbsp;A
common stock and Class&nbsp;B common stock are entitled to receive dividends out of funds </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">208 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
legally available if our board of directors, in its discretion, determines to issue dividends and then only at the times and in the amounts that our board of directors may determine. See the
section titled &#147;Dividend policy&#148; for further information. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><I>Liquidation Rights</I>.&nbsp;&nbsp;&nbsp;&nbsp;On our liquidation, dissolution, or <FONT
STYLE="white-space:nowrap">winding-up,</FONT> the holders of Class&nbsp;A common stock and Class&nbsp;B common stock will be entitled to share equally, identically, and ratably in all assets remaining after the payment of any liabilities,
liquidation preferences and accrued or declared but unpaid dividends, if any, with respect to any outstanding preferred stock, unless a different treatment is approved by the affirmative vote of the holders of a majority of the outstanding shares of
such affected class, voting separately as a class. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>No preemptive or similar rights </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of our shares of Class&nbsp;A common stock and Class&nbsp;B common stock are not entitled to preemptive rights, and are not subject to redemption or sinking
fund provisions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, our legal counsel will opine that the shares of our Class&nbsp;A common stock to be issued under this offering will be fully paid and <FONT
STYLE="white-space:nowrap">non-assessable.</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Preferred stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Under
our amended and restated certificate of incorporation, our board of directors has the authority, without further action by the stockholders, to issue up to 10,000,000 shares of preferred stock in one or more series, to establish from time to time
the number of shares to be included in each such series, to fix the rights, preferences and privileges of the shares of each wholly unissued series and any qualifications, limitations or restrictions thereon and to increase or decrease the number of
shares of any such series, but not below the number of shares of such series then outstanding. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our board of directors may authorize the issuance of preferred stock
with voting or conversion rights that could adversely affect the voting power or other rights of the holders of the Class&nbsp;A common stock. The issuance of preferred stock, while providing flexibility in connection with possible acquisitions and
other corporate purposes, could, among other things, have the effect of delaying, deferring or preventing a change in our control that may otherwise benefit holders of our Class&nbsp;A common stock and may adversely affect the market price of the
Class&nbsp;A common stock and the voting and other rights of the holders of Class&nbsp;A common stock. We have no current plans to issue any shares of preferred stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Registration rights </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain holders of shares of our Class&nbsp;A common
stock and Class&nbsp;B common stock are entitled to certain rights with respect to registration of such shares under the Securities Act. These shares are referred to as registrable securities. The holders of these registrable securities possess
registration rights pursuant to the terms of our amended and restated investors&#146; rights agreement and are described in additional detail below. The registration of shares of our Class&nbsp;A common stock and Class&nbsp;B common stock pursuant
to the exercise of the registration rights described below would enable the holders to trade these shares without restriction under the Securities Act when the applicable registration statement is declared effective. We will pay the registration
expenses, other than underwriting discounts, selling commissions and stock transfer taxes, of the shares registered pursuant to the demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registrations described below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">209 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Generally, in an underwritten offering, the managing underwriter, if any, has the right, subject to specified
conditions and limitations, to limit the number of shares the holders may include. The demand, piggyback and Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights described below will expire no later than three years after the closing
of our IPO. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Demand registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain holders of our
Class&nbsp;A common stock and Class&nbsp;B common stock are entitled to certain demand registration rights. The holders of (i) 40% of these shares issued upon conversion of our Series C redeemable convertible preferred stock, or (ii)&nbsp;a majority
of these shares, may request that we register all or a portion of their shares. We are not required to effect more than two registration statements which are declared or ordered effective. With respect to (ii), such request for registration must
cover a majority of such shares then outstanding with an anticipated aggregate offering price that would exceed $10&nbsp;million. With certain exceptions, we are not required to effect the filing of a registration statement during the period
starting with the date that is 60 days before the date of the filing of, and ending on a date 180 days following the effective date of the registration statement for this offering. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Piggyback registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering,
certain holders of our Class&nbsp;A common stock and Class&nbsp;B common stock are entitled to, and the necessary percentage of holders waived, their rights to notice of this offering and to include their shares of registrable securities in this
offering. In addition, in the event that we propose to register any of our securities under the Securities Act, either for our own account or for the account of other security holders, the holders of these shares will be entitled to certain
piggyback registration rights allowing the holder to include their shares in such registration, subject to certain marketing and other limitations. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Form <FONT
STYLE="white-space:nowrap">S-3</FONT> registration rights </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain holders of Class&nbsp;A common stock and Class&nbsp;B common stock are entitled to certain
Form <FONT STYLE="white-space:nowrap">S-3</FONT> registration rights. Holders of (i)&nbsp;shares issued upon conversion of our Series C redeemable convertible preferred stock with an aggregate original issue price of $500,000, or (ii) 20% of these
shares, can make a request that we register their shares on Form <FONT STYLE="white-space:nowrap">S-3</FONT> if we are qualified to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> and, with respect to (ii), if the
reasonably anticipated aggregate net proceeds of the shares offered would equal or exceed $3&nbsp;million. With respect to (ii), we will not be required to effect more than two registrations on Form <FONT STYLE="white-space:nowrap">S-3</FONT> within
any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Anti-takeover provisions </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws, which are summarized below, may have the
effect of delaying, deferring or discouraging another person from acquiring control of our company. They are also designed, in part, to encourage persons seeking to acquire control of us to negotiate first with our board of directors. We believe
that the benefits of increased protection of our potential ability to negotiate with an unfriendly or unsolicited acquirer outweigh the disadvantages of discouraging a proposal to acquire us because negotiation of these proposals could result in an
improvement of their terms. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Certificate of incorporation and bylaws to be in effect in connection with this offering </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Because our stockholders do not have cumulative voting rights, stockholders holding a majority of the voting power of our shares of Class&nbsp;A common stock will be
able to elect all of our directors. Our amended and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">210 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
restated certificate of incorporation and our amended and restated bylaws provide for stockholder actions at a duly called meeting of stockholders or, before the date on which all shares of
Class&nbsp;A common stock convert into a single class, by written consent. A special meeting of stockholders may be called by a majority of our board of directors, the chair of our board of directors, or our chief executive officer or president. Our
amended and restated bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to our board of directors. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As described above in &#147;Management&#151;Composition of our board of directors,&#148; in accordance with our amended and restated certificate of incorporation, our
board of directors is divided into three classes with staggered three-year terms. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The foregoing provisions will make it more difficult for another party to obtain
control of us by replacing our board of directors. Since our board of directors has the power to retain and discharge our officers, these provisions could also make it more difficult for existing stockholders or another party to effect a change in
management. In addition, the authorization of undesignated preferred stock makes it possible for our board of directors to issue preferred stock with voting or other rights or preferences that could impede the success of any attempt to change our
control. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These provisions are designed to reduce our vulnerability to an unsolicited acquisition proposal and to discourage certain tactics that may be used in
proxy fights. However, such provisions could have the effect of discouraging others from making tender offers for our shares and may have the effect of deterring hostile takeovers or delaying changes in our control or management. As a consequence,
these provisions may also inhibit fluctuations in the market price of our stock that could result from actual or rumored takeover attempts. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Section&nbsp;203
of the delaware general corporation law </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">When we have a class of voting stock that is either listed on a national securities exchange or held of record by
more than 2,000 stockholders, we will be subject to Section&nbsp;203 of the DGCL, which prohibits a Delaware corporation from engaging in any business combination with any interested stockholder for a period of three years after the date that such
stockholder became an interested stockholder, subject to certain exceptions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Choice of forum </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State
of Delaware lacks subject matter jurisdiction, any state court located within the State of Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) and any appellate
court therefrom is the sole and exclusive forum for the following claims or causes of action under the Delaware statutory or common law: (i)&nbsp;any derivative claim or cause of action brought on our behalf; (ii)&nbsp;any claim or cause of action
for a breach of fiduciary duty owed by any of our current or former directors, officers, or other employees to us or our stockholders; (iii)&nbsp;any claim or cause of action against us or any of our current or former directors, officers or other
employees arising out of or pursuant to any provision of the DGCL, our amended and restated certificate of incorporation, or our bylaws (as each may be amended from time to time); (iv) any claim or cause of action seeking to interpret, apply,
enforce or determine the validity of our amended and restated certificate of incorporation or our amended and restated bylaws (as each may be amended from time to time, including any right, obligation, or remedy thereunder); (v) any claim or cause
of action as to which the DGCL confers jurisdiction to the Court of Chancery of the State of Delaware; and (vi)&nbsp;any claim or cause of action against us or any of our current or former directors, officers, or other employees governed by the
internal-affairs doctrine, in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">211 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
all cases to the fullest extent permitted by law and subject to the court&#146;s having personal jurisdiction over the indispensable parties named as defendants. This choice of forum provision
will not apply to claims or causes of action brought to enforce a duty or liability created by the Securities Act, the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our amended and restated certificate of incorporation provides that the federal district courts of the United States of America will be the exclusive forum for resolving
any complaint asserting a cause or causes of action arising under the Securities Act, including all causes of action asserted against any defendant to such complaint. For the avoidance of doubt, this provision is intended to benefit and may be
enforced by us, our officers and directors, the underwriters to any offering giving rise to such complaint, and any other professional entity whose profession gives authority to a statement made by that person or entity and who has prepared or
certified any part of the documents underlying the offering. Additionally, our amended and restated certificate of incorporation provides that any person or entity holding, owning or otherwise acquiring any interest in any of our securities shall be
deemed to have notice of and consented to these provisions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Limitations on liability and indemnification </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">See the section titled &#147;Executive compensation&#151;Limitations on liability and indemnification.&#148; </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Exchange listing </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Class&nbsp;A common stock is listed on the Nasdaq
Global Market under the symbol &#147;VERA.&#148; </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Transfer agent and registrar </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The transfer agent and registrar for our Class&nbsp;A common stock is American Stock Transfer&nbsp;&amp; Trust Company, LLC. The transfer agent&#146;s address is 6201
15th Avenue, Brooklyn, New York 11219. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">212 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_18"></A>Certain material U.S. federal income tax consequences to
<FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following is a summary of certain material U.S. federal income tax consequences to <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holders (as defined below) of the purchase, ownership and disposition of our Class&nbsp;A common stock issued pursuant to this offering. This discussion is not a complete analysis of all potential U.S.
federal income tax consequences relating thereto, does not address the potential application of the Medicare contribution tax on net investment income, and does not address any estate or gift tax consequences or any tax consequences arising under
any state, local or foreign tax laws, or any other U.S. federal tax laws. This discussion is based on the Code, Treasury Regulations promulgated thereunder, judicial decisions, and published rulings and administrative pronouncements of the Internal
Revenue Service (IRS), all as in effect on the date of this prospectus. These authorities are subject to differing interpretations and may change, possibly retroactively, resulting in U.S. federal income tax consequences different from those
discussed below. We have not requested a ruling from the IRS with respect to the statements made and the conclusions reached in the following summary, and there can be no assurance that the IRS or a court will agree with such statements and
conclusions. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This discussion is limited to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders who purchase our Class&nbsp;A common stock pursuant to this
offering and who hold our Class&nbsp;A common stock as a &#147;capital asset&#148; within the meaning of Section&nbsp;1221 of the Code (generally, property held for investment). This discussion does not address all of the U.S. federal income tax
consequences that may be relevant to an individual <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in light of such <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s particular circumstances. This discussion also does not
consider any specific facts or circumstances that may be relevant to <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holders subject to special rules under the U.S. federal income tax laws, including: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">certain former citizens or long-term residents of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">partnerships or other pass-through entities (and investors therein); </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;controlled foreign corporations&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">&#147;passive foreign investment companies&#148;; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">corporations that accumulate earnings to avoid U.S. federal income tax; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">banks, financial institutions, investment funds, insurance companies, brokers, dealers or traders in securities;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-exempt</FONT> organizations and governmental organizations; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt"><FONT STYLE="white-space:nowrap">tax-qualified</FONT> retirement plans; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who acquire our Class&nbsp;A common stock through the exercise of an option or otherwise as compensation;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">qualified foreign pension funds as defined in Section&nbsp;897(l)(2) of the Code and entities all of the interests of which
are held by qualified foreign pension funds; </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons subject to the alternative minimum tax; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons subject to special tax accounting rules under Section&nbsp;451(b) of the Code; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons that own or have owned, actually or constructively, more than 5% of our Class&nbsp;A common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons who have elected to mark securities to market; and </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">213 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">persons holding our Class&nbsp;A common stock as part of a hedging or conversion transaction or straddle, or a constructive
sale, or other risk reduction strategy or integrated investment. </P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If an entity or arrangement that is classified as a partnership for U.S. federal
income tax purposes holds our Class&nbsp;A common stock, the U.S. federal income tax treatment of a partner in the partnership will generally depend on the status of the partner, the activities of the partnership and certain determinations made at
the partner level. Partnerships holding our Class&nbsp;A common stock and the partners in such partnerships are urged to consult their tax advisors about the particular U.S. federal income tax consequences to them of holding and disposing of our
Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>THIS DISCUSSION IS FOR INFORMATIONAL PURPOSES ONLY AND IS NOT TAX ADVICE. PROSPECTIVE INVESTORS SHOULD CONSULT THEIR TAX ADVISORS
REGARDING THE PARTICULAR U.S. FEDERAL INCOME TAX CONSEQUENCES TO THEM OF ACQUIRING, OWNING AND DISPOSING OF OUR CLASS A COMMON STOCK, AS WELL AS ANY TAX CONSEQUENCES ARISING UNDER ANY STATE, LOCAL OR FOREIGN TAX LAWS AND ANY OTHER U.S. FEDERAL TAX
LAWS. </B></P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Definition of <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For purposes of this discussion, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is any beneficial owner of our Class&nbsp;A common stock that is not a
&#147;U.S. holder&#148; or a partnership (including any entity or arrangement treated as a partnership) for U.S. federal income tax purposes. A U.S. holder is any person that, for U.S. federal income tax purposes, is or is treated as any of the
following: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an individual who is a citizen or resident of the United States; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a corporation created or organized under the laws of the United States, any state thereof or the District of Columbia;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">an estate, the income of which is subject to U.S. federal income tax regardless of its source; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a trust (1)&nbsp;whose administration is subject to the primary supervision of a U.S. court and which has one or more U.S.
persons who have the authority to control all substantial decisions of the trust or (2)&nbsp;that has a valid election in effect under applicable Treasury Regulations to be treated as a U.S. person. </P></TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Distributions on our Class A common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As described under the section
titled &#147;Dividend policy,&#148; we do not anticipate declaring or paying, in the foreseeable future, any cash distributions on our capital stock. However, if we distribute cash or other property on our Class&nbsp;A common stock, such
distributions will constitute dividends for U.S. federal income tax purposes to the extent paid from our current or accumulated earnings and profits, as determined under U.S. federal income tax principles. Amounts not treated as dividends for U.S.
federal income tax purposes will constitute a return of capital and will first be applied against and reduce a holder&#146;s tax basis in our Class&nbsp;A common stock, but not below zero. Any excess will be treated as gain realized on the sale or
other disposition of our Class&nbsp;A common stock and will be treated as described under the section titled &#147; &#151;Gain on disposition of our Class&nbsp;A common stock&#148; below. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below regarding effectively connected income, backup withholding and FATCA (as defined below), dividends paid to a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder of our Class&nbsp;A common stock generally will be subject to U.S. federal withholding tax at a rate of 30% of the gross amount of the dividends or such lower rate specified by an applicable income
tax treaty. To receive the benefit of a reduced treaty rate, a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must furnish us or our withholding agent with a valid IRS Form <FONT STYLE="white-space:nowrap">W-8BEN</FONT> (in the case of
individuals) or IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> (in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">214 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the case of entities), or other appropriate form, certifying such holder&#146;s qualification for the reduced rate. This certification must be provided to us or our withholding agent before the
payment of dividends and must be updated periodically. In the case of a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> Holder that is an entity, Treasury Regulations and the relevant tax treaty provide rules to determine whether, for purposes of
determining the applicability of the tax treaty, dividends will be treated as paid to the entity or to those holding an interest in the entity. If the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our Class&nbsp;A common stock
through a financial institution or other agent acting on the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s behalf, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be required to provide appropriate documentation to
the agent, which then will be required to provide certification to us or our withholding agent, either directly or through other intermediaries. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder holds our Class&nbsp;A common stock in connection with the conduct of a trade or business in the United States, and dividends paid on our Class&nbsp;A common stock are effectively connected with such
holder&#146;s U.S. trade or business (and are attributable to such holder&#146;s permanent establishment or fixed base in the United States if required by an applicable tax treaty), the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder will be
exempt from U.S. federal withholding tax. To claim the exemption, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder must generally furnish a valid IRS Form <FONT STYLE="white-space:nowrap">W-8ECI</FONT> (or applicable successor form) to
the applicable withholding agent. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">However, any such effectively connected dividends paid on our Class&nbsp;A common stock generally will be subject to U.S. federal
income tax on a net income basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may
be subject to an additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders that do not provide the required certification on a timely basis, but that qualify for a reduced treaty rate,
may obtain a refund of any excess amounts withheld by timely filing an appropriate claim for refund with the IRS. <FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties
that may provide for different rules. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Gain on disposition of our Class A common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Subject to the discussions below regarding backup withholding and FATCA (as defined below), a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder generally will not
be subject to U.S. federal income tax on any gain realized on the sale or other disposition of our Class&nbsp;A common stock, unless: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the gain is effectively connected with the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s conduct of a
trade or business in the United States and, if required by an applicable income tax treaty, is attributable to a permanent establishment or fixed base maintained by the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder in the United States;
</P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder is a nonresident alien individual present in the United States
for 183 days or more during the taxable year of the disposition, and certain other requirements are met; or </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">our Class&nbsp;A common stock constitutes a &#147;United States real property interest&#148; by reason of our status as a
United States real property holding corporation (USRPHC) for U.S. federal income tax purposes at any time within the shorter of the five-year period preceding the disposition or the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s
holding period for our Class&nbsp;A common stock, and our Class&nbsp;A common stock is not regularly traded on an established securities market during the calendar year in which the sale or other disposition occurs. </P></TD></TR></TABLE>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Determining whether we are a USRPHC depends on the fair market value of our U.S. real property interests relative to the fair market value of our other trade or business
assets and our foreign real property interests. We believe that we are not currently and we do not anticipate becoming a USRPHC for U.S. federal income tax purposes, although there can be no assurance we will not in the future become a USRPHC. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">215 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Gain described in the first bullet point above generally will be subject to U.S. federal income tax on a net income
basis at the regular U.S. federal income tax rates in the same manner as if such holder were a resident of the United States. A <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder that is a foreign corporation also may be subject to an
additional branch profits tax equal to 30% (or such lower rate specified by an applicable income tax treaty) of its effectively connected earnings and profits for the taxable year, as adjusted for certain items. Gain described in the second bullet
point above will be subject to U.S. federal income tax at a flat 30% rate (or such lower rate specified by an applicable income tax treaty), but may be offset by certain U.S.-source capital losses (even though the individual is not considered a
resident of the United States), provided that the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder has timely filed U.S. federal income tax returns with respect to such losses. Gain described in the third bullet point above will generally be
subject to U.S. federal income tax in the same manner as gain that is effectively connected with the conduct of a U.S. trade or business, except that the branch profits tax generally will not apply. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-U.S.</FONT> holders should consult their tax advisors regarding any applicable income tax treaties that may provide for different
rules. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Information reporting and backup withholding </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Annual reports are
required to be filed with the IRS and provided to each <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder indicating the distributions on our Class&nbsp;A common stock paid to such holder and any tax withheld with respect to those
distributions. These information reporting requirements apply even if no withholding was required because the distributions were effectively connected with the holder&#146;s conduct of a U.S. trade or business, or withholding was reduced or
eliminated by an applicable income tax treaty. This information also may be made available under a specific treaty or agreement with the tax authorities in the country in which the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder resides or
is established. Backup withholding, currently at a 24% rate, generally will not apply to payments to a <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder of dividends on or the gross proceeds of a disposition of our Class&nbsp;A common stock
provided the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder furnishes the required certification for its <FONT STYLE="white-space:nowrap">non-U.S.</FONT> status, such as by providing a valid IRS Form
<FONT STYLE="white-space:nowrap">W-8BEN,</FONT> IRS Form <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">W-8BEN-E</FONT></FONT> or IRS Form <FONT STYLE="white-space:nowrap">W-8ECI,</FONT> or certain other requirements are met, and
if the payor does not have actual knowledge, or reason to know, that the holder is a U.S. person who is not an exempt recipient. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Backup withholding is not an
additional tax. If any amount is withheld under the backup withholding rules, the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder should consult with a U.S. tax advisor regarding the possibility of and procedure for obtaining a refund or a
credit against the <FONT STYLE="white-space:nowrap">non-U.S.</FONT> holder&#146;s U.S. federal income tax liability, if any. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>Withholding on foreign entities
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Sections 1471 through 1474 of the Code, which are commonly referred to as FATCA, impose a U.S. federal withholding tax of 30% on certain payments made to a
&#147;foreign financial institution&#148; (as specially defined under these rules) unless such institution enters into an agreement with the U.S. government to withhold on certain payments and to collect and provide to the U.S. tax authorities
substantial information regarding certain U.S. account holders of such institution (which includes certain equity and debt holders of such institution, as well as certain account holders that are foreign entities with U.S. owners) or an exemption
applies. FATCA also generally will impose a U.S. federal withholding tax of 30% on certain payments made to a <FONT STYLE="white-space:nowrap">non-financial</FONT> foreign entity unless such entity provides the withholding agent a certification
identifying certain direct and indirect U.S. owners of the entity or an exemption applies. An intergovernmental agreement between the United States and an applicable foreign country may modify these requirements. Under certain circumstances, a <FONT
STYLE="white-space:nowrap">non-U.S.</FONT> holder might be eligible for refunds or credits of such taxes. FATCA currently applies to dividends paid on our Class&nbsp;A common stock and would have applied also to payments of gross proceeds from the
sale or other disposition of our Class&nbsp;A common stock. The U.S. Treasury Department has released proposed regulations under FATCA providing for the elimination of the federal withholding tax of 30%
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">216 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
applicable to gross proceeds of a sale or other disposition of our Class&nbsp;A common stock. Under these proposed Treasury Regulations (which may be relied upon by taxpayers prior to
finalization), FATCA will not apply to gross proceeds from sales or other dispositions of our Class&nbsp;A common stock. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prospective investors are encouraged to
consult with their own tax advisors regarding the possible implications of FATCA on their investment in our Class&nbsp;A common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">217 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_19"></A>Underwriting </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We are offering the shares of Class&nbsp;A common stock described in this prospectus through a number of underwriters. J.P. Morgan Securities LLC, Cowen and Company, LLC
and Evercore Group L.L.C. are acting as joint <FONT STYLE="white-space:nowrap">book-running</FONT> managers of the offering and as representatives of the underwriters. We have entered into an underwriting agreement with the underwriters. Subject to
the terms and conditions of the underwriting agreement, we agreed to sell to the underwriters, and each underwriter severally agreed to purchase, at the public offering price less the underwriting discounts and commissions set forth on the cover
page of this prospectus, the number of shares of Class&nbsp;A common stock listed next to its name in the following table: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="89%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Name</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">J.P. Morgan Securities LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,196,950</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,522,885</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Evercore Group L.L.C.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,273,232</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,993,067</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters are committed to purchase all the Class&nbsp;A common shares offered by us if they purchase any shares. The underwriting
agreement also provides that if an underwriter defaults, the purchase commitments of <FONT STYLE="white-space:nowrap">non-defaulting</FONT> underwriters may also be increased or the offering may be terminated. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters propose to offer the Class&nbsp;A common shares directly to the public at the public offering price set forth on the cover page of this prospectus and
to certain dealers at that price less a concession not in excess of $0.54000 per share. After the initial offering of the shares to the public, if all of the Class&nbsp;A common shares are not sold at the public offering price, the underwriters may
change the offering price and the other selling terms. Sales of any shares made outside of the United States may be made by affiliates of the underwriters. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
underwriters have an option to buy up to 748,959 additional shares of Class&nbsp;A common stock from us to cover sales of shares by the underwriters which exceed the number of shares specified in the table above. The underwriters have 30&nbsp;days
from the date of this prospectus to exercise this option to purchase additional shares. If any shares are purchased with this option to purchase additional shares, the underwriters will purchase shares in approximately the same proportion as shown
in the table above. If any additional shares of Class&nbsp;A common stock are purchased, the underwriters will offer the additional shares on the same terms as those on which the shares are being offered. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriting fee is equal to the public offering price per share of Class&nbsp;A common stock less the amount paid by the underwriters to us per share of
Class&nbsp;A common stock. The underwriting fee is $0.90 per share. The following table shows the per share and total underwriting discounts and commissions to be paid to the underwriters assuming both no exercise and full exercise of the
underwriters&#146; option to purchase additional shares. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Without<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>With full<BR>option to<BR>purchase<BR>additional<BR>shares<BR>exercise</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.90</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">4,493,760.30</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5,167,823.40</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">218 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We estimate that the total expenses of this offering, including registration, filing and listing fees, printing fees
and legal and accounting expenses, but excluding the underwriting discounts and commissions, will be approximately $750,000. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A prospectus in electronic format may
be made available on the web sites maintained by one or more underwriters, or selling group members, if any, participating in the offering. The underwriters may agree to allocate a number of shares to underwriters and selling group members for sale
to their online brokerage account holders. Internet distributions will be allocated by the representatives to underwriters and selling group members that may make Internet distributions on the same basis as other allocations. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We<I> </I>have agreed that we will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell,
grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, or submit to, or file with, the SEC a registration statement under the Securities Act relating to, any shares of our common stock or
securities convertible into or exercisable or exchangeable for any shares of our common stock, or publicly disclose the intention to undertake any of the foregoing, or (ii)&nbsp;enter into any swap or other agreement that transfers all or a portion
of the economic consequences associated with the ownership of any shares of common stock or any such other securities (regardless of whether any of these transactions are to be settled by the delivery of shares of common stock or such other
securities, in cash or otherwise), in each case without the prior written consent of J.P. Morgan Securities LLC, Cowen and Company, LLC and Evercore Group L.L.C. for a period of 90 days after the date of this prospectus, other than the shares of our
common stock to be sold in this offering. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The restrictions on our actions, as described above, do not apply to certain transactions, including (i)&nbsp;the issuance
of shares of common stock or securities convertible into or exercisable for shares of our common stock pursuant to the conversion or exchange of convertible or exchangeable securities or the exercise of warrants or options (including net exercise)
or the settlement of RSUs (including net settlement), in each case outstanding on the date of the underwriting agreement and described in this prospectus; (ii)&nbsp;grants of stock options, stock awards, restricted stock, RSUs, or other equity
awards and the issuance of shares of our common stock or securities convertible into or exercisable or exchangeable for shares of our common stock (whether upon the exercise of stock options or otherwise) to our employees, officers, directors,
advisors, or consultants pursuant to the terms of an equity compensation plan in effect as of the closing of this offering and described in this prospectus, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT>
agreement with the underwriters; (iii)&nbsp;the issuance of up to 10% of the outstanding shares of our common stock, or securities convertible into, exercisable for, or which are otherwise exchangeable for, our common stock, immediately following
the closing of this offering, in acquisitions or other similar strategic transactions, provided that such recipients enter into a <FONT STYLE="white-space:nowrap">lock-up</FONT> agreement with the underwriters; (iv)&nbsp;our filing of any
registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> relating to securities granted or to be granted pursuant to any plan in effect on the date of the underwriting agreement and described in this prospectus or any assumed
benefit plan pursuant to an acquisition or similar strategic transaction; (v) the establishment of a trading plan pursuant to Rule 10b5-1 under the Exchange Act for the transfer of shares of our common stock, provided that such plan does not provide
for the transfer of shares of our common stock during the lock-up period; or (vi) the filing of any registration statement required by the terms of existing registration rights agreements described in this prospectus. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our directors and executive officers, and certain of our significant shareholders (such persons, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> parties&#148;)
have entered into <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements with the underwriters prior to the commencement of this offering pursuant to which each <FONT STYLE="white-space:nowrap">lock-up</FONT> party, with limited exceptions, for
a period of 90 days after the date of this prospectus (such period, the &#147;restricted period&#148;), may not (and may not cause any of their direct or indirect affiliates to), without the prior written consent of J.P. Morgan Securities LLC, Cowen
and Company, LLC and Evercore Group L.L.C., (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">219 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
any option or contract to sell, grant any option, right or warrant to purchase, lend or otherwise transfer or dispose of, directly or indirectly, any shares of our common stock or any securities
convertible into or exercisable or exchangeable for our common stock (including, without limitation, common stock or such other securities which may be deemed to be beneficially owned by such <FONT STYLE="white-space:nowrap">lock-up</FONT> parties
in accordance with the rules and regulations of the SEC and securities which may be issued upon exercise of a stock option or warrant (collectively with the common stock, the <FONT STYLE="white-space:nowrap">&#147;lock-up</FONT> securities&#148;)),
(2)&nbsp;enter into any hedging, swap or other agreement or transaction that transfers, in whole or in part, any of the economic consequences of ownership of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such
transaction described in clause&nbsp;(1) or&nbsp;(2) above is to be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise, (3)&nbsp;make any demand for, or exercise any right with respect to, the
registration of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities except for a registration statement on Form S-8, or (4)&nbsp;publicly disclose the intention to do any of the foregoing. Such persons or entities have further
acknowledged that these undertakings preclude them from engaging in any hedging or other transactions or arrangements (including, without limitation, any short sale or the purchase or sale of, or entry into, any put or call option, or combination
thereof, forward, swap or any other derivative transaction or instrument, however described or defined) designed or intended, or which could reasonably be expected to lead to or result in, a sale or disposition or transfer (by any person or entity,
whether or not a signatory to such agreement) of any economic consequences of ownership, in whole or in part, directly or indirectly, of any <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, whether any such transaction or arrangement (or
instrument provided for thereunder) would be settled by delivery of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities, in cash or otherwise. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
restrictions described in the immediately preceding paragraph and contained in the <FONT STYLE="white-space:nowrap">lock-up</FONT> agreements between the underwriters and the <FONT STYLE="white-space:nowrap">lock-up</FONT> parties do not apply,
subject in certain cases to various conditions, to certain transactions, including: (i)&nbsp;transactions relating to the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities acquired in this offering or in open market transactions after the
completion of this offering, provided that no filing under the Exchange Act or other public disclosure shall be required or shall be voluntarily made during the restricted period in connection with subsequent sales of Class&nbsp;A common stock or
other securities acquired in such open market transactions during the restricted period, other than any required filing under Section&nbsp;13 of the Exchange Act; (ii)&nbsp;transfers of <FONT STYLE="white-space:nowrap">lock-up</FONT> securities by
gift, including, without limitation, to a charitable organization, or by will or intestate succession to the legal representative, heir or beneficiary of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or any family member, or to a trust
whose beneficiaries consist exclusively of one or more of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party and/or a family member; provided, however, that such transfer is not for consideration; (iii)&nbsp;transfers or dispositions of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities to a corporation, partnership, limited liability company or other entity, all of the beneficial ownership interests of which, in each case, are held by the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or any family member; (iv)&nbsp;transfers of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities by operation of law pursuant to a qualified domestic order or other court order or in
connection with a divorce settlement; (v)&nbsp;if the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a corporation, partnership, limited liability company, trust or other business entity, distributions or transfers of the <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities to (x)&nbsp;another corporation, partnership, limited liability company, trust or other business entity that is a direct or indirect affiliate (as defined in Rule 405 promulgated under the
Securities Act) of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party, (y)&nbsp;any investment fund or other entity controlling, controlled by, managing or managed by or under common control with the
<FONT STYLE="white-space:nowrap">lock-up</FONT> party or affiliates of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party (including, for the avoidance of doubt, where the <FONT STYLE="white-space:nowrap">lock-up</FONT> party is a
partnership, to its general partner or a successor partnership or fund, or any other funds <FONT STYLE="white-space:nowrap">man-aged</FONT> by such partnership), or (z)&nbsp;limited partners, general partners, members, managers, managing members,
stockholders or other equity holders of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party or of the entities described in the preceding clauses (x)&nbsp;and (y); (vi) transfers or dispositions of Class&nbsp;A common stock or Class&nbsp;B
common stock to us as forfeitures (x)&nbsp;to satisfy tax withholding and remittance obligations of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party in connection with the vesting or exercise of equity awards granted pursuant to our equity
incentive plans or (y)&nbsp;pursuant to a net exercise or cashless exercise by the stockholder of outstanding equity awards pursuant to our equity incentive plans; provided, however, that in each case, any such equity incentive plans exist as of the
date of the underwriting agreement and are described </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">220 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
in this prospectus; (vii)&nbsp;transfers of the <FONT STYLE="white-space:nowrap">lock-up</FONT> securities pursuant to a change of control of the company (meaning the consummation of any bona
fide third party tender offer, merger, consolidation or other similar transaction made to all holders of Class&nbsp;A common stock the result of which is that any &#147;person&#148; (as defined in Section&nbsp;13(d)(3) of the Exchange Act), or group
of persons other than the company or its subsidiaries, becomes the beneficial owner (as defined in <FONT STYLE="white-space:nowrap">Rules&nbsp;13d-3</FONT> and <FONT STYLE="white-space:nowrap">13d-5</FONT> of the Exchange Act) of more than 50% of
the voting capital stock of the company) after this offering that has been approved by the independent members of our board of directors, provided, that in the event that such change of control is not completed, the
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities owned by the <FONT STYLE="white-space:nowrap">lock-up</FONT> party shall remain subject to the restrictions described herein; or (viii)&nbsp;transfers of the
<FONT STYLE="white-space:nowrap">lock-up</FONT> securities arising as a result of the termination of employment of the <FONT STYLE="white-space:nowrap">lock-up</FONT> party to us pursuant to agreements that are in effect as of the date of the
underwriting agreement for this offering and disclosed in the prospectus, under which we have the option to repurchase such <FONT STYLE="white-space:nowrap">lock-up</FONT> securities or a right of first refusal with respect to transfers of such <FONT
STYLE="white-space:nowrap">lock-up</FONT> securities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have agreed to indemnify the underwriters against certain liabilities, including liabilities under the
Securities Act of 1933. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Our Class&nbsp;A common stock is listed on the Nasdaq Global Market under the symbol &#147;VERA.&#148; We do not intend to list our
Class&nbsp;B common stock on any securities exchange. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In connection with this offering, the underwriters may engage in stabilizing transactions, which involves
making bids for, purchasing and selling shares of Class&nbsp;A common stock in the open market for the purpose of preventing or retarding a decline in the market price of the Class&nbsp;A common stock while this offering is in progress. These
stabilizing transactions may include making short sales of Class&nbsp;A common stock, which involves the sale by the underwriters of a greater number of shares of Class&nbsp;A common stock than they are required to purchase in this offering, and
purchasing shares of Class&nbsp;A common stock on the open market to cover positions created by short sales. Short sales may be &#147;covered&#148; shorts, which are short positions in an amount not greater than the underwriters&#146; option to
purchase additional shares referred to above, or may be &#147;naked&#148; shorts, which are short positions in excess of that amount. The underwriters may close out any covered short position either by exercising their option to purchase additional
shares, in whole or in part, or by purchasing shares in the open market. In making this determination, the underwriters will consider, among other things, the price of shares available for purchase in the open market compared to the price at which
the underwriters may purchase shares through the option to purchase additional shares. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the Class&nbsp;A common
stock in the open market that could adversely affect investors who purchase in this offering. To the extent that the underwriters create a naked short position, they will purchase shares in the open market to cover the position. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The underwriters have advised us that, pursuant to Regulation&nbsp;M of the Securities Act, they may also engage in other activities that stabilize, maintain or
otherwise affect the price of the Class&nbsp;A common stock, including the imposition of penalty bids. This means that if the representatives of the underwriters purchase Class&nbsp;A common stock in the open market in stabilizing transactions or to
cover short sales, the representatives can require the underwriters that sold those shares as part of this offering to repay the underwriting discount received by them. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These activities may have the effect of raising or maintaining the market price of the Class&nbsp;A common stock or preventing or retarding a decline in the market price
of the Class&nbsp;A common stock, and, as a result, the price of the Class&nbsp;A common stock may be higher than the price that otherwise might exist in the open market. If the underwriters commence these activities, they may discontinue them at
any time. The underwriters may carry out these transactions on the Nasdaq Stock Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In addition, in connection with this offering certain of the underwriters (and selling group members) may engage in passive market making transactions in our
Class&nbsp;A common stock on the Nasdaq Stock Market prior </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">221 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
to the pricing and completion of this offering. Passive market making consists of displaying bids on the Nasdaq Stock Market no higher than the bid prices of independent market makers and making
purchases at prices no higher than these independent bids and effected in response to order flow. Net purchases by a passive market maker on each day are generally limited to a specified percentage of the passive market maker&#146;s average daily
trading volume in the Class&nbsp;A common stock during a specified period and must be discontinued when such limit is reached. Passive market making may cause the price of our Class&nbsp;A common stock to be higher than the price that otherwise
would exist in the open market in the absence of these transactions. If passive market making is commenced, it may be discontinued at any time. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Other than in the
United States, no action has been taken by us or the underwriters that would permit a public offering of the securities offered by this prospectus in any jurisdiction where action for that purpose is required. The securities offered by this
prospectus may not be offered or sold, directly or indirectly, nor may this prospectus or any other offering material or advertisements in connection with the offer and sale of any such securities be distributed or published in any jurisdiction,
except under circumstances that will result in compliance with the applicable rules and regulations of that jurisdiction. Persons into whose possession this prospectus comes are advised to inform themselves about and to observe any restrictions
relating to the offering and the distribution of this prospectus. This prospectus does not constitute an offer to sell or a solicitation of an offer to buy any securities offered by this prospectus in any jurisdiction in which such an offer or a
solicitation is unlawful. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Canada </I></B></P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(A) Resale Restrictions </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The distribution of the
securities in Canada is being made only in the provinces of Ontario, Quebec, Alberta, British Columbia, Manitoba, New Brunswick and Nova Scotia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the
securities regulatory authorities in each province where trades of these securities are made. Any resale of the securities in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may
require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities.
</P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(B) Representations of Canadian Purchasers </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">By
purchasing the securities in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser is entitled under applicable provincial securities laws to purchase the securities without the benefit of a
prospectus qualified under those securities laws as it is an &#147;accredited investor&#148; as defined under National Instrument <FONT STYLE="white-space:nowrap">45-106&#151;Prospectus</FONT> Exemptions or Section&nbsp;73.3(1) of the Securities Act
(Ontario), as applicable, </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser is a &#147;permitted client&#148; as defined in National Instrument
<FONT STYLE="white-space:nowrap">31-103&#151;Registration</FONT> Requirements, Exemptions and Ongoing Registrant Obligations, </P></TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">where required by law, the purchaser is purchasing as principal and not as agent, and </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">the purchaser has reviewed the text above under Resale Restrictions. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">222 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(C) Conflicts of Interest </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Canadian purchasers are hereby notified that certain of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National
Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> &#150; Underwriting Conflicts from having to provide certain conflict of interest disclosure in this document. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(D) Statutory Rights of Action </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Securities
legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the
remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser of these securities in Canada should refer to any
applicable provisions of the securities legislation of the purchaser&#146;s province or territory for particulars of these rights or consult with a legal advisor. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(E) Enforcement of Legal Rights </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">All of our
directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial
portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against
us or those persons outside of Canada. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:arial">(F) Taxation and Eligibility for Investment </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Canadian purchasers of the securities should consult their own legal and tax advisors with respect to the tax consequences of an investment in the securities in their
particular circumstances and about the eligibility of the securities for investment by the purchaser under relevant Canadian legislation. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Australia
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus is not a disclosure document for the purposes of Australia&#146;s Corporations Act 2001 (Cth) of Australia (Corporations Act), has not been
lodged with the Australian Securities&nbsp;&amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A. You confirm and warrant that you are either: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(a) or (b)&nbsp;of the Corporations Act; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#147;sophisticated investor&#148; under section 708(8)(c) or (d)&nbsp;of the Corporations Act and that you have provided
an accountant&#146;s certificate to the company which complies with the requirements of section 708(8)(c)(i) or (ii)&nbsp;of the Corporations Act and related regulations before the offer has been made; </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a person associated with the company under Section&nbsp;708(12) of the Corporations Act; or </P></TD></TR></TABLE>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:arial; font-size:10pt">a &#147;professional investor&#148; within the meaning of section 708(11)(a) or (b)&nbsp;of the Corporations Act.
</P></TD></TR></TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor
under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </P> <P STYLE="font-size:8pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">223 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">B. You warrant and agree that you will not offer any of the securities issued to you pursuant to this prospectus for
resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>European Economic Area </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In relation to each Member State of the
European Economic Area (each, a Relevant State), no shares have been offered or will be offered pursuant to the offering to the public in that Relevant State prior to the publication of a prospectus in relation to the shares which have been approved
by the competent authority in that Relevant State or, where appropriate, approved in another Relevant State and notified to the competent authority in that Relevant State, all in accordance with the Prospectus Regulation, except that the shares may
be offered to the public in that Relevant State at any time: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a) to any legal entity which is a &#147;qualified investor&#148; as defined under Article 2 of the
Prospectus Regulation; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b) to fewer than 150 natural or legal persons (other than qualified investors as defined under Article 2 of the Prospectus Regulation),
subject to obtaining the prior consent of representatives for any such offer; or </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(c) in any other circumstances falling within Article 1(4) of the Prospectus
Regulation, </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided that no such offer of the shares shall require us or any of the representatives to publish a prospectus pursuant to Article 3 of the Prospectus
Regulation or supplement a prospectus pursuant to Article 23 of the Prospectus Regulation. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the purposes of this provision, the expression &#147;offer to the
public&#148; in relation to the shares in any Relevant State means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as to enable an investor to decide to purchase or
subscribe for any shares, and the expression &#147;Prospectus Regulation&#148; means Regulation (EU) 2017/1129. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>United Kingdom </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No shares have been offered or will be offered pursuant to the offering to the public in the United Kingdom prior to the publication of a prospectus in relation to the
shares which has been approved by the Financial Conduct Authority, except that the shares may be offered to the public in the United Kingdom at any time: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a) to any
legal entity which is a qualified investor as defined under Article 2 of the UK Prospectus Regulation; </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b) to fewer than 150 natural or legal persons (other than
qualified investors as defined under Article 2 of the UK Prospectus Regulation), subject to obtaining the prior consent of the representatives for any such offer; or </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(c) in any other circumstances falling within Section&nbsp;86 of the FSMA, </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">provided
that no such offer of the shares shall require the Issuer or any Manager to publish a prospectus pursuant to Section&nbsp;85 of the FSMA or supplement a prospectus pursuant to Article 23 of the UK Prospectus Regulation. For the purposes of this
provision, the expression an &#147;offer to the public&#148; in relation to the shares in the United Kingdom means the communication in any form and by any means of sufficient information on the terms of the offer and any shares to be offered so as
to enable an investor to decide to purchase or subscribe for any shares and the expression &#147;UK Prospectus Regulation&#148; means Regulation (EU) 2017/1129 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain of the underwriters and their affiliates have provided in the past to us and our affiliates and may provide from time to time in the future certain
commercial banking, financial advisory, investment banking and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">224 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
other services for us and such affiliates in the ordinary course of their business, for which they have received and may continue to receive customary fees and commissions. In addition, from time
to time, certain of the underwriters and their affiliates may effect transactions for their own account or the account of customers, and hold on behalf of themselves or their customers, long or short positions in our debt or equity securities or
loans, and may do so in the future. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Hong Kong </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">No securities have
been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#147;professional
investors&#148; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong (SFO) and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the
Companies Ordinance (Cap. 32) of Hong Kong (CO) or which do not constitute an offer or invitation to the public for the purpose of the CO or the SFO. No document, invitation or advertisement relating to the securities has been issued or may be
issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if
permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#147;professional investors&#148; as defined in the SFO and any rules
made under that Ordinance. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued,
circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to
confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such
restrictions. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Israel </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This document does not constitute a
prospectus under the Israeli Securities Law, 5728-1968 (Securities Law) and has not been filed with or approved by the Israel Securities Authority. In Israel, this prospectus is being distributed only to, and is directed only at, and any offer of
the shares is directed only at, (i)&nbsp;a limited number of persons in accordance with the Israeli Securities Law and (ii)&nbsp;investors listed in the first addendum (Addendum) to the Israeli Securities Law, consisting primarily of joint
investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50&nbsp;million and
&#147;qualified individuals,&#148; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case, purchasing for their own account or, where permitted under the Addendum, for
the accounts of their clients who are investors listed in the Addendum). Qualified investors are required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Japan </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The offering has not been and will not be registered under the
Financial Instruments and Exchange Law of Japan (Law No.&nbsp;25 of 1948 of Japan, as amended) (FIEL), and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan
(which term as used </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">225 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for <FONT STYLE="white-space:nowrap">re-offering</FONT> or
resale, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws,
regulations and ministerial guidelines of Japan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Singapore </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">This
prospectus has not been and will not be lodged or registered as a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for
subscription or purchase, of the securities may not be circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in
Singapore other than (i)&nbsp;to an institutional investor under Section&nbsp;274 of the Securities and Futures Act, Chapter 289 of Singapore (SFA), (ii) to a relevant person pursuant to Section&nbsp;275(1), or any person pursuant to
Section&nbsp;275(1A), and in accordance with the conditions specified in Section&nbsp;275, of the SFA, or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Where the securities are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(a) a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share
capital of which is owned by one or more individuals, each of whom is an accredited investor; or </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">(b) a trust (where the trustee is not an accredited investor) whose
sole purpose is to hold investments and each beneficiary of the trust is an individual who is an accredited investor, securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation or the beneficiaries&#146; rights and interest
(howsoever described) in that trust shall not be transferred within six months after that corporation or that trust has acquired the notes pursuant to an offer made under Section&nbsp;275 of the SFA except: </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(i)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to an institutional investor or to a relevant person defined in Section&nbsp;275(2) of the SFA, or to any person arising from an offer referred to in Section&nbsp;275(1A) or Section&nbsp;276(4)(i)(B) of the SFA;
</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where no consideration is or will be given for the transfer; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">where the transfer is by operation of law; </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(iv)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Section&nbsp;276(7) of the SFA; or </TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(v)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </TD></TR></TABLE>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Switzerland </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The securities may not be publicly offered in Switzerland
and will not be listed on the SIX Swiss Exchange (SIX) or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art.
652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither
this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">226 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the
securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority
FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes (CISA). The investor protection afforded to acquirers of interests in collective investment schemes under the
CISA does not extend to acquirers of securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">227 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_20"></A>Legal matters </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Cooley LLP will pass upon the validity of the shares of our Class&nbsp;A common stock being offered in this prospectus. Goodwin Procter LLP will pass upon certain legal
matters in connection with this offering. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_21"></A>Experts </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The financial statements of Vera Therapeutics, Inc. as of December&nbsp;31, 2019 and 2020, and for each of the years in the
<FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, have been included herein and in the registration statement in reliance upon the report of KPMG LLP, independent registered public accounting firm, appearing
elsewhere herein, and upon the authority of said firm as experts in accounting and auditing. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_22"></A>Where you can find additional
information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have filed with the SEC a registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> under the Securities Act with respect to the
shares of Class&nbsp;A common stock offered by this prospectus. This prospectus, which constitutes a part of the registration statement, does not contain all the information set forth in the registration statement, some of which is contained in
exhibits to the registration statement as permitted by the rules and regulations of the SEC. For further information with respect to us and our Class&nbsp;A common stock, we refer you to the registration statement, including the exhibits filed as a
part of the registration statement. Statements contained in this prospectus concerning the contents of any contract or any other document are not necessarily complete. If a contract or document has been filed as an exhibit to the registration
statement, please see the copy of the contract or document that has been filed. Each statement in this prospectus relating to a contract or document filed as an exhibit is qualified in all respects by the filed exhibit. The SEC also maintains an
internet website that contains reports and other information about issuers, like us, that file electronically with the SEC. The address of that website is www.sec.gov. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We also maintain a website at www.veratx.com. You may access our annual reports on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> quarterly reports on Form <FONT
STYLE="white-space:nowrap">10-Q,</FONT> current reports on Form <FONT STYLE="white-space:nowrap">8-K,</FONT> and amendments to those reports filed or furnished pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act with the SEC free of charge
at our website as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. The reference to our website address does not constitute incorporation by reference of the information contained on our
website, and you should not consider the contents of our website in making an investment decision with respect to our Class&nbsp;A common stock. Information contained in, or accessible through, our website is not a part of this prospectus, and the
inclusion of our website address in this prospectus is only as an inactive textual reference. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">228 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="toc210084_23"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Index to financial statements </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="95%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Page</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Interim financial statements&#151;nine months ended September&nbsp;30, 2021 and 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Condensed financial statements (unaudited)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_1">Condensed balance sheets</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_2">Condensed statements of operations and comprehensive loss</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">F-3</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_3">Condensed statements of redeemable convertible preferred stock and stockholders&#146;
 equity (deficit)</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_4">Condensed statements of cash flows</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_5">Notes to unaudited condensed financial statements</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Years ended December&nbsp;31, 2020 and 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Audited financial statements</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_6">Report of independent registered public accounting firm</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_7">Balance sheets</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_8">Statements of operations and comprehensive loss</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_9">Statements of redeemable convertible preferred stock and stockholders&#146; deficit
</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_10">Statements of cash flows</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B><A HREF="#fin210084_11">Notes to financial statements</A></B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">F-29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin210084_1"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed balance sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(In thousands, except share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restricted cash, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">89,760</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restricted cash, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-marketable</FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 91,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 54,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Liabilities, redeemable convertible preferred stock, and stockholders&#146; equity (deficit)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 964</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">367</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,042</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restructuring liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accrued and other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,690</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Commitments and contingencies (Note 12)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Redeemable convertible preferred stock, $0.001 par value; 0 and 182,772,372 shares authorized, issued and
outstanding as of September&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Preferred stock, $0.001 par value; 10,000,000 and 0 shares authorized as of September&nbsp;30, 2021 and
December&nbsp;31, 2020, respectively; no shares issued and outstanding as of September&nbsp;30, 2021 and December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Class&nbsp;A common stock, $0.001 par value; 500,000,000 and 273,986,920 shares authorized as of
September&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; 20,968,376 and 355,296 shares issued and outstanding as of September&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Class&nbsp;B <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, $0.001 par value; 14,600,000
and 21,593,607 shares authorized as of September&nbsp;30, 2021 and December&nbsp;31, 2020, respectively; 309,238 and 0 shares issued and outstanding as of September&nbsp;30, 2021 and December&nbsp;31, 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">192,665</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(107,209</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,477</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total liabilities, redeemable convertible preferred stock, and
stockholders&#146; equity (deficit)</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 91,167</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 54,554</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin210084_2"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of operations and comprehensive loss </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited)
</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(In thousands, except per share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="76%"></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="7%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 9,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 5,362</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,086</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,903</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,416</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,817</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,817</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(9,681</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(151</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(775</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,691</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(857</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> (15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center">$ (1.46)</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">(32.64</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average shares used in computing net loss per share
attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">10,793,436</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">322,811</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:236pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited
condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin210084_3"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of redeemable convertible preferred stock and stockholders&#146; equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>For the nine months ended September&nbsp;30, 2021 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="29%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Class A common<BR>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Class B common<BR>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>stockholders&#146;<BR>equity<BR>(Deficit)</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">355,296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Class&nbsp;A common stock issued pursuant to initial public offering, net of issuance costs</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,002,500</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,411</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Conversion of preferred stock into common stock</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(182,772,372</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(139,576</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,464,775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">309,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,560</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Class&nbsp;A common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,805</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="33" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Balances as of September&nbsp;30, 2021</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-RIGHT:1px solid #000000; BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>20,968,376</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>21</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>309,238</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>192,665</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>(107,209</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>85,477</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of redeemable convertible preferred stock and stockholders&#146; equity (Deficit) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>For the nine months ended September&nbsp;30, 2020 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands, except share data) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable<BR>convertible preferred<BR>stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>14,015,773</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>40,095</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>322,007</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom"><B>$</B></TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>1,486</B></TD>
<TD NOWRAP VALIGN="bottom"><B>&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(38,034</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><B>$</B></TD>
<TD VALIGN="bottom" ALIGN="right"><B>(36,548</B></TD>
<TD NOWRAP VALIGN="bottom"><B>)&nbsp;</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Issuance of common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,045</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="25" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Balances as of September&nbsp;30, 2020</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>14,015,773</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>40,095</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>326,052</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>&#151;</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>1,697</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>(48,572</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>)&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;</B></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"><B>(46,875</B></TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>)&nbsp;</B></TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:120pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:60pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin210084_4"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Condensed statements of cash flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(unaudited) </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(in thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(15,762</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(10,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Depreciation, amortization and accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">144</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">893</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Impairment loss on property and equipment and intangible asset</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restructuring payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(88</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">125</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance costs for convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Gain on sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,691</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">775</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Change in fair value of <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">645</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Prepaid expense and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,012</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">264</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(183</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,270</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(7,427</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by (used in) investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">796</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">550</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of Class&nbsp;A common stock upon initial public offering, net of underwriting
discounts and commissions</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51,176</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment of offering costs related to initial public offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,765</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment issuance costs related to convertible promissory notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(24</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(112</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,489</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net increase (decrease) in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">32,487</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,037</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents and restricted cash, beginning of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">53,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents and restricted cash, end of period</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Reconciliation of cash and cash equivalents and restricted cash to the balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,191</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,451</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">70</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 86,484</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 21</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Reclassification of redeemable convertible preferred stock into common stock upon initial public
offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-marketable</FONT> equity securities received as partial proceeds from
sale of PNAi technology</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 1,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Lease assignment</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> 136</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right"> &#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these unaudited condensed financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B><A NAME="fin210084_5"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial"><B>Notes to unaudited condensed financial statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B>(Amounts in thousands,
except share and per share data) </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Organization and description of the business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Description of business </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Vera Therapeutics, Inc., (the
&#147;Company&#148;) is a late-stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company is headquartered in South San Francisco, California and was
incorporated in May 2016 in Delaware. In 2017, the Company acquired all of the outstanding shares of PNA Innovations, Inc. (&#147;PNAi&#148;), which was based in Woburn, Massachusetts. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Reverse stock split </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On May&nbsp;7, 2021, the Company filed a
certificate of amendment to its fourth amended and restated certificate of incorporation to effect a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">11.5869-for-one</FONT></FONT> reverse stock split of its issued and outstanding
Class&nbsp;A common stock. Adjustments corresponding to the reverse stock split were made to the ratio at which the Company&#146;s redeemable convertible preferred stock converted into Class&nbsp;A common stock. Accordingly, all share and per share
amounts related to Class&nbsp;A common stock, stock options and restricted stock awards for all periods presented in the accompanying unaudited condensed financial statements and notes thereto have been retroactively adjusted, where applicable to
reflect the reverse stock split. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Initial public offering </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On
May&nbsp;13, 2021, the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> for its initial public offering (the &#147;IPO&#148;) was declared effective by the Securities and Exchange Commission (the
&#147;SEC&#148;), and the shares of its Class&nbsp;A common stock commenced trading on the Nasdaq Global Select Market on May&nbsp;14, 2021. The IPO closed on May&nbsp;18, 2021, pursuant to which the Company issued and sold 4,350,000 shares of its
Class&nbsp;A common stock at a public offering price of $11.00 per share. On May&nbsp;20, 2021, the Company issued 652,500 shares of its Class&nbsp;A common stock to the underwriters of the IPO pursuant to the exercise of the underwriters&#146;
option to purchase additional shares. The Company received total net proceeds of $48,411 from the IPO, after deducting underwriting discounts and commissions of $3,852, and offering costs of $2,765. Prior to the completion of the IPO, all shares of
redeemable convertible preferred stock then outstanding were converted into 15,464,775 shares of Class&nbsp;A common stock and 309,238 shares of Class&nbsp;B common stock. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Since inception, the Company has been primarily performing
research and development activities, establishing and maintaining its intellectual property, hiring personnel and raising capital to support and expand these operations. The Company has incurred recurring net operating losses since its inception and
had an accumulated deficit of $107,209 as of September&nbsp;30, 2021. The Company had cash and cash equivalents of $86,191 as of September&nbsp;30, 2021, and has not generated positive cash flow from operations. The Company has funded its operations
primarily through the issuance of common stock, redeemable convertible preferred stock and convertible notes. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Management believes that the Company&#146;s cash and
cash equivalents as of September&nbsp;30, 2021, will be sufficient to fund its operating expenses and capital expenditure requirements for at least 12 months from the issuance </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
date of these unaudited condensed financial statements. While the Company believes that its current cash and cash equivalents are adequate to meet its needs for the next 12 months, the Company
will need to raise additional capital in order to achieve its longer-term business objectives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Basis of presentation and significant accounting policies
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying unaudited condensed
financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;) and applicable rules and regulations of the SEC regarding interim financial reporting. The U.S.
dollar is the Company&#146;s functional and reporting currency. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Unaudited interim condensed financial statements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying condensed balance sheet as of September&nbsp;30, 2021, and condensed statements of operations and comprehensive loss, condensed statements of cash
flows, and condensed statements of redeemable convertible preferred stock and stockholders&#146; equity (deficit) for the nine months ended September&nbsp;30, 2021 and 2020, are unaudited. The balance sheet as of December&nbsp;31, 2020, was derived
from the audited financial statements as of and for the year ended December&nbsp;31, 2020. The unaudited condensed financial statements have been prepared on a basis consistent with the audited annual financial statements as of and for the year
ended December&nbsp;31, 2020 and in the opinion of management, reflect all adjustments consisting solely of normal recurring adjustments, necessary for the fair presentation of the Company&#146;s financial position as of September&nbsp;30, 2021, and
the condensed results of its operations and its cash flows for the nine months ended September&nbsp;30, 2021. The financial data and other information disclosed in these notes related to the nine months ended September&nbsp;30, 2021, are also
unaudited. The condensed results of operations for the nine months ended September&nbsp;30, 2021, are not necessarily indicative of the results to be expected for the full year ending December&nbsp;31, 2021, or any other period. These unaudited
condensed financial statements should be read in conjunction with the Company&#146;s audited financial statements and the notes thereto for the year ended December&nbsp;31, 2020, included in the Company&#146;s final prospectus dated May&nbsp;13,
2021, for the IPO filed with the SEC on May&nbsp;17, 2021, pursuant to Rule 424(b)(4) relating to the Company&#146;s Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1,</FONT> as amended (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-255492).</FONT> </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging growth company status </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is an emerging growth company as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth
companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act until such time as those standards apply to private companies. The Company has elected to use this extended transition period for
complying with certain new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date that it (1)&nbsp;is no longer an emerging growth company or (2)&nbsp;affirmatively and
irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these unaudited condensed financial statements may not be comparable to companies that comply with the new or revised accounting pronouncements as of
public company effective dates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation
of the Company&#146;s unaudited condensed financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
contingent assets and liabilities at the date of the unaudited condensed financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect
the reported amounts of assets and liabilities include the accrual of research and development expenses, restructuring liabilities, fair value of common stock and stock-based compensation expense, and the valuation allowance for deferred tax assets.
The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Deferred offering costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred offering costs consisting of legal,
accounting and filing fees relating to the IPO are capitalized. The deferred offering costs were offset against the Company&#146;s IPO proceeds upon the closing of the IPO. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentrations of credit risk and other risks and uncertainties </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company
maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash and cash
equivalents to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits of cash and cash equivalents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s
future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#146;s future operating results and cause actual results to vary materially from expectations include, but are not limited to,
uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#146;s current and potential future product candidates, uncertainty of market acceptance of the Company&#146;s product candidates,
competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s product candidates require approvals from the U.S. Food and Drug Administration and comparable foreign regulatory agencies prior to commercial sales
in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the Company was unable to maintain approval for any product
candidate, it could have a materially adverse impact on the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to evolve. The extent of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic on the Company&#146;s business, operations, and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and spread of the outbreak and its impact on the Company&#146;s development
activities, planned clinical trial enrollment, future trial sites, contract research organizations, third-party manufacturers, and other third parties with whom the Company does business, as well as its impact on regulatory authorities and the
Company&#146;s key scientific and management personnel. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly uncertain and subject to change. To the extent possible, the Company
is conducting business as usual, with necessary or advisable modifications to employee travel and with the Company&#146;s employees working remotely. The Company will continue to actively monitor the evolving situation related to the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may take further actions that alter the Company&#146;s operations, including those that may be required by federal, state or local authorities, or that the Company determines are in the best
interests of its employees and other third parties with whom the Company does business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic may affect the Company&#146;s business,
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
operations and development timelines and plans, including the resulting impact on expenditures and capital needs, remains uncertain. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash and cash equivalents </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers all highly liquid
investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted cash </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restricted cash represents cash held by a financial
institution as collateral for a letter of credit securing its operating lease for office and laboratory space and as collateral for a credit card, which are classified within current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets on
the condensed balance sheets. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive loss </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive
loss consists of net loss and other gains and losses affecting redeemable convertible preferred stock and stockholders&#146; equity (deficit) that, under U.S. GAAP, are excluded from net loss. The Company has no items of other comprehensive loss for
the nine months ended September&nbsp;30, 2021 and 2020. As such, net loss equals comprehensive loss. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and development costs </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development costs are expensed as incurred and consist primarily of employees&#146; salaries and related benefits, including stock-based compensation and
termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external expenses to conduct and support
the Company&#146;s operations that are directly attributable to the Company&#146;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related services by the third parties
are recorded as prepaid expenses until the services are rendered. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs incurred in obtaining technology licenses including upfront and milestone payments incurred
under the Company&#146;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for the Company&#146;s research and
development activities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research contract costs and accruals </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from time to time. These agreements are generally cancellable, and the related costs are
recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies or
clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining the accrued balances at the end of any reporting period. Actual results could differ
materially from the Company&#146;s estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible preferred stock </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of issuance costs. The carrying
value of the Company&#146;s redeemable convertible preferred </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock is adjusted to reflect dividends if and when declared by the Company&#146;s board of directors. No dividends have been declared by the board of directors since inception. The Company
classifies its redeemable convertible preferred stock separate from total stockholders&#146; equity (deficit), as the redemption of such stock is not solely under the control of the Company. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes compensation expense
based on estimated fair values for all stock-based payment awards made to the Company&#146;s employees, nonemployee directors and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using
the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected
volatility of the Company&#146;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted stock awards is measured by the fair value of the Company&#146;s common stock on the date of the grant. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For all stock options granted, the Company calculated the expected term using the simplified method (derived from the average midpoint between the weighted average
vesting period and the contractual term of the award) for &#147;plain vanilla&#148; stock option awards, as the Company has limited historical information to develop expectations about future exercise patterns and post vesting employment termination
behavior. The estimate of expected volatility is based on comparative companies&#146; volatility. The risk-free rate is based on the yield available on United States Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues corresponding
to the expected term of the award. The Company records forfeitures when they occur. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the shares of common stock underlying the stock options has
historically been determined by the board of directors with the assistance of management and input from an independent third-party valuation firm, as there was no public market for the common stock. The board of directors determined the fair value
of the Company&#146;s common stock by considering a number of objective and subjective factors, including the valuation of comparable companies, sales of redeemable convertible preferred stock, the Company&#146;s operating and financial performance,
the lack of liquidity of common stock, and general and industry specific economic outlook, amongst other factors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records compensation expense for
service-based awards on a straight-line basis over the requisite service period, which is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of
the awards that are ultimately expected to vest. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company did not record an income tax provision for the nine months ended September&nbsp;30, 2021 and 2020 as net operating losses have been incurred since inception.
The net deferred tax assets generated from net operating losses are fully offset by a valuation allowance. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss per share attributable to common
stockholders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net loss per share of common stock is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for multiple classes
of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the
Class&nbsp;A and Class&nbsp;B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net
loss per share attributed to common stockholders is therefore the same for Class&nbsp;A and Class&nbsp;B common stock on an individual or combined basis. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s participating securities include the Company&#146;s redeemable convertible preferred stock, as the
holders were entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The Company also considers any shares issued on the early exercise of stock options subject to repurchase to be
participating securities because holders of such shares have <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> dividend rights in the event a dividend is paid on common stock. The holders of redeemable convertible preferred stock, as well as
the holders of early exercised shares subject to repurchase, did not and do not have a contractual obligation to share in losses of the Company, and therefore during periods of loss there is no allocation required under the <FONT
STYLE="white-space:nowrap">two-class</FONT> method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic net loss per share attributable to common stockholders is calculated by dividing the net loss attributable
to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject to repurchase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock method or the <FONT
STYLE="white-space:nowrap">if-converted</FONT> method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per share attributable to common stockholders is the same as basic net loss per share
attributable to common stockholders, because potentially dilutive shares are not assumed to have been issued if their effect is anti-dilutive. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company leases office and laboratory space under operating leases and laboratory equipment under capital leases. Leases for which the Company assumes
substantially all risks and rewards incidental to ownership of the leased assets are classified as capital leases. The leased assets and the corresponding lease liabilities (net of interest charges) are recognized on the balance sheet as property
and equipment, based on the cost of the equipment, and borrowings, respectively, at the inception of the related lease. Each lease payment is apportioned between the reduction of the outstanding lease liability and the related interest expense. The
interest expense is recorded on a basis that reflects a constant periodic rate of interest on the outstanding finance lease liability. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leases for which
substantially all risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis
over the period of the lease. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restructuring costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restructuring
costs primarily consist of contract termination costs related to leases and employee termination costs. The Company recognizes restructuring charges when the liability has been incurred. Key assumptions in determining the restructuring costs include
the terms and payments that may be negotiated to terminate certain contractual obligations, cease use date of leased property and equipment, and the timing of employees leaving the Company. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accretion expenses related to restructuring costs are included in general and administrative expenses. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value option </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible notes issued in 2020, for which the
Company elected the fair value option, are accounted for at fair value on a recurring basis with changes in fair value recognized in the statement of operations and comprehensive loss. Interest accrued on the convertible notes was recorded to
interest expense during the periods in which the convertible notes were outstanding. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value measurements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is defined as the exchange price to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability
in an orderly transaction between market participants at the measurement date. Fair value should be based on the assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of
inputs to the valuation of an asset or liability as of the measurement date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Fair value measurements are classified and disclosed in one of the
following three categories: </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;1&#151;Quoted unadjusted prices for identical instruments in active markets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;2&#151;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not
active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;3&#151;Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions
developed by the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The carrying amounts of the Company&#146;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and
accrued expenses approximate their fair value due to their short-term nature. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Money market funds are highly liquid investments that are actively traded. The pricing
information for the Company&#146;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities (Note 5) are measured at fair value using an option pricing valuation
methodology. The option pricing methodology relies on risk-neutral valuation which calculates the value of an asset by discounting the expected value of its future payoffs at the risk-free rate of return. The fair value of the <FONT
STYLE="white-space:nowrap">non-marketable</FONT> equity securities is derived from quoted prices for similar instruments and observable inputs in active markets. This approach results in the classification of these securities as Level&nbsp;2 of the
fair value hierarchy. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of September&nbsp;30, 2021, and December&nbsp;31, 2020,
the Company held $84,810 and $52,301, respectively, in money market funds with no unrealized gains or losses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently adopted accounting pronouncements
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2019, the Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) <FONT
STYLE="white-space:nowrap">2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes. </I>The standard simplifies the accounting for income taxes by removing certain exceptions to the general principles in Topic 740.
The amendments also improve consistent application and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The Company adopted this standard as of January&nbsp;1, 2021. The adoption of this standard did not have
a material impact on its unaudited condensed financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;20, 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, to reduce cost and complexity and to improve financial reporting for
share-based payments issued to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). This includes allowing for the measurement of awards at the grant date and recognition of awards with performance conditions when
those conditions are probable, both of which are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
earlier than under current guidance for nonemployee awards. The Company adopted this standard as of January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a
material impact on its unaudited condensed financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT>
<I>Disclosure Framework &#150; Changes to the Disclosure Requirements for Fair Value Measurement</I>, which amends ASC 820, Fair Value Measurement. This standard modifies the disclosure requirements for fair value measurements by removing,
modifying, or adding certain disclosures. The Company adopted this standard as of January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a material impact on its unaudited condensed financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In February 2016, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02,</FONT> <I>Leases (Topic 842)</I>, subsequently amended by ASU <FONT STYLE="white-space:nowrap">2018-10,</FONT> ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT> ASU <FONT
STYLE="white-space:nowrap">2018-20,</FONT> ASU <FONT STYLE="white-space:nowrap">2019-01</FONT> and ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of
leases for both lessors and lessees of a contract. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification on the balance sheets. Leases with a term of
12 months or less may be accounted for similar to existing guidance for operating leases today. The Company intends to use the modified retrospective approach to adopt this standard effective January&nbsp;1, 2022. Additionally, the Company intends
to use the package of available practical expedients, which allows it to (i)&nbsp;not reassess whether any expired or existing contracts are or contain leases; (ii)&nbsp;not reassess the lease classification for expired or existing leases; and
(iii)&nbsp;not reassess the treatment of initial direct costs for any existing leases. The Company is currently evaluating the impact this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In June 2016, the FASB issued ASU <FONT STYLE="white-space:nowrap">2016-13,</FONT> <I>Financial Instruments&#151;Credit Losses (Topic 326): Measurement of Credit Losses
on Financial Instruments</I>. The objective of the standard is to provide information about expected credit losses on financial instruments at each reporting date and to change how other-than temporary impairments on investment securities are
recorded. The guidance is effective for the Company beginning on January&nbsp;1, 2023, with early adoption permitted. The Company is currently evaluating the impact the standard may have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT
STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40).</FONT> This standard simplifies the accounting for convertible debt instruments and
convertible preferred stock by removing the existing guidance in ASC <FONT STYLE="white-space:nowrap">470-20</FONT> that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host
convertible debt or preferred stock. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> is effective for the Company for annual reporting periods, and interim reporting periods within those annual periods, beginning after December&nbsp;15, 2023,
and early adoption is permitted. The Company is currently evaluating the impact this standard will have on its financial statements and related disclosures. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Other financial statement information </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Prepaid expense and other current assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid expenses and other
current assets consist of the following. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>September&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid insurance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,837</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right"> 27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid contract costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">889</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Receivables on exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">786</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,569</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accrued expenses and other current liabilities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities consist of the following. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="74%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>September&nbsp;30,<BR>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>December&nbsp;31,<BR>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,051</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Related party payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">994</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,711</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">535</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Related party payable represents amounts due to Ares Trading S.A. (&#147;Ares&#148;), an affiliate of Merck KGaA, Darmstadt, Germany,
related to manufacturing technology and <FONT STYLE="white-space:nowrap">know-how</FONT> transfer services performed for atacicept pursuant to the license agreement between the Company and Ares (see Note&nbsp;11). </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Neubase asset sale </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;27, 2021, the Company entered into an
asset purchase agreement with NeuBase Therapeutics, Inc. (&#147;NeuBase&#148;), whereby the Company agreed to sell all assets relating to its investment in PNAi, including all inventory, machinery, intellectual property, goodwill, and licenses, and
NeuBase agreed to assume certain related liabilities. The sale of the Company&#146;s investment in PNAi closed on April&nbsp;26, 2021. The Company received $796 in cash and 308,635 shares of NeuBase common stock, with a fair market value of $1,759
based on the closing price reported on the Nasdaq Capital Market on the date the sale closed. Of the total NeuBase shares issued to the Company, 162,260 were placed in escrow to secure certain obligations under the asset purchase agreement. In
connection with the sale, the Company also assigned certain leases for research and laboratory equipment to NeuBase (see Note 13). The Company recognized a gain of $2,691 on the sale of assets to NeuBase. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2021, there were 54,070 shares eligible for release from escrow. Per the terms of the agreement, the shares may be released from escrow upon the
execution of a joint instruction letter. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. <FONT STYLE="white-space:nowrap">Non-marketable</FONT> equity securities </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has an investment in NeuBase common stock with restrictions on the sale or transfer of the shares. Fair value is determined using alternative pricing sources
and models utilizing market observable inputs. The Company reports the restricted equity securities as <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities on the balance sheet, and determines current or <FONT
STYLE="white-space:nowrap">non-current</FONT> classification based on the expected duration of the restriction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recorded a cumulative net unrealized loss of $645 in other expense for the nine months ended
September&nbsp;30, 2021. The carrying value is measured as the total initial cost, less the cumulative net unrealized loss. The carrying value of the <FONT STYLE="white-space:nowrap">non-marketable</FONT> equity securities as of September&nbsp;30,
2021, is summarized below. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="92%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Initial cost as of April&nbsp;26, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,759</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(645</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Convertible notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March 2020, the
Company issued convertible notes to certain existing investors of the Company for cash. The principal amount of the convertible notes was $5,000 in the aggregate with a fixed accrued interest rate of 4% per annum. The convertible notes were either
due on or after December&nbsp;31, 2020, or upon a change of control of the Company, unless earlier converted. No principal or interest was payable prior to maturity as the convertible notes and any accrued interest would automatically convert upon a
qualified financing event at a conversion price equal to 85% of the price per share of the qualified financing. Holders also had the option to convert their notes to shares of Series B redeemable convertible stock at a conversion price equal to
$4.2926 per share on the maturity date or upon a change of control of the Company, if no qualified financing occurred prior to such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to certain embedded
features within the convertible notes, the Company elected to account for the convertible notes under the fair value option. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April and May 2020, the Company
issued additional convertible notes to certain existing investors of the Company for cash. The principal amount of the convertible notes was $602 in the aggregate with the same terms as the convertible notes issued in March 2020. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the outstanding principal and accrued interest of $134, were automatically converted into 11,404,246 shares of the Company&#146;s Series C redeemable
convertible preferred stock in connection with the closing of the Company&#146;s Series C redeemable convertible preferred stock financing (see Note 7) at a conversion price of $0.5030 per share, which was 85% of the $0.5918 original issuance price
of the Series C redeemable convertible preferred stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Redeemable convertible preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company&#146;s redeemable convertible preferred stock consisted of the following balances. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Issue<BR>price<BR>per<BR>share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares<BR>authorized</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares issued<BR>and<BR>outstanding</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Carrying<BR>value</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>liquidation<BR>preference</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">Seed-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="17" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">139,338</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="20" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company issued 135,180,800 shares of Series C redeemable convertible preferred stock for a
purchase price of $0.5918 per share, payable in cash. Gross proceeds to the Company were $80,000. The Series C redeemable convertible preferred stock financing triggered the automatic conversion of the Company&#146;s outstanding convertible notes
into 11,404,246 shares of Series C redeemable convertible preferred stock based on price of $0.5030 per share (85% of the $0.5918 original issuance price of the Series C redeemable convertible preferred stock). In addition, the Company issued
22,171,553 shares of Series C redeemable convertible preferred stock to Ares as the initial payment for the Company&#146;s license of atacicept from Ares (see Note 11). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In May 2021, immediately prior to the completion of the IPO (see Note 1), all outstanding shares of redeemable convertible preferred stock were automatically converted
into 15,774,014 shares of common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Common stock </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of
September&nbsp;30, 2021, the Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 500,000,000 shares of Class&nbsp;A common stock and 14,600,000 shares of Class&nbsp;B common stock, each with a par
value of $0.001 per share. Each share of Class&nbsp;A common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s stockholders. Class&nbsp;B common stock is
<FONT STYLE="white-space:nowrap">non-voting.</FONT> The holders of Class&nbsp;A common stock, voting exclusively and as a separate class, have the exclusive right to vote for the election of one director of the Company. Class&nbsp;A common
stockholders and holders of Class&nbsp;B common stock are entitled to receive dividends, as may be declared by the board of directors. Through September&nbsp;30, 2021, no cash dividends have been declared or paid. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Stock compensation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2021, the Company adopted the 2021 Employee
Stock Purchase Plan (&#147;ESPP&#148;) and the 2021 Equity Incentive Plan (&#147;2021 EIP&#148;), each of which became effective in connection with the IPO. The Company has reserved 220,251 and 2,213,773 shares of Class&nbsp;A common stock for
future issuance under the ESPP and 2021 EIP, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company may not grant any additional awards under the 2017 Equity Incentive Plan (&#147;2017
EIP&#148;). The 2017 EIP will continue to govern outstanding equity awards granted thereunder. As of September&nbsp;30, 2021, there were 1,510,665 shares available for issuance under the 2021 EIP. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2017 EIP and 2021 EIP </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Stock option activity under the 2017 EIP and
2021 EIP was as follows: </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number<BR>of<BR>options</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>exercise<BR>price per<BR>share</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Weighted-<BR>average<BR>remaining<BR>contractual<BR>life (years)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Aggregate<BR>intrinsic<BR>value&nbsp;(000s)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance&#151;December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,188,064</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(145,805</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.77</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(3,095</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.38</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance&#151;September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options exercisable&#151;September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">82,944</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.42</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.96</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,155</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested and expected to vest&#151;September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.43</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.35</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">34,521</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="16" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate intrinsic value of stock options exercised during the nine months ended September&nbsp;30, 2021, was
$206. The weighted-average grant date fair value of options granted during the nine months ended September&nbsp;30, 2021, was $6.66 per share. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>ESPP
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The ESPP enables eligible employees to purchase shares of the Company&#146;s common stock at the end of each offering period at a price equal to 85% of the
fair market value of the shares on the first trading day or the last trading day of the offering period, whichever is lower. Eligible employees generally include all employees. Share purchases are funded through payroll deductions of at least 1% and
up to 15% of an employee&#146;s eligible compensation for each payroll period. The number of shares reserved for issuance under the ESPP increase automatically on the first day of each fiscal year, beginning on January&nbsp;1, 2022, by a number
equal to the lesser of 440,502 shares, 1% of the total number of shares of the Company&#146;s capital stock (including all classes of the Company&#146;s common stock) outstanding on the last day of the calendar month prior to the date of the
increase, or such lower number of shares. (including no shares) approved by the Company&#146;s board of directors. As of September&nbsp;30, 2021, no shares have been issued pursuant to the ESPP. The ESPP generally provides for <FONT
STYLE="white-space:nowrap">six-month</FONT> consecutive offering periods beginning on September&nbsp;14, 2021. The ESPP is a compensatory plan as defined by the authoritative guidance for stock compensation. As such, stock-based compensation expense
has been recorded for the nine months ended September&nbsp;30, 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables summarize the stock-based compensation expense for stock options and restricted stock awards granted to employees and nonemployees that was recorded
in the Company&#146;s statements of operations and comprehensive loss for the nine months ended September&nbsp;30, 2021 and 2020. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">606</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,444</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">184</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="84%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine&nbsp;months&nbsp;ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>&nbsp;&nbsp;&nbsp;&nbsp;2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">182</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nonemployees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">188</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of September&nbsp;30, 2021, the Company had $10,348 of unrecognized stock-based compensation expense related to unvested stock options
and restricted stock awards, which is expected to be recognized over a weighted-average period of approximately 3.15 years. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of stock options granted during the nine months ended September&nbsp;30, 2021 and 2020 was estimated
using the Black-Scholes option pricing model based on the following weighted average assumptions. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">75.4%&nbsp;&#150;&nbsp;76.6%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.0%&nbsp;&#150;&nbsp;75.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.6% &#150; 1.1%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.4% &#150; 1.7%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted stock awards </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October
2020, in conjunction with the Series C redeemable convertible preferred stock issuance, the Company restricted 49,636 shares of fully issued and outstanding Class&nbsp;A common stock held by the Company&#146;s Chief Executive Officer and founder.
The restriction allows the Company to repurchase shares that have not vested. The vesting term of restricted stock is one year. The grant date fair value of the restricted shares was $6.37. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the activity for the Company&#146;s restricted stock for the nine months ended September&nbsp;30, 2021. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Number&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>shares</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(37,226</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="4" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For the nine months ended September&nbsp;30, 2021, the Company recognized $236 of stock-based compensation expense related to restricted
stock awards that vested during the period. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Employee benefit plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited
to a maximum annual amount set by the Internal Revenue Service. There were no employer contributions under this plan for the nine months ended September&nbsp;30, 2021. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Licenses and collaborations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Yale University </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2017, PNAi entered into a collaborative research agreement (the &#147;Yale CRA&#148;) and license agreement (the &#147;Yale License Agreement&#148;) with Yale
University, which were assigned to the Company upon the closing of the acquisition of PNAi by the Company in 2017. The purpose of the agreements was to fund the Yale University research program in the field of
<FONT STYLE="white-space:nowrap">nanoparticle-sized</FONT> nucleic acid mimics and peptide nucleic acids as gene editing therapeutics in return for an exclusive license to certain related patent rights owned by Yale University and the option to
license any patents discovered or generated under the terms of the collaborative research agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Yale CRA required funding the labs of collaborators with
$1,500 per year for a minimum of two years. The Yale CRA expired in 2019. No payments were made to Yale University pursuant to the Yale CRA during the year ended December&nbsp;31, 2019 with no future obligation under this commitment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the Yale License Agreement, PNAi paid an initial fee of $37 and had the option to issue 5% of the
company&#146;s common stock on a fully diluted, as converted basis. If the shares were not issued, the agreement could be terminated at Yale University&#146;s option. After the completion of the merger with PNAi, the Company exercised the option and
issued 264,301 shares of common stock to Yale University with a fair value of $100. Under the Yale License Agreement, the Company reimbursed Yale University for patent related expenses. The Company reimbursed Yale University $45 for patent related
expenses for the year ended December&nbsp;31, 2019. The Company and Yale agreed to terminate the Yale License Agreement in 2020 and there are no future payment obligations under the Yale License Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ares trading S.A. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company entered into a license
agreement with Ares (the &#147;Ares Agreement&#148;), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and
commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the Ares Agreement, the Company issued to Ares a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of 22,171,553 shares of
Series C redeemable convertible preferred stock resulting in Ares becoming a related party to the Company. The Series C redeemable convertible preferred stock had a deemed issuance price of $0.5918 per share, or $13,121 in the aggregate. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2020, the Company paid Ares $25,000 in milestone payments upon delivery and initiation of the transfer of specified information and materials. The Company is
obligated to pay Ares aggregate milestone payments of up to $176,500 upon the achievement of specified BLA filing or regulatory approval milestones and up to $515,000 upon the achievement of specified commercial milestones. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of $13,121 and milestone payments of $25,000 were recorded to research and development
expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Ares is performing manufacturing technology and <FONT STYLE="white-space:nowrap">know-how</FONT> transfer to the Company over a period not to exceed two
years from the effective date of the Ares Agreement. The Company recorded related party expense of $1,256 due to Ares for these services during the nine months ended September&nbsp;30, 2021. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered royalties of low double-digit to
<FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-</FONT></FONT> licensed product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale
of a product in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii)&nbsp;the expiration of the last valid claim of a licensed patent that covers such licensed product in, or its
use, importation or manufacture with respect to, such country; and (iii)&nbsp;expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to sublicense
its rights under the Ares Agreement, the Company is obligated to pay Ares a percentage ranging from the mid single-digit to the low double-digits of specified sublicensing income received. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Commitments and contingencies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate future minimum lease payments for operating leases as of September&nbsp;30, 2021, are as follows. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Operating<BR>leases(1)</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Sublease<BR>income</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2021 (remaining 3 months)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">587</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(462</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,901</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,458</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,964</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,537</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(2,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,953</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,569</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,916</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(7,925</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Future minimum lease payments include repayment of outstanding restructuring liabilities. </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Facilities leases
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2015, PNAi entered a lease for approximately 3,800 square feet of office and laboratory space for a term of 39 months in Woburn, Massachusetts. In
January 2018, the Company elected to renew this lease for three years, beginning in August 2018. This lease expired in July 2021. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2018, the Company entered
into a lease for approximately 24,606 square feet of office and life science research space, which commenced on October&nbsp;1, 2018, when the Company obtained control of the rented space for a term of 84 months in South San Francisco, California
(&#147;the South San Francisco Lease&#148;). In connection with the South San Francisco Lease, the Company maintains a letter of credit issued to the lessor in the amount of $293, which is secured by restricted cash that is classified as noncurrent
based on the term of the underlying lease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s total future minimum commitment due pursuant to the South San Francisco Lease is $9,916 as of
September&nbsp;30, 2021. In November 2020, the Company entered into a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> sublease agreement for the facility, under the terms of which the Company is entitled to receive $7,925 in sublease
payments over the term of the sublease, which ends concurrently with the original lease in September 2025. As tenant, the Company remains responsible for the $9,916 minimum lease commitment on the facilities. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recorded rent expense totaling $1,605 for the nine months ended September&nbsp;30, 2020. No rent expense was recorded for the nine months ended
September&nbsp;30, 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equipment lease </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company had certain
leases on research and laboratory equipment which were assigned to a certain third party as of September&nbsp;30, 2021. The Company recorded rent expense totaling $256 for the nine months ended September&nbsp;30, 2020. No rent expense was recorded
for the nine months ended September&nbsp;30, 2021. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Restructuring and related activities </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2019, the Company completely vacated its leased facilities in Woburn, Massachusetts. In connection with vacating the leased
spaces, the Company recorded a discounted lease-related restructuring liability, which was calculated as the present value of the estimated future facility costs for which the Company would obtain no future economic benefit over the term of the
lease, reduced for actual or estimated sublease rentals. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July 2020, the Company initiated a restructuring plan to reduce operating expense as a result of the disposal of
PNAi technology. The restructuring plan included reducing the number of employees, vacating leased facilities, and ceasing use of leased equipment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result of
this restructuring plan, the Company completely vacated its leased facilities in South San Francisco, California, which was subleased to a third party in November 2020, and returned certain leased equipment to the lessor. The Company recorded a
discounted lease-related restructuring liability of $2,228 and $768 for the abandonment of the leased facilities and equipment, which was calculated as the present value of the estimated future lease costs for which the Company would obtain no
future economic benefit over the term of the leases. In addition, the Company recognized restructuring liability of $321 related to severance and other employee termination costs related to the reduction in the number of employees. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The activity related to the restructuring liabilities for the nine months ended September&nbsp;30, 2021, is as follows. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B><FONT STYLE="white-space:nowrap">Lease-related</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>exit costs</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="right"><B>Employee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="right"><B>termination</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,596</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">116</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">28</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(863</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(12</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(875</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Lease assignment to NeuBase</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(136</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of September&nbsp;30, 2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,729</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="12" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Net loss per share attributable to common stockholders </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the
periods presented, because including them would have been anti-dilutive (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="78%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="right" STYLE="border-bottom:1.00px solid #000000"><B>Nine months ended</B><br><B>September&nbsp;30,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2021</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="right" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;A common stock options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,894,671</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">164,588</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,137</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,898,808</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,374,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; font-family:arial; font-size:10pt">
<TD COLSPAN="8" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15. Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October
2018, the Company entered into a sublease agreement for a portion of its South San Francisco office space, the term for which commenced on December&nbsp;7, 2018. The Chief Executive Officer of the sublessor is a member of the Company&#146;s board of
directors. The initial sublease was established for approximately 400 square feet of space. Prior to the initial expiration of the sublease in April 2019, the space was expanded to approximately 3,700 square feet with the term of the lease extended
for an additional two years. The monthly rent charged by the Company to the subtenant is subject to escalating rent payments according to the terms of the Company&#146;s lease agreement, and the subtenant is required to reimburse the Company for
monthly facility operating expenses based on its proportionate share of total square footage pursuant to the lease. The Company&#146;s lease agreement provides that 50% of any profit resulting from the excess of the amount collected from the
subtenant less the sum of monthly rent, operating expenses and reimbursement of direct expenditures made by the Company in order to arrange and maintain the sublease is to be shared with the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
lessor. To date, no profit has been realized on the sublease arrangement as the monthly collections from the subtenant are equivalent to the Company&#146;s cost of rent, operating expense and
recovery of professional fees to arrange the sublease. In June 2020, the sublease agreement was terminated. During the nine months ended September&nbsp;30, 2020, the Company recognized $160 of sublease income under this agreement, which was recorded
as a reduction to the Company&#146;s rent expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an
exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to
inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases (See Note 3 and Note 11). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. Subsequent events </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2021, the Company entered into a lease agreement for approximately 5,000 square feet of office space in Brisbane, California. The term of the lease is three
years, and rent will be approximately $288 for the first year with scheduled annual 3% increases. The lease includes renewal options for the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December
2021, the Company entered into an asset purchase agreement (the &#147;Amplyx Agreement&#148;) with Amplyx Pharmaceuticals, Inc. (&#147;Amplyx&#148;), a wholly owned subsidiary of Pfizer Inc. (&#147;Pfizer&#148;), under which it acquired MAU868, a
monoclonal antibody that was under development by Amplyx for the treatment of BK virus infections. MAU868 is subject to a license agreement between Amplyx and Novartis Pharma AG, as successor in interest to Novartis International Pharmaceutical AG
(&#147;Novartis&#148;). Under the Amplyx Agreement, the Company obtained a worldwide, exclusive license from Novartis to develop, manufacture and commercialize MAU868. The Company also assumed certain liabilities of Amplyx. In partial consideration
for the Amplyx Agreement, the Company made an upfront initial payment of $5.0&nbsp;million to Amplyx. The Company may also be obligated to make certain milestone payments to Amplyx in an aggregate amount up to $7.0&nbsp;million based on certain
regulatory milestones, and may be required to pay Amplyx <FONT STYLE="white-space:nowrap">low-single</FONT> digit percentage royalties based on net sales if MAU868 is successfully commercialized. The Company may also be obligated to make certain
milestone payments to Novartis in an aggregate amount of up to $69.0&nbsp;million based on certain clinical development, regulatory and sales milestones, and may be required to pay Novartis <FONT STYLE="white-space:nowrap">mid-</FONT> to high-single
digit royalties based on net sales if MAU868 is successfully commercialized. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2021, the Company entered into a Loan and Security Agreement (the
&#147;Loan Agreement&#148;) with Oxford Finance LLC (the &#147;Lender&#148;) as lender and collateral agent. The Loan Agreement provides for a term loan in an aggregate maximum principal amount of $50.0&nbsp;million (the &#147;Loan&#148;), of which
$5.0&nbsp;million was funded in December 2021, and the balance of which is available to be drawn at the Company&#146;s option in minimum draws of $5.0&nbsp;million during 2022. The Loan matures in December 2026, which may be extended by 12 months
subject to certain clinical data milestones. The Company is required to make monthly interest-only payments for 48 months, which may be extended to 60 months if the final maturity date is extended. Initially, the Loan bears interest at 8.254%, with
a floating interest rate tied to LIBOR. The Company is permitted to prepay the loan, subject to certain conditions. Upon the maturity date or prepayment of the Loan, the Company is required to make a final payment equal to 5.0% (or 7.0% if the
maturity date is extended) of the aggregate principal amount of the Loan. The Loan Agreement does not contain any financial covenants and the Loan is secured by the Company&#146;s assets. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_6"></A>Report of Independent Registered Public Accounting Firm </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">To the Stockholders and Board of Directors </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Vera Therapeutics, Inc.: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Opinion on the Financial Statements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have audited the accompanying
balance sheets of Vera Therapeutics, Inc. (the Company) as of December&nbsp;31, 2019 and 2020, the related statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#146; deficit, and cash flows for
each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31, 2020, and the related notes (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material
respects, the financial position of the Company as of December&nbsp;31, 2019 and 2020, and the results of its operations and its cash flows for each of the years in the <FONT STYLE="white-space:nowrap">two-year</FONT> period ended December&nbsp;31,
2020, in conformity with U.S. generally accepted accounting principles. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B><I>Basis for Opinion </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">These financial statements are the responsibility of the Company&#146;s management. Our responsibility is to express an opinion on these financial statements based on
our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and
the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We conducted our audits in accordance with the standards of the PCAOB.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess
the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures
in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits
provide a reasonable basis for our opinion. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">/s/ KPMG LLP </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">We have served as the
Company&#146;s auditor since 2018. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">San Francisco, California </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">March&nbsp;19,
2021, except as to note 15B, which is as of May&nbsp;10, 2021 </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_7"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Balance sheets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(In thousands, except share
amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Assets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,565</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54,261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restricted cash, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment, net</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,381</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial"><B>Liabilities, redeemable convertible preferred stock, and stockholders&#146; deficit</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">342</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">909</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capital lease payable, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring liability, current</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">962</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,060</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,406</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Capital lease payable, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring liability, noncurrent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,634</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued and other noncurrent liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">764</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">286</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,834</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,326</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Commitments and contingencies (Note 11)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock, $0.001 par value; 15,907,207 and 182,772,372 shares authorized as of
December&nbsp;31, 2019 and 2020, respectively; 14,015,773 and 182,772,372 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;A common stock, $0.001 par value; 23,000,000 and 273,986,920 shares authorized as of
December&nbsp;31, 2019 and 2020, respectively; 322,007 and 355,296 shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;B <FONT STYLE="white-space:nowrap">non-voting</FONT> common stock, $0.001 par value; no shares
and 21,593,607 shares authorized as of December&nbsp;31, 2019 and 2020, respectively; no shares issued and outstanding as of December&nbsp;31, 2019 and 2020, respectively</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Additional <FONT STYLE="white-space:nowrap">paid-in</FONT> capital</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total liabilities, redeemable convertible preferred stock, and
stockholders&#146; deficit</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">5,381</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">54,554</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_8"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Statements of operations and comprehensive loss </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(In thousands) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended</B><br><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">45,206</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,410</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,039</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total operating expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,961</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,241</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD>
<TD HEIGHT="4" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss from operations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,961</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(52,241</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other income (expense):</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest income</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Interest expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(51</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,076</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total other income (expense)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,171</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Loss before provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,853</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,412</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Provision for income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss and comprehensive loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net loss per share attributable to common stockholders, basic and diluted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(40.14</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(166.93</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Weighted-average common shares outstanding, basic and
diluted</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">295,328</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">319,963</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:260pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_9"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Statements of redeemable convertible preferred stock and stockholders&#146; deficit </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(In thousands, except share amounts) </B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="71%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom"></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000; BORDER-RIGHT:1.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Redeemable convertible<BR>preferred stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.00pt solid #000000">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Common stock</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Additional<BR><FONT STYLE="white-space:nowrap">paid-in</FONT><BR>capital</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Accumulated<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ROWSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000;border-bottom:1.00px solid #000000"><B>Total<BR>stockholders&#146;<BR>deficit</B></TD>
<TD VALIGN="bottom" ROWSPAN="2" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-RIGHT:1.00pt solid #000000; BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Balance as of December&nbsp;31, 2018</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,015,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">312,082</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,172</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(26,180</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(25,008</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Class&nbsp;A common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,925</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Balance as of December&nbsp;31, 2019</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,015,773</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,095</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">322,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,486</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(38,034</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(36,548</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Class&nbsp;A common stock upon exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,289</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">282</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock, net of issuance costs of $389</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">135,180,800</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">79,611</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock upon extinguishment of convertible notes</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,404,246</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,171,553</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:8pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="29" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:arial"><B>Balance as of December&nbsp;31, 2020</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE="BORDER-RIGHT:1.00pt solid #000000; BORDER-BOTTOM:1px solid #000000"><FONT SIZE="1">&nbsp;</FONT></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">355,296</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,099</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(91,447</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(89,348</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:303pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these financial statements </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_10"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Statements of cash flows </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(In thousands)
</B></P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:9pt" ALIGN="center">


<TR>

<TD WIDTH="82%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from operating activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,854</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(53,413</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Adjustments to reconcile net loss to net cash used in operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">509</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">251</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Impairment loss on property and equipment and intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,185</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Loss on disposal of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">94</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restructuring costs, net of cash paid</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,423</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><FONT STYLE="white-space:nowrap">Non-cash</FONT> interest expense on convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">134</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance costs for convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Gain on issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(63</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,076</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Prepaid expense and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(135</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Grants receivable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">159</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">567</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Accrued and other current liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">60</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">110</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Other liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(478</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash used in operating activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,289</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(34,809</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from investing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchase of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(99</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from the sale of property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">57</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash used in investing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(125</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(42</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Cash flows from financing activities</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from exercise of stock options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">230</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment of issuance costs related to issuance of redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(389</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Proceeds from issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,602</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment of issuance costs related to convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(23</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Payment on capital lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(188</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(130</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:4.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net cash (used in) provided by financing activities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(137</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,290</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Net (decrease) increase in cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,551</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">50,439</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents and restricted cash, beginning of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash, cash equivalents and restricted cash, end of year</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Reconciliation of cash and cash equivalents and restricted cash to the balance sheets</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,195</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,654</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">343</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Total cash and cash equivalents and restricted cash</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3,558</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">53,997</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial"><B>Supplemental disclosure of cash flow information</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Cash paid for interest</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">51</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">32</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Purchases of property and equipment through capital leases</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock for license</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Issuance of Series C redeemable convertible preferred stock upon extinguishment of convertible notes</P></TD>

<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,736</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:9pt; font-family:arial">Receivables on exercise of stock options</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:7.5pt; font-family:arial"><I>The accompanying notes are an integral part of these financial statements. </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B><A NAME="fin210084_11"></A>Vera Therapeutics, Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:arial" ALIGN="center"><B>Notes to financial statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center"><B>(Dollar
amounts in thousands, except per share data) </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>1. Organization and description of the business </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Description of business </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Vera Therapeutics, Inc., (the
&#147;Company&#148;) is a clinical stage biotechnology company focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The Company is headquartered in South San Francisco, California and
was incorporated in May 2016 in Delaware. In 2017, the Company acquired all of the outstanding shares of PNA Innovations, Inc. (&#147;PNAi&#148;), which was based in Woburn, Massachusetts. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidity </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying financial statements have been prepared
assuming the Company will continue as a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business, and do not include any adjustments to reflect the possible future effects on
the recoverability and classification of assets or amounts and classification of liabilities that may result from the outcome of this uncertainty. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has
incurred recurring net operating losses since its inception and had an accumulated deficit of $91,447 as of December&nbsp;31, 2020. The Company had cash and cash equivalents of $53,654 as of December&nbsp;31, 2020 and has not generated positive cash
flow from operations. To date, the Company has been able to fund its operation primarily through the issuance of redeemable convertible preferred stock and convertible notes. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company expects to continue to generate operating losses for the foreseeable future. There can be no assurance that the Company will ever earn revenues or achieve
profitability or, if achieved, that they will be sustained on a continuing basis. If the Company is unable to obtain funding, the Company will be forced to delay or reduce some or all of its product development programs, which could adversely affect
its business prospects, or the Company may be unable to continue operations. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient future funding on terms acceptable
to the Company to fund continuing operations, if at all. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company believes that it has sufficient resources to fund its operating expenses and capital
expenditure requirements for at least 12 months from the issuance date of these financial statements. While the Company believes that its current cash and cash equivalents are adequate to meet its needs for the next 12 months, the Company may need
to raise additional equity or borrow funds in order to achieve its longer-term business objectives. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>2. Basis of presentation and significant accounting policies
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Basis of presentation </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The accompanying financial statements
have been prepared in conformity with accounting principles generally accepted in the United States of America (&#147;GAAP&#148;). The U.S. dollar is the Company&#146;s functional and reporting currency. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Reclassification </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Certain reclassification of prior period amounts related to restructuring activities has been made to conform to the current year presentation. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Emerging growth company status </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company is an emerging growth
company, as defined in the Jumpstart Our Business Startups Act of 2012 (&#147;JOBS Act&#148;). Under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards issued subsequent to the enactment of the JOBS Act
until such time as those standards apply to private companies. The Company has elected to use this extended transition period for complying with certain new or revised accounting standards that have different effective dates for public and private
companies until the earlier of the date that it (1)&nbsp;is no longer an emerging growth company or (2)&nbsp;affirmatively and irrevocably opts out of the extended transition period provided in the JOBS Act. As a result, these financial statements
may not be comparable to companies that comply with the new or revised accounting pronouncements as of public company effective dates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Use of estimates
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The preparation of the Company&#146;s financial statements requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Management estimates that affect the reported amounts of assets and
liabilities include useful lives of fixed and intangible assets, the accrual of research and development expenses, restructuring liabilities, fair value of common stock and stock-based compensation expense, and the valuation allowance for deferred
tax assets. The Company evaluates and adjusts its estimates and assumptions on an ongoing basis using historical experience and other factors. Actual results could differ materially from those estimates. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Segment information </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company operates as a single operating
segment. The Company&#146;s chief operating decisionmaker, its Chief Executive Officer, manages the Company&#146;s entire operations as a whole for the purposes of allocating resources, making operating decisions and evaluating financial
performance. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Concentrations of credit risk and other risks and uncertainties </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents. The Company
maintains bank deposits in a federally insured financial institution and these deposits may exceed federally insured limits. The Company is exposed to credit risk in the event of default by the financial institution holding its cash and cash
equivalents to the extent recorded in the balance sheet. The Company has not experienced any losses on its deposits of cash and cash equivalents. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s
future results of operations involve a number of other risks and uncertainties. Factors that could affect the Company&#146;s future operating results and cause actual results to vary materially from expectations include, but are not limited to,
uncertainty of results of clinical trials and reaching milestones, uncertainty of regulatory approval of the Company&#146;s current and potential future product candidates, uncertainty of market acceptance of the Company&#146;s product candidates,
competition from substitute products and larger companies, securing and protecting proprietary technology, strategic relationships and dependence on key individuals or sole-source suppliers. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s product candidates require approvals from the U.S. Food and Drug Administration and comparable
foreign regulatory agencies prior to commercial sales in their respective jurisdictions. There can be no assurance that any product candidates will receive the necessary approvals. If the Company was denied approval, approval was delayed, or the
Company was unable to maintain approval for any product candidate, it could have a materially adverse impact on the Company. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impact of the <FONT
STYLE="white-space:nowrap">COVID-19</FONT> coronavirus </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic continues to rapidly evolve. The extent
of the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on the Company&#146;s business, operations and development timelines and plans remains uncertain, and will depend on certain developments, including the duration and
spread of the outbreak and its impact on the Company&#146;s development activities, planned clinical trial enrollment, future trial sites, contract research organizations, third-party manufacturers, and other third parties with whom the Company does
business, as well as its impact on regulatory authorities and the Company&#146;s key scientific and management personnel. The ultimate impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic or a similar health epidemic is highly
uncertain and subject to change. To the extent possible, the Company is conducting business as usual, with necessary or advisable modifications to employee travel and with the Company&#146;s employees working remotely. The Company will continue to
actively monitor the rapidly evolving situation related to the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic and may take further actions that alter the Company&#146;s operations, including those that may be required by federal, state or
local authorities, or that the Company determines are in the best interests of its employees and other third parties with whom the Company does business. At this point, the extent to which the <FONT STYLE="white-space:nowrap">COVID-19</FONT>
pandemic may affect the Company&#146;s business, operations and development timelines and plans, including the resulting impact on expenditures and capital needs, remains uncertain. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Cash and cash equivalents </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company considers all highly liquid
investments with an original maturity of three months or less when purchased to be cash equivalents. Cash equivalents consist of money market funds and are stated at fair value. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted cash </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restricted cash represents cash held by a financial
institution as collateral for a letter of credit securing its operating lease for office and laboratory space and as collateral for a credit card, which are classified within current and <FONT STYLE="white-space:nowrap">non-current</FONT> assets on
the balance sheets. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Comprehensive loss </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Comprehensive loss
consists of net loss and other gains and losses affecting redeemable convertible preferred stock and stockholders&#146; deficit that, under U.S. GAAP, are excluded from net loss. The Company has no items of other comprehensive loss for the years
ended December&nbsp;31, 2019 and 2020. As such, net loss equals comprehensive loss. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Property and equipment, net </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property and equipment are recorded at cost, less accumulated depreciation. Depreciation expense is recognized using the straight-line method over the useful life of the
asset category, for which each category the useful life is estimated at five years. Leasehold improvements are capitalized and amortized over the shorter of the lease term or the estimated useful life of the related asset. Expenditures for repairs
and maintenance of assets are charged to expense as incurred, whereas major improvements are capitalized as additions to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
property and equipment. Amortization of assets under capital leases is included in depreciation expense. Upon retirement or sale, the cost and related accumulated depreciation of assets disposed
of are removed from the accounts and any resulting gain or loss is reflected in the statement of operations and comprehensive loss. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Impairment of long-lived
assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company reviews its long-lived assets, including property and equipment and intangible assets, for impairment whenever events or changes in
circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition are
less than the carrying amount. The impairment loss, if recognized, would be based on the excess of the carrying value of the impaired asset over its respective fair value. During the years ended December&nbsp;31, 2019 and 2020, the Company recorded
asset impairments totaling $10 and $1,185, respectively, on certain intangible assets and certain laboratory and office equipment (see Note 3). </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research and
development costs </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Research and development costs are expensed as incurred and consist primarily of employees&#146; salaries and related benefits, including
stock-based compensation and termination expenses for employees engaged in research and development efforts, allocated overhead including rent, depreciation, information technology and utilities, contracted services, license fees, and external
expenses to conduct and support the Company&#146;s operations that are directly attributable to the Company&#146;s research and development efforts. Payments made to third parties under these arrangements in advance of the performance of the related
services by the third parties are recorded as prepaid expenses until the services are rendered. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Costs incurred in obtaining technology licenses including upfront
and milestone payments incurred under the Company&#146;s licensing agreements are recorded as expense in the period in which they are incurred, provided that the licensed technology, method or process has no alternative future uses other than for
the Company&#146;s research and development activities. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Research contract costs and accruals </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company enters into various research and development and other agreements with commercial firms, researchers, and others for provisions of goods and services from
time to time. These agreements are generally cancellable, and the related costs are recorded as research and development expenses as incurred. The Company records accruals for estimated ongoing research and development costs. When evaluating the
adequacy of the accrued liabilities, the Company analyzes progress of the studies or clinical trials, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates are made in determining
the accrued balances at the end of any reporting period. Actual results could differ materially from the Company&#146;s estimates. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redeemable convertible
preferred stock </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records all shares of redeemable convertible preferred stock at their respective fair values on the dates of issuance, net of
issuance costs. The carrying value of the Company&#146;s redeemable convertible preferred stock is adjusted to reflect dividends if and when declared by the Company&#146;s board of directors. No dividends have been declared by the board of directors
since inception. The Company classifies its redeemable convertible preferred stock separate from total stockholders&#146; deficit, as the redemption of such stock is not solely under the control of the Company. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-Based compensation </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company recognizes compensation expense based on estimated fair values for all stock-based payment awards made to the Company&#146;s employees, nonemployee directors
and consultants that are expected to vest. The valuation of stock option awards is determined at the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model requires the Company to make assumptions and
judgements about the inputs used in the calculations, such as the fair value of the common stock, expected term, expected volatility of the Company&#146;s common stock, risk-free interest rate and expected dividend yield. The valuation of restricted
stock awards is measured by the fair value of the Company&#146;s common stock on the date of the grant. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For all stock options granted, the Company calculated the
expected term using the simplified method (derived from the average midpoint between the weighted average vesting period and the contractual term of the award) for &#147;plain vanilla&#148; stock option awards, as the Company has limited historical
information to develop expectations about future exercise patterns and post vesting employment termination behavior. The estimate of expected volatility is based on comparative companies&#146; volatility. The risk-free rate is based on the yield
available on United States Treasury <FONT STYLE="white-space:nowrap">zero-coupon</FONT> issues corresponding to the expected term of the award. The Company records forfeitures when they occur. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of the shares of common stock underlying the stock options has historically been determined by the board of directors with the assistance of management
and input from an independent third-party valuation firm, as there was no public market for the common stock. The board of directors determines the fair value of the Company&#146;s common stock by considering a number of objective and subjective
factors, including the valuation of comparable companies, sales of redeemable convertible preferred stock, the Company&#146;s operating and financial performance, the lack of liquidity of common stock, and general and industry specific economic
outlook, amongst other factors. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company records compensation expense for service-based awards on a straight-line basis over the requisite service period, which
is generally the vesting period of the award. The amount of stock-based compensation expense recognized during a period is based on the value of the portion of the awards that are ultimately expected to vest. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Income taxes </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for income taxes using the asset
and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been recognized in the financial statements or in the Company&#146;s tax returns. Deferred tax
assets and liabilities are determined based on the difference between the financial statement and tax basis of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Changes in
deferred tax assets and liabilities are recorded in the provision for income taxes. The Company assesses the likelihood that its deferred tax assets will be recovered from future taxable income and, to the extent it believes, based upon the weight
of available evidence, that it is more likely than not that all or a portion of the deferred tax assets will not be realized, a valuation allowance is established through a charge to income tax expense. Potential for recovery of deferred tax assets
is evaluated by estimating the future taxable profits expected and considering prudent and feasible tax planning strategies. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company accounts for uncertainty in
income taxes recognized in the financial statements by applying a <FONT STYLE="white-space:nowrap">two-step</FONT> process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood
that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed <FONT STYLE="white-space:nowrap">more-likely-than-not</FONT> to be sustained, the tax position is then assessed to determine the amount of
benefit to recognize in the financial statements. The amount of the benefit that may </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
be recognized is the largest amount that is more likely than not of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax allowance, or
unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Net loss per share attributable to common
stockholders </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Net loss per share of common stock is computed using the <FONT STYLE="white-space:nowrap">two-class</FONT> method required for multiple classes
of common stock and participating securities based upon their respective rights to receive dividends as if all income for the period has been distributed. The rights, including the liquidation and dividend rights and sharing of losses, of the
Class&nbsp;A and Class&nbsp;B common stock are identical, other than voting rights. As the liquidation and dividend rights and sharing of losses are identical, the undistributed earnings are allocated on a proportionate basis and the resulting net
loss per share attributed to common stockholders is therefore the same for Class&nbsp;A and Class&nbsp;B common stock on an individual or combined basis. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company&#146;s participating securities include the Company&#146;s redeemable convertible preferred stock, as the holders are entitled to receive noncumulative dividends on a pari passu basis in the event that a dividend is paid on common stock. The
Company also considers any shares issued on the early exercise of stock options subject to repurchase to be participating securities because holders of such shares have <FONT STYLE="white-space:nowrap">non-forfeitable</FONT> dividend rights in the
event a dividend is paid on common stock. The holders of redeemable convertible preferred stock, as well as the holders of early exercised shares subject to repurchase, do not have a contractual obligation to share in losses of the Company, and
therefore during periods of loss there is no allocation required under the <FONT STYLE="white-space:nowrap">two-class</FONT> method. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Basic net loss per share
attributable to common stockholders is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of shares of common stock outstanding during the period, adjusted for outstanding shares that are subject
to repurchase. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Diluted net loss per share is computed by giving effect to all potentially dilutive securities outstanding for the period using the treasury stock
method or the <FONT STYLE="white-space:nowrap">if-converted</FONT> method based on the nature of such securities. For periods in which the Company reports net losses, diluted net loss per common share attributable to common stockholders is the same
as basic net loss per common share attributable to common stockholders, because potentially dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Leases </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company leases office and laboratory space under operating
leases and laboratory equipment under capital leases. Leases for which the Company assumes substantially all risks and rewards incidental to ownership of the leased assets are classified as capital leases. The leased assets and the corresponding
lease liabilities (net of interest charges) are recognized on the balance sheet as property and equipment, based on the cost of the equipment, and borrowings, respectively, at the inception of the related lease. Each lease payment is apportioned
between the reduction of the outstanding lease liability and the related interest expense. The interest expense is recorded on a basis that reflects a constant periodic rate of interest on the outstanding finance lease liability. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Leases for which substantially all risks and rewards incidental to ownership are retained by the lessors are classified as operating leases. Payments made under
operating leases (net of any incentive received from the lessors) are recorded on a straight-line basis over the period of the lease. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restructuring costs
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Restructuring costs primarily consist of contract termination costs related to leases and employee termination costs. The Company recognizes restructuring
charges when the liability has been incurred. Key assumptions in </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-34 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
determining the restructuring costs include the terms and payments that may be negotiated to terminate certain contractual obligations, cease use date of leased property and equipment, and the
timing of employees leaving the Company. Accretion expenses related to restructuring costs are included in general and administrative expenses. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value
option </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The convertible notes issued in 2020, for which the Company elected the fair value option, are accounted for at fair value on a recurring basis with
changes in fair value recognized in the statement of operations and comprehensive loss. Interest accrued on the convertible notes is recorded to interest expense. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Fair value measurements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value is defined as the exchange price
to sell an asset or transfer a liability (exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants at the measurement date. Fair value should be based on the
assumptions market participants would use when pricing the asset or liability. The valuation hierarchy is based upon the transparency of inputs to the valuation of an asset or liability as of the measurement date. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Fair value measurements are classified and disclosed in one of the following three categories: </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;1&#151;Quoted unadjusted prices for identical instruments in active markets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;2&#151;Quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not
active, and model-derived valuations in which all observable inputs and significant value drivers are observable in active markets. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:arial">Level&nbsp;3&#151;Model derived valuations in which one or more significant inputs or significant value drivers are unobservable, including assumptions
developed by the Company. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The carrying amounts of the Company&#146;s cash and cash equivalents, prepaid expenses and other current assets, accounts payable and
accrued expenses approximate their fair value due to their short-term nature. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Money market funds are highly liquid investments that are actively traded. The pricing
information for the Company&#146;s money market funds are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level&nbsp;1 of the fair value hierarchy.
There were no transfers between Levels 1, 2, or 3 for any of the periods presented. As of December&nbsp;31, 2019, and 2020, the Company held $2,470 and $52,301, respectively, in money market funds with no unrealized gains or losses. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The estimated fair value of the convertible notes, which is classified as Level&nbsp;3 of the fair value hierarchy, is determined by using a scenario-based analysis that
estimates the fair value of the convertible notes based on the probability-weighted present value of expected future investment returns, considering possible outcomes available to the noteholder, including conversions in subsequent equity
financings, change of control transactions, settlement and dissolution. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently adopted accounting pronouncements </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In November 2016, the FASB issued Accounting Standards Update (&#147;ASU&#148;) <FONT STYLE="white-space:nowrap">2016-18,</FONT> <I>Statement of Cash Flows &#150;
Restricted Cash</I> <I>(Topic 230)</I>. This standard requires companies to include amounts generally described as restricted cash and restricted cash equivalents in cash and cash equivalents when reconciling
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-35 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">beginning-of-period</FONT></FONT> and
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">end-of-period</FONT></FONT> total amounts shown on the statement of cash flows. The Company adopted this standard as of January&nbsp;1, 2019 on a retrospective basis. The adoption of
this standard did not have a material impact on its financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On June&nbsp;20, 2018, the FASB issued ASU
<FONT STYLE="white-space:nowrap">No.&nbsp;2018-07,</FONT> <I>Compensation&#151;Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting</I>, to reduce cost and complexity and to improve financial reporting for
share-based payments issued to nonemployees (for example, service providers, external legal counsel, suppliers, etc.). This includes allowing for the measurement of awards at the grant date and recognition of awards with performance conditions when
those conditions are probable, both of which are earlier than under current guidance for nonemployee awards. The Company adopted this standard as of January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a material
impact on its financial statements. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2018, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2018-13,</FONT> <I>Disclosure Framework &#150;
Changes to the Disclosure Requirements for Fair Value Measurement</I>, which amends ASC 820, Fair Value Measurement. This standard modifies the disclosure requirements for fair value measurements by removing, modifying, or adding certain
disclosures. The Company adopted this standard as of January&nbsp;1, 2020 on a retrospective basis. The adoption of this standard did not have a material impact on its financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Recently issued accounting pronouncements </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In February 2016, the FASB
issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2016-02</FONT><I>, Leases (Topic 842)</I>, subsequently amended by ASU <FONT STYLE="white-space:nowrap">2018-10,</FONT> ASU <FONT STYLE="white-space:nowrap">2018-11,</FONT> ASU <FONT
STYLE="white-space:nowrap">2018-20,</FONT> ASU <FONT STYLE="white-space:nowrap">2019-01</FONT> and ASU <FONT STYLE="white-space:nowrap">2019-10,</FONT> which sets out the principles for the recognition, measurement, presentation and disclosure of
leases for both lessors and lessees of a contract. The new standard requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed
purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. A lessee is also required to record a <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">right-of-use</FONT></FONT> asset and a lease liability for all leases with a term of greater than 12 months regardless of their classification on the balance sheets. Leases with a term of
12 months or less may be accounted for similar to existing guidance for operating leases today. The Company intends to utilize the modified retrospective approach to adopt this standard effective January&nbsp;1, 2022. Additionally, the Company
intends to utilize the package of available practical expedients, which allows it to (i)&nbsp;not reassess whether any expired or existing contracts are or contain leases; (ii)&nbsp;not reassess the lease classification for expired or existing
leases; and (iii)&nbsp;not reassess the treatment of initial direct costs for any existing leases. The Company is currently evaluating the impact this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In December 2019, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2019-12,</FONT> <I>Income Taxes (Topic 740): Simplifying the Accounting for Income
Taxes</I>, which is intended to simplify the accounting for income taxes. This standard removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing standards to improve consistent application. The new
standard will be effective beginning January&nbsp;1, 2022. The Company is currently evaluating the impact this standard will have on its financial statements and related disclosures. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In August 2020, the FASB issued ASU <FONT STYLE="white-space:nowrap">No.&nbsp;2020-06,</FONT> Debt&#151;Debt with Conversion and Other Options (Subtopic <FONT
STYLE="white-space:nowrap">470-20)</FONT> and Derivatives and Hedging&#151;Contracts in Entity&#146;s Own Equity (Subtopic <FONT STYLE="white-space:nowrap">815-40).</FONT> This standard simplifies the accounting for convertible debt instruments and
convertible preferred stock by removing the existing guidance in ASC <FONT STYLE="white-space:nowrap">470-20</FONT> that requires entities to account for beneficial conversion features and cash conversion features in equity, separately from the host
convertible debt or preferred stock. ASU <FONT STYLE="white-space:nowrap">2020-06</FONT> is effective for the Company for annual reporting periods, and interim reporting periods within those annual </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-36 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
periods, beginning after December&nbsp;15, 2023, and early adoption is permitted. The Company is currently evaluating the impact this standard will have on its financial statements. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>3. Other financial statement information </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Prepaid expense and other
current assets </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Prepaid expenses and other current assets consist of the following. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Prepaid expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">332</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">336</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deposits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Receivables on exercise of options</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">83</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">370</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">557</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Property and equipment, net </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Property
and equipment, net consists of the following as of December&nbsp;31, 2019. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Equipment under capital lease</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">929</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Laboratory equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">734</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Leasehold improvements</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">421</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Furniture and fixtures</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">269</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Office equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">61</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,414</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accumulated depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,020</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total property and equipment, net</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,394</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Depreciation and amortization expense for the years ended December&nbsp;31, 2019 and 2020 was $432 and $251, respectively, including
amortization expense related to capital leases of $184 and $108 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended
December&nbsp;31, 2019, the Company disposed of certain laboratory equipment, incurring a loss on disposal of $94, which is included in research and development expense in the Company&#146;s statement of operations and comprehensive loss. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During the year ended December&nbsp;31, 2020, the Company determined that its property and equipment had no future alternative use and recorded an impairment charge of
$1,185. The Company recorded an impairment charge of $1,039 for laboratory equipment and furniture and $146 for office equipment to research and development and general and administrative expense, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-37 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Accrued and other current liabilities </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Accrued and other current liabilities consist of the following. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">318</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">128</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accrued payroll</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">405</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total accrued expenses and other current liabilities</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">423</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">533</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>4. Convertible notes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In March, April, and
May 2020, the Company issued convertible notes to certain existing investors of the Company for cash. The principal amount of the convertible notes was $5,602 in the aggregate with a fixed accrued interest rate of 4% per annum. The convertible notes
were either due on or after December&nbsp;31, 2020 or upon a change of control of the Company, unless earlier converted. No principal or interest was payable prior to maturity as the convertible notes and any accrued interest would automatically
convert upon a qualified financing event at a conversion price equal to 85% of the price per share of the qualified financing. Holders also had the option to convert their notes to shares of Series B redeemable convertible stock at a conversion
price equal to $4.2926 per share on the maturity date or upon a change of control of the Company, if no qualified financing occurred prior to such date. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Due to
certain embedded features within the convertible notes, the Company elected to account for the convertible notes under the fair value option. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table
provides the changes in the fair value of the convertible notes for the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="91%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Issuance of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5,539</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in fair value of convertible notes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,210</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Conversion into Series C redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(6,749</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the outstanding principal, and accrued interest of $134, were automatically converted into 11,404,246 shares of the
Company&#146;s Series C redeemable convertible preferred stock in connection with the closing of the Company&#146;s Series C redeemable convertible preferred stock financing (see Note 5) at a conversion price of $0.5030 per share, which was 85% of
the $0.5918 original issuance price of the Series C redeemable convertible preferred stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-38 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>5. Redeemable convertible preferred stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company&#146;s redeemable convertible preferred stock consisted of the following balances (in thousands, except share amounts). </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="46%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Issue</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>price</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Shares</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>authorized</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Shares<BR>issued&nbsp;and</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>outstanding</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Carrying</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>value</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>liquidation</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>preference</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series Seed</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1.01</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,010,456</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,789</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,020</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series <FONT STYLE="white-space:nowrap">Seed-1</FONT></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,787,640</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,430</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series A</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,120,111</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12,851</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,136</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series B</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.29</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,097,566</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,737</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,882</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Series C</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.59</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">168,756,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,481</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">99,870</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="13" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"> &nbsp;<P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:4pt">&nbsp;</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">182,772,372</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">139,576</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">139,338</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company issued 135,180,800 shares of Series C redeemable convertible preferred stock for a purchase price of $0.5918
per share, payable in cash. Gross proceeds to the Company were $80,000. The Series C redeemable convertible preferred stock financing triggered the automatic conversion of the Company&#146;s outstanding convertible notes into 11,404,246 shares of
Series C redeemable convertible preferred stock based on price of $0.5030 per share (85% of the $0.5918 original issuance price of the Series C redeemable convertible preferred stock). In addition, the Company issued 22,171,553 shares of Series C
redeemable convertible preferred stock to Ares Trading S.A. (&#147;Ares&#148;), an affiliate of Merck KGaA, Darmstadt, Germany, as the initial payment for the Company&#146;s license of atacicept from Ares (see Note 9). </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the Series Seed, <FONT STYLE="white-space:nowrap">Seed-1,</FONT> A, B, and C redeemable convertible preferred stock (together the &#147;redeemable
convertible preferred stock&#148;) have various rights, preferences, privileges, and restrictions, with respect to voting, dividends, liquidation, and conversion as follows: </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Voting </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On any matter presented to the stockholders of the Company for
their action or consideration at any meeting of stockholders of the Company (or by written consent of stockholders in lieu of meeting), each holder of outstanding shares of redeemable convertible preferred stock is entitled to cast the number of
votes equal to the number of whole shares of common stock into which the shares of redeemable convertible preferred stock held by such holder are convertible as of the record date for determining stockholders entitled to vote on such matter. Holders
of redeemable convertible preferred stock may vote, on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis, together with the holders of Class&nbsp;A common stock as a single class. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Dividends </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Through December&nbsp;31, 2020, no dividends have been
authorized, declared, or paid. The Company may not declare, pay or set aside any dividends on any other class or series of capital stock (other than dividends on shares of common stock payable in shares of common stock) unless the holders of
redeemable convertible preferred stock then outstanding first or simultaneously receive a dividend on each outstanding share of redeemable convertible preferred stock in an amount at least equal to (a)&nbsp;in the case of a dividend on common stock
or any class or series that is convertible into common stock, that dividend per share to equal the product of (i)&nbsp;the dividend payable on each share of such class or series determined, if applicable, as if all shares of such class or series had
been converted into common stock and (ii)&nbsp;the number of shares of common stock issuable upon conversion of such share of redeemable convertible preferred stock, in each case calculated on the record date for determination of holders entitled to
receive such dividend or (b)&nbsp;in the case of a dividend on any class </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-39 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
or series that is not convertible into common stock, at a rate per share determined by (i)&nbsp;dividing the amount of the dividend payable on each share of such class or series of capital stock
by the Original Issuance Price of such class or series of capital stock (subject to appropriate adjustment in the event of any stock dividend, stock split, combination or other similar recapitalization with respect to such class or series) and
(ii)&nbsp;multiplying this fraction by an amount equal to the applicable original issue price; provided that, if the Company declares, pays or sets aside, on the same date, a dividend payable to the holders of redeemable convertible preferred stock
is calculated based on the dividend on the class or series of capital stock that would result in the highest preferred stock dividend. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Conversion
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Each share of redeemable convertible preferred stock is convertible, at the option of the holder, at any time and from time to time, and without the payment
of additional consideration by the holder, into such number of fully paid and nonassessable shares of common stock as is determined by dividing the applicable original issue price by the applicable preferred stock conversion price in effect at the
time of conversion. The preferred stock conversion price for each share of redeemable convertible preferred stock is initially equal to the original issue price applicable to such share. Each such initial preferred stock conversion price, and the
rate at which shares of redeemable convertible preferred stock may be converted into shares of common stock, is subject to adjustment. No fractional shares of common stock will be issued upon conversion of redeemable convertible preferred stock. In
lieu of any fractional shares, the Company will pay cash equal to the fraction multiplied by the fair market value of a share of common stock. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Liquidation
preference </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In the event of any voluntary or involuntary liquidation, dissolution or winding up of the Company, the holders of shares of Series C redeemable
convertible preferred stock then outstanding are entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall be made to the holders of Series Seed, Series <FONT
STYLE="white-space:nowrap">Seed-1,</FONT> Series A, and Series B redeemable convertible preferred stock, equal to one times the original issue price of the Series C redeemable convertible preferred stock. If upon any such liquidation, dissolution or
winding up of the Company the assets of the Company available for distribution to its stockholders are insufficient to pay the holders of shares of Series C redeemable convertible preferred stock the full amount to which they shall be entitled, such
holders will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would otherwise be payable in respect of the shares of Series C redeemable convertible preferred stock held by them
upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Thereafter, the holders of Series Seed, Series <FONT
STYLE="white-space:nowrap">Seed-1,</FONT> Series A and Series B redeemable convertible preferred stock then outstanding are entitled to be paid out of the assets of the Company available for distribution to its stockholders, before any payment shall
be made to the holders of common stock, an amount per share equal to the greater of (i)&nbsp;one times the applicable original issue price, plus any dividends declared but unpaid thereon, or (ii)&nbsp;such amount per share as would have been payable
had all shares of such series of redeemable convertible preferred stock been converted into common stock immediately prior to such liquidation, dissolution, or winding up. If upon any such liquidation, dissolution or winding up of the Company the
assets of the Company available for distribution to its stockholders are insufficient to pay the holders of shares of redeemable convertible preferred stock the full amount to which they shall be entitled, the holders of shares of Series Seed,
Series <FONT STYLE="white-space:nowrap">Seed-1,</FONT> Series A, and Series B redeemable convertible preferred stock will share ratably in any distribution of the assets available for distribution in proportion to the respective amounts that would
otherwise be payable in respect of the shares held by them upon such distribution if all amounts payable on or with respect to such shares were paid in full. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-40 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">After the payment of all preferential amounts required to be paid to the holders of shares of redeemable convertible
preferred stock, the remaining assets of the Company available for distribution to its stockholders will be distributed among the holders of shares of Series C redeemable convertible preferred stock and common stock, pro rata based on the number of
shares held by each such holder on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Redemption </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The holders of the Company&#146;s redeemable convertible preferred stock have no rights to cause the redemption of their shares outside of a liquidation or winding up of
the Company, a change in control, or a sale of substantially all of the Company&#146;s assets (a &#147;deemed liquidation event&#148;). A deemed liquidation event would constitute a redemption event that may be outside of the Company&#146;s control
as a result of the preferred stockholders&#146; control of the Company&#146;s board of directors. Accordingly, the redeemable convertible preferred shares are considered contingently redeemable and are classified as temporary equity on the balance
sheets. The carrying value of the redeemable convertible preferred stock has not been adjusted to its redemption value as redemption was not probable as of the balance sheet dates presented. The carrying value of the redeemable convertible preferred
stock will be adjusted to its redemption value in the future, if redemption becomes probable. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Classification </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company has classified its redeemable convertible preferred stock separate from total stockholders&#146; deficit in the balance sheets as the redeemable convertible
preferred shares are contingently redeemable upon a deemed liquidation event and in that event there is no guarantee that all stockholders would be entitled to receive the same form of consideration. No accretion to redemption value was recorded
during the years ended December&nbsp;31, 2019 and 2020 as a deemed liquidation event was not considered probable. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>6. Common stock </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company&#146;s certificate of incorporation, as amended and restated, authorized the Company to issue 273,986,920 shares of
Class&nbsp;A common stock and 21,593,607 shares of Class&nbsp;B common stock, each with a par value of $0.001 per share. Each share of Class&nbsp;A common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#146;s
stockholders. Class&nbsp;B common stock is <FONT STYLE="white-space:nowrap">non-voting.</FONT> The holders of Class&nbsp;A common stock, voting exclusively and as a separate class, have the exclusive right to vote for the election of one director of
the Company. Class&nbsp;A common stockholders and holders of Class&nbsp;B common stock are entitled to receive dividends, as may be declared by the board of directors. Through December&nbsp;31, 2020, no cash dividends had been declared or paid. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>7. Stock compensation </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>2017 Equity Incentive Plan </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2017, the Company&#146;s Board of Directors adopted the Vera Therapeutics, Inc. 2017 Equity Incentive Plan, which provides for the grant of qualified stock options,
nonqualified stock options and other awards, including restricted stock awards, to the Company&#146;s employees, directors, and consultants to purchase up to 286,578 shares of the Company&#146;s Class&nbsp;A common stock. The grants of stock options
and restricted stock awards generally vest either (i)&nbsp;over a four-year period, with 25% vesting on the first anniversary of the grant date and on a ratable monthly basis thereafter for the following three years, or (ii)&nbsp;on a ratable
monthly basis over a three-year period and expire ten years from the date of grant. Certain awards provide for accelerated vesting upon a change of control, as defined in the 2017 Equity Incentive Plan. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-41 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2020, the Company&#146;s Board of Directors voted to amend the 2017 Equity Incentive Plan to increase the aggregate
authorized number of Class&nbsp;A common stock to be 3,052,169 shares. No other changes were made to the 2017 Equity Incentive Plan. As of December&nbsp;31, 2020, there were 1,150,088 shares available for future grant under the 2017 Equity Incentive
Plan. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Stock-based compensation expense </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following tables
summarize the stock-based compensation expense for stock options and restricted stock awards granted to employees and nonemployees that was recorded in the Company&#146;s statements of operations and comprehensive loss for the years ended
December&nbsp;31, 2019 and 2020. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">223</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR></TABLE> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="88%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Employees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">233</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Nonemployees</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total stock-based compensation expense</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">331</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company had $4,219 of unrecognized stock-based compensation expense related to unvested stock options
and restricted stock awards, which is expected to be recognized over a weighted-average period of approximately two years. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The fair value of stock options granted
during the years ended December&nbsp;31, 2019 and 2020, was estimated using the Black-Scholes option pricing model based on the following weighted average assumptions. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected term (in years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;&#150;&nbsp;6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5.5&nbsp;&#150;&nbsp;6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Expected volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">74.0%&nbsp;&#150;&nbsp;74.3%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">86.1%&nbsp;&#150;&nbsp;92.5%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Risk-free rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.19%&nbsp;&#150;&nbsp;2.22%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.41%&nbsp;&#150;&nbsp;1.67%</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Dividend yield</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-42 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following table summarizes the Company&#146;s option activity for the year ended December&nbsp;31, 2020. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="60%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Number of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>options</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>exercise</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>price per</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>share</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Weighted-</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>average</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>remaining</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>contractual</B></P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>life (years)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>intrinsic</B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>value</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>(000s)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance&#151;December 31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7.88</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.19</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,865,091</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.98</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(33,291</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cancelled and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(134,892</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.75</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2.99</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9.79</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Options exercisable&#151;December 31, 2020</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,830</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">3.84</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.17</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested and expected to vest&#151;December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,818,708</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2.96</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">9.92</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate intrinsic value of stock options exercised during the year ended December&nbsp;31, 2019 and 2020 was $6 and $1,
respectively. The weighted average grant date fair value of options granted during the years ended December&nbsp;31, 2019 and 2020 was $4.06 per share and $2.24 per share, respectively. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Restricted stock awards </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, in conjunction with the
Series C redeemable convertible preferred stock issuance, the Company restricted 49,636 shares of fully issued and outstanding Class&nbsp;A common stock held by the Company&#146;s Chief Executive Officer and founder. The restriction allows the
Company to repurchase shares that have not vested. The vesting term of restricted stock is one year. The grant date fair value of the restricted shares was $6.37. The following table summarizes the activity for the Company&#146;s restricted stock
for the year ended December&nbsp;31, 2020. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Number&nbsp;of<BR>shares</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">49,636</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Vested</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(18,613</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">41,363</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">For each of the years ended December&nbsp;31, 2019 and 2020, the Company recognized $1 and $55, respectively, of stock-based compensation
expense related to restricted stock awards that vested during the periods. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>8. Employee benefit plans </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company sponsors a qualified 401(k) defined contribution plan covering eligible employees. Participants may contribute a portion of their annual compensation limited
to a maximum annual amount set by the Internal Revenue Service. There were no employer contributions under this plan for fiscal 2019 and 2020. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>9. Licenses and
collaborations </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Carnegie Mellon University </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2012, PNAi
entered into a license agreement with Carnegie Mellon University (as amended, the &#147;CMU License Agreement&#148;), which was assigned to the Company upon the closing of the Company&#146;s acquisition of PNA in 2017.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-43 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
The CMU License Agreement provided exclusive, worldwide rights to certain patents and <FONT STYLE="white-space:nowrap">know-how</FONT> relating to synthetic oligomers. Under the CMU License
Agreement, the Company is obligated to pay Carnegie Mellon University up to $9,000 in aggregate milestone payments upon the achievement of specific sales-based milestones, which have not yet been met. The Company is also responsible for
reimbursement for future patent expenses and payment of future royalties based on any sales of a licensed product at a percentage in the low single digits. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">If the
Company were to sublicense the technology licensed pursuant to the CMU License Agreement, the Company would be obligated to pay CMU a percentage ranging in the low double-digits of specified sublicensing income received, subject to reduction for a
specified percentage of sublicensing income payments above a specified threshold that the Company may be obligated to pay other third parties. The Company did not achieve any of the development or sales milestones. Accordingly, no royalty or
development milestone payments were made nor required to be made under this agreement. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Yale university </I></B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In 2017, PNAi entered into a collaborative research agreement (the &#147;Yale CRA&#148;) and license agreement (the &#147;Yale License Agreement&#148;) with Yale
University, which were assigned to the Company upon the closing of the acquisition of PNAi by the Company in 2017. The purpose of the agreements was to fund the Yale University research program in the field of
<FONT STYLE="white-space:nowrap">nanoparticle-sized</FONT> nucleic acid mimics and peptide nucleic acids as gene editing therapeutics in return for an exclusive license to certain related patent rights owned by Yale University and the option to
license any patents discovered or generated under the terms of the collaborative research agreement. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Yale CRA required funding the labs of collaborators with
$1,500 per year for a minimum of two years. The Yale CRA expired in 2019. No payments were made to Yale University pursuant to the Yale CRA during the year ended December&nbsp;31, 2019, with no future obligation under this commitment. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the Yale License Agreement, PNAi paid an initial fee of $37 and had the option to issue 5% of the company&#146;s common stock on a fully diluted, as
converted basis. If the shares were not issued, the agreement could be terminated at Yale University&#146;s option. After the completion of the merger with PNAi, the Company exercised the option and issued 264,301 shares of common stock to Yale
University with a fair value of $100. Under the Yale License Agreement, the Company reimbursed Yale University for patent related expenses. The Company reimbursed Yale University $45 for patent related expenses for the year ended December&nbsp;31,
2019. The Company and Yale agreed to terminate the Yale License Agreement in 2020 and there are no future payment obligations under the Yale License Agreement. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Ares trading S.A. </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company entered into a license
agreement with Ares (the &#147;Ares Agreement&#148;), pursuant to which the Company obtained an exclusive worldwide license to certain patents and related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and
commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could potentially treat some autoimmune diseases. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As consideration for the Ares Agreement, the Company issued to Ares a <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of 22,171,553 shares of
Series C redeemable convertible preferred stock resulting in Ares becoming a related party to the Company. The Series C redeemable convertible preferred stock had a deemed issuance price of $0.5918 per share, or $13,121 in the aggregate. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-44 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company has paid Ares $25,000 in milestone payments upon delivery and initiation of
the transfer of specified information and materials. The Company is obligated to pay Ares aggregate milestone payments of up to $176,500 upon the achievement of specified BLA filing or regulatory approval milestones and up to $515,000 upon the
achievement of specified commercial milestones. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The <FONT STYLE="white-space:nowrap">non-refundable</FONT> license issue fee of $13,121 and milestone payments of
$25,000 are recorded to research and development expense. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Commencing on the first commercial sale of licensed products, the Company is obligated to pay Ares tiered
royalties of low double-digit to <FONT STYLE="white-space:nowrap">mid-teen</FONT> percentages on annual net sales of the licensed products covered by the license. The Company is obligated to pay royalties on a licensed
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">product-by-</FONT></FONT> licensed product and <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">country-by-country</FONT></FONT> basis from the first commercial sale
of a product<B> </B>in a country until the latest of (i) 15 years after the first commercial sale of such licensed product in such country; (ii)&nbsp;the expiration of the last valid claim of a licensed patent that covers such licensed product in,
or its use, importation or manufacture with respect to, such country; and (iii)&nbsp;expiration of all applicable regulatory exclusivity periods, including data exclusivity, in such country with respect to such product. If the Company were to
sublicense its rights under the Ares Agreement, the Company is obligated to pay Ares a percentage ranging from the mid single-digit to the low double-digits of specified sublicensing income received. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>10. Income taxes </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The provision for income taxes for the years ended
December&nbsp;31, 2019 and 2020 consisted of the following. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="90%"></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Current:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Federal</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total current provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred provision</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total provision for income taxes</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">A reconciliation of the provision for income taxes computed using the U.S. statutory federal income tax rate compared to the income tax
provision included in the statement of operations and comprehensive loss is as follows. </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>Year ended<BR>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Tax at U.S. statutory rate on income before income taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(2,409</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(11,217</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Change in valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,986</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and development credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(635</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">122</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">State taxes</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">45</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">109</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total provision for income taxes</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Deferred tax assets and liabilities are determined based on the differences between financial reporting and income tax bases of assets
and liabilities, as well as net operating loss carryforwards and are measured using </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-45 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
the enacted tax rates and laws in effect when the differences are expected to reverse. The significant components of the Company&#146;s deferred tax assets and liabilities are as follows. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="80%"></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="5%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net operating loss carryforwards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,267</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">9,681</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Research and other tax credits</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,603</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,652</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">25</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Intangible assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8,019</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Stock-based compensation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">119</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Reserves and accruals</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">108</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">554</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,068</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">21,050</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(10,002</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(21,050</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax assets, net of valuation allowance</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">66</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="5"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD>
<TD HEIGHT="5" COLSPAN="4"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Deferred tax liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Property and equipment</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total deferred tax liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(66</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Net deferred tax assets</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As of December&nbsp;31, 2020, the Company has federal and state net operating loss carryforwards of $44,007 and $3,531, respectively, of
which $10,246 of federal net operating loss carryforwards and $3,531 of state net operating carryforwards will begin expiring in the year 2032 and 2036, respectively, if not utilized. The Company also has $33,761 of federal net operating loss
carryforwards as of December&nbsp;31, 2020 that does not expire as a result of recent tax law changes. The Company has $2,159 and $1,156 of federal and state research and development tax credit carryforwards, which will begin to expire in the year
of 2037 and 2033, respectively. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Utilization of the federal and state net operating loss and tax credit carryforwards may be subject to a substantial annual
limitation due to the &#147;change in ownership&#148; provisions of the Internal Revenue Code of 1986. The annual limitation may result in the expiration of net operating losses and credits before utilization. The Company has not performed an
analysis to determine if such ownership changes have occurred. An analysis will be performed prior to recognizing the benefits of any losses or credits in the financial statements. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">Management assesses the available positive and negative evidence to estimate if sufficient future taxable income will be generated to use the existing deferred tax
assets. Based on the weight of all evidence including a history of operating losses, management has determined that it is not more likely than not that the net deferred tax assets will be realized. A valuation allowance of $10,002 and $21,050 for
the year ended December&nbsp;31, 2019 and 2020 has been established to offset the deferred tax assets as realization of such assets is uncertain. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company
accounts for income taxes in accordance with authoritative accounting guidance which states the impact of an uncertain income tax position is recognized at the largest amount that is &#147;more likely than not&#148; to be sustained upon audit by the
relevant taxing authority. An uncertain tax position will not be recognized if it has less than a 50% likelihood of being sustained. As of December&nbsp;31, 2019 and 2020, the Company had no material unrecognized tax benefits. No significant
interest or penalties were recorded during the years ended December&nbsp;31, 2019 and 2020. We are currently unaware of any uncertain tax positions that could result in significant additional payments, accruals, or other material deviation in this
estimate over the next 12 months. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-46 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal
course of business, the Company is subject to examination by the United States and state jurisdictions where applicable. There are currently no pending income tax examinations. The Company&#146;s tax years from inception to 2020 are subject to
examination by the federal and various state tax authorities due to the carryforward of unutilized net operating losses. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Coronavirus Aid, Relief, and Economic
Security Act (the &#147;CARES Act&#148;) was enacted March&nbsp;27, 2020. The CARES Act provided for various payroll tax incentives, changes to net operating loss carryback and carryforward rules, business interest expense limitation increases, and
bonus depreciation on qualified improvement property. Additionally, the Consolidated Appropriations Act of 2021, which was signed on December&nbsp;27, 2020, provided additional COVID relief provisions for businesses. The Company has evaluated the
impact of both statutes and has determined that any impact is not material to its financial statements. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>11. Commitments and contingencies </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The aggregate future minimum lease payments for operating leases as of December&nbsp;31, 2020, are as follows. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="81%"></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Year ending December&nbsp;31,</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Operating</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>leases(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Sublease</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>income</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2021</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,838</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(1,746</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2022</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,295</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,804</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2023</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,351</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,864</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2024</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,221</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,926</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">2025</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,075</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,483</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total payments</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">11,780</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">(8,823</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">)&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:7.5pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="2%" VALIGN="top" ALIGN="left">(1)</TD>
<TD WIDTH="1%" VALIGN="top" STYLE="font-size:8pt">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Future minimum lease payments include repayment of outstanding restructuring liabilities </TD></TR></TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Facilities leases
</I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2015, PNAi entered a lease for approximately 3,800 square feet of office and laboratory space for a term of 39 months in Woburn, Massachusetts. In
January 2018, the Company elected to renew this lease for three years, beginning in August 2018. In connection with the lease, the Company maintains a letter of credit issued to the lessor in the amount of $50, which is secured by restricted cash
that is classified as noncurrent based on the term of the underlying lease. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In April 2018, the Company entered into a lease for approximately 24,606 square feet of
office and life science research space, which commenced on October&nbsp;1, 2018, when the Company obtained control of the rented space for a term of 84 months in South San Francisco, California (the South San Francisco Lease). In connection with the
lease, the Company maintains a letter of credit issued to the lessor in the amount of $293, which is secured by restricted cash that is classified as noncurrent based on the term of the underlying lease. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The Company&#146;s total future minimum commitment due pursuant to the South San Francisco Lease is $11,128 as of December&nbsp;31, 2020. In November 2020, the Company
entered into a <FONT STYLE="white-space:nowrap">non-cancellable</FONT> sublease agreement for the facility, under the terms of which the Company is entitled to receive $8,823 in sublease payments over the term of the sublease, which ends
concurrently with the original lease in September 2025. As tenant, the Company remains responsible for the $11,128 minimum lease commitment on the facilities. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company recorded rent expense totaling $1,726 and $2,089 for the years ended December&nbsp;31, 2019 and 2020, respectively. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-47 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial"><B><I>Equipment lease </I></B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The
Company has certain leases on research and laboratory equipment with total future minimum commitments of $581 as of December&nbsp;31, 2020.<I> </I>The Company recorded rent expense totaling $416 and $298 for the years ended December&nbsp;31, 2019
and 2020, respectively. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>12. Restructuring and related activities </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">During
the year ended December&nbsp;31, 2019, the Company completely vacated its leased facilities in Woburn, Massachusetts. In connection with vacating the leased spaces, the Company recorded a discounted lease-related restructuring liability, which was
calculated as the present value of the estimated future facility costs for which the Company would obtain no future economic benefit over the term of the lease, reduced for actual or estimated sublease rentals. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In July 2020, the Company initiated a restructuring plan to reduce operating expense as a result of the disposal of PNAi technology. The restructuring plan included
reducing the number of employees, vacating leased facilities, and ceasing use of leased equipment. </P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">As a result of this restructuring plan, the Company completely
vacated its leased facilities in South San Francisco, California, which was subleased to a third party in November 2020, and returned certain leased equipment to the lessor. The Company recorded a discounted lease-related restructuring liability of
$2,228 and $768 for the abandonment of the leased facilities and equipment, which was calculated as the present value of the estimated future lease costs for which the Company would obtain with no future economic benefit over the term of the leases.
In addition, the Company recognized restructuring liability of $321 related to severance and other employee termination costs related to the reduction in the number of employees. The Company expects this restructuring plan to be completed in 2021.
</P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The activity related to the restructuring liabilities for the years ended December&nbsp;31, 2019 and 2020 are as follows. </P>
<P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="70%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B><FONT STYLE="white-space:nowrap">Lease-related</FONT></B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>exit costs</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:arial" ALIGN="center"><B>Employee</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:9pt; font-family:arial" ALIGN="center"><B>termination</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">261</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(102</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of December&nbsp;31, 2019</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">173</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Restructuring costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">321</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,317</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Accretion</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Cash payments</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(609</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(309</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(918</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Balance as of December&nbsp;31, 2020</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,584</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">$</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">2,596</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-48 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>13. Net loss per common share </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The following outstanding potentially dilutive shares were excluded from the computation of diluted net loss per share attributable to common stockholders for the
periods presented, because including them would have been anti-dilutive (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> basis). </P> <P STYLE="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="77%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="4" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD>
<TD HEIGHT="4" COLSPAN="8" STYLE="BORDER-TOP:2.00pt solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00px solid #000000"><B>December&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:9pt">
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2019</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="BORDER-BOTTOM:1px solid #000000"><B>2020</B></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Redeemable convertible preferred stock</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,209,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15,774,014</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Class&nbsp;A common stock options issued and outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">158,599</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,855,507</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Unvested restricted stock awards</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,340</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,363</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD COLSPAN="5" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:arial">Total</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">1,378,538</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000" ALIGN="right">17,670,884</TD>
<TD NOWRAP VALIGN="bottom" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>14. Related party transactions </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October
2018, the Company entered into a sublease agreement for a portion of its South San Francisco office space, the term for which commenced on December&nbsp;7, 2018. The Chief Executive Officer of the sublessor is a member of the Company&#146;s board of
directors. The initial sublease was established for approximately 400 square feet of space. Prior to the initial expiration of the sublease in April 2019, the space was expanded to approximately 3,700 square feet with the term of the lease extended
for an additional two years. The monthly rent charged by the Company to the subtenant is subject to escalating rent payments according to the terms of the Company&#146;s lease agreement, and the subtenant is required to reimburse the Company for
monthly facility operating expenses based on its proportionate share of total square footage pursuant to the lease. The Company&#146;s lease agreement provides that 50% of any profit resulting from the excess of the amount collected from the
subtenant less the sum of monthly rent, operating expenses and reimbursement of direct expenditures made by the Company in order to arrange and maintain the sublease is to be shared with the lessor. To date, no profit has been realized on the
sublease arrangement as the monthly collections from the subtenant are equivalent to the Company&#146;s cost of rent, operating expense and recovery of professional fees to arrange the sublease. In June 2020, the sublease agreement was terminated.
During the years ended December&nbsp;31, 2019 and 2020, the Company recognized $279 and $160, respectively, of sublease income under this agreement, which was recorded as a reduction to the Company&#146;s rent expense. </P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">In October 2020, the Company entered into the Ares Agreement with Ares, pursuant to which the Company obtained an exclusive worldwide license to certain patents and
related <FONT STYLE="white-space:nowrap">know-how</FONT> to research, develop, manufacture, use and commercialize therapeutic products containing atacicept, a recombinant fusion protein used to inhibit B cell growth and differentiation, which could
potentially treat some autoimmune diseases. (See Note 9.) </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15A. Subsequent events </B></P>
<P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On January&nbsp;27, 2021, the Company entered into an asset purchase agreement with Neubase Therapeutics, Inc. (&#147;Neubase&#148;), whereby the Company agreed to sell
all assets relating to its investment in PNAi, including all inventory, machinery, intellectual property, goodwill and licenses, including the CMU License Agreement, and Neubase agreed to assume certain related liabilities. </P>
<P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>15B. Subsequent events </B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">On May&nbsp;7, 2021, the Company filed a certificate
of amendment to its fourth amended and restated certificate of incorporation to effect a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">11.5869-for-one</FONT></FONT> reverse stock split of its issued and outstanding Class&nbsp;A
common </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-49 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial">
stock. Adjustments corresponding to the reverse stock split were made to the ratio at which the Company&#146;s redeemable convertible preferred stock will convert into Class&nbsp;A common stock.
Accordingly, all share and per share amounts related to Class&nbsp;A common stock, stock options and restricted stock awards for all periods presented in the accompanying financial statements and notes thereto have been retroactively adjusted, where
applicable, to reflect the reverse stock split. </P> <P STYLE="margin-top:16pt; margin-bottom:0pt; font-size:12pt; font-family:arial"><B>16. Events (unaudited) subsequent to the date of the report of the independent registered public accounting firm
</B></P> <P STYLE="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:arial">The sale relating to the Company&#146;s investment in PNAi closed on April&nbsp;26, 2021. The Company received $796 in cash and 308,635 shares of Neubase common
stock, with a fair market value of $1,759 based on the closing price reported on Nasdaq on the date the sale closed. Of the total Neubase shares issued to the Company, 162,260 were placed in escrow to secure certain obligations under the agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:arial" ALIGN="center">F-50 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>4,993,067 shares </I></B></P>
<P STYLE="font-size:100pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g210084g01o02.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:67pt; margin-bottom:0pt; font-size:18pt; font-family:arial" ALIGN="center"><B><I>Class&nbsp;A common stock </I></B></P>
<P STYLE="margin-top:67pt; margin-bottom:0pt; font-size:24pt; font-family:arial" ALIGN="center"><B>Prospectus </B></P> <P STYLE="font-size:67pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:arial; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:arial; font-size:14pt">
<TD VALIGN="bottom"><B>J.P. Morgan</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>Cowen</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><B>Evercore ISI</B></TD></TR>
</TABLE> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:10pt; font-family:arial">February&nbsp;10, 2022 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g210084g01o02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g01o02.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[27*4&AO=&]S:&]P(#,N,  X0DE-! 0
M    ):Z^ED8X0DE-!"4      !                      .$))300Z
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M8F]O;       0W)N0V)O;VP      $-N=$-B;V]L      !,8FQS8F]O;
M    3F=T=F)O;VP      $5M;$1B;V]L      !);G1R8F]O;       0F-K
M9T]B:F,    !        4D="0P    ,     4F0@(&1O=6) ;^
M  !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@            0G)D
M5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O;VP!     %!G
M4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2;'0
M      !4;W @56YT1B-2;'0               !38VP@56YT1B-0<F- 60
M         !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T
M;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C
M=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG       X0DE- ^T
M     ! #O_XU  (  @.__C4  @ ".$))300F       .             #^
M   X0DE-! T       0    >.$))3009       $    'CA"24T#\P
M"0           0 X0DE-)Q        H  0         ".$))30/U      !(
M "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H
M   &       ! #4    ! "T    &       !.$))30/X      !P  #_____
M________________________ ^@     ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@  #A"24T$"       $     $   )    "0      X
M0DE-!!X       0     .$))300:      ,U    !@             !O0
M!,@          0                         !              3(   !
MO0                     !                         !     !
M    ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q    !
M  !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !
MO0    !29VAT;&]N9P  !,@    &<VQI8V5S5FQ,<P    %/8FIC     0
M    !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O=7!)1&QO
M;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN    #6%U=&]'
M96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !);6<@
M!F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M     $QE9G1L;VYG          !"=&]M;&]N9P   ;T     4F=H=&QO;F<
M  3(     W5R;%1%6%0    !        ;G5L;%1%6%0    !        37-G
M951%6%0    !       &86QT5&%G5$585     $       YC96QL5&5X=$ES
M2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z06QI9VYE
M;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E<G1!;&EG
M;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +8F=#;VQO
M<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4    )=&]P
M3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<         #&)O='1O
M;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P      .$))300H
M       ,     C_P        .$))3001       ! 0 X0DE-!!0       0
M   %.$))300,     !NS     0   *     Z   !X   ;,   !N7 !@  ?_8
M_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'0B!865H@!\X
M @ )  8 ,0  86-S<$U31E0     245#('-21T(               $  /;6
M  $     TRU(4" @
M                   18W!R=    5     S9&5S8P   80   !L=W1P=
M ?     48FMP=    @0    4<EA96@   A@    49UA96@   BP    48EA9
M6@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E9    TP   "&
M=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D=&5C:   !#
M   ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P   @,=&5X=
M  !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D($-O;7!A;GD
M &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ               2<U)'
M0B!)14,V,3DV-BTR+C$
M                         %A96B        #S40 !     1;,6%E:(
M                  !865H@        ;Z(  #CU   #D%A96B        !B
MF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C         !9)14,@
M:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T<#HO+W=W=RYI
M96,N8V@
M        9&5S8P         N245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C
M;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q.38V+3(N,2!$
M969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M         &1E<V,         +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO
M;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N8V4@5FEE=VEN
M9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M          !V:65W       3I/X %%\N !#/%  #[<P !!,+  -<G@    %8
M65H@      !,"58 4    %<?YVUE87,          0
M      */     G-I9R      0U)4(&-U<G8        $      4 "@ / !0
M&0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T <@!W 'P @0"&
M (L D "5 )H GP"D *D K@"R +< O #! ,8 RP#0 -4 VP#@ .4 ZP#P /8
M^P$! 0<!#0$3 1D!'P$E 2L!,@$X 3X!10%, 5(!60%@ 6<!;@%U 7P!@P&+
M 9(!F@&A :D!L0&Y <$!R0'1 =D!X0'I ?(!^@(# @P"% (= B8"+P(X D$"
M2P)4 ET"9P)Q GH"A *. I@"H@*L K8"P0++ M4"X +K O4#  ,+ Q8#(0,M
M S@#0P-/ UH#9@-R WX#B@.6 Z(#K@.Z \<#TP/@ ^P#^00&!!,$( 0M!#L$
M2 15!&,$<01^!(P$F@2H!+8$Q 33!.$$\ 3^!0T%' 4K!3H%2058!6<%=P6&
M!98%I@6U!<4%U07E!?8&!@86!B<&-P9(!ED&:@9[!HP&G0:O!L &T0;C!O4'
M!P<9!RL'/0=/!V$'= >&!YD'K >_!]('Y0?X" L('P@R"$8(6@AN"(((E@BJ
M"+X(T@CG"/L)$ DE"3H)3PED"7D)CPFD";H)SPGE"?L*$0HG"CT*5 IJ"H$*
MF JN"L4*W KS"PL+(@LY"U$+:0N "Y@+L O("^$+^0P2#"H,0PQ<#'4,C@RG
M#, ,V0SS#0T-)@U #5H-= V.#:D-PPW>#?@.$PXN#DD.9 Y_#IL.M@[2#NX/
M"0\E#T$/7@]Z#Y8/LP_/#^P0"1 F$$,081!^$)L0N1#7$/41$Q$Q$4\1;1&,
M$:H1R1'H$@<2)A)%$F02A!*C$L,2XQ,#$R,30Q-C$X,3I!/%$^44!A0G%$D4
M:A2+%*T4SA3P%1(5-!56%7@5FQ6]%> 6 Q8F%DD6;!:/%K(6UA;Z%QT701=E
M%XD7KA?2%_<8&QA &&48BABO&-48^AD@&449:QF1&;<9W1H$&BH:41IW&IX:
MQ1KL&Q0;.QMC&XH;LAO:' (<*AQ2''L<HQS,'/4='AU''7 =F1W#'>P>%AY
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MUX<[AY^(!(AIB,Z),P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M4;[K:*P*G6C.Z%3S0L*C,E<<B> I^*0;?7DGI]7/3Z ^HJB0 "(@  (B(@
M =Q$1^   #Y$1'] YO\ J"K9#]!KIS!H]JHUOF1(+V.Q.Q32'N=_3?-O3E:1
M4/0.YHN-# JF1PS=1C%ZI/6QJ8B2Q+5,.XEU[E*NQJQ>9/:!Q-]O9=H+:3FQ
MN-+P6W*=I/-O5Q==#I@[+X<+#8,**ZZ\1A5CL;?P(@6'WDFF;U4?LK^0ZGYD
MCR%3H<H59M8-=0W>S&?3UUMM&>,@$)-3('_#F,,?HO4V4GD7(D@U<K0M>;+&
M*J=E%H$;+RUGF2MW/V:OL7[M%J^?^PC7T]PW@+KB/)PX^V/AI_6W5P5+);6R
MD"20@:#.=A(DV.>1E4LJ\S+X7$ZV\;2-U\E7S9CV4?YD^0!-:Q3:3:?->X^9
M;1G//%N=6JZ65P8J"(&60@*K!I*JJ1E2I\.=9=&!K$,FL=)A'('.=10[B1D7
M#^6?/Y!UU1B<38X2RBL,?"L,$0ZG0,DTA #33N #)*^AS.?(!5"HJJ*U+*\S
MEY#MC^@'HH\A\O79.R2:]3TMZ>.UF_5O<5?7;'*\S%1#A!"VY'L2YZ]C*E>X
M*"B?XCMBS==+WIT1]=& A&DU9WC8#N&,(Y0254)B9SB3$</0"7)7(1W!,-K$
M!)=3Z_U<((/+OH9)"D2G0:0$@'[@MY;@ZC78'XF/15^I]?D-GY:JT;@_Z3_&
M+.,9.]DMJ+W89E9)%20@L(UBOTZ+C5_$/7:-;5>VMY>3B '[^D_5I]=4.00\
MHY,0[CJB_P#:]=L[+C,3;Q1@D+)?2R3.P\F,5N8%C/?X1-*.WQ'M4FF*30\2
M5B?,( !]-G9/UT*]BO'TINFDE$K)8ZV#V6J,\*9RMY"W.L8WV&35$O9)1>$B
MJ!CY^N4A^PJ)I6)J*A>Y2G2'\P85O[7,VC@W6.Q<\>QM85NK=];Z@2/<7*C8
MWHF,Z/7KV/VV+A/X7D7ZE6'^R/\ .H#=[OI^]T--(2:R-4B1FR^&H-%P^EK?
MC*+D6ESK,2U*91>6N&,'2DC+,8Y!$JCEY(U:7ND9%,T5GDT^C&R8JCL+A_VB
MX/-R1VT_/B[V0A4ANG4P2N2 $@NQRHS$D!5F2!W)"HKFL"?'S0@LOWJ ;)0'
MF'U3J=?,;^=06(+K-ED7+995NX;JIKH+H*'26062."B2R*J8E.FJF<I3IJ$,
M4Y#E Q1 0 >7X@$$$ @@@@C8(/0@@]"".XK![=JO?= 7K&3.R[-GICM!9C2F
M=:Q".'6(,DS3L#2>7JI!M1<2%6LCE<WJ2.1ZG&(JR*$MY*.[A5F;Y]*%&=K\
MI*V'0'M#X*3%LV;Q403'RR!;VU1=+932'2RQ =%MIG(4IH""4JJ?=R*D4[87
MAE'@RG<@&U8G\8'D?5A^K#KW!-6E>:GJ3IQ2L:-N=L\-Z48+MV?LX3PQ%1K"
M)&[",9@BO8[E9WI%0@Z948U99#[I8IM9%0K=$546K)F@^F99TPA8R1D&LIA\
M1>YR_AQUA'SS2DEF;8BAB77B3S. >2*,'J=$LQ5$#2.JGSFE2&-I'.E'ZDGH
M% \R3_S/0&M:EU$NIAL+U&<HN+9D^8<5W&<)(.S8PPI!R+D]+H<8H)DD'"R8
M@W+9;D[:>(3MRDFI'SY8ZK:,;0L$1C",NG^&N%L;PS:"&U02W<BCWN_=0)[A
MNY /7PH%/]7"IY0 "Y>3FD:N7-S)<MMCI!^% 3RCYGU;U;\AH=*C^A829LDM
M'P-=B).>G)9TDQBH:%8.I26DWJYO%%G'QS%)=X\=+&_*DW;(J*J&^"$$?CEB
MDD2)&DE=(XT!9Y)&"(BCNS,Q"J!YDD 5C@$D  DGL -D_0"I2<:=#_JFY5BV
MTS7M1+M"1SM CA$V1K!0<6/Q24*!B>K!9%ME9L#<YBB ^FO%)*!W_,4/GM4[
MKCSA.T<I)F()&!T1;17%VNP='4EM#+&?J'-92V-TPV(B/[Q53^A(/ZBO(]A^
MECU ]5X-[:LV:NY%KU0C2BI*7& 3A<B5&(0#_FINR8YEK7$0301[%!U,NV"
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MRYN1G2CZ_84@OO-VNKX4_<N151@ZQ!,P!>=M]ID$D5QC*Y7F/F\D70)+.%C
MA'1K9]+/H]@ZMF7RUGA+"?(WTG)! O8:,DLC=(X8E)'-+(W11L =68JBLPQ8
MHGFD6-!MC^@ [DGR _Y =2!6R5Z='2EUFZ==&CD*/76%WS:^C$D;[GJS1;56
MY3KY9,!D&%8!87042F^L84FE:@ER&=-4&:MED;#*H#)GYCXEXNRG$MPQGE:"
MQ5C[OCXG(AC4'X6EUKWB?6N:60'1)$2QH>6K';VL5NOP@%R/BD(^(GSU^ZOR
M'Y[-2=\JM9-?PHFFLFHBLF15)4ATU4E"%.FHF<HE.FH0P"4Y#E$2G(8!*8HB
M @("(< D'8.B.H([@^M*K.[Y?3A85V8V'H&7,"V"%UTJ5FLJI]DJ97X@"QKZ
M)*@L]-:\1P;=L:#KMRF':)(27B7*;6I :12MZ#$9&,E8BU[1X?\ :9?8K&W%
MGD(GR<L40^S)Y'^)7V!X5Y(3XDL* ET<%IOA\$MRLKQ1L^.CED#H1&"?O !T
M(]5'8,>Q\NO-K8(:?;7;7/#FJ>)*KA'!-+C:-CVHM?18QK$HJ/9)^J4@R%@L
M4HKY/I^R3"Q <RTW)*KO7BWB4QR()((I:]R62O<O>37]_.T]S,Q+,W1479*Q
MQ)^&.) =)&H"J/F23GQQI$@2-0JCL!_F3YD^9/4U'IUK-^W.@^F=BL=*DTF6
M<LO/%L7X9,!DS.X66D6*R]EOZ3<X' Y:+7P6?,55$EFA;4_JS5\DHU>J$-8^
M!^'AQ#FXHIT+6%F!=7W[KHK 16Y/_P#(DTK#H?"64J05W6/>3^!"6'XV^!/D
M3W;_  C9]-Z'G6LJ>O7DD\=R,B[<OY!^Y7>OGSU=5T\>O'2IUW3MVZ7.HNY<
MN5U#K+KK'.JLJ<ZBAS',(CU*JJBJB*%50%55 5551H*H&@       !H56B22
M23LGJ2>Y/J:M0=$+H6Q.R4' ;>;C0KX<)O%?>XBPZLH\BG&5R-5Q(6Z71PW.
MVD&F.0<)'+ PS-9J\NZB0R3MTA4"-V]NU+QWQ\^,DDPV$D47RCEO;T<KBTV/
MZB ':FYT?O'8$0 \J@S$F*5LK$2 33#X2=HG[P'[3?PGR'[0[].]XZIU&J4*
MN1%/H]9@*;4J^R2C8&L5:'CX"OPL>@'B@QBH:*;M(^/:)!\)MVC=)(GSXD#N
M/-#S337$KS7$LD\TC%I)9G:21V/=G=R68_,DFIH * %  '0    >@ Z"NP\\
MJ_:ZQ<Z33<C5B9I.0:I7+Q3K$S4CIZJVV%CK#7IEBK_:-).'EF[N/?-S=@'T
MG#=0H& IP #% 0]8)Y[65)[::6">)@T<T+M'(C#L5="&4_,$5^$!@0P# ]P0
M"#]0>AJB[UN^AE':L1$UMKJ'%R2V R/"+93Q.*CV7?8<._<$01M%8?N5'4E)
M8U</%DVTFRDEG,E2G:Z#@'S^M.U JV^^!./GRSIA\RZ#(%=6EY\*"]Y1UAE4
M:5;K0+*R!5G (Y5E \6$O;$1@S0@\G=T[\GS7SY?4?L]_P /:K[&R4C#2+"8
MAW[V*EHIZUDHN4C72[&1C9%BNFZ9/V#UJHDY9O6;E))PU=-U4UVZZ::R2A%"
M%,&UG575D=5='4JZ. RLK AE92"&5@2"""""01JHL$@@@D$'8(Z$$=B#Y$5L
M[NC7OJKO[IA4KY;'S=QFG&[P<7YK23!!%20M<(R:KQET*T1!(J+:]UYS'SJP
MHMF[%&P&L45'D]O% /.5^-N'QP[G)K>%2+&Y7WNQ)V0L,C$-!S'>S;R!H^I+
M&/PW;J]6:SG\>%6)^-?A?^\//7\0T?(;V!VJ5WE1K*K [J1Z0U'J :GY!P'/
M R86E5#\68EM;M(3_@W*<"T>#6)<RA"G5)&/P=/*W9"(E,JM6IN630*#H6ZB
M=@X9SLW#N7MLC'S-$#X-W"#_ %]I(1XJ>G,NEEBWH"6--G6]^%Q"L\31G0)&
MU;]UAV/T\CZ@D5JQK_0[=BZ\6_&U^@WM9N]#LDU4;97I$@)O8:PU^0<1<M'.
M *)B&.U>MEDO52.HBL4I54%%$CD.;K*VN(;NW@NK>02P7$4<T,B]GCE4.C#S
M&U(.CHCL0"*K#*R,R,-,I((/D0=&K07TTG49_93E*0T1RK/>CC[,TJYG\(/Y
M)SV:UG+HMB?<Z:FLN<J;2-R5&LR'BVX'*F%WBV;%BU5DKFY5YJGVH<->]VB\
M06D>[BR01WZJ.LMGOX)R!W:U8Z8ZWX#LS'EA J3QMQRMX#'X7V8_0-U)'R##
MJ/XAKN:O4<T'4W3BE4!_J/NHN&Q>?6VH6,)WW6'-;YQW^.'3!QYQ]TSHFBXB
MYD3"0?!RPQFR</:DQ,/CVL3VY'_K#8(QP'0WLRX:^S<><U=QZO<G&/=PP^*"
MPV&3Z-=,%E;_ +I81T/,*@LE<>(XA4[6,[8CS?T^BCI]2?2J]&',27S/65*!
MAG&$(O8K_DNU1%0JL0AW '$K,.B-DUG:P%,1E&,4S*2$M)+^+6,BVKR1=J)M
M6JRA=D7MY;X^TN;ZZD$5O:PO-*Y\D0;T!^T['2HHZNY55!) J.1&D=40;9B
M!\SZ^@'<GR'6MJIHKJ#0]&-8,9:Y4,J#HE1B0>7&S$;E;NKQD*8 CVY7!]W
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ML^UC($NK'XSR/AAE//$""8P*7NA7BOQ]65(F(^F7M7[Y=B+' OF?^KE$1*0
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MN(E22* B(]Q'E"::6XFEN)Y&EFGD>661SMY))&+N['S9F))^9JS@!0%4
M =@!V%=BYY5^TXI7@^:\T8CQ]7YJ&R!+)2!I>)?1KNH1122<[(L9%FJV<-E&
M1%2)L47;991,CB5<,&IP,(%7,(=N2N-Q>0O98WM(R@1U87$A,<2,K A@Y&V*
MD D1AV'<BL>:XAA!\1NNOP+U8@G7;R_,CSK4WYLQVZQ+EW).-723I(:7<[!
MM#/2 1RZB6<BN6%D3@4QBB24AS,9%$Y3&*HBZ34*82F >==6<_O-K;W&P3+#
M&[<O8.5'.H[?A?F4@C8(T:K!ULZWK9UOOKRWKSUW^=9Y]/#*3-/\588EW)$E
MI1PI;ZB"QR@#EXDS1:V.,0\_S&<&8LF$JV;I_E]%C+N! #%$38.3A(,=PHV
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MD -5R?/BOVG%*<4IQ2H8/J#?X2>TG^)PC_Y 8NY=_9U_IAB?I??^W7=8=_\
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M@5N6SR*QK_[/N)?L++K;7,G+C<FR07!8Z2"?9%O=;/155F,4Q)"B&0R-OPE
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MP6E[%*JHW+%( !R]%1M?N>0Z?L]QV&P-U85 0$ $! 0$ $! >X" _(" A\"
MA\@(?KS6]2%?>*5\ Q3"8"F*(D$"G ! 1*82@8"F /DHB4Q3  ]A\3 /Z" \
M4K[Q2G%*<4J&#Z@W^$GM)_B<(_\ D!B[EW]G7^F&)^E]_P"W7=8=_P#V2;_!
M_O$K6C<ZAJMUM2^DQ_#2TB_R[8[_ -'3YR5Q?_I1GO\ S.Z_WAJTVO\ 9H/_
M  D_V14AO*Y7O3BE.*4XI3BE0*?4):(2FW^FG[1,?0RTSF/5YY-9&K<<R1.O
M)V/'\BQ:I92JT>W2(=5T_-&Q$/;HYJD51T]=T\L0Q24=2Q2'V#[.>($PN;]V
MN7"6656.UE9CI8KA6)M)F).@H9WA8GHJS<[$!-C!OX/&AVHV\6V7Y@ZYE_,
M$?-0*UR7.EZKM7>>A/UNJ=9Z72M*]O[FSJ]]J;)C5<'Y>M+]-I!7RO-"$9P6
M/+C-NSD;1%UA&I48NKS,DLBPMT6W9Q+MTE;F[4;9HGC_ ($GBGGSF&A,MO,S
M2W]E"I,EO(VVDN844;>!SMY44%H7+. 82WA3=C>JRK#*=..B.3T8>2DGLP[
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M#?/S^]!3Y^0 !YZF>31"GD![A>Y^I[_IJOD(!WZ__/2NQ  % "E "E*  4H
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M4XI3BE.*4XI3BE.*4XI3BE.*4XI7\G.1(AU%#E333*8ZBAS 0A"$ 3'.<QA
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M"%N:2-D1F+!C^7/#4K<(Q8&)XWN[>&&2-FZPR7<4XNG0\P_JI7,D0+ :5PS
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44IQ2G%*<4IQ2G%*<4IQ2G%*__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g210084g02b10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g02b10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1.^4&AO=&]S:&]P(#,N,  X0DE-! 0
M    $Z*^4"8X0DE-! 0      #(< @   @  ' )0  I!;G5J($MU:G5R' (%
M !=0;W=E<E!O:6YT(%!R97-E;G1A=&EO;CA"24T$)0      $*^G[W$?EHWB
M-=V!0=(7AD8X0DE-!#H      /\    0     0      "W!R:6YT3W5T<'5T
M    !0    !0<W138F]O; $     26YT965N=6T     26YT90    !#;')M
M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585
M  X 00!0 $X (  M "  40!4 $$ (  M "  ,0      #W!R:6YT4')O;V93
M971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F
M4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O
M9D--64L .$))300[      (M    $     $      !)P<FEN=$]U='!U=$]P
M=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;       4F=S36)O
M;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L<V)O;VP
M $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP      $)C:V=/
M8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M1W)N(&1O=6) ;^            !";" @9&]U8D!OX            $)R9%15
M;G1&(U)L=                $)L9"!5;G1&(U)L=                %)S
M;'15;G1&(U!X;$"!J008        "G9E8W1O<D1A=&%B;V]L 0    !09U!S
M96YU;0    !09U!S     %!G4$,     3&5F=%5N=$8C4FQT
M    5&]P(%5N=$8C4FQT                4V-L(%5N=$8C4')C0%D
M       08W)O<%=H96Y0<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M
M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P         -8W)O<%)E8W12
M:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P      .$))30/M
M   0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@             _@
M.$))300-       $    6CA"24T$&0      !    !XX0DE- _,       D
M          $ .$))32<0       *  $          CA"24T#]0      2  O
M9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R     0!:
M!@       0 U     0 M    !@       3A"24T#^       <   ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@     ________________
M_____________P/H   X0DE-! @      !     !   "0    D      .$))
M300>       $     #A"24T$&@     #00    8             !DL   TH
M    !@!G #  ,@!B #$ ,     $                          0
M       -*   !DL                      0
M   0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"
M=&]M;&]N9P  !DL     4F=H=&QO;F<   TH    !G-L:6-E<U9L3',    !
M3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M!V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I
M;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M    26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O
M<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   9+
M %)G:'1L;VYG   -*     -U<FQ415A4     0       &YU;&Q415A4
M 0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .
M8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       )
M:&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=
M  EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.
M;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M      QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M 0$!          $  @,$!08'" D*"Q   00! P($ @4'!@@% PPS 0 "$0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                _^+__TE#0U]0
M4D]&24Q%  $)OLS^_AX "(!P041"10(0  !P<G1R0TU92TQA8B 'T  ' !H
M!0 I #5A8W-P05!03     !!1$)%                     0  ]M8  0
M  #3+4%$0D4
M              ID97-C    _    '1C<')T   !<    "MW='!T   !G
M !1!,D(P   !L   H@9!,D(R   !L   H@9!,D(Q  "CN   H@9",D$P  %%
MP  ".+1",D$Q  -^=  ".+1",D$R  6W*  ".+1G86UT  ?OW   D)%D97-C
M         !I5+E,N(%=E8B!#;V%T960@*%-73U I('8R
M
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M?CQ\/7P^?#]]0']!@D*%0XE$C4621IA'FDB;29U*GTNC3*9-JDZO3[10NE'
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MHWTEEPCB2'T<E#')6'TED7JOSGU+CQZ5UGV&C0U[3GW7BSQ?M'XWB8E!RW[
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M@74$:)(#@IJZB*/KC,*H%Z!HBP&5))T5B6Z!:YH7B"EL\9==AR=7BI3OAF9
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M[Y 2I,,D98\PF)L#>8R-@EFU<:"OQRRC/)TMP1>009GJNU]\I9;PMC]HB)1
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MTIRZAL$2*YX&ALH  (>3@ "3N[%3E)*$5*T$DG!T6:C<D(ACLJ3ICM]22J%
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MAWAEM9X\AJU6GYMYA?%&EICZA5PU&Y</A0(A6I9"A10(O)7?@]$  (  @ "
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M:F"[O?ZOA6+ZN.>;LF3XLY.')6;BKDYR%VC:J7-<76K"I3Y%BVPWHCXKQFP
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MAGD%M'=D@VRW>&N6F9JE]&S_EVV3CVY-E2. 0V^1DMIL,'#9D*]7*7(6CK=
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M@9G!;#\#WYBA;+X  (  ?]!Y_*%!:GMMH)[,:^)@-)Q_;4%1N9I=;I5" 9B
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MCY&=AQ8$J(YV@R8  (  @ !W$9K=D==J@)B>D,1=%998CX9.NI0KCD@_;9)
MC4XNQ)#*C/0;AI!EC*0$QXTI@SL  (  @ !VLYI%F>MJ2Y@&F(-<W96NELM.
M<Y-AE0P_'I%ED]8N8X_[D](;,(^,D3T$U8P<@T4  (  @ !V:YG6HBMJ I>-
MH'M<BY4GGEQ.')+,G$0^TI#$FQDN)X]+F? ;!X[-DD8$V(M2@T8  (  @ !N
M!JTY89-B ZI=8Y)5.J>W98-'::4[9U<X3:,=:/<G-J(7:AL2*J1_::<  )C3
M;F(  (  @ !M@ZP0:3]ANJD;:H]4_:9&:^%'0*.@;2HX-Z%@;E,G/Z Q;QL2
M<:(M;HH  )<M<VD  (  @ !M%ZJ!<+-A.:>3<7-4F*2T<C=&WJ(#<P$W[9^Y
M<[HG&YYR="X2DJ 3<Y@  )6@>#   (  @ !LH:CJ> A@KZ8#>%-3_:,L>)Q&
M:J!Z>.\WB9XS>4$FW9S<>6P2EYXR>/4  )0P?&,  (  @ !L**>0?VQ@.*2O
M?U!3@:'9?RM%XY\F?P0W,9S0?O0FG9MP?O(2DIR&?N,  )+H@    (  @ !K
MO::'AO)?V:.EAG=3):#'A>1%A9X+A5 VV)NKA.4F;YHHA-42DIL#A+@  )'&
M@    (  @ !K9*6WCGU?D:+2C:]2WY_GC+)%.IT>B[LVAIJ\BQLF.YDEBTH2
MI9FHB:$  )#;@    (  @ !K)*4/EA!?5*(FE/52G)\SDY]$\YQ?DEDV0)GT
MD;,EZ9AAD;P2@IBMC(,  ) G@    (  @ !J\*2AG>-?5J&DG*A2F9Z8FO=$
MV)NBF58V,YD7F,\E_)=JEN<2JI>IC)X "X^*@ @  (  @ !AL[A\8(E5]+5\
M8E))H;*09!@\8:_#9<,MNZV,9R4<DJU$9[@(7*ZD9VL  )-8<M@  (  @ !A
M,+>19]M5Q[1/:0))DK$5:C@\;ZX+:V8MY:N?;&0<\*L*;+H(\:P);&D  )(7
M=VX  (  @ !@ZK8+;NQ5=[*_;Y))7:]R<$4\0ZQ1<0<MUJG.<:<=%*D%<<D)
M7*FE<9T  )#A>X   (  @ !@JK1D==A5);$:=AE(_:W0=F$\!*JK=KHMJJ@@
M=PL=%Z<R=P8)J*=Z=S@  (^_?Q8  (  @ !@:++U?-)4Z:^L?+](OJQ=?*T[
MN:DT?)PMCJ:5?*(=&:6.?)D)ZJ6(?1D  ([!@    (  @ !@+K':@_%4QZZ!
M@Y=(HZLD@RH[FZ?Q@L$M;Z5(@H,=):00@J *)Z/,@CD  (WC@    (  @ !?
M_;#\BQ14M:V-BGU(F*H?B;P[BZ;AB0@M7:0QB+8=*Z+>B2 *9:)*AH@  (TS
M@    (  @ !?V;!7DD94LJS+D7Y(F*E(D'8[A:7YCXDM2Z-!CV4=&*'LCKP*
M?*$?AQ<  (R<@    (  @ !?P:_=F:!4NZPLF+U(HZB1EX$[AZ4TEH0M4J)M
MEBT=,Z$!DTX*DJ BAR8  (P @    (  @ #!$V<57^VNTVDY8K2;[6L^96"(
M(FTD9^YS:6[X:FE=MW"Y;-%&QW)%;Q LSW,F<-T*!'8J<12_(&0E:M&M2V:*
M;(6:CFB_;BR&Z&K2;\MR1FS/<6!<J&ZQ<NM%R7!)=%,KZ'#Q=5T);71H=6N]
M26&5=:>KAF0@=DZ9!V9]=O.%<VBS=Z5P^&K2>%Q;@6S0>1%$RFYP>:\K#V[9
M>@H(Z7+<>BV[=U]+@%VIN&'U@ ^70V1L?\B#[F;!?XUOEVD!?VE:4FL8?TU#
MSVR^?RDJ0FSD?NT(=G&S?H:YS%U5BP2H(& 7B=R5LF*FB+6":64,AY=N4F=B
MAHY9-6F0A:="YVLYA,TIB6L9A!H(%')9@C^X<5O E;.FU%Z2D[N4<&$MD;6!
M,6.BC[9M+68#C=18/&@WC!U"&FGCBJ HY6E^B;$'P7+EA3ZW7%IYH&.ES%U6
MG9Z3:E_UFKJ ,6)PE]YL/63>E3%7:F<:DL!!<6B[D*\H8&@7C\H'?'-9A1"V
MCEE_JPZE!5QBIWR2G%[^H[Y_7V%VH AK;F/GG)E6K68LF8] UF?)ER<G[&;B
ME2('1'.XA.JV"EC4M:RD?ENUL3^2 UY$K*5^NF"QJ"%JSV,=I -6'V5@H'Y
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MHW&,::%9Y7+1:[Y&YG0';;HR.'3U;V 8TG3);]P  (  =LB8A6JA;""*/VQ
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MWH> C$59#8;OB^5-+X8?BR1 /X4LBCLR+X1GB; B-H0&B@$.Y8.@A_(  (
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MMIA :UI0.);G;)Y$T967;<XX:I1A;N,J:I.?;[$9W90S;\X'+I*Q<",  (
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M-Y&.C^5."9!RCZ-"PX\5CLXV;XV0C=LHXHQ7C<(8^8P(C*$'<HE4A0D  (
M@    (  @ !0IJIA5$U&8JB85M([3:<-63TN[*7D6VD@AJ797/<.EZBC70@
M * (8'P  (  <2X  (  @ !/QJB46RI%Q*;,73<ZOZ4>7S(NA:/!8/<@6Z-M
M8BL.QZ6R8@<  )UL914  (  =?@  (  @ !//:938>]%+:268XXZ0:+K91@N
M$:%^9GD@$Z$'9U8.T:+A9PH  )K>:>X  (  >CP  (  @ !.QZ0+:*=$HZ)9
M:=XYI*"V:P$MH9]);  ?P)Z_;)$.QJ _;"@  )AW;RL  (  ??\  (  @ !.
M2Z(+;W%$*Z!K<$XY,Y[%<1$M*YU,<:0?C)RE<?8.P)W9<8X -98 =0D  (
M@    (  @ !-UZ!J=F!#RI[3=O XY)TH=U4LZYN>=Y$?6)K7=YP.V)NI=UX
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M&VZ07C=4$' C87A!K'&89( M=7*E9PD3T7/&9\<  (  <>2/RF7#7+Z"4V?
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M<W2@><5<<'5X>F)0B'8>>M5#FG:=>R4U?W;_>V0E?7<?>Y(1UW>Y>V   (
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MCXE26/Y5*XD16[M)JHC>7E4\]8C$8+PNH8CN8L8=R8GY8_@)I(JH8_T  (
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M/'SP?CU0UWU/?I)%F7UO?K0Y1WUD?K<KFWU/?KH;T7TD?L0)C7W2?S,  (
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MRY$,7C](W)!Y8&<^"H_L8FTQV(^'9#DCY(^O98<2FY&D98X"!HW+9V<  (
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M8(9C@<1%B(92@? ZV(7V@=<O#(5P@:<AFX41@:81+X48@<,"88,1@74  (
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M!YH\8CH\A)EO8]PQ]IB\958F0)A'9HL81YCM9P8(@)A,9U\  (G>;GP  (
M?8   (  @ !%9)>X:.@[W9<,:BDQ7I98:T EJ)72; H7^Y9,;$L(=94/;*\
M (?&="\  (  @    (  @ !$Q963;[X[2I4*<*<PY)1;<5\E3).^<=,7N)0
M<= (DI(I<F0  (80>6<  (  @    (  @ !$.Y/"=IPZSY-:=SDP@I*N=Y8D
M^)(!=[P7:)(>=YD(@H_2>)L  (2R?<H  (  @    (  @ !#R9)!?9 Z;9'V
M?>TP,I%/??@DPY"(?=H70I!S?<@(4HWP?G@  (-%@    (  @    (  @ !#
M@)$$A,8Z)9#.A/0O\9 RA+,DF8]9A&472H\%A(<(A8Q9@U@  ()Q@    (
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MA&I<:^A5 VP$;5])I&UI;KP]+&Z+;_,O>&]/</D?2V\=<8@+_G/0<6X  (
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M\X-<3&!.JX.63]U#A(0$4SXW"H2:5F$HO(6 60(75H>)6EP$<8?56Z(  (
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M)G$L<*M)0W)O<;L^A'-D<J8RH70&<V<E-W0]<^L5!72'<],$8GE#==\  (
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MDXG+491".(GF5(LWM8H75U KQ8I_6;X=F8N86VP,.8T56]8  (9.8-\  (
M<8X  (  @ !*A87Z6&=!'(9+6NDVO(:473PJUX;S7SL<W(?48(0+Y(B>8+\
M (-49;H  (  =H@  (  @ !)C8)47T= %X+(84\UJX,C8RLJ 8.!9+\<((0Q
M9:L+B(2W9<(  ("J:MX  (  >NL  (  @ !(FW[Q9CP_)W^/9\XTPG_^:3<I
M'H!/:E<;E8#!:O@+.X%@:OT  (  <'D  (  ?KX  (  @ !'NGOB;4P^37RP
M;G S_GTV;V@H<7U]<"(:^WVF<&P+$WZ&<(<  (  =E4  (  @    (  @ !&
M^'DQ=%T]E7HM=1TS7'K+=:<GYGL%=@,:<GKG=A,*U'PV=FP  (  >T<  (
M@    (  @ !&3W;0>VP\ZW@#>] RO7B\>_@G77CM?  9^GB$>_L*;7IO?*T
M (  ?W@  (  @    (  @ !%TW3;@KP\AW9$@N R;W<@@I\G.G<Y@DL:)'9R
M@EL*SGBU@@8  (  @    (  @    (  @ ! F9E%2*LWLIBM2^4MHYB43M0A
MJIE143L2>9PR4E,#4IF^5&   (2R7XH  (  < T  (  @  _-Y6\3P0V5)6.
M4=DL+)695&(@2Y9 5F81;IBA5R\#"94563\  (&N9$   (  =0$  (  @  ^
M09(657@U.I(95^$K'I(^6@(?.I+76Z 0H)3#7!\"TI#/7BX  (  :2,  (
M>70  (  @  ];XY]6_TT4(Z?7?8J&([57ZD>9X]D8.@/_Y#782H"JHT&8SH
M (  ;E8  (  ?5@  (  @  \FHL48IHS=(MI9"8I1(NM970=F8PB9DL/IXT0
M9F<"F8G%:(<  (  = 0  (  @    (  @  [RX?R:5TRIHB':H$HD(CE:VL=
M!HE":_$//XFD:]8"IH<#;C   (  >3L  (  @    (  @  [%84I<"DQ](7^
M<.\G^(9W<7D<C8:_<;0.YX:N<88"EH3%=%,  (  ?9@  (  @    (  @  Z
M?(*[=PHQ78//=WPG=H1E=ZX<+H27=Z@.HX1)=Y(";H,">BL  (  @    (
M@    (  @  Z#8"J?B<PYX'V?D\G"X*L?C$;XX+,?@$.D8)<?BX"B8&(?O\
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M*J KGBR=+9HNE2^1,(TQB3*&,X,T@35_-G\W?SB .8(Z?SM^/'P]?#Y\/WU
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M[USP6_%6\DSS/?0J]1+U]O;6][/XC?EB^B_Z]/NQ_&;]$?VS_DW^X?]Q__\
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M;-)MOFZJ;Y9P@G%L<E9S0'0I=1)U^W;D=\UXMGF>>H9[;GQ6?3Y^)7\-?_2
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M:ET)A"F31DN_@S*.^CK8@F:*:"KV@:&%?++VB@*P2*)WB(BKI)%4AQFFN7_
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MLRB$+G>;KER#36KYJ7Z"C5XMI(N!_%%*GX.!F$2BFE:!33B;E/2!$2UOCUN
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M>-1[KT:M>IY\E#(E?+E]I-;O;AB#!<-;;[^"4:]$<52!KII[<MZ!-857=&^
MUW 2=A2 BEKJ=]& /47]>;]_]#&M>_M_G=4T;(^-S\&=;D6,#:V2;^R*8YD
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MAF:E;T22B%.?<@R.9$#J=1*)_B\(>%R%'<298G"P(+)V9-RK@9^R9R6FE(R
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MD1:$ GTICT>#I7!KC7N#,6,WB[6"L57GB?*",TB%B$F!QSNMAIN!6"]WA/J
M["2D@V6 ?HBMD ^+JGR"CDZ*J6_(C(F)?6*DBL.(,E5FB0F&Y$@[AV.%GSN!
MA<Z$6B]MA$V# R3(@M:!HH@ECT>3+7P,C9*1C&]4B\>/GF(GB?N-@53KB$J+
M8D?:AK2)13M5A2.'(R]D@[J$Y"3E@F""G8>YCK.:?GN>C0&8.&[ABS&5A6&Z
MB5Z2D52%AZ^/FD=\AB>,H3L9A**)I2]=@T*&B23]@@"#;X=HCD:AGGM&C)6>
MLFY_BKR;,F%9B-^7750TARR3AT="A:F/L3KQA#.+V"]-@N>'ZB40@;.$&X!"
MH QD6W3VG3AFOVDDFH)I(5S+E\)KC5 ME-UN%4.4D=MPRS> CK]SJRP#BY5V
MWB'8B&YZ9'^ZGKIK_720F_1MF6B]F3)O05QVEF1P_T_KDW]RW$-JD(ITXC=S
MC8!W"BPDBFUY<R(XAU]\$G\VG3)S8W/QFH-T4V@ZE\=U3EOXE0)V84^)DBQW
MD4,KCTUXXS=;C%MZ3BP^B6-[Y2*,AG)]G'Z>F[5ZFW-)F1-Z\V>'EFA[3%MP
MD[![M4\7D/)\-$+@CBM\R3<[BU-];RQ/B'A^,"+5A:1^_WX$FG:!P7*QE^"!
MB&;OE3V!0EK<DHV ]DZSC]F NT*6C2J D#<:BFF :BQ<AZF 4",2A/6 .WU]
MF7Z(W7(TEO&($F9XE$^'(EIHD:"&'TY-CO"%'D)EC$"$*#<'B9>#."QIAO6"
M02-&A&&!3GT2F*Z/SG''EBJ.;&8+DXF,S5H D-N+#$WUCC*)2$(MBXR'AC<"
MB-^%QRQYAEF#_2-P@^>".7R]F!V6E7&7E9Z4J&7;DN^23EG&D"J/M4VZC7V-
M(D'NBNV*F#;8B%6(%2R A=N%@2.2@X2"_7Q\E[2=*'%7E2R:IF65DG.7C%E_
MCZ:4(4V!C/:0OD''BFJ-93;#A^**%RR!A7V&PR.N@S6#G73KJ5!CZ&I/I>-F
M/5]@HG)HH50?GM!K'DBYFNYMOCUOEMEPD#*^DI]SC"C CDAVV2 BB?AZ8G1U
MJ#5K(VH0I+ALNE\MH21N;E/_G6IP1$BIF8-R0CUTE7ET;C+=D4]VO2D'C0YY
M3"">B-M\ W05IKQR%&F?HTES#5[9G[5T'%.QF_UU4TATF"-VK3U?E"YX,#+K
MD!IYSBE"B_9[FR$*A^)]?G.LI3QXT6DGH=1Y/UY7GDQYN5-6FJ)Z3T@MEMQ[
M!3TZDOY[UC+NCP1\O"EPBOU]P2%GAPM^TW- H_9_?&C H)=_9UWPG19_3U+M
MF7)_.D?NE;9_03T4D>]_7C+LC@Y_A2F6BB1_OB&UAE5__W+AHON&'FANGZ"%
MA5VCG!V$SU*CF'F$#D>OE,*#6CSXD/^"N#+LC3."("FTB6B!CB'WA;R!!'*2
MHC>,CV@OGMN+=5UJFU**'%)HEZJ(ID=VD_J'.CS9D$&%V3+TC':$@RG2B,:#
M*B(MA3V!X7)9H9F2Q6?[GCR1(ETRFJ^/)%(QEP*,]D=$DU2*SSRICZN(KS+E
MB^2&H2GPB#^$D")9A->"F7(KH3"8U6?]G<B6O5TOFB:4!%(<EF"0_$<[DJ:.
M##RTCP.+-#+VBUZ(=2H$A]J%N2)\A(6#+VH)LM=C:E_\KNAEJ57AJKEH#4NP
MIB1JFT& H2MM6#>)F^AP32X]EG1S:R6]D-EVTQZ@BUQZ8&F8L?)J0%_7K=)K
MRU76J6EMB4NZI+%O>$&<GZYQFS>YFG1S\RZ%E0]V<"8HCXUY*!\VBC![]6E;
ML(1PPE^3K&#_XO__24-#7U!23T9)3$4  @EQNU6LI_)RVTN9HS5T-T&2GCQU
MP3?+F15W>BZXD\=Y42:"CF-[5A^WB2M]9&DDKOEW"%]/JMMW@U5?IG9X&DMK
MH<AXWT%VG.%YT#?-E])ZXR[=DI]\#B;,C5Q]6R GB$M^JFCJK:)].5\<J8M]
M054MI2E]5$LTH(%]=T%DFZA]Q#?.EK!^+B[\D9=^IR<+C'9_-B"%AXU_RFBW
MK)F#8U\ J'J"^547I!6">TL>GV^!_D%/FI^!ES?4E;"!3"\9D+"!$R=!B["
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M=YB"W8I\>"6"NGR2>+&";FX0>4B""5]*>@"!IE!=>N:!3$'F>^6 \3/N?1>
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M@0AZ>5B8@-I[)4K&@,%[WCUI@+A\IC"<@-1]@R4G@0Y^<HOZ@%" @7^[@!F
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M$U0J;1ES6D4A<-UUPC:>=/AX:REJ>5M[99OJ6<1QY8YO73US-(!=8)=T>G'
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M?$A]\RF$?;A^I2'9?RQ_5VYF='B!?F3P=:"!E5L"=J*!<E"W=YV!+T94>+J
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M9UM\/S=$;=-]:BKC=&I^O9DJ0NZ =HP92*^ 97YX3D" 5' \4]> 0F&H6:>
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M6 Z!CF_E6_"!D&4#7\*!:%FI8ZB!+4X<9\" ^T*B;!: V#?'<)6 Q"V =4R
MM"2A>>2 H'F;5BZ)&6])6D"(;F1Q7C^'?EDI8E&&<$VI9IN%;D(^:R>$>3>/
M;]2#D"U]=+*"H"2Z>7.!K7D>5+202F[66.V._6/^70Z-15B^84"+8$U59:N)
MB4(':EV'P3=@;S>& BUC=$"$/B3.>1B"BG=L<P91!6SQ=%=5*V(<=<Q99%;5
M=U5=L4M">/!B'3^R>K%FO32O?)AKF"I7?L1PX"%D@1-VF778;QA8O6O/<-5<
M3&$N<IY?XE8;='-CA4JV=F)G0S]6>'YK,#2&>L%O3RIL?41SRR&]?]IXG72'
M:W%@@FJ4;9)C:F T;ZUF5E5!<=%I2TH.=!-L6#[C=H9OC#1/>2%R["IU>_)V
MEB(*?LAZ>W-,:!YH.6EG:I)J=5\7;/ELM51\;V1N^TEL<?QQ4SY[=,)SRS0A
M=ZYV92I_>LEY.")-?=E\+W(?92EOXVA29^5Q<UX@:I!S %.B;4)TBTCV<!YV
M*3XJ<S)WX30$=F9YL"J0><1[J2*%?0Q]MW$A8IQW=F>"99=X85UP:']Y-U+Z
M:W!Z!$A>;HEZWCW1<=A[TC/5=4M\V"J0>.9]\B*U?&!_#W!38&M^TF;%8YQ_
M&5S'9KE_-5)E:>!_0$??;3%_5SUY<+5_@C.Z=%=_O2J9>"A__2+<>]& .&^P
M7IF%Y68T8?>%C5Q!94&$[U'P:).$,T=X;!&#A#TA;\F"YS.-<Y6"62J@=XJ!
MQR+\>UV!,F\Y722,JF7'8*J+OUO69!:*95&.9XB(VT<N:R6'8#SS;P"%^3-G
M<OB$GRJ.=Q>#1B,5>P"!_VS2>LU1%6-*>X=5+EEM?&)98$\I?45=KT2D?BUB
M)3HP?RUFU3!5@$IKOB<X@9IQ#A^ @P1VLFMH=Q]856)$>#Q;Y5B5>5Y?@TZ$
M>H)C-40O>[-G"3GN?01K#S!*?G)O1R=H@!)SUA_L@;]XHFI <Z=?H&$M=1]B
MEU>[=HMEF$W&=_1HJ$.E>7!KUCF:>Q)O+S P?-!RLB>*?KEV>R!)@*%Z:VDH
M<'IFWV =<CUI.%:[<^UKETT-=9YN!$,1=VAPB3D]>5=S,3 ->V%U^B>A?8UX
M^""9?ZI\"F@D;:1N"U\S;ZEOQE7D<9EQ@DQ&<XQS0T*D=95U&#CS=\YW#B_V
M>AMY&2>Z?(9[2"#>?M=]?&<[:RIU)EY?;6UV1%4M;YEW5$NW<<1X84(U= =Y
M?3C-=G)ZN2_R>/I\!B?4>Z!]9B$7?B5^P69\:0=\$5W#:X=\F%2K;>=\^$M&
M<$%]2T'.<K5]L#B$=51^+B_D> 5^OB?G>MY_3R%&?9)_UV7D9SV"N5TY:>Z"
MK%0O;'R"7$K>;OZ!\D%V<9R!G#@Z=&J!7"_ =T*!+B?U>C^ ^R%L?1J P65R
M9<N)'%S0:*2(@U/+:UB'@$J';?N&4T$X<+>%.S@7<Z6$.R^I=J6#3"?Q><B"
M7R&+?+J!@&*$@MQ0X5GT@O%4]U$4@R!9*D?3@TM=@SY;@VYB#34#@YMFUBQ-
M@]MKV"1BA$-Q-1W5A,1VQV%#?VI7MUD#?]U;3U!'@$I>^T<V@*IBQ#WT@0AF
MMC35@7MJWRQ;@@)O."2J@K%SWAY2@W%XI6!#?!U>D%@,?.%AGD^$?9!DN4:/
M?BYG[#V ?M!K0S28?XQNR2Q:@%QR=B3B@4]V81Z^@DEZ6U]4>0YE7E<B>A=G
MV4ZE>P-J7T7P>^1L^CT'?,YOLC14?=)RD2Q.?NEUCR4-@!QXNQ\<@4E[YUYP
M=D]L'U9.=YAN!DWC>,%O\T5&>=QQZCRE>P9T #07?$YV-BQ"?:-X@24P?Q%Z
MZA]K@&Y]1UVE<^1RRU67=6QT(4U'=LYU;D3">"%VP3Q!>7YX*#/Z>O1YKBQ%
M?(%[1B53?BA\Z1^M?[=^>EST<<EY1%3R<X]Z"$RW=2AZLD1.=JM[63OJ>#5\
M%#/0>=A\YBQ=>X5]RB5Y?5]^KQ_C?Q]_@%QF< )_C%2(<@=_QTQG<]%_QD09
M=7-_LCO'=QQ_NS.F>.Q_W2Q">L& %"6/?+R 0" /?J2 7%O\;I"%FE0D<+^%
M3$P+<K2$GD//='B#T3N7=CR#(S.1>"F"CRP]>B*"#R6;?$*!C" R?D*!#UB*
MBSI085#XBI14@4D:B@!8OD#=B5Y=*SAQB*=ATS RA^YFP2B=AT)KY"'8AK9Q
M51Q@AE%VV5=QA_U6UU 5A[A:@4A,AUI>14 ^AN)B+C@0AEAF2# 2A==JGBB_
MA69O("(UA1MSXASMA/%XIU:8A-5=24\[A-A@=4><A+ACLS^HA'9G$S>OA"AJ
MG"_J@^AN6"C5@[ER-B*!@Z]V1AUG@[YZ3%72@=UCKTYV@AUF4T;<@C=I!S\C
M@C1KV#=0@BANSR^_@BQQ["C@@C]U)2*^@G)X@1W0@K9[QU41?REJ#4W!?ZML
M)D8Y?_YN3#Z7@#%P@C<*@&%RX2^;@*1U7RCH@/1W[B+Q@6!ZD1XI@=1]%U1?
M?,1P6TT=?8IQZD6Q?A=S>CXM?GQU%3:^?MQVS2^(?TUXIRCS?])ZBR,<@'1\
M=!YS@1=^.U/%>K-V>4R4>[AW@$5"?'MX=#W9?0QY;C9[?9=Z@R]K?C)[LBD(
M?M9\[B-$?ZI^(1ZP@'M_,U-!>.=\64P6>B]\UD35>R9]+3V&>^!]@C9 ?(Q]
M\B\Z?5)^>"D#?@]_#B-O?O]_EA[A?_V  U+@=W&"'DO,>/:"%T2@>A^!OSUQ
M>NV!6#95>Z.!&B]H?'R ^"DG?6. Z".*?GZ SA\(?YB K$[8D_U/HTA*DH13
MTD%QD1%8'3H]CX5<I#+AC=EA=BN[C"-FDR5!BGIKY!^4B/9Q;QL9A[1VYTW,
MD/I5N4=2C^U9?4" CJ]=7SE]C3]A<3)LBZUEP2N6BAUJ3R5LB)]O R  AU)S
MY1NUAD=XITT4C?A;RT:,C2Q?'#_5C"EBA#CJBNAF'#(1B8EIXRMYB#%MX"60
MANUQ]R!;A=UV+QP[A0EZ/DQXBQ%AT$7JBGQDI#\QB:]GCSA[B*QJGS')AXEM
MX"MEAF]Q1B6OA6ITP""HA)=X31RO@_A[JDO:B%YGSD53B!!J(3ZNAWMLB#@0
MAJAO"#&BA;]QN2M<A.)TBB7/A!=W8B#L@WUZ01T0@Q!\[$M!A>]MQT3&A?%O
ME3Y A9EQ;C?$A/9S7C%SA#EU<"MC@XEWI"7P@O%YVB$F@HQ\"1UA@DY^ TJ\
M@]!SDT1,A"!TW#WDA )V(C>&@XMW>S%,@O5X\BM:@FUZ@B82@?=\%R%;@<!]
MG!VD@:Y^[TI,@@!Y+T/G@I=Y\CV5@J]ZGS=6@EY[6#$M@>I\,BM%@8M]("8:
M@3)^%B&$@1E^^1W:@2Q_M$G[@'Q^I4.7@5)^VSU5@9U^YC<Q@6Q^^3$D@0]_
M,"M4@,I_?"8H@)9_T2&:@)Z &QX%@,2 5   __\  /__  #__P  ;69T,0
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M@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM. I)+3@*22TX"DDM.
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M@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6 KHS%@*Z,Q8"NC,6
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MP+!ZL,"P>K# L'JPP+!ZL,"P>K# L'JPP+!ZL,"P>K# _YTW&O^;12[_F4Y
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M_KHQ.NW*,#O:W3(_RN<X5;SL/6FMY41YG]M.AY337)*-S&B;B,ARH83$>::
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MBXY?U8N.7]6+CE_5BXY?U8N._KD6#=32"P;"[@X6L?P9*J+_)3V4_S),B?Q
M68'V36)Z\%AI<^Q?;VSI9'-HYVIV9N5O>63D<WIBXW9\8>-Y?6#B>WY?X7Y^
M7N& ?UW@@X!<X(6!6]^(@5O?B(%;WXB!6]^(@5O?B(%;WXB!6]^(@5O?B(%;
MWXB!6]^(@5O?B(%;WXB!U,@) \37"@>R^Q 9H_\<*Y7_*#N*_SA(@?]%4GK\
M4EIR]UE@:_1>9&;R9&AB\&EJ8.YM;%[M<6U<[71N6^QV;UKL>7!9ZWMQ6.M]
M<5CJ?W)7ZH)S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S5NF$<U;IA'-6Z81S
M5NF$<U;IA'-6Z81SQ,T( ;3=" ND_Q(:E_\?*HO_+C:!_SU!>?]*27'_4E!I
M_UA58_U=6%_[8UM<^6==6OAK7UCW;F!7]W%A5O9T857V=F)4]7=C4_5Y8U/T
M?&12]'YD4?2 95'T@&51](!E4?2 95'T@&51](!E4?2 95'T@&51](!E4?2
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MDU$W_Y=31?^95E+]F5M@]9A@;>V69WGEDW&$WY![CMJ-A);5B(J<T820HL^
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MI*3.<JJFS7"QJ,UON:G+;\&IPW'!J;QRP*JW<\"JMW/ JK=SP*JW<\"JMW/
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M/2W_L4 S]+A%..J_3#SBQU5 T\):4L>Z86.[LV=RL*UM?J>G<XF>H7J2EIV
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MPJ=RF<*G<IG"IW*9PJ=RF<*G_XTF"?^4-!7_H38;_ZHV(?^S-B7UOCDGZLE
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MX$TXM=M32JC565J<T%]HD,QE<X;):WU]QG&%=<1WBV[#?I!IP8:49,"/EV#
MFII=P*6;6\"QFUK!P9M;O,J<7;?*G5VWRIU=M\J=7;?*G5VWRIU=M\J=7;?*
MG5VWRIU=M\J=_Y$F"?^?+Q'_JBT4_[<H%>W()A+:W"D.S.0V'<'F0"ZVXT@^
MJN!.3)[=5EF2VEUEB-9C;W[4:GAVTG!_;M!WA6C/?XECSH>-7\Z0D%O-FI)9
MS:635\ZRDU;/PI-6R]"45\7/E5?%SY57Q<^55\7/E5?%SY57Q<^55\7/E5?%
MSY57Q<^5_Y,F"?^C+ [_L"8/]< ?#=_5&P?-Y"<3P>LT([7J/3.IYT5"G>5+
M4)'C4ER&XEAF?.!?;G3?9G5LWFUZ9MYU?V'=?8)=W(:%6MN/B%C9F(I6V*&+
M5-BLBU38MXQ3V,F+4];6BU/6UHM3UM:+4];6BU/6UHM3UM:+4];6BU/6UHM3
MUM:+_Y<D"?^I)@K^N!P)YLX1!<[C%PC [B87M/ R**CN.SB<[4-&D>Q+4H;L
M4EQ\ZUED<^M>:VKJ9'!EZ&QU8>9T>%[D?'M;XH-]6>"+?U;?DH%5WIJ#4]ZB
M@U+=JH11W;:$4=V_A%'=OX11W;^$4=V_A%'=OX11W;^$4=V_A%'=OX11W;^$
M_Y\A!O^P&P7IQ0T#T-D+ L#N& RS]B8<I_4Q+)OU.SJ0]41'A?5,47SU4UIS
M]5E@:_-?9F7P9FIA[6UM7>MT<%KJ>G-8Z(%T5N>'=E3FC7A3Y91Y4>2;>E#D
MH7M/XZI\3N.P?$[CL'Q.X[!\3N.P?$[CL'Q.X[!\3N.P?$[CL'Q.X[!\_Z@<
M NN\# '-S D P> ,!++Z&1"E_"<@FOTR+H_]/3N%_D5%>_]-3G+_5%5K^UI:
M9/A@7V#V9V)<]&UE6?)R9U?Q>&E5\'YJ4^^#;%'NB6U0[8]N3NR4;TWKFG!,
MZZ%Q2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+ZJ9R2^JF<DOJIG)+ZJ9R][,- ,S#
M" "_T0@ L>\.!J3_&Q.9_RDACO\T+H3_/SE[_T=!<?].2&K_5$YC_UI27OY@
M5EK\9EA7^VQ:5?IQ7%/Y=EY1^'I?3_=_8$[VA&%,]8EB2_6.8TKTE&1)\YIE
M2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYF2/.>9DCSGF9(\YYFS;L% +W'!@"Q
MV <!H_\0")C_'Q2-_RP@@_\W*WK_031P_T<[:/]-06'_5$5<_UI)6/]?2U7_
M94U2_VI/4/]N44[_<E),_W=32_][5$G_?U5(_H161_Z(5T;]C5=$_9-81/R6
M643\EEE$_)991/R6643\EEE$_)991/R6643\EEE$_)99O;\$ +#.! "BX 8"
ME_\3"(S_(A.#_RX=>?\X)6[_/BUF_T4R7_],-UG_4CM5_U@^4?]=0$__8D),
M_V9#2O]J1$G_;D5'_W)&1O]V1T7_>DA#_WY(0O^"24'_ADI _XM+/_^/2S__
MCTL__X]+/_^/2S__CTL__X]+/_^/2S__CTL__X]+K\8" *+6 @"6]PH"B_\6
M!X+_) ]W_RT7;/\S'F/_.B1<_T(H5O])+%'_3R]._U4Q2_]:,TC_7C5&_V(V
M1/]F-T/_:3A!_VPX0/]P.3__<SH^_W<Z/?][.SS_?CPZ_X,\.O^&/3K_ACTZ
M_X8].O^&/3K_ACTZ_X8].O^&/3K_ACTZ_X8]_W4D!O]V-1#_=T,<_X!*)_^%
M4C/_AED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E
M>NMDJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1CWX'48]^!
MU&/?@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_=T,<_X!*)_^%4C/_
MAED^_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMD
MJGSJ8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1CWX'48]^!U&/?
M@=1CWX'48]^!U&/?@=1CWX'48]^!_W4D!O]V-1#_=T,<_X!*)_^%4C/_AED^
M_X5@2/^!:%+_?&]:_'=Y8O=S@VCT;XQN\6R3<N]JFG7M9Z!X[&6E>NMDJGSJ
M8J]]Z6&U?NA@NW_H7\. YU_+@>9>U8'@8-N!UV+>@=1CWX'48]^!U&/?@=1C
MWX'48]^!U&/?@=1CWX'48]^!_W8D!O]W-1#_>4(<_X)))_^'43+_B%@]_X=?
M2/^#9E'_?FY:^WEW8O=U@FGT<8IN\6V2<^YKF7;L:)]YZV:D>^IDJGWI8Z]_
MZ&*U@.=AO('G8,2"YE_.@N-?UX/<8=N#TF/=@\]DW8//9-V#SV3=@\]DW8//
M9-V#SV3=@\]DW8//9-V#_W<D!O]X-1#_?$$<_X5()_^*3S+_C%8]_XM=1_^'
M9%'_@FQ:^WQT8O=X?VGS=(AO\'"0=.ULEWCK:IY[Z6>D?NAFJH#G9+""YF*V
M@^5AOH3E8,>%Y6#3A=UBV8739-R%S&7;ALEEVX;)9=N&R67;ALEEVX;)9=N&
MR67;ALEEVX;)9=N&_W@D!O]X-1#_?D ;_XA')O^-3C'_CU4\_XY;1O^+8E#_
MAFE9_(!Q8O=[>VGS=H5P[W*.=>QNE7GJ:YQ]Z&FC@.=FJ8+E9;"$Y&.WA>1B
MP(?C8<N'WV+5A]5DVH?-9=F(QF?9B<1GV(G$9]B)Q&?8B<1GV(G$9]B)Q&?8
MB<1GV(G$9]B)_WDC!O]Y-!#_@#\;_XI&)O^033#_DE,[_Y%:1?^/8$__BF=9
M_(1N8?=^>&GR>8)P[W2+=NMPDWOI;9M_YVJB@N5GJ83D9;"&XV2YB.)BPXGB
M8M"*V&38BLYFV(K'9]>+P&C6C+YIUHR^:=:,OFG6C+YIUHR^:=:,OFG6C+YI
MUHR^:=:,_WDC!O]Z-!#_@SX;_XU%)?^33"__E5$Z_Y171/^274[_CF58_(AK
M8?>"=&GR?']P[G>(=NMSD7SH;YF YFNAA.1HJ8?B9K&)X62[B^!CQXS<8]2,
MSV;6C,=HU8W :=2.NFK4CKAKU(ZX:]2.N&O4CKAKU(ZX:]2.N&O4CKAKU(ZX
M:]2._WHC!O][-!#_A3T:_X]$)/^62B[_ETXX_Y=40O^56DS_DF%6_(YI7_:'
M<&CR@7IP[7N%=^IVCGSF<9>!XVV?AN!JJ(G=9[",VF:[C=9EQX[19M2/QVC3
MC[]JTY"Y:]*1LVS2D;)MTI&R;=*1LFW2D;)MTI&R;=*1LFW2D;)MTI&R;=*1
M_WLC!O]\-!'_B#P:_Y)#)/^82"W_FDPW_YI20?^96$K\EU]4]I-F7?"-;F;K
MAW=OYH"!=N%[BWW<=9.#UW&<A])NI(O/:ZR.S&FUD<EHP)+':,^3OVO1D[AL
MT).R;="4K6_0DZMOT9.K;]&3JV_1DZMOT9.K;]&3JV_1DZMOT9.K;]&3_WPC
M!O]]-!'_BCL9_Y1!(_^:1BS_G$LU_YU0/_^=5DCXFUU1\9AC6^N3:V3DC75M
MWH9^==B AWS1>H^#S':7B<=RGXW$;Z>1P&VPD[YLNY6[:\B6MFW/EK!OSI:K
M<,^6IG'/E:5RSY6E<L^5I7+/E:5RSY6E<L^5I7+/E:5RSY6E<L^5_WPC!O]]
M-!'_C#H9_Y= (O^<12O_GTDT_Z!.//NA5$7TH%I.[)UA6.69:6'>DW-JU8Q[
M=,Z%@WW(?XN$PGJ3BKYVFX^Z<Z.3MG&KEK-OMIBQ;\*8K7#-F*ARS9BD<\V8
MH'3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7GW3.EY]TSI>?=,Z7_WTC!O]_,Q'_
MCCD8_YD_(?^>0RG_H4<R_Z-,.OBE4D/PI%A+Z*-?5.&?:%W7F'!HSI%X=,:*
M@'W A(B%NG^/B[5[EY"Q=Y^4K76GEZISL9FG<[V;I7/+FZ!URYJ==LR:FG?-
MF9EWS9B9=\V8F7?-F)EWS9B9=\V8F7?-F)EWS9B9=\V8_WXB!O^ ,A#_D#@8
M_YL_(/^@0BC_I$8P_J9+./2H4$#LJ5='Y*E=4-RE9EK0G6YHQY5U<[^.?7VY
MB82%LX.,C*U_DY&I?)N5I'FDF:%WK9N>=[F<G'?(G)EXRIR7><N;E7K,FI1Z
MS)F4>LR9E'K,F91ZS)F4>LR9E'K,F91ZS)F4>LR9_WXB!O^",A#_DC<7_YP]
M'_^A0"?_ID0N^ZE)-?&L3SSIKE5#X:]=2]6H9%G+H6MGPIES<[F3>GVRC8&%
MK(B)C*:$D)&A@)B6G7V@FIE\JIR6>[:=E'O$GI)\RIV1?<J<CWW+FX]]S)J/
M?<R:CWW,FH]]S)J/?<R:CWW,FH]]S)J/?<R:_W\B!O^$,1#_DS87_YX\'O^C
M/R7_J$(L^*U',N^P33GFM%0_W;-;2="L8EG&I&IFO)UQ<K27=WRLD7Z%IHR&
MC*"(C9&:A966EH*>FI* IYV/?[*>C8#!GHR R9Z+@,J=BH#+FXJ RYN*@,N;
MBH#+FXJ RYN*@,N;BH#+FXJ RYN*@,N;_W\B!O^%, __E386_Y\['?^E/23_
MJT$J];!%+^RU3#3CNE0YV+=92,NO85C!J&AFMZ%O<J^;=7RGE7R$H)&#BYJ-
MBY&4BI.6CX>;FHN%I9V(A+"?AH2^GX6%R9Z%A,F=A83*G(6$RYN%A,N;A83+
MFX6$RYN%A,N;A83+FX6$RYN%A,N;_X B!O^'+P__ES46_Z Z'/^G/"+^K3\G
M\[-$+.FZ2S#AOU(UT[I81\>S7U>\K&9ELJ5M<:F?<WNAFGJ$FI:!BY22B)&.
MCY"6B8R9FH2*HIV!BJV??XJ[GWZ*R)Y_B<F=@(C*G("(RYN B,N;@(C+FX"(
MRYN B,N;@(C+FX"(RYN B,N;_X$B!O^)+@__F345_Z(X&_^I.B#[L#TD\+A"
M*.:_2BK=PT\TSKU61L*V7E:WL&5DK:EK<*2D<7J<GWB#E)M^BHZ7AI"(E8Z5
M@I*6F7Z0H)QZCZN>>(^XGW>0R9YYCLJ=>HS+FWN,RYM[C,N;>XS+FWN,RYM[
MC,N;>XS+FWN,RYM[C,N;_X$B!O^++0[_FS04_Z0W&?^L.![XM#HA[;U (^3&
M22/7QTPSR<%51;VZ7%6RM&-CJ*YI;Y^I;WF6I7:"CJ%\B8>=@X^!FXN4?)B4
MF'>7G9MSEJB=<9:UGG"6QIURE,J<=)++FW61RYIUD<N:=9'+FG61RYIUD<N:
M=9'+FG61RYIUD<N:_X(B!O^-+ W_G303_Z8T&/^O-1OTN#<<Z<,^'.#-11_1
MRTLRQ,540[B_6U.MN6%AHK1H;9FO;G>0JW2 B*=ZAX&D@8U[HHF2=:"1EG">
MFYEMG::;:IVSG&F>PYQKG,N;;IC,FF^7S)EOE\R9;Y?,F6^7S)EOE\R9;Y?,
MF6^7S)EOE\R9_X,A!O^0*PW_H#,1_ZDR%?VS,1?POC07Y<L[%=K4/QW+STDP
MOLE20K+$65&GOV!?G+IF:Y*V;'6)LG)^@:]XA7JL?XMTJH>0;ZB/DVJGF99G
MIJ289*:QF6.GP9EDI<V89Z#-F&B?S9=HG\V7:)_-EVB?S9=HG\V7:)_-EVB?
MS9=HG\V7_X0A!O^3*0O_HC /_ZTN$OBX+!+KQB\0X-4X"]+:/1S%U$@NN,]0
M0*S*6$^@Q5Y=E<%D:(N]:G*#NG!Z>[=V@72U?8=NLX6+:+*.CV2QF))AL*.4
M7K"PE5VQOY5=L="48*K0E&&HT)1AJ-"48:C0E&&HT)1AJ-"48:C0E&&HT)1A
MJ-"4_X8A!O^7* K_IBP-_[$H#O+ )@SCT"@'U-\R"\G?/AF]VT<LL=9//:31
M5DR9S5Q9CLEB983&:&Y[Q&]V=,%U?&W ?()HOH2&8[V-B5^\EXQ;O**.6;RO
MCUB]OHY7OM2.6;;3CUJTTY!:M-.06K33D%JTTY!:M-.06K33D%JTTY!:M-.0
M_X@A!O^<)PC_JB<*_+@A">G*&P75WB $R>4P#[[C/1VTX48LJ-Y..IS:54B1
MUEM5AM-A8'S09VETSFYP;<UU=F?+?'MBRX1^7LJ-@EK*EX17RJ.&5<JOAE3+
MOH93S-6&5,39B%7!V8E5P=F)5<'9B57!V8E5P=F)5<'9B57!V8E5P=F)_XT=
M!?^B)0;_L!\%\L(4 ]G;#@')YB 'O>@O%++G.B*GY4,QF^-*/I#A4$J&WU=4
M?-Y>773=961LVVQJ9MMT;V':?'-<V81V6=F.>579F'M3VJ-\4=JP?5#;OGU0
MW--\4-3@?E'0X']1T.!_4=#@?U'0X']1T.!_4=#@?U'0X']1T.!__Y4: _^I
M'P/[NA("U,T+ ,GF#P*\[2 +L.TN&:7L.2>:ZT(UC^I)087I4$M[Z%=3<NA=
M6FKG8V!DYVIE7^=R:5OG>FQ7YX)N4^>+<5#GE7).Z)]T3.BJ=4OHM79*Y\-V
M2NC==DODX'5+Y.!U2^3@=4ODX'5+Y.!U2^3@=4ODX'5+Y.!U_YT6 ?^Q$@'3
MPPD Q]$* +OR$02O\R$/H_,N'9GS.2J.\T(VA/-*07OS4DER\U=0:?-<5F/S
M8UI=\VE>6?-P857S=V-2\W]F3_*'9TWPCVE+[YAK2N^@;$GNJ6U([K-M1^W
M;D;MQVY&[<=N1NW';D;MQVY&[<=N1NW';D;MQVY&[<=N_Z</ -.Z!P#%QP<
MNM8) *WZ$P:B^B(2E_HO'XW[.BN#_$,U>OU,/G']445H_59+8?Y;3US^8E-7
M_FA65/UO6%'[=5I.^GQ<3/F#74KXBE](]Y%@1_:984;VH&)%]:=C1/2Q9$/T
MM61#]+5D0_2U9$/TM61#]+5D0_2U9$/TM61#]+5DUK($ ,2^!@"WS 8 K-P)
M :#_%@B5_R44B_\R'X+_/"EY_T4R;_]*.6?_3S]?_U5#6O];1U7_84I2_V=,
M3_]L3DW_<D]+_WA12?]^4D?_A%-%_XM40_^154+^F%9!_9Y70/VF6$#\J5A
M_*E80/RI6$#\J5A _*E80/RI6$#\J5A _*E8QK@$ +;$! "JTP4 GO(- I3_
M&@F*_R@3@?\T'7?_/"5M_T(L9?]',EW_3397_U,Z4_]9/4__7S],_V1!2O]I
M0TC_;D1&_W-%1/]Y1D+_?D=!_X1(/_^*23[_D$H]_Y5+//^<3#S_GTP\_Y],
M//^?3#S_GTP\_Y],//^?3#S_GTP\_Y],M[P# *G+ @"<VP, DO\0 HG_'0B
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M@7^W@X!_R(1_@-V#?W_>@7]_WX" ?N!_@'[@?X!^X'^ ?N!_@'[@?X!^X'^
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M4I.H:5N+I6]CA:)V:GZ??&]XG(1T<YJ,>6^9EGQKEZ%_:)>M@&:7O(%EF-&
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M9DO(\F9+R/)F2\CR9DO(\F9+R/)F_Y(- -ZF! #.M 8 PK\& +G," "PW0P
MI^4= Y[E+0N4Y3D6BN1"(('C2BIWXE S;^%8.VG@7T%CX&9&7M]N2EK?=4Y6
MWWU14M^&4T_?D%9-WYM72^"G6$G@M5E(X<992.'?64??\%E&W/5;1MSU6T;<
M]5M&W/5;1MSU6T;<]5M&W/5;[9P$ -&M! #"N 4 M\,% *W1" "D[1 !F^T@
M!9+M+@Z)[#H8@.Q#(7;L2BIN[% Q9NM6-V#K7#Q;ZV1 5^MK0U/K<D90ZWI)
M3>R#2TKLC$U([)9.1>VA4$/MKE%"[KQ10>_,4D'OY5) [?%10.WQ44#M\5%
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M;%J>[6Q:GNUL6I[M;%J>[6Q:GNUL_WP0 ?^.$ #VG@T V*T) ,VX"0#'Q @
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M7TR\\&%-M_5B3;;U8DVV]6)-MO5B3;;U8DVV]6)-MO5B_XD+ .&< P#0J@4
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M/#CW[#PX]^P\./?L/#CW[#PX]^P\OZH  +&S  "DOP  F,H! (S8! "$^@X
M?/L; G3[)@5L_# *9?PX$%[]0!58_D<94_Y-'4__5"!+_UHB2/]A)47_9R9"
M_VTH0/]U*CW_?2LZ_X8M./^1+C;_FR\T_Z8P,_^R,3+_OC(Q_] R,?_6,C'_
MUC(Q_]8R,?_6,C'_UC(Q_]8RLJ\  *6Z  "8Q@  B](  '_? @!Y_Q$!;_\9
M F?_(@1@_RP'6O\T#%3_/ ]/_T,32O])%4?_3Q=#_U490/];&S[_81P[_V8>
M.?]M'S;_=" T_WTA,?^&(R__D20M_YLE+/^E)BO_KR8J_[LG*?^^)RG_OB<I
M_[XG*?^^)RG_OB<I_[XGIK8  )C"  "+S@  ?ML  '7Y!P!K_P\!8O\6 EO_
M'@-4_R8%3O\N!DG_-0A%_SP+0?]##3[_2 X[_TX0./]3$37_6!(S_UX3,?]D
M%"[_:A4L_W(6*O]Z%R?_@Q@E_XX9)/^8&B/_H!HB_ZH;(?^M&R'_K1LA_ZT;
M(?^M&R'_K1LA_ZT;FKX  (O*  !^UP  <.,  &?_! !>_PT 5O\2 4__&0))
M_R #0_\G!#__+@4Z_S0&-_\Z!S/_/P<P_T0(+O])"2S_3@DI_U,*)_]8"B7_
M7@LC_V0+(?]L#!__= T=_WT.&_^'#AG_CP\8_YD/&/^;$!C_FQ 8_YL0&/^;
M$!C_FQ 8_YL0_TPJ _](,P7_3S0&_U0W"/]:00[_7$H6_UI4'?]78"3_5&LJ
M_U!X+_]-A#/_2H\V_T>9.?]&H3O_1:D\_T2P/O]#MS__0L __T+)0/]!U4'_
M0>1!_T'N0O]!]D+_0?U"_T+_0?E$_T'T1O]"[T?_0N]'_T+O1_]"[T?_0N]'
M_T+O1_]"_TTI _]*,@3_43(&_U<V"/]</P[_7DD6_UU3'?]:7B3_5VDJ_U-U
M+_]0@33_38TW_TJ7.O](GSS_1Z<]_T:N/_]%M4#_1+U!_T3&0O]#T4+_0^)#
M_T/L0_]#]4/_0_Q#_$3_0_5'_T/O2/]$ZTG_1.M)_T3K2?]$ZTG_1.M)_T3K
M2?]$_TTI _],, 3_5#$%_UDT"/]?/0[_84<6_V!2'?]=7"3_6F<K_U9S,/]3
M?S3_3XHX_TV4._]+G3W_2J0__TBL0/](LT'_1[M"_T;#0_]&SD3_1=]$_T7J
M1?U%\T7[1?M%]T;_1/!)_T7J2O]&Y4O_1^5+_T?E2_]'Y4O_1^5+_T?E2_]'
M_TXI _]/+@3_5RX%_UTR!_]C.P[_9486_V50'?]A623_760K_UIP,/]6?#7_
M4X<Y_U"1//].FC__3:) _TNI0O]*L$/_2K=$_TG 1?](RD;]2-M&^DCG1_A(
M\D?U2/I&\4G_1^I+_TCC3/])WDW_2MY-_TK>3?]*WDW_2MY-_TK>3?]*_T\H
M _]2+ 3_6BP%_V$O!_]G.@[_:D05_VI.'/]G5R3_8F$K_UYM,?];>#;_5X,Z
M_U2-/?]2ED#_4)Y"_D^E1/Q.K47[3;1'^DR\2/E,QTCV2]1)\TOE2?!+\$GM
M3/E(Z4S_2N%._TO:3_],TU#_3=-0_TW34/]-TU#_3=-0_TW34/]-_U H _]5
M*@3_72D%_V4M!_]L. W_;T(4_V]+'/]L52/_:%XJ_V-I,?]?=#;]7'\[^UF)
M/_E6DD+W5)I$]5.B1O12J4CR4;%)\5"Y2N]/PTON3\]+ZT_B2^=/[DOD3_A-
MWT_^3M51_T_.4O]0R5/_4,E3_U#)4_]0R5/_4,E3_U#)4_]0_U$G _]8)P3_
M82<$_VHL!O]Q-@S_=$ 3_W1)&O]R4B+_;ELI_6AD,/EE<#;V87L[\UZ%0/!;
MCD/N699&[%>>2.I5IDKH5*U,YU.U3>53OT[C4\Q.X5/?3MU3[4_84O=1T5/]
M4LI4_E/$5O]3OU?_4[]7_U._5_]3OU?_4[]7_U._5_]3_U(G _];)0/_920$
M_VXJ!O]V- O_>CT1_WI&&/]X3R#[=%@H]F]A+_%K;#;M9W8\Z6. 0.9@BD7D
M79)(X5N:2M]9HDW=6*I/VE>R4-A6O%'55<A2TE7;4\Y6ZU/+5O95QE;]5K]8
M_5:Z6?U7MEK]5[9:_5>V6OU7MEK]5[9:_5>V6OU7_U,F _]?(@/_:2$#_W,H
M!?][,@K_?SL0_X!$%OM^3![T>U0E[G9=+>EQ:#3D;7([X&E\0=QEA4;88HY*
MU%^63=%=G5#.7*52S%JM5,E9ME;'6<)7QEG05\)9YEB_6?-9NUK[6;5;^UJP
M7?M:K5W[6:U=^UFM7?M9K5W[6:U=^UFM7?M9_U8D _]B( /_;2 #_W<F!/]_
M, C_A#D-_89!%/6%21ON@E$BYWU:*N%X9#+<<VXZU&YW0=!J@$?,9HE,R&21
M4,5BF%/#8*!5P%ZH6+Y=L5F[7;Q;N5S)7+=<X%RT7>]<L%[Y7:M?^5VH8/E<
MI6'Y7*5A^5RE8?E<I6'Y7*5A^5RE8?E<_U@B _]E'@/_<1\#_WLD _^$+@?_
MB38+^(L^$>^+1A?HB$X>X817)ME^83'1>&HZRW-S0L9O?$C";(1-OFF,4;MF
MDU6X9)M8M6.C6K-AK%RP8+=>KF#$7ZQ@V%^I8>M?IV'W7Z)C]U^?9/=?G63X
M7IUD^%Z=9/A>G63X7IUD^%Z=9/A>_UL@ O]H' +_=!T"_WXC _^(*P7]C30)
M\Y [#NJ00Q3BCTH:VHI4)="#73#)?F<ZPWAO0KYT>$BY<8!.M6Z(4K)KCU:O
M:9=:K&>?7*EEJ%^F9+)AI&2_8J)DT&*@9.=BGF7U8IIF]6&89_9@EFCV8)9H
M]F"6:/9@EFCV8)9H]F"6:/9@_UT? O]J&@+_=QP"_X(A O^+*03YD3$'[Y4X
M"^:6/Q#=E$<7THY1),J(6R_"@V0YO'YL0;=Y=$BR=7Q.KG*$4ZIOBU>F;9-;
MHVN;7J!JI&"=:*YCFVBZ9)EHRV67:.-DE6GS9)-J]&.1:_5BD&OU89!K]6&0
M:_5AD&OU89!K]6&0:_5A_U\= O]M& +_>AL"_X4? O^.)P/UE2X%ZYDU".&<
M.PS6F$,6S)-/(L2-6"Z]AV$XMH)I0;!^<4BK>GE.IW> 4Z-TB%B?<9!;FV^8
M7YANH6*5;:MDDFRW9I!LQF:/;-]FCFWQ98QN\V2+;O1CBF[T8HIN]&**;O1B
MBF[T8HIN]&**;O1B_V$< O]O%@+_?!H!_X@> ?^1) +RF2L$YYXQ!=V@-@G1
MG$$5QY=-(;^15BVWC%\WL8=G0*N";DBE?G9.H'M]4YQXA5B8=HU<E'257Y%R
MGF*.<:AEBW"T9XEPPVB'<-MGAG'N9H9R\F6%<O-DA'+T8X1R]&.$<O1CA'+T
M8X1R]&.$<O1C_V,: O]Q%0'_?Q@!_XH< ?R4(0+NG"<"XZ(L ]BD,@C,GT 4
MPYI+(+J552RSD%TWK(ME/Z6';$>@@W--FX![4Y9]@E>2>HI<CGB28(IVFV.'
M=:5FA'2Q9X)TP&B =-5H@'7L9W]V\F9_=?-E?W7S9']U\V1_=?-D?W7S9']U
M\V1_=?-D_V49 O]T% '_@1<!_XT: ?F7'@'KH",!WZ8F M*G, ?(HSX3OYY)
M'[:94RNNE%LVIX]C/Z"+:D:;AW%-E81X4I"!?U>,?X=<B'V08(1[F6. >J-F
M?GFO:'MYO6EZ>=%I>7KJ:'IZ\F9Z>?)E>GGS9'IY\V1Z>?-D>GGS9'IY\V1Z
M>?-D_V<7 O]V% '_A!8!_Y 7 ?6;&@'GI!T!VZL? <ZJ+P;$ICT2NJ%('K*=
M42JJF%DTHI1A/IR0:$66C&],D(EV4HN&?5>&A(5;@H*-7WZ EV-Z?Z%F=WZL
M:'5]NVES?LYI<W[H:'1^\69T??)E=7SS9'5\\V1U?/-D=7SS9'5\\V1U?/-D
M_VD6 ?]X$P'_AQ0 _Y,5 /&>%0#CJ!8 U:X; <JM+0; J3L1MJ5&':VA4"FE
MG%@SGIA?/)>49D20D6U+BXYT48:,>U:!B8-;?(>+7WB&E&)TA)]E<8.J9V^#
MN&EM@\MI;8/F:&Z#\F9O@O)E<('S9'"!\V1P@?-D<('S9'"!\V1P@?-D_VL4
M ?][$@'_BA( _Y82 .VB$ #>K0X T+$9 ,6P*P6[K3D/LJE$&ZFE3B>@H58R
MF9U>.Y*:9$.+EVM*AI1R4("2>55[CX!:=XV)7G*,DF%NBIQD:XFH9VF)MFAG
MB<AH9XGC9VB)\F9IA_-E:H;S9&J&\V1JAO-D:H;S9&J&\V1JAO-D_VX2 ?]^
M$ #_C1  ]YH. -NG"@#3L L RK06 ,"T*02VL3<.K:Y#&J2J3"6;IE4PDZ-<
M.8R@8T&&G6E(@)IP3GN8=U-VEGY8<92&7&R2D&!HD9IC99"F96.0M&9AD,9F
M89#A9F&0\F5CCO-D9(ST8V2,]&-DC/1C9(ST8V2,]&-DC/1C_W$0 ?^"#P#_
MD0T WI\) -.J"0#,LPD Q+@3 +JX)@.QMC4,I[-!&)ZO2B.6K%,NCJE:-X>F
M83^ I&=&>J%N3'6?=5%PG7Q5:YR$6F::CEUCF9A@7YBD8EV8LF1;F,-D6YC>
M8UN8\&-<E?5B7I/U8EZ3]6)>D_5B7I/U8EZ3]6)>D_5B_W4. /^&#0#KE@@
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M3D7"_TY%PO].1<+_3D7"_TY%PO].WY   ,R?  "_J@$ L[,! *F] @"?QP4
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M7&N \EIK@/M9;'[\6&U^_%AM?OQ8;7[\6&U^_%AM?OQ8_VD0 ?]X#@#_A0P
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M4U29_U-4F?]35)G_4U29_U-4F?]3_W@& .&)  #0E@( QJ$# +RI P"SL $
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M.3[+_SD^R_\YRI8  +RB  "OJ@  H[,  )B\  "-Q@, @L\' 'C9"P!SWA@
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MB XF_Y4/)?^A$"3_KA$C_[H2(O_*$B+_T!(B_] 2(O_0$B+_T!(B_] 2G+(
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M_S?-2/\WS4C_-\U(_S?-2/\W_T8D O]/( +_5A\"_UTD _]A+ 3_8S4&_V1
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M4'EO\DYY;_Y->6__3'EO_TMY;_]+>6__2WEO_TMY;_]+_V / /]M#0#_>0P
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M3&2 _TMD@/]+9(#_2V2 _TMD@/]+_VD( /MX! #<A $ SX\$ ,:7!0"_G04
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M2+N6,D6[HS1#N[(T0KO%-4.[XC1"N?,U0;C]-T"W_S= M_\W0+?_-T"W_S=
MM_\WSHL  +^8  "RH0  IZD  )RP  "1N   AL " 'O(!P!TRQ( <,PB 6O+
M, -FRSP'8<M%#%S*3A%8RE855,I=&5')9!Q.R6P?2\ET(DC(?B1%R(@G0\B5
M*$'(HBH_R+$K/LG$*S[)X2H^Q_(K/<;\+3S%_RX\Q?\N/,7_+CS%_RX\Q?\N
MQ),  +:?  "II@  G:X  )*W  "&OP  >\<# '#/!P!GU@T 9-<: &#8*@%<
MV#8#6-A!!E382@I0V%(-3=A:$$K78A-'UVD61==R&$+7?!I V(<</=B3'CS8
MH1\ZV; @.=G#(#G9WR YU^\@.-7Y(C?4_R,WU/\C-]3_(S?4_R,WU/\CN9P
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M"1__JPD>_[H)'?_)"1S_W0D<_]T)'/_="1S_W0D<_]T)F+   (JZ  !\Q
M;\T  &+8  !5W@  2>0  $3[!0 __PX ._\5 #C_'  T_R0!,?\K 2W_,0$J
M_S8")_\\ B7_0@(C_T@"(/]. Q[_50,<_UT#&?]G!!?_<@05_W\$%/^,!1/_
MF@42_Z8%$?^R!1'_O 41_[P%$?^\!1'_O 41_[P%C+@  'W"  !OS   8M@
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M08I?\T")7_\_B6#_/HA@_SZ(8/\]B&#_/8A@_SV(8/\]_U</ /]B# #_; P
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M9_Q!?&C_0'QH_T!\:/\_?&C_/WQH_S]\:/\__UL, /]G"0#W<0< WGH% -2
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M07%O_T!Q</] <7#_0'%P_T!Q</] _U\( /]K! #A=@  U'\# ,N&!0#%BP8
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M-VR!ACMI?Y ^9GZ;06-^J$-A?;9$8'W)1%]]Y4-@??9"8'W_06%]_T!A??]
M87W_0&%]_T!A??] _V<  .-T  #2?P  QX@! +Z/ @"VE0$ KI@& *::%0"?
MFB8"F)DS!I&7/PR+E4@4A9-0&G^16"!ZCU\E=HUE*G*+;"YNBG,R:HA[-F:'
MA#ECAHX\8(69/UV$ID%;A+1"6H3'0UJ$XT):@_1!6X/_0%N#_T!;@_\_6X/_
M/UN#_S];@_\__VH  -YX  #-@P  PHP  +F3  "PF   IYT" *"?$@"9GR,!
MDYXQ!8R=/ N%FT82?YE.&'J75AYUEETC<)1C*&R2:BQHD7$P99!Y-&&.@C=>
MC8PZ6HR7/5B,I#]6B[) 5(O%0%2+X4!4BO,_58K^/U6)_SY5B?\^58G_/E6)
M_SY5B?\^[V\  -9\  #(AP  O9$  +28  "JG   H*(  )FD$ "3I2 !C*0N
M X6C.0E_HD,/>:!,%G2?4QMOG5H@:IQA)6:::"ECF6\M7YAW,%N7@#18EHHW
M5965.5*5HCM0E+ ]3Y3#/4^4WSQ/D_(\3Y+]/$^2_SQ/D?\\3Y'_/$^1_SQ/
MD?\\Y'0  ,^!  #"C   N)8  *V<  "CH0  F*@  )"J#0"+JQL A:LJ GZJ
M-@9XJ4$,<JA)$FVG41AIIE@<9*1?(6"C9B5=HFTI6:%U+%:A?B]3H(@R3Y^3
M-4V?H#=+GJ\X2I[!.$F>W3A)G? X29S\.$F;_SE)F_\Y29O_.4F;_SE)F_\Y
MVWH  ,B'  "\D@  L9H  *:@  "<I@  D:P  (>Q" "!LA8 ?+,F 7:R,P1Q
MLCT):[%'#F:P3Q-BKU887JY='%JM9"!7K&LC5*QS)E"K?"E-JH8L2JJ2+TBI
MGS!&J:TR1:F_,D2JVC)$J.\R0Z?[,T.F_S-#I?\T0Z7_-$.E_S1#I?\TT($
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M%S32TA<UT.P6-,_W&#/._QHSSO\:,\[_&C/._QHSSO\:LYD  *:A  ":J0
MCK$  (&Y  !UP   :L<  %[- P!4U @ 3-T- $K=& !(WB8 1MXR 43?/ )"
MWT4#/]]-!#W@504[X%T&.>!F"#?@;PDUX7H*,^&&##'AE TPXJ,.+N*S#B[C
MQPXMX^,.+>#R#BS?^P\LW_T0+-_]$"S?_1 LW_T0J*   )RG  "/L   @[@
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M @S_O@(,_\("#/_" @S_P@(,_\("A[8  'F_  !KR0  7M,  %#;  !#X
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M+J%/]2Z?3_\NGD__+IU/_RZ=4/\NG5#_+IU0_RZ=4/\N_TP0 /]4#0#_70X
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M-7Y@_S1^8/\T?F#_-'Y@_S1^8/\T_U4( /]@! #H:0  VG # -!U!0#*> <
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MGS-3AZTU4H>^-5&'UC51ANXU4H7[-%*%_S12A?\S4H7_,U*%_S-2A?\SXVP
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M*$&DSB=!H^HG0*+X*$"A_RE H/\I0*#_*4"@_RE H/\IR7X  +J+  "OE
MHYH  )B@  "-I0  @JH  '6P  !LLPP :;08 &6T)P%AM#,"7K0]!%JT1@=6
MLTX*4[-5#5"S7!!-LF,32K)K%D>Q=!A%L7X:0K"*'4"PEQX^L*8@/+"W(#RP
MS" \K^@@.Z[W(3JM_R(ZK/\C.JS_(SJL_R,ZK/\CP(8  +.2  "GF0  G)\
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M!R;9^0@FV/X))MC^"2;8_@DFV/X)I)T  )BE  "+K0  ?K0  '&\  !EPP
M6<D  $W-  !#TP$ .MD& #7D#0 SY!8 ,>0@ ##E*@ NYC, +>8\ "OG1  J
MYTP!*.A4 2?H70$EZ6<"(^ES B+J@0(@ZI$#'^NA QWKL@,<[,<#'.SA QOJ
M\0,;Z?D#&^GY QOI^0,;Z?D#FJ0  (VL  !_M0  <KT  &7%  !9RP  3-
M $'5   XW   +^$" "WQ#0 K\1, */(< ";R)  D\RL (O0R "'T.0 ?]4$
M'?5) !OV40 9]UH!%_=E 17X<@$4^8$!$_F2 1+ZH@(1^K,"$/O& A#[W0(0
M^^D"$/OI A#[Z0(0^^D"CZL  (&T  !SO0  9L8  %G-  !+TP  0-D  #7>
M   LXP  )O$  "3^"@ A_Q  '_\6 !S_'  9_R( %_\H !7_+@ 3_S4 $O\\
M !#_0P ._TP #?]6  O_8@ )_V\ "/]_ 0?_D $%_Z !!/^N 03_O $#_\<!
M __' 0/_QP$#_\<!@[0  '6]  !GQ@  6L\  $O5   _W   ,^$  "GE   A
M[   'OT  !K_!0 7_PP %?\0 !+_%  0_QD #O\>  W_(P +_R@ "/\N  ;_
M-0 #_ST  /]&  #_40  _UT  /]K  #_>P  _XL  /^9  #_I0  _ZP  /^L
M  #_K   _ZP _R<L ?\J*@'_*RH!_RHN ?\F- +_)3\"_R-+ _\A6 /_(&0$
M_QYP!/\=>P3_'84%_QV.!?\=E@7_'9P&_QVB!O\<J ;_'*X'_QRT!_\<NP?_
M',,'_QS.!_\=WP?_'>L'_!WU!_D=_@;W'O\']QW_"/8=_PGV'?\)]AW_"?8=
M_PGV'?\)_RDJ ?\L)P'_+B<!_RTJ ?\L,@'_*ST"_RE) _\G50/_)6$$_R-M
M!/\B> 7_(H(%_R&+!O\ADP;_(9H'_R&@!_\AI0?_(:L(_R&Q"/\AN C_(<$(
M_R'+"/PAW CY(>D(]B'T"/,B_0?R(O\)\2+_"O$A_POP(?\+\"'_"_ A_POP
M(?\+_RPF ?\P) '_,2,!_S$F ?\R+P'_,3H"_R]& _\M4@/_*UX$_REI!?\H
M=07_)W\&_R>(!_\FD ?_)I8(_R:="/XFHPG])JD)_":O"?LFM@GZ)KX)^";(
M"?8FV0GR)N@)[R?S">TG_0KK)O\+ZB;_#>DF_PWH)O\.Z";_#N@F_P[H)O\.
M_R\C ?\S( '_-1\!_S<C ?\X+ '_.#<"_S9" O\T3@/_,EH$_S!E!?\N< ;^
M+7L'_"V$"/HLC GX+),)]RR9"O8KH KT*Z8*\RNL"_(KLPOQ*[L+[RO&"^XL
MU OJ+.8+YBSR"^0L_ WB+/\/X2S_$. L_Q#?+/\1WRS_$=\L_Q'?+/\1_S,?
M ?\W&P'_.AH!_ST@ ?\_* '_/S(!_ST^ O\[20/_.54$^S=A!O<U; ?U-'8(
M\C-_"? RAPKO,H\+[3*6"^PQG SJ,:(,Z3&I#.@QL WF,;D-Y3'##>,RT0W?
M,N4,W#+Q#]@Q_!'5,?\2TC'_$]$Q_Q30,?\4T#'_%- Q_Q30,?\4_S<; ?\[
M%P#_/Q8 _T,< /]&) '_1BX!_T0Y OQ"1 /V/U $\3U<!NT\9P?J.W$)Z#IZ
M"N4Y@POC.(L,XCB2#> WF0W?-Y\.W3>F#MLWK0_9-K80US;!$-4VSA#1-^,1
MS3?Q$\HW^Q7(-_\6QC?_%\4W_QC$-_\8Q#?_&,0W_QC$-_\8_SL7 /] $P#_
M11, _TD8 /],( #_3"D!^DLS ?)(/@+L1DH$YT16!N-#8@C?06P*W$!U#-D_
M?@W5/H8/TSV-$-$]E!'//)L2S3RB$\P\J13*.[$4R#N[%<<[R!;%/-P6P3SM
M%[X\^1F[//\:NCS_&[D\_QNX//\;N#S_&[@\_QNX//\;_SX4 /]$$ #_2A$
M_T\4 /]1&P#[4B, \5$M >E/. 'B344#W$M1!=9)7 C11V8+SD9P#LM%>!#(
M1( 2QD.'%,1"CA7#0I46P4&<%[]!I!B]0*P9O$"V&KI PAJX0-(;M4'H&[)!
M]AVP0?\>KD'_'JU!_QZL0?\>K$'_'JQ!_QZL0?\>_T(1 /]'#0#_3PX _U,1
M /]6%0#S5QP Z%8E .!5,0'74S\"SU),!<I05PG&3F$-PTQJ$,!*<A*]27H5
MNTB"%KE'B1BW1Y 9M4:7&[-&GQRQ1:<=L$6Q'JY%O!^L1<P?JD7C(*=&\R&E
M1O\AHT;_(J)&_R&B1O\AHD;_(:)&_R&B1O\A_T4. /]+"@#_4PP _U<- /E:
M$ #K6Q0 WUH< -1:*P#,6CL"QEA(!<%64PF\5%P-N5)E$;50;12S3W47L$Y\
M&:Y-A!JL3(L<JDN2'JA*FA^F2J,AI$FL(J-)N".A2<8DGTK>))U*\"2;2OTE
MF4O_))E+_R282_\DF$O_))A+_R282_\D_T@, /]/" #_5@@ ]5L) .E>"@#D
M7@T U5\5 ,M@)P#$7S8"OEY#!;A;3@FT65@.L%=A$JQ5:16J5' 8IU-X&J52
M?QRB488>H%".()Y/EB*<3I\CFDZH)9A.LR:73L(GE4[6)Y-.[">13_LGD$__
M)Y!0_R:/4/\FCU#_)H]0_R:/4/\F_TH) /]3!0#X6@0 XE\# -IB!@#48PD
MS6,2 ,1E(P"\93("MF- !;%A2PFL7E0.J%Q=$J5;91:A66P8GUAS&YQ6>AZ:
M58(@F%2*(I54DB234YLFD5*E)X]2L"F-4KXJC%+0*HI3Z2J)4_DIB%3_*8=4
M_RB'5/\HAU3_*(=4_RB'5/\H_TP% /]6 0#I70  W&," -%G!0#,: < QF@0
M +UJ( "V:2\!L&@\!*IE1PFE8U$-H6%:$IU?81::7FD9EUQP')5;=QZ26GXA
MD%F&(XU8CB6+5Y<GB5>A*896K2N%5KHL@U;,+()7YBR!5_<K@%C_*H!8_RJ
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MH"U@;ZTO7V^]+UYOU"]>;^TO7V_[+5]O_RQ@;_\L8&__+&!O_RQ@;_\LZUX
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M*TZ"S"M.@N@K3H'X*D^ _RI/@/\I3X#_*4^ _RE/@/\IVVH  ,=U  "Z?P
ML(<  *:,  "<CP  CY$  (:3!0" E!( >Y4A '>5+0%RE3@$;91"!VF32@ME
MDE$.8I%8$EZ07Q5;CV886(YM&U6.=AY2C8 A3XR+(TV+F"5+BZ4G28NU*$B+
MRBA(BN<G28GW*$F(_R=)A_\G28?_)TF'_R=)A_\GT6\  ,%[  "UA   JXP
M *"0  "5E   B9<  'Z:  !WFPX <YP< &^=*0%KG#4"9IP_!6*;1PA?FD\+
M7)I6#UB97!)5F&,54YAK%U"7<QI-EGT=2I6)'T>5E2%%E:0C1)2S(T.4R"-#
ME.4C0Y+U)$.1_R1#D/\D0Y#_)$.0_R1#D/\DRG4  +N!  "PBP  I)$  )J5
M  "/F0  @YT  '2B  !NHPL :J07 &:E)0!CI3$!7Z0[ UND1 58I$L(5:-3
M"U*C6@U/HF$03:)H$TJA<15'H'L81*"&&D*?DQQ GZ(=/I^R'CV?QAX]G^,=
M/9WT'CV<_Q\\F_\?/)O_(#R;_R \F_\@PGP  +6(  "ID   GI8  ).;  "'
MGP  >Z0  &^H  !CK 0 7ZT1 %RM'P!:KBL 5ZXV 52N0 -1K4@%3JU/!TNM
M5PE)K5X+1JQF#42L;@]!K'@1/ZN$$SRKD14ZJZ 6.:NP%SBKPQ<XJN$7-ZGS
M&#>G_ADVIO\:-J;_&C:F_QHVIO\:NH0  *Z/  "BE@  EYL  (NA  !_I@
M<ZL  &>O  !:M   4[8, %&W%P!/MR0 3;@P $JX.@%(N$,"1KA+ T2X4@1!
MN%H&/[AB!SVX:PDZN'4+.+>!##:WC@XTMYT/,[>M#S*WP0\QM]X/,;;R$#"T
M_!$PL_\2,+/_$S"S_Q,PL_\3LHX  *65  ":FP  CJ(  (*H  !UK0  :;,
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M 1/C^@$3X_H!EJ(  (FI  ![L0  ;KD  &'   !4Q@  2,H  #W/   STP
M*MD  "+> @ >ZPH '.P0 !OM%P 9[1\ %^XF !7N+0 4[S4 $_ ] !'P1@ 0
M\5  #_);  [R:0 -\W@ #/2*  OUG  *]:X "?;"  GVV0 (]>T "/7M  CU
M[0 (]>T BZD  'VR  !ON@  8L(  %7)  !'S@  .](  #'8   GW0  '^$
M !GH   6^ 8 %/H- !+[$@ 0_!< #OP=  W](P ,_2D "OXP  C_.  &_T$
M _],  #_6   _V8  /]W  #_B0  _YL  /^K  #_NP  _\X  /_/  #_SP
M_\\ ?[(  '&Z  !CPP  5LL  $C1   ZU@  +]T  "7A   <Y0  %.D  !'W
M   /_P$ #?\)  O_#0 (_Q  !O\4  /_&   _QX  /\C  #_*@  _S(  /\\
M  #_1P  _U0  /]C  #_<P  _X4  /^7  #_I   _[(  /^R  #_L@  _[(
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M!. D^0;>)/\'W"3_"-LD_PG:)/\)VB3_"=HD_PG:)/\)_RX; /\Q%P#_,A8
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M%J@\_Q:H//\6ISS_%J<\_Q:G//\6_ST- /]"" #_2 H _TL, /I,#P#L3!0
MX4H= -9*+ #.2SL!R4I( L1(4P3 1UT'O$9F";I$;@NW0W8-M4-]#K-"A!"Q
M08L1L$&2$JY FA.L0*(4JD"K%:E MA:G0,07ID#9%Z-![1B@0?L8GT'_&9Y!
M_QF=0?\9G4+_&)U"_QB=0O\8_T ) /]&!0#_3 4 \4\' .90"0#C3PT U4\5
M ,Q1)P#%438!OU!# KI/3@6V35@(LTQA"K!*:0VM27 /JTAX$:E'?Q*G1X84
MI4:-%:-&E1:A19X8GT6G&9Y%LAJ<1;\:FD71&YA%Z1N61O@<E4;_&Y1&_QN3
M1O\;DT?_&Y-'_QN31_\;_T(% /]* 0#R4   X50! -E6!0#350D S%42 ,-6
M(@"\5S(!MU8_ K)42@6M4U0(JE%="Z=09 ZD3FP0HDUS$I],>A2=3($6FTN)
M%YE*D1F72ID:E4FC&Y-)KAV22;L>D$G,'HY*Y1Z-2O8>BTO_'HM+_QV*2_\=
MBDO_'8I+_QV*2_\=_T4  /]-  #E5   V5D  ,]; P#*6P8 Q%H/ +M;'@"U
M7"X!KUL[ JI:1@6F6% (HE99"Y]58 Z<4V@1F5)O$Y=1=A654'T7DU"$&9!/
MC1J.3I8<C$Z?'HI.JA^(3K<@AT[((85.XB&$3_,@@T__((-/_Q^"4/\?@E#_
M'H)0_QZ"4/\>_T<  /-1  #?6   T5T  ,E@ @##8 0 O5X- +5@&@"N82H
MJ6 W J1>0P2?74T(FUM5"YA970Z56&01DE=K$X]6<A:-57D8BU2!&HA3B1R&
M4Y(>A%*<'X)2IR& 4K0B?U+$(WU2WB-\4_$B?%/^(7M4_R%[5/\@>U3_('M4
M_R![5/\@_TH  .E4  #:7   S&$  ,-D  "\9 ( MF,* *]D%P"I92< HV0T
M IYC0 2984H'E5]2"Y%>6@Z.76$1BUMH$XE:;Q:&6788A%A]&H%8AAQ_5X\>
M?5:9('M6I")Y5K$C=U;!)'96VB1U5^\D=5?](W58_R)U6/\A=5C_(758_R%U
M6/\A_TT  .57  #37P  R&0  +]G  "W:   L6<' *EH% "C:20 GF@R 9EG
M/02494<'D&1/"HQB5PV(85X0A5]E$X->;!: 77,8?5UZ&GM<@QUY6XP?=EN7
M(71:HB-R6J\D<5J_)7!:U25O6^TE;UO\(V];_R)O6_\B;UO_(6];_R%O6_\A
M^D\  .%:  #/8@  Q&<  +MK  "S;   K&H$ *1K$@">;"$ F6PO 91K.@./
M:40&BFA-"89F50V#95P0@&1B$WUB:15Z8G 8>&%X&G5@@!US7XH?<%^4(6Y>
MH"-L7JTE:UZ\)FI>T29I7NPE:E_[)&I?_R-J7_\B:E__(FI?_R)J7_\B\%(
M -U=  #+90  P&L  +=N  "O;P  IVX! *!O$ ":<!\ E' L 8]O. .*;4(&
MAFQ+"8)J4@Q^:5D/>VA@$G=F9A1U9FX7<F5U&G!D?AUM8X@?:V.2(FEBGB1G
M8JLE96*Z)F1BSR9D8NHF96+Z)&5C_R-E8_\B96/_(F5C_R)E8_\BZU4  -A@
M  #(:   O&X  +-Q  "K<P  HG$  )MR#@"5<QP D'0J 8IS-@*%<D %@7!(
M"'UO4 MY;5<.=FQ>$7-K9!1P:FP7;6ES&FMI?!QH:(8?9F>0(61GG"-B9JDE
M8&:Y)E]FS29?9N@F8&;Y)&!F_R-@9O\C86;_(F%F_R)A9O\BZ%@  --C  #$
M:P  N7$  +!U  "G=P  GG4  )9V#0"0=QD BW@G (9W,P*!=CT$?'5&!WAS
M3@MU<E4.<7%<$6YP8Q1K;VH6:6YQ&69N>AQC;8,>86R.(5]KFB-=:Z<E6VNW
M)EIKRB9::^<E6VOW)%MJ_R-<:O\B7&K_(EQJ_R)<:O\BXUL  ,YF  # ;@
MMG0  *QY  "C>P  F'D  )!Z"P"*>Q8 A7PD (%\,0%\>SL$=WI$!G-Y3 IP
M>%,-;'=:$&EV81-G=6@69'1O&&%S>!M><H$=7'&,(%IQF")8<*8D5G"U)55P
MR"55<.4E57#V)%9O_R-6;_\B5V__(E=O_R)7;_\BWU\  ,II  "\<@  LG@
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M'D6#_AY%@O\>18+_'D6"_QY%@O\>RFT  +IX  "O@0  I8<  )J+  "/C0
M@8X  '21  !NDPH :905 &:5(@!CE2X!8)4X ER50019E$D&5I10"%235PI1
MDUX,3I)F#TR2;A%)D7@41I"#%D20D!A"CYX90(^M&C^/P!H_C]P:/XWQ&C^,
M_1L_B_\;/XO_&S^+_QL_B_\;PG,  +5^  "JAP  GXP  )20  "(DP  >Y4
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M"RJM_PLJK?\+K8L  *"2  "5F   B9T  'VC  !QJ   9*T  %FQ  !-M
M0K@  #NZ"@ XNQ, -[P> #6\*0 TO3( ,[T[ #*]1  QODP +[Y5 2Z^7@$L
MOF@!*KYT BF^@@(GOY$#)K^B R2_M ,CO\L#([[H R.\]P0BN_\%(KO_!2*[
M_P4BN_\%I)(  )B8  ",G@  @*4  '.K  !GL   6[4  $^Y  !$O   .L
M ##$!  JQPL *,@3 "?)'0 FR2< )<DP "3*.0 CRD( (LM+ "'+50 @S%\
M'\QL !W->@ <S8H &\V< !G.K@$8SL4 &,WD !C,] $8ROP!&,K_ AC*_P(8
MRO\"FYD  (^?  ""I@  =:T  &BS  !<N0  4+T  $3!   YQ   ,,@  "C,
M 0 @T 8 &=4+ !;7$  5V!D %=DB !39*P 3VC0 $]H] !+;2  1W%, $=U?
M !#=;0 0WGX #M^1  [@I  -X+@ #.#2  O?[0 ,WO< #-W[  S=^P ,W?L
MDI\  (6G  !WK@  :K4  %V\  !0P0  1,4  #C)   NS0  )=$  ![5   6
MV@$ $=X& !#G#0 .YQ( #>@9  SH(0 +Z2D "NHQ  GJ.P 'ZT4 !>M1  3K
M7@ #ZVX  >N   #JE   ZJ<  .N\  #KT@  Z^D  .SO  #L[P  [.\ AZ<
M 'FO  !KMP  7KX  %'%  !#R0  -\T  "W1   CU@  &]L  !/?   .XP
M#.X"  KV"@ ']@X !?82  /V&   ]1X  /4E  #U+@  ]3<  /9"  #V3@
M]ET  /9N  #V@0  ]I4  />G  #WMP  ^,<  /C0  #XT   ^-  >Z\  &VX
M  !@P   4L@  $3-   WT0  *]<  "'<   8X   $>0   SG   '[P  !/H
M  '_ P  _P@  /\-  #^$   _A0  /\:  #_(0  _RD  /\S  #_/@  _TL
M /];  #_;   _X   /^2  #_H0  _ZT  /^S  #_LP  _[, _QPF /\<) #_
M&B4 _Q4G /\1+@#_$#H _PY' ?\-4P'_"U\!_PIK ?\*=0'_"G\!_PJ' ?\*
MC@'_"I4!_PJ; ?\)H '_":4 _PFK /\)L0#_";@ _PG! /X)S #\"=X ^0GK
M /4)]@#S"?\ \@K_ /$*_P'Q"_\!\0O_ ?$+_P'Q"_\!_Q\C /\?(0#_'B$
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M!<<C_P;&(_\&QB/_!L8C_P;&(_\&_RP2 /\N#P#_,!  _S,4 /\S&P#_,B4
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M$9@\_Q&8//\1_SH! /]   #O10  X4@  -E(!0#31@D S$42 ,1'(@"]2#$
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MH1A[3:X9>DZ]&GA.T1IW3NL:=T_Z&79/_QEV3_\8=D__%W9/_Q=V3_\7^$8
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M'65:R!UE6N0=95KV'&5:_QME6O\:95K_&65:_QEE6O\9Z$\  --9  #$80
MN68  +!H  "G:0  GF4  )=F#0"19QD C&@G (=G,@&#9CT"?V5&!'MD309X
M8U0)=6);"W)A80UP86D/;6!P$FM?>11I7X(69UZ-&65>F!IC7J4<85ZT'6!>
MQQU@7N,=8%[U'&!>_QM@7O\:85[_&F%>_QIA7O\:Y%(  ,]<  # 9   MFD
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M&U)K_AI2:O\:4FK_&5)J_QE2:O\9U%P  ,-F  "V;@  K'0  *)W  "6=@
MB74  (%V 0!Z=P\ =G@; ')Y)P!O>3(!:W@\ FAX1 1E=TP&8G=3"%]V6@I=
M=6$,6G5H#UAT<!%5<WD34W.$%E%RD!A/<IX937&M&DQQOQM+<=D;3''P&DQP
M_1I-</\936__&4UO_QE-;_\9SF   +YJ  "R<@  J'@  )U[  "0>@  A'H
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M$SN&_Q,[AO\3O'$  *][  "E@P  F8<  (R(  !_B0  <XP  &60  !<DP
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M> $@N(@!'[B9 1VYJP$<N< !'+C? 1RV\@$;M?P"&[3_ ANT_P(;M/\"GX\
M )25  "(FP  >Z$  &ZF  !BJP  5K   $JS   _M@  -;D  "R\   DOP8
M'\(- !W"%  <PAX &\,F !K#+P 9Q#@ &,1! !?$2@ 6Q54 %<5A !3&;P 3
MQG\ $L:1 !''I  0Q[D #\?4 !#&[@ 0Q/H $,/_ !##_P 0P_\ EY8  (N<
M  !^H@  <:D  &2O  !8M   2[@  $"[   UO@  *\$  "/%   ;R0$ %,P&
M !#0"P .T1$ #=$9  W1(0 ,T2H #-$T  O2/@ *TDD "=-5  G38@ (TW(
M!M2$  74F  $U*L  ]7   '5W  !U>T  =7V  '5]@ !U?8 CIT  ("D  !S
MJP  9K$  %FX  !,O0  /\   #3#   JQP  (<H  !G.   2T@  #=8!  G;
M!0 &W T !-P1  /=&  !WB   -XH  #?,0  X#P  .%'  #B5   XV,  .-T
M  #DB   Y)L  .6N  #EP0  Y=4  .;G  #FYP  YN< @Z0  '6L  !HLP
M6KL  $W!  ! Q   ,\@  "C,   ?T   %]0  !#9   +W0  !>$   #D
MY0<  .8-  #G$0  Z!8  .D=  #J)0  ZRX  .TY  #O10  \%,  /%D  #Q
M=@  \HH  /.<  #SK0  ]+L  /3(  #TR   ],@ =ZT  &JU  !<O0  3\0
M $#)   SS0  )]$  !W6   4W   #N    CC   !Y@   .H   #N    [@
M .\$  #P"@  \0X  /,2  #T&   ]B   /@J  #Z-0  _4,  /Y2  #_8P
M_W8  /^)  #_F@  _Z8  /^P  #_L   _[  _Q8C /\5(0#_$2$ _PTD /\)
M*P#_!C< _P-$ /\ 40#_ %T _P!H /\ <@#_ 'L _P"# /\ B@#_ )$ _P"6
M /\ G #_ *$ _0"F /L K #Y +, ]P"[ /4 Q0#S -$ \@#D /$ \0#O /H
M[@#_ .X _P#M /\ [0#_ .T _P#M /\ _QD@ /\8'0#_%1T _Q ? /\.*0#_
M##0 _PI! /\'30#_!5D _P1D /\$;@#_ W< _P.  /\#AP#_ XT _0*3 /L"
MF0#Y IX ]P*D /4"J@#S ;  \0&X .\!P@#M <\ ZP'C .H![P#H OL YP3_
M .8%_P#F!O\ Y@;_ .8&_P#F!O\ _QP; /\;&0#_%Q@ _Q4= /\3)0#_$3
M_Q ] /\.20#_#%4 _PM@ /\+:@#]"W, ^PM\ /D*@P#W"HH ]0J0 /0*E@#S
M"IL \0JA .\)IP#M":X ZPFV .@)P #F"<T Y GB .(*\ #?"_L W@S_ -P-
M_P#<#?\ VPW_ =L-_P';#?\!_Q\7 /\>$P#_&Q( _QP9 /\;(@#_&"P _Q4X
M /\31 #^$E  ^1%; /409@#S$&\ \!!W .X0?P#L$(8 ZA", .D0D@#H$)@
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M!+,C_P2S(_\$_RD+ /\J!0#_+@@ _R\, /\M$ #S*Q< Z"@B . F+P#9)CT
MTB=* ,TG50#**%\ QRAH <4H;P'#)W<!P2=^ ;\GA &^)XL"O">2 KLGF0*Y
M)Z "MR>I [8HLP.T*+\#LRC/ [ IY@2M*?8$JRK_!:DJ_P:H*O\&J"K_!J@J
M_P:H*O\&_RT% /\P  #_,P( ]C0& .\R"@#H+A  W"P8 -$N* #++S< QC!$
M ,$P3P"^,%D!NS!B ;@P:@*V+W$"M2]X K,O?P.Q+X8#L"^- ZXNE 2M+IP$
MJRZD!:DOK@6H+[H%IB_*!J0PX@:A,/,'GS#_")XQ_PB=,?\(G#'_")PQ_PB<
M,?\(_S   /\U  #O.   XCH  -LY! #6-0D SC03 ,8V(@"_.#$ NC@_ +8X
M2@&S.%0!L#== JTW9 *K-FP#J39S!*@V>02F-8 %I#6'!:,UCP:A-9<'GS6@
M!YXUJ@B<-;8(FS7%"9DUW0F6-N\*E#;]"I,W_PJ2-_\*DC?_"I(W_PJ2-_\*
M_S,  /8Z  #D/P  V$(  ,Y" 0#)/@8 Q#L/ +L^'0"U/RP L3\Z *T_10&I
M/T\!ICY8 J,]7P.A/6<$GSQM!9T\= :<.WL&FCN"!Y@[B@B6.Y,)E3J<"I,Z
MI@N1.K(+D#O #(X[U0R,/.P-BCS[#8D\_PV)//\,B#S_#(@\_PR(//\,_S<
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M$G-)R!-R2N,3<4KU$G%*_Q%Q2_\1<4O_$'%+_Q!Q2_\0[$,  -E,  #(4P
MO5<  +18  "L5P  I5(! )Y3#P"85!P DU0I (]4-0"+4T !B%-( H524 2"
M45<%?U!>!GU09 A[3VL)>4]R"W=.>PUU3H0.<TV.$'%-F1%O3:43;4VS%&Q-
MQ11K3N$4:T[T$VM._Q)K3O\2:T[_$6M._Q%K3O\1Z$8  --0  #$5@  N5H
M +!<  "F6@  GU8  )A6#0"25QD CE@F (E8,@"&6#T!@E=% G]630-\550%
M>51;!G=480AU4V@)<U-P"W%2> UO4H$/;5*+$&M1EQ)I4:,39U&Q%&91PQ5E
M4MX595+R%&52_Q-E4O\295+_$F52_Q)E4O\2Y$H  ,]3  # 6@  M5X  *Q@
M  "B7@  FED  )):"P"-6Q8 B%PC (1<+P" 6SH!?5M# GE:2P-V65($=%A8
M!G%87P=O5V8);5=M"VM6=0UI5GX/9U:)$655E1)C5:$48E6O%6%5P19@5=L6
M8%;Q%6!6_A1@5O\385;_$F%6_Q)A5O\2X$T  ,M6  "]70  LF$  *AC  "=
M80  E5T  (U>"0"'7A, @U\@ ']?+ ![7S<!=UY  G1>2 -Q74\$;UQ6!6Q<
M7 =J6V,):%MK"V9:<PUD6GP/8EJ'$6!9DQ)>6: 475FN%5M9OQ9;6=@66UGO
M%5M9_11<6?\37%G_$EQ9_Q)<6?\2W%   ,=9  "Z8   KV0  *1E  "99
MD&   (AA!@""8A$ ?F,= 'IC*@!V8S0!<V(] 6]B1@)L84T$:F%4!6=@6@=E
M8&$(8U]I"F%?<0Q?7GH.75Z%$%M>D1)979X46%VL%5==O1967=465EWN%5==
M_!177?\35UW_$E==_Q)77?\2UE,  ,1<  "W8P  K&@  *!H  "59P  BF,
M (-E @!]9@\ >&8: '1G)P!Q9S( ;F<[ 6MF0P)H9DL#9652!6-E609A9%\(
M7F1G"EQC;PQ:8W@.6&.#$%9BCQ)48IP34V*J%5)BNQ518M(546'M%5)A^Q12
M8?\34V'_$E-A_Q)38?\2T58  ,!?  "S9@  J6L  )QK  "0:@  A6<  'UI
M  !W:@T <VL7 &]K) !L;"\ :6PX 69K00)C:TD#86M0!%YJ5P9<:ET'6FEE
M"5AI;0M5:'8-4VB!#U%GC1%/9YH23F>I%$UGN11,9\\43&;K%$UF^Q--9O\2
M3F7_$DYE_Q).9?\2S%H  +QC  "P:@  I6\  )AN  ",;0  @&P  '=M  !Q
M;@L ;6\4 &EP(0!F<2P 9'$V 6%Q/@%><48"7'!- UEP5 57<%L&56]B"%-O
M:@I0;G,,3FY^#DQMBA!*;9@126RG$DALN!-';,T31VSJ$TAK^A)(:_\22&K_
M$4AJ_Q%(:O\1QUX  +AG  "L;@  H7(  )-R  "'<0  >G$  '%R  !K= <
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M@ 4SCXX&,8^>!S".KP<OCL,'+X[A!R^,] @OB_\(+XK_""^*_PDOBO\)L'8
M *5_  "8A   BH0  'V%  !PAP  98H  %J.  !/D@  1I4  $&8#  ^F!0
M/9D? #N9*  ZFC$ .9HZ #>:0@ VFDH -9I2 3.:6@$QFF0!+YIO BV:>P(L
MFHH#*IJ: RF:K 0HFL $)YG> R>7\@0GEOT%)Y7_!2>5_P4GE?\%J7X  )Z%
M  "2B0  A(H  ':,  !JCP  7I,  %27  !)FP  0)\  #>B!  RHPX ,:,7
M #"D(0 NI"H +:0R "RE.@ KI4, *J5+ "FE5  HI5X )J5I "6E=@$CI84!
M(J66 2"FJ $?I;L!'J77 1ZD[P$>HOL"'J'_ AZA_P(>H?\"HH8  )>,  "+
MCP  ?9$  &^4  !CF   5YT  $VA  !#I0  .*@  #"K   HK@< )*\0 ".O
M%P AKR$ (+ I !^P,0 >L#H ';%" !RQ3  ;L58 &K%A !FR;P 8LGX %K*0
M !6RH@ 4LK8 $[+. !.QZP 3K_D $Z[_ 1.N_P$3KO\!FHT  )"2  "$EP
M=9H  &B?  !;HP  4*@  $6L   [L   ,;(  ">U   @N   &+H' !2\#@ 3
MO!4 $KP> !&])@ 1O2X $+TW !"^00 .ODP #KY7  V^90 ,OW0 "[^&  J^
MF0 (OJP ![["  >^WP (OO  "+WZ  B]_  (O?P DY0  (>9  !ZGP  ;*4
M &"J  !3KP  1[,  #RV   QN   )[L  !^^   7P0  $<0!  S("  (R0X
M!\D4  ;)'  %R20 !,HL  /*-@ "RD   ,M,  #+60  RV@  ,MY  #,C
MRY\  ,NS  #+R   S.(  ,SO  #,\0  S/$ BIH  'RA  !OIP  8JT  %6S
M  !(N   .[L  #"^   FP0  '<0  !7(   /RP  "LX   32 @  TPH  -,/
M  #4%   U1H  -8B  #7*@  V30  -H_  #<2P  W%H  -UJ  #=?0  W9$
M -VD  #>M@  WL@  -[>  #>X@  WN( ?Z(  '&I  !DL   5K<  $F\   \
MP   +\0  "3'   ;RP  $\\   W2   'U@   -L   #>    WP,  . )  #A
M#@  XA(  .,7  #E'@  YB<  .@Q  #J/0  [$L  .Q:  #M;   [H   .Z4
M  #NI0  [K0  .["  #NQ@  [L8 =*H  &:R  !8N0  2\   #W%   OR0
M),T  !G1   1U@  "]L   />    X0   .4   #H    Z0   .H   #K!@
M[0L  .\/  #P$P  \AH  /0C  #W+@  ^3L  /M*  #\6P  _6T  /V   #^
MDP  _J(  /ZM  #^KP  _J\ _Q ? /\.'0#_"AT _P$@ /\ * #_ #4 _P!!
M /\ 3@#_ %H _P!E /\ ;@#_ '< _P!_ /X A@#\ (P ^P"2 /D EP#X )P
M]P"B /8 IP#U *T \P"U /( O0#Q ,D [P#< .X ZP#M /< [ #_ .L _P#J
M /\ Z@#_ .H _P#J /\ _Q,< /\1&0#_#1D _P8< /\#)0#_ #$ _P ^ /\
M2@#_ %8 _P!A /\ :P#] ', ^@![ /< @P#U (D ] "/ /( E #Q )D \ "?
M .X I #M *L [ "R .H N@#H ,8 YP#6 .4 Z #D /4 XP#^ .( _P#A /\
MX0#_ .$ _P#A /\ _Q48 /\3% #_#Q0 _PT9 /\+(@#_""T _P0Y /\!1@#_
M %$ _@!< /H 9@#V &\ \@!W .\ ?@#M (4 ZP"+ .H D0#H )8 YP"< .8
MH0#D *@ XP"O .$ N #? ,, W0#1 -L Y@#9 /, UP#] -4"_P#4 O\ U /_
M -0#_P#4 _\ _Q@3 /\5$ #_$@\ _Q(5 /\1'0#_#B@ _PPT /\*00#Y"$P
M]097 /$&80#M!FH Z05R .8%>@#D!8$ X@6' . &C0#?!I( W0:8 -L&G@#9
M!J4 UP:M -0&M0#2!L  T ?/ ,X(Y0#,"?0 R@O_ ,@,_P#'#/\ QPS_ ,8,
M_P#&#/\ _QL. /\9# #_& T _Q@1 /\7& #_%"( ^Q$N /,0.@#M#D8 Z U2
M .4-7 #A#64 W@UM -L-=0#8#7P U0V" -,-B0#1#8\ T V5 ,X-G #-#J,
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MK &N(+<!K"'& :LAW0&G(N\"I2+] J,C_P*B(_\"HB/_ J$C_P*A(_\"_R4
M /\H  #R*@  Y2L  -\H!0#<(0L TB$4 ,DD) ##)3( OB8_ +HG2@"W)U0
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M!H@UR@>'-N4'A3;V!X0W_P>#-_\'@S?_!X(W_P>"-_\']#(  .,[  #200
MQD0  +U#  "W/P  L3L) *H[% "E/"( H#TP )T].P"9/44 ECU. 90\5@&2
M/%T"D#QC HX[:@.,.W$$BCMX!(@Z@ 6'.H@&A3J2!H,ZG >!.J@(@#JU"7X[
MQ@E].^$)>SSS"7L\_PEZ//\(>CS_"'H\_PAZ//\([C<  -U!  #+1@  OTD
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M#65*_ QE2O\+94K_"V5*_PME2O\+X$0  ,M-  "]4@  LE8  *95  "<4@
ME4X  (Y."0")3Q0 A5 @ (%0+ !^4#< >U!  7A02 %U3T\"<TY5 W%.7 1O
M3F,%;4UJ!FM-<@=I37L(9TV%"F5-D0MD3)T,8DVK#6%-NPY@3=$.8$WL#F!-
M^PU@3?\,8$W_"V!-_PM@3?\+W$<  ,=0  "Y5@  KED  *)8  "85@  D%$
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M#%)8_PQ26/\,S5$  +Q9  "P7P  HV$  )9@  "+7P  @5L  'E=  !S7@P
M;UX5 &M?( !H7RL 9F U &-@/0%A7T4!7U], EU?4P-;7UH$65YA!5=>:095
M7G((4UY]"5%=B0M0798,3EVD#4U=M Y,7<@.3%WF#DU=]PU-7/\,35S_#$Y<
M_PQ.7/\,R50  +E<  "M8P  GV,  ))C  "'8@  ?&   '1A  !N8@D :6,2
M &9C'0!C9"@ 860R %YD.P!<9$,!6F1* EAD40)69%@#5&1?!%)C9P508W '
M3F-Z"$QBA@I+8I0+26*B#$ABL@U'8L<-1V+D#4AA]@Q(8?\,2&#_"TE@_PM)
M8/\+Q%@  +5@  "J9@  FV8  (UF  ""90  =F0  &YE  !H9@4 8V<0 &!H
M&@!=:24 6VHO %EJ. !7:D !56I' 5-J3@)1:E4#3VE=!$UI9 5+:6T&26AX
M!T=HA E&:)(*1&>A"T-GL0Q"9\4,0F?B#$)F]0Q#9O\+0V7_"T-E_PM#9?\+
MOUP  +%D  "F:@  EFD  (EI  !]:0  <6D  &=J  !B; $ 76T- %EN%@!7
M;R$ 57 K %-P-0!1<#T 4'!% 4YP3 %,<%,"2G!: TAP8@1&;VL%1&]U!D)O
M@@= ;H\)/VZ>"CUNKPH];L(*/&[@"CUM] H];/\*/6O_"CYK_PH^:_\*NF
M *UI  "@;@  D6T  (1M  !X;0  ;&X  &%P  !;<@  5G0* %)U$@!0=AT
M3G<G $QW,0!+>#D 27A! $AX20%&>% !1'=7 D)W7P- =V@#/G=S!#QV?P8Z
M=HT'.7:<"#=UK0@W=< (-G7>"#=T\@@W<_X(-W+_"#=R_P@W<O\(M68  *EO
M  ":<0  BW$  'YQ  !S<@  :',  %QV  !4>0  3GL% $I]#P!(?A@ 1G\C
M $5_+ !#@#4 0H ] $& 10 _@$P!/8!4 3R 7 (Z?V4".']O S9_? 0T?XH$
M,G^:!3%^J@8P?KT&,'[:!C!]\ 8P>_T&,'O_!C!Z_P8P>O\&L&P  *1U  "4
M=0  AG4  'EV  !N=P  8WD  %=]  !/@0  1X0  $*&#  _AQ, /8@= #R(
M)P [B3  .HDX #B)0  WB4@ -HE/ #2)6 $SB6$!,8EL 2^)> (MB8<"+(F7
M RJ(IP,IB+H#*8C4 RF&[@,IA?P$*83_!"F$_P0IA/\$JG0  )Y[  ".>@
M@'H  '1[  !H?@  78$  %*%  !)B0  08P  #F0!0 UD0\ ,Y(7 #*2(0 Q
MDBD ,),R "Z3.@ MDT$ +)-* "N44@ JE%P *)1G ">4<P$EE((!))23 2*3
MI $AD[<!()// 2&2[ $@D/H"((__ B"/_P(@C_\"I'P  )>   "'?P  >X
M &Z"  !BA0  5XD  $V.  !"D@  .I8  #*9   JG D *)T1 ":=&0 EG2(
M))XJ ".>,@ BGCH (9Y" "">2P ?GU4 'I]@ !R?;0 ;GWP &I^- !B?GP 7
MG[( %I_) !:>Z  6G/< %IO_ 1>;_P$7F_\!G8,  (^&  ""A@  =(<  &>+
M  !;CP  4),  $:8   \G   ,Z   "NC   CI@  '*@+ !JI$0 8J1@ %ZDA
M !:J*0 5JC$ %*HY !.J0P 3JTT $JM8 !&K90 0JW0 #JN&  ZKF0 -JZP
M#*O!  RJWP ,J?( #:C\  VH_P -J/\ EHH  (F,  !ZC0  ;)$  &"5  !4
MF@  29\  #^C   UIP  *ZH  ".N   ;L   %+,!  ^U"@ -MA  #+86  NV
M'P *MB< ";8O  BV.0 'MT, !K=/  2W6P #MVH  K=[  "WC@  MZ$  +:T
M  "VRP  MN4  +7Q  "U]P  M?< CY$  (&4  !REP  99P  %BA  !,I@
M0:L  #>O   LL@  ([4  !JX   3NP  #KT   G !0 #P0T  ,$1  #!%P
MPAX  ,(F  #"+P  PSD  ,1$  #$4   Q%X  ,5O  #%@0  Q94  ,6H  #%
MO   Q-$  ,3F  #$[@  Q.X AI@  'F>  !KHP  7:D  %"N  !$LP  -[8
M "RY   BO   &;\  !'"   ,Q0  !L@   #+    S <  ,P-  #-$0  S18
M ,X=  #/)   T"T  -(X  #41   U%(  -5A  #5<P  UH<  -:;  #6K0
MU[\  -C.  #8W0  V-T >Z   &ZF  !@K0  4[,  $6X   XO   *[\  "'"
M   7Q@  $,D   K,   "T    -0   #7    V    -H%  #;"P  W X  -X3
M  #?&0  X2$  .,J  #E-@  YT,  .=3  #H9   Z7<  .F,  #JGP  ZJX
M .JZ  #JPP  ZL, <*@  &*O  !5M@  1[P  #G    LQ   (,@  !;,   .
MT   !]0   #9    W0   .$   #C    Y    .8   #G 0  Z0<  .L,  #L
M$   [A4  / =  #S)P  ]C,  /=#  #X5   ^68  /EZ  #ZC@  ^IX  /NI
M  #[L   ^[  _PL; /\'&0#_ !D _P < /\ )0#_ #( _P _ /\ 2P#_ %<
M_P!B /\ :P#_ ', _0![ /L @@#Z (@ ^ "- /< D@#V )@ ]0"= /0 H@#S
M *D \0"P .\ N #N ,, [ #1 .L Y@#I /, Z #^ .@ _P#H /\ Z #_ .@
M_P#H /\ _PX8 /\*%0#_ 10 _P 8 /\ (@#_ "X _P [ /\ 1P#_ %, _0!>
M /H 9P#W &\ ]0!W /, ?@#R (0 \ ") .\ CP#N )0 [ ": .L GP#I *4
MZ "L .8 M #D +\ XP#, .$ X@#? /  W@#[ -X _P#= /\ W0#_ -P _P#<
M /\ _Q 3 /\-$0#_!A  _P(5 /\ '@#_ "D _P V /\ 0@#Z $X ] !9 /$
M8@#N &L [ !R .H >0#H '\ YP"% .4 BP#D )  X@"6 .$ G #? *( W0"I
M -H L0#8 +L U0#( -( W0#1 .T T #Y ,\ _P#. /\ S0#_ ,T _P#- /\
M_Q$/ /\.#0#_# T _PL2 /\'&0#_ B0 _P P /8 / #O $D Z@!3 .< 70#D
M &8 X0!M -\ = #= 'L VP"! -D A@#6 (P U "2 -( F #0 )X S@"F ,P
MK@#* +@ R #$ ,8 UP#% .H PP#W ,( _P#! ?\ P +_ , "_P#  O\ _Q0+
M /\0!@#_$ D _Q . /\.% #_"AX ]08I .L$-@#C T( WP-. -L$5P#6!&
MTP1H - $;P#.!78 S 5\ ,H%@@#)!8@ QP6. ,8%E #$!9L P@6C , &JP"^
M!K4 O0;" +L(U "Z">D MPOX +4,_P"T#/\ M S_ +0,_P"T#/\ _Q<$ /\4
M  #_%@, _Q0) /\1#@#R#A4 Z PA -X*+@#6"SL T Q' ,P,40#)#%H Q@UB
M ,0-:@#"#7$ P UW +\-?0"]#H, O Z* +H.D0"Y#I@ MPZ@ +8.J0"T#[0
ML@_! +$0U "N$>L JQ+Z *D2_P"H$_\ IQ/_ *<3_P"G$_\ _QH  /\;  #Y
M&P  ZQD  .44!@#E$ X V0X7 ,\1)@#($C0 Q!-  +\42P"\%%0 N15= +<5
M9 "U%6L M!5Q +(5> "Q%GX KQ:% *X6C "L%I0 JQ>< *D7I@"G&+  IAB]
M *08SP"B&N< GQKW )T;_P&<&_\!G!O_ 9L;_P&;&_\!_QT  /<A  #H)
MW24  -0A 0#/&P@ RA<1 ,(:( "\'"T MQTZ +,>10"P'D\ K1Y7 *L>7P"I
M'V8 J!]L *8?<P"E'WD HQ^  *(?AP"@((\ GR"8 )T@H@";(*P!FB&Y 9@A
MR@&6(N0!E"/U 9(C_P&1(_\!D"/_ 9 C_P&0(_\!_R(  .LI  #=+@  SR\
M ,<M  #!)P, O2(- +8C&@"P)2@ K"8T *@F0 "E)TD HB=2 * G6@">)V$
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M!70W_ 5T-_\$=#?_!'0W_P1T-_\$YS4  -(]  ##0@  N$0  *Q"  "D/@
MGSD  )HX#@"4.AD D#HF (T[,0"*.SL ASM$ (0[3 "".U,!@#I: 7XZ8 %]
M.F<">SIN GDZ=0)W.GX#=CJ(!'0ZDP1R.IX%<3JK!6\[NP9N.\\&;3OJ!FT\
M^@9L//\%;#S_!6P\_P5L//\%XCD  ,Q"  "^1P  L4@  *5&  "=0P  ES\
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M8$7_!F!$_P9@1/\&UD$  ,-)  "V3@  IT\  )M-  "22P  C$<  (5'! "
M1Q  ?$@: 'A()@!U23  <TDZ '!)0@!N24D!;$A0 6I(5@%H2%T"9DAD F5(
M; -C2'4$84=_!6!'B@9>2)<'74BE"%M(M A;2,<)6DCD"%I)]@A:2?\'6DC_
M!EI(_P9:2/\&T44  +],  "R4@  HU$  )=0  "-3@  ADH  (!* 0!Z2PX
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M@@5*6(\&25B>!TA8K@A'6, (1UC="$=8\@A'5_\'2%?_!TA7_P9(5_\&P5$
M +)9  "C7   E%L  (=;  !]6@  <E@  &M9  !E6@, 8%L. %U<%P!:7"$
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M!3AHJ 4W:+H%-VG3!3=H[@4W9_P%.&;_!3AF_P4X9O\%M%X  *=E  "590
MAF0  'IE  !O90  9&8  %EH  !2:@  36P$ $EN#@!';A8 16\@ $1P*0!"
M<#( 07 Z $!Q0@ _<4D /7%1 #QQ60$Z<6(!.'%L C9P> (U<(8#,W"5 S)P
MI@0Q<+@$,'#0!#%O[ 0Q;OL$,6W_!#%L_P0Q;/\$KV0  *%I  "/:   @6@
M '5I  !K:0  8&L  %5N  !-<0  1G,  $)U"P _=A( /7<< #QW)0 Z>"T
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M !B,XP 9BO4 &8G_ 1F(_P$9B/\!G7<  (QV  !]=@  <G<  &5Y  !:?
M4(   $:$   \B0  -(P  "V0   EDP( 'Y4, !V6$@ <EAH &Y<B !J7*@ 9
MES( &)@Z !>80P 6F$T %9A8 !289  3F', $9B$ !"8E@ 0F*D #IB_  Z7
MW0 /EO( $)7\ !"4_P 0E/\ E7T  (5\  !X?   :WX  %^!  !4A@  2HH
M $"/   VDP  +9<  "::   >G0  %Z # !*B#  0HQ( $*,9  ^C(0 .I"D
M#J0Q  VD.@ ,I$4 "Z10  JD7  )I&H !Z1[  :CC@ $HZ$  J.T  .BRP #
MHN8  Z'S  .A^P #H?L C8,  '^"  !QA   9(<  %B,  !-D0  0I8  #B:
M   OG@  )J(  !ZE   7J   $:L   RN!P 'KPT  Z\2  *O&0 !KR$  *\I
M  "P,@  L#P  +!'  "P4P  L&$  +!Q  "P@P  KY<  *^J  "OOP  KMD
M *[K  "N]   KO0 AXD  'B*  !JC@  79,  %&8  !%G0  .Z(  #"F   G
MJ@  'JX  !:Q   0M   "[8   6Y P  N@H  +H.  "Z$P  NQD  +LA  "\
M*   O#$  +T\  "^2   OE8  +YE  "^=P  OHP  +Z?  "]LP  OL<  +[>
M  "]ZP  O>L ?Y(  '"5  !BF@  59\  $FE   ]JP  ,J\  "BT   >M@
M%;D   Z\   )OP   L(   #$    Q00  ,8*  #&#@  QQ(  ,@8  #)'P
MRB<  ,PP  #./   SDD  ,]9  #/:@  SWX  ,^3  #/I@  S[@  ,_(  #/
MVP  S]L =YP  &BA  !;IP  3JX  $&T   TMP  *+H  !V]   3P   #<0
M  ;'    R@   ,X   #0    T0   -("  #3"   U0P  -80  #9%0  VQP
M -TD  #@+P  XCP  .-+  #D7   Y&\  .6#  #EF   Y:D  .6V  #EPP
MY<, ;*4  %^L  !1L@  1+D  #6\   HP   ',0  !+(   ,RP   \\   #3
M    V    -P   #?    WP   .$   #C    Y ,  .8(  #H#0  Z1$  .P8
M  #N(@  \2X  /,\  #T30  ]5\  /9S  #WAP  ]YD  /BE  #XL   ^+
M_P,7 /\ %0#_ !4 _P 8 /\ (P#_ "\ _P \ /\ 2 #_ %0 _P!> /\ 9P#]
M &\ ^P!V /D ?0#X (, ]@"( /4 C@#T ), \@"8 /$ G@#P *0 [@"K .T
MLP#K +T Z@#+ .@ X0#G /$ Y@#] .4 _P#D /\ Y #_ .0 _P#D /\ _P<3
M /\ $0#_ !$ _P 5 /\ 'P#_ "L _P W /\ 1 #^ $\ ^@!: /< 8P#T &L
M\@!R /  >0#O '\ [0"$ .L B@#J (\ Z "4 .< F@#E *  Y "G .( KP#@
M +D W@#& -P V@#: .P V #Y -8 _P#6 /\ UP#_ -@ _P#8 /\ _PH0 /\#
M#@#_  T _P 2 /\ &@#_ "8 _  R /< /P#T $H \0!5 .T 7@#J &8 Z !N
M .4 = #C 'H X@"  .  A0#> (L W "0 -L E@#8 )P U0"C -, JP#1 +4
MS@#! ,P T0#+ .< R0#U ,@ _P#( /\ R #_ ,@ _P#( /\ _PP, /\&" #_
M @H _P / /\ %0#\ "  \0 L .P .0#I $4 Y0!/ .$ 60#> &$ VP!H -<
M;P#4 '4 T@![ -  @ #. (8 S ", ,L D@#) )@ QP"@ ,4 J ## +$ P0"\
M +\ RP"] ., O #R +L _0"[ /\ N@#_ +H _P"Z /\ _PX% /\)  #_"04
M_P8+ /\!$ #P !D Y@ E .$ ,@#< #\ U@!) -$ 4P#. %L RP!C ,@ :@#&
M '  Q0!V ,, >P#! ($ P "' +X C@"\ )0 NP"< +D I "W *X M0"Y +,
MR "Q -\ L 'O *\!^P"N O\ K0/_ *T#_P"M _\ _Q   /\.  #_#0  ]@L#
M /('"@#B 1$ VP(= -(#*P#, S< R 1# ,0$30#!!%8 O@5= +P%9 "Z!6L
MN 5Q +<%=@"U!7P LP:# +(&B0"P!I$ KP>9 *T'H0"K!ZL J0BW *@)Q@"F
M"MT I0OP *,,_0"B#?\ H0W_ *$-_P"@#?\ _Q$  /P2  #L$P  XA,  -L/
M P#6"0L S@@4 ,8*(@# ##  O T\ +@-1@"U#4\ L@Y7 + .7P"N#F4 K0YK
M *L.<0"J#G@ J Y^ *</A0"E#XT I ^6 *(0GP"@$*D GQ"U )T1Q0";$=X
MF1+Q )<3_P"6%/\ E13_ )44_P"4%/\ _Q4  .T;  #@'P  TA\  ,D;  #$
M% 4 P1 . +H2&P"T$RD L!0U *P50 "I%4D IA52 *0660"B%F  H19F )\6
M; ">%G( G!9Y )L7@ "9%X@ F!>1 )88FP"4&*8 DQFR )$9P0"0&M@ C1ON
M (L<_0"*'/\ BAS_ (D<_P")'/\ ]!T  .0E  #3*0  QRH  +PF  "V(
MM!D+ *X:%0"H'", I!TO *$>.@">'D0 FQY, )D>5 "7'UL E1]A )0?9P"2
M'VT D1]T (\@? ".((0 C""- (H@EP")(:( AR&N (8BO0"%(M$!@B/K 8$D
M^P& )/\!?R3_ 7\D_P%_)/\!["4  -LM  #),0  O#$  +$N  "K*0  IR0%
M *,C$0">)!T FB4J )8F-0"3)C\ D29' (\F3P"-)E8 BR=< (DG8@"()VD
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M F8V_P)F-O\"V#<  ,0^  "U0@  ID$  )L_  "3/   C3@  (@V!P"$-Q$
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M@0-31HX#4D><!%!'JP101[T$3T?6!4]'[P1/1_T$3T?_ T]'_P-01_\#Q$4
M +5-  "C30  E4P  (E+  !_2@  >$8  '%'  !L1P< :$@0 &1(&@!A220
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M T)3IP1!4[@$05//!$%3[ 1!4OL#0E+_ T)2_P-"4?\#ND\  *I4  "85
MB50  'U3  !S4P  :5$  &)2  !<4P  6%0* %15$@!251L 3U8D $Y6+0!,
M5S4 2U<\ $I71 !(5TL 1UA2 $986@%$6&,!0UAM 4%8>0) 6(8"/EB5 SU8
MI0,\6+<$/%C-!#Q7Z@,\5_H#/5;_ SU6_P,]5O\#ME,  *57  "45P  A58
M 'E6  !O5@  954  %Q6  !76   4ED' $Y:$ !,6A@ 2ELA $A<*@!'7#(
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M 2IIY0$J:/8"*V?_ BMG_P(K9_\"J6$  )5@  "$8   =V   &QA  !B80
M6&,  $YF  !':   0&L  #IN!0 V;PX -' 5 #-P'@ R<28 ,'$N "]Q-0 N
M<CT +7)% "QR30 K<E< *G)A "ER;0 G<GL )G*+ "1RG $C<JX!(W+# 2-Q
MX@$C</0!(V__ 2-N_P$C;O\!H64  (YD  !_9   <F0  &AE  !>9@  5&D
M $EL  !";P  .W(  #1U   N> H *WD1 "IY&  I>B$ )WHH "9Z,  E>S@
M)'M  "-[2  B>U( (7M< "![:  ??'8 '7R& !Q[F  ;>ZH &GN_ !I[W@ :
M>?( &WC^ !MW_P$;=_\!F6D  (AI  !Y:0  ;6D  &-J  !9;   3V\  $5S
M   ]=P  -7H  "Y]   G@0, (H,- ""$$@ ?A!H '80B !R%*@ ;A3$ &H4Y
M !F%0@ 8ADP %X96 !:&8P 5AG$ %(:! !*&DP 1AJ8 $86[ !"%U@ 1@^\
M$8+[ !*"_P 2@?\ D6X  (%M  !T;@  :6X  %UP  !3<P  27<  $!\   W
M@   +X,  ">'   AB@  &HT& !6/#0 3D!, $I : !*0(@ 1D"H $)$R !"1
M.P /D40 #I%/  V17  ,D6H "Y%Z  J1C0 (D)\ !Y"S  >/R0 'C^8 !X[T
M  B-_  (C?\ B7,  'MS  !O<P  8W4  %=X  !-?0  0X$  #F&   PB@
M*(X  "&1   :E0  $Y<   Z:"  +G X "9P3  B<&@ 'G"( !IPJ  2<,P #
MG#T  IU(  "=5   G6(  )QR  "<A   G)<  )NJ  ";OP  FML  )KL  ":
M]0  F?@ @GD  '9Y  !H>@  7'X  %&"  !&AP  /(P  #*1   IE0  (9D
M !F=   2H   #J,   FF!0 #IPP  *<0  "G%0  J!P  *@C  "H*P  J30
M *D_  "I2P  J5D  *EH  "I>@  J8X  *FA  "HM0  J,L  *?D  "G[P
MI_, ?8   &^!  !AA   58D  $F.   ^E   -)D  "J>   AH@  &:8  !*I
M   -K   !Z\   "R    LP<  +,,  "S$   M!4  +0;  "U(@  MBL  +<U
M  "W0   N$X  +A=  "X;@  N((  +B7  "XJ@  M[X  +?2  "WY@  M^H
M=H@  &>+  !:D   3I8  $*<   WH@  +*<  "*K   9KP  $;,   NV   $
MN0   +P   "^    O@   +\&  # "P  P0\  ,(3  ##&0  Q"   ,4I  #'
M-   R$(  ,E1  #)8@  R74  ,F*  #)GP  RK$  ,K!  #)T0  R=D ;I,
M &"8  !3G@  1J0  #JK   OL   )+4  !FX   0O   "K\   '!    Q
M ,@   #*    R@   ,P   #- P  S@@  - -  #1$   TQ8  -8>  #:*
MW30  -Y#  #?5   WV<  .!\  #@D0  X*0  ."R  #@O@  X,, 9I\  %FF
M  !,K0  /[0  #*X   DO   &+\  !##   (QP   ,H   #-    T0   -4
M  #8    V0   -L   #=    WP   .$$  #C"@  Y0X  .<3  #J'   [2<
M / U  #Q1@  \E@  /-K  #S@   ])0  /2C  #TK@  ]+( _P 3 /\ $0#_
M !$ _P 5 /\ 'P#_ "P _P Y /\ 10#_ %  _P!: /X 8P#[ &L ^0!R /<
M> #U 'X ] "$ /( B0#Q (X \ "3 .X F0#M )\ [ "F .H K@#H +@ Y@#%
M .4 VP#C .T X@#[ .( _P#A /\ X0#_ .$ _P#A /\ _P 0 /\ #@#_  T
M_P 2 /\ &P#_ "@ _P T /X 00#[ $P ]P!6 /0 7P#Q &8 [P!M .P = #J
M 'H Z0!_ .< A0#F (H Y0"/ ., E0#A )L X "B -X J@#; +0 V0#  -8
MT #3 .@ T@#W -$ _P#1 /\ T #_ -  _P#0 /\ _P - /\ "0#_  H _P /
M /\ %@#[ "( ]P O /0 .P#P $< [0!1 .D 6@#E &( X@!I .  ;P#> '4
MW !Z -H @ #8 (4 U0"+ -, D0#1 )< SP"> ,T I@#+ *\ R0"Z ,< R0#%
M .( Q #R ,, _@#" /\ P0#_ ,( _P#" /\ _P,& /\  0#_  8 _P , /D
M$0#Q !T ZP I .< -@#C $$ WP!+ -L 5 #5 %P T@!C ,\ :@#- '  RP!U
M ,D >P#( (  Q@"& ,4 C ## ), P0": +\ H@"] *L NP"V +D Q "W -H
MM@#M +0 ^@"T /\ M #_ +0 _P"T /\ _P0  /\   #_    _P & .P #0#E
M !8 W@ B -< +P#1 #L S0!% ,H 3@#& %< Q !> ,$ 9 "_ &H O0!P +P
M=0"Z 'L N0"! +< AP"U (X LP"5 +( G@"P *< K@"R *P OP"J -$ J #H
M *@ ]P"G /\ IP#_ *8 _P"F /\ _P8  /\%  #Q P  Z    .$ !P#5 !
MS0 ; ,< )P## #, OP ^ +P 2 "Y %$ M@!8 +0 7P"R &4 L !J *\ < "M
M '8 K !\ *H @@"I (D IP"1 *4 F@"C *0 H0"N *  NP"> <T G0+F )P$
M] ";!/\ F@7_ )H%_P"9!?\ _PH  /$.  #D$   V0\  ,X+  #( PL P@ 3
M +P"'P"W RP LP0W + %0@"M!DH J@92 *@'60"F!U\ I0=E *,':P"B"'$
MH AW )\(?@"="(4 FPF. )H)EP"8"J$ E@JL )4+N@"3"\P D@SE ) -]@"/
M#O\ C@[_ (X._P"-#O\ ]A$  .87  #6&P  QQD  +X5  "Y$   MPH- +$+
M%P"L#20 J XP *4..P"B#D0 GP], )T/4P";#UH F@]@ )@09@"7$&P E1!R
M ),0>0"2$($ D!"* (\1E "-$9\ BQ&J (H2N "($LL AA/F (44]P"#%?\
M@Q7_ ((5_P""%?\ [1H  -PA  #*)0  NR(  +$?  "K&@  J10& *42$0"@
M%!X G!4J )D5-0"6%CX E!9' )(63@"0%E4 CA=; (P780"+%V< B1=M (@7
M= "&&'P A1B& (,9D "!&9L @!JG 'X:M0!]&\< ?!SB 'H=]0!Y'?\ >!W_
M '@=_P!X'?\ Y2(  - I  "_+   L"H  *<G  "@(P  G1\  )H:#@"5'!@
MD1TD (X>+P",'CD B1Y! (<?20"%'U  @Q]6 ((?7 " 'V( ?Q]I 'T@< !\
M('@ >B"! 'DAC !W(9< =2*D '0BL@!S(\, <B/? ' D\P!O)/\ ;R3_ &XD
M_P!N)/\ W2D  ,@P  "W,@  J#   )XN  "7*@  DR<  ) C"@",(Q, B"0?
M (0E*@"")30 @"8] 'TF1 !\)DL >B92 '@F6 !W)EX =29E '0G; !R)W0
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M@@%>,XX!732< 5LTJ@%:-;L!6C72 5DU[0%9-?P!6#7_ 5@U_P%9-?\!R#@
M +<^  "D/@  ECT  (L\  "#.@  ?3<  '@T  !T- L <#43 &TU'0!J-2<
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M 4I!I0))0K4"24++ DE"Z ))0OD"24'_ DE!_P%)0?\!O4,  *I%  "810
MBD4  ']%  !V0P  ;T   &A   !C00$ 7T$- %Q!% !90AT 5T(F %5"+@!3
M0C8 44(] $]"0P!/0TL 3D-2 $U$6@!,1&, 2D1M 4E%> %(184!1T64 45%
MHP)%1K0"1$;) D1&YP)$1?@"1$7_ D5%_P)%1?\!ND8  *9(  "42   AD@
M 'M'  !R1@  :D(  &-#  !>1   6D4+ %9%$@!41AL 448C $]&*P!.1C,
M3$<Z $M'00!*1TD 24A0 $A(6 !'2&$ 1DEK $1)=@%#28,!0DF2 4%)H@)
M2;,"/TK' C]*Y0(_2?<"0$G_ D!(_P) 2/\!MDD  *)*  "12@  @TH  '=*
M  !N20  944  %Y'  !92   54D( %%*$ !/2A@ 3$HA $I+*0!)2S$ 1TLX
M $9,/P!%3$8 1$Q. $--5@!"35\ 04UH $!-= $^38$!/4V0 3Q-H $[3K$"
M.D[& CI.Y ([3?8".TW_ 3M,_P$\3/\!LTT  )Y,  "-3   ?TP  '1,  !J
M3   8$H  %E+  !43   4$T% $Q.#@!)3Q4 1T\> $5/)@!$4"X 0E U $%0
M/0! 440 /U%+ #Y14P ]4EP /%)F #I2<@ Y4G\!.%*. 3=2G@$V4J\!-5+$
M 352X@$V4O4!-E'_ 390_P$W4/\!KD\  )E/  ")3P  >T\  '!/  !F3P
M7$X  %1/  !/40  2E(! $93# !#5!( 050; $!5(P ^52L /58R #Q6.@ [
M5D$ .E9) #E740 X5UH -E=C #57;P T5WP!,U>, 3%7G $P5ZT!,%?" 3!7
MX $P5O0!,5;_ 3%5_P$Q5?\!J%(  )52  "$4@  =U(  &Q2  !B4@  6%,
M $]4  !)5@  1%<  $!9"  ]6A  .UH7 #E;(  X6R< -UPO #9<-@ U7#X
M-%Q& #-=3@ Q75< ,%UA "]=;  N77H +%V) "M=F@$J7:L!*EV_ 2E=W@$J
M7/(!*EO^ 2M;_P$K6O\!HU4  (]5  !_50  <E4  &=6  !>5@  5%<  $Q9
M  !%6P  /UT  #I?!  V8 T -&$3 #)B'  Q8B, ,&(K "]C,@ N8SH +6-"
M "QC2@ J9%, *61= "AD:0 G9'8 )F2& "5DEP D9*D (V2] ")DV@ C8_$
M(V+] 21A_P$D8?\!G%@  (E8  !Z60  ;ED  &-9  !:6@  4%P  $A>  !!
M8   .F,  #1F   O: H +&D0 "II%P I:A\ *&HF "=J+@ F:S4 )6L] "1K
M1@ C:T\ (FQ9 "!L90 ?;'( 'FR" !ULE  <;*8 &VNZ !IKU  ;:NX '&G\
M !QH_P <:/\ E5P  (-<  !U7   :5T  %]=  !67@  3&$  $-D   \9P
M-6H  "]M   H< 0 (W(- "%R$@ @<QH 'W,A !YS*  ==#  ''0X !MT0  :
M=$H &714 !=U8  6=6X %75^ !1UD  3=*( $G2V !%TSP 2<^P $G+Z !-Q
M_P 3<?\ CF   'U@  !O80  96$  %MB  !19   2&<  #YK   W;@  ,'$
M "EU   B>   ''L' !=]#@ 6?1, %7T; !1^(@ 3?BH $GXQ !%^.@ 1?D0
M$'].  ]_6@ .?V@ #7]X  Q_B@ +?IT "GZP  E]Q@ *?>0 "GST  M[_0 +
M>O\ AF4  '=E  !J90  868  %9H  !,:P  0F\  #ES   Q=P  *GH  "-^
M   <@0  %80  !"'"  -B0X #(D4  R)&P +B2, "HDK  F),P (B3T !HE(
M  6)5  $B6$  HEQ  &)@P  B98  (BI  "'O@  A]H  (;L  "&]0  AOH
M?FH  '%J  !G:P  6VP  %!P  !&=   /'@  #-]   J@0  (X4  !R(   5
MC   $(\   R2!@ &DPP  I,1  "4%@  E!T  )0D  "5+   E34  )5   "5
M3   EED  )9I  "5>@  E8X  )2A  "4M0  D\P  )+F  "2\@  DO< >'
M &UP  !@<@  5'4  $EY   _?@  -8,  "R(   CC0  &Y$  !24   /EP
M"IH   2= P  G@D  )\.  "?$@  H!<  * =  "A)0  HBT  *(W  "C0P
MHU   *-?  "C<0  HX0  **9  "BK0  H<(  *'<  "AZP  H/( <W8  &9W
M  !9>P  38   $*%   XBP  +I   "25   ;F@  %)X   ZA   )I    J<
M  "J    JP0  *L*  "L#0  K1$  *T6  "N'   KR0  + M  "Q.0  L48
M +)5  "R9@  LGD  +*.  "QHP  LK<  +'*  "QX   L>D ;'X  %^"  !2
MAP  1HT  #N3   PF0  )IX  !RC   3IP  #:L   >N    L@   +4   "W
M    N    +D"  "Y"   N@P  +L0  "\%   O1L  +\C  #!+0  PCH  ,))
M  ##6@  PVP  ,2"  #$EP  Q*L  ,2\  #$RP  Q-H 98D  %B.  !+E0
M/YL  #.B   HJ   ':T  !2Q   -M@  !KD   "\    OP   ,,   #$
MQ0   ,8   #'    R00  ,H)  #+#0  S1$  ,\8  #2(0  U2T  -8\  #8
M30  V5\  -IS  #:B@  VYX  -NN  #;N@  W,, 7I8  %&<  !$HP  .*H
M "RQ   @MP  %;L   V^   $P@   ,4   #)    S0   -    #2    T@
M -4   #6    V0   -L   #>!0  X H  .(/  #E%@  Z"   .PM  #M/@
M[5$  .YE  #O>@  [X\  /"?  #PJP  \+, _P 0 /\ #@#_  X _P 2 /\
M'0#_ "D _P U /\ 00#_ $T _@!6 /L 7P#X &8 ]@!M /0 = #R 'D \0!_
M /  A #N (D [0"/ .L E0#J )L Z "B .8 J@#E +, XP#  .$ T@#@ .H
MWP#Y -T _P#= /\ W0#_ -X _P#> /\ _P - /\ "@#_  D _P / /\ & #_
M "0 _@ Q /L /0#X $@ ] !2 /  6@#M &( ZP!I .D ;P#G '4 Y0!Z .,
M?P#B (4 X "* -X D #< )8 V@"= -@ I0#5 *\ T@"Z -  R@#. ., S0#T
M ,L _P#+ /\ RP#_ ,L _P#+ /\ _P ( /\  P#_  4 _P , /P % #W !\
M\@ K .\ -P#K $( YP!, .0 50#@ %T W0!D -H :@#8 '  U0!U -( >@#0
M (  SP"% ,T BP#+ )( R0"9 ,< H0#% *H PP"U ,$ PP"_ -H O@#N +T
M_ "\ /\ O #_ +P _P"\ /\ _P   /\   #_    ^0 ' /$ $ #J !H Y  E
M -\ ,0#; #P UP!' -( 4 #. %< RP!> ,D 90#& &H Q0!P ,, =0#! 'H
MP "  +X A@"\ (T N@"4 +D G "W *4 M0"P +, O0"Q ,\ KP#H *X ^ "N
M /\ K0#_ *T _P"M /\ _P   /\   #]    [@ ! ., # #: !0 T0 ? ,P
M*P#( #8 Q0!  ,( 2@"_ %( O !9 +H 7P"X &4 M@!J +0 ;P"S '4 L0!Z
M +  @0"N (@ K0"/ *L F "I *$ IP"K *4 N "C ,@ H@#B *$ \P"@ /X
MH #_ *  _P"@ /\ _P   /8   #J    X    -, !@#)  \ P@ 8 +T ) "Y
M "\ M@ Z +0 0P"Q $P K@!3 *P 60"J %\ J0!D *< :@"F &\ I !U *,
M>P"A (( H "* )X DP"< )T F@"G )@ M "6 ,, E0#< )0 [P"3 /L DP#_
M ), _P"2 /\ ^04  .H+  #<#0  RPH  ,(%  "\  H M@ 1 +$ ' "N "@
MJ@ S *< /0"D $4 H@!- *  4P"> %D G !? )L 9 ": &H F !P )< =@"5
M 'X DP"& )(!CP"0 9D C@*D (P"L0"+ \  B076 (@&[0"(!_H APC_ (8(
M_P"&"/\ [P\  -X4  #*%0  O!(  +,0  "N#   JP8- *<#%0"B!2  GP<L
M )P(-@"9"#\ EPE' )4)3@"3"50 D0I: ) *7P"."F4 C0IK (L*<@"*"WD
MB N" (<+C "%#)< @PRB ($-L " #<  ?PW8 'T.[P!\#_T >P__ 'L0_P![
M$/\ YA<  -$>  "]'0  KQP  *89  "A%0  GA $ )T-#P"8#AD E XE )$/
M+P"/$#D C!!! (H02 "($$\ AQ!5 (406P"$$6$ @A%G ( 1;@!_$74 ?1%^
M 'P2B !Z$I0 >!*@ '<3K@!U$[X =!35 ',5[@!Q%OT <1;_ '$6_P!P%O\
MW!\  ,8E  "S)0  I2,  )PA  "6'@  DAD  )$4"P"-%!0 B14? (86*0"#
M%C, @1<\ ( 70P!^%TH ?!=0 'H75@!Y&%P =QAB '88:0!T&'$ <QEZ '$9
MA !O&I  ;AJ= &P;JP!K'+L :AS0 &D=[ !H'OL :![_ &<>_P!G'O\ T28
M +TJ  "K*@  G2H  ),H  "-)0  B"(  (8=!@"#&Q  ?QP: 'P=) !Z'2X
M=QXV '8>/@!T'D4 <A]+ '$?40!O'U@ ;A]> &P?90!K(&T :2!V &@A@0!F
M(8T 92*: &,BJ !B([@ 82/- & DZ0!@)/H 7R3_ %\D_P!?)/\ RBP  +8O
M  "D+P  EB\  (PM  "%*@  @"@  'TD  !Z(@T =B,5 ',C( !Q)"D ;R0R
M &TD.@!K)4$ :B5' &@E30!F)50 925: &0F80!B)FD 829R %\G?0!>)XH
M72B7 %LII0!:*;4 6BK* %DJYP!8*O@ 6"K_ %@J_P!8*O\ Q3$  *\S  ">
M,P  D#,  (8R  !_+P  >2T  '4J  !R* H ;R@2 &LI&P!I*24 9RHM &4J
M-0!C*CT 8BI# & J2@!?*U  7BM7 %PK7@!;+&8 62QO %@M>@!7+8< 5BZ5
M %0NHP!3+[, 4R_' %(OY0!2+_< 4B__ %(O_P!2+_\ P38  *HV  "9-@
MBS8  ($U  !Y,P  <S$  &\O  !K+@8 :"T0 &0N& !B+B$ 8"\J %XO,0!<
M+SD 6R]  %DO1@!8+TT 5S!3 %8P6P!4,6, 4S%L %(R=P!1,H0 3S.2 $XS
MH0!-,[$ 333% 4PTXP%,-/8 3#3_ $PT_P!,,_\ NSD  *8Y  "5.0  ASD
M 'PY  !T-P  ;C0  &DS  !E,@( 83(- %XR% !<,QX 6C,F %@S+@!6,S4
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M/0!'/$0 1CU+ $4]4P!$/EP 0SYF $(_<0!!/WX 0#^- #] G  ^0*T!/4#
M 3U W0$]0/(!/4#_ 3X__P$^/_\!KD   )I   ")00  ?$$  '%!  !H0
M83P  %L]  !6/@  4CX% $X_#@!,/Q4 23\= $= )0!&0"P 1$ S $- .@!"
M04( 04%) $!!40 _0EH /D)C #U#;P \0WP .T.+ #I$FP Y1*L!.42^ 3A$
MVP$Y1/$!.4/^ 3E#_P$Y0_\!JD(  )9#  "&0P  >$,  &Y#  !E0P  74
M %9   !10@  34(" $E## !&0Q( 1$0: $)$(@!!1"H /T4Q #Y%.  ]13\
M/$9' #M&3P Z1E< .4=A #A';  W1WH -DB) #5(F0 T2*H -$B] #-(V0 T
M2/  -$?] #1'_P U1O\ ID0  ))%  ""1@  =48  &I&  !A10  640  %%$
M  !,1@  2$<  $1'"@!!2!  /TD8 #U)(  \22< .DHN #E*-@ X2CT -TM$
M #9+3  U2U4 -$Q? #-,:@ R3'< ,4R& #!,EP O3:@ +DV[ "Y-U0 N3.\
M+TS] "]+_P P2_\ H4<  (Y(  !^2   <4@  &9)  !=2   54@  $Q)  !'
M2@  0DL  #],!@ [30X .4X5 #=.'0 V3R0 -4\K #-/,P R4#H ,5!" #!0
M2@ O45( +E%< "U19P L474 *U&$ "I2E0 I4J8 *5*Y "A2T@ I4>X *5#\
M "I0_P J3_\ G$H  (E*  !Z2P  ;4L  &-,  !:3   44P  $A-  !#3P
M/5   #E2 @ U4PP ,U02 #%4&0 P52$ +E4H "U5+P L5C< *U8^ "I61@ I
M5D\ *%=9 "=79  F5W( )5>! "17D@ C5Z0 (E>W ")7SP B5^P (U;Z "-5
M_P D5?\ EDT  (1.  !U3@  :4X  %]/  !63P  35   $52   _4P  .58
M #-8   O6@@ *UL/ "I;%0 H7!T )UPD "9<*P E7#, )%TZ "-=0P B74P
M(5U6 "!>80 ?7FX 'EY^ !U>CP <7J$ &UZT !I=S  ;7>D &USY !Q;_P <
M6_\ D%$  'Y1  !P40  9%(  %M2  !24P  2E0  $%7   [60  -5L  "Y>
M   H8 , )&(, ")C$0 A8Q@ 'V0@ !YD)P =9"X '&0V !ME/@ :94< &651
M !AE70 796H %F5Z !5EBP 499X $V6Q !)ER  29.< $V/W !1B_P 48O\
MB50  'A5  !K50  8%8  %=6  !/5P  1ED  #U<   V7P  ,&(  "ED   C
M9P  '6H' !EL#@ 8;!, %FT: !5M(0 4;2D %&TP !-M.0 2;D( $6Y, !!N
M6  /;F4 #FYU  UNAP -;IH #&VM  MMP@ +;.  #&OS  UK_0 -:O\ @ED
M ')9  !F60  7%H  %1:  !*7   05\  #EC   Q9@  *FD  "1L   =;P
M%W(  !)U"0 /=P\ #G<4  YW&P -=R, #'<J  MW,P *=SP "7='  AW4@ '
M=U\ !7=O  1W@  #=Y0  7:G  !VNP !==4  73K  )T]@ "=/P >UT  &U=
M  !B7@  65X  $Y@  !%8P  /&<  #-K   K;@  )'(  !YU   7>0  $GP
M  U_!@ )@0P !8$1  .!%@ "@1T  8$D  "!+0  @C8  ()   ""3   @ED
M ()H  "">0  @HT  (&@  " M   @,L  '_G  !^\@  ?OD =&(  &AB  !>
M8@  4V0  $EG   _:P  -G   "UT   E>   'GP  !>    1@P  #88   B)
M!  "BPH  (L.  "+$P  C!@  (P?  "-)@  C2\  (XY  ".1   CE$  (Y@
M  ".<0  CH4  (Z9  "-K0  C,,  (S?  "+[@  B_8 ;F@  &1G  !8:0
M36P  $)Q   X=@  +WL  "9_   >A   %H@  !",   ,CP  !I(   "5
ME@<  )<,  "7#P  F!,  )D8  ":'P  FR8  )LP  "<.P  G$@  )Q7  "<
M:   G'L  )R0  ";I0  F[H  )K0  ":YP  FO$ :FT  %YO  !1<@  1G<
M #M\   Q@@  )X<  !Z,   6D0  $)4   J9   $G    *    "B    HP$
M *,&  "D"P  I0X  *82  "G%P  J!X  *HF  "K,0  JSX  *Q-  "L70
MK'   *R%  "LFP  JZ\  *O#  "KV0  JN@ 9'4  %=Y  !+?@  /X0  #2*
M   ID   'Y8  !:;   0GP  ":,   &G    J@   *X   "P    L    +$
M  "R P  M @  +4-  "V$   MQ4  +D=  "[)@  O#,  +U!  "]4@  O60
M +YY  "^D   O:0  +VW  "]Q@  O=< 7'\  %"%  !$BP  .)(  "R9   A
MGP  %Z0  !"I   )K@   +(   "V    N0   +T   "_    OP   ,    #!
M    PP   ,0%  #&"@  QPX  ,D3  #+'   SB8  - U  #110  TE<  -)K
M  #3@@  TY<  -.I  #2N   TL0 58P  $F3   ]F@  ,*(  "6H   :K@
M$;0   FY    O0   ,$   #$    R    ,L   #-    S0   ,\   #0
MT@   -0   #8    V@8  -T,  #@$0  XQH  .8G  #G.   Z$H  .E=  #J
M<@  ZX@  .N;  #LJ   [+( _P - /\ "P#_  L _P 0 /\ &@#_ "8 _P R
M /\ /0#_ $@ ^P!2 /@ 6@#V &( \P!I /$ ;P#P '4 [@!Z .P ?P#K (0
MZ0"* .@ D #F )8 Y "= .( I0#A *\ WP"[ -T RP#; .8 V0#W -@ _P#8
M /\ UP#_ -< _P#4 /\ _P ( /\ ! #_  0 _P - /\ %0#^ "$ ^@ L /<
M. #T $, \ !- .T 50#J %T YP!D .0 :@#B '  X !U -X >@#= '\ VP"%
M -D BP#5 )$ TP"9 -$ H #/ *H S0"U ,L Q #) -T R #Q ,< _P#& /\
MQ@#_ ,8 _P#' /\ _P   /\   #_    _P * /@ $0#Q !P [  G .D ,@#F
M #T X@!' -T 4 #9 %@ U0!? -( 90#0 &H S@!P ,P =0#* 'H R0!_ ,<
MA0#% (P PP"4 ,$ G "_ *4 O0"P +L O0"Z -  N #K +< ^P"V /\ M@#_
M +8 _P"V /\ _P   /\   #]    \P % .D #@#A !8 VP A -4 +0#1 #<
MS@!! ,H 2@#' %( Q !9 ,( 7P#  &4 O@!J +P ;P"[ '0 N0!Z +< @ "V
M (< M ". +( EP"P *  K@"J *T MP"K ,@ J0#C *@ ]0"G /\ IP#_ *<
M_P"F /\ _P   /X   #Q    Y0   -< "@#- !$ QP < ,( )@"_ #$ O  [
M +H 1 "W $P M !3 +( 60"Q %\ KP!D *T :0"L &\ J@!T *D >@"G ($
MI@") *0 D0"B )L H "E )X L@"= ,$ FP#: )H [P"9 /T F #_ )@ _P"8
M /\ _0   /    #A    T0   ,8 ! "]  T MP 5 +, ( "P "L K0 U *L
M/@"H $8 I@!- *0 5 "C %D H0!? *  9 "> &D G0!N )L =0": 'L F "#
M )8 C "5 )8 DP"A )$ K0"/ +L C0#/ (P Z0"+ /@ C #_ (P _P", /\
M\P(  .('  #,!P  OP0  +<   "Q  @ JP 0 *< &0"D "0 H  N )X -P"<
M $  F@!' )@ 3@"6 %0 E0!9 ), 7@"2 &0 D !I (\ ;P"- '8 BP!^ (H
MB "( )( A@"= (4 J0"# +@ @0#* (  Y0"  /4 ?P#_ '\ _P!_ /\ Z T
M - 0  "^$   L0X  *@-  "C"   H (, )P $P"8 !T E0 G )( ,0"0 #D
MC@%! (P!2 "* DX B0)4 (<"60"& E\ A -D (,#:P"! W( @ 1Z 'X$A !]
M!8X >P6: 'D&IP!X!K4 =@?( '4(XP!U"?0 = K_ ',*_P!S"O\ W14  ,07
M  "Q%P  I18  )P3  "6$0  E T$ ),(#0".!Q4 BPD@ (@)*@"%"C, @PL[
M ($+0@" "TD ?@M/ 'T,5 ![#%H >@Q@ '@,9P!W#&X =0UV '0-@ !R#8P
M< V9 &\.I@!M#K4 ; [) &L/Y@!J$/< :1#_ &D0_P!I$/\ T!T  +D>  "H
M'@  FQT  )(;  "+&0  B!4  (<1!P"%#A  @0\: 'X0) ![$"T >1 V '<1
M/0!V$40 =!%* ',14 !Q$58 <!%< &X28@!M$FH :Q)S &D3?0!H$XD 9A.6
M &44HP!C%;, 8A7& &(6XP!A%O8 8!?_ & 7_P!@%_\ QR(  + C  "?)
MDB,  (DB  ""(   ?AT  'P9  !Z%0T =Q45 '06'P!Q%B@ ;Q<P &X7. !L
M%S\ :Q=% &D82P!H&%$ 9AA8 &487@!C&68 8AEO & 9>0!?&H4 71N2 %P;
MH0!;'+  6AS# %D=X !8'O0 6![_ %@>_P!8'O\ OR<  *DH  "9*   BR@
M ((G  ![)0  =B,  ',@  !Q' D ;AP1 &L<&@!I'2, 9QTL &4=,P!C'CH
M8AY! & >1P!?'DT 7AY4 %P?6P!;'V( 62!K %@@=@!6(8( 52&0 %0BG@!3
M(JX 4B/  %$CW0!1)/( 423_ %$D_P!1(_\ N2L  *,L  "3+   ABT  'PL
M  !T*@  ;R@  &LE  !I(@4 9B$. &,B%@!A(A\ 7R,G %TC+P!<(S8 6B,]
M %DD0P!7)$H 5B10 %4D5P!3)5\ 4B5H %$F<P!/)G\ 3B>- $THG !,**P
M2RF^ $LIV@!**?$ 2BG_ $LI_P!+*?\ LRX  )XO  ".,   @3   '<O  !O
M+@  :BL  &4J  !C)P$ 7R<, %PG$P!:)QL 6"@D %8H*P!5*#( 4R@Y %(I
M0 !0*48 3RE- $XI5 !-*EP 3"IE $HK< !)*WP 2"R+ $<MF@!&+:H 12Z\
M $4NU@!%+N\ 12[^ $4N_P!%+?\ KC$  )HR  "),P  ?#,  '(S  !K,0
M92\  & M  !=+   62P) %8L$ !4+!@ 4BP@ % L* !.+2\ 32TV $PM/ !*
M+4, 22U* $@N40!'+ED 1B]C $4P;0!#,'H 0C&) $$QF !!,J@ 0#*[ #\R
MTP _,NX 0#+] $ R_P! ,O\ JC,  )8U  "&-0  >38  &XU  !F-0  83(
M %PP  !7,   5# & %$P#@!.,!4 3#$= $HQ)0!(,2P 1S$R $8Q.0!$,4
M0S)' $(R3P!!,U< 0#-@ #\T:P ^-7@ /36' #PVE@ [-J< .S:Y #HVT0 Z
M-NT .S;\ #LV_P [-O\ IC8  )(W  "".   =3@  &LX  !C-P  738  %<S
M  !3-   3S0# $LT# !)-!( 1C4: $4U(@!#-2D 034O $ U-@ _-CT /C9$
M #TW3  \-U4 .SA> #HX:0 Y.78 .#F% #<ZE0 W.J4 -CJX #4ZSP V.NP
M-CK[ #8Y_P W.?\ HC@  (XY  !^.@  <CL  &@[  !?.@  63D  %,V  !.
M-P  2C@  $8X"@!$.1  03D7 #\Y'P ^.28 /#DM #LZ-  Z.CL .3M" #@[
M2@ W.U, -CQ< #4\9P T/70 ,SV# #,^DP R/J0 ,3ZV #$^S0 Q/NH ,3[Z
M #(]_P R/?\ GCL  (L\  ![/   ;CT  &0]  !</0  53P  $XZ  !).P
M13P  $$]!P ^/0X /#T5 #H^'  Y/B, -SXJ #8_,0 U/S@ -#]  #- 2  R
M0%  ,4!: #!!90 O07( +D*! "U"D0 M0J( +$*U "M"RP L0ND +$+Y "U!
M_P M0?\ F3T  (<^  !W/P  :S\  &%   !9/P  4C\  $D^  !$/P  0$
M #Q!!  Y0@T -T(2 #5#&0 S0R$ ,D,H #%$+P P1#8 +T0] "Y%10 M14X
M+$58 "M&8P J1F\ *49^ "A&CP G1Z$ )D>S "9'R0 F1N< )T;X "A%_P H
M1?\ E4   ()!  !S0@  9T(  %Y"  !50@  3D(  $5"   _1   .T4  #=&
M   T1PH ,4@0 "](%@ N21X +$DE "M)+  J23, *4HZ "A*0@ G2DL )DM5
M "5+8  D2VT (TM\ ")+C0 A3)\ (4RQ "!,QP @2^8 (4OW ")*_P B2O\
MD$,  'Y$  !O1   9$4  %I%  !210  2D8  $%'   \2   -TD  #)+   N
M30< *TX. "E.$P G3QH )D\A "5/*  D3S  (U W ")0/P A4$@ (%!2 !]1
M70 >46H '5%Y !Q1B@ ;49P &E&O !E1Q0 94>0 &E#V !M/_P <3_\ BD8
M 'E'  !K1P  8$@  %9(  !.2   1TD  #Y+   Y3   ,TX  "Y0   H4P(
M)%0+ ")5$  @518 'U8> !Y6)  =5BP '%8S !M7.P :5T0 &5=. !A760 7
M6&8 %5AU !18AP 46)H $U>L !)7P@ 25^$ $U;T !15_P 45?\ A$D  '1*
M  !F2P  7$L  %-+  !+3   1$T  #Q/   U40  +U0  "E6   D60  'EL'
M !I=#0 871( %UT9 !9>(  57B< %%XN !->-P 27D  $5]* !%?50 07V(
M#U]Q  Y?@P -7Y8 #5^I  Q>O@ ,7MH #5WP  U<_  .7/\ ?DT  &Y.  !B
M3@  6$\  $]/  !(4   0%(  #A4   P5P  *EH  "1=   ?7P  &6(! !-E
M"0 19@\ $&84  ]F&P .9R( #6<I  UG,@ ,9SL "V=%  IG4  )9UT !V=L
M  9G?0 %9Y  !&:C  )FMP #9<\ !&7I  1D]0 $9/P =U$  &E2  !=4@
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M  !Z1   >E   'I?  !Z<   >H,  'J8  !ZK   ><(  'C?  !X[P  =_<
M:EL  %];  !66P  3%P  $)@   Y8P  ,&@  "AL   @<   &70  !-W   .
M>P  "7X   2! @  @@@  (,-  "#$   A!0  (49  "&(   AB@  (<Q  "'
M/   ATD  (=7  "':   AWL  (>0  "&I0  A;H  (73  "$Z@  A/0 96
M %Q@  !180  1F0  #QI   R;0  *7(  "%W   9>P  $H    V#   (AP
M HH   "-    C@0  (X)  "/#0  D!   )$4  "2&0  DR   )0I  "5,P
ME4   )9.  "67P  E7(  )6(  "5G0  E+(  )3(  "3X@  D^X 864  %9F
M  !*:@  /VX  #5T   K>0  (7\  !F$   1B0  #(T   :1    E    )@
M  ":    FP   )P"  "=!P  G@L  )\.  "A$@  HA@  *,@  "E*0  IC8
M *9$  "F50  IF@  *9]  "FE   I:D  *2]  "DT0  I.0 6VP  $]P  !#
M=0  .'L  "V!   CAP  &8T  !&2   +EP  !)P   "@    HP   *8   "H
M    J0   *H   "L    K00  *X)  "P#0  L1$  +,7  "U(   MBL  +<Z
M  "W2P  N%P  +AQ  "XB   N)T  +BQ  "WP@  M]  5'8  $A\   \@@
M,8D  ":0   ;EP  $IT   RB   #IP   *L   "N    L@   +8   "X
MN    +H   "[    O0   +X   # !0  P0L  ,,0  #&%@  R2   ,HN  #+
M/@  S%   ,QD  #->@  S9$  ,VD  #-M   S<  38,  $&*   UD0  *9D
M !Z@   3I@  #*P   .Q    M@   +H   "^    P@   ,8   #(    R
M ,H   #+    S0   ,X   #0    T@$  -4(  #9#@  W14  .$A  #B,0
MY$,  .56  #F:P  YH(  .>6  #GI0  YK  _P ) /\ !0#_  8 _P . /\
M%@#_ "$ _P M /\ . #] $, ^0!- /4 50#R %T \ !C .X :0#L &\ Z@!T
M .D >@#G '\ Y@"% .0 BP#C )$ X0"9 -\ H0#< *H V@"V -< Q@#5 .$
MTP#T -( _P#1 /\ T0#_ ,\ _P#* /\ _P ! /\   #_  $ _P , /\ $@#Z
M !T ]@ H /, ,P#P #X [ !( .@ 4 #E %@ X@!> -\ 9 #= &H VP!O -D
M= #6 'H U !_ -( A0#0 (P S@"3 ,P G #) *4 QP"P ,8 O@#$ -0 P@#N
M ,$ _@#  /\ P #_ +\ _P"^ /\ _P   /\   #_    ^@ ' /$ #P#K !@
MY@ C .( +@#@ #@ VP!" -4 2P#1 %( S@!9 ,L 7P#) &4 QP!J ,8 ;P#$
M '0 P@!Z ,$ @ "_ (8 O0". +L E@"Y *  MP"J +8 MP"T ,H L@#F +$
M^ "P /\ KP#_ *\ _P"P /\ _P   /\   #W    Z@ " .$ # #7 !, T  =
M ,P * #) #( Q@ \ ,( 10"_ $T O !3 +H 60"X %\ MP!D +4 :0"T &X
ML@!T +$ >@"O (  K0"( *P D0"J )H J "E *8 L0"D ,$ HP#< *$ \@"A
M /\ H #_ *  _P"A /\ _P   /<   #H    V0   ,L " ## !  O0 8 +D
M(@"V "P M  V +( /P"O $< K !- *L 5 "I %D IP!> *8 8P"E &@ HP!N
M *( = "@ 'H G@"" )P BP"; )4 F0"? )@ K "6 +H E #/ ), ZP"2 /L
MD@#_ )( _P"1 /\ ]P   .<   #3    Q@   +L  @"S  P K0 2 *H ' "G
M "8 I  P *, . "@ $  G@!' )P 3@": %, F0!8 )< 70"6 &, E0!H ),
M;@"2 '0 D !\ (\ A0"- (\ BP": (H IP"( +4 A@#' (4 Y "$ /4 A #_
M (, _P"# /\ [    -,   #! 0  M    *P   "F  < H  . )T %@": "
MEP I )4 ,@"3 #H D0!! (\ 2 "- $T C !3 (L 6 ") %T B !C (< :0"%
M &\ @P!W (( @ "  (H ?@"6 'T HP![ +  >@#" 'D W0!X /$ =P#] '@
M_P!X /\ W@H  ,0+  "R#   I@L  )T(  "9!   E0 * )$ $0". !D BP C
M (D + "' #0 A0 [ (, 0@"" $@ @ !. '\ 4P!] %@ ? !> 'L 9 !Y &H
M> !R '8 >P!T (8 <P"2 '$ GP!P *T ;@"^ &T!U@!M NT ; /Z &P#_P!L
M _\ SA   +<1  "F$@  FA$  )$0  "+#@  B0L# (<%# "$ 1, @0$< 'X"
M)0!\ RX >@,V '@$/ !W!$, =05( '0%3@!S!50 <059 ' &7P!N!F8 ;09N
M &L'> !J!X, : B0 &<)G0!E":P 9 F\ &,*U !C"^P 8@SZ &(,_P!B#/\
MPQ8  *T7  "=&   D!@  (<6  "!%   ?1$  'P.!@!\"@X > H6 '4+'P!R
M"R@ < PP &\,-P!M##X ; Q$ &L-2@!I#4\ : U5 &<-7 !E#6, 8PYK &(.
M=0!@#H$ 7PZ. %T/G !<$*L 6Q"] %H0U@!9$?  61'] %D1_P!9$?\ N1L
M *4=  "4'@  B!X  'X=  !X&P  =!@  '$5  !Q$0D ;Q 1 &P0&0!I$"(
M9Q$J &81,@!D$3D 8Q$_ &(110!@$DL 7Q)1 %T26 !<$E\ 6A-H %D3<@!7
M%'T 5A2+ %05F0!3%:D 4A:Z %$6T@!1%^T 41?] %$7_P!1%_\ LB   )XB
M  ".(@  @2,  '<B  !P(0  ;!X  &D;  !G& 0 9A4. &,6%0!A%AX 7Q8F
M %T6+0!<%S0 6A<[ %D700!8&$< 5AA- %485 !3&%P 4AED %$9;@!/&GH
M3AN( $T;EP!+'*8 2ARX $H=SP!)'>L 21W[ $D=_P!*'?\ K"0  )@E  "(
M)@  >R<  '$F  !J)0  9B,  &(A  !@'@  7AP+ %L;$@!9'!H 5QPB %4<
M*0!4'#  4QTW %$=/0!0'4, 3QU* $T>40!,'E@ 2Q]A $D?:P!(('< 1R"%
M $8AE !$(J0 1"*V $,BS !#(^D 0R/Z $,C_P!#(O\ IB<  ),I  "#*@
M=BH  &TJ  !E*0  8"<  %PE  !9(P  5R$' %4A#P!2(18 4"$> $XA)0!-
M(BP 3"(S $HB.0!)(D  2")& $<C30!%(U4 1"1> $,D:0!")74 0":# #\F
MD@ ^)Z, /B>T #TGR@ ]*.@ /2CY #TG_P ^)_\ HBH  (XK  !_+0  <BT
M &@M  !A+   7"L  %@H  !4)@  428$ $XE#0!,)1, 2B8: $@F(@!')BD
M128O $0F-@!#)SP 02=# $ G2P _*%, /BE< #TI9@ \*G( .RJ! #HKD  Y
M*Z$ ."RR #<LR  W+.8 ."SX #@L_P X+/\ G2P  (HN  ![+P  ;S   &4P
M  !=+P  6"X  %,K  !0*@  3"H  $DJ"P!&*A$ 1"H7 $(J'P!!*B4 /RHL
M #XK,P ]*SD /"M  #LL2  Z+%  .2U9 #@N9  W+G  -B]_ #4OCP T,)\
M,S"Q #(PQP R,.4 ,S#W #,P_P T+_\ F2\  (<Q  !W,@  :S(  &(R  !:
M,@  5#$  $\O  !++0  1RX  $0N" !!+@X /RX4 #TN'  [+B( .2\I #@O
M+P W+S8 -C ^ #4P1@ U,4X -#%7 #,R8@ R,FX ,3-] # SC0 O-)X +C2P
M "TTQ0 M-., +C3V "\S_P O,_\ E3$  (,S  !T-   :#4  %XU  !7-
M430  $LR  !&,0  0C(  #\R!0 \,@T .3,2 #@S&0 V,R  -#,F #,S+0 R
M-#0 ,30[ # U0P P-4P +S95 "XV8  M-VP +#=[ "LWBP J.)P *3BN "@X
MPP H..( *3CU "HW_P J-_\ DC0  '\U  !Q-@  93<  %LW  !4-P  338
M $<V  !"-0  /38  #HV @ W-PL -#<0 #(W%@ Q.!T +S@D "XX*P M.3(
M+#DY "LY00 J.DD *CI3 "D[7@ H.VH )SMY "8\B0 E/)L )#RM ",\P@ C
M/.  )#ST "4[_P E._\ C38  'PX  !M.0  8CD  %@Z  !1.0  2CD  $0Y
M   ].0  .3H  #4[   R.P@ +SP. "T]%  L/1H *CTA "D]*  H/B\ )SXV
M "8^/@ E/T< )#]0 "- 6P B0&@ (4!V "! AP ?09D 'T&K !Y!P  >0=X
M'T#S !] _@ @/_\ B3D  '@Z  !I.P  7CP  %4\  !-/   1SP  $ \   X
M/0  -#X  #!    M004 *D(, "="$0 F0Q@ )$,> "-#)0 B0RP (40S "!$
M.P ?1$0 'D5. !U%60 <164 &T5T !I%A0 91I< &4:I !A&O@ 71=P &$7Q
M !E$_0 :1/\ A#P  ',]  !F/@  6S\  %(_  !*/P  1#\  #U    V00
M,4,  "Q$   G1@$ )$<* "%(#P @210 'DD; !U)(@ <22D &THP !I*.  9
M2D$ &$I+ !=+50 62V( %4MQ !1+@@ 32Y0 $DNG !)+O  12]D $DKP !-*
M_  42?\ ?S\  &]   !A00  5T(  $Y"  !'0@  04(  #I#   R10  +4<
M "A)   C2P  'DT& !M/#0 84!$ %U 7 !90'@ 54"4 %% L !-1-  243T
M$5%' !%14@ 045\ #U)M  Y2?@ -49$ #5&D  Q1N  ,4=$ #5#L  U0^@ .
M3_\ >4,  &I$  !=1   4T4  $M%  !$10  /D8  #9(   O2@  *4P  "1/
M   ?40  &E,  !16"0 15PX $%@3 !!8&0 /6"  #E@H  U8,  -6#D #%A#
M  M83@ *6%H "%AH  =8>0 &6(P !5B?  18LP $5\H !5?F  57\P &5OP
M<T8  &1'  !92   4$@  $A(  !!20  .DH  #)-   K4   )5(  "!5   :
M6   %5H  !!=!@ ,8 P "F 0  E@%0 (8!P !V C  5@*P $8#0  V ]  %@
M20  8%4  &!C  !@<P  8(8  %^:  !?K@  7\0  %[B  !>\   7O@ ;$H
M %]+  !52P  3$P  $5,   ]3@  -5   "Y3   G5@  (%D  !I<   57P
M$&(   UE!  (9PL  V<.  !H$P  :!@  &@?  !I)@  :2X  &DX  !I0P
M:4\  &E=  !I;0  :8   &F4  !HJ0  :+\  &?<  !F[@  9O< 9D\  %I/
M  !13P  2D\  $%1   X5   ,%<  "A;   A7@  &F(  !1E   0:   #&L
M  =N P !< D  ' -  !Q$   <10  '(:  !S(0  <R@  ',Q  !S/   =$@
M '-6  !S9@  <WD  '..  !SHP  <KD  ''2  !QZP  </0 85,  %93  !/
M4P  154  #M8   R7   *F   ")D   ;:   %&P   ]O   +<@  !G8   !Y
M    >@8  'H*  ![#@  ?!$  'T5  !^&P  ?R(  ( J  " -0  @$$  (!/
M  " 7P  @'$  ("&  " G0  ?[(  '[*  !^Y0  ??$ 7%@  %18  !)6@
M/UT  #5A   L90  (VH  !MO   4<P  #G<   E[   #?P   ((   "$
MA@$  (8&  "("@  B0T  (H0  "+%0  C!L  (XB  "/+   CS@  (]&  "/
M5@  CV@  (]^  "/E0  CJL  (W!  "-W   C.L 65T  $Y?  !#8@  .&8
M "YL   D<0  ''<  !1\   .@0  "(4   ")    C0   )    "2    DP
M )0   "6 P  EP@  )@,  ":#P  FQ,  )T:  "?(P  H"X  * \  "@3
MH%X  *!T  "?C   GZ(  )^W  ">RP  GN  4V0  $=H   \;0  ,7,  "=Y
M   =?P  %(4   V+   &D    )0   "8    G    )\   "A    H@   *0
M  "E    IP   *@$  "J"0  K T  *T2  "P&0  LB,  +(Q  "R0@  LE0
M +)I  "R@   LI@  +&L  "ROP  L<X 3&X  $!S   U>@  *H$  !^(   5
MC@  #I4   ::    GP   *0   "H    K    *\   "Q    L0   +,   "U
M    M@   +@   "Z    O 8  +X,  # $0  PQD  ,4F  #%-P  QDD  ,9=
M  #'<@  QXH  ,B?  #(KP  R+P 1GH  #F!   NB0  (I   !>8   /GP
M!Z4   "J    KP   +,   "W    O    +\   #!    P@   ,0   #%
MQP   ,D   #+    S0   ,\#  #2"@  UA   -P:  #=*@  WCP  -]0  #@
M90  X7L  .&1  #BH@  XJT _P " /\   #_  , _P , /\ $P#_ !T _P H
M /X ,P#[ #X ]P!( /, 4 #P %< [0!> .L 9 #H &D YP!O .4 = #C 'D
MX@!_ .  A0#> (P W "3 -D G #6 *8 TP"Q -$ P #/ -H S@#Q ,P _P#+
M /\ RP#_ ,8 _P#! /\ _P   /\   #_    _P ( /L $ #V !D \@ D .\
M+@#M #D Z !" ., 2P#@ %( W0!9 -D 7P#6 &0 TP!I -$ ;@#/ '0 S@!Y
M ,P ?P#* (8 R ". ,8 E@#$ *  P@"K ,  N0"^ ,T O #J +L _ "Z /\
MN@#_ +H _P"V /\ _P   /\   #^    ]  $ .L #0#D !0 WP ? -L *0#8
M #, TP ] ,X 10#* $T QP!3 ,4 60## %\ P0!D +\ :0"] &X NP!S +H
M>0"X (  M@"( +0 D "R )H L0"E *\ L@"M ,0 K #A *L ]@"J /\ J@#_
M *H _P"J /\ _P   /T   #N    X@   -4 "@#- !$ QP 9 ,0 (P#! "T
MOP W +L /P"W $< M0!. +( 4P"P %D KP!> *T 8P"L &@ JP!M *D <P"H
M 'H I@"! *0 B@"C )0 H0"? )\ K "> +L G #2 )L [@": /\ F@#_ )D
M_P"9 /\ _@   .X   #>    RP   ,$ !0"Y  T M  4 +$ '@"N "< JP P
M *H .0"G $$ I !( *( 30"A %, GP!8 )X 70"= &( FP!G )H ;0"8 ',
MEP![ )4 A "4 (X D@"9 )  I@". +0 C0#( (P Y@"+ /D B@#_ (H _P"+
M /\ \    -L   #'    N@   +    "H  H I  0 *  & "= "$ FP J )H
M,P"8 #L E@!! )0 2 "2 $T D0!2 (\ 5P". %P C !A (L 9P"* &X B !U
M (< ?@"% (@ @P"4 (( H "  *\ ?P#  'X W0!] /( ?0#_ 'T _P!] /\
MX    ,8   "U    J@   *(   ";  4 E0 - )( $P"0 !P C0 D (L +0"*
M #0 B  [ (8 0@"% $< @P!- (( 4@"! %< ?P!< 'X 8@!] &@ >P!P 'H
M>0!X (, =@"/ '4 G !T *H <@"Z '$ T0!P .P < #[ '  _P!P /\ S00
M +<&  "G!P  FP8  ),$  ".    B@ ( (8 #P"$ !8 @0 > '\ )P!] "X
M?  V 'H / !Y $( =P!' '8 3 !U %( <P!7 '( 70!Q &, ;P!K &X = !L
M 'X :P"* &D F !H *8 9P"V &8 RP!E .< 90#W &4 _P!E /\ P P  *L-
M  ";#@  CPX  (8-  "!"P  ?@<! 'P!"P!Y !$ =P 8 '4 (0!S "D <0 P
M &\ -@!N #P ; !" &L 1P!J $T :0!2 &@ 6 !F %\ 90!G &, < !B 7H
M8 &' %\"E0!> J, 7 .S %P#QP!;!.0 6P7T %L&_@!;!O\ M1   *$2  "1
M$P  A1,  'P2  !V$0  <PX  '(,! !Q!PT ;@02 &P$&P!I!2, 9P4J &8&
M,0!D!C< 8P8] &('0P!A!TD 7P=. %X(50!="%P 6PEC %H);0!8"G@ 5PJ%
M %8+DP!4"Z( 4PNS %(,QP!2#.0 40WU %$-_P!1#?\ K14  )D7  ")&
M?1D  '08  !M%P  :A0  &<1  !G#@< 9@P. &,,%0!A#!T 7PPE %T-+ !<
M#3, 6PTY %H-/P!8#44 5PU+ %8.40!5#ED 4PYA %(.:P!0#W8 3A"# $T0
MD@!,$*( 2Q"R $H1R !)$>4 21'W $D2_P!)$?\ I1D  )(<  "#'0  =AX
M &T=  !F'   8AH  %\7  !>% $ 7A$* %L0$0!9$1@ 5Q$@ %41)P!4$2X
M4Q$T %$1.P!0$D$ 3Q)' $X23@!,$E4 2Q-> $D39P!(%', 1A2  $45CP!$
M%9\ 0Q:P $(6Q0!"%^, 0A?V $(7_P!"%_\ GQT  (P@  !](0  <2(  &@B
M  !A(0  7!\  %D<  !7&0  518& %05#@!1%10 3Q8< $X6(P!,%BH 2Q8P
M $H6-P!)%ST 1Q=# $872@!%&%( 0QA: $(99 !!&7  /QI] #X;C0 ]&YT
M/!RN #L<PP ['.$ .QWU #L<_P \'/\ FB$  (<C  !X)   ;"4  &,E  !<
M)   5R,  %,@  !1'@  3QP" $T;# !+&A$ 2!L8 $<;( !%&R8 1!LM $,<
M,P!"'#D 0!Q  #\=1P ^'4\ /1Y8 #P>8@ Z'VT .1][ #@@BP W(9L -B&M
M #4AP0 U(=\ -2'S #8A_P V(?\ EB,  (,F  !T)P  :"@  %\H  !8)P
M4R8  $\D  !,(@  22   $<@"0!$'P\ 0A\5 $ @'  _(", /B I #P@+P [
M(38 .B$] #DA1  X(DP -R)5 #8C7P T(VL ,R1Y #(EB0 Q)9H ,"6K # F
MOP O)MP ,";R # F_P Q)?\ D28  '\H  !Q*@  92H  %PJ  !5*@  3RD
M $LH  !()0  1"0  $$D!0 _) T /202 #LD&0 Y)!\ -R0F #8D+  U)3,
M-"4Z #,F00 R)DH ,2=3 # G70 O*&D +BEW "TIAP L*9@ *RJJ "HJO0 J
M*MH *RKQ "LJ_@ L*?\ C2@  'PJ  !M+   8BT  %DM  !1+0  3"P  $<K
M  !#*   /R@  #PH @ Y* L -R@0 #4H%@ S*!P ,B@C # H*0 O*3  +RHW
M "XJ/P M*T< +"M1 "LL6P J+&< *2UU "@MA0 G+9< )BZH "4NO  E+M@
M)B[P "8N_0 G+?\ BBL  '@M  !J+@  7R\  %8O  !.+P  2"X  $,M   _
M+   .RP  #<L   T+ D ,BP. # M$P N+1H +2T@ "LM)P J+BT *BXU "DO
M/0 H+T4 )S!. "8P60 E,64 )#%S ",Q@P B,I4 (3*G "$RNP @,M0 (3+O
M "(Q_  B,?\ ABT  '4O  !G,   7#$  %,Q  !+,0  13$  $ P   [,
M-C   #,P   P,08 +3$- "LQ$0 I,A< *#(> "<R)  E,RL )3,R "0S.@ C
M-$, (C1, "$U5P @-6, 'S5Q !XV@0 =-I, '#:E !LVN0 ;-M( '#;M !TV
M^P =-?\ @C   '$R  !C,P  630  % T  !)-   0C,  #TS   W,P  ,30
M "XU   K-0( *#8+ "4W$  D-Q4 (C<; "$X(@ @."@ 'S@P !XX-P =.4
M'#E) !LZ5  :.F  &3IN !@Z?P 7.Y$ %SND !8[MP 5.]  %CKL !<Z^@ 8
M.?\ ?3(  &TT  !@-0  538  $TV  !&-@  0#8  #HV   T-@  +C@  "HY
M   F.@  (SL( " \#@ >/1( '3T8 !P]'P ;/B4 &CXM !D^-  7/CT %C]'
M !4_40 4/UX %#]L !- ?  20(\ $4"B !% M@ 00,X $3_K !(_^0 2/O\
M>34  &DW  !<.   4CD  $HY  !#.0  /3D  #<Y   Q.@  *SP  "<]   B
M/P  'D$$ !I""P 80Q  %T,5 !5$&P 41"( $T0I !-$,0 21#H $45# !!%
M3@ 015L #D5I  Y%>0 -18P #46?  Q%L@ +1<D #$7E  U$]@ -1/\ =#D
M &4Z  !8.P  3SL  $<\  ! /   .CP  #0\   N/@  *$   "-"   ?1
M&D8  !5("  22@T $4H2 !!*&  /2QX #DLE  U++0 -2S8 #$M   M+2@ *
M2U8 "4MD  A+=  '2X< !4N:  1+K@ $2L0 !4K@  5*\  &2?H ;CP  & ]
M  !4/@  2SX  $0^   ]/@  -S\  #%    J0@  )$4  !]'   :20  %4P
M !%.!0 .40L "U$0  I1%  )41L "%$B  =1*0 %43( !%([  -21@ !4E(
M %)?  !2;P  4H$  %&6  !1J0  4;\  %#<  !0[@  4/< :$   %M!  !0
M00  2$$  $%!   [0@  -$,  "U%   F2   ($L  !M-   64   $5,   Y5
M!  *6 H !E@.  )8$@  61<  %D=  !9)0  62T  %DV  !900  64T  %I:
M  !::0  67P  %F0  !9I0  6+H  %C5  !7[   5_8 8T0  %9%  !-10
M144  #]%   W1P  +TD  "A,   B3P  &U(  !95   16   #5H   E= P $
M7PD  & -  !@$   810  &$9  !B(   8B<  &(Q  !B.P  8D<  &)5  !C
M9   8G8  &*+  !BH   8;8  &'/  !@Z@  8/4 74@  %))  !*2   0T@
M #I*   R30  *E   "-3   <5P  %EH  !%=   -8   "&,   -F 0  9P8
M &@+  !I#@  :A$  &L5  !L&P  ;2(  &TJ  !M-   ;4   &U.  !M70
M;6\  &V$  !LF@  ;+   &O(  !KY@  :O, 6$T  $Y-  !(3   /DX  #51
M   L5   )%@  !U<   68   $&0   QG   ':P   6X   !P    <@,  '('
M  !S"P  =0X  '81  !W%@  >!P  'DC  !Z+0  >CD  'I'  !Z5@  >6@
M 'I\  !YE   >*H  'C!  !WWP  =^\ 5%$  $Q1  !"4@  .%4  "]9   F
M7@  'F(  !9G   0:P  "V\   5S    =P   'H   !\    ?@   '\"  "
M!@  @0H  (,-  "$$0  AA4  (@<  "))0  BC   (H^  ")30  B5\  (ES
M  "(BP  B*(  (>Y  "'T0  AN@ 4E8  $=7   \6@  ,E\  "AD   ?:0
M%F\  !!T   *>0   GT   "!    A0   (@   "*    C    (T   "/
MD 0  )((  "3#   E1   )<5  "9'0  FR<  )LT  ";1   FE8  )IJ  "9
M@@  FIH  )BP  "8QP  E]X 2UP  $!@   U90  *VH  "%Q   7=P  $'T
M  F#   !B    (P   "1    E0   )@   ":    FP   )T   "?    H
M *(   "D!0  I@H  *@.  "J%   K1T  *TJ  "M.0  K4L  *U?  "M=P
MK)   *NG  "KN@  J\L 168  #EK   N<0  (W@  !E_   0A@  "8T   "3
M    F    )T   "A    I0   *@   "K    JP   *X   "O    L0   +,
M  "U    MP$  +D'  "\#0  OQ,  ,(?  #"+@  PD   ,)4  #!:P  P8,
M ,";  #!K0  P;P /G(  #)X   G@   '(@  !*0   *EP   )T   "C
MJ    *T   "R    M@   +D   "[    O    +X   #     P@   ,0   #&
M    R    ,L   #.!0  T0T  -84  #7(P  V#4  -E)  #:7@  VW4  -N,
M  #<GP  W*L _P   /\   #_    _P ) /\ $ #_ !D _@ D /P +P#Y #D
M] !# /  2P#M %( Z@!9 .< 7P#D &0 X@!I .  ;@#> ', W !Y -H ?P#7
M (8 U ". -$ E@#/ *$ S "L ,H NP#( -( Q@#N ,8 _P#% /\ Q0#_ +\
M_P"Z /\ _P   /\   #_    _@ % /< #@#R !4 [@ ? .L *@#I #0 XP ]
M -X 10#9 $T U !3 -$ 60#. %X S !C ,H : #) &T QP!S ,4 >0## (
MP0"( +\ D "] )L NP"F +D M "W ,@ M@#F +4 ^P"T /\ M #_ +, _P"N
M /\ _P   /\   #X    [0   .4 "P#= !$ UP : -( ) #/ "X RP W ,<
M0 ## $< P !. +X 4P"\ %D N@!> +@ 8P"V &@ M0!M +, <P"Q 'D KP"!
M *T B@"K )0 J0"@ *@ K0"F +X I0#; *0 ] "D /\ HP#_ *, _P"B /\
M_P   /8   #F    UP   ,L !@#$  X O@ 5 +L 'P"Y "@ MP Q +0 .@"P
M $$ K0!( *L 3@"I %, IP!8 *8 7 "D &$ HP!G *$ ; "@ ', G@!Z )T
M@P"; (X F0"9 )< I@"6 +8 E0#, )0 ZP"3 /T DP#_ ), _P"3 /\ ]P
M .0   #0    P0   +<  @"O  L JP 1 *< &0"E "( HP K *( ,P"? #L
MG !" )L 2 "9 $T EP!2 )8 5P"5 %L DP!A )( 9@"0 &T CP!T (T ?0",
M (< B@"3 (@ H "' *\ A0#" (4 X@"$ /< A #_ (0 _P"$ /\ Y0   ,T
M  "\    KP   *8   ">  < F@ . )8 % "4 !T D@ E )$ +0"0 #4 C0 \
M (P 0@"* $< B !, (< 40"& %8 A !; (, 8 "! &< @ !N 'X =P!] ($
M>P"- 'H F@!X *D =P"Z '8 TP!V .\ =@#^ '4 _P!U /\ T    +L   "K
M    GP   )<   "0  ( BP + (@ $ "& !< A  @ (( )P"! "\ ?P U 'T
M/ !\ $$ >P!& 'D 2P!X %  =P!5 '8 6P!T &$ <P!I '$ <0!P 'L ;@"'
M &T E0!K *, :@"T &H R0!I .@ :0#Y &D _P!I /\ P    *P   "< @
MD (  (@   "#    ?P & 'L #0!Y !( =P : '8 (@!T "D <P P '$ -@!P
M #P ;P!! &T 1@!L $L :P!0 &H 5@!H %P 9P!D &4 ; !D '8 8P"" &$
MD !@ )\ 7P"O %X PP!> .$ 7@#T %T _P!= /\ M <  * )  "0"P  A L
M 'P*  !W!P  = 0  '$ "0!O  \ ;0 5 &L ' !I ", :  J &< ,0!E #8
M9  \ &, 00!B $8 8 !, %\ 4@!> %@ 70!? %L : !: '( 6 !^ %< C !6
M )L 50"K %0 O@!4 -H 4P#O %0 ^P!4 /\ J0T  )8.  "'$   >A   '(0
M  !L#@  :0P  &<) P!F! L 9  0 &( %P!@ !X 7@ E %T *P!< #$ 6@ W
M %D / !8 $( 5P%' %8!3@!5 E0 4P)< %(#90!1 V\ 3P1[ $X$B@!-!9D
M3 6I $L%O !*!M0 2@?M $H'^0!*!_\ H1   (X2  !^%   <Q0  &H4  !D
M$P  8!$  %X/  !=#04 70D- %H&$@!8!QD 5@<@ %4')P!3!RT 4@@S %$(
M. !0"#X 3PE$ $X)2@!,"5$ 2PI9 $H*8@!("VT 1PMZ $8,B !$#)@ 0PRI
M $(-O !"#=4 0@WN $(-^P!"#?\ FA0  (<6  !X&   ;!D  &,9  !=&
M618  %83  !4$0  5 X( %,-#@!1#10 3PT; $T-(@!,#2@ 2PTN $H-- !)
M#3H 1PY! $8.1P!%#D\ 1 Y7 $(/80!!$&P /Q!Y #X0B  ]$9@ .Q&I #L1
MO  Z$=8 .A'P #H2_0 [$?\ DQ@  ($:  !S'   9QT  %X=  !8'   4QL
M % 8  !.%@  3!,# $P1"P!*$!  2!$7 $81'@!%$20 1!$J $(1, !!$3<
M0!(] #\21  ]$DP /!-4 #L37@ Y%&D .!1V #<5A0 V%98 -!:G #06N@ S
M%M, ,Q;N #06_  T%O\ CAL  'P=  !N'P  8R   %H@  !3(   3AX  $H=
M  !(&@  1A@  $46!P!#%0X 0143 #\5&@ ^%2  /14G #L5+0 Z%C, .18Z
M #@600 W%TD -1=1 #086P S&68 ,AES # :@P O&I0 +ANE "T;N  M&]
M+1OL "X;^P N&_\ BAX  '@@  !J(@  7R,  %8C  !/(@  2B$  $8@  !#
M'@  01L  #\: P ]&@P .QD1 #D9%@ W&AT -AHC #4:*0 T&C  ,QLV #$;
M/@ P'$8 +QQ/ "X=60 M'60 +!YQ "L?@0 J'Y( *1^D "@@MP G(,X )R#K
M "@@^@ I'_\ AB   '0C  !G)   7"4  %,E  !,)0  1R0  $(C   _(0
M/1\  #H>   W'@D -1X. #,>$P Q'AH ,!X@ "\>)@ N'RT +1\S "P@.P K
M($, *B%, "DA5@ H(F( )B)O "4C?P D(Y  (R.B "(DM0 B),P (B3I ",D
M^0 D(_\ @B,  '$E  !C)@  62<  % H  !))P  0R<  #\F   [)   ."(
M #4B   R(@8 ,"(- "XB$0 L(A< *B(= "DB(P H(RH )R,Q "8D.  E)4$
M)"5* ",F5  B)F  (2=M " G?0 ?)X\ 'BBA !XHM  =*,H '2CH !XH^  ?
M)_\ ?B4  &XG  !@*0  5BD  $TJ  !&*@  02D  #PH   W)P  -"8  # F
M   M)@, *R<+ "@G$  G)Q0 )2<: "0G(0 C*"< (B@N "$I-@ @*3X 'RI(
M !XJ4@ =*UX '"MK !LK>P :+(T &2R? !@LL@ 8+,D &"SG !DK]P :*_\
M>B<  &HJ  !=*P  4RP  $HL  !#+   /BL  #DK   T*@  ,"H  "LJ   I
M*P  )BL( ",L#@ B+!( ("P8 !\L'@ >+24 '2TL !PM,P ;+CP &BY% !DO
M4  8+UP %R]I !8P>0 5,(L %#"> !0PL0 3,,< $S#E !0P]@ 5+_\ =BH
M &<L  !:+0  4"X  $@N  !!+@  .RX  #8M   Q+0  +"T  "<O   D+P
M(3 % !\Q#  <,1  &S(5 !HR'  9,B( &#(I !<S,0 6,SD %3-# !0T30 3
M-%D $C1G !$U=P 1-8D $#6< ! UL  .-<8 #S3D ! T]0 0-/\ <BP  &,N
M  !7,   33   $4P   ^,   .#   #,P   O,   *3$  "0R   A,P  '34"
M !HV"0 7-PX %3<3 !0X&0 3.!\ $C@F !(X+@ 1.38 $#E  ! Y2P ..5<
M#CID  TZ=  ,.H8 ##J9  LYK  *.<$ "CG>  LY\0 ,./P ;B\  %\Q  !3
M,@  2C,  $(S   [,P  -C,  #$R   L,P  )S0  "$V   =.   &3D  !4[
M!@ 2/0P $#X0 ! ^%0 ./AP #CXC  T^*@ ,/C, ##X\  L_1P */U( "#]@
M  <_;P &/X$ !3^4  0_J  #/KP !#[7  4^[  %/O< :3,  %LT  !0-0
M1S4  #\U   Y-0  -#4  "XU   I-P  (S@  !X[   :/   %C\  !)!!  .
M0PH #$0.  I$$P )1!D "$0@  =$)P &1"\ !40X  -%0@ "14X  $5;  !%
M:@  17P  $60  !$I   1+D  $31  !$Z@  0_4 9#8  %<W  !,.   0S@
M #PX   W.   ,3@  "LY   E.P  (#T  !I    60@  $D0   Y'!  +20D
M!TH-  1+$0 !2Q8  $L<  !+(P  2RL  $LT  !+/@  3$D  $Q7  !,9@
M3'<  $N,  !+H0  2[4  $K.  !*Z0  2O4 7SH  %([  !(.P  0#L  #H[
M   T.P  +CP  "<^   B00  '$,  !9&   220  #DL   M. P '4 @  E$,
M  !1$   4A,  %,8  !3'P  4R8  %,O  !3.0  4T4  %-2  !380  4W(
M %.'  !2G   4K$  %'*  !1YP  4?0 63X  $X^  !%/@  /CX  #@^   P
M0   *4(  "-$   =1P  %TH  !)-   .4   "U,   95 @  5P<  %@+  !9
M#@  6A$  %H5  !;&@  7"$  %PJ  !<-   7#\  %Q-  !<6P  7&P  %R!
M  !;EP  6ZT  %K%  !:Y   6?, 5$(  $I"  !"0@  /$(  #1#   L1@
M)4D  !Y,   73P  $E,   Y6   *60  !5L   !>    8 0  &$(  !B#
M8PX  &01  !E%@  9AP  &<C  !G+0  9SD  &=&  !G50  9V8  &=Z  !F
MD0  9:@  &7   !DW@  9/  3T8  $=&  ! 10  -T<  "]*   F30  'U$
M !A5   260  #5P   A@   "8P   &8   !H    :@   &L$  !L"   ;0P
M &\.  !P$@  <A<  ',=  !T)@  =#(  '0_  !T3@  <U\  '1R  !SB@
M<J$  '&X  !QU   <.P 3$H  $5*   [2P  ,DX  "E2   @5@  &%L  !)?
M   -9   !V@   !K    ;P   '(   !U    =@   '<   !Y @  >@8  'P*
M  !^#@  @!$  ((6  "$'@  A"D  (0V  "$10  A%8  (-J  "#@0  @ID
M (&Q  " R0  @.4 2DX  #]0   U4P  *U<  ")<   98@  $F<   QL   %
M<0   '4   !Y    ?0   ($   "#    A0   (8   "(    B0   (L$  "-
M"   CPT  )(0  "4%@  EB   )8L  "6.P  EDP  )5@  "5=@  E)   ).G
M  "2O0  DM4 1%4  #E9   O70  )&,  !II   2;P  #'4   1[    @
M (4   ")    C0   )$   "3    E    )8   "8    F@   )P   ">
MH 8  *(+  "E$   J!<  *DC  "I,0  J4,  *E6  "H;0  IH<  *>>  "F
MLP  I<< /EX  #)C   G:@  '7   !-X   ,?P   X4   "+    D0   )8
M  ";    GP   *(   "D    I0   *<   "I    JP   *T   "P    L@
M +4"  "W"0  NQ   +X8  "^)@  OC@  +Y+  "]80  O'H  +N4  "ZJ0
MNKD -VH  "MP   @>   %H    V(   %CP   )8   "<    H@   *<   "L
M    L    +,   "V    MP   +D   "[    O0   +\   #"    Q0   ,@
M  #*    S@@  -(0  #5&P  U2P  -1   #45P  TVX  -2&  #4FP  TZL
M_P   /\   #_    _P % /\ #@#_ !4 _  @ /D *@#V #0 \0 ] .T 1@#I
M $T Y@!3 .0 60#A %X W@!C -P : #9 &X U0!S -, >0#0 (  S@"( ,L
MD0#) )P Q@"G ,0 MP#" ,P P #L +\ _P"^ /\ O0#_ +< _P"R /\ _P
M /\   #_    ^@ ! /, "P#M !( Z  ; .4 )0#D "X WP X -@ 0 #2 $<
MS@!. ,L 5 #( %D Q@!> ,0 8P#" &< P !M +\ <P"] 'H NP"! +D BP"V
M )4 M "A +( KP"P ,( K@#C *X ^@"L /\ K0#_ *D _P"F /\ _P   /\
M  #R    Y@   -T !P#2  X S0 6 ,H ( #( "D Q0 R ,  .@"\ $( N0!(
M +< 3@"U %, LP!8 +$ 70"P &( K@!G *P ; "J ', J0![ *< A "E (X
MHP": *$ J "? +D G@#2 )T \@"< /\ G0#_ )P _P"9 /\ _    .X   #=
M    S    ,$  @"Z  P M@ 2 +( &@"P ", KP L *T - "I #P I@!" *0
M2 "B $T H !2 )X 5P"= %L G !@ )H 9@"9 &P EP!T )4 ?0"3 (< D0"3
M )  H0". +$ C0#& (P Z "+ /T C #_ (P _P", /\ [0   -@   #%
MMP   *P   "F  @ H0 . )\ %0"= !X FP F )H +@"7 #4 E0 \ ), 0@"1
M $< D !, (X 40"- %4 BP!: (H 8 ") &8 AP!M (4 =@"$ (  @@", (
MF@!_ *D ?0"\ 'P W !\ /4 ? #_ 'P _P!\ /\ V0   ,$   "Q    I
M )P   "4  , D  , (T $0"+ !@ B0 @ (D * "' "\ A0 V (, / "" $$
M@ !& '\ 2P!] $\ ? !4 'L 6@!Y &  > !G '8 < !U 'H <P"& '$ DP!P
M *( ;P"T &X S !N .T ;@#^ &X _P!N /\ Q    *\   "@    E    (P
M  "&    @0 ( 'X #@!\ !0 >P ; 'D (@!X "D =P P '4 -@!T #L <@!
M '$ 10!P $H ;P!/ &T 5 !L %L :P!B &D :@!H '0 9@"  &4 C@!C )T
M8@"M &$ P@!A .0 80#X &$ _P!A /\ M    *    "1    A@   'X   !Y
M    =0 # '$ "P!O !  ;0 6 &P '0!K "0 :P J &D , !H #8 9@ [ &4
M0 !D $4 8P!* &$ 3P!@ %8 7P!= %T 90!< &\ 6@!Z %D B !8 )@ 5P"H
M %8 NP!6 -@ 5@#Q %8 _P!6 /\ J $  )0%  "%!P  >@<  '(&  !L!
M:0$  &< !P!D  T 8P 1 &$ & !@ !\ 7P E %X *P!= #  6P V %H .P!9
M $  6 !% %< 2P!6 %$ 50!8 %, 80!2 &H 4 !V $\ A !. ), 30"D $P
MM@!, ,T 3 #K $P ^@!, /\ G0D  (L+  !\#0  < T  &@-  !B#   7PH
M %T& 0!< 0D 6@ . %@ $P!7 !D 5@ @ %4 )@!3 "L 4@ Q %$ -@!0 #L
M3P!! $X 1P!- $T 2P!5 $H 70!) &< 1P!S $8 @ !% )  1 "A $, L@!#
M ,@ 0P#F $, ]0!# /\ E0T  (,/  !T$   :1$  & 1  !:$   5@X  %0-
M  !3"@0 4P8+ %$#$ !/ 14 3@$; $P!(0!+ 2< 2@(L $D",@!( C< 1P,]
M $4#0P!$ TH 0P11 $($6@! !60 /P5P #X&?@ ]!HX / >? #L'L0 Z!\8
M.@?C #H'\P Z"/P CA   'P2  !N%   8A4  %H5  !4%   4!,  $T1  !+
M#@  2PT& $H*# !)"!$ 1P@6 $4('0!$"", 0@@H $$)+@! "3, /PDY #X*
M0  ]"D< / I/ #H+6  Y"V, . QO #8,?@ U#(X - V? #,-L0 R#<< ,@WC
M #(-]  R#?X B!,  '<5  !I%P  7A@  %48  !/&   2A8  $<5  !%$P
M0Q " $,." !"#0X 0 T2 #\-&  ]#1\ / TD #L-*@ Y#3  . XW #<./0 V
M#D4 -0Y- #,/5P R#V( ,1!N "\0?0 N$(X +1&@ "P1L@ K$<@ *Q'F "L1
M]@ L$?\ @Q8  '(9  !D&@  61L  %$;  !+&P  1AH  $(8   _%P  /A0
M #P2!  [$0H .A 0 #@0%0 W$!L -1$A #01)P S$2T ,A$S # 1.@ O$D(
M+A)+ "T35  K$U\ *A1L "D4>P H%(P )Q6> "85L  E%<8 )17D "45]@ F
M%?\ ?AD  &X;  !@'0  5AX  $T>  !''@  0AT  #X<   Z&@  .!@  #<6
M   U%0< -!0- #(4$@ P%!< +Q0= "T4(P L%2H *Q4P "H5-P I%C\ *!9(
M "<74@ F&%T )!AJ ",9>0 B&8H (1F< " 9KP ?&<0 'QGB " 9]  @&?\
M>AL  &H>  !='P  4R   $H@  !$(   /A\  #H>   W'0  -!P  #(9   P
M&00 +A@+ "P8$  J&!0 *1@: "<8(  F&28 )1DM "0:-0 C&CT (AM& "$;
M4  @'%L 'QUH !X==P ='8@ '!Z; !L>K0 :'L, &A[@ !H=\P ;'?\ =QT
M &<@  !:(0  4"(  $@B  !!(@  .R(  #<A   S(   ,!\  "T=   K'0
M*!T( "8=#@ E'1( (QT7 "$='0 A'20 (!XJ !\>,@ >'SH '1]# !P@30 ;
M(5D &B%F !DA=0 8(H< %R*9 !8BK  5(L$ %2+? !4A\@ 6(?X <R   &0B
M  !7(P  320  $4E   ^)   .20  #0C   P(@  +"(  "DA   F(0  )"$&
M "(A#  @(1  'B$5 !TB&P ;(B$ &R(H !HC+P 9(S@ &"1! !<D2P 6)5<
M%25D !0F<P 3)H4 $B:8 !$FJP 1)L  $";= !$E\0 2)?T <"(  &$D  !4
M)@  2B8  $(G   \)@  -B8  #$E   M)0  *20  "8D   B)0  'R4# !TF
M"@ ;)@X &2<2 !@G&  7)Q\ %B<E !4H+0 4*#4 $RD^ !(I20 1*54 $2IB
M ! J<0 /*H, #BJ6  XJJ0 -*KT #2K7  TJ[@ .*?L ;"0  %TF  !1*
M2"@  $ I   Y*   -"@  "\H   K)P  )R<  "(H   >*0  &RH  !@K!P 6
M*PT %"P1 !,L%@ 2+!P $2TC ! M*@ 0+3( #RX\  XN1@ -+E( #2Y?  PO
M;@ ++W\ "B^2  DOI0 )+KD ""[0  DNZ0 *+O< :"<  %HI  !.*@  12L
M #TK   W*P  ,2H  "TJ   I*@  )"H  " K   ;+0  &"X  !4O!  2,0H
M$#(.  \R$P .,AD #3(@  TR)P ,,B\ "S,X  HS0@ ),TX "#-;  8T:@ %
M-'L !#..  ,SH@ ",[8  C/-  ,SYP $,O, 9"H  %8L  !++0  0BT  #HM
M   T+0  +RP  "LL   F+   (BT  !TO   9,0  %3(  !(T P /-@D ##@-
M  HX$0 ).!8 "#@=  <X)  &."P !#@T  ,X/@ ".4H  #E7   Y90  .7<
M #F+   XGP  .+,  #C*   XY@  -_( 7RT  %(N  !(+P  /S   #@O   R
M+P  +2\  "DO   D,   'S$  !HS   5-0  $C<   \Y P ,.P@ "#T-  4^
M$  #/A0  #X:   ^(0  /B@  #XQ   _.P  /T8  #]3   _80  /W,  #^'
M   ^G   /K   #W'   ]Y   /?( 6C   $XR  !$,@  /#(  #4R   P,0
M*S$  "8R   @-   &S8  !8X   2.P  #ST   P_ P (00@ !$,,  !##@
M1!(  $46  !%'0  120  $4M  !&-@  1D(  $9.  !&70  1FX  $6"  !%
MF   1*T  $3$  !#XP  0_( 530  $HU  !!-0  .34  #,T   N-   *#4
M "(W   =.@  %SP  !(_   /00  #$0   A& 0 #2 8  $D*  !*#0  2Q
M $P4  !-&0  3B   $XH  !.,@  33T  $Y*  !.6   36D  $U]  !,E
M3*H  $O!  !+X0  2O( 4#@  $8X   ].   -S@  #$W   J.0  )#L  !X]
M   80   $T,   ]&   +20  !TL   ).    4 0  %$(  !2"P  4PX  %01
M  !5%0  5AL  %<C  !7+   5S@  %=$  !74@  5F,  %9W  !6C@  5:4
M %2]  !3W0  4_  2SP  $(\   [.P  -3L  "T\   F/P  'T(  !E%   3
M2   #DL   M/   %40   %0   !7    6 $  %H%  !;"   7 P  %T.  !?
M$0  8!8  &(=  !B)@  8C$  &(^  !A3   85T  &%P  !@B   8*   %^W
M  !>U   7>X 1T   #\_   Z/P  ,4   "E#   A1@  &DH  !-.   .40
M"E4   18    6P   %X   !A    8P   &0!  !E!   9P@  &@+  !J#@
M;!(  &X7  !O(   ;RH  &\V  !N10  ;E4  &YH  !M?P  ;9@  &RP  !K
MR@  :N@ 1$0  #Y#   U1   *T<  "-+   ;3P  $U0   Y8   (7    F
M  !D    9P   &L   !M    ;P   '    !R    = (  '4&  !W"@  >0X
M 'P2  !^&   ?R(  '\N  !_/0  ?DT  'UA  !]=P  ?)   'NH  !ZP
M>=\ 0T<  #E)   O3   )5   !Q5   46P  #F    =E    :@   &X   !R
M    =@   'D   !\    ?@   '\   "!    @P   (4   "' P  B@@  (P-
M  "/$0  DAD  )(E  "2,P  DD0  )%7  "0;0  CX8  (Z?  "-M0  C,T
M/4X  #)1   H5@  'EP  !5B   .:   !VX   !T    >0   'X   ""
MA@   (D   ",    C@   )    "2    E    )8   "8    FP   )X&  "A
M#   I!$  *8;  "F*0  ICH  *5-  "E8@  I'L  *.4  "AJP  H;\ -E<
M "Q<   A8@  %VD   ]P   '=P   'X   "$    B@   (\   "4    F
M )L   ">    GP   *(   "D    I@   *@   "K    K0   +    "S!
MMPP  +L2  "['P  NS   +M#  "Z6   N7   +>+  "WH0  M[, ,&(  "5I
M   :<   $'@   F     B    (\   "6    FP   *$   "F    J@   *X
M  "P    L0   +0   "V    N    +L   "]    P    ,,   #'    RP,
M ,\,  #3%0  TB4  -(X  #13@  T&4  ,]^  #-E@  S*D _P   /\   #_
M    _P # /\ "P#\ !$ ^0 ; /< )0#S "\ [@ X .D 0 #F $@ X@!. -\
M5 #< %D V0!> -4 8P#3 &@ T !M ,X <P#+ 'H R "" ,8 C ## )< P "C
M +X L@"\ ,@ N@#J +D _P"X /\ L0#_ *H _P"G /\ _P   /\   #[
M]@   .T !P#G  \ X@ 6 -\ ( #> "D V0 S -$ .P#, $( R !( ,4 3@#"
M %, P !8 +X 70"\ &( N@!G +D ;0"W '0 M0![ +( A0"P )  K@"< *P
MJ@"I +T IP#> *8 ^0"E /\ HP#_ )T _P"; /\ _0   /8   #K    WP
M -$  P#*  P Q0 2 ,, &P#  "0 O@ L +D -0"V #P LP!# +  2 "N $X
MK !2 *L 5P"I %P IP!A *8 9P"D &T H@!T *  ?0"> (@ G "5 )H HP"8
M +0 E@#- )4 \0"4 /\ E0#_ )  _P". /\ \P   .8   #1    P@   +@
M  "Q  @ K0 / *H %@"H !X J  G *8 +P"B #8 GP \ )T 0@"; $< F0!,
M )< 40"6 %4 E !: ), 8 "1 &8 D !N (X =@", ($ B@"- (@ FP"& *P
MA0#! (0 Y@"# /T A #_ (, _P"! /\ Y    ,L   "Z    K    *(   "<
M  0 F  , )8 $0"4 !D DP A )( * "/ #  C0 V (L / ") $$ B !& (8
M2P"% $\ A !4 (( 6@"! &  ?P!G 'X ;P!\ 'H >@"& '@ E !W *0 =0"W
M '0 U !S /0 = #_ '0 _P!T /\ RP   +8   "F    F@   )(   "*
MA@ ( (, #@"! !0 @0 ; (  (P!_ "H ?0 P 'L -@!Z #L > !  '< 10!U
M $D = !. ', 5 !Q %H < !A &X :0!M ', :P!_ &D C0!H )T 9P"N &8
MQP!E .H 9@#_ &8 _P!G /\ N    *0   "5    B@   ($   !\    =@ $
M '0 # !R !  <0 6 '  '0!P "0 ;@ J &T , !K #4 :@ Z &D /P!H $0
M9P!) &4 3@!D %0 8P!; &$ 8P!@ &T 7@!Y %T AP!; )8 6@"H %D O0!9
M -\ 60#X %H _P!: /\ J    )4   "'    >P   ',   !N    :@ ! &<
M" !E  X 9  2 &, & !C !\ 8@ E &$ *@!? #  7@ U %T .@!< #X 6P!$
M %D 20!8 $\ 5P!6 %8 7@!4 &@ 4P!S %$ @0!0 )$ 3P"B $X M0!. -
M3@#P $X _P!/ /\ G    (D   ![ P  < ,  &@#  !B 0  7P   %T ! !;
M  L 60 / %@ % !7 !D 5P @ %8 )0!5 "H 4P P %( - !1 #D 4  _ $\
M1 !. $L 30!2 $L 6@!* &, 20!O $< ? !& (P 10"= $4 L !$ ,< 1 #H
M $0 ^@!% /\ D@0  ( '  !Q"@  9@H  %X*  !9"0  50<  %0$  !2  <
M4  , $\ $ !. !4 30 ; $P ( !+ "8 2@ K $D , !( #4 1P Z $8 0 !%
M $8 0P!. $( 5@!! %\ 0 !K #X >  ] (@ / "9 #P JP \ ,$ .P#@ #L
M]  [ /\ B0H  '@,  !J#@  7PX  %<.  !1#@  30P  $L+  !*" ( 200)
M $@ #0!& !$ 10 6 $0 ' !# "$ 0@ F $$ *P _ #$ /@ V #T /  \ $,
M.P!* #H 4@ Y %P . !H #8 =0 U (4 - "6 #0 J  S +P ,P#8 #, [P S
M /L @@T  '$/  !D$   61$  %$1  !+$0  1Q   $0.  !"#0  00L% $$'
M"P _!0X /@,2 #P"&  [ AT .@,B #D#*  X RT -P,R #8$.0 U!#\ - 5'
M #,%4  Q!EH , 9F "\'<P N!X, +0>5 "P'IP K![H *P?2 "L'ZP K!_<
M?1   &P1  !?$P  5!0  $P4  !&%   0A,  #X2   \$   .@X! #H-!@ Z
M"@P . D0 #8(%  U"!D - D? #())  Q"2D , DO "\*-@ N"CT +0I% "P+
M3@ K"UD *0QE "@,<P G#(, )@V5 "4-IP D#;L (PW2 ",-ZP C#?< >!(
M &@4  !;%@  41<  $@7  !"%@  /18  #D5   W$P  -1$  #,0 P S#@@
M,@T- # -$0 O#18 +0T; "P-(0 K#2< *@TM "D.-  H#CL )PY$ "4.3@ D
M#UD (Q!E "$0<P @$(0 'Q"6 !X0J0 =$+T '!#8 !T0[@ =$/D <Q0  &06
M  !7&   31D  $49   _&0  .A@  #47   R%@  ,!4  "X3   M$00 +! *
M "L0#@ I$!( *! 8 "80'@ E$"0 )! J ",1,0 B$3D (1%" " 22P >$E8
M'1-C !P3<0 :$X( &125 !@4IP 7%+L %Q/4 !<3[@ 8$_H <!8  & 9  !4
M&@  2AL  $(<   \&P  -AL  #(:   O&0  +!@  "H6   H% $ )A,' "43
M#  C$Q  (A,5 " 3&@ ?$R$ 'A0G !T4+@ <%38 &Q4_ !H620 9%E0 &!=A
M !87<  5&($ %!B3 !,8I@ 2&+H $A?2 !(7[  3%_H ;!D  %T;  !1'0
M1QT  #\>   Y'0  -!T  "\<   K&P  *!H  "89   D&   (A<$ " 7"@ >
M%PX '!<2 !H7%P 9&!X &1@D !@9+  7&30 %AH] !4:1P 4&U( $QM? !(<
M;@ 1''\ $!R2 ! <I0 /'+D #AS0  X;Z@ /&_@ :1L  %H=  !.'P  11\
M #T@   V'P  ,1\  "T>   I'0  )1T  ",<   @&P  '1L! !L;!P 9' T
M%QP0 !8<%0 5'!L %!TB !,=*0 2'C$ $1XZ !$?10 0'U  #R!=  X@;  -
M('P #2"/  P@H@ +(+4 "R#*  L@Y0 ,'_0 91T  %<?  !,(0  0B$  #HA
M   T(0  +R$  "H@   F'P  (Q\  " >   ='@  &2   !8@!  4( L $B$.
M !$A$P 1(AD $"(?  \B)@ .(R\ #B,W  TC00 ,)$T "R19  HD9P ))'@
M""2+  <DG@ ')+$ !B3'  8CXP '(_$ 8A\  %0A  !)(P  0",  #@C   R
M(P  +",  "@B   D(0  (2$  !XA   :(0  %B,  !,D P 1)0@ #R8-  XG
M$0 -)Q8 #"<=  LG(P *)RL "2@T  @H/@ '*$D !BA5  4I9  $*70  RF'
M  (IFP !**\  "C%  $HX0 !)_  7B(  %$D  !&)0  /24  #4E   O)0
M*B0  "8D   B(P  'R,  !LD   8)0  %"8  !$H P /*0@ #"P,  HL$  (
M+!0 !RP:  8L(0 %+"@  RTP  (M.@ !+44  "U2   N8   +G$  "V$   M
MF0  +:T  "S"   LX   +/  6B0  $TF  !#)P  .B<  #,G   M)P  *"8
M "0F   A)@  '28  !DG   5*0  $2L   \L P -+@< "3 ,  8Q#@ #,1(
M 3(7   R'@  ,B4  #(M   R-@  ,T(  #-.   S70  ,VT  #.!   RE@
M,JL  #'!   QWP  ,?  5B<  $HI   _*@  -RH  # J   K*0  )R@  ",H
M   >*0  &BH  !8L   2+@  #S    TQ @ *- < !34+  (V#@  -Q   #@4
M   X&@  ."(  #@J   Y,P  .3X  #E*   Y60  .6D  #E]   XDP  .*@
M #>_   WW@  -O  42L  $8L   \+   -"P  "XL   J*P  )2L  " L   ;
M+0  %R\  !,Q   0,P  #34   DW @ %.@8  3L*   \#0  /0\  #X2   _
M%P  0!X  $ E  ! +P  0#H  $!&  ! 5   0&4  #]X   _CP  /J8  #Z]
M   ]W   /?  32X  $(O   Y+P  ,B\  "TN   H+@  (B\  !TP   8,@
M$S4  ! W   ,.@  "3P   4^    000  $((  !#"P  1 T  $80  !'%
M2!D  $@A  !(*@  2#4  $A!  !(3P  2&   $=S  !'B@  1J(  $6Y  !%
MV0  1/  2#(  #XR   V,@  ,#$  "LQ   E,@  'S0  !DV   3.0  $#P
M  P_   (0@   T0   !&    2 (  $H%  !+"   3 L  $X.  !/$0  414
M %(<  !2)0  4C   %(\  !12@  45H  %%M  !0A   3YT  $ZU  !-T@
M3>X 0S8  #LV   T-0  +S0  "<U   A.   &CL  !0^   000  #$0   ='
M   "2@   $T   !/    40   %,"  !4!0  50@  %<+  !9#@  6Q$  %T7
M  !='P  72H  %TV  !<1   7%0  %MG  !;?@  6I<  %FO  !8RP  5^H
M/SD  #@Y   S.   *SD  ",\   </P  %4,  !!'   +2@  !4X   !1
M5    %<   !:    7    %T   !?    8 0  &('  !D"P  9@X  &@2  !K
M&0  :R,  &HN  !J/   :DT  &E?  !H=0  9X\  &:H  !EP@  9., /3T
M #<\   N/0  )4   !U$   620  $$T   I1   $50   %H   !=    8
M &,   !F    :    &H   !K    ;0   &\"  !Q!@  = H  '8.  !Y$P
M>QL  'LG  !Z-0  >44  'A9  !X;0  =X8  ':?  !UMP  =-( /$$  #)"
M   H10  ($H  !=.   05   "ED   )>    8P   &<   !K    ;P   '(
M  !U    =P   'D   ![    ?0   '\   ""    A ,  (<)  "*#@  CA,
M (\>  ".*P  CCL  (U.  "+8P  BGP  (J5  "(K0  A\4 -D<  "Q+   B
M3P  &54  !!;   *80   6<   !M    <@   '<   ![    ?P   (,   "&
M    B    (H   "-    CP   )$   "4    EP   )H!  "=!P  H0T  *44
M  "D(0  I#$  *-$  "B60  H'   )^+  "=H@  G;< ,%   "55   ;6P
M$F(   MI   !<    '<   !]    @P   (@   "-    D0   )4   "8
MF@   )P   "?    H0   *,   "F    J0   *P   "P    M <  +@.  "Z
M&   NB<  +DY  "X3@  MV4  +9^  "UE@  LZL *5L  !YB   4:0  #'$
M  )Y    @0   (D   "/    E@   )L   "@    I    *@   "K    K
M *\   "R    M    +8   "Y    O    ,    #$    R    ,T'  #2$
MTAT  -$O  #01   SUL  ,US  #+C0  RJ$ _P   /\   #[    ^@   /P
M" #X  \ ]0 7 /0 ( #Q "H ZP S .8 .P#B $, W@!) -H 3P#6 %0 TP!9
M -  7@#. &, RP!H ,D ;@#& '4 PP!] ,$ A@"^ )( NP"> +D K@"V ,,
MM #H +, _P"O /\ I0#_ )X _P"; /\ _0   /<   #R    \    .<  P#A
M  P W  2 -@ &P#6 "0 T@ M ,P -@#& #T P@!# +\ 20"\ $X N@!3 +@
M6 "V %T M0!B +, 9P"Q &X KP!V *P ?P"J (H J "7 *4 I@"C +D H0#9
M *  ^0"> /\ F #_ )( _P"/ /\ \P   .P   #C    TP   ,@   #!  D
MO0 / +L %@"Y !\ MP G +, +P"O #< K  ] *H 0P"H $@ I@!- *0 4@"C
M %8 H0!; )\ 80"> &< G !O )H > "7 (, E0"0 ), G@"1 +  D #( (X
M\ "- /\ B@#_ (4 _P"" /\ YP   -T   #&    N    *X   "H  0 I0 ,
M *$ $@"A !D H  B )\ *0"; #  F  W )8 /0"3 $( D@!' )  2P"/ %
MC0!5 (P 6@"* &$ B !H (< < "% 'L @P"( ($ E@!_ *< ?0"\ 'P XP!\
M /T ? #_ '@ _P!V /\ U@   ,    "O    HP   )D   "3    CP ) (T
M#@"+ !0 B@ < (H (P"( "H A0 P (, -@"" #L @ !  '\ 10!^ $H ? !/
M 'L 5 !Z %H > !A '8 :0!U ', <P"  '$ C@!O )\ ;@"R &T SP!L /0
M; #_ &L _P!I /\ P    *L   ";    CP   (<   "     ?  $ 'H # !X
M !$ >  7 '@ '@!W "0 =0 J ', , !Q #4 <  Z &X /P!M $0 ; !) &L
M3@!J %0 : !; &< 8P!E &T 9 !X &( AP!@ )< 7P"J %X P@!> .D 7@#_
M %X _P!= /\ K    )D   "*    ?P   '<   !Q    ;0   &H " !I  X
M:  2 &< & !G !\ 9P E &4 *@!C "\ 8@ T &$ .0!@ #X 7P!# %X 2 !=
M $X 6P!5 %H 70!8 &< 5P!R %4 @0!4 )$ 4P"C %( N !1 -P 40#Y %(
M_P!2 /\ G0   (L   !\    <0   &D   !D    8    %X !0!<  L 6P /
M %L % !: !D 6@ ? %D )0!7 "H 5@ O %4 - !4 #@ 4P ] %( 0P!0 $D
M3P!0 $X 6 !- &( 2P!M $H >@!) (L 2 "= $< L0!' ,P 1@#P $< _P!'
M /\ D    'X   !P    9@   %X   !9    5@   %,  0!2  @ 4  - $\
M$ !/ !4 3@ : $X ( !- "4 3  J $H +@!) #, 2  X $< /@!& $0 10!+
M $0 4P!# %T 00!H $  =0 _ (4 /@"7 #T JP ] ,, /0#F #T ^P ^ /\
MAP   '4#  !H!@  70<  %4&  !0!@  3 0  $H!  !)  0 1P * $8 #@!%
M !$ 10 6 $0 &P!# "  0@ E $$ *@!  "\ /P T #X .@ ] $  .P!' #H
M3P Y %D . !D #< <0 V ($ -0"3 #0 I@ T +L - #= #0 ]0 U /\ ?@8
M &T)  !@"P  5@P  $X,  !("P  1 H  $((  ! !0$ /P$' #X "P ]  X
M/  2 #L %P [ !P .@ A #D )0 W "H -@ P #4 -0 T #P ,P!# #( 3  Q
M %4 , !@ "\ ;0 N 'T +0"/ "P H@ L +8 + #0 "P [@ L /P =PH  &<,
M  !:#@  4 X  $D.  !##@  /@T  #L,   Y"P  . D# #<%"  V @T -0$0
M #0 $P S !@ ,@ = #$ (@ P "< +P L "X ,@ M #@ + !  "L 20 J %(
M*0!= "@ :P G 7H )@&, "4 GP E +( )0#* "4 Z  E /< <@T  &(.  !6
M$   3!$  $01   ^$0  .1   #8/   S#@  ,0T! # +!0 P" H +P8- "X%
M$0 L!!0 *P,9 "H#'@ I R, * 0I "<$+P F!34 )04] "0%1@ C!E  (@9<
M "$':0 @!WD 'P>+ !X'G0 >![  '0;& !T&XP =!?, ;0X  %X1  !2$@
M2!,  $ 3   Z$P  -1(  #$1   N$   + \  "H. P J#0< *0L+ "@)#@ G
M"1$ )0@6 "0(&P C"2  (@DF "$)+  @"C, 'PH[ !X+1  ="T\ ' Q; !L,
M:0 :#'D & R+ !@,G@ 7#+  %@S% !8,X0 6"_  :1   %H2  !.%   114
M #T5   W%0  ,10  "T3   J$@  *!$  "80 0 D$ 0 (PX( ",-#  B# \
M( P3 !\,&  >#1T '0TC !P-*@ ;#3( &@XZ !@.1  7#E  %@]< !4/:@ 3
M$'L $A"- !$0H  1$+, $ _) ! /Y  1#_( 91(  %<4  !+%@  0A<  #H7
M   T%P  +Q8  "H5   G%   )!,  "(3   @$@, 'A$& !T0"0 <$ T &P\0
M !D0%0 8$!L %Q A !80*  5$3  %!$Y !,10P 2$DX $1): ! 2:0 0$WD
M#A.,  X3G@ -$[$ #1+%  P2X0 -$O$ 8A0  %06  !)&   /QD  #<9   Q
M&0  +!@  "@7   D%@  (18  !\5   <% ( &A,$ !D2!@ 7$@L %1(. !02
M$@ 3$Q@ $A,? !$3)@ 1%"T $!0V  \500 .%4P #A97  T690 ,%W4 "Q>'
M  H7F@ )%JT "!;!  @6W0 )%>X 7Q8  %$8  !&&@  /1H  #4;   O&@
M*AH  "49   B&   'Q@  !P7   9%@$ %Q8# !46!  3%@D $18- ! 7$0 /
M%Q8 #A<<  X8(P -&"H #!DS  P9/  +&D< "AI3  D:80 '&W$ !AN#  4;
MEP $&JH  QJ_  ,9V@ $&>P 7!@  $X:  !#'   .AP  #,<   L'   )QP
M ",;   @&@  '1D  !H9   7& $ %1@" !(9!  0&P< #AL,  T<$  ,'!,
M"QP9  H<'P )'2< "!TO  <>.0 &'D, !!Y0  ,?7@ "'VX  1^    ?E0
M'JD  !Z]   =V   '>P 6!H  $L<  !!'@  .!X  # >   J'@  )1T  "$<
M   >'   &QL  !@;   6&P$ $QL" !$<!  .'@< #!\+  H@#@ ((!( !B$7
M  4A'0 $(20  B(L  $B-0  (D   "--   C6@  (VL  "-^   CDP  (J<
M "*\   AUP  (>T 51T  $@?   ^(   -2   "X@   H(   (Q\  " >   =
M'0  &AT  !8=   3'@  $1\"  X@!  -(@< "B0+  8E#0 $)1   B84   F
M&@  )B$  "<I   G,@  )ST  "=)   H5P  *&<  "=[   GD   )Z4  ":[
M   FU@  )>T 42   $4A   [(@  ,B(  "PB   F(0  (B$  !X@   ;'P
M&"   !0@   1(@  #R,   TE P *)@8 !B@*  ,I#0  *P\  "P2   L%P
M+!X  "PF   M+P  +3D  "U&   M5   +60  "UW   LC0  +*0  "NZ   K
MU@  *NX 32(  $$D   X)   ,"0  "DD   D(P  (2(  !TB   9(@  %2,
M !(D   /)@  #2@   HJ @ &+ 4  BX)   O"P  , X  #(0   S%0  ,QL
M #,B   S*P  ,S8  #-"   S4   ,V   #-S   RB@  ,J$  #&X   PU@
M,.\ 224  #XF   T)P  +2<  "@F   C)0  'R0  !LE   6)@  $B@  ! J
M   -+   "BX   8P 0 ",@0  #0'   U"@  -PP  #@.   Z$@  .A<  #H?
M   Z)P  .C(  #H^   Z3   .EP  #IO   YA@  .)X  #BV   WU   -N\
M1"D  #HI   Q*0  *RD  "8H   B)P  '2@  !@I   3*P  $"X   TP   )
M,@  !34   $W    .0(  #L%   \"   /@L  #\-  !!$   0Q0  $,;  !#
M(P  0RX  $,Y  !#1P  0E<  $)J  !!@0  0)H  #^R   ^SP  /N\ /RP
M #8L   O+   *BL  "4J   ?*P  &2T  !0O   0,@  #34   @X   $.@
M #P    _    00   $,"  !%!0  1@@  $@+  !*#@  3!$  $T6  !-'@
M32@  $TT  !,0@  3%$  $MD  !+>P  2I0  $FM  !(R@  1^P .S   #,O
M   M+P  *"T  "(O   ;,0  %30  ! W   -.@  "#T   )     0P   $8
M  !(    2@   $P   !. 0  3P0  %$'  !3"P  50X  %@2  !9&0  6"(
M %@N  !7/   5TL  %9>  !6<P  58T  %2G  !2P@  4N8 .#,  #$R   L
M,0  )3(  !TU   6.   $3P   Q    '1    $<   !*    30   %    !3
M    50   %<   !9    6@   %P#  !>!P  80L  &0.  !F$P  9QP  &8G
M  !F-   940  &17  !D:P  8H4  &&?  !@N0  7MP -3<  # U   H-P
M(#H  !@]   10@  #$8   9*    3P   %,   !6    60   %P   !?
M80   &0   !E    9P   &D   !L 0  ;@8  '$+  !T#P  =Q4  '<@  !V
M+0  =CT  '5/  !T8P  <WL  '*5  !PKP  ;\D -3H  "L[   B/P  &D,
M !)(   ,30  !5(   !7    7    &    !D    :    &L   !N    <0
M ',   !U    =P   'H   !\    ?P   (($  "&"@  B@\  (P7  "+)
MBC,  (E%  "'6P  AG(  (6+  "#I0  @KP +T   "5$   <20  $TX   U4
M   $6@   &$   !F    :P   &\   !T    >0   'T   "     @P   (4
M  "'    B@   (P   "/    D@   )8   "9 @  G@D  *(0  "B&@  H2D
M * [  "?4   G6<  )J!  ":F0  F:\ *4D  !].   55   #EL   5B
M:0   '    !W    ?0   ((   "&    BP   (\   "3    E0   )<   ":
M    G0   *    "C    I@   *H   "N    L@   +<*  "[$0  NA\  +DP
M  "W10  M5P  +1T  "QC@  KZ0 (E0  !A;   08@  !VH   !S    >P
M ((   ")    D    )4   ":    GP   *,   "F    J    *L   "N
ML    +,   "V    N@   +T   #"    QP   ,P!  #3"P  U!4  -,F  #1
M.@  T%$  ,UH  #+@0  RI8 _    /8   #R    \0   /, !0#T  P \@ 3
M /  ' #M "4 Z  N .( -@#> #X V0!$ -0 2@#1 $\ S@!4 ,L 60#) %X
MQ@!C ,0 :0#! '  O@!X +P @0"Y (T M@": +, JP"Q ,  KP#F *X _P"E
M /\ F@#_ )0 _P"/ /\ ]    .P   #H    YP   -\   #9  D T@ 0 ,\
M%P#/ "  S  H ,8 , #  #< O  ^ +D 1 "W $D M0!. +, 4P"Q %< KP!=
M *T 8@"K &D J0!Q *< >@"E (4 H@"3 *  H@"= +8 FP#4 )D ^0"6 /\
MC0#_ (@ _P"$ /\ Z    -\   #9    R0   +\   "X  0 M0 - +, $@"Q
M !H L  B *T *@"I #$ I@ X *0 /0"B $, H !( )X 3 "< %$ FP!6 )D
M7 "7 &( E0!I ), <@"1 'T CP"+ (T F@"+ *P B0#% (@ [@"& /\ ?P#_
M 'H _P!X /\ V0   ,T   "[    K@   *4   "?    G  ) )D #P"9 !4
MF0 = )@ ) "4 "L D0 Q (X -P", #P BP!! (D 1@"( $L A@!0 (4 50"#
M %L @@!B (  :P!^ '4 ? "" 'H D@!X *, =P"Y '8 X !U /\ <@#_ &X
M_P!L /\ QP   +4   "E    F0   (\   ")    A0 $ (0 # "" !$ @@ 7
M (( '@"  "4 ?@ K 'P ,0!Z #8 >0 [ '< 0 !V $0 =0!) ', 3P!R %4
M< !< &\ 9 !M &X ; !Z &H B@!H )L 9P"O &8 S !E /4 9 #_ &$ _P!@
M /\ M    *    "0    A0   'T   !W    <P   '  " !O  X ;P 2 &\
M& !O !\ ;0 E &L *@!I #  :  T &< .0!F #X 90!# &, 2 !B $X 80!5
M %\ 7@!> &< 7 !S %L @@!9 ), 6 "F %< OP!7 .H 5P#_ %8 _P!4 /\
MH0   (X   !_    =0   &P   !H    9    &$ ! !@  L 7P / %\ $P!?
M !D 7P ? %T )0!< "H 6P O %D ,P!8 #@ 5P ] %8 0P!5 $D 4P!0 %(
M6 !1 &$ 4 !M $X >P!- (P 3 "? $L M0!* -P 2@#Z $H _P!* /\ D@
M (    !R    9P   %\   !:    5P   %4  0!3  < 4@ , %( $ !2 !0
M4@ : %$ 'P!/ "0 3@ I $T +@!, #, 2P X $H /0!) $, 2 !* $8 4@!%
M %P 1 !G $, =0!" (8 00"8 $  K@!  ,L /P#R $  _P!  /\ A0   '0
M  !G    70   %4   !/    3    $H   !(  0 1P * $< #0!& !$ 1@ 5
M $8 &@!% !\ 1  D $, *0!" "T 00 S #\ .  ^ #X /0!% #P 3@ [ %<
M.@!B #D ;P X (  -P"3 #8 IP V ,  -@#H #8 _@ V /\ ?    &L   !>
M @  5 ,  $T#  !' P  0P$  $$    _  $ /@ ' #T "P ]  X /  1 #P
M%@ \ !H .@ ? #D )  X "D -P N #8 ,P U #H - !! #, 20 R %, ,0!>
M #  :P O 'L +@". "T H@ M +@ +0#= "T ^  N /\ <P$  &0%  !7!P
M30@  $8(  ! "   .P<  #@%   W P  -@ $ #4 "  T  P -  / #0 $@ S
M !8 ,@ ; #$ (  P "0 +P I "X +P M #8 +  ] "L 10 J $\ *0!: "@
M9P G '< )@") "8 G0 E +, )0#/ "4 \  F /\ ;08  %X)  !2"P  2 P
M $ ,   Z"P  -@L  #(*   P"   +@8" "X#!@ M  H +  - "P $  K !,
M*@ 7 "D '  H "  )P E "8 *P E #( )  Y ", 0@ B $L (@!7 "$ 9  @
M ', 'P"% !\ F0 > *X '@#' !X Z0 ? /H : D  %D,  !-#0  0PX  #P.
M   V#@  ,0T  "T-   J#   * L  "<)!  F!@@ )@0+ "4##@ D 1  ) $4
M "(!&  A 1T (0 B "  *  ? "X '@$V !T!/P < 4D &P%4 !H!80 : 7
M&0&" !@ E@ 8 *H & #! !@ X0 8 /0 8PP  %4.  !)#P  0!   #@0   R
M$   +0\  "D.   F#@  (PT  "(, P @"P8 ( D) !\'#  >!@X '@41 !P%
M%0 ;!1H &@4? !H%)0 9!2L & 4S !<&/  6!D8 %@92 !4'7P 4!VX $P>
M !('E  2!J< $@6\ !($V0 2 ^\ 7PX  %$/  !&$   /!$  #41   O$0
M*A$  "80   B$   ( \  !T. @ <#04 &@T' !H+"@ 9"@T & D0 !<)$@ 6
M"1< %0D< !0)(@ 4"BD $PHQ !(*.@ 2"T4 $0M1 ! ,7P /#&X #@R   X,
ME  -"Z< #0NZ  T*T@ -"NH 7 \  $X1  !#$@  .A,  #(3   L$P  )Q(
M ",1   ?$0  '!   !H0 @ 8#P0 %@X' !4."0 4#0L $PP- !(,$  2#!0
M$0P: !$-(  0#2@ #PTP  X..P -#D8 #0Y1  P/7@ +#VT "@]_  D/DP )
M#Z8 " ZY  @.T  '#N@ 6!$  $L2  ! $P  -Q0  # 4   I%   )10  "$3
M   =$@  &A(  !<1 @ 5$04 $Q ' !(0"0 1#PH $ X,  X.#@ .#Q( #1 8
M  T0'@ ,$"4 #! M  L1-@ *$4$ "1%-  @26@ '$FH !A)\  42D  $$J0
M Q&X  ,1SP "$>@ 51(  $D4   ^%0  -18  "T6   G%@  (A4  !X4   ;
M%   &!,  !42 P 3$@4 $A$' ! 1"0 /$0H #1$+  P2#@ +$A$ "A(5  D3
M&P )$R( "!,J  <4,P %%#X !!5*  ,56  "%6<  15Z   5C@  %:,  !2W
M   4SP  $^D 4A0  $86   [%P  ,A<  "L7   E%P  (18  !P6   9%0
M%A0! !03!  2$P8 $1((  \2"  .$PD #!0*  H5#0 (%A  !A83  46&0 $
M%Q\  Q<G  (8,  !&#L  !E'   950  &60  !EW   9C   &*(  !BW   7
MSP  %^H 3Q8  $,8   Y&0  ,!D  "D9   C&0  'Q@  !L7   8%@  %14"
M !,5!0 1% 8 $!0&  X5!P ,%@@ "A<*  <9#  $&@X  AL2  $;%@  &QT
M !PD   <+0  '#@  !U$   =4@  '6(  !UU   =B@  '*   !RV   ;T
M&NL 3!@  $ :   V&P  +1L  "8;   A&@  '1D  !D9   7&   %!<# !(6
M!  0%P0 #A<$  P9!0 *&@< !QP)  ,="P  'PT  " 0   @%   (1H  "$B
M   A*@  (34  ")!   B3P  (E\  ")R   AB   (9\  ""V   ?T0  '^T
M2!H  #T<   S'0  *QT  "0=   @'   '!L  !@:   6&0$ $QD! !$9 0 .
M&@$ #!P"  H= P ''P4  R$(   B"@  ) P  "8.   F$@  )A@  "<?   G
M)P  )S(  "<^   G2P  )UP  "=N   FA0  )IT  "6T   DT0  (^X 1!T
M #D?   P'P  *!\  ",>   >'0  &QP  !@;   4'   $1P   X=   -'P
M"B$   8B 0 #) 0  "8&   H"   *@L  "L-   M$   +14  "T<   M)
M+BX  "XZ   N2   +5@  "UJ   M@0  +)H  "NR   JT   *>\ 0"   #8A
M   M(0  )B$  "$@   ='P  &AX  !8>   2'P  #R$   TB   *)   !B8
M  (H    *P(  "T$   O!@  , D  #(,   T#@  -1(  #48   U(   -2H
M #4V   U0P  -5,  #1F   T?   ,Y8  #*O   QS0  ,.\ /",  #(D   J
M)   )",  " B   <(0  %R$  !,C   0)0  #2<   DI   %*P   2X    P
M    ,@   #0!   V!   . 8  #H)   \#0  /A   #X4   ^'   /B8  #XQ
M   ^/P  /4X  #UA   \=P  .Y$  #JK   YR0  ..T -R<  "\G   H)@
M(R4  !\D   9)0  %"8  ! H   -*P  "2X   4P    ,P   #4    X
M.@   #P    ^ 0  0 ,  $('  !$"@  1@T  $D1  !)%P  2"$  $@L  !'
M.@  1TD  $9;  !%<0  1(L  $.E  !"PP  0>@ -"H  "PJ   G*   (B<
M !PH   6*@  $2T   TP   ),P   S8    Y    /    #X   !!    0P
M $8   !(    2@   $P#  !.!@  4 H  %,.  !4$P  5!P  %,G  !3-
M4T,  %)5  !1:@  4(,  $^>  !-N0  3.  ,"T  "LL   F*P  'RP  !@N
M   2,@  #34   @Y   "/0   $    !#    1@   $D   !,    3@   %$
M  !3    50   %<   !9 0  7 8  %\*  !B#@  8Q4  &,?  !B+   83P
M &!.  !?8@  7GL  %R6  !;L   6<\ +S   "HO   B,   &C,  !,W   .
M.P  "#\   %$    2    $P   !/    4@   %4   !8    6P   %T   !@
M    8@   &0   !F    :0   &T%  !P"P  =!   '08  !S)0  <C0  ')%
M  !P60  ;W$  &V+  !KI@  :L  +C,  "4U   =.   %#P   Y!   '1P
M $P   !1    50   %D   !=    80   &4   !H    :P   &T   !O
M<@   '0   !W    >@   'X   ""!   A@L  (H1  ")'   B"L  (8]  "$
M4@  @V<  (&!  !_FP  ?K( *3H  " ]   60@  #T@   A.    5    %H
M  !@    9    &D   !N    <@   '8   !Z    ?0   (    ""    A0
M (@   "+    C@   )(   "6    FP,  * ,  "B$P  H"$  )\S  "=1P
MFEX  )AW  "7CP  E:< (T,  !E(   13@  "54   !<    8P   &H   !Q
M    =@   'L   "     A@   (H   ".    D0   ),   "6    F0   )P
M  "@    HP   *<   "K    L    +8$  "\#0  NA<  +DH  "W/   M%(
M +)J  "OA0  K9P '$X  !-4   +7    60   !L    =    'P   "#
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M_____________________________________________________P
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M=#$      P0A   !                     0                    $
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MFW^YP)N(O;Z9B<"\E8K#NI&+QKB-C<BWBH_*MHB1S+6%D\VT@Y;/LX&9T+.
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MFZR#R9:K@\J1JH3+CJF$S(NIA<V(J(;.AJB'SH.HB<Z!IXS/@*>-SX"GC<^
MIXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-SX"GC<^ IXW/@*>-S]_$
M"0ORQ1 C\\060_3!'&G>PA6/P< CK*^Y3+:FM&6]HK)UP*"P@,.=KH3%EZV$
MQI.MA,>/K(3(C*N%R8FKALJ'JX;*A:J(RH.JB<N!JHO+@*J,RX"JC,N JHS+
M@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,RX"JC,N JHS+@*J,R]K%" KK
MR0TB[L@20N_&%6C0T@J'L;XOKJ6X5+B?M6B\G;-VOYNQ?\&9L(3"E*^$PY"O
MA<2-KH7%BJZ&QHBMAL:'K8?&A:V(QX.MB<>!K8O'@*R+QX"LB\> K(O'@*R+
MQX"LB\> K(O'@*R+QX"LB\> K(O'@*R+QX"LB\> K(O'@*R+Q]7&" G9S H@
MY<\-0-C5"U^]U@N(I<0TIIRW6KB9M6N[E[1WO9:S?[Z5LH7 D;&%P8ZQA<&+
ML(;"B;"'PHBPA\.&L(C#A:^)PX.OBL2"KXO$@:^+Q(&OB\2!KXO$@:^+Q(&O
MB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q(&OB\2!KXO$@:^+Q-+(" ?3SPH=U=0+
M/<+9"V.KWA"#F\XSF93$4Z:1OF>OD+ITM)"W?;F1M82\CK.&OHRRAK^*LH?
MB+*(P(:QB,&%L8G!A+&*P8*QB\&!L8S"@+&,PH"QC,* L8S"@+&,PH"QC,*
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MJ*N%RJ&IA,V;IX//E::#T(^EA-**I(;3AJ.(U(.CC-2!HY'4@*29TX"FH=&
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M@Y?.LX"=T+)_I-&L?J7/J'ZGS*1_J<FA@*S&H8"LQJ& K,:A@*S&H8"LQJ&
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MQXJ1L<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS
M=[2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^@
M& /_HBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJQXJ1
ML<2(E+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS =[2[
MO'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^@& /_
MHBP0_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJQXJ1L<2(
ME+;#A9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS =[2[O'BT
MN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^@& /_HBP0
M_Z [)?^<23S_EU=3^))D9^R0;'GBCW6)V8Y^E]&-AZ+,C(VJQXJ1L<2(E+;#
MA9:XPH.9N<*!F[G!?YZZP7VAN\%[I+O >J>[P'FJO,!XKKS =[2[O'BTN[QX
MM+N\>+2[O'BTN[QXM+N\>+2[O'BTN[QXM+N\>+2[O'BTN_^A& /_HRL0_Z Z
M)?^<2#S_EU93^)-C:.R2:7KAD7.*V(]\F-".A*3*CHRMQHV0M,2*D[?#AI6X
MPH28N<&!F[K!?YV[P'V@O,![I+S >J>]P'FLO<!XL+V]>+.\N'BSO+AXL[RX
M>+.\N'BSO+AXL[RX>+.\N'BSO+AXL[RX>+.\N'BSO/^A& /_HRH0_Z$Y)?^=
M2#W_F%54]Y1A:>N49GO@DF^,UI%XFLZ0@J;(CXFPQ(^/ML.+D;?"B)2YP827
MNL""FKS ?YV]OWV@OK][I+Z^>JB_OGBMO[UXL;ZX>+*^M'FSO;1YL[VT>;.]
MM'FSO;1YL[VT>;.]M'FSO;1YL[VT>;.]M'FSO?^B& /_I"D0_Z$X)?^=1SW_
MF554]Y9>:>N58WO@E&R-U9)UG,V1?ZC'D8>RQ)&.ML.-D+C!B9.ZP(:6O+^"
MF;V_?YR^OGV@O[U[I<"]>:K O7BPP+AYL,"T>;&_KWJRO:]ZLKVO>K*]KWJR
MO:]ZLKVO>K*]KWJRO:]ZLKVO>K*]KWJRO?^C& /_I"D0_Z(X)?^>1CW_F515
M]Y=<:>N78'S?EFF-U9-RG<R2?*K%DH6TQ)*,ML*/C[G!BY*[P(>5O;Z#F+^]
M@)S O7V@P;Q[I<*\>:O"N7FOPK1YK\&P>K# K'NROJQ[LKZL>[*^K'NROJQ[
MLKZL>[*^K'NROJQ[LKZL>[*^K'NROO^C& +_I2@0_Z(W)?^?1CW_FE-5]YE:
M:>N97GS?EV6.U)5OG<N4>:O%DX*TQ)2*M\*1CKG C)"\OXB3OKV$E\"\@)O"
MNWV@P[M[IL2Z>JW%M'JNQ*]ZK\*L>[# J'RQOZA\L;^H?+&_J'RQOZA\L;^H
M?+&_J'RQOZA\L;^H?+&_J'RQO_^D& +_I2@0_Z,V)?^?13W_FE-5]YI7:>N;
M6WS?F6*.U)=KGLN5=JS%E("TPY6(M\&3C;K CH^]OHF2P+R%E<*[@9K$N7V@
MQKE[J,>T>JO'KWNMQ:M[KL.G?*_!I'VQOZ1]L;^D?;&_I'VQOZ1]L;^D?;&_
MI'VQOZ1]L;^D?;&_I'VQO_^D& +_IB<0_Z,V)?^@1#W_FU)6]YQ5:>N<6'S?
MFUZ.U)EGGLJ7<ZS%EGRTPY>%M\&6B[N_D8V^O8N0P;N&E,2Y@9G'MWZ@R;9\
MJ<JN>ZK(JGRLQJ9]K<2C?J_!H'ZQOZ!^L;^@?K&_H'ZQOZ!^L;^@?K&_H'ZQ
MOZ!^L;^@?K&_H'ZQO_^E& +_IB8/_Z0U)?^@1#W_G%%6]YY3:>N>57O?GEJ-
MU)MDGLJ9;ZS%F'FTPYF"N,&9BKN^E(R_O(Z.P[F(DL>W@IC+M7ZAS:]\I\VI
M?:G*I7ZKQZ)_K<2??Z_"G8"QOYV L;^=@+&_G8"QOYV L;^=@+&_G8"QOYV
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MR)F#K<67A*_"EH2PP):$L,"6A+# EH2PP):$L,"6A+# EH2PP):$L,"6A+#
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ME)O3>IB?T7B<HM!WGZ3.=:*FS72FJ,URJ:G,<:VJS'"RJ\MPMJO+;[RKR'#
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M6T7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J87$7ZF%Q%^IA<1?J87+V] P"MS0$
MGM\  9+_#0B'_QD2?O\I&W7_-2-L_SPJ9/]#+U[_2C18_U W5/]6.E'_6SQ.
M_V ^2_]D0$K_:$%(_VQ"1O]P0T7_=$1$_WA%0O]]1D'_@4= _X9(/_^,23W_
MD4H]_Y%*/?^12CW_D4H]_Y%*/?^12CW_D4H]_Y%*/?^12J[%  ">UP  C_4
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MOJVR=;ZLKG:_K*IVOZNH=\"JJ'? JJAWP*JH=\"JJ'? JJAWP*JH=\"JJ'?
MJO^+$0'_C2 &_XXT%/^-12;_EDTS_YE00?^:54__FEI=]YA@:>^5:'7HDG"
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M=YIPR(*A:L6.I6;#FZAEPZRG8<*]JF.XOZMFL+^L::J_K&REOZMMHL"J;:+
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M8_]./UW_54-8_UU'4_]D2E#_:TU-_W)/2O]Y44?_@E-%_XM40_Z45D']GE=
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M.3'_I#HP_Z\[,/^R.S#_LCLP_[([,/^R.S#_LCLP_[([,/^R.["X  "@QP
MD=@  (3O  !\_PT!;_\1 V;_&09>_R$*5O\I#U#_,A-+_SH61O]!&4+_2!L_
M_TX=//]3'CG_62 W_UXA-?]D(C/_:2,Q_W D+_]W)2W_?B8L_X<G*O^/*"G_
MERDH_Z J*/^C*BC_HRHH_Z,J*/^C*BC_HRHH_Z,J*/^C*J'"  "1T0  @N$
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M53SY\%5 \/150^?W5$/G]U1#Y_=40^?W5$/G]U1#Y_=40^?W5-NA  #%L
MM;H" *C' @"=U@0 D_P. 8O_'0:#_RL/>O\U%W'_/!]H_T(F8/])+%G_3S%3
M_U8U3O]=.$G_93M%_VT]0?]V/S[_@$$[_XM#.?^813C_I$8V_[)'-?_$2#7_
MW4DT__!)-_[X23?^^$DW_OA)-_[X23?^^$DW_OA)-_[X2<FK  "VM   J,$
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M'1W_L!T=_[ ='?^P'1W_L!T=_[ ='?^P'9S   ",S@  ?-X  '#U  !E_P
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M9DV_\6A/N/!I4;+P:5*O[VE2K^]I4J_O:5*O[VE2K^]I4J_O:?]_"@#ME@
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M.3/\_SDS_/\Y,_S_.3/\_SDS_/\Y,_S_.<&H  "OL0  HKT  )3*  "'V
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M)?]-=RO_2H,O_TB.,_]&F#;_1*$X_T.I.O]"L#S_0K@]_T'!/O] RS__0-Q
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M:UR:[VI?EO!I89+Q:&./\69CC_%F8X_Q9F./\69CC_%F8X_Q9O]K$ '_?@D
M\9 $ -:> P#,J@8 Q+0& +Z^!0"XR!  L,@D Z?&-0V=PT(;D\!,*(J]5#.!
MNEP^>;=D1G&U:TYKLW149+%^6E^PB5]:KY9B5JZE95.NN692K]ME4JOR9E6D
M\F98G_)F6IOS95R7\V1<E_-D7)?S9%R7\V1<E_-D7)?S9/]P#0#_A 0 W98
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M4$>[_U)'N_]21[O_4D>[_U)'N_]21[O_4N:*  #/FP  OZ<  +*P  "GNP
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M'R+__Q\B__\?(O__'ZRK  "=M@  C\(  (#.  !SW   9^D  %__!@!8_PX
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M8FR"]F!M@/=>;W_Y7&]]^EMP?/M:<'S[6G!\^UIP?/M:<'S[6O]?$0'_;PH
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M5E>6_E98E?Y56)7^55B5_E58E?Y56)7^5?]O! #F@@  TI$  ,:=  "[I@$
MLJX  *JW 0"BP@4 G,08 )7#*@2-PCD-A<!$&'V^3B%UO%8J;KI>,FBY9CAB
MMVX^7;9X0UBU@D=4M(]+4+2=3DVSKE!+M,502[/J4$JQ_U%,J_]23J7_4E"A
M_U)1GO]149[_45&>_U%1GO]149[_4?]V  #=B0  RI<  +ZB  "SJ@  J;,
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M0KG_1$*Y_T1"N?]$0KG_1-V(  #'F   N*,  *NK  "@M   E;X  (O( P"
MT0< >.$- '3A'0%NX2L#:. W"&'@0@Y<X$T45^!6&5/@7QU/X&DB2^!S)4?@
M?BA$X(LK0N":+3_AJR\^XL$O/N+E+SS?^C$YWO\T.=G_-CK0_S@[S/\Y.\S_
M.3O,_SD[S/\Y.\S_.<V2  "\H   K:@  *&Q  "5NP  B<4  '[/ @!TV@8
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M5'QP_U)[</]0>V__3GMO_TU[;O]+>V[_2WMN_TM[;O]+>V[_2_]7$0#_8PH
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M3V9__TUG?O],9W[_3&=^_TQG?O],9W[_3/]A"@#_;P  X'X  -")  #&DP$
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M1$V<_T1-G/]$39S_1.IU  #2A@  PY,  +>=  "LI   HJL  )BS  ".NP$
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M(+J:  "JHP  G:L  )"T  "#O0  =\8  &O/  !?U@  5-X$ %'P$ !-\!L
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M!!#_IP0/_[T%#O_@!0[_]@4.__\%#O__!0[__P4.__\%#O__!96O  "&N@
M=\4  &C0  !:VP  3.$  $#G   W\P  ,O\  "[_!P J_PX )O\3 "/_&@ ?
M_R  &_\F !C_*P$5_S(!$O\X 1#_0 $._T@!#/]2 0G_70(&_VL"!/]] @+_
MD (!_Z," /^V @#_S0, _^P# /_L P#_[ , _^P# /_L XBY  !XQ   :=
M %O=  !+XP  /ND  #+N   K_P  )O\  "'_   =_P@ &O\- !;_$0 3_Q8
M$/\:  [_'P +_R0 "?\J  ;_,  "_S<! /]  0#_2@$ _U8! /]D 0#_=0$
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M&KMG9"&W9&TGLV)V+*]??S"L7H<TJ5R0-Z=;F3JD6:,\H5FN/I]8O3^=6-%
MFEGL/YA9_C^76O\^E%O_/)%;_SN/6_\ZCUO_.H];_SJ/6_\ZCUO_.O],$@#_
M5@T _V ) /]H"@#Z;PP \W,. .5W$0#:>1L SWDN L=W/@F_=$L1N7!6&K-M
M8"&O:FDHJF=R+:=E>C*C8X,VH&&,.9U@E3R:7I\_EUVJ095=N$*37<M#D%WH
M0X]>_$&.7_] BU__/HI?_SV(7_\\B%__.XA?_SN(7_\[B%__._].$0#_6 H
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M0G)O_T%R;O\_<F[_/G)N_SYR;O\^<F[_/O]6"@#_8@  YF\  -=Y  #,@0$
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M/EV _SY=@/\^78#_/O]B  #D<0  SWX  ,.(  "YD0  L)<  *>;  ">H0
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M,M5\  #"B@  M98  *B=  "=HP  DJH  (>Q  !\MP  <+X# &C"#@!FPQT
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M#BWBX XMWO@/*]W_$BK<_Q0IVO\6*-K_%BC:_Q8HVO\6*-K_%K.8  "EH
MF:<  (NP  !^N   <<   &7(  !9S@  3M,  $3;!  _Z0T />D7 #OJ(P Y
MZBX -NLX 33K0@$Q[$L"+^U5 RWM7P,J[FL$*.YX!2;OB 8E[YH'(_"N!R+Q
MR <B\.T'(>S_!R'K_P@@Z_\*'^K_"Q_J_PL?ZO\+'^K_"ZB?  ";I@  C:\
M '^X  !QP0  9,H  %C0  !,U@  0=T  #CD   U]@P ,_<4 ##W'@ N^"<
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M 0#_R@$ _^H! /_S 0#_\P$ __,! /_S 82W  !TP0  9<P  %;8  !'WP
M.>4  "WJ   C[@  '/T  !C_   5_P  $?\$  __"P -_PX "?\1  ;_%0 #
M_QH  /\@  #_)@  _RX  /\W  #_00  _TT  /]<  #_;0  _X(  /^6  #_
MJ   _[H  /_#  #_PP  _\,  /_# /\D+P'_)2\!_R@O ?\G,0'_)#8"_R ^
M O\:20/_%U8#_Q5D _\3<@3_$G\$_Q**!/\2E 3_$IT%_Q*D!?\2K ;_$K,&
M_Q*Z!O\2PP;_$\X'_Q/?!_\3ZP?_$_8'_Q/_!_\3_P;_$_\&_Q3_!_\4_PC_
M$_\(_Q7_"?\5_PG_%?\)_Q7_"?\E+@'_*2T!_RLL ?\K+@'_*3,"_R0[ O\?
M1@/_'5,#_QMA!/\9;@3_%WL$_Q>'!?\7D07_%YH&_Q>A!O\7J0?_%[ '_Q>W
M"/\7P C_&,H(_QC;"/\8Z C_&/0(_QC]"/\9_PC_&?\(_QG_"?\9_PK_&/\+
M_QK_"_\:_PO_&O\+_QK_"_\F+0'_+"D!_RXH ?\O*@'_+2\"_RDW O\G0P/_
M)% #_R)=!/\@:@7_'G<%_QZ#!O\>C0?_'I8'_QZ>"/\>I0G_'JP)_QZS"?\>
MO K_'L8*_Q[3"O\>Y0K_'O$*_Q_\"OX?_PK]'_\+_!__#/P>_PW\'_\.]R'_
M#O<A_P[W(?\.]R'_#O\J*@'_+R8!_S(D ?\S)0'_,BH!_S$T O\O/P/_+4P#
M_RI9!/\H9@7_)G(&_R5^!_\EB0C_)9()_R6:"O\EH0O_):@+_R2P#/\DN S_
M)<$,_R7.#?\EX0W\)>\-^2;Z#/8F_PWU)O\/]"7_$/0E_Q'R)O\2[2?_$NTG
M_Q+M)_\2[2?_$O\N)@'_-"(!_S<@ ?\Y(0'_."4!_SDO O\X.P+_-4<#_S-4
M!?\Q80;_+VT'_RYY"?\MA K_+8T,_RR6#?\LG0W_+*4._2RL#_PLM _[++T/
M^2S)$/8LW1#S+>P/[RWX#^TM_Q+K+/\4ZBS_%>DL_Q;E+?\6X"[_%N N_Q;@
M+O\6X"[_%O\R(P'_.!T!_SP; ?\^&P'_0"(!_T$K ?] -@+_/D(#_SQ/!?\Y
M7 ;_.&@(_39S"_LU?@SX-8@.]S21#_4TF1#S-* 1\C.H$O SL!+O,[D3[C/%
M$^LTUQ/G-.H2XS3W%.$T_Q?>,_\9W#/_&MLS_QK4-/\:SC7_&LXU_QK.-?\:
MSC7_&O\V'P'_/!D!_T$6 /]$%@#_1QX!_TDG ?](,@+_1CT#_T1)!?I"5@?V
M0&()\C]N#.\]>0_M/(,0ZCR,$N@[E!/G.YP4Y3ND%>,ZK17B.K86X#O"%M\[
MTA;:.^@7U#KV&M Z_QS-.O\>RSK_'LHZ_Q_$._\?P#S_'L \_Q[ //\>P#S_
M'O\Y&P'_0!4 _T41 /]*$P#_3AD _U B ?]0+ ']3C<"]DM#!/!)4 ?K2%T*
MYT9I#>-%=!#@1'X3W4.'%=M"D!?809@8U4"@&=- J1O10+(<ST"]'<U S!W*
M0>0>QD#T(,) _R*_0/\CO4#_([M _R.V0?\CLT+_(K-"_R*S0O\BLT+_(O\]
M%P#_1!$ _TH. /]0$ #_5!4 _U8= /U6)@'S53$!ZU,] ^522P;?4%@*VDYC
M#M1,;A/02G@6S4F!&<M(BAO(1Y(=QD>:'\1&HR'"1JPBP$6W([Y%Q22\1=PD
MN$;P);5&_R>R1O\GL$;_)ZY&_R>J1_\FITC_)J=(_R:G2/\FITC_)O] % #_
M2 X _TX+ /]5#@#_61$ _UP6 /1='P#J7"H!XELW MI:1@725U,+S%5>$,A3
M:!7$47(9P5!['+Y/A!^\38PBN4V5)+=,G2:U2Z<GLTNQ*;%*ORJO2M$JK$OK
M*ZE+_"RF2_\LI4S_*Z-,_RJ?3?\JG4W_*9U-_RF=3?\IG4W_*?]#$0#_2PP
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M-(!?_S-_7_\Q?E__,'Y?_S!^7_\P?E__,/]-"0#_5@  [F$  -UI  #1;P
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M,VEN_S-I;O\S:6[_,_]6  #K8@  V&X  ,EV  "_?0  MX(  +"%  "HAP8
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M(SVMV"(]J_4C/*G_)3NG_R8[IO\F.Z3_)CND_R8[I/\F.Z3_)LQZ  "[B
MKI(  **9  "7G@  C*0  ("J  !UKP  :;0  %ZY!@!;NA0 6;LD %:[,0%3
MNST#4+M'!4V[4 =*NED*1[IB#42Z;!!!NG<3/KF$%3RYDQ<YN:,8.+FW&3>Z
MUADWN/0:-;;_'#2T_QXSL_\?,[+_(#.R_R SLO\@,[+_(,&#  "TD0  II@
M )N>  "/I0  @JL  ':Q  !KM@  7[P  %3! P!,Q0T 2\49 $G&* !(QC4
M1<=  4/'2@- QU,$/L==!CO'9P@YQW,*-\> ##3'D TRQZ$.,<BU#S#(TP\P
MQO00+L3_$RW"_Q4LP?\6*\#_%RO _Q<KP/\7*\#_%[B-  "JEP  GIX  )&E
M  "$K   >+(  &NY  !@OP  5,,  $K( @! S0< .M(. #G2&P XTR@ -],U
M #;40  TU4L!,]55 3'68 (OUFP#+==Z!"O8BP4JV)T%*-FQ!B?:S08GU^\&
M)M3_"272_PLDT?\,(]#_#2/0_PTCT/\-(]#_#:Z6  "@G0  E*0  (:L  !Y
MM   ;+L  &#"  !4Q@  2,L  #[0   UU00 +=T* "SA$P KXA\ *>,J "CD
M-0 GY#\ )N5* "3F50 CYF$!(>=N 2#G?@(>Z) "'>FD AOIO (:ZN("&N;\
M AGE_P,9Y/\$&./_!1CC_P48X_\%&./_!:.=  "6I   B*P  'JU  !LO0
M7\0  %/*  !'S@  /-,  #+:   JWP  )>X) "/P$0 A\1D '_$B !WR*P ;
M\S0 &?0^ !?T2  5]5( $_9? !+V;@$1]X !$/B4 0_YJ@$.^<8!#OGM 0WV
M_P$-]/\!#?/_ 0WS_P$-\_\!#?/_ 9FC  "+K   ?+4  &V^  !?Q@  4LT
M $72   YV   +]X  ";B   ?Z@  '/L& !G_#@ 7_Q, %/\: !+_(0 0_R@
M#O\P  W_.0 +_T, "?].  ;_7  $_VP  O^   '_E@  _ZT  /_*  #_\
M__\  /__  #__P  __\  /__ (VK  !]M0  ;K\  &#(  !2T   0]<  #?=
M   KX@  (N8  !GJ   5^0  $O\  !#_"  ._PX #/\1  G_%@ &_QP  _\B
M  #_*@  _S,  /\]  #_20  _U<  /]I  #_?@  _Y4  /^L  #_QP  _^@
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M#\HT_1+'-/\3Q33_%,,T_Q7#,_\5P#3_%;\T_Q2_-/\4OS3_%/\V%0#_.Q
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M))1,_R.33/\BD4W_(9%-_R&13?\AD4W_(?]""@#_20  _U$  .97  #=6P$
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M)G5>_R9U7O\F=5[_)O]+  #P50  WE\  ,UG  ##;   NV\  +5P  "O;PH
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M*DN&S"I+A>XI3(3_*4R#_RA,@_\G38'_)DZ!_R9.@?\F3H'_)N%C  #)<
MNWL  +"$  "FB@  FXX  )&1  "$DP  >I4" '67$@!RF"( ;Y@P FJ7.P1F
MET4(8I9.#%^55@];E%T36)-E%U63;AI1DG@=3I&$($N0D2-)D*$D1Y"R)D60
MRB9%C^TE18W_)46,_R5&B_\D1HK_)$:*_R1&BO\D1HK_)-AI  ##=@  M8$
M *N*  "?CP  E9,  (J6  !^F@  <)T  &N?#@!HGQP 9J J 6*@-P)?GT$%
M6Y]*"%B>4@M4GEH.49UB$DZ<:Q5+G'482)N!&D6;CQU"FI\?0)JP(#^:R" _
MF>L?/YC_(#Z6_R$^E?\A/Y3_(3^4_R$_E/\A/Y3_(<UP  "\?0  L(@  *2/
M  "9E   CI@  (.=  !WH   ::0  &"G" !=J!0 6ZDD %FI,0%6J3P"4ZE%
M!%"H3@9-J%<)2JA?#$>G: Y$IW,10:9_%#ZFC18\IIT7.J:O&#FFQQ@YI>H8
M.*/_&C>A_QLWH/\<-Y__'#>?_QPWG_\<-Y__',1X  "UA0  J8\  )V5  "2
MF@  AI\  'JC  !NJ   8JP  %6P  !0L@X 3K(; $VS* !+LS4 2;,_ 4:S
M20)$LU($0;-;!C^S9 @\LV\*.K-[##>SB@XULIH/,[.M$#*SQ1 RLND0,;#^
M$C"N_Q0OK?\5+ZS_%B^L_Q8OK/\6+ZS_%KN!  "NC@  H94  )::  ")H
M?:8  '&K  !EKP  6;0  $ZW  !#O 4 0+T1 #^]'@ ^OBL /+XV #N_00 Y
MOTL!-[]4 C7 7P(SP&H$,<!W!2_ A@8MP)<'*\"J""K!P@@JP.<'*;W]"BB\
M_PPGNO\-)[G_#B>Y_PXGN?\.)[G_#K*,  "EE   F9H  (VA  !_IP  <JT
M &:S  !:N   3[L  $2_   ZQ ( ,,D( "[*$0 MRAT +,LI "O+-0 KS$
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M  /M_P #[?\  ^W_ )6A  "&J0  >+(  &FZ  !;P@  3<@  $#,   TT0
M*M8  "';   9X   $N0   _P 0 -^0H "_H/  G[%0 '^QP !/PD  '\+
M_#<  /Q"  #\4   _&$  /UU  #\C   _*0  /S!  #\ZP  _/\  /W_  #]
M_P  _?\  /W_ (FI  !YL@  :KL  %S$  !.S   /]$  #+7   GW0  '>$
M !7E   .Z   "O$   C]   %_P,  ?\)  #_#@  _Q(  /\7  #_'P  _R<
M /\Q  #_/@  _TT  /]?  #_=0  _XT  /^F  #_P@  _^<  /_\  #__P
M__\  /__ 'RS  !LO   7<8  $[/   _U@  ,=T  "7B   :Y@  $>H   SN
M   %\@   /\   #_    _P   /\   #_!0  _PH  /\.  #_$@  _Q@  /\A
M  #_*P  _SD  /]*  #_70  _W,  /^,  #_I   _[D  /_4  #_W@  _]X
M /_> /\8+ #_&2D _QDH /\5*P#_$#  _PLX ?\#1 '_ %$!_P!> ?\ ; '_
M '@!_P"" ?\ C '_ )0!_P"< /\ H@#_ *@ _P"O /\ M@#_ +X _P#( /\
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M ?\*A '_"HT!_PJ4 ?\*FP'_"J(!_PJH ?\*KP'_"K<!_PK  /\*S #_"N
M^PKO /<*^@#U"_\!]0S_ ?0-_P'T#?\"] W_ O0-_P+T#?\"] W_ O\B(@#_
M)!T _R0< /\B'0#_'B( _QPL /\9. #_%D4!_Q-2 ?\27@'_$&H!_Q!U ?\0
M?P'_$(@!_Q"0 ?\0EP'_$)X!_Q"E ?T0K '\$+,!^A"] ?D1R0'U$=T!\1'M
M >X1^0'L$O\"ZQ/_ NH3_P/I$_\#Z1/_ ^D3_P/I$_\#Z1/_ _\F'0#_*!@
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M#[ T_Q"O-/\0KC3_#ZXT_P^N-/\/KC3_#_\U#@#_. < _SP" /] !@#_00L
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M&85,_QF%3/\9A4S_&?]   #\1P  Y5   -56  #*60  PEH  +U8 P"X5PX
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M)5ELQR58;.@E66S](UEK_R%::_\?6VO_'EMJ_QY;:O\>6VK_'NM3  #38
MPFD  +9Q  "L=@  HWD  )EY  "-=P  AWD+ (-[& !_?"@ >WPU G=[0 5S
M>DD(;WE1#&QX60]H=V$3979H%F)U<!E?='H<7'2%'UISD2%7<J C57*P)%-R
MQ213<N<D4W'\(E1Q_R!4</\?57#_'E5O_QU5;_\=56__'>57  #-9   OFT
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M&T&&_QM!A?\;0H7_&D*$_QI"A/\:0H3_&LUG  "\=   KWX  *6&  ":B@
MCHP  (*-  !UD   9Y0  &&5" !>EQ0 7)<C %J8+P!7F#H!5)A$ U*73 5/
MEU0'3)=<"4F690Q'EF\.1)5Z$4&5B!,_E)<5/92H%CN4O18[E-\6.I+X%SJ0
M_Q<ZC_\7.H[_%SJ._Q<ZCO\7.H[_%\5N  "V>P  JH4  )Z+  "4CP  B)(
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M!R&R_P<ALO\'(;+_!ZV*  "@D0  E9<  (B=  ![HP  ;J@  &&M  !5L0
M2K0  #^W   TNP  *[X# "3"#  BPA0 (L,? "'#*@ @Q#0 '\0_ ![%2@ =
MQE8 ',9C !O'<P :QX4 &<>9 !C(K@ 7R,L %\;Q 1?$_P$6P_\"%L'_ Q;!
M_P,6P?\#%L'_ Z.1  "8F   BYX  'VE  !PJP  8K$  %:V  !*N0  /KT
M #3    JQ   (L@  !G,!  3T H $=(1 !#2&@ 0TR4 #],P  [4/  .U$@
M#=56  W590 ,UG@ #-:-  O8I  *V+X "=GF  K6_@ +U/\ "]+_  O2_P$+
MTO\!"]+_ 9J8  ".GP  @*8  '*M  !DM   5[H  $F_   ]P@  ,L8  "C)
M   ?S0  %]$  !'6   ,VP4 "-X+  ;?$0 %WQH !. D  +A+@ !XCH  .-'
M  #D5@  Y&<  .5[  #FD@  YJH  .?(  #G\   Z/\  .C_  #H_P  Z/\
M .C_ )&?  ""IP  =*\  &6W  !7O@  2<,  #S'   PRP  )<\  !S4   4
MV0  #MT   GA   "Y0   .D&  #I#0  Z1$  .H8  #K(0  [2L  .\W  #Q
M10  \E8  /-H  #S?@  ])<  /6P  #VT   ]_,  /?_  #W_P  ]_\  /?_
M (6G  !VL   9K@  %C!  !*R   .\P  "[1   CU@  &=P  !'@   ,XP
M!.<   #J    ]0   /0   #U!0  ]0L  /8/  #V%   ^!T  /HG  #\-
M_T,  /]5  #_:0  _X$  /^:  #_L@  _\\  /_M  #_^0  __D  /_Y 'BP
M  !HN@  6<,  $O+   [T0  +=@  "'=   6X@  #N8   CJ    [0   /
M  #X    _P   /\   #_    _P   /\&  #_#   _Q   /\8  #_(@  _S
M /]   #_4P  _VD  /^!  #_F0  _Z\  /_#  #_U0  _]4  /_5 /\3* #_
M$R4 _Q$E /\-)P#_!BT _P U /\ 00#_ $\ _P!< /\ :0#_ '0 _P!^ /\
MB #_ )  _P"7 /\ G0#_ *0 _P"J /\ L #_ +< _P#  /\ S #_ -\ _P#L
M /\ ^ #_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\6)0#_%B(
M_Q0A /\0(P#_"B@ _P P /\ /0#_ $L _P!8 /\ 9 #_ '  _P!Z /\ A #_
M (P _P"3 /\ F@#_ *  _P"F /\ K0#_ +0 _P"\ /X R #] -D ^P#I /H
M]@#Y /\ ^ #_ /@ _P#X /\ ^ #_ /D _P#Y /\ ^0#_ /\:(@#_&AX _Q@=
M /\3'@#_#B( _PHL /\'.0#_ T8 _P!3 /\ 8 #_ &L _P!V /\ ?P#_ (@
M_P"/ /\ E@#_ )T _P"C /X J0#\ +  ^@"Y /< Q #U -( \P#F /( ] #Q
M /\ \ #_ .\ _P#O /\ [P#_ /  _P#P /\ \ #_ /\>'0#_'AD _QP7 /\7
M& #_$QX _Q$H /\.- #_#$$ _PI. /\(6P#_!V8 _P9Q /\&>@#_!H, _@:+
M /P&D@#Z!ID ^ :? /8&I@#T!JT \@:U / %P #M!<X ZP7D .D&\P#F"/\
MY0K_ .0+_P#D"_\!Y O_ >0+_P'D"_\!Y O_ ?\A& #_(1, _R 1 /\;$@#_
M'!H _QHD /\6+P#_$SP _Q%) /\050#\#F$ ^0YK /8.=0#T#GX \@Z& / .
MC@#N#I4 [0Z; .L.H@#J#JH Z ZS .8/O0#E#\P X0_C -T0\P#9$?\!UA+_
M =03_P'3$_\"TA/_ M(3_P+2$_\"TA/_ O\E$P#_)1  _R0- /\C#@#_(Q0
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M"YPU_PN<-?\+G#7_"_\S @#_-0  ]CH  .4^  #<0   U#T$ -(W"0#+.!4
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M4*89=%"U&G-0R1IQ4.@:<%'\&'!1_Q=P4?\5<%'_%'%0_Q-Q4/\3<5#_$_5
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M'&59PQQD6>,<9%GZ&F19_QAD6?\795G_%659_Q1E6?\495G_%.]&  #:4@
MQEL  +IA  "P90  IF8  )UC  "580  CV(. (MD' "'92L @V4W 7]E0@-\
M9$L&>&-3"'5C6PMS8F(.<&%J$&U@<A-K8'L5:%^&%V9>D1EC7I\;85VN'&!=
MP1Q?7>$<7UWX&E]=_QA?7?\78%W_%F!=_Q5@7?\58%W_%>M*  #45@  PUX
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M&4]K_QA/:_\74&K_%E!J_Q50:O\54&K_%=U5  #%80  MVH  *QQ  "B=0
ME'0  (ET  !\<P  =G4  '%W$ !O>!T ;'DK &EY-P%F>4 #8WE)!6!X40==
M=U@)6W=@#%AV: Y5=7$14G5\$U!TB!9-=)<72W.F&$ESN1E(<]4927+S&$EQ
M_Q=*<?\62G#_%4MP_Q1+</\42W#_%-1:  # 9@  LV\  *AV  "=>0  CW@
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M#S:'_P\VA_\/-H?_#[YM  "P>0  I8(  )F'  ",B   ?X@  '**  !FC0
M6I$  %"5  !)EPD 1Y@3 $68( !$F2L 0YDV $&:0 ! FD@!/II1 CR:6@(Z
MFF0#-YIO!369?08SF8P',9F=""^9L @NF<H(+ICM""Z6_PHME/\*+9/_"RV2
M_PLMDO\++9+_"[9U  "J@0  GH@  ).-  "&C@  >(\  &N2  !?E0  5)D
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M 9^/  "4E0  AYL  'FA  !KIP  7JP  %*Q  !%M   .K8  "^Y   EO
M';\  !7#   /Q@4 "\H-  G*%  (RAT !\HG  ?*,@ &RSX !<M+  3,6@ #
MS&H  LQ^  ',E   S*L  ,W(  #,[0  S/\  ,O_  '*_P !RO\  <K_ )>6
M  "*G   ?*,  &ZJ  !@L   4K8  $6Y   YO   +K\  "/#   ;Q@  $\H
M  W-   (T0   =0)  #4#@  U14  -8>  #8)P  V3$  -L^  #<2P  W5L
M -YN  #>A   WYL  -^T  #>V0  W_<  -__  #?_P  W_\  -__ (V=  !_
MI0  <*P  &&S  !3N@  1;\  #C"   LQ@  (<D  !C-   0T0  "]4   3:
M    W@   . !  #A"0  X@X  .03  #E&P  YR0  .DO  #K/   [4L  .Y=
M  #N<0  [XD  /"B  #PO   \.,  ._Y  #P_P  \/\  /#_ (&E  !RK0
M8[4  %2]  !&Q   -\@  "K,   ?T   %=4   [:   'W@   .(   #F
MZ0   .H   #L    [@4  .\,  #Q$   \Q<  /4@  #X*P  ^SD  /U*  #^
M7@  _W0  /^-  #_I@  _\   /_A  #_]0  __4  /_U '2N  !EMP  5L
M $?(   XS0  *M(  !W8   3W0  #.(   /F    Z0   .P   #P    \P
M /0   #V    ^    /H   #]!P  _PT  /\2  #_&P  _R@  /\W  #_2@
M_UX  /]V  #_CP  _Z8  /^Z  #_T0  _]$  /_1 /\/) #_#B( _PLA /\#
M) #_ "D _P R /\ /@#_ $P _P!9 /\ 90#_ '  _P!Z /\ A #_ (P _P"2
M /\ F0#_ )\ _P"E /\ JP#_ +( _P"Z /\ Q0#_ -, _P#G /\ ] #_ /\
M_@#_ /\ _P#^ /\ _@#_ /X _P#^ /\ _@#_ /\1(0#_$!X _PT= /\''P#_
M ", _P M /\ .@#_ $@ _P!5 /\ 80#_ &P _P!V /\ ?P#_ (< _P". /\
ME0#_ )L _P"A /\ IP#^ *X _0"V /P P #[ ,T ^0#B /@ \ #W /P ]@#_
M /4 _P#U /\ ]0#_ /4 _P#U /\ ]0#_ /\5'0#_$QH _Q 9 /\+&0#_ !T
M_P I /\ -@#_ $, _P!0 /\ 7 #_ &< _P!Q /\ >@#^ (, _ "* /H D0#Y
M )< ^ "= /< HP#U *H ] "R /( NP#Q ,@ [P#< .X [ #M /H ZP#_ .H
M_P#J /\ Z@#_ .H _P#J /\ Z@#_ /\8&0#_%A4 _Q,3 /\.$P#_"QH _P<D
M /\", #_ #X _P!+ /\ 5P#_ &( _ !L /@ =0#U 'X \@"% /$ C #O ),
M[@"9 .P H #K *8 Z0"N .< MP#F ,, Y #4 .( Z0#A /< WP#_ -T _P#=
M /\ W0#_ -T _P#= /\ W0#_ /\;$P#_&A  _Q8. /\2#@#_$A4 _P\? /\,
M*P#_"3@ _P9% /L#40#W EP \@)F .X"< #J G@ YP*  .8#AP#D XX X@.5
M .$#G #?!*, W02K -L$M #8!<  U@70 -,&YP#0"/@ S@K_ ,P+_P#+#/\
MRPS_ ,L+_P#+"_\ RPO_ /\?$ #_'@L _QH' /\9"P#_&!$ _Q89 /\2) #Z
M$#  \PX^ .X-2@#I#%8 Y0QA .(,:@#>#7, VPU[ -D-@P#6#8H U V1 -(-
MF0#0#J  SPZI ,T.LP#+#K\ R@_0 ,81Z0#"$OD OQ/_ +T3_P&\$_\!O!/_
M ;P3_P&[$_\!NQ/_ ?\B# #_(00 _R   /\A!0#_'PP _QP1 /88' #L%2@
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M!_\O  #R-   XCP  -)!  #'0@  P$   +LZ 0"V-@X L#D< *H[+ "F/#H
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M$'5&PA!S1N 0<D?W#W%'_PYQ1_\-<4?_#'%'_PMQ1O\+<4;_"_,Y  #@1
MS$P  +Y1  "T4P  JE(  *).  "=2@$ ETL1 )--( "/3RX C$\Z 8A/10*%
M3TX#@T]6!(!.709^3F0'?$UL"7E-= MW3'T,=4R'#G-,D@]Q2Y\1;TNM$FU+
MOQ)L2]P2:TSU$6I,_P]J3/\.:DO_#6I+_PQJ2_\,:DO_#/ ]  #;2   QU
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M$UE8_Q%:6/\06EC_#EI7_PU:5_\-6E?_#>-(  #+4P  NUL  +!A  "D8@
MEV$  (Y?  "%7   ?UX' 'M?$P!X82$ =6(N ')B.0%O8D,";&%+ VIA4P5G
M85H'96!B"6-@:@M@7W,-7EY]#UM>B1%979825UVE$U5=MA147<X45%WN$U1=
M_Q%57/\055S_#E5;_PY66_\-5EO_#=Y,  #'5@  N%\  *UD  "@90  DV0
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M#45J_PU%:O\-16K_#<M8  "Z8P  K6P  *%Q  "2<   A6\  'IO  !N<
M97,  &!U!P!==A( 6W<? %EX*P!7>#8 57@_ 5-X2 )1>$\#3W=7!$QW7P5*
M=V@'2'9S"45V?PM#=8T,076=#C]UK@X^=<4./77H#CYS_0T^<O\-/G'_##]Q
M_PP_</\,/W#_#,5>  "U:0  J7$  )QU  "-=   @'0  '5T  !I=@  7GD
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M!;%T  "E?@  F84  (J$  !]A   ;X4  &.(  !8BP  38\  $.3   ZEP
M,IH' "Z;$  MFQH +)PD "N<+@ JG3@ *9U! "B=2P GGE4 )IYA "6>;@ C
MGGX!(IZ0 2">HP$?GKD!'I[= 1Z<^ (>FO\"'IG_ QZ7_P,>E_\#'I?_ ZI]
M  ">A0  DXL  (6*  !UBP  :(X  %N1  !0E0  1ID  #N=   RH   *J,
M "*F"0 ?IQ$ 'J<: !VH)  <J"T &Z@W !JI00 9J4P &*E8 !>J9@ 6JG8
M%:J) !2JG@ 3J[0 $JO3 !*H]0 3I_\!$Z7_ 1.E_P$3I/\!$Z3_ :.&  "7
MC   C9$  'V2  !ME0  8)@  %2<  !(H   /J0  #2G   JJP  (:X  !FQ
M   2LP< #[40  ZU%P .M2$ #;4K  VU-@ ,MD$ "[9.  JV7  )MFP "+9_
M  >VE  &MJH !;;%  :VZ@ 'M?\ "+3_  BS_P )LO\ ";+_ )J-  "0DP
MA)@  '2<  !EH   5Z0  $NH  ! K   -;   "JS   AM0  &+@  !&[   ,
MO@( !L +  + $0 !P1D  ,$B  #"*P  PC8  ,-"  ##4   Q%\  ,1Q  #$
MAP  Q)T  ,2U  #$V@  Q/8  ,/_  ##_P  P_\  ,/_ ).4  "'F@  >*
M &JF  !<K   3[$  $&U   UMP  *;H  !^]   6P   $,,   K&   #R@
M ,P%  #,#   S1$  ,X8  #.(0  T"H  -$U  #30P  U%(  -1C  #5>
MU8\  -6G  #6P@  UND  -;]  #6_P  UO\  -;_ (J;  ![H@  ;*D  %ZP
M  !0M@  0KH  #2]   HP0  '<0  !3'   -RP  !LX   #2    UP   -D
M  #:!0  W L  -T0  #?%0  X1T  .,G  #E,P  YT(  .A4  #H9P  Z7X
M .F7  #JKP  ZLX  .OO  #K_@  Z_\  .O_ 'VC  !NJP  7[(  %&Z  !"
MP   -,,  "?'   ;RP  $L\   O3   "V    -T   #A    Y    .4   #G
M    Z0   .L'  #M#0  [Q$  /$9  #T)   ]S$  /E!  #Z50  ^FH  /N$
M  #[G0  _+8  /S2  #][0  _?0  /WT '&L  !AM0  4KT  $3$   TR0
M)LT  !K2   0V   "-T   #A    Y0   .@   #L    [P   /$   #S
M]0   /<   #Y 0  ^P@  /X.  #_%0  _R$  /\O  #_00  _U8  /]M  #_
MAP  _Z   /^V  #_R@  _]0  /_4 /\+( #_!QX _P = /\ ( #_ "4 _P N
M /\ .P#_ $D _P!6 /\ 8@#_ &T _P!V /\ ?P#_ (< _P". /\ E #_ )H
M_P"@ /\ I@#_ *T _P"U /\ O@#_ ,L _P#A /\ \ #^ /T _0#_ /T _P#]
M /\ _0#_ /P _P#Y /\ ^0#_ /\-'0#_"QH _P09 /\ &@#_ !\ _P J /\
M-P#_ $4 _P!1 /\ 7@#_ &@ _P!R /\ >@#_ (( _P") /\ D #_ )8 _P"<
M /X H@#\ *D ^P"P /D N0#X ,8 ]@#9 /4 ZP#T /D \P#_ /( _P#S /\
M\P#_ /, _P#S /\ \P#_ /\0&0#_#A4 _P@4 /\ % #_ !D _P E /\ ,@#_
M $  _P!, /\ 60#_ &, _@!M /P =0#Z 'T ^0"$ /< BP#V )$ ] "7 /,
MG@#R *0 \ "L .X M #M ,  ZP#/ .D Y@#H /4 Y@#_ .< _P#F /\ Y0#_
M .4 _P#E /\ Y0#_ /\2% #_$!  _PP/ /\#$ #_ !4 _P @ /\ + #_ #H
M_P!' /H 4P#W %X ] !G /$ < #O '@ [0!_ .L A@#J (P Z "3 .< F0#E
M *  XP"G .$ L #? +H W0#) -L X #8 /  UP#^ -4 _P#4 /\ TP#_ -,
M_P#3 /\ TP#_ /\5$ #_$@P _PX) /\+# #_"1( _P,: /\ )@#] #, ] !
M .\ 30#K %@ Z !A .4 :@#B '( X !Z -X @ #< (< V@". -@ E0#4 )P
MT@"C -  K #. +8 S #$ ,H V0#( .T QP#[ ,4 _P#$ ?\ PP'_ ,0!_P#$
M ?\ Q '_ /\8"P#_%04 _Q   /\0!@#_#PT _PP4 /P''P#Q RL YP Y .(
M1@#> 5$ V@); -4"9 #2 VP SP-T ,T$>P#+!(( R@2) ,@%D #&!9@ Q 6@
M ,(&J0#!!K0 OP;! +T(U0"[">P N O] +8,_P"U#?\ M W_ +0-_P"T#?\
MM W_ /\;!0#_&   _Q<  /\6  #[$P8 ^A . .X,%@#C"2( V@DP -,*/@#.
M"TH R@Q5 ,<-7@#%#6< P@YO ,$.=@"_#GX O0^% +P/C0"Z$)4 N!"= +<0
MIP"U$;( LQ'  +(1U0"N$^X JQ3^ *D5_P"G%?\ IQ7_ *84_P&F%/\!IA3_
M ?\?  #_'   ^AX  .L>  #C'   WQ4% -X.#0#3#A@ RQ$H ,43-P# %$0
MO!9/ +D760"W%V$ M!AI +,9<0"Q&7@ KQJ  *X:B "L&Y  JQN9 *D;HP"G
M'*X IAR\ *0=SP"A'NH!GA[\ 9P?_P&;'_\!FA__ 9H>_P&9'O\!F1[_ ?\B
M  #_(0  ["<  . J  #4*0  S20  ,H<" #$&1( O1PB +<>,0"S(#X KR%)
M *TB4P"J(UP J"1D *8D; "D)', HR1Z *$E@@&@)8L!GB64 9TEG@&;)JH!
MF2:W 9@FR0*5)^8"DB?Y I H_P*/*/\"CB?_ HXG_P*.)_\"CB?_ O\F  #R
M*0  XS$  -(T  #(-   P#   +LI @"X(PX L28< *PH*P"H*C@ I"M$ *$L
M3@"?+5< G2U? )LM9P&9+6X!F"YU 98N?0*4+H8"DRZ0 I$NF@./+J8#C2ZS
M XPNQ0.*+^$$AR_V!(4O_P2$+_\#A"__ X,O_P.#+_\#@R__ _LI  #K,0
MV3@  ,D\  "_/   MCD  + R  "L+0L IR\7 *(Q)@">,S0 FC1  )@U2@"5
M-5, DS5; 9$U8@&/-6D"C35Q HPU>0.*-8(#B#6+!(8UE@2$-:(%@C6O!8$U
MP 9_-MP&?3;T!GLV_P5[-O\%>C;_!'HV_P1Z-?\$>C7_!/4M  #D-P  T#\
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M"V1'_PED1O\(9$;_!V1&_P9D1?\&9$7_!N@[  #01@  OTT  +-1  "E40
MFDX  ))+  "-1P  AT@+ (-*%@!_2R0 ?4PQ 'I-/ !W344!=4U- G--50)Q
M35P#;TUC!&U,:P5K3',':4M]"&9+B0ED2Y8*8DND"V%+M Q?2\H,7DOJ"UY+
M_@I>2_\)7DK_"%Y*_P=>2O\'7DK_!^,_  #+20  O%$  +!5  "A5   EE(
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M"$]6_PA05O\'4%;_!]-*  # 5   LEP  *->  "570  B5P  '];  !V60
M<%H  &M<#0!H71@ 9EXD &1?, !B7SH 8%]# 5Y?2P)<7U("6E]: UA?8055
M7FH&4UYT!U%=?PE/78T*35V<"TM=K Q*7<$,25WC#$E<^@I)6_\)2EO_"$I:
M_PA*6O\'2EK_!\Y.  "\6   KF   )]A  "18   A5\  'M?  !P70  :E\
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M!KU<  "O9@  HFT  )%L  "":P  =VL  &QL  !A;@  5W   %!S  !,=0H
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M 2.+G@$BB[,!(8S. 2&*\0$@B/\"((;_ B"%_P(AA?\"(87_ JMR  "A?
MCWL  (!Z  !S>@  9GP  %M_  !0@@  1H8  #R*   TC0  +)$  ":3#  D
ME!, (Y0< "*5)@ AE2\ ()4X !^60@ >EDP '998 !R69  :EW0 &9>& !B7
MF0 7EZX %9?) !:5[@ 6D_\!%I+_ 1:1_P$6D/\!%I#_ :5[  "9@P  B8$
M 'N   !L@@  7X0  %2(  !)BP  /Y   #64   MEP  )9H  !V> 0 6H P
M%*$2 !2A&P 3H24 $J$N !&B.  1HD, $*)/  ^B7  .HVL #:-]  VCD@ ,
MHZ< "J+   NBY@ ,H/X #9__  V>_P -G?\ #9W_ )Z$  "2B0  @X@  '.(
M  !EBP  6(X  $R2  !!EP  -YL  "Z>   DH@  '*4  !6H   /JP0 "JX,
M  >M$@ &K1L !:TD  2N+@ "KCD  :Y%  "N4@  KF$  *YS  "NAP  KIT
M *ZT  "NU0  K?0  *W_  "L_P  J_\  *O_ ):+  ",D   >Y   &N2  !=
ME@  4)H  $2?   YHP  +Z<  "6K   <K@  %+$   ZT   )MP   ;@)  "X
M#@  N10  +D<  "Z)0  NB\  +LZ  "\1P  O%8  +QG  "\>P  O)$  +RI
M  "\Q   O.L  +O^  "[_P  N_\  +O_ )"2  "#F   <YL  &.?  !5HP
M1Z@  #NM   PL0  );0  !NW   2N@  #+T   6_    PP   ,0"  #%"@
MQ0X  ,84  #'&P  R"0  ,HN  #,.@  S4D  ,U9  #-;   SH,  ,Z;  #-
MM0  SMH  ,[V  #-_P  S?\  ,W_ (:9  !WH   ::8  %JL  !,L@  /K8
M #"Y   DO   &;\  !'"   *Q0   LD   #,    T    -$   #2 0  TP@
M -4-  #7$0  VA@  -PA  #?+   X3H  .)*  #C70  Y'(  .2+  #EI0
MY<   .7F  #E^   Y?\  .7_ 'JA  !KJ0  7*\  $VV   _O   ,+\  "/#
M   7QP  #\H   ?.    T0   -8   #<    WP   .    #B    Y    .8#
M  #H"0  Z0X  .P5  #N'@  \2L  /0Z  #U30  ]F$  /=Y  #XDP  ^*T
M /G&  #YY   ^?,  /GS &VJ  !>L@  3[H  $#!   QQ0  (LD  !;.   -
MT@  !-@   #=    X0   .0   #H    ZP   .T   #O    \0   /,   #V
M    ^ ,  /H+  #]$0  _QL  /\I  #_.P  _T\  /]F  #_?P  _YD  /^O
M  #_PP  _]8  /_6 /\$' #_ !D _P 9 /\ ' #_ "( _P K /\ . #_ $8
M_P!3 /\ 7@#_ &D _P!R /\ >@#_ (( _P") /\ CP#_ )4 _P"; /\ H0#_
M *@ _P"O /\ N0#_ ,4 _P#9 /X [ #] /L ^P#_ /L _P#[ /\ ^@#_ /0
M_P#P /\ \ #_ /\'& #_ 14 _P 4 /\ %@#_ !L _P F /\ - #_ $( _P!.
M /\ 6@#_ &0 _P!M /\ =0#_ 'T _P"$ /\ B@#] )  _ "6 /H G0#Y *,
M^ "K /< M #U +\ ] #. /, Y@#Q /8 \ #_ .\ _P#O /\ [@#_ .X _P#J
M /\ Z@#_ /\+% #_!A$ _P 0 /\ $ #_ !8 _P B /\ +@#_ #P _P!) /\
M5 #^ %\ ^P!H /D < #W '@ ]0!_ /, A0#R (L \ "2 .\ F #M )\ [ "F
M .H K@#H +D YP#' .4 W@#C /  X@#^ .  _P#@ /\ X0#_ .$ _P#A /\
MX0#_ /\-$ #_"0T _P$, /\ # #_ !( _P < /\ * #\ #8 ^0!# /8 3@#R
M %D [P!B .P :P#J '( Z !Y .8 @ #D (8 X@", .$ DP#? )H W0"A -L
MJ@#8 +0 U0#  -( TP#0 .H S@#Z ,T _P#- /\ S0#_ ,P _P#, /\ S #_
M /\0# #_# < _P," /\ " #_  X _P 6 /8 (@#P "\ [  \ .D 2 #E %,
MX0!< -X 90#; &P UP!S -0 >@#2 (  T "' ,X C@#, )4 R@"= ,@ I0#&
M *\ Q "[ ,( RP#  .4 O@#U +T _P"\ /\ O #_ +P _P"\ /\ O #_ /\1
M!0#_#@  _PH  /\( 0#_! H ^  0 .D &@#C "@ W@ U -D 00#3 $P SP!6
M ,L 7P#) &8 Q@!N ,0 = #" 'L P0"" +\ B0"] )  O "8 +H H0"X *L
MM@"W +0 QP"R .  L0'R *\"_P"N _\ K03_ *T$_P"M!/\ K03_ /\4  #_
M$   _P\  /(-  #J"@  Z0,) -T $@#4 !\ S0$M ,@".@#$ T4 P -0 +T$
M60"[!6$ N05H +<&;P"U!G8 M =] +('A "Q"(P KPB5 *T)G@"K":@ J@JU
M *@*Q0"F"]\ I WT *(._P"@#O\ GP[_ )\._P"?#O\ GP[_ /\7  #_$P
M[Q@  .09  #;%@  TA " ,\)"P#("!8 P0HD +P,,@"W#3X M Y) +$.4P"O
M$%L K1!C *L0:@"I$7$ J!%X *81@ "E$8@ HQ*1 *$2FP"@$Z8 GA.S )P3
MPP";%-X EQ;T )46_P"4%_\ DQ?_ )(7_P"2%O\ DA;_ /\:  #T'0  Y2,
M -4E  #*)   PAT  +X6! "[$!  M!,= *\5*P"K%C@ IQA# *4930"B&58
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M G4P_@)S,/\"<S#_ G,O_P)S+_\"<R__ O J  #<-0  QSL  +H_  "L/
MHC@  )PS  "8+P  E2X0 ) P' ",,BD B3,U (8T/P"$-4D @C51 ( U6 !^
M-5\!?35F 7LV;@%Y-78">#6  G8UBP-T-9<#<C:D W VM 1O-L@$;3;G!&PV
M_ -K-O\#:S;_ FHV_P)J-?\":C7_ NHP  #3.@  PD$  +-#  "E00  FSX
M )4Z  "0-@  C#4- (@W& "$."4 @3HQ '\[/ !\.T4 >CQ- '@\50%W/%P!
M=3QC 7,\:@)Q/',"<#Q\ VX[AP-L.Y0$:CNA!&@[L05G/,4%93SE!60\^@1D
M//\#8SO_ V,[_P-C._\"8SO_ N4U  #-/P  O48  *Y'  "?10  E4,  (Y
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M!%=$_P-81/\#6$3_ ]H]  #$1P  M4X  *1.  "63   BTL  (-)  !]10
M>$8" '1'$ !P2!L ;DDG &M*,@!J2SP :$M$ &9+3 %D2U,!8DM: F!+8@)?
M2VH#74MT!%M*?P592HP%5TJ:!E5*J@=42KT'4TK<!U)*]@922O\%4DG_!%))
M_P-22/\#4TC_ ]1!  # 2P  LE$  *!0  "23P  ATX  'Y,  !X2   <DH
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M \9,  "U5@  I5H  )19  "&6   >U@  '%7  !F5@  85@  %U9! !96A
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M S1IGP,S:;(#,6G+ S%H[0,Q9_\#,6;_ S)E_P,R9/\#,F3_ [=;  "I9
MEF0  (9C  !X8P  ;6,  &1D  !990  4&@  $EK  !#;00 0&X. #YO&  ]
M;R( /' K #IP-  Y<3T .'%% #=Q3@ V<5< -'%A 3)Q;0$Q<7H!+W&* BUQ
MG (K<:\"*G'( BIPZP(J;_\"*FW_ BIL_P(K;/\"*VS_ K%A  "D:0  D&@
M (!G  !T9P  :6<  %]H  !5:P  2VX  $-Q   \=   -W8* #1W$@ S>!P
M,G@E #%Y+@ P>3< +WD_ "YY2  L>E( *WI< "IZ:  H>G8 )GJ' 25ZF0$C
M>JP!(GK% 2)YZ0$B=_\!(G;_ 2)U_P(B=/\"(W3_ JQH  "=;@  BFT  'ML
M  !O;   96P  %IN  !0<0  174  #UX   V?   +G\" "F!#0 G@A0 )H(>
M "6")P D@B\ (X,X "*#0@ A@TL ((16 !^$8@ >A'$ '(2" !N$E0 :A*D
M&(3! !B#Y@ 8@?T &8#_ 1E__P$9?O\!&7[_ :9P  "5<P  A'(  '9Q  !K
M<0  7G,  %1V  !)>0  /WT  #>!   OA   )X@  ""+!0 ;C0X &HT5 !F-
M'@ 8CB< %XXP !:..0 5CD, %(]/ !./6P 2CVH $8][ !"/CP /CZ0 #H^[
M  V/X  .C?H #XO_ !"*_P 0B?\ $(G_ *%Z  ".>0  ?G<  ')W  !D>
M6'L  $U^  !"@@  .88  "^*   GC@  ()$  !B5   2F 4 #IH.  V:%  ,
MFAT "YHF  N:,  *FCL "9I&  B:4P &FV$ !9IR  2:A@ "FIL  )JQ  &9
MSP "F?   IC_  27_P %EO\ !9;_ )F!  "'?P  >GX  &M^  !=@0  4(4
M $6)   [C0  ,9(  "B6   ?F0  &)T  !&@   ,HP( !J4*  &E$   I18
M *8?  "F*   IC(  *<]  "G2@  IU@  *=H  "G?   IY$  *:H  "FPP
MI>D  *7\  "E_P  I/\  *3_ )&'  ""A@  <H8  &.(  !5C   29$  #V6
M   RF@  *)X  !^B   7I@  $*D   NL   $KP   +$&  "Q#   LA$  +(7
M  "S'P  LR@  +0R  "U/P  M4T  +5=  "U<   M88  +6=  "UM@  M=P
M +3W  "T_P  M/\  +3_ (N/  !ZC@  :I$  %N5  !-F@  0)\  #6D   J
MJ   (*P  !:P   /M   ";<   &Y    O0   +X   "^!@  OPP  , 0  #!
M%@  PAT  ,,G  #%,@  QD   ,91  #'8P  QW@  ,>1  #'J0  Q\<  ,?L
M  #'_@  Q_\  ,?_ (.7  !QF@  89X  %*C  !%J0  .*X  "RS   @MP
M%KH   Z]   &P    ,,   #'    R0   ,H   #,    S0,  ,X)  #0#@
MTA,  -0;  #8)0  VS(  -U"  #=5   WFD  -Z!  #>G   W[4  -_9  #?
M\P  W_\  -__ '>?  !HI@  6:T  $JS   [N   +;L  !^_   4P@  #,8
M  /)    S    -    #5    V0   -H   #<    W@   .    #B!0  Y L
M .<0  #J&   [20  / R  #Q1   \E@  /-O  #TB@  ]*0  /2_  #TWP
M]/,  /3T &JH  !;KP  3+<  #V]   MP0  '\8  !/*   +S@   -(   #7
M    W    .    #E    YP   .D   #K    [0   .\   #Q    \P   /8'
M  #Y#@  _!8  /\B  #_,P  _T<  /]=  #_=@  _Y$  /^I  #_O@  _]@
M /_; /\ & #_ !8 _P 5 /\ & #_ !X _P G /\ -@#_ $, _P!/ /\ 6@#_
M &0 _P!M /\ =0#_ 'T _P"$ /\ B@#_ )  _P"6 /\ G #_ *, _P"K /\
MM #^ +\ _0#/ /L YP#Z /@ ^0#_ /D _P#Y /\ ]0#_ .X _P#I /\ YP#_
M /\ % #_ !$ _P 1 /\ $@#_ !< _P C /\ ,0#_ #X _P!* /\ 5@#_ &
M_P!H /\ < #_ '@ _0!^ /P A0#Z (L ^0"1 /@ F #W )X ]0"F /0 K@#R
M +D \0#' .\ X #N /( [ #_ .P _P#L /\ ZP#_ .4 _P#@ /\ W@#_ /\#
M$ #_  X _P - /\ #0#_ !, _P > /\ *P#_ #@ _P!% /X 4 #[ %H ^ !C
M /4 :P#S '( \0!Y .\ ?P#N (8 [ ", .H D@#I )D YP"@ .8 J0#D +,
MX0#  .  TP#> .L W #[ -L _P#: /\ V@#_ -D _P#4 /\ T@#_ /\'#0#_
M  D _P & /\ "0#_  \ _P 8 /L )0#X #( ]0 _ /( 2@#M %0 Z@!= .<
M90#D &P X@!S .  >@#> (  W "& -H C0#7 )0 U "; -( I #/ *T S0"Y
M ,L R0#) .0 R #V ,8 _P#% /\ Q@#_ ,< _P#' /\ QP#_ /\*!@#_ 0
M_P   /\ ! #_  L ]  2 .\ 'P#J "P Y0 X .( 0P#= $X V0!7 -0 7P#1
M &< S@!M ,P = #* 'H R "  ,8 AP#% (X PP"6 ,$ G@"_ *@ O0"S +H
MP@"Y -L MP#P +4 _P"V /\ M0#_ +4 _P"U /\ M0#_ /\,  #_!   _P
M /X   #V  , Z  - .  %P#9 "0 T0 Q ,T / #* $< Q@!1 ,, 60#  &
MO@!G +P ;@"Z '0 N0![ +< @@"U (D LP"1 +( F@"P *0 K@"O *P O0"J
M -  J #K *< ^P"F /\ I@#_ *4 _P"E /\ I0#_ /\-  #_!P  ] D  .H)
M  #B!   V@ ' ,\ $0#( !P P@ I +X -0"[ $  MP!* +0 4P"R %L L !B
M *X : "L &\ JP!U *D ?0"H (0 I@"- *0 E@"C *  H0"K )\!N0"= \P
MG 3H )H&^0"9!_\ F C_ )<(_P"7"/\ EPC_ /\0  #W$   Z!0  -P5  #.
M$0  Q@T  ,($"P"\ !0 MP$A +(#+@"N!3H JP9$ *@(30"F"%4 I E< *(*
M8P"@"FH GPMQ )T+> "<"X  F@R) )D,DP"7#)X E0VJ )0-N "2#<P D [J
M (X0_ ",$/\ BQ#_ (L0_P"+$/\ BA#_ /L3  #M&@  W2   ,PA  "_'0
MMQ<  +,1  "R"PT JPT9 *<.)@"C#S, GQ ^ )T11P":$5  F!)7 )827@"5
M$V4 DQ-L )(3<P"0%'P CQ2% (T5CP"+%9H BA6G (@6M0"&%LD A!?G ((8
M^P" &?\ ?QG_ '\9_P!_&/\ ?QC_ /4:  #D(P  SRD  , J  "S)@  JB(
M *4<  "D%0@ H!03 )L6(0"7&"T E!DX )$:0@"/&TL C1Q2 (L<60")'6
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M 6,O_P%C+_\!8R__ >(N  #*.   NCT  *@\  ":.@  D3<  (HS  "&,
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M10 &"?\"4#__ E __P)1/O\!43[_ <\[  "]10  JD<  )E&  "+10  @40
M 'E"  !T/@  ;S\  &M # !G014 94(A &-#*P!A0S4 7T0^ %Y$10!=14T
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M D)+_P)"2O\"0DK_ L)'  "S3P  GD\  (U.  " 3@  =4T  &Q,  !C2@
M7DP  %I- @!63@X 5$\8 %)0(@!142P 3U$U $Y2/0!-4D4 3%)- $I25 !)
M4ET!1U)F 452<0%#4GX"05*- C]2G0,^4J\#/5+& SQ2Z0(\4?X"/%#_ CU/
M_P(]3_\"/4[_ KY+  "N4P  FE(  (E1  !\40  <5   &A0  !>3@  6%$
M %12  !14PP 3E04 $Q5'P!+5BD 258R $A6.@!'5T( 1E=* $174@!#5UH
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M ;%9  ">7   BUP  'M;  !O6P  95L  %Q<  !17@  26   $-B   \90
M.&<* #5H$@ T:!L ,VDD #)I+0 Q:34 +VH] "YJ1@ M:D\ +&I9 "MK90 I
M:W( *&N" "9KDP D:Z< (VN] ")JX  C:?D!(V?_ 2-F_P$C9O\!)&7_ :Q@
M  "88   A6   '9?  !J7P  86   %=@  !-8P  1&8  #UH   V:P  ,&X$
M "QP#@ J<14 *7$> "AQ)@ G<B\ )G(W "5R0  D<DH (G)4 "%S8  @<VT
M'G-] !USD  ;<Z, &G.Y !ESW  :<?< &G#_ !MO_P ;;O\!&VW_ :9F  "1
M90  ?V0  '%D  !F9   760  %)F  !(:0  /VP  #=O   P<P  *78  ")Y
M"  ?>Q  'GL7 !Q['P ;>R@ &GLP !E\.0 8?$, %WQ. !9\6@ 5?&< %'UX
M !)]BP 1?9\ $'VU  ]]U0 0>_4 $7G_ !%X_P 2=_\ $G?_ )YK  "*:@
M>FD  &UI  !B:0  5VH  $QM  !#<   .70  #%X   I>P  (G\  !N"   4
MA0D $880 !&&%P 0AQ\ $(<H  Z',0 .ASL #8=&  R'4P +AV$ "H=Q  F'
MA  'AY@ !H:N  6&R0 &A>P !X3_  B#_P )@O\ "8+_ )5Q  "#;P  =&X
M &EN  !<;P  4'(  $9U   \>0  ,GT  "J!   BA0  &XD  !2,   /CP,
M"I(+  :2$0 $DA@  I(@  &2*0  DC,  ),^  "32P  DUD  )-I  "3>P
MDI   )*F  "1OP  D>4  )#Z  "/_P  C_\  (__ (UW  !]=0  <'0  &)U
M  !5>   27P  #^    TA   *XD  "*-   :D0  $Y0   Z7   )FP   9T(
M  "=#@  G1,  )X:  ">(@  GRL  )\U  "@0@  H%   *!?  "@<0  H(<
M )^=  "?M0  GMH  )WV  "=_P  G/\  )S_ (9]  !X?   :7P  %M_  !.
M@P  08@  #:,   LD0  (Y8  !J:   2G@  #:$   :D    IP   *D#  "I
M"@  J@X  *L3  "L&0  K2(  *XK  "O-P  KT4  *]4  "O9@  KWL  *Z4
M  "NJP  KLD  *[O  "M_P  K?\  *W_ (&$  !QA   88<  %.+  !&D
M.98  "Z;   CH   &J0  !*H   ,K   !*\   "R    M@   +<   "W @
MN @  +D-  "Z$@  NQ@  +TA  "^*P  P#@  ,!(  # 6@  P6X  ,&&  #!
MH   P;H  ,'C  # ^0  P/\  ,#_ 'F-  !HD   690  $N:   ]H   ,:4
M "6K   :KP  $;,   NX   "NP   +X   #!    Q    ,4   #&    QP
M ,@%  #*"P  S \  ,X5  #0'P  TRL  -4Z  #53   UF   -AW  #8D@
MV*P  -G)  #9[   V?L  -C_ '"9  !@G@  4:0  $.J   UL   *+8  !RZ
M   1O@  "<$   #%    R    ,L   #/    T@   -,   #6    V    -L
M  #=    WP<  .(-  #E$P  Z!T  .PJ  #M/   [5$  .YG  #O@0  [YP
M /"W  #PTP  \.P  /#T &>F  !8K0  2;0  #JZ   JO@  ',(  !#&   '
MR@   ,X   #2    U@   -P   #@    XP   .0   #F    Z    .L   #M
M    [P   /("  #U"@  ^!$  /P<  #_+   _S\  /]5  #_;@  _XH  /^D
M  #_N@  _]$  /_A /\ % #_ !( _P 2 /\ % #_ !D _P E /\ ,@#_ #\
M_P!+ /\ 5@#_ &  _P!H /\ < #_ '@ _P!_ /\ A0#_ (L _P"1 /\ F #_
M )X _@"F /T K@#\ +D ^@#( /D X@#X /0 ]P#_ /8 _P#V /\ [P#_ .<
M_P#B /\ W@#_ /\ $0#_  X _P . /\ #P#_ !0 _P @ /\ +0#_ #H _P!&
M /\ 40#_ %L _P!C /X :P#\ ', ^@!Y /D @ #W (8 ]@", /4 D@#S )D
M\@"@ /  J0#N +, [0#! .L U@#J .X Z0#^ .< _P#G /\ Y0#_ -T _P#5
M /\ T0#_ /\ #0#_  H _P ( /\ "0#_ !  _P ; /\ * #_ #4 _P!  /H
M2P#V %4 \P!> /$ 9@#N &T [ !T .L >@#I (  YP"& .8 C0#D ), X@";
M .  HP#> *T W "Y -H R@#7 .8 U #X -( _P#2 /\ T@#_ ,X _P#) /\
MQ@#_ /\ " #_  , _P   /\  P#_  T _  6 /< (@#S "X [P Z .P 10#H
M $\ Y !8 .$ 8 #> &< VP!M -D = #5 'H TP"  -$ AP#/ (X S0"5 ,L
MG@#) *< QP"S ,4 P@## -P P0#Q +\ _P"_ /\ O@#_ +X _P"] /\ NP#_
M /\   #_    _P   /\   #V  @ [@ 1 .< &P#A "< W0 S -D /@#3 $D
MSP!2 ,L 60#( &$ Q@!G ,0 ;0#" ', P !Z +\ @ "] (@ NP"0 +D F "X
M *( M0"M +, NP"Q ,X L #J *\ _ "M /\ K0#_ *X _P"N /\ K@#_ /\"
M  #_    _0   /(   #H    W@ , -, %0#, "$ R  L ,0 . #! $( O0!+
M +H 4P"X %H M@!A +0 9P"R &T L !T *\ >@"M (( K "* *H DP"H )T
MI@"H *0 M0"B ,8 H0#C )\ ]@"> /\ G@#_ )X _P"> /\ G@#_ /\&  #[
M    [@4  .($  #5    RP & ,, #P"] !D N  E +0 ,0"Q #L K@!% *P
M30"I %4 IP!; *4 8@"D &@ H@!N *$ =0"? 'P G@"% )P C@": )@ F "D
M )8 L "5 ,$ DP#< )( \@"1 /\ D #_ )  _P"/ /\ CP#_ /T*  #P#@
MX1$  ,X0  #"#0  NP<  +< "@"Q !( K  > *@ *0"E #0 H@ ^ )\ 1P"=
M $\ FP!6 )D!7 "7 6, E@)I )0"< "3 W@ D0.  ) $B@".!)4 C 6A (H%
MK@")!KX APC8 (8)\ "$"O\ @PO_ (,+_P"#"_\ @PO_ /80  #F%P  TAP
M , :  "S%@  K!(  *@-  "F!PT H@46 )T'(@"9"2X E@HX )0+00"2#$H
MD Q1 (X-6 ",#5X BPUE (D-; "(#G0 A@Y] (4.AP"##I, @0^? ( 0K0!^
M$+X ?1#; 'H1] !X$O\ =Q+_ '<2_P!W$O\ =Q+_ .\7  #;(0  QB0  +0C
M  "H(   H!P  )L7  "9$00 F X0 ),0&P"/$2< C!(R (D3/ "'$T0 A11,
M (,44P"!%5H @!5@ 'X6: !]%F\ >Q9X 'D7@P!X%X\ =AB< '08J@!S&;L
M<AG4 &\:\0!N&_\ ;1O_ &T:_P!M&O\ ;1K_ .<@  #0*0  O"L  *LJ  ">
M*   EB0  ) @  "-'   C!<, (@8%@"$&B( @1LM 'X<-P!\'4  >AU( 'D>
M3P!W'E4 =A]< '0?8P!S'VL <2!T ' @?P!N(8L ;"&8 &LAIP!I(K@ :"+/
M &8B[@!E(_\ 9"/_ &0B_P!D(O\ 9"'_ . F  #(+P  M#$  *,P  "6+@
MC2L  (<H  "$)   @B ( 'X@$@![(AX >",I '4D,P!S)3P <25# ' F2P!N
M)E( ;2=9 &LG8 !J)V@ :2AQ &<H>P!E*(@ 9"F5 &(II !@*;4 7RG+ %XJ
M[ !<*O\ 7"G_ %PI_P!<*?\ 7"C_ -@L  ##-0  K34  )TT  "0,P  AC$
M ( M  !\*P  >2@# '8G$ !R*1H <"HE &TK+P!K+#@ :BQ  &@M1P!G+4X
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M 4DY_P%)./\!2CC_ <<Z  "S0   GC\  (X_  "!/@  =ST  ' [  !J.
M9C@  &(Y!P!?.A$ 7#L; %H[)0!9/"X 5STW %8]/@!4/D8 4SY- %(^50!1
M/ET 3S]F $T_< !,/WT!2C^+ 4@_FP%'/ZP!13_! 40_XP%$/OL!1#[_ 40]
M_P%$/?\!13S_ <,^  "O0P  FD(  (I"  !]00  <T   &L_  !E/   8#P
M %P^! !9/@\ 5S\8 %5 (@!302L 4D$T %!"/ !/0D, 3D)+ $U#4@!+0UH
M2D-D $A#;@!'0WL!14.) 4-#F0%"0ZL!0$/  3]#X0$_0_D!/T+_ 3]!_P%
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M ;A)  "B2P  CDH  'Y*  !R2@  :$H  %])  !52   4$H  $Q+  !)3 <
M1DT0 $1.&0!"3R( 04\K $!0,P _4#L /E!# #Q12@ [45, .E%< #A19P W
M47, -5&" #-1DP$R4:4!,%&Z 2]1V@$O4/8!+T__ 3!._P$P3O\!,$W_ ;1-
M  "=30  BDT  'I-  !N30  9$T  %M-  !130  2T\  $90  !"4@, /U,-
M #U4%0 \5!X .E4G #E5+P X53< -U8_ #961P U5E  ,U99 #)79  P5W$
M+U>  "U7D0 K5Z, *E>X "E7U@ I5O4 *57_ "I4_P$J4_\!*E+_ :]1  "8
M40  A5$  '90  !J4   8%   %A1  !.4@  1U,  $%5   [6   .%D* #5:
M$0 T6AH ,ULB #);*P Q6S, +UP[ "Y<0P M7$P +%Q6 "M=8  I76T *%U\
M "9=C@ D7:$ (UVU ")=T@ B7/, (EO_ "-:_P C6?\ )%C_ *A5  "25
M@%0  '%4  !F5   7%0  %15  !*5@  0U@  #Q;   V70  ,& % "UA#@ K
M814 *F(= "EB)0 H8BX )V,V "9C/@ E8T< (V-1 ")D7  A9&D 'V1Y !YD
MB@ <9)X &V2S !EDS@ :8_$ &V'_ !M@_P <8/\ '%__ *%9  ",6   >U@
M &U8  !B6   65@  %!9  !'6P  /EX  #=@   Q8P  *F8  "1I"0 A:A
M(&H7 !]J(  >:R@ '6LP !QK.0 ;:T( &FQ, !EL6  7;&4 %FQT !1LA@ 3
M;)H $FRO !%LR@ 1:^\ $FG_ !-H_P 3:/\ $V?_ )E=  "%70  =5P  &A<
M  !>7   55P  $M>  !"80  .60  #)G   K:@  )&T  !YP 0 7<PL %701
M !1T&  3="$ $G4I !%U,@ 1=3L $'5&  ]U4@ .=5\ #75N  QU@0 +=94
M"G6J  ATPP )=.< "G/]  MQ_P ,<?\ #'#_ )%B  !_80  <&$  &1A  !:
M80  3V(  $5E   \:   ,VP  "MO   D<@  '78  !=Y   1? 0 #7\,  M_
M$@ *?QD "7\B  A_*@ &?S0 !7\_  1_2P "?U@  7]G  !_>0  ?XX  '^C
M  !^NP  ?>   'WW  !\_P  >_\  'O_ (EG  !X9P  :V8  &%F  !49P
M26D  #]M   U<0  +'4  "1Y   =?   %H   !"#   ,A@( !HD*  &)#P
MB10  (H;  "*(P  BRP  (LW  "+0P  BU   (M?  "+<0  BX8  (N<  "*
MLP  B=,  (CS  "(_P  A_\  (?_ ()M  !S;   :&P  %IM  !.;P  0G,
M #AW   N>P  )8   !V$   5B   $(P   N/   $D@   )0&  "5#   E1
M )85  "7'   F"0  )@N  "9.0  F4<  )E6  "9:   F7T  )F4  "8JP
ME\@  );N  "6_P  E?\  )7_ 'MT  !O<P  87,  %-V  !&>@  .W\  #"$
M   FB   '8T  !22   .E@  "9D   &<    H    *$   "B!@  H@P  *00
M  "E%   I1P  *<D  "H+P  J#T  *E,  "I7@  J7(  *B)  "HH@  J+P
M *?E  "F^P  IO\  *7_ '=[  !H>P  67X  $N"   ^AP  ,HT  ">2   =
MEP  %)P   Z@   'I    *@   "K    K@   *\   "P    L00  +,*  "T
M#@  M1,  +8;  "X)   NC$  +I   "Z4@  NV4  +M]  "ZEP  NK$  +K2
M  "Z\P  N?\  +G_ &^#  !?A@  48L  $.0   VEP  *IT  !^B   5IP
M#:P   6P    M    +<   "[    O@   +\   #     P0   ,,!  #$!P
MQ0T  ,<1  #*&0  S20  ,XS  #/1   T%@  -!N  #1B   T*0  -#!  #1
MY@  T?@  -'_ &>/  !7E   29H  #NA   NIP  (:T  !:S   .N   !KP
M  #     PP   ,8   #+    S0   ,X   #0    T0   -0   #6    V@(
M -P)  #?#P  XQ<  .8D  #G-@  Z$D  .E?  #J>   ZY0  .NO  #KS
M[.@  .SV %^>  !0I   0JL  #2R   FN0  &;X   ["   $Q0   ,H   #-
M    T0   -@   #;    WP   .    #B    Y    .8   #I    ZP   .X
M  #Q!0  ]0T  /D6  #\)0  _3D  /Y/  #_9P  _X(  /^=  #_M0  _\L
M /_D /\ $0#_  \ _P / /\ $0#_ !8 _P B /\ +P#_ #L _P!' /\ 4@#_
M %L _P!D /\ ; #_ ', _P!Z /\ @ #_ (8 _P", /X DP#] )D ^P"A /H
MJ0#X +0 ]P#" /8 V@#U /$ ] #_ /, _P#S /\ Z0#_ .  _P#8 /\ TP#_
M /\ #@#_  L _P * /\ "P#_ !$ _P = /\ *@#_ #8 _P!! /\ 3 #_ %8
M_@!? /L 9@#Y &T ]P!T /4 >@#T (  \@"& /  C0#O )0 [0"; .P I #J
M *X Z0"Z .< S0#E .D Y #[ ., _P#B /\ W@#_ -$ _P#, /\ R #_ /\
M"0#_  0 _P ! /\ ! #_  X _P 8 /\ ) #] #  ^P [ /< 1@#S %  [P!9
M .P 8 #J &< YP!N .8 = #D 'H X@"  .  AP#> (X W "5 -H G@#6 *@
MU "S -$ PP#/ -\ S@#T ,P _P#+ /\ RP#_ ,4 _P"_ /\ O #_ /\  @#_
M    _P   /\   #]  L ]P 3 /$ '@#M "H Z@ U .< 0 #B $H W0!2 -D
M6@#5 &$ T@!G -  ;0#. ', S !Z ,H @ #( (< Q@"/ ,0 F #" *$ P "M
M +X NP"\ -  N@#M +D _@"X /\ N #_ +< _P"S /\ L #_ /\   #_
M_P   /D   #N  4 Y0 . -X & #8 ", T@ N ,\ .0#+ $, QP!, ,0 5 #!
M %L OP!A +P 9P"[ &T N0!S +< >@"U ($ M ") +( D@"P )L KP"G *P
MM "K ,8 J0#D *< ^ "F /\ I@#_ *4 _P"E /\ I #_ /\   #_    ]0
M .H   #>    T  * ,@ $@#" !T O@ H +L ,P"Y #T M0!& +( 30"P %4
MK0!; *P 80"J &< J !M *< <P"E 'H I "" *( C "@ )8 GP"A )T K@";
M +X F0#8 )< \0"6 /\ E@#_ )< _P"7 /\ EP#_ /\   #U    YP$  -0
M  #)    P  $ +@ #@"S !8 KP A *L + "H #8 I@ _ *, 1P"A $\ GP!5
M )T 6P"; &$ F@!G )@ ;@"7 '4 E0!] )0 A@"2 )$ D "< (X J0", +@
MBP#- (D ZP"( /T B #_ (@ _P"( /\ B #_ /D&  #I#   U X  ,,,  "W
M"0  L (  *L "0"F !  H@ : )X )0"; #  F  Y )8 00"4 $D D@!0 )
M5@". %P C0!B (L :0"* '  B !X (< @0"% (P A "8 (( I0"  +0 ?@#(
M 'T!YP!\ OD >P/_ 'L$_P![!/\ >P3_ /$.  #>%0  Q14  +04  "I$0
MH0X  )X*  "; PP EP 3 ), '@"0 2D C0(S (H#/ "(!$, A@5+ (4&40"#
M!E< @@=> ( '9 !_"&P ?0AT 'P(?@!Z"8D > F6 '<*HP!U"K, <PO' '(,
MY@!P#?L < W_ &\-_P!O#?\ ;PW_ .@6  #0'@  N1T  *D<  "=&@  E18
M ) 3  "/#@, C@H. (D+%P"&#", @PTM ( --@!^#CX ? Y& 'L.30!Y#U,
M>!!: '8080!U$&@ <Q!Q '$1>P!P$8< ;A&4 &P1H@!K$K( :1+' &@3YP!F
M$_T 913_ &44_P!E$_\ 91/_ -\>  #&)   L"0  * C  "4(0  BQ\  (8;
M  "#%P  @A(( '\1$@!\$AT >10H '84,0!T%3H <A9! '$62 !O%T\ ;A=6
M &P770!K&&0 :1AM &@9=P!F&8, 9!F0 &,:GP!A&J\ 8!K$ %X;Y !='/L
M7!S_ %P;_P!<&_\ 7!O_ -4E  "]*@  J"D  )@I  ",*   @R4  'TB  !Y
M'P  >!L# '89#P!R&A@ ;QPC &T=+0!K'34 :1X] &@>1 !F'TL 91]2 &,@
M60!B(&$ 82!I %\A<P!=(7\ 7"&- %HBG !9(JP 5R+  %8CX0!5(_D 5"/_
M %0B_P!4(O\ 5"+_ ,TK  "V+@  HBX  )(N  "%+0  ?"L  '8H  !R)@
M;R,  &TA# !J(A4 9R,? &4D*0!C)#$ 8B4Y & F00!?)D@ 729/ %PG5@!;
M)UT 62=F %@H< !6*'P 5"B* %,IF0!1*:H 4"F^ $\IW@!.*?< 32G_ $TI
M_P!-*/\ 3BC_ ,@P  "P,@  G#(  (PR  " ,0  =C   ' M  !K*P  :"D
M &8H"0!C*!$ 8"D< %XJ)0!<*RX 6RLV %DL/0!8+$0 5RU, %4M4P!4+5L
M4RUC %$N;@!0+GH 3BZ( $POEP!++Z@ 22^[ $@OVP!(+_8 1R__ $<N_P!'
M+?\ 2"W_ ,0T  "K-0  ES4  (<U  ![-0  <C0  &LR  !F+P  8BX  %\M
M!0!<+A  6B\8 %@P(@!6,"L 53$S %,Q.@!2,D( 43)) % R4 !.,U@ 33-A
M $LS:P!*,W< 2#2% $<TE0!%-*8 0S2Y $(TU@!"-/0 0C3_ $(S_P!",O\
M0C+_ , X  "G.   DS@  (,X  !W.   ;3<  &8V  !A,P  73(  %DR @!7
M,PT 5#05 %(U'P!1-2@ 3S8P $XV. !,-S\ 2S=& $HW3@!).%8 1SA? $8X
M:0!$.'4 0SB# $$YDP! .:0 /CFX #TYTP \.?, /#C_ #TW_P ]-_\ /3;_
M +L[  "B.P  CSL  '\[  !S.P  :CH  &(Y  !=-P  6#8  %0W  !1. L
M3SD3 $TY' !+.B4 2CHM $@[-0!'.SP 1CQ$ $4\2P!$/%, 0CQ< $$]9P _
M/7, /CV! #P]D0 Z/:, .3VV #@]T0 W/?( -SS_ #@[_P X._\ .#K_ +8]
M  ">/@  BSX  'P^  !O/@  9CT  %X]  !8.P  4SH  $\[  !,/ @ 23T1
M $<^&0!&/R( 1#\J $,_,@!"0#H 04!! $! 20 ^05$ /4%: #Q!9  Z07
M.$%_ #=!CP U0J$ -$*T #)"S@ R0?  ,D#_ #- _P S/_\ -#[_ +%   ":
M0   AT   'A!  !L00  8D   %M   !4/P  3C\  $I   !&004 1$(. $)#
M%@! 0Q\ /T0G #Y$+P \1#< .T4^ #I%1@ Y14X .$98 #9&8@ U1FX ,T9\
M #%&C0 P1I\ +D:S "U&S  M1N\ +47_ "Y$_P N0_\ +D/_ *Q#  "60P
M@T,  '1#  !H0P  7T,  %=#  !00P  2$,  $1%  !!1@$ /D<, #Q($P Z
M2!P .4DD #A)+  V230 -4H[ #1*0P S2DP ,DI5 #!+7P O2VL +4MZ "Q+
MBP J2YT *$NQ "=+R@ G2^T )TK_ "A)_P H2/\ *4?_ *=&  "11@  ?T8
M '!&  !E1@  6T8  %1&  !,1P  1$@  #]*   [2P  -TP) #5-$  S3A@
M,DX@ #%/*  P3S  +T\X "Y/0  L4$@ *U!2 "I07  H4&@ )U!W "50B  D
M4)L (E"O "%0R  @4.L (4__ ")._P B3?\ (TW_ *%)  ",20  >DD  &Q*
M  !A2@  6$H  %!*  !)2P  0$P  #M.   U4   ,5($ "U3#0 L5!0 *E0<
M "E5)  H52P )U4S "95/  E5D4 )%9. ")660 A5F4 'U9T !Y6A0 <5I@
M&U:L !E6Q0 95ND &E7_ !M4_P ;4_\ '%+_ )M-  "&30  =4T  &A-  !=
M30  5$T  $U.  !%3P  /%$  #93   Q50  *U@  "9:"0 C6Q  (EL7 "%<
M'P @7"< 'UPN !U<-P <74  &UU* !I=50 876$ %UUP !5=@0 4794 $UVJ
M !%=P@ 17>< $EO^ !-:_P 36O\ %%G_ )11  " 40  <%$  &11  !940
M45$  $E2  !!4P  .%8  #)9   K6P  )5X  !]A P :8PP &&01 !=D&0 6
M9"$ %60I !1E,0 393H $F5$ !%E4  095T #V5K  YE?0 -99$ #&6E  ID
MO  *9.  "V/Y  QB_P -8?\ #6'_ (U5  !Z50  :U4  %]5  !650  3E4
M $17   \60  -%P  "Q?   F8@  'V4  !EH   3:P4 $&T-  YN$@ -;AH
M#&XB  QN*P +;C0 "FX^  AN2@ ';E< !FYE  1N=@ ";HH  &V?  !MM@
M;-8  &SS  %K_P ":O\  VK_ (5:  !T6@  9EH  %Q9  !360  2%H  #]=
M   V8   +F,  "9G   ?:@  &6T  !-Q   .= , "G<*  5W$  !=Q4  '<<
M  !W)   >"T  '@W  !X0P  >%   'A>  !X;P  >(0  'B9  !WL   =LT
M '7P  !U_P  =/\  '3_ 'Y?  !N7P  8EX  %E>  !-7P  0F(  #EE   P
M:   )VP  !]P   8=   $G<   U[   (?@   H (  "!#0  @1$  ((7  "#
M'@  @R8  (0P  "$.P  A$@  (17  "$:   A'P  (23  "#J@  @L4  ('K
M  "!_@  @/\  (#_ '=E  !I9   7V,  %)D  !'9P  /&L  #%O   H<P
M('<  !A\   1?P  #(,   :'    B@   (P#  ","0  C0X  (X1  "/%P
MD!X  )$G  "2,@  DC\  )).  "27P  DG,  )*+  "1H@  D;P  )#E  "/
M_   CO\  ([_ '%K  !F:@  6&L  $MM   _<0  -'8  "I[   @@   %X4
M !")   +C0  !)$   "5    F    )D   ": P  FP@  )P-  ">$0  GQ8
M * >  "B*   HC4  *-$  "C50  HVD  **   "BF@  H;,  *#8  "@]@
MG_\  )__ &YQ  !?<@  474  $1Y   W?@  +(0  "&*   7CP  $)0   J9
M   !G0   *    "D    IP   *@   "I    J@   *P&  "M"P  KQ   + 5
M  "R'@  M"D  +0Y  "T2@  M5T  +5S  "UC@  M:@  +3&  "S[0  LO\
M ++_ &9Z  !7?0  28(  #R'   OC@  (Y0  !B:   0GP  ":0   "I
MK0   +    "T    MP   +@   "Y    NP   +P   "^ @  P @  ,(.  #$
M%   QQX  ,@L  #)/0  RE   ,IF  #*?P  RIL  ,JX  #*W0  RO4  ,K_
M %Z&  !/BP  09$  #.8   GGP  &Z4  !&K   )L    +4   "Y    O0
M ,$   #&    R    ,D   #+    S    ,X   #0    T@   -0%  #9#
MW1(  .$>  #B+@  XT(  .17  #E;P  YHP  .:H  #EQ0  Y><  .;V %:4
M  !(FP  .J(  "RI   ?L   $[8   N\    P0   ,4   #)    S0   -(
M  #6    V@   -L   #>    X    .(   #D    YP   .D   #M    \ H
M /01  #X'P  ^3(  /I(  #[7P  _'H  /V7  #]KP  _<<  /WD /\ #@#_
M  T _P , /\ #@#_ !, _P > /\ *@#_ #8 _P!" /\ 30#_ %< _P!? /\
M9P#_ &X _P!T /\ >@#_ ($ _0"' /P C0#Z )0 ^0"< /< I0#U *\ ] "\
M /, SP#Q .P \ #^ .\ _P#O /\ XP#_ -< _P#. /\ R@#_ /\ "@#_  8
M_P $ /\ " #_ !  _P 9 /\ )0#_ #$ _P ] /\ 1P#^ %$ ^P!9 /D 80#V
M &@ ] !N /, = #Q 'H [P"! .X AP#L (X Z@"6 .@ GP#F *D XP"U .(
MQ@#@ ., WP#X -T _P#= /\ U #_ ,D _P#" /\ O@#_ /\  P#_    _P
M /\  0#_  T _P 4 /T ( #Z "L ]P V /, 00#O $L [ !4 .@ 6P#F &(
MXP!H .$ ;@#? '0 W !Z -H @0#8 (@ U "0 -( F #/ *( S0"N ,L O #)
M -, QP#P ,8 _P#$ /\ Q #_ +L _P"V /\ LP#_ /\   #_    _P   /\
M  #W  @ \  0 .L &@#G "4 Y  P .$ .P#< $4 U0!- -$ 50#. %L RP!B
M ,D 9P#' &T Q0!S ,, >@#! ($ OP") +T D@"[ )P N0"G +< M0"U ,@
MLP#F +( ^P"Q /\ L #_ *X _P"J /\ IP#_ /\   #_    _@   /$   #E
M  ( W  - -, % #- !\ R@ J ,< - #$ #X P !' +P 3@"Z %4 MP!; +4
M80"S &< L@!M +  <P"N 'H K "" *H BP"H )4 IP"@ *4 K0"C +X H0#;
M *  ] "? /\ G@#_ )\ _P"= /\ FP#_ /\   #\    [@   .    #0
MQ0 ( +X $ "Y !D M0 C +, +@"P #< K0!  *H 2 "H $\ I0!5 *, 6P"B
M &  H !F )\ ; "= ', FP![ )H A "8 (X E@": )4 IP"3 +< D0#, )
M[ "/ /\ C@#_ (X _P". /\ CP#_ /P   #O    VP   ,D   "]    M0 "
M *X # "I !, I0 = *( )P"@ #$ G0 Z )H 0@"8 $D E@!/ )0 50"3 %L
MD0!@ )  9P". &T C0!U (L ?@") (D B "5 (8 H@"% +$ @P#$ ($ Y "
M /D ?P#_ (  _P"  /\ @ #_ /0"  #@"0  QP@  +<'  "L P  I@   *
M!P";  \ F  7 )4 (0"2 "H CP S (T / "+ $, B0!) (< 4 "& %4 A !;
M (, 80"! &@ @ !P 'X >0!\ (0 >P"0 'D G0!X *P =@"^ '4 W0!S /0
M<P#_ ', _P!S /\ <P#_ .D-  #/$   N1   *D0  ">#@  EPL  ),&  "0
M  L C  1 (D &@"& "0 @P N ($ -@!_ #X ?0!$ 'P 2P!Z %$ >0!7 '<
M70!V &0 = !L ',!=0!Q 8  ;P*- &X"F@!L ZH :P.[ &D$U@!H!O$ : ?_
M &<'_P!G!_\ 9P?_ -\4  ##%P  KA<  )X6  "3%0  BQ(  (80  "$# (
M@P8- ( #% !\!1X >0<H '<(, !U"#@ <PE  '()1@!P"DP ;PI3 &T+60!L
M"V$ :@MI &D,<@!G#'X 9@R+ &0-F0!B#:D 80V[ & -V !>#O, 70[_ %T.
M_P!=#O\ 70[_ -0<  "Y'0  I!X  )4=  ")'   @1H  'L7  !X$P  >! &
M '<-#P!S#A@ < XB &X/*P!L$#, :A [ &D00@!G$4D 9A%/ &015@!C$ET
M81)F & 2;P!>$GL 7!.( %L3EP!9$Z< 5Q2Z %84U0!5%?, 5!7_ %05_P!4
M%?\ 5!3_ ,HB  "P(@  G2,  (TC  "!(@  >2$  ',>  !O&P  ;A<  &T3
M# !J%!0 9Q4> &46)P!C%B\ 81<W & 7/@!>&$4 71A+ %P94@!:&5H 61EB
M %<:; !6&G< 5!J% %(;E !1&Z0 3QNW $X;T !-'/$ 3!S_ $P<_P!-'/\
M31O_ ,,F  "J)P  EB<  (<H  ![)P  <B8  &PD  !H(0  9AX  &0;" !B
M&Q$ 7QP: %T=(P!;'BL 6AXS %@?.@!7'T$ 5B!( %0@3P!3(%< 42%? % A
M:0!.(70 32&" $LBD0!)(J( 2"*T $<BS0!&(^\ 12/_ $4B_P!&(O\ 1B'_
M +PJ  "D*P  D2L  ((L  !V*P  ;2H  &8I  !B)@  7R0  %TB! !;(0X
M6"(6 %8C'P!4)"@ 4R0P %(E-P!0)3X 3R9% $XF3 !,)E0 2R=< $DG9@!(
M)W$ 1B=_ $4HCP!#**  02BR $ HRP _*.T /RC_ #\H_P! )_\ 0"?_ +<M
M  "?+@  C"\  'TO  !Q+P  :"X  &$M  !=*P  6B@  %<G  !4)PP 4B@3
M % I' !.*24 32HL $LJ- !**SL 22M" $@L20!&+%$ 12Q: $0L9 !"+6\
M0"U] #\MC0 ]+9X /"VP #HMR  Z+>L .BW_ #HM_P Z+/\ .BS_ +(P  ";
M,0  B#(  'DR  !M,@  9#(  %TQ  !8+P  52P  %$L  !/+0D 3"T1 $HN
M&0!)+R( 1R\J $8P,0!%,#@ 0S _ $(Q1P!!,4\ 0#%7 #XQ80 ],FT .S)[
M #DRBP X,IP -C*O #4RQP T,ND -#+_ #4Q_P U,?\ -3#_ *TS  "6-
MA#4  '4U  !I-0  8#4  %DT  !4,P  4#   $PQ  !),08 1S(/ $4S%@!#
M,Q\ 0C0G $ T+@ _-38 /C4] #TU1  \-DP .C95 #DV7P W-FL -C9X #0W
MB0 R-YH ,3>M "\WQ0 O-^@ +S;^ # U_P P-?\ ,#3_ *DV  "2-@  @#<
M '(X  !F.   73<  %8W  !0-@  2S0  $<U  !$-@, 03<- #\X%  ^.!P
M/#DD #LY+  Z.3, .3HZ #@Z0@ V.DH -3I3 #0[70 R.V@ ,#MV "\[AP M
M.YD +#NL "H[PP I.^8 *CK] "HZ_P K.?\ +#C_ *0X  "..0  ?#H  &XZ
M  !C.@  6CH  %,Z  !-.@  1C@  $(Z   _.P  /#P+ #H\$0 X/1D -STA
M #8^*0 T/C  ,SXW #(_/P Q/T< ,#]0 "X_6@ M0&8 *T!T "E A  H0)<
M)D"J "5 P0 D0.4 )#_\ "4^_P F/?\ )CW_ )\[  "*/   >#T  &H]  !?
M/0  5CT  $\]  !)/0  0CT  #P^   Y/P  -D$( #1!#P R0A8 ,4(> "]#
M)0 N0RT +4,T "Q$/  K1$0 *D1- "A$6  G16, )45Q "-%@@ B194 ($6H
M !]%OP >1., 'T3[ !]#_P @0O\ (4'_ )H^  "%/P  =$   &=   !<0
M4T   $Q   !&0   /D$  #A#   T10  ,$8# "U'#0 K2!( *D@: "E((@ H
M22D )TDQ "5).0 D24$ (TI* ")*50 @2F$ 'TIO !U*?P ;2I( &DJF !A*
MO0 72N  &$GZ !E(_P :1_\ &D?_ )5"  " 0@  <$,  &-#  !80P  4$,
M $E#  !"1   .T4  #5'   P20  *TL  "9-"0 D3A  (DX6 "%/'0 @3R4
M'T\L !Y/-0 =3ST '%!' !I040 94%T %U!K !90?  44(\ $U"D !%0N@ 1
M4-X $4_X !)._P 33?\ %$W_ (]%  ![1@  :T8  %]'  !51P  34<  $9'
M   _1P  -TH  #%,   K3@  )E   "!3 P <50P &E81 !E6&  75B  %E8G
M !56,  45CD $U=" !)730 15UD $%=H  ]7>0 .5XP #5>@  M7M@ +5M0
M"U;T  Q5_P -5/\ #E/_ (A)  !V2@  9TH  %M*  !12@  2DH  $-*   [
M3   ,TX  "Q1   F5   (58  !M9   57 < $5X- !!>$P 07AH #EXB  Y>
M*@ -7C, #%X]  M>2  *7E0 "%YB  =><P %7H8  UZ;  )>L0 "7<P  EWN
M  -<_P $6_\ !5O_ (%.  !P3@  8DX  %=.  !.3@  1TX  #Y/   V40
M+E0  "=7   A6@  &UT  !5@   08P, #&8+  AG$  &9Q4 !6<<  1G)  "
M9RT  6<W  !G0@  9TX  &=<  !G;0  9X   &:5  !FK   9<<  &7K  !D
M_   9/\  &/_ 'I2  !J4P  75(  %12  !+4@  0E,  #E5   P6   *%L
M "%?   :8@  %&4  !!H   ,:P$ !FX)  !O#@  ;Q(  &\8  !P'P  <"<
M '$P  !Q.P  <4@  '%6  !Q9@  <7D  '&/  !PIP  ;\$  &_G  !N_
M;?\  &W_ '-8  !E5P  6E<  %%6  !&5P  /%H  #)=   J80  (F0  !IH
M   4;   #F\   IR   $=@   '@%  !X"P  >0X  'H3  ![&0  ?"   'TI
M  !],P  ?4   'U.  !]7@  ?7(  'V(  !\H0  ?+H  'OB  !Z^@  >?\
M 'C_ &U=  !@7   5UP  $M=  ! 7P  -6,  "MG   C:P  &F\  !-S   .
M=P  "'L   )^    @@   (,!  "$!@  A0L  (8/  "($P  B1D  (HA  "+
M*P  BS<  (Q&  "+5@  BVD  (N   "+F0  BK,  (G8  "(]P  B/\  (?_
M &AC  !>8@  46(  $1E   X:0  +FX  "1S   :>   $WT   V!   &A0
M (D   "-    D    )(   "2    E 4  )4*  "7#@  F!(  )H8  ";(0
MG"T  )T\  "=3   G%\  )QV  ";D0  FZL  )K)  ":\   F?\  )C_ &5I
M  !7:0  26P  #UQ   P=@  )7P  !N!   2AP  #(P   21    E0   )D
M  "=    H    *$   "B    I    *4!  "G!P  J0P  *H1  "M&   KR(
M *\P  "O00  KU0  *]K  "NA0  KJ$  *Z^  "MY@  K/P  *S_ %YQ  !/
M=   0GD  #5_   HA0  '8P  !.2   ,F    YT   "B    I@   *H   "N
M    L    +$   "S    M    +8   "X    N@0  +P*  "^$   P1<  ,,D
M  ##-0  Q$D  ,1>  #%=P  Q9,  ,6O  #%T0  P_(  ,/_ %9\  !'@@
M.H@  "R/   @E@  %)T   VC   #J0   *X   "R    MP   +L   "_
MP@   ,(   #%    Q@   ,@   #*    S0   ,\   #2"   U0X  -L8  #=
M)P  WCH  -]0  #@:   X(0  .&A  #AO0  X>(  .#T $Z+  ! D@  ,ID
M "6A   8J   #J\   6U    N@   +\   #$    R    ,X   #1    U
M -4   #8    V@   -T   #?    X@   .0   #G    ZP4  .\.  #T&0
M]2L  /9!  #W6   ^'(  /F0  #YJP  ^,0  /CA /\ "P#_  @ _P ) /\
M# #_ !( _P : /\ )@#_ #( _P ^ /\ 2 #_ %( _P!: /\ 8@#_ &D _P!O
M /\ =0#^ 'L _ "! /L B #Y (\ ]P"7 /4 H #S *H \@"W .\ R0#M .8
M[ #[ .L _P#K /\ W0#_ ,X _P#& /\ P@#_ /\ ! #_    _P   /\ !0#_
M  T _P 5 /\ (0#_ "P _P X /\ 0P#] $P ^0!4 /< 7 #T &, \@!I /
M;P#N '4 [ ![ .H @@#H (D YP"1 .0 F@#B *0 X "P -T P #: -P V #T
M -4 _P#3 /\ RP#_ ,$ _P"[ /\ MP#_ /\   #_    _P   /\   #_  H
M_0 1 /D &P#V "< ]  R /  / #L $8 Z !. .0 5@#A %P W@!C -P : #9
M &X U0!T -( >P#0 (( S0"* ,L DP#( )T Q@"H ,0 MP#! ,P P #K +X
M_P"] /\ O0#_ +0 _P"N /\ JP#_ /\   #_    _P   /H   #R  4 Z@ .
M .4 %@#@ "$ W0 K -L -@#3 #\ S@!( ,H 3P#' %8 Q !< ,( 80#  &<
MO@!M +P <P"Z 'H N "" +8 BP"T )8 L@"A +  KP"N ,$ K0#@ *L ]P"J
M /\ J0#_ *8 _P"A /\ GP#_ /\   #_    ]P   .@   #<    T  * ,H
M$0#% !L P@ E +\ +P"\ #@ N !! +4 2 "R $\ L !5 *X 6P"L &$ J@!F
M *@ ; "G ', I0![ *, A "A (X GP": )T IP"; +@ F@#0 )D [P"8 /\
MEP#_ )8 _P"4 /\ D@#_ /\   #V    Y    -(   #%    NP % +4 #@"P
M !4 K  ? *H *0"H #( I0 Z *( 0@"@ $D G@!/ )P 50": %H F !@ )8
M9@"5 &P DP!T )( ?0"0 (< C@"3 (P H0"+ +  B@#% (@ Y@"' /L A@#_
M (< _P"' /\ A@#_ /@   #E    S0   +T   "S    J@   *, "@"? !$
MFP 9 )D (P"7 "P E0 T )( / "0 $, C@!) (P 3P"* %0 B0!: (< 8 "&
M &8 A !N (, =P"! ($ ?P"- 'X FP!\ *H >P"\ 'H VP!X /4 > #_ '@
M_P!X /\ > #_ .T   #1 @  NP(  *P!  "B    FP   )8 !0"1  T C0 4
M (L '0"( "8 A@ N (0 -@"" #T @ !# 'X 20!] $\ ? !5 'H 6P!Y &$
M=P!I '4 <0!T 'P <@"( '$ E@!O *4 ;@"V &T S@!L .X :P#_ &L _P!K
M /\ :P#_ -\+  #"#   K@P  )X,  "3"P  C <  (@"  "%  D @0 0 '\
M%P!\ "  >@ H '@ , !V #@ =  ^ ', 1 !Q $H < !0 &X 5@!M %T ; !D
M &H ;0!H '< 9P"$ &4 D@!D *$ 8P"R &$ R0!@ .D 8 #\ &  _P!@ /\
M8 #_ - 0  "V$0  HA(  ),2  "($0  @ \  'P-  !Y"0$ > ,+ '4 $0!S
M !H <  C &X!*P!L 3, :@(Y &D#0 !G T8 9@1, &4$4@!C!5D 8@5A & %
M:@!?!G0 70:! %P'CP!:!Y\ 60>P %<'Q@!6">< 5@K[ %4*_P!5"O\ 5@K_
M ,85  "M%P  F1@  (H8  !_%P  =A8  '$3  !N$   ;0T% &T)#0!J"10
M9PH= &4*)@!C"RX 8@PU & ,/ !?#$( 7@U( %P-3P!;#58 60U> %@.: !6
M#G, 50Z  %,.CP!1#I\ 4 ZQ $X.R !-$.H 31#] $T0_P!-$/\ 31#_ +P;
M  "E'   DAT  (,>  !W'0  ;QP  &D:  !F%P  9!0  &00" !B#Q  7Q 8
M %T0(0!;$2D 6A$Q %@2. !7$CX 5A)% %023 !3$U, 41-; % 390!.%'
M3!1] $L4C !)%)P 1Q6N $85Q0!%%>@ 11;^ $46_P!%%?\ 117_ +4?  ">
M(0  BR(  'PB  !Q(@  :"$  &(?  !?'0  7!H  %L7 @!:%0T 5Q84 %46
M'0!4%R4 4A@M %$8- !/&#L 3AE" $T92 !+&E  2AI8 $@:8@!'&FT 11MZ
M $,;B0!"&YH 0!NL #\;P@ ^'.4 /1S\ #X<_P ^&_\ /AO_ *\C  "8)
MAB4  '<F  !L)@  8R4  %TD  !9(@  5A\  %0=  !3' L 41P2 $X=&@!-
M'2( 2QXI $H>,0!)'S< 1Q\^ $8@10!%($T 0R!5 $(@7P! (6H /R%W #TA
MAP [(9@ .2&J #@BP  W(N, -R+[ #<B_P X(?\ ."'_ *HF  "4)P  @2D
M ',I  !G*0  7RD  %@H  !4)@  42,  $\B  !,(@< 2B(0 $@B%P!'(Q\
M120F $0D+@!")#0 024[ $ E0P _)4H /293 #PF7  Z)F< .29U #<GA  U
M)Y8 -">H #(GO@ Q)^$ ,2?Y #(F_P R)O\ ,R7_ *4I  "/*@  ?2P  &\L
M  !D+0  6RP  %4K  !0*@  3"@  $HF  !')P0 1"<- $(H% !!*!P /RDC
M #XI*P ]*3( /"HY #LJ0  Y*D@ ."M0 #8K6@ U*V4 ,RMR #$K@@ P+)0
M+BRG "PLO  K+-X +"SX "PK_P M*O\ +2K_ *$L  "++0  >2X  &LO  !@
M+P  6"\  %$N  !,+@  2"P  $4K  !!*P  /RP+ #TL$0 [+1D .BXA #DN
M*  W+B\ -B\V #4O/@ T+T4 ,R]. #$P6  P,&, +C!P "PP@  J,)( *3"E
M "<PN@ F,-P )C#W "<O_P H+_\ *"[_ )PN  "',   =C$  &@R  !=,@
M53(  $XQ  !(,0  1#   $ O   \,   .C$) #<Q$  V,A8 -3(> #,S)0 R
M,RP ,3,S # T.P O-$, +31, "PT5@ J-6$ *35N "<U?@ E-9  (S6C "(U
MN0 A-=D (33V "(T_P C,_\ (S+_ )@Q  "#,P  <C0  &4T  !:-0  434
M $LT  !%-   0#0  #HS   W-   -#4& #(V#@ P-Q, +S<; "XW(@ M."D
M*S@Q "HX.  I.4  *#E) "8Y4P E.5\ (SEL "$Z?  @.HX 'CJB !PZMP ;
M.=4 '#GU !TX_P =./\ 'C?_ ),T  !_-@  ;C<  &$W  !7-P  3C<  $@W
M  !"-P  /#<  #4X   R.0  +SH" "P["P J/!$ *3P8 "@]'P F/28 )3TN
M "0]-0 C/CT (CY& " ^4  ?/EP '3]I !L_>0 :/XP &#^@ !8_M0 5/M(
M%C[S !<]_P 8//\ &#S_ (XW  !Z.   :CD  %XZ  !3.@  2SH  $4Z   _
M.@  .3H  #(\   N/@  *4   "9!"  D0@X (D(4 "%"&P @0R, 'T,J !Y#
M,@ <0SH &T1# !I$30 81%D %T1G !5$=P 31(H $D2> !%$LP 01-  $$/R
M !%"_P 20O\ $T'_ (D[  !V/   9CT  %H]  !0/0  2#T  $(]   \/0
M-CX  "]    J0@  )40  "%& P =2 P &TD1 !E)%P 821X %TDF !9)+@ 5
M2C8 %$I  !-*2@ 12E8 $$ID  ]*=  .2H< #4J;  Q*L  *2LH "TGL  Q(
M_P -1_\ #4?_ (,^  !Q/P  8D   %9   !-0   14   #]    Y00  ,D(
M "M%   F1P  (4D  !Q+   63@< $U . !)0$P 14!D $% A  ]0*0 .4#$
M#5 [  U11@ +45$ "E%?  E1;P '4($ !5"6  -0JP "4,4  T_H  -/^P %
M3O\ !DW_ 'U"  !K0P  740  %)$  !*1   0T,  #Q$   U10  +D<  "=*
M   A3   '$\  !=1   25 , #E<*  M8$  *6!4 "%@<  =8)  &6"P !5@V
M  -80  !6$P  %A:  !8:0  6'P  %B1  !7IP  5\   %;E  !6^0  5?\
M %7_ '9'  !F1P  64@  $]'  !'1P  0$<  #A(   P2@  *4T  ")0   <
M4P  %E4  !%8   -6P( "5X)  1?#@  7Q(  %\8  !@'P  8"<  & P  !@
M.P  8$<  &!4  !@8P  8'8  &"+  !?H@  7[L  %_B  !>^0  7?\  %W_
M &]+  !A3   54P  $Q+  !$2P  .TP  #).   K40  (U0  !Q7   66P
M$5X   U@   (8P   F8'  !G#   9P\  &@3  !I&0  :B$  &HI  !J-
M:D   &I-  !J70  :F\  &J%  !JG0  :;8  &C=  !H]P  9_\  &;_ &E1
M  !<4   4E   $I/   _4   -5,  "U6   D60  '5T  !9@   09   #&<
M  9J    ;@   &\#  !P"   <0T  '(0  !T%   =1L  '8C  !W+   =S@
M '9&  !V5@  =F@  '9^  !VEP  =;$  '33  !S]0  <_\  '+_ &-6  !8
M50  4%0  $15   Y6   +UL  "9?   =8P  %6<  !!L   *<   !',   !V
M    >@   'P   !\ P  ?@@  '\,  "!$   @A0  (0;  "%)   AB\  (8]
M  "&30  A5\  (5U  "%CP  A*D  (/)  ""\0  @?\  (#_ %];  !66@
M25L  #U>   R80  )V8  !YK   5<   #G4   EY   !?@   ($   "%
MB    (H   "+    C0$  (X&  "0"P  D0\  ),4  "5&P  ER8  )<T  "7
M1   EU8  )9L  "5A@  E:(  )3!  "3Z@  DO\  )+_ %UA  !/80  0F0
M #9I   J;@  'W0  !5Y   .?P  !X0   ")    C@   )(   "6    F
M )H   ";    G0   )\   "A P  HP@  *4-  "G$P  J1P  *HH  "J.0
MJDL  *IA  "I>@  J)D  *BU  "GW0  I_@  *;_ %9H  !(;   .G   "YV
M   B?0  %X0   Z*   'D    )8   ":    GP   *,   "G    J@   *L
M  "M    KP   +$   "S    M0   +@%  "Z#   O1(  , <  # +0  P$
M +]5  "_;@  OHL  +ZH  "^R0  O>\  +S^ $YT  ! >0  ,G\  "6'   9
MC@  $)4   ><    H@   *<   "L    L    +4   "Y    O    +T   "_
M    P0   ,,   #&    R    ,H   #- @  T L  -42  #6(0  US0  -A)
M  #98   VGP  -J:  #;M0  V]D  -OR $:"   XB0  *Y   !V8   2H
M"J<   "N    M    +D   "^    P@   ,@   #+    S@   ,\   #2
MU    -8   #:    W0   -\   #B    Y@   .H*  #O$P  \"4  /(Z  #S
M40  ]&L  /2)  #UI0  ];\  /7= /\ !@#_  , _P % /\ "P#_ !  _P 7
M /\ (@#_ "T _P Y /\ 1 #_ $T _P!5 /\ 70#_ &0 _P!J /\ < #] '8
M^P!\ /D @P#W (H ]0"2 /, FP#P *8 [@"S .L Q #I .0 YP#Y .8 _P#E
M /\ TP#_ ,< _P"_ /\ NP#_ /\   #_    _P   /\  @#_  L _P 2 /\
M'0#_ "@ _P S /\ /@#\ $< ^ !/ /0 5P#Q %T [@!C .P :0#J &\ Z !U
M .8 ? #D (, X@"+ -\ E0#< )\ V0"K -4 NP#2 -0 SP#R ,T _P#, /\
MQ0#_ +H _P"T /\ L #_ /\   #_    _P   /\   #_  8 ^0 / /4 %P#S
M "( \0 M .T -P#G $  X@!) -\ 4 #; %< UP!= -0 8P#1 &@ SP!N ,P
M=0#* 'P R "$ ,4 C0#" )@ P "D +T L@"[ ,8 N0#H +@ _0"W /\ M@#_
M *T _P"G /\ HP#_ /\   #_    _P   /4   #K  $ Y  , -X $P#9 !P
MTP F -$ , #, #H R !" ,0 2@#  %  O0!6 +L 7 "Y &$ MP!G +4 ;0"S
M '0 L0!\ *\ A0"M )  J@"< *@ J@"F +L I0#: *, ]0"C /\ H@#_ )X
M_P": /\ EP#_ /\   #^    [P   -\   #0    QP ' ,$ #P"\ !< N0 @
M +< *@"U #, L  [ *T 0P"K $D J !/ *8 50"D %H HP!@ *$ 9@"? &T
MG0!T )P ?0": (@ F "4 )8 H@"4 +( D@#) )$ ZP"1 /\ D #_ )  _P",
M /\ B@#_ /P   #L    V0   ,<   "Z    L0 " *L # "G !( I  ; *$
M) "@ "P G@ U )L / "8 $, E@!) )0 3P"2 %0 D !: (\ 7P"- &8 BP!M
M (D =@"( (  A@", (0 F@"" *H @0"^ (  X "  /D ?P#_ '\ _P!_ /\
M?@#_ /$   #8    P@   +,   "H    H    )D !P"5  X D@ 5 )  '@".
M "8 C0 N (H -@"' #T A0!# (0 20"" $X @0!4 '\ 60!^ &  ? !G 'H
M;P!Y 'H =P"& '4 E !T *, <@"U '( SP!Q /$ < #_ '  _P!P /\ <0#_
M .$   #$    L    *(   "7    D0   (L  @"&  L @P 1 ($ & !_ "$
M?0 I 'P , !Y #< >  ] '8 0P!T $D <P!. '( 5 !P %H ;P!B &T :@!K
M '0 :@"  &@ C@!G )T 90"O &4 Q@!D .@ 9 #] &, _P!C /\ 9 #_ ,\%
M  "V!P  HP@  )0(  ")!P  @@,  'X   ![  8 =P . '4 $P!R !L <0 C
M &\ *P!M #( ;  X &H /@!I $0 9P!) &8 3P!E %8 8P!= &( 90!@ &\
M7P![ %T B0!< )D 6P"J %D OP!9 .$ 6 #X %@ _P!8 /\ 60#_ ,(,  "J
M#0  EPX  (D.  !]#@  =@T  '$*  !O!@  ;0 * &L $ !I !8 9P > &4
M)@!C "T 80 S &  .0!? #\ 70!% %P 2P!; %( 6@!9 %@ 8@!7 &P 50!X
M %, A@!2 )8 40"G %  NP!/ =L 3@+T $X#_P!.!/\ 3@/_ +@0  "A$@
MCA,  '\3  !T$P  ;!(  &<0  !E#@  8PL# &,&# !A!!$ 7@,9 %P$(0!;
M!2@ 608O %@&-0!6!SL 50=" %0'2 !3"$\ 40A6 % )7P!."6D 30EV $L*
MA !)"I0 2 JF $<*N@!&"M@ 10OS $4,_P!%#/\ 10S_ + 4  "9%@  AQ@
M '@9  !M&   91<  %\6  !<$P  6A$  %H.!@!:# T 5PP4 %4,' !3#20
M4@TK % -,0!/#C@ 3@X^ $T.10!+#DT 2@Y5 $@/7@!'#V@ 10]U $,0A !!
M$)4 0!"F #X0NP ]$-P /1'V #T1_P ]$/\ /A#_ *D9  "2&P  @1P  '(=
M  !G'0  7QP  %D;  !5&0  4Q8  %(3  !2$0H 4! 0 $X1& !,$2  2A(G
M $D2+@!($S0 1Q,[ $430@!$$TD 0Q12 $$46P _%&4 /A5R #P5@0 Z%9(
M.!6D #<5N0 U%=@ -1;U #86_P V%O\ -Q7_ *,<  "-'@  >R   &TA  !B
M(0  6B$  %0?  !0'@  31L  $P9  !+%@8 218. $<7%0!%%QP 1!@D $(8
M*@!!&#$ 0!DX #\9/P ]&48 /!I/ #H:6  Y&F, -QMO #4;?@ S&Y  ,ANB
M # ;MP O&], +QSS "\;_P P&_\ ,!O_ )T?  "((@  =R,  &DD  !>)
M5B0  % C  !+(@  2"   $8=  !%' ( 0QP, $$<$@ _'1D /ATA #P>)P [
M'BX .A\U #D?/  W'T0 -A], #0@5@ S(&  ,2!M "\@?  M(8X +"&@ "HA
MM0 I(=  *2'R "DA_P J(/\ *R#_ )DB  "$)0  <R8  &4G  !;)P  4R<
M $PF  !')0  1"0  $(A   _(0  /2$) #LA$  Y(A8 ."(> #8C)0 U(RL
M-"0R #,D.0 R)$$ ,"1* "\E4P M)5X *R5K "HE>@ H)8P )B6? "0ELP C
M)<X (R7P "0E_P E)/\ )23_ )0E  " )P  ;RD  &(J  !7*@  3RH  $DI
M  !$*   0"<  #TF   Z)0  -R8& #4F#@ T)Q0 ,B<; #$H(@ P*"D +R@P
M "TI-P L*3\ *RE' "DI40 H*EP )BII "0J>  C*HH (2J= !\JL@ >*LP
M'BKO !\I_P @*?\ (2C_ ) H  !\*@  ;"L  %\L  !4+   3"P  $8L  !!
M*P  /"L  #@J   U*@  ,BL# # K#  N+!$ +2P8 "PL'P J+28 *2TM "@M
M-  G+CP )BY% "0N3P C+EH (2]G !\O=@ =+X@ '"^; !HOL  8+\H &"[M
M !DN_P ;+?\ &RW_ (PK  !X+0  :"X  %LO  !1+P  22\  $,O   ^+@
M.2X  #0N   P+@  +2\  "LP"@ I,1  )S$5 "8Q'  E,B, )#(J ",R,0 A
M,SD (#-" !\S3  =,U< &S-D !HT=  8-(8 %C2: !0SK@ 3,\@ $S/L !0S
M_P 5,O\ %C'_ (<N  !T+P  93$  %@Q  !.,@  1C(  $ Q   [,0  -C$
M #$Q   K,P  *#0  "4U!@ C-@T (382 " W&0 ?-R  'C<G !TX+@ ;.#8
M&C@_ !DX20 7.54 %3EB !0Y<0 2.80 $3F8 ! YK0 ..,< #CCK ! X_P 0
M-_\ $3;_ (,Q  !P,@  830  %4T  !+-   1#0  #TT   X-   ,S0  "TU
M   H-P  )#D  " Z @ =.PL &SP0 !D]%0 8/1P %STC !8]*P 5/C, %#X\
M !(^1@ 1/E( $#Y?  \^;P ./H$ ##Z5  L^J0 */L$ "CWD  L]^P ,//\
M#3O_ 'TT  !K-@  73<  %$W  !(-P  03<  #LW   U-P  ,#<  "HY   E
M.P  (#T  !P_   7008 %$,- !)#$@ 10Q@ $4,? !!$)P /1"\ #D0Y  U$
M0P ,1$X "T1;  E$:@ '1'P !D20  1#I0 "0[T  T/@  -#]@ $0O\ !D'_
M '@X  !G.0  63H  $XZ  !%.@  /CH  #@Z   S.@  +3L  "<]   A0
M'$(  !=$   31@, #TD*  U*#P ,2A0 "TH;  E*(P (2BL !THT  5*/@ $
M2DD  DI6  !*90  2G<  $J+  !*H0  2;D  $G=  !)]0  2/\  $C_ '(\
M  !B/0  53X  $H^  !"/0  /#T  #8]   O/@  *4   "-"   =10  %T<
M !-*   /3 ( "T\)  =0#0 #41$  %$7  !1'@  428  %$O  !1.0  440
M %)1  !28   47(  %&'  !1G0  4;4  %#8  !0]0  3_\  $__ &Q   !=
M00  44$  $=!  ! 0   .4   #)!   J0P  )$8  !Y(   72P  $DX   Y1
M   +4P$ !E8'  !7#   6!   %@3  !9&0  6B$  %HI  !:,P  6C\  %I,
M  !:6@  6FP  %J!  !9F0  6;$  %C1  !8]   5_\  %?_ &5%  !810
M344  $5$   ^1   -44  "U'   E2@  'DT  !A0   24P  #E8   I9   $
M7    %X$  !?"0  8 T  &$0  !B%0  8QL  &0C  !D+0  9#@  &1%  !D
M5   9&8  &1[  !CDP  8ZT  &+,  !A\@  8?\  &#_ %]*  !32@  2DD
M $-(   Y20  +TP  "=/   ?4@  &%4  !)9   -70  "&    )C    9@
M &@!  !I!0  :@H  &L-  !M$0  ;A8  ' =  !Q)@  <3$  ' ^  !P3@
M<%\  '!S  !OC0  ;Z<  &[&  !M[P  ;/\  &S_ %I/  !03@  2$T  #U.
M   S40  *50  "!8   87   $6    QD   &:    &L   !O    <@   '0
M  !U    =P0  '@)  !Z#0  ?!   'T6  !_'@  @"@  ( U  " 10  ?U8
M ']K  !_A   ?J   'V^  !\Z0  >_\  'K_ %94  !.4P  0E0  #=6   L
M6@  (E\  !AC   1:   "VT   -R    =@   'H   !]    @    (,   "$
M    A@   (<"  ")!P  BPP  (T0  "0%@  DA\  )(L  "2.P  DDT  )%B
M  "1>@  CY<  (^T  ".X0  C/L  (S_ %59  !(6@  .UT  "]A   D9@
M&6P  !%R   *=P   GT   ""    A@   (L   ".    D0   ),   "5
MEP   )D   ";    G00  )\*  "B#P  I!8  *8A  "F,0  ID,  *57  "D
M<   HXX  *.K  "AT   H/4  )__ $YA  ! 9   ,VD  "=N   ;=0  $7P
M  N#    B0   (X   "3    F    )T   "A    I    *4   "G    J0
M *L   "M    L    +(   "U"   N X  +P6  "\)0  O#<  +M,  "Z9
MN8$  +>B  "WP   M^H  +?\ $9K   Y<   *W<  !]_   3A@  "XX   &5
M    FP   *$   "F    JP   +    "S    MP   +<   "Z    O    +\
M  #!    Q    ,<   #*    S04  -$.  #4&0  U"L  -1   #36   TW0
M -.2  #2L   TM,  -+R #YY   Q@   (X@  !>1   -F0   Z    "G
MK@   +,   "X    O0   ,(   #&    R@   ,H   #-    SP   -(   #5
M    V0   -T   #?    XP   .<%  #K#P  [!\  .TS  #N2P  [V0  .^"
M  #PGP  \;D  /'8 /\   #_    _P $ /\ "0#_  X _P 5 /\ '@#_ "D
M_P T /\ /P#_ $@ _P!0 /\ 6 #_ %X _P!E /T :P#[ '$ ^0!W /@ ?@#V
M (4 \P"- /$ EP#N *( ZP"O .@ P #F .  XP#X .( _P#; /\ RP#_ ,$
M_P"Y /\ M #_ /\   #_    _P   /\   #_  D _P 0 /\ &0#_ ", _P N
M /T .0#Y $( ]0!* /( 4@#N %@ ZP!> .D 9 #F &H Y !P .( =@#? 'T
MW0"& -D CP#5 )H T0"G ,X M@#+ ,X R0#P ,< _P#% /\ NP#_ +0 _P"M
M /\ J0#_ /\   #_    _P   /\   #[  ( ]@ - /$ $P#M !X [  H .D
M,@#C #L W0!$ -@ 2P#3 %$ T !8 ,T 70#+ &, R0!H ,8 ;P#$ '8 P@!^
M +\ AP"\ )( N@"? +< K0"U ,$ L@#D +$ _0"O /\ K #_ *4 _P"@ /\
MG #_ /\   #_    ^P   .X   #D    W  ( -, $ #/ !@ RP B ,D *P#&
M #0 P0 ] +T 1 "Z $L MP!1 +4 5@"R %P L !A *X 9P"L &X J@!V *@
M?P"F (H HP"6 *$ I0"? +8 G0#1 )P \P"; /\ G #_ )8 _P"3 /\ D #_
M /\   #V    YP   -,   #&    O0 # +@ #0"S !, L0 < *\ )0"N "X
MJ0 V *8 /0"C $0 H0!* )\ 3P"= %4 FP!: )H 8 "8 &8 E@!N )0 =P"2
M ($ D ". (X G ", *T B@## (D Z "( /\ B0#_ (< _P"% /\ @@#_ /,
M  #C    S    +P   "P    IP   *$ " ">  \ FP 6 )D 'P"8 "< E@ O
M ), -P"1 #T C@!# (P 20"+ $X B0!4 (< 60"% &  A !G (( ;P"  'H
M?@"& 'P E !Z *0 >0"X '@ V !W /< > #_ '@ _P!W /\ =0#_ .8   #+
M    MP   *@   ">    E@   (\ ! "+  P B  2 (< &0"% "$ A  I ((
M, !_ #< ?0 ] 'P 0P!Z $@ >0!- '< 4P!V %D = !A '( :0!Q ', ;P!_
M &T C0!L )T :@"O &D R !H .T :0#_ &D _P!I /\ :0#_ -(   "X
MI0   )<   "-    A@   ($   !\  @ >0 . '< % !V !P =  C ', *P!Q
M #$ ;P W &X /0!L $, :P!( &H 3@!H %0 9P!; &4 8P!C &T 8@!X &
MAP!? )8 70"H %T O@!< .0 7 #[ %P _P!< /\ 7 #_ ,(   "J 0  F ,
M (D$  !_ @  >    '0   !P  0 ;0 , &L $0!I !< :  > &8 )0!E "P
M8P R &( . !@ #T 7P!# %X 20!< $\ 6P!6 %H 7@!8 &@ 5P!S %4 @0!4
M )$ 4@"C %$ MP!1 -8 40#U %$ _P!1 /\ 4@#_ +8'  "?"0  C0L  'X,
M  !S"P  ; H  &@'  !E P  8P ' &$ #0!? !, 70 : %P (0!; "< 60 M
M %@ ,P!6 #D 50 _ %0 10!3 $L 40!2 %  6@!/ &0 30!O $P ?0!* (T
M20"? $@ L@!' ,P 1P#O $8 _P!' /\ 1P#_ *P,  "5#@  @Q   '40  !K
M$   8P\  %X.  !;#   6@D" %D$"@!7  \ 50 5 %, ' !2 ", 40 I $\
M+P!. #4 30$[ $P!00!* D@ 20)/ $@"5P!& V$ 10-M $,#>@!" XL 0 .<
M #\#KP ^ \@ /03J #T%_  ]!O\ /@;_ *00  ".$@  ?!,  &X4  !D%
M7!,  %82  !3$0  40X  % ,!0!0"0P 3P<1 $T'%P!+"!\ 20@E $@)*P!'
M"3$ 1@DX $0*/@!#"D4 0@I- $ +50 _"U\ /0MK #P+>0 Z#(H . R< #<,
MKP U#,< -0SI #4-_0 U#?\ -@S_ )T3  "'%0  =A<  &D8  !>&   5A@
M % 7  !-%0  2A,  $D1  !)#@< 2 T. $8-$P!$#1H 0PXA $(.* ! #BX
M/PXU #X//  ]#T, .Q!+ #H05  X$%X -A!K #00>0 R$(H ,1"< "\0L  M
M$,D +1'L "T1_P N$?\ +Q#_ )<6  ""&0  <1L  &0<  !9'   41P  $P;
M  !'&@  1!@  $,5  !"$P( 01(+ $ 1$  ^$A< /!(> #L3)0 Z$RL .!,R
M #<3.0 V%$  -!1( #,440 Q%%P ,!5H "X5=P L%8@ *A6: "@5K@ G%<<
M)A7J "<5_P H%?\ *17_ )$:  !]'   ;1X  & ?  !6'P  3A\  $@>  !#
M'0  0!P  #X:   ]&   .Q<' #D6#@ X%Q0 -A<; #48(@ S&"@ ,A@O #$9
M-@ P&3T +AE& "T:3P K&ED *AIF "@:=  F&H8 )!J9 "(:K0 A&L4 (!KH
M "$:_@ B&O\ (QK_ (T=  !Y'P  :2$  %PB  !2(@  2B(  $0A   _(0
M/"   #D>   X&P  -1P$ #0<#0 R'!( ,!T8 "\='P N'24 +1XL "L>,P J
M'CL *1]# "<?30 F'U< )!]D "(?<@ @'X0 'Q^7 !T?JP ;'\, &Q_G !L?
M_0 ='_\ 'A[_ (D@  !U(@  92,  %DD  !/)0  1R4  $$D   \(P  .",
M #4B   S(   ," ! "XA"@ L(1  *R$5 "HB'  H(B, )R(I "8C,  E(S@
M(R-! "(D2@ A)%4 'R1A !TD<  ;)(( &225 !<DJ@ 6),$ %23E !8D_  7
M(_\ &2/_ (4B  !Q)   8B8  %8G  !,)P  1"<  #XG   Y)@  -28  #$E
M   N)   *R4  "DE!P G)@X )283 "0G&0 C)R  (B<G "$H+@ @*#8 'B@^
M !TH2  ;*5, &2E? !@I;@ 6*8  %"F4 !(IJ  1*<  $2CD !$H^P 3*/\
M%"?_ ( E  !N)P  7R@  %,I  !)*@  0BD  #LI   V*0  ,B@  "XH   J
M*   )BD  "0J!  B*PP ("L1 !\L%@ =+!T '"PD !LM*P :+3, &"T\ !<M
M10 6+E  %"Y= !(N;  1+GX $"Z2  XNIP -+;T #2W?  TM^0 .+/\ $"S_
M 'PH  !J*@  6RL  % L  !&+   /RP  #DL   T*P  +RL  "LK   F+
M(BX  !\O   <, D &C$. !DQ$P 7,1H %C(A !4R*  4,C  $S(Y !(S0P 1
M,TX $#-;  XS:0 -,WH ##..  HSH@ (,KD "#+9  @R]  *,?\ "S'_ '<K
M  !F+0  6"X  $TO  !#+P  /"X  #8N   Q+@  +2X  "DN   C,   'S(
M !LS   7-04 %#8, !(W$0 1-Q8 $3<= ! X)  /."P #C@U  TX/P ,.$H
M"SA7  DX90 '.'8 !3B*  ,XGP !-[4  3?3  (W\0 #-O\ !3;_ ',N  !B
M,   5#$  $DQ  !!,0  .3$  #0Q   O,   *S   "4R   @,P  &S8  !<X
M   3.@( $#P)  T]#@ ,/1, "ST9  H](0 )/2D "#TQ  8^.P %/D8  SY2
M  $^80  /G(  #Z&   ]G   /;(  #W0   \\   //\  #S_ &TR  !=,P
M4#0  $8T   ^-   -S0  #(S   M,P  )S0  "(V   =.   &#H  !0]   0
M/P( #4$(  E##0 &1!$  T06  )$'0  1"0  $0M  !$-@  1$$  $1.  !$
M7   1&T  $2!  !$F   0Z\  $/-  !"\   0O\  $+_ &@V  !8-P  3#@
M $,X   [-P  -38  # V   I-P  (SD  !X[   8/0  $T   !!"   -10$
M"$<'  -)#   20\  $H3  !+&0  2R   $LH  !+,@  2ST  $Q)  !,5P
M2V@  $M]  !+E   2JP  $K*  !)[P  2?\  $G_ &(Z  !4.P  23L  $ [
M   Y.@  ,SD  "PZ   E/   'S\  !E!   31   $$<   Q)   (3    D\%
M  !0"@  4 T  %$0  !2%0  5!L  %0C  !4+   5#<  %1$  !44@  5&,
M %1W  !4CP  4Z@  %+&  !2[0  4?\  %'_ %P_  !//P  13\  #X^   W
M/0  +SX  "=    @0P  &48  !-)   /3   "T\   92    5    %<"  !8
M!P  60L  %H.  !;$0  718  %X=  !?)@  7S$  %X]  !>3   7ET  %YQ
M  !=B0  7:,  %S!  !;ZP  6O\  %K_ %9$  !+0P  0T(  #Q!   R0@
M*44  "%(   :2P  $TX   Y2   *50   UD   !;    7@   &    !B @
M8P8  &4*  !F#@  :!$  &H7  !K'P  :RD  &LV  !K10  :U8  &IJ  !J
M@@  :9T  &B[  !GYP  9O\  &7_ %%(  !(2   048  #='   L2@  (TT
M !M1   350  #ED   A=   !80   &0   !G    :@   &P   !N    <
M '(%  !S"0  =0T  '<1  !Z&   >R$  'LN  !Z/0  >DX  'EB  !Y>0
M>)8  '>S  !UX   =/P  '/_ $Y-  !'3   .TT  #!/   F4P  '%@  !-<
M   -80  !F8   !J    ;P   '(   !V    >0   'P   !]    ?P   ($
M  "# @  A@<  (@,  "+$0  CA@  (XD  ".,P  C40  (Q8  "+;P  BHP
M (FJ  "(SP  AO<  (7_ $U1  !!4P  -%4  "E:   >7P  %&4   UJ   %
M<    '8   ![    ?P   (,   "'    B@   (T   ".    D0   ),   "5
M    F    )H%  "=#   H!$  *,:  "C*   HCH  *%.  "@90  H($  )Z@
M  "=P0  F^X  )K_ $99   Y7   +6$  "%G   6;@  #G4   5[    @0
M (<   "-    D@   )8   ":    G0   )\   "A    I    *8   "H
MJP   *X   "Q P  M L  +@1  "Y'@  N2\  +A#  "W6@  M78  +27  "T
MM0  L>(  +#\ #]D   Q:0  )6\  !AW   /?P  !H<   ".    E    )H
M  "@    I0   *H   "N    L0   +(   "U    MP   +H   "\    OP
M ,,   #&    R0   ,X*  #2$P  TB,  -$W  #03P  SFH  ,V*  #*JP
MR\L  ,OO #=Q   I>   '8   !&)   (D0   )H   "A    IP   *T   "S
M    N0   +X   #"    Q0   ,8   #)    S    ,X   #2    U0   -H
M  #>    X0   .4   #J"P  ZQ<  .HK  #J0P  ZEX  .IZ  #KF0  Z[4
M .O5 /\   #_    _P ! /\ !P#_  T _P 2 /\ &P#_ "4 _P O /\ .@#_
M $, _P!+ /\ 4P#_ %H _0!@ /L 9@#Z &L ^ !R /8 > #T (  \0") .\
MD@#L )T Z0"J .8 O #C -P WP#W -T _P#, /\ O@#_ +4 _P"P /\ K0#_
M /\   #_    _P   /\   #_  8 _P - /\ % #_ !\ _P I /L ,P#W #T
M\P!% .\ 30#L %, Z !9 .4 7P#C &4 X !J -T <0#: '@ U@"  -( B@#/
M )4 S "B ,@ L@#% ,D P@#M ,  _P"[ /\ L #_ *@ _P"D /\ H0#_ /\
M  #_    _0   /H   #X    \  ) .P $0#H !D YP C .4 +0#> #8 U@ ^
M -$ 1@#- $P R@!2 ,@ 6 #% %T PP!C ,  :0"^ '  O !X +D @0"W (T
MM ": +$ J0"N +P K #A *H _ "H /\ H #_ )D _P"6 /\ E #_ /\   #Y
M    \@   .<   #;    T0 $ ,H #0#' !0 Q  = ,( )@"_ "\ NP W +<
M/P"T $4 L0!+ *X 40"L %8 J@!< *@ 80"F &@ HP!P *$ >0"? (0 G0"1
M )H H "8 +$ E@#, )4 \0"4 /\ D0#_ (L _P"( /\ A@#_ /<   #L
MW@   ,D   "\    M    *\ "@"K !  J0 7 *@ ( "G "@ H@ P )\ . "<
M #X F@!$ )@ 2@"6 $\ E !5 ), 6@"1 &$ CP!H (T <0"+ 'L B0"( (<
MEP"% *@ @P"^ ($ Y "  /\ @ #_ 'P _P![ /\ >0#_ .D   #7    P0
M +$   "F    G0   )< !0"4  T D@ 2 )  &@"/ "( C@ J (L ,0") #@
MAP ^ (4 0P"# $@ @0!. '\ 5 !^ %H ? !A 'H :0!X ', =@!_ '4 C@!S
M )\ <0"S '  T !O /8 ;P#_ &\ _P!M /\ ; #_ -H   "_    K    )X
M  "3    C    (4   ""  D ?P / 'X %0!] !P ?  D 'H *P!W #$ =0 W
M '0 /0!R $( <0!( &\ 30!N %, ; !: &L 8@!I &P 9P!X &8 A@!D )<
M8@"J &$ P@!@ .L 80#_ &$ _P!A /\ 8 #_ ,4   "M    FP   (T   "#
M    ?    '<   !R  4 <  , &X $0!L !< ;  > &L )0!I "P 9P Q &8
M-P!D #T 8P!" &( 2 !@ $X 7P!5 %T 70!< &8 6@!R %D @ !7 )  5@"C
M %4 N0!4 -X 5 #[ %0 _P!5 /\ 50#_ +8   "?    C0   '\   !U
M;@   &D   !F  $ 8P ) &$ #@!@ !, 7P 9 %X ( != "8 6P L %H ,@!8
M #< 5P ] %8 0P!5 $D 4P!0 %( 6 !1 &$ 3P!L $X >@!, (H 2P"< $H
ML0!) ,X 20#S $D _P!) /\ 2@#_ *H!  "4!0  @@<  '0(  !J"   8P8
M %X$  !;    60 % %< # !6 !  5  5 %, &P!2 "( 40 H %  +0!. #,
M30 X $P /@!+ $4 2@!, $@ 5 !' %T 1@!H $0 =0!# (4 00"8 $  JP!
M ,4 /P#J #\ _P!  /\ 0 #_ * (  "*"P  >0T  &P-  !A#0  6@T  %4+
M  !2"0  4 8  $\"" !.  T 3  2 $L %P!* !X 20 C $< *0!& "\ 10 T
M $0 .@!" $$ 00!( $  4  ^ %H /0!D #P <@ Z (( .0"4 #@ IP W +X
M-@#C #8 ^0 V /\ -P#_ )@-  "##@  <A   &41  !;$0  4Q   $X0  !*
M#@  2 T  $<* P!'!PH 100. $0"$P!" AH 00(@ $ #)0 ^ RL /00Q #P$
M-P [!#X .@5% #D%3@ W!5< -@5B #0&<  R!H  ,0:2 # &I0 O!;L +@7=
M "X&]0 M!_\ +@?_ )$0  !]$0  ;!,  %\4  !5%   3A0  $@3  !$$@
M01   $ .  ! #08 0 H, #X)$  \"18 .PH< #D*(@ X"B@ -PLN #8+-0 U
M"SL ,PM# #(,3  P#%8 +PQA "T,;P K#'\ *@R2 "@,I0 G#+L )0S= "4-
M]0 F#?\ )PW_ (L2  !W%   9Q8  %L7  !1&   21<  $,7   _%0  /!0
M #H2   Y$0$ .0\( #@.#0 W#A( -0X8 #0.'P R#B4 ,0\L # /,@ O$#H
M+1!" "P02P J$%4 *!!A "80;P D$(  (Q"3 "$0IP ?$+T 'A#@ !X1]P ?
M$/\ (!#_ (84  !S%P  8QD  %<:  !-&P  11H  $ :   [&0  .!@  #46
M   T%   ,Q($ #(2"P Q$A  +Q(5 "T2'  L$R( *Q,I "H3,  H$S< )Q0_
M "842  D%%, (A1? " 5;0 ?%7X '161 !L5I0 9%;L &!7> !@5^  9%/\
M&A3_ ((7  !O&@  7QP  %,=  !*'0  0AT  #P=   W'   -!L  #$:   O
M&0  +A8  "P7"  K%@X *1<3 "@7&0 G&"  )1@F "08+0 C&#0 (AD] " 9
M1@ >&5$ '1E= !L::P 9&GP %QJ/ !4:HP 4&;H $AG; !,9]@ 4&?\ %1C_
M 'T:  !K'0  7!\  % @  !'(   /R   #D?   T'P  ,1X  "T=   K'
M*1L  "<;!0 E&PP )!P1 "(<%@ A'!T (!TC !\=*@ >'3( '!XZ !L>1  9
M'DX %QY; !8>:0 4'WH $AZ- !$>H@ 0'K@ #A[8  \>]0 0'?\ $1W_ 'H=
M  !G'P  62$  $TB  !$(@  /"(  #8B   R(0  +B$  "H@   G(   )!\
M "(@ @ @( H 'B$/ !TA%  <(1H &R(A !DB)P 8(B\ %R(X !4C00 4(TP
M$B-8 !$C9P 0(W@ #B.+  TCGP ,([0 "R/0  LB\  ,(O\ #2'_ '8?  !D
M(@  5B,  $LD  !!)   .B0  #0D   O(P  *R,  "@C   D(P  (",  !TD
M   ;)0< &28- !<F$0 6)A< %2<> !0G)0 3)RP $B<U !$H/P 0*$H #BA6
M  TH9  ,*'0 "BB'  DHFP ')[$ !2?,  8G[  ')OX "";_ '$B  !@)
M4R8  $@G   _)P  -R8  #$F   M)@  *24  "4E   B)0  '2<  !DH   6
M*@0 %"L+ !(L$  1+!0 $"P; ! L(@ .+"D #BTR  TM.P ++48 "BU2  @M
M8  &+7  !"V#  (MF   +*X  "S)   LZP !*_P  BO_ &TE  !=)P  3R@
M $4I   \*0  -2D  "\H   K*   )R<  ",G   ?*   &RH  !<L   3+@(
M$# (  XQ#0 -,1( ##$7  LQ'@ *,28 "#(N  <R-P %,D(  S).  $R7
M,FP  #)_   RE0  ,:P  #''   PZ@  ,/P  ##_ &@I  !8*@  3"L  $$L
M   Y+   ,BL  "TK   I*@  )2H  " K   <+   %RX  !,P   0,@( #C0'
M  HW#  '-Q  !3<4  ,W&P "-R(  #<J   X,P  .#X  #A*   X6   .&@
M #A\   WD@  -ZD  #;%   VZ@  -OT  #7_ &,L  !4+@  2"\  #XO   V
M+@  ,"X  "LM   G+0  (BT  !TO   8,0  %#,  ! U   .-P$ "CH'  8[
M"P "/ X  #T2   ^%P  /AX  #XF   ^+P  /CH  #Y&   ^5   /F0  #YW
M   ^CP  /:<  #W#   \Z0  //T  #O_ %XP  !0,0  1#(  #LR   T,0
M+C   "DO   D,   'C(  !DT   4-@  $#D   T[   */0  !4 %  !!"@
M0@T  $,0  !$%   11H  $8B  !&*P  1C4  $9!  !&3P  1E\  $9S  !%
MB@  1:0  $3   !#Z   0_X  $+_ %@T  !+-0  034  #DU   R-   +3,
M "8T   @-0  &C@  !0Z   0/0  #4    E"   $10   $<#  !(!P  2@L
M $L.  !,$0  3A4  $\<  !/)0  3R\  $\\  !/2@  3UH  $YM  !.A0
M3:   $R\  !+YP  2_X  $K_ %,Y  !'.0  /CD  #<X   Q-P  *3<  "$Y
M   ;/   %3\  !!"   ,10  !T@   )*    30   $\   !1!   4@<  %0+
M  !5#@  5Q$  %D7  !:'P  62D  %DV  !91   650  %AG  !8?P  5YH
M %:W  !5XP  5/T  %3_ $X]  !#/0  /#P  #4[   L/   )#X  !Q!   5
M1   $$@   M+   %3@   %$   !4    5P   %D   !;    70(  %X&  !@
M"P  8@X  &02  !G&   9R(  &8N  !F/   9DT  &5@  !E=P  9),  &.Q
M  !AW0  8/P  %__ $E"  !!00  .C\  #!    F0P  'D8  !5*   03@
M"E(   -6    6@   %T   !@    8P   &4   !G    :0   &L!  !M!0
M;PH  '(.  !U$@  =QL  '8F  !V-0  =48  '19  !T;P  <XL  '*I  !P
MS0  ;_<  &[_ $9&  ! 10  -48  "I(   @3   %U$  !!6   )6@   5\
M  !C    :    &L   !O    <@   '4   !W    >0   'L   !]    @ ,
M (,(  "&#0  B1,  (H=  "**P  B3P  (A/  "&9@  A8$  (2@  ""P@
M@?   '__ $9+   Z3   +D\  "-3   86   $%X   ED    :0   &\   !T
M    >    'P   "!    A    (<   "(    BP   (X   "0    DP   )8
M  "9!P  G0T  *$4  "@(0  H#$  )Y$  "=6P  G'8  )F6  "9M0  EN4
M )7^ #]2   R50  )EH  !M@   19P  "6T   !T    >P   ($   "&
MBP   )    "4    EP   )D   "<    GP   *$   "D    IP   *H   "M
M    L08  +4-  "X%@  MR8  +8Y  "U4   M&H  +*)  "PJ@  KL\  *WU
M #=<   K80  'F@  !-P   +>    (    "'    C@   )4   ":    GP
M *0   "H    K    *T   "P    LP   +4   "X    NP   +\   ##
MQP   ,L%  #1#@  T1L  - N  #/10  S5\  ,M^  #)G@  R+X  ,7I "]I
M   C<   %GD   V!   !BP   ),   ";    H@   *@   "N    M    +@
M  "]    P    ,(   #%    R    ,L   #.    T0   -8   #;    WP
M .0   #H!@  ZQ$  .HC  #J.@  Z50  .=R  #EDP  X[,  ./4 /\   #_
M    _P   /\ ! #_  L _P 0 /\ %P#_ "$ _P K /\ -0#_ #X _P!' /\
M3@#_ %4 _ !; /H 80#X &8 ]@!M /0 <P#R 'L [P"$ .T C@#J )D Y@"G
M ., N0#? -4 VP#W -8 _P#  /\ L@#_ *H _P"E /\ H@#_ /\   #_
M_@   /P   #\  , _@ + /\ $0#_ !H _0 D /D +@#T #@ \ !  .P 2 #I
M $X Y@!4 .( 6@#? %\ W !E -@ :P#4 '( T ![ ,T A0#* )$ QP"> ,,
MK@#  ,4 O0#K +L _P"P /\ I #_ )P _P"8 /\ E0#_ /\   #Z    ]
M /$   #R    Z@ % .< #@#B !4 X0 > .$ * #8 #$ T  Y ,L 0 #( $<
MQ0!- ,( 4P"_ %@ O0!> +L 9 "Y &L M@!S +0 ? "Q (@ K@"5 *L I "H
M +@ I@#< *, ^P"? /\ E0#_ (\ _P"+ /\ B0#_ /D   #O    YP   -\
M  #/    R    ,$ "@"_ !$ O  8 +L (0"Y "H M  R +$ .@"N $  JP!&
M *@ 3 "F %$ HP!6 *$ 7 "? &, G0!J )L <P"9 'X E@", )0 FP"2 *T
MD #' (X \ "- /\ A@#_ (  _P!] /\ ? #_ .T   #@    T0   +\   "S
M    J@   *8 !0"B  T H0 3 *  &P"? ", FP K )@ ,@"5 #D DP _ )$
M1 "/ $H C@!/ (P 50"* %L B !C (8 :P"$ '8 @@"" (  D@!^ *, ? "Z
M 'H X0!Y /\ =P#_ '( _P!P /\ ;P#_ -T   #+    M@   *<   "=
ME    (X  0"+  H B0 0 (@ %0"' !T AP E (0 + "" #( ?P X 'T /0![
M $, >0!( '@ 3@!V %0 =0!; ', 8P!Q &X ;P!Z &T B0!L )H :@"N &D
MS !H /8 9P#_ &4 _P!D /\ 8P#_ ,H   "T    H0   ),   ")    @@
M 'L   !X  4 =@ , '4 $0!T !@ <P ? '( )0!P "P ;@ R &P -P!J #P
M:0!" &@ 2 !F $X 90!5 &, 70!B &8 8 !R %X @ != )( 6P"E %H O@!9
M .D 60#_ %D _P!8 /\ 6 #_ +D   "B    D    (,   !Y    <0   &T
M  !I  $ 9@ ) &4 #@!D !, 8P 9 &, ( !A "8 8  L %X ,0!< #< 6P \
M %H 0@!8 $@ 5P!/ %8 5P!4 &  4P!L %$ >0!0 (H 3P"> $X M !- -H
M30#[ $T _P!- /\ 30#_ *H   "4    @@   '4   !K    9    &    !=
M    6@ % %@ # !7 !  5@ 5 %8 &P!5 "$ 4P G %( + !1 #$ 3P W $X
M/0!- $, 3 !* $H 4@!) %L 2 !F $8 <P!% (0 1 "7 $, K !" ,D 0@#Q
M $( _P!# /\ 0P#_ )X   ")    > ,  &H$  !A!   6@,  %4!  !2
M4  " $X "0!-  T 3  1 $L %P!* !P 20 B $@ )P!' "T 10 R $0 . !#
M #X 0@!% $$ 30 _ %8 /@!A #T ;@ [ 'X .@"1 #D I@ X +\ . #H #@
M_P Y /\ .0#_ )4#  " !P  ;PD  &(*  !8"P  40H  $P(  !)!@  1P,
M $8 !@!$  L 0P / $( $P!! !@ 00 > #\ (P ^ "D /0 N #L -  Z #H
M.0!! #@ 20 W %( -@!= #0 :@ S 'H ,@", #$ H0 P +@ +P#> "\ ^0 O
M /\ , #_ (P)  !X#   : T  %P.  !2#@  2PX  $4-  !!#   /PH  #X(
M @ ]! @ / $- #L $  Z !4 .0 : #@ (  V "4 -0 K #0 ,  S #< ,@ ^
M #$ 1@ O %  +@!: "T 9P K '< *@") "D G0 H +, )P#1 "< \@ G /\
M)P#_ (8,  !R#@  8Q   %81  !-$0  11$  $ 0   \#P  .0X  #<-   V
M"P0 -@@* #4&#@ T!1( ,@07 #$%'  P!2( +P4H "X&+@ M!C0 *P8\ "H&
M1  I!TX )P=9 "8'90 D!W4 (P>' "('FP @!K  ( ;+ !\%[0 ?!OX 'P?_
M ( .  !M$0  7A(  %(3  !($P  01,  #L3   W$@  -!$  #(0   P#P$
M, T& # +"P O"A  +0H4 "P+&0 J"Q\ *0LE "@,*P G##( )@PZ "0,0P C
M#$T (0U8 " -90 >#74 ' V( !H-G  9#;$ & S* !<,ZP 7#?P & S_ 'L1
M  !I$P  6A4  $X6  !%%@  /18  #@5   S%0  ,!0  "T3   K$@  *A #
M "H/"  I#@T * X1 "8.%@ E#QT ) \C ",/*0 A$#$ (! Y !X00@ =$$P
M&Q!8 !D09@ 7$'8 %1") !00G@ 2$+, $1#. !$0[@ 2$/X $A#_ '<3  !E
M%0  5Q<  $L8  !"&0  .AD  #08   P%P  +!<  "D6   G%0  )A0! "42
M!  C$@L (A(/ "$2%  @$AH 'A,@ !T3)P <$RX &A,V !D40  7%$H %A16
M !049  2%'0 $12' ! 4G  .%+$ #13*  T4ZP .$_X #A/_ ',5  !A&
M4QH  $@;   _&P  -QL  #(:   M&@  *1D  "88   D&   (A<  " 6 0 >
M%@@ '18- !L7$@ :%Q< &1<= !@8)  6&"L %1@T !08/0 2&4@ $1E4 ! 9
M8@ .&7( #1F$  P9F  *&:T "1C&  D8YP )&/H "A?_ &\8  !>&@  4!P
M $4=   \'0  -1T  "\=   J'   )AL  ",;   A&@  'AH  !P:   :&P4
M&!L, !8<$  5'!4 %!P; !,<(@ 2'2D $1TQ ! =.P .'44 #1Y1  P>7@ *
M'FT "1Z   <>E  %':H  QW"  ,=Y@ $'/@ !1S_ &L:  !;'0  31X  $(?
M   Z'P  ,A\  "T?   H'@  )!X  "$=   >'0  '!T  !@>   5'P( $R )
M !(A#@ 0(1( $"$8  XA'P .(B8 #2(N  PB-P *(D$ "2)-  <B6@ %(FD
M R)\  $BD0  (J@  "'    AY0  (/@  "#_ &<=  !7'P  2B$  $ A   W
M(@  ,"$  "HA   F(   (B   !\?   <'P  &2   !8A   2(P( $"0'  XF
M#  ,)A  "R85  HF'  ))B( ""8J  8G,P $)ST  R=)  $G5@  )V8  "=Y
M   GCP  )J8  ":_   EY   )?D  "3_ &,@  !4(@  1R,  #TD   T)
M+B,  "@C   D(@  (2(  !XA   :(@  %R,  !,D   0)@( #B@'  LJ"P (
M*PX !BL3  0K&  "*Q\  2PG   L,   +#H  "Q%   L4P  +&,  "QV   L
MC   *Z0  "N^   JY   *OH  "G_ %\C  !0)0  1"8  #HF   R)@  *R8
M "8E   C)   'R0  !LD   7)0  %"<  !$I   .*P( "RT&  <O"P $, X
M # 1   Q%0  ,1P  #$C   R+   ,C8  #)"   R3P  ,E\  #)R   QB0
M,:(  #"\   PY   +_L  "__ %HG  !,*   0"D  #<I   O*0  *2@  "4G
M   A)@  '"<  !@H   4*@  $2P   XN   +, $ !S(%  ,T"0  -0P  #8/
M   W$@  .!@  #@@   X*   .#(  #D]   Y2P  .5L  #AN   XA0  -Y\
M #>Z   VY   -?P  #7_ %4J  !(+   /2P  #0L   M*P  *"H  "0I   >
M*@  &2L  !0M   1+P  #3$   HT   '-@   C@$   Z!P  .PH  #T-   ^
M$   0!0  $ ;  ! )   0"X  $ Y  ! 1P  0%8  $!I  ! @   /YL  #ZW
M   ]XP  //P  #S_ % O  !#+P  .2\  #(O   L+0  )RP  " M   :+P
M%3$  !$S   --@  "3@   4[    /0   $ !  !!!   0P<  $4+  !&#@
M2!$  $H6  !*'@  2B@  $HT  !)0@  25$  $ED  !(>P  2)<  $>T  !&
MX   1?P  $3_ $HS   _,P  -C,  # Q   J,   (S$  !PS   6-0  $3@
M  T[   (/@   T$   !#    1@   $@   !*    3 0  $X'  !/"P  40X
M %02  !5&0  52(  %0N  !4/   5$L  %->  !3=   4I   %&N  !0UP
M3_L  $[_ $4W   \-P  -38  "\T   F-0  'C<  !<Z   1/0  #$$   =$
M    2    $H   !-    4    %,   !5    5P   %@"  !;!@  70L  %\.
M  !B$P  8AL  &(G  !B-   844  &!7  !@;0  7XD  %VG  !<S   6O@
M %G_ $$\   Z.P  -#D  "HZ   A/   &$   !%#   ,1P  !DL   !/
M4P   %8   !9    7    %\   !A    8P   &4   !G 0  :@4  &T*  !P
M#@  <Q4  '(@  !R+0  <3T  '!/  !O90  ;H   &V?  !KP0  :?$  &C_
M #]    Y/@  +C\  "1"   :1@  $DH   Q/   $5    %@   !=    80
M &4   !H    :P   &X   !Q    <P   '4   !X    >P   'X#  "!"@
MA0\  (<7  "&)   A30  (1&  ""70  @78  '^6  !^M@  ?.<  'K_ #]$
M   S10  *$@  !U,   34@  #%<   -=    8P   &@   !M    <0   '8
M  !Z    ?@   ($   "#    A@   (D   "+    C@   )(   "5 0  F0D
M )X0  ">&@  G2D  )P\  ":4@  F&P  ):+  "4J@  DM0  )#Z #A+   L
M3@  (%,  !59   -8    V<   !N    =    'H   "     A    (H   ".
M    D@   )4   "7    F@   )T   "@    HP   *<   "K    KP   +0)
M  "X$   MQX  +4P  "S1@  L6   *]^  "LH   J\$  *GN #%5   D6P
M&&$   YI   %<0   'D   "!    B    (\   "4    F@   )\   "D
MJ    *D   "L    KP   +,   "U    N0   +T   #!    Q@   ,L   #1
M"@  TQ0  -$E  #0.P  S50  ,IQ  #(D@  Q;,  ,/> "EB   <:0  $7$
M  =[    A    (T   "5    G0   *,   "I    KP   +0   "Y    O
M +X   #"    Q0   ,@   #,    T    -0   #:    WP   .0   #J
M[@P  .T:  #L+P  ZDD  .AE  #FA@  Y*4  .+& /\   #_    _P   /P
M 0#\  @ _@ . /\ % #_ !T _P F /\ , #_ #H _P!" /\ 20#^ %  ^P!6
M /D 7 #V &( ] !H /( ;P#P '8 [0!_ .H B0#G )4 Y "C .  M0#; -
MU0#V ,H _P"V /\ J #_ )\ _P": /\ E@#_ /\   #[    ]@   /,   #S
M    ]@ ) /H #@#] !8 ^P @ /< *@#R #, [0 [ .D 0P#F $D X@!/ -X
M50#; %L U@!@ -( 9P#/ &X S !V ,D @ #& (P P@": +\ J@"[ ,$ N #I
M +8 _P"G /\ F@#_ )( _P"- /\ B@#_ /H   #Q    Z@   .<   #G
MY  ! .  "P#; !$ V@ : -L (P#1 "P R@ T ,8 .P#" $( OP!( +P 3@"Z
M %, N !9 +8 7P"S &8 L0!N *X =P"L (, J0"1 *8 H0"C +4 H #8 )X
M^P"5 /\ BP#_ (4 _P"  /\ ?@#_ .\   #C    V@   -,   #&    OP
M +D !@"W  X M  4 +0 '0"S "4 K@ M *L - "G #L I !! *$ 1@"? $P
MG0!1 )L 5P"9 %X EP!E )4 ;@"3 'D D "' (X EP", *D B0#$ (@ [P"%
M /\ ? #_ '8 _P!S /\ <@#_ .    #0    Q@   +8   "I    H0   )T
M 0"9  H F  0 )@ %@"7 !X E  F )$ +0"/ #0 C  Z (H /P"( $4 AP!*
M (4 4 "# %8 @0!> (  9@!^ '$ ? !] 'D C0!W *  =0"V ', WP!R /\
M;@#_ &D _P!G /\ 90#_ ,P   "^    JP   )T   "3    B@   (4   ""
M  4 @  - '\ $0!_ !@ @  @ 'T )@!Z "T =P S '4 . !T #X <@!# '
M20!O $\ ;0!6 &P 7@!J &@ : !U &< A !E )8 9 "K &( R0!A /8 8 #_
M %P _P!; /\ 6@#_ +T   "I    EP   (D   !^    >    ',   !O  $
M;0 ) &P #@!K !, :P 9 &H ( !H "8 9@ L &4 ,@!C #< 8@ \ &  0@!?
M $@ 70!/ %P 5P!: &$ 60!M %< >P!6 (X 50"B %, NP!2 .D 4@#_ %
M_P!/ /\ 3P#_ *T   "8    A@   '@   !N    9P   &,   !@    70 %
M %P "P!; !  6P 5 %L &P!: "$ 6  F %8 + !4 #$ 4P V %( / !1 $(
M3P!) $X 40!- %L 2P!F $H = !) (4 2 "9 $< L0!& -@ 1@#\ $4 _P!%
M /\ 10#_ )\   ")    >    &P   !B    6P   %8   !3    40 " $\
M" !/  T 3@ 1 $X %@!- !P 3  A $H )@!) "P 2  Q $< -P!% #T 1 !$
M $, 3 !" %4 0 !@ #\ ;@ ^ 'X /0"2 #P J0 [ ,< .P#S #L _P [ /\
M/ #_ ),   !^    ;@   &$   !8    40   $P   !)    1P   $4 !0!$
M  L 0P . $, $@!# !< 0@ = $  (@ _ "< /@ L #T ,@ [ #@ .@ _ #D
M1P X %  -P!; #4 :  T '@ ,P", #( H@ Q +P ,0#G #$ _P R /\ ,P#_
M (D   !V P  9@4  %D'  !0!P  208  $,%  !  P  /@$  #P  P [  @
M.@ - #H $  Y !0 .0 9 #< '@ V ", -0 H #0 +@ S #0 ,@ [ #  0P O
M $P +@!7 "T 9  L ', *P"' "H G  I +4 *0#< "D ^P I /\ *@#_ ($$
M  !N"   7PH  %,+  !*"P  0@L  #T*   Y"0  -@@  #4%   T @8 ,P *
M #( #@ Q !$ ,0 5 #  &@ O !\ +@ D "P *@ K #  *@ W "D /P H $D
M)P!4 "8 8  D &\ (P"" "( EP A *X (0#, "$ \P A /\ (@#_ 'L)  !H
M#   6@T  $X.  !%#@  /0X  #@-   S#0  , P  "X+   M"0, +08( "P$
M#  K @\ *@$2 "D!%P H 1P )P A "8 )P E "T )  T ",!/0 B 48 (0%1
M !\!70 > 6P ' %_ !L E  : *H &@#% !H ZP 9 /\ &@#_ '4,  !D#@
M50\  $H0  ! $   .1   #,0   O#P  + X  "D.   G#0$ )PP% "<*"@ F
M" T )0<0 "0&%  B!AD (08? " ')  ?!RL '@<R !T'.@ <"$0 &@A/ !D(
M7  7"&L %@A] !4'D0 4!Z< $P:_ !(%Y  2!?H $@7_ '$.  !?$   41$
M $82   ]$@  -A(  # 2   K$0  *!$  "40   C$   (@X$ "$-!P A# L
M( L. !\+$@ ="Q< ' P< !L,(@ :#"D &0PQ !@,.0 6#4, %0U/ !,-7  2
M#6L $ U^  \-D@ .#:< #0R^  T,X  -#/4 #0S_ &T0  !<$0  3A,  $,4
M   Z%   ,A0  "T4   H$P  )1,  "(2   @$0  'A$# !P0!0 <#P@ &P\,
M !H.$  9#Q0 %P\: !8/(0 5$"@ %! P !(0.0 1$$0 $!!0  X070 -$&L
M#!!\  L0D  )$*4 "!"\  <0WP '$/0 !P__ &D1  !8%   2Q4  $ 6   W
M%@  ,!8  "H6   F%0  (A4  !\4   =$P  &A," !D2!  7$@8 %A(* !42
M#@ 4$A( $A(8 !$3'@ 1$R4 $!,N  X3-P -%$  #!1+  L46  )%&< !Q1X
M  84C0 $%*,  Q.[  (3W0 !$O0  A+_ &43  !5%@  2!<  #T8   T&
M+1@  "@8   C%P  (!<  !T6   :%0  &!4" !85!  4%04 $A8( !$6#0 0
M%Q  #A<5  X7&P -%R( #!<I  L8,@ )&#P !QA'  485  $&&,  AAU  $8
MBP  %Z$  !>Y   7W0  %O4  !;_ &$6  !2&   11H  #L:   R&@  *QH
M "4:   A&0  'A@  !L8   8%P  %A<" !07 P 2& 4 $!D'  X;"P ,&P\
M"QL3  H;&  ('!\ !QPF  4<+P $'#@  AQ$   =40  '6   !UR   <B
M'*   !NY   ;W@  &O8  !K_ %X8  !/&@  0AP  #@<   O'0  *1P  ",<
M   ?&P  '!H  !D9   7&0$ %!D" !(: P 0&P0 #AT'  P>"P )'PX !B 1
M  4@%@ #(!P  2$C   A*P  (34  "%    A3@  (5T  "%O   AA@  ()X
M ""X   ?W@  'O@  ![_ %H;  !+'0  /QX  #4?   M'P  )QX  "(=   >
M'0  &QP  !@;   5&P  $AP  ! = @ .'P0 #"$&  DB"@ %(PT  B00   E
M$P  )1D  "8@   F*   )C(  "8]   F2@  )EH  "9L   F@P  )9P  "6W
M   DWP  (_D  "/_ %4>  !'(   /"$  #(A   K(0  )2   " ?   ='@
M&AT  !8>   3'@  $"    XA   ,(P( ""4%  4G"0  * L  "H.   K$0
M+!8  "P=   L)0  +"X  "PZ   L1P  +%8  "QI   L@   *YH  "JU   I
MWP  *?L  "C_ %$B  !$(P  ."0  "\D   H(P  (R(  !\A   <(   %R
M !,A   0(P  #B0   LF   (*   !"H$   L!P  +@D  # ,   Q#P  ,Q,
M #,9   S(0  ,RH  #,U   S0P  ,U(  #-E   R>P  ,I<  #&S   PW@
M+_L  "[_ $PE   _)@  -2<  "TF   G)0  (B0  !XC   9(P  %"0  !$F
M   .*   "RH   <L   #+P   #$"   S!   -0<  #<*   Y#0  .A   #L5
M   ['0  .R8  #LQ   [/@  .TX  #M@   Z=P  .9(  #BP   WVP  -OP
M #7_ $<I   [*@  ,BH  "LI   E)P  (28  !LG   5*   $2H   XL   *
M+P  !C$   $T    -@   #@    [ 0  /00  #\'  !!"@  0PX  $41  !%
M&   12$  $4L  !$.0  1$@  $1;  !#<0  0HT  $&K  ! T@  /_H  #[_
M $(M   X+@  +RT  "DK   D*@  '2H  !<L   1+@  #3$   DT   $-P
M #H    \    /P   $$   !$    1@   $@#  !*!P  3 L  $X.  !0$P
M4!P  % G  !/-   3T,  $]5  !.:@  388  $RD  !*R@  2?@  $C_ #XR
M   U,0  +B\  "DN   @+@  &3$  !(S   .-P  "3H   (]    0    $0
M  !'    20   $P   !/    40   %,   !5 0  6 8  %H+  !=#@  7Q4
M %X@  !>+   73P  %Q.  !;8P  6GX  %B=  !7P   5?(  %3_ #HV   S
M-   +3(  "0S   ;-@  $SD   X]   (00   $4   !)    3    %    !3
M    5@   %D   !;    70   &    !B    90   &@%  !K"P  ;Q   &\8
M  !N)0  ;30  &U&  !K6P  :G4  &B4  !FM@  9.D  &+_ #@Y   R-P
M*#D  !X[   5/P  #D0   =)    30   %(   !6    6@   %X   !B
M90   &@   !K    ;0   '    !S    =@   'D   !]!   @0L  (41  "$
M'0  @BP  ( ^  !^5   ?FL  'N*  !ZJ@  =]8  '7] #@]   L/@  (D$
M !=&   /2P  !U$   !7    7    &(   !F    :P   &\   !T    >
M 'L   !^    @    (,   "&    B@   (T   "1    E@,  )L,  "=$P
MFR$  )HS  "720  E&(  )-_  "0H   CL4  (SS #%$   E2   &DT  !!3
M   (6@   &$   !H    ;@   '0   !Y    ?P   (0   ")    C0   )$
M  "3    E@   )D   "=    H    *0   "H    K    +(#  "W#0  MQ<
M +4H  "R/@  L%8  *QS  "JE   J;0  *7E "I/   >5   $EL   IB
M:@   ',   ![    @@   (D   ".    E    )H   "?    I    *8   "I
M    K0   +    "S    MP   +L   #     Q0   ,L   #1!   U0X  -,=
M  #0,@  S4L  ,IF  #&AP  PJD  ,'+ ");   68@  #&L   %T    ?0
M (<   "0    EP   )X   "D    JP   +$   "V    N@   +P   #
MQ    ,@   #+    SP   -0   #:    X    .8   #K    \08  / 3  #N
M)P  [#\  .I;  #G>@  Y)L  ."[ /\   #[    ]@   /,   #T  4 ]@ ,
M /H $0#_ !D _P B /\ + #_ #4 _P ] /\ 10#\ $P ^@!2 /< 6 #U %X
M\P!D /$ :@#N '( [ !Z .D A0#E )$ X0"@ -T L@#8 ,X T@#V ,$ _P"M
M /\ G@#_ )8 _P"0 /\ C #_ /H   #R    [    .D   #I    [  % /(
M# #X !( ]P ; /4 )0#P "X ZP W .8 /@#B $4 W0!+ -@ 4 #3 %8 T !<
M ,T 8@#* &H R !R ,4 ? #" (@ O@"6 +H J "W +\ M #H *X _P"= /\
MD #_ (@ _P"# /\ @ #_ /    #E    W@   -H   #;    W    -@ !P#1
M  X T0 5 -( '@#+ "< Q0 O ,  -P"] #T N@!$ +< 20"U $\ L@!5 +
M6P"N &$ K !I *D <P"G '\ I "- *$ G@"> +( FP#5 )D _ ", /\ @@#_
M 'L _P!V /\ = #_ .(   #3    R@   ,<   "\    M@   +   0"O  L
MK  1 *T & "M "  J  H *0 +P"@ #8 G0 \ )L 0@"9 $< EP!- )4 4P"3
M %D D0!A (\ :@", '4 B@"# (@ E "& *< @P#" (( \ !\ /\ <P#_ &T
M_P!J /\ : #_ ,\   #!    N0   *T   "@    F    )0   "1  8 D  -
M )  $@"/ !D C@ A (L * "( "\ A@ U (0 .@"" $  @ !% 'X 2P!\ %(
M>@!9 '@ 8@!V &P = !Y '( B0!Q )T ;P"T &T WP!L /\ 90#_ &  _P!>
M /\ 7 #_ +X   "Q    H    )(   ")    @@   'P   !Z  $ >  ) '<
M#@!X !0 =P : '0 (0!R "< <  M &X ,P!L #@ :P ^ &D 1 !H $H 9@!1
M &0 6@!C &0 80!P %\ ?P!> ), 70"I %P R !; /< 5P#_ %0 _P!2 /\
M40#_ +    "?    C0   '\   !T    ;@   &H   !F    90 $ &, "P!C
M !  8P 5 &, &P!A "$ 7P G %T + !< #( 6@ W %D /0!7 $, 5@!+ %4
M4P!3 %P 4@!H %  =P!/ (D 3@"? $T N@!, .D 2P#_ $D _P!' /\ 1P#_
M *(   "-    ?    &X   !E    7@   %D   !7    50 ! %0 !P!3  T
M4P 1 %0 %@!2 !L 40 A $\ )@!. "L 3  Q $L -P!* #T 20!$ $< 3 !&
M %8 1 !A $, < !" ($ 00"7 $  KP _ -< /P#_ #X _P ] /\ /@#_ )0
M  !_    ;P   &,   !9    40   $T   !*    2    $< ! !'  H 1@ .
M $8 $0!' !8 10 < $0 (0!" "8 00 K $  ,0 ^ #< /0 ^ #P 1P Z %
M.0!; #@ :0 W 'H -@"/ #4 IP U ,8 - #U #0 _P T /\ -0#_ (@   !T
M    90   %@   !/    2    $,    _    /0   #P  @ \  < .P , #L
M#P [ !( .@ 7 #D '  W "$ -@ F #4 +  T #( ,P Y #$ 00 P $L +P!6
M "X 8P M ', + "( "P H  K +L *P#J "L _P K /\ + #_ '\   !L
M70$  %$"  !( P  0 ,  #L"   W    -    #,    R  4 ,@ ) #( #0 Q
M !  ,0 3 #  &  O !T +0 B "P *  K "X *@ U "D /0 H $8 )P!1 "8
M7@ E &X ) "" ", F0 C +, (@#> "( _P C /\ ) #_ '<   !E!   5@8
M $L'  !""   .@@  #4'   P!@  +04  "P#   K  , *@ ' "D "P I  X
M*0 1 "@ %0 G !D )@ > "4 )  D "H (P Q "( .0 A $, ( !. !\ 6@ >
M &D '0!\ !P DP ; *P &P#- !L ]@ ; /\ ' #_ ' %  !?"   40H  $8+
M   ]"P  -0L  # +   K"@  * D  "4(   D!P( (P0& ",""0 B 0P (@ /
M "$ $@ @ !8 'P ; !X (  = "8 '  N !L -@ : #\ &0!* !@ 5P 7 &8
M%@!X !4 CP 5 *8 % ## !0 [@ 4 /\ %0#_ &L(  !;"P  30P  $(-   Y
M#0  ,0T  "P-   G#0  (PP  "$,   ?"P$ '@H% !T("  =!@L ' 4- !P$
M$  ;!!0 &008 !D$'@ 8!", %P0K !8$,P 5!#P % 1' !,#5  2 V, $0-U
M ! "B@ 0 :( #P"\  \ Y0 / /X $ #_ &<+  !7#0  20X  #X/   U#P
M+@\  "@/   D#@  ( X  !T.   ;#0$ &0T$ !@,!P 8"PD %PD, !<)#@ 6
M"1( %0D6 !0)&P 3"2$ $@DH !(),  1"3H $ E%  \)4@ ."6$ #0ES  P(
MB  +")\ "@>W  H&VP *!?8 "@3_ &,-  !3#@  1A   #L1   R$0  *Q$
M "40   A$   '1   !H/   8#P$ %@X$ !4.!P 4#0D $PT+ !,,#0 2#!
M$0P4 ! ,&0 0#!\ #PPG  X-+P -#3D # U%  L-40 )#6  " UQ  8-A@ %
M#9T ! RT  ,,T@ "#/$  @O_ %\.  !0$   0Q$  #@2   O$@  *!(  ",2
M   >$0  &Q$  !@1   5$ ( %! % !(0!P 1#PD $ \* ! .#  .#@X #@\2
M  T/%P ,$!T #! D  H0+  )$#8 "!!!  803@ %$%T  Q!O  $0A   $)P
M  ^T   .U   #O,   [_ %P0  !-$@  0!,  #84   M%   )A0  "$3   <
M$P  &1(  !82   4$0, $A$& !$1"  0$ H #A +  T1"P ,$0T "Q(1  H2
M%0 )$AH "!(A  83*0 %$S,  Q,^  (32P  $UH  !-L   3@@  $IL  !*T
M   1UP  $?4  !'_ %@2  !)%   /14  #,6   K%@  )!4  !\5   :%
M%Q0  !03 0 3$@0 $1(' ! 2"0 .$@D #1()  L3"@ )% T !Q4/  86$P $
M%A@  Q8?  (6)P  %S   !<[   72   %U@  !=J   6@   %ID  !6T   5
MV0  %/<  !/_ %44  !&%@  .A<  # 8   H&   (A<  !T6   9%@  %A4
M !,4 P 2$P8 $!,'  \3!P -% < "Q4(  D6"0 && P  QH.  $:$0  &A8
M !L<   ;)   &RT  !LX   ;1@  '%4  !MG   ;?0  &Y<  !JS   9VP
M&/D  !?_ %$6  !#&   -QD  "X:   F&@  (!D  !L8   8%P  %18! !,5
M!0 1%00 #Q4$  T6!  +%P4 "1D&  8:"  "' H  !X-   @$   (!,  " 9
M   @(0  (2H  "$U   A0@  (5(  "!D   @>@  'Y4  !^Q   >VP  '?H
M !S_ $T9   _&P  -!P  "L<   D'   'AL  !H:   7&   %!<" !(7 @ 0
M& $ #1D!  L: @ (' , !1T$  (?!@  (0@  ",+   E#@  )A$  "86   F
M'@  )R<  "<R   G/P  )DX  "9@   F=P  )9(  "2O   CV@  (OL  "'_
M $@=   \'@  ,1\  "@>   B'@  '1P  !D;   6&@  $AH  ! ;   -'
M"QT   @?   $(0   2,"   E!   )P8  "D)   L#   +@\  "X3   N&@
M+B,  "XN   N.P  +DH  "U<   M<@  +(X  "NL   JU   *?L  "C_ $0@
M   X(0  +B$  "8A   @(   '!X  !@=   4'0  $!X   X?   +(0  !R,
M  ,E    )P   "D    L 0  +@,  # &   S"@  -0T  #81   V%P  -A\
M #8I   V-@  -D4  #57   U;0  -(D  #*H   QSP  ,/H  "__ #\D   T
M)   *R0  "0C   ?(0  &R   !8@   1(0  #B,   HE   &*    BH    M
M    +P   #(    T    -P   #D#   [!@  /@H  $ .  !!$@  01H  $ E
M  ! ,0  0$   #]2   ^9P  /8(  #RB   ZQP  .?@  #C_ #HH   P*
M*2<  ",E   ?(P  &"0  !(E   .*   "BH   4M    ,    #,    V
M.    #L    ^    0    $(   !% @  1P8  $H*  !-#@  314  $P?  !,
M*P  2SH  $I,  !)80  2'P  $>;  !%OP  0_,  $+_ #8L   M*P  )RD
M ",G   ;*   %"H   XM   *,   !#,    W    .@   #T   !     0P
M $8   !(    2P   $T   !0    4P$  %8&  !9"P  6Q   %L9  !:)0
M630  %A&  !76@  570  %23  !2M0  4.H  $__ #,P   L+@  )RP  !XM
M   6+P  $#(   HV   #.@   #\   !"    1@   $D   !,    3P   %(
M  !5    6    %H   !=    8    &,   !G!@  :PP  &P2  !K'@  :RP
M &D]  !G4@  9FH  &2)  !AJP  7]P  %W_ #$S   L,0  (C(  !DU   1
M.0  "CT   )"    1P   $P   !0    5    %@   !;    7P   &(   !E
M    :    &L   !N    <0   '4   !Y    ?08  ((-  ""%@  @"0  'XU
M  !\20  >V$  'A_  !VGP  <\8  '#W #$V   F.   '#L  !)    +10
M DL   !1    5@   %L   !@    90   &D   !N    <@   '8   !Y
M?    'X   ""    A0   (D   ".    DP   )@&  "<#@  FQH  )@K  "6
M0   DED  )%S  "-E0  B[4  (CH "L^   @00  %4<   U-   "5    %L
M  !A    :    &X   !S    >0   'X   "#    B    (P   "/    D@
M )4   "9    G0   *$   "E    J@   +    "W!P  N!$  +4A  "R-0
MKTT  *II  "HB   IJ@  *+1 "-(   83@  #E0   1<    9    &T   !U
M    ?    (,   ")    CP   )4   ";    H    *,   "F    J0   *T
M  "Q    M0   +D   "^    Q    ,H   #2    V@H  -86  #2*0  SD$
M ,I<  #%?   PIT  ,&] !Q5   17   !V4   !N    =P   '\   "(
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M^_S^______________________________________________________\
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M________________________________________
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M_O]M9G0Q      ,$(0   0                    $
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M#/^C-Q3_KD =_[A(*O_!4#S^Q5E0]\A@9NO*9WS=PVV1S[QQI<6T=+6]L'G
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M8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&)A]HQB8?:,8F'VC&+SQ \
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MH#X:_ZA')O^N433_KUM%_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN
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M_ZUE5_BI;VCMHWAYXYM_A]N2A934BXR>SX61ILN E:S'?)FQQ7F>M<)VH[G
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MQIJ1F,F6CZ'+D(NHS(R)K,6,B;# C(FPP(R)L,",B;# C(FPP(R)L,",B;#
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M-!F _SL@=O]#)VW_3"QF_U0P8O]@,U[_:35<_V\W6O]T.%G_>3E8_WTZ5_^
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MT&VYH\]LPZ;%9\.FP&G'H<!IQZ' :<>AP&G'H<!IQZ' :<>AP&G'H<!IQZ'
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MDIV+NHR:D[Z'F)O A)>EPH"6K\)_DK.\@)&XM8"1N+6 D;BU@)&XM8"1N+6
MD;BU@)&XM8"1N+6 D;BU@)&XM8"1N+7_DAH#_Y E!_^;+ K_IS0/_[(\%O^[
M1"'YQ4LP\<Y10>?26%3:SEYIRL9E?+V]:XRPMG":I;!VI9RJ?*V3IH*TC*.)
MN8:@D+V!GIF_?9ZBP7N>K\%YF;.\>I>XM7J7N+5ZE[BU>I>XM7J7N+5ZE[BU
M>I>XM7J7N+5ZE[BU>I>XM7J7N+7_DAD#_Y E!_^=*PK_JC,._[4\%?R_1"#T
MR$HN[=-0/^/85E/3TEUHQ<IC>[?":8NJNV^8G[9THY6Q>JR-K8"RA:J'MW^G
MCKMZII>^=Z:@OW2FK;]SH;2[=)ZXM72>N+5TGKBU=)ZXM72>N+5TGKBU=)ZX
MM72>N+5TGKBU=)ZXM72>N+7_DQD#_Y$D!_^?*PG_K#,-_[@[%/C#0Q[OS4HL
MY]I//=W>55'-V%MGOL]B>K#(9XFDPFV7F;QRH8^X>*F&M7ZP?[*%M7FPC+AT
MKY6[<*^?O&ZOK+QMJ[6Y;J>YM&ZGN;1NI[FT;J>YM&ZGN;1NI[FT;J>YM&ZG
MN;1NI[FT;J>YM&ZGN;3_E!D#_Y(D!_^B*@C_L#(,_KPZ$O+'0ASHTTDIX>%,
M.]3C4U'&W5IEM]5@>*G/9H>=R6N4D<5PGH?!=J9_OGRL>+R$L7*ZB[1MN9.V
M:KB<N&>WI[AGM[>V:+*[L6BRN[%HLKNQ:+*[L6BRN[%HLKNQ:+*[L6BRN[%H
MLKNQ:+*[L6BRN['_E1@#_Y4C!O^E*0?_M#$*^,$Z$.O.0AC@W4<EU>5+.\OG
M45"]XUECK]Y?=*+898.6TVJ/BLYOF7_(<Z%UQ'BG;L%]JVF^A*YEO8NQ8;R3
MLE^\G;)?O*RQ8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM8K^^K6*_OJUBO[ZM
M8K^^K6*_OJW_EA@#_YDA!?^J* ;_N3 (\,@X#>'80!/4XT4FRNM+.\'L3T^S
MZ%=@IN5?;YKB9GR.W&R&A-5QCWK0=95SS7J;;,I_GV?'A*)CQHJD7\21IES$
MF:=:PZ2G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2PIUK$L*=:Q+"G6L2P
MIUK$L*?_F!<"_YX@!/^O)@7XP"X&YM S"-7A/!3)ZD4HO_)*.[7Q3DRI[U9;
MG>U?:)+J9W.'XVU\?MYR@G;:>(APUWV,:]2"D&;2AY)CT8R57\^2EES.F9A9
MSJ*96,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-JYI8S:N:6,VKFEC-
MJYK_FA<"_Z4> _^W(P/MR28#UMXI!LGI.Q>^\T0IL_A).JCW34B?]E55E/5?
M8(GQ:&B [&]P>.AU=7+E>GEMXG]]:>"$@&7?B8)BW8Z$7]R3AEW;F8=:VJ&)
M6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(E8V:B)6-FHB5C9J(G_
MG!8"_ZT; O;!'0';VA,!R>@I";WS.QFR_4,HIOY'-IS]3$.3_55-BOU?5H'Y
M:5UY]7!B<_)V9V[P?&IJ[H%M9^R&;V3KBW%AZH]R7^F4=%WHF75:YZ!W6.:F
M>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGA8YJ9X6.:F>%CFIGC_HA4!
M_[<5 -C/"P#*YQ,"O/,I"['].QFD_T FF?]%,H__2SR'_U1$?_]?2WC_:5!Q
M_W!4;/UV6&G[?%IF^H%<8_B&7F'WBU]?]I!A7O:58ESUFF-:]*!D6/.E95CS
MI658\Z5E6/.E95CSI658\Z5E6/.E95CSI658\Z5E6/.E95CSI67_K1  UL,(
M ,C3"@"[]!4#K_\J#:/_-QB7_STBB_]#+('_2C1Z_U(Z<_]>/V[_:$-I_V]'
M9O]U26/_>TMA_X%,7_^%3EW_BD]<_X]06O^345G_F%)7_YY35O^C5%;_HU16
M_Z-45O^C5%;_HU16_Z-45O^C5%;_HU16_Z-45O^C5%;_HU39N@4 Q<<' +G9
M" "L_Q<%HO\K#97_,Q:)_SD>?O] )77_2"MM_U P9_]:-&/_93=@_VTY7O]S
M.US_>#U:_WT^6/^"/U?_AD!6_XM 5?^/053_E$)3_YI#4?^?0U'_GT-1_Y]#
M4?^?0U'_GT-1_Y]#4?^?0U'_GT-1_Y]#4?^?0U'_GT/&O@4 M\T% *KD" &?
M_QD&E/\H#(?_+A-[_S49<?\]'FG_12-B_TTF6_]6*5C_7RQ6_V@M5/]N+U/_
M<S!2_W@Q4?]\,5#_@#)/_X0S3O^(,TW_C#1,_Y(T2_^6-4O_EC5+_Y8U2_^6
M-4O_EC5+_Y8U2_^6-4O_EC5+_Y8U2_^6-4O_EC6WQ , J=0" )SY"P*3_QL%
MA?\C"GG_*0]N_S$49?\Y&%W_01M7_TH>4_]2(%#_62)-_V C2_]F)$K_:R5)
M_V\E2/]S)D?_=R9&_WLG1?]^)T7_@BA$_X<H0_^+*4/_BRE#_XLI0_^+*4/_
MBRE#_XLI0_^+*4/_BRE#_XLI0_^+*4/_BRG_@QP#_X G!_][,PW_AC@1_XY
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MY7;_>QP#_W<G!O]W, K_@C4._XH\%?^/1AW_DD\G_Y%<,O^.:#W_BG1(_X:
M4O^!BUK\?95A^'B=9_5TI&WR<:IQ\&ZP=.YKMG?L:;YZZF?'?>=ESG_B8M:
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M@E'9W()1V=R"4=G<@E'9W()1V=R"4=G<@E'9W(+_CQ,"_Z03 ?ZX$@#6S L
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M(C?_I"(V_ZTC-?^X(S7_N2,U_[DC-?^Y(S7_N2,U_[DC-?^Y(S7_N2.MM@
MG\0  )+2  "$X0  ??\- 7+_$P)H_QL$7_\C!EC_*PE1_S,+3/\Z#4?_00]#
M_T@10/].$CW_5!,[_UH4.?]?%#?_914U_VL6,_]R%C'_>A<O_X(7+O^+&"S_
MDQ@K_YP9*O^G&2K_IQDJ_Z<9*O^G&2K_IQDJ_Z<9*O^G&2K_IQFAOP  DLP
M (3<  !X]P  ;O\* 6/_$ ):_Q4#4O\=!$O_) 9&_RP(0?\S"3S_.@HY_T +
M-?]%##+_2@TP_U -+O]4#BS_60XJ_UX/*/]D#R;_:@\E_W$0(_]X$"+_@!$@
M_X@1'_^1$1__D1$?_Y$1'_^1$1__D1$?_Y$1'_^1$1__D1'_7"(#_U<M!?]8
M,P?_7S8)_V,]#?]E1A+_9E 7_V5>'/]D;B+_87PG_U^**_]>EB[_7*$Q_UNJ
M,_]:LC7_6;HV_UC#-_]8S3G_5]@Y_U;@.O]5YCO_5.P\_U/Q//Q2]3WX4OD]
M]5']/?-1_SWS4?\]\U'_/?-1_SWS4?\]\U'_/?-1_SW_7"(#_U<L!?]:,@?_
M834)_V4\#?]G11+_:$\7_VA<'?]F;2+_8WLH_V&(+/]?E"__7I\R_UVI-?];
ML3?_6KDX_UK!.O]9RSO_6-4\_U??/?]6YC[_5>L^_53P/_E3]3_V4OE \U+]
M0/!2_S[P4O\^\%+_/O!2_S[P4O\^\%+_/O!2_S[_72$#_U@L!?]<, ?_9#,)
M_V@Z#?]K0Q+_;$X7_VQ:'?]J:B3_9W@I_V2%+O]BD3+_89PV_U^F./]>KCK_
M7;8\_UR^/O];R#__6M)!_UG=0O]7Y4/]5NI$^57P1/54]47Q5/I%[E3^1.Q4
M_T+L5/]"[%3_0NQ4_T+L5/]"[%3_0NQ4_T+_7B$#_UDL!?]?+@;_9C()_VPX
M#/]O01'_;TP7_W%7'O]N9R7_:W4K_VB",/]ECC7_9)DY_V*C//]@JS[_7[-!
M_UZ[0O]=Q$3_7,Y&_UK<1_Y9Y$CZ5^I)]5;P2O!5]DKM5?I*Z5;^1^=6_T7G
M5O]%YU;_1>=6_T7G5O]%YU;_1>=6_T7_7B$#_UDK!?]B+0;_:C (_V\V#/]R
M0!'_=$H8_W55'O]R9";_;W(M_VQ_,_]IBSC_9I8\_V6@0/]CJ$/_8;!&_V"X
M2/]>P4K_7<M+_US:3?I:XT[U6>I/\%?Q4.M6]E'G5_M.Y%C_2^%9_TGA6?])
MX5G_2>%9_TGA6?])X5G_2>%9_TG_7R #_UHK!?]E*P;_;2X(_W,U#/]W/A'_
M>$@7_WE2'_]W8"?_=&XN_W![-?]MASO_:I)!_V>;1?]EI$G^8ZQ,_6&T3OM@
MO%'Z7L93^5W45?5;XU;O6NI8Z5CR6>59]U;@6OM3VUO_3]=;_TW76_]-UUO_
M3==;_TW76_]-UUO_3==;_TW_8" #_UTI!?]H*0;_<2L'_W@S"_]\/!#_?487
M_WY0'_]]72C_>6HP_W5V./]Q@C_\;8U%^FJ72_AGGT_V9:=3]&*O5O-@N%GQ
M7\%<\%W-7NU<X&#H6NQAX5KR8-I;]EO37/I7SUW]4\Q>_U',7O]1S%[_4<Q>
M_U',7O]1S%[_4<Q>_U'_81\#_V G!/]K)@7_=2D'_WPQ"O^!.A#_@T07_X1-
M'_^#62C_?V8R_'IR._AU?D/U<8A+\FV24>]IFE;M9J);ZF.J7^A@LF/F7KQF
MY%S(:>%;VFO=6NIKTUSP9LU>]6'(7_E<Q&#\6,%A_E7!8?Y5P6'^5<%A_E7!
M8?Y5P6'^5<%A_E7_8A\#_V,E!/]O) 7_>2@&_X$P"O^%.0__B$(6_XE+'O^)
M5BCZA6(S]8!N/?!Z>4?L=8-0Z7",6.5KE5[A9IUDWF.D:=M@K6W77[=OU%[#
M<-%>TG'-7>=QQU_N:\)A\F:^8O9ANF/Y7+=C_%BW8_Q8MV/\6+=C_%BW8_Q8
MMV/\6+=C_%C_8Q\#_V8C!/]R(@3_?2<&_X4N"?^*-P[_C4 5_X])'OJ/4RCT
MC%\T[H9J/^E_=$OC>'Y5WG*&7MAMCV73:IAJSV>@;<QEJ'#)8[%SQF*\=,1A
MR77!8>!VO&/J<;=D[VJT9?-EL&;V8*YG^5RN9_E<KF?Y7*YG^5RN9_E<KF?Y
M7*YG^5S_8QX#_V@A!/]U( 3_@24%_XDM"/^/-0S_DCX4_)1''?663RCND5LT
MYXMF0>"$;T[9?7E8T7>"8,QSBF?';Y-LQ&R;<,!IHW.]9ZQVNF:V>+AEPGFV
M9=5YLF;F=JYH[&^J:?!IJ&GT8Z9J]U^F:O=?IFKW7Z9J]U^F:O=?IFKW7Z9J
M]U__9!X#_VL@ _]X'@3_A"0%_XTL!_^3- O_ESP2^)E%&_";32?HEUDTX9!B
M0M>);$[.@W58R'U^8<-XAFB^=(YMN7"6<K9NGG6R;*=XKVJQ>ZUIO7RJ:<U]
MJ&KC>J5LZ7*B;.ULH&WR9IYN]6*>;O5BGF[U8IYN]6*>;O5BGF[U8IYN]6+_
M91T"_VT> _]['0/_AR,$_Y J!O^7,@K]G#L0])]#&>RA2R7CG%8SVI9@0<^.
M:4['B')8P()Z8;I]@FBU>8INL762<ZQRFG>I<*-ZIFZL?:-MN'ZA;<=_GV[@
M?IQPYW6:<.MOF7'P:)=Q\V27<?-DEW'S9)=Q\V27<?-DEW'S9)=Q\V3_91T"
M_V\= _]^' /_BB($_Y,I!?^;,0GYH#D/\*-!&.>F22/>H50QTII>0,B39TW
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M;&J4[6QJE.UL:I3M;&J4[6S_<18"_X,1 ?^4$P'_HA0 ]; 4 .:^% #9S!4
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M0D;TQT-%]-]#1/3P0T3R^D)$\OI"1/+Z0D3R^D)$\OI"1/+Z0D3R^D+1H@
MP*X  +*X 0"GQ ( G-($ )+M# ",^QP#@OLH!WG[,0QP_#D2:?Q!%V+\21Q<
M_% @5_Q9(U3]8B91_6HH3_US*DS^>RQ*_H,N2/Z-+T;_F#%$_Z(R0_^N,T'_
MNS1 _\LT/__C-#__[S4__^\U/__O-3__[S4__^\U/__O-3__[S7$J@  L[,
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M%"+_JQ0B_ZL4(O^K%"+_JQ0B_ZL4(O^K%"+_JQ2<O@  C<L  '[:  !PY@
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M7DS S5Y,P.I<3K_Y64^\_E50NOY54+K^55"Z_E50NOY54+K^55"Z_E7_A0(
MW9@  ,VF @#!L0, M[H# *[&!@"GTPH H-T5 )G=* 20VS<.AME"&7W62R1U
MU%0M;=)<-6?18SQAT&M!7,]R1EC/>TE4SH1-4,Z/4$W.FU)+SJE32<ZY5$C/
MSU1(SNM32<[X4$K+_TY*RO]-2LK_34K*_TU*RO]-2LK_34K*_TWGCP  T9\
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M*SK\]"LZ_/<K.OSW*SK\]RLZ_/<K.OSW*SK\]RN]J   KK   *&\  "5R
MB=0  '[H!0!W_Q(!;_\< F?_)@5@_R\(6?\W"U3_/PY/_T<12_].$T?_5A5$
M_UT60O]D&$#_;!D]_W4:._]^&SG_B1PW_Y0=-O^@'C7_K!\S_[D?,__('S+_
MXB R_^<@,O_G(#+_YR R_^<@,O_G(#+_YR"PK0  HK<  )7$  "'T   >]T
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M&@+_<Q\#_WHF!/]^+P;_@3@+^X%!$O. 2QKL?%<CYG=C+>!Q;3C:;7= TVF
M1L]EB4O+8Y%/R&"94L5?H57"7:I7P%RS6;Y<OUJ\6\Y;N%OE6[=>]56W8O]/
MM6/_2K)D_T:P9/]#L&3_0[!D_T.P9/]#L&3_0[!D_T/_51\"_V$: O]M& +_
M=QT"_WXD _^$+ 7^AS4)]8@^$.V'2!CE@U0BWGY?+M1X:3C.<W- R6Y\1\1K
MA$S :(Q1O6645+ICG%>W8J5:M&"N7+)@N5ZP7\=>K5_?7ZQB\5FL9?Y3JF?_
M3JAG_TJF9_]&IF?_1J9G_T:F9_]&IF?_1J9G_T;_5QT"_V08 O]P%@+_>QP"
M_X,B O^)*@3YC#('[XX[#>>.1!;>BE$AU(1<+<Q^9CC%>&]!P'1W2+MP@$VW
M;8A2LVJ05K!HF%FL9J!<JF6I7Z=DM&"E8\)AHV/58J)E[5VB:?M7H6K_49]K
M_TR>:_])GFO_29YK_TF>:_])GFO_29YK_TG_61P"_V<6 ?]S%0'_?AH!_X<@
M O^-)P/TDB\&ZI0X"^&40A/6CTX@S(E9+<6#8S>^?6M N'ET2+-U?$ZN<H13
MJF^,5Z=ME%NC:YQ>H&FE8)YHL&.;9[UDF6?.9)AIZ&&:;?E:F6[_5)=N_T^6
M;O]+EF[_2Y9N_TN6;O]+EF[_2Y9N_TO_6QH"_VD4 ?]V% '_@1@!_XH= ?R1
M) +PERP$Y9HT"-R:/Q'/E$P?QHY7++Z(8#>W@FE L7YQ2*QZ>4ZG=X!3HW2(
M6)]QD%R;;YA?F&VA8I5LK&23;+EFD6O)9I!MY&21<?9<D7+^5I!R_U&0<O]-
MD'+_39!R_TV0<O]-D'+_39!R_TW_71@!_VL3 ?]Y$P'_A!8!_XX; ?B5(0'K
MFR@#X: P!M6>/1#*F$H>P9)4*[F,7C:QAV8_JX)N1Z9^=DZA>WU3G'B%6)AV
MC5R4=)5?D7*>8XYQJ66+<+5GB7#%9XAPX&:*=/1>BW;\6(IV_U*)=O].B7;_
M3HEV_TZ)=O].B7;_3HEV_T[_7Q<!_VX1 ?][$@'_AQ0 _Y$8 ?29'0'GH","
MW:4K!,^A.P_%G$@=O)93*K207#6LBV0_IH=L1Z"#<TV;@'I3EGV"5Y)ZBER.
M>))@BG:<8X=UIF:$=+)H@G3":(!TVVB#>/)@A'K[681Y_U2$>?]/A'G_3X1Y
M_T^$>?]/A'G_3X1Y_T__814!_W 0 ?]^$0#_BA( _Y05 /"=&0#CI1X!UZ@H
M \NE.0[!GT8;MYI1*:^56C2GD&(^H8MJ1IN'<4R5A'A2D(%_5XQ_AUR(?9!@
MA'N98X!ZHV9]>;!H>WF_:7IYUFE\?/!A?G[Z6GY]_E5^??]1?GW_47Y]_U%^
M??]1?GW_47Y]_U'_8Q0!_W(/ ?^!$ #_C1$ _)@2 .RA$P#?JA8 T:PF \>H
M-PV\HT0:LYY/)ZJ96#.CE& ]G)!H19:,;TR0B792BX9]5X:$A5N"@HY??H"7
M8WI_H69W?JUH=7Z]:7-^TFEV@>YB>(+Z6WB"_E9Y@?]1>8'_47F!_U%Y@?]1
M>8'_47F!_U'_91,!_W4. /^##@#_D X ]9L. .BF#@#9KP\ S*\D L*K-0RX
MIT,9KJ).)J:=5C&>F5X[EY5F1)"1;4N+CG11AHQ[5H&)@UM\AXM?>(:58G2$
MGV5Q@ZMH;H.Z:6V#SFEOANMC<H?Y7'.&_59SA?]2<X7_4G.%_U)SA?]2<X7_
M4G.%_U+_:!$!_W@- /^&#0#VDPP WJ ) -:I"@#2L@T Q[(B KVO,PJSJT$7
MJJ=,)*&B53"9GETZDIID0HN7:TF%E')0@))Y57N/@5IVC8E><HR28FZ*G65K
MB:EG:(FX:&>)RVAIB^EC;(WY7&V,_5=MBO]2;8K_4FV*_U)MBO]2;8K_4FV*
M_U+_:Q !_WL+ /^*"@#BF 8 UJ,( -"L"0#+M0L P;8? ;BT,0FNL#\6I*Q*
M(IRH4RZ4I%LXC*!B0(:>:4B FW!.>IEW4W66?EAPE(=<;).08&B2FV-DD:=E
M8I"V9F"1R69BDN=B993X7&>2_5=GD?]29Y'_4F>1_U)GD?]29Y'_4F>1_U+_
M;@X _W\) /&.!0#9FP4 SZ8' ,FO!P#$N0@ N[H< ;*X+P>HM3T3G[%(():N
M42N.JEDUAJ=@/H"E9T5ZHFY+=*!U46^>?%5JG(599IN.76*:F6!>F:9B7)FT
M8UJ9QV-;FN5@7YOW6V":_E9AF/]289C_4F&8_U)AF/]289C_4F&8_U+_<@L
M_X,% -^3 0#1GP0 R:H& ,&R!0"[O00 M+\8 *N^+ 6BNSH1F;A%'9"U3RB'
MLE<R@*]>.GFM94)SJVQ(;JES36FG>E%DIH-67Z2-65RCF%Q8HZ1>5J.S7U6C
MQE]5I.1=6*3V6%JC_U1;H?]06Z'_4%NA_U!;H?]06Z'_4%NA_U#_=P< \(D
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M14?(_T-(Q_]"2,?_0DC'_T)(Q_]"2,?_0DC'_T+>C0  RYP  +VG  "QL
MIKH  )S$ P"3SP< BMT, (7?'0%^WRP%=MXW"V_>0Q-HW4T:8MQ5(%W;7298
MVV4J5-IM+E#:=C)-VH U2MJ+-T?:ESE%VJ0[0]NT/$+<R#Q"V^4[0MKT.D+9
M_CI#V/\Y0]C_.4/8_SE#V/\Y0]C_.4/8_SG0E@  P:,  +*L  "GM0  G,
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M&"S_[Q@L_^\8+/_O&"S_[QBKJP  GK4  )#!  ""S   ==D  &GD  !A_PD
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M/^\=_S_W'O\__AW_/_\=_S__'?] _QS^0/\;_D#_&_Y _QO^0/\;_D#_&_Y
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M7&N R%QK@>59;H/W4G&$_TURA/](<H3_1W*$_T=RA/]'<H3_1W*$_T?_9@T
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M3E>@_TI9H/]&69__15F?_T59G_]%69__15F?_T7_=0  X(8  ,^3  #$GP$
MNJ<! +&N  "IM@  H;T- )N]( &4O#$'B[H]$(.W2!I\M5 B=;-8*F^R7S!J
ML&8V9:]M.V"M=3]<K'Y#6*N'1U6JDTI1JI],3ZJN34VJP$U-JMQ-3JKR25"J
M_D92J?]#4JG_0E*I_T)2J?]"4JG_0E*I_T+R?   UXP  ,B9  "]HP  LJL
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M+C_0_RX_T/\N/]#_+C_0_R[*E   NZ$  *VI  "BL0  EKL  (O$  " S0,
M==@( &_D$0!JY" !9.0M U[D. =9Y$$+5>1+#U'D5!)-Y%T62N1E&$?D;AM%
MY'<=0N2"'T#DCB$^Y9LC/.6J)#OFO"0ZYM,D.>7N)#GC^B,YXO\D.>+_)#GB
M_R0YXO\D.>+_)#GB_R2_G@  KZ8  *.N  "7N   BL(  '[,  !SU@( :>4)
M &3O% !?\" !6? K U3P-05/\#X'2_%&"D?Q3@Q$\5<.0O%?$#_R9Q(]\G 4
M.O)[%3CSAQ8V\Y08-?2B&3/TL1DR]<4:,?7B&C'T\1DQ\?X9,?'_&3'Q_QDQ
M\?\9,?'_&3'Q_QFRI   I:L  )BV  "+P   ?LH  ''5  !EW@  7O4* %G\
M$P!3_!X!3OPG DK], -%_3D%0?U !C[^2 <[_D\)./]7"C;_7@LS_V<,,?]P
M#2[_? XL_XD/*_^6$"G_I! H_[01)__'$2?_X1$F__(1)O_V$2;_]A$F__81
M)O_V$2;_]A&GJ0  F;,  (N^  !^R0  <-,  &3>  !8YP  4O\) $W_$0!'
M_QD!0_\B 3[_*@(Z_S(#-_\Y S/_/P0P_T8%+?]-!2O_5 8H_UL')O]C!R/_
M;0@A_WD)'_^'"1[_E0H=_Z,*'/^Q"AO_P L:_]8+&O_?"QK_WPL:_]\+&O_?
M"QK_WPN;L0  C;P  '['  !PT@  8]X  %7D  !+]0  1O\% $#_#@ [_Q0
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M3WMMR5!Z;N9-?''X1GYS_T%_=/\]@'7_.H!U_SJ =?\Z@'7_.H!U_SK_70X
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M26:%_T-HAO\_:H;_/&J&_SQJAO\\:H;_/&J&_SS_9P0 ]G8  -R"  #.C0
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M-T^D_S=/I/\W3Z3_-T^D_S?D>@  SXD  ,*5  "VGP  K*4  **L  "8LP
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M&S3<_QNYG   JJ0  )ZK  "2M0  A;X  'G'  !MSP  8M8# %CA" !5ZA,
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M(0 T_RD!,/\P 2W_-P(J_SX")_]$ B7_2P,B_U,#(/]< QW_9@0;_W($&?^
M!1?_CP46_Y\&%?^O!A3_P 84_]8&$__I!A/_Z083_^D&$__I!A/_Z0:7KP
MB+H  'K%  !LSP  7MH  %#@  !$Y@  //4  #?_!  S_PT +_\3 "O_&@ H
M_R$ )?\G 2'_+0$>_S(!&_\X 1G_/P$6_T8"%/]- A'_5@(0_V "#O]L @S_
M>P,+_XL#"O^: PK_J ,)_[4#"/_" PC_P@,(_\(#"/_" PC_P@.*N   >\,
M &S.  !>VP  3^(  $+G   V[   ,?\  "S_   G_P< (_\. "#_$@ <_Q@
M&/\= !7_(0 2_R8 $/\L 0[_,0$-_S<!"O\^ 0C_1@$%_T\! ?]9 0#_9@$
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M4#L%_TY&"/]+4PO_2& ._T9L$?M%>!/X1((5]D.,%_1"E!CS09P9\4&C&^]
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M0(U=S4&,7N@_C6'Y.(UB_S..9/\PCF3_+(YE_RR.9?\LCF7_+(YE_RS_50X
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M/W-R_SEU<_\U=G3_,79T_S%V=/\Q=G3_,79T_S'_708 _VD  .)T  #4?0
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M,E^'_S)?A_\R7X?_,E^'_S+]:   X'8  ,V"  #"C   N9,  +"9  "HG0
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M*42J_RG1@   P8T  +68  "IGP  GJ4  ).L  "(L@  ?;@  '&^!@!NOQ4
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M$#+:L1$QV\<1,=KG$3#8]A(PUO\3+]3_$R_4_Q,OU/\3+]3_$R_4_Q.SF@
MIJ$  )JI  "-L0  @+H  '3!  !HR0  7,\  %+5 P!(W @ 1>42 $/E'@!!
MYBH /N8U 3OG/@$YYT<"-^=0 S3H600RZ&(%,.AM!B[I>0<LZ8<(*^J6"2GJ
MIPHHZKH*)^O6"B?I\ HGY_T))N;_"B;F_PHFYO\*)N;_"B;F_PJHH   G*<
M (^P  ""N0  =,(  &C*  !;T0  3]<  $7=   ^[@D //(1 #GS&P V\R4
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M 0'_I@$ _[4! /_& 0#_R@$ _\H! /_* 0#_R@&&MP  =\$  &C,  !:UP
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M+*A,VRRF3>\JI$_])J10_R.C4?\@HU+_'J)2_QVB4O\=HE+_':)2_QW_2@\
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M,X%A_RV"8O\I@F/_)H)D_R6"9/\E@F3_)8)D_R7_4P8 _UT  .=G  #;;P
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M*FQS_RAL<_\H;'/_*&QS_RC_7   YV@  -5S  #)>P  P((  +B&  "QB
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M%P"1DR@!BY(V!86000M_CDH1>HQ2%G6*6AMQB&$?;8=H(VJ&;R=FA'<K8X.
M+F""BC%=@98T6H&C-EB LC=6@,4W5H#C-EB!]S%9@?\M6X+_*EN"_RE;@O\I
M6X+_*5N"_RGL9@  V',  ,=^  "\AP  LXX  *F2  "@E0  EI@! )"9$P"*
MF20!A9@R!'^6/@EYE$@.=)-0%&^15QEKD%X=:(YE(62-;25@C'4H78M^*UJ*
MB"Y7B90Q5(FA,U*(L#11B,,U4(CB-%*(]C!3B/\L5(C_*56(_RA5B/\H58C_
M*%6(_RCF:P  T'@  ,*#  "WC   K9(  *.6  ":F@  CIX  (>?$ "#GR
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M)$&HK25 J, E/ZC?)3^F]"- I?\B0*7_(4"D_R! I/\@0*3_($"D_R#*?@
MNXL  *^5  "DFP  F:$  (ZF  ""K   =[$  &JV  !CN X 8;@= %ZX+ %:
MN#@"5[A"!5.X2PA0MU,+3;=;#DJV8Q!'MFL31+5U%D*U@1@_M8X:/;6<'#NU
MK!PZM< =.;7?'#FS]!PYLO\<.;'_&SFP_QLYL/\;.;#_&SFP_QO!A@  M),
M *>:  "<H   D:<  (6M  !YLP  ;;@  &*] 0!6P@< 4\,4 %+#(P!0Q# !
M3<0[ DK$10-'Q$X%1<17!T+#7PE PV@+/<-R#3O#?@\XPXP1-L.;$C7#JQ,S
MP\ 3,\/@$S/!]1,RP/\4,K__%#&^_Q0QOO\4,;[_%#&^_Q2XD   JYD  )^@
M  "3IP  AZX  'NT  !NNP  8\   %C% 0!-R@4 1,\, $/0%P!"T"4 0- R
M #_1/0$]T4<!.]%0 CG260,VTF,$--)N!3+2>@<PTH@(+M*8"2W3J0DLT[X*
M+-/?"2O1\PHJS_X+*<[_#"G-_PTIS?\-*<W_#2G-_PVNF   HI\  ):F  ")
MK@  ?+8  &^]  !CPP  5\@  $S-  !"T@, .=D) #7?$  TWQL ,N G #'A
M,@ PX3T +N)' "WB4 $KXEH!*N-E BCC<0(FY'\#)>2/ R/EH00BY;0$(>7-
M!"#D[ 0@XOL$'^'_!1_@_P4?X/\%'^#_!1_@_P6DG@  F*4  (NN  !]M@
M<+X  &/&  !6RP  2]   $#5   VW   +^4' "WM$  K[A@ *>XB "?O*P E
M[S0 (_ \ "'P10 ?\4X '?)8 1OR9 $9\W$!&/.! 1?TD@(5]*4"%/6Z A/U
MU@(3].\"$O+\ A+P_P(2\/\"$O#_ A+P_P*:I   C:T  '^V  !QOP  8\<
M %;.  !)TP  /=H  #/?   JXP  )O0% "3[#0 A_!, 'OT; !S](@ 9_BD
M%_XQ !7_.0 3_T$ $?]* !#_50 ._V$ #/]O 0S_@ $*_Y,!"?^F 0C_N@$'
M_]0!!__K 0;_]@$&__8!!O_V 0;_]@&/K   @+8  '*_  !CR0  5M$  $C8
M   [W0  ,.(  ";F   ?\   '/\  !G_"0 6_PX %/\3 !'_&0 /_QX #?\D
M  O_*P )_S( !O\[  /_1   _T\  /]<  #_:P  _WT  /^0  #_HP  _[0
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M$LHXZ!+'.?<2Q#G_$<(Z_Q#!.O\/P#K_#K\Z_PZ_.O\.OSK_#K\Z_P[_/1,
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M(I1/_Q^44/\<E%'_&I11_QB44?\8E%'_&)11_QC_20@ _U   /M8  #E7@
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M('=B_QYW8O\>=V+_'G=B_Q[_4@  [%P  -QF  #.;0  Q'(  +UT  "W= $
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M*$^$JBI-A+PJ3837*DV#\2=/@_\D4(/_(E"#_Q]0@_\?4(/_'U"#_Q_>:0
MR74  +R   "RB   J(T  )V1  "3DP  A98  'Z7"P!YEQD =9<H 7&7-0-L
MEC\&:)5("F244 UADU<179)>%5J19AA7D&X;5(]W'E&.@2!.CHTC2XV:)4F-
MJ29(C;LG1XW4)T>,\"1(C/\B28O_($J+_QY*B_\>2HO_'DJ+_Q[5;@  PWL
M +>%  "LC0  HI(  )>6  ",F0  ?YP  '6>!0!PGQ, ;9\C &F?, %EGCL$
M89Y%!UV=30I:G%0-5YM<$52:8Q11FFL73IET&4N8?QQ(F(L>19>9($.7J"%"
ME[HB09?3(D&6[R!"E?X>0I7_'4.4_QQ#E/\<0Y3_'$.4_QS,=0  O($  +&,
M  "FD@  FY<  )&;  "%GP  >:,  &JG  !EIPX 8Z@< &"H*P%=J#8"6:=
M!%:G2093IE$)4*99#$VE8 Y*I6D11Z1R%$2D?19"HXD8/Z.7&CVCIQL\H[D<
M.Z/2&SNB[QL[H/X:.Y__&3R?_Q@\G_\8/)__&#R?_QC$?   MHD  *J2  "?
MEP  E9P  (FA  !]I@  <:H  &2N  !:L0@ 5[$4 %6R(P!3LC !4+([ DVR
M1 -+L4T%2+%5!T6Q70E#L64+0+!O#3ZP>@\[L(<1.:^6$S>OIA0VK[@4-;#1
M%#6N[Q0TK?X4-*S_%#2K_Q0TJ_\4-*O_%#2K_Q2[A0  KY   *.7  "8G0
MC*,  ("H  !TK0  :+(  %RV  !0N@$ 2;P- $B\&0!&O2< 1;TS $.]/0%!
MO4<!/[U0 CV]6 ,ZO6$%.+UK!C:]=P@TO80),KV3"C"]I LOO;<,+K[0"RZ\
M[@PMNOX-++G_#2RX_PXLN/\.++C_#BRX_PZSCP  II<  )N=  "/HP  @ZH
M ':P  !JM0  7KH  %*^  !'P@$ /<<& #C)$  WR1L -LHG #7*,P TRST
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M  SK_P ,Z_\ #.O_  SK_P"7HP  B:L  'NT  !MO   7\0  %+*  !%S@
M.=,  "_8   EW0  '>$  !CL @ 6]PL %/<1 !'X%P 0^!X #ODE  WY+0 +
M^C4 "?L_  ?[2@ $_%<  _UF  +^=P  _8L  /V?  #\M0  _-$  /SM  #\
M_   _/T  /S]  #\_0"+JP  ?;0  &Z]  !@Q@  4LT  $32   WV   +-T
M "+A   9Y0  $^H  !#Z   ._P8 #?\,  K_$  '_Q0 !/\:  '_(   _R<
M /\P  #_.@  _T4  /]3  #_8@  _W4  /^*  #_GP  _[,  /_'  #_Y0
M_^4  /_E  #_Y0!_M   <+T  &''  !3T   0]8  #;=   JX@  '^8  !;J
M   0[0  #/H   G_   &_P   O\$  #_"0  _PT  /\0  #_%   _QH  /\A
M  #_*0  _S0  /]   #_3@  _UX  /]R  #_AP  _YH  /^J  #_N0  _[D
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M N\:Z@+L&_<"Z1O_ N@;_P/G'/\#YAS_ ^4<_P/E&_\#Y1O_ ^4;_P/_+1L
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M#[ Z_PZO.O\-KCK_#*TZ_PNM.O\+K3K_"ZTZ_PO_/ T _T & /]%! #_20D
M_TL- /E*$0#M21H XT8F -I&-@#11D4!RT51 \9$7 7"0F8(OT)O"KQ!=PNZ
M0'\-N#^&#K8_CA"T/I41LCZ=$K ^IA.O/K 4K3Z]%*L^S16I/N85IC_W$Z1
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M%H90_Q2&4?\4AE'_%(91_Q3_1P  ^$\  .17  #570  S&   ,5@ @#!7@4
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M&&QA_QCU40  XEP  ,]E  ##:P  N6\  +%Q  "J<0  HF\( )MO%P"6<"<
MD&\U HMN0 6&;$D(@FI2#'YI60][:& 2=V9F%'5F;A=R978:<&1^'6UCB!]K
M8Y,B:6*@)&9BKB5E8K\F9&+:)F1C\B)E9/\>9F3_&V=D_QEG9?\89V7_&&=E
M_QCP4P  W5\  ,MH  "_;P  MG,  *YU  "F=0  G7,% )9S% "1="0 BW,R
M H9R/@2!<$<(?6]/"WEM5PYV;%X1<VMD%'!J;!=M:G,::VE\'&AHAA]F9Y$B
M8V>>)&%FK"5@9KTF7V?6)E]G\2)@:/\>86C_'&)H_QIB:/\98FC_&6)H_QGL
M5P  V6(  ,=K  "\<@  LW<  *IY  "A>0  EW<! )!X$0"+>"$ AG@O 8%W
M.P1\=44'>'1-"G1R50YQ<5P1;G!C%&MO:A9H;G$99FYZ'&-MA!Y@;(\A7FR<
M(UQKJB5::[LF66S3)EIL[R-;;/\?7&W_'%UM_QI=;?\976W_&5UM_QGH6@
MTF8  ,-O  "X=@  KWL  *9^  "=?@  D7P  (I\#P"%?1X @7TM 7Q\.0-W
M>D,&<WE+"7!X4PQL=UH0:79A$V9U:!9C=&\887-X&UYR@AY;<HT@67&:(E=Q
MJ"15<;DE5''0)51Q[B)6<?X>5W'_'%=Q_QI8<?\96''_&5AQ_QGC7@  S6D
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M'4.'ZAQ$AOL:1(;_&$6&_Q=%A?\7187_%T6%_Q?-;0  O7@  +&"  "GB@
MG(X  )*0  "&DP  >94  &R7  !FEPX 8Y@; &&8*0!>F#4!6I<^ U>71P55
MED\'4I96"4^57@Q,E&8.2I1O$$>3>1-$DX450I*3%T"2HA@^DK,9/9+)&3V1
MZ1@]D/H7/H__%CZ/_Q4^C_\5/H__%3Z/_Q7%<P  MW\  *R)  "ACP  EI,
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M!R:R_P@FLO\()K+_"":R_PBOC0  HI0  )>:  "+H   ?J8  '&K  !EL
M6;0  $VW  !"NP  .+X! "_""0 MPQ( +,,> "O#*0 JQ#, *<0] "C%1P G
MQ5$ )L5< "7&:  CQG8!(L:& 2#&F $?QJL!'L?! 1[&Y $=Q/@"',+_ QS!
M_P,<P?\$','_!!S!_P2EE   FIH  (ZA  "!IP  <ZX  &>T  !:N0  3KT
M $+    XPP  +\<  ";+!  >T H &]$1 !K2&@ 9TB4 &-,O !C3.@ 7U$0
M%M10 !7570 4U6L $]9\ !+7CP 1V*0 $-F[ !#9W@ 0U?, $-/_ !#2_P$0
MT?\!$-'_ 1#1_P&<F@  D:$  (.H  !UL   :+<  %N]  !.P0  0L4  #?(
M   MS   )-   !S5   5V@4 $.(+ !#C$0 .Y!H #N0C  WE+0 ,Y3< "^9"
M  KF3P )YUT ".=M  ;F@  %YI4 !.:K  +FQ  !YN8  .?Y  #G_P  YO\
M .;_  #F_P"3H0  A:D  '>Q  !IN0  6\   $[&  !!R@  -<X  "K2   A
MU@  &=L  !+?   -XP  "_$(  GS#@ '\Q, !/(:  +R(@  \BH  /(T  #R
M/P  \DP  /)<  #R;0  \H(  /*8  #SK0  \\8  /3E  #T]@  ]/L  /3[
M  #T^P"'J0  >;(  &JZ  !<P@  3LD  $#.   STP  *-@  ![=   5X0
M#^0   KH   %\P   _T!  #\"   ^PT  /L1  #[%@  _!X  /PF  #\,
M_3P  /Y)  #^6@  _FT  /^"  #_F   _ZP  /_   #_V   _^0  /_D  #_
MY ![L@  ;+L  %W$  !/S0  0-(  #+9   FW@  &^(  !+F   ,Z@  !>T
M  #T    _P   /\   #_    _P0  /\)  #_#@  _Q(  /\8  #_(0  _RL
M /\W  #_1@  _U@  /]K  #_@   _Y4  /^F  #_LP  _[L  /^[  #_NP#_
M&R8 _QPD /\:) #_%2< _Q M /\*-@#_!4, _P%0 ?\ 7@'_ &L!_P!V ?\
M@0#_ (H _P"2 /\ F@#_ *  _P"F /\ K #_ +( _P"Y /\ P@#_ ,T _P#?
M /\ [ #_ /@ _P#_ /T _P#] /\ _0#_ /T _P#] /\ _0#_ /T _P#_'R,
M_Q\A /\>(0#_&2, _Q,I /\.,@#_#$  _PE- ?\'6@'_!&<!_P-S ?\#?0'_
M X<!_P./ /\"E@#_ IP _P*B /\"J #_ J\ _P&V /\!O@#_ <D _P'; /\
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M ?T0C@'\$)4!^A"; ?D0H0'W$*@!]A"O ?00MP#S$,( \1#0 .T0Y0#H$?(
MYA'^ >02_P'C$O\!XA+_ >(2_P'A$O\!X1+_ >$2_P'_*18 _RH3 /\I$@#_
M)Q, _R@< /\G)P#_(S, _R _ /\=3 #_&U@!_!ED ?@9;@'V&'@!\QB! ?$8
MB0'O&) ![AB7 >P8G@'J&*0!Z1BL ><8M 'F&+\!Y!C- > 9XP'<&O$!V!K^
M M0;_P+2&_\"T1O_ M ;_P+0&_\"T!O_ M ;_P+_+1( _RX/ /\N#0#_+Q
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M"IPZ_PF<.O\)G#K_"9PZ_PG_.P( _SX  /=$  #F1P  WT@! -I&!@#90 L
MS4(9 ,5$*P"^1#L N41( ;5#4P.Q0EP$KD)E!JM!; >I0'0)ID!["J0_@PNC
M/XH-H3Z3#I\^G ^=/J40FSZQ$9H^OQ&8/M02EC_M$90__ ^30/\.DD#_#))!
M_PN20?\+DD'_"Y)!_PO_/0  _T,  .E)  #>3@  TT\  ,U. P#*20@ PDD4
M +M*)@"U2S8 KTM# JM*3@.G25<%I$A@!Z%'9PF>1F\*G$9V#)I%?0Z8184/
MED2.$)1$EQ*20Z$3D$.L%(]#NA6-0\T5BT3H%8I%^A*)1O\0B4;_#HA&_PV(
M1O\-B$;_#8A&_PW_0   \D<  .-/  #44P  RU4  ,14  # 4 0 N4\1 +)0
M(@"L43( IU$_ J)02@.>3U,%FTY<")A-8PJ53&H,DTMQ#9%*>0^.2H 1C$F)
M$HI)DA2(2)P5ADBH%H5(M1>#2,<8@4CD&(%*]Q6 2O\2@$O_$(!+_P^ 2_\.
M@$O_#H!+_P[_0P  [$L  -U3  #.6   Q%H  +U:  "X5P$ L50. *I6'@"E
M5BX GU8[ 9M51@.75% %DU-8")!27PJ-468,BU!M#HA/=!"&3WP2A$Z%$X).
MCA6 39D7?DVD&'Q-LAEZ3<,:>4W?&GA.]!=X3_\4>$__$GA0_Q!X4/\/>%#_
M#WA0_P_]1@  YT\  -97  #(7   OU\  +=?  "Q7   JED, *1:&@">6RH
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M&VA9JAQF6KH=95K1'65:[AME6_X79EO_%69<_Q-G7/\29US_$F=<_Q+M3@
MVED  ,AA  "\9P  LVH  *ML  "B:@  F6<" ))G$0"-9R$ B&<O 81F.P)_
M940$>V1-!GAC5 EU8EL+<F%A#7!A:0]M8' 2:U]Y%&E?@Q=F7HX99%Z:&V)>
MJ!QA7K@=7U[.'5]>[!M@7_T885__%6%?_Q-B7_\28E__$F)?_Q+J40  U%P
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M'$]LYQM1;/H846S_%5)L_Q12;/\34FS_$U)L_Q/<7   QV<  +EO  "O=@
MI7L  )Q\  "1?   @G@  'IY!P!U>10 <GHC &YZ+P%K>3H":'E# V1X2P5A
M=U((7W=9"EQV8 Q9=6@/5W1P$51T>A-2<X863W.3&$URH1E,<K$:2G+&&DIR
MY1I+<OD73'+_%4QR_Q--<O\237+_$DUR_Q+48   PFL  +5T  "K>P  HG\
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M#SF)_P\YB?\..8G_#CF)_PZ_<@  LGT  *>&  "<B@  D8X  (:1  !ZDP
M;94  %^7  !4F0$ 3YD/ $Z:&@!,FB< 2IHR $B:/ %&FD0!1)I, D*:5 -
MF5P$/IEF!3N9< <YF'P(-YB*"C68F@LSF*L+,IB_##*8WPLQEO4+,97_"S&4
M_PLQD_\+,9/_"S&3_PNX>@  K(4  *&+  "6D   BY0  '^7  !RFP  9IT
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M A2Z_P*AD@  EI@  (J>  !]I   ;ZH  &*O  !6M   2K<  #ZZ   SO0
M*L   "'$   9QP4 $\L+ !',$@ 1S!L $,PE  _-+P .S3H #LU&  W-4@ -
MSF  #,YP  O.@P *SI< "<ZL  C.Q@ (SN@ ",W[  G+_P )R_\ "<O_  G+
M_P"8F   C9X  '^E  !QK   9+,  %>Y  !*O0  /L   #+#   HQ@  '\H
M !?-   1T0  #-8%  C9#  &V1( !=H;  3:)  #VRX  =LY  #<10  W5(
M -YB  #><P  WH@  -^=  #?LP  W\X  .#N  #?^@  W_\  -__  #?_P"/
MGP  @:8  '.N  !EM0  6+T  $K"   ]Q0  ,<D  ";,   =T   %-0   [9
M   )W0   ^$   #C!P  XPT  .02  #E&0  YB(  .<K  #I-@  ZT,  .Q2
M  #L8@  [78  .Z,  #NH0  [[<  ._1  #OZP  \/8  /#V  #P]@"$IP
M=:\  &>W  !9OP  2\8  #S*   OS@  )-(  !K8   2W   #.    7C
MYP   .L   #K    [04  .X+  #P$   \14  /,>  #T)P  ]S,  /E   #Z
M40  ^V,  /QW  #]C0  _:,  /ZV  #^R0  _]\  /_?  #_WP!WL   :+D
M %K!  !,R@  /,\  "[4   BV@  %]X  !#B   )Y@   .D   #L    \
M /8   #V    ]P   /@   #Z!P  ^PT  /T1  #_&0  _R,  /\O  #_/@
M_T\  /]B  #_=P  _XT  /^?  #_K@  _[H  /^Z  #_N@#_%B, _Q4A /\2
M(0#_#B0 _P8J /\ ,P#_ $$ _P!. /\ 7 #_ &@ _P!T /\ ?@#_ (< _P"/
M /\ E@#_ )P _P"B /\ J #_ *X _P"U /\ O0#_ ,< _P#6 /\ YP#^ /,
M_@#^ /T _P#\ /\ ^P#_ /L _P#[ /\ ^P#_ /L _P#_&B  _QD> /\6'@#_
M$"  _PHE /\$, #_ #T _P!+ /\ 6 #_ &0 _P!P /\ >@#_ (, _P"+ /\
MD@#_ )@ _P"> /\ I #_ *H _P"Q /T N0#[ ,, ^@#0 /@ XP#W /$ ]@#\
M /0 _P#T /\ \P#_ /, _P#S /\ \P#_ /, _P#_'1P _QP9 /\9&0#_%!L
M_PXA /\,+ #_"3D _P5& /\"4P#_ %\ _P!K /\ =0#_ 'X _P"& /\ C@#_
M )0 _@"; /P H0#Z *< ^ "N /4 M0#S +\ \0#+ /  WP#N .X [ #Y .L
M_P#J /\ Z@'_ .D!_P#I ?\ Z0'_ .D!_P#_(!< _Q\4 /\<$P#_%Q4 _Q8=
M /\3* #_$#0 _PU! /\,3@#_"5H _PAF /\(< #^!WD _ >! /H'B0#X!Y
M]@:6 /,&G0#Q!J, [P:J .T&L@#_XO__24-#7U!23T9)3$4 " GJ!KL Z ;(
M .8&W #D!NP X@CZ . *_P#>"_\ W0O_ -T,_P#<#/\ W S_ -P,_P#_(Q(
M_R,0 /\A#@#_'A  _QX8 /\<(P#_&"\ _Q0[ /\220#\$%4 ^ ]@ /0/:@#Q
M#W0 [PY\ .T.A #K#HL Z0Z2 .<.F0#F#J  Y ZG .(.KP#@#K@ W@[% -P.
MV@#6$.P TA'Z ,\2_P#-$O\!S!+_ <L3_P'*$_\!RA+_ <H2_P'_)P\ _R<,
M /\E"0#_)@T _R43 /\C' #_("@ ^QPU /4:0@#O&$\ ZA=: .8690#C%FX
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M!*8L_@6D+/\$HRW_!*(M_P2B+/\$HBS_!*(L_P3_,@  _S,  /DX  #I.0
MXCD  -XU!P#>+@T T2\; ,DQ+ ##,SL O3-( +DT4P&V,UP!LS-E K S;0*N
M,W0#K#)[ ZLR@P2I,HH$IS*3!:4RFP:D,J4&HC*P!Z RO@>?,M$'G#/J!YHS
M^P>8-/\'ES3_!I8T_P:6-/\%EC3_!98T_P7_-0  _S@  .H^  #?0@  U4(
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M"WI&_PIZ1O\)>D;_"7I&_PGU/@  YD@  --/  #'5   O54  +94  "P4
MJ4P+ *)-& "=3B@ F$XV )1.00&034L"C4U3!(I,6@6'2V$&A4MH"(-*;PF
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M#&%7_PSG3   T58  ,%>  "V8P  K68  *1F  ";9   D%X  (E>#@"$7QL
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M$E-BGQ-28JX546+"%5!BX1518O8246+_$%)B_PY28O\-4F+_#5)B_PW95@
MQ&   +=H  "L;@  HW$  )IS  "/<0  ?VL  'AK!0!R:Q( ;FP? &ML+ !H
M;#<!9FQ  F-K2 -@:T\$7FI6!EQJ70=9:64)5VEM"U5I=PU3:((/4&B/$4YG
MG1--9ZP42VC %$MHWA1+9_423&?_#TQG_PY-9_\-36?_#4UG_PW26@  P&0
M +-L  "I<@  H'8  )9W  "*=@  >7$  '%Q  !K<0\ :'$< &9R* !C<C0
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M?   EW\  (R!  "!@0  <H   &5_  !=?P@ 67\3 %> ( !5@"L 4X$V %&
M/@%/@$8"38!. DM_50-)?UT%1G]F!D1^< A"?GL)/WZ("SU]EPP\?:<-.GVZ
M#CI^U@TZ?/$-.GO_##I[_PLZ>O\+.GK_"SIZ_PO :0  LG0  *=\  "=@0
MDH0  (>&  ![AP  ;H<  &"'  !5AP$ 4(@. $Z(&@!-B28 2XDP $F).@!(
MB4(!1HE* 42)4@)"B5H#0(AC!#V(;04[B'@&.8>&"#>'E0DUAZ8*-(>Y"C.'
MTPHSAO ),X7_"3.$_PDS@_\),X/_"3.#_PFY<   K7H  **"  "7AP  C8H
M (&,  !UC@  :(\  %J0  !/D0  1Y(* $22$P!#DQ\ 09,J $"3-  _DST
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M 1BG_P(8IO\"&*;_ ABF_P*EB0  F8\  (^4  "#F0  =9X  &BB  !<I@
M4*D  $2L   YK@  +[   ":S   >M08 &;</ !BW%P 7MR$ %K<J !6W-  4
MN#X $[A) !*X5  2N6( $;EQ !"Y@P /N9< #KFL  VYQ  -N.< #K;[  ZU
M_P .M/\ #K3_  ZT_P"<D   DI4  (:;  !YH   :Z8  %ZK  !2KP  1K(
M #JU   OMP  );H  !V]   5P   $,,&  O&#@ *Q14 "<4>  C%*  'Q3(
M!L8]  7&20 %QE<  \9F  +&=P !QHL  ,:@  #%M@  QM(  ,7O  #%_
MQ?\  ,7_  #%_P"5E@  B9P  'NC  !MJ0  8*\  %.T  !&N   .KL  "Z^
M   DP0  &\0  !/'   .R@  ",X!  '0"@  T!   - 6  #1'@  TB<  -,Q
M  #4/   U4D  -98  #6:0  UGP  -:2  #6IP  UK\  -;@  #6\P  UOX
M -;_  #6_P",G0  ?J0  &^K  !AL@  5+D  $:]   YP0  +<0  "+'   9
MRP  $<X   S2   %U0   -L   #< P  W0H  -X/  #?%   X1P  .(D  #D
M+@  YCH  .=)  #H60  Z&L  .F!  #IF   Z:T  .G%  #IX@  Z?(  .GU
M  #I]0" I0  <:T  &.U  !5O   1\(  #G&   LR@  (,X  !;2   /U@
M"-L   #?    XP   .4   #G    Z $  .H'  #K#0  [1$  .\8  #Q(0
M\RL  /8X  #W2   ^%H  /EM  #ZA   ^IL  /JO  #ZP@  ^MH  /K?  #Z
MWP!TK@  9;8  %:^  !(Q@  .<L  "O0   ?U   %-H   W?   %XP   .8
M  #I    [0   .\   #Q    \P   /4   #V @  ^ D  /H.  #]$P  _QP
M /\H  #_-@  _T<  /]:  #_;@  _X4  /^:  #_JP  _[D  /^\  #_O #_
M$2  _Q > /\,'@#_!"$ _P G /\ , #_ #X _P!, /\ 60#_ &4 _P!P /\
M>@#_ (, _P"+ /\ D@#_ )@ _P"> /\ I #_ *H _P"P /\ N #_ ,( _P#.
M /\ X@#^ /  _0#[ /L _P#[ /\ ^P#_ /H _P#Z /\ ^@#_ /H _P#_%!P
M_Q(: /\.&@#_"!P _P A /\ +0#_ #H _P!( /\ 50#_ &$ _P!L /\ =@#_
M '\ _P"' /\ C@#_ )0 _P": /X H #] *8 _ "L /L M #Y +T ^ #) /<
MW #U .P \P#X /, _P#R /\ \0#_ /  _P#P /\ \ #_ /  _P#_%Q@ _Q46
M /\1%0#_#!< _P4= /\ * #_ #8 _P!# /\ 4 #_ %P _P!G /\ <0#_ 'H
M_ "" /H B0#X )  ]P"6 /4 G #T *( \P"H /$ L #P +@ [@## .P TP#J
M .< Z0#U .< _P#F /\ Y0#_ .4 _P#E /\ Y0#_ .4 _P#_&A, _Q@1 /\4
M$ #_#Q$ _PT9 /\*) #_!3  _P$^ /\ 2P#_ %< _@!B /H ; #U '4 \@!]
M /  A #N (L [ "1 .L EP#I )X YP"D .8 K #D +0 X@"_ .  S0#> .,
MW #R -H _0#8 /\ U@#_ -4!_P#5 ?\ U0+_ -4"_P#_'A  _QP- /\7"P#_
M%0X _Q05 /\1'P#_#BH _PLX /T(10#X!E$ ] 1< .X$9@#J!&\ Y@-W .0$
M?P#B!(8 X 2, -X$DP#=!9H VP6@ -@%J #5!;$ T@6[ - &R0#.!^  S CQ
M ,D*_P#'"_\ Q@S_ ,4,_P#%#/\ Q0S_ ,4,_P#_(0P _R & /\< P#_'0H
M_QL0 /\8& #_%", ]A$P .\./@#J#DH Y0U6 .$-8 #=#6D V0UQ -4->0#3
M#8$ T0V( ,\-CP#-#I8 RPZ= ,H.I0#(#JX Q@^Y ,00R #"$-\ OA'R +L2
M_P"Y$_\ MQ/_ ;83_P&V$_\!MA/_ ;83_P'_)08 _R,  /\C  #_) , _R$*
M /T=$0#Q&AL Z!8G .$4-0#:$T, TQ1/ ,X560#+%6, R!9K ,46<P##%WL
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M Y N_P.0+?\#D"W_ Y M_P/_,   \C,  .0Z  #6/0  S#P  ,<Y  ##,04
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M!VQ%_P?L/P  V$D  ,=0  "[5   L54  *E4  "A4   F4H" )))$0"-2A\
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M#%Y0G@U<4*T.6U' #EI1W@]:4?4,6E+_"EM2_PE;4?\(6U'_"%M1_PC?2@
MR5,  +M:  "P7P  IF$  )UA  "47@  B%<  (!6"@!Z5Q4 =E<B '-8+@!P
M5SD ;5=! 6I720)H5E "9E97 V167@1B564%8%5M!UY5=PA<58(*6E6.#%E5
MG U75:L.5E6^#U55VP]55?,-557_"U95_PE65?\)5E7_"%95_PC;30  Q5<
M +A>  "M8@  HV4  )IE  "08P  @UP  'M;!@!U6Q( <5L? &Y<*P!K7#8
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M#49CT0U&8^\,1F+_"D=B_PE'8O\)1V+_"$=B_PC*6   NF(  *YI  "C;@
MFG$  )!R  "$<0  =&L  &EI  !C:0L 7VD5 %QJ(0!::BT 6&LV %9K/P%5
M:T<!4VI. E%J50-/:ET$36IE!4II;@9(:7D'1FF&"41IE0I#:*4+06FW#$!I
MSPQ :.X+06C_"D%G_PE!9_\(0F?_"$)G_PC%70  MF8  *IM  "@<P  EG8
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M!2U^_P4M??\%+7W_!2U]_P6S;@  J'@  )U_  "2@P  B(8  'V'  !PB
M8XD  %6*  !+B@  08H" #N+#@ YBQ< .(PB #>,+  VC#4 -(P] #.,1@ R
MC4\ ,8U8 "^-8@$MC&X!*XQ[ 2J,BP(HC)P")HRO B6,Q@(EB^@")8K[ R6(
M_P,EB/\#)8?_ R6'_P.M=@  HX   )>%  "-B0  @HP  ':.  !ID   7)(
M %"3  !$E   .I4  #&6"  MEQ$ +)<: "N7)  JERT *9<V "B8/P GF$@
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M  :N_P"8C@  CY,  (*8  !UG0  9Z(  %JG  !.JP  0:T  #6O   KL0
M(;0  !BV   1N0  #;P#  >^#  #O1(  ;T9  "^(@  OBL  +XV  "^00
MOTX  +]<  "_;0  OX   +Z5  "^J@  OL(  +WD  "]]@  O?\  +W_  "]
M_P"2E   A9H  'B@  !JI@  7*L  $^P  !"LP  -;8  "JX   @NP  %[X
M !#!   +Q   !,<   #)!P  R0T  ,D2  #*&0  RR(  ,LK  #--0  SD$
M ,Y0  #/8   SW(  ,^'  #/G0  S[,  ,_.  #/ZP  SO@  ,[^  #._@"(
MFP  >J(  &RH  !>KP  4+4  $*Y   UO   *;\  !["   5Q@  #LD   C,
M    T    -,   #5    U@8  -@,  #9$0  VQ8  -P?  #>*   X#0  .)!
M  #B40  XV,  .-W  #DC@  Y*0  .2Z  #EU   Y>H  .7S  #E\P!\HP
M;JH  &"R  !1N0  0[X  #7"   HQ@  ',D  !/-   ,T0  !-4   #:
MW@   .$   #B    Y    .4#  #G"0  Z0X  .L2  #M&@  [R0  /(Q  #T
M00  ]%,  /5F  #U?   ]I,  /:I  #WO   ]\X  /??  #WWP!PK   8;0
M %.[  !%PP  -L<  "?,   ;T   $=4   K;    WP   .(   #E    Z0
M .P   #M    \    /$   #S    ]00  /<*  #Z$   _!8  /\A  #_+@
M_T   /]3  #_:   _X   /^6  #_J   _[8  /^_  #_OP#_#1P _PH; /\"
M&P#_ !X _P D /\ +@#_ #P _P!* /\ 5@#_ &, _P!M /\ =P#_ '\ _P"'
M /\ C@#_ )0 _P": /\ H #_ *8 _P"L /\ M #_ +T _P#) /X W0#] .T
M_ #Z /L _P#Z /\ ^0#_ /H _P#Z /\ ^@#_ /H _P#_$!D _PT7 /\&%@#_
M !@ _P > /\ *@#_ #< _P!% /\ 4@#_ %X _P!I /\ <@#_ 'L _P"" /\
MB0#_ )  _@"6 /T G #\ *$ ^P"H /D KP#X +@ ]@## /0 T@#S .< \@#V
M /  _P#O /\ \ #_ .\ _P#O /\ [@#_ .X _P#_$A0 _P\2 /\+$@#_ !(
M_P : /\ )0#_ #, _P!  /\ 30#_ %D _P!D /T ;0#[ '8 ^0!] /< A #U
M (L ] "1 /, EP#Q )T \ "C .X J@#L +, Z@"] .@ RP#G .$ Y0#Q .,
M_0#C /\ X@#_ .$ _P#A /\ X #_ .  _P#_%!  _Q$. /\-#0#_!P\ _P(5
M /\ ( #_ "T _P Z /\ 1P#Y %, ]0!> /( : #P '  [0!X .L ?P#I (4
MZ ", .8 D@#E )@ XP"? .$ I@#? *X W "X -H Q0#6 -D U #L -( ^0#1
M /\ SP#_ ,X _P#. /\ S@#_ ,X _P#_%PP _Q0( /\/!0#_#@L _PP1 /\'
M&@#_ 28 _  T /0 00#M $T Z0!8 .8 8@#C &H X !R -X >0#; (  V0"&
M -8 C0#3 ), T0": ,\ H0#- *H RP"S ,D OP#& -  Q0#H ,, ]@#! /\
MP +_ +\#_P"_ _\ OP/_ +\#_P#_&P8 _Q<  /\4  #_$P4 _Q$- /\.% #Y
M"A\ \ 8L .8#.0#@ T8 W -1 -8$6P#2!&0 SP5L ,P%<P#*!7H R 6! ,8%
MAP#%!HX PP:6 ,$&G0"_!J8 O0:P +L'O "Y",T N KE +4+]P"S#?\ L0W_
M + -_P"P#O\ KP[_ *\._P#_'@  _QL  /\;  #Z&@  ]18% /81#0#K#A4
MX@LB -@+,0#0##X RPU* ,<-50#$#EX P0YF +\.;0"]#G0 NP][ +D/@@"W
M$(H MA"1 +00F@"R$*, L!&M *\1N@"M$<H JA+E *<4]P"E%?\ HQ7_ *(5
M_P"B%?\ HA7_ *(5_P#_(@  _R   / C  #F)   X"$  -P9!0#;$ P T!$9
M ,@3*0#"%3< O19$ +D73@"U%U< LQA@ + 89P"N&&X K!EU *L9? "I&80
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M GXN_P+T+@  Y#<  -(]  #%/P  NS\  +0\  "O-0  J2\+ *,O%P">,28
MF3(S )8R/@"2,T@ D#-0 (TS6 "+,UX!B3-E 8<S; &&,W,!A#-\ H(SA0*
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M!6L^H 9J/JX&:3_ !V<_W@=G/_4&9D#_!69 _P1F0/\$9C__!&8__P3E/0
MST8  +],  "T3P  JE   *)/  "92@  D40  (I!#0"$0AD @$,F 'U$,@!Z
M1#P =T1$ '5$3 %R1%,!<$-9 6]#8 )M0V<":T-O VE#>01H0X,%9D./!F1#
MG0=C0ZL'84.]"&!$V0A@1/,'8$3_!E]$_P5?1/\$8$3_!&!$_P3@00  RDH
M +M0  "P4P  IU4  )Y3  "53P  BTD  (-'"P!]1Q4 >4<B '9(+@!S2#@
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M"5!0S@E/4.T(4%#_!U!0_P904/\%4%#_!5!0_P702P  OU0  +):  "G7@
MG6   )1@  ")70  ?%<  ')4  !L4PX :%09 &54) !B5"\ 8%0X %Y40 !<
M5$@!6E1/ 5E45@%75%T"551E U14;@125'D%4%2&!DY4E =-5*0(2U2U"$M4
MS E*5.L(2U3^!TM4_P9+5/\%2U3_!4M4_P7,3@  NU<  *Y>  "D8@  FF0
M )%D  "&8@  =UL  &U8  !F6 P 8E@6 %]8(@!=62P 6UDV %E9/@!7648
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M!3MB_P4[8O\%/&'_!#QA_P2^6P  L&,  *5J  ";;P  D7(  (9R  ![<0
M;&T  &!K  !5:0  3V@- $UI%P!+:2$ 26HK $AJ- !':CT 16M$ $1K3 !"
M:U0!06M< 3]J90(]:G ".VI] SEJC 0W:IP$-FJN!35JQ 4U:N4%-6GY!#5I
M_P0U:/\$-6C_!#5H_P2Y8   K&D  *%P  "8=0  C7<  ()W  !W=P  :70
M %QS  !1<0  2' * $5P$@!#<1T 0G$G $!R,  _<C@ /G)  #UR2  [<E
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M 1Z!_P&H=   GGT  )."  ")A0  ?H@  '&*  !EBP  6(P  $R-  ! C@
M-HX  "R/   ED P (Y 3 "*0'  AD"4 ()$N !^1-@ >D4  '9%) !R15  :
MD6  &9%N !B1?@ 6DI  %9*D !21N0 3D=@ $X_T !2._P 4C?\ %(S_ 12,
M_P&C?0  F(,  (Z(  "$C   =X\  &F1  !=DP  4)4  $67   YF   +ID
M "6:   =FP( %IT, !6=$P 4G1L $YTD !*=+0 1GC< $9Y! !">3  /GE@
M#IYG  V>=P ,GHH "YV>  J=L@ )G<P "9SL  J;_@ +FO\ "YG_  N9_P"<
MA   D8H  (B.  ![D@  ;98  &"9  !4G   2)\  #R@   PH0  )J,  !VE
M   5IP  $*D%  NK#0 (JA, !ZH;  :J)  %JBX !*HX  *J1  !JE   *I>
M  "J;@  JH$  *J5  "IJ@  J<$  *CD  "H]@  I_\  *?_  "G_P"5BP
MC)   '^5  !QF@  8YX  %:B  !*I@  /:@  #&J   FJP  ':T  !2P   .
ML@  ";4!  *V"@  M@\  +85  "W'0  MR4  +<O  "X.0  N$8  +A4  "X
M9   N'8  +B+  "WH   M[8  +?3  "V[P  MOP  +;_  "V_P"/D@  @I<
M '2=  !FH@  6*<  $NL   ^KP  ,;$  ":S   <M@  $[@   V[   &O@
M ,$   #"!   P@L  ,,0  #$%0  Q!P  ,4D  #&+@  R#H  ,E'  #)5P
MR6D  ,E]  #)E   R*H  ,C#  #(Y   R/0  ,C]  #(_0"%F0  =Y\  &BF
M  !:JP  3;$  #^U   QN   );H  !J]   1P   "\,   /'    R@   ,T
M  #.    SP,  - )  #1#@  TQ(  -49  #7(@  VBT  -TY  #>20  WEH
M -]N  #?A0  WYP  -^R  #>RP  WN8  -_T  #?] !YH0  :Z@  %RO  !.
MM0  0+L  #&^   DP0  &<4  !#(   )S    ,\   #3    V0   -P   #=
M    WP   .$   #B!0  Y L  .80  #H%@  ZB   .TK  #P.@  \4L  /%>
M  #R<P  \XL  /.B  #SM@  \\D  //A  #SX0!MJ@  7K$  %"Y  !!OP
M,L0  "3(   7S   #M    ;5    V@   -X   #B    Y@   .D   #J
M[    .X   #P    \@   /0&  #V#   ^1(  /P<  #_*0  _SH  /]-  #_
M8@  _W@  /^0  #_HP  _[,  /_!  #_P0#_!QD _P$7 /\ %P#_ !H _P A
M /\ *P#_ #D _P!' /\ 5 #_ %\ _P!J /\ <P#_ 'L _P"# /\ B@#_ )
M_P"6 /\ FP#_ *$ _P"H /\ KP#_ +@ _P#$ /X U0#\ .H ^P#X /H _P#Y
M /\ ^ #_ /@ _P#V /\ \P#_ /$ _P#_"Q4 _P43 /\ $P#_ !0 _P : /\
M)P#_ #0 _P!" /\ 3P#_ %L _P!E /\ ;@#_ '8 _P!^ /\ A0#^ (L _0"1
M /L EP#Z )T ^ "C /< JP#V +, ] "^ /, S #Q ., [P#S .X _P#M /\
M[ #_ .L _P#L /\ [ #_ .L _P#_#1$ _PD0 /\ #P#_ !  _P 6 /\ (@#_
M "\ _P ] /\ 2@#_ %4 _0!@ /H :0#X '$ ]@!Y /0 ?P#S (8 \0", .\
MD@#N )@ [ "? .L I@#I *X YP"X .4 Q0#C -H X0#M -\ ^P#> /\ W0#_
M -T _P#= /\ W0#_ -T _P#_#PT _PP+ /\#"0#_  P _P 2 /\ '0#_ "D
M^P W /@ 1 #U %  \@!: .X 8P#L &L Z0!S .< >@#E (  XP"& .$ C #?
M ), W0"9 -L H0#9 *D U0"R -( O@#0 ,X S@#F ,P ]@#* /\ R@#_ ,D
M_P#( /\ R #_ ,@ _P#_$0@ _PT" /\'  #_!0@ _P . /\ %@#W "( [P P
M .L /0#H $D Y !4 .  70#= &4 V0!M -4 <P#2 'H T "  ,X AP#, (T
MR@"4 ,@ FP#& *0 Q "M ,( N #  ,< O0#? +P \0"[ /X N0#_ +@ _P"X
M /\ N #_ +@ _P#_%   _P\  /\-  #_#   _P<) /@!$ #H !H XP H -T
M-@#8 $( T@!- ,X 5P#* %\ QP!F ,4 ;0## '0 P0!Z +\ @0"] (@ NP"/
M +D EP"W )\ M0"H +, LP"Q ,( KP#8 *X"[0"L _L JP7_ *H&_P"I!O\
MJ0;_ *D&_P#_%@  _Q(  /<2  #L$0  Y@X  .4&" #= Q( U ,@ ,T$+0#(
M!#H PP5& +\%4 "\!E@ N09@ +<'9P"U!VX LP=U +$(>P"O"(( K@F* *P)
MD@"J"9L J JE *8*L "E"[\ HPS4 *$-[0"?#OX G0[_ )P/_P";#_\ FP__
M )L/_P#_&@  ]QD  .H>  #?'@  U1H  - 3 @#.# L QPL6 , -)0"Z#C(
MM@X_ +(/20"O$%( K!!: *H080"H$6@ IA%O *01=@"B$7T H1&% )\2C@"=
M$I< G!*B )H3K0"8$[P EQ30 )05[ "2%OT D!?_ (\7_P".%_\ CA?_ (X7
M_P#Z'0  [B,  -\H  #0*@  QR<  ,$A  "]&04 N1(0 +(5'@"M%BP J!<X
M *080P"A&4P GQE4 )P:7 ":&F( F1II )<;< "5&W< E!M_ )(<B "0')(
MCQR= (T=J0"+';< BA[* (@?YP"&(/H A"#_ 8,@_P&#(/\!@B#_ 8(@_P'U
M)   Y2P  -,Q  #&,P  O#$  +8M  "P)0  K!T, *8>& "A("8 G"$R )DB
M/0"5(D< DR-/ )$C5@"/(UT C21D (LD:P"))'( B"1Z (8D@P"$)8T @R68
M 8$EI & )K(!?B;% 7TGX@%[)_<!>2C_ 7@H_P%X*/\!>"C_ 7@H_P'O*P
MW3,  ,HY  "^.P  M#H  *TV  "F+P  H2@' )LG$P"6*"  D2DM (XJ. "+
M*T( B"M* (8K4@"$*U@ @BQ? ( L9@!_+&T ?2QU 'LL?@%Z+(@!>"R4 78M
MH %U+:X"="W  G(NW0)Q+O0"<"__ F\O_P)O+_\!;B__ 6XO_P'H,0  TSH
M ,,_  "W00  KD$  *8^  ">.   ES$! )$N$ ",+QP B# H (0Q,P"!,CT
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M!%H^S 1:/^P$63_^ UD__P-9/_\"63__ ED^_P+6/P  PT<  +5,  "J4
MH%   )=/  ".2P  A$4  'I !@!U/Q$ <4 < &U * !K03( :4$[ &=!0@!E
M04D 8T%0 &%!5P!@05X!7D%F 5U";P);0GH"6D*& UA"E -70J,$54.S!%1#
MR0140^D$4T/] U-#_P-40_\#5$/_ E1#_P+00@  OTH  +)0  "G4P  G50
M )13  "*4   ?TH  '5% @!N0PX :T09 &=%) !E12X 8D4W &%%/P!?148
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M!$5/_P-%3_\#14[_ T5._P/$3   M54  *E;  "?7@  E6   (M@  " 7@
M<E<  &=3  !>40< 65$1 %=1&P!4424 4E(O %%2-P!/4C\ 3E)& $U330!,
M4U4 2E-= 4E39@%'4W "15-] D13BP-"4YL#052L!$!4P00_5.($/U3X T!3
M_P- 4_\#0%/_ T!2_P/ 4   LE@  *9>  "<8@  DF4  (AE  !]8@  ;EP
M &-9  !95@, 5%8. %%6& !/5B( 35<L $Q7- !*5SP 25A$ $A82P!'6%,
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M B]B_P*S7@  IV8  )QM  "3<0  B',  'US  !R<@  9'   %AN  !-;
M0FH# #QI#@ Z:A8 .6H@ #AJ*  V:S$ -6LY #1K00 S;$D ,FQ2 #%L7  O
M;&8 +FQS "QL@@$J;),!*6RE 2ALN0$G;=8!)VOR 2=J_P$G:O\!*&G_ BAI
M_P*N9   HVP  )ES  ".=@  A'@  'EY  !M>   8'<  %-V  !(=0  /G,
M #1R"@ Q<Q$ ,',: "]S(P N<RL +70T "QT/  K=$0 *71- "AU5P G=6,
M)75O "1U?P B=9  (76B "!UMP ?==( 'W3Q !]S_P$?<O\!(''_ 2!Q_P&I
M:P  GG,  )1Y  "*?   @'X  '1_  !G?P  6G\  $U^  !#?@  .'T  "]]
M @ H?0T )GT4 "1]'  C?B4 (GXM "%^-@ A?C\ 'W]( !Y_4@ =?UX '']K
M !I_>@ 9?XP %W^? !9_LP 5?\X %7[O !9\_P 6>_\ %GO_ !=[_P"D<@
MFGH  (]_  "%@@  >X0  &V&  !@AP  5(<  $B(   \B   ,H@  "B(   @
MB 4 &HD. !F)%0 8B1T %XHF !:*+@ 5BC< %(I! !.*3  2BU@ $8ME !"+
M=0 /BX< #HJ;  V*KP ,BL@ #(GJ  V'_  .A_\ #H;_  Z&_P"?>P  E($
M (J%  " B   <XL  &6-  !9CP  3)   $&2   TD@  *I(  "&3   9E
M$I8&  Z7#@ -EQ4 #)<=  R7)@ +ER\ "I<Y  F71  (EU  !I=>  67;@ #
MEH   9:4  "5J   E;X  )3@  "4]   D_\  9+_  &2_P"8@@  CH@  (6,
M  !WCP  :I(  %V5  !0F   1)H  #B;   LG   (IT  !F>   2H   #:("
M  >C"P !HQ   *,7  "C'P  HR<  *,Q  "D/   I$@  *16  "D90  HW<
M *.+  "CH   HK8  *'2  "A\   H/L  *#_  "@_P"1B@  B8X  'N2  !M
MEP  8)L  %.>  !&H0  .:,  "VD   CI@  &:@  !&J   ,K   !:X   "O
M!P  KPT  *\1  "P&   L"   +$H  "Q,@  LCX  +),  "R6P  LFP  +*!
M  "QEP  L:P  +#&  "PZ   K_<  *__  "O_P",D   ?Y4  '&:  !CGP
M5:0  $>H   ZJ@  +:P  "*N   8L   $+,   JU   "N    +L   "[
MO <  +P-  "]$0  OA8  +\>  # )P  P3(  ,)   ##3P  PV   ,-T  ##
MBP  PZ$  ,.X  #"UP  PN\  ,+Z  #!_@"!EP  <YT  &6C  !7J   2:T
M #NQ   MLP  (;8  !:Y   .NP  ![X   #!    Q0   ,<   #(    R0
M ,H%  #+"P  S0\  ,X4  #0'   TR8  -8R  #800  V%,  -EF  #9?
MV90  -FK  #9PP  V>$  -GP  #9] !VGP  9Z8  %FL  !+L@  /+<  "ZZ
M   AO0  %<    W$   %QP   ,H   #.    T@   -4   #6    V0   -L
M  #=    WP<  .$,  #C$0  YAD  .DD  #L,@  [4,  .Y6  #O:P  [X0
M .^<  #OL@  [\8  ._=  #OY !JJ   6Z\  $RV   ^O   +\   "#$   4
MR   #,P   +0    U    -D   #>    X@   .4   #F    Z    .D   #L
M    [@   / "  #R"0  ]0\  /@7  #\(P  _S,  /]&  #_6@  _W$  /^)
M  #_GP  _[$  /_   #_Q@#_ !4 _P 4 /\ % #_ !< _P = /\ * #_ #<
M_P!$ /\ 40#_ %P _P!F /\ ;P#_ '< _P!^ /\ A0#_ (L _P"1 /\ EP#_
M )T _P"D /\ JP#_ +0 _@"_ /T S@#[ .8 ^0#V /@ _P#W /\ ]P#_ /<
M_P#P /\ [ #_ .D _P#_ Q( _P 0 /\ $ #_ !$ _P 7 /\ ) #_ #( _P _
M /\ 3 #_ %< _P!A /\ :@#_ '( _P!Y /T @ #\ (8 ^@", /D D@#X )@
M]@"? /4 I@#T *X \@"Y /  Q@#N -X [0#P .L _@#J /\ Z0#_ .D _P#G
M /\ XP#_ .  _P#_!PX _P - /\ "P#_  P _P 3 /\ 'P#_ "P _P Z /\
M1@#^ %( ^P!< /@ 90#U &P \P!T /$ >@#O ($ [@"' .P C0#J ), Z0":
M .< H0#F *D XP"S .$ OP#? -  W0#I -H ^0#9 /\ UP#_ -4 _P#5 /\
MU0#_ -0 _P#_"0H _P$% /\  P#_  D _P 0 /\ &0#[ "8 ]P T /0 0 #R
M $P [@!6 .H 7P#G &< Y !N .( = #@ 'L W@"! -P AP#: (T U@"4 -0
MFP#1 *, SP"M ,P N #* ,< R #@ ,8 \P#% /\ PP#_ ,, _P## /\ PP#_
M ,, _P#_"P$ _P,  /\   #_  , _P + /, $@#N !\ Z@ M .8 .@#B $4
MW@!/ -D 6 #4 &  T0!H ,X ;@#, '0 R@![ ,@ @0#& (< Q ". ,( E@#
M )X O@"G +L L@"Y ,  MP#4 +4 [ "S /L LP#_ +( _P"R /\ L0#_ +$
M_P#_#0  _P8  /\#  #W    ]  # .< #0#@ !@ V@ E -, ,@#. #X R@!)
M ,8 4@## %H P !A +X : "\ &X N@!T +@ >P"V ($ M "( +( D "P )D
MK@"B *P K0"J +H J #+ *8 Y@"E /< I #_ *, _P"B /\ H@#_ *( _P#_
M$   ^PP  .\.  #F#0  WPD  -H !@#0 !$ R0 = ,0 *@"_ #< NP!" +<
M2P"T %0 L@!; *\ 8@"M &@ JP!N *D =0"H 'L I@"# *0 BP"B )0 H ">
M )X!J "< K4 FP/& )D%X@"8!O0 E@C_ )4)_P"4"?\ E G_ )0)_P#\$0
M\14  .,9  #6&0  S!4  ,<0  #$!PH O0,4 +<$(0"R!BX K@@Z *H)1 "G
M"4T I I5 *(*7 "@"F( G@MI )P+;P";"W8 F0Q^ )<,A@"6#)  E R: )(-
MI@"1#;, CPW% (T.X@"+$/8 B1#_ (@1_P"'$?\ AQ'_ (<1_P#V&0  YR
M -8D  #()0  OR(  +D<  "T% $ L0T. *H.&0"E#R< H1 S )T1/@":$4<
MF!)/ )425@"3$EP D1)C ) 3:0".$W  C!-X (L3@0")%(L AQ26 (85H@"$
M%;  @Q;! ($7W0!_&/0 ?1G_ 'P9_P!\&?\ >QG_ 'L9_P#O(0  W2D  ,HM
M  "^+P  M2P  *XG  "H(   HQ<( )X6$P"9%R$ E!DM )$:. ".&D$ BQM)
M (D;4 "'&U< A1Q> (0<9 ""'&L @!QS '\=? !]'88 ?!Z1 'H>G@!X'ZL
M=Q^\ '8@U !T(?  <B'_ '$B_P!Q(?\ <2'_ '$A_P#H*   TC   ,(U  "W
M-P  K34  *4Q  ">*P  F"," )(>$ "-(!L B2$G (8B,@"#(SP @2-$ 'XC
M2P!\)%( >R19 'DD7P!W)&8 =B5N '0E=P!S)8$ <2:- &\FF0!N)J< ;2>X
M &PGS@%J*.T!:2G_ 6@I_P%H*?\!:"C_ 6@H_P'A+@  RS8  +P[  "Q/0
MIST  )\Y  "7,P  CRT  (@G# "#)Q8 ?R@B 'PI+0!Y*C< =RH_ '4J1P!S
M*TX <2M4 ' K6P!N*V( ;"MJ &LL<@!I+'T :"R) &8ME@%E+:0!9"ZT 6,N
MR@%A+^D!8"_] 6 O_P%@+_\!8"__ 6 N_P':-   Q3P  +=!  "L0P  HD,
M )E   "0.@  B#0  ( N" !Z+1( =RX> ',O*0!Q,#, ;S [ &TP0P!K,4H
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M DT^_P%-/O\!33W_ 4T]_P')0   N$@  *Q-  "A4   EU$  (Y/  "$2P
M>44  &Y   !F/0L 8CT4 %\]'@!</B@ 6CXQ %@^. !7/D  53]& %0_30!3
M/U4 4D!= %! 9@!/0' !3D!\ 4Q!B@%+09H"2D&K DE"O@)(0MX"2$+V DA"
M_P)(0O\!2$'_ 4A!_P'%1   M4L  *E0  ">5   E50  (M3  " 4   =4H
M &I&  !A0@@ 7$$1 %E"&P!70B4 54(N %-"-0!10CT 3T)# $]#2P!.0U(
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M 3I-_P&Z3@  K%8  *%;  "77P  C6$  (-A  !X7@  :5@  %]6  !44@
M3$\+ $E/$@!'4!P 15 E $-0+0!"4#4 05$\ $!11  _44P /E)4 #Q270 [
M4F< .E)S #A3@@$W4Y(!-5.D 313MP$S5-$!,U/Q 313_P$T4O\!-%+_ 312
M_P&V4@  J5H  )Y@  "49   BV8  (!E  !T8P  9EX  %Q<  !16   1U4'
M $)5$ ! 51@ /U8A #U6*@ \5C( .U8Y #I700 Y5TD .%=1 #=86@ U6&4
M-%AQ #)8@ $Q6) !+UFB 2Y9M0$M6<\!+5GO 2Y8_P$N5_\!+E?_ 2Y6_P&R
M5P  I5\  )ME  "1:0  AVH  'QJ  !Q:   8V4  %AB  !-7P  0UT" #Q;
M#0 Z7!0 .%P= #=<)@ U72X -%TV #-=/@ R748 ,5Y. #!>5P O7F( +5YN
M "Q??0 J7XX *5^@ "A?LP$G7\P )U_M 2=>_P$G7?\!*%W_ 2A<_P&M7
MHF0  )AJ  ".;@  @V\  'EO  !N;@  8&L  %1I  !)9P  /V4  #5C"0 R
M8Q$ ,&,9 "]D(0 N9"D +60Q "QD.0 K94( *F5* "AE5  G95\ )F9K "1F
M>@ C9HL (F:= "!FL0 ?9LD 'V;K "!E_@ @9/\ (&/_ 2%C_P&I8@  GFH
M )5P  "*<P  @'4  '5U  !I=   7'(  $]Q  !$;P  .FX  #!M P I; T
M)VP4 "9L'  E;20 )&TL "-M-  B;3T (6Y& "!N4  >;EL '6YG !QN=@ :
M;H< &6^: !AOK@ 6;\8 %F[I !=M_  8;/\ &&O_ !AK_P"D:0  FG$  )!V
M  "&>0  ?'L  '%[  !D>P  5WH  $IY   _>   -7@  "MW   B=@< '78/
M !QW%@ ;=QX &G<F !EW+@ 8=S< %WA  !5X2@ 4>%8 $WAC !)X<@ 1>(,
M$'B7  ]XJP .>,, #G?F  YV^@ /=?\ $'7_ !!T_P"?<0  E7@  (M\  ""
M?P  =X$  &J"  !=@@  4((  $2"   X@@  +H(  "2"   <@@  %(() !&#
M$  0@Q8 $(,>  Z#)P .@S  #8,Y  V#1  ,@U  "X-=  F#;  (@WX !H.1
M  6"I0 #@KL !(';  2!\@ %@/\ !G__  9__P":>0  D'X  (:#  !]A0
M;X<  &*)  !5B@  28L  #V,   QC   )HP  !V-   5C@  #X\#  J0#  &
MD!$ !(\8  ./(  !CRD  (\R  "0/0  D$D  (]6  "/90  CW8  (^*  ".
MGP  CK0  (W/  ",[@  C/L  (O_  "+_P"4@   BX4  (*)  !TC   9H\
M %F1  !,DP  0)4  #26   HE@  'I<  !68   /F@  "IL   *<"0  G X
M )P3  "<&@  G"(  )TK  "=-0  G4   )U.  "=7   G6X  )R!  "<EP
MG*P  )O&  ":Z   F?D  )G_  "8_P".B   AHP  'B0  !JE   7)<  $^:
M  !"G0  -IX  "F?   ?H0  %:(   ZD   (I@   *@   "I!   J0H  *D.
M  "I$P  JAH  *HB  "K*P  K#8  *Q$  "L4P  K&,  *QW  "KC@  JZ0
M *N\  "JW@  J?0  *G]  "I_P")C@  >Y,  &V7  !?G   4:   $2D   V
MI@  *J@  !ZI   4JP  #:X   :P    L@   +4   "U    M0,  +8)  "W
M#@  N!(  +@9  "Z(0  NRL  +PX  "]1P  O5@  +UK  "]@0  O9D  +VP
M  "]S   O.H  +SW  "[_@!^E0  <)L  &*@  !3I0  1JH  #BM   JKP
M'K$  !.T   ,MP   [D   "\    OP   ,(   #"    PP   ,0   #&!@
MQPP  ,@0  #*%@  S"   ,\K  #0.@  T4L  -%>  #2<P  THL  -*D  #3
MNP  T]@  -/M  #3]@!SG0  9*,  %:I  !'KP  .;,  "JV   =N0  $KP
M  J_    PP   ,8   #)    S0   ,\   #0    T@   -0   #6    V0(
M -L(  #>#@  X1,  .0=  #H*@  Z#P  .E/  #I9   ZGP  .N5  #KK
MZ\(  .S5  #LY0!FI@  6*P  $FS   [N0  *[P  !W    1Q   "<@   #,
M    SP   -,   #9    W0   .    #A    XP   .4   #G    Z@   .P
M  #N!   \0L  /42  #X'   ^RL  /T^  #^4P  _FH  /^#  #_FP  _ZX
M /^^  #_R@#_ !( _P 0 /\ $0#_ !, _P 9 /\ )@#_ #0 _P!! /\ 30#_
M %@ _P!B /\ :P#_ ', _P!Z /\ @0#_ (< _P"- /\ DP#_ )D _P"@ /\
MIP#^ *\ _ "Z /H R0#Y .$ ^ #S /< _P#V /\ ]0#_ /$ _P#I /\ Y #_
M .$ _P#_  \ _P - /\ #0#_  X _P 4 /\ (0#_ "X _P \ /\ 2 #_ %,
M_P!= /\ 9@#^ &T _ !U /L >P#Y (( ^ "( /< C@#V )0 ] "; /, H@#Q
M *H [P"T .T P0#K -4 Z@#L .@ _ #G /\ Y0#_ .8 _P#@ /\ V0#_ -0
M_P#_  L _P ( /\ !@#_  D _P 0 /\ ' #_ "D _P V /\ 0@#[ $X ]P!7
M /0 8 #R &@ [P!O .T =@#L 'P Z@"" .@ B #G (X Y0"5 ., G #A *0
MWP"N -T N0#: ,H UP#D -0 ]@#1 /\ T #_ -  _P#/ /\ RP#_ ,< _P#_
M  , _P   /\   #_  0 _P - /H %@#V ", \P P /  / #M $< Z0!1 .4
M6@#B &( WP!I -T ;P#: '8 V !\ -0 @@#2 (@ T "/ ,T E@#+ )X R0"H
M ,< LP#% ,$ P@#8 ,  [P"_ /X O@#_ +T _P"\ /\ O #_ +P _P#_ @
M_P   /\   #_    ]  ' .T $0#H !P XP I -\ -0#; $$ U@!+ -$ 5 #-
M %P R@!C ,@ :0#& &\ PP!U ,$ >P"_ (( O@"( +P D "Z )@ N "B +4
MK "S +D L0#+ *\ YP"N /@ K #_ *L _P"L /\ K #_ *L _P#_!   _P
M /8   #N    YP   -\ # #6 !4 SP B ,H +@#' #H PP!$ ,  30"\ %4
MN0!< +< 8P"U &D LP!O +$ =0"O 'L K0"" *L B@"I )( IP"< *4 I@"C
M +, H0## )\ W@"> /( G0#_ )P _P"< /\ FP#_ )L _P#_!P  ]@D  .D+
M  #?"@  U00  ,X !0#& !  P  : +L )P"W #( LP ] +  1@"M $\ J@!6
M *@ 7 "F &, I !H *( ;P"A '4 GP!\ )T A "; (T F0"7 )< H@"5 *X
MDP"] )$ TP"0 .T CP#\ (X _P"- ?\ C0'_ (T!_P#Y#@  ZA(  -P5  #-
M%0  Q!$  +X,  "Z @H M  2 *X '@"J "H I@ U *( /P"@ $@ G0%0 )L"
M5@"9 EP EP-C )4#:0"3 V\ D01V ) $?P".!8@ C 62 (H&G@"(!JH A@>Z
M (4(SP"$"NL @@O\ ($,_P" #/\ @ S_ ( ,_P#Q%0  X!T  ,T@  #!(0
MN!T  +$7  "L$   J D- *('%@"="2, F0HN )4+. "3#$$ D Q) (X-4 ",
M#5< B@U= (@-8P"'#6H A0YQ (,.>@""#H0 @ Z/ 'X/FP!\#Z@ >Q"X 'H0
MS@!X$>P =A+_ '42_P!T$_\ =!/_ '03_P#H'@  TR8  ,,J  "X*@  KB@
M *<C  "@'   FQ,# )8/$ "0$!L C!$G (D2,@"&$SL A!-# ((42P" %%$
M?A17 'P47@![%64 >15L '<5= !V%GX =!:* '(7E@!Q%Z0 ;QBT &X8R0!M
M&>@ :QK\ &H;_P!J&_\ :AO_ &H;_P#@)@  RBT  +PQ  "P,P  IS$  )\L
M  "7)@  D!\  (H7# "%&!8 @1DB 'X:+ ![&S8 >1L^ '<<10!U'$P <QQ3
M '$=60!P'6  ;AUG &T>< !K'GH :AZ% &@?D@!G'Z  92"P &0AQ0!C(>0
M8B+Z &$B_P!A(O\ 82+_ &$B_P#7+   PS0  +8X  "J.0  H3@  )@U  "0
M+P  B"@  ( A" ![(!( =R$= '0B)P!Q(C$ ;R,Y &TC00!K(T@ :2-. &@D
M50!F)%L 921C &,E:P!B)74 826! %\FC@!>)IT 72>M %LHP0!;*.  6BGW
M %DI_P!9*?\ 62G_ %DH_P#/,@  OCD  +$]  "F/P  G#\  ),\  "*-@
M@3   'DJ P!R)@\ ;B<9 &LH(P!I*"P 9BDU &4I/ !C*4, 82I* & J40!>
M*E< 72I? %PK: !:*W( 62Q] %@LBP!6+9H 52VJ %0NO0!3+MP 4B_U %(O
M_P!2+O\ 4B[_ %(N_P#*-@  NCT  *U"  "B1   F$0  (]!  "%/   >S<
M '(Q  !K+ P 9RT5 &0M'P!A+B@ 7RXQ %TN.0!<+T  6B]& %@O30!7+U0
M5C!< %4P9 !3,6X 4C%Z %$QB !0,I< 3C*H $TSNP!---@ 3#3S $PT_P!,
M-/\ 3#/_ $PS_P#&.@  MD(  *E&  ">20  E4D  (M'  "!0@  =ST  &TW
M  !D,@D 8#(2 %TR' !:,B4 6#,M %8S-0!5,SP 4S1# %(T2@!1-%$ 4#19
M $\U80!--6P 3#9W $LVA0!*-Y4 2#>F $<XN %'.-,!1CCQ 48X_P%&./\
M1CC_ $8W_P#!/@  LD4  *9*  "<30  DDT  (A+  !^1P  <T(  &D]  !?
M-P8 6C80 %<W& !4-R( 4C<J % W,@!/.#D 33A  $PX1P!+.$X 2CE6 $DY
M7P!(.FD 1SIU $4[@P!$.Y, 0SRD 4(\M@%!/= !03WP 4$]_P%!//\!03S_
M 4$\_P"^0@  KTD  *-.  "94   CU$  (50  ![3   ;T8  &5"  !:/0(
M5#L. %$[%0!/.Q\ 33LG $L[+P!)/#8 1SP] $<\1 !&/4L 13U4 $0^7 !#
M/F< 0C]S $ _@0 _/Y$ /D"B #U M0$\0<X!/$'N 3Q!_P$\0/\!/$#_ 3T_
M_P&Z10  K$P  *%1  "75   C54  (-4  !X40  ;$L  &%'  !60@  3T ,
M $P_$P!)0!P 1T D $9 + !$0#, 0T Z $)!0@!!04D 0$)1 #]"6@ ^0V4
M/4-Q #M#?P Z1(\ .42@ #A%LP$W1<L!-T7L 3=%_P$W1/\!.$3_ 3A#_P"W
M20  J5   )Y5  "46   BUD  (!8  !V5@  :%   %U,  !32   2D4) $9$
M$0!$1!D 0D0B $%%*0 _13$ /D4X #U%/P \1D< .T9/ #I'6  Y1V( .$AN
M #9(?  U2(T -$F> #-)L0 R2<D ,4GK #))_@ R2/\ ,DC_ #-(_P"T3
MIU0  )Q9  "27   B%T  'Y=  !S6@  954  %M2  !03@  1DH% $!)#@ ^
M218 /4D> #M*)@ Z2BX .4HU #A+/0 W2T0 -DM- #1,5@ S3&  ,DQL #%-
M>@ P38L +DV< "U.KP L3L< +$[I "Q-_0 M3?\ +4S_ "U,_P"P4   I%@
M )E=  "/80  AF(  'MA  !P7P  8EL  %A8  !.50  0U$! #M/#  X3Q,
M-D\; #5/(P T4"L ,U R #)0.@ Q4$( ,%%* "Y14P M4ET +%)I "M2>  I
M4H@ *%.: "=3K0 F4\4 )E/G "93_  G4O\ )U'_ "=1_P"L50  H%P  )9B
M  "-9@  @V<  'AF  !M90  8&$  %5>  !*6P  /U@  #56"  Q51  ,%87
M "Y6'P M5B< +%8O "M7-@ J5SX *5=' "A74  F6%H )5AG "18=0 C688
M(5F8 "!9JP ?6<( 'UGE !]8^@ @6/\ (%?_ "%7_P"H6@  G6(  )-G  "*
M:P  ?VP  '5L  !J:P  76@  %%E  !&8P  .V   #%> P J70T *%T3 "9=
M&P E7B, )%XJ "->,@ B7CH (5Y# "!?3  ?7U< 'E]C !Q@<0 ;8(( &6"5
M !A@J0 78,  %F#B !=?^0 87O\ &5[_ !E=_P"D8   F6@  )!N  "&<
M?'(  ')R  !F<0  6&X  $QL  !!:P  -FD  "UG   C9@@ 'V8/ !UF%0 <
M9AT &V8E !IF+0 99S4 &&<^ !=G2  69U, %6A? !-H;@ 2:'\ $6B2 !!H
MI@ /:+T #FC@ !!G]P 09O\ $67_ !%E_P"?9P  EF\  (QS  ""=@  >'@
M &UX  !@=P  4W8  $9T   [<P  ,7(  "=Q   ><0  %G * !-P$  3<!<
M$G ? !%Q)P 0<2\ $'$X  YQ0@ .<4X #7%;  QQ:0 +<7H "G&-  AQH0 &
M<;8 !G#2  =P[P (;_\ "6[_  EN_P";;P  D74  (=Y  !^?   ='X  &9^
M  !9?@  37X  $!]   U?0  *GP  "%\   8?   $7P$  Q\#  *?!$ "7P9
M  A\(0 '?"D !GPR  1\/0 #?$@  7Q5  !\8P  ?'0  'R'  ![G   >[$
M 'K+  !YZP  >?H  'G_  !X_P"6=P  C'P  (.   !Y@P  ;(0  %Z%  !1
MA@  18<  #F'   MAP  (X<  !J'   2AP  #8@!  :)"@ !B0\  (D4  "(
M&P  B",  (DL  ")-@  B4(  (A.  "(70  B&T  (B!  "'E0  AZL  (;$
M  "%Y@  A/@  (3_  "$_P"0?@  AX,  'Z'  !QB0  8XL  %:-  !)CP
M/)$  #"1   DD0  &I(  !*3   -E   !I4   "6!@  E@P  )40  "6%0
MEAT  )8D  "6+@  ECD  )9&  "650  EF4  )9X  "5C@  E:0  )2\  "3
MWP  D_4  )+_  "2_P"+A@  @XH  '6-  !GD   690  $R7   _F0  ,IH
M ":;   ;G   $IT   R?   $H    *(   "C 0  HP<  *,,  "C$   I!4
M *0<  "E)0  IB\  *8\  "F2P  IEL  *9N  "EA   I9L  *2S  "CT
MH^\  *+\  "B_P"&C0  >)$  &J5  !<F0  3IT  $&@   SH@  )J,  !NE
M   1IP  "JD   &K    K0   *\   "P    L    + %  "Q"P  L@\  +,4
M  "T&P  M20  +<P  "W/P  MU   +=B  "W>   MY   +:I  "VP@  MN0
M +;U  "U_@![DP  ;9@  %^=  !0H@  0J8  #2I   FJP  &JT  !"O   )
ML@   +0   "W    N@   +P   "]    O@   +X   #  @  P0@  ,(-  #$
M$@  QAD  ,DD  #*,@  RT,  ,M5  #,:@  S(,  ,R<  #+M0  S,X  ,SI
M  #,]@!PFP  8:$  %*F  !$JP  -K   ">R   :M0  $+@   >[    O@
M ,$   #$    R    ,L   #+    S0   ,X   #0    T@   -4#  #8"@
MVQ   -X8  #B)   XS4  .1(  #E7   YG,  .:-  #FI0  YKP  .;3  #G
MYP!CI   5:H  $:P   XM0  *+D  !J\   /P   !<0   #'    RP   ,\
M  #4    V    -P   #=    WP   .$   #C    Y0   .@   #J    [08
M /$.  #U%@  ^"4  /DX  #Y30  ^F,  /M\  #\E0  _*H  /R[  #]RP#_
M  \ _P . /\ #@#_ !  _P 6 /\ (P#_ #  _P ] /\ 20#_ %0 _P!> /\
M9@#_ &X _P!V /\ ? #_ (( _P") /\ CP#_ )4 _@"; /T HP#[ *L ^@"U
M /D PP#W -L ]@#P /0 _P#S /\ \@#_ .P _P#B /\ W #_ -8 _P#_  P
M_P ) /\ " #_  H _P 2 /\ '@#_ "L _P X /\ 1 #_ $\ _P!9 /X 80#\
M &D ^@!P /@ =P#W 'T ]@"# /0 B0#R (\ \0"6 .\ G0#M *4 [ "O .H
MO #H ,T Y@#H .0 ^@#C /\ X@#_ .  _P#5 /\ S@#_ ,L _P#_  8 _P !
M /\   #_  0 _P . /\ &0#_ "4 _0 R /L /@#W $D \P!3 /  7 #N &,
M[ !J .H <0#H '< Y@!] .0 @P#B (D X "0 -X EP#< )\ V0"I -8 M #3
M ,0 T #> ,X \P#, /\ RP#_ ,H _P#( /\ P@#_ +X _P#_    _P   /\
M  #_    ^P + /8 $P#Q "  [0 L .H . #G $, XP!- .  5@#< %T V0!D
M -4 :P#2 '$ T !V ,X ? #, (, R@") ,@ D0#& )D Q "C ,$ K0"_ +L
MO0#/ +L ZP"Y /P MP#_ +< _P"V /\ M #_ +$ _P#_    _P   /\   #V
M    [@ % .< #P#A !D VP E -4 ,0#2 #P S@!& ,H 3P#' %< Q !> ,$
M9 "_ &H O0!P +L =@"Y 'P N "# +8 B@"S ), L0"< *\ IP"M +, JP#%
M *D X0"G /4 I@#_ *4 _P"D /\ I #_ *0 _P#_    _    /$   #H
MX    -0 "P#, !, QP ? ,( *@"_ #4 O  _ +@ 2 "U %  LP!7 +  7@"N
M &0 K !I *L ;P"I '4 IP!\ *4 A "C (P H0"6 )\ H0"= *T F@"\ )@
MT@"7 .X E0#^ )0 _P"5 /\ E0#_ )4 _P#\ 0  \ 4  .,'  #5!0  S
M ,4 ! "^  X N  7 +, (P"O "X JP X *D 00"F $H HP!1 *$ 5P"? %T
MG0!C )L :0": &\ F !V )8 ?0"4 (8 D@"0 )  FP". *< C "V (H R0"(
M .< AP#Y (< _P"& /\ A@#_ (8 _P#T#   Y!   -$2  #%$0  O0X  +8(
M  "Q  @ JP 1 *8 &P"A "8 G@ Q )H .@"8 $, E0!* ), 40"1 %< CP!=
M (X 8P", &D B@!P (@ =P"& (  A "+ (( E@"  *, ?@"Q 'T Q ![ N$
M>@/U 'H%_P!Y!?\ > ;_ '@&_P#J$P  UAH  ,8=  "Z'   L1D  *H3  "D
M#0  GP4, )D % "5 !\ D0(I (T#,P"+!#P B 5$ (8&2P"$!E$ @@=7 ($'
M70!_!V, ?0AJ 'L(<@!Z"'P > F& '8)D@!T"J  <PJO '$+P0!P#-\ ;PWV
M &X._P!M#O\ ;0[_ &T._P#A'   RR,  +PF  "Q)@  J"0  * >  "9&
MDQ " (X+#@"("Q< A PB ($-+ !^#34 ? X] 'H.10!X#DL =PY1 '4/6 !S
M#UX <1!E ' 0;@!N$'< ;!"" &L0CP!I$9T :!&M &82P !E$M\ 9!/V &,4
M_P!C%/\ 8A3_ &(4_P#6)   PRH  +4N  "J+P  H"T  )@H  "0(@  B1L
M ((3" !]$1( >1(< '83)P!S%#  <10X &\5/P!M%48 ;!5, &H64P!H%ED
M9Q9A &46:0!D%W( 8A=^ &$8BP!?&)D 7AFI %P9O !<&M@ 6AOS %H<_P!9
M'/\ 61S_ %D<_P#-*@  O3$  *\U  "D-@  FS0  )(Q  ")*P  @24  'D=
M P!S& X ;QD8 &P:(@!I&RL 9QLS &4<.P!D'$$ 8AU( & =3@!?'54 71U<
M %P>9 !;'FX 61]Y %@?AP!6()8 52"F %0AN !3(=( 4B+Q %(C_P!2(_\
M4B+_ %(B_P#(+P  N#8  *LZ  "@/   ECL  (TX  "#,@  >BT  '(F  !J
M( P 9B 3 &,A'0!A(28 7R(O %TB-@!;(CT 6B-$ %@C2@!7(U$ 52-8 %0D
M80!3)&H 425V % E@P!/)I, 3B>C $PGM0!,*,X 2RCN $LI_P!+*/\ 2RC_
M $LH_P##-   LSL  *<_  "<00  DD   (D^  !_.0  =3,  &PM  !C)P@
M7B81 %PF&0!9)R( 5R<K %4H,@!4*#D 4BA  %$H1@!0*4T 3BE5 $TI70!,
M*F< 2RIS $DK@ !(*Y  1RRA $8MLP!%+<L 12[L $0N_P!$+O\ 12W_ $4M
M_P"^.   L#\  *1#  "910  CT4  (5#  ![/@  <3D  &<T  !>+@0 6"L.
M %4K%@!2+!\ 4"PG $\L+P!-+38 3"T\ $HM0P!)+4H 2"Y2 $<N6@!&+V0
M12]P $,P?@!",(T 03&> $ RL0 _,L@ /S/J #\S_@ _,O\ /S+_ #\R_P"[
M/   K4,  *%'  "620  C$D  (-(  !X1   ;3X  &,Y  !:-   4C , $\P
M$P!,,!P 2C D $DQ*P!',3( 1C$Y $0Q0 !#,D< 0C)/ $$S6 ! ,V( /S1M
M #XT>P ]-8L /#:< #LVKP Z-\8 .3?H #DW_  Z-_\ .C;_ #HV_P"W0
MJD8  )Y+  "430  BDX  (!,  !U2   :D,  & ^  !6.0  334) $DT$0!'
M-1D 134A $,U* !!-2\ 0#4V #\V/0 ^-D4 /3=- #PW50 [.&  .CAK #DY
M>0 X.8D -SJ; #4ZK0 U.\0 -#OF #0[^P U._\ -3K_ #4Z_P"T0P  ITH
M )Q.  "240  B%(  'Y0  !S30  9T@  %Q$  !2/P  2#H& $0Y#P!!.18
M/SD> #XY)@ \.2T .SHT #HZ.P Y.T( .#M* #<\4P V/%T -3UI #0]=P S
M/H< ,3Z9 # _JP O/\( +S_D "\_^@ P/_\ ,#[_ # ^_P"Q1P  I$T  )E2
M  "/50  AE8  'Q5  !Q4@  9$P  %E)  !/10  14 # #\^#0 \/A, .CX;
M #D^(P W/BH -C\Q #4_.  T/T  ,T!( #) 40 Q05L ,$%G "Y"=0 M0H4
M+$.7 "M#J@ J0\  *43B "I#^0 J0_\ *T+_ "M"_P"N2@  H5$  )=6  "-
M60  @UH  'E:  !N5P  85(  %=.  !-2P  0T<  #I#"@ V0Q$ -$,8 #-#
M(  R1"< ,40O #!$-@ O13T +45& "Q%3P K1ED *D9D "E'<@ H1X, )D>5
M "5(J  D2+X (TC@ "1(]P E1_\ )4?_ "9'_P"J3P  GU4  )1:  "+7@
M@5\  '=>  !K7   7U@  %55  !+40  0$T  #5*!P P20X +DD5 "U)'0 L
M220 *THK "I*,P H2CL )TM# "9+3  E2U8 )$QB "-,<  A3(  ($V3 !]-
MI@ >3;L '4[= !Y-]@ >3/\ 'TS_ "!+_P"G4P  G%H  ))?  "(8P  ?F0
M '1C  !I80  7%X  %);  !'6   /%4  #)2 @ J4 P )T\2 "90&0 E4"
M)% H "-0+P B43< (5%  "!120 >4E, '5)? !Q2;0 :4WT &5.0 !A3I  6
M4[D %5/9 !93]  74O\ &%'_ !E1_P"C60  F&   (]E  "%:   >VD  '%I
M  !F9P  660  $UA  !"7P  .%P  "Y:   E6 @ (%<. !Y7%  =5QP '%@C
M !M8*P :6#, &5@\ !A810 665  %5E; !19:0 36GH $EJ- !%:H0 06K<
M#EK5 !!9\P 06?\ $5C_ !%8_P"?7P  E68  (QK  "";0  >&X  &YO  !B
M;0  56H  $AH   ^9@  ,V4  "EC   @80$ && + !5@$  48!< $V > !)@
M)@ 28"X $6$W !!A0  /84L #F%8  UA9@ ,8G8 "V*)  IAG0 )8;( "&'+
M  AAZP )8/T "E__  M?_P";9@  DFT  (AQ  !^<P  =74  &IT  !<<P
M3W(  $-P   X;P  +6X  "1L   ;:P  $VL$  YJ#  -:A( #&H9  MJ(0 *
M:BD "6HR  AJ/  ':T< !6M3  1K80 ":W$  &J$  !JF   :JT  &G&  !I
MYP  :?@  &C_  !H_P"7;0  C7,  (1W  ![>@  <'L  &-[  !6>@  27H
M #UY   Q>   )W<  !UV   5=@  #W8"  EV"@ $=@\  '85  !V'   =B0
M '4L  !U-@  =4$  '5.  !U7   =6P  '5^  !TDP  =*@  '/   !SXP
M<O<  '+_  !Q_P"2=0  B7H  (!^  !V@   :8$  %N"  !.@@  08(  #6#
M   I@@  'X$  !:!   0@@  "H(   *#!P  @@T  ((1  ""%P  @AX  ((F
M  ""+P  @CL  ()'  ""50  @64  (%X  "!C0  @*(  '^Z  !_W0  ?O0
M 'W_  !]_P"-?   A($  'N$  !NA@  8(@  %**  !%BP  .8P  "R,   A
MC   %XP  !"-   )C@   H\   "0 P  CPD  (\.  "/$@  D!@  ) ?  "0
M*   D#(  ) _  "030  D%T  (]P  "/A0  CIP  (ZS  "-T   C/   (O^
M  "+_P"(A   @(@  '*+  !DC0  5I   $B3   [E0  +I8  "*6   7EP
M#Y@   B9    FP   )T   "=    G0,  )T)  "=#0  GA$  )X7  "?'P
MGRD  * U  "@0P  H%0  *!F  "?>P  GI,  )ZK  "=Q@  G>D  )SY  "<
M_P"#BP  =8X  &>2  !9E@  2YD  #V<   PG@  (Y\  !>@   .H@  !Z0
M  "F    J    *H   "J    J@   *L!  "K!P  K P  *T0  "N%@  KQX
M +$I  "Q.   L4@  +%:  "Q;P  L8@  +&@  "PN@  K]T  *_R  "O_0!X
MD0  :I8  %R:  !-GP  /Z,  #&F   CIP  %ZD   ZK   %K@   +    "R
M    M0   +<   "W    N    +D   "Z    O ,  +T)  "^#@  P!0  ,,>
M  #%*P  Q3P  ,9.  #&8@  QGH  ,:4  #&K0  QL@  ,7E  #%\P!LF0
M7IX  $^D  !!J   ,JP  "2O   6L0  #;0   .W    N@   +T   #
MQ    ,8   #&    R    ,D   #+    S    ,X   #0!@  TPT  -@3  #<
M'@  WBT  -]   #@5   X6L  .&%  #AGP  X;<  .'/  #AY@!@H0  4J<
M $.M   TL@  );4  !>Y   -O    ;\   ##    QP   ,H   #/    TP
M -8   #7    V@   -P   #?    X0   .,   #F    Z0$  .P+  #P$@
M\Q\  /0Q  #V1@  ]UP  /AT  #XCP  ^:8  /FX  #XR0#_  T _P + /\
M"P#_  X _P 3 /\ 'P#_ "P _P Y /\ 10#_ %  _P!9 /\ 8@#_ &H _P!Q
M /\ =P#_ 'X _P"$ /X B@#] )  _ "7 /H G@#Y *< ]P"Q /8 O@#U -(
M\P#L /$ _@#P /\ \ #_ .8 _P#< /\ T@#_ ,T _P#_  < _P $ /\  @#_
M  8 _P 0 /\ &P#_ "< _P S /\ /P#_ $H _@!4 /L 70#Y &0 ]P!K /4
M<@#S '@ \@!^ /  A #O (H [0"1 .P F0#J *$ Z "K .8 M@#D ,< X@#C
M .  ]P#> /\ W0#_ -D _P#, /\ Q0#_ ,$ _P#_    _P   /\   #_  $
M_P - /\ %@#\ "( ^0 N /8 .0#S $4 [P!. .P 5P#I %X Y@!E .0 ; #B
M '( X !W -\ ?@#= (0 VP"+ -@ D@#5 )L T@"D ,\ KP#- +X RP#5 ,D
M[P#' /\ Q0#_ ,0 _P"^ /\ N #_ +4 _P#_    _P   /\   #^    ]P )
M /$ $0#K !P YP H .0 ,P#A #X W0!( -@ 40#3 %@ T !? ,X 90#, &L
MR@!Q ,@ =P#& 'T Q "$ ,( C #  )0 O@"> +L J "Y +8 MP#( +4 Y@"S
M /H L0#_ +  _P"P /\ K #_ *D _P#_    _P   /H   #Q    Z  # .
M#0#8 !8 T0 B ,T +0#* #< Q@!! ,( 2@"_ %( O0!9 +H 7P"X &4 MP!J
M +4 < "S '8 L0!] *\ A0"M (T JP"7 *D H0"G *X I0"^ *( V "@ /(
MGP#_ )X _P"> /\ G@#_ )P _P#_    ]P   .L   #A    U@   ,L "0#%
M !$ OP ; +L )@"W #$ M  Z +$ 0P"N $L JP!2 *D 6 "G %X I@!D *0
M:0"B '  H !V )X ?@"< (8 F@"0 )@ FP"6 *< E "V )( R@"0 .D CP#\
M (X _P"- /\ C #_ (T _P#X    Z0(  -L#  #, 0  Q    +T  @"V  T
ML  5 *L ( "G "H I  T *$ / "> $0 G !+ )H 4@"8 %@ E@!= )4 8P"3
M &D D0!P (\ =P"- (  BP"* (D E0"' *$ A0"O (, P0"! .  @ #U '\
M_P!_ /\ ?P#_ '\ _P#N"@  W X  ,H0  "^#@  M0L  *\#  "I  < HP 0
M )X & "9 ", E@ L ), -0"0 #X C@!% (P 2P"* %$ B !7 (8 70"% &,
M@P!J ($ <0!_ 'H ?0"$ 'L CP!Y )P =P"J '4 NP!T -0 <@#P '( _P!R
M /\ <0#_ '$ _P#C$0  S1<  +\9  "S&0  JA4  *,0  "="@  EP$* )$
M$@"- !L B0 E (4 +P"# #< @  ^ 'X 10!] $L >P!1 'D 5P!X %T =@!D
M '0!:P!R 70 < )_ &X"BP!L Y@ :P.F &D$MP!H!<X 9P?L &8(_0!F"?\
M90G_ &4)_P#6&@  Q"   +8C  "K(P  H2   )D;  "2%   C X! (8'#0"
M!!0 ? 8> 'D'* !V"#  = @X '()/P!P"44 ;PI, &T*4@!L"E@ :@M? &@+
M9P!G"W  90QZ &,,AP!B#)4 8 VD %\-M@!>#<X 7 [M %P/_P!;$/\ 6Q#_
M %L0_P#-(0  O"@  *\K  "D*P  FBD  )(D  ")'P  @A@  'L1!0!U#0\
M<0T7 &X.(0!K#BH :0\R &<0.0!E$$  9!!& &,030!A$%, 7Q%: %X18@!<
M$6L 6Q%V %D2@P!8$I( 5A.B %43M !4$\L 4Q3L %(5_P!2%O\ 4A7_ %(5
M_P#&*   MBX  *DR  "?,@  E3$  (PM  "#)P  >B$  '(:  !K$PL 9Q,3
M &04' !A%"4 7Q4M %T5- !<%3L 6Q9" %D62 !8%D\ 5A=6 %477@!3%V<
M4AAR % 8?P!/&8X 3AJ? $P:L !+&\< 2QOI $H<_0!*'/\ 2AS_ $H<_P#!
M+0  L30  *4W  ":.   D#<  (<T  !]+P  ="D  &PC  !D' < 7AD0 %L:
M& !9&R$ 5QLI %4;, !4'#< 4AP] %$<1 !/'4L 3AU2 $T=6@!+'F, 2AYN
M $D?? !''XL 1B"< $4AK@!$(<0 0R+F $,B_ !#(O\ 0R+_ $,B_P"\,@
MK3@  *$\  "7/@  C3T  (,Z  !Y-0  ;S   &8J  !>) ( 5R - %0@% !1
M(!T 3R$E $XA+ !,(3, 2R(Z $DB0 !((D< 1R). $8C5P!$(V  0R1K $(D
M>0!!)8@ /R:9 #XFJP ])\$ /2?C #TH^@ ]*/\ /2?_ #TG_P"X-@  JCT
M )Y   "40@  BD(  ( _  !V.P  ;#8  &(P  !9*@  424+ $TE$0!+)1D
M224A $<F* !%)B\ 1"8V $,F/0!")T0 02=+ #\H5  ^*%T /2EI #PI=@ [
M*H8 .2N7 #@KJ0 W++\ -RS@ #<L^  W+/\ -RS_ #@L_P"U.@  IT   )Q$
M  "11@  AT8  'U$  !S0   :#L  %\V  !5,0  3"L' $<I#P!%*A8 0RH>
M $$J)0 _*BP /BLS #TK.0 \*T$ .RQ( #HL40 Y+5L ."YF #8N<P U+X,
M-"^5 #,PIP R,+T ,3'> #$Q]P R,?\ ,C#_ #,P_P"Q/@  I$0  )E(  "/
M2@  A4H  'M)  !P10  94   %L[  !2-@  2#$$ $(N#0 _+A, /2X; #LN
M(@ Y+RD ."\O #<O-@ V,#X -3!& #0Q3P S,5D ,C)D #$R<0 P,X$ +S23
M "XTI@ L-;L +#7; "PU]0 M-?\ +33_ "XT_P"N00  HD@  )=,  "-3@
M@TX  'E-  !N2@  8D4  %A   !./   13<  #TS"P Y,Q$ -S,8 #8S'P T
M,R8 ,S,M #(T-  Q-#P ,#5$ "\U3  N-E8 +39B "PW;P K-W\ *CB1 "@X
MI  G.;D )CG8 "<Y]  H.?\ *#C_ "DX_P"K10  GTL  )1/  "+4@  @5,
M '=2  !L3P  7TD  %9&  !,0@  0CT  #@X"  T. \ ,C@5 #$X'0 O."0
M+C@K "TY,@ L.3D *SI! "HZ2@ I.U0 *#M? "<\;0 E/'T )#V/ ",]H@ B
M/;< (3[4 "$^\P B/?\ (SW_ ",\_P"H20  G4\  ))3  ")5@  ?U<  '56
M  !J4P  74\  %-,  !*2   0$0  #9 !0 O/0T +3T3 "L]&@ J/B$ *3XH
M "@^+P G/C< )C\_ "0_2  C0%( (D!= "%!:@ @07H 'D&- !U"H  <0K4
M&T+1 !M"\0 <0O\ '4'_ !Y!_P"E30  FE,  )!8  "&6P  ?5P  ');  !G
M6   6U0  %%2  !(3@  /4H  #-'   J0PL )D,0 "5#%@ D0QX (T0E ")$
M+  A1#0 ($4\ !Y%10 =14\ '$9: !M&:  91G@ &$>* !='G@ 61[, %$C.
M !5'[P 61_\ %T;_ !=&_P"B4@  EU@  (U=  "$8   >F$  '!@  !E7@
M65H  $]8  !$5   .5$  "].   F2P8 ($H. !Y*$P =2AH '$HA !M+*  :
M2S  &4LX !=+0@ 63$P %4Q7 !1,90 3374 $DV( !%-G  03;$ #D[,  ]-
M[@ 03?\ $4S_ !%,_P">5P  E%T  (MB  "!90  =V8  &UF  !C9   5F$
M $I>   _6P  -5@  "M6   B5 $ &E(* !92$  54A8 %%(= !-2)  24BP
M$5(T !%2/@ 04T@ #U-4  Y38@ -5'( #%2$  M4F  )5*T "%3%  E4YP *
M4_L "U+_  M2_P";70  D60  (AH  !^:P  =&P  &ML  !?:@  4F<  $5D
M   Z8@  ,&   "9>   =70  %5L% !!:#  .6A$ #EH8  U;(  ,6R< "ULP
M  I;.@ )6T4 !UM1  9;7@ $6VT  UN   %;E   6Z@  %O   !:X@  6O8
M 5K_  )9_P"79   CFL  (1N  ![<   <G(  &=Q  !9<   3&X  $!L   U
M:P  *FD  "%G   89@  $68!  QE"@ '90\ !&44  -D&P "9",  &0L  !D
M-0  9$   &1,  !D6@  9&D  &1[  !DCP  8Z0  &.[  !BW0  8O0  &+_
M  !A_P"3;   B7$  (!U  !X=P  ;7@  &!W  !2=@  1G4  #ET   N=
M(W(  !IQ   2<0  #7$   9Q"   < T  ' 2  !P%P  ;Q\  &\F  !O,
M;SL  &]'  !O5   ;V0  &]U  !NB@  ;:   &VV  !LU@  :_(  &O_  !K
M_P".<P  A7@  'U[  !S?0  97X  %A^  !+?@  /GX  #)^   F?0  ''P
M !-\   -?   !GT   !]!0  ? L  'P/  !\$P  ?!D  'PA  !\*0  ?#0
M 'M   ![3@  >UX  'MO  !ZA   >IH  'FQ  !XS@  =^\  ';^  !V_P")
M>@  @7\  'B"  !K@P  784  $^&  !"AP  -8@  "F'   =AP  %(<   V(
M   &B0   (H   "*    B08  (D,  ")#P  B1,  (D:  "*(@  BBP  (HX
M  "*1@  B58  (EH  ")?   B)0  (>K  "&Q@  A>H  (7[  "$_P"%@@
M?88  &^(  !ABP  4XT  $6/   XD0  *Y$  !^2   4D@  #9,   24
ME@   )<   "8    EP   )<%  "7"P  F X  )@3  "9&@  F2(  )HN  ":
M/0  F4T  )E>  "9<P  F(L  )BC  "7O   EN(  );W  "5_P" B0  <HP
M &2/  !6DP  2)8  #J9   LF@  'YL  !2<   ,G@   Y\   "A    HP
M *4   "E    I0   *4   "F @  IP@  *<-  "H$0  J1D  *LC  "K,0
MJT$  *Q3  "L9P  JX   *J:  "JLP  JM   *GO  "I^P!UCP  9Y0  %F8
M  !*G   /)\  "VB   @HP  $Z4   NG   !J0   *L   "N    L0   +(
M  "R    LP   +0   "U    M@   +@$  "Y"P  NQ   +T8  "_)   OS4
M ,!'  # 6P  P'(  ,"-  #!I@  P,$  +_C  "^\P!JEP  6YP  $VA   ^
MI0  +ZD  "&K   3K0  "[    "S    M0   +@   "\    OP   ,$   #!
M    PP   ,0   #&    QP   ,D   #+    S@@  -$/  #5&   V"<  -DY
M  #:30  VV0  -M^  #<F0  W+   -S)  #<XP!=GP  3Z4  $"J   RKP
M(K(  !2U   *N    +L   "_    PP   ,8   #+    S@   -$   #1
MU    -8   #9    VP   -X   #@    Y    .<&  #K#@  [QD  / J  #R
M/P  \U4  /1M  #TB   ]*$  /2V  #TQP#_  D _P & /\ !P#_  P _P 1
M /\ ' #_ "@ _P T /\ 00#_ $P _P!5 /\ 70#_ &4 _P!L /\ <@#^ '@
M_ !^ /L A #Z (L ^0"2 /< F0#V *( ] "L /, N0#Q ,L \ #H .X ^P#M
M /\ [ #_ .$ _P#2 /\ R0#_ ,0 _P#_  $ _P   /\   #_  0 _P . /\
M%P#_ ", _P O /\ .P#] $8 ^@!0 /< 6 #T %\ \@!F /  ; #O '( [0!X
M .P ?@#J (4 Z0", .< DP#E )P XP"F .$ L0#? ,$ W0#= -L ] #9 /\
MU@#_ ,\ _P#$ /\ O0#_ +D _P#_    _P   /\   #_    _P + /P $P#W
M !X ]  J /( -0#N $  Z0!* .8 4@#C %D X !@ -X 9@#< &P V@!R -<
M> #4 'X T@"% -  C0#. )4 S "? ,D J@#' +@ Q0#- ,, ZP#  /X OP#_
M +X _P"V /\ L #_ *T _P#_    _P   /\   #Y    \@ & .L #P#F !D
MX0 D -X +P#: #D TP!# ,\ 3 #, %, R0!: ,< 8 #% &8 PP!K ,$ <0"_
M '< O0!^ +L A@"Y (X MP"8 +4 HP"S +  L0#" *X X "L /< JP#_ *H
M_P"H /\ HP#_ *  _P#_    _P   /4   #K    X0   -8 # #/ !, R@ >
M ,8 *0#" #, OP ] +L 10"X $T M@!4 +, 6@"Q %\ L !E *X :@"L '
MJP!W *D ?P"G (< I0"1 *, G "@ *D G@"X )P S@": .X F0#_ )< _P"6
M /\ E@#_ ), _P#]    \0   .4   #9    S0   ,0 !@"]  \ MP 8 +,
M(@"P "P K0 V *D /@"G $8 I !- *( 4P"@ %D GP!> )T 9 "; &H F@!P
M )@ =P"6 (  E "* )$ E0"/ *( C0"P (L PP") ., B #Y (8 _P"& /\
MA@#_ (8 _P#S    XP   -$   #%    O0   +8   "N  L J  2 *0 ' "@
M "8 G  O )H -P"7 #\ E0!& )( 3 "1 %( CP!8 (T 70"+ &, B@!J (@
M<0"& 'D A "# (( CP!_ )L ?@"I 'P NP!Z -4 > #R '@ _P!W /\ =P#_
M '< _P#G!P  T0P  ,,-  "X#   K@@  *@   "B  4 FP . )8 %0"2 !\
MC@ H (L ,0"( #D A@!  (0 1@"" $P @ !2 '\ 5P!] %T >P!C 'H :P!X
M ', =@!] '0 B !Q )4 < "D &X M !L ,H :P#J &H _ !J /\ :@#_ &H
M_P#:$   QA0  +@6  "M%0  I!(  )P.  "6!P  D  ) (H $ "% !@ @0 A
M 'X *@![ #( >0 Y '< 0 !U $8 <P!, '( 40!P %< ;@!> &T 90!K &X
M:0!W &< @P!E )$ 8P"? &( KP!@ ,0 7P#D %\!^ !> O\ 7@+_ %X"_P#.
M&   O1T  + @  "E'P  FQP  ),7  "+$0  A P  'X$"P!Y !( =0 ; '(
M(P!O "L ;0$S &L!.@!I D  9P-& &8#3 !D!%( 8P19 &$$8 !?!6D 7@5S
M %P&?P!:!HT 60>< %<(K0!6",$ 50GA %0+]@!4"_\ 5 O_ %0+_P#&'P
MMB4  *DH  ">*   E"4  (LA  "#&P  >Q0  '0. P!N"0T :0@4 &8)'0!D
M"B4 8@HM & +- !>"SH 70M  %L,1P!:#$T 6 Q4 %<-7 !5#60 5 UO %(-
M>P!0#HH 3PZ: $X.K !,#\( 3!#C $L0^0!+$/\ 2Q'_ $L0_P"_)@  L"L
M *0O  "9+P  CRT  (8I  !])   =!X  &P7  !E$0< 7PX0 %P/%P!:$!\
M6! G %80+@!4$#4 4Q [ %(10@!0$4@ 3Q%0 $X15P!,$F  2Q)K $D2> !(
M$X< 1A.7 $44J0!$%+X 0Q7? $,6^ !#%O\ 0Q;_ $,6_P"Z*P  JS$  * T
M  "5-0  BS0  ($Q  !X*P  ;R8  &8@  !>&0$ 5Q0- %04$P!1%!L 3Q4C
M $X5*@!,%3$ 2Q8W $D6/@!(%D0 1Q=, $475 !$%UT 0QAG $$8= ! &8,
M/QJ4 #T:I@ \&[L .QO; #L<]@ \'/\ /!S_ #P<_P"U,   J#8  )PY  "1
M.P  ASH  'XW  !S,@  :BT  &$G  !9(0  41L) $P9$ !*&A< 2!H? $8:
M)@!%&RT 0QLS $(;.@!!'$$ 0!Q( #X<4  ]'5D /!YD #L><0 Y'X  .!^2
M #<@I  V(+@ -2'6 #4A]  U(O\ -2'_ #8A_P"R-   I#H  )D^  "//P
MA3\  'L\  !P.   9S(  %TM  !4*   3"(% $8?#@!#'Q0 01\; #\?(@ ^
M("D /2 P #L@-@ Z(3T .2%% #@B30 W(E< -B-B #0C;@ S)'X ,B2/ #$E
MH@ O);8 +R;2 "\F\@ O)O\ ,";_ # F_P"O.   HCX  )9"  ",0P  @D,
M 'A!  !N/0  8S@  %HS  !1+@  2"@! $ D#  ](Q$ .R08 #DD'P X)"8
M-B0L #4E,P T)3H ,R9" #(F2@ Q)U0 ,"=? "\H;  N*'L +"F- "LJH  J
M*K0 *2K/ "DK\  J*_\ *BK_ "LJ_P"L/   GT(  )1&  "*1P  @$<  '9%
M  !L0@  83T  %<X  !.,P  1"X  #PI"0 W*!  -2@5 #,H'  R*", ,"@I
M "\I,  O*C< +BH_ "TK2  L*U( *RQ= "HL:@ H+7D )RV+ "8NG@ E+K,
M)"_- "0O[@ E+_\ )2__ "8N_P"I/P  G44  )))  "(2P  ?DP  '1*  !J
M1P  7D(  %0]  !+.0  030  #@O!@ R+0T ,"T3 "XM&0 M+2  *RTG "HN
M+@ I+C4 *2\] "@O1@ G,$\ )3!; "0Q:  C,7< (C*) "$RG0 ?,[$ 'C/+
M !XS[0 ?,_\ (#/_ "$R_P"F0P  FDD  )!-  "&3P  ?%   '-/  !H3
M7$8  %)#  !)/P  /SL  #8V @ N,@P *S(1 "DR%P H,AX )C(D "4S*P D
M,S( (S0Z "(T0P A-4T (#58 !\V90 >-G4 '#>' !LWFP :-Z\ &3C( !DX
MZP :./\ &S?_ !LW_P"C1P  F$T  (Y1  "$4P  >U0  '%3  !F4   6DP
M %!)  !'10  /4$  #,]   J.0D )3<. ",W%  B.!L (3@B " X*  ?.#
M'CDX !TY00 <.DL &CI6 !D[8P 8.W( %CN% !4\F0 4/*T $SW& !,]Z0 4
M//T %3S_ !8[_P"@2P  E5$  (M5  ""6   >5D  &Y8  !D5@  6%$  $Y/
M  !%2P  .D<  #!#   G0 4 (#X- !T^$0 </A< &SX> !H^)0 9/BT &#\U
M !8_/@ 5/T@ %$!3 !- 8  207  $4&" !!!EP /0:P #D+$  Y"YP /0?P
M$$'_ !! _P"=4   DU8  (E:  " 70  =EX  &Q=  !B6P  5E<  $Q5  !!
M40  -DX  "Q+   C2   &T4) !=$#P 51!0 %$4; !-%(@ 212D $44Q !%%
M.P 01D4 #T90  Y'7@ -1VT #$=_  M'DP )1Z< "$>^  A'X  )1_8 "D;_
M  M&_P":50  D%L  (=@  !]8@  <V,  &IB  !@80  4UX  $=:   \5P
M,E4  "A2   ?4   %TX$ !%,#  /3!$ #DP7  Y,'@ -324 #$TN  M--P *
M34( "4U-  =.6@ &3FD !$Y[  ).CP !3J0  $VZ  !-VP !3?(  4W_  ),
M_P"66P  C6(  (1F  !Z:   <6D  &AI  !<9P  3V0  $)A   W7P  +5P
M "-:   :6   $E<!  U6"0 )50X !U43  95&@ $52(  U4J  )5-   53X
M %5*  !65P  5F4  %5W  !5BP  5:   %6V  !4U   5/$  %/]  !3_P"3
M8@  BF@  (!L  !W;@  ;V\  &-N  !6;   26H  #UH   R9@  )V4  !UC
M   58@  #F$   E@"  #8 T  %\1  !?%P  7QX  %\F  !?+P  7SH  %]%
M  !?4P  7V$  %YR  !>AP  79P  %VR  !<SP  7.\  %O]  !;_P"0:@
MAF\  'UR  !U=   :G4  %UT  !/<P  0G(  #9P   K;P  (&X  !=M   0
M;   "FP   )K!@  :PL  &H/  !J%   :AH  &HA  !I*@  :30  &E   !I
M3@  :5P  &EM  !H@@  :)@  &>N  !FR@  9>T  &7\  !D_P"+<0  @G8
M 'IY  !P>P  8GL  %5[  !(>@  .WH  "]Z   C>0  &7@  !%W   *=P
M W<   !W @  =P@  '8-  !V$   =A4  '8;  !V(P  =BX  '4Z  !U1P
M=58  '5H  !T?   =)(  '.J  !RQ   <>D  '#[  !P_P"&>0  ?WT  '9_
M  !H@0  6H(  $R"   _@P  ,H0  "6#   :@P  $8,   J#   "@P   (0
M  "%    A ,  (,(  "##0  @Q   (,5  "$'   A"8  (0R  "$/P  @T\
M (-@  ""=0  @HP  (&D  " O0  ?^,  '[Y  !^_P""@   >H0  &R&  !>
MB   4(H  $*+   UC0  )XT  !N-   1C@  "HX   "/    D0   )(   "2
M    D@   )(!  "2!P  D@P  )(0  "3%0  DQT  )0H  "4-@  E$4  )-7
M  "3:P  DX(  )*<  "1M@  D-@  (_S  "/_P!^AP  <(H  &&-  !3D
M19,  #>5   IE@  ')<  !&8   )F0   )L   "<    G@   *    "@
MH    *    "A    H00  *()  "C#@  I!0  *4=  "F*@  ICH  *9,  "E
M8   I7@  *62  "DK   I,D  */K  "B^@!SC@  9)$  %:5  !'F0  .9P
M "J>   =H   $:$   BC    I0   *<   "I    K    *X   "N    K@
M *\   "P    L0   +(   "S!@  M0T  +<3  "Y'@  N2X  +I   "Z5
MNVH  +J%  "YH0  N;L  +K>  "Y\@!GE0  6)D  $J>   [H@  +*8  !VH
M   1J@  !ZP   "O    L0   +0   "X    NP   +P   "\    O@   +\
M  #     P@   ,0   #&    R ,  ,L+  #/$@  T2   -$R  #21@  TUT
M -1V  #4D@  U:L  -7$  #4X@!;G0  3*(  #VG   OK   'Z\  !&Q   '
MM0   +@   "[    O@   ,(   #'    R@   ,P   #,    S@   -    #2
M    U0   -@   #;    WP   .(   #F"P  ZQ,  .PD  #M.   [DX  .]G
M  #P@@  \)P  /"R  #QQ0#_  , _P ! /\ ! #_  D _P / /\ & #_ "0
M_P P /\ / #_ $< _P!1 /\ 60#_ &  _0!G /P ;0#Z ', ^0!Y /@ ?P#V
M (4 ]0", /, E #R )T \ "G .X LP#L ,0 ZP#A .H ^ #I /\ YP#_ -D
M_P#+ /\ P@#_ +T _P#_    _P   /\   #_    _P , /\ % #_ "  _P K
M /X -P#Z $( ]@!+ /( 4P#P %L [@!A .P 9P#J &T Z !S .< >0#E '\
MXP"& .$ C@#? )8 W0"@ -L K #8 +L U #1 -, \ #0 /\ S@#_ ,@ _P"]
M /\ M@#_ +( _P#_    _P   /\   #_    _0 ( /< $ #S !H [P F .T
M,0#H #L XP!% .  30#< %4 V0!; -8 80#3 &< T0!L ,\ <@#- '@ RP!_
M ,D AP#' )  Q0": ,, I0#  +( O@#% +P Y0"Z /L N #_ +< _P"P /\
MJ0#_ *4 _P#_    _P   /X   #U    [  # .4 #0#? !4 V@ @ -0 *@#0
M #4 RP ^ ,@ 1P#% $X P@!5 ,  6P"^ &$ O !F +H ; "X '( M@!X +4
M@ "S (@ L0"2 *X G@"L *H J0"[ *@ U0"F /, I #_ *, _P"A /\ FP#_
M )@ _P#_    ^P   /    #E    V    ,X "0#' !$ P@ : +X ) "[ "X
MMP X +0 0 "Q $@ K@!. *P 5 "J %H J0!? *< 90"E &L I !Q *( > "@
M ($ G@"+ )P E@"9 *, EP"R )8 QP"3 .@ D@#^ )$ _P"0 /\ C0#_ (L
M_P#Y    ZP   -T   #/    Q@   +P ! "U  T L  5 *P '@"H "@ I0 Q
M *( .0"? $$ G0!( )L 3@"9 %, EP!9 )8 7@"4 &0 D@!J )  <0". 'H
MC "# (H CP"( )P A@"J (0 O "" -P @0#V (  _P!_ /\ ?P#_ 'X _P#L
M    V@   ,D   "^    M@   *X   "G  D H0 0 )P & "8 "( E0 J )(
M,@"0 #H C0!! (L 1P") $T AP!2 (8 6 "$ %T @@!D ($ :P!_ ', ?0!]
M 'L B !X )4 =@"C '4 M !S ,P <0#M '  _P!P /\ < #_ '  _P#?!0
MR@H  +P+  "Q"0  J 0  *$   ";  , E  , (\ $P"* !L AP D (0 + "!
M #, ?P Z 'T 00![ $< >0!, '< 4@!V %< = != '( 9 !P &T ;P!V &P
M@@!J (\ :0"= &< K@!E ,, 9 #D &, ^@!C /\ 8@#_ &, _P#0#@  OQ(
M +(3  "G$@  G1   )4+  "/ P  B0 ' (( #@!^ !4 >@ > '8 )0!T "T
M<0 T &\ .@!N $  ; !& &H 3 !I %( 9P!8 &8 7P!D &< 8@!Q &  ? !>
M (D 7 "8 %L J0!9 +P 6 #< %@ ] !8 /\ 5P#_ %< _P#&%@  MAH  *H=
M  "?'   E1D  (T4  "%#P  ?@D  '<!"@!R !  ;@ 7 &H 'P!H "< 90 N
M &0 - !B #L 8 !  %\ 1@!= $P 7 !3 %H 6@!8 &( 5P!L %4 =P!3 (4
M4@"4 % !I0!/ ;@ 3@+2 $T$\ !-!?\ 307_ $T%_P"_'0  L"(  *,E  "9
M)0  CR(  (4=  !]&   =1(  &X- @!G!@P 8P,1 %\"&0!= R$ 6P0H %D$
M+P!7!34 5@4[ %0&00!3!D< 409. % '50!.!UX 30AG $L(<P!)"8$ 2 F2
M $<*HP!%"K8 1 O0 $0,[P!##?\ 0PW_ $0-_P"Y)   JBD  )XL  "4+
MBBH  ( F  !W(0  ;AL  &84  !?#P4 60L- %4*$P!3"QL 40LB $\,*0!-
M#"\ 3 PV $L-/ !)#4( 2 U) $8-40!%#EH 1 YD $(.< ! #G\ /P^0 #X0
MH@ \$+8 .Q#1 #L1\0 [$?\ .Q'_ #P1_P"T*0  IB\  )HR  "0,@  AC$
M 'PM  !R*   :2,  &$=  !9%@  41$( $P/$ !*$!8 2! = $80) !%$"L
M0Q$Q $(1-P!!$3X 0!%% #X230 ]$E8 /!)A #H3;0 Y$WP -Q2- #84GP U
M%;, -!7- #,6[@ T%O\ -!;_ #06_P"O+@  HC0  )<W  ",.   @C8  '@T
M  !N+@  92H  %PD  !4'@  3!@$ $84#0!"%!( 0!09 #\4(  ]%2< /!4M
M #L5-  Y%CH .!9" #<62@ V%U, -1=> #,8:@ R&7D ,!F* "\:G0 N&K$
M+1O* "T;[  M'/\ +AO_ "X;_P"L,@  GS@  )0[  "*/   @#P  '8Y  !K
M-   8B\  %DJ  !0)0  1Q\  $ :"@ \&1  .AD6 #@9'0 V&B, -1HI #0:
M,  S&C< ,AL^ #$;1P O'%  +AU; "T=9P L'G8 *AZ( "D?FP H'ZX )R#'
M "8@Z@ G(/X *"#_ "@@_P"I-@  G3P  )(_  "'00  ?4   '0^  !I.@
M7S4  %8P  !-*P  1"4  #L@!P V'@X ,QX3 #(>&0 P'B  +QXF "X?+0 M
M'S0 +" [ "L@1  J(4X *2%8 "<B90 F(G0 )2.% ",CF0 B)*T (23% "$E
MZ  B)?T (B3_ ",D_P"F.@  FC\  (]#  "%10  >T0  ')#  !G/P  73H
M %,V  !*,0  02P  #@F P Q(PP +B(1 "PB%@ J(AT *2(C "@C*@ G(S$
M)B0Y "4E00 D)4L (R96 "(F8P A)W( 'R># !XHEP =**L &RG# !LIY@ <
M*?L '2G_ !XH_P"C/@  F$,  (U'  "#20  >DD  '!'  !F1   6C\  %$[
M  !'-P  /C(  #4M   L* D *"</ "<G%  E)QH )"<A ",H)P B*"X (2DV
M " I/P ?*DD 'BI4 !TK8  ;*V\ &BR! !DLE0 7+:D %BW! !8MY  7+?H
M&"W_ !DM_P"A00  E4<  (M+  ""30  >$T  &Y,  !D20  6$0  $]   !&
M/0  /3@  #,T   J+P8 )"P- "$L$@ @+!@ 'RT> !XM)0 =+2P '"XT !LN
M/  :+T8 &"]1 !<P7@ 6,&T %3%_ !,QDP 2,:@ $3*_ !$RX@ 2,OD $S'_
M !,Q_P">10  DTL  (E/  " 40  =E(  &U0  !B3@  5DD  $U&  !$0P
M.S\  #$Z   G-@, 'S(+ !PR$  ;,A4 &3(; !@R(@ 7,RD %C,Q !4T.@ 4
M-$0 $S1/ !(U7  1-6L $#9]  \VD0 .-J8 #3>\  TWW0 --O8 #C;_  \V
M_P";20  D4\  (=3  !^5@  =58  &I5  !@4P  54\  $Q,  !"20  .$4
M "Y!   D/0  '#H( !8X#@ 5.!( %#@8 !,Y'P 2.28 $3DN ! Y-P /.D$
M#CI,  T[60 -.V@ "SMZ  H[C0 )/*( !SRX  <\U0 (//  "3O_  H[_P"8
M3@  CE0  (58  !\6P  <EL  &A:  !>6   4U4  $E2   ^3@  -$L  "I'
M   A1   &$(# !) "P 0/Q  #C\5  X_'  -0", #$ K  M -  *0#X "4%*
M  =!5@ &064 !$%V  -!B@ !09\  $&T  !!T  !0>X  4'\  ) _P"55
MC%D  (->  !Y8   <&   &9@  !=7@  45L  $57   Z5   +U$  "5/   <
M3   %$H   Y("  +1PX "$<2  ='&0 &1R  !4@H  -(,0 "2#L  $A'  !(
M4P  2&(  $AS  !(A@  2)L  $BQ  !'S   1^T  $?[  !'_P"26@  B6
M (!C  !W90  ;F8  &5F  !99   3&   $!=   U6P  *ED  "!7   750
M$%,   M2!P %40T  5 1  !0%@  4!T  % E  !0+@  4#@  %!#  !04
M4%X  %!O  !0@P  3Y@  $^N  !.R0  3NL  $W[  !-_P"/80  AF8  'UI
M  !T;   ;&T  &%K  !3:0  1F<  #ID   O8P  )&$  !I?   27@  #%P
M  9<!@  6PL  %H/  !:$P  6AD  %DA  !9*0  63,  %D_  !93   65H
M %EK  !8?@  6)0  %>K  !7Q0  5ND  %7[  !5_P",:   @FT  'IP  !R
M<@  9W(  %IQ  !,<   /VX  #-M   H:P  '6H  !1H   -9P  !V<   !F
M P  9@D  &4-  !E$0  9!4  &0<  !D)   9"X  &0Z  !C1P  8U4  &-F
M  !C>@  8I   &&G  !@P0  7^8  %_Z  !>_P"';P  ?W0  'AW  !N>
M8'@  %)W  !%=P  .'8  "MV   @=   %G,   YS   '<@   '(   !R
M<04  '$*  !Q#@  <!$  ' 7  !P'@  <"<  ' S  !O0   ;U   &]@  !N
M=   ;HL  &VB  !LO   :^(  &KX  !I_P"#=P  ?'L  '-]  !E?@  5W\
M $E_   \?P  +X   ")_   7?@  #WX   =^    ?P   '\   !_    ?@
M 'X%  !^"@  ?@T  'X1  !^%P  ?B   'XK  !].0  ?4@  'U9  !\;0
M?(0  'N<  !ZM@  >=H  'CU  !W_P" ?P  =X(  &F#  !;A0  388  #^(
M   RB0  )(D  !B)   /B0  !XH   "+    C    (T   "-    C    (P
M  ", P  C @  (T-  "-$0  C1<  (XB  ".+P  CC\  (U0  "-9   C'L
M (R5  "+K@  BLT  (GO  ")_P![A0  ;8@  %Z*  !0C0  0H\  #21   F
MD@  &9,   Z4   &E0   )8   "8    F@   )L   ";    FP   )L   ";
M    G    )T%  "="P  GA   )\7  "@)   H#0  *!&  "@60  GW   )^*
M  ">I0  GL(  )WH  "<^0!PC   88\  %.2  !$E@  -ID  ">;   9G
M#YT   6?    H0   *,   "E    J    *D   "I    J0   *H   "K
MK    *T   "N 0  L D  +(/  "S&   M"<  +0Y  "U30  M&0  +1^  "S
MF@  L[0  +/5  "S\ !DDP  59<  $>;   XGP  *:(  !JD   .I@  !*@
M  "K    K0   +    "T    M@   +@   "X    N0   +H   "\    O0
M +\   #     PP   ,4'  #)#P  RAH  ,LL  #,0   S58  ,YO  #-BP
MS*@  ,S"  #,X@!8FP  2:   #JE   LJ0  '*L   ^N   $L0   +0   "W
M    N@   +X   ##    Q@   ,@   #(    R@   ,L   #-    SP   -(
M  #5    V0   -T   #A!0  Y@\  .<>  #H,@  Z4@  .I@  #K>P  ZY<
M .RN  #LP@#_    _P   /\   #_  8 _P - /\ %0#_ "$ _P L /\ . #_
M $, _P!, /X 5 #[ %L ^@!B /@ : #V &X ]0!T /0 >@#R (  \0"' .\
MCP#M )< ZP"A .D K0#G +T Y0#8 .0 \P#B /\ X #_ -  _P#$ /\ O #_
M +8 _P#_    _P   /\   #_    _P ) /\ $0#_ !P _0 G /D ,@#U #T
M\0!& .T 3P#K %8 Z !< .8 8@#D &@ XP!N .$ <P#? 'D W0"  -H B #8
M )$ U "; -( I@#/ +0 S #) ,D Z0#( /\ QP#_ ,$ _P"W /\ KP#_ *L
M_P#_    _P   /\   #_    ^  % /( #@#N !< Z@ B .8 + #A #< W0!
M -@ 20#3 %  T !6 ,X 7 #, &( R@!G ,@ ;0#& ', Q !Y ,( @0#  (H
MO@"4 +P GP"Y *P M@"^ +0 W0"S /< L0#_ +  _P"H /\ H@#_ )X _P#_
M    _P   /D   #O    Y@   -\ "P#6 !( T  < ,P )@#( #  Q  Z ,
M0@"] $H NP!0 +@ 5@"V %L M0!A +, 9@"Q &P L !R *X >@"L (( J0",
M *< F "E *4 HP"T *  RP"? .X G0#_ )P _P"9 /\ E #_ )$ _P#_
M]@   .H   #=    SP   ,< !@#   \ NP 7 +< ( "S "H L  S *T .P"J
M $, IP!) *4 3P"C %4 H@!: *  7P"> &4 G0!K )L <@"9 'L EP"% )0
MD "2 )T D "L (X OP", .( BP#Z (D _P") /\ A@#_ (, _P#T    Y
M -0   #(    OP   +4  0"N  L J0 2 *4 &P"A ", G@ L )L - "8 #P
ME@!# )0 20"2 $X D !3 (X 60"- %X BP!D (D :P"' ', A0!] (, B "!
M )4 ?P"D 'T M0![ ,\ >0#Q '@ _P!W /\ =P#_ '4 _P#E    T0   ,,
M  "X    KP   *@   "@  8 F@ . )4 %0"1 !X C@ F (L +0"( #4 A@ \
M (0 0@"" $< @ !- '\ 4@!] %@ >P!> 'D 90!X &T =@!V ', @0!Q (X
M;P"= &T K@!L ,0 :@#G &D _0!H /\ : #_ &D _P#5 P  PP<  +8(  "K
M!@  H@   )L   "4    C0 * (@ $ "# !@ ?P @ 'P )P!Z "X =P U '4
M.P!T $$ <@!' '  3 !O %( ;0!8 &L 7P!I &8 9P!P &4 >P!C (@ 8@"7
M &  IP!> +L 70#< %P ]@!< /\ 6P#_ %L _P#)#0  N1   *P1  "A$
MEPT  (\(  "(    @@ % 'L #0!W !( <P : &\ (0!L "@ :@ O &@ -0!G
M #L 90!! &, 1@!B $P 8 !2 %\ 60!= &$ 6P!J %D =0!7 (( 50"1 %0
MH@!3 +4 40#/ %  [P!0 /\ 4 #_ %  _P"_%   L!@  *0:  "9&0  CQ8
M (<1  !_#0  =P8  '$ " !K  X 9P 4 &0 &P!A "( 7@ I %T +P!; #4
M60 [ %@ 00!6 $8 50!- %, 5 !2 %P 4 !E $X < !, 'T 2P"- $D G@!(
M +  1P#' $8 Z0!& /L 1@#_ $4 _P"X&P  JB   )XB  "3(@  B1\  ( :
M  !W%0  ;Q   &@+  !A! H 70 0 %D %@!6 !T 5  C %( *@!0 #  3P U
M $X .P!, $$ 2P!( $D 3P!' 5< 1@%A $0"; !# GD 00.) $ #F@ ^!*T
M/03$ #P%Y0 \!_@ / ?_ #P'_P"R(@  I2<  )DI  ".*0  A"<  'LC  !Q
M'@  :1@  &$2  !:#0, 4P@, $\%$0!,!1< 2@8> $@&) !'!BH 10<P $0'
M-@!#"#T 00A# $ (2P ^"5, /0E= #L*:  Z"G8 . N' #<+F0 U"ZP - S"
M #,,Y  S#?D ,PW_ #0-_P"M)P  H"P  )4O  "++P  @"X  '<J  !M)0
M9"   %P:  !4%   3 \& $8,#0!##!( 00P8 #\,'P ^#"4 / TK #L-,@ Z
M#3@ . T_ #<.1P V#E  - Y: #,.9@ Q#W0 , ^% "X0F  M$*L +!## "L1
MY0 L$?H +!'_ "T1_P"J+   G3$  )(T  "'-0  ?30  '0Q  !J*P  8"<
M %@A  !/&P  1Q8  $ 1"0 [$ \ .1 4 #<0&P V$"$ -! G #,1+0 R$30
M,1$[ # 10P N$DT +1)7 "P28P J$W$ *1." "<4E0 F%*D )17  "05XP E
M%OH )A;_ "85_P"F,0  FC8  (\Y  "%.@  >SD  '$V  !G,0  72T  %0H
M  !,(@  0QT  #L7!0 U% T ,A,1 #$4%P O%!T +A0D "P4*@ K%3$ *A4X
M "D60  H%DH )Q=4 "878  D&&\ (QB  "$9DP @&:< 'QF^ !X:X  ?&O@
M(!K_ " :_P"C-   F#H  (T]  "#/@  >3T  &\[  !E-P  6S(  %(M  !)
M*   0",  #@> 0 P&0H +!@/ "H8%  I&!H )Q@@ "89)P E&2T )!HU ",:
M/@ B&T< (1M2 " <7@ ?'6P '1U^ !P=D0 :'J4 &1Z\ !@?W0 9'_8 &A__
M !L>_P"A.   E3T  (M!  "!0@  =T(  &U   !C/   63<  $\S  !&+@
M/2D  #4D   M( < )QT- "4=$@ C'1< (1T= "$=)  @'BL 'QXR !X?.P =
M'T4 '"!/ !HA7  9(6H &")[ !8BCP 5(J, %".Z !,CV@ 4(_4 %2/_ !8C
M_P">/   DT$  (E$  !_1@  =48  &Q$  !B00  5SP  $TX  !$-   /#
M #,K   J)@, (R(+ " A$  >(14 '"(; !LB(0 :(B@ &B,P !DC.  8)$(
M%B5- !4E60 4)F@ $R9Y !(FC0 1)Z( $">X  XGU@ 0*/0 $2?_ !$G_P"<
M0   D44  (=(  !]2@  =$H  &I)  !@1@  54$  $P^  !#.@  .C8  #$R
M   H+0  ("D) !LG#@ 9)Q( &"<8 !8G'P 5*"4 %"@M !,H-@ 2*4  $BE+
M !$J5P 0*F8 #BMW  XKBP -+)\ #"RU  LLSP ,+.\ #2S_  TK_P"91
MCTD  (5,  !\3@  <T\  &E.  !>2P  4T<  $I$  !"0   .3T  "\X   E
M-   '3 % !8M#  4+!  $RT5 !(M'  1+2, $"TJ  \N,P .+CT #2](  TO
M50 ,,&, "C!T  DPB  (,9P !C&Q  8QRP &,>L !S#\  @P_P"72   C4T
M (-1  !Z4P  <50  &=2  !=4   4DP  $E*  ! 1@  -4(  "L^   B.@
M&C<! !(T"0 /,PX #C,3  TS&0 -,R  ##0H  LT,0 *-3L "#5&  <U4@ %
M-F  !#9Q  (VA   -ID  #:O   VR   -N@  #;Y  $U_P"430  BE(  (%6
M  !X6   ;UD  &58  !;50  45(  $=/   \3   ,4@  "=$   >00  %C\
M ! \!P +.@T "3H1  @[%P &.QX !3LF  0[+@ ".S@  3Q#   \3P  /%X
M #QN   \@0  /)<  #RL   [Q0  .^<  #OX   [_P"14@  B%@  ']<  !V
M70  ;5X  &-=  !:7   3E@  $)4   W40  +4X  "-+   :20  $D8   U$
M!@ '0PP  T,0  !#%0  0QL  $,C  !#*P  0S4  $-   !#30  0UL  $-K
M  !#?@  0Y0  $*J  !"PP  0>8  $'Y  !!_P".6   AEX  'UA  !S8P
M:V0  &)C  !780  25T  #U:   R6   )U4  !Y3   540  #D\   E-!0 "
M30L  $P.  !,$P  2Q@  $L?  !+*   2S(  $L]  !+20  2U<  $MG  !*
M>P  2I   $FG  !)P   2.0  $CX  !'_P"+7P  @V0  'IG  !Q:0  :6H
M %YI  !09@  0V0  #=A   L7P  (5T  !A;   060  "E@   -7 P  5PD
M %8-  !5$   514  %0;  !4(P  5"T  %0Y  !410  5%,  %1D  !3=P
M4XT  %*D  !1O0  4.(  %#X  !/_P"(9P  ?VL  '=N  !O<   97   %=N
M  !*;   /6L  #!I   E:   &F8  !%D   +8P  !&(   !B 0  808  & +
M  !@#@  7Q(  %\7  !?'@  7B@  %XS  !>0   7D\  %Y?  !=<@  78@
M %R@  !;N0  6M\  %GW  !8_P"$;@  ?'(  '5U  !K=@  774  $]T  !"
M<P  -7,  "AR   =<   $V\   QN   $;@   &X   !N    ; (  &P'  !K
M"P  :PX  &L2  !J&0  :B(  &HM  !J.@  :4D  &E:  !I;   :(,  &>;
M  !FM0  9=@  &3U  !D_P" =0  >GD  '![  !B>P  5'P  $9\   Y?
M+'P  !][   4>@  #7H   1Z    >@   'H   !Z    >0   'D!  !X!@
M> L  '@.  !X$P  >!H  '@E  !X,@  =T$  '=2  !W90  =GP  '65  !T
MKP  <\X  '+Q  !Q_P!^?0  =8   &>!  !8@@  2H,  #R$   NA0  (84
M !6%   -A0   X4   "&    AP   (@   "(    AP   (<   "'    AP0
M (<)  "'#@  B!,  (@<  "(*0  B#@  (=*  "'70  AG,  (:-  "%IP
MA,4  (/L  ""_@!XA   :H8  %R(  !-B@  /XP  #&.   CCP  %H\   V0
M   "D0   )(   "3    E0   )8   "6    E@   )8   "6    EP   )<
M  "7!P  F T  )D3  ":'P  FBT  )H_  ":4@  FF@  )F#  "9GP  F+H
M )?B  "6^ !MB@  7XT  %"0  !!DP  ,Y8  "27   6F   #9D   &;
MG0   )\   "A    I    *4   "D    I0   *4   "F    IP   *@   "I
M    J@0  *P,  "N$P  KB$  *XS  "N1P  KET  *YV  "NDP  KJX  *W-
M  "L[P!AD0  4Y4  $28   UG   )I\  !>A   -HP   *4   "G    J@
M *P   "P    L@   +0   "S    M    +4   "W    N    +D   "[
MO0   +\!  ##"P  Q14  ,4E  #&.0  QT\  ,=H  #&A0  QJ(  ,:\  #&
MW@!5F0  1YT  #BB   II@  &:@   VK    K0   +$   "T    MP   +H
M  "_    P0   ,0   ##    Q0   ,8   #(    R@   ,T   #/    T@
M -8   #;    X P  .$8  #C*P  Y$$  .5:  #F=   YI$  .6L  #EQ #_
M    _P   /\   #_  $ _P * /\ $@#_ !T _P H /\ - #_ #X _0!( /H
M4 #W %< ]0!= /0 8P#R &D \ !O .\ = #M 'L ZP"! .D B0#H )( Y@"<
M .0 J #B +< WP#- -P [@#9 /\ V0#_ ,H _P"^ /\ M0#_ +  _P#_
M_P   /\   #_    _P & /\ #P#\ !@ ^  C /0 +@#P #@ ZP!" .@ 2@#E
M %$ X@!8 .  70#> &, W !H -D ;@#6 '0 U ![ -$ @@#/ (L S0"5 ,H
MH0#( *\ Q0#! ,( XP#  /L P #_ +L _P"P /\ J #_ *0 _P#_    _P
M /\   #[    \P ! .T # #H !, XP > .  * #: #( TP \ ,\ 1 #, $L
MR0!1 ,8 5P#$ %T P@!B ,$ 9P"_ &T O0!T +L >P"Y (0 MP". +0 F0"R
M *< KP"W *T T "K /( J@#_ *D _P"A /\ FP#_ )< _P#_    _P   /0
M  #I    X    -4 " #. !  R0 8 ,4 (@#! "L O  U +D /0"V $4 LP!+
M +$ 40"O %8 K@!; *P 80"J &8 J0!M *8 = "D 'P H@"& *  D@"> )\
MG "N )D PP"7 .< E@#_ )4 _P"2 /\ C0#_ (H _P#\    \    .,   #4
M    R    +\  P"Y  T LP 3 *\ ' "L "4 J0 N *4 -@"C #X H !$ )X
M2@"= %  FP!5 )D 6@"7 %\ E@!F )0 ; "2 '4 D !^ (X B@"+ )< B0"F
M (< N "% -8 A #V (( _P"! /\ ?@#_ 'P _P#M    W0   ,P   #!
MN    *X   "G  D H@ 0 )X %P": !\ EP G )0 +P"1 #< CP ] (T 0P"+
M $D B0!. (@ 4P"& %D A !? (( 90"  &T ?@!W 'P @@!Z (\ > "> '4
MKP!S ,< <@#L '$ _P!P /\ < #_ &X _P#=    R0   +P   "Q    J0
M *$   "9  , DP , (X $@"* !D AP A (0 *0"! #  ?P W 'T /0![ $(
M>0!( '@ 30!V %( = !8 '( 7P!Q &< ;P!P &P >P!J (@ : "7 &8 J !E
M +P 8P#A &( ^@!A /\ 80#_ &$ _P#- 0  O 4  *\%  "E @  G    )0
M  "-    A@ ( ($ #@!\ !0 >  ; '4 (P!R "D <  P &X -@!M #P :P!!
M &D 1P!H $P 9@!2 &0 60!C &  80!I %\ = != ($ 6P"0 %D H0!7 +0
M5@#0 %4 \@!5 /\ 5 #_ %4 _P#!#   L@X  *8/  ";#@  D@L  (D%  ""
M    >P " '4 "P!P !  ;  6 &@ '0!F ", 8P J &$ , !@ #8 7@ [ %T
M00!; $8 6@!, %@ 4P!6 %L 5 !D %( ;@!1 'L 3P"* $T FP!, *X 2P#&
M $H Z@!) /X 20#_ $D _P"Y$@  JA8  )X7  "4%@  BA,  ($0  !Y"P
M<0,  &L !@!E  T 80 1 %T & !: !X 6  D %8 *@!4 #  4P V %$ .P!0
M $$ 3@!' $T 3@!+ %8 20!? $< :0!& '8 1 "% $, EP!! *D 0 "_ #\
MX@ _ /@ /@#_ #\ _P"R&0  I!X  )@?  ".'P  A!P  'H8  !R$@  :@X
M &((  !< 0@ 5P . %, $P!0 !D 3@ ? $P )0!* "L 2  P $< -@!& #P
M1 !" $, 20!! %$ /P!: #X 90 \ '( .@"! #D DP X *4 -@"Z #8 VP U
M /0 -0#_ #4 _P"L(   GR0  )0F  "))@  ?R0  '4@  !L&P  9!4  %P0
M  !4# $ 3@8* $H"#P!' !0 1  : $( ( !  "4 /P K #X!,0 \ 3< .P(^
M #D"10 X TT -@-6 #4$80 S!&X ,05^ # %D  O!:, +0:X "P&U  L!_
M+ C_ "P(_P"H)0  FRH  ) L  "&+0  >RL  '(G  !H(@  7QT  %<7  !/
M$@  2 X$ $$*"P ^!Q  .P85 #D'&P X!R$ -@@F #4(+  S"#( ,@DY #$)
M00 O"4D +@I3 "P*7@ K"VP *0M\ "@,CP F#*( )0RW "0,TP C#?  ) W_
M "4-_P"D*@  F"\  (TR  "#,@  >3$  &\N  !E*0  7"0  %,?  !+&0
M0Q,  #P0!@ U#0P ,PP1 #$,%@ O#!P +@TB "T-*  K#2X *@TU "D-/0 G
M#D8 )@Y0 "0.7  C#VH (@][ " 0C@ ?$*( '1"W !P0U  =$?( '1'_ !X1
M_P"A+P  E3,  (HV  " -P  =C8  &TS  !C+P  62H  % E  !((   /QH
M #@5   P$0@ +! . "H0$@ H$!@ )Q > "40)  D$"H (Q$R "(1.@ A$4,
M(!). !X26@ =$V@ &Q-X !H3BP 8%*  %Q2U !84T0 6%?$ %Q7_ !@4_P">
M,P  DS<  (@Z  !^.P  =#L  &LX  !A-   5R\  $XK  !%)@  /2$  #0<
M   M%P4 )A,, ",3$  B$Q4 (!,: !\3(0 >%"< '10O !P5-P ;%4$ &A9+
M !D65P 7%V4 %A=V !08B0 3&)X $ABS !$9S@ 1&>\ $AG_ !,9_P"<-@
MD3L  (8^  !\/P  <S\  &D]  !?.0  534  $PP  !#+   .B<  #(B   J
M'@$ (AD) !X7#@ <%Q( &A<7 !D8'@ 9&"0 &!DL !<9-  6&CX %1I) !,;
M50 2&V, $1QT ! <AP /'9P #AVQ  T=RP -'>P #AW_  \=_P"9.@  CS\
M (1"  ![1   <4,  &A"  !>/@  4SH  $HV  !!,@  .2T  #$I   H)0
M(" & !H=#  7'!  %1P5 !0=&P 4'2( $QTI !(>,@ 1'SP $!]& ! @4P .
M(&$ #2%Q  PAA0 +(ID "B*N  DBQP )(N< "B+[  LA_P"7/@  C$,  (-&
M  !Y2   <$@  &=&  !<1   4C\  $D[  ! .   .#0  "\P   G+   'B<#
M !8C"@ 2(0X $2$3 ! B&0 0(B  #R(G  XC+P -)#D #"1$  LE4  *)5X
M"29O  <F@@ &)I8 !":L  ,FQ  $)N4 !";W  8F_P"50@  BD<  (%*  !X
M3   ;TP  &5+  !;2   4$0  $=!   _/@  -SL  "TV   D,0  &RT  !,J
M!P /* T #2<1  TH%@ ,*!T "R@E  HI+0 )*3< !RI"  8J3@ $*UP  RML
M  $K?P  *Y0  "NI   KP0  *^,  "OV   J_P"21@  B$L  ']/  !V40
M;5$  &-0  !:30  3TH  $='   ^1   ,T   "D\   @.   %S0  !$Q!0 ,
M+PP "2X0  <N%0 &+QL !2\C  ,O*P ",#4  # _   P3   ,5D  #%I   Q
M?   ,9$  #&G   POP  ,.$  ##U   O_P"02P  AE   'U4  !U5@  :U8
M &)5  !84P  3E   $5-   Z20  +T4  "5"   </@  %#L   XY!0 )-PL
M!#8/  $V$P  -AD  #8@   V*0  -C(  #<]   W20  -U<  #=G   W>0
M-X\  #:E   VO0  -N   #7U   U_P"-4   A%8  'Q:  !R6P  :5L  &!;
M  !760  3%8  $!2   U3@  *DL  "!(   71@  $$,   M!!  $0 H  #\.
M   ^$0  /A8  #X=   ^)@  /B\  #XZ   ^1@  /E0  #YD   ^=@  /8P
M #VC   \NP  /-X  #OU   [_P"*5P  @EP  'E?  !P80  :&$  %]A  !4
M7@  1UL  #I7   O50  )5(  !M0   230  #$L   9* P  20D  $@-  !'
M$   1Q0  $8:  !&(@  1BP  $8W  !&0P  1E$  $9@  !%<P  18D  $2@
M  !$N   0]P  $+U  !"_P"(70  ?V(  '=E  !N9P  9V@  %MF  !.8P
M06$  #1>   I7   'UH  !57   .5@  !U0   !3 0  4@8  %$+  !1#@
M4!$  $\6  !/'@  3R<  $\R  !//P  3TT  $Y=  !.;P  3H4  $V=  !,
MM0  2]@  $KU  !*_P"%90  ?&D  '1L  !M;@  8FT  %1K  !':0  .F<
M "UE   B9   &&(  !!@   )7P   %X   !>    70,  %P(  !;#   6@\
M %H3  !9&0  62(  %DM  !9.@  64@  %A8  !8:P  5X$  %>9  !6L@
M5=(  %3T  !3_P"!;   >7   '-S  !H<P  6G(  $QQ   _<   ,F\  "5N
M   :;   $6L   EJ    :@   &D   !I    :    &<#  !F"   9@P  &8/
M  !E%   91P  &4G  !D-   9$,  &13  !D90  8WL  &*4  !AK0  8,T
M %_Q  !>_P!]=   =W<  &YY  !?>0  47D  $-Y   V>   *7@  !QW   1
M=@  "G4   !U    =0   '8   !U    =    '0   !S @  <P<  ',,  !R
M$   <A4  '(@  !R+   <CL  '%,  !Q7P  <70  '".  !OJ   ;L8  &SM
M  !K_P![>P  <GX  &1^  !5?P  1X   #F!   K@@  'H$  !*!   *@0
M ($   ""    @P   (,   "#    @@   ((   ""    @@   ((%  """@
M@@\  ((7  ""(P  @C(  ()#  "!5@  @6P  ("&  !_H0  ?KT  'WF  !\
M_ !V@@  :(,  %F%  !+AP  /(D  "Z*   @BP  $XL   J+    C    (T
M  "/    D0   )(   "1    D0   )$   "1    D0   )(   "2 @  DPD
M )0/  "4&0  E"<  )0X  "43   DV(  )-\  "3F   DK,  )'8  "0]@!J
MB   7(H  $V-   _D   ,)(  "&4   4E0  "I8   "7    F0   )L   "=
M    GP   *    "@    H    *    "A    H@   *,   "D    I0   *8'
M  "H$   J!P  *@M  "I0   J58  *EO  "IBP  J*@  *?'  "F[ !?CP
M4)(  $&6   SF0  (YP  !2=   *GP   *$   "C    I@   *@   "L
MK@   *\   "O    L    +    "R    LP   +0   "V    MP   +H   "]
M!P  OQ   +\?  # ,P  P$D  ,!B  # ?@  P)L  ,"W  "_V !3EP  1)L
M #6?   FHP  %J4   NG    J@   *T   "P    LP   +8   "[    O0
M ,    "_    P0   ,(   #$    Q@   ,@   #*    S    ,\   #3
MV@<  -L3  #=)0  WCL  -]3  #@;@  WXP  -VI  #=P@#_    _P   /\
M  #_    _P ' /\ $ #_ !D _P D /\ +P#\ #H ^0!# /4 2P#S %( \0!9
M .\ 7@#M &0 ZP!I .D ;P#G '4 Y@!\ .0 A #B (T X "7 -T H@#: +$
MU0#% -( Z #0 /\ SP#_ ,0 _P"X /\ KP#_ *D _P#_    _P   /\   #_
M    _P " /L #0#W !4 \P ? .\ *0#J #0 Y@ ] .( 10#> $P VP!3 -@
M6 #4 %X T@!C -  :0#. &X S !U ,H ?0#( (4 Q@"0 ,( FP#  *D O@"Z
M +L V0"Y /< N #_ +0 _P"I /\ H@#_ )T _P#_    _P   /\   #V
M[@   .< "@#A !$ W  : -< (P#0 "X RP W ,< /P#$ $8 P0!- +\ 4@"]
M %@ NP!= +D 8@"X &@ M@!N +0 =0"Q 'X KP"( *T DP"J *$ J "Q *8
MR "D .T H@#_ *( _P"; /\ E0#_ )$ _P#_    _    .X   #C    V
M ,T !0#&  X P0 5 +T '@"Y "< M0 P +( . "O $  K !& *H 3 "H %$
MIP!6 *4 6P"C &$ H0!G )\ ;@"> '8 FP"  )D C "7 )D E "H )( O "0
M -\ C@#[ (X _P"+ /\ A@#_ (, _P#X    Z0   -P   #,    P0   +@
M  "R  H K  1 *@ & "E "$ H@ I )X ,@"< #D F0 _ )< 10"5 $H E !0
M )( 50"0 %H CP!@ (T 9P"+ &\ B0!X (8 A "$ )$ @@"@ (  L@!] ,P
M? #Q 'L _P!Z /\ =P#_ '4 _P#F    TP   ,8   "[    L0   *<   "A
M  4 FP - )< $P"3 !L D  C (P *P"* #( B  X (8 /@"$ $0 @@!) ($
M3@!_ %, ?0!9 'L 8 !Y &@ =P!Q '4 ? !S (D < "8 &\ J0!M +\ :P#F
M &H _P!I /\ :0#_ &< _P#3    PP   +4   "K    HP   )L   "2
MC  * (< $ "# !8 ?P = 'T ) !Z "L >  R '8 . !T #T <@!" '$ 2 !O
M $T ;0!3 &P 60!J &$ : !J &8 = !D ($ 80"1 %\ H@!> +8 7 #5 %L
M]P!; /\ 6@#_ %H _P#%    M@(  *D"  "?    E@   (X   "'    @  %
M 'H # !U !$ <0 8 &X '@!K "4 :0 K &< ,0!F #< 9  \ &, 00!A $<
M7P!- %X 4P!< %L 6@!D %@ ;@!6 'L 5 "* %( FP!1 *X 4 #( $\ [@!.
M /\ 3@#_ $T _P"["@  K T  * -  "5#   C @  (,"  !\    =0   &X
M" !I  X 90 3 &( &0!? !\ 70 E %L *P!9 #$ 6  V %8 .P!5 $$ 4P!'
M %$ 3@!0 %4 3@!> $P : !* '4 2 "$ $< E0!% *@ 1 "_ $, Y !" /P
M0@#_ $( _P"R$0  I10  )D5  ".$P  A!$  'L-  !S"   ;    &4  P!?
M  L 6P / %< % !4 !H 40 ? $\ )0!. "L 3  P $L -@!) #P 2 !" $8
M2 !% %  0P!9 $$ 8P _ &\ /@!^ #P D  [ *, .@"X #D V0 X /4 . #_
M #@ _P"L%P  GQL  ),=  ")'   ?QD  '45  !L$   9 P  %T&  !6  8
M40 , $T $ !* !4 1P : $4 ( !$ "8 0@ K $$ ,0 _ #8 /@ ] #P 1  [
M $L .0!4 #< 7P V &L - !Z #( C  Q )X , "S "\ S@ O .\ +@#_ "X
M_P"G'@  FB(  (\D  "$)   >B$  '$=  !G&   7Q,  %<.  !0"@  20,(
M $4 #0!! !$ /@ 6 #P &P Z "$ .0 F #< +  V #( -  X #, /P Q $<
M, !0 "X 6P M &< *P!V "H B  H )P )P"P "8 R0 E .H )0'[ "4!_P"B
M(P  EB@  (LJ  "!*@  =R@  &TE  !D(   6QL  %(5  !+$   0PP" #T'
M"0 Y PX -@$2 #,!%P Q 1P , $B "\")P M BT + ,T "H#.P I!$, * 1-
M "8%6  E!64 (P9T "(&A@ @!IH 'P>N !X'Q@ =!^< '0CX !T)_P"?*
MDRT  (@O  !^+P  ="X  &HK  !A)@  6"$  $\<  !'%P  /Q(  #@.!  Q
M"PH +@@. "L'$@ I!Q< * @= "<((P E""D ) DP ",)-P A"D  ( I* !\+
M50 ="V( &PQR !H,A0 8#)D %PRM !8,Q@ 5#>8 %0WY !8-_P"<+0  D#$
M (8T  !\-   <C,  &@Q  !?+   52<  $PC  !$'0  /!@  #03   M$ 8
M)@T+ "0,#P B#!, (0P9 !\,'P >#24 '0TL !L--  :#CT &0Y' !<.4P 6
M#F$ % ]Q !,0A  2$)@ $1"N ! 0Q@ 0$.@ $!#[ !$0_P"9,0  CC4  (0X
M  !Z.0  <#@  &<V  !=,@  4RT  $HH  !")   .1\  #$:   J%0$ (Q$'
M !T0#0 ;#Q  &0\5 !@0&P 7$"$ %A I !40,0 4$3H $Q%% !(240 1$E\
M$!)O  X3@@ .$Y8 #1.K  L3P@ +%., #!3Z  T3_P"7-0  C#D  ((\  !X
M/0  ;ST  &4Z  !;-P  4C(  $DN  ! *@  -R4  "\A   H'   (!@# !D4
M"@ 5$@X %!(2 !,3&  2$Q\ $10F !$4+@ 0%#@ #Q5"  X63P -%EP #!=L
M  L7?P )&), "!BH  88OP '&.  !QCU  D8_P"5.   BCT  (!   !W00
M;4$  &0_  !:/   4#@  $<S   ^,   -BL  "XG   G(P  'Q\  !<:"  2
M%PT $!<1  \7%@ .&!P #A@C  T9+  ,&C4 "QI   H;3  )&UH !QQI  4<
M?  $'9$  AVF  $=O  "'-T  ASR  ,<_P"3/   B$$  ']$  !U10  ;$4
M &-$  !900  3ST  $8Y   ^-@  -3(  "XN   E*@  '24  !0A!  /'0L
M#1T0  P=%  +'1H "AXB  @>*@ ''S, !B ^  0@2@ #(5<  2%G   A>0
M(8X  "&D   AN@  (=L  "'R   @_@"00   AD4  'U(  !T2@  :TH  &))
M  !81@  3D(  $4_   ]/   -3D  "LT   B+P  &2L  !(H!  -) H "2,.
M  8C$@ %(QD !"0@  (D*  !)3$  "4\   E2   )E4  "9E   F=P  )HP
M ":B   FN0  )MD  "7R   E_@".10  A$D  'M-  !S3P  :D\  &!.  !7
M2P  34@  $1%   \0@  ,3T  "<Y   >-0  %3(   \N P *+ H !2L.  $J
M$0  *A8  "H>   J)@  *R\  "LY   K10  +%,  "QB   L=0  +(H  "N@
M   KMP  *]8  "KR   J_P",20  @DX  'I2  !Q5   :%0  %]3  !640
M3$X  $-+   W1P  +4,  ",_   :/   $C@   PV P &,PD  #(-   R$
M,10  #$;   Q(P  ,2P  #(W   R0P  ,E   #)@   R<@  ,H<  #&>   Q
MM0  ,-0  ##R   O_P")3P  @%0  'A7  !O60  9ED  %Y9  !55P  25,
M #Y/   R3   *$@  !Y%   50@  #D    @] @ !/ @  #L,   Z#P  .1(
M #D8   Y(   .2D  #DT   Y0   .4X  #E=   Y;P  .(4  #B<   WLP
M-](  #;R   U_P"'50  ?UH  '9=  !M7P  95\  %U?  !27   1%@  #A5
M   M4@  (D\  !A,   02@  "D@   -& 0  108  $0*  !##0  0A   $$5
M  !!'0  028  $$Q  !!/0  04H  $%:  !!;   0($  #^9   _L0  /M
M #WR   \_P"$7   ?&   '-C  !L90  9&8  %ED  !+80  /EX  #);   F
M60  '%8  !)4   ,4@  !%$   !/    3@,  $T(  !,#   2PX  $L2  !*
M&0  2B(  $HL  !*.0  2D<  $I6  !):   27X  $B6  !'KP  1LT  $7Q
M  !$_P"!8P  >6<  ')J  !K;   8&L  %)I  !$9@  -V0  "IB   ?8
M%5X   U=   &6P   %H   !9    6    %<$  !6"   5@P  %40  !4%
M5!T  %0G  !4-   5$(  %-2  !39   4GD  %*2  !1JP  4,H  $_O  !.
M_P!^:@  =VX  '!Q  !F<0  6'   $IO   \;0  +VP  ")J   7:0  #F<
M  9F    90   &4   !E    8P   &(   !B!   80@  &$-  !@$   8!<
M & A  !?+@  7SP  %]-  !>7@  7G0  %V-  !<IP  6\4  %KM  !9_P![
M<@  =78  &MW  !==@  3W8  $%U   S=0  )G0  !ES   0<@  !W$   !Q
M    <0   '$   !Q    ;P   &\   !N    ;@(  &X(  !M#   ;1$  &T:
M  !M)@  ;#4  &Q&  !K6   :VT  &J&  !IH0  :+X  &?H  !F_@!Y>@
M<'P  &%\  !3?0  1'T  #9^   H?@  &WT  !!]   '?0   'T   !]
M?@   '\   !^    ?0   'T   !\    ?    'P   !\!@  ? P  'P2  !\
M'0  ?"P  'P\  !\3P  >V4  'M^  !ZF@  >;8  'C?  !W^@!S@   98$
M %:#  !(A   .88  "N'   =AP  $8<   >(    B    (D   "*    C
M (T   "-    C    (P   ",    C    (P   "-    C00  (X,  ".$P
MCR$  (XR  ".1@  CEL  (UT  "-D   C*T  (O.  "*\P!HA@  6H@  $N+
M   \C0  +8\  !Z0   1D0  !Y(   "3    E0   )<   "9    FP   )P
M  ";    FP   )P   "<    G0   )X   ">    GP   *$#  "B#   HA8
M *,F  "C.@  HT\  *-H  "BA@  HJ(  *+   "AZ !<C0  39   #^3   P
ME@  (9D  !*:   'FP   )T   "@    H@   *0   "H    J@   *L   "J
M    JP   *P   "M    K@   *\   "Q    L@   +0   "W 0  N0T  +D:
M  "Z+0  ND,  +I;  "Z=P  NY0  +NQ  "YT@!0E0  09@  #*<   CH
M$Z(   BD    IP   *H   "L    KP   +(   "W    N0   +L   "Z
MO    +T   "_    P    ,(   #$    Q@   ,D   #-    T@$  -0/  #5
M'P  US4  -A-  #8:0  UX8  ->C  #6O0#_    _P   /\   #_    _P #
M /\ #0#_ !4 _P @ /P *P#X #4 ]  _ /  1P#N $X ZP!4 .D 6@#G %\
MY0!D ., :@#A '  WP!V -T ?@#; (< V "1 -, G0#/ *L S0"] ,L X #)
M /L QP#_ +T _P"Q /\ J0#_ *, _P#_    _P   /\   #_    _    /8
M"P#Q !$ [0 ; .D )0#D #  WP Y -H 00#5 $@ T0!. ,\ 5 #- %D RP!>
M ,D 8P#' &D Q0!O ,, =P#  '\ O@"* +L E0"X *, M@"T +0 S0"R /(
ML #_ *P _P"C /\ G #_ )< _P#_    _P   /H   #Q    Z    .  !@#9
M  X T@ 6 ,X 'P#( "D Q  R ,  .@"] $$ N@!( +@ 30"V %, M !8 +(
M70"P &( K@!I *P ;P"J '@ J "" *8 C@"D )L H0"K )\ P "= .8 FP#_
M )H _P"4 /\ C@#_ (H _P#_    ]@   .@   #<    S@   ,8  0"_  L
MN@ 1 +8 &@"R "( K@ K *H - "H #L I0!! *, 1P"A $P GP!1 )X 5@"<
M %P F@!B )D : "7 '  E0!Z )( A@"0 ), C0"B (L M0") -, AP#W (8
M_P"$ /\ ?P#_ 'P _P#R    XP   -(   #%    N@   +$   "K  < I0 .
M *$ % "> !P F@ E )< +0"4 #0 D@ Z )  0 ". $4 C0!* (L 4 ") %4
MB !; (8 80"$ &D @@!R '\ ?0!] (L >P": '@ JP!V ,0 = #K ', _P!S
M /\ < #_ &X _P#?    S    +\   "T    JP   *$   ":  ( E  + )
M$ ", !< B  > (4 )@"# "T @0 S '\ .0!] #\ >P!$ 'D 20!X $X =@!4
M '0 6@!S &( < !K &X =0!L (, :@"2 &@ HP!F +@ 9 #> &, ^P!B /\
M8@#_ &  _P#,    O    *\   "E    G0   )0   ",    A@ ' ($ #0!\
M !( >  9 '4 'P!S "8 <0 M &\ ,@!M #@ :P ] &H 0@!H $@ 9P!. &4
M5 !C %L 80!D %\ ;@!= 'L 6P"* %D FP!7 *\ 5@#+ %4 \@!4 /\ 5 #_
M %0 _P"^    L    *0   "9    D    (@   "!    >0 " ', "@!O  \
M:P 4 &< &@!E "  8P F &$ + !? #( 7@ W %P / !; $( 60!' %< 3@!6
M %4 5 !> %( : !0 '0 3@"# $P E0!* *@ 20#  $@ Z !' /\ 1P#_ $<
M_P"T"0  I@L  )L,  "0"@  A@4  'X   !V    ;P   &@ !0!C  P 7P 0
M %L %0!8 !H 5@ A %0 )@!3 "P 40 Q %  -@!. #P 30!" $L 2 !) %
M2 !8 $8 8@!$ &X 0@!] $  C@ _ *( /0"X #T W0 \ /@ / #_ #P _P"L
M$   GQ(  )02  ")$0  ?P\  '8,  !N!0  9@   &   0!9  @ 50 - %$
M$0!. !8 2P ; $D (0!( "8 1@ K $4 ,0!# #8 0@ \ $  0P ^ $L /0!3
M #L 70 Y &D -P!X #8 B0 T )P ,P"Q #( S@ R /$ ,0#_ #$ _P"F%@
MFAD  (X:  "$&@  >A8  ' 2  !H#@  7PH  %@#  !1  0 3  * $@ #@!$
M !( 00 6 #\ &P ] "$ /  F #H +  Y #$ -P W #8 /@ T $8 ,P!/ #$
M60 O &4 +@!S "P A0 K )@ *@"M "D Q@ H .H * #^ "@ _P"A'   E2
M (HA  !_(0  =1\  &P:  !C%@  6A$  %(-  !+!P  1  & $  "P \  \
M.  2 #8 %P T !P ,P A #$ )P P "P +@ S "T .@ K $( *@!+ "@ 50 F
M &$ )0!P "0 @0 B )4 (0"I "  P0 @ .0 'P#Y !\ _P"=(@  D28  (8H
M  !\)P  <B4  &DB  !?'0  5Q@  $X3  !&#@  /PL  #@%!P T  P ,0 0
M "X $P L !@ *@ = "D (@ G "@ )@ N "0 -@ C #X (@!' "  4@ ? %X
M'0!M !P ?@ : )( &0"G !@ O0 7 -\ %P'U !<"_P":)P  CBL  (0M  !Y
M+0  <"L  &8H  !=)   5!\  $L:  !#%   .Q   #0- @ M"0D *04- "8#
M$  D 1, (@(9 "$"'@ @ B0 '@,J !T#,@ ;!#H &@5$ !D%3P 7!EP %@9J
M !0'?  3!Y  $@>E !$'NP 0!]L $ CR ! )_P"7*P  C"\  ($Q  !W,@
M;C$  &0N  !;*@  424  $D@  ! &P  .!8  #$2   I#@0 (PP) !\)#0 =
M!Q  &P<5 !D(&@ 8""  %PDG !8)+@ 5"C< $PI! !(+30 1"UH $ MI  X,
M>P .#)  #0RE  P-NP +#=D "PWQ  P-_P"5+P  BC,  '\V  !V-@  ;#4
M &,S  !9+P  4"L  $<F   ^(0  -AT  "X8   G$P  (! % !D."@ 5# X
M% P1 !,,%@ 2#!P $0TC ! -*P /#30 #@X_  T.2@ ,#U@ "P]G  H0>0 (
M$(T !Q"B  80N  %$-0 !1#O  80_P"2,P  B#<  'XZ  !T.P  :SH  &$X
M  !8-0  3C   $4L   ])P  -2,  "T?   F&@  'A8! !<3!@ 1$ L #@X.
M  X/$P -$!D #1 @  P0*  +$3( "A$\  @22  '$E4 !A-E  03=@ #$XL
M 12@   3M@  $]$  !/N   3^P"0-@  ACL  'P^  !S/P  :C\  & ]  !7
M.0  338  $0Q   \+@  -"H  "PF   E(@  'AX  !8: @ 0%0D #!,.  H3
M$@ )%!< "!0?  <5)@ &%2\ !!8Z  ,61@ !%U,  !=B   8=   &(D  !B?
M   8M0  %]   !?M   7^P"..@  A#\  'M"  !R0P  :$,  %]"  !6/P
M3#L  $,W   [-   ,S   "PL   D*0  &R0  !,? @ -&PD "1D-  89$0 $
M&18  AD=  $:)   &BT  !LX   ;1   '%$  !Q@   =<@  '8<  !R=   <
MLP  ',X  !OM   ;_ ",/@  @D,  'E&  !P2   :$@  %Y&  !51   2T
M $,]   [.@  ,S<  "HR   @+0  %RD  ! E @ +(@D !2 -  $?$   'Q0
M !\;   @(@  ("L  "$V   A00  (4\  "%>   B<   (H4  "&;   AL@
M(<T  "#M   ?_ "*0P  @$@  'A+  !O3   9DT  %U+  !420  2D8  $)#
M   Z0   +SL  "4W   <,P  $R\   TL @ '*0@  2<,   F#@  )1(  "89
M   F(0  )BD  "8S   G/P  )TT  "=<   G;0  )X(  ">9   FL   )<P
M "7N   D_0"(2   ?TP  '90  !N40  95(  %Q1  !33P  2DP  $%)   U
M1   *T   "$\   7.0  $#8   HR 0 #, <  "\+   N#@  +1$  "T6   M
M'@  +2<  "TQ   M/0  +4H  "U9   M:P  +8   "R7   LKP  *\L  "KN
M   J_@"%30  ?5(  '55  !L5P  8U<  %M6  !350  1U$  #M-   P20
M)48  !Q#   3/P  #3T   8Z    . 4  #<)   V#0  -0\  #04   T&P
M-"0  #0N   T.@  -$<  #17   T:   -'T  #.5   RK0  ,<H  #'N   P
M_P"#4P  >U@  '-;  !J70  8ET  %M=  !/6@  0E8  #92   J3P  ($P
M !9)   .1P  "$0   !"    00,  #\'   ^"P  /0X  #T1   \&   /"$
M #PK   \-P  /$0  #Q3   \90  .WH  #J2   ZJP  .<@  #CM   W_P"!
M6@  >5X  '%A  !I8P  8F0  %=B  !)7@  /%L  "]8   D50  &5,  !!1
M   *3P   4T   !,    2@   $D$  !("   1PP  $8/  !&%   11P  $4G
M  !%,P  14   $50  !$80  1'8  $./  !"J   0<8  $#L   __P!^80
M=F4  &]H  !H:@  76D  $]F  !"9   -&$  "A?   =70  $EL   M9   "
M6    %8   !6    5    %,   !2!   40D  % -  !0$   3Q@  $\B  !/
M+@  3SP  $]+  !.70  3G(  $V+  !,I0  2\(  $GJ  !(_P![:0  =&P
M &YO  !D;P  56T  $=L   Y:@  +&D  "!G   490  #60   -B    8@
M &$   !@    7P   %X   !=    7 0  %P)  !;#0  6Q(  %L<  !:*
M6C8  %I&  !96   66T  %B%  !7H   5KT  %7H  !3_@!Y<   <W0  &EU
M  !;=   3',  #YS   P<@  (W$  !9O   -;@  !&T   !M    ;0   &T
M  !L    :P   &H   !I    :0   &D#  !H"0  : X  &@5  !G(0  9R\
M &<_  !F4@  9F8  &5_  !DF@  8[<  &+A  !A_ !W>   ;7H  %]Z  !0
M>@  0GH  #-[   E>P  &'H   YY   $>0   'D   !Y    >@   'H   !Z
M    >    '@   !W    =P   '<   !W 0  =P@  '<.  !W&   =R8  '8V
M  !V20  =5\  '5W  !TDP  <Z\  '+3  !Q]P!Q?@  8W\  %2   !%@@
M-H,  "B$   :A   #H,   2$    A    (4   "&    B    (D   "(
MAP   (<   "'    AP   (<   "(    B    (@'  ")$   B1P  (DL  "(
M/P  B%4  (AM  "'B0  AJ<  (7'  "$[P!FA   5X8  $B(   YB@  *HP
M !N-   /C0  !(X   "0    D0   ),   "5    EP   )@   "6    EP
M )<   "7    F    )@   "9    F@   )L   "=!P  G1$  )TA  "=,P
MG4D  )QB  "<?P  G)P  )RY  ";X@!:BP  2XX  #R1   MDP  'I4  !"6
M   $F    )H   "<    G@   *$   "D    I@   *<   "F    IP   *<
M  "H    J0   *H   "L    K0   *\   "Q    LPD  +,5  "T)P  M#T
M +55  "U<   M(X  +2L  "TS !-D@  /Y8  "^:   @G0  $9\   6A
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M_____________________________________________P
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M^OO\_?[_;69T,0     # 2$   $                    !
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M________SYJ!;5I&B.K________________________________$?#XF$
M5+#______________________________^"#/       +H?M____________
M_________________ZQ3$       %VW6____________________________
M^X Q        "6',____________________________TEH"         %W,
M____________________________J#4          %S3________________
M____________?0T          %36___________________________N?44
M         $34___________________________\JF0O @  !"(W25C.____
M________________________Z:1K02@_8W^5I[K:____________________
M___________5LJRRS.3Z________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________ENY=W
M8LC_________________________________VYYG-@H  HS_____________
M___________________(?S\%     %[/____________________________
M_]F!.0       #RJ_____________________________YY,         ".0
M____________________________W&\:         !!]^?______________
M____________KT@           !O[O__________________________A!,
M          !DYO_________________________L40            !7WO__
M______________________^X%0            !(UO__________________
M______]T%              XS_________________________FB6A,
M       CQ?_________________________?FUPL           -NO______
M____________________[[%]53DB$0<! A$BLO______________________
M________W[^EF9B:H*R]VO______________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________X[Z=@'S[____________________________
M____\K>$5S . !VL_______________________________2BDP5      !R
M\____________________________]9_-@        !+R?______________
M____________^I$^           OJ___________________________P%H
M           :E?__________________________C20            (A/__
M_______________________G7@              =___________________
M______^T)0              :O________________________]]
M        6_3_______________________TK                3.O_____
M_________________Z4                 /.'_____________________
M_S ,                +=G_____________________F8IA)P
M    )]?______________________^V^B54G            )=S_________
M_________________LJ==EU*/#(M+# Y1][_________________________
M______WFW=;2T-/9Y/__________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________OU+O6
M_________________________________^>XCVI++Q5O________________
M_______________DH6<T!P     \R?___________________________]:"
M.P         2E___________________________[84Q            ;___
M________________________ID(             4.'_________________
M_______L:0              -\G_______________________^S+P
M        (K;_______________________]Y                $*?_____
M__________________(T                 )G_____________________
M_ZD                  (S______________________T8
M     '______________________WP                   '3_________
M____________EP                   &K_____________________S@
M                 &/______________________RDB 0
M &'______________________[FC@%<W%P           &C_____________
M______________K3KI2&?'5Q<')W@93_____________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____V[J=@FEIT_______________________________R)-E/1D    =GO__
M_________________________]N.3!,         ;O__________________
M________VWPL            1=?_________________________BRH
M        (K3________________________"1                Y?_____
M__________________]] 0               '______________________
M_^<V                 &K______________________YT
M     %C______________________T8                  $?X________
M____________Z0                   #7I____________________E@
M                 "7;____________________O
M !C.____________________ZP                    _"____________
M_________P                    JY_____________________R<
M              JU_____________________W                    VY
M_____________________^"<C'!50C,F&Q0/#0X2&B:_________________
M____________^>38TL[,R\S/UN#\________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________Z].\X___________________
M_____________]*IA65(+!(!A?____________________________&K<3P/
M        3^#_________________________U7\U            '[+_____
M___________________C=1T              (G_____________________
M__^0(P               &?______________________]5#
M     $CV_____________________XH                  "[=________
M_____________S@                  !?(____________________O@
M                  2V____________________G
M  "E____________________N@                    "3____________
M________W                     ""_____________________P
M              !T_____________________Q,                   !H
M_____________________T(                   !@________________
M_____WH                   !=_____________________]$
M          !A______________________\D                  !F____
M___________________)K)F)?79Q;&EG9F=K<'J,____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________XL6JD7EA=_______
M_______________________=IG=0+ P     ,<3_____________________
M____X)).$P           (_________________________2<!T
M     &#______________________^YO#P               #?B________
M_____________Y8<                 !3 _____________________T
M                  "C____________________K@
M  ")____________________G@                    !R____________
M________O                     !?____________________V@
M              !-____________________^@                     [
M_____________________PX                    J^?______________
M_____S,                    ;Z?___________________UX
M           /V____________________X\                    &T/__
M_________________]                      RO__________________
M__\K                    R/____________________^
M        R______________________W%@$%!0,!       !!@T8R_______
M_________________.OAV,_,S<_0TM37W.+J________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________':QO______________________________\<:CA&A-
M,A@ %:O__________________________[E\1A@          ''_________
M_______________7?"\              #OC_____________________]]D
M"0                RU_____________________W0#
M  "-____________________Q14                   !J____________
M________F0                    !+____________________M@
M               P_?__________________UP                     9
MY___________________]@                     %T_______________
M_____PX                     P?___________________R\
M            K____________________U(                     GO__
M_________________WD                     CO__________________
M_Z4                     @/___________________]@
M        =/____________________\V                    ;?______
M______________]\                    :?_____________________7
M#0                  :/______________________<
M    8?_______________________U \1DY465UA9&AL<'9^B?__________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________[]6[HXMS6I7_________________________
M__B_CF1!(04      %+\_______________________WG588
M !?!_____________________^5L%@                "-____________
M_________V,                   !>____________________G0
M               U_/__________________H0                     1
MV?__________________R@                      N_______________
M____[@                      H?___________________PP
M            BO___________________RT                     =O__
M_________________TT                     9/__________________
M_V\                     4O___________________Y0
M        0/___________________[P                     ,/______
M_____________^H.                    (O____________________]$
M                    %?____________________^!
M    "_7____________________("P                   NS_________
M____________7@                   .7_____________________R1P
M                 -K______________________YT!              <.
M%\7________________________5N;S!Q\[5V^'F[?3[________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________X
MW\______________________________[,:EB&U4.R$' #+>____________
M____________UY)9*0            "@______________________^)-@
M              !G_____________________V8                    R
M]O__________________E0                     #R/______________
M____IP                      H/__________________UP
M            ?/___________________P                      7O__
M_________________R4                     0___________________
M_T@                     +/___________________VH
M        &/___________________XL                     !?/_____
M_____________Z\                      .'__________________]4
M                     ,____________________\D
M     +[___________________]4                     *[_________
M__________^+                     )_____________________+#@
M                 )+_____________________5P
M (;_____________________J@H                  'G_____________
M_________VT                  &;_______________________=5
M             $7_________________________:B,K-3]*56!J=7Z'D9S_
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____^C/MIV#:4ZY_________________________^RR@UPZ'0(       ![
M_______________________%;2D               ! ________________
M_____X,;                   'R___________________D@
M            F/__________________I                       :O__
M________________W0                      0?__________________
M_PX                     '?___________________SD
M         .C__________________V                       ,[_____
M_____________X4                      +?__________________Z@
M                     */__________________\L
M     )#__________________^\6                     'W_________
M__________\^                     &S___________________]I
M                 %K___________________^9
M $G____________________2%@                   #G_____________
M________6                    "G_____________________H@
M             !G_____________________]58                   3_
M_____________________[LO                  #X________________
M______^K*0                #/________________________R4<
M!Q,@+CY2:(3M________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________]-7)________________
M____________^M*PDG==0B@,  !*________________________Q7U%%P
M           1V/___________________\10                    G___
M________________H@P                     :/__________________
ME                       -O__________________V@
M        !^S__________________Q4                      ,3_____
M_____________T@                      *+__________________W4
M                     (/__________________YT
M     &G__________________\,                      %+_________
M_________^</                     #[___________________\S
M                 "O___________________]8
M !C___________________^!                      7_____________
M______^L                      #____________________>(@
M              #R____________________7                     #?
M____________________GP                    #,________________
M____Z$H                   "W_____________________Z 6
M          "<______________________]Z @                !W____
M____________________>@L               5,____________________
M_____Z)7:'2 C9RKO-#G________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________________________^WC____
M_______________________2HWI8.BDC'!8.!@  G___________________
M__^L4@X                 :?__________________Y$,
M        -/__________________>0                       ./_____
M____________S0                       ++__________________Q,
M                     (7__________________T\
M     %W__________________X,                      #K_________
M_________[(                      !S__________________]L#
M                  +___________________\J
M  #[__________________]/                      #G____________
M______]T                      #4__________________^;
M              # ___________________$!P                    "M
M___________________P,P                    ":________________
M____9P                    "&____________________HP
M          !R____________________XT0                   !<____
M_________________Y$&                  !!____________________
M_^M?                   =_______________________*2P
M        ________________________RU<   P8)#$_3F!TBZ?'________
M___________________7Y_+_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________KU,W'PKZZM[.PK:FHI?______
M_____________]U^4S\P(QD1"0(          -O_________________=@
M                     *?_________________N@
M     '7__________________P<                      $;_________
M_________TX                      !K__________________XP
M                  #]_________________\$
M  #;__________________$9                      "^____________
M______]$                      "D__________________]K
M              "-__________________^1                      !Y
M__________________^W                      !F________________
M___>(0                    !3____________________2@
M           _____________________=P                     K____
M________________K H                    6____________________
MYT4                     _____________________XH
M        _____________________]9-                    _?______
M______________^G+@                  U?______________________
MF"H           88+45@X/_______________________ZAC=(&/G*N[S>+Z
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________GR[>IG96.B82 ?'AT<&QH99#_________
M________O&I(+1D*                 #'__________________P
M                  /__________________T(
M  #<_________________XX                       "R____________
M_____\X                       "-__________________\I
M              !K__________________]:                      !.
M__________________^&                       T________________
M__^N                       >___________________4%P
M           *___________________Z/0                      ____
M________________90                      ____________________
MC@                      ____________________O!D
M        [___________________\4X                     V/______
M_____________XL                     O____________________\Q#
M                    H?____________________^1&0
M    >O_____________________R= H                17___________
M____________Z'03'RPX15-B<H6;M-+U___________________________7
MZ/3_________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M__________________________________________________OW\_'N[.OK
M[/'__________________]FRF8=Y;61=5E%+1D$\.#(M*"/$____________
M_____TLE"P                    "2_________________X@
M              !F_________________]<                        ]
M__________________\S                       8________________
M__]L                        __________________^=
M            ___________________)#                       ]O__
M_______________Q-0                      W___________________
M6P                      R___________________@@
M        M___________________J08                     H_______
M____________TR\                     C?___________________UX
M                    =____________________Y,'
M    7O___________________\U#                    0/__________
M__________^'$                   '/_____________________87@
M                 /______________________OTX       X<+#Y2:H:E
MR/_______________________\)\C)JGML76Z/W_____________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_____________________________________^[AU\_)P[ZZMK&MJ:>FIJ>N
M_________________[Z&;5M,0#<O*"(<%A +!      4________________
M_]<%                        __________________\T
M            ]O________________]V                        TO__
M______________^P                        LO_________________A
M)                       EO__________________40
M        ?/__________________>0                      9O______
M____________H                       4?__________________QR,
M                    //__________________[DL
M    )____________________W0                     $/__________
M_________Z,6                     /___________________]A,
M                 /____________________^(#P
M /_____________________+4P                   /______________
M________I3@           D=-$YKC/_______________________YDY0U%?
M;GV.H+7+Y?_____________________________K^?__________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________KS+FLH9F1BX:!?'AT<&MH9F9H\?__
M______________]A13(C& X&                GO________________]^
M                        =?_________________#
M        4O_________________[-P                      ,O______
M____________:@                      %O__________________E@
M                     /__________________OQL
M     /__________________YD(                      /__________
M_________VD                      /___________________Y "
M                 /___________________[DL
M /3__________________^A<                     -G_____________
M______^1&                    +S____________________*4P
M             )W_____________________F"X             $"E&9L3_
M____________________[G\=#!HH-T97:7Z5K\SN____________________
M_____^>@JKG(V.G\____________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_________________________________________________?7PZ^;BW]O8
MU-+1T-+7X/_________________.GHI\<6EA6U913$A#/CHV,B\N,?______
M___________2)1$#                     /__________________0@
M                     /__________________?0
M     /__________________L L                      /;_________
M________W3D                      -S__________________V(
M                 ,7__________________XD
M *___________________Z\B                     )G_____________
M_____]9(                     (+___________________]R
M             &G___________________^A*                    $[_
M___________________37                    #/_________________
M____EBX              !4R4G?_____________________X'(3   !#Q\O
M0EAPBZC([/_______________________\IO;GZ.GK##V.______________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________________________________^>#2R,"ZM;"LJ*6BGYV;
MFYR@I___________________@F162T,\-C K)R(=&!,."00  -3_________
M________D@                       *W_________________S!X
M                 (O_________________^U(
M &W__________________X                       %'_____________
M_____ZD;                     #K__________________]!"
M             "/___________________5H                      S_
M__________________^/%                     #_________________
M__^X/@                    #____________________E;0,
M          #_____________________GS<              ! O4'3_____
M________________W7(4      87*D%:=92VVO______________________
M_[Q81%1D=8::K\CC_______________________________2S>'Q________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______\^_K[_?______________________[KFHG9:/BH:"?WMX=G1R<W5X
M?Y#_________________ZT\Z,"@A&Q40"P<"         "/_____________
M_____VD                       #__________________YL*
M              #__________________\@Y                      #_
M__________________!C                      #_________________
M__^*#@                    #___________________^P-
M          #____________________56P                    #_____
M________________A1H                   /L____________________
ML4D              !@Y78'_____________________Y7L>       ,(3A2
M;X^SV?_______________________[M8*3E)6FR E[#-[?______________
M______________^SGK3%U^O_____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________Z[^?AW-G6
MU-+0T-#1T]G@Z_?__________________[B*?G=Q;&AD85Y;65A75UE>97'_
M_________________[\Q'Q80"@4               #_________________
M_^U6                      #H__________________^"!
M          #,__________________^K+P                    "S____
M_______________25P                    ";___________________W
M?!                    "%____________________HC<
M    !2N4____________________RV$"            #"Q0=I[1________
M____________]8TP       -(SM7=IF^Y?_______________________\-C
M&"H[3%]TC:?&Y_____________________________^H?Y:HN]#G________
M_____________________________?______________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________=SL6_O+FVM+.Q
MLK*UN<#)U>/___________________^7;&1>65513TQ*2$=&2$M066:A____
M______________^G)@X' @                !6___________________.
M4                      Z___________________T>0L
M       A____________________GS(                    .________
M____________Q%@                (,5J$____________________Z7\?
M           &)TMQFL+I_____________________Z=)      (7+TIHBJ[5
M_/_______________________]-U'B8X2EYUCZO+[___________________
M__________^N<H68K,+;]O__________________________________W^__
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________O[*JIJ.AH)^?H:.F
MK+3 S=WL____________________BEI33TM(1D1#0D%"0T=.66E]________
M____________GBX&                    ____________________PU8
M                 !5!____________________YWL:              DT
M8(NT_____________________Y\_          0E2G&9PNO_____________
M_________\9F#P   !,J1&*#I\WU_________________________^N.-2L^
M46B!G;S>______________________________^^=G^4J<'<^?__________
M________________________TMCS________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M___________________________________________________________V
M\O#O[^_Q\_C]____________________________^+"?FI>6EI:8FY^DK+;"
MT>'N_____________________HY02D=%1$1$149'2U%::(.I____________
M_________Z9! 0          !S9CC[KA_____________________\9E"@
M    !"=,<YS$[/_______________________^6(+P  $RI$8H*FS/3_____
M______________________^K4#9*87N6M-;Z________________________
M_______2AWR8L<OI____________________________________U,[M____
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M_______________________________________________________MY>/C
MY.;H[?'Y______________________________VQE)*2E9F=HZFRO-#M____
M______________________^=4T=)35%68'.*K];\____________________
M______^R5@ :-5!MBZ[2]______________________________-;SY?>YFW
MU_G________________________________NGX.FPN'_________________
M____________________X\[K____________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M____________________________________________________________
M________________
M
M
M      #_____________________________________________________
M____________________________________________________________
M_________________________________________________________P
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M! ,! 0             ( 00&!P(%"0,*_\0 <1    8"  (% PD0!Q(*!PD
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M#R(PXM:Y[@]S8P=[G"-LDCFMXB-DCR/>M<=%G'C;7EPNH-73BGV:QF)B&C=
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M :"][B&@ 6  &!;7X;=1P^N+A*-(6<3<L89PX0.M?;\Y3*H0R?(3H.K,JW5
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M<?*7LM9K2X_V[PP: $G5U2UHW;W.#1O) U61]#/]D<-3LYY/K#767;+=IO\
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M:+TQ.C0!J3?>O4ZORL4%?5U5=6^2OR:5%975,]95U$E!M$7SU-3*^:>9]MI
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MCUA"J%,/(!Y\^?(0Y" \NP>7(?#Q_/@.!-AOU]FA]1T/;HI4!^*^WQ.N=_\
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M@?(PQR.B>[9\F/I(B8Y<C@)&>8_,W1=;);WX!YBO254D*?).*Y+24),2$/\
M.S[J39+RM:A8FN5^2!)'6)/(OH: @XB%C7* I+-(R/;,D#D0(!!""K!N'MO8
MMOT\>YV\>_T!OW>A6:C;3R.5=%/AL^%U4E#4U%'534OTOMK1"^IP^FIZ*AJ"
MUNSH#9J2DI*:EIY&V?%3PQ0L(C:&K%Y_9?J><ZDNJ6F2T/,!35Z%%V*"X9MQ
M1L[7:VM6Y.HH,Z^])JHZ<9U"NS,A%L!20,1NS7ZKY,[<A40J$58"#TC7#-GL
M9XR"<P<;W?>Y<T7._0<++7UFT/D3K&N)PFLIZ@84[!Z>MI/)_M9!54-"[#:S
M"8XZ*9NS@%/U?#Z^JIJ8@6CAE=$&F)QC/>:]WCP)ZRUZZUC4X:T1M3E6/4;$
MP2X==V)&L_3B&L"Y>6$[75[8DB]>Q3)LS<K&3(46Z2:"*:""::)(DAJY'F1S
MFDW+F_5X_-N2ZS;O-K$GT\>*R\#VQ\C^SV"OV?PJDQ.FPR:$0UD,>PNV##7G
MJL-')-6NCV>9T\\U/3Q1RRD-S-8UK0UH:T9O1N+'@XUG7VU4U^VMM0K3-1=9
MK"07#SO1A'-U'*@JKF1;):V!-,55!$Y@*  )AY\@RAU+4O)<XL<3O)FB)_\
MG6TPCRD^2[ *&'#,%BQ7#,/@S=#1T>PVV,,$68ES@R-FSX:P$DFP Y ++QX\
M.&T/_?VQ??T-O< ^$=;@ >Z(Y2*.?_\ +'?-%^FMF?+'L&->MX\+<3L7MD!S
MU+L! 'I/9OT4IJQ9(FX5^'M$$H[5AYZ.:2L8J_C)*&>*,GR";EL=Q%3#1C*1
MZQDE""HTD&;5V@?FFN@DH4Q QG-<QQ:X6(-B+@^HM)!]:]&H*ZFQ.AI,1HW2
M/I*ZGBJJ9\L$]-(Z&9H=&Y]/4QPU$#BTW,<\4<C=SF Z+O<A9:81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+\\GJPG#GJ
MF!F(3;6O>"3AGW!NC9\?MFZ;)V3NNA;#NB+V-T+J!*U-:JTB=<V.M2<C>K;5
MZVZ95074FBTZG49%N5F_D%VJ>>D[%XC5S,EI*G'\3P^BHW4,--34%11TSB_$
M:YM,97/JA9T,+Y ',:'.Z2>-_FL8XK58@!&6.93QRO>V0N=()2&",M<?[G<7
M.9Q -@?.[;3>]2$FH.<X*:NYK%*U)2:VRV3N>%@4=#TNYT/3]GAX/9UDBHZ]
M4*%V!-3ML5A;BT:)3AI"6=-U5W[I\B1DW3;DZ?/[9Q2PX_*R::KFDZEA[G]?
MFIIJV%[Z<.?35#Z0=7+X''*,A==I#B;NLLC#W9J>]F-O))HP.#-X (S&_"QT
M&ZQU!7I[G++-3")R^/MR+"Y.NO:>SMTW#<B9**,Z/TX\A]K/#_C2G,W#OL!%
M^&)_S*G6./KMWWNW^D>I,9IUD)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MM%<3>LY_<F@-P:LJ[F+9V"_Z]L]4AG4VNY;1+>2F8Y1HT6D5V;5\Z29D4. K
MJ-V3I4A.9B(*C] .OQ:EEKL,KJ.%[62U5-+!&YXNQKI&%MW6UMKP!YVTL>KV
M$QVEV8VTV6VBKHZB6BP7',-Q*KCI1$:E\%'5Q32M@$Q$1E+&.#,Y#;Z$B]UI
MO2NV]YI[G?\ #]N:E:P@W\-IN%V7$S6M[E9[2W>L%[4[IA&4A\TE2J:C5R5>
M,<NC$;H.4@3,B!5N9C)I8=!78B^O?A^)4U' YE%'5,DHJJ:H:^\W0D/;+1TO
M1C0D93)FUN&V&;H]J=FMD6[*4^V6R>+[0UL55M158%5T6/X3A^'/BE&&1XH)
MJ>2@Q?$Q*PF=L3FRB L%G-,EW9)LYO%YBHL7T+Y5MWQUZKVL[)L"'4U4YJ2Y
MJ[)U5BJQE5K<693\NG8[!!F.EU1'F)VXJ<CJ%((E'I"3RW'CCN%;<QX_0;+X
MGM#0R[*/PESL,JL)IWP59QF*LZ-XQ/$J#0P,+@8\]B&M-KV/>8.<(K]CZC!:
MW'Z#!*QFT<>)QBOI<4J&30-PF:CNPX;1UF5PE>&VE:T$.NTV#EW7LQ[,Y<_G
M:MJ]@<Q_](=4?IX'Q\LS?HRVC_S9[5[C_P#>.RIW#LVA/?VZ]BL#9; 3N\H.
MS8UL!U#:H<;#_P##ORZ<5LO5U_;;.ID9<F<7(PJ,DO+-ABY8S,T@R<0TR_@W
MB+D[!R[9G.#R-<"4[=PJF*0D$IN8B =+LQC\6TV#4V,Q4M31-J):V%U)5NA=
M44\U!6ST%1%(:>26!Q;/326='(]I;8AQ!6BQ[!I< Q6IPJ:IIZM],(7"II>F
MZ"9E1!'4Q21B>*&8-=%*PVDC8X$D%C2++86= M.F$6MI?5E8FYM_8')[ SDY
M$K=-ZO#V>?A4W1&B?D6OE6\5)-$C&12^@ QR"(\S&#D)C"/EN.>2'9#:#'L0
MVDJG;2T.+8I'215\^!;7;2;/PU;:&)T%(Z:FP7%:**22*)Q8)'L+B">8 W--
MC^(TM+#1QFEDIZ=TSH65%#25)C,[FNDRNGAD< XM;<7X#DK+V'JQ_P!*7C[X
M%U_T]FO^D?L?_&OE"_\ B=M__P!1*]]$F(_<L,_V1AGZJL?@:\A5-NLXN.D;
M"X8/M?S<@NUF+)-SB NV]A@6Z#A-.6?.P14(@NJF!D^0\E% [C#G-;.[.4^Q
MOELH,%PK%=IZG"L1\F.T.)5%%CFU6/[04[<0I-JMFZ:FJ(HL8KJP1R-IJJK9
MTC3F F>VY!N<ZJK9,1V:GJ:B&C$T&-4-/'+345)2N$,M%B,KXW&GBC<X.?$Q
MQO<78W< T#>HE*(\Q !'S_+Y#GT/8<ER7CQZUP%%(1YBF01'QZ(846'(>I4\
MBC]2)]R'YL)8<AZ@GD$?J1/N0PEAR'J">01^ID^Y#"6'(>H)Y!'ZF3[D,)8<
MAZ@J@BD \P3( A_8AA+#D!W:'U\%S*4I>8%   1YCR\_G^+"E5PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+QC]57VC
M#GB-?576FQW==W16+K)QP6>H\=VLN#]MIN2F:G'33)UMT;J]G4;I$3<.XCY6
M.H;K6EU?R$:0THS8L6CD';OMMCZ29\D\T]&*C#Y8FO=%+L[5XX^M9%-+$[J(
MI^B,,D4C)(GS=9A:U[@"7%GFZVO>VS6M<!*PFQZP(.CS-!!?<@.:="1<&PL#
M>X4Q?4^'VW9#A9H"^]-_ZEXFME%<65";VYI22KDU0YA%"P/TXV*:S=3@ZQ S
M$K78\K:%G)%E6X074FS<'<,0<^577TFT3:)N,50P_#:["J0MB<RBQ%LD=4Q[
MF R/='(YSV1R.\Z%CG.+&W!=P&329^@9TDL<SKF\D5LA[K7UO>YN;W&IWF:^
M:19*81,(F$49T?IQY#[6>'_&E.9N'?8"+\,3_F5.L<?7;OO=O](]28S3K(3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H4(?T0N7^TVK7X[;3FC;]LDGX
M%C_/7KTU_P#>6I?Y3ZO^JN'J:^;Q>9*G1+SZ7(.8ARYCYL@ #<!<[SQ/>>/I
M46'$7[]?C7$Y0Y=P>/H[@$?#T@';X8.X[]QW$@Z]V]+ <!SW#@H^<+7[3<-S
M^R38WXR;?GGODO).R%*222<7VJ))-R2=J,6)).MR>:[3;_3:FMM_BF#_ .YJ
M!2&ST-<8F$3")A%JIS^W9#_VLK!_C/7,\9JO\(# OY)=J/ZW[+KHHOM3K?\
M6##?]W8IX/H6*;;M%A@I%N#9Y-1D,C!R3Y \+Y%%69GV[EOY.)5DUH6?39JE
MCA67C6)V2995X8$%%@22, <QY:-J]HMG\0@;35^-X7@E/LYB>)TAP(]6J,>V
MEI:R![,"EQ<X#M*RAE;A+:BKPZBEPP1XM5$TTD\<;&EV3L_14E5$\N9!-5.J
MXH7-J(^E9343X9"^K$/6Z(R!LP:R5[9LT+/J@:[<;-_L>\,&[UT9I%M&"=C]
M8&CV2C)ER=FBC JS!G\LDR<-^LB_>G:P;3JB;)!)X<RAS*F,DR+CXIY3]O\
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MFG60F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(H5P_]$!O_ -J;J_\
M&YM[X/D'CFC;]L53^!Z'\^K/'9N7IM5_>:P3^4S:77_^L;->.VRV>[XD:8GL
MY]JV*@KS9)2#E8:!MECK];.]IM-G9Z-9S,?$6&;6=-C@_P#6B2BY213B&4LG
M"1\I'NYM2.1< <N7[IT_6S1M942/8]D<TC(KPP32 %D,DA<VTCFEK\H#B&O:
M38$+GV;%XJ< CVBJ*G":&EJ:6IKL.HZW$(X,3Q6CHYW4L]5A]%E=))!UED\$
M4DCHVU$U-410&1\3@.W8\2O#Y)#62Q^[-7/CW*05B:H#2[U]Q\T<F@Y:LE6,
M-Y)^;UP<E?/6; $F_3.9^[;,B +I=-$U;,3PZ3H<E;3.Z=V2$":,F1_2LA+6
M#-=QZ66./2_G/:.*MR;#[9PC$3+LIM$P81 VIQ1SL&Q -P^!T#ZILM8[J^6G
M8ZECDJ09"V]/')./J3'/'82G$!HV$C1F)C;VN(N)ZFRD DG]Q@6K(S&2?SD7
M'.B.5GQ$CHOY*LV*/9'(8P.GL)*-4/*+L7!$ZW5]$UKGNJH UK6N<3*P -?)
M)$T[]SI(96#_ $HWC>TVLP;'[5U,XI:;9K':BI,DT/5X,)KI9A+3TU)6U$;H
MXX'/:^"CKJ*JF:X Q055/*_*R5CCT>U^)+4^H=3I;HGK!Z]45ZC'.H1[34R6
M=S9FLDT4E$7-<1CU3)RS9*#0>V)TZ07!JUK\=(RZZZ;)FLJ6W68E245$<0E>
MY]-E:YCH&&9TC7G1T;6WS@"[W$:-8U[OX*R-GMB=HMIMI/H4H*-M-C+)98JJ
M#%)!AK*"2&1D#V5[ZD---(:F6&DCC>T/DJZB"G:TR2L:=ZH+%<((N"<P(NDF
ML0#!R,!52%.7F';R'D8.8>?,X&X!W7 *Y5P+7.:;7:2#8@BX-C8C0CD1H5]<
ME0F$6JG/[=D/_:RL'^,]<SQFJ_P@,"_DEVH_K?LNNBB^U.M_U@PW_=V*+:N>
MS+G4PB81,(F$3")A$PB81,(F$3")A$PB81=*H]<%.H4IPY%.< ^A*(\@$0 .
M[M\/-W]^/'I_=W>Q6R\@G=:_+MMXW[MRX=><^V+Z/H"_E .T>7=X<^_NY3X[
M-Q^/@HSGF.W=\E]!??QMNWWH+]R _L@Y<_:%[/,'8'/O\?>\>>+<..G=K[?5
M<*0XD6%KV_>==-V_UJO7G/MR^/\ 2E#M[@\![/-X^?GCB+^P^K7=W\N]1G/Q
M<+Z;SRUY\.5DZ\Y]L'9SYB)2^GT>'O>GS8]=N/KM\WQ=J9SV:VL .[X_3V<T
MZ\Y]L'?[0O9\7Y_>[\ 7XCTFWQ_(F<]F[EQ]OR>GBZ\Y[/HBCX#] 7X>[OY^
M'/&GI[^SN^7LU0O.O#B-/G]=_D3KSGVX?<%\WN?JY_!@ 7WZ>KAIO]NOR79W
M=G@]_P"VWK3KSGVY?<Z!>[EW=WR[L6';[#;<-=W/QK9G/[>V^_QWIUYS[8OH
M'H%\?/R#P\_8';V^?&G;P^+4^@\.*9SS':-.'?SY:G33DKANZ64,H!S (%1.
M</H2A]$7ER$1 /3[F+6\>+^A2UQ-QV7T&[=ZU;]><^W#[@GYOPXT\$'YO'#E
M&<]GM\>I.O.?;@/?_2E_-R\.7OCBWCP?V=J9SV>KP?W=Z=><^W+W^T+Z?0';
MR^,/-BU]V_EZK<NV_=RU3.?9\W?I?V'FG7G'MR_<%_-BW[.WVZ>-=UV=W9ZD
MZ\X]N7[@OYO'%OV7X]WC7AKHF=W9ZO&Y.O.?;A]P7\@8MZ>[B;BX[]>%QWIG
M/9X[TZ\Y]L4>T?Z0O8';V=WO>?&G/Q\_L[4SG7AINMW:_*."=><^V+]R7L[?
M<]/Q>G%O7\O$6W\;>@^AG//V;_%O;V)UYQ[<!_N"_F\/R8[N).GJLF=W8/1X
MW_*G7G(?TX?<%]/:/9X>CWPY=N+>/G^+OWVXL[CR\6T&O'M]!OHJ]><>V+]P
M&+=MN^_+7<#Q]/-5-<2-U]>%OE*_/OZIA=+?KOC T;2V&SO5#VD!M)U:M@RR
MG#%IJ)V6M0F$#K!2JQ=/T;**ZKMODY&7L-<6NNVZ\X-,RT?%S#>P'6BXE^S2
M)Z-LI#3U&"XG(^AV:=)2-IZ>-N+UKZ9E4Z>O#YJBN'6&-M#'/T-,\Y6%S<HN
M6F^JJW2-JHVMDJ2UW2/<(X@\,(:S((B=UO.+[$:.U&B]/?4[)R_V'AGAI+8C
M3B41DSW?9C>$?<6R<.SWI/4QE>9IG3[';H6'H^NRUDL[ HLY&*K#ZL(OX.-6
M;LU9.=1(WF7O*;114L.*R,I#A1CZO2E[<%+W8?'.8ATT4,DDLSI#&_S7O#\I
M-K-;J!GTI<8O/Z?-F=K4-:V3<-+-)&4&X#KW=J;#0"<^:-9*81,(F$49T?IQ
MY#[6>'_&E.9N'?8"+\,3_F5.L<?7;OO=O](]28S3K(3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$4*X?^B [ ^U-U?^-W;N:-OVQ5/X'H?SZL7IM5_>
M:P2^_P"F9M)ZOH7V:_8N=PX+:;:MOM-L$MUIB2);'K6W7M/0CZ=(1+G8E8A(
M:N(3D;,2M9?VVNI3<+7*]'VR.@Y]HPGDH./,JW05*X5<5SX)3SU76NEEC)JH
M*R2)@CZ-]3 UC&2W<TN;F9&QDC0;/:T:@WO3AGE0Q;#MG)-GAA>&5+C@.(;,
M4^*RR8E%608+B-9/7R4D]/2U\&'5YIJBKK9*"HKZ6>>D-9*&/(#,N/CP&T4D
M;K2%9W:[Q\'1*'K374S%MTZH<M]KFIKHSV'3TIMVM6U7L0^);&ZKN8?UE>'<
M2S-TX9+&3Z#-=K9.SU+:D8R66.*FAI8'QM9 1.RDJ65<)<YT1=&\RQMZ5\1:
M9&Z$M<,PR&>5K&^FV@J9\,PNJK<;Q?'\<@JZ@XB7817[28/4X'BDE'#'71T]
M4PT53FIH\2CJVT]1!%*UKF=)'+KR;]3\>1ZL"ZHFXK@U>Q=XH$BP>6&/ISX:
M/2:);-EW5C#U)JA2EFTQ(HS>S)8$U;BE+]<;$237=("W1.&,[9IK3%U:KE9D
MGI2P2L@>(8*>KJJL1Q6B )+ZJ0%TV8%C6 D."Z"E\M'2]:&,[*X1-%+@V-4T
MD5"_&X&XKBF+X3@."RU>)N]WF2TL#J# :5KH<&-*&39W1PY)'L&Z;7P0:CN&
MAZ=HB6?7DL30ZA+U2KV>-MLM!65D:?KSFO34P\+7UHN$EG4DS>O2.XR5B'M>
M41>O&'K/ZW.5FA\Z; J.HPV'#I3,YD$+HHINE<R9I?&^*24F,M:7N9)(",N2
M[S8+EL,\JVT^#[7XEMC11X6VKQ?$Z?$Z_#I<.IJO#Y325K*ZDI8A71U=53Q4
M\\4+H9XJ@5;'00R]8,L3'MEU$1R,/$Q<0V4=*MXN.91R"KYVZD'JB+%LDV24
M>/WRSAZ]='(D4SAV[76=.5A.LX645.<YMO&P1L9&V^5C&L;<DFS0&BY)))L-
M222=Y-UYU/,^IGFJ'B-KYY9)GMBBC@B#Y7E[A'!"R.*&,%Q#(HHV1QMLQC&M
M  ['*U:3"+53G]NR'_M96#_&>N9XS5?X0&!?R2[4?UOV771Q?:G6G_\ <.&_
M[NQ1;5SV9<XF$3")A$PB81,(F$3")A$PB81,(F$3"+&E?YZK_P!XI_YA]W\_
MH\ D7^4<^&[X^P7*LNWGO\<OF[>)^?R\/@^0=V+'2P]79OW7_=;<+*/''U^#
MO3O\P]OP=G;[O,!]'?XXY7W::Z:;]^^W'X[:63=S&GKUT[K$=N[@G=\/N=G@
M'X _7CO&[U[N1T/JUW7U3?ZN_7B?C/[%7) !T[^_XM=.%QK?==0M5UH;*GM+
M8I'J5H/5',)2EH!S*J('@B3+=6S)6-O7TDUO*-D19+UDR_3;)%=.$EU?*KKI
MKFS"BZ7KE2")>A,=.8R\@Q](#-THC /F@-,.:X%W7-R05SE!U]NTF/-F;B)P
MV2CP=]%)4N8:(5D;L1;7QT+6OS1-Z%V&YP8FB61LCR][VR.6T^P/,'/X_P W
MCV>_W\\S-]]!PWFW+M^86ONTMTFIYFWL^?AKZ-UE7T_+MR>1MIW7YF_;[-Q!
M%M\)D&XOR/+C;]]^W>BIS /A[?#E[O/T<O=\ Y8/+Y!?L[1VCVZJ;$^K3C?N
MMVW[N)NKMH ])7S]75#T>'+L[L'Y=.T:\=VEN'-5,.IY6OV\+]ME:X]=M=+V
M[=/838#ER5"IW<^?=Z?E[WY\&_$^C3C?AN%N/(GFIW[M_9X]/S)RY^?M[^WS
M?#W^(>;TXL/1VG7MY7WCO]82_LW$#G\W/GN6)WLUZ+4)\=9DJBE]Z@<*N6[G
MEB5/US%0@$-.>L0#+G9D2\J<4F)DEEE2IH]8;$.=PE?INKF>/K9F%/F^J]7R
M&?+;_P /I/,#B;:N! %S9ULII=FL<ELUM,U[<-3:QM^Q1KNOLNOV/#HQ"&VH
MWMBUVB)C8MPB9:(CXFJP=>LD!+6>!M%1I%L/5[4VV,T14I5;1D4IV/JE-D;+
M;W\RVNL'&1=FVT!H6.Q-P?1NA$#F4L#V2.=+)+%*R*6*>IA$L)I7$3RN:8G3
M3QQ0MC,#W216W!Y$?O@<P+G BP ()!:TV=F'FC0Y02XD. #HX5Z'XSHW8%6<
MDK]XDM9-=OS3MM!V6WRA7AJI(/>&MNVD)YZ&^GUMC&%6A@XB'[.&MEEV_5;1
M9(M^<M.905KU;7H7:2OP)U-*WI*=E6:)@=)%"P!LS1BKG",>YK87NF?[F-<^
M&*BEAB<P=.Z2&KDDM 39@?.+,YT<[>WZB+_W0O&4=+8.+PX@Z %C1*W7:>T3
M[ZNT]*0MU0UK<:HRG4$[K(+M H%C:PVMXR)H]<A8[:UMJ,LUF")W>P6*4BJ+
M5Y"OV-FXCWEAM#2>CSL]+5=3&'0,8^G-5!.8SU=H<*B$OJG/GFD?1PSL<PFG
MBC8^HE9+$X.$<+HR'7FY^D)L[*6ZYC[UUFBS;.(((!)( +2""7!RE'FHXVM;
MLWZZVUUX'AOT[U<3Y?A_)_*.3KK;=>P/IOV=Y/8.">/B^7]P3Y>/R\_;V>&1
MK[.V]OETYZ6]">.'CEIKQ0/ESR0=/X/I!)^55M%[^^W_ ,$@#AVKQ>]5DNU>
MV*6JZHH7';JS0-JHT9N)_>:<RXQZ?PX[ )L1]J4\MH#YKG"-IB+:%/-;19-Y
MROG%N1RRMT+9W#*1C(@P!W.Q[&T9FK*O *K$(ZE]$VFJ#@\^(TXIV58]T1%]
M2?")'0@%LF62YA=#:\MQ@5[LY#&5+(RQLADCZ=D3W.LWHVG,0;7#KBW'0MWJ
M57J5 6L_!_7'5LNR-Z5D-A[@DH&2-Q$L^*V6BJA(;)L;JIU2R;UBIB:A+K8*
MG!J-(%^M".R,61&3=DLW2DT9 3:C:UT#L;E%/"88V4E$QP.&.PALD[(&MGGC
MP^1D<T#)GC.!*UU[W:]S;%9% '=7:7%I)<\C++TUFZ907CS00-'!H&N\-.B]
M'\YM9B81,(F$49T?IQY#[6>'_&E.9N'?8"+\,3_F5.L<?7;OO=O](]28S3K(
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$4*H?^B!7_ .U-U?\ C<V]
MV?E][X=&W[8JG\#4/Y[6+TVJ_O-8)_*9M+_5C9KEI[+]VMYJYO%YDF$3")A$
MPB81,(M5.?V[(?\ M96#_&>N9XS5?X0&!?R2[4?UOV7711?:G7?ZP8;W_8[%
M/'J6U<]F7.IA$PB81,(F$3")A$PB81,(F$3")A$PBZ51ITE%#>7;ATCG'D)^
M0ATC"(@/9W\^_P!.3Z.'@_/Z=RH+=;YMYXZZ\!OY<%QZG^Z&_P"^?J_#B_,
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M=+)+MK!?DO4YX3C>L]^]:H*+;,(^?!K2K!*5@D.T0;)L9B36 '[<J46V.8C
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M<[7"Q,F^=6J2+B%3GY%2?;6HM-5K:=/NI[.,T:+3FRJH5HM=&=<UX854DO\
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MJV1PN_[7'*R7I*F:1DAE,H,TL1+8IIXVR#H9"T=%*T3-:7[JC'<M)/O2",H
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MMWWNW^D>I,9IUD)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*%</_1
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MQ)]/+QQ5/+*_55._VYNT/A'L[>_L_*,;OVZ:\1X]EU-SS.[F=#KVC73=K\@
MLK]54]'T9O#^Z\_R\[?N[?9?3M.[@-;>D2[F>W4\?V>.5?+*_55//^S-R^'G
MRQ^_</DY\M /BB[N9Y;]?5>ZLR2K91\XBTY)!23:-6CYU'$>)G?-F3Y5VBR=
MN&A3BX1:O%X]^BU<*)E2<*,W::)C&;*E)3=I);<9@ XMOJ&N) )%[@$M=E)%
MC9VMQ97713MB94.BE;3RR20QSECQ%)+"V-TL;)#YCI(F30ND8UQ<QLL9> 'M
M)O/++?55/NSA^7X\J]&O8+:^.SLW65JYYGUW\=R>65^JJ>']4-^0?Y<G33C>
MV[>/WZZ<-+E+NOO/'G\O@*GEE0$/YJKVC[<X\_C'E\601V<]VO;OOP''V<5-
MW&^NX<[6]HO[57RROU53[LWY\GT7Y6MPYVU WD^S0:1<\SZRKEJHH)E>D<X\
MD%! !.8>0@ <A 1'L$/ >P0R.&[T^CN\>U5-)N=2=#ON>7!6WEE0_JJ@C_VS
M=H_#CX_C[+<]3ZN:IN3Q('>= GEEOJJGW9OS_+MY^?%N%O8;\^/+CV:ZZ)<\
MSZ_V^-+<E3RROU13GV=G3-X^_P#JY\^WLYX/=OU&_=Z[*;GX1MKK?EZ?V[M-
M;*OEE?JJGW9OS_#YL<AQ]>^UMW[_ (A%SS/K_;ZN:IY9;P54]WIF[O1V_!\/
M;XR0 ;#706[S;U]W"_KFYXD]USO[=?7ZM.%?+*_55.T?;F[/@'\/PY&EN?K]
MHTTW"]^Z_"+GF=!SW^L_%ZD\LK]54^[/^?Y>_DZ:ZC?XL+'0:]XTL+I<\SZ_
MV^/0J>56^JJ=_MS=W+_M?+S>.1OX=FGL\<>]3F/,[N?&_=XY\$\LKW"JI]V;
M\@_!YP[^X<6ONY;M]^!^>W)+NWW/K/C2_H/'4("ZOU50/[L_GY<NT?1V]@<@
M'W\?)\5^W?OXH;\R?3V7OH>W34W(]"KY97ZJI]V;\^3F_P!%OI&_G[?5N530
M2-2[U^GY5XK^K=6W755I_#H[N56L,O/QEQV/<*=9(SB2M_#&QJ):G1BFMZC&
MXTMLYF;'L6P5:5?0= I386*LP1Q9U5)5I&M)-)WW^P-/55$V*,@F@9$^"E@G
MBEPJ/%G3&HJ<D%X)2UD5-%("^>H<7-:[H&&-W2!T>OQ-\;!"7L<XWD+7-E,0
M:&M#G#, X%SK-#01?>018@S7]3CLU%LG#S)HZT>W2;HU0W;OO7M<MUVW)9=^
M/+W&43:UGK32\0^T+6923G:[9T(].1BVB2SN,@!4<P$9(RK*-2E'?/;30U$6
M)QNJVPLJ:C#<,JY88:&+#A3NJJ.*<T\E)"XL9)%GR%VA> 'EK+A@R:,L,3NC
MS9&R2,:7/,A<&D#."0VP=:]@ +W.\DF>N<^LM:-W3Q%ZKT UC'>R96:9$E(^
MR3B:-?I]NNCQE5Z8T9OKG<IAC3H.==PU-J#61C5+):)1%I"Q)Y2+;.7A7<DQ
M07S:'#ZO$2X4L;'9'0L)DFA@:Z6H<YL,+'3/C$DLA:X,C9F>ZSB&V:;6I9XH
M;=(XBX<[S6/>0Q@N]Y# XAK;@7MJ2 K_ &%O:@:OEJ-%7 ]F9I["GZY6(&?8
M4FXSE/;SMQL,34JG'V&Y0<%(UFKK66SST-!0@6&4C>OR$BW(CS2%14E%+15%
M6V=T(BO3Q2S/B?4015#HH(WS3/BII)&SRB&)CGR&-CLH!'*Y\K8RP.#[/<U@
M<&$L#GD- +C8#4C?PWV6XP[0 ?.'R\WX S%&H!YJZHSH_3CR'VL\/^-*<S<.
M^P$7X8G_ #*G6./KMWWNW^D>I,9IUD)A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M"+&E@YK*_P#>']P0Z0]_R_-D@7MZ>WF?D.@UWGE>R38GO/>#<[OE\%?/\O/M
M[/C[O<R;:$C4;B=?EMQL0.X7UUCY.&OLW]ZK\OP_+\W+ '/6^@MRO:XOW&VA
M]&A4>/'CUW3Y?F_+[XY&_3AXWGV7//@GCY_D]2?$ >]W?DR=U]XN-->1]&ZQ
M'?N3VD^G?\JTW4M3JU7:NP=E?-5)2Y;_ !4*R=Q4BSBBG8N862FUV75W[)@T
M<&C8V*DFD-%,E3*'30;+NGSA\^='<YBQTQCGGJ.D+Q,U@+7!HL6.<18M ):U
MC@UH/ .<XEQN.HQ+:-N(;/8+@7N?!3'!JBJECJ()*@MF9504C)<\,TTK!43U
M$$M54RM#6N?(R.%D,,88MR?+O\/Y.W,FPYVUMJ/7Z>SA??O*Y?QNX_OT3Y?+
MM\/D.#?M'9NUM8Z>L;MVG.SQX[_ U"IW]WY?/[WN"'AX\_%?7]IUUW\#\2G=
MO^3EZ>\'CPMP<_R_#YO-S[_'\O*;6MJ.8&OQCG;GIV);Y/5SYVW</DO=M.73
M6Y_6ZO/W.SM^0?#RR#<ZFV^V_P :=VGL53+W-N1MWZ:>/9=6GP_'\7A^ /./
M9D^LWWC77M&G#AQYC>%3ZO9[>/QGD-4_+[WR\1^7/';8&]K>@6MOOQ&G'M"?
M)Z?' >+)X=G?R[.?Y1_7^'(%AV&VG'6VG'?\1MW)QUW7UM\@_9\2PS8D',6:
MEV& KSX8R;E6/5HR4";L=>&,=BNB9*2]<ZD\CK  ,!*#L6$?(Q_KR"0P[M\S
M8OG+A/(I9&0U$,DK2Z-CLSF]'%+F:0;MR3-='YURW,YKLE\[6ES0#2YI+7 &
MQW;R+'AJ"#IJ;:;K7%U%G<7#?N?9-3T9%%W?"R]AU3=]>W.QS=GH2T:%OL%7
MVA0;,ZN,<A3[+%,J[,PE)A+O7:[7W<98H264MIDYIVR?H,[3%[B@Q6@I)\0?
M[G2,BK*>JIXXXJCI#!%-1U,38'&:)SI&25$E/++*UT3V"&[&N83"^S)%(]L8
MZ0%S'1N)+<N8MD8YSK-.GFM< W4',03_  AK/5?!7/03;7K:]5_3B#6I[,U_
ML60:U@\A.."/]6ZGI4##O:U-S-$K\G"S5[W#2J]LN^/6G5#K,:K'PC]6VN;%
M-R+;*K,>BD-2:>2N+IJ6JIF.E#8P6UE;.]XEC94R-D93T,\M+3M-[/F>]HA;
M%&TPR$C+F#!E<UQRZZL8 +&S=7/:USCN(: 0ZY6SM5:"V;7>*78O$#<341I&
MW^I.(U6%KEBE+ ^C95W!:1CR,FJ[_750?N(UBXUQ/(.9"<LD\Q>IF@):GTG5
MSR;V QL.+68E1RX/2X; *ASZ:9KQ++&V)KV-DKW7(%3.P.<VKC<UL<,;VGI&
M3U%6V.F='4R-PE=(2T!XM8&Y!M&#_!!MYI%R3<6RM;=X,V,T&NXWL-_,6-M"
M1SY=UU>5.[Y>?P^/D >YD=I'#37NW=UQIKQ'=._QRX^RY/>GQ\A^#^0!^#'*
MW;Q]?<+;S?4<D]EQV\/G([O4JA\'R^#X.S)  WFQY%M_;XL;JMM[;KZ[PZWK
M_;JOS2^JQ<96SJQQ#7[2\D[TW-ZLHS/0S:M: W?P=W#B$U_MAQM'UR1ONYK#
M>8"$EE:P&@FTI%S[2KP8^NUI90LS%1[-[*O4VSCU/8[ J.?#*?$&]>963NQ'
MI<2H<;@PRHHFTG0OIZ..GEEC$W7W6:Z20$17:X96@E:BNJGMG=$3'T;#$>CD
MAZ1L@<"YS\UGD9+ 6#1?-H7$%I]E/4VY.&E>$C7CFO[8:;FB$7EK9,[?$Z%-
MPRUML1I9I-(:M4]+G@*XI4ZQ4S@>"AA7CSN)5HS)*+O'BKLRH\/M*Q[,9J1)
M0NP][F0/= _$3BLCBZ,?5IJWI91+/+J^7*6-S$!K&@66QI'!T#+2"0#S<PB$
M(T T# R,6 MKEYB^BG=FB64HF<2O#-*[Z4C7<#L<FO)(=:[BTK97:].3N!);
M5F]4:62]L(AN>Q5TL%<6[B@5IY5;2Z//Q40LD_3E*C8&[T$6^UPG$F8<)&S4
MW6VFLH<0B F-/DJL/DJ74W2D1R]-!T=7/%)".C<\.#A(PML;$\3I2US'B-P8
M^-QRYB629+V\YN4W8"#<[_7;W?AWV-<[?IR4<;:JAZ-J2VR-J3US,ZHDI2,G
M7;>914U^_7DH_:< J6QZSJY7476I*79V" 4MCM+8KVHJ6"#K"4&@KJ2*'$&F
MCG-57P-A=61UK62,SM?UQN5])*##6O<WIHXW12="UU.V?)(\NET<A,8:]@CC
M_@.B#R;$9"UY-V.:T!N9HS;Q<-<0I3S$.RGH:3@9('!XZ8C7D4_*S?/XMV9F
M_:JLW0-9**=,I..<B@L<$'T<\:OFB@E7:.45TTU2ZII<PL<PC-&6N:7-:\9F
M[B6N#FN%]X<US3N<T@V5XZWOQO?TJ&FM-44W5?%W8&-/2L2:$IPWP3I[\T5Y
MO-W5%9'9TZDF+9Q=['8EX]("&-TV\>HU05,(*+)G4*4X;^IJJBJP&!U0Z)Q9
MB]0&]'34E,!>BIR=*6"%IX6)!-AO6*QC653PT$ T[#J][O\ Q'\'.(X[[7X"
MPT4W\T"RDPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%8'CTCF,83J<S"81#Z'E]
M$/,0_8\^7R'"IR#74ZF^_O\ G5/6Y+VZGPE_BY-^6G=?QHHR#F?9\R>MR7MU
M/A+_ !<A,@YGV?,GK<E[=3X2_P 7)ON[-WCVID',^SYD];DO;J?"7^+D)D';
M[/F3UN2^J*?X'\7"9!V^/0GK<E[=3_!_BY-]^@U\<+;]W<F0<S[/F3UN2]NI
M_@_Q<7_?Q_;Z4R-[4];DOJBG^!_%P#9,C>U/6Y+VZGPE_BXOV#NUMOO:U]P/
M#UID',^SYE]$F2:0F$#''I$,0>8E[C<N8_L>_L\>8><!Q?2W;=2&@$G77QPL
MOGZW)>W4^$O\7'H'MY]_H[NW51D',^SYD];DO;J?"7^+@&QOR3(.WV?,GK:C
M[=3Q\2^/]SD>/B^;QHF0<SPY</0GK<E[=3X2_P 7"9!S/L^9/6Y+VZG^#_%Q
MX]:9!V^/0GK<C[=3X2_Q?1CQX[O&B9!S/L^;M3UN2]NI_@_Q<)D',^SYD];4
M?;J=GI*'X"X4Y!S.O<?C!*>MR7MU/\'^+A1D';X]">MR7U13_ _BY-]V[37Q
MW<AIIN3(WM3UN2]NI\)?XN+G@2.XE2&@<+]X'S+L.0>;(52<@#N#")A$PB81
M,(HSH_3CR'VL\/\ C2G,W#OL!%^&)_S*G6./KMWWNW^D>I,9IUD)A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(HSH_3CR'VL\/^-*<S<.^P$7X8G_,J=8X^NW?>
M[?Z1ZDQFG60F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBC.C]./(?:SP_XTIS-
MP[[ 1?AB?\RIUCCZ[=][M_I'J3&:=9"81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3"*,Z/TX\A]K/#_C2G,W#OL!%^&)_P RIUCCZ[=][M_I'J3&:=9"81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB810TXKN(B]:9+&1VN8"HR\T&J]Z[MF5+N_E6$6K3]!Q=0
M=S=:BU(@IED+-:Y&]0+.+EG8.8V!CVTS+NXF:,U1C5MOA.&08D'NJ)ZB"-M;
M08>PTS8G2BHQ&::&*8MES,,$/02&0%I+RZ-@+"XO;CSS.B+<K6N\R61^=Q:!
M'$S,[+;4O)+0T6MON0L3W/Q9V^C6>%:4ZJUU[6X37VJ=I;%"T/)5I9'E;VOM
MACJZ.@Z0WCBBT)885).Q6*07E>NMG3IC7ZPFS;&L:D[#9%!@D55"_IZB1DCJ
MRKP^G=#D<QM124<E0^6<N#G&$EK6 L#20YTC7.Z,L=1+5.C</,9;(V5QS;@9
M&LRM989B,URXN %K93F%IQRTNQ@8:1G)951".AXQW*R2R+9T]519Q[51X\52
M:,D7+UT=-!%0Y&[5!=RN8H)H)*JF*0V@C:]_1LM>1Y:T-NT O=86S.<&@7XN
M<&C>3;591( N3H-;ZG3GH+V]"\[4N++1!>+1[+FM<T$>?AUBHTJPZ[V5Y07A
M-ES+HR75@J NN@"!RF!QY#JPB(IE6%0IB!U)PFO.!1L,,37#%IGV=640%C20
MM]^:CH[W:?-SYK:@6U6$:B%M6Z[C];MW,D/_ (K^ ;=2*^?%X>_LQG/O9[3_
M $*S4^X^(?<H/R_#_P!;5_K,/PC^+D_03Y\7A[^S&<^]GM/]"L>X^(?<H/R_
M#_UM.LP_"/XN3]!/GQ>'O[,9S[V>T_T*Q[CXA]R@_+\/_6U'6H?A._%R?H+X
MN.,WAS:(+NG5WEVS5LDHNX<+ZWV@D@@@B05%EEE5*85-))(A3'44.8I"$*8Q
MA H"(2,&Q%Q#6PPN<X@-:VNH'.))L &MJB22=  $-5  27D "Y)9(  -222S
M2P^7D51KQG\.+YJV>LKS*O&;Q!)TT=M=<[/<-739=,JJ#ALX1IAT5T%TCE41
M62.=-5,Q3IF,4P",NP7$F.<QT,+7,<YKFNK:!KFN:2' M=5 @@@C4>Q!50$
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M%8]Q\0^Y0?E^'_K:GK,/PC^+D_03Y\7A[^S&<^]GM/\ 0K'N/B'W*#\OP_\
M6TZS#\(_BY/T%9.>-?AI9NH]B\V"_:O9=9=M%,W.OMF(.Y1PV:+OW*$<V5IQ
M5GRS=BV<O5TFQ%3HM&Z[E0I44E#EJ&"8FYKWM@C<R(!TCFUE"\,#G!K2[)4N
M(!<0 2+7-E3UNG!#2\@NOE!9(";"YM=FMAJ>7%7OSXO#W]F,Y][/:?Z%93[C
MXA]R@_+\/'QU5_6IZU ?X3OQ<GZ&[MW)\^+P]?9C.?>SVG^A6/<?$/N4'Y?A
M_P"MIUJ'X3OQ<GZ"?/B\/7V8SGWL]I_H5CW'Q#[E!^7X?^MIUJ'X3OQ<GZ"?
M/B\/?V8SGWL]I_H5CW'Q#[E!^7X?^MIUJ'X3N?\ <Y/T/9O5DPXU^&F4267C
M-@/Y%%N]?QJZS#7NS'B2,C%/%XZ48+*MZ<HFF]C9!JY82#0YBN&;UNNU<)IK
MHJ$+6_ \3C+1)!$PN8R1H=6T+;QR#,QX)J0"U[2'-()N#<:*&U=.ZY;)>Q+3
M9DFA:;.%LE[@Z$<U>_/B\/7V8SGWL]I_H5E'N/B'W*#\OP_];5768?A'\7)^
M@GSXO#W]F,Y][/:?Z%8]Q\0^Y0?E^'_K:=9A/\(_BY!\;$^?%X>OLQG/O9[3
M_0K'N/B'W*#\OP_];3K,/PC^+D_05D'&OPU&D3Q ; ?C*ILR2!XP->[,&0(P
M564;)/CL@IW62LU'"*K=-T9,$#KI*HE4%1,Y2U^X>)Y!+U>/HR\QB3KE#T?2
M!K7EF?K.7,&N:ZU]Q''11UN"^7.<UKVR27M>U[9=U]+J]^?%X>_LQG/O9[3_
M $*RCW'Q#[E!^7X?^MJ>LP_"/XN3]!/GQ>'K[,9S[V>T_P!"L>X^(?<H/R_#
M_P!;3K,/PC_Y)/T4^?%X>_LQG/O9[3_0K'N/B'W*#\OP_P#6TZS#\(_BY/T%
M\5^,[AP:%34>WY]'H*.6C0'4E0=D1K(CA^Z18LTUWS^HMF;<'#QR@W3.X723
M%55,@F 3!DC!<2=<,@CD<&N=DCK*&1Y#&E[LK&5+G.LUI) !T!.X*#50-U+R
M .)9(!J;;\MMZE" @(<P\>7Q@ _@'-7S'$:'L/CDLC>JX1,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M8;+TMJ
MK<;6(9;/HE=NS6"=.W<6C.L".BM32+-2.E6O/F0R\7-1ZJC"=AG(K1,XQ-U.
M69/&X%3#*I*ZLH'2/HJF6E=*UHD,+LA?D?TD9.ALZ.2[XW@9V/.9K@;WH=&Q
M]L[6NLU[1<7LV1N1X'8YNAYV!W@$=%+\.&C)Z>@+/,:OJ,C/UF??VB&E',6F
M=RVG9.QL[B\?J\A*F^,>WQL;;$$'Y'+5E9HV.GV2#>68-':-4>(5\,,D$57,
MR*6-L,C \AKHV1/@:,HLT6ADDANT"\4DD9\Q[FF'11/(<Z-A(M8EC;Z$D:VO
M[XEQ^$[SG7.JW9R#ERY!RY<N7AR\W+S9AD Z$7'(JXM9)ZY(GN)QM@)+D=;6
MK/780H-  A$VMH?63UT![Y?GTCB\!IU3JP%*!!6!<1/Y,N0*EPHFT C:(FU+
MJML@<0[,^)L)BR 6#&M8'-.8^<2,HT)M]&#*92;DQAECNT<YU^^Y6S<QU78<
MAZ@F$L.0]03"6'(>H+'[9!A9ZO8ZV9QU0M@@I:$,Z!,%1;%E6#AB+@J0F("A
MD07%0I!.0#B4"B8O/I!7%(898IFM#W121R-:XV!+'AP!-C8::D GL5+V!S'L
M][G:YMP-1F!%QNW7NK6BU@E*I-0IQ'77B5.L0-;(]\B#<7A(.+:QA'0MP.H"
M N"M05%$%% 3$XD YP*!AF:4SS33N:&&::64L!S!IDD<_*#87MFM>P[AN4AH
M  WV:UMR!<Y0!<^KM[SO659;4V'(>H)A+#D/4$PEAR'J"UDPURFPW#;=M%DQ
M56M>N-=Z]4AC-0*1BEK^S;.L:4H1[Y8QEU)0=EKM#M1;)%:%B$EBKKF>G3;9
M#ZASJ2&DZ-H$-54U0ES$N<:B&DAR9;6#6"G<0;^^>=/.*H$=I727T=&QF2PL
M"USS<=X=8\[=@6S<QU78<AZ@F$L.0]03"6'(>H+7&U]?DVA1YBDJR7K0C,*0
MRAY$C4'JK<8B=C9LH%;&5;E4!8T<5N(BN3R8*BIR.) (:]2SNI:F.<-#\C9&
MY<Q:;RQ/A)T!%@R1QL;W( MQ%+V!S,N[5ITT]ZYKANU%RVQ/);&*4"@   !V
M>&6;6].JJM>UP"?7ZKJN$L.0]03"6'(>H)A+#D/4%K2@:[3HLYM>9))C(#M'
M8J>P54!:E;!#JEU_0Z(,610%E1>IB2C)R0.S%;F TD=KY#HM2KKY$]2:AE(T
MQM8:2E%*"#<R-%34SA[M!YW_ &@MXZ-&NEA0R/*9"3F#WEX!'O;M:TC7M:3I
M;?S6R\QU78<AZ@F$L.0]03"6'(>H+65SUPE;KQJ2YGDS,E-56*SV!%@#0JY)
M@]DHMBI!VQW KIF9=53L!Y JQ4G(JF:@V%-,JPK)WXZE\5/5T[8VO;61QQN<
M7%IBZ*>.8/:,I#B<A98D6#R1?<J#&TOC?N,>:P WYA;7=X]NS<L*NPY#U!,)
M8<AZ@F$L.0]03"6'(>H+6NK==(ZRA+!"HR9Y<L[LG:>Q!<J-"LSMU=G[$LNP
M5XL$B+N 43AU[(I%I.Q.0SU)H1V=!L984$\JLJG5<L4AC;'T5)24E@XNS-I*
M>.G:\W  <_)F<!>Q-KFRI9&&!P%R"][[$W +SF-A8 "^X6T&ESJ3LK,556'(
M>H)A+#D/4$PEAR'J"UJCKI)';\AM@)(PK/\ 7<30#0W52@FFG%6*9L!94'GE
MND99<TP9F9L+< (FW*H"YA4%,E\U#C2-H^C;D;6/JQ)G-RY]/'!ER6M<!A\_
M-<C3<-:.C'2=)<_W,1Y>&CBZ_P 7#X@ME985=AR'J"82PY#U!,)8<AZ@M;;=
MUXEM;7T[0UI0\,G-JP:II%-H5\=#UEL,5/E(#8Z[8JG6318-1,*Q/)%6%8 .
M*8)FRZ&K=0U4=4QC9'1ME 8XEH/2PR1&Y )%A(3NWBRMRQ-D8YGO;V\X#46(
M/9RYK9!0Y!X>'8'<'( #\GP9AC0<MUN-M!O/%757)1,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%Y[M^
M(W9[CBR6UV64IB>O$.(9UPZJ452$=#>#MT.#M'BA#;1++\T/0*T&?73H(0/S
M,C&!&"G(C,#,J]4)OCAM,W"'5!CJ'5!P_P!TV5>=_5KNQHX2:$,$ CSM8'S9
MC,7WC< T@$C"Z>4U)9F8&";H1&,I>Y@IQ,93KF'GYF'2UK'>5Z$!W!X9H!\_
ML^=9J9*)A%&7B&V3?=<6'A[^91[5&]<O6[Z]KN^M9Z+D7\R\A;#%32[4:N]:
M3L4SA7;5W&>7>O9"/GRK( DR08('<'>H;&@IX*F/$NE94.EI\/J*NF,)\QLE
M.SI+3M$;WO:X#*&L+-2+D^]-B:1T9B(+0UTK&.N0-'FU[NL-.5P2;6)W''>'
M?:.Q-@[/X@HB8M51O^KZ/.UV!H]SK%65J@?-LD[N*.T*&ET[9:4K9$Z\39TB
M)6N#8S%-:\NKY5G"02%2>LHZ[B%+!34N'.$$U+63QS2ST\THE+J4]%U.J/FM
M= ^I/6'"G>,[8!3S6Z.HC<ZB"1[Y9P9&R1L<UK"T 6=YV<7!(<!YHO?0@A2\
MS4K*3"*RDE%$8]ZJDY;LU$FJZB;MV05&C4Y$S&*Y<IE<-!4;H" *K)@Z;"=,
MIB>71Y^4*M<@6<Z[FC*SW[KN RLLUYS.O9MF.))%A=038$WL "2=+ #>3?2P
M&I[ O&6W<?.X*!KJOS+B4J=QCKAQ#1D71]U--77)G3K7PXQ$_J&N6ZQA7H&<
ML:<=:[1=KO:*YJ1=Q8D8VVZXADMLQ[:;:ILXVQ]I3[/T=75O88JBF,&'!]70
M"MIWS4^*2LK98(>E>V(RPPP4K)ZWHV.,4SS12EKB2S6/K'QQ!^9LC72GHY6@
M%DD&8-)LVX#B39IUO:_FG0>TB9@.0IPY\C%*8HCS 1 P 8!Y#R$.8#W#VAW#
MYLXH7XBQXB][&VH)[#RTM:RVG<N>2B81>>_%KQ);,X?-GZI?0I8^;UC/A:(R
MW5T]<8.7SB7B]5[>O4)&1=DCKTM;F5MM$[2JS$5YF?5+ZFDBSV16;MK:3=0[
M=GOL)PREQ&EK1(7,JHA Z"05#V ,?5TE.]QA=3M@='$V=[Y7FM$Q)B:RF<T/
M<["J:B2"2++8L)>Y[<K"2&12/M?/GNYS6M'F!@U)?OML?@SW;:=U4"?>7Y1V
M%\KLQ7$K(R4K]5@HJ."XZXI6QH="N*T[8^TXN6KZT3;FKV+?/[06R$:.4FT]
M&-G"*;E[:QK#F8=/$V#*::9DKH']+42R2""IGI9'RBII:.2.0RP/!:R$0Z Q
MFUVMO02]*''SKM<='!@(#O.;_<W/;?*0#K<.!&HL3,'-,KZ81:.XC=MN-)ZB
MLU\CHAS.3J!HJ"K+!*(GIE@%FM$LRKT$_L:%:9/YAK4(>0DD9FX23)JLXCJS
M'RCIJBX>)MVRV=AM(*ZMAIG/#&.$DDKR^-A$4+#)((S*]C#,\#)"PN ?(6M)
M N1:FD$43Y"0,K21<.L3;0>:UQ%SH#:P)%R!<KS.UIQZ;EN]KX0BE=U1_2]H
M:NX;93<%@842:81,-L3=3?:45(Q<DI*65.PU,;+;*7!Q.GFD# W>(%X>PI[*
ML-?BY&E2\OTM9L_1TM/CCB*AD]'58LRACDJ&"5T%$^C<QS!T+H9Q#%42.K73
M2T[FM;%U9DS^E:S!AK)9#2@F/SVQB5P#0W.\R7;JX.#SD(CLTM-G7=:UO:+.
M,6S3")A%X]FXW]N2L_9ZP!V5 F;?O25U3K61L]1K4M2JS3*AQ1.N':Q75>0@
M]K/K)+V=^X0CTF,+?(#6S%6U6>*:P+6QQ,#-'?=>-GJ9C8I;NJ8H<,%95AE1
M4PU4]7+A<>*PTS&/HG4T<);.YK)*26MEZ*$"I$4CV!NNZV\ES3:,F7(VX86Q
ML$@C+G.#G.).K@UP:+7.@LO0;A@V38]M:0IMYMHQ*UB?K6J)E)*!:K,("PJU
M&XS]/1ML"P<OI19C!7-K!(6R&9C*2I&L;,MD4Y.03(1XMSV)T\5)7U%/ )1$
MSHI&LF=FEB$\,<_02NRLO)%TG1N)8TDM)+6GS1EP/=)$USK%UW D;CE>YN8<
MKVO;AVC4[^S!5Y,(M$\2MSE]<:7O&PH>W(TQ6D0[RS.9$]22NSF2;1;5PJ6M
M1-<5FX#UPGK*\ZG#P+=%_P!9=3#MDR;-W"SHA,SL-@;55]+3/A=.)YF19&S=
M7#0\V=(^7HY,L<3,TCSET#;D@ JU.YS(GO:X,+&EP+FYKD;FAO$N-@!Q.G%1
M[UEM'B&5W=I[5MWMVM+5,'TBUM7$E4JM3WL075MK<5^))$/6-N4N<P1Z\NEZ
M3L[:N5%Q!HJK4:&E)X5VQX-)U8=C54N''#ZZLIX*F"/W1=!A51+4],*N%DLH
ME9T?5XSEIH1#TT^<CK+^B\XDAEADDIGCC,C'_4<T[ UH=&X@9'FSW$!YN W7
M0:V.^?0=GZ\T ^?X_D68F$6+7BP$J=-M=I5=1S%*MUR;GE7LP=TG$M$XB,=2
M"CF4.Q0<O2QR!6XJO3,VSAV#8B@MT55N@0U<4;I9H(FM>\S3PQ98\O2.Z21K
M+,SN8W.<UFW.KB J7NRL>[096/=K>UPTD7M<VN. 7B,X]4CWS6>&:YVRVPT;
M&;GC[%'.V7KUK&RE@*E16^D-?[@E9*V1U/L=GBSA<Y2P2-4U29.X,Y4T+8JW
M,7B(C)^G["K['O#LI0R8I#%#)*Z@=3SYG154;G35+:VIHHHXG5+8)(W4[6,G
MKA)"!G9)'#(YLD4BU)KIFTN8V$Y,8+BT ,NWI"XL(:0QS?-9J_5S7N<TN$;?
M=ADZ1?,VKUL8QV[QNBZ;G,11(QT'!"JI',DL4BJ8F3.4PIJD(H01Z)R$, E#
M@+$7#A9P)! -P"">(N#WC3EHMQO5UA$PB\W^)'B8WKI'>E?9-:>26U-)'A8R
M%BV-=)(O;TX4H&V+C=W!+@C:DW59G::K3*XY95U2E224I6AL4B5T_P"L*NZ5
MT>&X5A^(4,AZT8JUG2&1QF+!3@56&10L%,^GRU#9XZB8],RI:8GD-,=V_5,.
M:>6%Y/1WB:0/X!S L+G2:.Z0",C*1D()L21F%]I<%F][9O"B3+[81G"5[B'-
M2?3D>6 JD/!Q[6^:\J>P(-&K/*;LC:4;-UY6-L)7,:^E+&VM!6BR!)V%9"9F
MZ?XN.8?%AU4R.#*8)#4MA>):B1T@I:E]/(Z7K%+2.9(7,!+61.AU^IR.\X-K
MI9^GB#G:/LUSFW8;"1N9@'1N<-&[PXA]_?-%PIG9IEDIA$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(L3"
MA48MP4V$6FU8M^5B KZMW+ 106Y2!*OUHL(I9 :!,GARN?\ C!8PSP615_YL
M" * !LN&:8P]7,TO5\Q?T'2OZ'.=[^BS='F-SYV6^IUU5.1F;-E;F.I=E&8D
M#*#>U]VF_=IN66=V6U4F$3"+"[=K?7FP%(96^4.FW56N/#2->4MM8A;&I!2!
M_(B=]#'F&3PT8\,+=N)G+(4%A%!$1/S23$MV*>:$/$,TL0E;ED$<CV=(WX+\
MI&9O8;C?S5+F,?;,T.RD.;F -G#4$7X@[CO"^%1U=K.@/YR5HFO*/2Y.SKE=
M621J=4@JZ^L+DKAVZ*XG'40P9KRJY73]\X*J_.X4*N\=*@8%'"ICS+4U,[8V
M3U$\S(A:)DTTDC8Q8-/1M>YS67:&@Y0+AK0=&BQK&,OE:UMR2<H N2223;>2
M23WDK.\LJI,(O@Z:MGS9PS>-T7;1VBJV=-7*1%V[ENL0R:R"Z*A3)K(JIF,F
MJDH4Q%"&,4Q1*(AD@EI#FDM<T@M<"06D&X((L000"""""+C5" 001<'0@[B.
M16"5G4>J:7#.ZY3M9Z_J5>?R+:8?0-9IU>@85Y+LE&2K.5=1<5'-&+B2:*QT
M>HV?*H'=(*,&9TE2&:H"2]+4U,\C99JFHFE8TL9)+/+(]K'!P<QKGO<X,<'O
MS-!RG,XD$DJEK6M&5K6M;\%H 'J&BV$ <@Y>;LRQN5281,(L,>ZXU[)6]CL&
M1HM.?7V+C5H:,N[NM0SBWQ\.X!P#B)8V55D>9:1BX.W8+L$'J;18'3@%$3>7
M5Z5WIYQ ^E$\[::1XDDIVS2-@>\6LY\37!CW"PU<TG0<@J2QA<'EK2X#*'%H
MS!IW@.M>W9>RNZC1Z7K^)- T.HUBE09GCF1-#5*!BJY%&?O3 =X^&.AVC-H+
MMV<H'<N?(^67. &5.80YXFGFJ'])432SR6#>DFE?*_*V]FYY'.=E%S87L+FP
MU*EK6M%FM#1<FS0 +G>;#B>)649:4IA%00 0$!#F AR$/1D6'C=ZMR+ ?8HU
M?Z^5NS^QS1?FEIL82$J%A^9."]?*I#)(K-TXBMRW4.OP481NX<(%81;AJU*B
MNLD"704.4U\5%2&2Q"IJ!'.X/FC$\H9*\$'-(T/L\DM!)<#FMK?54=''<'(R
M[19I+6D@7)L#;07).G$D[UG^656F$3"+6[O3>HI ES3?ZMUV^)L?JP["(\I=
M<=$O?4A 6?S9%7C5"V?J@E*+7UZ![U<0 4>@(9?;553.@R5-0WJU^K6GEM3Y
MLMQ ,]H0<K;B/*-!HK?11G-]39Y]\_FCSK[\VFM^-]_%9S%Q49!QK&'A8YC$
M1$6T;1\9%QC5!C'1S!FB1NT9,635-)LT9M6Z::#9LW331013(DD0A"E*%ESG
M/<Y[W.<]Q+G.<2YSG.-W.<XDDDG4DDE5@ "PT 5_D*4PBZ^3B8N::E93$<QE
M697;!^5I(M$'K8KZ*?-Y2+> @X342!U&R;-I(L' %\JS?-6SMN=-P@DH60YS
M3=KBTD.;=I+3E>TL<+@@@.:YS3KJ"1N*@@.%G $7!L1<7:0X'O! (Y$ K$_8
MLUE\VQ=E^QU1AV.5'JY=@#4X$;L5OU 8KR 6H6 SH(^M8C&^2!_Y/J BSZ/5
MQ%/+O6*CH.K&HG-."7"G,TAA!<XN);$79&W<2XV:/.).\DIE;F+\K0YPL7
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/")A$PB81,(F$3")A%__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g210084g03c19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g03c19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[15N4&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!Y            "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !#T   EF          $
M     0             )9@  !#T                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   0]     %)G:'1L;VYG   )9@    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !#A"24T$#      *QP    $   "@
M2    >   (<    *JP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 2 "@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $$ D$# 1$
M A$! Q$!_\0 'P !  $$ P$! 0            <&" D* 00%"P(#_\0 9!
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M'3\+>6;FL;W4FSB2/V-;Q)I>&SBSR;II=C.(]VT8@R-D>=C<9QGF3V9P!DG
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M)M]9_D3KL@\Q)?76ON\.'6\Y?\G/O4W2>3;ZS_(O>Q\'C\6?PX^'H%LJB B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M6ZMB2N^=CI(&VH8)I):SIF,>Z,3L9G:YIP\%J"5CGF,;@X9^Z8YH=M.';7.
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MN01 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M#V[L\\Y5XW.UN[[K W?GQS[.7;X%6HH** B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MY!. 20-Q_)B[;<@DS/;;DE;[?!VVY>FV>C'P8Z<XSGQ#$!SAR#B!X 2%5P/
M/B7YZJF\G(_8E_-$=[_&=Z1]J8'@'Q!.JIO)R/V)?S0WO\9WI'VI@> ?$$ZJ
MF\G(_8E_-#>_QG>D?:F!X!\07SY+7QT6E9>,?!BP9GC'^B2.7XO%_J&D[/\
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M_?I?ZQR^Q'1[]@-#_0^F?V*!4 **S" B B BG?BS]\YQR_3S4'_,*.B\T_\
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M2>HW.4';[S1ZEJ,4SK$5^[%.Z-L3IH[4[)G1-:&MB=(V0/,;6M:UK"XM#6@
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MU%]9H>+8N\3B]8K3YV]69LV%F-SMV[ECQ?3#I-<Z.G3Q4@JS"V+7$ZP)26F
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M9'Y77_%PR777*J,<WSAVTR:&V1*T%EQ1DFW(YDN^?15_WG49K/BK?*ZVY27
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M/TVL:T[79?9AC?- ZS,#7JN9-+/%.7,? QV UQ,FX2ONZN-C\9W<1V\$<FG
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M?^R%'^&5?Z^->2Z??>+TU_W2Z1_]'N?F_I"WZ1N1?(Q 1 1 1 1 1 1 1 1
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MW?<S;IWVSG,9IIK$CI9Y99Y7XW2S2.ED=@8&Y[RYQP.0R3R0-:T - :!V
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MIP7[*9+%D3&:?HX1]O08Q-J]G1*L&J]0AT.:2QTAKU8WB&I*Z+2YM(A,\U0
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M8)W/HRRRURRPSB1AKYH*\A<&_= Q  ]A/:I/'M5YI 1 1 1 1 1 1 1 1 1
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M[?[.'6[?G-CUTGSDX,7DH_0;[%[WP? +=5$!$!$!$!$!%U4WCRI_I1G^S0O
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MR:U&"O"]\ ;+)PII99)92S!:QK=S>=KQ97.G$36.X;F, >2T9+=SR7 'D,@
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MMC^-.R_T@S/X?\Y'+ZX_D&E;'^L3_OTO]8[_ +/Y5]B.CW[ :'^A],_L4"H
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M B B B^>];'\:=E_I!F?P_YR.71_L&E;'^L3_OTO]8Y?8CH]^P&A_H?3/[%
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M$0$0$0$0$0$0$0$0$0$0$4;@L>I(!9! 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M(J?M3[9C:7Y/X!^M(O>X?9I](?Q&T;_BU[Z,GV->B_C/JOR*G[4^V8VE^3^
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MM!M1T8=)Q(VY:87[XL&:3=$U^.=&S/,SFAP=B8QF,-YM8&AW$W \L'O'.1R
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M!*G2I],[;9U**TUSG/1TC RR232232N+Y97ODD>[FY\CW%SW./?+G$D_E*N
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M;T!$!$!$!%F9[!7]^D^?H*G7]Z( -,?#M]Y4'Z=H_P!EOKWOP<_?!)^CK/\
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M]"N;"&@IML.'$LY#<H8EBV47EK3*45&PUD<HMU-*T?576C-NCG^N@HE];@[
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MGO+K[ZFIP=HO2; <,:I2^Z8]G_VC^S<T9_B6-/Z_7\?\WB'$ZZ60$0$3Z_\
MB"("+/CP;>T:+C/ TYQ#ON9HMF.<[)(^_KR,]O,W[;':J4+:I3&9QC.,;8+-
MV[3;&=-^UWUVUQ]9_J7*\DGP)=$WM=  ;'2/ ?9K1NY=)=6!RR25KQS'++1D
M8(R"">!_ASD:/A,UX$/R(-&[(I"/V%T\\B&$'^(GP=J\;LBCZA5<(>2R<LAY
MU,-K%UUUV41R0I",9ZPCS_A%*MK)3%8Z,9^Z--TUZ>C'3TYQC/6_P<UY&=..
MC3BZ @:G&2&VJSW?<2#DQDSGN_,UI/?[%H3I3(T]'M7 #\FG)VQ2 =K>TE@
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MTO7?WC1O^BT%Y'9'/O&N37Z,'7_>40ZW^#;[^NC'Z3C_ *N1:$Z5?>[J_P#
MY/Z6K0^'>*YO0$0$0$0$69GL%?WZ3Y^@J=?WH@ TQ\.WWE0?IVC_ &6^O>_!
MS]\$GZ.L_P!;66W^./EO- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 18<.R;_Y<5?_ )J//_%RA\\_JTOOEZ$_H/4O[?$NO/J;
M/V%Z3?I2G_9'K&,.*UTH@(@(@(@(M@C@?][# ?Z=,_[ZOX^L'U+_ /L4Z*?P
MCI%_[DU5<%?#E_M+UW]XT;_HM!>1V1S[QKDU^C!U_P!Y1#K?X-OOZZ,?I./^
MKD6A.E7WNZO_  .3^EJT/AWBN;T!$!$!$!%F9[!7]^D^?H*G7]YX -,?#M]Y
M4'Z=H_V6^O>_!S]\$GZ.L_UM9;?XX^6\T!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!
M$!% =\<BH9QU:&Z2SZ/V*LB9N3E,DE\0A#M)XU7S$F7-3>KDT[<T.,%M#.F4
M/*0S<I)HY/9J$ET=$K.H;&5X6(<AI^FSZD]T5>2L)A@1033LBELO+7N$==CO
MNWD,/-Q8P$M:7ASV@TY)6Q %P=M[[@W+6C(&7'O<R.S)[3C 7BQSE=5<HMS-
M0-I,Q+<E,CG<)CTS711>CKB83^KB#%-D0**RPS/<G.40LI(\8=DYB1*WJ#XU
M+4;,XNBV)R).VU)=(MQ4^NN,!8(Z\\D#9FFS#7M'%:Q+"/N(IR6;#N+L2Q.<
MUK96$P$K2_8-V<N =CN2YHRYH/A'//YBKEABU50$0$0$0$0$0$0$0$0$0$6'
M#LF_^7-8?YJ//_%RQ\\_JTOODZ$?H/4_S_Z_%_V/XUUY]39^PO2;]*4_[(]8
MQAQ6NE%S_-T_#_\ ;_2"+@$7/^G\'UQ]?Y/]!%P"+8(X'_>PP'^G3/\ OJ_C
MZP?4O_[%.BG\(Z1?^Y-57!7PY?[2]=_>-&_Z+07D=D<^\:Y-?HP=?]Y1#K?X
M-OOZZ,?I./\ JY%H3I5][NK_ ,#D_I:M#X=XKF] 1 1 1 19F>P5_?I/GZ"I
MU_>> #3'P[?>5!^G:/\ 9;Z][\'/WP2?HZS_ %M9;?XX^6\T!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!%81>?&*U96CKZ%5O+F9_J%KFBFQ+1@U[SJUIBY61(69
M9'W.OHZLEZM=*'E/5T??&G:3/E?)MD+=)WA QH'%1O$C9?&9;GZ&J5(76)[,
M,D=Q\(KU9Z$-2!M:-XD;8D;"&QL-F2-_"98(<Z*-SRT<41216\D3SM:T@L!W
M.;(Y[BXC&T;CN.T$9QWR!GEG/\ZZXGV'%+7BJ][F4,65!65_<D^2T#0-;4]E
M6 XS[DP;9:U\C\I4K%.[$GC,*77A;66I:UY4+Y&F6PTM6A8=XXX;R":SJ]>:
MI,UD,PN6M/TS2YWN?'U=M;2^JMCDB:UH>99FT*8>'=S&6S$.DXC=AD+FO!);
ML;)+*T#.[=*7%P)/+ ,CR,?DY*^-:Q(5Y^5!YSOH9MKKKG5'(7]N(QC3'1CM
M4K>YI4VNV<?XVVI6-M\^/?.V?&,+'8DC:&M; 0"3F2K6E=S\+Y8GO(\ +B!W
M@%5,;7$DEX)\621H\'8UP'\BZG@LU^42'Y72SWT)^MR^)5^14A_174.$WPR>
MNE^>G@LU^42'Y72SWT(=;E\2M\BI^X3A-\,GKI?GIX+-?E$A^5TL]]"/6Y?$
MJ_(J?T=.$WPR>NE^>G@LU^42'Y72SWT'6Y?$J_(J7T=.$WPR>NE^>G@LU^42
M'Y72SWT'7)?$J_(:7T=.$WPR>NE^>G@LU^42'Y72SWT'6Y?$J_(J?ASYO_V.
M78G";X9/72_/3P6:_*)#\KI9[Z#K<OB5>7_^*G_+_H_/^-.$WPR>NE^>G@LU
M^42'Y72SWT'6Y?$J_(J?T=.$WPR>NE^>G@LU^42'Y72SWT(=;E\2M\BI^X3A
M-\,GKI?GIX+-?E$A^5TL]]!UN7Q*WR*G[A.$WPR>NE^>L;7.3C[9MBRF"K*T
MB+Y*D+;'W),YJ#)!HKRD5G..AI).-I(^8/TQN3C._:IO\%GX=_NQQ5]51\''
M3SX0==Z)V^BG1Z36*^G:3?K6Y*K]*I-@FFN1RQL>V>>F9'/8TN#FM> !@N&<
M'I7X"NF?17HGI6O5]?UB/39KFH59J[)X[U@R1QUG,>]I@@L!H:XAI#BTDD'!
M R+&?L-^3'Y)WCUM%_?@Y5^QV^&?\1;W_$=#_P#E%O;]=_X-_P ::GR35/H/
M^*?8;\F/R3O'K:+^_ ^QV^&?\1;W_$=#_P#E$_7?^#;\::GR/5/H*?8;\F?R
M3O'K:+^_0^QV^&?\1;W_ !'0_P#Y1/UW_@W_ !IJ?)-3_IZCC\G@_BYI]AOR
M9_).\>MHQ[]_G#[';X9_Q%O?\1T/_P"43]>#X-_QIJ?)-3_NHE/L-^3/Y)WC
MUM&/?H?8[?#/^(M[_B.A_P#RBA^O!\&_XTU?D>J?05E^XGU6]PJBXC')TVO\
M?DR%5)MU[3I*'5/JFT62AW6(ML%,;WEMU[NB/3GY[AGMMLFYV.Z#L[X'T9^I
M_P!"U_H;\%71SH]TATYFFZM1GUM]FG8BT^U+$VWKNHW("Z>+K,;Q)!/'(T"9
M^UK@PAI:6CCWX6M6TKI%T\UC5M'N&[I]F+2VPV8G68F/=!I5.O*&QRB)[=DL
M3V',;02TD9!R8\[(G'F])PAY+*"CWO8PJLG;;353)9&L(SGK"/'08F5NIZ8[
M7HSG[DXK?7IZ,]'3C&<=.?!S9D?TXZ--+:X#M3CR65*K'?<2=CV0M>W_ /%P
M6F.E,;1T>U<@OR*<G;)(X=K>T.>0?XPM%H=TKG) 1 1 1 19C>P<H2'#F8]I
MU&ZO0O\ @-G!F,HG!>VG=MK)H%C&,J6Y2E49TZ-L]L7DWN>V<8SMKG.NN<:;
M^'*1T?0R!S0PGZ^41]LBCE;@U;_[65CV@^ @9'>*]Y\';0[7Y <_L=8/<N<T
M_P#BUN^T@_Q9PMNCP6:_*)#\KI9[Z'(G6Y?$K>'_ %*G[C^3L6\.$WPR>NE^
M>G@LU^42'Y72SWT(];E\2K\BI_1TX3?#)ZZ7YZ>"S7Y1(?E=+/?0AUN7Q*WR
M*G[A.$WPR>NE^>G@LU^42'Y72SWT'6Y?$K?(J?N$X3?#)ZZ7YZ>"S7Y1(?E=
M+/?0CUN7Q*OR*E]'3A-\,GKI?GIX+-?E$A^5TL]]!UR7Q*OR&E]'3A-\,GKI
M?GJH_K^/^L6JJ("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("*
M.[0GR^N8QE_::VL6V'0UP2MC?"JO01I7)W%0IT/-R;A5-)3"(<SMZ8E,<8J=
M9-+&)L+W[@CT5F+UB)(IN:E=MF7AOM5J;-I<Z>VZ5L3 "!V013S/<21AD4,C
MR,G;M:XB1[BP9#'O.<!K "X^DYK0/REP"MC^V 4CO5U$6PG8K<5L%_V7&ZEC
MZ%+6[L<X0F9OMS,/']>AM1?@[$3@ND6MB1((H\]>DQZEV5%+C8,EF!"(_?7*
M?J>O"WJ%-TE-LFG59;<KG66!L\,=*34&FHW'&L&:I&Z6/;$ P%HG,)<%3ZPS
M9&_#R)'A@PW):2\,.\@[0&N.#S/?VY(PI[O&[HY1$699"^,4IEKG+)K&*X@\
M*A*9D/E,TG4P5&)F*.,YTI?HI$FXY3HG6*SG.5RJ.,*-(B4&*W8DS)!1V/H4
M)=0F?%')%"R&"6S8GG,@A@KP@&25XACFF<&Y: R&&61Q< UAYXGDD$;02'.)
M<&M:W&YSCV ;BUN3^4@?E5NC#V0FH) H@21/"[:1J99+E$#EQ+@QP\G:F9:7
M?>_&%&T67L3.E!:W+K>9*F"-Z^J][.:L&)3Y$N7(HEKH_P"^2DZ.78Q8<9JC
MA#"+$):^8]>A-'ZYE]7_ $<;=M'%AS;?57D$1M:Z8\-4Q88=G<O&XD'(;W!#
M]F']UX_<]QN'?[.:NAJ6V(]<\;7S.'HGGP/Q)G]@C,E<DZ1.V3YNCROO8?-X
M9E.N5J'"#.KL0Y)(P_K4[=I*4#=B3L)"^(/$<?WG%6ZDE*5L$Q9QN%')+$TD
MNKND;O$$P+0&SL86F6,%QB<[A/+962,;6:X/!([,D ]YP'+(\()S@]_&1R(4
MGBU4RLH[(Y]XUR:_1@Z_[RB'M_@V^_KHQ^DX_P"KD7G^E7WNZO\ P.3^EJT/
MAWBN;T!$!$!$!%F9[!9]^F]_H*G71\IX#_W#3'P[?>5!^G:/]EOKWOP<_?!)
M^CK/];66W^./EO- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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I(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g210084g04d28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g04d28.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1CB4&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!Y            "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !8@   F0          $
M     0             )D   !8@                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   6(     %)G:'1L;VYG   )D     -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !CA"24T$#      ..P    $   "@
M70   >   *Y@   .'P 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 70"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
M      ,  0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+
M$  !! $# @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52
MP6(S-'*"T4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S
M1B>4I(6TE<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  ("
M 0($! ,$!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A
M<H*20U,58W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%
MM)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1
M #\ ]3L?LK<^"[:"[:T2XQK#6_G.0<?-9>X,%=E;BTOVV-+"!.S7<K"I8YRC
ME,^UBL6^B=QJ)+9W#Z.]K7(A3=3. <"T\$0>R=)!2#%Q*<2KTJ2\LF1ZEC[2
M- V ^]]C]OM51WU?Z:Z]UY;9ZCLAN68ML ]5C?38[;O^A_P:TDDB+WU71E*-
M\)(OLT,GHN%DY)RGFYES@&N?5=97+6CVLVU/8W;JB8'3,; W^@ZUPLB1;;9:
M!!<[V>L]^S<ZQV_;]-6TD;-5:UJW]-Q<A]C[ XFYK6OA[AHP[VQM=[?<FSNF
MXV<*Q<ZUII)-9JM?602-N[]$]F_V_OJVDFQC&))B "=R/Y?UDF4B "20-G*/
MU<P3'Z;+@&7#[3=[O^,_2>[AO^OJ*1^K^%ZOK,MR*[#:+R67V %V\7/:ZK=Z
M+J[=NRS]'_-K323N(]T([Z:\BFRBT$UVM+'@$M,.&UWN9M<W^RJF#T7 P+FW
MXX?ZC:&8H+['O'IUZL;M>YS=W\I7U"RUE98'D@V.V-@$ZD%WYOT?HI"1 (!(
M!W55G9S[/J_@/MLMWY#3:YSWM;D7-:7..XD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M$.D=+-EHGVO%WY6DRGBK4_BK(]2,B96G8Y\D37VXV"5PJ;D@CC=S1%TA.]
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MZ21[B][WN+WO>X[<Y[G$N<YQ))<222=D[5[6M8T-8T-:T!K6M :UK0-  #0
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M$PB81,(F$3")A$PBJ%5_U[]U?NK<<_XJ<ELUL?ZKVOW/H_SB\O0;W]BSAO\
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M$3")A$PB81,(F$3")A$PB815%XJ_WR<O_P![JX_PITUFLQWU3*?NG+_-JB]
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MCE\*7'\C#%#Q/?QL1_M6$;6P$>O0 S"P4&@#N UT"L!5-<:\HB0(4>ATRFH
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M$?G$<B./H.]U1J'X:T)__1;"/COC>'78\9<51 =PCXAR[ /B;<"QEUPEX=O
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MS6W6;USD]+]:I/H.<0P=B&-C#&!\KVOD=2HSDAY?[YWI8?4/UCG#T>LDG9Z
M@+TFSF%DIA$PBK]/?K4ZI_=^Y ?Q&XT9LX_U&N?NGC?YKE5 [ZYC_:)OY2!6
M!S6*=,(F$3"*!]?_ .K?R#'_ ,U'_1%[GEW"G]DOPL?#P+_Y?G7<9[_:7P%_
MVI_I:%3QGJ*X=,(F$3")A$PBJ%RK_OIX<?O>U3^#N[\UN0^J8O\ =)G\TMKT
M/@+ZP\(__-Y?_P#,?"ZM[FR7GB81,(F$3")A$PB81,(F$50KZ ?+?XVCT_\
MJ Y1^K_\6\;>G7_W9K9OU5H_\CR'\I07H&*_L9\9?X6<#?T?QHK>YLEY^F$3
M"+I2,G&Q#19_+2#&+8-RB==[(NT&31 @>DRSERHDBF4/68YRA^W*.<UH+G.#
M6CO+B !\).@%+##-8D;#7AEGE>=,BAC?+(X^IK&!SG'V %5_M7+_ (KTI7NU
MCY#:?9/Q'LDB&]^KDK.K&Z].PW@8A^_F7!^O@!$&*AQ$!  \!S"DR>/B.I+M
M4.WKE$T;GD^QC7.>?B"ZRAX/..\FWGI<(<12PZV;#\3=@JM'K=;L0Q5F#UET
MH ]*PTW-K44D/8H56WUM94/ 1UWQ[V_),"F'] #V"9J,#64RJ=0$BRDT1#H(
M"94H#UR/RK6=]1CN6/VFE:+?W[XF1_\ C6R_0SXA@ZY6]PI@6_\ ]QQ?P[#+
MK6SJI6R%J\2/2P5B_?3E*U'D-O.=Z#1N%NX#I"'YKW:-ZTSK-F)A_1$6S.]7
MFQ$)U'J<3UXJA"]1*B<X 07CMM_U'%6?AL358!\C9IGZ]?F;]G<J?0APO5)\
MJ>$GAT$'ZG@\7Q)FY=>G3Y<5BZ1.N[5SE)Z<X'5!E^=UA #,Z1Q;U>@H ]//
MM^V=MN40 W@'E6,+2-61IE2!^<()3BJ1C=" <2@)QIS9=_=#CZX/I?-8LN'^
M*R&NTD?L]=?8@K^"RIL2Y/CG./:?]RXK!\/P/U]C+9R>>G )]+JC2!Z-I^2+
MEO.  V7E[$5HBGBLVU)Q[I\*JCU_22;R6S[)MSM%+^B592,(J(!VNR0P]"O%
MLD_W>3;'OT5Z43"._H'3OL[]'7E'P)]$'@_JC5+P>V+KA[F3B#B_(V6NUW.?
M!@Z7#VB>\M$Y;Z-D#9T'B SE@*%ZY%\KKVF<1,[:+[KD]?Q[PQOTRG::;C-;
M"DW,/7^;(K$2 H]GH)2E *^30[ZM>R,WK!MN@!^*JV#0]@(_ $_1"DK_ *E\
M'\!8LM^IR-X9@R\T8!Z$2<239K;QZ7EI<>OK*[K#@MQ*:.4GC[1]3M[Q$W;*
M\V2K-[3='4$0$5%W&R)6U*N51$.HJ.#JG'UFRK<1C00XU(I'#KN?FL'?K)G=
M(2?:=J.;PH^$"1CHHN*,ACXW=#'A6UL#& !K3686O0:P:Z:8&CV*P%8USKVD
M(D;4RB4RHMTB@1)"L5>$@$4R!Z"$2BF+0A"AZBE* !\V9D<$$0 BABB [A'&
MQ@'P!H"Y.]F,OE'%^2RN2R+W'9?>O6K;B?676)9"3[25F62K6IA$PB81,(F$
M3")A$PBJ%5_U[]U?NK<<_P"*G);-;'^J]K]SZ/\ .+_]?B7H-[^Q;PW_ (=\
M8?T#P6K>YLEY\F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*HO%
M7^^3E_\ O=7'^%.FLUF.^J93]TY?YM47H''?UEX//3__ !_C_P"G^)/Q=RMU
MFS7GZK'RST>IO/4K^"@&6K0V)$2]5FZ'-;9ID3<*PV=15UJT[/51^#^-DY"%
MA]G04([UW8)FO(C/QD985)6'2<2T='I#M,1?%"XV21UOQ9[)8[#*<[X92U\,
ML;)6\KFM>^J]XL1LD/9N?&&O(:YQ44T?:,( 87#1:7C8!!!(/0D!P&B1UT5P
M<1]57O46LIF V*?5+.PS>QKM<"U/24.>*UIKZ-L+]%9A1ZVNZAZ_*SB,0DB9
MPO-3,)%/E7+]5BBP:1<?'($NS-NO<M1R5A;,<=6"#MKS^>U8?&TAT\H#Y&1E
MY.@QCW-TT.+B]SR4+',:0[EV7.=I@TUH/H'0'7P^O7< K1YJ5*F$5-];2N\:
M39=[VG:5?V-8*HA))!386+-7[:ZF7"VX=RILG^OZ_"3#B1CX5OIJ2T:TE&,B
ME"%\X0LO('C5;*%NE);=6649XZ$-22M%*6GMI'F2%K *5(N;8DD8&N>;K+Q8
MYI=YKV-!$1@:R!AD:9"\.(WT Z[\]X'(T$G79F/?=U!.N;F6E;V078/*C7XE
MHNR:5YIX_;S 0V%4U:P,CWW8W'+IYI\JZ<]]!IW7^>]GL=W[PUZ]KRP=+Y:I
MK8:SNQ5GY\GC_K:83<NJN4]WH#EWOIZ]'U*P/YK+/->W4$WNFEN]R0=V^_NZ
M_$L;Y<\L;5Q\L%/KM6J</+JSD:M-R$G80D3,19I/E&/FR,+'.V)BR)11,NZ<
MKK.$FJ+AF'<EA7$Q/D3P^>'C->";*\/XG"X&AD7Y.G)DK=S*^-^+&O'9=6\3
MIBI/7(M@QNDFFD?*R!DM;]+R=KMOO7@H\%>+X^H9?(9/*VZC:-AE*O6QYKB<
M3/A;-XS9-B*<&N0\1Q1L9&Z5\<WTYG9Z,LT+E?IBZ5^MR[VV,J<]L$:R=EC[
M:1]7V@.UT@[RTC)^:91T'/HMG15FI'T0^<MUS)=0\F<12+Z)P_X:>!,OC\38
MR>5;PI?R=&G:\G<45[N"#9;4#)3%4R&6JT<?DX@YQ;%:HV)H9V<KVD<X:.3S
M?@OXOQ-[(UJV,ES->A9GA\9Q#X,C(8HI"UDMBC1GLW:+WQ\LCH+<,<D?-HAS
M0'&Q+%^QDVR3V->M)!FN4#H.V+E%VV6((=0.DN@=1)0H@("!B'$!#Q <]3K6
MJUR%EFI8@M5Y0'13UI8YX9&GN<R6)SF/!]!:XA<!-!-6D=#8AE@F8=/BFC?%
M(P^IS'AKFGV$ KMY.HE ^O\ _5OY!_\ [4?]$7N>7<*?V2_"Q\/ O_E^==QG
MO]I? 7_:G^EH5/&>HKATPB81,(F$3"*DW,&SUJ!MO#-"=L,'"K+\M*T]01EI
M9A'*K,V^J]N1B[M)-XX1.HV0DIJ&CUER *2;Z6C&ASE</VJ:NJR4D;)<6'O8
MPG(L(#G-;L"M::2-D= YS6D]VW-'>1OTWP=T;MO'^$EU6G:LM9X/[L;W5Z\L
MS6R/SW#T[(W&-C@U[H*MF9K3ISHJ\\@!9#(6W9S:KS)/1Z<(OF/)N%CRB9_+
MQ;$H=>IGC]HV*'3T]165( =/7U'+2]@[W-'PN _&5-'6L3'44$TI]4<3WGY&
MM*P>4W1IV$$X3.V-:1 I]14"4O=68"0 ](G[W*I=GIZ^UTR)UJLSW5B!NN_F
MFC&OE<%M(.&^(K.O%L!FK&^[L,7>EW\'9P.VL#DN77%2'#K)\E=#,_V*[:H?
M:\/4!2SQC"/S  "(^@ ZY"[)8]ONKU,>GZYA]'^.MK#X/N/+'U'@OBN3T;;P
M_E=?*:@'X5B"O/+ALF(@GR0U2_,4>@EB+,UFS=?V%B ?"/[.@" ^KKD1S&+'
M^[JQ_8R!_P#%VM@WP5^$9PV>#<]$/78HR5AU]9L=EKXUP#SPXLJ#V6&Q9:=-
M_@A6-7[;M7E/'H'DAKE$E 5ZCZ/)B;KZNN/*^/\ 1.Y_[77LR;^#DA=OX1\'
M>I/T*N.V@F7#5ZNN_P =SG#U#7I\X7,K 6GV'13Y;FG'/0(.L\B+.8? H0?%
M?D:H4QO'H4%I'6,<WZB(= $50)Z^UT\<>5:I]Q'=D/J9CKQ[_P!E7:/E*M'@
MSXB;]=7>$*/K\;X[X-:0/22V'-S.Z>KEW[%N#E['K (L>.G+I\'I#_N 66*[
M0#X@)?C"XAO ?F-V1#_" /'I3RFT^YHY-W_4I&_RA9W_ /SI/T/9F_5>,?!]
M%_VMHV-?>;+/=ZQL>HE;?E3W%T820W#?EG)F'^C,ZK^G:TB?YA,I:MTPIT@'
M_P :D40Z^(!XY7RA*?<XS).^%E6,?_Z6V:^/2K] F.CZV?"-P!"![H1W.([K
MA\ H\-6&N]7FO/R=5Y9[9YF\I$OA%=-0<3Q8EH=S$UB4H]6UU='3).V66M;7
M6I,I<K.[N=+G[C18UG#2-+BQ;RT8O88JMQL;-A90-(K.64'SMG*Y 9RJQN.>
MTMC=%'!*1VLD=@Q.ED,L,DL(:UT3=/:7MC:U_:>=L,]SP'@WX%=X'N)+=CCN
MO89/>@R=[,8R.5U"E=P+<G!C:,>,R=3&Y6>6S#DY^>O.RG8N33UO$OI+62VO
M4H);G?8NBC2E\7-6-E1ZD3G[ML[;LPV+\SEC!5+5<2=3I[-854^O^$(!^=T7
M-EW]1%CZX/H?+8M.'PAD=9N_@>0O#/%_!93'+)DN.<[(WO-3&8/AZN\^N.6U
MD,].!^SI@_Y-?R1<M)\>W:>7<95TU1ZK,M.Z!IT$*)1]*;64VE.[>7#IUZ>6
M49B<>@"!2#UZO%LB\_3,DV,>D5:<3#\ =9?:^7EW\"K]$/ %0:H^#V>\YON9
M>(N+<E:#COHY\&"J<.M_Q1+KO!)0>($?+CUOW(;E7L)-0>KEF]W1(T",<AZT
MSQVEXO6+<J(AU#L$ IA 1 QS>G'DT.^K7<C,#WM=:,+3ZP6U6UQH^I4_1"EK
MC6*X0X#Q! TR6+AJ'+3L]3A/Q+/G'EW]\3\ "[L?P8XELWB4B^TA5+?(HF Z
M<CLI:;VI(%.4>H'[YLF5M3D3=>@CU4'J( /3P#I5N)QS3S&I'*[[*P7V3\MA
MTA_"HYO"CQ_+&88N)[^/A<-&'"MJX&+7J[+"UZ# /8&CT^LJP%6UWK^C)BC2
MJ+3J>B( 44JM6(2OIB4 Z 421+%H40 /  Z= #P]&9D<,,/2*&*(=VHXV,Z>
MKS0%R5_+Y;*.YLGE,CD7 DAU^[9MN!)V3NQ+(=D]2=]ZS')5KDPB81,(F$3"
M)A$PB81,(F$3")A$PB81,(JCUO7;1ER\O]K)9K@M(*:IH,@Y;N9A%2/>,7]M
MVZBRK;IL# AE*W75W+R0KL<"Q%(^0>NEU'3DJODP\:Q>*NQ^&/B!K^)^*)Z%
M/A?!9^'#SY..3%>,YS*\7T9ZKJOBK2:%2*C7DQ]<2AU>=O.Z64::/4\CFC+X
M*\'2\E8>-KN)<W3%B*F]MJ-]/&<+2NO1R]N0+]X%L-^<L+9X(XXVQQ\O,;<9
M[*O+$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB815%XJ_P!\G+_]
M[JX_PITUFLQWU3*?NG+_ #:HO0..OK+P>?\ -_C_ .G^)%;K-FO/UY[_  H5
M()=.'UN43J>P;Q*TV^::O$!6M;6;=M>FUY>%VQ3VY9MZSX^"IM"VPU+82+^\
MNZK763N3<N:TREJ^XKMLAJ[;Z[T?"E@U\U#].K5V3078));45&6-K'U)G<C3
MD?TK#),YC8&S2$- D<R021/DADQK;>:!W1Q(+2 PO!)Y@.O9^<X $DM'?K?0
M@$?7^#G@H^#XZ_S**D8YW,;!N<Y..INL<J*Q8)Z;?N&0.YVP)\REG6]9F4=I
M(MFYIV>=NHITU:-&L&MW)B":=G$LCI<ELO:YK*T,<89)B9(XXVAVHX_(H;0C
M8"2>SC:'ASG&0;=LJHY8M:.^8D[[79) V29B7GX2=:&AW*^.<^LE,(F$5?I[
M]:G5/[OW(#^(W&C-G'^HUS]T\;_-<JH'?7,?[1-_*0*4;GKZC[$C!A[U4J_;
M8WR;I-)M/13.2!KWQ S9RJQ4<I*+,'*B!A)WIFH@Y)T*8BI3$*8.8R.$PF9=
M3?F,-B<N<=99<H#*XVEDFU+<;FN98KLNP3LBE!:WSV-!( !V.BVM+*9/&BRW
M&Y+(8X7(75K7B%VS2-B!X(=#,ZM+$Z2,ASO-<2!LZT2O(/46G]E\7]B7S16J
M';&=?0C9>_UK2^P7I4M;<G=).7I6HRE:E7I';/7?(/7#Q1"EWB7;M/BU=D?B
M7:KC ^6G75B;=;QA@*>4H,XMPM&F^AEI35XFX<DAB=C:V=Y.>9T59['15*^7
MC:Z[2(:ZN919JR-!K@KHN%N-:V0['@[PA6KHM8J!K>$^/Z@?+Q%C<6"(Z]?)
MN:]DW$&,QKR*\U>65N3I0%DN/L.9**QNIJ>,XV;Q0F9*B5N9U'L:LNDH[8-(
M@WDUJ#9NOIY1,5 8VVMU>2C&ZQ')>VK%3@-Y>MV-H O8:3DFO:4+XH/!AX/K
MLLMK%8>7A7)AP\8FX3R&1X1O12D'K8BP-JC7L%VSIUF"Q%,-GSQM=3GLOQ]P
MN:M?,9&MQ1A+D;IL/D<G7J<4X++5 0TR8Z[E*]F6,L(:V>JV2K=IOU'8@A?R
M@R[^3K;]=#M4O=[R8;I?G(PVV*G#VQ%3P\4#6&L'I-A(4? $W#I>453#\Y0C
MDPB(W?0EQ]B!OA[PD6,A#'UCQW'."Q^<C>-:[)V6PSN&\LT$]TT\MZ1NO.;(
M27'G_H@X3R'3,<%PU)']'W.%LK;Q3V^IXH9)N:Q[B.]T<4=5CNYKHPJ :*VY
MR59\BMBN[A0[78V;H1_*;7*]6(]%S")1+1PRJ3B#,_7B2*@U*=%&/;!*N75A
M@E'D@@E,.TDG9/E/P8<>^&6#PO<7S<0\+9K+5YW$<9XG$X>K'+C&4*\M; RX
MQ]N2BV5L+71QU8O'II\MBW6+D++\\;)1[SQOPIX.)O!]P]%B,YB\?-%KZ&\C
MD,E.Z.ZZW+'-E8[P@9:<SM2'OL2FK%%C[S8:[WU(7NB=Z-0&^M63S\D,>SIU
MBQG$I?BM>V,A1+(*ING\DA$6MK$N7Y@$0#RD8#U W4!(J<H@8?KW%^$_@G)V
MFXY^9;A<N[3?(G$]:WPSF.<Z'9Q4,Y#1FM.!(!=3%F,[!:]P()^>K_ W$]&!
MUQN-=DL> 7>4\'/7SF.#.I#I+>*EMQ0 @$\MDPR#1VP:4O@(" " @(" " @/
M4! ?$! 0\! 0] YWX((V#L'J".XCUKDN[O6N$6TYR)E,<YBD(0ICG.<P%*0A
M0$3&,81 "E* ")C"(   (B/3"J 20 "22  !LDGH  .I)/<%6&V<Q^/U:F%Z
MK$W-;:%Y0[1#4'2D%-;@MZ:Y1,46\C&T!C.HU\_:(8IEK.[A&B/@9=RD00-F
MODR=*-QC;*9YA_::K'V9=^HMA:\,/3^V%@'I(7;T/!SQ;=KMOV,:W!XMVB,M
MQ-:K<.XYS3H\\,^7EJNN#1!#:,=F1W<QCCT6,_E)Y>;''LZYT34]*P:Q>VA;
MN1=L2FK&9!0>R19OJ/5#Z3$JH$$%^[6#9U;=%$HMW#1$XB8MG;Y*?ZA4BJL]
M$EZ0/D(]8K5B[X=/L1GIH@=ZS?(W@]PW7,\4Y#B6TW8?C^#J!K4@]O4M?Q#G
MXH 6D[9ST\'<C/NV2.'0^;/.S@#==NWOC;8]J<EIBW6:^[.C-'22J&LZU7:[
M7("4K]VOQ'5.@(B5(X:&:K5B89K$LDU:)"1/,QJZ\PDA! RD=%E\++:FHR6+
M[Y'S6!4.J\<;(V.CFF!B8UVQHQN!#W2.=S@EX#-.]G\%GA8QG#V*XTIX+@JM
MCZ6)PDW%$+7YN[<N7+4%O&8ET>1MV*Y9()&7J\C32K48816F:VJY]LRP^E2'
M!?00HHI2YMS6<R22:1E+/R1Y"2_EP3(4G:5;+;,*R#M 7J*:35)$O7LIID(!
M2%WODFGH!WC4FM?5+UUV]>L=OK\  ] 7B[O"CQ8'N=6^ARCS.+N6CP9PA7Y=
MG>FN&$,G3NYG/<\][G$[)Y/D%<2%.G?M.1DR >@+'9+O90]?4!+8+-) 8!ZC
MU*8! >H@(#CR/C?35:[]G)-)_'D=W^GU^E6_HK>$ =(N(YZW_(Z6,I$? :E*
M$CV:(TOKL^#G#=B/5'B]HE4W3Q.^UC4I,YO#IU,>2BW9SF^<QC"81\1'KEXQ
M.,'^]]0^CSJ\;OXS3\O>L>3PG^$67?-QQQ2T'T19O(0#XA#/& /8  LUC.,'
M&J%$HP_'K1\48GZ!H_4]#9G+^TIV\"F8!_: Y*VA19[FE4;^QKPC\3%K9N..
M-;((L<7\43@]XFS^6D!^$/MN"SR-UIKB&$!A]?TF*$!Z@,;5()B(#\X"U8)"
M _M#QR9L$#?<PQ-_8QL'X@%JI\UF;(U9RV3L ]XGOVI0?NDKEF*3=! H%012
M1*   %23(F4  .@  $*       >@ #IDF@.X +6N<YQVYQ<?6XDGY2N7*JB8
M1,(F$5*+^[LP\U='2+:BSKN)@-6;HK(2B4A5R(2C:Z3NB7SVQL4'$\B^)$U
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MW6O3M95WQH#8[P73?NB:1UU'7ETN[$13*)U%CK]KR14DR%$QU#& A2@)C"
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MSI:S'R,@>P"+LKRHH(MTRHMT4D$B !2)(ID23*4 Z !2$ I2@         =
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M<0U\6W-S8BY'B710SMONC KF*PZ-L$@?OJV0RQAO3?GMV!M:UF8QDEPX^.[
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M;[PK>9KK,?*YK@()MZ(.OID'J5O<TJR4PB81,(F$3")A$PB81,(F$5/N5_\
M?3PU_?!J7\'=WYV/"?UKQG_@=<_IG!K19KZM@?W=@_F.15P<XY;U,(F$3"+@
M<M6SQ(R#MN@Z0. @=%RBFND8!#H(&35*8A@$/ 0$!\,N:]["',<YCAW.:XM(
M]/0@@]_54<UKAIS0X>IP!'R%139./^AKB!@MVD]1VD#]1,%CUO3IOM";](1\
MY0SGJ)O6(^GUYMJW$.?I_6F<S%7_ )-D[L'=W?4IVK"EQ>,G^KXZC-K>NUJ5
MY-;[_=QGO]*B%SP*X?+*J+LM"4FMK*")A4I!9:@F((B(]4?B3)P (" CU+Y
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M3>B3!#_H;Y^/ZN/D6@QW/T__ -+N(*']6O\ <KG_ )VR&_7_ #>G]GB[3P?
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M]]G.(R?E;D6?B^=7>3<OU_\ J*U\6/Q?3Y:Q6@:!Y(#^GSNVV'^\Z;XPD_\
M:Z?7'_3Y\?1!PUZ. \3\>:XG/XLNW\:>3<M_='=^*AB/\M(_U]"&X[[_ %?Z
M;G9O(?G[OK/C U_R=C2)NGJ_S_/E1Q'P^WW/ >"Z?9Y/B=_R[S8VJ>2LF=[X
MCR/7U5<4W\5'I\2XC<:=TJ_TW.GD:/S^0JG&UK_D\EHWP](^@?F^8,N^B?"C
MNX$X;_QK7$;OQYSX/P^M4\CW_3Q%E?BCQH_%1_K\'1:EXO;1-_3\W^42GS^2
M;<?FW^3R6C?#_3Y\H>*<5^MX&X7'POS[OQYO\'^7JGD:[Z>(<N?@;CQZ>O=2
M_P#CV[*Y XK7DW]/S2Y:J?/Y&7T>VZ_U>2T;X!Z?1X^CH/4 RAXKH#W'!7"(
M_90YM_X\Y_\ /QJOD:SZ<_FC\$E!O_H#Z/P]5J/%"S&_3YC\P3?/TN.HT>O_
M *#2J0AX^/0!Z>KT=0&GT6UAW<&\'#_J67=_&S3E7R+-Z<]G?BGI =?8*'R>
MK0]N_&_6WP:>WX'X26]2D?R/EH8M/CD=[MMH-$6DUMB1CMLS&Q:Y"1LFTL-<
M>4M]/^<*S/MKDY?,'<%(PZC=5C#D4EU8V#]ER?A,P]CP;4(I.&X9O')'8%V*
M>7PXF*3$0XVQ/)$^O99=CKB.U ZDV.1D\<S2'S:A$DW!U>$;\?%=B1F6?&(&
MC(BX )+KVW'V8V->V2(P.D+HI!.YS3&YAVV/S^5GL:?17*)  \W\Y+FN(#X?
M&'1&A9$@]!\ .$%4ZJ<0$/ W94((]>H"7/&QGN%3]4X$I@?_ (^?S\1^6>W:
M'X%W9QN9&N3B*?I]MQN-?OX>SAA_ 1T)].B-Y=5<S&P?S;EWKU]V0\ G.++)
M8Q_3_2*0NY($OCX /DT2!Z1  P<MP6\^=P?D(P>_L.*I!K]B)\-.?@VX^TJH
MI9]O=G*S]?;,,SK\)CO,_ /7T[M<9JESS8=.Z;OXOV H>D)?CULB"4-T]7E8
MKD#))EZ^L0;#^P QXWP#)OGP?%%<_P#$\0XV<#XIL!&3\&_C5#!Q*WW&0P\H
M_P"-QMJ,_P#^>1<._P!GH^):F)\( V#\QSP\F1#IT [/=-;[?SB)ROK5Y/K\
MP)*]/G-E0?!Z[O;QG#[0_"6?P%E3?P['P(?HG Z' R'VMR$(/R.GUZ.FC\*U
M+8^>[(H=YU+Q0G1#Q,,;O7;$$)^GJ(G(:#E@((_[9<X!ZQ'*&MP \^9EN+:X
M/=VN"Q,^OA,>>BV/@;OV*HEXE:/.IX60_P!YD+L>_B?CWZ/Q^M:'V=S79!U<
M\3M32O3TA7^5*_;'ITZB0D]HB%(/7QZ =8G3T"8/3@8O@EY\WBW+0_\ *.%!
M\A\7SLQ^, JAN<0-[\)3DZ_VO,ZZ>OZ9CV=WXO;T.H;PY4-R]7W".=7$H=3^
M8=_Z<D0'YP2\\/ZVHI^SMII"/K /'H."X4<?I?', ]7C'#V9C/I]UV,=D-]&
M]%W?[$&1S0'G</2$ZZ]GE*#Q\ +W1$_O0M"<E]Q->H3?!OD@W, ]!-!6/CE8
MT? ?2!DMY,5Q+T]'\W P^'YOCUP>&<,[ZAQUPV[V3UN(ZQ_\6#>WU?KO7ZD&
M7OM^J\.Y1O[5+C)A^"\TZ^);C\M9IL C(\1.8+$"_IBEKRA38%_W(5O:<THI
MT_\ %)G$?4 Y0<(PO^I\7\'/[]<V2OP;U[;.*@ W[2%4YN0>ZP>=;ZR*E>37
MQ17)"?\ %![O@WM)S.K"8=9/0O,&($/T@6XN;8E>P'K$QZQ!3R0@'3Q$AS!T
M\0ZAXY4\%V=ZBX@X-F]7+Q3BHMGU#QJ:N=GT=/PJ@S\.MOQF=CZZT[#W'?']
M*9("/@*T+SKT&B82S#?=U9.7KVRV3C)R+BA((>D#BKJ\Q2]/1U$W3T^/3QP>
M ^("-PNPEG?=XMQ-P[*3\ &4!/P#K[.H5/HDQ@.GC(1:[S)B<FT#X?TH?ZZ]
M:Y!Y[\3TPZN]IK18=!$1F]?[/@@* >D3^>:6Q\F >L3]GIZ^F/H XM/N,4V7
M]HR.*L?)V%Z3?Q*[Z)<)K;KI8/\ C:MR+Y1)7:1W'Y"N9ISZX6/#BF')S3C%
M4.@"E-72+KZI1'U&3G%8XY1_88H"'0>OHRU_@_XUC&SPQF7CUPTI; ^6 2!5
M9Q+@'D@9:D".\/F$9^23E6:1O+KBC,B0L5R;X_2!S_HI--R:[76'KZ/Y$EB%
M4!_8) ']F84O!_%L.S+PQQ#&!WN=ALB&C_&\6Y?2/2LAN<PK^C<OC"?4+U7F
M_>F7?X%G++=FF9/IYMVYK&0[70"]ROM5=]1'T 'D)93KU]73TY@/P>:B^J8?
M*1_L\?;9_&A"R&Y"@_W%ZF[]C9A=^)Y6:1UDKLQT")GH64$W02A'2C%[V@'T
M"'=EU>O7U=,PI*MF'?;5YXM=_:0R,U\/,T*=D\,AU'-$\^IDC''_ ,)*^UD"
ME3")A$PBXG +F06*V.FDY,DH#=19,RR*:XD,"1U4B*(G53(IV3*)E52,<H"4
MJA!$#!5O+S-Y@2W8Y@T@.+=]0"00"1O1((!ZZ/<J'>CRD Z.B1L ZZ$C8V >
M\;&_6%3/BK?N0=]M&\F>WKAJ2?AM4;+E]2,FVO==V6H23Z=AZ_2;0K8WCV;V
M7=4$XY9I:UXH((C$CI)VQ!Z:7.0YF1.TXKQ_#V/JX-^'IY>O/EL9#EWOR.1K
M6XF5YI[M85F,@QM)QE:^JV7MR\L+'\@B!T\Z#"V<I9FR+;T]*6.G;DI-;6JR
MP/,D<<$O:ES[4XY"V8LY.7F#F[Y^]JNCG%+H$PB81,(F$7&JDDN0R2R2:R9N
MG:35(50AN@@(=HAP$H]! !#J ]! !#Q ,J"0=@D'UCH45>Y=JU;<J-5]V;(-
M^WQ^W_V_((II=OL[&XT]GM>3*7M=GJ/3KUZ=1Z>D<V;"3AKFR3_LGC>\D_[E
MROK4! %F/0U](F_E(%8C-6ITPB81,(F$3")A$PB81,(F$5#N8U@MK2X<:4JQ
MIG<&RFU W;![=LTGKRL1DW&LZ]&4C9]0<195WL_%'-9#2-GBG24>=%-J>,.J
MY&0(J0K<_>\&UZCZ7$QM9K#8Q^0PD^'JQ9&U+!*^Q+>Q=QLQ:RO*!6$=65CI
M XO$H#>R+27#F\]+.V?$B''W[8JY".]*^K#'(P1,KW(#'MTL9[;FF8X-(#2S
M9YP>BO8@KY=!%<4E4!6235%%<H$71\H0#^26(!C 15/KV%"@8P%.!@ P@'4>
M$<.5SF[:[E<1S-.VNT2-M) ):>\'0V/0NC!V =$; .CT(V-Z(]!'<?:N7+55
M,(F$3")A$PB81,(F$5.[_P#KS\:?W?>4W_2WC;G94/\ :)Q)_A%PO_,^(UH;
M/^V/%_N7E?Y?&JXF<:M\F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3"*B50D=F&YQ;&L[_0>TXC7EHU;1M31NR)!UK,U7\X:PMFYK0ZLJ[5CL1[:
MB5BSM;A!LJPH6MGFSR#A0DY"0C5$78]Y<BQGT#8VM'Q!BYLC5RE_+28R-F2%
MKL\I4PU5M8/?CV53:JNI3OL@V!!V;1V$\SW<BYV!]OZ(+4KL;;95EIUZ;+;G
M53#SU9KLID+6V#,(I1.QL9[+GYCY[&#9%[<X-=$F$3")A$PB81,(F$3")A$P
MB81=5RQ9/">3>,VKI/Q_DW+=)<GCZ?S52&+X^OP\<O9))&=QO>P^MCG-/R@A
M6N8QWNFM=KNYF@_C!6%R6J-6S0F-,:UH$L8_7M&DJ=77XFZ^GM"ZCE1'KZ^O
M7,V++Y6$ 0Y/(0@=PBNV8P/@#)1I8[J-)Y)?3JO)[RZO$XGX26':PI[Q?XT2
M77SCQXT8_P"O7KWW4M!==>OI$?+U]3J/[<S6<4\31?4^(\['^PR^09_%L!0.
MP^(?U?B\<X^MU&L[\<16#R'!?AI*&,=UQ=T44YNO4S/6E5C3!UZ_HFCHUH)/
M3_@B&9\?'?&<8 ;Q3G2!Z'Y*U(/C$DC]_'M8[^'<"_W6(Q_^+5B9\G*UNO@"
M^*;X/_AX @+/1U=AA+^B-;E[96!)X=/S!KM@BQ((!Z!+T$/2'CDX\(7&6B'Y
MVS,#W^,PT[6^N^OC->7?7OWWJ(\,8$G8QT3#ZXI)X?Y*5G]>BY/D(\;T@'N$
M/M&'-Z -"<C.1<1V ]  F1CM5%(@ '@ %3  #PZ=,M^CWB5WU2?%S==_3^'.
M')NO?U,F*<3\951PWB1[B.Y'^UY3*,_%<^3U;7&/";7+<P&A=I\JJZ!?T$XS
ME9OATB3YNRC/7B:2\/1T,4P#ZP'*_1QDG#4^*X4L[[S+PI@6N/L+H*,)^0CV
M*T\.U0?I=W-1#U,S.0('P"2=_J^/TH?A^=,.D;RGYB10A^B<FZ&\T)?F_-M=
M2L*9@#U <A^OH'J CUJ.,@?JO"G!DOPX1T/HU_N2Y7/X>]5.".M,S6>C]HR#
M9#ZO[=!+_P#*^;.\4]L+04S'5KG'RACGSV)D64>O-IZ*G&[=VZ9K(-EG*R>D
MXZ;%))90AU5(Z7CI(A"B9D_9N@3<)R5^+,2VQ!):X%X6ECCFBDD; <[ YS&/
M:YS6M.;D@V0" )(9(R3I\;VDM-LF&NF*1D/$.78YS'M8Z3R?( YS2&EQ\1;)
MT.B2Q['_ &+@[1'F3\$)P_WMH[>O(NX7ZW11:[57\UI2R0,-./Y=*X[#:*5"
MYELRI7+5JF=C#0<R0T?*/DTYA9Q97[0&[8A)(JOIOA@XPP.<P7#E.A4E-FU'
M!FZUB:".$T\<\7*9JCE<XB2:>$B2)A,+6UHW\SB8B.1X&P>1QV1RL]F=G90O
MDQ\L<<CGB>TPPS]J>8 <K(Y 6O=YY,KFZ YM_H-SY[7IR81,(F$3")A%7Z>_
M6IU3^[]R _B-QHS9Q_J-<_=/&_S7*J!WUS'^T3?RD"L#FL4Z81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$58+1Q9K]KWM7^0#O:>[HZT5<"-H
M.M0UW9,J&PAG'Q5/8*VC 'KSAR6OW%S381[;&!90!E7:2JI5F_;(5/JJG%=B
MI@+'#S<3@I:MKF=/:GHR/R#YAXT*]DV!9:PV:3;DS*<IA/8L(;IVCO3386*?
M)1Y1UW(LFAT(X8[#&UFQ_2>TA$?8EW93F!CIV=IY[N8@MWH6?SE5N4PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3"+B<(]X070%19$%T5$15;J"DNEY0AB>405#J*:Q
M.UVDU \2' I@\0RYKN5S7::[E<'<KAS-.CO3@>A:=:(](V%0C8(V1L$;!T1L
M:V#Z"/0?05772'&2J:&F[A.UJ^;@L[B]O5I>RM-A["?VZ-?6%RE$M7-G%FZ;
M($^,;B/@XN,6ECF4<J1S5-H813*'3H\YQ/;S\%."U0PU5M%C8JS\=CHZ<L==
MIF<VJ'L<X^+-DGEE;"--$CB\=5JL=B(<;)/)#9O3&RXR3-M673L=*X,:Z;E+
M0.U+8V,+^\M&E8_.:6V3")A$PBJ1R_J&_+MK9U!:/F9*&EG+UB(/:C-KURY,
MNPPL!5W"+X]XUZTD8XSY6 2&/2N=6<QQQ7LS@]U9PA]:7';X:;'P6A)?8V1@
M:X<LL;987;='H%I@LEK@WM'<W8RAP B'8.D%F&"=LKF$1G1Z=Q(=Z>XA[!ZO
MUPUW^=KE./:AC>06N9'<UNV-7-@WXCP\<%;IT+L.NVU><DE=L;@DS2&OVUTN
M%4K57@XK55JU+7I%M)*Z_5DY&D3BZ5;<ND64M:);CL?:;2AK25JY'-VDSZ\D
M(C8*E-O+8,$,TDKW6XK<C7-\8Y6S,!D );%1@E87EX<_U .!V>>0^:"X!H##
M&"/-V03H:V>_7+W8;KRHU_Y^U#LC5?FWC]O/NOY076L'/GSO>QN.7EO-/Y.-
MD["['F[NR7??/'FGM=^:=P[]V7G=$E>.##V>SN5K?-D\?OQ86AR:JY37/XS6
MK^ZV>7DY^X\W+TW0.+K+-L<S4$W1W+U^F0=W*YPZ>W7?TWHZN3FC62F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(J_3WZU.J?W?N0'\1N-&;./]1KG[IXW
M^:Y50.^N8_VB;^4@5@<UBG3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818!8-KZ
MNJ0SP6G9%"K0U48<+.$];Z_$&K@V%%XY@ G@D)!N,1Y[;QT@XB/. -_.*#!Z
MLS\LFU7,GD1U+4W9]E6L2]KS]EV<,C^T[,M$G9\K3S]F7-#^7?*7-!T2-VE[
M&[YG-&M [(&M]V^O3?HVOKP5WI=HDI^&K-NK%BF*HY29VB*@YZ+EI*N.UU7J
M"#6=8L'3AS$N%EXV1021?I-U%%X]\B0HJ,W!4[)()HFQOEAEC9*"Z)[XW,;(
M &DF-S@ \ .:26DZ#FGN<-U#FDD @EO1P!!(WW;'H_\ GU*)I[]:G5/[OW(#
M^(W&C,Z/]1KG[IXW^:Y50N^N8_VB;^4@5@<UBG3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PBVG*!R&((F #E,41(8Q#@!@$!$IRB!B&#KU*8H@8H]! 0$ '"*E.P
M.(4A=+9,65EM'S05>OU:OP:4G4GMMEFB<%2-ZZ]D7]HGIF[^7N4A)UOD1?NY
MK.FD82,DHVDKNTYJ/@Y:*LF[K9AL$+(G5>?4DLCRV81,)DGH66B)C(#V(9+C
MJ_-RN=SL=.!R.D8Z*!\)>YS@YK=D'7)OKRO:?UP'4/=KH-'E[P-')=9\:9O3
M".P5];[#BB3-D:,(:G.;M1GUGB:K7VVT=J;5=-+!'0]\J$G=)1>8W'<(QM+-
M[#4TFD6TK(K1CY^PFWEDCM9..\:XLUG\D;G/G$%AL3YI#5JU&F)SZ\S8&".G
M"XL,<Q+S+I[6NC;$;$6<W(\ G0;S-+@T<[WG8YP7$E[NNV@#0UT.X\E;C,ZE
MY,ZSEN2F[]%LHJ4T5O..J\FWJSG1T>G($O\ QV<R#%T\ONZMBMK \=MDT'#)
MM'JPR[%!B_563D4W!#,,R.!ES$6V8NAD'/9D<>Z9AE%]W+XMDPUP;7HUC&T'
M8)<'AQ<T M(\Z,N,=B,S21@&&4 Z[,;YX3H\TC]DZV-$: /0^B?/E4\8/I(:
M%^N#7OXBS6^1\M[UY'[RL_DE-V\'VZ+[HSYT^53Q@^DAH7ZX->_B+'D?+>]>
M1^\K/Y).W@^W1?=&?.GRJ>+_ -)#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,
M^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_
M$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23M
MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I'
MZ%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGB_])#0OUP:]_$6/(^6]Z\C
M]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI
M\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQ
MY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]
MNB^Z,^=/E4\8/I(:%^N#7OXBQY(RWO7D?O*S^23MX/MT7W1GSI\JGC!](_0O
MUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\7_I(:%^N#7OXBQY'RWO7D?O*
MS^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4
M\7_I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!](_0OUP:]_$6/(^
M6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I'Z%^N#7OXBQY'RWO7D?O*S^23MX/MT7
MW1G^<GRJ>+_TD-"_7!KW\18\CY;WKR/WE9_))V\'VZ+[HSYT^53Q@^DAH7ZX
M->_B+'D?+>]>1^\K/Y).W@^W1?=&?.GRJ>,'TD-"_7!KW\18\CY;WKR/WE9_
M))V\'VZ+[HSYT^53Q@^DAH7ZX->_B+'D?+>]>1^\K/Y).W@^W1?=&?.GRJ>+
M_P!)#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'R
MWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^
MZ,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!](_0OUP:
M]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^2
M3MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/
MI(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z
M\C]Y6?R2=O!]NB^Z,^=/E4\8/I'Z%^?_ %8->^CY_P"^+]H?Y<>1\M[UY'[R
ML_DD[>#[=%]T9_G)\JGC!](_0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E
M4\7_ *2&A?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?*IXP?2/T+]<&O?Q%C
MR/EO>O(_>5G\DG;P?;HONC/G3Y5/&#Z1^A?K@U[^(L>1\M[UY'[RL_DD[>#[
M=%]T9_G)\JGC!](_0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\7_ *2&
MA?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?*IXP?20T+]<&O?Q%CR/EO>O(_
M>5G\DG;P?;HONC/G3Y5/&#Z2&A?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?
M*IXO_20T+]<&O?Q%CR/EO>O(_>5G\DG;P?;HONC/G3Y5/&#Z2&A?K@U[^(L>
M1\M[UY'[RL_DD[>#[=%]T9\Z?*IXO_20T+]<&O?Q%CR/EO>O(_>5G\DG;P?;
MHONC/G3Y5/&#Z2&A?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?*IXO\ TD-"
M_7!KW\18\CY;WKR/WE9_))V\'VZ+[HSYT^53Q@^DAH7ZX->_B+'D?+>]>1^\
MK/Y).W@^W1?=&?.GRJ>+_P!)#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/
ME4\8/I'Z%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/
M(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/M
MT7W1GSI\JGC!](_0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^
MN#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6
M?R2=O!]NB^Z,^=/E4\7_ *2&A?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?*
MIXP?20T+]<&O?Q%CR/EO>O(_>5G\DG;P?;HONC/G3Y5/&#Z2&A?K@U[^(L>1
M\M[UY'[RL_DD[>#[=%]T9\Z?*IXP?20T+]<&O?Q%CR/EO>O(_>5G\DG;P?;H
MONC/G3Y5/%_Z2&A?K@U[^(L>1\M[UY'[RL_DD[>#[=%]T9\Z?*IXP?20T+]<
M&O?Q%CR/EO>O(_>5G\DG;P?;HONC/G3Y5/&#Z1^A?K@U[^(L>1\M[UY'[RL_
MDD[>#[=%]T9_G)\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=/E4\
M8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W1GSI\JGC!])#0OUP:]_$6/(^6
M]Z\C]Y6?R2=O!]NB^Z,^=/E4\8/I(:%^N#7OXBQY'RWO7D?O*S^23MX/MT7W
M1GSI\JGC!])#0OUP:]_$6/(^6]Z\C]Y6?R2=O!]NB^Z,^=<R?*'C.J43)<B=
M%JE >R)D]N4 Y0,  (@(EL @ @ @/3T]! ?7EIQ64:=.QM]I[]&G8!UZ^L:K
MVT)[I8S_ -(WYU.F8"D3")A$PB81<2J""X "R*2P%$1*"J9% *(^D0 X#T$?
M7T].5!([B1\!(_$J$ ]X!^%0UN>D2%JA*6TKT,U?.(K;^H;/(I@,>U\A UC8
M,#-SSP3NU&Y%091;-RY%JD91TY!/R+5!=<Y$C9U&PV%]@RR.:'TKD3#Y[MRR
MUWLC;YH.N9S@.8Z:-[<0-E1RLY@SE:#J2-Q[AYK7 GY._7LZ=5+_ '!C[$T]
MV1^QF%SO^R=^^/SJ30]0^0*&K%1Y)]OO5%R:0K96L5O6>[*_.2':CB%9S%LL
M&DGM=:"S45(]<B_:U*Q*E7;-5VS3N D>+-U'3,CC-BL-;0MPND<)9+%)\;?.
M.V1,N"0\P'*.4RQC1()YN@.CJPM\]A &@UX/=WGEUT]/<5,O<&/L33W9'[&8
M7._[)W[X_.K]#U#Y H7KM%DV/(';%U=PC5*K6356C:Y!R(FCCE>3=0LV^)"R
M- 9)JG?-QCV=RK*HN'35!L[\X FS7<J,WI&V;)8:['U(1(XRQVKTDC?/VUDL
M=%L;N8CE/,8I1H$D<IY@ 6[L#?ICR6C1:P Z'H+]CXMCY5-'<&/L33W9'[&8
M7._[)W[X_.K]#U#Y H2T=0I2H1NR4+)"-6"L]NW;%MB"":-=]YKEDM3N1@WP
M&9JN2H \9*$6!HX%)XW WDW3=!4!(&PR-ID[J9BE<X18^G!)[MO++%'RR-\X
M-WRGIS#;3Z'$*&&,L[7F:!S3/>WN/FNUKX/3T4V&CV(E, ,FG42B ?S9'TB'
M^XS7\[_LG?OC\ZFY1Z ![==WM4-\<Z-)47CWHBD6R%:QEJIVFM856S1IACGQ
MH^P5ZD0<1,L1>L%7;%X+219N4!=,G3EHX%/RK=PLB<BALW)6!/D;\\,CGQ37
M;4L3O/;S1R3R/8[E< X;:X'3@"-Z(!Z*R-NHXPYH#@Q@<.AT0T C?7>CT[RM
M>05&DKMIR\U:JPK61L$O'LD8UD48YD+A5&8CG2A0=/E6K1'LMT%C]I9PD4>S
MV $3F*46/L-@N02S2.;&QSB]WGNT"QP]RT.)V2!T!21NV$-:-]-:T/2/2=?C
M4R=P8^Q-/=D?L9A<[_LG?OC\ZOT/4/D"B#9=(D)^Y<?96'AFKJ/I.WYBSVE<
M!CT CH%UH?=M-0>"DX415>@>S6VNQX-F*;IT0SX'AT"LFCQRWS:M@1P9)CY'
M!T]*.*$>>>>1N1H3ENP"&ZBAE=MQ \WEWS%H,<C-NB(:"&R\SNX:'92-WU[^
MK@-#9Z^K9$O]P8^Q-/=D?L9A<[_LG?OC\ZDT/4/D"B"4I$@YW[1;HC#-3U>'
MU!M>KR4AUCR@WGK)=-,RL(R[F90KU87<?5+ N#I%LJU; Q%)RN@LZ:)N,YEA
MHQMB R.[9]ZG*QOG]8HH+S)'<WN1I\T8Y203S; (!Y8RWZ:UW*.7LW@GIK9=
M&0-=_4-)[M=/@4O]P8^Q-/=D?L9@\[_LG?OC\ZDT/4/D"AO7=&DH/8^_IV6A
M6K:(NEXI\O5W(C'+A(QL7J6A5I^X*@@JJX9 C.0TFS%)\BU65%L+E)-1JL@N
MKF6+ ?6H1LD<7PPS-E'G#E<^U-(T;.@[;'-/FD@;T3O8%H:.9Y+1HD:Z#KIH
MWKX_P[4R=P8^Q-/=D?L9A\[_ +)W[X_.KM#U#Y H7T)19.F428A[/"-8Z3=;
MBY%6ENW,:.>"> O/(/9]VJCWRS)5TB4).K6&&D@;'5*[9 [!F_;M'R#EJCFY
M"PV:PQ\4CG,%/'1$^<W4D&/JPS-T0#YDL;VD@<KB.9I<T@F.-G*W3FC?/(?0
M>AD<0?3W@@^L;T0#T67[/K"E@UIL. A8MJZF)RC6V'BFH$9MQ<R4E 2#)@W!
MPX%%N@*SI9),%EUDD4A-VU5$R%,8(JDW96ZLDDCFQQV(7O.W'3&2M<XZ&R=-
M!.@"3W $JY[06/  V6N [AU(('7IKX5RZWK1H'7="@Y>+:-9:&I=6B9-L*;1
M<6\A'0;%F]0%=N*J"PI.454_*HJJHJ=GMIJ'()3"MS=K;M21R.=')8G>P[<-
ML?*YS3HZ(VT@Z(!'<0"J1LY8V-<T;#&@]QZAH!ZCOZK#-\T63N5(@HBL0C60
MDF>Y^.-K<H ,<S%.O43D-J^\6U]Y9ZJV1.$95:],R1FI%#.WQ6@LF#=V^<-F
MJTN/L-AGD?+(YK74LE$#YSMR6,=;@A;INSYTTD;=ZTW?,XAH)"1G,T -!(?&
M==!T;(TG>]=P!.N_ITV>BF?N#'V)I[LC]C,+G?\ 9._?'YU?H>H?(%#6P:-)
M3>S-"3\5"M7,/3;9=9*SN@&.1"/8RVK[=7HY8S==5)P\!>9DV#0$V2+I5(5@
M<+)IMTE5T\RO8#*U^-\C@^:*!L0\\\Q99BD<-@$-TQI=YQ:#K0).@;'-!<PA
MHT"[9T.GFD#V]3ZMJ9>X,?8FGNR/V,P^=_V3OWQ^=7Z'J'R!1!#TF0:[\V+<
MW$*U)5YW4&F*O$R/6/,5U/52Z;ZEK R!F10SU 6,?<JPN+EPU2:NO. )-%W"
MS-ZFVSGV&G&U8!([MH[U^9[?.Z1308YD1YO<G;X)AR@DMY=D .!,89J5[B!R
MF.)H[O=-=,7=/1T<WKZ?B4O]P8^Q-/=D?L9@\[_LG?OC\ZDT/4/D"B#6E(D(
M"Y<@Y68AFK6/NVX(>T55<1CUPD8%KH72-,</2I-U%E60$LU1L<>+9\FU='%@
M+PB!F3MFY<9MNPV2#&,9(XNKTI(9AYPY9'9+(3ANSH.W#/$[;21YW+OF:X"-
MC-.E): '2!S>X['91MWZ=><TC1T>G=K2E_N#'V)I[LC]C,+G?]D[]\?G4FAZ
MA\@4-\?*-)4G3&OJI:H5K'6&$@^YRK$PQST6SGOKM7R8NF*KIHM_)J)F[:#A
M4GCT[74! ,S(6&SW)Y8I'.C>X%KO.;L!C1O3@".H/> 59&W3 '- /78Z'O)/
M>-C\*V<CZ+)WOCQOJCU&$:R=KN6E]HU2LQI31S$TA8;%1YV(A6(/7ZK1BS%W
M)/&S<'3UTV:-Q4\JY<(HD.H6N-L-KY''SS2.;##=JRRN\YW+''/&^1W*W;G:
M:TG302=: )Z)(W<<@:T%Q8X =!LEI &SH#KZR IF+'L0*4!9-.H  #_-T?3T
M\?\  S"YW_9._?'YU?H>H?(%">\*%*VYEK)&MPC5^I7]VZNMLR4#1K3NM<KM
M@(]FGPB\5; X!HU 5!:-Q6>./T&S=8_YN;''6F0&[VTCF]KCK<$?NW;FE8!&
MWS0>79'NCIH[R0HI8R[L^5H/+*QSNX::"=GKW_ .I_ IM[@Q]B:>[(_8S7<[
M_LG?OC\ZET/4/D"AFP4:3>\@=575K"-5*M7-3;SK4W(]J.(5I.7"UZ!DJVS%
MD=4CYR,@RI=G6!RV:KM6GFX4WJ[95XQ(YS8[#6X^W Z1W:RVZ,D;?..V0Q7V
MRNYO<CE,T0T2">?S00'$1EFY&.#1H,D!.AWDQZ'QZ)^+X%,W<&/L33W9'[&8
M7._[)W[X_.I-#U#Y H:KE&DF&^=L7)W"M4JS9-;Z5@8.0$8Y0KR7J<YN=W8F
MH,TU3O6PL6UJKZ@KN6R#=UWX"-%G!VKLK?-EL-=0J0MD<98K%V21OG#3964Q
M&=GH>8Q2= 21R]0-C=@9Y[SRC1# .[O'-OI\84R]P8^Q-/=D?L9A<[_LG?OC
M\ZOT/4/D"B#2M)D:G7;8PL4,U8NY+<&ZK.P2$8]WY: MFT[78Z\] [15PFD#
MZ%DF+L&JATW34%@;NV[=RFJB3-OV&S2PNBD<YK*5"%Q\]NI(:D,4K=. )Y9&
M.',-AVMM)!!,<;-!P<T=9)".X^:Y[B/E!WKT*7A8,>@]&33KT'I_-D?L9A<[
M_LG?OC\ZDT/4/D"B+CY29"DZ$TA3+5#-8ZSU'4&M:Q8X\1CWHL)Z ID+$R[(
M7C%1TR=BUD&CA 7+-RX:K^3\JW761,10V=D[#;&2R$\,CGPS7K<T3_/;S1R3
MR/8[E<&N;S-<#IP#AO1 /11PLY88FN: YL<;7#H=.#0"-C8/4'J"0N#D#1I*
MZZDM5:JT*VD9V15K9F3,HQS(RQ6%K@Y)X(.7RK5JGY)BS<K=%5R>4!/R:8'4
M.0AJ8^PV"W%++(YL;1+S.\]VN:*1K>C02=N('0=.\Z'55D8',(#1L]VM#TCU
M_A]BF7N#'V)I[LC]C,+G?]D[]\?G5^AZA\@4+;4HLG8[IQRE82$:NXZB[IEK
M7;5P-'-PC*\YT#O.EH/C).54%GP'L]PK<=W5@F[=E&0!X9N5DT>.FV=4L-C@
MR3'R.:Z>BV&$>>>>09"C,6[ (;]*AE=MQ#?-Y=\Q:#8YNW1D-&@\EW=T'9R#
M?M\X@=-GKON!(FGN#'V)I[LC]C,'G?\ 9._?'YU?H>H?(%"3ZARBW(ZLWM.$
M:FJ4?I*\U)Y)]J. J5CF+WKR8C6/<3*@_4%Q&0<JX[VFT.T1!MY%9PFLNW25
MV#;3!BI*QD=V[LA!.UNG[,3*UB-SN?7+T>]@Y2[F.]AN@2(>S/;A^AR"%S?1
M[HO:1T^ 'JIM[@Q]B:>[(_8S7\[_ +)W[X_.IM#U#Y H8UK19.!V'R&G)B$:
MM8F[[*JL]5'(FCEPDHB.TGJNIO714&ZJR[($K%7)MB*#Y)JX4%H+M-$[-PV<
M+9MFP)*V/C9(XO@KS,E'GCE>Z[9E:-D .W'(QVVD@;T2""!8UNG2$@:);R]W
M<&-'Q=05,_<&/L33W9'[&87._P"R=^^/SJ_0]0^0*&M#T:2IM#D8:S0K6/DU
M]K;\LB3<PQSP30ESWMLBXUAWY9DJZ0*$A6IZ(D"MS*@Y9E= S>H-7J#ALCFW
M[#9K#7Q2.<P5:$>QS-\^&C6AD;IP!\V1CV[UHZVTEI!-D;=-TYHWS/[]'H7N
M(]?>-%9%MRJ+V?5&SJW Q+5Y.6'7ET@X9H!63874K+5N281S8'+HR#9N*[QP
MBD"[A=%!+M>46533*8X1TI^RN5)9'N;'%9@DD.W.TQDK'..@'$Z:"= $GN )
MZ*KV@L> T$EK@!H=Y!TLGK$(E'UJO,'L<T2>,8.)9NTO(ME/)N6S!NBNGY1,
M#IG["I#E[9#G(;IVBF,40$8II2^:5S7N+72/<T[(VUSB1T/4=#W%5:T:'FCN
M'H'J4>;PI$A;J9"15;AFKZ0:;@X]VAR@ Q[04X&D;[UK=+4]\J\4;I'".K$!
M+R MB*&=/0:BS8H.GJ[=LKE8^PV">1\LCFM=1R<(/GNW+8QMN"%NF@GSYI(V
M<Q'*WFYG$-!(LE9S- :T$B2%Q[AYK96.<>NNYH)]9UH GHI?[@Q]B:>[(_8S
M!YW_ &3OWQ^=2:'J'R!0U?*-)3.U-%6.,A6KB$I\Q?W5E=@,<B$>A-4*4AHL
MXMUE4G+SO$FY1;@5D@Y.B)_++E20*94N;!8:RI>C=(X23-KB(>>>8LG:]_4
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M ].H(&STV2 .\D *W>:=3)A$PBKA2Y7>CKD;MEE<8&1C=*H4VFDU<[2/4'$
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MI?8PBC>M;9TK=+Q<M94_9.L+7LC78-AV!K^N6^JS=UHX/#=AH-NJT;(.9NN
MY/\ F(^>&+/RA_S"=3" 9E2TKD$$%J:I9AK6=^+6)8)8X)^7W78RN:(Y=>GD
M<[2L#HRYS6EA<S7,T%I<W?=L#J/C4D]R9AZ&C8/_ -!+[&8JO7\_O4N[XG55
M:V?5WFOV-N-LML6*E)!_*G:]PCHEA.NJ\W:QXL'C!^DQO[FK7E^SFT).,DW-
M)@V?<&BY"R:'Z#9;"396SC+3,@^IY-=VT4;(@_M)99(&6'.D[1KXW28]MJC&
M^!T<D3+T[NT>TF)WS)1R#*4=N)U9LQM#D>]SR"UC&R&(-;REI#;)AL.#PYKS
M!&WE:0'B4+)R=U'8TK:=7CI7T)NTR]]FT[0 Z[6FH5W<K%+3;9-FDMJ<T(\;
MQ#!U&UYL65B7JS1JWD)6%6AYAXT<QFLK<,Y:L:8'$5AT%6&A :NL@(9V4Z\,
M#B]PRO;,=,]DMAQBE8'/?'%.)X6/;)F2Y>C*)R<7&))GV)!+^E2]CIY))!R@
MTRQP:US(M.8>5K7.C+'N!;TY[DQJZ;4N3Y3CK4S2MK@]F,6[N24K4EYCFKU>
M):TQMD:NB4>/GG\M"0\DWK17<K./7+!.)8NJ>M4FBTC#O+X.&LI *;!Q%:[*
MI/C)',C%F+MX*-&&I+6>WQZ2%D4\T3K)9%"QCW32-MMMO;%,RV3+4Y#.XXR+
MGFCMM#G=B_DDL69)FR[\7$CG,8\1$OD<X"-AA,0+VNX][\C-<W=.P5[4^JV6
MM8%+94=<:I.0C"D5N=*RA)+8(L%'3>J4N&/$OBPMGK$9')Q,J4&*-1;.9MU:
M9UXYG#5P7#N1HFO8RN5?DISC9:=N":2]9@,D\>/YPUUN[,)8^VJV99#+$2\V
MW-@;5@8V%6Y'*5; DBITQ5C%J.:*2-M>*3EB=9Y>80P,+'<DT36<C]-$(,G:
MO=SC(IGFD%F96%K;:$ZNJ;JZ35IJ$;=;2UME?JZ?Y)'>J*<:7A)ZK/VFP;!6
MF;.E2CB;N19%&1=U-91K%Q3NQ23PF-#P9XJ^LZI?92+*4-6Y)3JOJV+1\K,R
MMSL9X+3'X^O9>^[$V"GV9C;; =)*RM$PS29YLK91-5,X=8DF@9-*V2*$>)FG
M!SQOA+;,D;6UW.?.'AW8G3&NE>Y?&V+OG1]]U7>HR+TQ6->['L%@66B'->I%
M).P85Q*U0LM!Q\=-1L;6W%;685Q&4K\N]BH<7DT,?&JO?. VRQ.H.?'8+-T,
MI2EES-G(8ZO7:)6V+MT2/L&K/%/))#)+9;8#[)BL0LFFY8>TD#.S\4KMFCMY
M+'V:<[&4(ZUJ20ECHH*_*(Q/&^-H>QD1C+80^)Y:PE_*TGF[60LY]M<PF.TU
M'SMSING-Y.4=;*7?2,L$785R&NJ\$RKLA%$>5Q%*&L-/J-7KM;"<8%27F58I
M.;63:/W#ORUN)X0?BPQ@S%Q\43,8V..$RUAJBVP^Q'*667&:O<MVK%DP/);"
M)3 TNC8SE7<XVV2[Q" .<ZV7.DY92.W,38G,!C;V<L$$,40>WW?+VA:'%Q-A
M.&FV";K^$_T#L(8N3BW<O/+(RAIB?/8I*3E&6N[*V>2[EV5A%,&8/#D#N\1#
M14;#Q;1-!HR:$*F<ZG.<:8HX7P7\08_M8I610-=$(:XKQ1129*LYD+6<\LC^
M0'SIII9)I7ESWO.P!M<!<;?XOQ=D1NC+Y-/YY.T<][:LH=(3RM:WF/<QC6L:
M  T#JOV<Y\7KWQ,(J%:;XV[<UYRZW#N0;# U326P(VW.'&L:_L?8]^+?]D6.
MRU1]&;8G*Q=8.+J^GIV!J]=D*X^@=:R$Y%VY6Q'DI=VW/"1J)^ANY2G9PU*C
MV4DMZLZ$"U)6K5_%ZT<<P?49+ ]\MR.265DC7V6QNA$0:P'M'E8[(GLF>_FT
MQ_,>0.<0YQ(TXAPTT@ C3>_?7N5]<YY9"81,(F$3")A%0GEQQLVYN?9NA+]I
MNP0.M[1K*2.S?[;/LC8]?M5;HDUL755QV%4(W5U;@W^O=PP^Q(C63&$?PVS)
M>&CH)ZC'S# SM9-1(O0X?*4Z-3(5KL<EJ*TS;:8K5I(I+#*UN&O.ZU*]MBG)
M7?:+VOJL>Y[2YCN4'KCS1/D?&YC@TL(V[F<#R\['.;RCS7!P;K3M ?'TOMG/
M+(3")A$PB81,(F$3")A$PB\X.9_"38/)?;G'C;=.W'&U!71%ZUQ8F%-LU/1L
M$&DG ;=I^Q+G:8)^DY*Z:W67B*7!UYB1VS5:'8QZ\2G*P4?9+(J^Z;!YVMBZ
M>2ISTG3C(5[43IHIS&\F2I+7@BD:1RF!CYI)'%I#@YX?RR.BC QIX'ROB>UX
M:8W-< 6@CH[;B#UZD:'=KIZ-E>C^<RLE,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$7F_R@X1; WERDXU\D*QN*.@FFB[C07RM LM11EFC*M0DO
M;9G8#RDSJ"XNXZS;)+)4Z#GVSQH5BLQI%=?%DFZ\.1D_Z;%9VO0Q63QDM)SS
M?@LM\8BF+'.ED9"RNV>,CE=%6Y)7QEIY@Z>0<I#]MQI87/ECD#P QS3RD=-
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C81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g210084g05e37.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g05e37.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1H.4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &?*^9D(X0DE-! 0      "\< 5H  QLE1QP"   "YH < @4 &U9E<F$@
M+2!38VD@1W)F>" M(%8W8E]04DE.5  X0DE-!"4      !"PZ/.62GDQX$4<
M>\\:NZ> .$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             $GP  "=H          0                         !
M              G:   $GP                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $GP    !29VAT;&]N9P  "=H    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!)\     4F=H=&QO;F<   G:     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !+ * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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MK 8T;GOL< QM53![K+;'^UC$A\WF%_\ D_[LC_SQ_P"NU^L.>.G7A@D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M5:YCNQU.HW:[T^MW=<F5*XQM-)A'59=SQGI;'-1,@BHSAVHO%GJA%O1QWJ)
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MAH/OKQQ_&[+"$-3UUUA" \\CU:@]^FOWPU[_  @.NAC$TV$ X]^X?U>W_>\
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M !J[,_\ +7.N.=>/ G&N&G"DN#CH-V _81?S"192;5-ZQ<I.&R@=2I3;@*(
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MXYGEG7094&47OSUGUE#4]:8980ASS]NHKX4KJ<\J4[X==>4-WVZ84^_N,-W
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MQTWX/V>FT/B!886F\W)&;M!=0" 964=4PJAU3-*8(.8-",1&%=AF 22KMYM
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M@'?6,M; .TKY%S9!J>5).FYDS_$9 S;C"R8YM5FS#0+B&0Z?799W!JDJ=##
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M"OAYDT\ZQ\5Q+'4= [03(W3.S.BX,X=&<<"J*Y#H W1(UZ$W3%7*=P8ZO3I
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MI%)Q9:?572^6ZQ&6'%Q7E]@XF6*@PAUEK?DV9"QDH(=F0ZLM2SB%FT))IO\
MUI832RTDEQ%&WG0))Y3<X1+N.-A16 Q96Y,U^E-$@N)([%PJK=); 4?I-: E
MU-6ZK2E5"*+JM^VC=KNIPMY)$;/CMZ^I/I6,AIQ2C9"O;?(\\E6+U>JLS@:W
MC@AYY&-L,"WQ;3YRZK,VE4JN4;#>H1V'15)@QF;<O9UCO+8*K12E+X0M;8?E
MI<RK9<88=+CLT V5M.?-OML!1=>E4,+22IY114IV83>'9'Z"4WKJEWSBI-$M
MDD)*2A*ED (<*JBB:&2:YNVO(63>(6"E24RFWN>7X.2EV&"<E&J]+K!<EUTN
M++"O7(!*<N&8W"E <&3:*XKL+9DD$\]5M[,SZD6:1C*ER-CK0@MOI15F3<2A
M5H2I=>=,L[\TWVCA0S) 3 !(FVRH]FGL5%+S251VDP"JJ2:*<34,N74IOI"%
M$"JG?I-*MD U-[%*B,ZX(RMM%WJRQI<M8>8XZK%EJ%DFVC1!O8#S=)L%84Q>
MD2NVR9?G"&F%K:>^6@*Z>+CX<4V^,9IY_G0)51O7_#/RMFL-J$G.JFG6GFT*
M42U<>;=$W_-90@7D!GY=KM M2ZF;;3]-RKEQM3ZE?S&PA)22!C>2H7/I43]*
MKU]5VE*=FO.N%J9EVG;X]R8_V;ME"I0&1,WQ#&-D\DW&Y.9!KAG9]A9E/IXE
MWD9]#"66L5TG6H"[J^+JTNA.R+'BFY>0@H-$KIU[;/L67^3%K6W,.REFK4I$
MFQ+A!M"U7&S1Q,HESZ&9=I6#\ZZDMH7_ "FT.N5 \TS.E#A8ED)=? !<4NO8
MRZ5?I[0I(4IQ0^I#22"1]2E)3C&J^1L?0]?>F;;26W!M:Y6R,"2:\S4<$V]#
M =)@2J)@Z21;UW%P5<D*0J*Z)V;>ZY(F+"_9F;O1%PDHHN;'VAMY8=B.&7E+
M$L=I20*-/29MJ?ND"AF)B>6J70I0HJXEN7!K5#=VE-VV3^%>W&VK'ST@AUJS
MU*4E%H3LS_"Y!U:5%"A*ML(5-3*4*"D+<89F&VUI+;CB7/I-'H<:OZ29I;-6
MVUM)8]NCE1(L%0MJ^2CMH+$]R5 XBC +OI]S)VF(<2*W1LTS5K+,383$.92,
MC))1-5,;<AM[LW;;J96T;$L]"G2 A<E+_P %GJD_J9=E%N6>ZX":H9>947%8
M 9E/MVF^#VW^Q\HY:3R4S\A+IOS,S(3*K38EVT@%3DS+S#4O:#3-,7)I+09:
M'^HZ@%(.[FS_ +3\Y<[I+8"S[26N'MI>KPX3ZU892:LS0<IT]-8K0^2<*VAR
MBU7L-7\[,1*9@)-NUMM+>+$C9]FIP _6]]J6*W+2Z+2LR8,_9#K@:#Y0&YF2
M?/U?*6BPDD,O%();=05,3"05M*2:H'/I6<[919>0&9E(O% 5>0Z@8=JRHT*D
M5_4DB^V2$JKF=Q]8'KK/RCW1--M_R]P@'ZO;_O>W5M>G?[14FF-03EET(E3?
MK#[1W^SK[!#OW\^-6/?A7#0C&E#F2-^%,M3'0YX9@Z4ZW-33TW?C?[Q$-,<<
M1K3K/ Y\^4(Y)2!C5;:\,H<.C V7FJZ@C\D"M[-+H+'4$>H +YM+BH/<)1'N
M'7,EGY?:>NAM-"N29AU*B>Y+E8^UI4"V/@@$I^HC8E]M.&;MDR;C:4C/'M9(
M)!SO<8ZVZZ=Z===8_%,.>>?9J/'RP/GCY94AUUUSB60=$<*.TRI.""S< W.9
M=LL@FJ?H$' *-5%2%(Z0X5RI].@)T@7361XND2. -X(.?[994XX@4,,N\<>O
M:)G0_MS]=,>$(:<J98$XY\J9TJ3CRRA%(G9MC7HQS*/S&%-$ (W:(F1%]*/E
M?D,HB*076;E>R\HY%-C%L"*E5>O5D6Z7RU U6VA;B@E(%3BHFMU"1BI:U &Z
MVV*J6JA"4 J,02 *G=EA4G1(J<2<@,*DTCGWM4X>R)'T'(&3*A<8EG,VN0J%
MAR/CZPQIIZD/)J'3@ZC%S-0FHA&HST#,Q\&@QA92>EX^R_I/ Q44Q>1+!:*B
MG<?YK?F;.F+$5*VC+3*Y>26@RLS)K0S.MMN3)4M+S3XF&'FBX\MQ+*%L=DXX
MZI+Y#CB5=(^$3EH2FWMG&S'9-$S/R]H2RD3R7ER;A$BX\$E4LIMYM9^62E+E
MUT&B+S)N@BV-A/&X66)NMARJ^B;I+L?2M4BZDE#$3H=<K%V8P"UH31B95:4<
MSTO;5:K%,IR7F7 M314$RCX6#@DWMB-.X_9NTI1%G/R=D,S4HRU/(FW7YB90
M[.S+Z6;C+A6PS+MRS3 +A9EVPM0<6MQR9F"&@SLGQTLVTV]I+(M"V'Y*9>G+
M%,LVF1E'9:4EVY><?6XP/F)B9=F7*S*5.3*RR%I4E")5A(4'.A81]AK:PJ1*
M[ZSPR[D#+0LI(%7F8TSQ\)W#B(FY1<BCYDAYVLY4C)Q^JHV:-B-(9XBBDTBA
MSH4VX!?"6G G]:$D-JNHH$K:0*)4: !;::*4J\XDDJ<'$\1^D5!.1(J 3C12
MLZ<3E@#0!,5V$L,18FZKB*=BJ9J=JE(L7"#F/F(9T\C&$RWCIZ$D$6LM RAX
MJ4CI T5,,F4@FS?LW"C8B3E$Q[:VUMD!8I>!4E0(6AQ*5J;*VG$U0X@.-K1?
M;4I!*54-<@((J,=XR*214!0S2:$&B@#0BHIG6M4\<]<^A[:Q,-.NO32$-(0\
M.>?LU&67[?88</'-OZZ\X:;_ $Q'+WTQRTA#3AT*^.XD5PTA#3O /CEF-.,(
M:9=:?BOI6$-#^]< <*ZU[^%<:B$8"E/^LM+_ ,]B/X;+5]- TK'^D[ZTKG7H
MQ:/^H*?Y)]M\;"-?G+?]NE_$+U]G?W\[_.<E'>,*5XG'# U)K%X9CF/;#/33
MJE2F_G*7[ /XBFJ4:]WO%:]._P!HHVJSECEKN/#7HX8XQ;AJ?L.N@/LAJ/WK
MQRUP'#O[T--WEX?OY=R&F[#TPU/B<_&$--,#QKAWG=C[PAJ<>[G[4]X0U'AC
ME^VO7>ASR'9S[F7YJ,:GNQKZ4KA1UT<^O%I6AIO._P"^ZH%-<:"$-!CD?OB,
M,SWXB$-,J\N&&>.>O/OS,(\7"Z;9!9RJ(E2;HJ+JB "8032(90X@4.L1 I1$
M  -XCU!UZD8TXT'>32A[\.$-_"I\,3%%A[/$3RJR,<LHH=NF554%$%40*0YN
M$H@*A0 =X@.\ '>'>&B@1F..>[EY^\0"#@#4[J'K=$W+S+"#;$=R*ATT%%RM
MRF(D=415.FHH4!*0!$ $J1QXMVX!  [PU(!5ECAZ=8^>4"0,X]8N3:3#--^Q
M.91LJ90I#'3,F(BDH9,^\AP P;CE, #V#V]8;M4T(P.>& QK@,ZZTJ*UW5TB
M001AE[Y>'/NWFH:>G[X9X^%/9#P^WW#^.[3&N> SUT]?P>;?Y>(]JPU/7F>'
M7=4H<\_;IUUWU\8==>4 Y^[4#7PIH*8>W=D,,QZ]8<\^_2F)P&FAWUKQ.[<=
M8==>$--":^8IAXCUX[H0W<\\]_;I2M,=<N5?WW85XPKUUUIE%?'^PB^W_%CJ
MC^NO7Z?'WX1<_HZ/]44#5SKKSBW#2L(:@\JYX ?<_O"->MJ#:EPEL=8CF\VY
M\MZ=1H\0Y:1B!DVKB3FK#8)$%ABJQ6(1F51Y,STD#=PJBT0*1%JR:/Y>4<L(
M:-D9%ID++LJ=MB<1(V>PIY]8*R"0E#;:*!;SKBOI;0D* ))J24H *UI2;3[[
M<NV775!*$X95))R2 ,5$TPW9D@5,:=[%GE@=CS;FO[S$^,I"_P!'R@2*<S\)
M1<NU=E5)FXP+)#SQ])U%S$SUFA)86; 0DUXL99M.#$E=2[:+<1<=)O&69MO8
M^V;"EQ-S29=^5*PVM^3=4\AAQ1NI0^%-MN(!7] 7<*+]$%25*0%6)>?EYE9;
M05)<H5!#@"2I(S*2%*!WTK>IB 0#3J3K5L/''P _ IGPSCV1#G=_(??W?;O=
M4_-=^F60'&>J_N/#7RI'4\?8U\,XB-#?*!YRR#A'%=37QK*DK\_=+RE6G%B!
MC'R+Z)BF]=GIUT,4VE6CZ-*_>N(MHR%T[8NRMF2ST6R2+X[1ZTZ;\*MF++VF
MMZ;:MAI4U*6?9JYT2O:.LMS#YFI66;#RV%MN]D@/K<N-N(*G$MA2BWVC:^5_
M%S:NUME-G95^Q7$2TY:%I(D?FU-MO*EF?EIF9<4RV\EQHNK+"6TJ<0L(2I:@
MF_<4G\>3[SID'-V+[>IDJ43L$_1[P:MM[&9DPCW\O$NJ[!SK499M%-6,8=^R
M<2;QF#MFQ9E<L$F(NDEGY';Y[/Q6V8LK9BW9-%D-*EI2T+-3.F5+CKS<N\)F
M9EEAA;RW'NR<2PARXXXX4.*<"%!M2&T1\(MJ[7VKV>FWK9=1,SEGVDN1$VEM
MME<RR9:6F6U/-LH;9#J"^ILJ;0A*T)05)OWUJY:X2\H?M,V[:TI#6?N#=]CS
M(F586C+XQ]!5U&OP5?M]F1K<7Z)E6\0A9_2M;+)-) 9-W,N#3+EFLC(-P:.T
MT&?SU);23<QM.]9"VV1)I?G95%U*@ZE4FA]0=*RLA1=4P0M!2$I2OZ DI!/Z
M ;1_!_9:S/A0-HY830MR6L>S[7=G%/J4B87-"74[+JE_])#(3,%+:D)#@*$E
M2U!2@?H^[PY_GV]>_P!6MVQK32AU]M<\:X9'./E70]?MEA3C$=!308'AX_D'
M' X1$67><BT/&4.-@R#;J_3H?I.A3>S\HUCB.G/")BM&*:ZA5Y%\H ?U+%BD
MY>+#N!) X[@UYIJ<E9)OM9J898;K2\XH)JJF0!4"M7_*D*4< !45C*V18=L6
M_-?)6+9L[:<S=O*:DY=Q\MHJ 7'5(24,- GZGGE-M)_J6(P*?;"QNX$%*Y3,
MXV]@;<))>!PO?$(M8@COZ1JYL45 &>I" \15623A-0H@*1C@(;\*=J++!HVF
M=>&96W)/A)SR+H;)QJ10$;JU$;NGX5;2 4G)_9>SG0:&6F]I;*4^D@4HM$D_
M-I;(P!#BD*!_4!0TKU=VL<(3LFR@9.R2F/K!(JE08PN5JI9\9.7SDX\*;6->
M7.)B(>7=J&$")MHF3?*J'$"IE.)B@;TR^T-E3"TMB8+#BC0-S3;LL2<@$*?0
MA#A.5U"U&N0)K&/M#X:[7R##LVW9S5KR;(*G9JP)Z2MQ#2$BJG'VK-F)B:EV
MTBI+DQ+M)2!51 K38\! 0 0$! 0 0$! 0$![! 0ZA >W>'5K-"A&!KX&O###
M+=YXUT,YG"G#=PB//U<^SJTY=U-U--,<M,##KOZYXQKMM99K<;/.SOE++4;'
MDF;+78 C"C02A1.2?R+:Y%C4<=P2B93IG40EKK.P3%T5(X*@U67,G\HH:RMB
M6<+6M62D5+N-/.DS+HS:E&4*F)MT'0HEFG5IK@5!-<(\\T^9:7>? O*0C^6G
M_)U1"&DZ8%Q20<<JQI!!W6!V'\5QN&*Z=O?,X20.[QG#)$NHNX2FLO75J%BN
M5SL1VZ1Y6S3L@L=22CX BC5.#HK")"2EHV-9QR3S ;:;:H5:+R)5F\XVVEB2
ME17Y>S)!E!$HP4IJ5*0P ZMM%T*JX^ZM%\7^K?"_X.3>UTJW;5L3ALNP#,A"
M7J)^<MJ9+Z67DRA=4AMAE<P?E!-K[0JF;LK+2[[B'.QPCCR3G* Z_I?MF)FF
M4J9+RKEJC9KC'+O2H336;D(VR3:$ZDZFH.'L$K80>)>D[=5HYY+2'1Q\3-,F
MLHHLYYQ9SLQ)?]K35EIM&6?<4?FGDEQ2%AU;;KB5U<;;<4[>%YYE"EJ 0AQ*
M5U/T?MA(6/M*4[!6%MN[LG;%E2S2$6#(*^68F652;,Q(RSC5R4FIQAJ4+2NQ
MD+0?:8:)>?E'76*)N3:'RK@F_)QXT''QJK9P-'.Y2ROF\;22OHDZR",]$RM>
MC4GK^QGB2*+-V<X\2C6<=,H-G4!8G]>>NAE?1;MI6//)3\C)*;F4A"U30;1+
M"X*=HVXA%5N]F*I"U!*4+ 4TZMHJOXGX8;&?$#969=_WGVBE'[$F%S$FBPWY
MIZU5.O46F4FI)]Y26)+YA02X9="G7)B54MN<DV9E#98NG(4\IM"8&BY*I2*[
M';*V66;G+F'9]Z@'I"TSM#142FHIJ]CU^*:K^6JL@M2<C5E15H?SN=3=OHDS
M5C#/E>F?#_:B5F76[+M%PJ:GV$V?;##E 'Y=2PVW:#1-Y)>DW2W-!8 <:=2L
M!(0X"KYY^+OPTM+8^U)JV9"50-G9J?<?LF8EE*6F0<=!>%ES:+J7&$D=JS+D
MWV7Y=*+KRGD.MM]0,.9.@LU8FQKEZL;PK^3:+5KS$HF4!59HTL\,SER,')P*
MG_ED>+L6+P@IIF3=MUDSID.4Q"^BT)-VSIZ;D7JEV3F7I9=!0*4RXMLK J:I
M6$WDT)JD@BM08YTRZE]EIY'Z76T.#@%I"@#@,16AXZ",J-@#Y>_?_=[M_P!+
MU#KPKT[_ &BZ"<:4[S3W$2INT?:/WZK%>%3GI^],A6(B'/;SSO\ K<?OEAIW
M9=\.LNNJ=SGKY#4]8]?O#K#HQR8VJVZU:SXO.H%Z,[QC5K(W,7> F58)$CRJ
M (#V@XA#[Q#KXBCKF>TB2Q;2GDBA6B7?2<JE "*\[S1',4TC[3^#3B+6^&R+
M.=-]#$Q;%E.@Y!$RM4R4&NG93Z3ED8ZOLW23UHU>H#Q(NVZ#I$WBDX2*JF/U
MD. ZZ2E06E"Q^E:4J&N8O#Q!W:;Z1\8OLKEWGF'!1QEUQE8W+;64*'<I)B8U
M7%J'//W>SOU'(\CGQ_'+7<ZZ]>>D>:H*BDH")R)K"0X)'4(*B9%1*()F.F4Z
M9E"%/PB8@*)B<N\H'*(@(#EAZ^&_6'77='Y1Z5-NEYVJD=8B)/.5DB&00.J4
M@=,JFF=54R*1C@8Y"'64,F00*94X@)A>)QIAQY'/+CN&,.L>J19T%YQ9'Z%N
M<E=-H@8Y(E4BW*<U&.?-GQO.GD]-Q+Q9DF5_(H%BT(R+FH!.<J:3.2*5X@K9
M)6-:WUW6TED!)<"OYRP6UBJ:I2VVM 5]*#VA4MMTMO%2*IHTA:H%2;Q)H1@"
M"#CC4@D&JL,T@I .I(%'S3$#.XER)'%*)U3U.9=()@ "8[F-:'DFI"AU[Q.X
M9I%+W[Q#ZL/:S7;69/(%2?EGE@:DMH*A0<2D'#?QC;]@IX6=MILQ-DA*4VS(
MLN*K0):FGDRKRC_TM/K)TPC2[86E>BG\@07'O%[#PTL1+?O'_-3QVS64 /9+
MH%,(]GR=XZU/8]VZ].LD_J::= W]FI:5:;G!7+2D=[_VB9&_9VS5HA/^A.ST
MDI5#_P#.V&7T))__ ,)P@:XQO?(Y#H$0N9M+7FGQ3DH[CMY*S0K%<O=N,DY?
M)*%'U"7?W;M^NBHE9EQ(4W+3"T[T,N*!SR*4G=6FZH(CY44XVDT4M .XK2/4
MQ30>8_O+MH]@K/7Y&>CDSH1TU69V+=S+)JN_BI1Y'$<Q[E992)E'4'$GF(A8
M3Q\LDP;I/FZQ$4^"I2)J624.,NMMK-5(=:4EM2@E:$K*5@#M$I=7V;@%]LJ)
M214U!2%FJ5)41@"E0) JDD5%<"4IO#)5*'2)K])'U:3Z*[(@BQ:H"92ZLTM]
M>,DU9+.7CVPI$$SBG@DBQ?OG[V13/48]KYHD>U>?O$XXE'9)>-6351)HPHGM
M<5  -&@#Y)4E* BCZC>(9"$WRO%-;V  Q4/TTU*O\:4J:_2,/JJ:"]RF*<I3
MD,!R& IBG*8#%,4P 8HE, B @(" @(=0@("&\!U8U(IJ//>,\\_,4!,5===:
M1^M-V/W/?RX0AJ1KSX^Y/L.$(;OAVCS]?;J*<QA3/K/?GR,*_?(==V4-#UZ#
M4;^C2$-3Z?O7K'D(0T\NL/Q"&D(P%*?]9:7_ )[$?PV6KPQ;5_T*SYQ:_N#_
M *DY=T;"-?G+?]NC_$+JP<B>'+3[^L7AF.8]8J4W\Y2_8%_B*:H16ASS\Z'C
MR\MV%:]-]/+JO1BC<\^\.1U7O[Z"E.?B37OW1;ZZ\#T(:5KF-Q],^(]L,<(0
MT IOZ\O <X0W_'V:<\,,:GPUPUZ$*?;G#3/+[TPX??OA#2HPQ'7ICOY9PAS\
M.?M\7.@&-1IUOP_+K[]>6YSSS[-//3B*YX\J&GXAUUUSAH!3F?WW[SYB$.>=
MV@KC7+2F[EO[MV>CKJL-,\]=_'0B$/5_+GGPT&X;N[NQRQTRRKE#C^_76^+>
MM;]&.K\HLL8 %5HLT1*(AO4<.DSHI$*']X=YQ.8 [$R'./R2B(5)!) &A!)X
M#'SR]XA1H#R(\13\QCS%34_',/! >B C1H4PAU'4WJJJ  ^)"]$)@W]BI=5N
M$8=]>^@RZKQBAO4\NNOM%RY);*.*V*A $09OFKE0 #_LS%6:B/\ NF<E$?
M$1ZNO4-_KH:FH(H/(\2*95Q[XJ6/IY'\>_ESCQQH^27@3L@,4%V#M<#I[_E=
M"Y.*Z2N[N*<YEDP_UDC;^T-YP?5S /#E7>,.-8A!PIN_>,BZM_;K7C^<HKAI
MO-.&="1U6GJ*F$--^-*^6''#0DT[X0W:8=:4X=_G"L.>?KTYX>F8UXGE74&D
M.NNZ&IKNQ.[[PAJ*<!PTSSQ J-?ON0U)%>OVA%?'^PB^W_%CJW_<Z_QBY_;Z
M_P HH&KG6NE->J^,6X:C'[G 5TXYCRPJ(1#?U\\]N\/'J'PTKB>OQG7<<.$3
M3#KK*AW8\8X8>7KV-LW[6FS+CJ2P)7#9"M^#,H)Y#D,5$*59U>ZZYA'D1(EB
M(]1=!.;FH911LNG @HF]EH9U/-HDSB6%C&R.]; VU(61:DTF?<^79GY7Y831
MJ$L.A:5H*U $H0L$CM#5*%ALK 152<9:<NX^R@M)OJ:7?+>JA0@TWJ&B=033
M$ 1S=V.\$[7&V7Y4+"NV7?-E?,.R-C? <3:7-N=YDD+2A)6>7DIC*,M#4O'\
M3:*?0ETX%D.1F=-3CX2L$B&=/JLE,VBPR=VGU22^RVU/V/8VR\]8DO:LG;$S
M:"VNR3)]DI#*$)ED./3*VGI@=HKY<O7ENWBZZE#326&_H\C#4P_.MS"F%RZ&
M@2HKJ"HU60E(4E-0+X& P JI16:GZ\M<@[LL,\<<^JUJ. C.P_+GGU;^[3OQ
M/Y--V7YTA^>NN--8:GKK2M>M(1S'\IQ%-YRGX'AW4HUA6\EF8&2TL\2<KMX]
M%>CVPBKI1NT35=.!2((B1N@F*JZG B02F.!@[/\ !9]4M:NT<PAE<RMG9UQQ
M##:D)6ZI-HR!2@+<4E" HT!6HW4)JH@@4CA_QSETS=B[-RRWT2R']I66E3#B
M5K0RE=G3X+A0VE2UW0:A" 5+-$BE:C\^3+A4*Y7-H&!;2K:;;1.92,4)9HBN
MW1?I-Z15R)N ;.2E<-53E /.&BO$=JX!5N*BH)](>CXT3*INT=FII;"Y9;^S
M@<4PX4K4TI5H3Q*"X@E"T@UN+% XDI6 FMT5? V53)63M+*(?1-)E]IG&DS#
M:5H0ZE%GR("^S< 6A1%+Z%5*%A2:JI>/"?9CA54\U[+MI4=BL,SM+4.%,V,F
M;I$E("ZXSD5'9W(J&Z;SS])RI]&*1#)&9F.*BOG %1^.MGDJ5M+*S*UE:WIN
MUTK*JE14B3=<4M2R25%9>QJ*U!))O8?KA\0)A ^%5OV<AH(3*['6%,I4D@(*
M9IXLI:2V  @-?(U!"B%!P)"4W/J^Q+G^75U]_K]^NP:GE7ERPQK0Q^?O7[XX
M:</",%9WS&IBF$AV%>BT+/DR]OUX''547<';-7TDW;>=R<]/.4@.LPJ%2C]\
MO9I!(@JE;@VCFO\ G"29%-B+8M1-F,)4E*79I]1;E622 I8%5..4Q2RRFJG5
M@5H4H'U+$;GL7LF=J)Y]4T^Y(V'932)NVK00@..-,+66V).40JB7;2M!T?+R
M32B4W@X^L%IAP1RTGK:=I9'%E5F R-E%0%$93+5B9H.O1YC&WJPN*Z\OYS$4
M2I-5.--J$:W](R)1%W(/';H0>K<SF9IUYY3SSAF)DD@ON $(&K<LT04,-#(!
M JK-1*B5'[ L#8^719S4J]*?PBQ!1<OLW)N+:[44^F:V@G4%$U:MHN"BG \X
M&F*!M"$HJRBP:I'93SD1S;'61K'4Z*:0>1L$O'+'DK9<#,7SF-=2C=W)IR+*
M A%9)HZ90B#&)DY64.Q>K= R8)'71PDQ//DDH6H"M$FI*G%7BD4NA9 6I*TM
MI0A;CBD+^D(2ZMO*VG.V'L\Y_#9&Q;.=FVVTKF2J799E90*;0\EM81V2YAY+
M3B'9E;S[#+#;S04ZMYQMIRHV:,R]C.&>O8ZY2&:J"DW64LN-,H1T+9C2<,CQ
M%D#0[I)JBS<N&Y0'_-P)JMGIRG:-I)%^<J!O(S:TRTOLY@I?EUU"@L!8I>N&
MHJM)^KZ2M"U-A7TW@JH'CEAL_;3Z$S%G-6%:5Y(EK6L9;MG/,/J 4V5E-U8*
MAB"^F\A-'%L%JCD;"8(V@$L<0\?9:X]E[!L_N&K5U::2[=/)^P868O>$S>[4
M1VY%:8F\6(](0MGJ3@7#^FH\4I!%*P;.HA??[%MU<C<2M2W;--+[:BI;DD%4
MH\R2"M<J*_S&3>4T/K; NEM7+OB%\.%6J\M"VY:7VH45_P ,M9EMN3DMJ%HJ
M5V7:[:+LM)[0$ F2GTW6K14.QFU*<6F89ZO,'[&68,I2+>-9&-DFC9_'R#%=
M)TR?,7:)'#5VT<HF.BX;.4%$UD%TCG352.51,QBF 1Z0A:7$I6VH*0I(4A22
M"E23BE22*@I(H01@0:CA\LO,O2SSLO,-.,OL..,O,NH4VZTZVHH<;<;4 I#C
M:P4K0H!25 A0J"(YL>5:<NF>SG0'*;M9A'(;4FS8M./D'BT>=E'H9,BEVKL'
MR"J"S(6\ZE#K)NTET5&RY$EDU4U"%.7-62M;;.T:VE*;?1LCM.N76VHH<2ZB
MR)@WVUI(4EQ+?:%!20H$5!!H1D-GF9:9VIV1EYQIJ8DW]K=FV)IA]M#LN^P[
M:\JVME]IP*;=9=O!#C2TJ0X@J2I)22#8>R+4:??IS,458E/2+N<QRUB&3I1X
M+J4<P]X=V9K?I9H_<G<KO)!T="K&?3"IW#HBSI ZRQAD%.FY1LG+R\ZNU4S)
M+KKTJAH+6HJ=4S,]LF:6E:KRE+40S><)4H$I)/UFOTM\>K3M39R7V%58Z$2=
MGR%L/SP98:#4FW/V0+/=L=AQAD-M-M-(7/%EA(0E24N7$CL04VEC//#; Y[Y
MB+(;&+R)05;'9X*2)&/8ULX4?HN5ZW830\=8',?$R<!95V2R[R#?244K%RP3
MJC60L#=X0R=FSK938IG+*G4)GI%#[S)6R4U"BI33B4H=*$+;=*25-J6@H<[2
MZIT*%,AM;\/'?B0WLYMWLY-JV:VEFK,L^>3+3_:(#B$(;FI1\S$FEZ9EYJ22
MXA+4RW+OI?EOD^T:DUMF]K@VM\[7JK=:7#$:)UZY*U.5ER.3G=7"37J!)=]%
M5V0?,$W[=!":;Q\,^DA1>2:K\(.98QK)TW?2#D^ 1./,RL[)RZ0B5FWF5..*
M"B_=:OJ0PM:0H .)2VI8"EE0;<2E*@M:HZE,;-R-H6]LYM#:SW;6W85F3K<M
M(LN(3)KF9L2Z)B?99?4TI?RKCLPTP2VRE"IN6<?<;4RRV-JYNEUC%68]F-EC
M*1:2TS(-<?2=JEXPJ:)+ >QVUM%.;B9HB=0B)[M7)FZH/%>(YO0,:S;&64;L
M2*!L[\I+V;:^SJ+/6E;RT2WS#C=!VR7'DH^9*0:#YAMR8!-?])M*22$@QQBR
M[>M;;#8/XP3&U3#DO(LS%J*LN6F;ROX?-RLFY,(LIIQ837^&3LK910@ ?\4^
MZNX%.J2=B_)B]#_R&L% TX?1A&V0207 (BE^C2>6+XG5P0$1'_)PKI8L&PA\
MGS?H^#>7<.NQ;8U_WDM.H-^]+%W*O;?(RW;X845V]^N%*U$?)5E_^02VZZNE
M<[O:KN:97:4SP\(W];;OE[QW?J]I=_TO5_/6KKT[_;KP[\DFN-!7+)5/?]HE
MS=H^T?OU73RIY<J=V H<:911$-.MVG6!/I"'//OT]J5W[Z8<]U#6D.NO".;V
MW1#]%8*!/@0 \^AYF'44 =PCZ*>M7J)!W=P!,KF+W[^+JZ@'6A;8M4?DG@*!
M;3K1/_HU)4!_^(:=\?57^SM/7[-VDLTJ_P#)YV1GDI_^N,/2[A'_ /HMA7-,
M;I86F!GL38]DS'%152J1#5PH([Q4=1C8D8[.(^)W+-4P]X".X>O6VV2Z7[-D
MG":E4LVDX#%3:0VK+#%23GCG' ]O9 6;MIM/)I3=0BV9YUI(% EF:>5-LI W
M!I] '*,GZR/5.7G&HQXMW#=TBDY;+HN6ZY 417;J$615(8-X'253$Q#D$.PQ
M1$![AU%:9ZG#F0* X5\LL\84SX?>D>W//V:=]#P\\P:<APKG#KKSC&TX[BK0
M:4:R3J*'',&SED[H[D%()U S3IJJLQD:W)JNW;U!.&@D&DO^G+*6C8\IW"\*
MU;R2S=M98\OI0E;904)<^:6IOY<([4.-A0"D.H"4I)<<*F_EU-K4;O:$I!4R
MHTFAK6EP!5^M+IS!!). 315\$#3'!0CGID3RJ^,GMO?XFV/<8Y#VW\O,QZ)U
M&X99F+C.OJG,9)-Q:<LNVKJ 91G2<'^>(AI-P6_I$74PR63.!=LE-B9U,NB>
MMV<E-G)!5+J[143..C D,R"2EU2P/[;BFW=0VH''&N6JTI9:DVW)]X'%+%.R
M&)_4]BD"O]20I.=5"D4$F$O*^;2S=4^4,YX3V(*-+)*MW%$PY44,O9,&+<D.
M19C/VFQ/%H-C)=$KT(RE-M2*1S%,J#!N']4>XN=V"LL%N5LRT-I7@%!3]HOF
M1D5$X?RV&4AQQLXU;F&":&A6JM4UM(MMQQM[YIJS2VI#C?RZ>UF$+00I"NT4
M2$+20"E3:A0BM!A$*WY"O9K4*+C,.:]J;.<@Z(4LDE;LLJ0U><AQ$.HBVB:U
M$Q\FT9J*$*?S52PNP)PD B@< #KRM;;OR NV'8.S5A) NI59]D,H?I_SNJ)#
MBL/U%L$G$UPC)VC_ !*VC>MVW[>MM5_M*6E:DS,MI70IO-MNK6EOZ5*2 D@!
M*BD4!,9;8>1(\F*P2!/_ ),Z+PP '$N_ROFYRL<0#K,81R21,#&[3<"90W]@
M '5J%?$/;!7_ />"D;D25G) Y4E*T[XQZ;#LM/\ \U!.55.OD_\ YE(U7S]Y
M%W8FA6RSBBX9+6'*RBRD3)-LKY&:BU11\Q%9=X67M\@@FF@]D2M0=E3!))H!
M%7234K0[N3PT]\2MOI7%FVFW$FI2F8D+)+:DBY7M#\BE82%+";P6/IH57;I4
MOIFQNRGP_M98;MBQWR4I2F8,G,6P'NU67^S$IV4Z&RXIF7+Q:<;65/%2&2]V
MP9E=%:[LRW#"Z\0SQ_MT[2>*;"]D7:+*JQ-VD+16(Z-:G*4IGU!G%FD=-+-S
M$6,JR=2*;=PFF9NBJ8Q5%!Q<O\7YA1;;VFV:V7M=*W"'%,2*[/M$)!HI0F$.
M/("TT*B$,HO9 UQCI5J?[/=DSS<V[L?:6T-E*:ED.2AGYR7M"RYEY2"I#0 E
MV)AIMT74)>6^^6BH+6TI/T'=*'M7E9MF!V2759X9VZL6F44D9EA6VZ&&\ONF
MR[F;E7\I%1:"+.D(RLG(3@2CXL5%6Z4G@CTF1&S9TL#L^^AS8&W4!*5VCLS-
MJ2D,N/'^)6=BEI+:5N&],EM*&PE!<7+H:*RHJ*1=CYC<9MN0=6AQMF=2VM:'
M4 ?+S*5H4L+%SZ6PL*.( <*BF[0'$[A[._E/-FG.]F)B^?>679]SNDNA'O\
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M<-"A"WI^3E2I:<U)0B86X4I4A1*4D*H"#YGG"TE*@D+Q749$A+3CF!H:$E
MJ",3AC&O,IMO9&A^GCGNS>8]C4L=V@(EFRR<[<P;\N, SXA>Y%S.GQ@W=1Z
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M[BUNA;");Z\]==J#UIP/,>7*/@>.1V;[FYGLCYIN(+',$/,L=GBDFW[ABX2
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M "5+H1WIJK 40Z4ZH'*4^\J8 4@G/"EZ"M.&OV\N/"4HU-"?3[]=]\A$1(
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MKGJ<3]SPTASRZK#3?^X]J\1^(1 Q2G*8AR@8I@$IBF #%, [P$H@.\! 0ZA
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M!D#1S(#QAO=:ELLORR;*LF77(V0TX'5(=6%SEH3"11,U:+J E*EI!_E2S?\
MP\N"0F^KZXT25D^R47WU)=F5)N@I!#;*32K; ))H:"\M7UKU   C<[M]WW]F
MM?SUX^=1O'#CF#A'OR\?3.)IJ &Z3LZN'Q[^+P$-4+T[Z^45 D;\>6G,'JL2
MQNT?:.JZ9>>?'CQZPI3$/ST'/>/ ^?/PSA^(<\\^S2M02#OSRKO.OGEI#KKK
MG&O&U5'A(8,N1@)QJL#P,BCU=9!0L,61<P=X;F:KD!ZM^X1U@MI&^TL>:/\
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MVI9Q"16E0-0,SICC2IW!1H#ZI*47.S3,JV2%/+N A"EFM"J@2@$E1"2$WBA
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M!IO[OOIOR/=G$=3T2>L<\-,^1B&AIRSW8ZGWKW\#"&AZZ\]_I"*^/]A%]O\
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MNV4> U)+1IVSI1BT:^G#OTUF3A)HNH!HUSB)FV4M+=; 2@H02+ZTATW24N
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M49I(3>I>6C"BRFO:-J2:J'Z2<4E)*P9TPAM%IJ;-EPI-R789B4M^)K+&3?Z
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M>T"%7DA-4E32T*0H*4A5TWU!1"*9.=<=><EGPCM$)*@MLFZH?3@0<0:*!J*
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M$NM-%%#R:JO$F7G:*56]>4$MR+:E$B\5*E"HG%1422=6*HS;8ZR%8:K$$(C
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MC92)%RU+-1::U-V:N?DT6@M!(6B15,-B;6DI!4%)8+A20"00* F.'#+:!SK
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MK.MMW#5RZ2;EE5UC*0*JC0_GPM619!T"+/I'+A13=<QC0Z[]-#3$8]:<*2Z
ME*5("DIK6I.)JLC"M /J - ":#' 1YI4?()W**JN19(B3.=<+))]&03/H0%6
MSILB]*D4C<7(K*33$Y2I=&:+>QAC&\_A&BIIPQP'VSW@^M<3OAVC8!'9 DI
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M;H5XDI&6%%L@F@W!^'HZR),6K:.:V)I'H%;!O^R?Q'M_9)L2C*FK0LH*4O\
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M-0F7"H%DH93*I2IR:5VREH^MV;4E]M+KO8-!Q+:$$)+04Y:3+.!P$N H -%
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MJYG;RE3MN&70:W5,2:."B1>\'7%U)%<,8^U?A4PC9GX8)M681=[5FU=H9D'
MEIM"PT233]<E),*2:TNJ$2VV,T;Q/E&?(\()EZ..8VK:GB6Y1ZRD.;%U#:,"
M;AW% WR2E*/4(;ODAU;M?0>S2 C8[;EI%:(E;" X(;G)FO< !PP$?#5JON3-
MMV;,O&\Y,3,^\ZK_ "=>"%J53>5*4=^)XQVU$0 !$1   -XB/4  ':(CW &M
M!C,1@:S9=A7\TQIE<8K65T^EXUJ\<-U@2C>C2D6RSIL10J+@S]!5!%9%\<J9
M616BBJAE7*95$AO);(!4HW: \\CRIPUX184Z";J1>J17=@1AD:@XUTYB,S1;
M)5F@L9R9-1Z]<JO7JB7%T0KJ@5--)(3@!S)-&J3=DB<Q2&42;$4.FF8YB!:)
MW9# =><7@"!CF34[N0X#+[91K!M)X\5N3,B#@L>C"ND'*JRB:2Y))258M#&:
MKNGRC=TT42*@"D;&0O1IHF/(RTF\5\S\_<QV MF4^82 ;H0022 0LN(3])4L
MA22+M4-M  56XM1N7U(ZO\-]H&[&>6M/;N3;:D(2VM3:I42C[H#S;<N'&G0I
M2R)F:G2I2@F6E)5I';%AN8Y)03FRX=M9G+\T56JS!H U?Q6\\:\4=#) 5\S7
M:KF;M!17,9R9%98@)].+=PFX!R AK5;(M*<V?M%J;2LLMM*0B982;O;M!P=J
MRM"BE"@I)44%1^ARXM*@L1]#[9;,V+\2]F9JQU2[4ZN>8=?LFTEA+J;/G52Q
M,E/,S+:77F2VYV0F$-5+LL79=Q"VW"#OW7+#&6F(:S42J91HZ*(@54H)KHJ%
M'<H@X3 Q@(J0>T"G.F8HE42442.FH;Z(LRTI2UY-J>DEE;+PP"Q=<;4,%-NH
M!-U:#6H"E)((4A2D*2H_F;M9LI;.Q=N3FS]N,)9GI-2?K96796:8<%YF;E'B
ME':R[R35"BA#B%!33S;3S;C:/W9&4M)5NQ1L!(A$3TA!2S&$E3<0!%RSN/<H
M1LB(E26, ,GAT7(\**IOZKY*9QW%'+2RV6IF7<F&R\PV^RX^SF7F4.)4ZUB1
M4N-A2,2*UQ(SC57PI25!*KJE(4E"O\5D$!7<2#D<LCE'S5Y]>-,6Y%SQC_.-
M(+DC(MCOE>LS/(HI,ZX\>5LTM7IQ9:&=%:R+J%:V"NLY.!\WBU%6S)275(H8
MZL$1LO\ 2FSZ56K9M@6C84]_#+.EI"8E5V;54RAN8#,PP$O J;2\N6F%M/E3
M@"EA@$"CY4G5WG6I8SLO.2HF9AU]MQ,R2&U=F'6G#V9HLH2ZTEQOZ:T[6M3V
M=U6-)/(^"I&KN:I0MGU2.N-@+)1:<ZK.R5E<KOG[A\WKIX.*FUYYU#+MB/FJ
M)6,6_5>.7*"8NI.45*U4;Y-JS;=:FDS<_M"').7+;I8##4LD-M)09D/NLB72
M^%%M:E..MI0E"J(:: 6%PN<LXL*98LL(><"T=J7ENF\HK#9;0YVA;NA21=2L
MJ)3]3BZB[]*. :AD:BXSAJ_E&UDMUD01C12=D:D:^BHU*N03!& .FF)R**Q+
MQF^34>E77&2.<9)0Z:KM1LA\V6].6;/VE,3-DRADY52G1<*ROM73-3#AF 30
MA+R%MD-D([()[( AL*5L,FT\TVA#[G:. (QI2ZD(0+FXW:$5J;WZCBH@9J3(
M*AR)E_6.<I"^TP@4/M'6!<6&VUN*P#:%+4:Z(25'+,"AP/A&39:4^\TPC]3S
MB&D_]3B@A/F1&1     #L   /8'5KFA))).9))YDUCN:4A*4I&20$CD!01$P
M$43516336063.DLBJ0JB2J2A1(HFJF<!(HFH0QB'(<!*<HB4P"41 92I2%)6
MA12I)"DJ22%)4D@A0(Q!! ((Q! (Q$0M"7$E"P%)4"%)(!!!%""#F#J-<CA4
M1B+)^",;9>6HR]MC#$4QY,L9NO!%(0[4G31I2$8QS\KJ(?"[A$$051)#@9)@
M*:Z@F2,J1NHALEB[66Q82;11)/ BU&'&)KMU/K(#Q)<>9*'V^SF%&ZHOF\Y5
M H:%05@;1V<L^TU2JGD7?E'$.-=FEI-;E EM=6U7V@ 1V=$IH=2 1EP&[!%<
M'+:/8-G ,6T61=NS;H*DC&9UE6<<55-,J@,FBCAPHV: 8&Z!W"QDDR&54$V
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MO%C=0D;(LZNJ=4XCP@8B13;^, 'Z%V/!F9':^S14KF=G7YIM(QON2#@6VD#
M5*GD@4QQ.=,?A6TOH>LQ\X!N>;0H[@\DI))T%$G<*[H[,S<6G.1$G#K+N&R4
MFQ<L5'#4X$<)$<I&2,=(P@8O$4##U&*)3!O*8!*(AK0 :$&@-#6ARC.*%X$9
M5%,(L*@XHKU".J\;G5E)A4IDAE'A$R&00-U&19($XB-BJ   LIQJKJ!O(*I4
MA%+5:W%+P. W#WWQ0AL(QS._*G(8^,91U;BY$A)QC*79JL)! KAJJ)#'2.90
MH"=(Y54C[TCIG 4U2$4*)3E$#% 0$!#5*T)<24J%4G0US&(R(.!QSB_+3+\H
M\E^7<+3J H)6 DD!:2A0HI*DD*2HI-0<"8YF;1>SN$X@@R>0;-RSA&KIXW C
MLC!I8T2/XSSQR?@?MWS!59^\A2HH-W*ZQYU[--DF+6%&*6=:9:UDE92.S24M
M)4H&H2EX7T7B1>"DDJ4V0 HGM5.@)0WV=?I'8+;UIM+UZ;>"I]YEIU);<==L
MYP,3)8;2H,+:?0AAB=*W%MMH$@Q)N+?=G1-MM:DX\MUUJ$S9IJR!$5RGQ\HW
MA(FJIN_-7#I$B;EL5N=D_<_Y/,-?-FA2\)$'"BA'+50JB %-JWL[M!/6%-K?
M6I0LZ_<=L^^4I6"D@*2VM5UN8;*4%*P$J5=+:R48QL/Q,^'&SVWUBRUEL--N
M[2*83,R&T_8!:F#?0Y<?FI9!7,V9,(<>!947FVU.(F64I=2DG=>OS\?9(IC-
MQ2IE&;U(5$P4(*:Q#%,9-5%8@CO(LBL0Z2A=XD$Q#&3.<G H;O=G6A*VI),S
MTFLKEWTE22I-Q:2%*2M#B?Z5MK2I"A4BJ24J4DA1_.O:G9FUMDK;M#9ZVF$L
M6C9SP;="%]HP\A;:76)B7= ':,3##C;S2BE*[BPEQ#;@6VG5W+6Q'@7+[FXS
M]DK<DXM=F.E(-95&QOHM:'E6R#L#!$NRM9'T?'3#MT=U,1[IA,Q(/3JRK&&1
MD%7"CG?+)VWM^R$R4O*332925!;4RJ50Z'V5*10/([1HN.,H0$,.(<8=N4:<
M?4V$A&FOV;+/%Q2VU=HYB%A924J .*#=4 %$U6%)<36B@@&]>PIA7R:^'J74
MU"Y&CUI[(2[DHC9H6UR:R$4W9R[>29+5DJL) ^AI%=NU19/7QX][+-">=+0L
MS'+.BF;YNV_B3;,Y.@V:XF7LU*3_ ,+,2;25NK6RMIP311,3';MI6M3C: XV
MTHW4OL.A!"_-+60PVW1X%;RB*K0X:( 6"GLZH1=)H I2@HBJKBTWA=Z.LV;6
M/9LXYB@5LQCFK=BR;$$PD0:M$2-VR)!.8QQ*DB0B91,8QA H<1C&#>/.''%.
M+6M:BI;BU.+4:54M:KRB0/\ )1)P  Q( C--IN@84  2!C@!@!X 4X1<4*U%
M9STY@'HV_P K>/8940$"%#LW\.\3CNW[A*4!_6#6!MR;#,J64D=I,@HH*$AH
M$%:M:!7Z!E6\JGZ33;=E;.5-3XFUI/827UU/Z5S"@0T@;RBI=)%;I2BM+XB[
M]:7'3X:0AI"&D(Q]EJX-\>8KR9?W9RIMJ/C^Y6]P<Y@(4$:W79&84WF$0 -Y
M68@'6'6( &O99\LJ<GY*42"534W+2X Q-7GD-C_WHM/N!IEYTX!MIQP_]Q)5
M[1A3R/U)7HGDY]FJ.=I'1=SM=LMV6XP$#*HWB]6>T1CC?VB"\-*1JA#=Y#%$
M.K=K:MO)@3.UELK2:I;=9EA0UI\M+,LK IB*.(6#K6IC%60@MV=*@YE"G#AG
MVCBU@D'>DC#='2S6H5W>6/#K<1CA6,E#GW<_AWZ=>_[UY:PZ\>O?2/=K\Y;_
M +='^(70Y'D:::9=;HD9CF/6*E-_.4OV ?Q%-4(U[N?VIGU2*UZ=#[[HHVJS
M7QPY9U/6O.+<--_ 9^/I[PASSS[M!P]=YSUSQ/'#N===>,:_UAZN]RKDR^SC
MXT54H&.BZ+77<B\!E"NRME!D;"^357438+"A+I^;$>$.8Q ,LU,<ITEDRT U
M436@RS'7'"*R/I &)S(ICS[LL?:,P5VUUNVM7+ZL3<;.LVCQ2/<.HQRFZ03=
MI)(K'0%9(3$.().$50,0QB&(J4Q#& =^J@02:&O<<MVF_#GEOI((S!]NL(PI
MM:90D,/;.^4KU"F7)8V=?]#58[5,ZKI&T6IZUJ]?=MTB$4%15A*2[:0*F)=R
MOFHI[]YP <5;LXN0LJ<F6R>V2UV;)2*D/OJ#+2T@ FJ5N!5*X@4SI&Z_#FP&
M=IMM=G[)F@@R+D[\U: <4E+:Y"SVG)^<;6I1 2EYB66R5?T]I>IA%\XX)(4/
M%N-H7)=N*]MC6L56"GI^S2S8CV<MZD<T;OB"]=K)C(/WDJ99)N'&L\>&%,3&
M77.8Y_3*!4M)2;<[,!3Z66&W'7W %N/E("OJ41>6I9*4G%:C2I436,5;A9MC
M:"W9JP;-+5G.3]HS<G)R$LLM2EFI><6R>R:2>Q9:EPE2\$--"]0(0 D92Y\-
M>WW_ !SIAN\1G&O=;X:G]_&O7[PAJ._*O1J3X_FJ&IZZ^T(<\_GJ*#SJ,,CU
MKO,.NOQ#4]'K6$.>O?\ </9R.HK7+SKH0#RIRS\W6%/49]"&IZTZX^FZ$.=V
MH  RX<\,N[#UWPZK#3\95.6/#N'K6D(:<3]Z D5W<ZZ>J+:N'_1F9_V0?L4)
M^&JD_J'/KO\ 0Q2K])ZXF+-Q5\SF/]I:_P )75;M< ,#0XG?AY<:\<:TBEO7
MN]XROJUEACURRZW1<AS[/MT!X'=NW\?$C/R#KGY0TK@>&HIY8GSA#2F6E-WH
M=XZPU17Q_L(OM_Q8ZH_N='2+G]OK_**!JOAK@3@-]?:FI'G%N&FM=]!OZQSS
M%!X(P%DC_I,G_L#3^*OJ\C]/"\?&@KX1:7F.7WC/P]H^L1Y_EOU8%:)Y#'=E
MQ]CQPSN[^'758AJKGKO](0U'=QZRZSA#GGD=!X<#RX=V..[DZZZ$.SL#W:4
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M*L0Q!*55,X%.D<"'$IPZ-RV6<,GB)BF1>,'3IBY(JU<KI'QCK2'4W%BHK7#
MC0]Q!*5#)25*2002(S<C/3%GOB8EE!*[I20H$H4*A2;R01]33J6WV5@A;,PT
MT^TI#K2%IYE;1VR^C8R0RJ\&NZ<5\).7(Y1D?ZJPKQC9L[(@?SB3;J(-D3>D
M%DS.U2JF<6-M6XUJ\1A&!5]-M>QBX6SV:B6@XL$*!#Q0 J[BL$ 4605$&\\&
M6TJ#: ?H_8#XBMR_S33DTVEF==E&0TMA25V<'W'6"Z"Q+K2XMQ)EVUI:04!N
MS7+2FG6%SCY1J92+[=*E8Y>4LZ$)7X9"47C6<&L\/"$D6BH*IL4%22(F#TLF
MJD59,Y$A<*'3>)&*1N<^ZSL_M!/6%/&8*?\ A"5MOR1=4RAY)"DH/UI6$O-K
M"5I6$%1HM!(2M4;1\1OAQL]M[LXBS"_?MA09F;.V@;ED6@_(NI<2M\7I=;*G
M9&9ERIAUA3R6D]HQ, *>8;KN[7IYA9H=E-1QA,U>IF,!%  %45$U#)+MUB@)
M@!5!8ATS\(F(82\:9C)F(8>^V;:$M:LDQ/RI)9?14!0 <0I*BEQI8!-%MK2I
M"@"02"4E22E1_.7:O9BT]CMH+2V<MA"$SUG.I0M;1*V)AEUM#TM-2ZU)25,3
M,NXV\B\E+B0NXZA#J5H36]W?XZ]WJ-<-?VC7J 9"D5%G&N79BB!130$?E*G#
M< A_W91W"<1[A#Y(#U"8-^L;.VI+2:5)*PZ_2@90JI"L<5JQ"!6E;U54I=2<
M8SEEV!/6DM*@A4O*U%^8=20"G/\ DI-"\HC(IHV#@I:30&]6C,B*1$4"\)"_
M68QA_6.80W;S&'>(CZMP !0  TF8F'IMY3SIO+6<A@$I&24C1*<A4[R2223U
M"4E):SI9N683<;;&9-5N+.*EK.%Y:SB30#() 2 !;<A>:3$W.#QU)V>'97NR
ML%Y. JKAT!)J6CVQ'RCEZQ9[A,LU;%CG0.%R[TT#E125$JCIJ5?V-6/:;]GS
M%JLR;[EG2CB69F<2@EAAU9;"6W%Z+47F[HQ)"B14(64V7+6D6IMJ16^VF;>2
M5M,%0#BTB^5*2-0 A522*4 -"I-;K41,GOW@/5XAV<_5[M8T@C,$<XR"5)4,
M"#O&HCRU$50TA'.+RJUZDJOL<W.DUH@NKSGRQT[ =&C"&#II:9R)-HH2<:DD
M @HJ=Y4V%C;I@3J*NJB*@\ B4VZ; RB)C:25F7\)6RF9BUII>C;<FV2VLG0)
MF%LD[P"!CC&*MITMR#C:,7)E;<LV!FI3JOJ&.] 6/S'5S$V/HS$N+,;8LA1*
M:(QM0JA0XPY2"F"K&I0$? -5A*(B(&618%5/Q&,;B.(F$3"(CKD]-+GIV;G7
M >TG)E^:74Y+F'5.D5H,BLC#(#+$1ZFFPTTVTG]+;:6TUW(2$C?F (R#KRY^
M.F_,\^/?%<-3U^_5?.$>[7YRW_;H_P 0NJ3D>1\,>7X,2,QS'K%2F_G*7[ O
M\13^7LU2C7NYZ_M]M:UZ<C[<=,_"*-JYUW]>N46X:CB,<NO/$[H1K];,F1UB
M9.4:K*ED:@E*2%5G[#5G8/9J7M*"BS%3'U%!FL4RMC\Z(<LO- ?T=!HMWB .
M2OVS]6'\[<RU,)6IAQ#B$.*:6I"@I/:(-%H"A4$I-0HBH"@4FB@1&0G;,G[,
M<8:M&5>DW9B59G669A'9N*EIE)5+O*;40M"7D4<:"TI4MM2' .S6A2JE&8:@
M)=@P"^1$?(HQBXGK-2;'<(UFGQP)BDC'MVC=P1*7D'"?"XG9.1%V5_(";S<I
M&J28JW0@?U9[JY=4/GNCPE1T-:4QU/XKH=PC)ARUNCP+A5LQ804'%H*N3,XB
M-(BG_5D 029QL:ATCMZXX"(MFC1NL\>N#(MVZ2RYTTS%J2VA2R*)0DJ( *E&
MZ"H@)2"5&@P !-<AH;C#2YE]EA!3VC[J&4%;B&FPIU00DK<<4EMM%5 K6M2$
M(2"I:DI!(T-?V/)&;,@Q*D&W5KF0:ZFE*5W'5D47=UW!57L'G;5EF#+T;'HI
M,9S-<W!**)4/#LA+*%K+9XK+O1*!)I^UU53TW:4T@M M335%LRCU2U9K+MX"
M?GD)%URT'6J_+2"UGL0HK53^8M/:&9&P]E+&F1-N)G;&G5*EYZVI$):GMKI^
M3[)QS9K9I]Y2GI3964FTI5:^TS,NDS[C299FM95ES*,/L-X,1NQ\D7=&XY?O
M02RDTSGLIVV2L:<4[.]\_20BX1OZ-KZ$<Q< 4(YBO%NTF**2*20[DR#KW-[-
MV:)@S<S\Q/S-_M$N3KZW0A15> 0V+K82E7Z4E*@D  9"->FOBSM:JRA8=E*L
MS9JR3+B5<E-GK.8D53#8:[%:WYI?;SBGG4$EYY#[2G5J4I69$;5M;#"OIF5K
MK61;KS4&BP<2T<03=.Q1DR**L#K )0)_E":1E"@0YC%+P&.4@*)\6>P.ZHQQ
MPIKN/ $CGG',^._CX];HK'?[.WM[_L'L^_3?OIB,=V8T.0&7K2&G/++3S&?I
M$>?=[0_GW:8=^1KXD8C&N[##$91'7CR/['.&JO;AUIA]H0TA#GX^//?J/Q3'
MQQWBF7GB:/S^-W6D0]OKY^K3B>.>&M:9[MV=*URB>7#KOB.F)W4PTQSKKEZZ
MQ$--?,8<Z]8=^,(<\^[GKU/X\\.OWAUUX]80U&._\<O>OEE"+:N'_1F9_P!D
M'[5":J3^H8Y$;QCOP/AQBE7Z3UK%FXJ^9S'^TM?X2NJW=.1PPQRKK36FG&D4
MMZ]WO&5]6M?'EIGQH.[&+D.>?'MTY>--.??A^\.NMV4/MT.F>G/]M3RW0\H:
M:8XG#AC7#KP&D(KX_P!A%]O^+'5']SH?TQ<_M]?Y10.>>?9U[M5\]X/MO([L
M<<1B1%OKKKGA6'//5H<B< ?+E7=7OQPAUUC& LD?])D_]@:?Q5]7T'Z?^\?,
M)W]"+2\QR]S&?A[1]HZ\XR'(4%*8_G&IID<.-V(:G'OIGD-<=>&_D!FAJ<_#
MUZ[N^$-/SOIW]<H0TA#4##AIIO\ ?"$8[RJLX"BS<6R.9.1M/F-*C#D_YQ.0
MND@UK#=P0 [V8RHO3&W[B)MSJ&$"D$0\%IK*9)Y"31<P$RK=,PN:6)<*'_1V
MEXG&@!.58VG8MEMS:2SIA](7+64I^W9M*OTKEK"EG;6=;5P?$IV &:E.I2*J
M4!%!R##S[249550D,E6KI9L>P,,1B9V,H>&I /KE+$?(*;F[%LWC*\K#*G3.
M]))&DVJI0BQ*9JOCYAIT/-R]&PS,S$FTV$7NT[.5O3+H4*@)2EM@MD@JOWP?
MH_2=GL:>D#9\W:X5.+M*Q;*VAGILOAGY83MN_+V')J8<3_,?<7-6DB>2E263
M+"5=0?F@0ZG,6L_KZ8YYUPX=91R^,89=Q17LPU!6K3BSV,=M7S2>JUHASD0L
M%-MD48ZD-9X%T<IRHR$>J<Y%$E"G:R#!=Y%ODEF+URB?PVC9[-I2RI=\$8AQ
MEU! <8?16XXT2,%)Q!K4*25(4"E1$;#LQM)/[+6HBTI(-O(6VY*S\A,55)VG
M9[]!,R,V@$%33J0%)4*+9>0T^T4NM(4.6F4J/,4U^JCF=DA19@5NB0R]%QKU
MQA&_\1BE1DIA\R3>.,3V=V B:5B[01&%6=IK*P\I))K L7FEH69,R#BA.([-
M-3<G6T*,F^, %+4D*^5<-?J0[1)-;BEC&/K38S;F4M&6;183J[7E$I!5L\^^
MRWM58P )4Q+,O+;1M#(-4I+O22C,(:4A,PVP4]G&+JI0,UTQ21=XA<4J[4J>
M?.Y1Q7G-DB)6N)R$@!#2$I5YZ%D'+F,2E3I)+OXF1C)&%=. \Z.R36*F*6!>
MLYQPJ4RIM25FIHM*T46 %E!JH46 F^A:%-K*4J6E5QN[M-IVQL?:BD+M28GK
M)M%E#;96Y9\[+3-UNO9-33#DN$N+9O*2V\P\W,-!2T-O!*EA5'MT3>K:NE6\
MSWRAX^A))5-%UCC&\G)9'RK>"=94X-M$0*3F><M')0*U6;Q\<DH+551JL]09
M*'1UYV;&H^DS+X6LJ'9R[5Y]Y9&"0EM%YU:@,$FAN@T3<H"*96U+&LYI4Y8<
MA/VLZPA2Q:EHM(L:PI"IJI]^=GPS*L75?S"25WW %!)<^N-\L+;-3^S! R.0
M:DI1,4UQTQF*KA^449N;+<IJ.%-2(M>8O1ZBT4W9Q I(NJYC5DLZ9L'I&[ZP
MJ>=,4(9MT>Q=G5K4U,6@R&6&REQB164EQQ:?T/3=VJ0E- 6Y8$@*HIRA3V8X
M)MU\3@%3<M8MHIM.W)MMV4GMH99+C5GV7)N IF+-V92\$OJ6^"IN<MIQ*'76
MBMN4!0ZJ:7T1UO&1TQQ-,,=3R\P:9UCY^AH*]5]\M<.664(:$9G+CPZ[JXTA
M$!W=_9^ ^(<[O9OTJ-=<,?<=W=K3&)%=,_<;CU7G2(^K34XYX];_  /$Y1'&
M'/OY^K3SQ\*Y#K+EDZ\.N^'Y_ESN'XJ\JXX8Y:<N.!QP$/Q^>JC[3"']_P#W
M?_[:H7IW^T7$:]WO'@;M'VC]^J^CGX#AAY98UBW$-3]]:=>.,(Y];<UGW)46
MFI*C\M20L[](!Z@!,GHJ*.8._B%69 ##U!P" =8[]:/MA,X2<H#JY,+&&E6F
MSYN_O'TS_L[V15S:&WEH'THEK(EUZDK5\Y.)!T ") D9FL;)[-U8_17#-*:J
M$X74K'FL;L1*)3&4GU3R3<#E$ ,!T8]9DV,!NO\ J.O=V!G[!E_EK*E$D8N(
M,PK3%ZJTX<$*2#7=RCE/Q4M?^,;>6^\E5YJ3FA93-"" FS4)E';I&!2N9;?=
M!&![3"N<9DDXQA-1LA#RS1%_%RS%W&23%P7C;O8]^@HU>-%R;PXT7#951%4N
M\.(AS!U;]9I"U(6EQ"BE:%)6A:<"E22%)4#CBD@$$^&<<[(!!!%010@XU!%"
M.1CE;Y)FP/\ "<SM*>3FNCQ89_9:R1,6C$9WQ_\ *+'L\92D36JK238YOGBT
M5*3*CB>52$4(YU;HZ'*(J,E1UNVVS2;1:LC:R72.RMJ4;8GPG)FU9)'8/(/^
M(6AJC0.*TL+<- H1C;(66%3-FK)O2JRXR3FJ6>-Y!SQND_53 7P,Q'9D[ILF
MNDV4<($<K%,9%N=5,JZI2?KF22,8%%"D_O"0H@7O$-:!0YTPWQFZC*N.Z/?2
M$-(1(2<I'0K%>2E7B#!@U*4R[IR<$TDP,<J9 $1ZQ.HH8J:9"@8ZBABD(4QC
M  R 2: 5)TB"0!4F@XQ1G32NWN%1.1PC)1;HR:K=ZQ5((B"2Z9U4TUP*8R7&
M9'H')  BZ>X>$4'*2:J5IUE+@N.).!' BA!I70*I0TTQ!!H1[)"T)B0>$Q*K
M 5=6FBJJ02I"D!2D@@**+Y4D*JFOTK2MM2T*YP;0FS>YGTBJOH9:1>1*TS+Q
M;YS*M7:\THU;LY'S,Z:R[<$V#1XO)H1JAB-W,E(6)&/.S2%!FR=Z=:EDK<Q*
M"5([5:%*<2HN !*[N)%$I5>""0DK6\$%(HE*OH_8/;^4EREKYAIMA_Y&7F&$
MRCK3<B7''Y83"5(0LKF'F$RZII(4ZS+R]GKF XX%O/,Z:8\R?)8QMC"/NK%O
MZ0F)=_%FK4<$A'G=LQ3;@S,X3<-A(A*-':Y3MP<@B9PD<C-1T0SE54F/L6WY
MVP9LEM:T=L2T_+I% XFB;A4AU"T)>;5BA12E5TEL*2%DQN_Q ^'-C?$:P5-O
MKEEN2@;F[+MAVCWR[H*B^TE^5?:=5)3;*5-O(;<6TAQ*)GL'5R[:(Z;PJL/*
MQK"8C$DSLY%J@\:J'3W*]$LF!R@<JG$=-4@#P*$$>(ARF(;K+KIHM6:G64.?
M-.K:=0%@!5P$* -%)1=%16A20:&HCXIF=F)6P;0FI!ZSI=F<D)AV6=)2'BEU
ME90HMNN7U%)(JAQ)%])!!H8K@!O'=XZ\\78T'\H3EU6BXEC*S0;A,LLT3>0\
M9-*;4JE)0))>3D)B7EWE=_2F/DXZ2=J4Y^_J,F -6OHLD_+Q;2$?R!X1S+L'
M?6/A18";1MEZ<M*18=L)BS+65.SDZU,EEIMEAAN9$FZRZTA,\VW.M&^OM3+L
MNN/-MB80PXCGNW5J]A)-RLI,N(M%R;D@PQ+N-!U2EN.*9+Z%H6KY=3DNKZ1<
M#KB$(4LMJ<2OYY+1:MK20OLA;;!8\VO[[!R+EBM9&,M:WCR&>.F3>PK,(F6@
MW"C*-:+13=G-(,85=".-$-FC]JCZ/005)]3RDAL<U9R)&6D[!;LZ8;2L2BY>
M40V\A*S+)6^R^D+=<#JULK<?27>V6M"SVBE@\7>?MM<RI]UZT%S3:RDO)<?4
MMM12';J'&R0A)0E+B0VH([,)6D7 #';GR=>;KG,SN8*+M$WJR(YD"Q4DJ-?N
M4I6TXR7\_I701@UMBTCFSTMI/!U 75C21EGK682%G,#'I32DV^?_ #Q\6-FI
M%B5L2T-E[,E38:96T"N9D&9HNRX;G[[OS3BW5-F3^8GKDL2RVN745L=JJ7$N
MTUU/8:V)@S4_*VO./">6[*A#4RXS<=*I:C892$!?S!98O.T<4'04K*.UOJ7U
M:$-P[M<'CJ^<0TA'+R6;?\K7RHV,,>,P](8IV"*T?,.1%R[C,'>=;NB@ECBO
M**I](11]7&:49:V)]Y!0<1=IC7 IJI]&KT*13_ MBIV=7]$]M4\+/DQB%ILN
M5*C./#(A+ZRMA0.:5,.)JDQ@GS\Y:S30Q9LY';.94,RX*-IUJ4"BQN(6#0@1
MW#UHO77CI&5B'?SN[_CU_5Z]0!SPINH>7CCEC$Z=5T^V'?PB.IZZUZY1$>[7
MYRW_ &Z([_:H7OY[M4G(TRH3XUR/MQ$2,QS IRIUXQ4IOYRE^P#^(IJE&1[L
M]>'KXQ6O,==:1@3,^>L8X!@8^PY-G5XEK,R Q$$R81$K.2LY+= =P6.C8^(9
MNUE%S)$$W2+^;M2")"JN$Q.0#>.T+4D[+:0[..%L.**&DH0MQ;B\[B$(!))W
MF@QQ(C8ME]C[>VQG'I*P91$RY*LB9G'7IF7E)>4EKX07WWIAQM(0%')%]P@$
MI0H)--6;7M#6O+%*2DX''^4\9XY>3"L-*L[+6C0^9,RMG:+%*-HV':VW>.%X
MUI;S/G;6P9'<R48O38%LYEHI=BZ*O/UO!S%K/STN%-RLY*2BG"VXEYHMS]H)
M4$A$M(- DH2_>4EV;*DEAI*EH4E04XUT.S-BK.V=M5;$W;.S]O6VS+)FI=V1
MGA,[,;,+;6ZI^UMIIY;;:'W+,#3;DG8B&7TVE-K1+3"'4%$I.[ X.P\YHJ/Z
M1SX(QLN]A(R&KV.X1</T%P]4VR9'"5&JR"!4&TS)$>G56M5^<LVTI<)%,CD&
ML9&HM(U+*V9(&6';.FXM;2&VI1M5)>19%%?+L!-T.*"JEZ94D+F%_5=0@)0-
M+VMVF;MA0D90&8EV9N8FYRVYMO\ [7VEM%PEM5K3ZUE;DJP60E%GV0VZMBS6
M%%LN/OK=?5>MBS3C.KR(0\C:6CB:%T5D,/#HNYV23=BH*9FZ[6(0>';+IF >
MD1<=$L7=NX!,)2CE;R0<_73KK"-,NJ(RXC+KN/=K%@OE;)>;*5FHU3C+-$']
M(0D<Y LI#XZC79DDFEGMJ:"ZD;*9&?,P>.ZG!HJ+LHA$X+N5>$%)!>@U*AOW
M;MU>-!7'<.0G ).8&IU)W##]/$ZGF#FRM5.#J;5TA#L6[=S*.S2D]*%;-4I.
MQS:J"+=U/3SIL@@,C+O$VZ)5W:Q=X)I(MD2I-4$$$H;9::*^S0ALN++KJD@)
M4XL_J<70?4H@7:JJ:!./T@1?F9Z<G!+IFYE^83)R[<I*(>=6XB6E6B2B7ETJ
M44LLI4I:^S;"4WUK61?6I1J$S,Q=>BWLU-/48^,CTA7=NW!MQ$R;P*4I2E Q
MU5EE#$2002*==PNH1%%,ZIR$-=RJ=/  5.5*X^M>Z/-GAF>M^X=V'?&L5<N4
M-C%_;9ZVDEY6[91L2UACJO7(9]*V-M6&J"*5:BI)F*3<D?(LF3P>F9/'*2B7
MG!$R H8BAAMA5*DXD\?7=PU'"+A%ZE,A7H:\SES,;&5*>>6:#;3#ZN3%57<J
M+@$//)HHR:2*2QR(K.$4%5.@\X3 JH(J\"R>\Q#D$O"H>L&M210X#CO&[,G=
MCQTMG#"M>66/=NUY;HN7QYY\/J]\_?GSI3+$T/?7,F(W=>/KW^#3'AQ_?AR\
M(0U/'#UPZIUC"&H'B<_'=N&Z$-3UUNA#\N?KW:C#3304ZS!'CW/SUW5B'/7O
M'U=_/M[=*=''+GCC3QQQUGK"@XZ=<LHCJ>MV/Y/C$0U'+#N.?+#\\-46I=5%
M25F4!-NHOTB()J=%PB**8G 17.4P@)DD^$.DX-YB%$3B' 4XA4@?4*[Z_;GO
MQ.>&ZE*_TFE=/SW19F*U5."51!NJ*0J(*F=;R@@4X$.4J'6/$=4P&$^XI1*0
M@ )S%$R8&K<QIC4U._QY=4BEO7N_;GUKCE[ZN?M[.1U:QP]Z<>&=,33#<:5B
MYW[^M,^A$/'N]WA]?W!ICCF!GEGAQKECA3=QK/GX[^[U,1TPH>>.F1QQ&ZGE
MG$0TP(X4\CPR\1"*^/\ 81?;_BQU1_6.[6O]._7WBY_;Z_RB@:N===:1;B'C
M[_Y^/9[NK44S[L?N:XY>'.)W>'6[/QQC >1QWV=, $!$&+,! .T#"HL( /KW
M" ^P0U?;_1G7ZCY@>7=S)BRYF.7N8SZ.\1'K[Q]6_KZO'=Z]><99C :\*9XF
ME,CKRB]A7\U]*5X:<X<\\^_4Y5.N6F?B-37.N.>41^>NO*&@KF2..XX9C&GE
MPTK"&E1CPW8]'/"$--:4PIG7RW]\(:GKKGRA%AV%/TA?,2Q*@;VH6>;L3@G6
M'2&K]2F@8$-NZA!*3DV3P '> J-$S!U@ AC)TWIFSFB,#,.O*&_L99VY7'1Q
MQ)&8)0",*1M^SU&+&VQG4_ZHLB1LYM7^(M&V9$OJ3K5<K*/LDX?0\H'/&>M8
MB^S!56QQ 4*_0;3*D3\'\].5Z,;N/49%C%2J!!ZODO50$>O=J/UVFP#DS)S#
M@'_.ZZRV#W(0XD8@?68-'Y?8JTUIP7:.T5E2JE5SE[/D+2FG&CP7,34HZ1JJ
M72=(N[L]?LY^KVZR>-*GO ]/VS/"-0SX<^N^&E>_U^VO#OT1YJI)+I*(KI)K
M(K$,DJBJ0JB2J9P$JB:B9P$AR'*(E,4P"!BB(& 0ZA@BH((!!%""*@@_JJ":
M$&OWK%25*0I*T*4A:3>2I)*5)4,04J&(((P(I30C.,$S>RULVV)ZI)3&"L4O
M)!<YE'#T*-7FSETH8=YE':S1@@=TH8>L3N!4,([^OKUC'+$LAU5]RS))2CBH
MB6:22=ZKB1>/C6L;=*_$+;F2:2Q+;7;0MLH "&C:TZXVV!DEM+KRPVD;D4'"
M+^I>+<:8Y2.AC_'U*I*:A>%8*I6(6 ,N'5O%RI&,FJCDQN$!,=<RAS"&\QA'
ML]4O)2<F")65EY:HQ[!EMLFM<RA(*LM:G#&L8>U-H+>MQ05;-M6K:I224?Q&
M?FIM*,:_0E]UQ+=*G!  %:  1?GV!V\[_M\->H[_ ,$#O\]>&HP_F<NJ>6^&
MIZ].AO\ 1#G[_OU%>-"!C7*F^FN6_"N.Z'77*&IZ\.L80_'485PIB<3Y4YY#
MO[H>T.=_@///BZ)&=</;G77#-U3>.L^J/#G=I2FF!W&F_CIAEW9 0W]5AH,N
MCSSK")AON^7O_P!7L'=]+U#JA>G?IR\OSW7$5QIPS%=_$1X&[1Z^\?OY]_UZ
MKXY>&M.>9W9UWXQ;[NL>N[NB'?SNYY#OT_/+VX>QSAIU7KHZ1R2VA7+C(^T8
MYK3)45 )*5JA1QRAQ=$<YFR;PH@(B  A,R<EQ]@ !1,8 ^4.N96XI4];JI=)
MJ XQ)H.="2D+X8.N.$Y#EC'VM\,6FME?A8BUGT72J4M;:.:!POI2EU4O0ZER
M1E)4)U)4  <*]96K5!DU;LVJ8(MFB"35LB7]5)!NF5%%,H#V%33(4I>[< :Z
M6E*4I2E(NI0D)2*9 "Z *Y4 &E#'Q<\\Y,/.OO*+CKSBWG5JQ*W'5EQ:E$9E
M2E$G6IB8]7V^[[??V:JTH=QQ&',\#4UBUQ\O'RWY9QR(\HU4KA@'(V'?*88>
MAG<S9=G@IJ=M"U2+#<ZR'LS6%Z<;$F<@ *:KVCNWSR89.%B=!'%??I'(*"SJ
M:*6M[V3?8M.4G]D)]Q+;-J_\193Z\I6V&DCLC71,R$A"P*7RGL4B\^2<3:*5
MR[K-ILIJJ6^B80G-R56?J&ZK9)()RJ%DD-BG0^3C(#:*J%$S?AZVLYJ%M54A
MYVK22*ZJ+&7@WY#2D:Z:."AT\7)HB[42=-'*2:K9V0S5V5B[:K@;2GV7[/F9
MB2FVE-/R[RV7FU?J0X@W%#<I.%4J22%)(4DJ208RHNS"&WV5A2%H2I!QQ!Q'
M(XX@TH10T-8OFC3^08I@K%WYE'M%V9BD834W*D9ED$0 P&04=LVT@T<.DMQ!
M*LJL@X714%04G2B#A37G4E!-45(.@%:'3 T/6!$5)4L8+ &XJ-*@:5 (KQ//
M&,KQ$J,JD*Q6Q2(@ @#M!_'R#%=4IS$4(T79N5%5"$$HB)G+9FIN$H&1*?C(
M2V137NH0>_#W,70JO+>""*Z@4Q\0.Z+?O]=D;'#,T8H69GT7.14XBTD3'(QD
M1C%Q5,P=G3(H8B3@IAZ^C,43D(4_ 4PJ$J0H))K6A!22,Q74<8AQ)4!2E00J
MAR--#SK[<8MJLTM99T><6)8J*[],F=259AIY!:M2KELHDIZ0(@5J8?-)(  C
MA(@M#*E(=,R12\*AY4O"Z+JQ2@44D*'"M=/"*4HK4F\@UQ"31)IKED8R--P<
M?8&0L))(5$!424WD$"*EZ-0IS%(IPF,0JQ"F06$G"<45#@0Y#\)R^=QI#J;B
MQ45!PP.!QH=*BH-,:$T(.(R$E.S$@^)B64$N!*TX@E)O)(!4FH"B@D+0%53?
M2DJ2I-4GEEM(X@EZLJ\M%>KII"VMSO'WIB3=>G4SL'B3*.0E")E8.GK$J<XY
M\W=R:DA%.0;.F[,(M0H(.@TBV)!Q@J>::4IZI4IQ2BZ"A00@+I<4I-UU1!6I
M;9HH)[,X*CZ?^'FUDG:Z&;-GYYEFS[B&I>5:8$B6YMHS$PJ6+G;M-.=I)M)6
MB6;EYILK:<>,TDWVC:^S+:9R)(E2[S8HQY-RS7T@RC6+HSMO'/BF=KK,&ZG$
MH#8SF+*V=J,Q.#<'*+@[,-ZQ^E].S<VMI1DIF82M3R>T91>*@A8"E+0@DFE]
M%U=S 5!*?J*KV$^,^STO/2R-I['LIQA$@Z92U9H-H:5,2[A9;EII] HITM3)
M6Q\Q0N=FZTEXE#;91N: [A ?#6Y1\X1S<\I-B*(GL90V5ZG$22&=:S>\7,J/
M;(B(?S+P%(Z=GDJY6GKL$WC&JP[N?N#AVVDG"#.+D;<-7CYYV9,T>JR[-\(+
M??EK5?L6<?95L_-6?:[L])OO-2Z/YDO+*F9MM'T.3K[<K()0ID*<=:DA..RR
M!=="^:[?V6VJ5;M*7:<%I-3,BW+OMH6Z:)=>#+*C]2)=LO3"B%D)0Y,%A#I-
MY!3P"=9AVD*C:YB%>SEOKET<S3L92%=5YM&3Z$O(0S*KN6"44M#HO(TB\3&Q
M# D,Q;M60'AX)R@S*\AHIPT^GF[)V:G)-F8:9DIJ1#".R?;F5.RRV6WW)I#I
M>2\6W2EUQ]PO+4M9#SZ"X4/.I7QU4]:K#[C:W'VI@N*OMJ;"'4N*;2RI%PH"
MD H0VD-I"4U;:(3>;04]C/)I8=?2ULRME7/4!9G><("Q4TL6ZM5<E8A[4 &B
MJJ(']-^;L&ZDW.U2Y,4Y:I@=0T?#)PSJ>8D<OV)6_!/B_M"AF0L>R-G9N318
M,W*SQ?1)S3#Z)[_M!((,O><4EB6G)!TLSE ''U/IEG"EMZ]TK8.RE/SD[/6H
MP^;08>ENS4^RZT6"9:H/:@(!<<8F$!<O_0WV:G456BG94P[QWAKYVCL(% !N
M%(UBVO=I2O[*>"[7E661)*SR94Z[CJIE!51Y=LCSB:R%5K+-NW'SMP5PZ34?
MRH,RG=-X*/E7C=-59N1)3.;.V*];]JR]GMGLVB2].3!H$RLDT09A]1/TBB2$
M-WJ)+RVTJ("B1Y)Z;1)2RWU8J_0TC5QU5;B !C2N*J8A 4=(J_DWMF"P[-V
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M*25 D)4ME*4$I(0;ZG%I"EA%RZI6.F+10RZ6D,K?6BA<",$HJ!A>QJK$$BE
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M%VA+>_DMG')<JNX=1FS[DF>75>RF'[G+.E%!BZG+N15=0LJ^5\V2$?TC=+G
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MI-*+/6M0024EPOM(64J*5K_D.$(2I5UI2@A=P@XBUTN%ME205-(<)= !(%0
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M@I4#B""*@@C$$8&*%*2[TS@S)$C^/.0BID4FR3%Y,2BA#&32\R1$)%I'QAE
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M>8B*]%OIN?E8V#A8QN=W)2\P^:QD7'-$@WJNGT@]50:-&Z8=:B[A9-(@=9C
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M""\Y<2_+)F[B+SA6VMQNI#P[2KM6"/T8*H:!!-\A38-U02 HH66ZF@ND)/\
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MRKOQ%>[F-*0_'O3KQAIW$X#'#CRQY#="&F.[#PW>V.'+ C%$TU']?];^[V
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MVIV:1L +%MJW+)LUUJ9M625+VC:$I*.KEIM1F.U0T^ZA:V5?..-A824E;;B
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M/OW:5_8C$ZX5IURAUO\ 2L--1W]=<-QHAIOSIA3TXGQ&=280TI^:=8:^.!A
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M-WO_ *>^%U/^(/>JOKK'BXQ]5UD3))L3MCF$G]<DZ=&4(4JA3' @++*I;SD
MR>\Z9P*!Q, <0 (2%+&-XGA04\@#Z1!2DZ4X@GW)'E%TL6#.,;)M&+<C=NF
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M/VG-JOS5H3DS/3*\3>>FGEO.G'2^LTW"@W1K1M$56[3\C95*S5R3J#K9\R'
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MEZ7HQ,%2,,8"(E\W#J==%YT +:R0M>T1+&3^97\M\@;,[*B:?(FTA:_85NU
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ME#;GU*2!]0MK$NQ,'YA"$LAE*9<K1>910J+J;M%)"U52:D!1 H":T.</([Y
MI5OJ^V/ 8?B[)6]GRE;7UI0P%3K-%35?4J6.[;CG&]U!C6JW8$V\G6*%/6&=
MG+S2*ZJRCR1L%;6_1,69%P;(^+;*7>:=L9V<6TY:#]CM&T'FE-N!V99F9AJ^
MZXW5+DRVVA##[H4H*6UFJ[4W)!:5)?#8*6DOJ[)*@1=04I-$I/Z4$U4E-!2]
ME'9EK_VG4(_J^'^MXB&M)77"O'6N[@(]_>!SK[ Q*&[1]H_?JYPI3AYD94RW
M5URSA$/#W\^_3##Q&65*8<,>A#?X=>$!]WMT) KQXZY;QNTW'6 \>4.>KV\[
M],AEZGVKSP\8=8\NJ0^OGJY^OV:@5W\P=,!A7 X;\>.,.[K'KNYPYY^W54.N
MO*'/(]FHKI0^>>X$Y^6E.#KH9PT_'6>GYQA#GGG[-V@[^\=:X\-P%(===>=8
M<[N[GGPTIUUPP'G6'5=>NM\--3UU0#7A"&FX8Y8=#GK3&E*PAIE4 5I7Q_.?
M#AA"&G/RQKGIB?W J80TJ._#NK@*_;[PAW^S[?9S]VHKC0<<<Z[^-!4=XIA3
M%[^7/KUAJ=^6/$UIA7+A]N:&G'OP!&>&._VX0AI2GV'+PTUA#ZON]_;^?JTU
M.&=-VG?EKW^#O]?#+\<8?C]_X=0#SVM>9]L*=P-1QSWO;T]\2.LFG'4@8$[O
M'?H,^<(:>6?COW'4X@^L(<_GSNT\_#+#H_L(=?CJL>[7YRW_ &Z/\0NAR.>1
MW[OSU2)3F.8]8J4W\Y2_8%_B*:H1D1KR&1PYT&O[Q6O,===<(HP^KG[0U7CU
MC]N!/>!%OGUY& <^//\ +=U:8UII3OX\_("L#UUUOKC#4]:;NN->$(:<-.L.
ML-T(:@C&M*G?NS_;#?"'V#IZT&//G4Z:YX0\QQB !N]8]7/WC]>H%1G4Z=PY
M=^\X@9Q)-> QZ]!W1'GLU/66-,:='O%3$=9PT[J\-<\"*FE,"?.$-3"&[4<_
M*O?NP]^-(5ASSXZ>N?MPKEK]H==;H:GK2G*$/9J-,-V'6(W;Z]T.<.>>?QTX
M#.F>=-U2<^6<.NNO:'N\.?;O#J^.A/$4W88\,]:CHP\=_7*AQ^T-3UUX<Q"(
M?=_+NW=7?SV1Y#JF!&'7=/K^^M<=.LX\_P _N[],LOMUNUB.OV]=(<\_GINU
MSQRY"FN>NZIQAUU^(<^&F8W'AH3Z''SS,.M\._L^O\--33QTJ._'B<,J:0TS
M[O>&A]?QACOZSA#V_ESU=H_CIEB<*[R2,JG6F_'#[N7YZQR'M%?'^PB^W_%C
MJC^YCU],7/[?7^44#5SKO'67C%N&HW4H?MH=?SCNA#2O77(X\(0Y_#NY\=*[
M\]WEX>FM(=>^O6Z(>KMZN_\ 'X=6_K\-.&>>>.!WY>&&%:5I$\<L=/;[XTPW
MQ'4Q$!]75J#SIQPTZQ'/#&L!QQAIGEC^=XPPR._=AFAIORKUB?M7*D(:=U=V
M&/'K,[L,4-.AKWBE80[?NTS]^O(]^ZD,O6&IZZYPA]NGG3S]!^8>4-1EO\_;
MW]80TKEW'C2M*TH?;,UI"&F->'+&O _OJ.2&@.? TR\-_6=(0Y^'X_7[=/?
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L0$\3>\/AJK4#@?4?>$3+=$@<?:._A[=P_2[.K5M>23OJ?&D34C(TY81__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g210084g06f46.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f46.jpg
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M  (# 0$        $!@,% 0('" D3"A(4%0#_Q  9 0 # 0$!
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D1Z(!&P-$ COT+QBJ59BJ[ T&H; 'R :L7^>EU?\ 99TWZ__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g210084g06f47.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f47.jpg
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M 0$! 0$! 0'_P  1"  2 !(# 1$  A$! Q$!_\0 &    @,
M    "0H#!0?_Q  B$  " @,!  (" P         $!@,% 0('" D3 !(*%!7_
MQ  : 0 # 0 #               $!0<&  $#_\0 *!$  P " 00! P0#
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M9/U^%R<A88WR16]1&GA?DD*,)OHZ(Y)IM$;&]'ST>G;CQ7D^FXCD-^CKR/\
M$^C_ #T4SYN.=<^:O$[@U-"*FLC.I%B856.^6*2XOEG%CJ1_H87KBP!(L*7!
MW]8?^YBM(&P5]$/W_O\ 5I^N:^D,C(EW><Y7M*=5;Y9SJZ)3CKC\BJP5^.SK
MD#K9U[Z*S55HDLJDCT2 2/!]$CQ_70F?XUW.>>W!_4GFW1$VT=E@;3"TXV*Q
M2'-*]@TO 9F*-@)!EMJG!8DL@I. "Q_O&DW@E_>+?;7.I_4+(R%7&BM[+&A_
M<BM7$J:!(YS#!'T0".0.B 1YZ$[8JE68JO('0;0Y 'V =;&_^]-U?DLZ;]?_
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g210084g06f48.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f48.jpg
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M @,!  (# 0$        $!@,% 0('" D3"A(4%0#_Q  9 0 " P$
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3&H; 'V :L7_O3=7_ "LZ+]?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g210084g06f49.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f49.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1"  2 !(# 1$
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M)OZIZ_-?\X)EISE LGKI\*R[6*4JG.*WKH8;JOM1=$ 0PTFI@>\@A>*FWD+
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+[XKJ_P"RS@OQ_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>g210084g06f50.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f50.jpg
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M  (" P$  @(#          0% P8! @<("1, $@H4%?_$ !D!  (# 0
M          4' 00& __$ "@1  (" 00" @ ' 0        $" Q$$  42(08Q
M$T$'%",R4G&!H?_:  P# 0 "$0,1 #\ O7K3W'Z$^53WC6O)O+>JV/EOG2T=
MC$Y%2%-6(81KFJ"-YLJ<];OBU4T2SWDJ=:*?:U]:9-!E2A1"&H R&QW:OF+L
MVO9<#QC8Y-URL6/*W"/$.5,TH7DCE R8L#,CB$!F6)I%0L[DNUJ%10,T\F7D
M"%'*1%^ X_8%@NP!'+JR!=5U[LG.EVN':OB'[Q1XO.?I'M[MG())8;G1>M\
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M7]XM]M<ZG\0LC(5<:%9YEAD/ZD*RN(I*!(YQA@CT0".0-$ CO53;%4JS%5Y
3T&H<@#[ -6+_ +TW5^*S1?7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g210084g06f51.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f51.jpg
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M 0$! 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !@   (#
M      D*!@<(_\0 (A   @(#  (" P$         ! 4#!@$"!P@)$Q0*$A4
M_\0 &0$  @,!                !0<#! 8"_\0 *A$  @(!! (! @8#
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E"/1 (Y T0".]5-L52K,57D#0:AR /L U8O\ SINK_*S1?7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g210084g06f52.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g06f52.jpg
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M 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !@  0 # 0
M  H%!@D'_\0 (Q   @(" @(" P$         ! 8#!0(' 0@3% D2"A46 /_$
M !D!  (# 0                4' @0& __$ "@1  (" @(" @$#!0
M  $" Q$$$@ %(3$&$T$'(G$C,E&!H?_:  P# 0 "$0,1 #\ D.^/R8LW>KMA
M?:I9.QSAUIZ1KS$V*].>BKE^X1VP"V%<1UCPZ)JM?+-L_&O=]7@05]67<85*
M737 LXH4Q8%R==/'I/CD?2]7'E1]=#V7<21Q2NL\D<.AD*EH89I4D6 0HQV8
M)O,ZD$@% F?R<HSS%#*T4 )4%06NK_<P4@ML1X'H CQ[/.8/+7LGXCMIZ-8.
MJW<YNV=8/J+3;;;];W^MF/6:R&G,_I6*32;-UQ<OC:)8E/J[,7=X F1T+<JT
MQ%/="2UA]U6&C6((L;Y7BYL?9=1%BK!,V+#DQSQY$AFCV69\;(2"(@02 (2I
M>*5]T.RHP,69\-HS%.7V4.4*E0%-%0ZECY86?(#**(]CBT-<?,YTL;]>(;:Q
MN\JBPM"8KL5\IR"YV$BQ<W=&#9VB]F?AE!@=G2G$SUN1F$,.).0W,V,4?&?&
M'"NR/B/;PY$\4<(E2*:6-)0=1(B.RK(%HZAP U6:NK/#"Y<+*K$ZEE!(]T2
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5=@:#4-@#[ -6+_GBZO\ *SA?G__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g210084g07g55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g07g55.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1<V4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %QJ^610X0DE-! 0      "\< 5H  QLE1QP"   "YH < @4 &U9E<F$@
M+2!38VD@1W)F>" M(%8W8E]04DE.5  X0DE-!"4      !"PZ/.62GDQX$4<
M>\\:NZ> .$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             #A@  !V,          0                         !
M              =C   #A@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   #A@    !29VAT;&]N9P  !V,    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M X8     4F=H=&QO;F<   =C     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MP  1" !, * # 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$
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M],DDDI=,DF>[8TNB8X'F=$E+JIGY6=C>G]DP79P?H\LL8PLU:UOMM^ENW?\
M05F+OWF_YI_\DE%W[[?\T_\ DD1]JG-_:77(!/1;->PR:=.(W:^?YJ<]0ZX-
MD=(+@]DF,BKVOEXVO/\ H]@I?OK_ -)_P:T=MI$%X$]PW7_JDS66, :QS=H^
MCN!D#PT*-CL/Q4UL++ZC?;MRNGNPZ]I/J.MKL]P+ *]E1W?I&O<YC_\ @O\
MBU=4(N_>9]Q_\DE%W[S/N/\ >@?L4R23,=N;,0=01YC1.@I220
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MJ'-SC?/-]\;#YPZXCLQSZK;S0<MNM]!2O36- J>>_3KIUTBGGG_&-VF'3O\
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M1'CZ[*TMGD/6FO7UWBY_,Z =_M )SCH<P=/.'X^W7;E:'*UB,OGIRTIZ$0%
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M]?7TVMO;.OM7+XY4K>T*'W^/+]NG*& = !CKA8+5MUIJ<\S3<_ME$)YDTRK
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MF7"Q@ZGY= "3,I?5P,MH"'"D<1EN$JBTSG D+_-J)ER&2T>$AWB)'GI2JI/
M4@\1J4T_U@@9J0N'^4>JQC-5L\O(Y=U+5E3]2_)QTK2,)3]Y%;,8!6EJMN%N
M[ISE<U2ZIA\J_C9J7IZJ35"_JB5D$ER0U7MI.5>(+R#I^LM@)_PPTXB73+8"
M[+/(\2.ONNRK"G$NM3\P[@[?F#A6VEQKRPTV"GC:*4@\-!!3,Z4E?'-!:1+!
M"$K70@M#SB02?U!9%2*$*XN($Q]#;G[D[_4>2C\HYR?+P9WE#U1&M+R.4!2_
M)GGZ_K&HYR]6IKJW]V-.R%'-H&OGZAJCJ2*D:Q<3T0P<+N5SNT5GT.4_FH@B
M7SLW/8<<6\.8C+M8:RI4OA[V*LR[#;<HS-(FUI?+DND^4VM+ 0HTN.%"LQ4\
MI#+WD3;*U.JJ74,E:B7%H+=$461^H*-LAF01'RYD[@.6=<I<O<W0D?'_ "C[
MJ*+\GY3#BYF Y/%>U:0EV7+6D8]4]84[?0U93<6^IVAJ?1) 1U-4]+E<TO P
M9)R+I9B-2**\WU*<1P2>G9U]2O#87_V@=$\YB4NR?S6!I(#3LDI2'$N/K/&5
MK0I+BUE"UGRZ \13,PTVE _.$>15H,K)\N8-R'.'A*4@Z4) ).=2)VNEI?EV
MJWN7+M+\FORBCBOG$=R16]'5#=G6K.*Y.,+=4E<G1K._U#E!C4KJ0A5;R?N@
MA72]?#6$0\O-F)4D6XH:2;+EB%S<"<=\/B4GC(?]G#+)7C"G43,NI>)/3AGG
MCARL.#0"_P MY 8_+%AQ,LE/%YZ2 L#8VF:XF0]^<\SAEPE3;@2RE(;'G>82
M31T*K4$!1420H6K#EVEP_*@N(I*OKJ&U&?*+MZ&AN7%6,_RBG-V-2U>YG;R.
M3M,RUYSV[JI^3E4C*H6TM/3$[//Z8F>4+(4&I'5U4;->*6?K.!:2Y6',F9_"
M9]Z7FR]X;,PO F6L,$VTWP2N)(3+"8:Q)HH4VA#;?FHD$O\ $PVI+B4BJD<6
M#;4RR%-D3I0F8J\4&@6T+ LJ%":J%5\(!*0W2@%!TM<C<9R^KVZ_Y(U+7X7G
M<L2Z^YB-H+E%5!5KMG7DE3UX4M3$5?%#2/)PH7E 51%+/6*=ZCVB_,EZC?E*
MI5#ZGXV3IJ2?-G$I406ZN?G_  [)L8P](2F#S<ZI_#FF4KEDN2R'5RBT8D_A
M[*@"95+I(:J0T'%!U"2$H$;FFIQQ3"7W)A#0#BE?K4E12"?+2\<BLDY&JN"@
M)J*F5/DP(_ECP'*1Y0$-?W'\IZHKOG-/3DDRO,O^6KBEF+NM"7HR01<%%7;U
M%6=XUW17[BD'IUV52\GZIV5V[:E(:&C).%-.O4W"/&\4JP=S#<-7AQPIN82Z
MVE4KAWD/*\C\JGB=7,MLRTP$!X%);GFB^75*4E0;3PG*2\\.O>=YRD%!(6Z"
M/U%S]*4I)4FO#Q&K:RD)K4U*>'[I;APUP'+[0QRZ]F5O#C(&F9KG7USVRVM:
MT=CN*Y5%_P"#2_36\'?OV\;-/CG??TJ;^G2]O2\/;;3O7/[6-^[C/'X=]GR_
M;.M>EQ_#Y]VI]_: 1P^WO'LRXUA-^1]#S.F5N?M"E?X]AZW[R8\?#MM36EL_
ML?K_ "(@[^_I!T#GUV4)J#<6SI>YKEZ=UAS%ND&\<.[4>,[,JF@KRS(_?:I]
M8;"OOD.[0L,@]_OXULI8=WYTYW/.\6MSZY?3O*'8!3+*N7SIEK?7E$@TZ>.-
M=NVS+OZ^^>=KB&?+OO+V@VCI[^WOLSVU&8-0*Y^^7.^L-L^]O:#CCZK/K]/7
M*VF]QG#OO]X,>-]G.W([U^F7VRJIWM!9?.E,CUJ,M+Z::7TA!GNRZ\^[Z[+W
MMO2F>=LQ33?:HA;>_2WO^T''NXZ+/:OO?+X=:TJ#2'?U[YP:^[3O"T-Z>NQ&
MQ--=A46O4:%E]<_8P?9LV_7EUVM=<NM/KI7;.EJB'\ZZ?M?I!E[^.-G190:[
MUH37,?R!GE"_T[[UYPNKCV]5G2A.1]O6FQK\:"+U[^76']?MZ]G&%FN8]/K?
MEM$_;O+7NL%@[).=JVN:T^]#G"%KH.6S##WY?9MTL-\CTI?<5.]-MQ[7+,7U
MK7Z7_G3.&/'&=AW[I\:UH/I$[[R@'CCV=.RPWJ+:<^MJ>V<!]^_O\X668_$=
MWU:6'?2M336VGPY9UUBWL/L-3G\<X,,.G341X\ SLN/87.5L]=N0YF%:\L\@
M._B8.K:._P!FN[3KL]:WIG32]*5RVMOG<NN@V^>6^?2':_O^V\2%B&.N>F'Q
M[ '#'*TJ*C?:OO\ *U;>\6AH;6SK]O4BM+P[0Z_#,7R^=*;9@[3OOO>%AK\>
M!]V>W.UH#F+[_8YCGI?6\6N7V['UMI:#3CKQ'9U[>JTY#D3H2-2?[:>E>D,Z
M][4&O33K#XU^WNM3IUO7LWJ10>T3O+^/>"UOWW[7ZPA=6W:'5J.71EKCE;'+
M(6)S'/,Y??VM%ZZ:'KD+\[Y4O#M3KO2VO3UVZ<HD%AT^].7KW2IA!U?"S;+3
M2G\=/3HZ_>%KQGCQT]%F=/AO7.V]MCN-XN7=J=\N</QX^/5:_'O[](GP[^W6
M#CCC?A:9ZG3+Z:?.W6'???6+J08\[7+#?T[@-XX=ML%Z>OTC-)I7*]-N>Y3\
M*Q;/]^;+\(=.O41R[L1'#HMF<Z;WM4;7.7K0UI2,?7W^0%_>PK%(8!F&&>W4
M,NGVCECUV@  --=16FNO+>QWN8&I-#6VF1OR^EZ=(,L>,]>_?MUQM;5_FY]K
MB]3<TUA>G=LO;;3*D''=WZ]O7I8#;EOISU/.N>];@EW[^V7ITSA]73978UII
MSYYD?S$ZP@V[,!'XX^-IO:E"==[D^Q_B*=-:@?:GP@UVX#T9\?$.L+7/KKD<
MNN?(Z$<J0RTJ.=N_L>AAV'EKS(VN".[^\A?#L[^CJVV;GD.@.>?L;BVF<7[^
MOMSZZ0QL-=Z=\P;?+G$$+LQ[NG+7LX&SXC+J<CF=Q2GK4U-+ZT]^5\O7L0!\
M?;GX]W1:?O>ML[ZV).5[?"!^WRM\/?G 'ALXXTQVVM==*5V%-^M-.5Z5@?CK
M7ONM-(,.GNZ^WMWVAYVJ: BMAI7;8^D*\O?IZ>FT/Z_#*UKK>U?KO06H=:?"
M)^WQO"#X\8[< R'7=CE8/N*[[7Y"QKK:M:Q3]NZ:5-]-Z7@]GU;<?K'3/6PZ
M;9:7M87.OK7<0WW_ 'TI^PSME!M^W?B'1UCV;<+-?YWKTZ_8TAI_'0\^@]=*
MP#CGX!E@/O ?#0;#6_I0:&E_0_#(WT"EOB;U'T(^.8A^/'M[MN&ZSD=+UN!3
MKD3OD/:)\._E[Z5W@TXZOB%E1E7NW+^:VTAGWU^QC&R\/$5!&/X2>BXZ;AI1
MJJRDXB78MI*,D6:Q1(LT?,'B2S5VV6((E40<)*)*%R,40' :E:FUI6A2D+2:
MI6V5)6A0-04J20I) J:@BPM2MQ%10T(U!H0:TS!L<A4'URMZVZ"#5!!LU11;
M-FR2;=NV;ID100013!-%!%%,I4TDD4RE3(D0A2D(4I2@4I0"V)))XB:FIJ22
M2<S4UN3O45)O6D9$ 6 TV I?EI:Q%1>FM8O8#OQ'+'QW=?&.-K?J?2X&MNO.
MW,Q*C:@O3X;].Z4AV;4(I?3.O?K$@^OIZMW&VR_*MR *\Z5^.ESEE#]N77?O
M2-&JBM24T];LS1QG@KM@<^4!T"',Q553Y@E%NMCAY(1YW.#[[##+$<TIX@34
MC84OD#E7/T_?%2N&FM:\LO2-T14\JDFIAS?*)D4YN.(ASR@8 QVX8B&. 8B&
M0 %L.5];ZYV-B0-?:PH(ST]NEL]!R][WB[OXPM*YDD;"FELJWUY>EP(FW=87
M5LR''''Q]OQRO2MC?.MJ6OOJ?O6+UUN*4^GR^UWQQEQOWO6MSJ>9IRR%MJYZ
MSON_>VRW:89;=_MZ-]E<LCSK2M<Z 9Z4%Z]16+OG6^FWRY[0[6)"#KQ\1Q'J
MR ,/;CEM@IG6NE<[FFU@+#]M:>E/A8=;DU^5+Z.U_;X=WB0@V;0PUW\>^T&F
MMA??^/K%.NAKEMW](=G+/G2HL<CGESI4Y$'*06&UZ"VVYI4CG\3E6$+#/9T;
M^G/[,LK*7KZWS%KWO7O0"+6VO/;E;^;WAVO?>VD2%AJ.WOTTR[],-<\[8VK7
M4UOGE;WY#.]8M<AI[9YW]LZY6M#'C7Z_9:G?;F;C*_2NQIRK$'>7[?.#;X6:
MFPRH;5-Z4TRSW^</Y@TQX]@=FVRE =OCEV!\] SIW\SZZ:POCLZ^!'W[5.61
ML!;6W+GI\ZW[:].P/IH8[NWH^SHQS#"RMK5.G,::YTWN*^L*;\Z<_P">=+&L
M&_@?#C/*RU[UM?>E\B+YCTT AWR^/=KP\M>OZ_99SZ_ON<](E\NG[?.$/'4.
MWCO#.RH]L[Y=1]:=2!%'?4:=^QM!K]0B ]W3GK[0RESN,JD$[:#G<4]:&&7[
M@$>_*V7R-WQGQCWVO8[SUUUB'NG=/:#JPV<=VEFEAMRVYC(;ZCE#K77OWS@Z
M_#/W?;8"=:>E21E8B_O\(=/C;Z_Q!9\+@Y:ZY?&G4U!-4'N^WV65SN/F*4!Y
M:7S/6'U_CYP>' ?98!3ITU&MM*6N-/=\>S_,+W=&[#3HR]X;!M+:4L+"E[;9
MVM3+F-(OUY[USYW^AU$.UIW7O;YQ(.KIXRZ;-+97&N?H"=[_ #AK?EW?E"$,
M?=T>SX]-AO;,Y]-O7:XO4UH*10:?7G\_MR@]V(;]N_?EGNLM7GEJ=[5]*G8]
M;C\[[?#:]MX--P8>P Z]G ;;2U:T%!D::99[7/( 5R(,,]S7YD]->SI#M>MZ
M[\CGK2U.5= 3$W@W8[?MLV[YTTRTJ*^IAO33^(73VY;=N_,1'X;;2FN>MM==
M#>]<ZY]2;R]+Z:;6 'WTAZVN?+EK2U]P0>\J3*#CNXRL'09"^52/H+4-^4._
M?N\+Q'C'?UX6G/:WQ%:5K36V9H*'*+\!W3;I6#7#7+KX[\=H64!L"0!S-?GI
MS!VT,,JY7Z=^U-##M?7VURO:_P =;Q(6[CX]6.P,<[2F]S3U]LM:$\S< VN_
M?VZTU-+0[4>N?/L>EM8D%E_OUMEV?G"#CCQL-=,\\Z4ZWJ==/O#OOX0?#M[[
M-<QMST)Z5 R'6'W]/:+J6(\[##+#9SM^W =W?;!8K3+49[4W.>_MI&0(%:UO
M3*WR(](MG^_-NYQL0[1XV^VV9MS!-".MOM4?O6?/0]_MZVA696KMF;[5'K[D
M^D2#CML(V J,NO\ -*Y;UAWZ0<<<!8;V]NO4'X6US&3OOLPLM^N(Z[ PV[MO
M;8*7V-2+]*GD-<[U](M]LK9:FNF^GI#]^W[;#\*>OJ*7Z7N<HGTT_B#7HXXT
MLSY;BVN=?VI#+GWWG"'C#7<.F[+.T/.EKT )-":6Z:D>PM6CNN6XK7>]H-=O
M</=WAJ'39GE8T&YRRJ<CG<:USUAEI[CW]CD>4/CLZNWXVOUWKOMZ^EHG?KU]
M/G2#CCZK.^MOA<YYVAWW^\(<@'9AVX=EF0-Z9BPK3G[4MD/:*+D:UWM7U@\<
M/#+3?X#[+2MS;BI4]* 6ZDZ6-\J0^%?C?/;XCYP!WY:CEG[0[K494I6@IL,L
MB-/8BGM ^U\A>WR/O#L]K?QG3.MJ<_2)!T9\<;==MIRTIG>H.=]<J?+4"'.W
M?>F6D'LSQ'=:U]M3MW\/6'ST&\+7J'9ALPT'VV4J+_$"HM2_Q^647+J-:ZUS
M'RACV=N_99?2GSN/;772F6T'KZ;:P<=O5N[;,MK#0G/[7'3.'?IUW](6(!J/
M:/3\<+2VM-,['E\0;6^%[0G(>@Y?:L/X\:8<;[6G?K>PI[Y[Y1/MWG7O:#CC
MJM-M1F!:O6YK46]]='??6#C?MXZK7L7)OS-]?;78.]M.^L+8.&?;[!V<#92@
MM?;33(4I2+J*V]/F->Q%APY;M$3N'2Z3=!(O/.LL<I$R@ #F8PB 9[ U,.1<
M1R"&YH!Q&E4\R:BYRH;;"\*6)(H ;\A;*NON=^?-=83I9^:5=M^=YHW2(V:B
M8HE,**1SB*IBCF7RBJIS% 0 P$,0I@YP#;D(24B]R:DZTK:GI;YYF-"E<1K2
MEJ#]^?\ $3?1\^WFXAL *E%\T12;O43" *<](I4P< 3$!%)? #@8OS0.)D\>
M<00MI4.%2JV!N#>E]KZ=1:E@!6-H(4!J0+BP-M;<LS0TWC;-^O=[,L_&V(R.
M=;]Z@_&AMRC+;+W^=[?"';+O[1(...!M#WGSU&7/.D.^^Q!QGNQ^'NQM+T)R
M)]>5:4S^PK2\.[;T^_UI![^.,+,J4O\ +(GI?*HL+:"D/IWW6#W<=>.'MM?7
M+E4_4UI[UA]>^E*_*#CW=O;9Z9Y4%.5^G,4R&=(=_7T](6[9O^'>/;::@BVY
MH:=-,R:@ZD:UB[Z[??V'I!KOZN[IZ-F6H#GC:C.EQRVRI7XTI8WK>L#;;K[\
MN>M\B+4@#9CKQQJ._/#&T&F=Z&OTU!'*IS)K:L#K3+OO(;6K2#WCW!AM[;4$
MUR-S;D*?"^AH;P^@]S73T^L/CCKL]QZ;GI[];Q.^^D+';LSZ]=,,.S?UV6I6
MU!72E+Y4IOZU SBTO36W3+.M?7;I!QV#]G99;(YTRY'OTAWZC^?6'9W?WUO]
MJ'*D2%LQZM,?M\.NROO2M+\N5=1IZ1=:=<Z?Q\>D,.,L/"S09;Y4S]].Q$/=
MZ_&#CCCVV7T]O?7F2/;G#OOOY0OAIJ ]&?5T!G9EH;YC.OKT%JTK:MXOWSR(
MYVZ\S:'Q\+-*YYFH^'(VM?8>D[^\%E=/N-^1]JUI7:Z"RGOK[UY>E?C4U0NP
M..P>FP\J:UJ;#>M/6]Z'E6+ZGOU'*#V_5U:=._+HLV!S^OKH";<Z#E#?;]^N
M?+:_.'QV<<;+!K4BHUM6G/;ZTK$[]>^]8+-^SWMTSKD@L&6WL>G*^5N@TA!Q
MW6<OVRVIE[Y>L._?N\+#3#8.W'9NXTWV4R&W72V];^U-];7.NHTIKOWGM#W<
M9Z>\>JRQH:?/F/OGEJ(F_=L_H.L%FUM_K_.@YZ%"ZL]@Y]@]VX,.^PF@K[WI
MR-\J]"+Q>MM1;U'ON:^T&H9>&H8AKGID/7:9BUZZC,5%C?EGD;UUAD;_ !UH
M<K9W'2'OPV<=-KZ"HR^NAI;W]JS:NO?*"UM;X:_&$+KV9Y:;=^[4=/=;'/44
MN30CIKF!6I)VRO:]-;7STVWRU^L'Q]F[N[<]]KTK7.AJ/2N6G.M]#6'V^>_O
MZ6V@TVX[\==FG?MW@&0:3+4$ZUSTI3W-*[T%!DSTIM3+7/VTV)N<W:WKZ9;]
M+Z=-<]I"PXZ.[#+8&FW6TRY=TVR%^$4H334Q:]\_>M]3GIE!AET=./CCGV#U
M6NE!ESKE\STM4<H5OSY4^%+>HZP8[Q^&6OV8[.@;2P.8J>@RSI;?,$[G2%-A
M][Y?S37F(?3QAQNW!:ZV^=;&O76FHK381.7=>]]S!9E[WSRSZ99G[4A!8<QL
M>]M:UZ \X06#UY'I;0U]]>=(0OCL$0ZNOI#2S2^^].G\$TOGE%^VH!Z].1SB
M\GMS --<>G< VQ6!;UU VWSBI)%: Z:5WYB*#_?'#_2-[;9&I&QIOKEH.?N/
M:9'>A]_2*1]P[O?[\K#OE3T^)--N68.<0?7G]/I>$/5]7O[L>FP]*WTT/SZT
MKK6*.O[_ $]Z<H?'' V"NO/L_'<<S8Q.^^Q"#HV<8=EH.6A/I2UZ@4H*97^)
M-//7NOK#M>^GK0C/O2)!KQH.[*P?'7>QZZ5N-*T'-EWF-[PL\MX88]._OZ>[
M2T-2,[BFF=K[VOG2VUHMK[&M.6WMR]\X!Z->-NSMM2=LZ9?OD*TI>W6E"'/+
MO37TAAP&N?78!D<K97UO\^40]G*W2$/0&(\;>VPZT%^_2U=<XHYF@[T](?'N
MXPV]MGO0'3I2E!IRWB=_7NNGI"$,>P<>.->W$17T->^@Y9^M:#3U%.^\O2CL
MVW]]16E:&W8R$2,1-3;*!9'>OC"!0'F(HDP%5PJ(")4DBB(!B( (F,80*0H"
M8PX &- *CPY5YFPK<U-O0TVR@2 *G+;6NU,_7Y:0PXK.KZA<'1A45VZ09@A'
M-Q76*3$0 RSHR9CE'><GFZ>.7- ==@0E('$:D:FPN<@,LM]*C*-96HUX00+9
M GXW///8Z12$?>:.?E)S//.4*4>X78"'4(!MW#;&K-3_ &5!OR/3*']7_O/_
M %0_1UYW\Y-_I4G[99Q,7NGG?YPH[LY;+^Z#T=>=_.3?Z5)^V658W1G\=NO*
M']7_ +S_ -4'HV\[^<F_TJ3]LLJQNCG??[PH[E_4_P#5I!Z-O._G)O\ 2I/V
MRRK&Z(?U?^\_]4'HV\[^<F_TJ3]LM*L;H]_3YVA_5_[S_P!4'HV\[^<F_P!*
MD_;+6K'_ $9?#O6']7_O/_5!Z-O._G)O]*D_;+/Z/_3\8?U?^\_]4'HV\[^<
MF_TJ3]LLJP#FBH[$/ZO_ 'G_ *H"476TR<GI194B?.#]TDI$70$+CF)$TUG2
M@9#D'-+NYP!C;+S$#^V]JV OWN+<\X@0HV)I:_$3IH<S7E3XQ)D+0\/%,7#1
M5,'ZKU$47KA8HD$Y!$#>30(!C"W3*8I%"B0YE05(1051,1,$]945&H- !85M
MQ;['X@>\;$I2G.Y.9&=.6HI>F1-;T$1Y*4'/PKHSRGEEG*11$R1FZWF\@B41
M'$A@*=,%0P$ $R)L5,#"9$@!@.P. CA72]KBV]*Y7J:Z;91AP*!J@DZV-"/E
M6]ZBO.D><)B\U,.9Y*9'FY8FA4SCEO.9@(FWXB(B.^T(9U"=#RIH;6B#S=/,
MS/\ NSU@]-7F_P U,?H)'_Z_ZK2C(_VZ?'+X1?ZO_>?^J#TU>;_-3'Z"1_\
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M^^0%3]>5^</'QXTUXQM;=@[VSV^ O81*?#O/+ND%AZ;UUMMN:V[I"%KQ@.W
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M^_[?'/E'/TDNA]THBX+(^0+,1)S+^4(*)2D(R\H85.=S *00-SA$P 40''#
M;;0/Z= #OK6ZL]=XU*/Z_5/P CH ! P 8H@)3!S@,40$! <P, AD("&>.8=8
M6U;[&NU.N69R-=="*F-W6IRSV]\MOI#L%-#73.N7UWB0;NCM^O@<;/IZ_<]F
M&_/T_;L4A;-V'3C[?>'QM![&M,P?6IJ3;?0:9Q==Z[BGR^A^T,>,,K4@6MR[
MRI]JC6(.ZW@LUY'.V?7VSM:V=PA#IB'9NQV=_P!6VTTL>FQ/[TI<WT-[T9T/
MKO37V_?2'98T]Q>MZYZFU>F^D2##VX\<; M0.N?W['(#2%?E3OZ]3!9?<_"E
M^HT-]?7*$%E;CU/M]Z_ML@ZO'+CN]F J[;9&Q[T/[4AU^%^_?YU"^W#'C;AN
M[LK#IO?(WW-]JTV&72+O[5IWI7?WO!IM$<NWP^W'P7%:FHH.NV@J:YUAGH!?
MT^/\4^+L._H:VJ!7ZWKM72)!QQI9?*@V^UMJ?&UA>'?><&6S3CP\.RSIET]+
M<N=_:%ZWS[^/QKS@L]R;>U][;FU(0O?GN'W= 9X=-I;U-Z9';YVH3RK04B_2
MVX^O,VKRA\#CG[\O9:Z5RU-;YZ<O372)V*6^E_G /U<>RP]-;Y7TO7^;>[^>
M_G!9\QF:=*Z7L-.EH=_.%O\ CAUZ!E9O0;\L_:ASTV)(K%V^U>F9O'/U8JI&
MKA-0JB8D(O&%.H4Y3$*9,J)5 .<!P**9BF P#@)1 0$ $!MN34MY?[LN9.M!
M6ND:EV7G_MOZ#,5.6T= $.10I3IF*<AP Q#D$#$,40Q Q3%$0$HAF @. AH.
M=M-<^QZF^5+GZQLBKCC"SLT[Y9"OSAWW6"R^H^-J?74Y:="4+//#LQRZ_JQ#
MP&T_@5KZ_4 GWH:1;6KZTOT_>A^(@'3C3'LV?#,+*;D^XI2M]M,ZY9"UH#/O
M.GKK][&#K#' ,<@QSV88[=?CO<R 2 3T]>>>5K5YNAI4TN:6UK33+[;/:'P]
M^S2UU!],OKIET]8F_P!_IKG!:@4A!:9#T)S[]3"%]666&.6?3A[M+3.]*9 @
MTSL1]-= *1?WO>M+VY5^N</CNW!\+6P]LNFP^V_2)W[[G[P?#C;QOLRI7ED3
MG[WKM0DG>'W[T[V@XZ=GAO[+,J#2AOE2F1IMN:4UL(=\M?CMZPNGV9Y9X8=.
MF_HL]?:]N6NHKGRSB\OG:]JUY9[<X._/M#ZM=N&[=:4I:^M\ZBF9I0@Z<\KY
MA[6]#^^6E=]X>'QX[[7Z&NYU!'==<J"DK]N_:%X!]>(]'ACTV$>@U]ZG6E^E
M><7XGL#G\:<H.L>[+WCN^(6#GZ::U'.HI_,.@][_ $&_OD8,0R\.-F0]@#8*
M4'ISVTM2QV %84-_CWK<>I$' YCEENT'9T=MEB>FNUAIEL<J:YYNQ87OOF->
M?I#L_C,CGI]_6](D+/>'2&[MR\0LO72FHUK30VY9_"+;8\COZ7^!@QZ]NP=F
M8=(Z899#N''*5OG:^];7UT'+,VRM"G33,C6QY#.M[C<4N[6GS^M_6FO7*L2#
MW:<;+-;@5'RIF*^Q K2N</KGWK"VYZ=F'QQS$-V%E+_Q_.IY4ZQ>F?K7[4L#
MO6#/HZ<Q[-@9YYXX65-LN=SM4:6YU ];0M?/E8>NIM:U*P^->GCV:6>M^O0G
MJ,O0TM$[RY=_/.#[->,]]F]@=* VMIR-\O<P/[Y=VV@]^?LM*@=:6J3IF*W'
M6GKO#Z6^<'5QU9#GT6&O(4UN:"XKEGV;0Z]];BW.##X^./MM: #H:WZUSA7[
M?"GR@RXXUP\++7%MSZU^?RY0OWWE7XP6:].65OCG['W0NK3#9AV8;. V:S0<
M-K<JTMSOIZTO2+USKK7UKKV=<CZ_MUT[]0LSI2HTI3:V5Z4-M<[Y5#]OXRS]
MLC%Y+\+,-FPO3^,(>%L%Z>OT&>MP<[[QDG6Q]U<]@?C%!_OS?UC>WC;;,YC/
M(Y:W%J_.A%,R1&'W[[ITCS*N$TOOA#$ S#' ,-N_/=U]=H5@<R,]N?K\O>,P
MFMS8'+?E\_7VCQGDD0'(Q-<^<.'3J(@ " ]>.RV)63H.7=?F*5Z1>%.ZLJVY
MVRI7N\(9)/>0-O\ "%V;<QV:V%9.WM]]M( (W/QUZ 9Y<X/2:6]/;_E"AV:[
M/KLXSR^/WB43STT.6_\ ;F>72L'I-(1R%,1_ZPO1TY_:&(6<9V&_=]Q6]XO"
MG_J'H?M!Z32Q_P GCL_="Z;PSZ]-=^Z%9.@^-N8O8\XE$[FEZY^W]M]+&E(/
M220Y8I]&"A? ,<,L.RSB/+XVVH*TMI:+1(U5SJ#[&VM;W@&33WD#?^Z%Z\.[
M/?9QGEOEGU]HE$\S;GTM87K8:;WM!Z32':F.S#RA<!\1XWVO&>72F?6+P@9\
M0UK>V?\ TCOXGI)+/,G3^Z%[ '/MM.,\O;3;I\;FAA1.55:TL<]=,]#!Z33_
M .;_ +PNF7?ACEH& VO&:UM[=F(0D#,_$7VRI>GP@])IYYI_WA<@Z<^/&SC.
MP^/WA1.YIH;W/_E^L'I-+>38'\(74=FMG&>6=?C6'"GGKOD-?[>]S&@.Z5BG
M-1IRYA0*S.)G#MAB7F+/0. E'+ OD%C8J+ICJ<ABB!B+&\GF'E!)'^JX"JUL
M>MZTMKZQCY:2KB%TTRH<Q0]*$;"]10&-^]))!EBGD&&:A?$/?\;:^,\O;.N=
M1E\(SHDW%1?0'X6[](?I-+>3/3]T*'=GCV[=0M>,\N_7O2D.%/.W4^_Z:#F-
M-8/2:6]/+_G0U'3'/3IV; M.,[#XT]J_QI"B<KWY:#;].>XWU@"33PU3Q'_G
M"X=G</;EC9QF]A<UU^_OOK$X4\[#8U_^W8C[0PDDL0Q$H8[C .6X1QWB.P/;
M:\9V'MGR-X42:T).PUKN 0*V ^/*/6DX35^]'#=GT\=&%L@H9&J=K]_&U.4"
MG4&NAM0UI7U.^M>=8OC\./AAMZ+9&M:>^OP^1SJ,J1B/OW]ZZ<X=E!7F.9&W
MOI6)"[.._3C"P=,[4K7??0^^E#I?7OVS[K#'CC+/MRL.N=NH'.]AKO;/2(._
MWSMZ7@X[N-?;:]ZZ'O\ >'?OWE\H71]6F[H\+0#(;>AMG3EE>X.44[_OGOS^
M,.RU=:WTI6V5; ^^E\HD'C]ONL&XOER%[U'O\-\WP_CZP6#D:D6J=JY=:9^E
M806';NE14[6!.?M2$&_CX>WMLO<W&U:9BM?3J>8.1AMW]_EZ1YE72261C!B
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MZTSJ-=(G=,_?T^64'&_C@;!MJ,[U_>^E?;2'>W?8A<:]>[P]V%F>7+.HM?L
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MT]>'=L+>_&]!S+24<FT=4_3M=2%?T[6S::KE51([U./FYN<F% 756=M5$SJ
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M)2A(4W1 2GR^$AMP!2C5T)-R>($TL5) -4DB)2NUY"$U0=6W<5[)WJ+5;7%
MSMU9_7)^A42<R]HNBKKZIH.K*);"\J685;0562-0M),6<E(3:RS*GX E32%1
MS4)&S3?BS./(F&9B73)H:EWVYL%A):\M+STTV^R^0EE 4XP$%(*4H 4X[Y26
M4+4@YMR:FU)672M:5M$*(->!#? M _5_:NI(%304'ZJ1KEX7R?$M>54-X#FI
MJUHB9I^L*HG:A=C+T?,2E1ULSF[\;O;VX.E[SW$G4\C3\]!W10E%OKO+K4V<
M"V6B8&6;$:#"-4*@855ME_$*)5N6\J7>2XRVVV AY#;3*FY)^46[+!#27$.3
M:WDS$V5K45K0159+:FL7)$N%RJTD*)(44J4H@N(6$KJKA(;":-T IK3]7'].
M63)G&LFD='M6S%@P:MV3%BS13;-&;-JD1!LU:MT2D20;-T4R(H(I$*FDD0I"
M%*4H 'F%*4I14I14I1*E*425*434J43<DDDDFY)K'8    "@   &0 L!Z1ZK
M2+!9""R$03>C=(I6E5T=54:[9)F:(RE%U]3\N"ZT+7-UE5)&2J& >-4S"3TG
M'.B-9R"=BG\QPV=LE3E;R"IB>BP?'!A\E/R3J'"7%,XAA<TP4HF<,QJ24%2L
MVTLBOE/(*Y:916Z%-N)!6RD'R^.>'U8E/X=/LN-CRTOX;BTG,<:I7%,"GTE,
MY*.(2:>>PL)FI1RGZ5H<;4>!U1&LWHQCBZ3DS3M&TU4K]230IMO=O1$Y4;]5
M65))59(-Z.I%-Q(-&QUUGL<I,1[9!Z5N4QC,TW;CR"8+*I\W!WD8WXOEY^<E
M&PPN;<Q?$I:4:2EDLR+2\1Q H:<6$I;=3+O+4V5D#S"A(5^E)X..LN8!X)FL
M.D9QQ3Z))&"X7,SCJB^'L0>1AN')6\V@J4ZR9EEM#@0"HMI4K@!4I.*N7I%I
M)7EWB51*-8R:;79#2MS-V,PZ)%RLI$1M)T@P/6CAK*)^<OV#Z8J.;>,)E%9R
MD\,,5YLZ3* '(.W'I];6#X5)LK?EUXQ^=\0XQ+H,PPP^]/3[R<.2MD\#+K<O
M)R[;LNI"%-@/E:%DJMH\-X<AW&L8GGT,3+>"?Y?X:P.87^6F'Y=G#\.95B2T
M/I"WV79F=FG&IE#CB73^7"%I !!ZQMXN/>P60C6:Q_Q<D/ZS+_U!IU>VR$:G
M&ABCMV:#T!NP\,K9IS.8MO3:]J=;_&-:C0#(YYBOSKZU-?IDK;-=,]KTH:?S
MM49UC7"Z/?LQZ<_MUVA.61L;WUS.IH +USM6HK%Y_36G*W\9:%VO[Z'+[Y?/
M2D2"R_I?+X9\L[Y["IA!QV98AV\:67]1Z[$C,9\Z?6'?K>A].\X ^OOSL%.6
M=>8K?*EM>\A_;VM![.^SF<@*_/;.@ZUSZOG[0=&?7Q\,++'T]@<B+YY[4ASM
MT[^]8+#WGU.73+7+6$&WC@<^-[GORISVK6O3/?-WWM;O8^O9LX[[+C,[_+(;
M]:5Y0_;77OVA:Z#AV>/MZ[#RSOGISOI8C(YVM%RS%?7X?+I#X'+V<#:7WI0U
MK>E-<SK7H,LQ6)V+_/L0<;^ WVN5[5R]Z4W-*[;^L.]NSM!CXZ65RYUITIWZ
M\HM,^6?+LPLO9AGVY<:=%I5-+$:4H=KTM7/I<$<H7U'.XWM7O7G#M>IKEG2N
M=OCESB0L-F@='1L^&  (8:VEZ9= *#+2^7I0BE;&PM=<SSYZ_>I(-<H?'U^Z
MU!&5;C,5!I]:5M>]84[OWS@M-J4WM0:4&^U.A&QK(./;MTXZ;45[%]:5-Q[:
M[5I#OL9]\H+7*$74APYV0;-0Z]-+:UC*X&=+'*@V$9I%:_W>A WSJ8L.!P!7
M^WX#G[NO'=G:K-B.GSO[5&6IY&(G,'G\\N\H\M*_XP+_ .RU?_--K:SIT]\^
M^64;1FKK]!]L\CIRDHQ2G*8ARE.0P"!BF #%, Z@8H@(" [0$,!M(O0D$7!!
M(((U!%Q')G*HNCK*^LUR-#P[)LK=TVOBIZLKWU59!LT,I25&HN99E">8JG(M
M)-YZ9*U:JD9@HLT71:.CD(B11PATV,23^(?Y?+H2DRHGVGYXE835A@*6EL)S
M6''.%)X;I-%9"H][X%\08;X9'B;$YAQQ.,.>')S#?#J4,*<"<0Q%;4N[-%T
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MB[P#4667=.T6M&UU"5ZDT:F(5*4D:<0D31#-^!RG S)O*NV<N8@%$QW,6V*
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MM#PJ[^<IWH$6\E^U8^ CAGG:CR]G#U*-_P#Z16M.9I C6HK3*_VH/I!A5_\
M.4Y_<271_P!*]^_HL/EZ!S(UH4_"V=O2^I$*#<=;\^7TVYPN;5^7[I3G8A)9
M=[K/(1U#7OM#Y>='*VN"C.XVSH:7MM> ZCGGOTUIN##PJ_\ G*<V?Y"2[?\
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MS&3?T)=Z_8/&B#6-85+%5JZK%W7C2KZ?E9&0BXU%IYDVIFE4HR$FZUX&)R^
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M"R$:W5Q.?3S\H9XBS\'[4>C=9"-4CR@5 HAC@)0$<1Z-H8!@.'=MS&V:,R=
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MRK:FF>?/.^D8#E]HQAB.FJX.F2ID%@(8H'*4I@$#9F(8ABF(8HB4!YI@YH&
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MC&F[*XW.I=;DF64S\V^2TI3%0NJZ)+$LMOB0H$ AY]* %I)0VKR0IV9]K/\
MX981-I5,2TQ-82@$*EVG:S39!/Z7G6G?+F6UJJD--&8*VZ<;@#J_*8Z&NJY2
M-W=>D*\H*O(M9P4B!UVK678K&1.L4!20>D076227-F4&$DFV>@<IDU69%2'(
M7M4SS17Y,VT])/@\/DSC9:)6*@AMQ7]-9%+44%4H>$5CY_BW@K'<*"WDLIQ"
M40:F9P\K>X$_[GY;A3,,T_UJ4VII/_S2+QUW 7FIJ"1M/H@D(@ !(-B&%,=
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M+TRA'D>OFL<U5>O5B-VR)1,HHH( &W I0#$3J'' I"% QCFP*4HF&TN>9/\
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MLM2X5^;7,)?:EP79=MY*/^ "G$!2"AQ:D(+)">%0 <%%1_5[\)O$L]XF_#_
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M%)("FUMJ,\)>*AXK3B\W+22F,+DL2<D,-GBZ5C%&V4 NS*&BTV64!:D\ XG
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MZCD8N6C7;O<J7>0RU,+0$LOE8:45HXG/+5PK4EOB\SRTJJCS.'@*TJ0%%2%
M8!Q!6IL&JT %0H?TA5Q4TI4B]*UI>E#&=-/PY)Q*FC/D@G%HEQ.I1PE5\J>)
M:O&T>N] _D_(@FF\>-D!(*@*B94IBIB0#&#7P*\LNT/EA005Z!125 ;U*4DB
MVAC+B'%PUO0JIR! K[F-$O(N9NQO<D+M96\6F$*D?W/WB1%ZUW#A:0EV(TS>
M#!,92,B:B0)%2#%-^LT8S,FW*RE2/XM4KHYEF2JA$CI[Y:>F91,RB6>+29R7
M7*3("4$.R[A2I3=5I44U*$GB;*5BE H5,8+:;<+:EIXBTL+0:D44+5L16FQJ
M*C*(1+R6>2+4E\555J2@X>1O@@[W;O\ E 55(IU%6(/X^]B(H62HJ@*R=L"S
MJ<0FNC0RLE%-(Q%H,(Y;BHY?QBT@1-R'.&+8NU)-,?F'$R3LI,2+*2TUPKE%
MOH>F&4J+?'0O\"E*XN,&B4J";1J\B7+JE\(+H6AQ7ZE5"PDA*B*TKPUM2AI4
MB/)=;R<^1S<G(WVT]=I3=-1);\ZV/3U\M!DJBH:LI5[6%54_*5BXIAW=]+S<
MY2U">LE-5A(5"\I^)@Z=CI6'J!JZ<,UF3N,"UF\1QB>3).33KBS),>;)OEII
MIX,-.I8#J9A#;;LP&WF0TEQ;CJD.-J2%!05!MF6:+J4)2"ZKA=34J'$I)7PE
M))":H56E .$C2D9WDV\B3DO\D9Q4TA<#=BWHJ0J]I%1<S+.ZEK&L988&",X-
M!4M&2M;U!4;^#I*%.Z<'BZ7A7#""9G5%1%@4X$,77B6-XGBWE)Q":+X:4M2$
M!MEI/F+ \QU26&VPMU82GC<6%+( '%ODS+,2_%Y2.'B !_4I5AD!Q$T V'K'
M5O.*(X (8CQQOMU51OWW3W&XC? )BAJ(:X=ME1W]-_2$8"'JRFZ@D:JB(699
M24E1$VVINK6357RB\!.NZ=@:M;1<B7 /).UJ:J>GYDA $P"REF:F("H)0V+:
M<;2TI:"E+[9=:410.-I<<9*TG8.M.(ZH.D8A25%0!!*#PJ&QH%4/.A!Z$1Y%
M:[HU"H4*3<U+#M*E=O4HUC"/'J320DI%:#D:F*PBF[DR1Y1X6G8>5FUFT=YR
MLWBXYZ^<$2;MEE"9>2Z6B\&UJ:2GC4XE)4E"?,2UQ+*:\"2XM" 54!4H 5)$
M.-(4$E0"B: 5N30JH-SP@GH"=(VKG%PQQ#CHUMJC* 3E ,1,&&^TJ-\Z'WR[
M^\(Q/I^'].^K7GR?IST3Z=]'<Q7ROHGSP8_SWG^3\CY/SP!0YOE?*\[/R?,$
M#6SX%>7YM/Z?'P<5J<?#Q<.]>$$](G$.+AK^JG%2^5:5KEGZQF '$,0T',+8
MQ8+(1#5X%X0MG4G1U.2;6'F&D5Z2J:M9)- ].7<Q2Y0,W?RYW2[9NYF9%/$D
M)#@L"ACJI2;T@1R)BN$(XSO5K&I:)&Z."F25;=W<G7==.J5DZ^;3IV-?N7[I
MH<651UZ[617#S:K'RCETV15.W&)AXQV[=IN4@CV#3U7AWPR?$4GCJY6;"<3P
MJ11/RN&AGC7B#"%D3?EN>:DH6PC@X4!IPNN.-MCAXN(>0\3>*D^&)WP^B;D^
M+"\8GUX=-8F7N!&&OK;"I3C:\I27$/KXRM:GF@RTRZL!9'"9:KV<HCD@Q5/H
M7?TC)5W>5>[5L'2<+ OJC<^F*F7*X'SE^[?JMGJ+-E%)O1*HLUC")>?2+(KG
MF(&470>%O#*O$3N(+>G$X;AF%2#T]B&(K:\Y#"4(466DM^8WQN/K2HI3Q@^6
MVZH<2DI0MXN\5#PRSAR)>25BF*XOB#,AAN&-O!A<PI:TAYPN%MW@;92I(*B@
MCS'&@HH;*W$=K!B(!CD. 8ATX9[K>5[V^\>OAV0B&#.VS)_,N7:Z;=!*5DS*
M*JFYI"@#U79M$= *4!,<P@4H"80 <@+"U36W, 5(I[<S&LD"AR'!<U I7*_I
MM09[QA$KR:=4,L"IG")4UA(@845#BLD4A!!?FD*/D@,H*A2IF$3\PA3G @G%
M,N\H7L#D<Z4.U=>^@U!:+W(S&5:C>EJ=+^\7_NC4O_2G&T/XHMIE_H]? Y.!
M7^T;']6EN76W7>'&C11W_MVYUBD]Y%,$(8P+.E1 ,033:G YAW *HIIACI\X
MQ0#:.>3@63<"G6N^EAKG2M+7K#C0!4$U%_[?;6(Q?NY*\"?01;H"B@4/)($S
M.1FU ^*SIPH7 .<./.,.!0,8$FY.<;F"?;0(34G,7RSV SOH#^\:S5:J"M-.
M0U.0^,="-6Z31LW:HEYJ+9!)!(HZ@FBF5,@".T0*4 $=1'.VC,U-B;TKD:4/
M/7?VC;E:M:6!Y#*!PX0:(*NG"I$F[=,RJRIQ "D(0N(F,._##  Q$PB   B(
M6@TI>]+7JH@YD>E[ZVL*4ZUMKT%;T&NMOWCD^]*\YF@V7E)%<4(QL9=*%B"K
MM47TU()M73M)BQ2<N6Z+N8>MFSE1)$5BIMFR*ZRJJ+1L\=%S=5^7EYF:+;CJ
M9=HNNAI"EE* I*$UT2%.*2V%KX4!:T@J'$(W8?)N8MB4CA3+C+3\_,)89,PY
MY;8/"IQQQ7]RE)::;<>4EI"W5(;4&VUKHD_.Z.OI+?2B>4*5Q$KQCE2/D*/>
M&%-]2T@B82+,WR)B)'76,(")9$R"9710$I$VQDU&;;YR]C*\8JZJK8;44F4)
M(,NK*BO[0I5*'S2D<0K0)(('ZID/ LOX';3*-<$V[,M-NJQA*1P8DVK]25LD
M*6EIE-:)ETN*\JREJ<4OS7/E#>ORIE[LIRG%BT'"U;4-;TO'5Q4,W4+A<ZK>
M+J=P^6C*2A3%35,RC(*/029)% ZC,ZH*KK1RDBL_>._OF$X#+ID!*I4&V&BI
MC@2A!#SB4(2\\\".%PO*%5)(_4E137A2$C^/_P"(?XD8MB_BV<QN?2J;G9R8
M=FVUONN_^SY-4PX9+#I!/$1*L23 0A(;HDO!;JT&86ZZN>F--4Q*4M=O6\0K
M6\73%8N*==O:+B$E9Z13BZJBE_-XN 0CH&6JPSF/E'<:JDWA%E_\%,G3:+:-
M$CMU6GYUQS_#%^&>*8E/STK@LPWB2WEN-R4OBJI/"G'TO>8X%,O*#3#+B Z2
ME,PPRVHA0 2"@_KC\,?\5?X@KG_">$>(\0P^;P&;6W*SV(S>&K=QQN6<PZ8,
MLK\S*E/YE]F:1+*<=7(/3$TVEQ*U>8X'4=XW,W)1B[6J5ZJH%&(H:>I:&HR%
MH2JF[:0?2$0TE)BH9>H:D8KK2!VSR?EI9FJBSEW"M1H+PXR\UYC+R!F+#[CX
M2\,RO@_P]+8#+-RC0:F5S"V9$?\ "RH2TVRQ*M.42'G&BAYYV8;JVMQ\!IQT
M(+R_3^/O&_\ VF\2,8OACDXRC#V$LR<V\2S-.O%Y;SLT$I4'6$*XFVVVW"ES
MA;4IU"/,+:9!ECLJ*;M:&HN,94K3L Q91[1E#MR,BE;HMDS())G2 IRI))'(
M7G<X5EE/**KJJ&4&WHPD 5I4FMS4G.Y)S)).9)YUK;Y_,S,Q-/./S#SCSSRR
MZZXXHJ4MQ=U*43JHDUI3:((K%ZT?/XU-X](6.@))&;J%545E!Y[=LLM&L"\P
MB@NG;A0?.%&)!,X!J5-P*?-.ES^),%+BFDE0\MAT//UXC7@05--!*02M:E47
MP !00E)N"FNQ@%MMUSA(6ZV6F550FG$L!U9*RD!%"4<9_3QDIK4&)/BV4/??
M3OH27CZL@EJ5=%D*6K\K=I&NXYZY+YJ#>-&1*\\_1<M5EF[Z.DXQU$OF0I%7
M1(\;1ZZ&;;R9A2T>2[P%(XBX@H#@'ZOT@GCJD!2PN@*2"<N(1TN/8!)XM)IE
MIUU*5MN\;#TJX@S$F\04AQ*EH6PH+!X'6'$N-O(/"M-0A:</ <DB(+.NYFM9
M^%GDGQ2%DVE*4*SH5Q5*!#%,#*M9L9NIIV<CCBFD+B.CI&GVCXI3-)-)]%K.
M(];:$) 2!YA"+H#CI<0V3F6T<"$B]P5!9%SG0CQ,A^'&',32YF?FQ/ D%3#4
M@W()F0D@A$^Z)B:?F4&_&VVN6;<IPN(4VI39A[E?49=K7TPFPB%X6FZNI6*8
M,JVKQ^*:M%4]2Y2K/("B*G@5G#6'J.:EG;Y!:-B2KQLS3-/OW$N$Q'DF*?AZ
MITSN)KPEIOR6'I[$,16EK#\(83YCT^ Y1Z8=9"'%)DV0'$!T-EQ^9JPS^AN<
M>E_T]^&$QC,NY,J3-RDAX3D@7L8F<0"$R#+GE<#,M+N*<9#4XL!HK <##$NE
M*WFUN+E6G:N2QR6W;=2#O,O#4?QHP%1O)F[R@8^&94U33=D=B=-A.S$-(P:-
M7"[:R$A(+P#6;=Q;Q-..@YR3AH]Z+>%A^>ZZ^MIIN8#;3B@')B696T\VRM*U
M>4P7VJM/K::2TMY<NHL&94M+:G$MAQ?'\8?B$[BPQ#"<*2R,(>+30G"R^W-S
M;38;4XKA<4CR677D*"$JET..- .+2V7BVGLZ\.[2@*O.UG*I3>Q<E%H&9(5'
M 3TS2LWZ/5.=0\0O*4^]8/9&,464.X2BG9W35!Z(2#-!"033=$T+2T\U^7F9
M:5G)?S Z&)R69FFD.@ ><VEY"_*<*1P*<;*%+;JVLJ0>&/GLAB>)84\N9PR>
MF\/?4V6G'I1]QA;C1-FG"A0#B H\2$K"N!RCC?"X H44A1= T6V-,77TE3GI
M[R!8]28+S#SL@FY61!8:HJE[YW4DPF42D?OC2KV0D'(MBJIE7>E;VKP$RT)5
MX\$J#5+#+:&F62D$I_+RS*6Y=A6:$<"&T)XB#^E2@=7YJ8,PJ;<><F)E9_J/
M3#SC[SO$0I?FO/+6ZY4W45K)*@ "#<=!T#(KTLN:4;N#OI1X=,U0.'(>3/)F
M* @5 $@,<K2/;@8Y8IHCSDV!1.<3.':SYPZ\E/L.-K#2APM)KY'#7A"32IKJ
MXKA!<)NHTR0$)3WLF\AQ)<2:KL'02*DUR&1X16B*"F8J2%&.N8F4:3+%"09'
M Z2Q<RB(>415  \HBJ "/-43$<!#0P"4Y1,0Y3#U9!!((%1['.A!V-]Z7CL0
M014&Q]#IF*F,E:#6U/3/N^^=;0A:XZ[M!#?W[,^[6TO?86 %1K>F0[K45BY4
MRWS!V]M;>^4&F6?6.W3NZN@1M1M?6YUI3I3E3.A,#>]NFV?OUY@0[.^N_M7W
MH*YQ(7&&W'V#QV0WH=\C:MJ\Z&HK3.F?2]UTI\QWZFW330?;U6NN5]#[UZ4^
MHAIGGF/EUAV:Z6RWUS^GKN1$@XX'[/&RO//L[=+T(/H(=]C^?A!I]N/5K:9;
M"O,],Z;4];=6?\4ZY0;NOKW]W 6NW78DWRVISJ.5=8;].FWOV8NI!]]KLT#'
M?F.EL%C+U]<KQFDYY:9FF]AG%M3[X_\ 6-[1WY=_;C;,Z]*4^VY.0^-;",1I
MW\K^WI2*<\\NKNQQZL<LK#<$;'Z5ORTI<F%K7Z^]*=:7O#L[ZT]]?C$@XXTL
M_D]=--/?*'?><%GQTII^_=-812<I5"&(8I3D, E.0Y<2G*(8&*8I@P$I@' 0
M$! 0Q 0&TO2M34;C7<"E1Z5'(WBY&]^A!]]^ENL:6\N^IAXH97S19J8YA,8K
M-P9)+'_12.51),/]%(I"!L  #/,+72QJ+6.?PI<C<:F^48<"3H1S!I3TH;=*
M1X_N94Q_^2_/$_V:U+A&?#\?3]]H< YVUKV( NRIG(?\)?GB?[,(6OF*V'/E
MZ5H>?UAP)Y]ZZ=Z1[(FD8VGF_E$P!R_/B"KU4,! HB/[DW(/.!%, ' P@(J*
M9BH<2\TA=+JE*I6R<P >6MA6YJ(S;0$@T))N*T%:&N5#8VT_B1J)_DE?_:3O
M_=1MJC<,AT&>?K&X618CR\F]2AKIJ8F*LK:<;QL?#,TW:K1+%W,OSN72$?'L
M(B';\]_*24K)NFD7&,VB"BCN0=MVQ/GJ!AQIJ<EY-I;TPX$);2%%(!4XHJ4$
M(2AM-5K6XM24-H2"I:U!(!)CML&P/$\>GI;#\,E5OO3+I;2M7].6:"&UO.NS
M,RNC+####;C[[KBDI;9;6LV$<->ME]-;7KQ4W",C/;P99E'(Q%UTVX,>[[DM
M43)-V4D_K*^YE"RJ@U#?94[/RC:C:<*Y8+-6AGS>/528,I]\MT(?GWIU#B H
MS+B&PF341^7PF6<"5./8@6U$.3[P"DR[(((25!!" \L_2EX?X9P_ 7Y6:6VG
M"I9UYUW'6&JXMXZQ:74\S+X?X85-L),EX9D' E>(SW XE3@;<=2I]V393*'(
M^O)&2IR\RD*_915-WLW9UI.(7HJ$77 )H%EG+MA62SR3=.G:S!TS17:IN5G:
MC0J$:1TT!JP=M&Z?USQAX:E<(?PJ<P1<S-X'CTDQ-86Z\4O3 >(0B8DW5,MH
M2J8;=4DE"4!2?-#7ZE-J)_,7@KQ7-8S+XO)8^B5D<?\ #TZ_*XLRSQ-2_D)4
MM4O.M)=6M29=;:%I*RM25>5YP*4.H X7@+ST*JFN7)>1!P$K3U&WD79NGM+*
MQ<DY@AG6$?/FN]6JPJ:B#TI):8=NGSY1VDBDDW=IRT:9)=RX>.R?5YK!%24M
M^&N$/S;,SB.#XTAN>2\PB8_*NO2R<51(52IHJ8EVVVT!!4I2T*9>"D)2VW'Q
M^5QU$[,_BCC4K*3,IAN,8&X](J8?5*F:::F_\H5/A!0\!,3#KCCJG E(0M+[
M"DJ4MQP?8>[2[VF[J:%IF[VDFZK> I>-2CV7G!DU';DW.,L[D'ZJ2+=):0DG
MBKA^_630135=N5CIHI$$J9?@F+8I-XWB4YBL\L+FIYXO.<(4$(J EMII*E*4
MEIEM*&FDE2BEM"05$@D_HG!<(DL!PJ2PC#T%$I(LAEOB(+BS4K<>=4D)"GGG
M5+==4$@*<6H@ 4 Y6O&Y&BE?U/RB:Q:WNWAT7/WS0$=!TYZJU=7<32U,&97:
MI4"H]JJ@X2LH&G*\575!=Z*SDD3--V1T&L5.Q$DPC9ACRY;&1+M8:RJ3EWVY
M):EN^:S+K==!FC,A+4PXPX[+\-:  K055*VUI4I"N2N5*B^H.+27?[:*6$I_
M1P_J0%!*ZTOD:6J(APGR=;B20J52H:UI%,TC07*)@:&H^E*0G8.[*YNJ;Z*>
MN@IRG)J[FDG582A(]E18W:3U4J(&626<UG>-54W !3(.A;CS/^T*4%H-L.J"
M9C#7'WGG&G)F=:DG)MUU$RZ&4\2GS,-M T-&99E#A=X01K_)5"JJ2"4O!"4I
M(0TIT("2@$D@)X2JEOU*)$>.H?DTFGEZN7NSO&;73.JDJ:<<,G],04T1>*H"
M=Y-+&Z>2NW4395;$+.:6F[XF:E]]4QK"0A0G9=\^6*Y85>N6L4<V_$QHT)F6
M,T&T-DAU;9J^WB:IM,P"II8#J)(ID6EJ2KRT(2.%356C@</SX'."M1^GB'Z"
MSP%! 4/TES^HJ_ZC8[QK<=\F;)LIVKJP).7$QE2U4-^T5&-H&YJ69P-VE,7R
MW37)4)'H79E=5X\DZ<FZ(G[H)*;8NV[M.'>(WDU>+&#@%5Q;N,U>)4%MIDMS
MRVFO\O6M3DVVIV:=D9J>>5^:(82EQM]J<"%)(*TF68"EN4*H"1(45@LI)\T
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M>>FGDOS,Q,!)0AUYQT)44$H2M1512FVV6R0#^I26FTDU(0D6'-:04I0V/U*
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M?VAYC?\ \Q'_ )D_>(;4J*AY%[+M'M14RX;+RDB8R:DW&:"[6$IR_OH#)G*
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M0U(L<M1ITNNM$/T4BF,!D&#9RM5@(.#$P1=.:80:E*8CLZR;7]WM\#/^(O\
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M5+B9=]UM*G%2ZF'UO.2SA90XXTLS#Z7>!:*MN%M#M'*/H1-E<M6BE/M'S]T
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MR=QG#5KFD^5+2,I)OR<^)1\'B<F&7GVD.U#LND#B5!=Y-(R]?5M>)3M.QL?
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M4ZS@:<9DR#YI$UXZ<=F -@J/C9 &(8@&'DVOP_Q^;'%C7XB>(EN&X;P"1P/
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MEC <5G')5S$"M+CS2D>:VT1+N'R9:6FIYL2$O,.!:$OK0I390MM+GRW\6_\
M%;)>#YSQ7X(_#Z5:GO&WAS $8[*^$Y?S)5[$)8*070<0;:<=F\0E,/4K%)J3
MEBJ87*H_II6H*=&^T+'7U3LU22]'TG!4M3-:4?5JL2_I*A(SU#07;435S"(G
M)N4EF,X\AY)U7K""EXA@M/@P>0<I!(LTYA(E1*F]U-^&?PK\.87CDL:S>.X-
MXCE);RWYE2)F;PU.(2CCZ)5F5+3#R!AYF6)EP-*=;F&G% L\;+0^,X;^(O\
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MFVV>L'D$L,.8&&'3CW:=F&>[?> ?#G4_2HH;"O.)Q'UKL*??E6MAKL>02#\
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MI-Z5K0_ &WL*91Q?*F-Y$H#\X3+8B(B(B/-*;': CF8!MPL7527;3EQ.BVE
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MOR&OI4=[P_2:&T0_* .G?NXPL*U:@9\]/7^8G"FU"?V-MM_:%Z41WA^4&F>
M_?;OMRLXSL/C]_C#A3:_RSM8VYY'VN88R:.\.\ ]]G&2=/B/K3WAPIW^(/7(
M'OE"]*(;PV?A!M_M9]&_M&SB/+W.GKR]?6]X4[F_3Y4YWV/2S])H_P"CT9A\
M>CITLXSL/C]XG"G_ ''0YCTTY_&%Z41WEU_&#XZ]%G&K*WRYYU[RAP)O<VSW
M]J5@]*(CH)1'^L'N'J]MG$KE[G7UOR]*9B'"G<^H^I'OZURB/*OIQ"?=-7K-
M1)LX$Z:#XQA#FJ-PR!P!0,'.70+@0"XAY5/F%$Q?)EYV;;G""*#4C2I.GVZ
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MFA%KT ^V5\F]=4J-ZW'">ZQQS*C@5(NWGJ98:X 0.KLVZ!AK;K<9_P"6Q_\
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MT/-H4DA0!CZ+@\\]AF)R,\P5)<EIIET452H"P%MJW2X@J;6DU"FU+204J,<
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ME&2I* 7"2X$*2V$,*-@A84K^L32H%13BCZBB& B7+(<-=W7GCJ(>.%O,)4"
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MWV^?6-@I8^OOZ#O.-@&GX0=8MG_<E^'39%@&GH,=8ME_<%^%D(/5^$^BV?\
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M"H!AP*! 44+SL1 0#F@.)NFW[7JD#05H!2MB,J5&8Y'(ZF\?Q32TZ[7RFG7
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MTM??4MY'R<ZO)^;PJ=X4+RLWDC'3]84S4]4W?4P8;J*V0)+5ZRI-U'2B5/\
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MMOF\=S!9""R$%D(+(060@LA!9""R$%D(+(060@LA!9"(?;X^E97>,M)8Y?\
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MT[W@Q\>. LK?J+9W^Q'N?0PIGR[[,>-Y_!:[<0SUQ$/M^K*VM>0]=N6VYO\
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MLG.@H5^3 NS"].*O)8U?)1B,*>\$\+3,;&/(N,I9&L*ROBJ^*BJ,;PM2Q<)
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ML54"D!7GI"H0@E*4#JE2U ,]:2$KJ2*7!K4$B]#G<C0D&U<R(V*!4D"AK8@
MZTOZ4-2*V-#'*\FB @1P #AD17+: ?-,([><'S!'8($S#+'JL7ER2B92*B@;
M<H*T-PE7*M>&N5: U*JQ[GP=B?Z7<,=50CB?E2HD53^GSFP<CPJ(=2@?J(6X
M0"$DQSI>W<'2-[ DE%E'--U@U;>:,ZKB44%7"K9,3G0CIZ.6YK:>B45U#J(H
M+G;2+$%7)8>7BA?/3..\\'>/\>\%NK&'N(F)!Y?',X9-%2I9U=AYK920N7?*
M4A)=:/Z@$AU#R4!$=%^*OX+>!OQ>PYN4\3R);Q"50I.'8](<$OBTAQ<1X$/E
MM:)B6*CQ*E)E+K"CQ*0EMS^H..9KDF7RQBXDB%*&JAJ7$I7:<[*4Z]6UP.>'
M?0DDU:"<HX@B2HGX%-B K&#$0^^X?^/OAM]M)Q+"\6D7J#C2PF6GF:BETN>=
M*.*&=E,)58"AS'X9Q[_ 9XM9?6?#?C7 <0E"HEM.+RD[ALTE(R2X95,^RLIH
M 5I* H7"0: [-1/) J^3<I.+S)*+A8-$QS.:<I*4>2,W.I%+B#%6H5F$,C3C
M9P8 (Z6C$9226;&.#&1@GG,?(]%XH_'=IV6<E/"TE,,OO(4A6*8BEI)EDJ24
ME3$FVJ8#CH!);<=< ;52K#E.$^X_##_!!+8/B<OC7XDXW)XZW)NH?8\.X.A]
M$C-.M*"D#$IZ9##SC'$/U2S,NTET?I7,\!*#'4/4-=4F1=M?_3M2Q]%U=%2C
M2+@'49'2C:"F(Y>,*[@Z7I5&24EV5W$)!NEXI=JS8K1X&:TN>ET)63E)/TOT
M'B?P9X5\;R,C)?A\MG%<>PZ4\[&9DE^79GY9UMSS'IZ:G&FVG<5F9U0+;25E
M92Z_YJFT2Z:?7/ 'XO?B/^$6+^(L>_'AR5\*>",;\1MR?@9AIZ5G,0PJ9\]:
M9>3E&,%#[C.$RV%L)>7,S-/)6WQ%/"_1-YQ3M5W4,43PT8M>9<Q,MFTJQA$R
M^E)R%AY--)TT>TNNJ*R52T^=)8CILV*(KI$4*8IT!(Z?*_E+%L$5+HG,(Q7#
M48EAQ6[+SF&3C+;ZF%-N%#C9:>XT.AIQ"J)(*D+35*@4<4?T=P[&L%\8,2N(
ML8@SAV+/,MNR^*L+X,.Q1#C86VN84W_[K,/)*:/)):=0:_J!;0))H&]UJX0*
MUNYO@E8<$A\D%*3"S%^>..F&!VR$#6+-U(,T4A_<Q+'JE9 <!!(YL,_,R7AM
MV13Y?A/QMXCP"72:-X4X_*8WATJ 1_3EI'Q!*SLS+-)-@U+SB&4V2VE";1UN
M,>'/UES'/#,K-*().(,(=8+P5<..3F&NH9=4H$&KZ2]PTXK ")A+>/?&!< K
MZ*4 0R44HB*$X &A@,B[11,(A_S6 B(9#;L?R?XC)("/Q"DU).:G?!F'*<57
MFUB++?%8U(;3>EH\V< \)E1K@DPD@U*48M,TTI93*E 7RXCU-R=)JF].HV[<
M_KO?:M#M,#"*$<O3E%** &I$UF"!)E83!B )(/?*&T#'.W&F<$\0S:2G'_Q(
MQ];!!K+X,SA'AE"AEP_F)&7=Q,@W!+<ZA>RJBL=IA_A[#BX/\J\)-3#O%9<P
MB?Q/AT!*7UF62:WJXV$ Z4-!"+*\^->+.&]T-$3]>R;Q0WG=1+).HF%67YP<
MX\G550E\\?+%/^Z @8IC+@ @W4S##E8)A6!X&'4^',)K,S!K-SZO-<FIUP$%
M3D]BTZ7)V<65'BX7GG DJ_IA-A'J7<%>0E"O$6*2F%L-I ;DDK9?F4(I0)8P
MZ3'E,H(_3QV"<U(4F\:%4$PM34@WO$KJ0I"\JL(B4<Q#:BX2JF;&FKMG+=%5
M4R,D0B$W(MJFDGC8\=&K3<:V%5XU>@DY47B6B0_;? 'X5XGXNQ9LX],.X(TN
M1<G<,5,R#Z6I]"5)2488EXRR9K^]+C[[3JE-LI"D-K2I*T?G?\;_ /$AX>_"
MSPH^/!N&/^*O*QN1P?Q+_E$_*S$_A?YDDKFL>7+)FE8;+,I2I+4FID)>F%MM
M.J92M85-EW-T4Q=&_<5[>5+4'4=S;NE5)6I9J>\^DI&I'S]%LX@9DU&RL.^.
MWKE]('09)HLIB:=2:,DK#(GDWIH9!G]-\1>)\%\689A& >&L!Q#"/%<C--R$
MBQAA9;EDRC86W,2WYN7=9>=EDT#X+S#89*%.N.)0MQQS\V^"/ OC3\-?%'C?
MQAX[_$B0\4?AWCDM-X].J\0IF&YS#I]3S3\O,I8F3,2,LVF6+LHXF6?2F8 E
MDM2P4T@#E2^6_(]45BO4U0MG*;E9L#&F:70,W,6DZ437.9FQ5434%F$D_5+Y
M_.N6YG!G4@";1)96)B88J'Z \!^#Y/P5@K<DGA>Q&:*9G%9U*+S$S2G @J/$
M):7"E-,IJ.*KCQ'&\Y'\^/QT_%+%OQP\7O3DJXJ2\&X&MV1\-R3I4E):2JCV
M(O,I *IN=HDJ*DCR&/*EDD\+A7IL+4Z=6-E3PRXQSAH<@/$9!CYV($5\IY(R
M0H/FY13,8A_G\\QL2\TR9?FF'W"%\7]H%4YB^PIK2M*T%=[;_!WY$86XD3K)
MFFW4J\E3$P9>BD<(5Q<;#I*N$C]-$V->*E8^J?):C*L1N.I/_#D.BFM)UTZ;
MIK4VZ6/YL[O!JET@J50M2)%.FY36*[2$B8%\BN0 $X!Y0WX>_%-^3=\?>(E!
MI:RF8EF5J;>2A!<9P^4:= 265D%+C:DJ)43Q UH30?VR_P /,E/RGX*_AVRL
MF7X_#[<RVP^A3KK4O.3,S-2R%.\;/'27>;*3Y::)H*5$=*1L75QU@4-/P8IH
MCS@ :6>9J".!,QJG8/SAZ@ <C6\CAC,L\^'3+O<#)XJF8007*C@3>7&1_4;T
ML*YW]]XIQ!^3D3*HF&_S$\/+HEHI4ABG]19_JD?J'])(U"ET/Z#'2-W5*UHT
MCE);UB@&ZTC@5(%:1?*F!HD/S3A__+DQ("RG.,)1 ><1-$X"(86[YQQ@FB67
M/TYUF!GZ,4RW/MF?FK:'0*J6C]67](UI_P#E;7]Z;7B1PCJYQ#&JJ=$,<P"C
M7H"(8Y@ ^N(X#AB&. YYX;!U\;-#_16#0YOI]_\ DY"-@"ZBJTTJ*T:(--:?
MUC?;;G',G*NN!J^_BH;DFT A=FI 4G.5U(U8K>O=\%ZM*MD96C7$3"K%H0M<
MT O(RP2:H>C9-&94]"J 9THS6(?G$[/"I]J1:G2X9GS7D2R6A*3!E'5>6\%N
M#\QY$R$HX?[D*1_4% % WC4\V7%(X>'A''Q%:>, $"GZ0M!)J,ZD BXN(YT-
M=+R\J#;C0UW=XE8U'$4;$LJ8C*TJVJ+JW#"LKJJ>HJEH6'94RRE*9?U9!\I.
M1G&4Y)R5=7A%EKO#OG<@[D',M'/X""H_GB;P&8(?F95ME3SBGE,,LS84S-N3
M#KBU/+;=0TYA@;4A*9=CAF0$@);;6'7'=9;FD_I0X2 . **FJ%L)2$\(4"I+
MI(42M1* 3=5* :I2=T7+LI3UV7I1>M8 M9WFU]6-)$GJWN0E)N+J&3+=G$T?
M4W*"<M(F185;0C:D8&=BI2F;LUUZL*[1<"N,]+R4)7L!N<G, =\I+J&EF7E9
M=ETM2\^VVXTA$RIYK#D<:2U,%]QM2'9H)9"2F@0A+C"X&YI(/"5 *<6I(4XR
M5 E2:+>-"%HX004H)432M5 JC;I]OR]Z*N_GZM:.JMJ2]6"K2@64=3$O-7?U
M#=A>=.5S4%477U O2T#05!EK2@KGZ485W1MZB:]<3B<Q$FNT2;U$TC8Y.M:Q
MJS2@X _,M,J2TU*.,3*E/(3,M34JF7:9FFT/.S$P&9B;>5+S$J?(24+$U5LJ
M(88:I,TE"E"JG M(2DE"D.<2B@E/ GC0A(4E?ZZ$%%32JE'39^X7EV7>N;U(
MBZ&\B\R>1J:^*F*N4O GZGNQJ:7J>C27 0E*^3IVG:HG*.9TI.1U\D G+URP
M7-"1,A2(00TV>I4F]1TA-[VL0P&8_*N3LM+MEN36Q^6;8FFD,O&?<=XG%L(=
M+R%R:_+ES^M3;P<*_)4MIU.M3,T@+2TXM7$XE?&I:%$I+:4T2%</"0L574TX
M>$)20% _6BET9]M35.MZK>LY.J4(*(1J61CF@Q\>_J!*/;IS+Y@P%9<63)W)
M Y7:M!77,V0431%93F<\?)N%LN++22AI3BU-(6>)2&ZDMI4?TU4E%$J-!55[
M91SQ4) 402  HC)2J"I%LB02!8 9",[QV6Q%]NM-,OH+ZC06AWZP<=>7AG[+
M#4Y4&E2.F7=Z#2'?2_QM\XNI#ACD Z:AUZ6P7I??Z=Z]8S0*UN1ED>N<4'^_
M-_7-VZ]_U6SISI>MK5Y'>V?2,?M[7^%_G%&G3X=_&FRRXK>M?;+,^U_@(9\O
MC[=YZPQ^S/CQ ;#URJ*5S)%AUVK7I$'\V[^!$(>K'W8XAC\>@;0[4-B.EP1[
M#46WZT=:?6E#3[<Q#MEE7F?L(D'''&MI4][WJ#G2G[=7??>4+KPPZ_JRPXPL
M.YI04(^I-K4_DB+TK6^G[WKK]8.OX>_/;E9M?;E]:[V^!I#I\;_2VEX>0<<8
MV'VI6]ZY?'I>M*YBD2Y[[I'C>Y(Y;!V<9;/#?;!=+#:MMLHS1K77E7<5U'OS
MV,9NB/Y(7_VD[P_)1UW]EM<;1D(Y,JRZGE6+W=<H2+G;WFEZCBL+Z(:K[IZ6
MI&-2N1GZ7N!9UC2$M4EQ)+PH.3(]6J>H:*BZLI)E>&Y=Q$@20GDWZTU"(J$<
M07>,S6%"9PY;<HJ5#4DMJ;>>69UM>(*9=0U/_EUI(\EM]33RI8)6GA;("%J%
M'.*IN8X'@5ASB<"FTI_I$-<0*FBL7JI-4\=:UU /Z8.?T=RV:>D:41N"I2H;
MH+LY&\&=E7]$U?7%W%[\[!LC_<K8Q1*N;U75+]E1]UK]M'WI2#^AKE;PZLJ:
M-?OHB4AI2/6G7<!3?-#V"NI=.(NHG9I,LV@3#+,S)H<72;4LM%IH*?FD*5*(
M2_/2[+:T(6A:5)0''=!1-)X?)26D%PDMJ6APC^P?J*E$(:("R4-*4H$U30D@
M1[0UVW+[N0NQKM"AJ0DJAJRHZ"JJ%IZ'3K.ZIZYB;T?N!7/T]==7K^0KB>&*
M"F*2O I2O&%01S5X^<R2\VQDE:5J.,,+MGR7YGP]/S<L7W0RRT^RIU?D320N
M6_/S3DVRD,(*RZ[+N,EM12 D)4GS$*H#J0W/-(>X$E2EA?  ML\*RTE+:B5D
M )0H'B S_P!JHE)E1_+AI.\!LPISUL;W?R%_R]4\R$E+B7E*A=W5O*YO!JR]
M$]Y!JX(^O,\Y>7#RU+C=VQNN=ME8IP:2CY9!A,,VR*O#6[@3TLHN!HS"</2S
M5:)Y#QFFL)EVI;\K^7*97A$^A[\RJ<"N,%*D<2#5.Y")M"Z55P%]2[%HI\M;
MZU+"^.JZ^64\ ;(X;BV49>J0Y9]'7!\DZ,?5/?!6M]E;7BTVARC'5VE-\G@:
MIIR(<<G^\^H:HI^GGE3TJG<M3].P]Z%/THS1J>HUC'E'KDL,PJA9>HX6+-K1
M_DSN(8HI#<HQ(LR[IPT3*\1+3BQ/RS;2W4M.JG5N+E7'EEM! 30J4BC:C&2O
MS*&6*EU;JG!YO!Y(4 6UDI2I2 T %!("B!4ZU($8UO3WRBA88D]5U:U(XD!J
M2[B*GJ)N;;<G%K*%I9/DW4HK7537=2EZ].+P:LJXY3XS321:UY+-D$KNT9Y6
ME8;SAQ3)R[2YX=*RVRRV$^5,*;?G58D4>:<3<#+<RB4<\S@3A824J805&94@
M.KH'!&/#/?W*6K-(*&@P#P^2"2@K!%?.)KQDCA"@@?J!B&YODM<KZ\A[5;*\
MTD>U;WCU;<Y,7DR-'O;N)&&E46*GR<C.]1C!Q5?QM3"6A7#>ZSE,//4N6@SQ
M=3(P[-G/P4TWJ2.C9SFHQ7!99+)EDK*I9F>;ETO)F$K!6GQ)^44ZMA;=9A)F
M\+'GMN!;14I2%H+16G6J7FEE073A<4R7. HN0N3\P#C!_I\*'R44 6!123Q
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MX 9503JG'G&$;?@:9F)K%L0F9QY1>FY^9=F7EG_6Z^XIUQ9T2GB6HZ!(L
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M+00A7FK"EJ.0L-!<=K'Y2EY1[KZPO$:W-P(NFG*1-R?KNZ?>WFOVPU6@GRF
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MJ-#&OOG].]H+.H^9[ZZFFH$(-./C9ESWORMG:IM;G76&??VA;1Z>CH^K4>@
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MS+R!1#KSBT)H!^DDD&P-*_W4W-3>L=)<G>Z=[>55<95,@S,6[RDY1*37?+(
M+6JZBAW!%XR#BQ4YH/(Z*E4D)"HI-(J\>*\>6E<'3AW-EAOAOXO_ (@2N$89
M->&<,F [C.(M>1.%I8)PZ1>%'@M2:A,U,M5:;:)"VV5JF%<)\@+_ '5_A$_
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M7G   ;' +:R*6(IW\NGQI2,Z[*!!.MJ"]:9'8#[13Z4J8,!&2'4 R9L]<=H
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M9_+EUM6F6^9Z5J4<_28[?\S9@&O^K].'4.6RR&7\^FO*\'I2IOI(<\,_,VF
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M$(2 E*$C^U*4T"0$@T  % F@M2GI .=IF.&10PST$,0Q$=F [1P#9G;$ DT
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M,["I'7EO#]F'&=E/:E*?OTB?.O=H+!M86RS-,@?N*^L(+/ET-@*\Z#]CZ(0
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MZ_\ P_6*;(RAAKV&]@V1#EZI^8@#0W5[PL@<T]?H88;/ZIO_ '61#K_]2?\
M\,4V1E#V#UA[#61-1T/S3 &O8;V#9 Y>J?F(5D6"R$%D(J-M_K&]UD8IT_\
MI3]8ILC**OPB_P!GV!9&/^E7_B^9BFR,H+(060AAH;J]X61#FGK]##'[TO\
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5H?E"LBP60@LA'H0_#_L_^ZR$?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g210084g07g56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g07g56.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[13P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %-2^4S(X0DE-! 0      "D< 5H  QLE1QP"   "YH < @4 %59E<F$@
M+2!38VD@1W)F>" M(%8W8@ X0DE-!"4      !!_=CUWV!2-Y)N*F:%AC%DT
M.$))300Z      #E    $     $       MP<FEN=$]U='!U=     4
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M;       0F-K9T]B:F,    !        4D="0P    ,     4F0@(&1O=6)
M;^            !'<FX@9&]U8D!OX            $)L("!D;W5B0&_@
M        0G)D5%5N=$8C4FQT                0FQD(%5N=$8C4FQT
M            4G-L=%5N=$8C4'AL0'D            *=F5C=&]R1&%T86)O
M;VP!     %!G4'-E;G5M     %!G4',     4&=00P    !,969T56YT1B-2
M;'0               !4;W @56YT1B-2;'0               !38VP@56YT
M1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;      .8W)O
M<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M  UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L;VYG
M   X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F       .
M         #^    X0DE-! T       0    >.$))3009       $    'CA"
M24T#\P      "0           0 X0DE-)Q        H  0         ".$))
M30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       !
M #(    ! %H    &       ! #4    ! "T    &       !.$))30/X
M  !P  #_____________________________ ^@     ________________
M_____________P/H     /____________________________\#Z     #_
M____________________________ ^@  #A"24T$"       $     $   )
M   "0      X0DE-!!X       0     .$))300:      ,U    !@
M       $LP  "=L          0                         !
M      G;   $LP                     !
M !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !2
M8W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T
M;VUL;VYG   $LP    !29VAT;&]N9P  "=L    &<VQI8V5S5FQ,<P    %/
M8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '
M9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90
M  !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P
M(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P  !+,
M4F=H=&QO;F<   G;     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M        37-G951%6%0    !       &86QT5&%G5$585     $       YC
M96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH
M;W)Z06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT
M"79E<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0
M   +8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO
M;F4    )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M    #&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M    .$))300H       ,     C_P        .$))3001       ! 0 X0DE-
M!!0       0    $.$))300,      I4     0   *    !,   !X   CH
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M)086HK*#!R8UPM)$DU2C%P
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$!_\  $0@!(0)> P$1  (1 0,1 ?_$ !X  0 !! ,! 0
M           ! P<("0(%!@0*_\0 6!    4# 0,'"@0$ @8&!0T  @,$!08
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M?J>^,(4NOY#*Z@T#A"'NUV4OZ=#YXCZ]H>O7\PJZUTK"&M:]53"X4Y FG7+
M<J\+J0.M:XPIZ_CD.]_'*Z$*9G70W]#<*\2+X0IC[UQRRR'YNA"W9NH"3E3'
MT/ST<('K6%76N_O"%-9=L.MT(5.-^)U3MCWPOA"K"%3"^O6NJ#ZTX4A#MJGM
MW]#VATA4Q][L"+Q]_:M#"&OG5XZOUPSKG#7TA37Y\X0J<L<<,OQAQSXPA0?G
M"[EZ\^O%#6M=]+\?8U[TIEWSAK6O*%+O*_7GJD(4X\<?IPX9GO2$._[ZZ>:G
MGEK\B[&O!Y?C66,-=]*4\SZW^_I=SAKRB.&[Y]W'?\:>=#Q/&@S^=]><6^OT
M\[J?*'PZ.&NSW^IGVPNOIPON]J&_*CYYW^OS].<U1SOB0IK6J0A4NRY8'C?7
M'\WXPAVTZW]LN?SRATA2@X:U7#B>,(4X7^>-/M47W^L(580^%:<<KLN_M2MY
M%;L[B(?.%:M9]->8A"E?45]OK"&NZH1VX4K\OMUK2'W]84Q].=X/(Y<N]<D-
M:U\:9\OGKRISAK6OE$=E^GIM]M=N^I>;Q3$XUZ"E./'AQJ8O499'\ZZ4AU>.
MNOL[JN-*<C6[5XY0X^VN'7SB?A0>UU.'#G6F-\3YPIAYWW]OO04OA"F .5V7
M(:Q&6$(4Z95&?++Z7><(;_?2N'/UU[0IZ0U\*<,ZD$W4][^8SK3*&OG#6O?3
M77ASX^L-:](CM^EN'3JU.O.^^Z[,W<^%W"+T^YORT8FEQZ\*WBZF1NSX"O.)
M"GOY\..5W*M#2^$-<-6H*@=,M#[798!J_1BL1^J_[?C;KX]]+Z#CS)'N"?.!
MQ.O:[RBF/]8_W"\;T2* =!K[YPCC5A#Q]?NYNC7/4ICQO%3CB?3ARA[<O7'/
MC](5>>N\(5/N+NM.'O<.E:H51??KEKRA"I4?7M36A"%Z<?3[7YWT-T(:UWZX
MTI?T%WS^6)KCSJUKRU=#6NCQ]]//6AD?4PUK/V](5=:Y\N-T(:UKW\::UKUO
MAK6O2Z'K[+>_ZU,+^-,[NV''O3C#EU.O*&M:[Z4O[].V&&//J"8:UKRA3WU4
M9\+Q4X0A2_WRY&ZX=.%>N*%/:_D?6G/'E"'UU[*<JU.9N]JY5]1<8:UUB+=]
MNCLUU[[^NH*77UX<<!RQ(XWTK?C%/D<^NN%!RB:OGZGA2_5<3G$A0"@ QIQI
MEAK'WA"F.1&CP.N-<$*>I[B_Y TZ&_NA]]?'WU;O+'6N>,/QK72%3#GUX_+L
M(0IUT;LJGMC3CQ0IAZ<S>::-3]4-7ICJMWG2^X].L-"%/;A3S\ZCRZPA[M>V
MFLJC7TQAZZ[0I7._I3UNOUA6$*?6\:YD$GSA"G3 7:%.E.1Z0A3#ROQ-PQOX
M]?+&$*OK]#J_VA"G2$1QWZ]7/W7^_-+\/8WY8U[W_.+=37/#S'XQFJ-?*OEC
MG2)"IZX];ZTX4[BF4(4X$YY$X'@,CUQ^2%/ECG7IG3&F=W#%"KF<<NG;YPA4
MICASNK=TKG3O3"$*&M1Y'Z^F&=>4(:UVTU?C>3Y#ARNAK72&M?2F9QXX]J"^
M[C6Z_.&M?>%*>6KJ8=-50JPA0@''580^-2X4QOZGGK[0^4*OXSUWA"GRYZKW
MA"H<NORSNNS]+[X0X>WI^%,";O+EQSOP&.%V<+^V7SA5'?/&$*E_/#H";^.'
MXO,(:]G30T'+',\:DW4IUP%>&+7?*%,SCAUPIAC^1@80[OIT?&EV(IA=3AEA
M6[IY0\\_//Y5A3O];L?EE[W(4X4Y7<OL,*0A5OZ>L(5,>&/L>/(]<QSA"@]M
M7GCWSZ0A5UKSA"I3TP-WITPPOYPA5/+'7,0AQZ?'Z6J7W_*\^W2@H>]879>W
MW,* ^EQY'Y]<X0OK6Z^N^RGK2[WQKEPISR(#6JC7D5.7GC3CB10W^65(0YM?
M.E10W\<^Y&(H>]T,=?2''L]7P^VZ@\N7O7C??6[WJNZ\^^/YK#XTNKG?6[I0
M>GD><./*'W[-??UNO7*X\M95QK5^.NOQRK$?KO\ MOXVJ'*M#CC=\B*\_*XP
MUK76*0_UCZ?S"\=='1?GO>@RS%!3B+AVP.(IGG%]-:SS& $1K6N-7MT]L_/F
M#=6E\UK5T*7<,-?/+G"%6F>M<X0J<-<<:#IP^10I?05QY#7G="%+N5]*#*[,
M<P*>0PAK6N,*:P.J'+YPA0G\9GSZ77WW\H1';PZ^/OW\/53F1UH<*\[N7.+T
MOX7>E+^<30T%],/87_<<XD.W=]-<?=ZZ=:9Z^9X8<X=*_?5WKRAQ^?;K?2AY
M4H:CG\[KM7+OITU2'M]G#Y;_ 'U.)QOPX<\*\#WJ*W5=N]_UIZ0]_P!_A;OJ
MU[\L/?&@([^CT_'S/E"KSU2$*G,TQ&/WP-<!\R3"'-T=W1KU4& NR\KO/EF8
M8Y^>>N<-U,<<O6Z_MRO'?!6%*USH?7U'(Y0A3[WW>OV[PA5UJE?KR,(C=;=N
MY[>O71T5*74][P/L(M36N!Y:SSB:974NNX4^EW+AE$A3'Z\1V].](0UXZ^],
MSYX<:^YAKVU^(4QY>5VM<(0OK7"EU*X7#A04-PX8W8]Q :U?#?\ +6N?ASU*
M@4KE45/;TP%2:UNO,*?76L+\(5JUK5\(:UKGJ<]9TKGG?P(AK6L(>_7PYJOU
M/S_$/37SQANMU>KV=52@Y5I0T&1^O \^<*GCS[\84SSY99UQQKQ%<L*0A0=J
M8BEW/1SX<4/'7;3F/EZF^Z^MW:L/;72'?X^&_P"]3&A%>-]3SIVY8&X7U$/+
MVSYTA6K6A3Z0A4XTPN-QSQ\C=EF>,(:U]*>9Y]?I=>/D8:U]X4SR]N)[W'#J
M80UU<]*CIVICUN\\\<8:XX0IAVSY9\(0J]J\KOQSA"IS[8UNKTNY]+SP1%_M
M[..[71OH?6[D<<R.]V=](H_/>ZNLZ1-#AY95]!H1(:]OQH*TOIE6['CZ798<
M(:[?*%,3R'K4>8I?PZPAKQUQX<W33'CRZWY4RYW84AKVU=?CE"E+N>!J*X\@
M:=?6$*4]#Y]??K?6$-:U]0OORH-7:Z0UK7V4K<#[:KZ5Y0AK793CVR-<3PRX
M8YPUKK#W[^KJ[_"G/C074NX'S/M=#TIQX^7O#FIYBF?W-="^[%C"KZZ[0AS:
MUPM]+=%JGGC^<<NO;*&.M7G[G,PIUUSXZSA"KHZ[UX]80I"%08]N-??I?0]<
MH0IGCV\Z^XY"$*=-<]5O[PA37TN\[[OHA2_+'651KE"%76KO2$-<_5\^FH>%
M*X'&^XW8\:>]_%K#C],H4YW]_3'Y=[X0IK7/SP\D1?VV^_=QZNFG6HYW<<L<
M>!QKY4=C^/.[CE$ZU]:85/'D/,X887GUB:U]H4N/K3ED=?2$*4KK,9PBL1^N
M_P"V_C:G'7/Y^]_!%,?ZQ?NOXWJ#(\A<,Q2ZM].-_J,(1QJZ^U;N-U><(4XZ
MI=Z8<_HA5UJ[53RA"IGE3 =<_*GO7DB/=XVW\_7TTIJF%;^8)J*ZOOK[&F'#
M*)I7+"[E<!WPX>L2&NVKKK#72%/KK/E]L80J$9#B#Z^>7E<*9(4ZZ]N>7E?"
M%7SUEKL<(0J9D5K?<.E#3&G"F'&^^$-_VX?/V4KAB3PNK\N!PYPI^;_IWAKP
MUK@ZY5-!?7@>1N-!](:]]:O4KAPSN).7#[PC7UM\[6$GV=8["HCC8AM#D_*8
MI(<U/KVC_$FJ&1.'V8BY/);--S22WA_NNE,<9XTV+3"VL*IR5OSD6ZHH\?'G
MK)7PSV':VSM2:_7.NM679;;+DXEE6X],.S"G Q+-N$'PT+#3RW7 "M*&PV@(
M4X'6\,_'+XM,?"#8[^>(DT6C:]H3:;,L21=642[DXMIQY;\VI!\3]+*LM+=<
M2W13J_#8"V_%\1&I",[:>V%$G<Q[3Y\<YB8<9<Q0PY*A4"?8DK'<8A7\ZW1&
M/P!_0  $6X!$:E4>3AWAL:2;8(0A] SWP@V'G)=+#5G/V>X@41-2<[,^.*"E
M5":<F67"<RXRHXT())CPK8G\:7Q/DK0,Q;5G;.6W9[BZKL]N4?LQQM-:[LK.
M-/S"FZ"H!F&)O*M:1G?C+RL+7>Z=OSMB![C8^4 HV9XI77GT=Y(0VL<Y.T1<
M"&.<L@#!;[DM$82Y-4@#:UAKS+WWVQ3;GP,MF5WW;"M&6M5H54F7FT_H9P"^
MB$**G95U0%*K6[*@DFB*X^H]BOXO_A?M*&9>WE3VQMH+"4J%J-B9LLN&E0W:
M<H%!+8)/]I.2\F+KZ"-C^)]HC!^<TQI^)\G1*9J4I?G7%C;W("65LH;WW6M(
M(:Z!0RN/&7Y[$OC,WG7M>PK O:]KWQ#:U@VU8;GA6O9D[9ZBK="GV%):<.']
ME,)WF'NK+JQ<;[C'IJRK9LBW91N?L6U+/M:2=&\W-6=-L3DNL8W.RZW$5O%U
M:BHK2+S5Q%,.7TI=AK*.3A5K7"_6O(PA3C6_6&O6$.C5_#G]E2^ARYX^E3A^
M+H9Z'OAWAS\_7]M7Z?9>F.6!YXC#A4?2ZN,,,.'YT,NXA3RRISU?3'C"%.%.
MGU]J7X>A0[-?.G'YX7_+CSK#KKZ0J^>M?+JA4K2\\NGMKE"(]ORW<-6[>:^Z
MI6N!''E=2M^J X1>WUK?H],16)J]O3AGZ7=J1(:US4ONPKG\X:UC#WTR\^>>
M&73YYP](580ITIK+6' PA4^^7/YX^L(4\\:_:_YX<J"B%7SUT^5T(5,_;TU?
M?C2Z$*M^LO2$*G*ORUVXY70A[^?[4Y<+_6MV XWG BIK#TUC'E9M+6Z!Q1]E
M[J0M5HF) -6)"W!3C<7$^XP$(VU %8I1(;+7)::G0I!KEJ)" ]06-:M1I G*
M2_JRRJ8>;900%+50%14$)%Y4I>Z%'=0FJCNI4L@'=2HT!BE!*2HU-+Z "IX
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MYD*&2M0:WLS\E,>$X/.+(ZN H9I.@#>U_P R^,O!*%^0@M<-[<M4WE 'R;W
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MH),&4:6,L0@WU(6MM25H4I"T*2I*T**5)4""E25@A04D@$$7A5*$$$P(!!!
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MX6W\.K?DMH%R@>5+(6$V1;38>9<86VTW,*F+.F%%EUQM2U3<L5;U4,I) 3B
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M[;.&8[<[Z^@IWK6HO'6>'YX=C8+*VTCCO#\\Q1C>3EOZZ3Y@?TK!'B(^WHW
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M?E4VE#8L1Z# < )/7)QWN-O--:8DJ<P+K;[7+$N)D6T)%.04&_* HBY:C]:
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M83<%O>B#D1!J^Q*W+ 6E82M"@M"@"E2"%)4%7A0*30I(!OKNFHIG'F!JSG+
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MX6S6SC_P_L*WK!V<L_921M*RV[3G+(L^09D6Y*:0T4S[*VVFFMY;#K+K96M
M6H(!4 JX?GWQ6D3I@[)#1+Q&/"59-\P;8N2KJ;AN-\@>-C[(%I+J&]KEEI;M
MFRAF5:06=80C@SQ665R;.(;&Y.MUP,*V_>E 2+.L?9WX=V*4D J5.! GF4[H
M.ZI"GTA0K3]N[F:<?9:"^-DFW_VF>M*V-L+2WA<CP-\R;I)IO)<!0 :8T-]
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MS)E2N'(WY>;8AI:9DVR%"@61=.\*S$[2TOZ=X?T![TL1HG0AB)4DJS/IM?\
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MG)2\V$*(IOM%Y"E-."@*7&U)6D@$*! C7!D[R4,@0^DN&"<Q%N)7^L3PS-2
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M:N"^*&U&UVS6P$M(_"ZRS;FTZT2MF(<0E@(LF7:EC^IM0M3KC#4T\5->'+M
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M6JJE&]1)OCQ)MA\2MNMO7U/;6;36I:Z2OQ$2CKY:LYE618LZ7#,DT0/VA:&
ML@#>43?%3C?A[=WTM;NYK;JWT='CJ%^,YEGCT[!N+X\GF61)TS+DB*/GG );
MV]IN7?\ $91*%P@&D1^--) 1#$[N(2DZEX$UL3>)2^NS6@5<)M!M!9>S5G.V
ME:TP&)=LI2A*:*>>=6H!#4NU4*==/]12D'=0E;BZ-H6H9V_A_P#AYM1MKM_8
MDU8\M-2]G6+-BTK1MOPW6Y.43+(4MN7_ %("4+F)MW<ET2[:RZ4.+=4D--N*
M'UHU=E%E!)B54VN#:K4-;RR.:4Q \QUY0CNG<F!];#P@5-3RU*0F(W%M5E%*
M$J@H99@+;N/*RTRQ.2[,U*O-S$O,-H>9>:6E;;K3B0I"T+22E25)(((.<8KV
MJV8MS8^W;1L#:&1F)"TY"9=9>;?;6D/!*U!$S+N* 3,2TP!XK#[94AU"@I*C
M?3[/5SWX6[./1NO\..^_M^T==BDH3IUB<U,K))5)CP7 <G4% .)-"*VZX#2C
M0C+,!?=;>$8;VO;HZT?5B8?EG4/RSSLN\VH*;>8<6TZA0-0I#C:DK2H&\%)!
M!O!CHR,Q$[+)3?+HAE-?@:X',(6S^'71<W19U=.2-7=,^8\1C'%9DB. 28)>
M@>F%=:Y/+.)/0+K)UI/ 6ULM8&T##K%JV5*31=24_J/ 0F<:)! 6S-(2'VEI
MK<I*P+R%!25*2?17PC^*?QX;MMF7V1M.W]L&;/0F9G["M.<5:,BNSP\A"VW)
MBTGB9$+4L(9<8F65I<(W$N)2I!N#MF^4ZV5<UK-A?/T:G+2MS-B-[)>,SXS;
MHO.R$R9"6X0Z3OK,CD#['6^//C&<Y0]^9&5(G?5;JL13%,,](&PW'T7!UA_#
M[:&QD;=V%-R3KEC6S9KTK9%H;[#OZF?DGE3%CJ<EY=U<TQXH4K?=<ETMMS"4
MMA55H2K]/YZU6[13LG;#+3DO/RDY*S,[(.;OCR<I:$MX5ILN+!+"G98J0AP-
MNJ20E:TJ6E.]&K>&[7T3B#WB5GQ7$9YD]\PUGYXR1C],G:?,F3"*KE.,RRX4
M]D!$N>BRW>^)&Y2,E*S.A2,F>RO<%4K-&D'WN<V6GYQ%KN6HMB49MW9*R['M
M=;KS02Q;]G*7N6J@O+;:?D9=&XHK#J9A:E-I;05)<\/B)5*I=4BF6H563M)/
MS]G@!1+EBSR#XLJ TA:FYEPK6GPU)2W^PE:@DH*LD,)[*GE6LU(L;-^(-G1T
MP7&\;9(=\H0#(F6+7@+Q#I"_@QF#\03"F@FUZ?&5$;B2'N#>G9\</UK*PNJH
MT*I(ZV()X>U;;^']FN3[UK[0LVM,VA9=G6-:DC9"?Y@S:DM9E"EUU3"?"E)U
M\U0YOSX2RR2TVM3NZ\GDI*Q;1W)9#+#C2)*TYRTY!Q\B75**G?$!EP%%PO2[
M8<)W@T@NK 40E(*#G7.O(';1V0FRV7\][3ZG::SP!4G$\0MX?I.C9G*-DE+!
MFQ]@RG+5"QWNJ3JSRU#*V*(U"HX('GVPQ<PE*+.R;A[(^-&S5G3;=FR.S"K&
MV>HK^VE$RR9E+QW0E]V1ETI:*5)20ZI,Q,3!N6"LIW#\MK=E=K+1L&T$[-[0
M2,CM0ML?H)VU9-V?D6E!6\I"T>(%)4H$I;=4R^TR5;RI1\#<-XX)Y/K:^E2H
MEG58L8\/M:,L@@;SDV?0IQ3%I 6L3:S&SXB?<G+796E+"&X4#PJB")0"UK!>
MBQ;Z[3:?QJV-DV=^1<GK7?4"4LRTF_*I2JE1XSUH(E0D5N)91,*!P28\-6#_
M  4;<VE:+S^V&U%A67*K?<=>>LO]3:T]-J6LK<6AMZ7LYAGQ2I2@MQ:RDG]S
M N!S_P 9>2GQ4S73K\S3Z99<<@"+--86<Y1BO'X#  W?X;5%G-1.5H!B$*RE
M*^9'=6A:6$)9S.$NYA8L1VY\:MJ;2*FK+;E;#EU;P!92)N=W213>F9E(:20!
M<6I5M:25%*B0"GU1L5_"Y\)-C@T^[8BMJ+1;W29[:9:)]'B"BMYNSDMM6<BB
MKT*,LMQ "/[3>!*MB^/<7XWQ,Q!C&+X%$,>QZQMU F>&QUJCB Y4.W^*M5)V
MI*E K7GWWC4KE5CEBDP0C#SC#!"%?%4[:$_:;ZIFT9V:GYE0H7IQ]Y]REW[0
MIU2R$C)*:)2+@!2/0<O+2\FRW+2K#,M+LI"&F)=I#+3:$BB4H;;2E"4@7 )
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M6GJ%[BN4*%RY0H6*#CC-LM:G5J<<(6I5Y.Z!D  E( "4I "4H2 E*0E*0$I
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MA: G;'FK/59EES-K3"V)AN>;5+RBF$.I;WFY1SQ27PI*"A0HD@KK0G FT_\
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MX=:UPH::TMJS;T<,\J,*7QGA]QBY.%]H*!YS3N.5Y.SI%3Z9!FR3(B6*\;@
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M#]JHL;:-^R'K<_E%I)6U_P!%2\_*V4[/IGTH59XE56G.-2<M^HF9>9FG4O\
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M5K2C>\S8,BN6:?F%UH2'GW&SN(_J<2TR]-*2 EB6?71$75A7E3=H5I7EJ9_
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M]KUC]04A2DK2I"TDI4A8*5(()!"TF])!K4$ C"E1&3>>(.!R(XCE'T<W-S5
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M!-H(%)B7LZ32MIK_ #-P^$Y,31>2M]#B!+;B XYKY7$F/+V;*)$O>)9+%'+
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ME[<R36SSCY4VJ=LQ]VUI:74HD-*;9>:E)IUM.ZGQ@]+)<-5EI%-TY>XJ\E+
MFRZ9RSKD:2Y07AO8PR*0X*S%F/PWW^< 4J$T.SAD1W.3W_P33Q3QI9G0JPKJ
MHL0$T2<..[?^-FT=HA;-CR\O8DNH$!T4G9\BA!/C.MIEVZC)$J5I)&Z\2D%6
M?]A?X4_A5L=X,S/6<[M=:C6ZLS6T2FWY1+@O)9LIM+<CNA5Z!,-S+B:"KBLM
ME./<88XQ*P%Q?&,$B>/X\6.QMVB(,#:PHCU&[<)8K*;4R?TY>=>XAJ5ZRYZU
M2:,PY0H--&,8L1S]HS]IOJF;2G)F?F%5WGII]R8<H3_2%.*6I( I1":(2*!(
M  IZ/EI66DV6Y:389E9=E*4-,2[:&&6TI%$I0VV$H0E(N  $:QMF#_Y-.VUF
M39L46]"AF30&RK&B;S-R$9?H29RF,9;V8@.Z]D:>&K)G"U2X_P [=09AQ&2
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MK/9F%MK:$Y-.S*O%F7&T+5X#(9:0TY_:J4XL-EOHIGY+7:%CT@&V8IEN*YW
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MLDK"JBE(XZ;E!8HVBVB9WYJ8-E(7+26Y1++=E23JD2K2JJ*Q,NI"U50-U1
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MO?T1E&.P"3,.VY\"9IK?=V=M9N90 2F3M1/@O4%X2B;ET*9<4< %RTNFM*K
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MH[/K??\ ]0EJ^P^=XC.S/]*__P!^9I_\P[Z4BY5;71'7&/K'@F[_ +SYAO\
M_ 6-_P#^PY5ZNNMRL?YC+@_ZU.#A=X4CP/TZ#"/D/].Y3_"9_P"-_CPCWOJM
MZM>[[UM>6&& Y\,JZP,?7F>>O7\1X[(<=8)?C^<Q.5HCG*+2B'2:.R5N3JU"
M ]P8'MD7-CRB)7(S2%:(Y6W*5)!:M*<2H3C,"<0:6: (PZD *6A)"556@46
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MZY*^<Q_Z>&^?\-S_ '/^?T^4/Y@N_P#2C)?5_J8/_GFI^F;K=.2N0QF,J_\
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MB;'G%6:9<S0FPA)8,L&O'\7>WJ[O@@N4(KN@W&D<8Y\4_AZS;IV9<VMLE&T
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MN*]E*]0H;S#59]KC'>QR@9AEKB%>PMXK[_NB:FD!(1,OI2D )"7G $BF"0%
M)%P_I%.6<:"V@FI0@DXDI!)[TCN6:(1..+75QCT7CK"X/PD(WQ>S,K:UK'D3
M8ELA;1.RI"F(/<1-Z((4:$2P9UTB6UDZ>Y9-N16A;KKH0EQUQP-A6XE:UK2@
M+42K<"B0G>-2K= J;S6-0 36@ *J;Q  )IA4C'O'HJT8Q85,>.)NPY<1=GF>
M$(^-P;F]V0JVQU0HW-M7D&)5S>X)B%J%:E.#<!R=6D4@,3J"#07N$TDXL98P
MWN$0;VONK4%*0I*DJ4E22"E224J20:@A0(((QK6% :@TH0:@W@\N\>)!B3%
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g210084g08h64.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g08h64.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1NL4&AO=&]S:&]P(#,N,  X0DE-! 0
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M:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T '4 <
M    "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT:6Y0<F]O
M9@    EP<F]O9D--64L .$))300[      (M    $     $      !)P<FEN
M=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R8F]O;
M    4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;       3&)L
M<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;       26YT<F)O;VP
M     $)C:V=/8FIC     0       %)'0D,    #     %)D("!D;W5B0&_@
M            1W)N(&1O=6) ;^            !";" @9&]U8D!OX
M     $)R9%15;G1&(U)L=                $)L9"!5;G1&(U)L=
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M8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N9P
M.$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$)@      #@
M       _@   .$))300-       $    'CA"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M    !*<   :4          $                          0
M   &E   !*<                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P  !*<     4F=H=&QO;F<   :4    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   2G     %)G
M:'1L;VYG   &E     -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MQ2LFR?FEP_-Z?3Q<#/.1B3$ #0#Y8\4
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M9&=XA:.EI];_Q  = 0$!  $% 0$              0,"! 4&!P@)_\0 :Q$
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MI/=_S%TR4E9J44Y(J%TP1*_O"&BQW8*PL)!(XQ6V=DIJ_N"MHT@K-XH^[E]
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M\;Q,C6\:1%K##K33KSQX'5GY!CPW>7;KM"1K$GA>9@6]K7\XQ1G;W,<^/O\
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M\A;C?R^=_#5?Y_M^GRP<\X693KX_H)];^.'74X6_AAS\O<(69V$6CT\1\.7
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M::?7NUTFR/6*F B28JK&(0#J'$")D$PF.8>B4!'("4E1W4@J5!(2D$D@ $F
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M[C;0=>;2I:2H8]8V_64E!L[[U6U#5+3,UVRG'7WE!#;:&]ITCBU*/!+:%+(
M)W4D@''>'Z->YR\&[B@[R:RO#IN4HM[>E5T2_IVDY]HK&U.PI:F:>;1#*5J6
M(<%([@).;E%IARW@7Y"2;&%1B%Y5NPE'KV*C_P!%_L8[%;2[ ]@-F=G]LJ9.
MUE5-;M.O9IW$/LT;U>Z"BD0^@E#ZV*=ICOW&RIH5*W4,K>90AYSXY^UCM/L[
MM/VG%3LISOJ.CI&Z1%1^+=J%(4I:UH!'Y-Y4)5_6 DP;#I,&8>(>&7&WJDS\
M.%P8D3(-\LX\\>8&Q]#ZWY8?NYRM?(2/28%Y@\QX9YC$^?5\'//(V7GEIQ_3
MW/PPZZZ&"U_73KZ?)@]WGSPM(!U-I$Z^OQC,VXC#Y^W7/&H>GW>O3ER&A?I*
M7FU;"U;4=/4]=14K:1A:%J1]1E6ORU*@6E&J<)648FM(T@Z3>SC98]5,FSMU
M3C9)>909/5&16JW+[ I':W;6S*5EQEMQRK:*7*AM+S2>[)>)6RJ$O"&R.Z)2
M'#""0%%0P53B6J=Y:@H@-F0D[IO^&RH,9S(!C, Q!^4>[J[@NC]I'_1%WX7;
M7*70Z-LII(WST*V/+7(:4UXM\\U>1=-> ZI5M,4]?#3%>)J$;3GL4^HG)SE*
MS4W3;Y]).XV02CI2'B2%]7J:C^(;-[7T-36UFTD;-HGR$UVRJ>B13UE.'=QR
MB>8C>;E$I;>0EP)2%I*D+45<*A):=H'$-H:+KB+MOK<*VW")#B%R <Y*?P_U
M2 JPV6T+[A]"_1F^E>^D7E7T"A"R>B5#0E=:-='?PAU":M'2,S<;5M0WR,Z,
M@I:JTY*\F6=TZ_D7 LY D\>#3>(/&?U8F1%REQVVZ_;.T^R79Q"7.\3M=PL;
M2?[A)824UC+=$7EH;*:9 ="1O#<WX*3O$P<E*VPS75*B".X2I32=[\0_/O[H
M)E1W >.<Z3CFI>Q ,(71-N8^D)NAN(N^N+J:I](Z)<W;7XPFF3>C>KI0NY.-
MJ6J&<RQO:I>K8]"EIL\NK!K/7$A33N+FHI)DR++4PG$3LE;L=*XI>UZWL_65
MU17--;-6*FA7L:EI=EA):;4A5&\T>_1N;P&ZZ5MK*E=VZ5H$;98AANJ;;2V5
M/ H<%0I3TA1!#B%?@)/^:$J _,F/S=9KVZ/T:=*KZ7C2SNO^DZKUG"777/75
MW:*Z*MVEX=ZDA<_=D^A)^EH.6K.LH.<;U%2",O4:4FZ?O5P1F%7+D[N:9O$W
MK*A&S>%ZG2.[2V5V0V34]F&"[55E94_Q6IIZ1-;5;[;CB&6EMEMXH;W4A()1
M "4*24J?)7O7 T]7O(K%;J&VT]RA;G=MPJ)4#(!4J9C>DDD00(%Y7OTQ<31>
ME#_V/]2NC37BUY=QL'66D2QH&MG%=N+R%IJ,394.+PRE6.'"_M!F4J>0CABV
MY&+&G!:#3K")B&46A&-,5$]7/[*^T%[:; I:Y;.SE5#":<4P:5-1N@,Q(!1N
MJ"E%9<)[PK65%1.);2_LI+*BML%T(65%95^)N9/$&T ",@  !C4?1)NJT!]+
M2*TM+\?I4+[&U+:8E/Z259TY,_;R_M_=#5URE-4TXA$Z68W<4VK4$2B>/8SZ
MDY ,5/J*:9Q@Q",/'1T:X9'6>\KM>JV_LE>R*'LI0]]L9>S6G4=QL]-4S6./
M!SOU5+H0HA2FPTL_S&U*WRI2E"=W$PBF?2^NN=":CO2E0+I06TI*2D(!,6,@
M?A5$" )Q<NF<E*WZ_2P7DW&WNW:W77_W0W;7 7:KZ+EUND'I757H]7<2E,S]
M&TA)5)>?2=6L6TJYO5KEW4+NKHIQ(+RJTHXCXE\NY<2_V127B,6Q=R@[)4U=
M1U-505E5M&I&U*G9^RFMHU*7&WGTMTKK"MP4C"4):4$! 3O*2 $=\0K4_P#S
M:Y3;B4.MH91W*7'U,IA24RM*P?YBB205%1) )/Y0<85TGJ*O9N]^B?N:H^^V
M\VC)VZZ+^DTIE.Y2L;K[\65\[>[^Y%*E;RH]Y1K>]F+8-22+VZNIX^KV+*3.
MW,YCCH U3:L6<:QBF6^V6_25':RM>H:5]%6KLP[]\8JJ$T9J*[O*=2732+4=
MP53:FBI(.ZH7,J4I1QO(6FC:2ZM);%8CNU-N]YNMA+D@+'^ 08-_2!C8*2N:
MT-+FOI1=#"ZSZ/6O6E9T5I27?7P4'I@T)=]?7-WLTS5%V$Y1\ATIZJZG2JNI
MG[.<G(9U4U2* $ZV6CGE+0%1Q;:)7?\ M<GQZ:S;-;V6VW5]H:<L/[*J:2HV
M,_4T**1UNJ0XD[C39:;2I"%I:;$((<#KC:U*"0$Y"VPBMIVZ584AY+B'TI=+
M@*(,E1WB;R2;@I*0H $P<T?0/W":,-WFD;I\/J=0A8B^^ZS2-OKN1N[I]Q7T
MJXJF-T=(JIH($VY*,D:@77F8II4$%&-%ZUD8E_)D>H@P<3@'=*(K;3M[M#:=
M3LW8*7"M5#5[/HZRH=%.D,JV@MMR)>2@!"U-K6H,I6D$'>"3 .-6S&F4NU!$
M!U"RA(*OQ!L1/X9D@&TP?''U!C\M6//?B%O+(/C:,KGY<)FUM!CFQ^N<=>4'
M#\^=5KF#YBT7];<K\,3VZSPM>7 <?3SS]V-F<CZY6\,[ZZ:WBY7YB/C[6^<8
M?OS]WPW^EGS_ $&GE),QEEB?*WS^O#XX.>?"R8T)Z/TC07G7#KKUP61/@>5\
MHO/TY886['+AOP]0\..ZT.EX\^$DWO;+A ],7C%^?"?@?7EQP!GSK[.&=KG-
MO#GKII^ML#;K+QYVP^>>?=9:8BT>6L#XWQ.NNOG@U>?.0<Y:Q&R($7RSS,Y\
M+QI(X9SAG[=7/5\@,5% ?T1/O%#\6O7^(>(6Q*_,?+X8H'^:H^'['$@?,Q\O
MUC!G_.$.=]LN<^,08^FH,^FES,M>=NO7ACQNX<[,N[X6#(>EQ$VX<.60'AB\
M>?6M_/ZX,=8!K#PQW=_#RRM)S T^.@OH>6F1%L(R)R/K''RY^]\/7AXVH(/"
MW@8G$RGTPL=H9A\.=EH#:1?SGC]8M-HBV+&AL>?/K7!XCMPU=W9:Y<;9?",L
MNCEAZ#2<]<_' '#;Z;.SL#YV<(_8'(QPL+:7YX'6=/CKX^)_3#Y\^_,//TD7
MD<,A89B_"8@<_#$ZY_*Q]OB;N>>ZU^/&V<>/+J+./6O6>"S(#/F?+,\/EAA>
M[:/GNW=EGQ S-O'APSCF,7YZ#VX\?'#Y\>><[,NB9^9RX>>>)UZ==6PMF(]N
M>6'Y!E9(@3K<3IJ/0:\L76!X6O/[F^'R'/.NP\^4<)OEG?UTQ.CUUEA:O'/9
MF.&89=P>8XVGAQN; 7@R,\X 'G>;XN?I;4P)L;^9]A&#TU!QRQ[OELVWAPTR
MO;/*UI_35\<SRO'G^NNCY]><=OA9\](/CKR,'G;EB==?33UP9<[^<+,N&<:#
MP\\A>.7-?KAU.#G\L\O&TB,M<X\\KVN?*9.6'7[VOZ86S+=EEESPQM<A S(M
M;P&F@D>6+K?C>]^N<8=G,YV^?CQXG$PN._;Z>MAC.T$9S;E-HBY]LYQ>7";?
M'X8=@^9UDY^P'#PR,XF%J\^/'\@\LK#;+7U/0F+^ .ES]N7+]S[WP^<]O/=9
MZB>,23&?B.A$8G5M+]<<%D\O#T]1?Q(\,F,$WY:35P^C4UH=[?K>5!W;M;R:
MTCKO:)7G$I18DY5LHFHLUC2?54?("Q;E23,=]-2@,H*,(9(TG)M 70%3?4.S
M:_::GTT%(Y4JI6%5#X04#NV4Q*COJ3)D@!"9<5!W4JW<8W'6F0GO'$HWU;J9
MF5*.E@3IF8 D21.-6M,W22^C\@IQ&X[2RO%;4Y5D!%1%Z+!%O!WL(S=$QDHK
M-P<96K>N[O*==(TFU=&83L:]7=S[%FY8)OFDXW6BG"B2W,;"H.T9;<KMCTO?
M4[^]1NI6JA<8J=W<=4PY25;FZ\4J+;B"&E*0X$N,J2XD*'&[5IMD[0951;50
MV\V87W;B7921^5:7&Q*"!JE64 @@QC&U#:4/T7>B=7=4T='7XPT5>"_2H!"L
MJXJM6\^MFI8FMH*)JZ[E*1O??P<M=] 4A-055Q,_#IL:GB:4/];A)N"A(+.E
M[;FIV=VJVQ2L.'9Y^Y-FI53TE*W14J0XTXJGJW!1-K14O5"5L*96MUIRH"6P
MT#N)2D;;9>S]@["#E-LYMJF4LH[U4NN+7O)"VPIY84G=A0*0E247G/&ZS/2X
MT=)"M6UW;*\^,<5F[ODJ'1];09(>IP66OBI6B4KQZ@HDKH\&6/!Y&T2NC/GD
MA>!!+MU ;-91=^ M X%6R-I)9-2JD6EA-&U7J<WVH%(\\:9I\IW]\I4\"C=C
MO 1*D)$''-!]DJW L;Q6IL"%?G0 I29B) .9_#H"3C8W'=V[O=V8[<\PW\;.
M<?/,YS;37QO&,T<?#C\_&-+6/!VHRR Z\L3!SSGKQSL]L],N6?&]OUPZZME%
ML'//.6JSPYS<^W4##KKJ^>"SKG<P,OC/IAA=V_';Y<=W;WS7761GQY'2( CG
M)(F^?"-/?EQ\/(UX88;]_#8.S'/PVV3E$<I(/SS'CKG>0RF9X<.>HUBWKIC&
M%\M\UV6CW=M4=[U\55-Z)NXI$(H:AJ9U'S,JC&_7DW&TY% :/@(Z6EW)GLW,
M1L>D1E'N#$4=$.J!$"JJI[JCHJG:%2U1T;)?J'BH--)6A!)0A;JH6XM"!#:5
M&"M-A N8.AQQ#2%..*W$)_,HR0 2 )"02;QH;W/'&I$EIP?1]W_W;7A0,]>Q
M2M7T(VEJ N_O"I>HZ4O"A99G*WL5"SI^[=![2LS2T/63-.H:G48H4_53&,29
M1LNBB^2FXYRQ!TAR#_9G;*2FF?V:5)J6*HA"ETC].^PRRHU2%+#SE.M*6=[O
M65J*EH44[BDJ(-I-JII7FZRDJU,O4[J%MO-[[;C:Y.Z1* H29&6[$A5L9-NA
MT'-'6Y.LV]X%(4O.2%71J3UO3LO6E9U56JE*(2+<[-[]FV]1RK]I'/G+%5:.
M5G?9UJC4C7+V./,&8OGC=?S_ &!V,[)=EGJQ_LYV=V1L5^O$5CVSZ)BG==0%
M;X94XE.^BF"P%II6BBF"TI<#6\E*AVS;?;;M1VBIFJ/:^U:BKIFR"ED[J$+6
MFP6X$)3WBQQ5-XM(&($/I\:),_?<;1WA;X&4E>N%7S-WJ<0UI6NU*<=7@4XS
M<OZAH5E>+]EPNX>UC!-&3M27IMG5BTM'J-G+9RT3>-UVZ??G-@;7;H3M%=&I
M-+W"*C?+U.'!3ND):J%4Y=%0EE:B A9:"%3O PH''314L%T,AP=YO*1&ZN M
M-U(WPG<*H(,;Q/#(XW!Y_/?;B!UQRR,W/C8^^,_7[<,'(>_GXV'@=<N=M>7+
M*US>,.C\NOIA8<[M>.&7OQS&R.7O''@/?.Y\[/7'A-_E%AA\\ZN=MG$GC;X6
MF(F3X\8C$ZZSZTPM@[,-W8&K(>S;:7O;("!X7L((UC,Y#%U&L\?$YW'CIBDS
M]/P-5P<Q3%40L54=-U#&/H:>@)R/:2L--1$DW49R,7*QCY)=G(1[YHLJV=LW
M2"K=P@H=)9,Y#B4<C;CC2T.-+6TZVI+B'&R4K0M"@4K0H&4J! *5 RD@$&1B
M$ @@@$$001((,R"#:#>0<_7&GE!_1O:"%V$K3T]0&BI<U2\]2=9L+P*;GHZD
MVH3D+6$4J1>*FH^87,M)(*Q2Y"JQC4KKV"/5$YV;5 RB@FY=_M'MVJ0XW4;6
MK76WF33.MJ>4&UL*$+;4D ).],*)&\K54Y8$4M.@@I9;!20I)W0H@BX(*I(C
M,:#01C)\MHCZ,TY?M&Z3<M<E=^]O^B&I&C"]16$1+594T8A:GT57#M,Q$7SU
MO N#P;:1?MW,@VB 1C4'*;)!!!/;(VQM-N@7LM%=4)V>M14:3O#W1)<#A@&Z
M4J<&^4)(25G?4DE6-989+H>+:.\  [S=N+1?*2!8$R8L#C#)?HO_ */,CRHI
M FAY<.5W5,FA+S2Q:%C !1ZV="^1%@GT>IA&I7@@Y/'0:<='JK$245:G,BD)
M-X>T_:"&P=LU^ZRDMH'?JLDIW2%G-9W93+I6J# 4)C&/[I32?Y#<J,G\,R="
M 9 Y;H USQER_P T.=%S2D/!+Z0=Q=W=ZSVF$S(4_*53!(KS<2S.J9PI',YQ
MJ9K,)Q2K@YG"T3[<,8LN85E6AU1$P[79^V-J;*[P;.KZFD2Z9<0RO^6M0!&\
MIM04C?BV_N[X  "M,:W6&7X[UI"R,B001<&)208D93%S:^*PCHL:.+5S<RZ9
M7*7<1RVCO]:#<<$93$;&(W6C-D;$F348U8(MFT.>4]D;'D#MT0.[63]H7,=<
MZBA]'\4VB16)575*_P"([OW[?=4LU7=SN=\5$E80%$)FR00!  &+W+0[LAI
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MYS8/:4T&TMH;1VHY75CU9LRIHP\A0=>#SQ:+1*G7$;K38;-DD[H@)3>V"II
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M<!W''&]YU$)0RRIUP+AH%94EM6YN=V 8"LBK&DDC=*B#<)5"3)4I02DB5?A
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MZ\?Q]@>%GW"HO^%/_O)Z_86P_P#*7V7_ ,=6_P#8G?KU.#^K&N4'7(5!D/\
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MP^D1;\+HF;Z8V4(0J9"D(4J::90(0A2E*0I"@!2E*4N!2D*4  I0
M#"WJZ4I2D)2D)0@!*4@ )"4B $@62!$ 6B!D!CH))42I1*E*,E1))*B9))-R
MHG,DF9.9Q[MJGP@Y7N>-HX=7MIPMOKP^.-@Y"WPUR-^ Y<HO=/AS^D8?///K
M9UUYBX!.)UUU\,&_G#M]>RR<\O(Z6S^/AQPX=3X?#QP;.[9[K,P.-B.1XZC7
MGYX:^>OSP8<XB/K8 !^M\M?']. PGJ /A@YYUV7B\<XT-O&>(\O'#KK+!89^
MD^HTT/M?/#"\M>L>=V/#QL]L[S\LC:\^V>+[Y:=<8Y^F ><\]7#;AGA^=GRM
MG?*^4WB\7FQSR=96SYZ3:?VQRXTOOHYU;ZYJJJ^N1KN*NGKRMHQZVJUK+0SN
M0IF8J%>//&LZ\CEHUTB\IFL&R0M3RCE*/FXNI#QK%=Y%-)@\C-O_ %;L5]J-
M;V8H3LFOIG-I;.1O_<U-O!JKH=^26FU.)4EY@+_$VA2D*:*CN** EL>&_:=]
M@_97[2]K[+[0U*OX9MO9SM,:FH:ITOTVV:*F=2X*':E-OM%U)2%-(J&W6GD-
M.*;4IQL(0GXK[NM(6]W0T9Z;6A'>W32\G>/7\I3- 'JR?FI=]*W;U%=?>(6I
MY9W2[EVX$5HZLT6C>7BI-H9L9=ZTIRH4%7)!(0_J81_':CLYMNFVC4)IJ'[U
M6L-)) ?^_P!&6"%&=]"TB4.)D_A+C<)42<=F5L78VSZ3:VSVMA[+;;VDU34M
M>TW0TR&*AFE6L--U#*6@U4-MI<6EM+B5!*5  ;@@?2/]';]%_>955Q5UM:7^
M7F.HRC:Z;)5\K=TSCIHMX)J2G3(.H:E'=9.IEK]E&$]$HMYF1/&1#FH63.I'
ML7&OJ<FFR,PTZSM_[7'-F(VAL;8]+WM6PZ[3)VL\\E;+"]U*75T].$*#I9=*
MTMJ<<[K?3WA0XV=P]!?_ +'CL;M[MGL_MSM=A(13TM(?[7*:DIZ?9M;64KKZ
MV:_:12"JH46EL(73I0TA::9E#Y=3WB%_1["0D/3</%4]3T6PA(&#CV<1#0\6
MU081D5%QS=-HPCX]DV(FW:,F;9))NV;()II(HIE(F4I2@%OG]QUUYQQYY:G7
M75K==<6HK<<<<45K6I2I*E+425*49)-R<S]$ )2D)2 E*0 E*0 $@6  $  #
M*+ 0/"J<_G;1?HZ\+>&HR/EBX6T.W?JR'5A[]G=98G/7CE8Y1[SI/#%T/APS
MN,Y^6OG@Y\!'?W]VK99:)!\_ F?G?#KU X>7GGKBV*N;K.8EJFA$MYLY:HH9
MP+)RN+9-%%G6M/NW$L50%V_37@&Z"L\T;]88';J-1:F;NRK"U6R,JW5K/>EL
M%FI&\E()E5,\D-Y*LZHAI1B4I652F-X:5"=T;LG?1-XR6DR,KHC> O)$0<L7
M1PW6QY3'IIRY_I;01>?&<:O:3NC0VTDX6#AW5:RM&D@VE7MQ-&-%G*,RE5D(
M2">1$Z5M*P[U>F9!B+F.J*-C)&)F9&)?.DX*I*5FDX^?8\ILS::MF...)90_
MWA9/XB 4%E96E39*%I#H4H*;4I*D)6@%QMU&\V<+S"7PD*44[N]EKO)B#!!*
M;$$2+*,$&",#P6@E5T(\=NG&D//U,FXKAQ5:3&IH:LA9H)K/9)VUE@)3%[M+
M*C>9!)/TXRGZ]361BV<6T;LWM#R24?3H0'(.;>9<2D#9C3)33I9*FEL[RH"
M4'O*5X"F64[[C( 4I2B0\B7"YA32+3O34+7O+*X4%0F2<MU:#O)MNJD@ "4D
M@$6?&_1^WE1<O3R*NDA,5%#M/X0WLM4<]'UB%9,YJHWET7V>J:GVL=>.UI_^
M$MHTHFJGCZ\631<0Q)>7;**783"3Z2.CF<[0TRT.E.S$,K(IT(::4QW*FVDU
MF^VX5TZG/NRB^TE-.F%[J"/O*-U(QI31K2;OJ6)6HE85O@DMP4E*P L!*B5F
M1)_(9.*D3Z.Z3CJ7>492U]ZE%P@476=%T^YI6CJFAI^EV=2I7JIH/HMVRO:1
M@_K&1"\B._A#<JTT92L_L)2ZL.:B7T=#OH7'_;&E3R'G:%+S@=8?<2\\TMMY
M37W64K2:/O"E(I5!@!V&>_=W^^"E)731G=4@/%(*5I24)4%(WN\NDEPB?YGX
MCNRK<1!3CHW35.Q-)0$334$V.TB(1BA'Q[=1T\?*D;MR=$HK/9!P[?NUU!Z2
MB[IZZ<.G"QCJN%U53F.;KCCJW5K==,N.**E&$I!4;V"0E*1>  D)%@!$8WH
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M[OV.\_\ [:=I>'6NN/LS[*/_ (*.U?\ K>TG_P"0:/'8_+U[>S5CQ[@M]UV
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ME"-I)&HKXG3*[1DHR#IXA)1"55.9H 1,=1 L4NX*/1;B<-_L2E^][7H6"-Y
M?2ZLBZ=QB73,B(.Y XD@$08.I9A"E<!X9P!SF3RRQ^48R9NI%XTCV+=5V^?.
M4&;-J@05%W3MRJ5!NW13+B8ZJZQR))D#,QS%*&NWM2B$@J)@)!))R  DD^ Q
ML<\?L3:(UQ['1IT7M'VX*/*0I;H;H:!H5XJF!0!Y-0-.1[2H),_1  ,M+3A9
M"3<'P #KNSJ8?>MX/6/FKJZJI49+SSKD7,)6M1 B9,)@7O86D8Y #= 2,@ /
M&! .41(X92)Q\8E_UVI+F;_+[[I42&09W>WK5I!0K4Q<%&U(N9=:>H%-0F6
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MRCXX7'7Q^AP;\_3+\K-#?C?A^V'"WQO^^,27P?W"C/\ C@G_ #%[GW^ZW.;
M,U;V?_%U9_ZQN_@?ECI7;L?\&4G_ *P09_\ G6IMY2,N.+WH_P#BK3W_ !.P
M_P";DW6XZO\ ^.U8_P#E#]N'\Q0U^8OY''8-A?WFV7_U"E_W*,8IG?[Z\:&W
MVZ%\D$/CNMY5M+_EM2_Z_9_^[1CTVB_Y+O\ ^KK/]I>,]?+?\.=N%O2O.# )
MT'/,<[ZY3&.C_KP^O6DX6KG+#+P[,O?9[?+21F! T\?'%SZO-_7QO\L&60#@
M&.6'N"RU@8$Z?+Y87N1)B\_,X>-GB<\OA?U%CKZ"1@SV<\CA9>+1\,YRSO\
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MT@Y(9-ZW?UNTCRTI$OFYOO-'M-W;15$TY)LR"*99J+E'(%!5VL)OAW[0]O\
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MX?VE#@.?GPSMY7M+_EK2_P"OH/\ =MX]-HK]EW_]75_[2^-O'EC/5O2LN$6
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MOB=9]?OX@86'D.W/G$/6R,KY<;Z^)S$Y7\(C%GW&ENH/PQ4D!'JB8%Q_%GB
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M0,12M)04/3%,T_'MHJ"IZ C6D1"0T8R2*BSCXN*CT6[)@R;)%*F@U:HHHI$
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MQ4F7_P! &NNH%L\7^"T?^-VER_X6VG;_ /&_I@^Q\5_OB=_RCGO^L+/O[_\
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M[7_R.C_O)G_P/U\\/N^SO\I+_P"PN?\ C#!]9U-_)9+_ !^U_P!$M/O>UO\
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MV^A*$IDCP(GCB_J8K^)J(Y6ABFCI(0Q*U74*9)<0#$P-7  4%3 &(BD<B:N
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MW5JDK(,AM"XQ48R+9Q#4C1DGT"%$3JJ&-TUW*YLU'#E8WWUG"IL3'4..8C@
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M:4UK;+24M-HHVT(6EW[JVC<;=J"MQ8+CL!82A" $0HW7NHJ#S^-L'_Q-/?\
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M%A&LQ#3+!%S%%E8B1E)C0^SW#@0%%25)WDD_F%R"DG6,P;6.6-33G>HWB %
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M!;$^OGZ?K@YYV^&ZSX="YSUM'"9,X==:>O'$^@)02(& 9=+7CC^(?W1];8E
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M%I%K9GX\=#;2,IRPY:::=<_")P[61Y^\?+$P<><OSLXGE\,M8UG3/3#EU?\
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ML-OURUY6\;>)R+/]!/#KQX3A\^'NW^=ELK]1:=9YF]QB98+!>][\Y''VF/+
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M<[>(L)L/3#!K]>.//'/.TSO&D@R,]!R]P9/.67P\NN5K8+:OEE]>6HPPL>_
M=F&66W$=>NVDGSBUHD&W'7/U%CBQY2-9O?2!EE@S =^KNSS]>&KM&R^MYC2-
M0#Y'/PXC"Q'#/SL8^'//P&*B@8 2)_RMI?VC;QMC5F?3TMUPQ0DG]E?(8D#_
M (S[NF.&';M[^[#AC;)8YW$CP,QXZ\+<\\3Z&9^7EYS/+"M8XGURN3'QCGB8
M6>_;Y;M7=[[2/.YGS-QE?401Z1BVX:>_'/S^6':@\"?$ZS.4YD>?.^)@WZM?
M./&RU\N-K^!,:G/GSB<#IGEK\N6$&\-6&/'/'CV867L1E8\[R3G;AY3&F*>!
MSF.5HY>,X./;P\=?C9/P\!YG*VN9U&'+]?3+TP^WGOW63G, #X^8%M)Y<\3P
MZ\N.#?S^?.>X)O\ ,1'+G;/X\'#H_IU;B6$_++B=#/B#\1H6%R.SG,..(63^
MNGAK-SEG/GB]#7JQY0</+G>/QQLL/4<K^PUO&=QRQ+]<!](PM6SPW;NX-6\=
MUEQIZ<!D,N'/.8MBYZ^O'CYG/@..,*7K:2-P5QCN*C[X;XKN[N)&<05>1,75
MM4Q,1*R#!!047$FVBW#@K]2);+ *3N5]G".:JX)N'29A MN6V9L#;6V0ZK9.
MRJ_:"&?PNKI:9QYMM1 (;4I"2@.$$D()WU"2 1ELJS:.S]G);77UM+1)<6EM
MM554-,!QQ1.ZE!=6G>42(2$W)MGG=KZ]:ZZ,H)*]62O(H*/NP<1S28;WC/JO
MI]I0J\2_%,&$FC5KB03@%6#TRJ0-'A) 6[DRB945#B<N.T3L^O76'9Z**K<K
MDN*;50IIGE5B7$25(-,E!>"T0=Y)0%) D@09W7>-A <+B$MD3WA6D-[I_K;\
M[NZ1K)!TQP!T\[\H?2(OO/1]-7DP5X5Q-)7?47-TY$4+64;4=W]65#4LE6",
MY5<XM3,BZB:F=1RL&E2\7&2RSUM3J\-*O6S1![-*+V^E_LB[+TU%LJJVAM+9
MBFMMKKGZ9Q.T*13=11T[33"FVD-5* IKO LO+=2E)=2M"2HI:2!\3_V6'VC=
ML.S;W9G8O9G:E3LC9>U*2KK:K:6S7BT_6/L.-M)I45C)[QIME+B'5H96E;A=
M1O'=!2K+WT:%\\Q0U[R^CM,3[]Q=S>#2TM/781$S)NY%&E;P*/.F_GZ5I=20
M<.'#"(JRC',A4K>FVARP\4XH*;?QC-FK,R0N>'^V7LI2-T5/VEV?2-L/M5"*
M7:A8:2VAUFHD4]0ZEL)3OMOI2P72-]?WAM*MX(3N\U_8K?:OMGMC1[:[*=J-
MI.[3VML=#5?LVLJE!574;,<(:?:>=,+J%4;_ '9[US?=4FJ2%N**1/=[#CB&
MX0#6&W5SX6^=.<R <C N,S,:9VX''V#/*#Q!.1TSZ]</GG#9SA:Y^1X_33Q]
M,3KJ=>IPN=OGJ\,./8'$VMQ/"\_KXZVO6GMGZSR\7SV<^.-FAF_GP%^$7'K>
MVDZ\>O2,+LP''7GX;\<NS'T<"/$WCPXS;PF!B^,B,K>O"+^,?$\><N=FWC9P
M)!YZQZ?(1-\/3J_6NG+#L/,FWI?*?#CIG;$PL,-7'+B/IR.NR(RYGS.OEEE^
MMF<^5^0^/0RP8X;,L_+  U;[0<+D"=!%C %AF.N2)UO]9)SX8=AB=)R(@&1Y
M7Y7]+C$PMV.OR^-KR,7YZ\!EY:_$WC&7//Z8!#''9QYW8[=MIGQ$Q$YY'U\#
M?,SE@#$:\O/YQI@]^?.&O9:VT@$B?74P;]0</E;J<M<,.[?ESYVD\A-C&=B>
M/EX93;$/GPOU[8@N%TFJ"SEPH5%!NDHNNJ;$2IHHD,HJH; !'HD(4QAP 1P
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M@)6E4 72M*A'K!LGD=D*"]G4N8*6TH(XF 01XI(T-YTC'9O#>&&P=V6.6KU
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M3KXY8+-?GJ#EP]SGX88+.<QQG]<L_EA@L,P8T^G.!\<N.3!9\_;KS],,+++
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M$0A3NQVH2%J).4G-92EV,E2U[4 GUU172U=3MXL&U*)@5E5Z??D&4IE(2?I
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M?9/L*CV125G:"B1M3:E8RBH>:J5.&EH@\D.(IVV$*0AQQM) >=>#A+H4&@A
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MT-L)?62E(4<<@KSDI7VJB9*EX26J6JJ9G).K@A(!L=]*JT#3U,S3V]>349I
M956+@:#++32F0$6G&-/L414DGL<U<?0%774>SVDO5U2U3-.O,4J%NK"$FHJ7
MD,4[0*K2XZM*<X2G>6HA*5$?%OV1]DMM]MJKM7V>V91N5-)6=EMH+J7BA7<T
MU?0K9VCL17>$%+=0[M.E:IA?O%T517;B2D+(JEYC:GI^[&L4)EZF2GY*E)-0
M\HV6 _4I*L#KQ\G&KHF-UKM%Q[*\BE&PG.J\(V%OTU#)@;=2D#>)"0F2HJB
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MH>U^WM+0U+E)14OWXLK4AU\O!E@+! 4EK=0Z7 D_A4O\")'X-],+-W79Z85
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MG=; #.6M_D+&,Q?R.>,O7STZXX0:^W,=8;\,M^08ZO=:#6.4S,9<+7B)RSY
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MST'PP8_EECZV3;X#/@-)U.DV],(_>\?#!9Q$6X\9SY^?CA@]_P N<[7CSO\
M 8?+]>K860!B(\<?3RRXVTY7DD9YY WRY9<2"1$6Q;DP!RCX^]^6'NUZ_<.O
MA[\+/&XXV@B-?V@F,IQ..67S&7/Y3@MJZ_6\>?SPPMV[=AX> X=F=IPC+Y:>
M8,9Y7Q>/'C/KZB?&V#+5MW;1X\=5I.D"=1()X&?*_,"\987STXZ#ERSP[63>
MVO5H!^-^6)A>N8<[]F&K(;3GK%]1RRSX@<#I-[\+'G^FLYW&':C+B1'.; ZP
M+_KB8H=24U3E8P,M2U6P,/4]-3S)6.FZ>J"-9S,++QZX8+,I.*D$7#)\U6
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M"7W:9IQS<%67V9*DD$H;=0$$@E*0D)@ 8R9H5LRCHRP5.J$ZOZFJJ^RD5DL
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MBQ!%E(4 (M!UQ4-#E%LK=Y>'4C5))!I6.D1I!3[9-%,B2!&;6]&H:89%2*F
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M*:(X*_NU93>?PR)B,:NT([W^#4.8K-MT6^C_  F:(.[1<!_S9I$ ^,:XF+Y
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MG.+6F<3J.NO#66=NVS!JN\=JE0;-TQ465-CT2%# -0 )C&,(E(0A0$YSB4A
M$Q@ <K;:W7$--)*W'"$I2D7)^  &9,  22 ,:5K2VA3CBMU" 2I1FPSYDDZ
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M3[HOXIRO^$^^_P#SU7@6C/Y%?ZU__?N8.?F'^@W_ +M.)*[W^/M_7^$2E_\
M,Q==:-_TE1_K$?[EK%7^1K_15_O%8Z,_1QJ8:4U[J/1QZ>C_ $,H)\<B]7>-
M5I.CAGB)NMQQRPZ&H<<;;#:*94A4Y )CCO%9GRW(\\;VA/X5)C-1,VT"!EG>
M3Z'ECK;3EZ,34MZ%Y=UK.-DD92["*H*4F91?V7ZK>A> UG7L:T8=6N=U[0R;
MP*QWWM#=%/!TVZ@ZN*G0UU6R'J79.RMKK=:4SM9[:+3#*=_OF_X:NG;=6Y*0
MC=6JH2&]U2C^%6\!:3&T&ZC:%?L]*%AS9Z*-;KAW>[5]\0ZMM*()5*4M'?D
M7$$WB;I2\VGJQK.\^AHE"4)+W33-.053.'C=LE'.']3TG%5DP"(71>+KNDT(
MF89D>F=-6)T7@J)))KH@5P?16;*J:*AV3M!Y3)9VRQ55%*E"EEU+=)6/4+G?
M)4A*4%3S"RWN+<"D05%*I2+3;09JJO:%&VET.[-=89?4M*0VI=13MU2.Z4E:
ME*"6W$A>^E!"Y "A^(U"DZ_IBMW];1M.O5GCJ[VK5J'JDJC)VU395(WAH:>6
M9(+.44TGY$XV?C%#N61UVY55CMC* N@LF3'6[-JZ!J@>JFTH1M.C%?2$.(65
MTJGWZ=*U)22ILEVG= 2L)44@+ W5))UTU;3UBZMMA2E*H:DTE1*%)"7TM-/*
M2DJ "P$/(E29$DB9!Q5*?JFGJJ+,'IV79RY("?E:6F3,SB<(ZH8-8K>7B'.)
M2]%XP6,5-P0,0*80 ##;#4T=51E@53*V#4TS-8P%@#O:6H25,O)@F4.)!*38
MD:8R,5-/4AXT[J70P^[3/;I/\NH9(2ZTJ0/Q() 4,KV.*FQD&$F@+J-?,Y!L
M"[EL+ABY1=H Y9.%&CQN*S<ZB8+M'2*S9RD)NL0<)*(JE(HF8H8G&G65;CK;
MC2]U"]UQ"D*W'$A:%;J@#NK0I*T*B%)(4"00<9$.(<3O-K0XF5)WD*"T[R%%
M*TRDD2E0*5"92H$&"",1'#1H[% 735NY%JX([:BX136%LZ2*<J;E 5"F%%PF
M50Y2+)]%0A3G I@ PXZ4K6C>W%J1OI*%[JBG?02"4*@C>22 2DR"0)%ABJ0A
M>[O)2K<4%IWD@[JP" I,@PH D!0@@$WOBE2--04M,4]/2,<DZEZ47D7-//5#
MK >,<2T<K$R*J*9%2HG.YCEUFIA735Z":AQ2Z!QZ5L[594L,55*TZI#%:EI%
M4V F'DL.I?:2HD%0"'4I6-TID@;TBV,3E*P\]3U#C:5O4BG%4ZR3+2GFRTX4
M@$ E3:BD[P, R(-\4IW1,8]KV%O!<.7YY6 IF=I>.8]8W^JTF]0R$+(2#_J1
M;BY^LC#!M&A%2NRH T,L0S<QS@H7,C:+S>S*C9:$-!FJK*:L>=A7?J72M5#3
M36]O;G<C[RXLIW-[?W2% "#A70M+KV=H*4X7:>E?I6FY3W24U#C+CCD;N]WA
M[A" =_=W)&[-Q3&]%.@O7D[Q73UNJU/0451<-'$34!PS$D])S<X\74-^C,5^
M<\*BB5(<0"/.*@ (D$V=6T4?P1G9*&UA8VF_M!]TD;CDTS--3MI O+0#ZE%5
MI=MKC$FA7_%W=I+6DI.SV:)AL [R(J'7WUJG\/\ ,)9"=V\-D'2:92U.S(7I
MWG5E-,#-6KII1])T@NHLW5,ZI^&CG$Q).DTT%E3-TG%23\BWZMR5%P88XJ@I
M D9(Y\M;5T_\%V/L^G<"UMN5]=7I"5@(JJAY##*"5)2%*324K2I05)'>D;Q(
M(&&DIG_XMM6M?;*4+114=&HJ2=ZF8:4\ZL!*E;H555#J85NJ/=!6Z 033[KR
M*2]5WNUJL4W0DZS3I&),<,0&&H&.1ASG0.(9H+U&O42OW?N&.)C (X@(9MM%
M+%#L'9R2"6=G&O?C,5&U'E5 2L?X2*1-*F]P+8Q;)!?K-M5Y!AVN%$R3EW&S
MFDL$I/\ @JJ55*O$GSBW2#]<*W@UX<>F2L*WDDHM;4!Z<H\B=)11B@/X2*KQ
M4F^+L,#WK-9Q$9MW^0G96RP(.S]G-%Y.<5=>37OSQ*4OLMGAW<:#%V+#QVEM
M',5VT'0TK*::B HF2.14RZX./>;VN,:O)6CV5S-\%\%?QB,Q3DHO5E='9. '
MVEQ!4JT/#THP9*)F(JF_>M(5N,6=JH18SJ6(1)3I*X#-O;4>[/N,?=WETZM@
M[,0EQ39$*J7$*K*Q.Z00O?>>+*D+2H*4V 08&-]V3V!_;?6L[/#27U]I]M(8
M8#B3#;*GD4-,ZH@A2$LL-&I4XE0*$*6K> G'$6"9N&46V2>F*I(KBXD)51,3
M&(M,2KI:3EUB&.8YQ(M).W2B?3.<P$,4HF'#&WS[45#]6^_5U2^]J:I]ZIJ'
M#_SC]0ZIYY>0C><6H@   $    #],Z"@H]E4%%LO9[09H-FT=+L^A9&35'1,
M-TM*V..XPTA))DD@DDDDXH=(C]8&G*F$PF">E%4X\1U$@H7I1<8"8[4'JR,A
M.H#CF6:'5D ;9N^\O/?4=V\_@3^%,<B0I8X[_F=^Y;<;%N[2-X#_ !C@"US8
M&4REL\V_"&D(RM;.50$#LZ4BRL2AAB'U[/ @]= ..I9C"H1HIF <>IG5B_K&
MQ#\3AO9"=W_VU03YI3NP1HLC#\K0&KJYY]VW*4^2G%+Y2V#&1QDBCX U87BT
M330%(HT;R(UE.IFP$!AJ/6:/FQ!*/W3 ZJIQ3#-5(^!5F3AZ4>D4IBCW#L1L
MO^*]I=GM* +%$L[3J9!/\NC4A30C([U8NF2I)_,V7+&",>1_;9VG'9?[.MNO
MM.%%=MAM/9W9^Z8/?;60ZBK4% [R"ULEK:+J%INEX,P05 XZ2M!,42" B4Q1
MZ0" B40$ *)3 .P0$,0$,P$-86^F'((W3!!S!C(VB-0;R+^F/S>1( T()RS!
M!.O+&T<35T8A2</(32RII)RFNEU38A5'+H&CE=J#DR9SII@4Y42]8J=1(#K
MH!1,8#%#H53LMU>T*EFE0$L)6E14I6ZVV76TN% (!)C>_"E()"=WQ/;6-HMH
MHJ=RH42XI*TPD;RU[BU(WHD 3%U*(!.]%Q&)N+JR+E5R-T@<-UE!P1*Y33*"
MIMA"'345 %# .13B43#]TG2,. [>IV94TR>\4$.('YBVHDH F5%*DI,";D3
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M3<I0XTL0=UP20>K]H^TU5V:&S76&&:AFJJ*I-4RYO)4M#3=,4EIQ)_E+&^H
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MIGPQ^.&S*^N[-[;H=HM([K:&Q=I-5 8=3$5%)4 K8?0H&4+*%M/-*3"D%:%
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MJ*EBD4A"%_B744@0I(<(#;>Z5-JWQ&I--::=Z+:EW]U]XCQ"L[KIJD'% R+
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MEZ#IZ1JF:D6IL"*3DG,OGA7+LQ.M]B19-@,*:(B?HW8[8FR-FT5?6[+;:/\
M%=J;4J34( 5O4J-HU+5(PTNY%.RPV@H0#NE:G%Q*K=L[2;5VC75-+2[0<<!H
M*&@9[E9(A\T5.Y4NK3,*><=6J5D3N!"19,G%=WU82]!593=:TZY20GJ6F(^<
MBU54TUT0>1SE-TB5=%0#D514.F!%B&*/23,; 0' P<[M.A8VE0U6SZI)735C
M#E.\E)*5=VZA2%$*3!2H;P*3-B!G<8X2CJWJ"MIZVG(2[2NI?:44@CO&U!2
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M4Y9B9/2]VD;2D;'4VVCY!RA+U+.*5!4*KI1Y)QS1B*,;&TND9)1Q[6H*XB5
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M?6TCD($FYUOG;QUMP, XOF3D,OA?T'PP]^ZUXSK;(9?3YSH;3XX 'GG;PV6
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MA82XU3O5#3925?>"P I323*2%]WON)A*MXM[L F1@J:@4P94I!4ARH:86L*
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M=QLPDS,J8RHLRO1:"J8510Z8]*W5MB]I]O\ 9U3AV-M2IHDO'>=:3W;M.M0
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MM0$G52C$F_$R;\<2-*1SF+@&#=^8#2:Q5Y&7.&HTO*N5I*4Z XB/5$?.ETT
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M*(O)\9C/GIQ*'3S,)>(8>.H=G.>063J1I:\D02,[GG('+.,6?C/0U\_:\PA
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M(Z:9*"BL8"@.)#M)! KEN X") 1/AT3!CNED[*VBEQDEQMIQ#[*B;/4SJ=]
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M(DX&-.NO&>.(+ELV=H*-GC=%TV6+T%6[E)-=!4HCCT5$52F(H41 /NF*8,0
M<,L;5*U-*"T*4A8/X5H)2I*M""F"#I((-AS.-*D)<24*2E:2/Q)4 I)%K$&4
MP,[_ $QX9LF<>W(TCVC5BU3$1(V:-TFS<G2'[W011*FF43#K$"YZQQM7'''%
M%;JUNK, K<*W%D"T*4HDGD28Y8B$(;2$MH2VD7"6TI0D$WLE( %[D "^-2+X
M=#.[Z]2HW57L961HNHI,X*S2T:U;R,7+.<  S]Q%KJM3(R*H%*#A=H^;HN3
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M Y3EED+98@C\/''+9OU[L V8VU7RM%H(B#PMPFV<SERT]?7JX@X8!O'GY;P
M!U6"03:-(SD#T\N5HM9UU]+X@G ,<<,\-8;0]-F6>K#5:6GQTYYR8F\7!O/(
MIPZZ^>)6VD\0;F\SI($FTF_PF!<!B$8H!F&H?+GXVU!4VB9O>ULLK^%L]=<.
MOCUZ8A\\]WIQRU7T@SU\/A%YD7KKS^/*]20QZHF ?M; _:']X/2V)7YCY?#
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M>'#YZZZ8T]TK[DZ-J"Z:]&J8"ZRDY>\=Q!)J+3C&CX=Y6C^'3D& U6C'2";
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M;>Z4G= !E2A,C<0"JXE1$'.<50_1CF:+=L7$^!&S4@YB94P#]\^_# RRIA$
M$ ,(B C; )?=4M>5W'#P2-!XV0D#4B+8R&&T)2D9 (0#J8UCP))X ZXB@0C-
MJ4A?OB7  QP RRQS8F'B8YQ$PZ\ QV!;2277"38&_)*0+">   !.N>>-:83
M!-A )S)C/S-R+\+X]!B!0Z6&. 8["X[0VY;+8C$F,M)SCGC7)M&MH$GC*AE?
M]0<CB6/^'O#"V41,^)D0;6DG43KF "8BY$,Q%^%Y&6F<'V,CU@[\QQ[LM? <
MASUY; P'*USZ'GG,6,P3,*(&5IZ9<^'QTYQ><\&W7N#9GAGALSPSU[=P!9$S
M)-P"+_(>\&#.EL)Y#KGUES.(:FONU:AY'?B&KOM(G(S (G0'+*W.,\^ &)UT
M<^N>)2VG0_A.L6(S.=IY WR$29PPE@PP -6(#QV\\XVU"9YP;:@2+1'C!U'#
M#$"VH_OUSRPQ46^:1,Q_6U8?M#PMB5^8^7P&+EH/.?KB0/\ C-_.-ZB&0[!M
ME\2!!OYCCQDS-CB#KXWXC'CPQ'GOPR^5@URO<>WK%K@WRMB^L#KRF_ZX> ?E
MEZ618QSBY ]N?48DG][_ !P?'GX=GC9SOSM] ?#P]</IU]?'TPA[,>W5OYPQ
MM,Y$'+R\S>2.4YZP<4>,>&?#J8P8\!RX;\\OAOL%\P9USR-SGG.1&8RPCF+\
M^%K_ %P]G/O];6>1RXC3/,@^9'/$UZ^7PQ *)5B*)*%#$,4U";!*8,A#@8HY
M#CO#'*UB-TB;1!X1[2#(-N=K0F9UT.=_G?/CX'$NT.)>L9+B!U$  "&-GU[4
MV2:@X_B$ _1*!F'3+F/WK:U@'==2-T+S@P$N#-,B_P#G(Y&V4C2F94A4RF8M
MFC0F^>BN8)U&)5@L5BNI&+J%*1+!9@HH<"]8T.; 4<3"&)VJ@]4(".(I&2'#
M#&V1U/?-BI2"HJ_ ^$B0EU(LK= _*ZG\8D0%!0.6,:#W:E-*.7XFR=6R8B9N
M4*_".*2DC%IU+*R%,,W,<R Z:+U?K8QV4 $&B"W3.]:$$?PJI+8&;9&Z*+GI
M 8#I%PY79].QM%QMYV"IE.[4-$D%U:2$-.J&J5),.92MJ""%&./K'W*-M;;8
M(#BI9<T;"I+B0?\ "2JZ!!A"[$%(Q@9=XY;+BX1<N$5R#TDU4EE"*E-TND)@
M.0P& 1$<1'',1'7B-NWH:;<24+;0I)L4J2"F(  ((B!:WE&6.N%:TG?"U)4(
MW2%$*!WI)!F=9]>)ESK6:J9@%4$;JO3("6-ESMTQ.J15H@D*#Y1%(OW4%F9T
M4E3D+T".&ZJA^K*LF6V&D=I*![^'E:64JFHI0X8!2ZM86R%J5=:'0I20H[Q0
MI 3O%*CC55HJ*QK[Z$J<4DAE\H22H*;2DI<*4BR5-% 40("T*)W0L#%BQ5-S
M-2/DV$2R6<**'*51;H'*U:D$2@9=VOT1(BD0,1$38G.(=!(BBIB$-RU374U"
MP7JAU*  2E (+CA$D);1(*E*TR S44I!(XMFCJ*QY+3#:E$D!2XA#8DRIQ?Y
M4@"YN2<D@D@'<E2B*;>0D3"2T6SEF\.P:L6RKI$HKE*U;IH"=-8HE61%7J^F
MH5-4I1,.8#@&'F2=J5K53455.^Y3N5+SKKB6E$I)<6I>Z4F4*W=Z!O),0>).
M._'9](NG8IGV6WD,--MH+B95"$)3O C\2=[=D[IOSMBI0=-0%-H*-X*)91:2
MI@,M[(@5-18Q0P*9=;-9<2ACT154.)0$0+ACA;%55E76K#E74.U"A(27%DA(
M-CN)$)1.9W4B3GD(S4]+34J2BF8:922"H-H *B,BL_F61,#>)@99WK>[#?LX
M:_AAZ:PVG ")D996B?:P!ORM(W'&>&O/+ZS\<C;U75;3%!4K4=<5I/15+4?2
M,))U+5%2SCU".A8" A6:TA+3$K(.3IMV4?',6ZSMXZ74(D@@DHH<Q2E$0RLM
M.U#K3##:G7GEH;:;0DJ6XXL[J$)2,U*40!>Y,<\:20D%2C 2"23: ,R;'3E/
MPQKA=[IW:&-["]4MKM-*"X^N%Z'HN<O&K%.FKQ:;E1IB@J9]E^T583HM7YRQ
MM.PH/6@R<J[,FS9@X2,LJ4#E$>2J-A;9I T:G9E:QW[[=,SWE.XDNU#L]VR@
M1*G%PH)0))(, QC$BI87O!#J%;J2M4&-U(S49 @"TGAPQ?[K29T>6-S*&D2]
MOJNR:7$.V@/&=[;BL8-&@7K<TBM#$]BJ11X6->++3#=>(;M&RZKIQ*)&CT$5
M'8=3;;)V9M%58=FIH:E5<%;IHTLK+Z?PI62IN-Y*0A06I2@$A!"R0DSC676P
MV'BXD-D2%DP"9(@'4V-LY!&8C%'N^TN=&"]>.HB5NWOZNMK5E>15$Q1%#'I^
ML(B06J2LZ?@UZGG*2CVB3D7@U)$TXW5GI"#601DFL.!9%5L5HHFJ?)4;(VG2
M*>34T%4RJF:0^\'&EI[MEQ8;0ZM0!!;6X0@*!*2N4R5 @:4/LN;NXXA6\HI3
M"A)4!O$1F"$W,Q8@ZB=BM7AZ:[<=EZ',\(X"!GUD,N?K\<L+US]?R[;!EQ(G
M3]?#6^MYB_"WP_?PP:^<<0\\AU^'98(,<Y $:7]B!YP,LL,I_:#[7&7KXX?Y
M^%GKQSO;D/+*>?.?MZX.W?ESLW?G9(G3..>L>$R8.H\;/#A?K7C^V%B&8;NS
M@./9GKWXV6$BP]!I-N5YOK.+!L>/CS$>-LN&#WY:^W,./.>%A UUD9Z'YFWZ
MQA\KY>%CRZM.#/';P[MG !WZ]?"TU/B(\@#!M;Q^@PMRY\;Z\R.&7O@Q[,M>
M(YX;?#+79E80(XSD,_B#<WF>>$>-\H&NGK?+#U!R'A[K46'&/EB9GH^OSQJE
M?#I6TW<]>O15TTC3CV<FZSBX*59ECIN#;2RK:?K=K0Q5(.F7[E&7J=.GG+H:
MEK12*(8::HMC)U J1V#,6BO*T.R7:VD>JDNH;0PM:#OH=*);IS4'O'4I*&2X
M &F>\([Q]26Y!,XPNOH;<""E2BH)4(W9A:R@0DJ!.Z1*MT&$WM>+,2^D"T?V
MM)Q56U&YK*GH^1H5*N5'JU#U4[IU-HUF:&I>J&+&KTX=*G95>C*NO A*8J!=
M!XFV;RA'J13B=L=,<_\ :]M!3BVFPPXH/EC=#[2705HJ'F5*9WBXD/,4[CK8
MW22DI)B21H-8T$RK> W L'=44D H0L!64I6M*5F0 9O;%8>:>.CI&/Z@:S$Q
M7$,QI=W4[::J.2NKO&1I5LC2<S>/33^0)4*=-+1KAB^J:Z2\*GH$R"RCF=EJ
M=40C6S@DC#JR&@;!VBI+:D(8<4XEI2&DU5/WW\YNF=2C<+@.\EJLIG7 ?PH0
MY*E I4$7[TT"0=\ %0WMQ6[^%2TS(T*FUI2(WB4QNW!Q?7]5+=@%-IU$HSO%
M(LK7TS=D%*)785R_KL*PIJG7U75)'A1L9"/IU9O"4O&2DZM(MVBT?(,F71@W
M,LZD89M)8/X54]\IH+IH%.W5=^:IA-/W+K@:94'EK2B7'5H0E*H*"LEP(0E9
M1J[]&Z%;JY[Q3>YNDKWD@E8W1?\ "E*B2#^*(1O**0<3RNG[<BI,I05!N'EX
M$@WO+CKLYX&!'4.A#R4C-2M.%DTW,FP!&48(S<#4,>=-J<CD310/BIA$2T%)
M2F[3V>KMWO'PFG'W9=2@JA94$I2ONR$JE"BAUM<F4@*W?SH<0C0:QK(;R@5A
MNP@7G\0G,2@IXR)(@I)WEX^09]NS'+MWY6X$9DS/(&8G,1GI\@+8W7+W-O#6
M+^'G@S^(>.H>>P,;6^ND3/QR\_+(9X6^A],QUK<QA\\YVD9P1KS$S?PY^L#6
M==6P6M^6GA/#Z9Y^6&%PX=V6X-FNTY#E;TTFT3K?@+#%/'GYWXG7+!K\A#LP
MX:MN>>.K;@#.,B9!U(XVX:P=<LH 9>X/C///2UHSTDNUR]<[?/T\Q'*8.>[9
MKX:[!\3U["\WGA&'7GKESRPMNL?#O],@V=HVA%]>'AG?30F#EXF!BZ9#U\OC
M<Z^ Q)R,C'P\>_EI=^SBXJ*9.I*3E))T@QCHV.8H*.GK]^]='2;,V3-LDJX=
M.G"J:#=!,ZRRA$R&,&M*5*4E"$J6M:@E"$@E2E*,)0E($E1, ) DF+2<0D $
MF  "29L !))G(1<G+/AC5>L=/30LN]8TU)USI27'4DQK%F\?TNYG[Q:;C4YM
MI'K(H/UF .7R9E?8EG#=-T02E5;F72!4A.M)TN49V%MFI4ZEC9=<XIDI2ZE%
M.X2@K!*=X;NH!*3?7&%533H )>;A4P0H&8L<IB"8(,7QEVCK][EKPIF!IZ@K
MU*!K2:JF[Q*]JFHZEJJAYYQ/78K31:;3KV(",=N22%*FJ P0H3+4ZK+ZSQ9"
MJ#@#$#9/T-;3(<6_2/LH:J?NCJGFUMA%5W1>[A>^ 4N!L!S=("BF5 '7(EQ"
MR E:22CO  091O;N\(S&];VQ4I.$NDNY+4MZ<O"W=T,$3%RD[5]XKZ+INFS1
M\,R;*/9F6J&K%F[,[>.;-$574D]D7Y6Z:":BSA0"$,8-DS0,KJ!]WHFU53R@
MA)8IT]^ZM9@(!;1WBU*)@)DE1, $SCE*C;6UWZ)%#5;6VB]L]D)[NB?KZERC
M92W^7<IW'2PV$1^'=0 F+1;%D7&:5&CCI,H3[BX"^N[F]LM*K-4*D0HFIH^9
M?01G_7_5RTK'(J^WL6<D#5T,:^7;$92/LSD63A<&ZO1Y.NV7M'99;%?15%)W
MH):+S2DI<W2 H)5&Z2B1O)!WDA0) !$\2V\T[/=N)61F <A$Y&]]#E(($F0+
M:I_3;T0*JO25N1I[28N2EKWT:@E:2-=JTO%I@U:&JF#<NF<O3B4 :1+(+SD>
MZ9.T',4@@H^34:N"]0/4J='*[L3:[-+]^<V96II.[0[]Y-.YW0:4 I#A7&Z$
M*"@0LPD2"3<8TBH84ONPZ@KDIW=X22- #F1!RG&T5N+Y:S>UNCI><B9OC-A#
MB/R'XAJU]N0#K'#3%A;TCA-[1>XX&PR)QJ!YY<9XZ0? ^IS G%MX="KU(=K+
M19D_K-HC[,HW6.5,CMJ"BBJ0)JF ")N$E%5 )U@D34(J('5(*9.EV#8NUD4(
M<8J 13N++B7$C>[MPA*22D&5(6D)G=!4"FP5O$XX7:FS5UA0ZS'?(3N%!.[O
MH!*@$J-DJ2HJ(WH20HR4P)L"$N]JE5R1-TU^JVX&*"SA=5!0 ( AB":**JAE
MC]'$2!]U(1R,JF&=N<J]M[/2V2VO[PX0=U"$K3)( &\I:$A*0<XWE1<()MCC
M:?9=6I<.(#2)_$I2D&!!F$I42I7#^J3 *@+XF5GQSO%4U>F"34YF38@B)NH;
M-!,@BET=F!2=)02A]]4RBI@Z1S#8A #*2(*E@/.* C?6XG?6K4F2HQ)LF$@P
M!C0IR'2E4PF6T _U$()2E.8RW9-KJ),29Q>-,O5&DBQ7;FS,L1$P%$/OIJF*
M0Y!V" E$>B& X' !UAEQU:TEUAY"A;=4H$Y@IDI4/,03P)OCD*56ZXV1_A &
MUR%&(][:3SQEU.9:?62QGJY""WQ;-2EQ5P$2E,NN?J2J$(<XX)  F Y4R&Z9
M""80MU[[N[]W2&D*5WD..*(W2<]Q "B"0D?B)_*5*$$P,<OWC?>*WE)3NC=2
M)*HRWE$@G=),)$C^J;"3BM)J \4,N0P&;(XIHB XE55Q %%0V"4@?HR#GB/3
M'=;;*!;3N$0M<%?$)_JI/,G\1R.0QF29((N!E:=[B0>0,#G)!B"8F/6'$H /
M1)D(YX"?: ;,@'/;CB&S&V@C=2)S5>."=#YD<[#&L$YS\_Q$$^F?*>-SB"?5
MLUAK\L._=G8)FQGPL. M  )@  GQD' \"+@?.]Y,Q?WR(Q! -N_7W!X /9B&
M5M1XF0<CK: <[9<K3(@S?3\LN&?//X\;#!D.KNXCACQV<,<,<+-28F"2( UC
MPN+V()XZ2TSZO[3SOXY0U S#B&'.(8#K^(6I B/$\LYR$<+>TB<3$I;23$"\
M@G@.<9FWQM?#"7'5NPU[A[=7S#A:^-Q!C74:DP8YQ$>&*/6XMQSZ\\2^WYZQ
M[-N0>[5;5KISO%_#7+CQ&&GZ9#QTN?GGBH(%Q2*/;M_>']VV)69GE\!PQJ"H
M$?+G_I8DC_C-L^\;=O\ >(^-LO++4:<.>I/G\='OZ]6 QXXAV[MGESMM,P=?
M:X&H.5\N9F+3B\CX<=??K3#M9X:Y?,^F7KE?$P<\_+#;9'IP^?(Y&VLYF^'7
M7ZSI@LRR(XZ9>7A:9RCP867D.T<</7L\K.(OKXQQ ]A;PMBW]QH(GX>/OA"/
M1#I".6.8Y9%'+P <!$;!)OZ1G!T^!F;FV6'*/?6<_E&)=QBE@Y(&/5A@J4/U
MT=9A ,!Q,G^,NK$.D&VVI()E&6]<&!98%@>1B,\R.$XTFU^&?A^F?A.).2$2
M-RR3<Q159E,J7,>@LW,'Z5$PES$#EP.37T5"%$-8B.5@2X65@A+L(,1*' 80
ML2!<&09S22#D)T.63OIB4 JO_63 WDZV,2/\X"<8=E'*[I4R[A0RJAQ'$QAR
M#$0$  -12AB(%*&!0 , ##''M5,VEIL)0 E( @#C%YU)XDR3QQP=2I2E J)4
M3),Y9Y : :#$)DF]G4C09%A,9,JCR-*J8PD(LD3!5 ##CU*3A'I#J$A5TTA^
MZ4ZHC75M41%84V44M/[H$E"E?@7$?B6VL#@2A2A<A Q@:"ZK>I)E24J<:*C(
M"TIA29-TH6DE1TWP+7)Q:SBCZG6<BW)"/Q4,8"@<R700Q^Z C[682MNCB _>
MZ[HY8XVWZ-J[/2WOFK9@"=W>E=E QW8!<F!EN3RQME4-8H[B:=R0;DB$S>#W
MA.X!>/S0<QD<9ZHRG/LQ"D8J*%5=K+'=OCIXBD+A0J:?02$Q2F%-)))-,#"
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MNI"A!203>RLQ)!%CCC2X4+L3NJ*DJ2,B#:,^&N>N=\2$G3$J4_\ 6S<SQ$^
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M]7^6%JVY:L\^1''5GCEANM<M;97OT3.5YM'#%STOG:W0$9VB\\<&ORQ >_M
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MZ;>=?IPI2WWEL );84MQ:FWDK0\AM"GFU @MJ4DC%#].VF&PN-U:X2VLC\*
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MT[DGCMX9W'$("Y&Z[M!?$=H5BG''2^KO'5MK<(0T I3+3E.V=U* A(0RZXV
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M5:[O&66>P<G1B=WCNFEGJM7'?#21J+09P"%(E<EIEFTC(=5G%(.X:*<,]?\
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MMFHVI5.4[CQ80BF=J%.);[PPTIM)3N%29D+SG2POCCMIUR]GTZ'T-!Y2WVV
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MA-[6\SQRRPZ^D<?3!A\/"R/4 <-)C(3'49C"?KZX0\Y<0V]V?=PQ7_6+W/,
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MO2TPT</FCH]..XYJO)*('?,%WK1<K<CE1@)V_3CCKD0Z34QR 1N44SFP P\
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MMU%;3%DI6_7JKG$NI0@H72%2F&EM$$H6$I2DI&043C84-#4@T5/4-;1;525
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MUP[OG[?K@ZC]_P#H]G[W;XV;_*W#H8=WS]O'GX>F'[-ECT]N&'1[\<>E9O\
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M .C_ *UIOYVZYVO[9:XO=\_;]<'4?O\ ]'_6M=_E[_IZ\<.[Y^WZX?L_[^H
M'\._#][C9O\ +POE[=7TQ-SGF2,N$\^6%U'[W]'YV;_+W_3%[OG[?KB?02P2
5*'2U=+9^\/&V@F23QP[OG[?KC__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g210084g08h65.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g08h65.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2:$4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )FB^F#(X0DE-! 0      "\< 5H  QLE1QP"   "YH < @4 &U9E<F$@
M+2!38VD@1W)F>" M(%8W8E]04DE.5  X0DE-!"4      !"PZ/.62GDQX$4<
M>\\:NZ> .$))300Z      #E    $     $       MP<FEN=$]U='!U=
M  4     4'-T4V)O;VP!     $EN=&5E;G5M     $EN=&4     0VQR;0
M  ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN=&5R3F%M951%6%0    !
M       /<')I;G10<F]O9E-E='5P3V)J8P    P 4 !R &\ ;P!F "  4P!E
M '0 =0!P       *<')O;V93971U<     $     0FQT;F5N=6T    ,8G5I
M;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L      BT    0     0
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M8VP@56YT1B-0<F- 60           !!C<F]P5VAE;E!R:6YT:6YG8F]O;
M   .8W)O<%)E8W1";W1T;VUL;VYG          QC<F]P4F5C=$QE9G1L;VYG
M          UC<F]P4F5C=%)I9VAT;&]N9P         +8W)O<%)E8W14;W!L
M;VYG       X0DE- ^T      ! #O_XU  (  @.__C4  @ ".$))300F
M   .             #^    X0DE-! T       0    >.$))3009       $
M    'CA"24T#\P      "0           0 X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$"       $
M  $   )    "0      X0DE-!!X       0     .$))300:      ,U
M!@             $.@  "0,          0                         !
M              D#   $.@                     !
M         !     !        ;G5L;     (    &8F]U;F1S3V)J8P    $
M      !28W0Q    !     !4;W @;&]N9P          3&5F=&QO;F<
M     $)T;VUL;VYG   $.@    !29VAT;&]N9P  "0,    &<VQI8V5S5FQ,
M<P    %/8FIC     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P
M       '9W)O=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E
M3W)I9VEN    #6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E
M5'EP90    !);6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0
M    5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M;&]N9P
M!#H     4F=H=&QO;F<   D#     W5R;%1%6%0    !        ;G5L;%1%
M6%0    !        37-G951%6%0    !       &86QT5&%G5$585     $
M      YC96QL5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $
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MX   C*   !O% !@  ?_8_^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$
M;6YT<E)'0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M              $  /;6  $     TRU(4" @
M                                       18W!R=    5     S9&5S
M8P   80   !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    4
M9UA96@   BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0
M  "(=G5E9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P
M! P    D=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E12
M0P  !#P   @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U0
M86-K87)D($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M               2<U)'0B!)14,V,3DV-BTR+C$
M                                             %A96B        #S
M40 !     1;,6%E:(                     !865H@        ;Z(  #CU
M   #D%A96B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D
M97-C         !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)
M14,@:'1T<#HO+W=W=RYI96,N8V@
M                            9&5S8P         N245#(#8Q.38V+3(N
M,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N
M245#(#8Q.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                             &1E<V,         +%)E9F5R96YC92!6
M:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2
M969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                              !V:65W       3I/X %%\N !#/%  #
M[<P !!,+  -<G@    %865H@      !,"58 4    %<?YVUE87,
M 0                        */     G-I9R      0U)4(&-U<G8
M   $      4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X
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MRHTQC9B-_XYFCLZ/-H^>D
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M?G_!"S>5>.,:Y'96ZA3,4@0BT<UM8,262JS8&33,<[J2*S=1Q5@6YINP;.E
M+R5E3#MF49?0YAV4[4AH(TSG)Y<OS:GG9BLKY?WIH\PIK$@;$)ECF*[.T\KH
M+[048TS.\RS'+>V'9%DJ)'R+.XLQR>JIU :&/,.Z%;EU5< L9)^Z> ,#LI"D
MAW,QQE?*F28?$='E\@6"/FI&#@E8OQHG M$GS]JSD95E%JR0ME7+4#LHSPP'
ML@*:AE2,T%CII*F*!!Z+(\GJ,_S.GRJDEIX:FJ$_<&KE:**22&GEG6$.J26D
MG[KNH00%:1U#$7OC8>T&>4O9S*:G.:V&JFI*-H/S HXEFFCBGJ(J=I^[9X[Q
M0=Z)9B&++&K,JL0!BF9)S'4,9U2$MLF+^=:VF:KD!4XVLI-I*6M,I:%TB13>
M#;K.V:#P5&IU)(3>%)@9FW4,B*JYD4%;LG[/5^=5]300"*EDHJ:KJZ^:M9X:
M>A@H58SO5.L<KQ;,@6'_ (9(E90Q"*[K1G?:7+<ARZES&<S5<>855%19=!0*
MD]37SY@RBG2D1I(DEVHRTY/> &%&*[3E$?(I$ADI1&-!<42* H8ZI  Q@(D0
MQ]Q 'H Q^3N QOD[]^XV[<.O,;GT'SU^]O3&R*M]2/ <O$^/TWXK!J,V,._Q
MK(AT[^CP;R]Z(]X^O6.,[#D/;KD/;$!HK8?_ %K(^IK_ ,#3$V W#$/B(V_.
MLCZFO_ TPQ*OJE$1C-S(25A7CX]FB=R\?/EX]HS:MTBB91=RY<)IH((IE 3'
M55.0A"@(F, :SBBDFD2&&-Y99&"1Q1(TDDCL;*B(@+,S'0*H))T Q345%/20
M2U55/#34U/&TL]142I#!#$@VGDEFD98XXU NSNRJH%R0!BD5ME2KDR/)5"^1
M]JCDEC-E']<F(.<9)N" !C(*.HPSI BQ2B!C)&4 X (")=PAKD5E!79=*(<P
MHJNAF*AQ%64TU-*4.YA'.B,5/!@+'GC@Y3GF2Y]3M69%G&5YU2+(8FJLIS"D
MS&G650"T;3T<TT0D4$$H6# $$C7%P_$1K^=9'U-?^!KB8[3$?B*V_.TEZFO_
M  -,18<AB 41J&[^RLCT>1M_P-_V^73$XITM#E@2-%DGBRY%U_!S%7 G**82
M&4*8@D H;MR9@, AOWB @/2(:D$CCY\+^?#W%L8LM[D:'>+=>W'=KB9(;ED*
M/> ;^GCIU<.6N[QO]M<4\;_QCWI?K?P_D:\L,-+_ 'WCEIX<>N.&&GV.G#AX
M[^.N[#%<F_EMOX,WM+K!./I]\6/P]?MBAZS/VZ/"UO \3BO#4X8=W''[-1RU
M/H>5[W\.!\=^'/KK^<..-^G/AY^!-S^A^7-UU;$.WCH#S^CI\OHT^9OQX<;;
MA;0#R)%[XGKS/EZZ>'KB/'K'T\=P:;NN9Z\/(8CKV'IUS.''''LTX\@-WC^F
M_3CIRPZZZ^N&IZ\NC_.&&@ZX^O/SO^Y8:88:C0_;@;:<+ @7'7!A]O1[=+6-
M]=3XG^!\L/MK],-./EN\=//Z^F&&F\#^+>(W^Q]>6&&FF_3?OT\K7UX\K<L,
M-/2]R/YU/@-V&''''U:?QKIZC?\ ,:^5KNNNOGB >7CN^K=QOWA?74>G ^W*
MWMNUQ)\.N?SOU:T=-;[OV.N_7]=?3$8:>VG/33CPW#377D==<,-3AAN[>.WW
MCJ+;N?MSY7W7/F>.%^'7#]!B?)NY!>D?DE[ [@\NJ3O/F?KBX7L-!N'$_IB1
M/T&-U '*$ Z?*/V:M70"]M0+?8:\?+Q]:M_,\3IB&LNNO+$8<<??J"--.&ZV
MG[>A%L.NOVP#C@=!Z_/E]/.^O'=@>NAB&_NXZ^.WU#OTO<Z;OD=_[<^'#7$V
MY];NN'N+8#]V_H^WU^C0^OF+7''UW;A>]MV _>VOV]O7#ZM_''LTY<+]<;?3
MS&_#YVZZ^N(Z:Z_+Y\?V^^(PXZ=3_.O\?OAAH>M;=='?;##3##3##]O3Q[=8
M^)ON\.7INMQ&\[K;G\:=?3#CW:GST];[S]^'MAU^N''?IR_G[_/U.'7+#0=
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MCY:.;1RB+2#091!&S1/S?-\US+-ZQZC-9Y9:A"8]B13$M.%.L,<("K$ PLZ
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M)3),P<75( ";';JJ9 '$:S&([<J[,PB=)&C:S!6U4,'"P9XQ878[K61S<$L
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MWB;5WS"JK<RZ)$U#MU54#F,DH<@W0U-13%VIYYH&9=ES#*\99-Y5MAE)%Q<
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MPP^/3C\Q&_V@'ZEIAA\>G'YB-_M /U+3#$I(2SB?*U2,Q*T306%<>4L*YS*
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MR<S()LN6,=2%IV6?L(]9[(-@<V"O+OUJ["12;M?IJ60U$5+EC"*FAGS!7EK
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MH@RY+EN09"ATME63TD3V_P"=Y4F[QC_F=A=CKRQV=:E7FNR<YS?.LY*6V?\
M$\TJZI4L+*(T>2T:J-%5;!1H!;&9HOX('X-N';%:L]E*C*)%   TE-7N:<=
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M;+(+%SAB:J[:>*VZYEUK[L_O5Z]FB!C  3N7<EC&R)@C<'BJA5%T8.K.^::
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M8E5J,GB@9E_N42SO&S"X(N UQ<$7&NF/#/QVG:ER_LO5(H=Z;.VJ%1K[+-!
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M3,8HJV4RSDO1-!2,TBPM3HY F%8&>,HZV4-%:2+8E6J3M[2@7A8QK9+"0-(
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M!^IM\O7&!!).\BVXM8$^@)MSN?(:G&(K7@]W8GAI)*Z2*#M3<<[9VBN\8HG
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MWM]=^&OO\\-3^_OX\MV&("8H=9@#SB :?MSZ^0\<,>><3#_I";OI /E[_/\
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M-;:;H56%9C-4.=N+/$3*3.X(^O.$6,_+NZ7'I^&)H.2VNL5<&RJ<*Y01D58
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MY+6*!;,2;*<>D=N>TJJUYT39VOSIK;L5X\RE&0:3R":S,-#76PRL* 34LZE
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MF'<4I" )C&,/84"@(B/8 :C?IOYVX\-WOQO<88P"LI*Y"GS(HG,BP0$YD04
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MY:E4J)I0W4W7AN/L[#3##3#%NVP1"OR AU[FW^^-],,6A&CO;AOW] %#=W=
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MQ".\:LP*@A6*AFO(RH" 2;NZJ#_<P%R+ 2(R1O 8C>=1<[A<GT!/+'/>E_"
M9&6CHYM9-GVU6N2-7['.R-HJ;5E5JP[&*BK9*(IU.)-:<EN;="PJU80B[]8:
MW9)AW3E[/54Y6L-[(_E:= [-/V>I@[&+,(HE[R.-8IBTLJ[;0H>^D$5,(GD[
MTM3QR1(LPCEV)3&JS2<%*U[+M0LY*LQ9!LK\-]PO(6 (LY#$K=25N2%R%(;;
M-^9QY)9GLV35@BE[Y&4*,EX*^%)#V9XO2&=S=S%0D;'2:XE.04L=^UK^-7RA
M8X<BS2I&[=.$,;D!QER.G9VC.9I&ZP/.R24YVXU$QA"3)'/(8W39+U0&T*9
M3>3C8:MPJMW!8,RK</\ "21>ZDH-I3N0V&V=+"^*74]M?)*HTYM<\*I%DK!6
M*N[F4:I)6A:)B;HM<)ZJVW'$+,2U/06L&56IFS!W&8S?Q-8!LG W@\G=C(1C
M59;.;(Z8=\8*T[,<DH0S+"&>'NDEAJ)$28B*E8%@]2KRWVX-F %F Q2KD^';
MB%V"@A"]@VULLH9DU?46C*K;9<;9L,7,OM13-BPN>WY#V;5XL\G-TY@>GW*5
M=R%29PUPQ8RRG&S%RGG..EEX99JLX-C=S&HTR;(EE5Q!U8D@*<N>3C\8*!J7
M,$%!F[I)&D[+54EX:D20U)I72G$=4I8,+5 ?OXR:022E/@"O1704>944M)FF
M64M?22E!+1U\$5722K;;7O8IX9(V*E;!6B8"38 .MQ9CG:^NN&<!+91O6"8^
MN,7=^S<RI./(9*T5->MXXQ>M9BU]E;6S2CV56-R!;D:H_>LTV\,RH!BR+99U
M;HA#P87USY6F9YF85S.6IF-/0O4UL[QU+3U54L1D9)'J(R\$/>JC%I'J!L$"
M)S?9QI!3Y901P4N7TU!20M-%345' M+3P0QL^RD<$,*QQERK,%1%CNURPO@O
MMU7U:>CQ98.6859)5DUL$C-2UD395US9'U?81J&0;(E22-,9R./U)*0_"[&%
MAKZE6W+19DVE5R1[M^; 9# $8-7;4Q#-&B)%M2B,.6--$9R:I:@*IHW[RG[P
M':91M!1RC5OO$5@" UV-EV@+;;;']/8O_4T?9YV!./G'[>60;!7JU8XW9Z>U
MU-P[QB[N5>N5@M+&W5>O7JN0\F\.ZB$,;%:,9%W.V&,K&.324HBWNS]C8222
M-2=Q*K'4GL_3I)+$V8K(0M2(9(8XFAED@D95 <U-V541I:K90FG4QE3,&N,?
MSKD*1#;5-L,S;2AA<Z=W8$D@1W/Q_%M!"!?T]^$(G62$0<NSE;),9="7!JZA
M[(X=0[MZPJT9:1-'OG=*CWHUVL%D7$#EFX3,5!5_&=G@+!7EG5@ET89G.%[.
MHQ<?XE"@C:/:#Q .JO*T7Q*)V7O)-D24D*.\E5$\<@$:%RDFN(M_18W#V(8D
M$JH:P.P-!?9D) ","OQ$"^Z%>N+S(.'H&[2%;>5%[9X*)EW%<?/F,HM%J.G+
M<PHIR<<8S*39*@ .8Z11*AX='K-7:C1FJL=HCT%5 *:IF@659EBD9!(JLH:Q
MWE6U1AN=3?98%=I@+GF1/WD:.5*E@#LD@D>HT/@>(X#=B;C/[1^C[-8)N'J!
MX\>OYQ6V\^9^O7C\B:EQ^T=96X6YZ^//Y\P?KB.NAAIINTY;N&NGUN//=ABU
MI[I$/II^TG5Y.W53:F_TXV)'VQ8FE_3[_3&:=8XLQIQG+:MEL.7WXFLL0SMX
M;I5&>M2[Z+DI1"6<)0N,\NY$,I"03&GSB$M").L6L:1+S!YMBZBK=D*EQB4-
M)*RS--WW-#E*UM,TYJTA(ECB"NJE+O4TE, \C3(4D(JFG1.[8-#3S/MKL&W&
MEJ#'($[LL+$EKD$ )(Y(4*;J-C9)N+,RBQQAJ5V][7&6&S*(83-+T8K9VXQ]
M(-YZT,Y^X,8.U;0M?>SR353'CJ/5C[J3#%89XQ9QR[GQ]:LNXO@%I0$+S&2K
M+FKV?B:.(&NV9_A%0O=PM'"TD.7RB._YE6#4_P"=D-6S =W%254@2\#HU/YU
MKL>Z&Q\7=_$P9U5Y5VK=W:TG=CNQ?5G12?B!%7>;<%X7E[M$P^S+99]E36"T
MU+&)9)=*12@V#3-C^?K\G$CC9RV:Y49QV'V1F>.V\I)L91?)U 34N#!G,)/U
M,!D<"+3N^:1Q-.X1"(T*]XQH1%*D@J@32EJQMJI*HR"EJ"(6*;.)-2SB533;
M:A?B5B?B0]X'5D,9&W9/^'\08.MV )QA^$VK;OC1Y'/F&S)CF!;/B3I<BQ.-
MXRQ,G;VTP*V8"?%"!LZ%(CB361Y1Y08&"KU)G*PQ&8MUJB($EF9FL+!VU[6J
MI)<T58ZS/LRK.ZV!1MF%3^86&"04=YC#+4R=S2HL[O+-%*=B&%I.Z;NV5NDR
MK*,DR%JF3)>SN2Y.U6_>5O\ A&64F7M5S RG:FDI:: U$]Q\(F4L7DMM@M<9
M(GMNZ]K-X9C5<#2S":G;!7F2+VS.K$ZB8UL_N6,X.:I+YI'5)F\4SK 0=ZF)
MVRXS3=)1%6B:5;9Y2]3C2N/V1^M3((!MM+7HR1Q2,5B6,.2L-5(DX9IF44$C
MP)'%56+2O/#'W$9E5AW?YMB558B"S 78M879 4ML@]Z ]V30*JLVV=FQEH;;
M_NY:XVD[+LU7%BX:-L;ISKE>70AEV;VWU,\]+*.Z0$?8+I%KKOT31N.ZRQ9V
MF=OJKALV:BPD# U4R?L]"9"L69PL&-5W8"]X&6"81H!/M10. IVZB4F)( K$
M@KJ,%KG*@M3N#:+:N;6+KM'X+,XUT1=2UQKCIMK5\=CC'-[_ "N _P#B?_\
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M-?*KAX[;2!UDX]_%IQ3=8>!#391)!&9*GNJ@0U;R!CM1.P:I6G71U=9K"!U
M)1E VE;;(-K/4AY+)=-J/8L/BM9"XU!!6^T"2+C6QN!;",]MJ;4-->PE5LFS
M?!.LE3<97W]7H<-.RZ<ADU[-8^CKO/P=7/(I)NJN3&LP^4H-@LUACY&'GY=E
M*3#9*NMX66BFW-CR7*YE>:/,I%ID=TEG>--FE"5!@1Y=@D2_F$'YB..-E=$*
MJ3(75C@]5.C*AA4NPN%5C=_@VCLDVV=ECLL6!%];C6V;W^=]IO\ !C5+C 8
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MFABDF(!$,<CA7E(9D4K$I+D,R*0-64:CHIB0I*J6(4D+K\1 T70$W.[0$ZZ
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MJ#X2J#;9MCY'_%;.FJLUI\A$RS'(C529K*AND_:3,Y$GSD@@[)6A,=+E"6L
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M^6;Z0^T=7#<#NTX:Z<.%_37UQ3CSH=]M^\^UNMQPQRQVF73C(FT+%TABH(^
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M8U3#CS!J/:P][>7T]K8=>9QC"]85Q)DU9%W?L<T^U2+8I2-9>5@V*TXS(0!
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M9OI#[1].KA>P\O?UO]CX8HQ\55$T4E%E3@FDD0ZJBAAW%(F0HG.<PCO "E*
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M"  (ZR) !)(  )))L !Q)-K #4\L%5G9416=V(554%F9F( 55%R22;  $DV
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M/'[[]_#=Y<?+##4^F&'MX[.![AU'J+\?/3>+^'G;<1A].N/0YC#0\AOMI?\
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M/]3@\+VTO;&W]@<M&;=L^S5"R[4;YM2S3*1<-!1M^<G4CDT-.ZGP.-4-AB
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MX??B#9=%^WYINED"ED.LMXXQ[:A4;OXU^Q<2#>,._;LCOW[!U!3D[/:/L_\
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M2R3SN\LTTCRRR.VT\DCL7=V8F[,S$LQ.IN;\L=HJJBJB *J*%50-%50  .0
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MY!*\4*QLX*G92%'<H4IXUC6,FS+PJ;+GBF26:1&,2A8TC!M8*0"20+'XBQ4
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M8U3O8[.J,X!^*^,EZYFZP&['28:=:Z=?0\\,-1O\Q:]NCH?IAAI;=X>]_/\
M0?+3# =2>OXX^6 PU''C_'IX^9],,-.N-M/D/ONPPU.&&HXCVY\[\;WTM<_K
MAC1:VYDVL8&WW^(J>#8RX5V$F'1ZY-S2EG@AE8Q:!R++LVD8,+79IM(E:N:'
M"PJSQ11)564R16R\DJ:12.^]CI,H>*G>6O>*1XT[U$[J01OM4ZL7VY$*7$TC
MVL=E:>3_ .'C[=1=AW0(#'9)+*2OQ;)4!6VM%'*Y86W6-.>[1>U1%2#IX^V7
MU'=3+)2W-'A'5TE+0T@$'>=_ G[J%;T]09"01BL-59ZYBH8SMY*/,[X^BX1!
M=RT2&TY#+LJ= %S;9FLH_J+ D+2$4 95D,UE4M6RJKO957+ZEY&"L>ZCO9P=
M8#:Y_M+%@/ZUKC8-R.Z4$+<DS(%N=#2Y;:BVH&L),6R)V3['+5_XV.JQ7XPC
M&[-;\>'/.LTF.1)2E2%88/PKJ%767E75?25;65U+)#")I,5$SKFR7+,JVTA?
M-XED[KO9'#0&GVPC;5.LRRE.]:2RB0WB53WAV@0,.]FLS=P; @ ';VB#8[17
M8O\ "+W6VT2"--<7_8]H/-\4-0,PV?IA=2=Q!5[W,L!C\DRQX2V3L/97]EJX
MRE=QU)1I%L:NH6'0E:_,C"WN\H68B-%K+VPQ2==F^/%04+B;:S!%V*R6G1MJ
MF3;A1XUBFV):E6M5!W9)(^\IZ?NB:B58W[Q,C)*"H[DW,:N1\1LQ!+("$(VH
MR "K;+/M? "00;>9Y_VJ'[Q!VVV;6P5I%RLDZ6?N;W#V&681IX-96:A8*2IB
M3F.3LT=(O%H"$LQ8N<AWC9:,LK9M(1CYL>PT&5*K!LS/>:%=D4[1J6#V1W2<
MAC$R@2/%MQR*0T;%74XCO)SLD0W''^_:WVN%V=+BQ"M9AKM6(*XPXQVQ]J:<
MI^.LFUS9CLMB@+-1):7F(F K.03-F<Q.1V#[%55 0G*5$W6:2AR66_54TE48
M:2K%E YK?&/WL?4Y]E%<U\FRJ*:III,TB22*H5$=Y:8%HXVKHYM4J&IXRYBI
MY=F:198KF%D#S(7J6IF=$D$+$,ER-E[@D1D6NNV0-IUNJE6L&!V5-MVL)9'R
M9D)QD-/(V*WF+B5BVNX.I \5DG8W.O(.Y%)"W-G+R*C&[9LY.W\5^*@!5Z5Q
M%N;"D=Q4[-3I24Z2NIJ6 4_Y:K%4981),0$7N9"%)A*AG)(!VML_"0XB-IHI
ME7DQN[%MM-C9:P!).T-?BN+:<+;[@G^TJ3GG7!MUSZ]M3BS%<F_E-OX,_M+J
MM./+3[XL?AZ_;%#W\?9K._KSMP/O^N*[=??#32Y\M=>N6_YX8>;3Q'&VHU_D
M?;=AYX:7_;VO^O'ZX8::V\>O:_K;QPPU/#]/EOT^V&&H^QT]OY^N&&G6\]>F
M&+2OT _M=$NM6BGQ8N4LE2L<!'29S+$+'/YB'>1S-\8[;<X(5HX<IN!,WW+%
M!,12_' NK8)!%/#*REUCECD9=/B$;JQ&ME^("VOL1>T$7! TN"/*]_73&F,)
MLHY6QQ&2C#'&:I]6+<M**Z3I;J798_K"LRSG"ER0WB5J/1'!:!'6>H1D+'QC
M^N0+]\VL#RW6=XT4L<\E/L.Y?-J6I=6J:&,->93,J&HE"%":8N)JA14-%*[E
MED=%,:0Q!N[C[MN.('0621CH/A)V5)&C6*J2@8 ;@Q#;3;S<6K5\/[:\EDR%
M:7+,\\QIE69%&V7=L]KT<AE>4/!,$H\M:H< YD2U:+AYE!P2<%VC47L\Q.=R
MW$LF^%Y&W2UN2K3.8**-YI&(B@(E9J5.\;:[RHD"=Z[(1W=C,L;"Q^$;+8K'
M4%[/(0H47<;-G:W! 3L@$?$/A+#=ON/+' ^W:VCX]!YM"P<JY\0+LI@'-JF6
M:9I(B*@K>)7D9BQI(,D;=+E1EYR8DU)F8IL6HM4,8EK#<A)Y26K\A9V*Y;(B
M]X&2T:,2E]SJU9LDQ)\,:*$29K351D/],0(JH*+S*38@ZD:FVX]W?4ZDDW3^
MU!;4UI/9[VPV]>9HL]HRNQ\ZZ8GF;:C%0[R,C9ZZ(S;T[AHPE"QCN2@J[=*K
M:K)%V"938/;/7;!4\96>O^%.(^=:2-?^(9.9"7RV5D#;$.TZNT<!46+(7"22
MP2Q1-&A=8I(Y:J)]&0KD8IPI F%R+G2P+"XT-KJ&#-M$"X*HP%PP-\W'#.TW
M,5*JI0>=UF=M@L?TB"F6YI1:'A[;:F-C!Y>I>3GH6G^,V2TM6M\'#SD; (*I
M*F<OUZZVD%8^0AJ(*W+$FF,E!M025$TB$*'EAB:,B!%C>;8(64[;HTMK *)2
MH96R>.8JNS+\:JH/^56:XVB2%!&F@(7Q(OBS++@#;!5KZZ5?VE7+^P2S2Q)3
M:DK+JUIH614B+''T:8KKZ H4B-="LS,M#V^?A(^$2C+L[KR-6D195E\HBWOB
MS#)PX,F6!45HS'L*)3L]Y&\Z2K)4)WG>1HT$<C2,T"R&55:1?BAHIR!LS:F^
MT#\(O8@%2%-@I.V5L Y79)"DVO4VSIE7P2F1[+*ZD E&VS.TO<92NJNX^QRT
M'E[:8J>8V\5"SAV#A]$*M:%%V2E22C19G^_9AJYCU4RL&3UC0,QI0T[&C$A>
M++D@62S1(]%E<U"S/'M*KAIWBG4&^B$-_<P,B)_AO(; SEB+!CWLZR@!B"19
M05-K:M<;@<8DA\*;<:S.^-"Y<KE7<VM%DQ&R*+M6<O'V>M8FGZ:^R% P%=K$
MO!O6N3<CR\3>#HS<G$R=<@J3!-W< XD)IW!UOE/6Y&'A;\I-*L3%EALQ1H9*
MF.84\LLLL<H:E@5H;QHZ2O-(1*%17EQ"5.S8NH8K9G%K[04KMJJ@K9R0VI!4
M* 5N?AVKQ91LJU?(N3W-NOLO9<8HA6HO#\+-.4'TZW;K04=)7N;L\PD<SB;7
M=VLRC&M@^28+P<<TE&39H:,>,'"G5U4]++3THBITBJKR/6.@*QDAW2!(DT$8
M$-FDV=KO'9&9MI6 M1'5GVG+( HC!U;4 N6/^8[6B[K"XW6.-@M=?U_(W:ZW
MW:>XMPT^7"_\_+3RPPTM?W]1RY\1?VONL6'FTN / ?;]/VWX>>)XGR"?1+Y>
MP.W5)WGS/CB\;AY#PQ)G^6;Z0^T=7#</(<.O7D.6*,:'[=#T25R@1V_H=3DR
M]$-_1OCV#5 HB'1T@$F(=0B'*$ Z!$=:;VQ?_=Z)+B[32L0#Q1%7_P"_^>/H
MS_9WI]K-NTE5;_@Y=0T][;A4U,TA'D32>MMW+9' ;$(_#6.$  "@K5H]_N -
MP;Y4AI,QO.8SL3B/:)A$>G7?9+&$RJ@'.G1__4_J'YL3YD^>/*?Q(J35=N^U
M,A-RF<55/>]__D;"D \ !"% X6 OOQEWK]NNTL#8V\?G?Z^^-)W?3'P0<HN!
M6!(PF\'7.V5WIJ)\E9,"F.4.<(3EE #EW*)\I,V\0*81*.YS^Q^NZV&/OH1_
M%SQZ/0%F&A\]/.V[K77AROAC!&T'LSX1VI:.KC_.-!B+M! 95Q%.7)#M+!6)
M)5,J?CBJ6-D9"9KLH $3 [F,=H [2(#1^F[9'5;*=EE6;YCDU2*K+:EZ:70.
M%LT4R7OW<\3 QRH22=EU-B=I=E[$45%-#5)W<\:NN\7T93_J1A9E;Q4C30W&
MF.6-KM6W-\&Q8(*KX^O9-N+9^=LEGD1C;-4HG7<[TB%9NBMR0]?RZF56/M*#
M=N3D-3V2+7!%$J49$5QFFB157M*_M%V&S.>.+/(9>RF:U",_^)9=3M59-,]]
MG:JJ",F>F+LUR8 RFS/-.,;/V;_#_MIGV69AF79R.#.Z?+*B."7+:BI2ES-N
M\B,H-)-,$IIPBK\2RS)+=E6&&0D ;9X[^& V3YB38U#.A<B[(>272:9C4S:2
MH\W2&BI3;@,^C;L5J\IR\(H(@=E*RLK!^&MS%<IM")B;DVU'8?.>Z_-94U)G
M]"1M)59/4QU)*D74-3W6H$A%B42.39.FT3C5?\4IXI7IZQ9J"IC=HY(:N-HR
MCH2KJ7L4L&!%RRWMIC<N7VD\+R5/6GZ5E2DW-@]37:LYJ@W*L6=@V<^"D<)'
M=2<0ZFFC!N<BJ0>&K-UDRF6012 SYW'MW.D9MWV4JR5\-112FZA:B)Z=T8"X
MVQ,ET!N!M,AW@#XF0'=>RN15?:.NC6@ACJXHC'+*MGE66$R%&$*1/&:F0%7/
M<I,K$))(]H(:AX^1&4KM-94R'%56(:C6I]VTBC59!I$I*-',2>05;%*X5=JI
M-/#WZRB7A$HN?EF;M$6KY\J*2BA?,ZJ>6OJXX8T[N20(E.B*+,A<@;1.RFTY
M8;3$WL &8VN/L7),NH>RG9^MK)ZUJBEI#4U><5$TKLT<D4"O*(DB5YNYA16[
MJFB6W>R.T$"F0(>@^-*82C5)A$'3;#*&(H[FG3<N\73]=0ZI@4<"!5'!&2)T
MV""IP+O;MDS 5/E"&M_RZC6BI8H3L][_ 'S,H%FD<DZDB[%%(1"0/@064$X^
M1>V_:63M5VAK<R5Y_P B&6#+*>9C_N]'"BHNS$"4A:I=7JYT6]IIW!=PH.+"
MR?M3;-^&$7*N4<XXPI:[1,RBD3+7&&"Q*E#?O!G6&CIS8I X;A_<F$6Y6Z.@
M@ZV6AR'.LS(%#E5=5*6!$D=-+W(X_%.RK#'PU>1003K>YQI$U92TX_K5$,9W
M[+2+MGR0$NWD%)QJ*3;ZO^=E#PNPALOY.SZ=R?F4,Q7V+>8>V?XXHF$BDA\:
M+>E'2]D%CR!4<UYFRA99TD/[P666$B2FS)V-I\N D[4YW0Y5LBYR^D=,QS9]
MQ""&G+10[6@$S-+&"/C4"Y'7MFKS_#E]++4$Z">13#3#QVW 9[?Z0%)X&^+\
MI/P;ERS)8H?)?PB67"9_F(AXE+5S9]I*#ZK;,U)?D$PHF5KYQ;R^1WS4#&3)
M*6DC0'+19>,FFE@9\@^LY.U-+ED,E'V2R_\ PJ.12DV;53+/G54AU/\ 6%XZ
M-6.IC@N%8!XVB:X&(H)*AEES*;\PRFZTR I21G_R$!I2-VT]N*L&%CCK)&1D
M;"QS"'AH]C$Q$6S;1\9%QC1NPCHY@S1(W:,6#%JFDV9LVJ"::#9LW23101(1
M-(A2%*4-,=FD9I)&:1W)9Y'8N[LQNS.S$EF8DL6))))-[G7L@
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M]##K'2Q C<S+WC7OOVI"[#T(QN>DDD@DF@@DFBBB0B2**1"II))IE I$TTR
M4A"$* %(0H 4I0      UT&I))))))).I).\D\2<<S[:#RY8^FHW\MVG.VG1
M]/1AQQZ]#;C]+GQ_?#KKVPTUUTZU\#YC?Y###C]G'9IQZW']QZ<K:X=?SUQP
M^KMZ1X --PUTW?Q;6WI^^'SX;NB<-3^W[^V&&HOX'V\;>7CSMAB=CORUO],?
MYIM8L!LD^7GO'/=Y8R3^X>OT./<K^7K^9+?Y^:)]F[1-Q\_G[>7.V_B,2^_Z
M>7\WQ3^/3QY-9^G7\^'IC#KTZ\<-01>WIRW<>!WC?SW<\,-+\R/+Y#JWAYL8
MORG_ ')C/\Y#_NCC5D>\^7Z8P?<//['%V5#^]F%_[BE_]6L6M=O,_OB5_M&+
MD^_C=OX\FL2#K8VW^7M[?7F#EUT;=>.&G'Y>EK^NO+GAAIUOUZW^VE\,-/#[
M\NM3O\=V&&I]=^[]OKAAIO\ 7KQOACR<Y4R&.<Q2$(4QSG.(%(0I0$3&,81
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MF6YQ2FMRVKCK*?OIX#)%M@+/32-%-$RR*LB,DBG^]1MKL2)M1NK-F^G7:JY
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M1WS:?!%X_P!*/Y64\?OYX; YM_UO_P!V'Q6:_G:S?RDF/UK4]\W^B+_T8_\
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MA+%# B1P%I)H!%-)(X*O&$51S=EJB::\TT:PLD:"%^[%^[5V=M#M$LU@K74
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M\WK#^KIMGP]L1AS!.\WK#^KJ=LV&[>1[6_7##F"=YO6'NU&V>0^?ZX8FBIE
5I0WCU!W=WFU@=23SQ>NX>0^F/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g210084g09i73.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g09i73.jpg
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M Q$!_\0 &  !  ,!                "04&" K_Q  C$  " @(" @,! 0$
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>3M5X.9 X18():K<9D2ZS'89F)YB>/%L^)?RM//_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g210084g09i74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g09i74.jpg
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M 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !@   (#
M  @) 08*_\0 (A   @(" 00# 0           P4"! $&!P ($A,)$105_\0
M& $! 0 #                !P@!!0;_Q  D$0 " @(" @(# 0$        "
M P$$!1(&$0 3!R$(%"(C,?_:  P# 0 "$0,1 #\ T*<V]PNT=Q/,)M#K<C X
MSXB ZOJ*5RVPL+4DUJN-K-G9=CE4*$KBVTC5)-2J.7%<4[%!=7B*R6U?/16
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G&FV[6ZBM<962=JO!S('"+!!+5;C,B7K,=AF8GN)Z\;9T+^5IY__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g210084g10j82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g10j82.jpg
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M 0$! 0$! 0$! 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !@   (#
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M[H0$+.76#I;)IR'XF[7I+SCKDMFX2[9KH>WA+V:MGKM;%7:P,!M7;=H;$\W
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L''D[SJ--MVMU%:XRLD[5>#F0.$6""6JW&9$O68[#,Q/<3UXVSX%_&T\__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g210084g10j83.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g10j83.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_X63<:'1T<#HO+VYS+F%D;V)E+F-O;2]X
M87 O,2XP+P \/WAP86-K970@8F5G:6X](N^[OR(@:60](E<U33!-<$-E:&E(
M>G)E4WI.5&-Z:V,Y9"(_/@H\>#IX;7!M971A('AM;&YS.G@](F%D;V)E.FYS
M.FUE=&$O(B!X.GAM<'1K/2)!9&]B92!835 @0V]R92 U+C,M8S Q,2 V-BXQ
M-#4V-C$L(#(P,3(O,#(O,#8M,30Z-38Z,C<@(" @(" @("(^"B @(#QR9&8Z
M4D1&('AM;&YS.G)D9CTB:'1T<#HO+W=W=RYW,RYO<F<O,3DY.2\P,B\R,BUR
M9&8M<WEN=&%X+6YS(R(^"B @(" @(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B
M;W5T/2(B"B @(" @(" @(" @('AM;&YS.GAM<#TB:'1T<#HO+VYS+F%D;V)E
M+F-O;2]X87 O,2XP+R(*(" @(" @(" @(" @>&UL;G,Z>&UP1TEM9STB:'1T
M<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+V<O:6UG+R(^"B @(" @(" @(#QX
M;7 Z0W)E871E1&%T93XR,#(Q+3$R+3(Y5# S.C0V.C0S*S U.C,P/"]X;7 Z
M0W)E871E1&%T93X*(" @(" @(" @/'AM<#I#<F5A=&]R5&]O;#Y!9&]B92!)
M;&QU<W1R871O<B!#4S8@*%=I;F1O=W,I/"]X;7 Z0W)E871O<E1O;VP^"B @
M(" @(" @(#QX;7 Z36]D:69Y1&%T93XR,#(Q+3$R+3(Y5# S.C0V.C0S*S U
M.C,P/"]X;7 Z36]D:69Y1&%T93X*(" @(" @(" @/'AM<#I-971A9&%T841A
M=&4^,C R,2TQ,BTR.50P,SHT-CHT,RLP-3HS,#PO>&UP.DUE=&%D871A1&%T
M93X*(" @(" @(" @/'AM<#I4:'5M8FYA:6QS/@H@(" @(" @(" @(" \<F1F
M.D%L=#X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)2
M97-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QX;7!'26UG.G=I9'1H/C(U
M-CPO>&UP1TEM9SIW:61T:#X*(" @(" @(" @(" @(" @(" @/'AM<$=);6<Z
M:&5I9VAT/C(U-CPO>&UP1TEM9SIH96EG:'0^"B @(" @(" @(" @(" @(" @
M(#QX;7!'26UG.F9O<FUA=#Y*4$5'/"]X;7!'26UG.F9O<FUA=#X*(" @(" @
M(" @(" @(" @(" @/'AM<$=);6<Z:6UA9V4^+SEJ+S1!05%3:UI*4F=!0D%G
M14),045S04%$+S=107-51VAV9$<Y>F%'.7=)1$UU34%!-%%K;$Y!*S!!04%!
M04%"04),04%!04%%028C>$$[05%%<T%!04%!44%"+RLT041K1FMB,DIL04=4
M04%!04%!9B]B04E104)G445"055%0F=51D)G:T="45E*0W=G1T)G9TQ$06]+
M0W=O2R8C>$$[1$)!341!=TU$07=11$$T4$5!.$]$0DU41D)15$5X=V)'>'-C
M2'@X9DAX.&9(>#AF2'=%2$)W8TY$03!914)!64=H55)&4F]F2'@X9B8C>$$[
M2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(>#AF2'@X9DAX.&9(
M>#AF2'@X9DAX.&9(>#AF+SA!04519T)!045!07=%4B8C>$$[04%)4D%135)!
M9B]%06%)04%!04A!445"05%%04%!04%!04%!04%11D%W24=!44%(0T%K2T-W
M14%!9TE$05%%0D%114%!04%!04%!028C>$$[05%!0T%W449"9V-)0U%O3$5!
M04-!44U$06=10T)G8T1"04E'06Y-0D%G35)"04%&25))>%%614=%,D5I8UE%
M54UP1VA">%=X46E00B8C>$$[571(:$UX6FDX0U)Y9W9%;%%Z4E1K<4MY63-0
M0TY546YK-D]Z3FAD55I(5$0P=4E)2F]-2D-H9UIH2E)&4G%3,%9T3E9+0G)Y
M-"]0128C>$$[,4]4,%I85T9L85<Q>&18;#E76C)H<&%M='-B5S5V63-2,61N
M9#1E6' W9D@Q*V8S3T5H66%(:4EM2VDT>4YJ;RM#:S535FQP95EM6B8C>$$[
M<6)N2C)E;C5+:G!+5VUP-FEP<7%U<W)A-G9O4D%!24-!44E$0E%514)1645#
M04U$8E%%04%H141"0T53355%1E523FA)9UIX9UI%>28C>$$[;V)(=T9-2%(T
M4TY#1E9*:6-V17I*1%)$9VAA4U5Y5VE9-TQ#0C-04TYE2D5G>&15:W=G2D-H
M9UI*:EI&1VED:V1&53,X<4]Z=WEG<"8C>$$[,"M0>FA*4VMT3515-5!2;&19
M5U9P8EA&,658,5)L6FUD;V%7<')B1S%U8C)2,61N9#1E6' W9D@Q*V8S3T5H
M66%(:4EM2VDT>4YJ;R8C>$$[*T1L2E=7;#5I6FUP=6-N6C9F:W%/:W!A86YQ
M2VUQ<39Y=')Q*W8O84%!=T1!44%#15%-4D%$.$$Y531Q-T9867$W1EA9<3=&
M6%EQ-R8C>$$[1EA9<3=&55!E-FQ95TMC-W4T4T)E,TYG0V9K3W K:DI2:$M8
M24YE5$Y#075205DS9B]M4'!%3E9T27!,<&@P8BLW42]3,5<O-%A-<28C>$$[
M1VEK965Z<F-V8D=/4#!G>2MX26)V.'AT8FQQ3&5/2S-8<U%#-V9E>' K1UI-
M9$9!8SDS07ED<UI4>4%#53-(;7)Z1E!8,4PK558O,R8C>$$[,F94+T%/26-C
M=4=N9T]J:50Q,F%83U(K-S=K0DIE,VMP<DI0234O>6Y9+W)/5T-)2%)X>FQM
M95I+:FMM1'-65F\W,CAI3EDU-450*R8C>$$[4S=$.5)Y2FE$,%IJ3$UC:55F
M8BMA=DU51E!4=C545"]!2#1F52\T;GEY<S9E0C9/4D186F\X<$@W+W9483 O
M36)7-'%#-&II=48W:R8C>$$[9V\S,W%A9FAL371&03AT;DQX.7-:4GI!2V97
M2#5J-E).4F)U2U,Q63E7+W9%2#!R4G8X06AC>' V2U$U8G5F:3=9>'DK;T=0
M,G-K<R8C>$$[=%-S3#5/9'!C2D]V9F=W2DAZ2%5F5&U,2T5O.'<W3$AM:$U8
M16=O:DET:G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[
M:7)S5F1I<G-64W974$UU:S93<"MS>3AP=C)B94]J4T@V3S,P-61I=U-N>6-8
M56%Z2&DK;S<Y,U9H1W)F;41Q,3!42%I!5V-0:5!I:R8C>$$[23DR3W<K9UIN
M-#E(16,Y,U(V:G1B2DQA4'!(,G-9;6UM;6M-:WIT2DDR-T\U3$UF;51M5T%"
M>6182U)K8DIS<DU+2%EQ-T9867$W1B8C>$$[6%EQ-T9867$W1EA9<79H;6UH
M:T5K3'1(274V=6A+<U!K4F=)0C5P:DEX3F<P5U1A5"M93W)7<$-89T8U0T\W
M9D1)4#EK0G8Y27I%>28C>$$[84]*-6)/,'=D<EI)-U,Y42LQ;D=J*UID2C%:
M4CE7;#1Z9G17.&Q&:T@P9"]O>D%Y-$I1-74X,"MS>#5F<$\O9#%45$M82V1I
M<G-69"8C>$$[:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&EQ;&0S9'1A44YC
M6$UI>%%O2W,W1V=Y55EM4F]-2C5)=T9Y3D)G1W8O;41C,T)A1%-G8B8C>$$[
M94AO8F<O,VIF-G8X=C8O;&UX=S9-1&57-V].5C)T2U<R4%ED+U9H-W4W<UAD
M:7I-87-X3E-4-VY--$(P>$I/-6%X5C)+=7A6,DMU>"8C>$$[5C)+=7A6,DMU
M>%8R2W5X5C)+=7A6,DMT;S=O=V1'2W-P<7)!,$E0<V-31D)),T1-3D$O34<U
M="M.=G%O3GA$,$9W4#=X9CA!5R]M+R8C>$$[6#@X=V,R:D(S:G,W;E-D<E-J
M=&LS2&8Q6B]A6&1T9'=,8U<P:7EW=4MQ-FUO>EA3:5EM:3<K1U-->&-4659C
M:7ID:7)S5F1I<G-69"8C>$$[:7)S5F1I<G-69&ER<U93>EAF349H;S%T-G1W
M955R9C--0VXT;E X04%E2GDS1FA->G,T,G$Q8TU-8FQZ-VYL,G1A.7%'<C-(
M<3-4,"8C>$$[:D(O9%%,.6A"-T1X.3@R*TQ$1T$R95<Q3W)N;4YY-61Y6%IA
M-'IS5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69"8C>$$[
M:7)S5E1(4F1E,4133&HQ8E8O9THO97=.=6IJ,TAJ-S56;'=X;4XS2C R<6YH
M3G@U9'HQ2%%V349H<DYT-G1U94UQ+S,P1$@T:U X028C>$$[165">E5:8TIG
M9#-Q9$QQ-%IO,TAN,TIN;%1K=7A6,DMU>%8R2W5X5C)+=7A6,DMP3C5L.'DR
M,FDR=TI!;'4U46919W(O=T%-,V=O+R8C>$$[2$PX1T$U1#5/1G).6DA$2'9K
M95%E5E@Q+V18.3 Y,6131U-A43%*4%EE04A91$YX0T%I2T1Y=5A,3$I,:6MB
M2VAK;70R2W5X5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+<3EJ9C-6:&1*9%=S:&IM:DY14C-(9U(S0GE--$-1;W1M
M3$Q,2"8C>$$[3&EI84PQ6'DQ-6QT=&%T:5%"1F1X1#DY1"]X<W9I<"]$3E!N
M=TA'9DHV<E(V>4]A4&1)8W=N3U5/83=&6%EQ-T9867$W1EA9<6QN;28C>$$[
M1%AB8E)R0G)I5#1P5W%S14YD,V(K9S<U8FAX1UIP>'18<6\T66-2-3E(:VPO
M9EA6+V136%8P-6MM:TY35#!(9T(T05IU;U%%4E%E4B8C>$$[>35:6DI'575:
M54UK,75X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU
M>%8R2W5X5C)+=7A66'-,-C9S3'%/-B8C>$$[=%A-8S!:<4-/:#A19D5(27IG
M2D-I,EES<W-C:$M035!7+TPK=3(R<S)!=4EV:&Q7:7IW.3!B*V@W2$Y,;7A'
M0G V-U-A<4]A2$5/9B8C>$$[5DTX<6-L,DMU>%8R2W5X5E-U-W5#,'1P3&TT
M64I$17!:,E!G36Q'2FMA1$1*35%I6DAK2&M'=F$Q8V%V<40S57121U!H9VDW
M26Y99B8C>$$[4'AZ9%EC46A';FM.6'%4;6YX2&PP4S=,6$=D:7)S5F1I<G-6
M9&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5B8C>$$[
M9&ER<U9D:7%9-D1R5GAP1V]*9%)62V9:;FDW3V@V:C4K1U9:<U%N1VY*,'5P
M3T=F14]85C8O85AC1C-B4C-.=7=E1U91>4U0035P6B8C>$$[4DU44F5V>'I%
M-&E1-496>4Q.,DMU>%8R2W9/+WI",3@S1GE.2V=B.7IB;71W4BLQ2B],+T%,
M2#EF>7I:-E!$431J,65D-U<Q6$9,=R8C>$$[>'E(4#-S3WI/9$TW1EA9<3=&
M6%EQ-T9867$W1EA9<3=&6%EQ-T9867%Y4'E8-60O4VPO-C@V,7-B66=Y03E(
M8G%%+VEF-V-X9%9M-"8C>$$[23!/6F1L,F)P4$9N6BMM3#%,3E$Y4S=&5TPO
M;4PO>6HV+SA!1V10*TET;5AO=G(K1'$K,2]W0S4K265:6G1N;4A9<3=&6%EQ
M-T98628C>$$[<3=&6%EQ-T9762]L.7(U=#=K-E9/,S=M-$YB8VXY;50K6"]:
M9G(K95E/<W<R3TED2&,Y:S9R:&PT6C5(;#<S;VUA>#9*,DMU>%9++R8C>$$[
M375S3'!/:WDS3F8S>F9U-V1F1U)H=#DS6$QS1TQJ;%1I-GI5949J375V5#-V
M2#-D;F1N8VQM66MS>#9K;G%C,UE$>'A.;7DQ:7)S5B8C>$$[9&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5E)';E=&>&8S<U9P8G)Y;&QA9SA!3S50<T)V:UIZ
M15):8DU/235*0TDU;#=&<$]M5S)M5R8C>$$[159N8FHT27AU>#9S>#9S9FYM
M:GE:1$TR6'-C1T=/2T%I3VE,>41C-T973"]!2FDO.&\K=B]'9% K271M6&]V
M<BM$<2LQ+S=N-&@U;"8C>$$[;3)E661I<G-69&ER<U9D:7)S5F1I<G-68E(R
M4C%D0U9:4T-R1'%#3VAX255':EEE=V57=%E85G1*:75A+W9L+V0S0RM%:6IF
M-RMU828C>$$[5%!I-$I5.6IO.5(T=4U3-CEF96UM5755-T98;6XU9S9T.6$Q
M65=32#EZ6D1I9F52=#(K-%5'8EA2-#9J9F4X>C)T;C1S;D-/569V628C>$$[
M<FU9-G R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%8V8C5'.'4O;S9Y
M*W4S0S!V3'!244AQ:UHS0R]-.51M<#%E8FE.1&M(<"8C>$$[*WI.2C1C94DO
M5DPW;55::4\P9&ER<U99=BM9=B]+4'(O=T%:,"\T:3):96DK=C1/<C=8+T%,
M;C1H-6QM,F599&ER<U9D:7)S5F1I<B8C>$$[<U9D:7)S5F1I<DMV>2LQ63)U
M<D=Y:U W;3A&0C1#4F0Q4#!I;WI$,6U/-#,S3S$W2C%(1&LT5'EL.3<P=DY5
M.4UH.5-V57-B0S1U,R8C>$$[*WI!:E!4>$E'=RMK-UI+165+4418;7E#141)
M.4$X5FUM:VUM96%1.'!*1TQU>#=S>'%4;2M!;U4X5$M2:U-4>DMZ0V@R2W5X
M5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W-O.&IE6&8P:F4O6$QH83)D
M<5%11#!E5'%&*U$V;DU45C5U155/6F1P,EIO+T5L>%,K;5 R;#9B;28C>$$[
M<&5N9&ER<U9D:7)&+W=!>&8K5698+VI/;B]%5WI,,%@Q+T(Q9F$O.7HX43AY
M>F)034]X5C)+=7A6,DMU>%8R2W5X5C)+=7A69D1.2B8C>$$[1$UK,%HT>5)S
M2%)H,EI454A!4EEP35I'2D)(35!A=$YV579R0S-U,"MZ3VEV5'=*1S0K9S=:
M;UIX-%I%4&)98V=N05-(54UB+TUE+R8C>$$[.4A327)25%)R<50T:#1P2#A2
M+S19<FU6;V]82RLU,79B1UAH>&E0.#0O8S@R>F%V3D]X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>"8C>$$[5D8V5G!L>G%D+T9:,C0K3U$W<V5I<4]R2#5:
M1$IK14):8G-'0U=766E(<U=N5T9V<#EL1F%7-CA9;VQO4$5N=7@Y>60X,&,U
M;5)S=B8C>$$[631S47AX15)Y0TEY3%ES86%*6D5I6F=*2D%3:3EY1G!5+U)8
M1%-$25A3+T%L,DMS6"]-6"]L2#$O=T---F8X0457>DPP6#$O0C%F828C>$$[
M+W=$8R]%4$US,GIZ1'-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7(P;CAU3"]!
M3F)32F)2:E9R5U0T4C1*2CA1+S193FUQ,7-+;&9E.28C>$$[3#)0;#1S6FHO
M3E S<$0K63$S-G5T>#(T4'<R.%%"2"M5-4Q(.$M::S9+3E%V=F-$=&I*955$
M=41&37I(575X5C)+=7A6,DMU>%8R2R8C>$$[=7A6,DMU>%8R2W5X5C9L-4PX
M=2]O=7<Y961A6#%Y05I!97%*,4-F>% Y;6%J5EIU33!/465Q-T\P;FA1<R]6
M3#A5>5!-5C)+>6%A2R8C>$$[0T8U<&U#4E)Q5V1Z,$%!<51H04I.0FI+46E,
M4$E-2CAU-C-,<DAN2U<U3E9H5T(P=#1Z*WEG6F9X4%4U;C5S6$)I<GID3'!.
M4V,R<"8C>$$[375N0V%:>FUV9#0W1E=,+T%*:2\X;RMV+T=D4"M)=&U8;W9R
M*T1Q*S$O-VXT:#5L;3)E661I<G-69&ER<U9D:7)S5F1I<G-69&ER<R8C>$$[
M5EI8*UA.,S97='E7-5!W,T5204@K56A$1#A+-6@V,DYW=G5D=#)0:W)+4C-H
M2V9.5G@V+VU++VMR5VMP:B\U1B]"+WAR;#)N1E%$:28C>$$[839F1FUK9E W
M=&MQ>35X2%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E=7*U$O3'8Q>38O4U9Y
M=&)7,V(Y,'!'>GE$*T,O<GI#,65B:"8C>$$[2$-/6F1V,E9O*T]82$PV4GDY
M-S!J3E<Y23=&5T$O;40U:35V*VE,6G9G46AR=&@S8G%%*VIQ8S)7:G<O>$@T
M3V<W5S%D+W4T+T@Y4R8C>$$[02],<B]L24<O=T--1"]R6$Q.8CE(>&-F<V8X
M079V.$%.+U4Y3GI5=E1U>%9I+S5I+W=$2U!R+WAN5"]I3%IL-DPV+V<V=G1F
M*S4K228C>$$[95I:=&YM2%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1E4Q.'$S
M2&]E67)#4W1+>6E0+VM:.$@O1S)5-F=80758;UHX3V%*."]V,E%&-R8C>$$[
M25IB>651.5AK9'9V66Y,26EG2$AY;35K*V%J:VU$<U9D:7)S5F1I<G-69&ER
M<U9D:7)S5E(R:6%44'%U;WA78T\S23%K9G-I1#=42"8C>$$[2SAU45%J6F(Y
M3G!Z;&U):#=$6E=D=EI7:U9R8G)X:&A52V<O:69C.3@P:W!'4G-V630X66A%
M4DA)2S)26G!.-7$Q-4Y(,#%P1DE.,R8C>$$[3%9,6D0O3C-9*WDU9G X4$A,
M>6-06&%O65E8+T%"2&LX:V0S:V1N9&EZ<U-Z361Y4V1Y5&TV06522DI.;&LO
M-61F.$%+44XO>&=F.28C>$$[835I83,V4&DW4'-F*RLO>F8Q4%1C,4PP-W-6
M678K678O2U!R+W=!6C O-&DR6F5I*W8T3W(W6"]!3&XT:#5L;3)E661I<G-6
M9&ER<R8C>$$[5F1I<G-69&ER<U9D:7)S5E9R2U%X6&M%9S9P26IF8W=/4FM,
M0EHT:E5W9DY2>51",DMU>%8R2W5X5C)+=7A6,DMU>%8R2W1Q<DUW5B8C>$$[
M45-X3D%"=5-4:6]&=E9V2TAL-&%2<'=-<6HV-V-586,O=T%O-THY2&8S>E1A
M;DYX>3(U0C9Z<R]3941$9C9J>B]5;C)9-VYR2C4T;R8C>$$[25AN;5E*1D=P
M6C-044%B;D-!4V%$1U5H15=E465195ET8FPQ9E5N=5=Q<TDK0S-J4#=+1' Y
M2C9N3C-H>$-%8651,6UP3V%F1C V2B8C>$$[6FQR:7-O+TQR+VQ)1R\T=U K
M=&-X3F(Y2'AD<#)0.$$S,RMB*W V8FUP96YD:7)&+W=!>&8K5698+VI/;B]%
M5WI,,%@Q+T(Q9F$O.28C>$$[>CA1.'EZ8E!-3WA6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,DMU>%9M6&M$>3<Y66TO
M4S%Y=B8C>$$[-VU%,'1L4#=4:G$S>5AT-R],34A76G%(0TAD9&QA4&E0:5,U
M1&LY1'I74%%U>%9G2#5G95EV56LO4D9S,S=U36<S8D1U=S-#9C=(<28C>$$[
M9F8U6G-T2&AR,4@T4% X06$R<G,K2$@T+W%95&UE-E(R2W-O+TQR+T%*4T)V
M*TU$+W)83517+U(X6&%D:B\S,RMB*W V8FUP96YD:28C>$$[<D8O>D8O-5(Y
M9CA!:D]N+T%"1G-Y.48Y9G=D6#)V.$$S4'A$>DQ.<SAW-T9867$W1EA9<3=&
M6%EQ-T9867$W1EA9<3=&5F$Y:DU6-28C>$$[4$=E<5-/=C--4FM9;7='9556
M36IZ56-K=V1I<G-69&ER<U9D:7)S5F1I<G-697AE5U%"-68P*V=P*S14.%)M
M:GHO5V9E.6QO=C=M4"8C>$$[=4-:-54U3'-6450V2&]R<UAF5#=:;EEK<WAH
M:DI*4%5K,'EZ>%HY-2MB461.:4\U:D@U0G(Y06%&+S%B<E@O:U1(+WI4:C0P
M*S@O3B8C>$$[9GEU3"M:2#5",S9!,$PO<3-7=B]!0TIJ+W=#86-F1VXS;C5R
M*U9X9GI)+TE+='1P96U7<VYQ5S%P1$)*4VY/3TY%86@W5E5$0DQ*228C>$$[
M.'E754U%26TT>$%0:T54:T<Q,DMQ5GIA5W0Q2#9D>D-K.&1A.$I&1')59#9-
M1&AJ26IK>&Y#36A5:%E1,S9!,$PO<3-7=CA!>4IJ+R8C>$$[04]A8VXT,"LX
M+TYQ+TLT=C5K9FM'369M1'!M;3)U:E%Y5W1P1$))8FQ63'A2<6A)-$]A5E5$
M8F)-=E(U2D=:<VLW3W(W5W=W:&E":B8C>$$[140Q9$(U1C4O;7EE9F1I<G-6
M9&ER<U9D:7)S5F1I<G-65G)+37DS:T59-G9):2]E=T=2:V%"6C1H8W=03D@K
M87)F,%!-5B](4VQ:5"8C>$$[2B]Y32M0.$$T,GEV5&TT0GE.9$1H>E-(;CDK
M-E9:8S1J<U9D:7)S5F1I<G-69&ER<U9D:7(R4'DQ+WEJ*VXO.%E%+U9M:GHO
M049N,R8C>$$[=EIA4"LU:B]!1E%M5U9/4S=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T972B]M5B]X=V]0*UEP4"M48VU:;6@K<RLU,5!B4#DP4#8S-D,X,B8C>$$[
M>F%V3D]X5C)+=7A6,DMU>%8R2W5X5C)+<'(U5G0O6#AX5T5D2S!L16XO278T
M+SA!:EA+9%%A9UA,,$U/3$Y%968S8G!T*UDQ<#97="8C>$$[>#-!2'<S15%*
M4#A!;$E3<"]#;54V2U9W<G5C=G1J2%=52'9$1DUZ2%5U>%8R2W5X5C)+=7A6
M,DMU>%8R2W93=$0X-&588EA2-T\S;B8C>$$[=2M%,%53<$EV<'EM:$$S1E%P
M1V%R3'!P;5))1#!U;3=1=WAX>$)L=4(S2#E33R]X>#57+S5B9BM353,O0412
M;&8U5$HS9F,S+W=!<"8C>$$[-% U,S)(.51V.&-E5G8X06QT+S5*5&8X,%DO
M;$UN9#EY+WEN9R]N9EEF,4\O=T%C959V*U<S+VML3B]Z4FHK57ED,S-,+TME
M1"MD.28C>$$[:"]5-R](2&QB+VQT+W=#4U4S+TY'4#542C-F8W8X<#10-3,R
M2#E4=CAC959V*U<S+VML3B]W03!9+VQ-;F0Y>2]W07 T4#4S,D@Y4R8C>$$[
M2S W>DQO;7!82#%E>75F5FU#;"M00U)D:#%.5U5$=FM*-$IX1FM.=4A767-H
M<4IS+T9-.'%C<#)+;UA59%1S9$YT>&-8<W9P46QG;B8C>$$[3&EZ9D5A:T-I
M9VYT:S19>DDP1W).;6IJ2$9),$5S+WAX-5<O-6)F*U-5,R]!1%)L=C542C-F
M8S1V.' T4#4S,D@Y5$AV3R]M4%)T5"8C>$$[,&U+0WAU4%=L5V1:1UAH279W
M:$A&87-Q:G%W>DLP=4-C2E=2,&1D,FYR35=81T)!,F(X*S1S27I09$DW1EA9
M<3=&6%EQ-T9867$W1B8C>$$[6%EQ>78X=6)4,61B:W5#4&AT-&E19CA!2V-H
M4BM&8W<Y8DMO5C-U,C=(>#-L2C=G;C,U:C)(<F%21F1Q2W1A>69%9D)*4&A0
M+T1"8R8C>$$[>'1&3W!6,W5F,GAI-'-9;"].4#-V3G,R<GI4<U9D:7)S5F1I
M<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)+4'DV+S530G8K340O<B8C>$$[
M6$U45R]2.%AA9&HO04XY+VTO<65M-7%8<#-9<7AF.$%-6"]L2#$O-'IP+WA&
M<WDY1CEF=V18,G8O8R]%4$US,GIZ1'-69&ER<U9D:28C>$$[<G-69&ER<U9D
M:7)S5F1I<C!N.'5,1#!D26QU,D9'=7!0:%!I:V9W:B]H:3)A<E=Z=59D>C!V
M62M,:'AM6#@T+V-Y5%5R2DPV=W5,4B8C>$$[+W-Z;WE6.$-2<V9O3RM9<TIC
M36=86EIS66Y!>%!54$9:;UI)6FYH:TA'4TYI:G%E>DMA15IV9V)&=D5Y:5EK
M9SAW<W=O9&ER<U9D:28C>$$[<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)+
M4'DV+S530G8K340O<EA-5%<O4CA8861J+T%..2]M+W%E;35Q6' S67%X9CA!
M35@O;"8C>$$[2#$O-'IP+WA&<WDY1CEF=V18,G8O8R]%4$US,GIZ1'-69&ER
M<U9D:7)S5F1I<G-69&ER<U98=W=Y5%1*1$=/56MJ0D559#)9,$%W128C>$$[
M,$Q41TIK44)Z3#)R5&)*3$=W=#=24'-W27%6.%-"=69P3RMA1V-U2U),,C)(
M1TE115(P0TEY3%DX,"]-2%-4839S3#)-9G5B=U909R8C>$$[2D8R66932TA.
M<F\X;'AR=65:-U<P+T1K-&AY;#DW1F-Z2%9/>%8R2W5X5C)+=7A6,DMU>%8R
M2W5X5C)+=7A6,DMU>%9L2#5D9CAP028C>$$[,R]'0B]W0F$U:6$S-E!I-U1S
M9BLK+WIF,5!48S%,,#=S5EEV*UEV+T%#:C8O=T1'9% X06E,6FPV3#8O9S9V
M=&8K-2M)95I:=&YM2"8C>$$[67$W1EA9<3=&6%EQ-T9867$W1EA9<7ER.'9T
M2DXQ<7AV6D(K-7-X565":V):4CE!<6-W.5IK<4YD-W1E>610>%I/23AO+V4Y
M3'I64"8C>$$[5$]X5DLO375J<G$R:WDR,5 S>2]V3&1V0U)2=#DO5$QS1UAG
M;&)I-GI4*TQJ365V5#-V2#-2:V1K8T9756M-<#9G:G%-,UE,>'A&1R8C>$$[
M:3%I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S
M5F1I<G-69&ER<U9D:7)S5F1I<G-68E)'9#%205=::28C>$$[07%J<5-E9WA*
M54-Z465W95=T2%A39$II='%F=FTO95A$94UJ1&8W=6UA5%!L-#57.6IO.5 T
M5TU2-CEF96UM5755-T9867$X-R]-2"8C>$$[441B,TDQ5T)F,TYW85A!2#=-
M;C@S*WDO6#@X,F5J>E=/13E(;F4Q=$QW>3A18VIZ.3=$<WIN5$]X5C)+=7A6
M,DMU>%8R2W5X5C)+=28C>$$[>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6
M,DMU>%8R2W5X5C)+=7A6;5 U9F%!8FDU3W%Z<BLU='I3,T(O86LO;2\R4#8O
M;&U$<B8C>$$[33%$:$A6,U!:3VPT<&5)95$U93DV2FUS96ED:7)S5F1I<6QD
M,FM&,V)35S%W;V5'5E-R<69!-4M-:D4R1T=306Y%>%!)=DE.93!7-"8C>$$[
M,&I52'1:86U-+T9"3#)D3W@K9FIM-G<U4D].=DEA=E1(1%!H4$QO;#)7=4TW
M1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W
M1EA9<3=&6%EQ-T9867$W1E5X,$A28FI6.5%3,6EQ12LQ4$PR4D(Q4'HX37%Z
M6E)#3G54<&1-8S K16-U<C$K,'1)3"8C>$$[4S)J=')D46M-4VA5565!>E-Y
M:UI'>3EF:F=)4D52>4-R:U=B<U9D:7)S5F1I<5=E64Y#='1:<T=T-5!H;%=R
M4515,U)V-DAV;'5(2R8C>$$[64<S1S%E;&IM:'=N;C!E4U@Y:F171C%*83-3
M1T]A33!)4%$K0DAI1&TV:$U31F@U2$QI;&IK67DU:%%Y5%<W1EA9<3=&6%EQ
M-T98628C>$$[<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ
M-T9697=S8G$O=6\W5S%1>5131V=!-D1X2CA!36I/66E,3%II>%-Y4R8C>$$[
M15DX>3EB.'8V1F)A3EE#,VDK2U9Q3E!.,V1V-D1S33!U8DM:;3-R=$IP6319
M8TDU.55Z>7!Y6%EQ-T9867$W1EA9<3=&56TX>2M7<B8C>$$[8E=R64%K4EAC
M45!O5# O-%9V1E0K1U@T335X;GEC3%=A3T]A4&1)8VDX<79R0S9S3' W5S9J
M36,P6F]1930X464T3V)I17A)5TAL8R8C>$$[=4M73UA$25561$I.8G-69&ER
M<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I<G-65C='
M=W5R*S93,719>DI.228C>$$[84%$<U!%;G-":UIZ15):8DU72U=36$1%5UAQ
M=FQN>3%B84QB14%I5S=L<#8P,5 K1EAW569J;6YZ-7IK4&LY5F\Y2$A$2'9K
M95I4;B8C>$$[2TA.9&ER<U9D:7)S5F1I<G-69&ER<U93>EAF3#EH<DYT-F1W
M=D=682MJ3V\K2D0O04)(=&QU3$U92%IX=%9P25IO,4QN,W9,=&$P2"8C>$$[
M54Y)=5!3=6MR1U0K-FY8-T1J,E!J-UIT.%=A37AS.'1Q9$I00V%L>3<P=7DQ
M>&Y9<3=&6%EQ-T9867$W1EA9<3=&6%EQ-T9867$W1B8C>$$[6%EQ-T9867$W
M1EA9<6U/:39$<4=R,TAP5W%5:D(O97IT.6A"-VYX.7-Q>35O=T<W:S9B4U1Z
M1V\X=3DV:F]8;"MW,&$R.4\S6&Q+,28C>$$[4%=N669%-2]G4&).4FQZ1UHS
M97 P=6MH:&I5969E;6563U,W1EA9<3=&6%EQ-T9867$W1EA9<3=&6%EQ<%AD
M<&)88T17.7I'<W-,:28C>$$[:DEW<4UL1U)I8D1#94]->%5H65E"<B\U9EA.
M=5=N,&]M-&@V;3-0.31V.$%Q+WIF<BME8DA$<D%D<&)/9S%86DUO-S0Y>#-D
M5TAU:B8C>$$[;WA2,4MS<&]Y:U5)4'5->F=85$5%8D9R1EA9<3=&6%EQ-T98
M67$W1EA9<3=&6%EQ-T9867$W1EA9<3)I3S="155S>D=I<4)5:RMW>"8C>$$[
M2E5!;EE-=S!$.'9R;31+>C9Q5&)W.5)B:BLX8B]7+VPO6#AS=V,R<T$R:G4W
M;E,Y:WEL=FLR2&0Q6B]A5VQT85%,8C(P87A1;TM+:28C>$$[:6=Z6%-K6D=Y
M-RM'3TU"55)15F-I>F1I<G-69&ER<U9D:7)S5F1I<G-69&ER<U9D:7)S5F1I
M<58V>#5A,&Y6;% Q;4QJ3BMZ8U(P5R8C>$$[4694,RMN3'-7955/5&DV:E(T
M.'8Q1&9V-G-),6(X=G17=%-:3$EI.&@X0CA-9TAU<#)0,$A-+TAR26YN<S90
M561K-4DW>#E1*S%J128C>$$[,$TP36AJ;5)O-48R6DA"5F@X=V-Y=U%E5'$U
M4DU44D9&6FA1-T9867$W1EA9<3=&6%EQ-T9867$W1E8X34TP,&=J:%)P2D<R
M5D5"6B8C>$$[:CAG34))2$Y-66U2;T-Y>6939GDK,6$V26MV4TQ/2'=0>%-%
M97EJ66938WA-;7-I3U<W=$Y0,E1K;'9,,&HW5V(V4#5A,&Y35D@Q828C>$$[
M3&Q.*S%C4U5A42]4,BMJ341,;FQ0;3=Z5#902&DK:V(Y+U9.37!C<#)+=7A6
M,DMU>%8R2W5X5C)+=7A6,DMU>%8R2W5X5C)+=7A6,B8C>$$[2W5X5C)+;V4Y
M,#)W=FLT6&1U:S8Y=6%G:V9).5(Y1U-J3U5E4F$X;4=%>%5G0WAU+W=$>30P
M:6%R5VMS;'%X-DPO94E0;V%J9CA.;28C>$$[5D17>4A09#%U6'-F2$PV4UDO
M86M.,RM83W1X5DYV2D9C3#)!2E)V=5E5+TA-;4]T9V5E>F=:3W@X;S5%1DMB
M:GER-6EG<C9L:$MA9B8C>$$[-S=(<68X435:8TY203E816YO8S!E8U0Y+W="
M>4%K<W)Y23!K9VM1+S5335 Q:DQ"24AQ-#5X5$A-1E)Y5$(R2W$P9&QE4VUK
M8T5J;B8C>$$[+TI2:BMO6D5Y039S>&EM95%+4'0O2W9M2V5N<#)%;W(O=G=E
M;B]X4&IL6C%%0C%C:4=H>E,U4E S9F5M,7 K6$]T>3!.>$I&8G(S0B8C>$$[
M2F1V=555+TA+6F$R035B=5AJ-TAY;FU112MS4'DT,&E':EAC<VPP=S9R+V1O
M9F]7<F8X041::E0Q<VIY,F,O1C)0:FHY4DUV<UI*6B8C>$$[86)95TMC3%,S
M4T)E+T)10V9M97 K;DU75353-6PR5U!$0T%Q24%21U)B2%EQ-T9867$W1EA9
M<3=&6%EQ-T9867$O+UH\+WAM<$=);6<Z:6UA9V4^"B @(" @(" @(" @(" @
M(#PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!;'0^"B @(" @(" @(#PO
M>&UP.E1H=6UB;F%I;',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @
M(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X
M;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B/@H@(" @
M(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$P+C Q/"]P
M9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \
M<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN
M<SID8STB:'1T<#HO+W!U<FPN;W)G+V1C+V5L96UE;G1S+S$N,2\B/@H@(" @
M(" @(" \9&,Z9F]R;6%T/F%P<&QI8V%T:6]N+W!O<W1S8W)I<'0\+V1C.F9O
M<FUA=#X*(" @(" @(" @/&1C.G1I=&QE/@H@(" @(" @(" @(" \<F1F.D%L
M=#X*(" @(" @(" @(" @(" @/')D9CIL:2!X;6PZ;&%N9STB>"UD969A=6QT
M(CYG,3!J.#(\+W)D9CIL:3X*(" @(" @(" @(" @/"]R9&8Z06QT/@H@(" @
M(" @(" \+V1C.G1I=&QE/@H@(" @(" @(" \9&,Z9&5S8W)I<'1I;VX^"B @
M(" @(" @(" @(#QR9&8Z06QT/@H@(" @(" @(" @(" @(" \<F1F.FQI('AM
M;#IL86YG/2)X+7)E<&%I<B(^1FEL92!.86UE.B @(" @(" @(" @(" @(&<P
M-F8T-BYA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C
M>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,CDM1&5C+3(P,C$@,#(Z,#DZ
M-#<F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M1&5C+3(P,C$@,38Z
M,SDZ-#<F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL
M=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z
M(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C
M:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS
M(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F
M;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C
M>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W
M:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@
M(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<P-F8T-RYA:28C>$$[
M57-E<FYA;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C>$$[3&]C86P@5&EM
M93H@(" @(" @(" @(" @,CDM1&5C+3(P,C$@,#(Z,34Z-3$F(WA!.T535"!4
M:6UE.B @(" @(" @(" @(" @,C@M1&5C+3(P,C$@,38Z-#4Z-3$F(WA!.U-C
M<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R
M<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R
M='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP
M;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T
M960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N
M=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @
M($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A
M<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA
M8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.
M86UE.B @(" @(" @(" @(" @(&<P-F8T."YA:28C>$$[57-E<FYA;64Z(" @
M(" @(" @(" @("!R<C,W-SDU,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @
M(" @,CDM1&5C+3(P,C$@,#(Z,38Z,S8F(WA!.T535"!4:6UE.B @(" @(" @
M(" @(" @,C@M1&5C+3(P,C$@,38Z-#8Z,S8F(WA!.U-C<FEP="!697)S:6]N
M.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N
M,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C
M>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E
M(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E
M<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E
M;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-
M5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I
M;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @
M(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @
M(" @(" @(&<P-F8T.2YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R
M<C,W-SDU,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,CDM1&5C+3(P
M,C$@,#(Z,3<Z,S(F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M1&5C
M+3(P,C$@,38Z-#<Z,S(F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N
M-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P
M:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R
M969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU
M86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF
M(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O
M8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4
M:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE
M;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X
M03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<P-F8U
M,"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C>$$[
M3&]C86P@5&EM93H@(" @(" @(" @(" @,CDM1&5C+3(P,C$@,#(Z,3@Z,C8F
M(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M1&5C+3(P,C$@,38Z-#@Z
M,C8F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T
M<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @
M(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C
M:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R
M92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL
M;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[
M(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG
M(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @
M(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C
M>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<P-F8U,2YA:28C>$$[57-E
M<FYA;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C>$$[3&]C86P@5&EM93H@
M(" @(" @(" @(" @,CDM1&5C+3(P,C$@,#(Z,3DZ,3,F(WA!.T535"!4:6UE
M.B @(" @(" @(" @(" @,C@M1&5C+3(P,C$@,38Z-#DZ,3,F(WA!.U-C<FEP
M="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO
M;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O
M<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T
M92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@
M<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@
M87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R
M:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@
M<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF
M(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE
M.B @(" @(" @(" @(" @(&<P.6DW,RYA:28C>$$[57-E<FYA;64Z(" @(" @
M(" @(" @("!R<C,W-SDU,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @
M,CDM1&5C+3(P,C$@,#,Z-#0Z,C4F(WA!.T535"!4:6UE.B @(" @(" @(" @
M(" @,C@M1&5C+3(P,C$@,3@Z,30Z,C4F(WA!.U-C<FEP="!697)S:6]N.B @
M(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP
M)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[
M*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N
M<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N
M*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@
M:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C
M>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T
M:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @
M("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @
M(" @(&<P.6DW-"YA:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,W
M-SDU,B8C>$$[3&]C86P@5&EM93H@(" @(" @(" @(" @,CDM1&5C+3(P,C$@
M,#,Z-#4Z,C F(WA!.T535"!4:6UE.B @(" @(" @(" @(" @,C@M1&5C+3(P
M,C$@,3@Z,34Z,C F(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C
M>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC
M('1Y<&4Z(" @(" @(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L
M:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@
M8VAE8VMS(&%R92!C;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!
M.U1H92!F;VQL;W=I;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M
M96YT.B8C>$$[(" @(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@
M9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z
M)B-X03L@(" @(" @(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF
M(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+28C>$$[1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q,&HX,BYA
M:28C>$$[57-E<FYA;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C>$$[3&]C
M86P@5&EM93H@(" @(" @(" @(" @,CDM1&5C+3(P,C$@,#,Z-#8Z,# F(WA!
M.T535"!4:6UE.B @(" @(" @(" @(" @,C@M1&5C+3(P,C$@,3@Z,38Z,# F
M(WA!.U-C<FEP="!697)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T
M;W(@5F5R<VEO;CH@(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @
M(" @($%R='=O<FLF(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I
M<R!C;VUP;&5T92X@4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C
M;VUP;&5T960@<&5R('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I
M;F<@9F]N=',@87)E('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @
M(" @(" @($%R:6%L+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O
M;&]R<R!A<F4@<')E<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @
M(" @0FQA8VLF(WA!.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[
M1FEL92!.86UE.B @(" @(" @(" @(" @(&<Q,&HX,RYA:28C>$$[57-E<FYA
M;64Z(" @(" @(" @(" @("!R<C,W-SDU,B8C>$$[3&]C86P@5&EM93H@(" @
M(" @(" @(" @,CDM1&5C+3(P,C$@,#,Z-#8Z,SDF(WA!.T535"!4:6UE.B @
M(" @(" @(" @(" @,C@M1&5C+3(P,C$@,3@Z,38Z,SDF(WA!.U-C<FEP="!6
M97)S:6]N.B @(" @(" @(#(N-B8C>$$[26QL=7-T<F%T;W(@5F5R<VEO;CH@
M(" @,38N,"XP)B-X03M'<F%P:&EC('1Y<&4Z(" @(" @(" @($%R='=O<FLF
M(WA!.R8C>$$[*BHJ5&AE('!R969L:6=H="!C:&5C:R!I<R!C;VUP;&5T92X@
M4&QE87-E(&5N<W5R92!M86YU86P@8VAE8VMS(&%R92!C;VUP;&5T960@<&5R
M('!R;V-E<W,N*BHJ)B-X03LF(WA!.U1H92!F;VQL;W=I;F<@9F]N=',@87)E
M('!R97-E;G0@:6X@=&AE(&1O8W5M96YT.B8C>$$[(" @(" @(" @($%R:6%L
M+4)O;&1-5"8C>$$[)B-X03M4:&4@9F]L;&]W:6YG(&-O;&]R<R!A<F4@<')E
M<V5N="!I;B!T:&4@9&]C=6UE;G0Z)B-X03L@(" @(" @(" @0FQA8VLF(WA!
M.R @(" @(" @("!#35E+)B-X03LF(WA!.RTM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM
M+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+2TM+28C>$$[/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.D%L=#X*(" @(" @(" @/"]D8SID97-C<FEP=&EO
M;CX*(" @(" @(" @/&1C.F-R96%T;W(^"B @(" @(" @(" @(#QR9&8Z4V5Q
M/@H@(" @(" @(" @(" @(" \<F1F.FQI/G)R,S<W.34R/"]R9&8Z;&D^"B @
M(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]D8SIC<F5A=&]R/@H@
M(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @(" @/')D9CI$97-C<FEP=&EO
M;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z>&UP5%!G/2)H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O="]P9R\B"B @(" @(" @(" @('AM
M;&YS.G-T1&EM/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O
M1&EM96YS:6]N<R,B"B @(" @(" @(" @('AM;&YS.G-T1FYT/2)H='1P.B\O
M;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O1F]N=",B"B @(" @(" @(" @
M('AM;&YS.GAM<$<](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N,"]G+R(^
M"B @(" @(" @(#QX;7!44&<Z3E!A9V5S/C$\+WAM<%109SI.4&%G97,^"B @
M(" @(" @(#QX;7!44&<Z2&%S5FES:6)L951R86YS<&%R96YC>3Y&86QS93PO
M>&UP5%!G.DAA<U9I<VEB;&54<F%N<W!A<F5N8WD^"B @(" @(" @(#QX;7!4
M4&<Z2&%S5FES:6)L94]V97)P<FEN=#Y&86QS93PO>&UP5%!G.DAA<U9I<VEB
M;&5/=F5R<')I;G0^"B @(" @(" @(#QX;7!44&<Z36%X4&%G95-I>F4@<F1F
M.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" \<W1$:6TZ=SXR
M,34N.3 P,# P/"]S=$1I;3IW/@H@(" @(" @(" @(" \<W1$:6TZ:#XR-SDN
M-# P,# P/"]S=$1I;3IH/@H@(" @(" @(" @(" \<W1$:6TZ=6YI=#Y-:6QL
M:6UE=&5R<SPO<W1$:6TZ=6YI=#X*(" @(" @(" @/"]X;7!44&<Z36%X4&%G
M95-I>F4^"B @(" @(" @(#QX;7!44&<Z1F]N=',^"B @(" @(" @(" @(#QR
M9&8Z0F%G/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4]
M(E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T1FYT.F9O;G1.86UE
M/D%R:6%L+4)O;&1-5#PO<W1&;G0Z9F]N=$YA;64^"B @(" @(" @(" @(" @
M(" @(#QS=$9N=#IF;VYT1F%M:6QY/D%R:6%L/"]S=$9N=#IF;VYT1F%M:6QY
M/@H@(" @(" @(" @(" @(" @(" \<W1&;G0Z9F]N=$9A8V4^0F]L9#PO<W1&
M;G0Z9F]N=$9A8V4^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IF;VYT5'EP
M93Y/<&5N(%1Y<&4\+W-T1FYT.F9O;G14>7!E/@H@(" @(" @(" @(" @(" @
M(" \<W1&;G0Z=F5R<VEO;E-T<FEN9SY697)S:6]N(#<N,# \+W-T1FYT.G9E
M<G-I;VY3=')I;F<^"B @(" @(" @(" @(" @(" @(#QS=$9N=#IC;VUP;W-I
M=&4^1F%L<V4\+W-T1FYT.F-O;7!O<VET93X*(" @(" @(" @(" @(" @(" @
M/'-T1FYT.F9O;G1&:6QE3F%M93YA<FEA;&)D+G1T9CPO<W1&;G0Z9F]N=$9I
M;&5.86UE/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z0F%G/@H@(" @(" @(" \+WAM<%109SI&;VYT<SX*(" @(" @(" @
M/'AM<%109SI0;&%T94YA;65S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @
M(" @(" @(" @(" @/')D9CIL:3Y#>6%N/"]R9&8Z;&D^"B @(" @(" @(" @
M(" @(#QR9&8Z;&D^36%G96YT83PO<F1F.FQI/@H@(" @(" @(" @(" @(" \
M<F1F.FQI/EEE;&QO=SPO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI397$^
M"B @(" @(" @(#PO>&UP5%!G.E!L871E3F%M97,^"B @(" @(" @(#QX;7!4
M4&<Z4W=A=&-H1W)O=7!S/@H@(" @(" @(" @(" \<F1F.E-E<3X*(" @(" @
M(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @
M(" @(" @(" @(" @(" @(#QX;7!'.F=R;W5P3F%M93Y$969A=6QT(%-W871C
M:"!'<F]U<#PO>&UP1SIG<F]U<$YA;64^"B @(" @(" @(" @(" @(" @(#QX
M;7!'.F=R;W5P5'EP93XP/"]X;7!'.F=R;W5P5'EP93X*(" @(" @(" @(" @
M(" @/"]R9&8Z;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @
M/"]X;7!44&<Z4W=A=&-H1W)O=7!S/@H@(" @(" \+W)D9CI$97-C<FEP=&EO
M;CX*(" @(" @/')D9CI$97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @
M(" @(" @>&UL;G,Z>&UP34T](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"]M;2\B"B @(" @(" @(" @('AM;&YS.G-T4F5F/2)H='1P.B\O;G,N861O
M8F4N8V]M+WAA<"\Q+C O<U1Y<&4O4F5S;W5R8V52968C(@H@(" @(" @(" @
M("!X;6QN<SIS=$5V=#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP+W-4
M>7!E+U)E<V]U<F-E179E;G0C(CX*(" @(" @(" @/'AM<$U-.D1O8W5M96YT
M240^>&UP+F1I9#I#1#<Y.#-$-C)"-CA%0S$Q.$%&.44R,C<Y-4%!-C1!03PO
M>&UP34TZ1&]C=6UE;G1)1#X*(" @(" @(" @/'AM<$U-.DEN<W1A;F-E240^
M>&UP+FEI9#I#1#<Y.#-$-C)"-CA%0S$Q.$%&.44R,C<Y-4%!-C1!03PO>&UP
M34TZ26YS=&%N8V5)1#X*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L1&]C=6UE
M;G1)1#YX;7 N9&ED.C<X,3DY-3)!,44V.$5#,3$X048Y13(R-SDU04$V-$%!
M/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I2
M96YD:71I;VY#;&%S<SYD969A=6QT/"]X;7!-33I296YD:71I;VY#;&%S<SX*
M(" @(" @(" @/'AM<$U-.D1E<FEV961&<F]M(')D9CIP87)S951Y<&4](E)E
M<V]U<F-E(CX*(" @(" @(" @(" @/'-T4F5F.FEN<W1A;F-E240^>&UP+FEI
M9#I#0S<Y.#-$-C)"-CA%0S$Q.$%&.44R,C<Y-4%!-C1!03PO<W12968Z:6YS
M=&%N8V5)1#X*(" @(" @(" @(" @/'-T4F5F.F1O8W5M96YT240^>&UP+F1I
M9#I#0S<Y.#-$-C)"-CA%0S$Q.$%&.44R,C<Y-4%!-C1!03PO<W12968Z9&]C
M=6UE;G1)1#X*(" @(" @(" @(" @/'-T4F5F.F]R:6=I;F%L1&]C=6UE;G1)
M1#YX;7 N9&ED.C<X,3DY-3)!,44V.$5#,3$X048Y13(R-SDU04$V-$%!/"]S
M=%)E9CIO<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(" @(#QS=%)E9CIR
M96YD:71I;VY#;&%S<SYD969A=6QT/"]S=%)E9CIR96YD:71I;VY#;&%S<SX*
M(" @(" @(" @/"]X;7!-33I$97)I=F5D1G)O;3X*(" @(" @(" @/'AM<$U-
M.DAI<W1O<GD^"B @(" @(" @(" @(#QR9&8Z4V5Q/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO<W1%=G0Z86-T:6]N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N8V5)1#YX;7 N:6ED.C<X
M,3DY-3)!,44V.$5#,3$X048Y13(R-SDU04$V-$%!/"]S=$5V=#II;G-T86YC
M94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z=VAE;CXR,#(Q+3$R+3(Y
M5# R.C X.C4Q*S U.C,P/"]S=$5V=#IW:&5N/@H@(" @(" @(" @(" @(" @
M(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!);&QU<W1R871O<B!#4S8@
M*%=I;F1O=W,I/"]S=$5V=#IS;V9T=V%R94%G96YT/@H@(" @(" @(" @(" @
M(" @(" \<W1%=G0Z8VAA;F=E9#XO/"]S=$5V=#IC:&%N9V5D/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#I#1#<Y.#-$-C)"-CA%0S$Q
M.$%&.44R,C<Y-4%!-C1!03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,BTR.50P,SHT-CHT,RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@26QL=7-T<F%T;W(@0U,V("A7:6YD;W=S*3PO<W1%
M=G0Z<V]F='=A<F5!9V5N=#X*(" @(" @(" @(" @(" @(" @/'-T179T.F-H
M86YG960^+SPO<W1%=G0Z8VAA;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z
M;&D^"B @(" @(" @(" @(#PO<F1F.E-E<3X*(" @(" @(" @/"]X;7!-33I(
M:7-T;W)Y/@H@(" @(" \+W)D9CI$97-C<FEP=&EO;CX*(" @/"]R9&8Z4D1&
M/@H\+W@Z>&UP;65T83X*(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @( H\/WAP86-K
M970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L 0P$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$!_\  $0@ $@ 2 P$1  (1 0,1 ?_$ !<  0$! 0
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C%:XRLD[5>#F0.$6""6JYC,B768\AF8G>)V\6SX%_&T\__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g210084g11i11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g11i11.jpg
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ME:^>W9<A#LIY:EN//+<6I6^:MW;E^4SWK5BW,<_K;,TDS\'R#I'.(;V:, #
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M?=;888;6\\\\M+;3+3:=K<==<7M*&VVT)VM:UJTE"=;4K>M:WO) )( !))P
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M3(X$CS&,&O?P=_HX_L_J?:ZG/];\\;X+P.M'X!6\Z-VNIF;G>Q0R6W)F4ZH
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M&Y#9:,]<>( .@ 3P;C=VW&O'DV2NS_\ 9CFGZ)]_^-I4/VY5=^&IVP?'_+Z
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MC@UPU&N\<:;#I=IVE69)+[FMCK\]&]"V-TC@QTQ?9K119B87/8USCS2!@+7
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MCE=8CC?)(Z/GA=;CK/97%<S<S00"YK"QQB_M1@\[L%QR"_.0TD  X(RKS?\
M#IKGF_U)T3T-6[L(<K]G"]- 5#G +FL.HS*R'ZG9^5V>>%M%TA6D@S>@'/\
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M6]:LW!XW(WQ V.:9T(;S\V (^FQ)"F_2N8<UYK#_  _G7/:/0H'T:;^Y4NJ
M:O%VVGY?)&XX2!!:VG7RUOY;3O7SUK?]N<->U34]3?XFI:C>U"3.>>[;L6GY
M[\T\DAS\5T5>E3IMY*E6M5;C'+7@BA;C[HVM"SG,!9*81,(F$3")A$PB81,(
MF$3")A$PB81,(J]^.?[2WW1_AI\%?\3>S,Z2]_DMP_\ ZTXA_P"%HBQH_P"M
M6/\ 15OQG5A&<VLE,(H#>IN']'M/J+X?OHOF]?U:]>?^I]8JG2PJ2H40_ Y'
MZ"Y5.IMCNT=PX2&M$=TBTU^C%I808N6=(C5SOPH?.>85&<Z'2;]:'2>(M,LR
M>#^D:E.:J_D>\.N:=;;/% 1&UQ9X\4EAC9'XC:[EYW-!RL::-[IJTK!S>$][
M7C(&&2L+2X9Z\K@TX&Y&<=C7YX8^%QV.!7>"6+UEU*T# /"[I[*L5 \P!A=6
M!R*>;]#7CK%9=M4GNW-+:]9BL,IS:WO7&L#1LD99:=:+<_)U:HZQ$("+Z+7N
M*Z3I-0BT>I"^2_!HD=G59'32":/3:].40C3[4(B8YEJ 0RO<UT4\,(;X1#W2
M/QJU20-B,[R!&9RV$!H+3(Y[<^*QQ)!8>8 8(<[.1CE$Q^J_"K\^77D-^YO1
M+/VSG=CMCE(+ .@6'OG>^].4FW<VOM<Z32K(*IO=NJWJJJ>@V>KCD$TQ(8HD
M4 R"@5!F W/4^WI:G%NHP7:]JQ%1LQP^.R2O%IVG:=X\-JO)5GB?/I].O-AT
M4KBSF+VLD#).1Q;@WWTHBQS&NE:7<I#C+++RN8X.:0V5[V[$#.P)&1E=SQOP
M_P!7Y*4L-^1ZQ+E^S=@])T[N7IJ_1>-4@2'[)0Z504<Y$<#"TN:4L#?,:>T"
M'@G6K2)/&[G'FP)SB":F2GV$*W>UVG<9'7.D,92I:9-0TNNZ[8>^E8GL>LOU
M"2=K8_6IC(Z0&%\<<!:YHY 69=,==["7^,3(^5LDKA&T![6MY1&&DNY6XQ@A
MQ<#G?? C)3O@M5&$'$<PZ7Z"MW2?/?+>7>I>2>;N6,4.MU YR"N>LX9(+?9Y
MKHD0D7F=)L%=K!:=7Z-/G5ZNQ0D9W[=\?/=UO2MK/QQ,Z1]NKIT-;4;=O2;N
MIVG6)9X[LNCN;)7:RLYK!6CEF8V6PULLAD(P'-'2TV@  Q\I?$QDS(F<H:6"
M8$.)=DE[@"0TD#"VKR/X=?<.42K5T=GVG)L?I!WBW'_-W-.O%?/5-37.?\+Y
M!82%ECU CS!-Q=8N9FZ$2LZ1<;:[;@$]V5]TD 8H'493#^)=XDH7!%6.AB+3
M!>NZG:ILU*<RV;]V)D1F;:\ &!D#6-$,(AD;R\PD,F<BIE61F7>.#+X<<3)#
M$W#8V$GE+>8\Q<3EQY@3@8QA:@L'PUN@U.L\@YF$LT_LQ/KOQ+Z?[F]D=G(#
M*;S:O06.?1=75X?6>;#3+TH7 M=FHO/:6&#U]5M)1WB9RPV,VQ$TE^-F1\3U
MYI;EJ2)M)M+A>;0=$HM=/9D<;!\ .EM/9RO=#%8LV'OD\!C@QD449.0:35>&
ML9S&0OM-L3R88P8:.; 9G8$M8T <QZEQ6_\ T>2JPOV+6MV2K<TML,CR/E<0
MB]<#'::\4H\%KL%\<:-19%)YO;^?GYI_[6=&K@VQ&PIJ"/KO01\J<(H]PM"C
M7"+8;X]W3\/CV]RM"PH3")A$PBB#X;_N'*_XDO;'^=#OV%)Z_!OX!2^PH3")
MA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(NO+%A8 43.G",
M$.%"CYI8P7)RF((T6+'1G9A B0FR5M1H<&#$9>DRY4AQMB/':<>=6AM"E:J8
MQ\CV1QM<^1[FL8Q@+GO>XAK6M: 2YSG$!H ))( &5!( ))  &23L !U)/D O
M"]V'X+74?BI]*[S[S\=N\UXCQKM'9+&2Y14>R3;H"E=7 PTL0K=WP4\"J%FE
M5<#U._LV2RUBLEPS,ET?+=)[D08$D8S)]ZI<;U.$JNG\/ZT+5^]1I1,N34FP
M2"I(XET&GO$DT399*=8Q0S2L>0'-#<.<'D<^^B^X^6Q!R,CDD<6"0N'.,X=(
M,-) >[+@"//J KC/@Z_ HA_#QNA+T%W"_5KJ?H257Y]6JL2DQ"B>?\S$&DMM
M6&:'*6"$*.66SG(;?X3LQ)!5U@4$E%1D<?-45>FM\7QIQ\>(X&Z=0KRU-.$C
M9IG6"SUFT^/)C:]D;GQQ11D\_AMEE+Y QY<.0-6=1T_U9QED<U\F"UH;GE:#
MU() )<>F<# R-\[>B7/-ULTPB81,(F$3"*.%A]A>5:G<W.>6;T1QT%=&)?X?
M+KY/H%;B31Q'3GV6QQ53I!,<41TY\F]P"3T67I:D)^Q^:T:WTM;@WBRY2&HU
M>'-9L47,\1EF+3[+XY(\9\2+$9=+'C?Q(FO9C)S@%:F77M%@L&K-JM"*P'<K
MHGVH6N8_IR29=B-_[+RUVXVW"D6TZT^TV^PXV\R\VAUEYI:7&G6G$Z6VXVXC
M>T.-N(WI2%IWM*D[TI.]ZWK><V06DM<"' D$$$$$'!!!W!!V(.X*VH((!!!!
M&01N"#T(/F"NELMJK%,$2K!<+&!J@&"GZYINRF!X(1$1\M[^J42*2(L*.GY)
MWOZG7D:^6M[^?RUO+]:K:NS,KTZUBW8D.&05H9)YGGLR*)KWN/W-*MS30UXW
M2SS101-^U)-(R*-O_>>\M:/B5"<Q\1;A! E+KG#A/3_4UKAN[C2!7GNA%[D$
M@R%:^3*RW09N@W/8 ]2MZV]/19Y:6&M_:;:7M32'.WA]'&OQQ,LZ[-I?"E1X
MYFR\1:A#2GD:/M>#IS/'U&20#HSU5G,=LC<CGI.*],>]T6FLN:U.T\KH]+JR
M6(V$]#):<(ZK&'S<)G8&Y'3/6_COQ&NQ?LA:;Q/Q_5Y7[&R5X+2._==895^;
M4V#7*PY7^:0'U(_;=@%SQA4=>TL*^TVEQS5WP/1OHW]/<USC*TS)\*C"WA[1
MW.'6-]FT+.J2-!Z20UX0X>T",@&CQ.++X_5P:=H4+O[=A[M4O-!Z.;%"8J;3
MC<M?+)@[=R/T:^'O3[PZT0]0=E[?ZDG[<1)? WFYRJ=REJ:A6EZ?%\GYMNL5
MN*UM6M;5$)NFV7-)2V[]HVA*-0[TAW*(,?"^BZ%PK'@M;8H4FW-6+,8Y9=7U
M/UJRXX_MQ"!P.2,'=!PM!8(?K.H:CK3]B8K-AU>B'#S91J>#$/>UYD!\P0 I
MC\^Y9S/DX=-?YAS^F\]")TC2AE-K8BN1'E-Z^E+LEH3$BZER-_/:ER9/VLAU
M:E...K6M2M\9J.JZGJ\QL:IJ%W49SG];=LS67C)R0TS/?R-[-;AH&    N@J
MTJE&/PJ=6O5CV]BO$R)IQYD,:WF.YW.2222=UQ>J\AYEW"FD.?=:I0*^4\DM
MMZ0%/1?MVFY;&EICD!\II;,\24BI==U$*BI4,E%TZ[J/*:TXOZJM)UC5-"NQ
MZCI%ZQI]V(%K9Z[^5Q8[!='(T@QS1/P.>&5CXGX',PX"INT*>I5W5;U>.S _
M!,<@) <,X<UP(<QXR>5['->W.Q"C9Q#X=/CCSQ;V[_R[C(L;<HBW5BK">.VF
MYS@.W4J1M=?U;S9J.%E):6XRDD/88*[8==87.6TXM&^GUWTD<9\1TSI^JZU+
M+2> ):]>"I2CL8(.+'J<$#IVY <8Y'.BY@'",$ C4:=PIH&E6!:I:>QEAN>2
M666>PZ+((S%X\D@C=@D<[ 'X)'-@X4VLX9=$F$3")A$PB81:;ZEZ&X7Q%8]G
MKG6Z!SR651MT8/M5F%BRA".E>VERH8M^1HC(AMNIVV[-:BJBLN?)#KR%;UK>
M-8NU*O+ZS9A@+MVB21K7.&<9#2>8@'8D# \RNET'@[BOB@3.X=X>U?68ZYY9
MYJ%&>Q!"_ <(Y+#&>"R4M(<V)T@D<W=K2-UGU/NM/Z%7X%LH=IKUSJY1"ECK
M#5C(\\&FZ;5M#NHQ(9(DQ'5LN:4T\VEW:V74J:=2AQ*DZNQ2Q3,$D,C)8W?9
M?&YKV'OAS20<=#OL=BM1J6F:EH]R;3]6H7-,OUR!/3OUIJEF(D9;SP3L9(T.
M!#FDMPYI#FD@@K)LN+!3")A$PB81,(F$3")A%7OQS_:6^Z/\-/@K_B;V9G27
MO\EN'_\ 6G$/_"T18T?]:L?Z*M^,ZL(SFUDIA$PB81,(F$3")A$PBI9]:U=@
M7[+Y3/M72ZO8[ 2+\9/<7%= >\#BI-(DI[08W=P19CIM.K_H,A1_T>0(;XP3
MY@GI%U@]*_2B:_,CEH@MR650Z' \M\9_/'?KM]_17385*81,(F$40?#?]PY7
M_$E[8_SH=^PI/7X-_ *7V%"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A%3;[%L!SW=Z$9^&ERPN1@<>J,.N] ^(GTFORWHCHOGI%Q)*D
M>6@9B&M#L2Z=M^[?B%TW'?BR G,X\G>G)_XH2#[[71(X^']./%%MC779G25N
M&JT@#@^RT%EC5I&.!#H*&>6#.0^V6Y#>1KU@SDV9?5&$AC<.M/!((:=V0@C^
MU)U=OLSODA6]5ZO@ZF "5:L"!P"M5H0- 5X$(B,P!04('ALCQ0D9!C(;CPAX
MZ#'8APXK#:&8\=EMII"4(3K7&R223222RO=)+*]TDDCW%SY)'N+GO>XY+G.<
M2YSB2222=UF@        #H -@![@%W&4*4PB81,(F$3"* GQ/>P6WB'B3M%T
MHA)X+;9,*NU$0:B2-QIP=-TM(:M%2(U]"D/L%(P0B34,EQ%HE#Y^XY%E:%1/
MJUZ#Z+=&IZ[QSHE&_&V:FV2S<F@>WFCF-*K-:BBD:?9=$^>.(2L<"V2/FC<"
M'X7,<8WY].X=U"Q6>8YRV*!D@/*Z/UB>.%[F'J'B-[^0M(<UV'@Y:O"8M:W%
MJ<<4I:UJ4M:UJVI:UJWM2E*4K>]J4K>][4K>][WO>][W\]Y][          8
M  V  &P '0+YNZ]5Z7_A.S_8GHKSX7Y_7O2ZN0<GY':?T6A%!W.15VZ@0@EQ
M[!A=5!VVWD)0.N P+3^E"G6J\2+"4D40XKK8YD8Q!^8?2Y'P;PWQ%#J%CA@:
MQJVL5!;?%+J4U'2HY(9'0"U/3I1LGLSV"W]:#9BAE,1>YID=*Y_KO!+M>U72
MY*L6K^H4:,W@M>RHRQ<<U[!(8(IYWF.**,'V,1/DCYPUI# P-MEK7PZ_-\4O
M%M74H%U]+7>*KZV[=Z2NICJKZ-[WI2FXU8*+CT*%'TO6MM1XE390PA*&6MI:
M0E.>16?2-Q*Z%]32I*7#-%XP:G#5*'201W=;B#M0D=CJY]QQ=N3DE=O#PKI+
M9&S76V-7L-Z3ZO8?>(]PA?BLT=@V 8P -@IL!PH>O#8@8 )&@Q$!K3$$4'@1
M1@V$RG_59B0833$6,UKY[^3;+2$:^?Y:SB)IYK,KYK$TL\TAYI)9I'RRO<>K
MGR/+GN/O<25T,<<<3&QQ,9'&T8:R-K6,:.S6M :![@ NRRTJTPB81,(F$3")
MA$PB81,(OA2M(2I:MZTE*=J5O>]:UK2=?/>][WO6M:UK7SWO>]:U_OWA.O1?
MSU>X=7N7;^L7OJ5](3)]EMUB)$I29CSCNA<54EQ X#"2YO>HPP# 3'$C8;>D
MM18<1EE"=:3^?B]NS+;LS6)B3)*]SCDYY1GV6#LUC<-:!L  OV)X6X?TWA;A
M_2=!TF&.&CIU.&"/PVM;X\@8#/;E(_I)[<Q?8GE=ETDLCG$[JR7X/WK$5Y][
M?8J?TOH0^F\:Z#5Y[I!5EGKBUP9>A+T!VOFDNN:7&&S)@_1,++DJ^[L3&7X7
MW]Y?X9 ^QWO#6HMI6WQ6)A%5FC<7<YPQLS2WD?G!Y26AS"=@01S'V6X\3_E'
M>CZQQAPM2U+0]'FU+B71[\3811A$EV?2;#9FW*I:,/GCCF\"U&P<[XG,E\%H
M\>;G]:5+Z1SOI$#\4YY?*9>QGTI7^(4ZSA+-"TE?^KM4D+.FLIUO^S7U+U^?
MY?V_EGHT4\$XYH)HIF_WHI&2#YL)"_/74]$UG1)O5]9TG4])GSCP=3H6J,I/
MNCM11//P"S3+JUB81,(F$3")A$PB815[\<_VEONC_#3X*_XF]F9TE[_);A__
M %IQ#_PM$6-'_6K'^BK?C.K",YM9*81,(F$3")A$PB81,(JQ/3$BXU_UK0;%
M4A?2HFR-8X: (HIR.VN#NQ0M=BOL>;4%D*"#(<VJ;W'A=A)7L\1Z8\\//UV[
MK&RI%/ #C%K8*?=]YZ#R'?KOV5G>%";WK6M[WOY:U^>][_LUK_OWA%3]:_<7
MHBJJ[959\/D(JZ<?%=PZ8P6M?/;0$"6SFG(.(<JZ8) M @O<[;$&'NDF>@']
MUV]0>D62,.I5',$RW+VC"'AL<JL;9W[;=R3\^@V[GJ%*3TI\1OQ?XZ+TZN>H
M>Y@.,V2]UO=KK8*R!;>0FS@S<G<&5(^JMUTW'9W%GI<AO-2'F7M/-JVEM2/D
MO9 USN@SCKA<3X<-VJW2_*(/H]&,,6&D] [1ZWNU//Q6I+$8Y5K7ZY[F=KYB
M.S-8BS&6"8F?$FLM2XT>2VV^E#[#3NEMI*#U^ _ *=&%"81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3"*"GOCUB8\S<RKU>Y2!CW_P!4>@+*
MGDGESERU:7^DO2"L?ZI%J/M)WI<3G7,1;B[GT T_N.-A"X<8=,(C7#,26C?\
M/:.S5;4LEN0U])TZ+UW5K?\ ]JJP[0QGH;5M_P"HK1C+G/<7-:X1N"Q[,QB8
M P<TTIY(6=WG^T?V&#VG'8 8!(SE9;XC\G!_('$85!</2+[T^VFRW3.^]=*I
MVJP=?[;<G$$+S>BSSFM/ZCR9WTC*] <WO8FM#A(]:GI+,F5(LZ[J[]9ONL>&
M*]2&-E73J3/Z.E0@RVO78.F6M]J1W]N5SW# (:)KPB"/ESS/<2^5_G)([[3C
M^ 'D  I?9IE?3")A$PB8111[![7\Z\7,ZIQR[*N'37UKCCN0\K%S^E]2)3DZ
MWM(]%0J;1"6+DNZTK[)=B<"PU_3O7WK6_E\^MT;@CB/6X?78*(IZ6T!TNLZM
M+'IFE11G_.&Y;,;)6CS%83O_ &"M)?XATK3Y/ DL>L7">5E"DQURZ]W]P00!
M[F./EXIC;[UIW]-_?/?M_1SWGE/\;\^F?DW=^S_=.G=ODP7=?4R0"\EK\UNF
MU6>C\T/C;U9";S6]:5]S5]>M(W'J/H_X?WU'4KG&>HLZT=$Y]+T-CP-V3:O9
MC-VW'G=LE"M"#TYQC? ]9XGU/'JE2OH-5W_U&H<MO47-/1T=*)WJ\#@.K+,K
MR#_9.=OU3\-CAENBE9WH:P=,]/7DT')B'KKU^Y$)GZ.(,PW8LYSGE/"*%4RB
M;84[]Z#NBPCQ(/*;:?BD_M4J<6_PF:]3?$SAVOIG"U&":*9M'1J<<?K)A>'Q
MC4;D_C7;X<!R3-EG;%,TN:^+!P)_FEIL[9':K+<UBS+&^,V+]ASO!$C2'&I!
M'R5ZN">:,QQE\9 +7YR34C8_]'RMBKL\W4?15=:YR_-4MB58Z<3?NHP<XY]2
M8SH\808!&YL5G>FU34$Z^Q.<1]MJ /2Y]@WZ_6_E$U!1:;G#=AVI-CPYM:[$
MVC+*!]H22QNG@8X[\ACL.8#R^))CF/#R^BZ?U@B#58A5+MG2P/-AC">A:QPC
MD<T;<P?$''?E9G ON\L>8^=>2./ ^.\V1,?&P),HP=/E/L=F;9:22(Z"MB+;
MCH;83(D-Q(<*)&81ID>)@#A[:G4Q/MG/G_BOBC4N,-9GUG4RQLLC60P5XN80
M5*L1<8JT(<7.Y6E[Y'N<>:2:220@<_*/2]%T>IH=".A4#BQI,DLK\>)/,\ /
ME?C !(:UK6@88QK6C.,F1><VMLF$3")A$PB81,(F$3")A%C]HME6I .?9[G9
M 52K8MK;Y(_92T &&@,Z_P#B3"9-^-#CHWO\M;=>1]6_DG7SWO6LHDDCB8Z2
M5[(V-&7/D<&-:/>YQ 'Q*S*&GW]5M14=,I6]1NSNY8*=&M-;LS.[1P0,DE>>
MX:TX&Y4'I7MPMU23(!>->,6OT!(2\Y">ZJ<U(YGY^#2&W%,2'E7VQPVR-Q=&
MNZ^TD"J4#)+FL:UN&3UIUMW-2=6=8)9IE66Z<EILOS!2:1L3XT@YI>4]6Q,=
MD?9=N"O4X_1;7T!C+7I+XFT_@]A:)6</U>37>,++" ]C1I-&5T&FMG;[++&J
M6X!$\_K8,M+5^"?'_4^W;U/]E]X,W</)WIQ[@G%'"W*^'L-K^6W!9Z;"F)Z)
MTB(A>M+:?L1P6C6]J0H<IO6M;C]&6+>^J7'S-/6G5YJ]0=VO(/CSC.X+WM[<
MN-E5_A'T'A<>#Z-.$ZVE66;-XMXH%;B#BI[A]F>I%+$=%T60@EKF4JMC. X3
M!VZ@-Z=^!Q7KY>IMR\Y7T#R\.;=0^1YS91!*970TO:4IDOU4N+=D3H8Z3O7V
MZ0$T=);A2%O:A%&1ZXHZ#I[_  FR:9TM&9E=K]S!(QQ8T^9C>TDAIZ\A:<'.
M'8(#?7.!?Y5%S2=*BTWC32+>NV:K2R'6J-B".[9CS[#-0K3M9%),P>R;D4['
M2L#?%KNF$D\LU/"OPUN;^/05GF'2D/JW2+V-9"V>PDP,>* A5QN2U/55@(*8
M\35^'22#$666FD9#SYB0/&N_=!S41$7-KI&A0:8R0O<+$\S0R1[F ,# 0[PV
M,/-L7 %Q<27%K=FXPO,?2MZ;=;])%NC%4@DX?T329W6J-*"V^2W+=+'1"_;M
MQL@'C,A?)'7BA8UE9DT[?$G=(9%NFZ> O(%WG_C,GAU4JMA2M3S%EYDHIRD_
M'E*^?_/4$N<SZRZ]*^K?UJ<EZDI=5^;Z'=?/6\J71],E=SFI'')G(D@YJSP>
M_- Z,D]\YSYY7,:9Z7O2/I<7JT?%6H7Z9 :^EK@@X@J/C!_HC#K4-]K8\;8C
MY"T?8+2 1A?ZGG7Z1^WPWV[W^J-IW\V@/8&:MZ&K#32?]2#&:N8\;:(<+2=:
M;U]C:U264?\ 0/HUK2<M?HRU%_5-6N1_L61'=CP.C0)6MD QMM)GL0MI_A(X
M<U3;BKT6\(:@3UM\..O\&WG./661VF33499<Y=[6GACC]IAR2GX[\1[G?YE*
M%YK]("(_[#:J7:[5PZ]SD)^?S>EPKA#N%(1(7KY;2B*8AL*5_5J2RG^OVY]<
M@^U#1O-'_P!J22I,1W(E$L6?N<!Y8'51ZIZ%M9.*^K<;\$V'[N_2FGZ?Q5I,
M1/\ 8CETV73=5+!YF2M*X#V@7GV$_7N13_ZKO7F/TWQ3[O\ ]HV-?.U=4YY"
M^7Y*WJZ<GFVO3B$_)2OK=#QOK1KZVDN?M:2_2XBVN4+]4C[3_ ]8@&/_ .6L
M9,_%HSU&4/HH.I>UPEQSP-Q1S_T%(:R- UJ7L/T7Q#%IY:3L,"R_!.'%NQ.X
M^<>Q_+'6EM1Z#WOF1DD^K2&@4JS0:_9U+WOZ?H_1:R+$6)*TJ_86E0M*D+_8
M7I*_V<R8-4T^SM#<@<X[<AD#)/\ \<G+)_X>NRYO6O1KQ]P\'/U?A+7*T+!E
MUN.C+<H =<_I"B+-(@C<8L'(W&1NM[V:TUVF5LW<+49'@:O7!,TX<.DI"(XT
M8('QURYD^5(5OZ4,,1VUN;WKZE*UK26TK6I*=YDDC(HWRR/:R.-I>][CAK6M
M&2XGL ,KDZ-"YJ=VKINGUIKE^[8BJU*D#"^:>Q,\1Q11L&Y>][@!T ZD@ D4
MQE_CM>88%S6$'<]ZX<I[,U41R[Q8%=A[DM)<^SV2'5HB<BDGAR]?US6B$@44
MVQ^;HMF1_P WSEW\74&R\C8++X@<&4",9&<<S6%X);YCF+78ZM!V7TQ6_DH<
M=S:8VU/K'#M347Q"0:7)-=DY'%O-X$]Z"I) V8?9=X++$ ?]F=S/;5OG+^H4
M3L]"K?3.:V&'::5;(&B 4S"TZA+S:77(\F-)C2$-2H!$?,9D020Z:RQ-'SH\
MB)+9:?96C72U[$-J&.Q \212-YFN&1[B"#@M<T@AS2 6D$$9"^<]>T+5N&=6
MNZ'K=.2AJ>GR^#:K2\I+26M>Q['L+HY89HW,E@FB<^*:)[)(W.8X$Y]EY:A5
M[\<_VEONC_#3X*_XF]F9TE[_ "6X?_UIQ#_PM$6-'_6K'^BK?C.K",YM9*81
M,(F$3")A$PB81,(J@?<7/Y]H]*4<I6ZZ:G7"+7>!J%7!7FJ'U5KF@T#VN]%Y
MUSY_U4KTBB)HAM!F36JYT^ITU7](EKK5EHTD'J9'&R2=1*<[=>N<_3K_ !W^
M-MXIDC'&#6#$V,3+L0(;)0C"@+%0R!%N.VB=-B"W)Q-P;&ER4NOL0'"1!<-I
MQ$=4Z6IO;[A0N?\ V_VX1:IC<(X?"!P:S#XURF)6QEI:O VO1N>5%@&/NK#>
MFF;A!$M!T0(EI9:2EMJP,1VRS;>M(1+TG6M81;44A"O]9"5?+^SZDZW\O_\
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M,0X<1EN-%B166X\:-'91IMEB.PRE#3++3:4H;:;0E#:$Z2E.DZUK-L
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M::<NEMQRLDJQLGE>7R>K")DS3 "[#&O$3FM;L#D-;8G\-;X7\?Q;..=.Z/:
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M&TS8BE\*:;3YKD9FA#9XHC)+&]A9S#VTU>J5>D X%8IE<!5.N"VM,#0%:$P
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MX46="@QHT)B6$EB$.1F4)GQISJ&GF[&H<-T;SQ*PNJR<H:[P6L\-X: &ET1
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MY:U*O$QTUB68QRNY3'$QQ8'<K)).5C7[Y&"=5IGF9'*'SX]B#!$DA)Y6\K2
M2"X@;;@9.%V_#6=> Z"0+]98D>B?B9^U+"GIO3:915QY5EN%V?B.10%&$3%J
MEL4;S_PX+\ZF(L)5U%=&#QM@-#&'%S'!,7/;I<O&%ASZLC-#X'X;B]6&J7@6
MU:=?F#I)2T<KKNL:B_$OJL(,\KWPQR%HQ([7W=4BTAK(C&Z_K5\\T.GUB#-.
M_< DG(KU(<$.GEPQC6O<,D%HEKQ+RS:)]ZA>D?69T5TWT$EEW=.KHQMY7)O/
M8N9]*UU[E@6;MS4FP;2EML]T0FAP^4<9;9AO1X[3LHE@:YQ75CH2<-<(UY=+
MX>) NV97#]+\12LR!8U:=@;RU\DFOIL6*\()<\.<X-CIT[19W66ZOKDK+FJ8
M/J\3 ?4=+8[K%3C=G,OE):?F5^,-(&2_*>N>S^<4"T.\KYZ(L/H#O"DJ2QQ_
MDC+)LJ)=TK37WF_V7:]5CG B.\MG\1FV8@Q-AQW4RVQ,MG6]YYC9U2"&3U>%
MK[EORK5@'N;[YGY\.!O3+I' @'/*0O:^'?1GK6L4&Z_K%BGPAPF""_B3B)SJ
MM>PTCFY-'H@>OZW9>P.\&*A"^*5[3&ZQ&Y:N3YL[YZ65HG[%Z$FJ<[E*TZSY
M9X8;)"*M)B*WM28'6^HQU0K3T!U;2D-DP@%P#5DS8R)4!U]I:D*QO4+E_P!K
M4Y_#@.XT^HYS8R.UFQM),?[S&<D8(RTD$A;X\;<(\#Y@]&VCG4-98"UW'O%=
M6"S?9(!@S<.:"\24-':' O@MVVV]0,3S',UKF@B<M'H5*YI6AM-Y[5 %+JHA
MO[(< K0N&'%Q=;^7VCB8D)IEM<A]6OM)4IW2Y,M[:GY+KKRU+WMX88H(VQ01
MLBC;]ED;0UH[G  &3U).Y.Y)*\JU35M4UR]/J6L:A<U/4+#N::Y>L2V;$F/L
MM,DKG.#&#V8XVD1QM 9&UK0 ,MRXM>F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81:S*=IXX#$M'C76>9AP;]MET!DT4OE6'B7KW D2XDZE-$995F
M&Y;84H?/C2ZVA[9F-(A2V7H2'(SR4$P>RV9A%$'PW_<.5_Q)>V/\Z'?L*3U^
M#?P"E]A0F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB\1_\ I'GZ;](^(9YP
MY/;5D5\7JGG/70ZN"VM_04Q;3-\N0JY3/DG>F7";K%=I TDQKZGV \&)O7V+
M93ZW/H?T/.T#3]&U76-8MTZ%6I<EDU2Y;E9#''4K5ZYJQR/>1ACY[#PQK<NF
MD>8HPZ3E:N5U^GQ#JMBGHW#.G7M6UO5)(J6F4-.KR6K<L\QE=*^**-KCF."%
M\CY'8CKQL=/*]D;'.%9HIF?6G1DT%MX'("OQ)8B2&=V.D"),!U#\&2.=@*9=
M@/PGFFWHK\532XSK;;C2T+2G>O4]&]-?HIXDOMX?H\15'SVW>J05[^GWJ-.Z
M9#X8KQ2WZ<%1YF)\.."1['3N<&1,D+@#A\3_ ,F/T[\(:--Q3K/!5UM"I$Z[
M>L:=JND:Q>T^-@\22S;JZ5J-RZR.%H=+8LQQ2Q5F,?+8EB:USAZ?OAK^MN#T
M[A9+JO14VOJ/LSI%[LM0-Q K1CJ_H/K<8(T*)5F,%'//2IM=IL(,1@"VDRY@
M*IN$*_.DKE.S8Z6(_P _>G:^WA_B*IPW!*V+1X=-K7M'X>TRNV**!]AT\,[_
M %6NUK)+$MB"=_K4_M".3PP\ .#NO]"O &N\<:/=XAAA@J5*]V:KKW&G$5QM
M+1ZHA;#*QDVIVB>;PH9Z[?4:39Y^8QO= &O:X6(;YOZX]3?\X[3:)7E+C$S\
MT\9Y(>8(]HM0Y>];U'Z-UZ.TJ#5(TMO7TS*]S^,J0]"E/C29AN2U]KGA?@:E
MJ&]N0Z=5/_TM9X=:D;VGL@8C#O.. 9+26N?G=>V_IKT=\!>QPQ0C]('$T6QX
MFXBJ/AX8H3C^WHO#CW"74)(G?T=W5Y QLT;)Z]9T;N53!Y'Q+E'!ZNU3>1T4
M#1P*%)=DLB(N_OQ:4E.T_B)\S*7(,V$HM.]I<*&Y\^>M/R0J1M"4IULZU2M3
MC$5:%D+/,-&[C_>>XY<]W[3B3[UYOQ%Q1Q!Q9?=J?$6JV]5N$%K'V9/U5>,D
M'P:E:,,K4ZX(!$%6&&$'<,R23M/,A:%,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(JF+%XM[L>K?0@\,7P6NMW;?K.DP*ZQ<[B4JE=Y]ZIKU
M2#KM,:,UQ\#IVX<T73(T0?2V1\(); -CL(Q5YJ6U-NR2J)'O\CGSR!COY]_+
ML5(CTMS?WE8R].3Y&]'\0X]5A-;V.M8_L/##77C9\\U*WJ*7@EQ?0J6V-C:'
M);9DPW8<MQ^7IR5J0A*]-)*!R^8)^X@?BTKC?#AAW =Y0!#^A&Q%FOT#M'K>
M'>+'7Q#M? V"X1?7/<F+,;" 'YI)\&(*FD39XT0\1(.C84AF$Y-E+94^X1W7
M;88&!UQL/-3HPH3")A$PB81,(F$3")A$PB81,(F$3")A$PBB#V/VOR#E=EWS
M.O(L7;>Y2$K3 XEQ@9NZ7=IU.THV]:7(CB0=$&1ENLND9]N*"UQ8*U3F(<QI
MM2=]AHO!.L:M6_2=@UM#T)I'B:YK4OJ5$@[XJ!X,^H2N&1''3BFYG@,<]A.5
MHM0XAHTIO4XA+J.I'/+IVGL]8L ]YBT^'68-BYT[V%K/:#7 +SE?%VOO9[^?
MXU([F*X+43XQ-\=KW(Z">$] ZQR 5/34OMX_4;TVVEU$VY*2TIH36XXZK2-5
M9,A6B<Z*EZ)P7I.N\.U*NG:#POJ>I:E'X\]G7;MDBG5OV(&0LT_U72FO=+!7
MKB:ZYDE[FL2/F):(VLP?M;^1QPYK,EKB_B[B/16T'.J:3IW#4IK32,96LRZA
M-K38M3EC;7MV'/JZ6R<43R01AC7D^.0J<L\<!((()!!R"-B".A!\B%]W$ @@
M@$$$$$9!!V((.Q!'4+VV_#&X!SKC_DWC=DK]"%UZ]=&H(:WW:SR($==LL#]E
M3L[%00,K800_!V8DN)L.&TXB% AZ8^3*YBI,N1[K-K>I<2"CK&M2>LZF[2=,
MHOLO;^MD@H5(Z\)>XY<7RACK,YSB2S//+RM,A _([CVI3T#BGBOA30)Y8N%M
M,XOXBLZ;I,,SOT;2LW-1GDMBM5:1 PP/)HQR!AD;4JUZYD='"S%B>6EQ*81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A%$'PW_<.5
M_P 27MC_ #H=^PI/7X-_ *7V%"81,(F$3")A$PB81,(F$3")A$PB810^[K[@
MX?PXL_25$"W3^NIC/R8_'>4P46Z\,M,(TX],LR8[[06BAXC:T2B!>YE0D:*/
M^TG-IDMM*3OKM&X+UC5JKM4F]6T708]Y]?UN8:?IC&CKX,DH\6[(<%K(Z<<Q
M+\,<6$Y6FMZY4KVH].K1V=5U>=S8Z^D:5"^[?ED>0UK#%%D19+F_TKF'E.6M
M=T57%C]-^BO71J?4J^[<Y0+3VXDO@_C(U#ERDI=UI34#O'MPRQ'YU3H<A.G(
M\X;R%!Q,V%)5"E36Y*-NZK?Q=P/PR\P<(Z5+QYKL6QUS5ZW@Z#5E&/UE'3)'
M".0#'-%/J4LKV2-#FU\'"]%I>ACC2_5BU7TEZ]IGHCX:G9XL5"[.Z;BN_!T<
MV#2:K7ZK-(.CX(X:4;V$YL9"E'QSP=U-NM:K=LN=;\P<OG*2^2XIY(3-%VBR
MZU]2FE=6](69N9T>Y%5LNNPC>A>H,2:TZ\W%)I9TRI/&:SJG%7%MKUWB;6[$
MIP1'4J/+&0QGI%&\-9'7CP '0TX8(CC(WW73T-9]%OH]A]5]'G!4>N:BS&>*
M..8X[,9F:"#/1X:KO-3(=B6K:U>U>MQ$ /C^TTR.L7P\/(9_CQGB;7'P "L&
MGH\]\\#2I'06C\+3_P!PLWZ>%-%+(1.P]R96D2#LXM&D,2YD"=$ECIDN&]K)
M-$TQ]9]45F,C>0XO9M,'C/+)XSN9[GC)P7EP():06D@VZ7ID](U/B.MQ.[B2
MY<O56OA94MG.CNJ2\GC4?T17]7HP5)?#C)CJ15GL?'%-%)'/%'(V#O-?@8><
MJ=>(=GN70+_TNNBY[<Z%1RL<*#%S_L'-.,P[00%,JG%X&_EK[S'&_H_][WK2
M'E[C*>C.ZF#A*C%,))9IIV-.1"X-8UV.@D<T9<WN&\F?/;(/JFM_RJ^--2TJ
M2CINCZ/H=V>)T4NJP/M6IX>=I:Z6A#8<(JTPS[#Y_71'U:WG#9&W91HT:%&C
MPX<=B)$B,-1HL6,TAB-&C,-I:8CQV&DI:989:0EMIIM*4-MI2A"=)UK6NJ
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M,(F$3")A$PB81,(F$3")A$PB81,(F$40?#?]PY7_ !)>V/\ .AW["D]?@W\
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MUJQE0H4<Y$$CY"8T)MEHH.Y/WK=&%"81,(F$3"+K#<5$X,7A."X1QN8,GQ7
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MBG_\]90\ 8P .O[E4PDG<D[>?WA9EEM74PB81,(F$3")A%KTY_VI*_\ L?\
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M2;-IJP6(FL$D^6MSF(-#AOG $A ?L2#@;9&!LKG<XA9J@;VCSGV;HWI"A=Q
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MY=.Y=T$+Y'IGF'K/1 G0'[<'D@>?\VZW20D.LU0IR0>7^^M6/H#%Q#VT';:
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MW=Q&FXC2E=14BLPQ%MJUZW(7EPE\".OAA#0&<D9+3@AQYLY/-@] OG3B74=
MU34(['#O#AX7H-JQQ2:<=8N:WXEELDSI+?K=Z.*9GB1OAB\ -,;/!YVGFD<!
M"OJ/AXQT2W>E^B/V1G=DOUJ>,<? J?#0JT+;*>=N)\<-&;@6BT9=^V5D2:':
MHC%<9MQBA)&.@+$NM_I:TU.$WG-SD^?E\A[O=WQ]5H@_ :/+&"=_[SCMOC&X
MSMG98]'\_P#LQZ^6FQ6*W#RE%*],!V)OF5<]-^@J9'GA8</T0.E21]R3#/VR
MD0G'[EPHR2H5>(:J1)ZBF7(@X8T/$5\P =OGOTR0//[R-SG\1T0EF !G..I
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M)&,#.3_ ^\JIC0[.7!N!G]_[O=]X7/\ 2OHVS\0_H+&UBG\[/G^UWPY3$/\
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MIMUC!]7J-O<F.0@)ZIN6=#@;2PLMQ$Z&I3[DB#*?A."W)!\L8]_FKC)2QG*
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MD0:9:FO@#?/>;]-6*D?=D(87NF6#H1Z@,:1]HZQ%J;$28\_/C2GG*VG.?O\
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4[OWA9EEM74PB81,(F$3")A%__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g210084g11i22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g11i22.jpg
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M 0$! ?_  !$( 1("4@,!$0 "$0$#$0'_Q  ?  $  04! 0$! 0
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MS+&]SN?L4I;3Y+-=FXWN^%KW!CG].LC = 1N(VWF<''[0'*1J6WP9_\ L_\
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M0I6JF,?(]L<;7/>]S6,8QI<][W$-:UK6@ESG$@-: 220 -E02 "20  223H
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M$T>P"&O9P]%(WH7 [:[,2,.P#L4&.!/^$'3,$@W3K9;4:>O<&R0>WD1"//\
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MD_>I<AW[2<0E/?-S:?M/H2A*>.NW;61M37;DIGM6'\\TI:QA>_0;LMC:Q@Z
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M51M/*0E"]K_-R&IUS6;Q>-(^U6@E.7O@_HFOCC+!&[775BW!K8!UY6?>2_\
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M1FK/0+=7+)$9>0EU$(K'TZE+GUH3N^(]-R8AV"^GCL-0GY2'!MJAB*-.U&'
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M_<(ORM:&TJ6M24(0G:EK6K24I2G7S4I2M[UI*=:UO>][WK6M:^>]X[=U(!)
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MG9)/F2>I*_4:***"*.&&-D,,,;(HHHF-9'%%&T,CCC8T!K&,: UC&@-:T
M !;J?@QUWKW1[IV;GE4[3TSD7-6:N$M-LD\[BTM^9.LNBVA &$P0NU3MT>N2
MB EX^\]."0XA @T%C-2G7V1\9+'5<+LLSRVH8[4]: 1LDD, B),G-RL;S2Q2
MAA<WG)+ USN0 [#>GS%_*8N\.X7&<,YG(<,8/B+-NOVJ&/CS+\FV**C[O[S<
ME?#B\CC7W8X;#:C6Q6I)8876GNC:Q\SR_H!_X$^+&?V^G'^V]O>_YZZWW+I=
M@%;^?YK3^B8JP *7IIS?YJCIK>HWY[TEE.M[UOL?R15?_2'V[?\ G-N=[?\
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M#^CTN:?-UV&*%%U"S,&F1CVE'-,1ID0,\7AQ)K;1&:Q)*IITX==?^2A=Z[_
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MGC9^,AE.M:1]DU5-M:3^:4)UKZ-T_D?*P]:F<L: Z,M1B8?]I[W@#Y"-9/\
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M./D,9).R6-<W;-G9T"6C?1H'1?2/"W\IWCGA[$P8F]3Q?$3:<+8*E_(^]Q9
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M-,-(UI+:$IUK6<G)))*]\LKWRR/<7/DD<Y[WN/4N>]Q+G.)ZDDDGS*N@
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M))))).R2>I))ZDD]ROU78QD;&QQM:QC&M8QC&AK&,: UK6M: &M:  UH
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M4_7;ZXW\OEXB>U^7SW]IZ0Y8G_I\M?R<%WY[_P#^:_+^??Y9/O61_P":R/\
MKM?]P*?S7]G?G[4F_AP5GSOZRCI]^C\E1K%V;V@Y7CB OC&+ ,+"E-"IB_1?
M/)^X9-4%[4"1J T W]_5'E;:=^YZ=;U)VW]CIU/VFE:H?:RG(_EQ0:[E=RDW
MH#HZ.B&AGQ:.CR[&^VUDT^&?9DVY4-KVFR35A:@-B(<%YF'Q(!*TRL\9UO\
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M4_75ZG_L5E?\0'(_]_":;^E_=*?KJ]3_ -BLK_B Y'_OX33?TO[I3]=7J?\
ML5E?\0'(_P#?PFF_I?W2GZZO4_\ 8K*_X@.1_P"_A--_2_NE?&1W#U'&COR7
M?%A;[*.RZ^Y]/?\ D>U?9M(4XOZ=?;_GOZ4[^6O^>_RPFF_I?J*L_F?JKT+U
MGG'/^J5#Q?87:GTND53H%8=(=VY+!GN5VY 8%C"KG0E2G%0YBQI*,J3%4M>X
M[VUM;6K:/GLA:T$CF[?(J]OUU>I_[%97_$!R/_?PFF_I?W2GZZO4_P#8K*_X
M@.1_[^$TW]+^Z4_75ZG_ +%97_$!R/\ W\)IOZ7]TI^NKU/_ &*RO^(#D?\
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M_#-R')#L@S%##HY5]V7M2I;CQ!J,B6ZY*4I2I"UO*4]M2MN;5O>_F1>H2""
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M8G)NQQN4-^?GA\JM0R$ +>X!RJWVOF94-BR0!A L$GUY^>"E3%N<^GET^_\
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M8IXQ\;8Y\\WP@]-DZ^0_C^-J.7XB.O0;\MZT#\_7_>!Y1&D_$U-U+GM_[*8
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MV%NQL]/AG!=*C%>7W^#1Y1OFEVD=!H%FT4YO0.DQY]?LDNNUB2IX?%OK (M
M>&JVS.%JFHD_8DFXD.02=[UT\QV/W?<J'- T1OJ"='H1HD=?OTI%Y4J4PB81
M,(JY7O\ Q%/_ *+O_LG*']A]_P"XJMG<_=^\*_,M*ZF$3")A$PB81,(F$3")
MA$PB81,(F$3")A$PB814.P_^'*_]9K_W5E3/M#\?V%4/[#[_ -Q6"[MS+G72
M7*<[T*BU*[N<]NP7I-#<M=?%GUTWH5;;F-5^[UA1.+)V#M81HC/;%'QVXY.
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M5:BZ9FRVM-?1)>2MH>@].WEZ)L^I]>_GZJW;)RCG-N%U4%8:>&( :2:C6"L
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*A$PB81,(F$7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g210084g11k91.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g11k91.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1N24&AO=&]S:&]P(#,N,  X0DE-! 0
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M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!Y            "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !2<   F+          $
M     0             )BP  !2<                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   4G     %)G:'1L;VYG   )BP    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $    !#A"24T$#      0ZP    $   "@
M5@   >   *%    0SP 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 5@"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M,-EK@Q@@%SC U
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MW$H6R5[IULA?,#S[GB*MU=J?GWR.3<?\@:;2(NGTBX3W7N?QE$@H9JZ)AJ[
MP,?U6P@+7"AU[E9$&U+2 4U6Z2H[FSKD,4E2&72].1B:H8HP+=W6S3O// E2
MP]B20P]\KNU6-N9&DM"0JIUVN20)*20[+/9(5^X\HDH4*&+#M5>2!^<1P %X
M!RT74_I3.L4:-\R;9&Z\<2-<%["?PVE\*.ECVNZP>H[MW%^.K\ANL)E^BU2
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M16*]6M\]ZK"R9_F_*=D5AH:[PO\ )U QFC3UY%7U1"9$A+ED+-FJS/.&9P@
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MCJ9SQ"W>LK(WF>GVVZ&ZJ35[-JQ<GMQ*\<D\K"UZD@#Q3 E@4<$AB5/ICZU
M*@C[GZ6?<).N1YM]K<)4;4\HO4E7Z[:B;K$ I;-(:"V+9#*Q3B)#90"!3"$N
M5T#Y,E]T)"BT#I,(^%+L=.*S(E"S/<J+V>E8LU%I32<QJ7[ZR6KBQ]DA=%XL
MR=ZJ)#V%NQ?I"NT[Q*UF*."8]W?%%,;"+PQ"\2M# 6[E 8_DE[22OU<=QVG-
M7,V?,S!_2%^1LEY+]^MT#;+V'QGR#J7ES0?$-R[\QGVN$U3HOBO54$<MMU&N
M$C$ 0G07^X \_P"X7&4B8F?E%Z,#J\40!K6ODF_4Y.FM8FKUT,L5=KNNGU%C
M=?+VXC?EJ[:;BW#8@1VDK"@;%&%))(X_I,KAC^?D4+4AEE(+B.19EA[D81J\
M2_258@*_J=KD@$^> 0/8[5#_ $MO9ZE4_ R.E+EP/M%O[!SWQ.G^W.5RM;BR
M))OR)[*3Q]V1@K+KL%<A8VZ5;8,C^%=5Y[S#JNAKY5[JW/U[DU,8CEBX).CJ
M4LW4+)!L:,%*QMHZ'JRA^W[-I?.!9(ODY)&@F)7T9;%JH36E@,<MN8MS>+C@
M5P6C=G6+U. 1YD?M\-W !A]X"M]0;D*!QDCQ/T@'3>QQ?)+A*6KD [<QY[\Y
MYH+PGCEXOL#WCEM8!Z9W/GI4'Y$!QMY^'9E7%CGD?+!5J5JU8J<J8[(QQ]>G
MAHV/DDZS=.U:4ER!8[A[.GK5H["[!7DU]J4U:-D2:UG@YC$!L.C3++),@"LL
MD3,R&X66=4;Z1S.%]-&82* SKQ(.?);M]B #^!^[2D_2X=[D>!\(Z7 %^)D_
M<_).]B1H%=K,N.6CQGCRN;=)OPG,N\-]%\@.05TOJTJ916JN 3)=$Y(P1(#7
M3ZII\[)0$1!V'*>C]>NPOU9!N(H=97+M)-'PVT86JU=K6O\ EZ%N1:B"<RL%
MKV^%]'OG19'>.GS<AC1AZ),C'P"2(AVNW$A9U'<>WCR4^_P> #L1'TL'D$UV
M+FE /K/C%7#IV4\"H2Q<>3=2[YURWE^8\&QJVR_';#2KR72[;4^+RRW+"78X
M8"T0MBIZFE*E8=6QY>1L7I#7&C9LK-M)%1.H)([OH"O3A&ED(B2Y'/7$\,UU
M.(UBD:%XY@WTO^8M/G)/4"E8AR:X* EG/K+R67M8AE4^>0#R/ZQ;KP"ZWUOR
M=\)[Y-^1?=ZLN]#]$\A:%9.@<4W%\^M_+8BC='MM>'8L/O5+Q%6MT#$Q29:#
M+)@0'44(JH24\),3;\I8YJ'ZAI4]5O*T>LH3&N:VML1U]@'GAMR6*T,K>GQV
M/+#([]D@$A'S F2-DC"1IGKN\L+^K(O<'E4LG"L@5V Y]PI  ()'YO!8<D\]
M4,]UKR)J/B'6?*B8\ONDC\DN/3_)/N%&H'3O*NG<%\B.@^)E+K$=7N1!<]L<
M_P GMPMUN5D7'C]7<J#-: ',_E(JE;:EHLD\<MWK8Z>MGW,NJCTE4VX*FLHV
M;%346=AK*VWGE:2XUF..Y"T$$09JHG,I*_+32%'5"!J&2181*TSA6>5T5I4C
MD:)1P@4E&#,QX;M"\\$#P2<N3,?2'>8=E[)'T+C-,X-!T6P>17*?%^IN=PB.
MGN=/C+'U;P@A_+<.V] #K-DCXE"J;[)>NS=:CV1S;$>6,!J0JWU63-R<,G36
MECHO8N6+\EB+6V]K,*#U?E7BI[MM2T-9I8R_Y?E)(Y7)6-5+%9>X1KF-J;O"
MJL85I$C7U._N!:+U.6 /![>#SQ[^P/@G-#Y%]+MW?MO8/#+F%?@/'RG2/?.6
M^.O0KU VMZ05)GB](F^LA=8D.=RLOUFD. [IH?,XABEU1JJ=.F;/*7T5HB0:
M=KS\?*Y[O1NOU]/=699MC.-?:V5>O) %[ U6.FU1;*)4G#>LUIS/,9JB0I7)
M"D/W+;'<DE:$*L:]ZQ,P8^>'9PW;RZ^0$':O#%B3^'!^A_/-\DL8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QGI(3[QWT>UU?N9=3[!W=L/J]R%:]K+^G&=LNJ
M]?1MW3S6VU[2O3B/3W:J/<>WN/<<C^D<'D?B.#S^!QE >9<U[0'<>!NV>J=&
MAX?GU@[9,SEDD>QLVJ2.A[3/=)8YW1+I'/\ 1)=%DKT?5[C#S$K++:MEA<N%
M1I0R26(ROKD7^AM6:)AV'HS5G>S'22.)*1B17B2LUBQ"WRZ>G(TL,B*@,48A
MFF/#-)VC51908@RL ID+,9 QX)?M4CD]P*L"3Y/< / '=FP=Z[QU:+H$\B+\
M=>^TA2;#3HQ'1"+)XWIA(D(R_5V,+F'VJ_Y"35RW%E $/I<9 JADPL0G;2HG
M3VW&46:[7U'M1=^RU\X,<K&L(MGWNPKR,(P9-<D/>& \M,J<CD/QYR^21PAX
MCD7RH[N8^!RP'W2$\<?J/[,O)D!F?&,8QC&,8QC&,8QC&,8QC&,9AN1T>Z>+
M*N@!N2@(IH(4DX*PL\,&2=!?D0Q3%(V0.*>]&1KQH[3B&2G8\%Q]#BQ&-MU[
MF"E0Q"L59EY/:64,%)'L2H9@I(Y 9N/<\O\ M_V_J&9F4QC&,8QD8E\4XX?>
MF.H'<HYP9TD533@U_*I-;?N3#H[:6AWFK*[&KF$/CLH2R.^DS3S#.M,M+0WZ
MIS :M8S"P:\!G''$QB0RCCV(D*]P(]@>>0/&3:=2]11:MM''OMS'I7#*^I39
MW5UK*Y+.C4EG%8H[$LZ&/M=OJ8%@#F]S4)#62*D(&PQ$9/0<L*Z#*PTT +*1
M4F$^GV/AR$<<T^&8*\G>TNCDLN-.)WZ+1O7V9E=$D5D=5=&'#*ZAE8'W#*00
M0?P(XR+K6;-*Q#;IV)ZEJO(LL%FM+)!8@E0\K)#-$R21R*?*NC*P/D$9K%"Y
M?S7E<83"\RY_2^>1!A6S3(RDUB%JX)AFT^SYLL:%""9))TCT;T^^AQU+>M-Z
M5I&M)U9#!!74I!#%"I/)6*-(P3^)"  G]9\YN[7>;K>S)9W>VV6WL1IZ4<VS
MO6;TL<?//IQO9EE9$Y^HJI"EB6(Y).;UF7(O,38 .SM2FPA-R:1% )D=C,_/
M)!6\DA86B_9\QH11"$/J&TY\%3R$N[1M:=*U7N;M[>X]O/=V\GM[N..[CVYX
M)'/'/'C&<!(42CRRV')6FU236*7*GC+D*]$&K'.G6E,3AK"B0W-LES+*ULRI
M+>TO2+2U-EK>0K>MY%L3ISV32IR$4]LCKRL?\6#PPY"?R ?"_P GC*=JGW4'
MW^X??[_U_?\ CGL?I5-*-G)(FI5DB1L\>W$V4]^!BG3;#%,M?!9C)PIP13\M
M'M,_S381[A R&OYM+>D?9@3SA8U$TH6)B\2B1PL3D\EXP#PC$^2R@'GSSSC@
M>? \^#X'D?@?QS!US;G:8^*B=4&EZBX%3*H.-U5H/4?#*'-1)#JB@] _+1RF
M)%M![.PVV=M&H04C:7TZ<U=\S9[G?YB?OD!#MZLG<X*]I#MW<L"OTGDGE?'M
MXQVK_BC^H9RR*M6&K"];FZY MVLD%$619T1$>BPD1C:DK;CGII(^I)T%"D(4
M@1PE0Z5(3M+>MIUO5GK2F,0F63T0W<(N]O3#?XPCY[0WZ^.?UXX'// Y_'CS
M_7G/9CRN,8QC&:?'\\H,38"K9%4FI1MH.V[LRQ 5V($G"MD>OS"GY0<1LUU1
M'KOYA2W]J?\ 7^=VO.?J=*=+T-K/O:/3FBI[JSWFQMZNIH0;*<R\^J9;T4"6
M7,O)]4M(3)_++9+V-_O;5"+56MSM;&L@[/1U\^PMRTHA'_%B.K)*T*B/_<P$
M 3^2!G,3M>@;1&/PMEA(FPQ!7LV3%S<<)*1[^VU:6VIT,YE\=:FUZTMM2F]J
M;7K2T;2K6MY([/5:O=4Y==N-=1VM"?CUJ6QJ07:DO:>5,E>S')$Q4_4I*$JP
M!4@CG-.C?O:RRES6W;5"W%SZ=JE8EJV$##A@DT#I(H8>& 8!AX/(SQ UV JL
M8Q"UF#B*]$#;7L>+A(X.*CV5.;]SBVPP66!T+<5^4XO3>E.*]5+VI6][RFKU
M.JT=*+7:;6T-3KX2QBI:VI!1J1ESW.4KUHXHE9V^IV" LWEB3YRM[87]G9>Y
MLKMO86Y.!)9NV);5APOA0TTSO(0H\*"W"CP !G,Y(9IYB$  F/!$%A"%$1I"
MRXY\@9E]X IP=\-9(3KJ%+%(6(22*MYA3;BAR'V-JVTZXE50S , Q 8<, 2
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MNS4Z]!YF^6K-89$4E>YK4BRRF8@\R\R(&7U.[L//;QSEHB17>0#ZG[>3[_F
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MFC2FRHQ5A >6Y'$KY\4<S,U&ZDSFW8-//YCF[U?Z 1=)FJ^N&IO)-Z7SSO\
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M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8R!?)SR
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M2](IU-'NJ=.>W%8GUVNFKLT<T,$LL0:W?$ZK3:9H79 M6PJ1F-I70LZQ3?\
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M.]:W-3KM@EZ"5Z-Q(E2=VD>M,L:I\M*>XN4"A>//<3QQ]^6S.AC(#J22G #
MD_6OW Y>S(#,^,8QC&0CT#I\F/.:YIR\ 2R]0,&;(+^;4YNL<]BBM;^%9;R6
M/O2V6UITI</71E?7$^ZE*6$#A;6<CSCJKK*[%L1T=T76K[CK2Q DTWKESINE
M*,W(3<]2SQ'NC1AR^OU$3#8;5U[8EAK=]I.ST/35:2D>H^IIY=;TU#(T<7HA
M?M/?VHOSM=I(I/I=@>%N;"0?)T%),C23=L#=/'5_+GPOX3Y;1')NIT"_=:Z;
M!V2NM=,[K(R:T1,==9YN,/$?W242@\;+0E;8.C&W0Q0&F(..&^KHT.?(C_\
M3';])_W%>@WFKI?$K=I#U-UD))-S]J[NWL3:W=ZK(W%F;7UK,>DJ0Q/6$&FU
MII35ZU2&K#(P""4P.\_NC-QKK=CH_5NVBZ=9$URZ_65Z0AUE29.TPI=F@;9S
MRRB9I=C<%F.:>Q)/*H^KTQWZY(9%8QC&,9PMCKT1;("9K$^&W(0D_&F1,H$[
MZZ00$<PL<AOW)WI;:]MKWMMUO:7&7-(=;4EQ"5:CMOJJ&]U>PTVTKI;UNTIV
M*%VM(/IFK68FBE3D>58HQ*.I#QN%="KJ"-S7W[>KO4]E1F:O<HV8;569?>.:
M!UDC;@^&'<H[D8%74E6!4D&(^)6&78%G>47$UPV[<K?$B79(G?H1;*88VXJD
MW3[=J^*]*1@ZXZ:4E;FVK'%2R7%)][>E<)\.-K?CAV?0_4%A['4?1,L%%[DQ
M_+;WIVPCMTYU%SR?4DNTXFJ;)@6[-O1OJY'<G/5]9T*DDM+JC40K#INITFM)
M6B'Y/5;B%E&YT_'CM2M9D6Q3!"AM=;J%0>&XG;/3,XC*&^:WT@_(?"!%($OL
M';;?8[XJ0)B:Y3V(O9(L)$.BLR4U)F3$C'!C,?&+;%CAFUODR!2'D>P<8<@M
MKONB?AYN.N#>>A/4IU: C6:S<:7M>>8,8X(DACD=FX7OE8A5C0J?J9E0\SU#
MU30Z=^76U'//-9[F2& )W+&A >1V=E4#D\*!R68$> "1:KC_ %:G]RYC2>MT
M$HDRHWV"%GH5PT?0A[++^ULD 2(J7'D#R48:R3'2+#3Y#+1HKZ&2"&M(>7R>
MXU-S1;2]J-@BI<H3M!,(V[XV( 99(W(4M%+&R2QLRJQ1U+*K<J)NA=K[*G7O
M56+068Q+&6':P!Y!5UY/#HP*. 2 RD D>3)&1N;>1QU+H+7.JNJ38!7-V26-
M%KU*K#"]-E6>VRNU-1,2RK>]:9']Z7#90Q6]-Q\2(<<YO:1_:KD>M>JH^DM*
M;D=9MEM[]F'4].::)@L^ZWU[N2C0C)\1Q=RO9NV&^BI0@M6GY6+@]#TSH7Z@
MV0K/.M+75()=AN=E(I,6MU54!K5MP >^3@K#5A'U6+<L$"^9.1463X+7N%D4
M7R"/%%G+U!W#<OVN>]KZHXX"_NG1MEL,)#*_TC#LTR6GQY:/=C@@R?J".,^>
M<=?6XYG@ESX6Z;X9V.FOBO9@@V74^MW[;#XC;7B4U+-7JF2Q3W&VUVO8FKKX
MNG;NTBO5GJUZ\QU-2S\TTDS,^>L5NN=AUO'N^@8))*6DO:D5.C:/,:V()]"L
M%G6Z^[<'Y:X^XJT9*LZV)IH_M"Q#Z 2-54=@"5)4E*DJTI*M:4E2=ZVE2=Z]
M=*3O7KK>MZWK>MZWZ;U]NL^J 0P#*05(!!!!!!'(((\$$>01X(SP<@@D$$$'
M@@^""/<$?<1GG*Y3&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9CF&"1X
MA1YY0X((0[YAIIC[0P@@@S2GB2BB7E(9'''90MU]]U:&FFD*<<4E*=[U<B/(
MZ1QHTDDC*B(BEG=V(5415!9F9B J@$DD  DY1F559F8*J@LS,0%50.2S$\
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M'S/6Z0A]*AIMC:A,:K2IPQ02IHM0ZQBG5EMI8FB:U%#VB4NU0R]RCKE\VV?
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M;5R>UZDV_6&PM;EF"R["3U9]A/&H *J(A#3J*Q!6NB+ AE81H(P/RQ!)G/X
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MIO=V.6'SUC. QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&8QIH<<&5(2!8P
M(SYAQQK[0H88@K2GB2BB7UMLCC#LH6\^^\M#332%..*2A.]ZN1'D=(XT:221
ME2.-%+N[N0JHBJ"S,S$!5 ))( !)RUF5%9W8*J*69F("JJCEF8GP  "23X \
MG.OC_LOYZRWV;DX+PF@Y'>M_[*BY?RPEXPG^C>O@&1WC]'FL:^W2FBNI%,J3
MO354;]9+T/\ (] P_P"Y6.MYXO\ (E@Z2AE0?^DDO4$B-^M-6C>[6C]',?E.
MI7_E1=/1/_E))NG1OZ&76*P_4UQA]T(Y;L'""#C0Q(^.$&   &8#!!"8:%##
M#%:2P,*(,PAMD<8=E"&6&&4(:::0EMM"4)UK7GCN\KO)([222,SR2.Q=W=R6
M=W9B69F8EF9B2Q))))SJ%545410JJ JJH"JJJ. J@<        #@9DY;E<8Q
MFD]&Z!6^64N>OMM(>&@:\*V07L9GY@M]TDE@$$(-C:VTNF'GE#!C(<=99^,^
MA3[[#"7'D<YU=U5I^B>G-IU1OII(=5J8%FL-#'ZT\C2S1UZ]>O%W()+%FS-#
M7A5GCC]213+)'&'D69Z>T.QZGW%'1ZJ-)+U^1HXA*_IQ1K'&\TTTTG#%(8((
MY)I"JN_8A$:.Y5&KS0_-;D'0XLDJ!C^A/3HY/RR:8'2)6P6<G2D>]DIAFK:G
M(ML)[T6A))TH$AI;+OS'P4)2M?DW2O\ ='?#_J^C-/JJO5<NSAG]'^#L'3=[
M:;J4%>Z.>./2C94DK2@,JS6;M=4>.02^F%#-W^]^#?5G3]J.*]8T"49(_4.Y
MFW-6AK(R#P\3OM/D;+31\J3'#5F9E=#'WDD#>_P[[E:?5-,X^#3P7/3X4YU^
MTB@DZ1^;;B:;24V60<W^?:63YV%7OU3[]M[VK2>G_A-\2MWR.GN@*W3]9^/3
MV?7V[@K3!?O9>GNG%W%IS[]L=O9ZU_;O"\GB#^P^BM9YW'5L^VF7\ZETEJY9
MXR??M.XW1UL"?@7@H75Y]N>/+^2CI-E_+Z'W&S_+K3K:X#E<6!S6)0I6M?%9
M5,?$L-U(:]/<A+K5ECU[3Z+2AI>]^K^ W6&XY;JSXE;KTG'+:OHBE5Z/HKW<
M=T9V'?MNHY5XY421[FHQY[E6,\@OX4].ZWQH.BM;WJ>!?ZHM3]1VV )[7%3M
MU^EC8^"5;63CGZ2S@ YM%7X5R2H%ZDXBC0STW]FU6.=21:;,M6O\):K'97Y:
M:]Z][VIS>CM:6K?N5K>]:])O2_#/H306/G:'36NDV7@G;[-9=UN68<DLVWW$
ME[8]S$\MQ9 8\<CP.(S9=;=5;:+Y:WN[BTO(&OHLFLUH!^X:[6I5I< #A>8"
M0/ /DY+.M:UKTUKTUK[-:U^;6OZL[KV]LY;&,8QC&,8QC-'N_-J/T8)D&YUR
M/FDBK^+'&N)<%F(@C\^BH6;!<&EX<M._MT3&FBO?T;7M.]ZWS74G1_375U9*
MW4.HJ[$0MZE2RP>#84)A^;/KME6>&_K["GRLU.S!(/;NXY&36EZBW73TSS:?
M8STS*.RQ"I62I;C^^*[2F62I<B/WQ6894^_MYX.19NL]NYIO2Z78VNQ5-GUW
M^!W1#VXR^!L)UZ_"@>BL#*#FE^[>_A"W*,^84E*6W;,GUTM/%?8WQ'Z.^KIW
M;I\0-'&"?X/]6VEI]3UXQQ]&KZNBA:#8D<GL@ZAI>JP 5]TO/(Z;[2Z,ZC^G
M<:]ND=H__C?I^!K.CF<_RKW3SR":F. .Z73V2@9BRZT\<&(;=3O';R)M8#\^
M';.&^1T.Q\* M,>2[RCND0E&TI2W#6,)3T7T*O;UK:=Q+[UVJ1(SKFB8S^?5
MK.^Z(^.-)[#=,SO/I]C,3\W\/^NZ(K/:8'@R4*MB1Z6Q!)#Q['IR]._'8_KI
MQVCF.I/AI<B@^VH5AV>OC\0]5]+V38B@^\);FB1;-%AQP]3<58 3W*(G]\\_
MR@^47CK_ #/7ZJ]Y-\K%UZ:Z]QZO-1O8*\&A.M[(Z'Q,9U05J99UO>R[#RD[
M9FV6'"%<^9VYO2?5_L[I;J/ZM/:7IC:N>?L?<V3)I[#$_FZ[=NH>JQ_D5]K&
M$[F""^0.<X06=QJ_%Z$[:FO^_J,02]$OD\VM>#VS >QEIL6X!8UASQEG^7=@
MYCVNMHMO*[M W:"^*H4DB&+TLJ*.1M6GHN>BGTL2U?F!U)4DF(FP8^3&4G:7
MQ6]YR^UTVTTEDU-K1L49^ RK,G"2QG@B6O,I:&Q"P(*S0221-S]+G)>E?I["
M$3TK$=B+G@E#]2,/=)8SQ)%(/OCD57'WJ,DG(S-O&,8QC&,8QC&,8QC.,F9F
M)KL4?.3LB'$0\4*Z;(R<@0V*$$*RGW.OD$/*2VVA.OZ5;]5*WI*=;4K6MZ>P
MV%'4T;6RV=NO0U]&%[%NY;E2"O7@C'<\LLLA5$51]Y/DD <D@'9IT[6PM04J
M->:W;M2K#7K5XVEFFE<\*D:("S,3^ \#DG@ G*WH&LGD:O3\FU+T[@NUI4)#
MN?-1%N[ QK>E(,F-)VP=6>>%Z]NQ8G2F9NT"[V_([CXQ]H1_R(0;CXML)+B7
MM!\+RP:'7OZ]#?=?Q \K/L /2LZ;I.<<&&@#'LMY ?4N?*4I4KS>AM)KOAZ.
MRL]7;]<@$2VU]*WJ>DG(X,-0GU(-EU!%Y$MLAZ6LE_)UQ8M1M-'9B/CP8H$2
M,BPA8Z. '9#! !':%##$'0EI@849A"&6&&6TI;:::0E"$)TE*=:UK6>Q5:M:
MC6@ITJ\%2I5ACKUJM:)(*]>")0D4,,,:K'%%&BA4C1555 "@ 9YQ///:FELV
M9I;%B>1YIYYY&EFFED8M))+(Y9Y)'8EF=B69B222<R\SYBQC&,8QC&,8QC&,
M8QC&?/)X6VJ(;^D-O5+L/8>3]?Z0QU3R:,5,PGGGY=]!O@5?<L=Z*A*I(^,4
MMSV&\7@2^>P+@%$EA(2:$CJFY /&03+L]&MLN^C[R)STW7GBI7*54U=8/3DT
M&GKUC)Z< DE3:)9DVI6Q(3.ADC9IO4XD(1B1'0$?,,&D1W+R<\3RLW'GA3%V
M"(=H '@@#CQYSZ&\\XR1QC&,8RN7E:TUKA%Q5IIO2M25#WI6D)UO6_Y1*G]O
MKK7KZ_Y<E-.3]HUQR>.)_O\ _P!GES%-_%M^U/\ GKF1Y.^,?+O+7EAG)>L"
MRJX%V4 GXN5@#68ZPURPQK90X<W"%E"2 2#$!2$C'NMGQQX;X,@6P\*K;B%M
M[W2_5&UZ1VJ;?4/$+ BDKRQ6$:2O9KRE&>"=$>.0H7CCD!CDC=7C1@P (,?N
M-/3WE)J-Y7,1=94>)@DL4J!@LD;$,O<%9E(964JS CSXCS@?@3XP>/7/1.>U
MOFE>N+#<@7+2%HZ; UFYV^:DS4#LNDGRI<$P.PRV,(*,+'1($;&#-,?$;#^;
M(,))LZNZCO=:[7[7W<=.2PE=*L$45<""M6C>21881*TTG:9)99&:261V>1OJ
M[0JK)],-=Z/US:SI_;;C759)WM3K6V5JN;%ETCC:>9:TD,;2>E%%$"(QQ'&B
M_<2=:\COHY/%SR4@8.'G:6WS@VNGOFQMDY!'U>E3FVC4,MGQLAK\&Y.(E8\O
M0PR](D8DDH)YC3D:4'\<Q)7%7=+0NHBM$("A)5ZRQQ/YX[E;Z&5@>!^<I((^
MDCD\^J='?&+KCHRU:L5=D=S'<B2*:GU#->V=4-&6,4T/^&P6*\R=[@F&=(Y5
M;B>.7LB,=H^/<EI'"N:5'DW.8UR*IU+C=QL0*02LPMS;Q1$A(2!Y;FM**D96
M3,-DY!_2&FW#"WU,L,,_#9;WZU:*I!'7@7MBB7A03R3R2S,Q^]F8EF/CR3P
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M#MMU9JT7-RFX:"&'CI2=F)J10SLDAJ.AX0,^0>9"'UIX\Y;+8 6G!FR2FGC
MVG^AZ<Z5WO5=N6GHZ1MRP1>M.S2Q00P1D]JF2:=XXPSMXCC!:1^&*(51RL9M
M=SKM+ D^QL"!)'[(U"/))(X')"1QJS$*/+,0%7P"P+*#5Z$F7?I%G1IB+)D8
MKP;B9-Q.FUMFPU@\IK!"'+'- E02$"R]=XG79@1T&2AI%@*8Z!+ADAR(HE?$
M6R;U4\ ^'"M#*L<O74T0/(*3U^E:TZ<I)%(I>&SN[,+AXIHV>'7PNKQN\[AE
MAHY#U65D1F3IR-_ ^I)=S+&Q#+(I[7BU\4B]K1L%DLN"'"Q@@]CH88D>(*
M*.""",P&$$(RV,(&(,TED844=E*&1QQV4(:89:0AMII"6VTI2G6M>;.[R.\D
MCM))(S/)([%W=W)9G=F)9F9B2S$DDDDDDYUBJJJJJH55 554 *J@<!5 X
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MQ\CKW/' .\V;S1]W,NJ)':9_[/Z(Z?Y.TV4W6&R3G_8WI]WHZ..0'CLM;ZU
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MIQ.P"B*G):IV6Y"2:8L2N<WM/A5+86?>=$;2+<1H#+/:Z?5H]E$BGP=]TK8
MM%!Y[YXX;5=0.4V('!R2&O)7J7#?A1_EUSQH6J-Z0@?R5XN!,VKD9#&TITV;
MT&I(3(WSD;KGN:^9.-'LU':>=4K5P&';WI'K8Z;U'4"B;HW9^K9=>_\ @YN)
M8*VU\^0NMN@QZ_<)QR42-JUTH!_@KL03P/VK=UI]/>U.R)25^U**22T_'CFU
M7^NS2;[F9EEKAO\ =E'M<NLVBM72"C;/3[#"6JMS Z2XF?KLH#-0LF*O>])(
M DXY\D(MG>];U\1AY:?=K:=[]=;UKC+56S2GEJW*\]2S"Q2:O9B>&:)Q[K)%
M(JNA]CPR@\$'VR=AFBL1I-!+'-%(.Y)8G62-U_%74E6'ZP<YW,&9,C7H_3X7
MG8L>PZ*;8;;8GU@4ZCP:4/V*T22$Z4ML1A2DMAQ@2-Z(F9T]3$5#B:V^61I:
MF&7^/ZMZSUW2<-6)X+.VWNVD:MH.FM8%EVVZMJ.62"-B$KTZZD2[#9VFBHZ^
M &6Q*&,<<G1=/=-7.H);#K+#K]5KT6?;[NZ637ZRNQX5IG +36)F'ITZ, >U
M;F(2&,@.Z:G2.8S1M@'Z?UXH*=Z VV\FNP0*G'ZAS  M.M.QU79?2GYZ>?:]
MK4Y<26D2$CM.Q $ 1:$CNP73?1FQL[2'K/KV>OL^JE20:G65BTF@Z+K3CAZF
MECE -G:2Q\1[+J"=!:MD&&JM2B!"\MNNI:<-"3IKI.*:CH2RG87I@J;;J6>(
M_38V;QD^C11N7I:B-C7K\^K.T]DF1)VSTW.'QC&,8QC&,8QC&,8S1^E=)H_'
MZ+9NE](L(=5I%0CE2E@GCTD.,!"_&:&92@<1D@TTPPP@8&/CP1B3Y$\D8$$8
M@LAEE>]K-9>W%^KK-;7>W>N2>E7KQE0SOVEF)9V5$1$5I)))&6..-6DD945F
M&O;MUZ-::W;E6"O G?+*_/"KR / !9F9B%55!9V(506(!B[QS\K.%>5U<FK/
MPZZHM8-;DF8FPAD14O S,(84TX^#]81$X$ <@6289?=CCVFG0#-C&,,$J*!.
M8&E>I.D]]TG9AJ[VD:CV8VEK.LL-B&=$(63TYH'DC+Q,RK+&2)$[D+*%=&;2
MU6ZUN[BDFUU@3K$X252CQR1LP)7O2158!P"48 JW# 'E6 L3G.9*XQC/FL\-
MNC<<G/I'"^=1;_67)NA]Z\I"^;<0F/)&%O,%Q'\+V>XF=7ZU8^0@\:K5QHSE
MGM$'(0@]9N/5KW"5QGN%"D(8PDN9%9CO3]W6NQ]-"R_R798H:H6[Z:QX);_I
M-1%2I'<-V6"<11.DAE@J5Y)32G5U"JQ:,@9#:[1W_2\A1#*&"%@_>W9Z892>
M."K.P7N'!SZ4\\PR3QC&:?(\\H$O;8>_2U&I\I>Z\(H" NLC684VVP8*]F;6
M%#V,D)V8C!%;D#]J&",895LXS>T;V2][\ZV;*0O62Q.E>5NZ2!99%AD8=O#/
M$&".WTKY92?I7\!Q:40L'**77PK%064>? 8CD>Y]C]YRG'DQXT^/<#RNSW&%
MXIS"*M@-DHDR'8X^E0 DT++;Z357]R3$DR"@IHW;RUN[)0[IW;BE*]WKO>\F
M]5M-E)=AADO6GA9)T:)IY"A3Y:4=I4MP5X\<<<9@EBB5"PC4$%2" .>>]?/.
M7WSG<V<8QC&,8QC&,8QE9?*_EMBZ-S%N:YWIIKLO(;!&]=XT6YM2$O7FGI(>
M_!<MQ"VU?4_08 B:H$XTM?P%1MD>?=0M0S?IT_26UK:W:&#8DG2[BO+I]T@\
ME:%PJ/FD'!_+:ZPL&P@('=ZE8*" [<Q&[IRVZ8DJ\"_1E2]08_?8@Y/HD\C\
MG9B,E:0<\%)22#P,E#CO4J[VOE](ZI5=O(A;M "3#096O8?$&JTH>7K\HUZ)
MVQ,5V88/@Y<?:=;'DX\IG>O5&1>YU5G2;2]J;?:9Z-AX6=/,<R>&AL1'D]T-
MF%H[$+<_5%(C??FW0NQ;&E6NP\^G8B60*?SHV_-DB<?<\4@>*0?<Z,/NR2LC
M,W,HY?\ U\@/*JF<F9U\US/QCU!]IZMO6MJ"FNOS#1:>(44G[6].;J@2)3K$
ML/KYAILY'/UOH;4ZG2NZU_'3_2EW;-].TZH]?2:H>.^#3PE#O+Z^#Q\W(8M3
M$WT,4-_M) \<[:_V3W->D/-34>GL+O\ BR7I WV?6/X^BO?<<>0&^6Y'G+QY
MPN=%E4_)7Q5K_D;NLFF6:0J<U6=&"L2 L>S+C&19[C#Q 9(#Q8&TO-O#Z<#+
M:+1IGXQ"7QRDK:TSX9\9/@;J/B_]BV+.YMZ+9:7YB&*W7JQWHIZ5IHY)J\U6
M2>MQ(LD2O!.DZ^GWRK)%,&3T_4/AS\4+_P /1LH8M;7VM/9&&5X)9WJ20V8%
M=(YHYTBGY1DD*S0M$>_LC*21%6[YWYS1(;F5'K-"@%$N1-8C&HX5\UQ+A92M
M+<?),*6A#;?QS"WGRG4LMMLMK>4AEMMI*$)]0Z0Z8U_1?3.EZ6U33O0TE*.G
M!+9=7L3=I:26Q.R*B>K8GDDFD$:)&K2%8T1 JCB.H=Y<ZDW6RWM\1K;V5EK$
MJ0J5BB!"I'#$&+-Z<,2)$A=F=E0,[,Y+'T=1YQ6>O<ZN?,;B+LNM7BO25=E4
M-[2DEAD\=3;4@ ZI*OEI2+)^!)11B-?%"DA!2V=I=90K4[8@2S#+!*.4E1D;
M\0&'@C\&4\,I^Y@#]V8]'N;O3VXUN[UTGIW=7<AN0$\E':)PS0RJ".^"=.Z"
M>,GMEADDC;E6(R&?$[H]FN'/)&C]*)T]V;AMB+Y)U9:M+;7,S-?'%?KM]':>
M7M]49TNFF0%W#(VE+6WY@\%K:E1[OIK:Z>22 Q3G_"JCFM8_RF0 I,.?/;/$
M4E!]N691^:<Z/K[34M?N(=II8^WIOJBG'U!H0"&%:M;=UN:EV3Z!/I-E';UD
MB<E^RO#*P F7GK3MOT3Z>,]ZD/,;A-B+Z#/5#H*^NPGCS9(U #4Z\[)$RMDK
M<%T$29;>8E4-&FDT!$K .B(F!(B,LADD"^:9OZ$J?%D[K01]&[ZNFO@N:\:B
M?J.M)ZC0 1K%6LSZ]H>&A)2-=AZ5@.86FDJI$XC0> 3=$C7[-M_K96LRP63>
MCU<J]HD)8O-%'95^>_AF-8/$5[PB2LRDMG<+R/K%+[;08+HU"D'#8*;;>;<&
M,84%-0,P"\L.;K%EBG=_,PUEKLFR3%3D05K3X1XSK>]K;VVZYX[N-1=T>PGU
MNPC"6("I#(PD@L0R*'@M5I1],U:S$RRP3+X>-@?!Y4=Y1NU]A6CM5F+1R @J
MP[9(I%/;)#,A\QS1."DB'RK ^XX)XSMU0E+=0C55O2=76IG1]YH;ROL]EMJK
MVY&.%5O>])^7FF4EUX[2O5*H^7+3O7VZWKS'XCZ"[ONE[!T_:O4>CLU.I>F)
M&_D[W22_-U("?(]+8QK/J;(((:I?G4^_([;HS;5M5O81L>3IMK#/I-X@^_5;
M-/E[$H_\Y3<Q7X"/(L5(B/;@XY_>N8U_B[/>[C9@:CSA%=C[#*3,LIW:8E)Z
MQQ-1;[ K3Y9,PW+D(@T180Q!Y,QZ1XHSI2T-*F=!U-K>H.FM5U36D]/7[375
MKZB0\R5S.B^K4F"@D6:MCOJ3Q@=RV(GCX[AQEC='[V3JJ;HZC2DV&[COST8:
M]?M_PGT0\@LQO(R1I5>LGS@L2ND253ZTCK&"PQ^$^1?&O):IDW7BMV"ND"!)
M.0\FXT%*1,C%2;;39'R<I"S@,;+@..CNMD#+)";9+95\45UY"5[3,5+M:]&9
M:LHE0,5;PRLK#SPRN%8>#R"1P1Y!.6=4]']1]%WTUG4NLEUMN6$6( TD%B&>
M!F9/4@LU99Z\H5U9'"2EHV';(JD@&;,VLYK-7NUUJG.*E8;W>)V/K-1JD45-
M6"=E'O@A1L<&WMQYYU6M*6XM7Y+0XS"'2C"7&1!&7B7FFE[5&C;V5RO0HP26
MKEN5(*\$2]SR2.> H'@ #R6=B$10SNRHI(PV+$%2"6S9E2&"%&DED<\*JJ.2
M3^)^X*.68D*H)(&=(_0?HVG?I$.GN^5_4YRP<$KUO=@0ZSR\>MM'WZ<Y=7@V
MPX2QW63DYEL.DW>WB>IJ((:"F&*M"?4X4FR;/(E%:]PU_P 2A\.M6.D]5!7W
M]BF)WL[0VC'KX-I8D,DU:E%' 7NTJ;_09VG@:U/ZSQLD!B&>=VND?X57#N[L
MDNMCG,0BIB(/8EIQ*%CEL.\@6O8G4=WIK&XBC**P:0,<[$Q_H\_"X8=@9OQ]
MI2FQV6V$;=5-.N;0TA+:=N.KEMK<<VE.MK<7O:UJ]5*WM6][WYRWQ$ZU=F8]
M07>68L>! !RQY/ $/@<^P'@#P,ZL=+Z  #[,K^ !Y,A/C\3W^^>[_0^O#'_O
M?*-_O9C_ -:Y;_?"ZT_XPWO^1_\ I97^#&@_X,K_ /*?_/C_ $/GPQ_[WRC?
M[V8_]:X_OA=:?\8;W_(__2Q_!C0?\&5_^4_^?'^A\^&/_>^4;_>S'_K7_K_X
MM8_OA=:'_P H;W_(#_5#C^#&@_X,K_\ *?\ SX_T/KPQ_P"]\HW^]F/_ %KC
M^^%UI_QAO?\ (?\ T<?P8T'_  97_P"4_P#GQ_H?7AC_ -[Y1O\ >S'_ *UR
MO]\+K3_C#>_J@_\ HX_@QH/^#*__ "G_ ,^4G\Y/HXO"*3YQ!/N28/C'+A3Z
MOJBUU:"DK:N<T0/[3X60J&Y#YR8&2RTV4T4 9'.11#:''R7!R'!"-2Y_=-Q?
M"&$[SK[=Q6=3>9:4-6]\PUF:T TJFA'KJ=NT[QH&-@BI-"L1!D,3&-\VJ?P;
ML=?R_9G2VLD2]54V99JYA6&. D(?FGN6((%#L0(@9T=G![%<!AEF_& _AOC;
MPRA<*X'(V[N[T''F22=5:-U(2I\I99 N>DI6U2+_ -65FC,$24BZEN+G)(,V
M)!T,&I@XIE;I'D/57]T+TYUWN9MQTW'<ZXV^UAK35]-T93DN)2K+!'#43:[&
MVU36:3M1$%G[8NU+2R,Y%3N*P#O]-\)-UTU12CNVK=+ZZC)+%-LNH[*5S9E$
MK-.VOIUA8N;3EBWH_9U:Q RJH^8[09,GO59[IT7\NY6L+C];>]-[J?-"$3-V
M?94G[69?H\J$@*+=TK6OB-5.OH>1K:DL6%7IIQ7.?8WQ+ZM^KJ#>5^@-/( 3
MHNCI5V'4<D9 )CO]7W:ZUZ3@CADT6I24!B(]J> QE/M+HGI_Z=1JYNK=BGC[
M5ZC0T]*C@_GU.G:LQFLH03VOM=@R$@%]>/*B1J/RGG_.DD.5.MAA21OY4G8"
MUD2]GF'-ZU[G9>RRSQLY)+6KU7O19SC:5J5MMM&E;UG7=-=#]+=)"5M'J*]:
MY9\W=K.TM[=;!S[OL-S>>QLKC$\MQ/9=%);L502,Y_==4;[J$QC:[&::O!XK
M4(A'5UM1?/"5-;52&E64 \<Q0*Q '<S$<Y(>=7D!C&,8QC&,8QC&,8QC&,8Q
MC&,8QE6JCYJ^,%[[/)^/U4ZW!3'5XHJ4 =KC(<TT,9)P;9#LU%0]A)C&:W-R
M<4T(6X:!$RQA+:!#%);7H(OX$?'M*$UIJ<=A6L*64IVN 63DLJN5".R@'D*Q
M/@_@<[G8?#7K?5=-P=6W]!:KZ&Q'!,MQI:K/'!:*+6GLTTG:[5AL-)&L<MBO
M&A,D8)4RQ=]I<D,X;&,8QC&,8QC&,8QC..EH>)GHXJ(G(R/F8HYI3!L9*ACR
M !;*O\)HD,MMT=]O?]*'&U)_I],U+U"CLZLU'94ZNPI64,=BG=KQ6JL\9]TF
MKSI)%(A^]71A^K-BK;M4;$5JE9GJ6H6#PV:LTD$\3CV:.:)DD1A^*L#^O($=
MXI/TC3A'#KF[5@M_$4[S6Y(,MO,#4KUOWB@"OE:L%,2]O:O<NNR:HQOU^V ?
M3[D*\Q/P[VW3#&Q\,NI)=#$C&3^".^%G>=&S'GN].G$\R[?IPNW)]33W33C/
M!^RI."I[C^&&OW@]'K?31[61@$_A#J1!J^I(Q[=]EUB.NW(5>%[-C6%EQX^?
M0\$4+[!67>'PW0>H\I@[AXE=R#@I^R#0--V!:?%WO5ICH\DX*"FX,@1-,C9Z
MTOLJ $FW8OG%T'+D?CN2,LZE3:_0M#\>(*]W5=,?'G1'IRA+:K4(^J=M.]_0
M5(994A-C5=>THXI*<4:L)VUG5%>B!'&(DA;M+YR^T^%\MBM=W/PNVJ[RQ'#+
M9;248A4W,CHA?TKW2MAW6T['\E\YI)KG,C=[2*" :A^ WEW])%:.G6&@WZN!
M]H&M<*]/Q\E;CZ_61.=&-%LM.R:Y"E01#;D(KYQIDVKR.H[:5-C;@CQ3=JC)
MF2ZY^,_P&ZPTPJ_W/^P3JWKJ+8_9,.HK4][KM77JE)#-U-U+:WU>G/%TYK2B
M=VQU$=^ULKMFGJJ\#2WH[=/4Z<^''Q,Z?V!L?%6J>G^EVJ"])L);&MMW9YN]
M?3TNGAUDMF.3<W%+=M2\]:"G7BL7YI!'5DAF[':11?/6N3$S;2Z?XERUZL2U
MM2UUMG5NO3DLB+0\MT* @XN*X["QM<K@.MIVW"QA>D/D:V6>6<5[7]6=&]!?
M#KIU[&\WW4'6?576^VAC7==2/HM+23L4EUU6CJ2[NT--H:TC$UJ$!+2L/F+T
MMFTQD6G4?5?56X2'5ZO5:'1=,:]W;6Z5-CL)V[V^EK^SL)0B.RVLR >M;FX$
M8YAJQP0?0934-](43KT3,>&L-O?_ &WX.]LL?L]?SZ]-V>L?$]-_FWZM>[^I
M.=X&^':^\/6DWX#YC1UN?/W_ ."V^/'/@<_MSE".J6]I-!'^V+8S<?\ +0\\
M>?PY_ <>?**9Y\':]3N_>,<#O?YT07C;T*6TC_P'9GR)8VKT_H]S6M;_ *=?
MT8-WH"/^+Z?ZHL<??/U)KHN?VB'IYN/Z#@5^I6'U[+41G_S6KLN!^SU-B"?V
M'^O/#G(O-(O7H1YET6/]?S[@?%.&'6GUU]ND*GNNV1&_3?YMK95_EUO W'1*
M'Z>B[\@_"QU9.W[.?E]16/[?.4-#J!AYZ@KH?O\ 2TL0^[V'JW91[^Q(_;A/
M _*4A/MD/.V\-^[7HO4#P?@48GTW^?X>Y6H6)YO_ ";^,M6OZ][^W!W_ $HI
MYCZ#HGCV]??[^4_T^E;KJ?W<J-9N2.'ZDL<_C%K-;'_5WPRD?U_UYX1XL]4+
M5M4[YR^4I?N^W:8,7Q_K*/7?Y_;H/AY"DI]?S:2O6]?FUO\ IW4]5:E!Q!T+
MTLAXXYG??V?^?NU'.4&FND_E.HMP1^$8UT7^D4&_^WC^GV*\/SW]>A_EOYDG
M:W_A>WK%:A]JU_3]M;YY";;_ -UK;>]?T;UE!UC&O'I](=%IQ[<ZBS-_7\SL
M9^?Z><J="S?G;S?MS[\7HH__ .35CX_HX/X<9ZD>$=-=WO<OW3S"GDJ_PFS_
M "K[$$UO^OT:KUD@VT:W^?T0E*=;_-K65/7%P?Q.AZ-KG\8NE-.[?UV*\YR@
MZ=@_E[/?2_J?<W>/ZDD3_1C?@/X[$J^),([38W=_X3EC\F_(^7^)Z^GK\1HK
MJ:F%^OI]OJU]O]/V8_O@=1J.(3I:P]P*W3'3</;^PKJNX?UX/3.J8\R"_*?O
M,FVVC<^>?(^< /\ 5FB]2^C&\3NE<^M%(:ITS5Y">CM#Q]P$NMYL$W7Y%@A@
MT&4$8MEFFH\O;)8S.RA"QU(,$40-\4=;R2&M[5?%#JW6;"K=-V&U'7D[I*;4
M:%:&Q&RLCQ.U.K!(G<K'M=&!1PK\,%[3KW>C])<JS5O0EA:1.$G%FS+)$P(9
M743S2*?('<K AUY!XYY&7X%> =-\%*W?(^$NTQT*S]'D8,FRV61B1Z\)]7U=
MN8;KL7&0(\A+_)H#W8)AXPIZ5,>/?+3O>AV1V&$6=??$"[UW9H23T8==5UL<
MZ5JT4S6']2T838EEL-'#WEA7A5%$*"-4/EBQ.5Z9Z8K]-PV4CLR6IK;QM+*Z
M")>V$.(D2(,_;V^HY9B[%BWW  "_N>?YT^1SV+XN^1]3^#T8?CKW\G-W^%UP
MM$8X)RQW\&9/X?1B6YH@2'6/2%>EF>1+%BQBFXQ23R&!=NNIV:7'SE3FL;H^
M9@YI@L#;'JIS6!0,X,_\4"BLW+_2">!EK_FM]79]+?7X^GP?J\^/I]_/CQG0
MA]&C:N_6#RL4S9^N>3WECSIBLSZG_+* 9JU:\3;RZS%%L1L/-PEV\7^7WB6E
M@R%#OUU_D?<^T5EJ0(BBC9545J4T)Z)U3'KH]1^2HZC3V3+%QJ',\NY@'>"T
MB/#MK=9$8<B06Z%*4J'"H'[.8ZKZAF\O-,O!)E^D0GP0 0T*,6'CCM=@.?)\
M$9]&N>99)XQC*M6+RTYG$]NX[PV+DH>=L75I&R!%/ZL<;$OU5J'KG0):(?W!
MR"4RUB79IGFEKK@:(EG0L>3$E/29X[S\(!-RD>ILM2N7G5DCJK&5'87$Q>2N
MC@2(2D?I):AD;O/)#J%4\.4Q&91(D8\EN>22!V\!B/!X)[NU@.!P./)]N><\
MKO\ $/<?\XT/_E$J>4T_^V-?]D__ $>7$W\6W[4_YZY8G(S,N,8QC&,8QC&,
M8QC&4;YQ_P#D^>45TXT_Z"\R\DMV#MW'?7VH#A>IQ_RRNZ\]%_/II,^@B+ZQ
M!!(TTUMXWH"F$*T(KV]ULO\ OAZ6I;I?KVG3?R^CW/N7GU4G?]@[%_Q]#MEU
M,[GEN(Z'<?K&<[4_V+W%B@1VT]MZNQH^P5+B]OVC67\/4!2[&OXM9X'"Y93M
M/5J_Q#E=YZM9D//Q5+@B934<+]I\Y*+4V% UN+1[5;>F++.E1T!$,:2K;\E(
MBM:UO:\YG2:FQO-K1U-4JLMV=8O4?^+@B +SV93XXAK0))8F;D=L4;G[LEMA
M=BUU*S=F!*5XRX1?SI'/"Q1( "2\LC)&@X/+,,COQ4Y5/\OY6T1?EL%=?Z=.
MRO6>SR+'HIM_H]V4R=*1(CFE+UN'IL>W%T>OMH7MEJ#K8&FDHTK>LDNK-M7V
MFU*:_N73:N"+4:2-N>5UM$%(IG! _+79#+>L$CN,UE^>>!FII:4M.D&L\&]<
MD>[?8>>;5CAGC!_Q(%"5XP/ 2)>/?+*9S.2^,8QC&,8RD/9?]07R$Y[Y%C>@
MG/\ J?U!P'OWM]K04>5(2;Z>&].D-ZTTRWN#MLH5SF:E2W]Z;A+Q%;6A;,,Q
MMB*M?X'=AO#Q#8[*=S\%+-_@D[?^A(Q@=B?"3*?9,]-Z<_[ZND=OT?)S)MM%
M\WU9TGSRTDJ10H>J-)".69OF]?!'N*M>).6M:N< AK+=UWLE<\RRB/7*G9/&
MF_SOE!R.%D)V@V9QDORDX[!#+)(F@0F4,:[MSN)8UK6NDU6/:UJZ0PJ4HZ-5
M1E..IU:8:/,,[S46ZW4VO@Z6V\T<&PJADZ5W$[!5AD=BWV#L96_\6VY"?DIF
M/.MMOP":LTD:<W>AEU%F3<48WEK3$-N:,8[C(H 'VC50?[ZA4?X1&/%J$>>)
M45S+MV\M>$4FL4VR[NC%Q?Z7%B2W+J?SL4F[W[I@A[/QPG*53H)!,U*,/)_(
M?D7AQ(B,<TI,O(1_L<VG@=HQTUJ:CL8Y:]^&62!Z)C9K?K1L5>-8%Y<D,""W
M'I^Q[^T@YZ-TMTMM^L(GN::*'[(@C6:[O[MB.AH== X5A+>VMDI6A^E@RP!G
MM2#D0P2,.W.O6V>/_5_+ &Y>//2I.0\8.77;4UW&G<UU%5:^7@LPZQ)4V)/6
M4:4W P,76+7H2X3'/ZPVN53NWHB57E @RM,^']-T[.LZLZIZ"M,=9J=LT_7_
M $I7[(I7$&SMB/J36JZLL42:W?NNS%2!>](-^B>OZ<8"^^0=6:'HF'3=<Z2"
M+KC?ZD5>C=UNOF+VJUD:UZ7Y">M2>O\ .6I]CJA+JJ^XO'T&.I:P-6TC_7OO
MC/\ 1>.>,M3DV*-Y3=FK?1)N20?+VBD@U",ILFR$RXQ#1TMS&YQ'08.79C$D
MG.:-+-3)N.'D)&+!'VEC7J5'0FC&PBV%I)F;N:2(1K$P X17@E69'"\D\D]W
MD@$#.:ZT^. ZUO0-M.A>F[FGK0F*O1V<NQGV,#2LK69J^[UMC46:S3F.$&*.
M(PA8D]2.5OJRPDB]YO\ )HXV6.LGCKWVHP0A,E*&V9BP>.MU;B@V%$FEES@3
MW1N<K4&.T\^\01$5*.TTA;K[XJ$[])"*'=^I'# M;9O)(L<42QRUK4KNP5(T
M$8L1R2,Q"JJQH68@ <D9QCS_  IV:O)-#U5T3,06:2*>CU7I8 H)9WCL#2;6
M*(#ZF/S5UT \!O?*6C>2:_(ZXT7JOD9QGMO/?%*IL15SYI#1?.;3U"@]'O8Q
MA.A>F]0GZ'$2I6J35'Q63.909]<'A9PDH6^211+"84%CT*]M(N@:4FH$,R]6
M["J(]]L:Z&Y!TY5G!]70T[58./M.1.%W-R-2E=6^SZTK,+,F<;K>@I^NK,U[
M1[[I[9:2AL)8='J[^UJ]/;CJ-H.PQ;S[*W4U4'7NQ;[,J-::U*8VLV*T8-=6
M[ 1_-[Q6/1"/1/9JM-BSKZQ6#(3<A+"QI#;B67&+$\"$\FM$-.+1I\6>^KRA
MFUZ((9:&TI[7S_U-\9/AMTAM=?I>H.J*='8[)4>*$0V["5XI',4<VPFK5YH=
M=#)(K*LEQX1VJTK<0H\B]K%\(?B/*EQ_X*["'Y)>YTLFO6DG';W#Y".>9&V
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M>_;'.K3K\[?K]F5/Q*V%HE--\,_B-L7(^A[FKU/3=8_AWR=2;K66$'X_X(Q
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MG3^.U=Y/?ZHOE[*^/O'I3>IY_P#R8/ZL?P&TEOSI_B1T;:''(BVOV[T[8Y_
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MJ>Q3J7<[*=&^FH]+IPWX*M:)E)L17K]*660"*18X@S&XH]<\A;"PP*=;.?\
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M>8%))# BAT%O,,*,TZ\T*LL5)#C:%(942.EQ2=O-Z57[%VQ!8:ZV5! +>B_
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M?=;WJL\<5;91N2'LUH8HAP3W.EZI.P) X7B.)SR> 2./<@9C=27B(]E9B?U
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MJHVF#HI89=9$+W9Y&V( -+CVH'4;9)&LE Z_8-.Z?.^G&:B/ZZLI6S4[S'V
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M0#VR6[H2Q^E++%W*_I2/'WH'"/V,5[D$B1R!6XY4.B/P1W(K<@9%/<H;@CD
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M+/L#;A4/<-7MK)^IORHYY/Q+0TEP&O&SK?/HVFKL9Y-.+D7GXJD#4L33SO\
M)JT^J&;?#%M3!22$]#$E6M1HW0VXM#"63WX74!J49<0+%ZC&(L2L0B'/^#@]
MO@2 @B<..!/VXK=![FI9:2#J^[%4;<S[,48DV4<"I8VC[.3M'VXR_,LLLFO:
M,H=+) QG?2FPS$\!'^5+8O(:=RV1YE7+(NC+B6X29L;HDP&Y&,S-ZG9J$EJ\
M?"D"2D2?)6J-D8<,DG;==E8Z<D6-&.V@A(%!L.*L=8UXW]+M['<AAP'E=U:,
MIPRLTBLH)_)NKL.?4(7;EZ![^HMEOH=Y=I#:BP;5:DLE:43M6U-6K:KW8;22
M5[,,&OF@LRI'W7:\U6!_26@AFT#JO;F^FT/GM1=KBXLFA2%U(!*9D@VH*/AK
M;*,R[=5K%5AX.$C86(C)#1I:"2UR\L\DP>-2:/&108ZL%JWZ\$410J83,0>X
M!%65N[TXXU1%15;D\GN8\A>0J@&7T'2YT>WV^Q6Z+";>+5I*CPRM;FLZZNU8
M["_L+-NU-:LSP^E&4C%:NIB><Q//9E<?:3UC@C?DCX]5KEQG2+ES2&FJS$,6
M*0I,#RB?DIZO2E).KLO6B6.O<VZ="1XAX4VZ2B7A(>+M$=(! NQTZ,+L\(_W
M+3; ZR6"VM:&R\<41C6>2W&J2(T<J2 T[-5V*M& 4=WB92P9">TK^2^[C]79
M[-"Q4'8W>2 I)'S$H(^I6'W^X 8'@@C)[YY1:_R^@4?FE29)&JO.Z?6:+61S
M2WI QBOU*%"@(9DL\E2B#26HV/&0^60I3Q+J5O.JVM:M[P6;$EJQ/:F(,UF:
M6Q*54*IDF=I'*J/"@LQX4> / \9HJH154>RJ%'[ .!_H&0#UCQ,KG9NV\C[#
M<NAWQ<;QBRUZ]5+ED=&<M#I[E^JPUJ#A+5(VI7-WNRK^ Q;Y#YJL!=1!IL@\
M)'NE5Y?_ &31)R-3<2TJ%RE!6KAKL4D$UIFM--\O*8FDB6'YGY+DF%>V8U3.
M@+!9!])7&T*O(LC,WT$$+]/'(YX//;W\>22O=VD^XRUV1&9L8QC&,JAX\>)=
M:\?KMUWIFNA7SJ'1>THHX-OM=XC>7U]Q,#S<:P#4Z%CZ_P @YQS"I)W'ZM,Z
M^=.FP!UFFGS4)DIE\0&.$#E]EN)=C!3J_+UZM:CZYAA@:U)S)99&FD:2Y9M3
M'N]- L:R+$@'T("S$X8X5C9W[F9Y.WN9@@\+SP.$5%\<GSQR?O/C+7Y$9FQC
M&5M\I/&X#RGYF;RB=Z/=^>U2>:EXNWIH\)R>8-M58L$%)5V:KA3W5N:=*9@D
M%1TH3L6PU$>O6V+)]KL?/,(VZR[*:G:-J+2W(ZT%F:,H\/KR7$6*6.19(Y *
MEJL9.&0=T<QEA=>0T9\$8I8A*I0L5!Y! "'D$<<'O5N/!/!7M(/WY.M7K<33
MJS7:A LNC0=5@HBMPH[Q+YCS$3!QX\9',O%E..E%.M!BLH<))=<??6G;KSBW
M%*5N/ED>:62:0@R2R/(Y "@O(Q9B%   +$\   >P'&9  H 'L  /V#P,YW,>
M5QC&5/;\2JT3Y21OE79.A7RU6BJ05P@.=4H^-Y=#TZ@#7^,JT3;W0I*H\XKG
M1[>N2#J,:@)CI-^N@4&H@]40*)M0.P)<[B4:EM1'7KQ12R0R69U>T\U@UVF>
M$%9K,M:#M:9^XU:\!DX7U"W![L/HCU1*68D!@HX4!>X -^:H9N>T<=[-QYX_
M5;#(C,V,8S5KQ6R;C3K-5 [)+4\JQ0DC#L6B!!J\I,P+AXS@Z9..C;M7K94)
M H7XGQ&PK+69Z$)WK;,C%&C+<97F@E$$T4QB2812*YBD:5$D[2#VLT$D,R@\
M?G12QN/=74\'*,.Y2O/'((YX!XY_4P(/["",B+QG\;ZEXOT"7HM5G;):W[1?
M[MU*Y6RV-58*8LU[Z#+JF;+,+AJ)6:71Z\*\1MI@*#J53@(8(4=KV!+,=,,*
MV]ILYMK92Q-'%$(J\%6&&$RLD5>NG9$GJ6)9YY6"^6DFFDD8D\MP HLBB$2E
M02>69V)XY+,>2>%"J//W* !^&6&R.S)C&,JAY$^)=;\E[%S<Z]="OD;3.?6R
ME79_FE=C.7-P-OL?/+M$=!J9LM;9OG$YUBNI$L<%%*D1^>=#IC,U&AIC9%+S
M#Y>R)?6[B75Q6EKUZ[3V8IH!:D>V9(8K$#UYE2%+,=.7F-W[39K3F-V+KP0.
M,,D(E92S-VJ5/8 G#%6[E))4N/('/:PY'@Y:_(C,V,8QC&,8QC&,8R%N^\=>
M[KSL_GC?1;7S)F3)2J0GZ?7N56>4+C' 3X\^%>C.P\ZZ?4M!GCR"W%%M5QJ9
M$*&$> DQ4))9*WM==&OLK9^6AM%!],<TEN) _<K*X>G9JS<J5X[3+V,I8,I\
M$62)ZBE>XKS[D!">/O'#JP\_LY_ YLO(>757B'*.:<9HS9[5+Y/0JESBI-RI
MSDG*(KE*@0*Y"ID9%U*%G':CHX?YLI2&_CO_ !'--MZ5I"<5RW->MVKM@J9[
M=B:S,44*IEGD:5^U1X5>YCVK]PX&510B*B\]J*%')Y/"C@>?V#)$S6R[&,8Q
MC&,8QC-?MD&]9ZM9:T--R59(L-?F8-BR0HL";,5]Z6CB0&IN)"M4+9*N7)1*
MR$G@"V2NST"04.TU,0LI'K(!?R0R"*6*4QK*(Y$D,3F14D",&,;M"\4JJ_':
MQBDCD )*.C<,*,.X$<D<@CD<<CD<<CD$<C[N01^((\9"'C+XT5;QAJ5QKE>M
M%JNTKT7I=FZY?+?;QJ9&2EAO%J$AXZ2.:@>=5&B46O1[497X<$2)K-3B TI$
M484@N3,/.)W]IM)MK-#++%% E:K%3KPPM.ZQP1-(ZJ9+,UBQ*Q>61B\LSM]7
M:.$55%D40B4@$L68NS-V@ECP">%55 X    'C\>3EC\C,R8QC&,8QC&,8QC*
MHQ/B96Q?*!?E5/\ 0;W<+A%U:Z4ZA5:5C.70E3Y]!=#*IYEO&CS*1SBJ7NXN
M'N46OM1SO4+I>E0 S1;<-\HX8Z]DN^XE.J^R(ZU>&!Y8)K$J-;DFL25A,(2R
MSV9J\':)Y"XJ00>H>TOSQQF$0@2^L68L P4$( H;CN_-4,WL..YFX^[+79$9
MFQC&,8QC&,8QC&,8QC&,8S&,$8/$*!*0IP4T9\0EM+CK*EL$M*9>0EYA;;S2
ME-K4G3C+C;J-[]S:TKUI6JJQ5E9?#*0P) (Y!Y'(((/D>Q!!^\<90@$$'V(X
M/[#E3?&/PCX9XAS_ %*9XF/=HB/ZHCG0IM5L?0+9=JY5(SF%213JQ#TUJVR<
MQ*Q<<U&)5MUHR5DW&4_+1<<\!7XN'AX^8VN]O[F.HEXUW:G\R5FBK0UY)6M3
M>M*\WHHB,W?]ZHG)Y=PTC.[88J\<!<Q]P#]OTEF8*$': O<20./UG\!XX MW
MD-F?&,8QC&,8QC&,8QC&,8QC.!M4&Y9ZO9*VS,R=<>L,!,0;5AA6(4F9@7):
M.) 1,Q(UEB+!7").+41HX!B?@9N%=*8:;E8B2!4^$]DAD$4L4I1)1'(DACD+
MA) C!NQS$\<@1^.UC'(C@$]CJW#"A'((Y(Y!'(XY'(]QR".1]W((_$'( \4_
M%>F>)=&M=+I]EM-M7>NDVCJ]KG;2)289PRW6UF+&D]PU4YI3Z!SRH0B!X<%(
M\'4J?"@[)T9*&(+EI$\XB1V^VGW%B*>:**'T*T52&.(SOVPPERGJ36IK%F=^
M7;F2:>1N.U%*HJJ,<42Q*0"S=S%V+=HY8\ \*JJJCQ[*H_$\GSEG<BLRY\71
MGAQQ-192E=DZII2B7U*UKCU15K6]NJWO6M[[,G>]:WZZUO>M;W^?>M?FSX(D
M_NFOA]'))&=3UB3&[(2-?I."58J2.>H >#QXY /ZAGZGQ=5]9>G'QT_TOQV)
M_P"5&V'\D?=_!(\?LY/[3F/^)MQ+^V7JO^3_ %'*A_[9_P#FRS_NG?A]_P $
M]9?^SM)_UAR_^%?67_%[I?\ ]Z-M_P!4<\?B;<3_ +9NJ?\ F<J/_MHQ_P!T
M[\/O^">LO_9VD_ZPX_A7UE_Q>Z7_ />C;?\ 5'//XFW$O[9>J_\ F<J'_MGQ
M_P!T[\/O^">LO_9VD_ZPX_A7UE_Q>Z7_ />C;?\ 5''XF_$_[9NJ_P"7_4<J
M/_B__;/_ $?]?3'_ '3OP]_X)ZR_]G:3_K#C^%?6?_%_I?\ ]Z-O_P!4<?B;
M<2_MEZK_ .9RH?\ MGQ_W3OP^_X)ZR_]G:3_ *PX_A7UE_Q>Z7_]Z-M_U1Q^
M)OQ+^V7JO_F=J'_MGQ_W3OP^_P"">LO_ &=I/^L./X5]9?\ %[I?_P!Z-M_U
M1SQOPVXEO6_]67JOYO['*A_5_P#UG_K_ .;_ "X/]T[\/2"/LGK+S_\ N_2?
M]8<J.J^L^1_WO=+^X_\ *C;?]4<^R:ILO"5:M"LI;>9&K\,.T\ZZIEUUIF.&
M;;<<:0P\AIQ:4Z4MM+KJ4*WM*7%ZUI6_O&E,EBG4L1A@D]:"9 X <)+$CJ&
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M\,0RM;3S:T*VG=\<DD,B2Q2/%+&P>.2-F21'4\JR.I#*RGR&4@@^0<H0"""
M0?<$<@_M!S"J--J'/Z[&4^AU6MTFI0C*QX:K5&#C*W78@=QYPAQB,A(84*,
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M59E965BK*0RLI(96!Y#*1P000""#R#Y&" 001R#X(/L1^!S\1T='P\>!$1
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M#^/^VUW_ .M[?J]OOQ^.1Y2?VY7_ /X7_P#=8_O.?"?S_P#AST7R/N/3FL'
M_$\UAR?P]_V>?#^'W6__ !LZ@_\ :MS_ $_EO/\ 3C\<CRD_MRO_ /PO_P"Z
MRA^#GPH]O[W/18__ -=U?O\ T5N>//L>>/V^,?P^ZW_XV]0^_/\ MM=_^MC\
M<CRC_MQO_P#7_P#G?^K_ .R_Z_\ BRO]YSX3\_\ ZN>B^/\ ^W=7^(\_^#>
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M(YXY\^_'W\?CF;\D'^JC_LD?PY;C'R(?ZJ/^Q;_AQC'R0?ZJ/_7_ *TC\_\
M7_@XQCY(/]5'_8H_AQC//R0?ZJ/^R1_#C&>/D@_U4?\ 8H_AQC'R0?ZJ/_5_
MK2/S?U?X.,8^1#_51_V+?\.,8^2#_51_V2/X<8Q\D'^JC_L4?PXQF&*[!&OG
M#!/119,8^D62'%=%(?CRG&4$(&.::4MP1];#K;Z67TMN*9<0[I.T+2K=Q5E"
MEE8!ARI((# $@E21P0"".1R.01CD'V/MX/ZC^&9OR0?ZJQ_5_K2/S?U?X.6X
MSQ\B'^JC_L6_X<8SS\D'^JC_ +)']'YO^U_HQC/'R0?ZJ/\ L4?PXQCY(/\
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MWRLMNS+7^8<R6/1DF=HO7D9G9Y>PCU&9W9FY+.Q)8Y8PRQHK<=RHH;M "\@
M'@#@ <^P  X]@/;);S3R_&,8QC&,8QC(]ZU!WRS\MZ-6^76T*@])L%(M$+0[
MS(Q>YH*G6Z4AC H"T$1&G6/K)$#)OC2F@E.:;(6*EMU+C:E-KV:4E>*W6EN0
MM8JQSQ/8@1NQIH4=6DB#G\WU$!3GW /@@^18X8HP0A7*D*Q]@2/!\?A[Y2SZ
M,_QBZ;XE<7Z-RGI 5% 9=[]TVV41JAOS)0!%%GUP^XJ2D29^9G)AV5E2A#Y
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M+?\ 2,?,>WT>PX_._;_D_K__ $8]#_+_ /A__.SPJK_9O_3W]&__ -6_R?\
MUC*_,_Y'W\^6_P!'YO'X^>/O\<>>0@X(/=['G\W_ .^?T2J'KVT:F)]?7VU.
MNZ]?S>OI#AZ]?_1GYT[ \W[Q_&Y9/_+/GU15'%6L/PKPC_DUS:\T\V,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
=8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g210084g12l01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g12l01.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[14B4&AO=&]S:&]P(#,N,  X0DE-! 0
M    %0:^4X(X0DE-! 0       \< 5H  QLE1QP"   "YH  .$))300E
M   0G((_CO'5'93"!:35(C7,[#A"24T$.@      Y0   !     !       +
M<')I;G1/=71P=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !)
M;G1E     $-L<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E
M<DYA;65415A4     0      #W!R:6YT4')O;V93971U<$]B:F,    , %
M<@!O &\ 9@ @ %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L
M=&YE;G5M    #&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[
M  (M    $     $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P
M=&YB;V]L      !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L
M      !#;G1#8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%
M;6Q$8F]O;       26YT<F)O;VP      $)C:V=/8FIC     0       %)'
M0D,    #     %)D("!D;W5B0&_@            1W)N(&1O=6) ;^
M      !";" @9&]U8D!OX            $)R9%15;G1&(U)L=
M     $)L9"!5;G1&(U)L=                %)S;'15;G1&(U!X;$!Y
M        "G9E8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S
M %!G4$,     3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M                4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0
M<FEN=&EN9V)O;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O
M<%)E8W1,969T;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<
M"V-R;W!296-T5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU
M  (  CA"24T$)@      #@             _@   .$))300-       $
M'CA"24T$&0      !    !XX0DE- _,       D           $ .$))32<0
M       *  $          CA"24T#]0      2  O9F8  0!L9F8 !@
M 0 O9F8  0"AF9H !@       0 R     0!:    !@       0 U     0 M
M    !@       3A"24T#^       <   ____________________________
M_P/H     /____________________________\#Z     #_____________
M________________ ^@     _____________________________P/H   X
M0DE-! @      !     !   "0    D      .$))300>       $     #A"
M24T$&@     #-0    8              GP   F9          $
M                 0             )F0   GP
M 0                         0     0       &YU;&P    "    !F)O
M=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M $QE9G1L;VYG          !"=&]M;&]N9P   GP     4F=H=&QO;F<   F9
M    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90   !(    '
M<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O<FEG:6YE
M;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E
M;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0
M     %)C=#$    $     %1O<"!L;VYG          !,969T;&]N9P
M    0G1O;6QO;F<   )\     %)G:'1L;VYG   )F0    -U<FQ415A4
M 0       &YU;&Q415A4     0       $US9V5415A4     0      !F%L
M=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL
M5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z
M06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E
M<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI
M8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M"FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M  MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_\
M #A"24T$$0       0$ .$))3004       $     SA"24T$#      *GP
M  $   "@    *0   >   $S@   *@P 8  '_V/_M  Q!9&]B95]#30 "_^X
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MP]-UX_-&E*2%M)7$U.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ<
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MB6U!GBS>E(9)5CXB-NJR%LQ G";Q.*<#4@#(1"H!!&\0Q?0G'S@A(Q@;S-S
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MV8%(TD9NSO)#+G/N@4*JJ(M",JW/Y"N;[)M5TFY"/5U;*GF_42.B.W(*.$4
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M]O1DZ5'#H.VAQZOU0./FX^/X<3VJO6.6?FG[O+QTXC>/EG4 ?'1GJZ>FG#L
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MO%9#HC?-;\TD\Z5@G='=8962/>WV$;%5W/GY., K^<.8YFN.9Q;25\ML/7[
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MH\[.37:D(Z*Y3SK^RNVO8[RTAM[A393V3PW$AC5..ZNLR,()MY.Y"S1[JLZ
M -T5CP20B!X)9)8P)XIU:-%<L8P5"'?9,$:%&R2#G(R:_>:ND/#YA1J(,F#Z
M*D%LU<XK^\;*=CGCVL=F*XIKB'CFKI-8%G+N/- R*<B=5DT1'KC55N=85UDV
MS9FRVL927*2J-F;+LU<#$CR6*W".[ @E5:.6/=RS;VZ0V-Q<S=W,=PNZ X;M
MF[G88R%2X:-D4,.;#<.]H!DZ9S@7G$:0>6#*S9&7AP_O0RV632A1M@KB-3@5
M(U^A5YQR_DW<78CWM%RHLNS<_P!Q-'=::$573ZTX>-TS]?+A2[.VBT.V;,16
MO VC)?RQ7!N)%D1KF)$B66(VK (I3#,LNHR0"=#<$]LLEC.7E$EJL"O'N1,C
M+"V6*R"7>+$?-4+\[0X.15JSFD;"6'(^,H3]A)#?8VU5<3V$@MABY2C5""ND
M?7FCXPN"O1GHE2X*Q*"H-#MUJW&Q#8SE)6,(1QE1;)E@VS)?1N@L)K>Z/:I;
M#P7ES/;R3&,8UCG6U24@'N)GDW05.\:'N4EL4@;)G22,<4# >&*&5(PX)SOJ
M9F3D/Q83>U!S@GAT';A\8?+C>;@[SV?N]]:_=7^EZ#[J<.@[:/C^O#='>'Q:
M?N]U-U?Z7H/NIPZ#MPCX?K#R;,"@[P^CQ^3XZ<TW5_I>@^ZG#HO;A\?UX;@[
MP^C]U-U?Z7H/W:V,T8K8#^_2Z(*[K<U!^IM$?W,U $UZ@_QG,&.>[)5 L(B
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M6-;RRG=&_+2$T@4W=)RWS2TFJZ]LQ1E6T$C6)YNG6,JKI(IC$BZ:PLJ21?S
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M-<5O/U/VS&?YR69+K@FW.64PIJUZ^*TTPNO4'_;U#Y,<AV:P;FR(64'_ %E
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MX4/?CT"F9.\/JM3AB?T9_%^=APH>_'H%,R=X?5:G#$_;#^+X=O+X<.%#WX]
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M',&B*KEX\=K)-VR":BJRA"$,8*XXY)9$BB1Y)9'5(XXU9W=W(541%!9F9B
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MU:\L4^3QWO\ S-XO?[.G(IOP'HQ]MR<G+T[N)XX[]OW^7'EZ-?%C5\GCO?\
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MEA)ND#4@5&ZQ(&Z<M\T8.N>6.OS59YR'3.9-0ATU$S&(=,Y3$.0Y!$IR'(8
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MW1<M==N3A+N81W<J/Q(%N(5WEG2V=%>VC 7<*JF'4[IOBXDW=SN2N[NC*@E
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MS,]KL^TGM;65P[NQ>:21Q'#$2!F;(K86P=87<,K;P>-(C(H W@ [NK'E@=R
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MZB5E",+@^O#=L=C8&H)2<[482)<N&L@@S?N3(I"XLS6$T-O9W+%2M]_,(J7
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MUYW3W3.&70NAY"7O]'BQ:5-29>M']NKK1\V;+R[$BUQ=C[1<X6VRW%FA93+
M&CD@BN)I5E4R@PA8[6Y?>F"*RP2%"P7)I[9AQO;X(W$DT#?,D(52--<NRI@9
M.\1IC6LU)*E6236)NP(JF10G7"'2/N3E Q=VDH4BB9M0ANDU"%.0=93E*8!
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M6((8P7"E54]WK@/*XYC [J5M ,  !0!G.QR**;=%)!(# FBF1),#'.H8")D
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FU/3"J1R;R?:*856O,?[O^ U<E7_7!;^!J?[=OA4-R/\ 7/U5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g210084g13m10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g13m10.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2*P4&AO=&]S:&]P(#,N,  X0DE-! 0
M    (I2^B%(X0DE-! 0      #,< 5H  QLE1QP"   "YH < @4 'U9%4D%?
M,C%?,# R-%]B=7-I;F5S<W-E8W1I;VY?=C$ .$))300E       0HEX>51N@
MZE>Q,O7XL/5'.#A"24T$.@      Y0   !     !       +<')I;G1/=71P
M=70    %     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L
M<FT    /<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4
M     0      #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @
M %, 90!T '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M
M#&)U:6QT:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $
M  $      !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L
M  !#;&)R8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#
M8F]O;       3&)L<V)O;VP      $YG='9B;V]L      !%;6Q$8F]O;
M    26YT<F)O;VP      $)C:V=/8FIC     0       %)'0D,    #
M %)D("!D;W5B0&_@            1W)N(&1O=6) ;^            !";" @
M9&]U8D!OX            $)R9%15;G1&(U)L=                $)L9"!5
M;G1&(U)L=                %)S;'15;G1&(U!X;$!Y            "G9E
M8W1O<D1A=&%B;V]L 0    !09U!S96YU;0    !09U!S     %!G4$,
M3&5F=%5N=$8C4FQT                5&]P(%5N=$8C4FQT
M    4V-L(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O
M;VP     #F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T
M;&]N9P         -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T
M5&]P;&]N9P      .$))30/M       0 [_^-0 "  (#O_XU  (  CA"24T$
M)@      #@             _@   .$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))32<0       *  $
M         CA"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"A
MF9H !@       0 R     0!:    !@       0 U     0 M    !@
M 3A"24T#^       <   _____________________________P/H     /__
M__________________________\#Z     #_________________________
M____ ^@     _____________________________P/H   X0DE-! @
M !     !   "0    D      .$))300>       $     #A"24T$&@     #
M-0    8             !/0   F+          $
M     0             )BP  !/0                      0
M               0     0       &YU;&P    "    !F)O=6YD<T]B:F,
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M;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$
M   $     %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO
M;F<   3T     %)G:'1L;VYG   )BP    -U<FQ415A4     0       &YU
M;&Q415A4     0       $US9V5415A4     0      !F%L=%1A9U1%6%0
M   !       .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0
M   !       ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '
M9&5F875L=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@
M  =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R
M5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S
M971L;VYG          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U
M='-E=&QO;F<      #A"24T$*       #     (_\        #A"24T$$0
M     0$ .$))3004       $     SA"24T$#      8"0    $   "@
M4P   >   )N@   7[0 8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 4P"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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MBJ;;\AN1CY(V%OI.=6X.],R0&NW#
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                 /_A5J!H='1P
M.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O #P_>'!A8VME="!B96=I;CTB[[N_
M(B!I9#TB5S5-,$UP0V5H:4AZ<F53>DY48WIK8SED(C\^"CQX.GAM<&UE=&$@
M>&UL;G,Z>#TB861O8F4Z;G,Z;65T82\B('@Z>&UP=&L](D%D;V)E(%A-4"!#
M;W)E(#4N,RUC,#$Q(#8V+C$T-38V,2P@,C Q,B\P,B\P-BTQ-#HU-CHR-R @
M(" @(" @(CX*(" @/')D9CI21$8@>&UL;G,Z<F1F/2)H='1P.B\O=W=W+G<S
M+F]R9R\Q.3DY+S R+S(R+7)D9BUS>6YT87@M;G,C(CX*(" @(" @/')D9CI$
M97-C<FEP=&EO;B!R9&8Z86)O=70](B(*(" @(" @(" @(" @>&UL;G,Z9&,]
M(FAT=' Z+R]P=7)L+F]R9R]D8R]E;&5M96YT<R\Q+C$O(CX*(" @(" @(" @
M/&1C.F9O<FUA=#YI;6%G92]E<'-F/"]D8SIF;W)M870^"B @(" @(" @(#QD
M8SIT:71L93X*(" @(" @(" @(" @/')D9CI!;'0^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@>&UL.FQA;F<](G@M9&5F875L="(^5D5205\R,5\P,#(T7V)U
M<VEN97-S<V5C=&EO;E]V,3PO<F1F.FQI/@H@(" @(" @(" @(" \+W)D9CI!
M;'0^"B @(" @(" @(#PO9&,Z=&ET;&4^"B @(" @(#PO<F1F.D1E<V-R:7!T
M:6]N/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @
M(" @(" @("!X;6QN<SIX;7 ](FAT=' Z+R]N<RYA9&]B92YC;VTO>&%P+S$N
M,"\B/@H@(" @(" @(" \>&UP.D-R96%T;W)4;V]L/D%D;V)E($EL;'5S=')A
M=&]R(#(U+C @*$UA8VEN=&]S:"D\+WAM<#I#<F5A=&]R5&]O;#X*(" @(" @
M(" @/'AM<#I#<F5A=&5$871E/C(P,C$M,#,M,3!4,3 Z,#@Z,30M,#@Z,# \
M+WAM<#I#<F5A=&5$871E/@H@(" @(" @(" \>&UP.DUO9&EF>41A=&4^,C R
M,2TQ,BTR.50P-#HR,#HR,RLP-3HS,#PO>&UP.DUO9&EF>41A=&4^"B @(" @
M(" @(#QX;7 Z365T861A=&%$871E/C(P,C$M,3(M,CE4,#0Z,C Z,C,K,#4Z
M,S \+WAM<#I-971A9&%T841A=&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIX;7!-33TB:'1T<#HO+VYS+F%D;V)E+F-O;2]X87 O,2XP
M+VUM+R(*(" @(" @(" @(" @>&UL;G,Z<W12968](FAT=' Z+R]N<RYA9&]B
M92YC;VTO>&%P+S$N,"]S5'EP92]297-O=7)C95)E9B,B"B @(" @(" @(" @
M('AM;&YS.G-T179T/2)H='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y
M<&4O4F5S;W5R8V5%=F5N=",B"B @(" @(" @(" @('AM;&YS.G-T369S/2)H
M='1P.B\O;G,N861O8F4N8V]M+WAA<"\Q+C O<U1Y<&4O36%N:69E<W1)=&5M
M(R(^"B @(" @(" @(#QX;7!-33I296YD:71I;VY#;&%S<SYD969A=6QT/"]X
M;7!-33I296YD:71I;VY#;&%S<SX*(" @(" @(" @/'AM<$U-.D]R:6=I;F%L
M1&]C=6UE;G1)1#YU=6ED.C8U138S.3 V.#9#1C$Q1$)!-D4R1#@X-T-%04-"
M-# W/"]X;7!-33I/<FEG:6YA;$1O8W5M96YT240^"B @(" @(" @(#QX;7!-
M33I$;V-U;65N=$E$/GAM<"YD:60Z.3<R031&-3@R1C8X14,Q,3@Q-S8Y13=!
M140X,3@U1$$\+WAM<$U-.D1O8W5M96YT240^"B @(" @(" @(#QX;7!-33I)
M;G-T86YC94E$/GAM<"YI:60Z.3DR031&-3@R1C8X14,Q,3@Q-S8Y13=!140X
M,3@U1$$\+WAM<$U-.DEN<W1A;F-E240^"B @(" @(" @(#QX;7!-33I$97)I
M=F5D1G)O;2!R9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @
M(#QS=%)E9CII;G-T86YC94E$/GAM<"YI:60Z.3@R031&-3@R1C8X14,Q,3@Q
M-S8Y13=!140X,3@U1$$\+W-T4F5F.FEN<W1A;F-E240^"B @(" @(" @(" @
M(#QS=%)E9CID;V-U;65N=$E$/GAM<"YD:60Z.3<R031&-3@R1C8X14,Q,3@Q
M-S8Y13=!140X,3@U1$$\+W-T4F5F.F1O8W5M96YT240^"B @(" @(" @(" @
M(#QS=%)E9CIO<FEG:6YA;$1O8W5M96YT240^=75I9#HV-44V,SDP-C@V0T8Q
M,41"039%,D0X.#=#14%#0C0P-SPO<W12968Z;W)I9VEN86Q$;V-U;65N=$E$
M/@H@(" @(" @(" @(" \<W12968Z<F5N9&ET:6]N0VQA<W,^9&5F875L=#PO
M<W12968Z<F5N9&ET:6]N0VQA<W,^"B @(" @(" @(#PO>&UP34TZ1&5R:79E
M9$9R;VT^"B @(" @(" @(#QX;7!-33I(:7-T;W)Y/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IA8W1I;VX^
M<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T
M.FEN<W1A;F-E240^>&UP+FEI9#IF9F5D9#0X."TP,3(V+31E8V4M83=E,"UA
M8V9A9C,R.3EA.#D\+W-T179T.FEN<W1A;F-E240^"B @(" @(" @(" @(" @
M(" @(#QS=$5V=#IW:&5N/C(P,C$M,#,M,#14,30Z,S4Z,#,M,#@Z,# \+W-T
M179T.G=H96X^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IS;V9T=V%R94%G
M96YT/D%D;V)E($EL;'5S=')A=&]R(#(U+C @*$UA8VEN=&]S:"D\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.CDV,D$T1C4X,D8V.$5#,3$X,3<V.44W045$.#$X-41!
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3$R+3(Y5# T.C(P.C$V*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&EM
M86=E+VIP96<@=&\@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O<VAO<#PO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@:6UA9V4O:G!E9R!T;R!A<'!L:6-A=&EO;B]V
M;F0N861O8F4N<&AO=&]S:&]P/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY-S)!-$8U.#)&-CA%0S$Q
M.#$W-CE%-T%%1#@Q.#5$03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,BTR.50P-#HR,#HQ-BLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U
M<F-E(CX*(" @(" @(" @(" @(" @(" @/'-T179T.F%C=&EO;CYS879E9#PO
M<W1%=G0Z86-T:6]N/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z:6YS=&%N
M8V5)1#YX;7 N:6ED.CDX,D$T1C4X,D8V.$5#,3$X,3<V.44W045$.#$X-41!
M/"]S=$5V=#II;G-T86YC94E$/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z
M=VAE;CXR,#(Q+3$R+3(Y5# T.C(P.C(S*S U.C,P/"]S=$5V=#IW:&5N/@H@
M(" @(" @(" @(" @(" @(" \<W1%=G0Z<V]F='=A<F5!9V5N=#Y!9&]B92!0
M:&]T;W-H;W @0U,V("A7:6YD;W=S*3PO<W1%=G0Z<V]F='=A<F5!9V5N=#X*
M(" @(" @(" @(" @(" @(" @/'-T179T.F-H86YG960^+SPO<W1%=G0Z8VAA
M;F=E9#X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @(" @(" @(" @(" @
M(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @(" @(" @
M(" @(" @(" \<W1%=G0Z86-T:6]N/F-O;G9E<G1E9#PO<W1%=G0Z86-T:6]N
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z<&%R86UE=&5R<SYF<F]M(&%P
M<&QI8V%T:6]N+W9N9"YA9&]B92YP:&]T;W-H;W @=&\@:6UA9V4O97!S9CPO
M<W1%=G0Z<&%R86UE=&5R<SX*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1%=G0Z86-T:6]N/F1E<FEV960\+W-T
M179T.F%C=&EO;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G!A<F%M971E
M<G,^8V]N=F5R=&5D(&9R;VT@87!P;&EC871I;VXO=FYD+F%D;V)E+G!H;W1O
M<VAO<"!T;R!I;6%G92]E<'-F/"]S=$5V=#IP87)A;65T97)S/@H@(" @(" @
M(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z
M<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$5V
M=#IA8W1I;VX^<V%V960\+W-T179T.F%C=&EO;CX*(" @(" @(" @(" @(" @
M(" @/'-T179T.FEN<W1A;F-E240^>&UP+FEI9#HY.3)!-$8U.#)&-CA%0S$Q
M.#$W-CE%-T%%1#@Q.#5$03PO<W1%=G0Z:6YS=&%N8V5)1#X*(" @(" @(" @
M(" @(" @(" @/'-T179T.G=H96X^,C R,2TQ,BTR.50P-#HR,#HR,RLP-3HS
M,#PO<W1%=G0Z=VAE;CX*(" @(" @(" @(" @(" @(" @/'-T179T.G-O9G1W
M87)E06=E;G0^061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD\+W-T179T
M.G-O9G1W87)E06=E;G0^"B @(" @(" @(" @(" @(" @(#QS=$5V=#IC:&%N
M9V5D/B\\+W-T179T.F-H86YG960^"B @(" @(" @(" @(" @(#PO<F1F.FQI
M/@H@(" @(" @(" @(" \+W)D9CI397$^"B @(" @(" @(#PO>&UP34TZ2&ES
M=&]R>3X*(" @(" @(" @/'AM<$U-.DUA;FEF97-T/@H@(" @(" @(" @(" \
M<F1F.E-E<3X*(" @(" @(" @(" @(" @/')D9CIL:2!R9&8Z<&%R<V54>7!E
M/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS=$UF<SIL:6YK1F]R
M;3Y%;6)E9$)Y4F5F97)E;F-E/"]S=$UF<SIL:6YK1F]R;3X*(" @(" @(" @
M(" @(" @(" @/'-T369S.G)E9F5R96YC92!R9&8Z<&%R<V54>7!E/2)297-O
M=7)C92(^"B @(" @(" @(" @(" @(" @(" @(#QS=%)E9CIF:6QE4&%T:#XO
M=F%R+V9O;&1E<G,O,C$O=C%S,'IJ.34T,VHX=SEN<S0X=&MG9F0X,# P,&=N
M+U0O5&5M<&]R87)Y271E;7,O3E-)4D1?26QL=7-T<F%T;W)?2W P=FEF+TPT
M:EE:8RYT:68\+W-T4F5F.F9I;&50871H/@H@(" @(" @(" @(" @(" @(" \
M+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @/"]R9&8Z;&D^"B @
M(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B
M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O<FT^16UB961">5)E
M9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @(" @(" @(" @(#QS
M=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S;W5R8V4B/@H@(" @
M(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^+W9A<B]F;VQD97)S
M+S(Q+W8Q<S!Z:CDU-#-J.'<Y;G,T.'1K9V9D.# P,#!G;B]4+U1E;7!O<F%R
M>4ET96US+TY325)$7TEL;'5S=')A=&]R7TAP3W=V-R\T9FE-.$TN=&EF/"]S
M=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @/"]S=$UF<SIR969E
M<F5N8V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@(" @(" @(" @(" @
M(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @
M(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D0GE2969E<F5N8V4\+W-T
M369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z<F5F97)E
M;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @(" @(" @(" @(" @
M(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L9&5R<R\R,2]V,7,P>FHY
M-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP;W)A<GE)=&5M<R].4TE2
M1%]);&QU<W1R871O<E](<$]W=C<O9FYP>7A8+G1I9CPO<W12968Z9FEL95!A
M=&@^"B @(" @(" @(" @(" @(" @(#PO<W1-9G,Z<F5F97)E;F-E/@H@(" @
M(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @(" @/')D9CIL:2!R
M9&8Z<&%R<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(#QS
M=$UF<SIL:6YK1F]R;3Y%;6)E9$)Y4F5F97)E;F-E/"]S=$UF<SIL:6YK1F]R
M;3X*(" @(" @(" @(" @(" @(" @/'-T369S.G)E9F5R96YC92!R9&8Z<&%R
M<V54>7!E/2)297-O=7)C92(^"B @(" @(" @(" @(" @(" @(" @(#QS=%)E
M9CIF:6QE4&%T:#XO=F%R+V9O;&1E<G,O,C$O=C%S,'IJ.34T,VHX=SEN<S0X
M=&MG9F0X,# P,&=N+U0O5&5M<&]R87)Y271E;7,O3E-)4D1?26QL=7-T<F%T
M;W)?2'!/=W8W+VET06Y8.2YT:68\+W-T4F5F.F9I;&50871H/@H@(" @(" @
M(" @(" @(" @(" \+W-T369S.G)E9F5R96YC93X*(" @(" @(" @(" @(" @
M/"]R9&8Z;&D^"B @(" @(" @(" @(" @(#QR9&8Z;&D@<F1F.G!A<G-E5'EP
M93TB4F5S;W5R8V4B/@H@(" @(" @(" @(" @(" @(" \<W1-9G,Z;&EN:T9O
M<FT^16UB961">5)E9F5R96YC93PO<W1-9G,Z;&EN:T9O<FT^"B @(" @(" @
M(" @(" @(" @(#QS=$UF<SIR969E<F5N8V4@<F1F.G!A<G-E5'EP93TB4F5S
M;W5R8V4B/@H@(" @(" @(" @(" @(" @(" @(" \<W12968Z9FEL95!A=&@^
M+W9A<B]F;VQD97)S+S(Q+W8Q<S!Z:CDU-#-J.'<Y;G,T.'1K9V9D.# P,#!G
M;B]4+U1E;7!O<F%R>4ET96US+TY325)$7TEL;'5S=')A=&]R7S)9,E-&9R]I
M54)L3&,N=&EF/"]S=%)E9CIF:6QE4&%T:#X*(" @(" @(" @(" @(" @(" @
M/"]S=$UF<SIR969E<F5N8V4^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T369S.FQI;FM&;W)M/D5M8F5D0GE2
M969E<F5N8V4\+W-T369S.FQI;FM&;W)M/@H@(" @(" @(" @(" @(" @(" \
M<W1-9G,Z<F5F97)E;F-E(')D9CIP87)S951Y<&4](E)E<V]U<F-E(CX*(" @
M(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L9&5R
M<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP;W)A
M<GE)=&5M<R].4TE21%]);&QU<W1R871O<E\R63)31F<O9S!W<7!,+G1I9CPO
M<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(" @(#PO<W1-9G,Z<F5F
M97)E;F-E/@H@(" @(" @(" @(" @(" \+W)D9CIL:3X*(" @(" @(" @(" @
M/"]R9&8Z4V5Q/@H@(" @(" @(" \+WAM<$U-.DUA;FEF97-T/@H@(" @(" @
M(" \>&UP34TZ26YG<F5D:65N=',^"B @(" @(" @(" @(#QR9&8Z0F%G/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E]+<#!V:68O3#1J65IC+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E](<$]W=C<O-&9I33A-+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E](<$]W=C<O9FYP>7A8+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E](<$]W=C<O:71!;E@Y+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E\R63)31F<O:55";$QC+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" @(" \<F1F.FQI(')D9CIP87)S951Y<&4](E)E<V]U<F-E
M(CX*(" @(" @(" @(" @(" @(" @/'-T4F5F.F9I;&50871H/B]V87(O9F]L
M9&5R<R\R,2]V,7,P>FHY-30S:CAW.6YS-#AT:V=F9#@P,# P9VXO5"]496UP
M;W)A<GE)=&5M<R].4TE21%]);&QU<W1R871O<E\R63)31F<O9S!W<7!,+G1I
M9CPO<W12968Z9FEL95!A=&@^"B @(" @(" @(" @(" @(#PO<F1F.FQI/@H@
M(" @(" @(" @(" \+W)D9CI"86<^"B @(" @(" @(#PO>&UP34TZ26YG<F5D
M:65N=',^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" @(" \<F1F.D1E
M<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @("!X;6QN<SII;&QU
M<W1R871O<CTB:'1T<#HO+VYS+F%D;V)E+F-O;2]I;&QU<W1R871O<B\Q+C O
M(CX*(" @(" @(" @/&EL;'5S=')A=&]R.E-T87)T=7!0<F]F:6QE/E=E8CPO
M:6QL=7-T<F%T;W(Z4W1A<G1U<%!R;V9I;&4^"B @(" @(" @(#QI;&QU<W1R
M871O<CI#<F5A=&]R4W5B5&]O;#Y!9&]B92!);&QU<W1R871O<CPO:6QL=7-T
M<F%T;W(Z0W)E871O<E-U8E1O;VP^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N
M/@H@(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @
M(" @("!X;6QN<SIP9&8](FAT=' Z+R]N<RYA9&]B92YC;VTO<&1F+S$N,R\B
M/@H@(" @(" @(" \<&1F.E!R;V1U8V5R/D%D;V)E(%!$1B!L:6)R87)Y(#$U
M+C P/"]P9&8Z4')O9'5C97(^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@
M(" @(" \<F1F.D1E<V-R:7!T:6]N(')D9CIA8F]U=#TB(@H@(" @(" @(" @
M("!X;6QN<SIP9&9X/2)H='1P.B\O;G,N861O8F4N8V]M+W!D9G@O,2XS+R(^
M"B @(" @(" @(#QP9&9X.D-R96%T;W)697)S:6]N/C(Q+C N,#PO<&1F>#I#
M<F5A=&]R5F5R<VEO;CX*(" @(" @/"]R9&8Z1&5S8W)I<'1I;VX^"B @(" @
M(#QR9&8Z1&5S8W)I<'1I;VX@<F1F.F%B;W5T/2(B"B @(" @(" @(" @('AM
M;&YS.G!H;W1O<VAO<#TB:'1T<#HO+VYS+F%D;V)E+F-O;2]P:&]T;W-H;W O
M,2XP+R(^"B @(" @(" @(#QP:&]T;W-H;W Z0V]L;W)-;V1E/C0\+W!H;W1O
M<VAO<#I#;VQO<DUO9&4^"B @(" @(#PO<F1F.D1E<V-R:7!T:6]N/@H@(" \
M+W)D9CI21$8^"CPO>#IX;7!M971A/@H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" *(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @( H@(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @"B @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @
M(" @(" @(" @(" @(" @(" @(" @(" @(" *(" @(" @(" @(" @(" @(" @
M(" @(" @(" @( H\/WAP86-K970@96YD/2)W(C\^_]L 0P ! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$!_]L 0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@!, )* P$1
M  (1 0,1 ?_$ !\  0 " @(# 0$            '" 8)! 4! PH""__$ &X0
M  $$ @(  @4##@@%#@H"$P4" P0& 0< " D1$A,4%1DA6-<6%S$T4557=)67
MF+.TU@HB-4%A<Y33&#94<74C)#(W.$>!AY&3EK'2U24G*#-"2&=XH<'P)D6G
MN$-$4U9B8[=E:(*(Q]'8X?'_Q  < 0$  04! 0               0(#! 4&
M!PC_Q !8$0 " 0," P,$"PX% @4#  L! @, !!$%$@83(10Q418B0=$',E)3
M56%QD9*QTA4C5'*!DY25H:+!T]3P,T)#@K(D-!=$8J3A)83Q1626)F.#A;3$
MU=;_V@ , P$  A$#$0 _ /GM+2Y:RA)2Y,A2E3YF5*4\XI2LJD.95E6<JSG.
M<Y^7.<Y\\Y^7//M.-$Y<?FK[1?\ */<CXJYAN\_*?KK@>U2?\H?_ .=<_P"U
MRO8GN5^B/544]ID_Y0__ ,ZY_P!KC8GN5^B/52GM4G_*'_\ G7/^UQL3W*_1
M'JI3VJ3_ )0__P ZY_VN-B>Y7Z(]5*>U2?\ *'_^=<_[7&Q/<K]$>JE/:9/^
M4/\ _.N?]KC8GN5^B/52GM4G_*'_ /G7/^UQL3W*_1'JI3VF3G[,A_\ YUS_
M +7&Q/<K]$>JE/:9/^4/_P#.N?\ :XV)[E?HCU4I[3)_RA__ )US_M<;$]RO
MT1ZJ4]JD_P"4/_\ /.?]KC8GN5^B/52GM4G_ "A__GG/^UQL3W*_1'JI3VJ3
M_E#_ /SKG_:XV)[E?HCU4KZ7OX//T6ZJ]UXG:YSL]JEK::]<R-,(IBI=QV#6
M?<B+2UL]1[#>*3;*UB;[PS7Q&59)8F98]C3[+EC#TCUOE7LEZ[JNAMI TJZ[
M(+E;TS 6]M+S#&;;9GGPRE=N]L;=N=QSG QGV4,4W,YB[MNW'G,,9SGVI'[:
M^D_X%7A49^SU/'Y_XW-^?2ISR[R]XM/?J['_ .RT[^DK/[%;>]?OR?;KQ\"K
MPJ/FGCOSN;\_G^S_ +ZG(\O>+/A8_H6G>GO_ /*4[%;>]?OR?;KS\"KPJ/E_
M\D\=\OV?_&YOSY?\_P#XU.3Y>\6]?_J[=>__ *+3NOR_])3L5M[U^_)]NGP*
MO"H^:>._.YOSZ5./+WBWX7;]"T[^DIV*V]Z_?D^W7CX%7A3_ #3AWYV]^?2I
MR/+SBSX6/Z%IW])3L5M[U^_)]NGP*O"H^:>._.YOSZ5./+WBSX6/Z%IW])3L
M5M[U^_)]NGP*O"H^:>._.YOSZ5./+WBSX6/Z%IW])3L5M[U^_)]NGP*O"H^:
M>._.YOSZ5./+WBSX6/Z%IW])3L5M[U^_)]NGP*O"H^:>._.YOSZ5./+WBSX6
M/Z%IW])3L5M[U^_)]NO/P*O"H^:>._.YOSZ5.3Y>\6_"[?H6G?TE.Q6WO7[\
MGVZ\? J\*?YIP[\[>_/I4Y'E[Q9\+']"T[^DIV*V]Z_?D^W3X%7A3_-.'?G;
MWY]*G'E[Q9\+']"T[^DIV*V]Z_?D^W7GX%7A4?-/'?+]G_QN;\^7_P"VIR?+
MWBWX7;KW_P#1:=U_]I3L5M[U^_)]NO'P*?"G^:<._.WOSZ5.1Y><6?"Q_0M.
M_HZ=BMO>OWY/MT^!5X5'S3QWYW-^?2IQY>\6?"Q_0M._I*=BMO>OWY/MT^!5
MX4_S3AWYV]^?2IQY>\6?"Q_0M._I*=BMO>OWY/MT^!5X5'S3QWW?]MS?GV?N
M_P"VIQY>\6?"Q\?^RT[O\?\ M*=BMO>OWY/MT^!5X5&?L]3QV?\ C<WY]*G'
ME[Q8>_5B?_LM._I*=BMO>OWY/MT^!5X5'V?\$\=Y_=^NYOSZ5./+WBSO^ZQS
MX]BT[^DIV*V]Z_?D^W3X%7A4?-/'?G<WY]*G'E[Q9U_^K'KW_P#1:=_24[%;
M>]?OR?;I\"KPI_FG#OSM[\^E3CR]XL^%C^A:=_24[%;>]?OR?;KS\"KPJ/FG
MCOSN;\_F^Q_OJ?S<GR]XM^%V_0M.]'=_Y3T4[%;>]?OR?;KQ\"KPJ/FGCON?
M[;F_/L?<_P!M3D>7O%GPL?#_ ++3N[P_[2G8K;WK]^3[=/@5>%1\T\=^=S?G
MTJ<>7O%GPL?T+3OZ2G8K;WK]^3[=/@5>%1\T\=^=S?GTJ<>7O%GPLWZ%IP__
M ,2G8K;WK]^3[=/@5>%1\T\=\OV?_&YOSY?_ +:G'E[Q9\+'KW_]%IW7_P!I
M3L5M[U^_)]NGP*O"H^:>._.YOSZ5./+WBSX6/Z%IW])3L5M[U^_)]NGP*O"H
M^:>._.YOSZ5./+WBSX6/Z%IW])3L5M[U^_)]NGP*O"G^:<._.WOSZ5./+WBS
MX6/Z%IW])3L5M[U^_)]NGP*O"HS]GJ>._.YOSZ5./+WBP]^K']"T[^DIV*V]
MZ_?D^W3X%7A4?-/'?G<WY]*G'E[Q9\+']"T[^DIV*V]Z_?D^W3X%7A4?-/'?
MG<WY]*G'E[Q9\+']"T[^DIV*V]Z_?D^W3X%7A4?-/'?G<WY]*G'E[Q9\+']"
MT[^DIV*V]Z_?D^W3X%7A4?-/'?G<WY_-]C_?4_FX\O>+/A9O1_Y+3O1W?^4I
MV*V]Z_?D^W3X%7A49^SU/'9_XW-^?2IQY>\6'OU8G_[+3OZ2G8K;WK]^3[=>
M?@5>%1\T\=^=S?G]/_M4_IS_ ,N>/+WBSX7;]"T[X_\ ]4^,_/3L5M[U^_)]
MNO'P*O"H^:>._.YOSZ5./+WBP_\ Z6;]"T[^DIV*V]Z_?D^W3X%7A3_-.'?G
M;WY]*G'E[Q9\+']"T[^DIV*V]Z_?D^W3X%7A4?-/'?G<WY]*G'E[Q9\+']"T
M[^DIV*V]Z_?D^W3X%7A3_-.'?G;WY]*G'EYQ9\+']"T[^DIV*V]Z_?D^W3X%
M7A4?-/'?G<WY]*G'E[Q9\+']"T[^DIV*V]Z_?D^W3X%/A3_-.'?G;WY]*G'E
MYQ9\+']"T[^CIV*V]Z_?D^W3X%7A4?-/'?G<WY]*G'E[Q9\+']"T[^DIV*V]
MZ_?D^W7GX%7A4?-/'_G<WY_G_"I]WY>3Y>\6_"[?H6G?+^">/6G8K;WK]^3[
M=>/@5>%1\T\=^=S?GTJ<CR]XL^%C^A:=_24[%;>]?OR?;KS\"OPJ/FGC_P [
MF_?I4Y/E]Q;\+M^AZ=_24[%;>]?OR?;I\"KPJ/FGCOSN;\^E3D>7O%G7_P"K
MMU[_ /HM._I*=BMO>OWY/MUX^!5X5'S3QWYW-^?2IQY>\6?"Q_0M._I*=BMO
M>OWY/MT^!5X4_P TX=^=O?GTJ<>7O%GPL?T+3OZ2G8K;WK]^3[=/@4^%/\TX
M=^=O?GTJ<>7G%GPL?T+3OZ.G8K;WK]^3[=>?@5>%1\T\=_/_ +[F_/Y_L_[Z
MG\_\_)\O>+?A=O3_ .2T[T]__E/3Z:=BMO>OWY/MT^!5X5'GY_X)X[S^[]=S
M?GG_ /K4X\O>+<Y^Z[9\>Q:=G_\ M*=BMO>OWY/MUX^!5X4_S3AWYV]^?2IR
M/+WBSX6/Z%IW])3L5M[U^_)]NGP*O"G^:<._.WOSZ5./+WBSX6/Z%IW])3L5
MM[U^_)]NGP*O"H^Q_@GCO+[GUW-^?2IQY>\6=WW6./#L6G?TE.Q6WO7[\GVZ
M? J\*CYIX[\[F_/I4X\O>+/A8_H6G?TE.Q6WO7[\GVZ? J\*CYIX[\[F_/I4
MX\O>+/A8_H6G?TE.Q6WO7[\GVZ]3_@6>%2AAY:.J ["D-.*3GZ[>_,^2DH5G
M&?+.U,XS\N/Y\9QG[&?DY(X\XL) ^ZS8)_ M.'?T/=:>%0;*V /WOT'_ #R?
M;KX<*C>;M!J=8A0[C:XL2'7@L6+&8L1AIB/&CC8S3##+2)F$-M,M(2VVVG&$
MH0G"4XQC&,<]UE@A:21FAB9F=V9C&A)8L223MZDDY)K3#=@8![AZ5]5:[BG\
MI$?QZ7^T.<["/_#C_$7_ (BJ&[S\I^NN#RNHIQ2G%*<4IQ2G%*<4IQ2G%*<4
MIQ2G%*<4K[&_X*!]H]Y/QOKQ^IW1SQ'V8/;Z#^+J'UVE;33?]7_;_&OJ[L^X
M=9TRUAZ1:+<-#VD[#C3QHJ2B8M:XDXI@*/>E2F(KT$;@F3Q)BBD$Y,-PID::
M='HDL C+L'Q^*RNIH7N(H7>%&*,XQC<J<Q@ 2"Q5,,^T';N3=@N@;9%U!"E@
M">H'IQG&?G_CX&I*YBU53BE.*4XI3BE.*4XI3BE.*4XI6HCQ.-H[HT5:]9[O
MU8FP-#M7=7^^5D)$,C#137,2^LTW3^=2-7N)$=8!2Y\VPH),TT89>S-*S4DX
M8&+.D+E1'>SX5M+'4(+RPNS'ON]5X>B1=\:7+6_.ONV&W+9D"K&4,[(-J*4,
MC*,,,:=F0JZ@X1)2>_ .%VY]!/?@'OZX!/2M?A3;?8;>5+UO:]U6C<^V]/5^
M^]L:EL*J5?5V_:P>UIN01#U)*ZVZ^[9:[ZT:SU/N6>)@T:9<[//DURCHJR-@
M7.N/EI+P5BKN1^B6STNPFN8;"*SLKZ2WTF:WFFNM/FCNK)S=C4KG1[C5+FZL
MU=IUBB"RSB8V\,@C <RYL%I&P7)909 0H8$.,%5D"*#W> Z$Y)K>]TO*6DWU
M/Z^%[M2+-K6V$M5U.8=U_<BEY-6FG3WQK2W*\;*;,FD=@S)PQ.4QG'+C.EV!
M*6TMDGW)"%JSY_KB11ZOJ*07$5W"MW*([F%($BG7=_B(EJ!;J'.3B$"/.=H
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MVGPKEIL][WVGQ+]]'MKBQ0.,R6KF7$)%I(,X%K,P7TX@F;H/DBE. <=$D()
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MPAB' 'PFF(D.*RC&$M,1V6VFT_(E.,<E$2-52-%1$ 5410JJH[@JJ  !Z
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M:AKE+$P2)-MI""A4>/BDB:5/8G2Y&),GUN$FGV4=V]\EO&MW("KS#.X@X#$
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MTF+(CLSHV&E2(3KS2VVY<=+[;K"GHZU8>:P\TXUEQ"<.-K1YIS4I"LK%0P#
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M#RH[\:8QAZ%*BR7O*[ZPN=.F$-R@&]!+#-&ZS6]S"Q(2>UN(RT4\+D$"2-F
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M9798&4SR8L[BV$TD"1I(IN+"::W9Q$[NL4\; +E)/-4QYQ1N9N++CIM'G*V
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MNKQR(Q5T="&5E88*LI ((.01D5! (((R"""#W$'H0?EJAJJ<6TU?Z]4"MN+
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M1O\ >VYW2>)KZ^OK^VN=)G2.V+!>SQN\L160)R[@2,JL[#+ Q[>BG",IW#8
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MD.78L#N.8WL6W;CN&"&SUZ=W6M@FJO%8WSJ;3$+5 FL5 T9$!]X!1FRCEDW
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M  Z]X [A^2L;Y=J*<4K[&_X*!]H]Y/QOKQ^IW1SQ'V8/;Z#^+J'UVE;33?\
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MZOMFIFJIK-0NLY<#SAE?C25.39.!L=<D$''SI?;:_P 0<+WVFZ9#I^A1QW<
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M$@1Q$%#N)D\HI6+;J%6J_"A@>O+28HEFF5R,T6ICV?JOJMM$69HZ*NJ9ZR\
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MCU*?W_?]]:E_;&ZZOJT>YB6MPE8'WQ,& &BJA(6B58<FV LPA(*$! ^,*<F
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M'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O]%O53(\1\XI[Z#??89_;XO\
M>\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGOH-]]AG]OB_
MWO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O\ 1;U4R/$?.*>^@WWV&?V^
M+_>\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGOH-]]AG]O
MB_WO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O]%O53(\1\XI[Z#??89_;
MXO\ >\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGOH-]]AG
M]OB_WO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O\ 1;U4R/$?.*>^@WWV
M&?V^+_>\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGOH-]]
MAG]OB_WO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O]%O53(\1\XI[Z#??
M89_;XO\ >\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGOH-
M]]AG]OB_WO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O\ 1;U4R/$?.*>^
M@WWV&?V^+_>\<N3WM_HMZJ9'B/G%/?0;[[#/[?%_O>.7)[V_T6]5,CQ'SBGO
MH-]]AG]OB_WO'+D][?Z+>JF1XCYQ3WT&^^PS^WQ?[WCER>]O]%O53(\1\XI[
MZ#??89_;XO\ >\<N3WM_HMZJ9'B/G%>B4:#>S2/_  L,_P#,._\ X?%__%J_
M_2\E8Y,C[V_>/\K>/R5#$8/4=Q](\*_EW5O&,UT!]G^117\^?\A8_IY]3/[=
MOQF^LUSX. ._N'H/JK[XW/!4\+EUQQUSI_0E..K4XXK-AV-C*EK5E2E9QBZ8
MQYY5G.?DQC'R_)CG@0X[XM  &M7    '*M>X=W^A6Y[);'_2'TF^U7X^"AX6
MWS/J%_TAV-^^G)\O.+OANX_-6O\ 3T[';>]#Z3_:I\%#PMOF?4+_ *0[&_?3
MCR\XN^&[C\U:_P!/3L=M[T/I/]JGP4/"V^9]0O\ I#L;]]./+SB[X;N/S5K_
M $].QVWO0^D_VJ?!0\+;YGU"_P"D.QOWTX\O.+OANX_-6O\ 3T[';>]#Z3_:
MI\%#PMOF?4+_ *0[&_?3CR\XN^&[C\U:_P!/3L=M[T/I/]JGP4/"V^9]0O\
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MGU4^"KT2^\V^_P!*SL?])G'EQKOCIWZJL/Y%.PP^,GTSZJ?!5Z)?>;??\_\
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ML?\ 29_\/L?<\N/+C7?'3OU58?R*=AA\9/IGU4^"KT2^\V^_TK>Q_P!)G_\
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MG8=\/I@Z_*$:AK6WS7YT 339<*Z)=GGB34NSR:?IEVEI$XN;Z);R:^@N9_\
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M8BSA1M6!%@AC0+T$<<$<:(,# 7&.F31MVJP  'G$8^/J2<^DDG-?S%:W_BZ
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M2G%*<4IQ2G%*<4JO78+M/H_J\,K17=-QS5H]O*/BJ^S'#&CT^>[";8>)RDP
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M+3ZUI,3QQ3ZE8V\\O+"V\]W!%-ODC254,;2!MYCDC;&.JNI&0P)D12,"51F
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M*99X!J-N9K:9+>XC#,6AGDNNQ)%)A?-D:ZQ"%/7<0?:L&,\F7 .PX8$J>F"
MNXD=>H"]>E=91>E_:C9D\&+H&C;W;"%EUD+W,$BAAS4IV=JDS<9% @7]/E)P
MEFL+MT.8(DE).66!ZH<R:0S%'1)$QNJXUW1[19'N=0MX5BNY+&1G8@+>10+<
MO;>U.9A"RN$&2VY53<S!3"PRL<*A)*A_1[5C@-W]Q((_(?"NRV[T7[?Z$IA/
M8FY>O&S=<TD/:&:<3L=G .P1T,[*7*:@-NK]8MSW85>A2XX:PH;57C,EA<84
M4F/^3>:++B'1-1G2UL=3M;FXDB,R11299HQM+8R -Z!E+Q9YJ Y=%'6I:"9
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M&[M&F$S6W:"6LHW>98(\/%).2 KH3MV-$TDB$%'<2 E%W$;6QC=MQNQC/4'
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MP&+S[*VE2Q"4YS=/T_A^2X99-7FE46FH.$DTQHEWQV%S)&X?MW5XI%66./\
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M;0XI5G^*4XI3BE.*4XI3BE8O=K8,HE0LMS,8>6-K 0B;E,148=FS$#XKDA$
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M@2VR,JBGSB0&=B6*JHZ>=NOAS@JZ*G%*<4IQ2G%*K%O_ /VR^F7]/9LWC/\
M3C_!/[19\L_=QYXQG_/C&?LXQQ4CN;Y/XBNSV5UY$VD_-V-KL\]J7<,N&S"(
M7,,+C&*[?1\-K#,.O;GU[*D0@6TZXRQC,*(Z1?%WBM#WYT>A7JFN$9TB1L;7
M47A58)T[3:JVY(V<QRV[$Y,EE<J#):RY\XA0T$C!3/!-M4"AE5@00"",$$ A
MAX,#T8?+^3%?,?X@6W.O^D>]76RL;@H-UU)N\+)UT:-U/0HBF%=$W,,C8DB9
M4KG3[0[9Z;<Z$1NQ*,=&'(!/7A(M7"H]MQQPU 8B6ZR>]\&:YJTG">N6IG@U
M#3;M+Z)-3U::Y;4+ RV/)FCN[<PW,=];6BF.1 EU'S(6D10&(MXN'U;AN"XU
M6RNK(-%<0O 186T<<:73K,'5() \8@FGSLWF-EYFQF(\YZ^H4+V7T98!(\T,
MV(&>@$HK4J.IQL@P\A+F/XS,F.[#0]%EQG,+CS(<A#<B)*:>C2&VWFG$)^<;
MQTT^[N+*[=8KFUE>&:,G=M>-BIVLH*NAQN1T+(Z%71BK GU2TX=UR^MH+RUT
MVYFM[F))H9%" /'(H93@N&5@#AD8!D8%6 8$"M_8_P 2GKKUNDTJ*;<L]Y?N
M,J=Z2*(/A2\ 10Q<)N:5*+-D@C;G\>>UB' @+E2I.&92EXCI;:R_I-0XAT_3
MS"',DQF8C[PH;8JX!9M[(.]@ !DGKG'3/HG!?L*<9<:IJDEHMCI::;'%@ZM-
M+%VNXG$IBMX!:P71'2)N9-,(XT+Q@%RS;+"0Q-_W%#B%+5/GZUUT3CL38-&J
MQCU5\L8V6TE^,J\7L+(_^K+$AEUM;U8UP0]L:6TGVK8Q.!,F F\\)-=J&E+6
M\##(@C?$\BD9'.G0_>\@]8[=L@CK<.I*5QTD^D\.R206$46M:Q [12ZI?VV[
M2K*:-BKC2]*ND_ZYT96"WVLP\M@QY>C031Q79FD!7@-5$0:_60PNO@QK66!X
M@-!C#1L-K*U.*1&AQ&VH[6%N+6ZYE#>,N.K6ZO*G%J5G+2-(D6.-%C11A410
MJJ,YZ   =22?$DGOKF[N\N[^XEN[ZYGN[J=MTUQ<RO--(V  7DD9G;"@*,G"
MJ HP  .XY76-3BE.*4XI3BE.*4XI3BE.*4XI7HE?:TC^H>_5JY*]X^4?74-W
M'Y#]5?RVZWC'U.@?DQ_(HO\ FQ_D+'/JE_;M^,WUFN=!; Z>@>@?:%48*?RD
M1_'I?[0YSJX_\./\1?\ B*MMWGY3]=<'E=13BE6HZ4];&NWG9C7?7I^X.4%J
M^0]A2U6QH$FRN"\T76-SV*EM(59<$F9[S54DB%*R5C>R)GYG83)S&Q$?U&O:
MJ=%TNYU(0"X-NUNO),G*W<^ZAM\[]CXV\W?[4YV[>F<B[#'S9 F<9!.<9[@3
M73Z"ZD;\[-QC4[3U.%&!H Q5ZQ/,6>_ZZUJ#>N%W7/;IM'#G-F6RH";#>+4X
M+() 4X#+(V,GB(\Y'&J:3Z?)U'6].THQ+>S.CS1RS+'#;W-U((8 IGG>.UBF
M>."$.O,F=5C3(RP-$A>0MMQA2 2Q"@DYP!D]2<' '6N_;Z.]J')55AKU&3B/
M7.D;FV*#R1L%.%L8J77DC9@^ZYQN42L46+5IVN2M0/CK$ M#P>P,S8T6,P+D
M/%!2)M!X@T@"9NV*P@N+&UDV1S.3-J2Q/8K&JQEI5N$GC:.2(/&022P"/M<F
M3IYN,JS#/@A(;)[AC!Z=_3Y*EJA^'#V%=NN@FMM4QZFZVVSNCKSK"VE@MSUQ
M8;YK6!V&.BF:7/O>NA%G,W76D^T5F7,-U!&R:M7V"RH[3*4..NHCNX5QQ3IH
M@U'L<W/NK.RU&ZA22"ZBM[IM.1N>MO<O$D-RL4H$<QMI9"F3G&,U6MN^4W8"
ML5!PREEW]5)4$E<CJ,@9]%8%N?I/MK6 W:6R(PT0G2-,VQM7751M-KV)K"N7
M&_0M7;'5KDR9J>MB=L&[ NL4,8E"(%G*4RHE@X8C,?1*D1V8,]43)LM>L[J2
MTM&9S?SVEK<S10VUU+!;M=6_:(TFN4B>W@:1%=HDGF1W4# )(S2T+!6<8V D
M EE#'! Z D$]3Z!6(Z+Z<]@NR00H=TS5*Y;$C9QL6P!D;1U35[Q92E<KS-L.
MC*+KVWW8#>K_ #Q=<D-%I4:EUXZXEA7JD87*QF/R]J&NZ;I4J17TLL1<1L9%
MM+N:")99##&]Q<0P206ZO(-@::1 3\76J4A>0$J <>@LH)P,D!2<DXZX [JS
M"!X?';PGI)?8B!J3,K4V-8D=SL'FKSK99>?JT&5E!;'=Q=(Q</JZ* ZM/B+Q
M:WX%;D.5F*_!GG&H$$C!DR++\2Z*E^-,:\Q>&Z2Q*&"XY:W<D8DB@>XY7(1Y
MD;,(:0<TAE3<RD"H02E-X7S=I;O&< D$X[^\=?#TXJ:H/AF[<JW4WL+V:W:'
M(Z\9USK#26QM9@6+/KTP3L,7<&R*M61R=@U 6?*WG7S1&H6!RSU9BU!:S--)
M86Y%;E,0B#3. W%=G-K&G:58.MR;F[O;6ZD,5PB1FSMI9'-M,T:6]R4FCY4O
M*>41D@'!92:NSL(GD?S<*K*,@D[B/;#.5Z=1D#/>.@K6/SK*QZ<4IQ2OL;_@
MH'VCWD_&^O'ZG='/$?9@]OH/XNH?7:5M--_U?]O\:W-=X:1?[MV-U/\ 6R:J
M!ZV5P)19[$4[J\U8B^O(9*[W&,]:Z_LX-U1WVK5)^VOPHT*OW.;=J>,J*Z*8
M.3JK9?3CF:SPV@W%M!I=Z+HS1PRR3@M'=I&MRT<$#+#):OJU@+N.'<6DA%O,
M\PN$C2:+!23*F5FD3;@D;>]"VW)8$[MC;2?0=P P<JP[MG(\9;%:]A!C=@RF
M]*IL887M0&..0I-LR$1%GV +$)C'1*<X,>M(CHY$,Z.QGU+4L8N-AR+GDIC&
MTLK0J4A,CF)&.62,L2BL<MDJN 3N;)'>>^LD9P,X)P,^!/I\.F?B'Y*I9UHJ
M?;,9;I\S<1BP/ID]=-3B8).V$&"E>KFTHM H\6TQ\UFM;&D"[T6?O\6^G+E8
M7@&ORD1I0D*$N%S#6!MVDVZJ./\ XZ_'X_D\?CJ3>ED<_%U-<8UJ*"3=C9[)
M=L&S1<$#EUH,1(I[([/Q(EC0$X_:9@B(\OS4S DV,T\PG^(LA(S_ !^*@_%T
MJW'%*<4IQ2G%*<4IQ2H!VJ0@'+E1Z,1FQ(%8KGK=V[,(SY$>**'5G7LMF53H
M9F9(<;:&-DKZF!:X\R2M$-X5K.TQY*TM^GG&_P!+5K6PU'4E4FXG7[BZ:J@E
MVN-0C9;Z6)0#OY.G<RU=1YRRZG:NN2*UUW]_N;6T_P B,+ZY]SR[=AV>-O R
M76R5<]&2UE4U$J*0+[H*Q9-LU6&9ZMMX6O6^H;F%:EC-T/9PI#&W]IU@Q&4U
M,J:4Y]IT[K\S$7';;5'VK:83MH>HH_7E'/;1!RK.5DU4X[3>0N5>QP<FSM)4
M(Q-D8O;A#DD&UA81=H:XRMO/ZN/O0]HC#V__ *V!]'N%.#_F(S@"U]*H],UM
M50=%UY4ZY1J5682!M=J=2"CJ]7 <!"UN)AB@PF/$'P(_K7''5-1H[:5.N..J
MPIQQ:E:B>>>ZFDN+F:6>>5MTDTSM)+(W=N=W)9C@ 9)/0 =PJ\JA0%4!0.@
M& /D K*>6JFG%*<4IQ2J1]>>@6B.L^X-D;KUTJX/6K8[!2 ]"L!J&0!U<2<-
MQ+$6%5J+&$P)B8\PJ/@+]><GFYT>-"8BQI;2%S%2^XXB]D#7N)M'TW1=1%FM
MKIS12![>%XY[J:"%[>&6Y9YI$W)%)(-L$<$;.[.R'"!-!IG#FGZ3>W-]:\XR
MW(==LCJT<*2.LCI&%16P75<-(SL% 4'VQ:[G.'K?TXI5/.V0'L.<E:4QHY\A
MD+ V/'F[,&!S3U<($@[2(^1/M9R);*C.@5J&]@C(/XCJMK4W_6$"70;)&DK=
M%JGQZ9R/F^.J<Q*WVC'^&IV>@;.)W"H7YO5^QIDS'8-V!N.U3:M'ZT5^/L&#
M#(4K;'L@ML[LR/L"73B,BSEF:^,D1ER*@]%<C#8\>C^_V_QQ^2IZ!AC&,_&/
M3TSD?/\ %6WD3_)0S_1\+]F:Y-4UV'%*<4IQ2H\VZX$:U/L]VRV@A2*XWKRZ
M+/W03)]B*U$*FMDE%;.,F>BOV0@ @X?*PI/H+]1)B-.^BKT?+.39!S>6@BB6
M>0W, C@<929S*FR)QZ5D;",/2&(JB3&Q\DJ-K98=ZC!ZCXQWCXZU(>"KX:%M
M\/;5NQ3=ZV63MEH[#M:UMA&C/!' 4/6GN(*;DX$$&G#!A)&ZN2+=*&VLC%<8
M@94"'18?M;;'M;G7\;\30\0W=M';VJ11:;VF%;@.)#=%W0%T(1-MN!"&A4^<
M0[,P4G:,:SMS"K,S9,@4[<8V@ G!\3U.?#T9K81W.[,XZD:&L.YTTN;?9 HH
M""PP4:;D5#Q,/ST06)ILPF$24+$QU9RE4A$"2N1/=@#4):7.3(9PN"^&?*[7
MK?1C>I8++%<3O.T8E?9;QES'!"9(A+*W?M,BA8Q)+YW+V-AZYJOW&T^2^Y#7
M!5XXUC#;%#2-M#2.%<H@\=IRQ5.F[<,;Z?W9[LOKVH]LK:&?#GKN-/#Z53I.
M77QNM*O L,\#/8!R7V8RBQ.YRP*3I>X+@P)!00X##1(D06*QF=E<8V2\,ZA=
M\)6<RS6]E);RWUXN%EU.ZDMTN(VN%5F$,5DEP8(;,/(L4HGG=WEF/+M:).=5
MMX=9G0I+.LJ00')CM8EE:-N62!O><Q[Y)R 70I&H5$PUSN<56]IQ2G%*<4IQ
M2G%*<4IQ2NM,J+I$%55]L:\?2-G*",F7Y480Z7Q%=R-;*R84>7-CC7)OJ$SG
MXD63*:BY=<CQWG4H;4I6NOLM7>XAH)6R 1%UDO/541"V!2^MU\!U[#1"#V(U
M.2FRZ':;Q+UI9E6 SIG%YC$WRQR ,CQ!DX8&1"($\N'U2,9Z^!^?'Q?'7>6
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M^7/\BB_N?Y"Q_1SZI?V[?C-]9KGU[A\@^JJ,%/Y2(_CTO]H<YU<?^''^(O\
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MS],7US+[5?-&RM4&O8V_1PNV:E?E;0 ^AE7H)<E5F,+$;/B2G,^3KD(11[3
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ME6,YPI*L9QG&<9SC.,^>,^7.?(()!&".A![P? ULN_NK]<4IQ2L/MVPZ!K]
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M1"P"1L*5[("8].#/]W-9=G1,25)8SVX7@,EPZW+HL^N:7K001J1&VEK;+';
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MAI4J1:]1"012_2G%"F! )=C'PC(H;(]:42;Q*D!2$4LB:H(@ [&5(8CFGB$
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MM41^41#6+857C&%S8L 7"1.SE1);R$L+5(!/<.[O^+O]1K@;+OM8OMGZ V@
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M%3H;,<C+4(P<51;M!V]L&EMKRY</0=*OKVMJY>$BKG-W80KDT*-^M%<-VW,
M:#"=:VP<'L-KK.D\+I@-\B4)D4H%$;%FB"3(B6<5(&1WGJ?#IX9SGN&>_'IZ
M9K9TXZI$=;R&E/+2RIU#*5MH4ZK",J2TE;JFVDJ7G&$86XM#>,YQE:DIQG.%
M4UKXT[VNK!/=].UP?UR"H6Q.S#F\;<,+!=@/6\!=QG7$9J>J>]PA:77:]&-D
M)@NT)&9@ XJ("8M#/'P1&W5G+%HDJDCIW]V!CPSD_LQ^WK@]*V&\5%.*5^5H
M0XA;;B$K;<2I"T+3A2%H5C*5(4G.,X4E2<YPI.<9QG&<XSCRXI6G#=)WK&%?
MOO2*;TIT61U5,M=)%4^CSHD"G42W;/O)/5]=:M<N'5]7%ZU0AU==V8%:GW 2
M=)[A&-AB!*'KM -8,T4R;2]N["87%E<SVDX5D$MO*\4FUAAEW(0=K>D'H2 <
M= :AD608<!QG)#*& QG!.>F?[[^E6(T[V>6GL#4.I59T-6:70 ^FX]@B6ZC7
M*&1H=:)!8D%MW7M4@ Z6/J9 8/9DQTBW(%F@'7!Z79CM('QAQ?(VU+++/(\T
M\DDTTK%Y)97:221R<EG=B69B>\L2359'3.>[ QCN &!\0    '0# K'._@C0
MXRQ:,OFR>JNF-_W.%9'V@=IV.] "6*B *J]$M$IVKG,46XD3,O!%QJ3 ILIX
M( )R%S,$"D5J0^F1FV>KZII\<L-AJ%Y:13',L=O<2PHYV[=Q5& WE0%+##%0
M 3@ 51RT9@Q52R]%8@$C/3O/RGNR1DD>FME>,83C"4XQA.,8QC&,8QC&,8\L
M8QC'R8QC'R8QCY,8YKJFJU'[6XCM3KNLM:V#EY3>KKXVK9"+H^BR4ZN6 C6B
M96&]18H:4.S6;38J)4AS1LW81)J4:%K:K 4N*$VZ>-5/H/Y/X_EJRW%158NO
MFW-8[0O?; 90!K P]K+L/];[9KJB#KI.R7,+IG4+2K1,$2,)>"P\"4CZ4)]4
MA0\Q&HRS<5YQZ=+;95)!&,^D9'R9/S>-2EN:_2]6:FV-LB 'AV&=1Z:?L\($
M0,.U^"9EAQS\R.,E'&!1UX2Q.>:1&<GM!2KD5+F74#Y:DX96H!D@>)Q6&]7+
M+&M>@=9$H5*':WB0@3U6C4$589]J@4]BCE2%+:KS!\J' $R&1: &(KRB >#-
M8D-NQ93:WV%O.*'H?[_^:Z;L1L ?6)6KZ>8UXU>!E[LYPK&F$+:+J(6N6O2=
M1,;]I<@I/GO-+0F78=9Q5LSG?5@Q"8$B>?D*BH9%E5 ,_P!_'C^__P D2'I2
M^G-GZPJE\L=9AU K8XY"6L(--3;$+Q!8,D8(<N*,DZ[4BDT39 \6!9!:BU7K
MY9D>6C1R@B!/9D1FU150NQO:@3IO<;+$O3B3ELI@^E *Y?S5NFAZX,HF[ANS
M[MLFPF4UFN78N'K=7@=6,KFNO5<H7)%H<1F-$#!%+-$7]_W\U2!G^^O?C [L
MG^%;"9+KC$:0\TPN2ZRPZZW&;6RTY(<;;4M#"')#C3#:W58PVE;[K;*,JPIQ
MQ",*5A45K+TEVY.V/L%'HLG0](J4;;]J&.V#85<W43NF;*4>UYO[ZC+56A#N
ML@HRPU:14NI<L!.-Q3P2,W-(")(*':PZ_JD(JJ(QGKW?%CP[_CZ_']57@WI?
MI^L=66R[#:\#M,L/";RV#LMD^I,&0]KD-0L19Q=L':"'G+5(3#@C M7LAPV2
MD0PX@(0G3F6<J@$@@@D$$$$="#Z"#TP1\HJ%>I6Z-=WMW;>FJ-28VMI_6@]K
MVB6^CX*MD)X8S=-14C:.6Y"5,M2Y$:&Y;95;9L+SLYBR$:V8EL35/,2XL2MY
M'D(,CNY5512[%B$0 *H))PJCHHZ  =!BK4<$4 80Q1Q"622=^6BIS)I79Y9G
MV@;I)9"SR.V7=B68DFKB\HJY3BE1ELK4VI=H")T7:>L*%LH;D2N#)'7>I5VT
MQI0N,6%6=(QQFPPI494/!^O S;<9[*8J"X<62SA$F!&?94!([CCY*HQI/O*]
M>GZ?0JQIJET?(R#*E':\2V4[51%!UL SJ@8(&@72.M P Y=$1=IUQH?5PTN+
MK27#%D4U#;%D82,]O5.!UZ]WQ=,]?3GNZ=_I\*F_J!VD/=H!VU21O5CNKV]?
M;"=IP9#]DF'W+:&4+B%A]H;;GU.I/08TZ/,:2W[&R;#/.I?:'V(@]#G-15",
M?W\9'\/3@_%7?]E>PYO0[^N& E("7+-T,%6C"C=UETW 6O@6QCI6<'Q$IUN^
MJ$^I)1G L!*^I^%-4T]B18(&,(RI4>/]_P!^GYJM-Q2H [$=AJAUQKVO;!<$
MIRQL?=VHM(!E/RTC8$8WM6X0:ZV3)E'6'XT"$%%K*FLYEX99(21\8,F7$D$V
M)#:I S\Q/S"I_P"*BJO=H>P1_K\(UX3K]$$WMRY7Z-52T<M<IE.17@"0I<T7
MM#+\.GW%1-0F,+]-X=(8#P_9W'94@W$1']!Y4@9S\G]^D?Q/Q5:'BHJM78C?
MQ'1JJ,U"IHVPMW5R\1W3]BNL*D5*I.T^D%;JF59R2A5A-)%2H 8G(F205<.3
MX0X607"&%SKP*NG%2,>DX_O^_P N/C(F#6ME.7/7=$M]FJ[M(L=IIU:L)^F/
MS\%7JF9,AH9$G6WBF(8_!%P)-D/#5SL0(7M2HV7_ &2-Z?J4*BH6[-=D4];0
M@>Q2Z":NHH@&VJ5F.A28V))A/:UU5:]GQA$>!*].82(VMFJ310[,=E,."I#\
MJ?+0YB!!)*D#/I ^6I+TIL.9M76%5OA,4+ EC3))HT #ERIV%7SH4T2 ' &2
MIJL4TE+G RPN8**YD5L:EDI$F1XV)<5IB=)5%0GVP[,6OKD*%%:UK0'L=$FO
MWRQ$X)#8F::6BCZ352%AD3AHR)3[A*GAHC\6#"M1X@@(+KR#85N)(/'RPRN3
M52!G^_V?*?1ZLD3!HK997;6N(=R.U\75CB+7LRFF@@.Q2;:$C%]9;,M^M"4@
M-9)E?JDLN*)3:B^4'2I=<#2<PYK+;\%IUM?FJ*QG<NZS>J[7K$(/I8ZT"+F3
M+IL\Y5NP+L-<K@(<LD:L@"I1@!J7:8@"(C$H^]/G501 ;E"Q\<U/L9P(!(JD
M#/\ ?3^__D] *[7K3O2N=FM :B[ 5)IF-7MN40#=QL%DBT54+09AH?D!Y4UI
MB+A1(-+]>**QW(L63")PY<*7&CRH[S*%",$@^@XJ<.*BO1*^UI']0]^K5R5[
MQ\H^NH/<?D-?RVZWC'U.@?DQ_(HO^;'^0L<^J7]NWXS?6:YL!L#J?WOX"J,$
M_P"4B'X]+_:'.=7'_AQ_B+_Q%4MWGY3]=<'E=13BE.*4XI3BE.*4XI3BE.*4
MXI3BE.*4XI7V-_P4#[1[R?C?7C]3NCGB/LP>WT'\74/KM*VFF_ZO^W^-?5(4
MZ\Z!-W5>R3.C=/%]BN%A9Y=^*:SI<^ZK. V1\<(97:981TZHL'CB13 LCF?F
M8/9&#VHCS*(49+?DB:IJ<=N+2/4;]+4(\0MDN[A;<1R%FDC$*R",)(SN73;M
M8NQ8$L<['E1EMYC3?D'=L7=D=QW8SD8&#GIBIAY@576,6&D4NW3*Z0M=0J]G
MGT\RU8JE.L( 4:F5>P,-J:9.UV22B27@AEEI:VVB8Q<6:VVM2$/X2K.,J5T8
M[46IQ$.0/$ZPUX+@2S1>R2H(ZE5N%#DV*P80D\>D1HPUIEXT;2VVDN4<0J<2
MPVC$Q]["$XPI656&NU^W RM8M8(-9ZT=@R!ARO6$9"- S(V6C+4H>5$DF),
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MR80,:Q$P8$#"V(#TF1!P3@1)^(4B8,(!)C\3VIIWV=Z4&*E!$EUGT%OC"1"
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M'+ 2I0(394WEN>()3QLI+L.9(9<5%>VKU6KT@ ,JE+K8&H58)'S$#5NL!QX
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M>7R<\*'LA\7@ #5L # '8K#H/T7_ .:W?8[?W'[S>NO7\ ?PH/D_\E][Y/\
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MYXF_#X_#_L-/[O#_ +6G8X/<M^<?[5>?@;>&;^ >T_I"=C_I9X\N>)OP^+]
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MXWD"UN#:M>B)NRK<):M-D;1<21O*D6,[MS1QN^<8PIR0< QN&[;GSL%L?$"
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M"RN7WH<V?18$2J1B&%YJV@M=:H\D]I>V5Q%;C3[2VTH64EK:+K-C<M8&06L
M,Z6$4\9E9W7H56=C*5J5CEPF R,-Q9FDW@L48!L9/>V#@#Y1TJ+K-U"[KFM
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M=77=:OH$KZ@UG<V-E=S6FE+VV72C=PS=GBN8]2MHXGT]-LUPS6[\\VMNMPJ
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$<4K_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g210084g14a81.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g14a81.jpg
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M4]\[ZJY[<OCK8?IY$=5G4?.V(/I6YMP^,:^UT;O+B&;9L<PHV2ANQ85?I<'
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M541<FSTS^R-/T,1L9JY[057CNMSNT!<?.U;HW8Y@&M,T269C1ZJY-18)$L?
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M(=7+(@>!$05S5;W<2,D)9!(*JG'6?W)H.Z+GYG"+(4_[JK[%8EKI"W9.-P
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MZYA)-W[)+P[U22[]'>[:59MQ59[KMNA"=J#<VL=!378]QC>".;(V.>O@1,>
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M'XZE[ K:7XWX&]VO_H2GO)ZCYY+'^B49_P"+7'958=\5;UY7!^.G8%;2_&_
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M*36I.92K_=\S,W*WJDKW*I_)^UY(3LV(CESPYG,R3D@J1EYSO6Q=$E@@DR+
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MQC@A<Q0%57[^JZ$RR'/I)GDF2(B<V29<W"OOL?1EIV^NON;2ZI]H; =J@B,
MK;ULH#)MX*$APH Z&*'O3MO/.L08H\6-@QHZ5^#8B0(D=I*66&T)A&Z)W",+
M>)$P9=(R/&KCJ,R+>VAN$1$1D@Y(I$1F2KSJ1*J\56HGT!NTX\M>,<#EI1$3
M-Z_KDB(B(B?]"<R(B)^)$2JT]Y/4?/)8_P!$HS_Q:Y==E5AWQ5O7E<'XZD[
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M5*F,9PSXLW+D1;J.[<9 /NC,)MN."&9..&B*JK]P" !D1Z$-Q4R04!LNVUJ
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M((GJ7_W'?ET\F"_DH5]60?N_'7,VA^.V*//=P^?IR")ZE_\ <=^76#LLL'6
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M[^URTZ83?OI[VZUL?4=A7P!;/)0^*GNC7OYV'/I[W]KCIA-^^GO;K3J.PKX
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M*]L]D=AWQ5Q7_P"7O3M/@T-R?/C5WT^W?@_CLDME/A2[>8YE.R.P[XJXK_\
M+WIVL,1]BNV07E#YQ.Q:?G31,EF8-F2'K2Y*A2([GA67(\C--\,WX-WL=PA*
M_!Y<PE>4Y4E.<5VNB;V8L ZVU>KVVV\! ZV-FFH#@DFDD,<]*YCPS5,\E5,\
ME6L5/VY8$NDF#,N& K],F6R0U*M\I^/AHY,-]@]ZTXP^M[WK>AS[8@(6A31#
M45(45/ACV*?8V,)QBSZJ[$J86G'E6[Y[%1C/MA8S\=5^/+9G_P ^QV]O:O\
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M5"IAQ2N>GLE7^(<'_P!HH7^IK#SS#T7/_9$[_22R?_U==OZ'W_M";_V-<_\
M^GKA5SY:U[IK6O>6X+-K8@U$K*:V4DNT;8-CR$(16Y95N;5Z#>+2%EY;AW4<
M94+)&*S#%.(75F SC7E)E=W%F'1(V5T/!>%+;B)@W;BMQC-A>K#;^6QW2:BD
MS<[[9;9,9U.V:1$23'B7)V4A#<SF 2QC2RR88RI+6H8DOTRT.H$-(;Q+;+K+
M6.Z"./"Y"MEQFQCTMW%J1N'I$-MDD6$,=1WPK<69!,,G$:]OB^3K&+!F&J=%
M)XGUD9.I?DB?$N1EPUN;9.MSTT3AFZG(@Y-$K-0%W6R1X<:YB\QTE\QK/Y$E
M"SR,K/P19&;?)FQ"N[L;<7&2S>.5L.VB(,3"&'<10696NS0G9"WNY7:39[>X
MZY:)*.+%1VV\M:DP2L(N)[FY+9C/C;P>1V&R[;]PZ$^0LG$-WM$IQA N,EMG
MI;#@,W"6(#<&-._T3.3&S)3<+G)ZWZNCOL9G^.>X?]G4W_B !SVCT%?\;L9?
MT<B?WFU7FSHE?XO8<_VR_P#\"Y7</GT7KQU3BE.*4XI6!,?X0JO\O2/^&+'Q
M2L]Q2M7[>,VH[U1ZG,UEBX>YI%K%E&;([A9R'2W(\D+9)8 BN%*O\P03*PK.
MT#&O#(&IAES<P5'FFMI(J-?.TPXJ/#C\'[?M^+NIM!Q4*P47^$9G^2@'^\'N
M*5G>*4XI6JF\*)NR[[AT6K75O*4B@UT=<C^PS4,T4C0W2PO8N@RM=!2:N,+#
MH]OEVNC#=O5*(Q9HQ.J5^&=+6.7#?/CJS#F*BF7'O_H7^SA6J]!M7L@P./1J
MF?UO9<50-1-.A+C<Y!/6=[V(Y81FKX>;D4K\0M:@D4S--;*4/$6Z7;K'87<B
M';'8@\\1,C-,I4X=_CQX9</@^#F1,LE3):_O!WV1&7=*]9"%.<'('SMA@5U@
M$]42E/?>*775#@!5H60ME6RNB^UP/9W UO%C+9L*KP)MD:PN<0.^212G#V5^
M#O\ X_86MN.FL[U#'1-A?W_7&ZZ12FKNP(RXE<A.1['*!I>V$$!IK-CLL<IK
MVO6+N0*'9#4F):3<#,Y9F-):C0#!14%]C]OQULQQ2G%*T1ZV/^IK?_\ FMG_
M /JN<\!=']_$S /])[A_=15UK9)_"5V_U%G_ (A*T-Y\M*[M3BE:I]0\';!,
MA%CZJ'; BE8NO-GRFK(!LL2%699^90;<$IE1D )=D@1,&GK@3!VI%PGB'L@%
M5D2,'R\MGS#XGIF WL,1X[KF)7[&[&<ON'&RM\VWNNW%J"U>[7,NUU;G-0'W
M5B!:H\RV%:6)0\N2XR9#[6J#$"3A;J,TR0802A<2+,5'FGA%DG2C/MQV%:)T
M11Q7S;>20;:[K<@ %DZXK=*2JYU9HFV<<0Q?BL\._M )J^T ;E7Q@0B8@TOI
MS&Z=V+=A6+*)BR:^1+"MLF;S5BH,M$CG9=PCCZJ2CSJG()[@U/V8*U;9#'2.
M,Q*##DS$=MG6F=(F,1'KQCZ1BNP6>4MOENMSF(LG#$2S7*--BNN0V[4X_<H[
MC-S"/8*U>T)X3Y29-K,;AO-OM V;@Q[4$"5(;WP(K9&$YR0R;9B+I/H+)B3"
MGT7YP.MIIQ2OHU_U_P#^ES_Z:N;1@_\ AHO]AXK_ .5KS5A<O\T__P!F#_QT
M:OGS5ZOZ<4JJMUIL#FM+*Q505GL5AE-0X8@=4;*_42[<Z7/BQV"CA^&<KI&&
M("+<P7.M"R>"<X/"FCX,,E(E('R=FP?R%,16\[E-ML" T3KLJ1=;>W=(I,M,
M..'&&"]#GQW94P16)"*3'Y.S+>9?>>C@VK[=E<-[R1U&6WG7201 &'59-"(D
M1#5P7&C%MM5UNH!H9-B0@)DJ"6G5HK?5[%*69D00O-FJ!Y9"?"?0?K%=M(58
M?3X$#B)%;A&QV8C5[M,MXJ/@"IC"*I<*W8B>9K$6RBY#/5[=<-ECL>VG)8LU
MNNL)([#P%!N,^V3!EXKG35==5Z&^CI66VM!&??E-&MSM-P@1T9-VW20/!NM7
MP3?$"D/,.[PP)'66GFU;@MMH(H+@J*27B4P$"1&'V72U(CP*FXVGXEOA568S
M;FCL7MM%E<J\"UE8ARVC:8LF[FNP;*9A$C+1*>U'\(N+(D%RI9(5P4Q8"$JP
M,E'5<GQ6[:G;DR5J.$[_ -&V\;D_;(SL.UR+ND8>7O6^(]'B%'8)S2CK;<6-
M%66,DX+#4$XPIG8(OBR2/HXGVYW<B\8N/A'U?:A=<$G$,D3/2JN&YN]".F3J
M&M6IS6JO*<4KZ._];'_RV?\ Z2.;1B_^%HG]%\#_ /)>'ZL+;_F[G^OW7^])
ME?/FKU?TXI7-^\ NK"4-NI[5D;9023&C[N*URA6JY!)[Y1^:#UM4:>(9L!2T
M%L,DR6$;%V?2V4%!%9J=M6)JTJ5  -2Y1#T#9INS%N19H6)7,/3&W','1KA>
M[9:9C 1FV9N(+I=99P8UMBZH["K8,.7@BC2KC<[4DNY--/3B:;8U20W>B"0[
M"&6VJ)<3;C/OMDID341B.V+KCQZ2+*5,CHAMLLOJ#)D#2$17_J<5MJ)L8S*L
M\>Z1:X[(W7DZ]9K*/- #,J7MV-+T@_1A:; 9F (8?5/E>$=CPAE7'R')@5!&
M*7.0Y#X[1L3R<+NV"(W;CM#EP$,(<A"W6Y^'.B,M86<:QB%ZDK!B-3GI>)EB
M.PG'I%RD +,Q6'8L)UH)&3@A-&4XKR2$:SN&\5YX7&G%*<A6]8P;UPFQ;A:Q
M<009%5)M"0W1)0VAYS>LQ3BE?3_\K_\ N?\ _/-H<_B7$_I1<?[IM=6 _P *
M.?Z@S_Q#]?/FKU?TXI6IN_1>USADU UC#V,'FITKLEN#; -IBQ*X3MY6I7(9
M2JK"!3+$S"$6,?9'AMJ?OTD%'(#YD&E@QI66&*6](7I^")&&8<.'(Q$]8);*
MXOP^3UKFVUQVX1K5&NEID7BYO36H!O2K?(MXR+8%C;FN,/M/7>;(C-2XUJ69
MA+F$UPW AC+;/D$O2^T\(LF^;$@([*-DZ@@Z+R@\LE6T,"&.V!DV;^[J)D%U
M9N6@CY=:N\J= -$!=)L .W5X=2WW0\'1(2!>KC6&K)"B.52WX";.M!.H2 AT
MH%P</#0,-D^X$(.[4<W9@-M8Y$5F:8>AL2;Q FVJ<_> &6]C28]9;1<3M[SH
MW.TK,P[;8]U;F0HTSD4&1-=<@C+8&R1N];X]XDDB%P@CN-OM!'7=C;6QDOL[
MX15E]0EO&PK;KC:..@VF\W9+T/YP:MHIQ2HY</X)V7^0BO\ N+_-WV>?QG'_
M &!C+_DV_P!5HG\(6C_;EB_OB%6D7-IKT%3BE079<4M-I!Z&"\K8+R8[+4!T
M*J<DA'D9E,*1(1@7;:,2<99RGORFH-H%R'8V'6\+?0I<5_-8==BLWF"].Y,L
M1MPB?&6C"L.-[HT)LN4VJ]QQ,T72T;]LE-@ZH$HMJB.AC+P#[MME-QM^CY@@
MM%'5Q'0+6*H:;F=;7E$<LS%J8R9!J1-:*H%JKFN=1*9Y8@:]NDL46:UHB2$!
M7)EHM&;%2^GA=Y88(Q+(&'194J(UN)J//IT.HJ(J38U$O'53J9B/TWIA@#<1
M8\/I0U*BEB-6YLVT&<5PI3>/TLIN1W;=,D.M-NEA(G&;N]=DC(MN&/N$8O&\
MTE(F+-Z^[(Z8FP^-G0XT>X"+X"PYA1;D(O!+CM 9MC?Q!R W 5Y4EJ[O%=MZ
M!M;KEBSQJ>,8MZIF3*)!K*4$Y,&:7CA%G2;E6A'9HUV0/FV"#5U!X9^9"E3(
MTLRQ.D,SIR',2WN8X@<MKMVDG:4:Y&K</,H[;S,5R8D*.-S>A,R1;D,P'[DD
MMZ R\TRXS#-ALV&"%6@W>T#-" R,]3Y2AR.#IMN/A'62\L)N2XT1-.2FH2QV
MY3C9N <@73%QQ%0RF_,-62IQ2LJ;_P )/?\ RH?^Y1^;!BC^&Y/^KVW^ZX58
M>P_P6Q_XT[_CY-8KFOUF*<4K2DA6]_R3<V2&D6R$ @WPK984>>??:(R #;.M
M4J!0(CE\,M2)>/%;VX&8L1$A2"9.1);55*^'E"'HW86+C@1J$RW+;MC\Y^QQ
M;:\;$$38;G*>(U2<^Z-CAFVTN]L8S#M\>/>HT9MLTNMPF-RP=YV[$Q2<APHY
M3VXK5S>EMB[)(73BH-H0HS8E<Y(D?:7)8Z2G7;<\\1HD&+'-@@M?3([8\*<7
M5<&;1%'N!AJ9"+6>AGLS;C@Y9EEB5;RR:-2Q81P(L RX/=4.$^$:BK""(;J#
M+TS5\72,/O,Q4M)VUU\9<A6RMD)Z"C-IY%;DBQ[@APX;4F:,Q)QC(!)$K23J
M39;PK#!G.8?:NS;CZSQF@TL=E#2=);DJY<$DS%?>B*DB0XS&6.L85:)6F,T!
M8S#:H^3E_P#-&K:*<4KLE[%W_!+;7^T59_JPGSZ.]!;_ !)Q=_2EO^Z85>->
MB4_C/8/]@K_>$NNBU;CV7-= 9;+ THR%%Y0E=>GK6E'B+'=2I:;.WA:L8[,*
M5AM&%9QG.$)QGNX]EUYQK->+V?Y8 ^CA#\5<4IXO9_E@#Z.$/Q5Q2OC(]L$2
M._*E'JW&BQF79$F3( 368\>.RA3CS[[SEK2VTRTVE3CKKBDH;0E2UJPG&<X4
MK!N6=ID9'-.W_7[0:8^J+$+.1DH&2I2,O87&CSU7/$5]].8\C"F6G5.)RP]C
M*<>"7W5*R4&:3)KFMC;542#@Z4Y!(-P1$B6N!-:SE+L.:EBW.*BRFLXSAR._
MA#R,XSA2,9QQ2LAXO9_E@#Z.$/Q5Q2GB]G^6 /HX0_%7%*Y;^RY7XOJWI@$6
MDE%&V9E.TJR/0-A-2JZ[AR8(LG9(5/?EV)"D-):5C,?$%"G%+2KQA&$92OD>
MVS"MKQC@D[->'+@U#6ZV^4I6V1'C2=ZQO]VB.RH<]K=KK76.X4EX9&.2Y^AN
MABLC^(-J#5OCS6H#BV&[O<H>AG.#2UR;,-P$R 69:DR/?Y#DN8%GP_-'[\]'
MFU5Z9X_"?/'_ &/^ /OS&'G>R_5BOHUUJ[KXTV_WLR?K-7R=ZUHS">^_KM#*
M?W7[IV[MMI_<(4XK]TNJ)Q^Y0E2U?'\2$J5GLQC.<13H?<!$N0RL8DO#@EVL
MRKQ5$3FPQW55$3OJJ)5-W9C/934]BZUM#VW;.X=>;3M14RXEB=$[4!(R[PBI
M+DB*M?PUUM0GTX6QKYEY&<IQA;5Y:<3G*EJ0G&%(JN<9RI:%H3C&?C6E2<=N
M4YQB)=#Y@,5R*3C(5X\"NUF1>"(J\%PQW$5%7V%2I&]FDQX4-G&-H=!5%$)O
M#[IBJD1 *(0XH5%4C$A%,^)"0IQ14KT>_/1YM5>F>/PGR7L?\ ??F,/.]E^K
M%5^M7=?&FW^]F3]9JZ_>PU;V3MK?FQQF*KFO^2=52)_A\G<%O&/"VFO1_!>"
MP&&>"[O>[_A/".]O9W>YC_K<[SL$V;8;P/>[[,LC][=>FVIF,^EUFP)3:-A+
M!T5:&):;<0GJ1$4C<<%1X("+VU>3>BTP?,PUAC"DB3=XUR&3?I+(ML6EVWDV
M0V]P]9..7:XHXBIVNA&VU1>VUKEI7](G/4=>$:<4IQ2G%*C-BBM3)578>5(0
MA1][.519DN"]C*:S8U8[LF$_'D)QG./W24NX2O':E>%)SG'%*]/M='_E!WTH
MLWK?BE5F6O>M@NTZEIJ8:LRK_<Z\<M D7%+W.9&C!06<)<DFR<<BY !++*:)
MIK;!-^,_8LUZS>2$2L5XMF*I5F>UT?\ E!WTHLWK?BE82-7X&;"81XP;[$BP
M2L9Q9K)A6<JD',9[R\%<+5C'=QW4J5E*,Y5E&$Y6OO*5F_:Z/_*#OI19O6_%
M*>UT?^4'?2BS>M^*53.S=KZPU)8Z+6+C-O#,_8#KR1+XN9="\ ?':N>N-=X(
M'9$(HXL; =NVV]?5]#_@G\MOV%$Z2A@0.+$8"HY*O[?C7_!:P]?Z@>G(_5PE
MJ7MT)7HQJK42WY%6G:3H,^'%[("QC]1;/"I5JRZ-G$QTI#B(RUKQG+;^6W'&
MFE.\4R7O+7SG=0_38/N(*CO[CK_E8_*LHJ)(1M92A<>RU<U30$RGSYN;8G$:
MVSB5X$LB /@ES)_BI?"$H6/<0M3+]OR_%5GTRRZOV,P5DT"_P+M'!D<B#+]4
MV01/LBR?B[,M,&>X+L,I$62Y$D1Y;33V4*>BOLR6L+8=;<4J%3/VNC_R@[Z4
M6;UOQ2GM='_E!WTHLWK?BE:0]9,!@<G7GB[DUSPRK3W_ !\D1*]G@\5[N^"\
MIRIG@.WOY[_@?!^$[$^$[W<1W?"G1V765:L(8%<BM6UTG<23P)+E9K1>6T%+
M6I(K;5W@SFF3SYW&0!Q1[524>%=4V5QVY%QN@N$^*#":5-Q)DQE55?1.V*,Z
MT1)[!*J(O%$SK1[PJOXF_P"A:_L<^9?5A=OO3"WO&P3]7Z[;TMC^J3_.MT^F
M4\*K^)O^A:_L<=6%V^],+>\;!/U?ITMC^J3_ #K=/IE5=L7<=3U9XH[<&S$0
M=+'64B@Q#KT@@*;S5:C9;T2'O2HK+BDDEU>G68G%CH:6E>!>(SSK$LB)8G[)
M8'\5XEWHVJ+@EU]I^WL%%=PE@./))+E=+=98[XMNV 46.ERNUNC.&I(J+)W@
M ;4>4;%G*;@0\E?<N8@HNEO!N-V,$W+#TDQ51EJNK<QWC1$1?N,E5",$*#JZ
MJ=2993,BD3$\8T,)G2I2#5"<B'7Z\%K&M+<9/G48AIG0!@8+MND/&%YAN213
MDX@@A&C)!F5P<PEGV@(:M.6O!3$@Y$>%%C/87V? [.G3+CB&UQ(4)>D:LOR)
M<O"]X"(B.BW)%F.K#CBS8:/V^^M.6I'[F0(!NN$D^[JC33;,1]QUU.5H0@VW
M.C*YP504RU(F[<4=B?"J_B;_ *%K^QS0^K"[?>F%O>-@GZOUE.EL?U2?YUNG
MTRGA5?Q-_P!"U_8XZL+M]Z86]XV"?J_3I;']4G^=;I],J$;.-$@.M-BG!$A,
M(J%H5R+#)B(\9:XA$=7"4R%)0AYEQE:F)++3N$.MN-+RCNN(6C*DYZ]L#O#N
M(=L>SZQ7BV87EVF\7]JV7*)U&81CI*@38\B/+C&]%LC$@&Y##ALN[IT")LR!
M5TDJ+S';4_*P[LBVF7^S3KA"N]CP/B6[VJ:-QG/'#N-NM,J7"E U(D/,&<>2
MRT\ O-.-J0)J DS2N&_OP>H_SG3_ *BJGJ'GV/['O8;ZT^ _>W;?F*^$/9<]
M$AZ[6)?:VOT?3WX/4?YSI_U%5/4/'8][#?6GP'[V[;\Q3LN>B0]=K$OM;7Z/
MKYN]8O4:RTZ\O9I-2&FUNKPU7:S(=REM.5JPTPQ7G'WG,XQG"&F6W'7%=B&T
M*6K"<NQ[V&^M/@/WMVU?[&*G;Z+7HDG7&VAVMXB0G#!L5<*SLMH1D@HKCST$
M&F@1513<=,&P',C,1152!J]D+W;F&N:QLJR2V6JF/NKZ6*E5_&(X FE]R)(=
MC/A&7\.Y9B3'764MJ4SB(ZT[E,E3##U+K ;"\E7K3X%7)L7%3J:MV>DL\ERW
M'/P7-/8RY^%;B.WWHK$DA$>VNW2,Z[B.9A5E7I=I5EZ\P%9&0PV^S;'65;1R
M3%;;=4Q1U9+;C:$P+SK4VA=974?-BL2L;'+QL/MX<PQ*K]2;D-X5^\EU" CB
M4JSCLSV86K'9G'Q_Y.5$Z'S8:J(O6GP&F:9Y+ANVY_[BM3E=%CT2,60]'7;!
M?WU9-05Z/TM-AQ4YU;,K8!$.?#-0'BB\*]7OP>H_SG3_ *BJGJ'D>Q[V&^M/
M@/WMVWYBK?LN>B0]=K$OM;7Z/I[\'J/\YT_ZBJGJ'CL>]AOK3X#][=M^8IV7
M/1(>NUB7VMK]'UV^U*>*V+5>M#YJ5B>8-T"G%BLUR/%;7+(D:\.ES)*VV&&F
M4*?D.N.90RVVTC*NZVA",83CX\]$/=2PUMGQ[A^R6K"T*SV:Z1;;;(?4;A*2
M,2#$M5O9BQ6WI=D?D$U'9$&F1<>-6V@!L50 $4^ZFPF7-Q/L:V98COL^XS[U
M?<&6*[7:<=PFLG-N-P@M2IDIQJ,^S'!R1(=<=<1IIL-9DJ"F=6#X57\3?]"U
M_8YQCJPNWWIA;WC8)^K]=8Z6Q_5)_G6Z?3*>%5_$W_0M?V..K"[?>F%O>-@G
MZOTZ6Q_5)_G6Z?3*UU.=56IJM/GBK1-.5PD-?NS,F&6J9)EQ&*'3 .P2[V7&
MHCT=IN;5+.!G!$R'F7R<PG&!-LH/KR+QOT*S8_N;#$FVVW!$^/("SFV[%PQL
M_-%Z=W>;8HHH)6(7")FYVV<S,4 ,([,9R:1K!1)*XMU^TLD8//W1HPY1J$Y]
MW142,PW)-<TE**:F7FB;S)%,C%I$WJZ*G=4W%4;C8YM6%>5&"D==TQ!42 28
M, \QKNVMT2[2P1%;"HDUFN6Q^*'(-K=CS,+FP9C,5X=,C3',)='\5VF U<I,
M/!9QC2T;Y(^$<!O/0COUK*]6=J:PE@1UD[A; =E,$(FUDR\T;@/M.-#<,MV]
M]XF0=N:&G*-*G<;L(NI%?2-(5HUEZ21E]1;-,T+,A)$4"$EL_P *K^)O^A:_
ML<USJPNWWIA;WC8)^K]7G2V/ZI/\ZW3Z93PJOXF_Z%K^QQU87;[TPM[QL$_5
M^G2V/ZI/\ZW3Z97T\(KP7[S?_I/]$U_F_P 7<[.;*YBVZ]1T5SDF&=2XEN 9
M=16#=WI2UVTD5&ND.Z0\U7-Q 1Q1R%241%$L4M\?IDX.\G9<A9+/IG<M6>_?
M3[KE>K+_ +N>G/CEFJK7S\*K^)O^A:_L<UKJPNWWIA;WC8)^K]7W2V/ZI/\
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MF)'G19D_$<IO%;$:'"L;49\6[2+ 3P>>B':HNF4P12"(ENGF!KK5.*5-M?\
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MOXN'#CW*R<\=OU73K=3A$IOI=EVSUH4.R(LDO5TDGM.GZ,U/=]:!W;%(U%2
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M_)+9]"I[Q+IC^8#WI+9?6G'8Z;%O$2!YPO?I.G7AVE>-4OR2V?0J>\2Z8_F
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M_6RZQ:IHW8I%90FW9^FG9V)#NNX]\&0P3 *TS",>M&6BK2F7LIS9_P!7#O\
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M99;;$HMF"+/&2PL>*"N(;S!BXC([B\Y-70*<4K+!?_7'OY)/_P!1$>;%A?\
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M?; J5->8>LC3BE94W_A)[_Y4/_<H_-@Q1_#<G_5[;_=<*L/8?X+8_P#&G?\
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M(V(ZR</4X7/;?&N,T)LMZ_W5'I-\Q&\\H,6(1)UR_P!R)PT%;*6E7#4C415
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MZ9:WEC@%SE-L%"@,LW-U 6XLFP>]60S&=%YO<;G)*Z!3BE;#])O_ +2&G_\
M;&%_]"3SMG0Y_P#;3@3_ %ZX_P!Q72N9;9/^S3%/^K0O[U@5^EGGU\KYZ4XI
M3BE.*4XI3BE.*5@JU_@>/_\ /(?UE+XI6=XI3BE.*4XI3BE.*5@H_P#"8O\
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MS@7[^97_ %7QV&>R_P .8\\Z8?\ JO3LCL<^#<+>077TU3X,757G OW\RO\
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MC]S3M4HR.5MDQ))<-IM@CD6&,\9L,J*M,D3EW(B::4 5MM54 4!4432F7O\
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MRL7)'6E7E,'@C@JO^?1_9KY]Q?\ FJ_FY_Y<UCI;<?O";Y*_\W5]OV/5FO=
M^.G<7_FJ_FY_Y<=+;C]X3?)7_FZ;]CU9KW0/CJK-TTXY?-;6.H@ ]-,DCK<*
M"F-?F</5]B(X0BY($,-.UNV1EFQL!,F;6ESJ^4',6!D;)(PY4)A^,]LN$#>L
MF(8%UG,XDB1X1//*Y9(\@)QNBPXC#"F,RV.)#D/JVU<$9G1GS@G(;8=;>,'
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M%VKVF:4)S:CCB3_D\&8U(C8RQ1N'XMR@1KE#>!'YC#X;R)+9,FWF6G6C4FW
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MY20@'>W)Q0PD$RR3XQU;%XFFU<0E <OFY^Z"7"?LQ'9>.S6;+V>C>"Q4MV3
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M,ISVZUB7"TS%,>-&AR(T<HKQ/&4E7$$A,-"(.[ USSXKFB)EW:WC W1;[/\
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MYM,>(S'@BQ$6"J&?Q_M^2L>>Z==963VC1"E#NRJ[K(6#&:[ID6U#X-0IN:[
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MP6?:PE6'U#)"X&'<JSV,I:7E.9+:'\4^RQV$9(G55.5$%13/#F(UR145%_\
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ME8>9^YL=%G/"&$JU8+<2!&<B1LL7VX%%EV?-N1H2@PFLBEW"4YJ+-40T!%0
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M.X2)(C*CP1X^#?;M+G3ITMY$>)#AQ(Y9Q^5*E/N-L1X[#:WGGEH;;0I:DIS
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M2;NVVZ5)PHMLFLI$D.Q); "AN$3)F;JL/%K98)MQMQ1=$4$D'2!(99Y)*ZZ
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M]2:AB[*JI@K#:Y9ZLC(H6T96Z:'=X-Y2VK<+8[(%I+[RP8IQ):2@BE*<.\F
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MI.L]:78-U.472FT*NIY6N]2W#<&I[I5M>VP-)K+!)^OTT':;,P'8-UV/(=H
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MBR4L.$#3=:1H =I9.<L_K82S5P]['E;?J65#CQ*N:;O3B3)>%KU$,9QG(8O
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M*K+*FQ4H'(M3EE7'V0L]*<S>GH]TQ.4U589E-X-:CPAN;$YNWQF5$^6C.9E
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M9<<K_!_G_JTW?L_!^FGEG\V_7?LN.5_@_P _]6F[]GX/TT\L_FWZ[]EQRO\
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..G?J(CI7///AES?IK_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g210084g14b82.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g14b82.jpg
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M(R0S04114W%UA)BQM<0E,E9WMS<X.4AR=H>VQV&A_\0 '0$!  (# 0$! 0
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MQ7X9_@[H7V1I_P"'K^4_AC5O^=-1_/;G^MI]LSU(?R@=W?G6OGZ>X^*_#/\
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M-<N<VJQTXI7])']3W?\ S=?_ (#_ /[3SR_$G_H7_P 3_P"170L/^5_]W_\
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MAY<K749?Y"ZBW=P;7W+UVY/(/[CCU=>F:C_+4I^JO.;\5-5_S;^>/]77T?\
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M<VO$/#!'P?#H5GI[_")%I/VB"XNY'Q$O/!3;,F&WC)R,#%<G_N+W6'Z9I_\
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M 2.5@D D ^K)QXFJ7[B]UA^F:?\ RW*_JIR?U^.!/],_9R?BJC];KB'ST_\
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MR;,?>E2Y<K;IV1*E2I#BGI$F3(>HJW7WWW5K=>>=6IQUQ2EK4I2LYR'%NC@
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M2F<J%QT8O'=SQ"<+(V;C89'))??',DZ3*^=RS+(G24'>%>1<]\T**=N2.[G
MZXP05((QU&#X>&0#ZA6.P>F_0 R+7((W3>E!T*GG)5FJ4.#KBHPXM7LDZ2.F
MS;!78\>OMLA3<R:'$3)14:B-.D2Q0R2Z^MZ!$6UE;4]2<RL^H7SM/&L4S-=S
MLTT2JRK'*3(2\:J[J$8E0KNH&&8&.5&,86/NG*]WYIZ=1W>AZ#J/(5>AND]0
MAB!8L(USJX44/6.%<3A(=3*_"GF+<-GD"@ZTE)D8,U((6* 4+%24(W*<=)12
M!0C-8DMR9TIUW&]]>R*B27ETZ1Q-!&CW$K+'"ZJCQ(I<A8F1$1HP K*BJ00J
M@2(T!) 0$G<2%P2P)()[O4Y).3UR2:M KI[U!79%3>J5,I-)C4VY$-@B!-("
M#*B&=N1&EG->O6 J- "X$<H0;J5B*BF')B7,-MN17<I4Z-'+BW?4;V43":YF
MN#/ MK(]Q(\S\A+B.Z$2/(S%%Y\2.0N,G</!WW0(T&-H5=K%@%!4;BI4D@*
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M>[N)TCN1><F>:2:![@2M.99(G<H[/*[O(2,NTDA8DNQ,<J/K@("5V95=K;<
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M/>Z[21C-:DN'79.A;JN&GZ20U856&52-= Y)8HJ;;L[4/=06H-"6>RV&FB;
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MC]16,C2GY5V%AE;"F$8A#7-G&E=E.6P?J+WL:XL-B/'L-$;+2"57MXN;.*$
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M@S\W;@/!R 5YIP\QN9MP-O,Y?@=V>5S=Q.<8\5VX\<-NZXK4-HZN]ECXEZ/
M0])<$:[1U+7HZ,-#S3I,S1.G3>3FC'J=6)< [ 9C7"VR*Q<+8BT3XA@<%DS:
MK6<U$FDD^7@;L.B6C&VCD>XYET=)MHVC:,)'<:IIXU#GRJT3%H(!-!#R4*/(
M%FFYZ[0CU,S ,P"X3G,00<E8G*84YQN;!.<$#*C:<YK;FSM_7BI;8F5H&-JK
ME)J)OIGK-N9)1"K]R.$.IS:)C5@HE5IT<M$$!AU F-!+"103!V-5MAN6(9'>
MJSH%J>4TK33;>>R661YA<3QZM- 49!!&FDV<=XZ3*49Y'N5,D2[)(A"W*<B8
M2%%LTC!\ #:IC##KN/-<H"#D !3@G(;=U VX!.Y]#WTIL[3VO;P>8A1[$;KL
M7%G9&-.LBD6H8MT/9\B&I#\E] =9\>16(P_(?>R-5%RZ\XYE2\Z&HVR6E]=6
M\18Q1RMR2YR_)?#P\S 4<P1LHDP -^[  K(C%E4G&2.N/#(Z''4],@XZGI6V
M^:56IQ2G%*<4J;-^[%_F4?\ X*XI4+BE.*4XI3BE.*5S$$WE9(%?ZL+!?P(&
M.CIPN5A@Q(=2FDYN#-4$Z&UENN&Y+F%8D1QP^\Q>Y(R7F,-B06G(C+<=A_"%
MRY77DT^)I=&BMI)#\*01,S3*B\N9]1N[!MJHS 1@VP=<NS$,<D> Q!R!*6 Q
M&3X9.5$:OZ\=>\1Y=*UG;>I39NJ!!DG>ZU3;!'JW1W8M^2,UB2>C$K'>Z-#J
MJ;$+Q&<B3X]>K18O87XHF/$Q:B4.%$;(OSY3DC(IC:@TJTO7C6VEGC,VN1::
M.:L96*WN6F,3YW*9942(%RW)5F)4*,;S#2,@)8*0(3)T)&2N,CKG:#GI\[ Z
MDUM&F;/M5OU)>#"[K2JUL#7YDF'NABW:FMU;JU%EA8(6V$XMDHA'::3$AINC
M&(16.;A[(8'2(I8:=\VVTU+!YU+BTA@O;=.1/-;7,:/ D%[!+-<!WD@5HKA;
M,H";B-D,;6I<,CQY)*R58,2K=Y0RDABR$!<8/52_[D@Y#XZ@^'2L>T%N;9UT
M,4@/M$77QL_86AX.WPL0$"+UV0-\U>B@^8P>$&CUBFAIT^EVS5,AZNNDR#U?
ML\6[05&"T7N2HN74K"T@CN)+-Y66UU%K&1I9$E#YMT=3&\<<2NJW$-Z!*$42
MPFW;EQMNW1&[-M#@ LF\  @CO'Q!)P=I3NY)#;AD]*ZYYQ*RTXI3BE.*4XI4
MU_\ ><#_ $2?Z;BE0N*4XI3BE.*5B=]M;%#HMTO,F%()1J94[':Y Z(K"94]
MBNAYA=V%&5E*\)D2FX:F&590O&''$YRE6,=F<UM";FXM[<,$,\T4(9OFJ99%
M0,>HZ*6R>HZ#QJ&.U68^"@GV#-<>1^I+9XK56^RMJ@T*;L+6]&HMJJ,^JP#D
M6E32&VJ>S.IX4U!)GRY)W%<MZG8)XK%,1&SE94-/1A=>?G.#(O=.E6;WFFI
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M\NC;"S-Q*;53D0%SRQWF? 7/S1([R!/FB1VD WL6-=J[BVT;CXG R>@'4^>
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M)9F"X']S-<*H7>K%L;">FW!8;@>HV6?ZS*#6)=C9.TV_C( ,C;1 X_/5KV
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MT>P>ZG?G_O(?S</^K<4R?H]@]U._/_>0_FX?]6XID_1[![J=^?\ O(?S</\
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M)9;H.;Q8KK3;72C(((7ECAT^+2A;W(C-TBM+<2Z<XG@,RK!%*NRXG92*CEN
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LJX08D1KSOFHT=ORO(\KS;+:/*[/+[.WR4X[>SMSV=OW.W/9]WBF /  5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g210084g14n19.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g14n19.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[2;D4&AO=&]S:&]P(#,N,  X0DE-! 0
M    )LB^F2@X0DE-! 0      $0< 5H  QLE1QP"   "YH < E  "')R,S<W
M.34R' (% "--:6-R;W-O9G0@4&]W97)0;VEN=" M($9I9RX@,C4N<'!T>#A"
M24T$)0      $&BW3(J#P$O#.[#:"E"T-.@X0DE-!#H      .4    0
M 0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N
M=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP
M"W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC
M    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P
M 0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"
M24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS
M%P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#
M<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O
M;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $
M      !21T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B
M0&_@            0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M              !";&0@56YT1B-2;'0               !2<VQT56YT1B-0
M>&Q <3<[8         IV96-T;W)$871A8F]O; $     4&=0<V5N=6T
M4&=0<P    !09U!#     $QE9G15;G1&(U)L=                %1O<"!5
M;G1&(U)L=                %-C;"!5;G1&(U!R8T!9            $&-R
M;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<
M    #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ .__C4
M @ " [_^-0 "  (X0DE-!"8       X             /X   #A"24T$#0
M    !    !XX0DE-!!D       0    >.$))30/S       )           !
M #A"24TG$       "@ !          (X0DE- _4      $@ +V9F  $ ;&9F
M  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8       $
M-0    $ +0    8       $X0DE- _@      '   /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H     /__________________________
M__\#Z   .$))300(       0     0   D    )      #A"24T$'@
M!      X0DE-!!H      S4    &              /\   % @         !
M                          $             !0(   /\
M          $                         $     $       !N=6QL
M @    9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L;VYG
M          !,969T;&]N9P          0G1O;6QO;F<   /\     %)G:'1L
M;VYG   % @    9S;&EC97-6;$QS     4]B:F,    !       %<VQI8V4
M   2    !W-L:6-E241L;VYG          =G<F]U<$E$;&]N9P         &
M;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X    -875T;T=E;F5R871E9
M  !4>7!E96YU;0    I%4VQI8V54>7!E     $EM9R     &8F]U;F1S3V)J
M8P    $       !28W0Q    !     !4;W @;&]N9P          3&5F=&QO
M;F<          $)T;VUL;VYG   #_     !29VAT;&]N9P  !0(    #=7)L
M5$585     $       !N=6QL5$585     $       !-<V=E5$585     $
M      9A;'1486=415A4     0      #F-E;&Q497AT27-(5$U,8F]O; $
M   (8V5L;%1E>'1415A4     0      "6AO<GI!;&EG;F5N=6T    /15-L
M:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )=F5R=$%L:6=N96YU;0    ]%
M4VQI8V5697)T06QI9VX    '9&5F875L=     MB9T-O;&]R5'EP965N=6T
M   115-L:6-E0D=#;VQO<E1Y<&4     3F]N90    ET;W!/=71S971L;VYG
M          IL969T3W5T<V5T;&]N9P         ,8F]T=&]M3W5T<V5T;&]N
M9P         +<FEG:'1/=71S971L;VYG       X0DE-!"@       P    "
M/_         X0DE-!!$       $! #A"24T$%       !     0X0DE-! P
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MQ $_   !!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!
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M&HQE(U$6IZY)5>F=1Q>J=/HZAB.+J,E@>R=")^DQXUVV5N]EG\M6DTBM%/\
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MS_H?]6M<TTNG=569U,L:?^^IL@
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
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M52EGL#.T?6&K[[=)EE-QZIV[N*,Y8P:<&=VBX340.4DN)"JD$#*  "(=G8>
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M;5.RJ.6Y5"%76Q2+<ZC!?:I/=S75U!/:BY\]I)IWAN/,C]I,SNQ9(95AMG#
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M9#S5V:G9X6ZU>N7&MODI2O6N#BK'!22 ""3^&FV*$E&/$P, & CEDY16*!@
MP ?L8 $!#(^>"6VGFMIT,<]O-)!-&V-R2Q.8Y$."1E64@\]JS(ZR(DB'*.JN
MI]58 J>>>00:J#,574Q2F*4Q2F*4Q2OR<Y$RB<YBD(4.YC',!2E /F(F$0
M#[B.!R<#DGH!U_"E6VM&Y]04@#&N>U-<U$I?VC6>\5B * ?<1EI5H';]^;<-
MA?W'-O8WD_\ W-K-+GY>6C?^W?BL;2Q+]Z2-?[SJ/YD5C]8^HKP*J7C"P<R>
M,S R?[9/TUZ]=JE$/F I,; Y5 P?4O@\7T[=P$,DXO"WB2?'EZ#JQST)L+E
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MA\8W#$^ONL$P!Z;B<=R:W1Z ZPG3CY)&9LJ!RBH,38GHID)4MEJO=5V(')P
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MB4Y)Y$C*0DK%NW\3+L#/V#E CE@]7(;PIJ!V261,?ZHTW5=.UBW]JTR[AO(
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M2"YP$!= UHCR$@7ZW<PF\,S#2;<Q_P QT#CD_9^+?$%D1Y>HRS(,9CN@ETI
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M3_$LMT#Z#8!R!7-W+F6[G9N<3.F/58W,8[\>XN<CD=0"<"IRQ2E*4"D*4I0
M *4I0*4H '8  H            !V ,\6/Q_SJTY[G/US7.*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2F*4Q2F*4Q2F*4[!]L4K1'U>NDKK;E3K2Z[UTU48ZJ<HZ;#2-G]
MXKK1%@VW2QB6JCV0JUICFJ16\A<';-!8E2LWEDE5Y4&<+-.W44X05BNX\*>*
MKC3+B&QO9C)IDKK$!(<FS9R%66-SDK IQYL1(15S)&%8,)+67(X SR3Z\9/X
M_KK5J?9A>=]KV)4]A\'MD3+F9<:EKR.Q-+/I%<Z[YIKY68;0UNI0K+&%4\?6
M)V9@I&NMQ%4[1E.RC @I1T9'H)6?:MX?AMY+7Q!:QK'[5+[)J"J  ]P4:2WN
M, 8WRQQRI,W&3'$QW.[L9?2;AB7MG)(1=\9/\(! =,YZ98%?_%TX%2VL\:J;
MIBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE,4IBE8X<@FZ#J?XU(.4$7"
M"G(F)!1%=,BR2@!JK;9@ Z:A3$, &*!@ P"'< 'Y@&2^E$B+6""0?V3)R#@_
M]=L>XYK!-RUN#T\_I_\ T9C_ #YJ^WX<KW_@*&_]%L?_ '&1GG2_[63_ 'V_
MSK+L3^JO^Z/\J?ARO?\ @*&_]%L?_<8\Z7_:R?[[?YTV)_57_='^5/PY7O\
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MZ 23>H6-X?;.R;;')J&^",+DQKM31 YW#FT*IHF@I3)8:'HNAINEDM&4-O\
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M(]M%<1$3CYGDM+*VN[-J41,5%FBT;)^!%%),L9]JVE+::Y;:E&I5-5M293@
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MPAZ;)>6<23R275ND=JN^Y=IHPL";2VZ8[OW8*@D;PI(' /%1JJS%0JLQ<X0
M$ECG'NXZ\\<5.>Z$71YOW"1QL?>/*ZDT-'><ZK'P&K&K*487&:UK5",YAM;G
MR4W%.'5=:25Z&19,%0BEGK]K!Q*C56102FI&-'P+[0?&MKKL=KINC7-P]@NZ
M6^8H]O%=R%HFMDV2*L[+;&-W.]$1I'4A6,:N)_3K%X6:6=%#^Z(QN#-'PP<G
M:2H+!@HY) W#@,<ZSNG3U5[OPEOG+ESRFG+S<>/>Q;ER*EM(S4]-2]D.GO/2
M#E-Z_P!4PKR16D%(0EYK]AJ\8DDJ9&-92OX<5(DF@^D5TNO\5>#H-?M]&_92
MVUOJ-M#IR7J1K'$1IE\63VIU4('-O+!/(H7+R)YRYWJBUHV5\;9IO-#M&P?9
MU.94 (5>N P958XPIV$C;DUE'T<>7>X:2KU9>2/-:T6M:4HE8U3O:PU:P3LB
MNSJZ%PK6R=A1M3JL)(/'#.M*R4=)URO15>:(MU6SDT9#+H^\M03)$>.M$M+@
M>#=*T2*%4N)[S3XIHD7++ ]G;R2SRJJM-Y.R6625BRL%DD!VL2<VGW#)[;-,
M6)"QR$$XRS>:P !)V[LJ%'\((! Z5CCTC.>]WK7.S6,QN;DRPVI&=1^*V&>Y
M:Y)='LXAQYW438MDD-7UQQ"O9%XA6RVB(,RA8!C'MV*(ENC:)51$]<\PDIXW
M\.V]QX<NH[#3&M'\,-;O;3^3'&=0L1:PB[=74*TGD^^\S.22]GY@)$@SCL+E
MTNE,DFX70*N,GW)&=MG4GEF "@=%DP1Q6=_!3;-H5X!];!_;=D61:RZZW)S=
M;Q3^PVV65FZ0Q1U<^+5D(MU(OS/Z\V1E6C@L$BR.T(C((*E8$*X3, 0/B.SA
M_P"='V>K#:Q>5<VOA\.L<*>7.?;E,ID4#9(/+;]YN#>X1N]WBLUJY%IJ.7.5
M$N"23@F-@I&>G(&,=QZUKQN-_P!B;"X]=%75DX[WOR:;;"U-NRV[/XAZLV9?
M:-M;;C=K+6Q6I;,F;Y'%4(^AJT>)=.&R,],H.",X=^,7V9OI)XRZ.VM[>UU'
MQW>QC3](>WO-/@M=<O+:VGL[+,%KYMJMN[(8VD\U5.P*C//'O)944Z[EFCL(
M_P!Y,K)(S01EM[D.^&W ,2<@\@$JJ.,+DFJ<-RMWW_\ )E<2M'I;7W9>7FX.
M?5ZT9M.ET^Y3<3R J=)KZT(->XD+;+N3>,=M)R=6L# YIY7SXAJP?LH?LZAH
MR3@#Y_V/IO\ SMUC4396-N++P[;7UI/-!$^G2SR^TF76?9X6(*PB#RV&Y9"R
M-,&#21RU;Y\OLD,6]VWW#JP!*R! L8$.X@_?+LR\$<A2.&49&UW<:/'C@SU7
M=%05YY1\+M^:>C];2@ZTW;O-OOF&UDWODQ%-X:+T1LFAUQO8FCS:C!Z:LR#I
M-=Z2,>6&O6%*43;M9:491<MBVJ>(?!NIR6^D:]IUXUZ@O+"P;3Y;IH(9"9=0
MM;J9XVCLI5%Q$F%+F*6'R@SQ(^17\JVOHPTT$J^42DD@D"C>,K&Z(@#,N48^
MA4DX!Q<WHRV*VTCJ".-72T)O;B_4[SPDJ-];\<>06R+MLJ2W=L=>8C%9S?M,
M=SS,(6!; P8322\;[PQF127D4VT85HVEX^NZGCN*"Y\-&[CDT_5IK7Q!+;G4
M].M;>U73K;9(J:=<".1I)&!>(%L;&;8TGO\ ER2Y-.+)=A")(5>W!\N0L?,<
M!274$ <X9@<< , 2"0LM[/%*GZ8I7 B !W$?Z#!X!/I2HH76MZ[">G%+3Q%X
M669-_N$XN*]M3<T&JF[;:N5.)FK^G4-RB"J3_8WJHUEYQ RC>D*"9DQ,I;BJ
MJ5KV'P+]GWM7DZUK\.+3B6RTZ92#<@<I<7:G:5MN \4+#,_WY![.0L\+?ZCM
MW06[>]R))1_#ZJA[GL6&0.B^]RN('2FZ(+NRN(CE5ST@GLJ[F7(6VDZ(MY7#
MI[,.7ZPR"-RW:F^.HZ=JOUE0D6U!D?$L\,H"UY*<JKFN*=)XI\:",-IFAR*H
M13#/?1$;8U *F"SV^Z-H]UIUP$'NP>\/,2&1?XB>3Z\D]\]0?S&<GTYEG-FS
M9DW0:,T$6K1JBDV:M6R1$&[9N@F5)!NW13*5-%!%(A$DDDRE333*4A"E*4 #
MRLDL26)))))))))))))Y)))))Y)))YJ_]?GG_&O/E*4Q2F*50VSZ'$;3UKL+
M64^0JD'L6CVRBS)#E Q315N@7]?D $H^@]VD@M_CV$/4 $,]K</:W-O<QD[[
M:>&X3!Q[\,BR)V(^\HZ@CU!IC(*YQN&/7KQG'?';OZ$&H@7LS^RI/274(W%Q
MNMJAHQYLK7-MJ[F'4-Y8#L73-@^+ V$ANPG<,H%._ !?403*J/;T[9ZC]J5F
MM]X:M]0A]\6-Y!.' _\ LMXA@8]#@/*]J><=!R.<[>E2;+HH3@2QLH']H8D4
M\8'"JWXXX-3W1$ #N(]@SYWKI:T.]0?K\\3^&*UCH&N%6_(_D!5;:%2LVL:]
M)RU9@:@Y:%<C-KV38JM4FZ\H[AW+?X2[@*_\:F&\RH9C))1?NKU1OZ%X<^SK
M6-;$5S>9TK3IH?.AN9%CFGF#8\L1V@GCD59%/F"28QH8\,GF;A4;<ZE#!E(_
MWLH)5E&Y54C(.6*\D$8PN1_:&*PHTI[5#H^];BJE0VUQ_GM+ZGG&#9">VJK>
MCWAS4+ >/%9PH^IT'1&S^3JQ9,IHY*2C'JTV+8Z$FI $$RT>A.WWV1WT%E--
M8ZHE]>QLQBM&M5MDGB#8 %Q)=%8YRGO[7 BW93S/NN=>/6%:11)#Y<9P"X<N
M5/=L!!E<]AD@<Y)XK-KJ[:KU+U,.EE;]P:'L<!LX-;Q*_(#3ESK9O>ROPHR3
M]*_P*8'30D6SF0IY;/&/:^]1:O&]GCHI*18)OHPJ*<'X*NKWPMXOBT_4HI;3
MVQAIE[;R\!7N-K6<P*EHV N&A*S*60P22%'V.2<U\L=W9F6)@_E9E5E]%R)%
M/&00NXE>&#JN1Q@ZSO9J.2CVZ:-V_P 8IY\==UI>S1]YHY%U1.<E*V4K)#-Q
M3),1[ILX.YQ+N66'P^'WJ\ '?OV >V^T;3A%>6FIHN%NXVMYR, >?!@QNQQR
MTD+;1S]V#MCF 0CH>N.!Q]?H..W))YJ33GFU7TQ2F*4Q2F*4Q2F*4Q2F*4Q2
MF*4Q2F*4Q2M5/6@Y(.>-73^W%+PL@:.N.U$V6CZ<NDKY+A)]L1)\WLCMLJ7]
M:BZC]?Q]QD&2Z/A40?M6AB*)G$APZGP=IPU'7K177=#:;KZ7/(Q;E?)!'0@W
M+P!@<[DW #@U1CA3P,].<G@_ ?(C/8D5AS[+/Q.;5/2FWN85@C"A8=KV(VK=
M?O7"( NUU_1UTW5I=L%3%[^[V6ZJHQ[WPB("M1&X )1 X9L?:UK!EO+#1(G_
M '=K&;ZZ4=YYP4MU?KAHH \B@=KD$\8J6T>' EN".6Q$A/4*,-(0?1FV ^AC
M^>98F>/5-TQ2N.X?</YXI7.*4Q2F*5P( 8! ?D/S^8?[,4JR$]QEXWVJ1M\Q
M9] :5L4OL%N@TODK.:NI$M)75JV70<MFUL?/X-=U8D&[EJU<()2ZKPB2[9NJ
MF4JB"1B2,6L:M D$<.J:C%':DM;1QWMRB6[$,"8$64+$2&8$QA20S#H3G";>
M!B2T$+%OO$QH2WS)7GZU=.LU>M4J!BJK3J]"52L03)&.A*Y6XMC"04/'MP$J
M#&*B(U!M'Q[-$!$$FS1NBBF B!2!FE+-+<2O-/+)--*Q:265VDED8]6>1RS.
MQP,EB3\:RJJH JJ%4<!5   ] !@#Z5WN8ZK3%*8I3%*X$ $.P^H8I7B]W0_+
M^J('@[^#L';P>+OW\/;]GOW'OV[=P]/EC_'D\]3ZGU^&>E/U\?QKS '8.WV]
M,4K5L'1WX1.=5MM.3M'L-JI37DN]Y6(M[)932#\NS98C!O.L3/TV#912CV%C
M'(1TY5%"&:R#(1(JL"J399OU_P#SZ\1"]-\D\,,_[+32 8XMJ>RH\DD<FPLP
M]IBDD9XY3RI) !4D'1&GVPC\LJS+YIE]YB3N("D9Z[2JJ& QG&<YKLMJ=)KB
MMM\W*$+.KM!DAS!M&LK5N]G7;T,.UFW.I0<&J,7&$)$+&B8--PLB\D8](Z@O
M7;%B<5DTT3I*66GC36;(:2(DLG_8D%U!8-+;EV1;S8)G8F0!I-JE%8XPKR @
MY&*O802&7=Y@\YD>3:^ =FXA<8X )SCU"G.0,5#MWI4<'=M5>AUQ/1]2U4]U
MK<*I>J;=M(P%9UAL&*GZ810L&H>WP4!\4D&I#J$=.VLD=VF\?-6;];N\:HK%
MQ6?C+Q%93W,W[0EO5NX9H)[?49);NV:.=@SA())0D9X* IMQ&S1_<9@:O86K
MJH$2Q%"&#Q!4?@$ %P"6'?!SR >HJQN_^AQP;Y$[BM6Y[0QVO4);8\FSF=N5
M#6FR'E.U_MN59N4W9I"\5Q"-=G4>/728O9!>O/Z^=W(K.98XA+.W+Y21TS[0
MO$6EV,-A$;&XCM4,=G/=VQFNK./&T)!()$4JB^X@F64","/E% K%+IMM+(9#
MYB%B2X1E"L3R20RL1D\G:0,\\<YO)R.Z5?%/D6QTH!V>PM)V?CM6$Z-IN_\
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M/USZ\8S@$@\8'&,G1Y[4)6'Y+9Q N?DG-&.JYMZKG6 !\M*082=%ETTC&_9
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MQ678QZZY""_E'L]-IH,TI@C!KP/B?7FU[4#,BE+2!3#:1M]X)G<\K@$@23,
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M;220D6X'X#QGX]TZPL]0TS2[N276"JP+-:8,5HSE3)(;H,$\V./<BK%O=)F
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M #DGX"E?/2ZFW)S9'62ZB])XP<>7JDEJ&D6V0UMJ@Y5%E*_(.B*B?9N\ILB
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M?UL#[R>H/4KU7IR &;;P @(=P]0'.+K>KCPE'OW*4>_S] ]?X^F4P/04KD
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M>8H1Q;QLTZ,119>FKMW;EPW8TTI5/2_ .OM#/^Q;I\PW#&2Q9CQ%<<L\&22
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MS$>?Z!,1VXY](4CS\>E1XZ#(P<=,8ZY/3X9Q]*R@'Y#_ "]/WY%CJ*J/_?\
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M(0$/>5B_4>_H@F/_  AP$Q@$A#%-LV\'F'<W$:]?5B.=H_#G/0'(![:\\XB
M Y=ONCCCMDYZ_ '@XP36/:RJKA95PX5.LNL<3JJJ&$QU#F$1$QA$1$1'[B.;
M_'0   8  P /@,G%1W))9B68YR2<]_UQVKQXJM,4R/6F*4Q2F*5Z<@\3CV#U
M^J4YTF+1P[4(GV%0R;=$ZQBD ?[QBD$"_OR^-"\B)P"[*HSD#+$*"?@"<FK6
M.%8^@^M:O]):RVSRWU_&<@]@\G-X:X)L)U-2=4U]I6U,J/5:;564Y)0\;&N_
M%$R*T])BG'&=.I5WY3D06!)8ZQRB<.]U.^L/#UX^CVFAZ5>^RK%'<7>I0&ZN
M+B=XXW9T&]1"@#@*BEAUSC@5!VT,]]"EU+>W$(FWM'%;LL<<<8=E4$;3O;C+
M'))///!JT_";B].;"T%"VB/Y/\EJ V<6F_LT*]0[ZQBZL0D9<YI@,@R8+P3L
M2KRQD#OY%<K@Y7$@NY7*! /X WO$VNPV>K2P2:)HMTP@LG,MU:O),#):QOL9
MEE0;4!"(-IPBJ"3MR=?3;)YK4.M[>Q!I)B$BF"QC$KC( 4X9L!FR.6RP/.*V
MJZGUY(:MJ!:S)[&OVTG*<B^D!M.R)1G,604GGE>&.]\9Q\<0T>S\H3-$E4U%
MB&77 5Q2\I)+@]0O8[^X\Y+*UL5V(OD6:-%#E=WO[6=R7?<-QW88*HXQS.0Q
M-!&$,SS<L=\S*\F& ]W*H@V^Z<>[U.,]<X":>I&U>9=?E=Z6WD=NK55;L%NM
M47KG76E+(RI<=7JG6IY] MS6)Z:+D%[%//G,<Y<.G*Z:7E^ADE/=UT&##KM2
MNK'PW(FDV^C:9?30V\$EY=ZE"UTTL\\*RL(4WQK%$N\@ %LD#/W27BH(YM05
MKF2[N($>2188;=@@18W*>^Y!+EL9ZX7@#CBK2\/.+\S?*/LJ3C>3W)6CMHC?
MFUZT@TH]_8Q\1.%A95FC^*I!):!=D?3TYYAEI>32.FB_<IE4(BF)/60\1Z[%
M9W5G&^B:-=&32;"=C<VKR21^:C$0(PE3;#$ HC0@E5/WFSFL5A9/+',5O+V,
M"ZN$ BF"(^UOODA#EFSDL <D8! 'N[2M.:PD]45EW7I3:.R-LKNIEQ+$L.T)
MAC-SS%)=FQ:!$,WC&-C0+%(G9G>)(+$74([>O% 5 BA4D^!U._CU"9)8[&SL
M J;/)LHWBC)WN^]E=Y,N0X3*E1M1<@G),U;6[P*5::6?+,VZ9@S@$8"@J "
M "3CDDGK5VLC:VJ8_7Z_$?C5,CU''7FF*K3 X(/I0\@CUJYE(N9H]1*'E51,
MP4,!&CE0PB+(YA  2.8>X^Z&,( '<0!N80'T1\0IX)X0X+H,..64#AN3R.>H
MS_/K6Q!.4(B<DJWW6)Y!]#\.>#QC..E7K=M&DBT<,GS9N^8O6ZS5VS=HIN&C
MMHY2,BX;.6ZQ3HN&[A$YTED52'252.8ARF(80&/!96#*2K*0002&5@<@@CD$
M'D$<@U(?0'Y_KZ'U!(Z&L9B\(>&9&4;'$XG\<$V$//K6F+9)Z4UPFU8V)P5
MJ\RV0)7"II/UB-6A%5RE RB;1HF?N1JW*G)_MO6<LW[5U'+)Y;$WMP24&<+D
MR$\;FP>H+,0<DYI@9S@9[?#_ #';!R,5E 0A2%*0A0(0H 4I2@ %*4H !2E
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M;0UDL ICW365FC$'Q'6$!^F+5/\ F_\ 9Y JCRY?V0C' VLMSJK!CGOOCEO
MN>ON9& !CD+E_.NYFSD-*R@D\%%.P8^!1<XXZGY5..SQ>J4Q2L1K7PMT]=]I
MK[9M(3TW+N-UT+?*U>DSUV1J*MUUOI&=T16$3Q+ZN.7!X=M6YY6PF1,_&22N
M<?%R[&4:,VPQBDO%K5Y!:BTB\N.,6,^G^8GFK/Y%S?IJ$Q#K* )#*GE9 V&!
MF1D+'?3C//(R"?H ./D.AK':O])KCI"RB<@\M&T;*R8O:Z>#KUA5U>M"0D-4
M8+?D!6:Z"<=JZ-D;"UB$>1=X?%G+C(V2Y/9..JSJ0L[HL4X2?R3^+=1=2!%:
MQLRRB22,78DD>66PEDD.Z\98RQT^!-D(CA5&F"Q N"MNP'(W'!SP0#VQDC ^
M?)8Y'QXI:4Z2.M&)$E-=[EVM4W:DYQY>.AD6>LK!%,V/']Q4S1TI&5D^O6%8
MD]@3J%.B_?+=?H:\-_>EGY74&^BW(1:65?%]TV1<V-I,OEZD%"-<PL7U RDH
MTHG:9;:,S.!#;R6[;0F)0Z!JIY8R3GDE3T&?=&./Q..@ 'Q-=H]Z07&M]"K5
ME2W[B2K;NER58D8E*9H C(6"7UC9M0/]AGEE=<*SS*P*T>WSS$E5BY5AJ9L^
M=(RC77"#MHW.6P>+]15UD\BR:19UE5F2YX1+F.Z6WV"Y$;1B:*,F5T>[905:
MY(9A5Q4=B>_/&>3D_'@\@9(!/IE:S0U[QIH6K-PWS;U$6?US](E-I-/G=>14
M93(^@-@U^V-&UN=A6[&J-K1$R3>$$D(M&M;4%57:)).3UWXHBB_3AKC4Y[JR
MM[.<"7V:::6.Y=YWN")R6DCD+2F)U:0[PQA\U2-JR!"5-< 9(XR.1@8SZ@C&
M!C/&.YSGC&0^1M*8I716*<0@(Q9\L *'_P"":H=^PN')P'RT^X#W @ !CJF
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M-FQE 5!4[9L8XH)Q]\\$EW<26T9AMY)I'AB)!,<3.Q1"1QD+@8'"_=!8 ,:
M@EBH(!8D G) [#/P''TJX.:E5JG+A8VE.J-JM[])5=C5*W.65\@@( NLS@8M
MU*ND4!, E\Y1!HH1+Q!X?,,7Q>G?,]K US<V]LA :XFC@4G. TKB-2V.=H+
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M,TT\$JAC'$4O'Y*?,:BMDLR&Q+>2\$,C(SB1H97C4RPEQ'%OV/D;MO))'
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M]_Z_H!RW!]#5V1G&1GT[T[A]_G\L8.<8.?3O^%,C&<C'KGBG</N']?\ 8/\
M+&".H(ID>H_&O4>/V,<B#B0>M&#<R[9L5=XY1:HBY>.$FC-N"JYTR"N[=K(M
M6R(&\QPX5202*=10A!OCCDD;$:,Q 9O=5FP$4LQ. >%4$L>@')XJC,JC+$ 9
M'4@<DX YQU/ '?I7M!V]!_=_7_5_C]QRW<WKT^ Q_*@52,XZCU-.P?8/Y8W-
MZ_D/\J;5ZX_7RZ4[!]OZ^W\/W?;T^64R?Q&/I5=J^@_7/Z_#I7/I_@'\@_\
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ML1%P$''M(F%A(YE$Q$6P0(V8QL9'-DF;%@S;I@!$&K1JBD@@D0 *FDF4A0
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M!)GS3:0OB.U:3@;TW$9+ ;@*M73')1+B[FNK>,J4MY H!*<IYC@,9 I)(4@
MGDGM7>7?CU=]<[CCM[\8B0L:_M,G$Q>\=32#HD'2]A5\7)4E;<P,FBHU@;O
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MP^;-)([*K-4F<A1*4I1,)A   3F["8P@ !XC>$I2^(>WKV* ?8 ^0<<QR<X
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M$IBF 0$I@$0, @(=P$,R5B(P<5^L4IBE,4IBE,4IBE,4JB=F75IK;7&P=C2
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M(O*]:9]*EO-\OX9Q7*S%:V7@'5$C(_44/5;;;59R/E*_-W>I)(5BSJ/R.I'
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M-=6;BLZ.NLVW?&3L+3[:O;B.+!IUY>4&U?U[7D=;1\K;XRU(TYBY;V"8A:9
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M2TCN397))M8?.@AN;0/$R"\,K+=L'GLFCCE@"6ADE*=$,2,#*[L9 &[/. "
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MAUQI5X';N()[IO+!01^Q04T*_3$?L)E$P'Z]LJ8](/2[U!#Z^P0./_[BA_\
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MT!"59J(NFVO*<DNW;7Y2*<(N;=;%7.OG3]G#U2^P5GDTVV$$<Q57OKA1) '
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MU4'L=N&/(P 3C."!NJM;!H#2MH3\N7UC35.X" +,(5K"N@ >X?E>PA8YX7L
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M=$V!FF;NDNO'$;KE4;JJIGOM+DVMQ'-M$B*2LL1X$T$BM'/ QX.R:%WB;!!
M<D$$ UEYP1Z_S'(_/]&N-37=38^MZ=='3 L/*S<,B:QP)5!6&M6Y@=2+N-64
M6$ %5>KVIC,5]RIV #N(U4P>@AE;V 6UU/ '\Q(Y"(I>/WT#8:"88Z":%DE
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MM*8I3%*8I3%*8I6-'+OE/K3AMH>Z[WVB^*2(K+,6\' HKI)3%VMSY-4E=IL
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M?7T[_A5E=CC[[LWCO%-P%1W'WR[WAVD'[2=?A]*[+HSUY\A_(C8=G5-F<1]
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M>$H\&=],.5GDW[596VF^ ]"GU#4'4W!17NG7[\\Y_HK&U!Y=5;*J2,,?,N)
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M%TM\)DJ^9L>'? ]3.E]0Z/HZZN)@MTL#VSPRW"NHVIIY+"[O V\$^R81GC(
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M8E%\XE)Z%C6\6HU1DUW\HQ9HQRKTJ9V23Y1PNF1HH[(JD=JFX,F9P55,R0'
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M).-SD!8T&=L4,:@)%$N3MCC55!+'&6)/1PPQP((XE"J.?4D\ LQ/+,<#)/.
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M[E,,6T?("("*:RA0\6<=>^&M=L,FXTVYV+DF2%!<Q #^(O;F15']\J1D9 )
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MPPC0V303S@!3#I$274C^GFWA80-@XW[[MI%P?=)&T[45A=SX8(44_P <I*_
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GI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g210084g14s55.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g14s55.jpg
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M42W.G33OF65WS)*YRV <  6&A<:YJ.Y"K@\*L-,<F52)W.%5#1(RMG=+)"I
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M%QM58K.<AYN4C$! Q<XJF-RJG:RDDR,BA=O7#(@/E,N26D487)\^ *R;@/F
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MZLWNVM[FX:.V@AEEC2]F@P($CD@$<<R2LF\P+;KM99"9-P9>I; 1PFY5!9B
M3&K=6)#9((!Q5H:;SBD<]=L[M*KL*N_9B8$'K"R/5)3$FDP%%I_- SS$)U]V
M&,9'4:@U"O1H(IB% 3&"LO[C*G2)LJ3:I[F>Y$0GD:3D(\<1;&522XFNG!8
M%RT]Q-(6<LQ+D9VA0)JHJEBH W$$X\Y"J@^QA54 # Z>[FLVR145,4IBE,4I
MBE,4IBE,4JI?FCW&X>/G&X=^H\4#+-R.E\QJ"VK%"F3Q^A=QN T"5<2Q!(BW
M]3&X4MU<)W<K;3,C2%NL/HUMM5MU6[ELK430A"YGMXO+!9=LLJHQP&4Y )P<
MX!\01TK879EPKIO&'$LND:K)=QVJ:'KNHAK*6*&;O&FZ=-=VX+RPSIRFEC42
MKR]S)D*Z$[A;3+E6O:8I3%*8I4#=$\9N+]4M&[C<ZP6D'I(X$&-O ;[T.E#[
MB&JY:4<K87H8&DVNO >DA@)2>2DB!-^&6,</T5+1XL9J,5(LR;A;:I?6D7(@
ME01AI'026]M.T+S(L<KVTD\,DEJ\B*@=[=XF;8A))12);11N=S YZ9PSJ&P<
M@.%8!P#X!@<9./$URJ/XY<>YQ>271Z=6)XNV$V+O$5)D7*\&1 N%TBWCK]>H
M-9JARR$JI4(%GN@J%9B<&JA T1TPF1,0RVY.G;D>3ZG>W-NMM-*KPH;<X$%N
MCN;6%[>W:6:.))IFB@=HD::1V"84DA5P6*-&+J"&.[^<Q WL&;"DE5W,-QV@
M=<GSG,%=4\(*W>NFU_IM-O-AY27@S; 1-R:M*M+!R24M5EK=CL5AKAL1=JZR
M+/&/L9B!ID:WB.AT9(=V3'A4:&[/,/%:^TUV2WM9+6>WBNT98UC6983&%BBE
MBCCEC>"0NB<TR*T+VTYD 9IVVH$EO;AG#*Q0C))7<&RS!B0P88)V@$,&7'\W
MW9N@^-'$Q$"J0 5,56ETBIV2D5@U5K-;ZM;1E;N# QFSQ-W6O'QMOG3#3H40
M3G&B)R8<</C85CT12?CM$DT+:I?.TS23\WGS17$J310RPO+ 7,3<B2-H5$8D
M=%18UC$;M%MY;%*F<J,8PN-JE05+*V#@'RE(8DX!R3G(SG/6LUY9RZE\7H==
MYGSR$7%TJI#V!-;$F;;;KH^'$0VD1X B&9NYVQ'4"AL5IJ&+&*)J@BX3+4,>
MQ&BM-LID7=W/?7$MU<LCSS,7E=(88 [L<L[)!'%'O8DEVV;F8EF)))J)$6-0
MB A5& "6; ]S+$G \PST'0=*D'*:HJ8I3%*8I6!=3Z&&Y'S2_P#4[%$)SP/.
M:=8[L:A!6HKY>6+K F69G1A;,Z8/A.SWHT-QN(W+G0XZWU(2]*8;VIQ,FXG2
MV@FN'#,D$3RL$ +%8U+$*"5!) Z9(&?$BKMH.CW/$.MZ1H-E)!%=ZUJ5EI=K
M+=-(EM'<7]S';1/.\44TJPK)*K2-'#*X0$K&YPIY_/KF,Z/0J1T,+'GQ U\J
M%:N8F(4;CLDXPRT!H1R!'(M1),V*U/9BSFFY;<:9+CHD)<2S)?;TEU?L,JSP
MQ3H&"311RJ& #!9%#J& ) 8 C(!(SX$CK4K6-,GT75M4T:Z>*2YTG4;W3+B2
MW9V@DGL+F6UF>%I$BD:)I(F:-GBC<H5+(C949=DVK=3%*H&2\J.NBN@V;D#W
M.>:3KR[T7E/.J0?!W^SD^=Q;#T:J]6Z-8:K>RLFA"S$.Y<TY=RZ->B@@2,=1
M88G3>;0DN5MHR^48R%=)LVMHKT7-TMN+:[N9XY+>)+EH[::SM8Y;=!<.C0W5
MW=FW1W<<LVMTWU4H$-,9G#%"BEBZHA#$IE@[E6.T$,B)N( .=RCIG-6=X-U"
M3V3E-7Z 0!,UDP2<L(:Q (I-9J )M-,M!JE6J&+,N0!3Q<,U8J\3T&*/BQ<D
MB+W#F21L!]YR(S:]0M!97DMLLAE1!$\<C)RV>*>&.>%GCW.$<Q2IO0.X5]RA
MF R9T;\Q V,$Y!&<X*DJP!\XR#@].GB!X5WXBPV3=X+50[%![BI!-6$/-$NS
M]2/A'"\L;\*28F(VWN3[MN.][Z*ZEK2_?(]VI.T*33LJ<M74OG<58,!C(4'*
MD'.,DC!'N'-19ZX^L#_CG]52!DJO:8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*8
MI3%*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*BSL/&Z+W2HLTCH<*;/K[%CK=J;
M8@$I(M_1BJ%HYH,[N5$4AW;+,^*RMYC>_=R$:VTYK:%;UE/<VL-W%RIP60.D
MF Q4[HV#H<CK@, 2//X&K_PWQ+JO"FHMJFC2Q0WCV5[IY>:&.X3NVH6[VMRH
MCD!7<T,C!7QE"=R]14IY458*8I3%*8I3%*8I3%*8I3%*8I3%*8I3%*B7O?.I
MO7^(==Y4-(Q0Y'I'-KI1X)6<T\_"&R[17B :/.ELQ_\ CNQXKLQ+SS;/_%6V
MA24?^+>LIKR W5I<VZL%:>"6(,02%,B%02!U(&<G%9#PEK,7#G%/#NOSPR7,
M.B:WI>JRV\3*LL\=A>PW3Q1L_D*\BQ%%9O)!()Z5VO'Z5*YKR7EW.ITV.2FT
M#G5)I4PC$;<:BD)55K0P%(FQFGO^,W'E/0%OLMN_\1#;B4K_ /%K>16T1@MK
M> D,88(HBPZ!C'&J$@'J 2,C-4_$>J1ZWQ#KVM11/!%J^LZIJD<,A5I(8[^^
MGNTB=E\EGC68(Q7R2P)'2I%R?5FIBE54$^&'"P=:)50;'Z8T+(79'2H[TCN/
M9R!FO]"^7C%EEW2IGR-[EF:M8S!>P&W+(2!SH3UIA%9XBR;*B)DB"[=GUN_D
ME29C:EU@[J0+"Q6.2VY:1+!-$MN(Y8D2.,1+(K")D5XMCJ&$D01@%0&P6W_[
M20D-DG<"6)#$DY(/E D-D$BI_HM'J_-:A7Z'2QGR/5ZN.9%AX"ID\D^W':VI
M:WYQ4M*GES!.;(<>G%31B?/+F"4F43*SIA"5(DNV^XGENII+B=]\LK%W;:J
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MLI$2(TS$BHD3I;[J8\5EJ.PE>FF6FVTI1J.SD>:TM9I#EY;:"1R  "[Q*S'
MP!DD]!T'FJFXNL+72N*^)]+L8S%9:;Q#K5A9Q%WD,=K9ZE<V]O&9)&:20I%&
MBEY&9V(W,Q8DF6<J:QZF*5KSE^0?=='^@<U=F\Q&W%?FS6_&^EVZ-3[(0K54
MHQ_Q7Y_Y,N$;"!EWB',MEN8C&+%2(!5@W4PT\[/KQ9=98BQI( AD:Z=8<NWN
MMMT\ T.74YX3/$LLUQ'JMQI86*06[+#"62*X9#'-(L:RH)22)$I>;)ED.P-W
M@1*P5B IA6;)&[RFZE0<J"<=/,;->-W2+%UGC%0N]NCAX]IEO6D#87*[&F0J
M\2,TFXV"D$3U>@D)Y:=  V.577#X4?++%Y$ 82BQ'2Y1;.Y\BUZG:QV=]-!"
M7,2B*2/F$-(J3PQSK'*RJBM)$LHCD8(@9U8A$SM$Z)RZ*QQDY!QX9#%<C))P
M<9'4]#XFN:&8LC/9C.SQ0(18=H$=8=L0"GAG84'=JG[3')/3;&=04EZ1ME*I
MD5@.RI2'%Z@ITZE#4ABA@38KJ1(=Q9PP)V+U4"--H\>A+GPZ].L0SDY(\!C
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M[FW*=QS+Y,7E#8OED,V1G+#P8_7'3!\1@>X*F"NUT!4 (:JU4**K=9K@R"$
M5\' BB@P4.,CMQ!PL4-A-,PX$"#%::CQ8D9EIAAEM#;2$H3K6J.662:22::1
MY997:2221B[R.Y+.[NQ+,S,268DDDDDYJ,         #  '0  =  / 5AR?Z
MX7OJUB_K1+R+^@'_ !3^0M/.?L#\;5)62J]K2+Z=,^>KWCKR24 -EP<E_M4>
M.](#DI@Q]YC=&N#FV77H3S#CC6W$(7[M:MH]M"5>S[2=;UBG%SNEC;%&9";L
M E6*DCDR],@CI74?H4[2TO.,^(DN[6WND7AAW5+F&.=5?TUTT;E656 ;!(W
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M[^2=Q_>/CU;&L?V?Z;\OW7\,IZF?2_A7?_)EO^]4WZ2[R)UK>_D+COVM>O\
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M]5/IH7WO5:??YOU4^?Y\IOO4\'_%5]_;O'J=]$^$.J_@UI^JGTT+[WJM/O\
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MV]]$T=LI$#2EKFU@0@2SQ)A6+9<$+@$B8LX-JHIBE,4J(N]?U07O_P H1_\
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M9E4%F(4#Q+$ #[)/05B57[5QN[K!MTOK7,[>Y9FB[];;J]\JQ]=A9KZEH//
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M7OY\*!M[4J5"8]I/OI3#3C#?M:]MQ/KUGO+D*-($?8K!6?:VQ6/@K-C 8X.
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M2N$4^4RC )!/7./ $]*RGA#A.^XSU=]'TZXM+:X33M2U(R7K3+"8=,M)+R9
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M:V[NQ\69HD9F/UR22:I>,[2VL.,.*[&SA2WL[+B77;2UMXP1'!;6VJ74,$*
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M5,)"CB/ )C< Y(8,5.W;@CKG'7<,>(-:J>D^/74[IRLJ'H/.1U4)Q/X<N?\
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M()^9#$CDFWN$YMJ]S;[X73G9*;HXYUD90%==Z&2,L !(@*Y9<$D8W*<.$;#
M@>.(T;\Q':N=[6?M0&X7"KQ?*T'XF<1HO-ZX&*6DW;AW+ -B.SY\@L7K\5A1
M[HDZX5A4\P;B5JN!ZP"-%)88;+L96'4G1A+'8QPR0PS-I,FKWT]S*Z11PM=R
M11JH1)">7;+#-M2,RRO+)&@D<1(T//VF0L&9><((U0 L6"!CG) ZMN7).T
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MZI2&JS.M7B=V@<5G\9L]Z=OEKA-QK<$?J5Y']50%D,NQW +7V/U+9:?$ O\
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M@SZA%:Q3(^)@3"BV<9B52KJS2;Y'!4*-NA#@EL/''$W4>MB+E2.G0G>0Q\,
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GQ'7&387+=4VF*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*4Q2F*5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g210084g15d15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g15d15.jpg
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M]3?B4X'_ 'K?FGU1N.T=XCC9J\)M_GJ;\2G _P"];\T^J-QVCO$<;-7A-O\
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MOP8^?W1?Y33T5LC?2\;=&M7\OWK[I)_\ROM,T.ZW]FMD4B*1%(F7S2#J;PI
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M34G5YGO"D<^T=Q]<;)RZ:DZO,]X4CGVCN/KE&MTM+7VT(ZF;FJTPR[8Z.[H
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MG5W--4+W$\@Q_G;TQ3(Z:I4Z9LBQADS8) @9K2W&;0]/U%^N#*Q+<;)HZUW
M=;-U4+:!>B !5WZNBNRD4$LUPZBRMK.IRG2LM!1PR-P@;@CF?%W4^4GRL0>+
MR+S! W7<V&T^!L/'\B!>XK6%G'4^&]P"$ 5K7U*9:MOA&"X1!%;_ &$&]KVO
MRVOOUUNH_?%?Q'2_T;B2[7[4_EV>D:3-Q>5SR[K!;^/6#*XXO*YY=U@M_'I$
M<7E<\NZP6_CTB:HN[RDA(U28K"$1H[7P$RBWSCC3Q;]\B9'MO6$<,8K!Y/\
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M&>HO>^_OW[JP[6WKVMW/)OW\_P"EGX0H^)IZ>^?03ZDO?ZP=?W_&_*]S;_\
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MD'&4>R7#?EGCUS;DYS(KF$-LX2Z.NF),9YH3Y$@K<CD2UTD&-PQ'*L=)-E_
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M1CD*5X_;+:K$J2=['+[@ER1PD[>,6)'N@SLFG<Y&AO=WP]=D8#ZTFYF;LM1
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1GR[@+^]YY#JZR7XI$4B?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g210084g17f77.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g17f77.jpg
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M2D78..7(J$XY;CL\;7DYB11C]DZ*8[!?Q$1=8F2G6C)8BL5$MIQRB\ER%38
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M94D)&ST8Z!5@QG$XDO<;2639&*YGESZ@.KW1]^Q.I6(*8IRE.0P&*8 ,4Q1
MQ3%,'2!BB'2 @(" @("(" ](9"+]PB81,(F$3")A$PB81,(F$6O-LT-WL_6]
MPU\RN5FU\M;H=:%-<*<LT;V:%:NU$@?*0[EZW=(M73MD#A@+HJ0.6R+M5=DL
MV>)MW*0<O'Y4//\ ]+5.I^/MCU/5J#3(S=EN?5G7T@_&-A4*9JJM1CZMKU5S
M 1M4D&=7I42DHPAYAQX8)21 +.2,Z4W?>1?-5!2"2<YR.9\OG]Q1CQ]OS^3
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M/\^L46IA-TAT=!B]'C <)X<>3Y\^9<C")A$PB81<=LX*Y3,H4HE KAVW$#"
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M^=/#2:^]/S _S,)OGL'S^=<R.MLLZ?LFRO<O:W#MNBIU41 W455(0W5'M@]
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M4 PB81,(F$3")A%[4$3N%D4$^CMBZJ:).L/07KJG A>D?'T!UC!TCT>(,(K
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M69U6F&U0^-[WN,;8IW310-:&Q1,W2'9ND,;Y!'AQW:D;'/<]P/$=(T.>=XY
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M]:V ^XT<?Y)I<&$AJ"A.V>P9#6\K=FR]?9*(VB1T^A!-=7/)D@I]#U>AMJS
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M&VQHJ02KPBVMY$(F2!:VG 5U(WM[NY[29)N/N61P]6DEGP^'O=E0VR8]0:>
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MNG=/?MS.M2P36#)/(XS2U6EE9[\NYFNTEL/@C;R8   );'&T-#6,:&AP: T
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MPGA2WK'E'TK>V%>F$3")A$PB81,(OYZ._P#_ !-\N_PSN8_[3^V<\TVO_O\
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M3=%6L+CF"(VQ!$+)C'5&9]WBE@P,,+]WEU*'S%;*81?9OV&[_ 7K;_VG9?\
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1]:5OB(OL)QI?59/AN\Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g210084g22i44.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g22i44.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\
M$0@!AP(% P$1  (1 0,1 ?_$ !\  0 !! ,! 0$            *!@<("00%
M"P," ?_$ %\0  $$ @(  00*"@T(!P4)  4#! 8'  (!" D1$A,4"A46.#EW
M>+2VMQ<8&2$V-UAU=I<:,3,Z<7.6L;*UN-;7(B-7<G32U-@R05-45933)"62
ME=4F)S0U459ADZ'_Q  = 0$   <! 0               0($!08'" ,)_\0
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MC0DN880QTW(.M#^C5NS55>#M$ARVBKIEJX0T>+,Q?I.2CQNRWKAAM:ZDAKA
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MUV"?BD2%A?YFCGE 6D8MN7">OS"J>L_#"J(S-Q,OG<+[36'9&\KN1U>!BLC
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MC8YSOOOMSOOMSRX?^7G;;;GG;;G_ /GGGGG.3],LM*<= R'MA-]BR>C[&A^
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MX628^UJ+%5%=\L^X4]?\QSJ2YRSV;%1L?Z7]8XQ49:BA%4"M*PD$] 6E) 1
MS*C9&4V-%Y9%)N FLKEQL\1F<HD@R2P6&O$"A^0D7/+6,A0ZNZ@5@@.T(22;
MD\5OF]25:R^?#IZXW56TYA3*( X/(Y:[NHZ/G>D?&3I>/3#L+(P$LN"2ZQ.?
M:G8F67G1Z,!GA9%X-3<"U&J;V%OXB<;#C+$@)''TYGBV;.3B^Y5!T;Z81OI+
M7-@0H'*W$S*VG;\ANJ:G.02,8&JRL_%X7#-T 8'4I('K(>D @0#9VX-R62R
MV>5-2$R<>OBROHR$WMS  = Y?7F6:>%!,(F$3")A$PB81,(F$3")A$PB81,(
MF$5+SA@B4A<O&.0I22MR,7D#!>.A'0UB:/HO!+MNJ%$/31,*'9E"NBFS%@Z+
M&!(UN[725?DV#715TD1::8M2_:")DJDD(&K[[D'7;K!>],2^J.O]NS2@S=^;
MQ<;UL[,4%9FT:-@Y_P PY]"HL2MFFII"(W8-F;2_<E6MA.@^VK8E!QI I[C/
M8+BUP#86((RM>YL1ERCG6P7J)65@UWU[* I4PXKV<SBV>TUP-8ZY4#256M4N
MP?8NW+KB48*^T11[&RYB%!K"#C)(V '7T<<'AY5L$-/0^S0@J4IV^ >  +J>
MGHV3ARW;0;,Y0VF<E;=I7G!23-(^A%FY3=3K]U]6;;I@&S\H@/X;,U&S+;5-
M^XX7W;;.MN=-E]DM"B;96%LMFWC*S/PI4PB81,(F$7&5>LT-5-UW;9'1)9)N
MKNJNDGJFX7Y2X004VWWXXT66Y71X22VYXW4Y62XTUV])IY8@$D  DD$@ $D@
M7N1S"QOR6/(B_3ARV:)<KNW"#5'C9/3E9PJFBEQNJIJDEIRHIMKIQLHKOHFG
MKSSY=U-]=->.=MN..0!)L 2<\@+G(7.0Y!F>9%J;\=;X)WN/^AT'^MZO,R_0
M'A?@OQU1Z%4JDKNQ)NAOEM7E]9U0L:3"+U1_!V^# Z3?$9&_G#_.3=,^%..]
M\)OL63T?8L/P!XRME.8RJE,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PBI1S/(.S<+M'<RBC5TU65;N6SF1"$'#=PCOLFL@NBJ\U41624
MUV3524UUW3WUVUWUXVXYXSU$$Y (AE((!!$;R"#F""&V((S!&U2ES1D7-!Y"
M1]ZJ5NX;NVZ#IJNBY:N44G#9RW5T6;N&ZVFJB*Z"R>VR:J*J>VJB2J>VVBFF
MVN^FW.O/'//F002""""0018@C(@@Y@@Y$'8IMNQ?;((F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PBQ3F_=3K]!9*8B"I6S)[(HV_6%2@?1
M?7KL+V,UB99MSQP[#RU]056V2.BQEGSSQP\#GW8XHUY_R5FFFWWL*(!/)\Y
M\9"NO4UW5=>(8@<K"5H2% *1X#R(8Z&&XU*HH9V;(O=0TQA4K&@YC#C.[)PW
M>Z"9."$D-V;A!UHVV;K)J;%"UE=7")A%BOUO_#ON1\JA3^SEUTPHG8WH^TK*
MC"@F$3")A%QW?K7JKGU'AOR]]76]3X=\J:M>77H]O5^'.R.NRNK?E7S.%N4M
M=E.$_.YTUYV\G&1%KC6OJW%[6O:^=KY7MLOE=.A:4%>HM\)T_P!N8%9]1C+!
MDMW6,)F068UP\IJSGLAG1[KV-A=@62^!=BU*V$PX.ZDB!"+B&P9[I+XJ(+;Q
MN)HC80#'2%UFXQB@ZMP>HI:Q]/%04KX'PU(KJ5L5/'B3YZ:E;)AO5,DSQ$YL
MLCGM$,SV;[+K5$CHQ1&&34F:Y@<7N#@6[VXEQCLYY$FJ&C6R '7 9#K1=7K[
M/U3V'LV/U%R!JTH1*5/#Y\"YBC5Q0DWA)VY#U5UHM7MBJ,+W+F$"M0Q4\I9M
M5R0F19@KSTT(&2<8#[ 2R$H)T6%5>&TLM9OE4QK*N:GDWYPQ&">.ACJJH5%,
M'8>QA96RL%+5Q-:Z3#[M8R5^^,,3)Y62.#+,/6!PU1O;FEY8W5=^4)NQIUV$
MD"3,D"QUC3'CE^M_<DNWOK_J_+[W#0#UWEIZ3AIR[^RS77K/JOIO\]ZOZ;S_
M $/I?\YZ/S?/_P KRY[:!6_##!M6^KO]3JZUKVZCJ;7ME>VVV5U"N[$FOR-\
MMJ\P+.IUC281>J/X.WP8'2;XC(W\X?YR;IGPIQWOA-]BR>C[%A^ /&5LIS&5
M4IA$PB81,(F$3")A$PB814C/IW%ZQADDL&:DN0\2B(IR;D1?EJ\>)"Q+/7C=
MX1=),4'"R3%DEYSD@^43U9C6*3@B17:CVKETC[4\$M5-%3P-UYIGB.)FLUI>
M]WN6-+B 7..36WUGN(:T%Q ,'.#07'( $D\@&T] XSL S.2Q]:]V^M[QIUV>
MH3EQLCVI?ZCJ0XYC4DX4FBVS1^ZV68:^U?/IV*7#'7TI%GR[8Z,2 J1\N.8D
M_1D'-Q.!XF#B0-.+X2W6K_RL7Y :S6@.Z^X<=;)KK.UFOCMOS3&O/?XOR?7>
M^FS,CUVW9ELRV]!V&ZRPRT+U3")A$PB81,(F$3")A$PB81,(O*:\16KK,(>(
M%WE?L*ZG;YB][?\ 9-VR>LXC('+1VT<W),EF[EJY1'[HN&ZZ6^BJ*R6^Z:J>
MVN^FVVNW'//6FC572MT=P%KJFG:YN#88'-=-&'-(HH 007 @@Y$',%8O4-<:
MB>S7>_2\1_KNYEZ(U!V%)Z)\)6@+'"UW,;#G%:= J5- *KBD8/2&:3&:A:$B
MO *$#XR$9.SJQ(Q(M&89PDBSY4':KKNWGJ[=HX52YCTB<'8_CKFD.:[&,3<T
MM((<#6SD$$9$$9@@V(61TP_(0 Y?DH@;Y6ZQM]JC^1^K/$FZR5#-:1L4!VOK
M_P!WEV]*NYDCMZB-'/9TI[K6MZU9#>]#7=6+5I8*;-B=<O0G8F+T<B .J/F$
M9FHYR,F\!XF4?(V?U\.?C55UI-^M/NA8Y6ZTZNTB]CE?*V6PV*R"'=R?%1+S
MN6\K"NVD4HF1'8*^F\O(]0N#]N=;H7]L-(XC9.U6Q!#J!'04HDX:ME84X6B?
M&O='@?&G9&QQ4RDJX^0 P+E]?7YKJ%FV&;;YY7R.61OK&W'R;+$!5%S<?>L)
M;9F9<;]M892]@ANH(.V.U KH4&Y[-H0X5"N]+W0TTHQA4MK#W94O/A5#A)^Q
MXKZ2+U8 G[<FO JL?3-<>$)9MN*XUK-+LO\ DX[CE<=MB1E?CM_:W=GQ<(*Q
M[#39XXG\$C]:=>+4G4;0LWK.ZB ]6!Q3H_\ 9%B-WD4AO7.Q*NB5T.NQ6O",
MJ@,K[B$8^)<M9!4JU ,73$9+'A UIL.4@;1M+K<M[:O(WD.5["YM>6;WIL[M
M]U%D\JLSN<9ZK0_M )':SPUU1^Q>2E!BS>I$L4F$.L^ !J%"+<TA#+BV8UA%
MK?+Q(?'8XPLR7D7-K%CD)C-J1]Z^OK]MG6V.3;VY>?:#?;;BX[>YVK)#N3U^
MM9UVX[0S&.G.TQR+7#X3_9*O=)%#(D^M,=5DH-V+3X(=#J)@K(C748<V(O&F
M\HG0>([S)O8LT+Z$7:)Q^U&A1HLH BS<AD\9&PN.<\G%GD%IID%&=CT 9R-P
M6A+Z>5Z%!75&/#TL6&=?NP]4F3O:=]8_3LM"^P-J5B8Y)R&C#C6/B;.AH>T;
M/1A$)+U_6\M():#^)0[VDD,_'S>O'FI@6CDOEK;+6S%ARWR.5]N=[9;RN_4^
M\0\)>\\:]7Y7;$:KF"43T^E47%0OK_"[.B\^M*S.Y,MJJ\!)>022M)6>()PZ
M@E!4Y/Q>'R:/E(JS& 9L]>"0"QO2114H#=6YL3=V5[&P:"/IRV9[%K1[-=YO
M$MZ^ANRX25VY?,7YHFO^S9B@["9]5*KDQ2\BT*[)R*#PB2=B?1TDK#8#73.F
MN(J8@-AQJ/4W!+.DKPGNP,S J+1@IPHAK26[,R+YG(<=N?I)MEE92V$^>>=-
M.=O^ESIKSMY>/)SY>=>/+Y>/O>3[_P#U>3[V%YK]X1,(F$3")A$PB81,(F$3
M")A$PB81:9^W-Y6N1MR9]=ZEF$[D;8I,XDP.A@8]_$YA"I+':\C]W2*!5C*:
MGL^GK6FT>D53HZS21"43L*D8YT1/M(9<=AEMA76XD4P&SBYSLMLSN#L-OFY-
MJV4];N%-:+K+1:PG]J.$HRW;N)V5&2D*5,KMW#E%=N3$3LH<GXP@#6T4C[P?
M8)PU8#1R+50G1<G+-##Y<H';R>OKLRY,ECN%\1&FY:SF^\"AML3PS&NPC#K3
M#HR!#0UF5NNP","^R@W*U.^E$[CT8>P#>OFD@F:,WFD@A =_%HJ9D8G<@#<Q
MT@>)8C;EE?HZ;+*"DKBC-\5P*LF*,#X9B],3.+%XY*V;(?*HC-:WFLAK>PH7
M)6@PD9%)'X;/(G(XP7V#F3(9=\)7<ARY06LT?N"$6]>(YCPA6NZW_AWW(^50
MI_9RZZ80[&]'VE9484$PB81,(L0N_$\E]8]/+]GT!//8Q,8O"-R0 ^.Y2X?"
MWW!88APY;<KI+(^D]$LJG_G$M]?-WY_R<S#0"@H\4TRT?P_$*=E5155>(JBG
MDUM26/>I7:KM4M=:[0<B-BL6DU3/1X#B=52RNAJ(:?7BE9;68[?&"XN"+V)&
M8.U0[_NFG?/\IJP__B!__1\[+_%?H!_=?#O_ ''\=:(_"_27^V*K_P"E_#3[
MIIWS_*:L/_X@?_T?'XK] /[KX=_[C^.GX7Z2_P!L57_TOX:W.=U)_,K2]CJV
M;8%@GWTIF4GJ&)/C\@)>AY?$W>G8"+M-%W'JZ2"/GZMFR"7'HTM./-3U^]Y?
M+SSS/)A]%A6[%-A^'4[*2BI<2FCIZ>/6U(F'"GO+6ZQ<ZVLYQS)S*W7@U3/6
M:+45552NFJ)J</EE?;6>[JAPN; #8 ,@,@O/ S>J\$PB]4?P=O@P.DWQ&1OY
MP_SDW3/A3CO?";[%D]'V+#\ >,K93F,JI3")A$PB81,(F$3")A$PBLG:=DUF
M *Q:N++"&B ZRRX6,,73R 2&05_N?.$%D(L$.R5$.\C8TJ6,#?1"D'CO59H1
MX%K.^1VQ(*N\KJ2FJI&35-*]C74K'RN#:B..HWMC;RR1QE[97,8QUWEHL6EP
M;K:L@;(]S 0UXN'$#-I+;D]:";6N2,N>U[7%[3UP^ZR6$^<Q@%3#H(4ZSI1B
M5, ,KHX_&24-4DR$S>1][%!Y*.)NBIASRRDQ?U$*F0-(DB+ ZLTU)G SYY5U
M+<4IVB62M#V8H987215\<K9Q$8!(V9S92UD8UHF:TA;&6L=&':L;VMD:8G9!
MEC%9UBP@MOK6L+7)VFPN;D&UR%?>K[;B-N,)*\BVL@9NH9*W,)EP*5QDY$9%
M'),W" 9-J,*!C[)B\3V=QJ4QL^R<):+-7(PTR4T6]-RN@C055'-1NB$N]N$\
M(GADAECFCEB+Y(M9CXW.!U98I8G V(?&X6M8GT:\/O:]VNU7 @@@V!V'E!!!
MV$$*YN4JF3")A$PB81,(F$3")A$PB81,(F$3")A$PBZ*3Q>-3:.'H=,XZ"ET
M1E(@A'Y/%I.('GXY(P)=JJQ*A#P,JW=C"X@FR769D!I!JX9O6JRK=RBJBIOI
MR1=PW;H-$$&K5!%LV;(IMVS9NGHB@W01TU310013UU32123UU3333UUTTTUU
MUUUXUXXXPB^N$3")A%9FRNN77NYI#$9=;]%4[:DKK]QPZ@LFL:M(9-C\,<\/
M&Y#A>+&)*%)$ "O!!HT?\;BG#7GAZU;.^.?6&Z*FA1N1D";':+[5>;"@F$3"
M)A$PB81,(F$3")A$PB81,(F$6#EE4+98JPI+;T"[6 JV?$A)1V26M>BZ:L+W
M'PT>HB]+CHM-V2=53\="ABRR1!PVG,TG0X.NY3Y359C^&;% H@C9:^?$3_UV
MY;+%72B]02$W34[ADT[(6;:CBX8L;'_95$<5O"2L5#R^,*A6[VG.:[AHH+'T
M1K9[L?BQDQK-C>A91 @_D!INBT;HDX]FSB/V_;LZ%A#'?#CLFK98\L"N;^7F
M)R%]A*GNVEXG;$5@ >&#!<!ZE%^H!J&2'["M:UQN)V)UG,90,CI./!W8:.M0
MD%5VB1 DVDST\4=;FXK&Q.?77X[K.3KU1Q&GZ7=5U(93P9E4KF5W6;.91%FS
MJ-M=)UV"MB>W)-/<<@X>$B @. DEA$Q4/4>/791 0+%.""ZQ#UC?8H$W^CZ!
M96[Z>QC2&%NVD:3.R>2Z"^TKS34Y,C3B125_ZSU^Z^O.=BAEUKHN]W1Y<<MF
M^RFO'*+-%NWU\NJ.O/)#_P O1]I69^%!,(F$3"+!7Q,_>&]F_B[4_KL/F>;F
M'#[1?ODWS,RQO2_@UC'<O_W8U QSOQ<UIA%)7[*_O:28?$M%/[1$=SC;%/SW
MUO?67ZH*Z(T=X'X;W*/27KS\,W2B81>J/X.WP8'2;XC(W\X?YR;IGPIQWOA-
M]BR>C[%A^ /&5LIS&54IA$PB81,(F$3")A$PB818/7T$K"?6Q5YL_?%"P5>E
MYC&94FB09A-+O$&H^=X+' ,>LAQ:(=*%Q>P B;>$6#&G]=2!4[#2$D&ZOF3@
MTS>AK[A\E53TE6R.@KZ@5T$D)+7/ZA>R2,LCDDIA2O,\M-(344TK:F,1SMB?
MJN$9:_PD#'/83)&TL(.=M\!!N0':XU0X6:X%INTGE!',B1ZLX,UF+N/]HZ/7
ME]D6O.+,G\GD+^+%M#C4T!(1>!1AF*9V2']JT:YC0FJ8P@1W($/;^.UX];+C
MQA67*F@<LS*JH,+9,+KA#34=/2T\4;96;VYDC9:B4N=3/US4ROK)2S5;O<E2
MTASV0ADAI:V]IH]9SW/<20;W!#0 'BVJ P7N;AO*;CM^H\,KVMA%A1J&VK4D
MZ=2R>/K*=Q:F6 R)U] TR4=B<9=#877K:?6.\BP4L3CB\O.\JR5TV*3J5R<R
M@@P]M/4DY,8GJ*I]-+-25< AIVTHEK7.FJ:@MEFE#YZDT],)7L;*(8[1 LIX
M8HR7:FL8PAK0X->QUW:UF6#6W#18-UG$ D:QSS<XGC67V6=>R81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A%JH[JI!IIV2I&'2KKEVVL^)QZN+$DDC.4J(KXI6,X%LK0ZYRUI2]C#YE
MYJQJ-R"4PZ-RJ1,A4G@!9\U@VL0=)3V 3&?B!A3#*YN =F=^,$7RZ>>W-QYG
M=38J[A77:K8V^@I^LG+$([7V@,I+Q@W(8JF4-E"S<25=PID/A[5TBW?);<@H
MNT2 QG3?2-BN560I%90H';MOS^OJ=JR)PH)A%BOUO_#ON1\JA3^SEUTPHG8W
MH^TK*C"@F$3")A%@KXF?O#>S?Q=J?UV'S/-S#A]HOWR;YF98WI?P:QCN7_[L
M:@8YWXN:TPBDK]E?WM),/B6BG]HB.YQMBGY[ZWOK+]4%=$:.\#\-[E'I+UY^
M&;I1,(O5'\';X,#I-\1D;^</\Y-TSX4X[WPF^Q9/1]BP_ 'C*V4YC*J4PB81
M,(F$3")A$PB81,(O*^\9#X4+NQ\=IOY@+SK#0K@K@?<+/+>L8K.RIOAGQ!:T
M,RA4RE;>Q./?5=H/D^B/K&C^:CW7NU6$]\)/1GJZ85[[+\6/*"G=9H-7Q,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PBU*>)!&XH>MSJ8C*1-%V+H85L:O!--]A(-;]DP(W(K.FU!0^
M*6&J!K*#3<!$G<2ESX# =+2LY(/%(WS;R<8;E6Q.;H*:%,WCV](VY7R^WYMG
M)G?U[=!6G7R!+0N,P-H,$Q-=J+AM-#G$;@K1X$7?L7,8A8J6,8FY!H-RK)R)
MT8R)B W'$-%T2FC'A%;?0H':?M6+H3O^[,\FXBWI;9_<6E[1'K_"HE&;4BDI
MKR9S*75&:O93GBWQ@[@:'X@E71.82&RQ?,;)&H[N!1:!A\IXD !P0);ERROF
M#>U[;.7Z.=9:]?KG87Y6+&PVD>*Q!\E*K)KZ61 TX8/2,4L&G[(EE26/'%2(
MM9<<6;!YU"9"R&&F6^K4X*28F&Z2"+[1%,H'+UY=BH#K?^'?<CY5"G]G+KIA
M1.QO1]I65&%!,(M-MK22<E#/9M[4I+LY&1NL[IJ&IB97]M>Z#OR\>OOE_<-F
M EDM5Y#7])/09'[';=/KX0"D3$4&E9BF(:5RTB\H7S2DB@:S"VUC<*E=U/6S
M%\/M0V1K),.U:*ED%Q'4UXD9U2?;%LC63/9#KFJ=+"J-Q<3+J&4=<QMCOMKB
M2[W#C;'8ZHWLB[07>Y *[.8S"Z7G4#K_ !9BK= VV64AAVMD&)(+[.#@JD><
MAKF0;DIU/ZX%B;\4@4@)P9IM&U!)7BVQ10W3&M],F3"7R) W)##0C&<1F<*%
MU&Z.<TT<3\*<\2"2A)93T]2^3#Q41LG=ONNPT;VQUWM>YSH8S&<7B&,=>'W:
M'%PEL<GCKG, DU26W%NO%V;X '&]:]KG,C>^$C+7<Q1F;>6N.K]>+2A&QM-4
M[!TD.XJ'[&N)PGHU8\)R[DCRYVD>G+%CMH7Y>:[L6>_&S9*\:!")NZ?@H@,!
MA&/5 A--<TV]#JG>]X)+KPZMMZ.LZ[-7KG;39-*[G1;%+ZU^HFWUO=7UXKZV
MSKK[<MMU"1SN]<W)A%)7[*_O:28?$M%/[1$=SC;%/SWUO?67ZH*Z(T=X'X;W
M*/27KS\,W2B81>J/X.WP8'2;XC(W\X?YR;IGPIQWOA-]BR>C[%A^ /&5LIS&
M54IA$PB81,(F$3")A$PB81>5]XR'PH7=CX[3?S 7G6&A7!7 ^X6>6]8Q6=E3
M?#/B"UH9E"IE*V]B<>^J[0?)]$?6-'\U'NO=JL)[X2>C/5TPKWV7XL>4%.ZS
M0:OB81,(F$3")A$PB81,(F$3"+7)8OB4U96_>&N^C!*!6 2G5A+"&+6:#-HN
MI"Q1(\!4D@QJ2>JGT]6*NHQ%51X%+KB9NKKLQ>@(;(0YH$3)W2DPJ:LHJVN9
M+ R.A:7/CD<X2R !I.],#29+!W7;WK[UDZ?>8G-D/F^1K',8029#86%P-ONC
MQ<U[:VQMR"%L;RUKT3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(M+7B$%^)Q>-3T\^7I.'3L>,LBT8-897O+*.M1P%759R_J')Q8V6LV
M77RU1[J03.['3:1 HP_#%A;$+18:7!)ER7.22,1TI@,B<_F%^(WX^(>/H6P+
MJON ,]4:QUJI]%P@MW G3*,&XO)I=;D9;EM%B;):2M)E8D>@4QL_1S(-'1U_
M)Y0"!DIL\7=EG2JG!/@BN4#>YO\ =] R'S9<BQC%^'M*Q1]Q:HRW:OB5X#K9
MK6VH2ZK;KDX@]  #E>UI;].OUS=%(W65.2:06)6U[6#&9Y+D+BCQHDT9UVF/
MW&-($R9ORCK=-B+&YSV@[;;+@96Y5F+1U$#J@IU6JB9UQ-W,@D%LS:P9-NRV
MC?,KF]Z6+,[5L\JP%CB#I:,B"4QGLBVCP5L9?N8V"V&"=#1!8?P17*!-_H^C
M)6JZ>PV.U^5[:1")L51L>#=I7B8YDN1*%E4-'?7[KZ_<<;D#+T@3<\[NW:ZG
M&SIXMLGQOPDGSHBFFGH0_P#+T?:5F?A05%63*',(KJ?31FV0>NXA"I3*&K-S
MLIHV=N0 )^60;.-TN>%=4%U6FJ2NR?/"FJ>^W.G/&W''.>4\AB@FE !,44D@
M!V$L8YP!MG8D6*N>"4#,5QG",,DD=%'B.)T%!)*P OC965<5.^1@=UI<QLA<
MT.R) !R49[[OO=?^@>K?_G<L_P")S"/PMJ_U6G_:D_U+N#^B/HM_>O'_ -VP
M[^$GW?>Z_P#0/5O_ ,[EG_$X_"VK_5:?]J3_ %)_1'T6_O7C_P"[8=_"6;4\
M[02+MYX1G8ZXI1&0L2*NA$ICNP@ X?.A^B *01U-%QPJ1W4<\K+\.-N5=>=O
M,UYUX\SCC[^;EW&JY^(Z9Z+5,C&1N.+.9JL)+;,AEL>N)-S?-<:^R*T$HMSJ
MJQS1N@KJK$*=F"4-:*BL9$R8OJGW<PMA#6:K2P:IM?/-1 \^AZX>3"*2OV5_
M>TDP^):*?VB([G&V*?GOK>^LOU05T1H[P/PWN4>DO7GX9NE$PB]4?P=O@P.D
MWQ&1OYP_SDW3/A3CO?";[%D]'V+#\ >,K93F,JI3")A$PB81,(F$3")A$PB\
MK[QD/A0N['QVF_F O.L-"N"N!]PL\MZQBL[*F^&?$%K0S*%3*5M[$X]]5V@^
M3Z(^L:/YJ/=>[583WPD]&>KIA7OLOQ8\H*=UF@U?$PB81,(F$3")A$PB81,(
MJ:F!.1AXX2(1&.-)9(D-6VHP"0D",6'.U%WK=NLL1D"P\M[5CQ[55<D^<("2
MKWEJS528#7[U1NU5]86Q/E:V:4PQ&^O(V,RN: TD!L8<S7<X@,:"]C=9P+GM
M:"X0-P#J@$\0)L/G-C8#;L)Y 5AE'NV<0E4RZH$5:Q -B_92.;)Q1\ZF$2>6
ME&VSN*SB9D'@J,H,%2I^I$F<&\KZPAIT<)>JRF(+#@Q/DFYX'WF3!9(H\6<*
MASO:M^K*13RBGD:)Z>%L;IR;1U1?."*5S'.;O,VN]FH-;Q$X)B&K;?1=MW#6
M'6N-]7C99MM>^>L+ @DB[8CL6T*=CY3U]7$QH&XCC1HLP('I\T&2^:[N(>#F
M#IY!:Z6!>M26.!T#FHPV=9R'RC"0XFFX':I-N%-Z5^&EF&PXB'RR"4NUFQTY
M=#!:>2 -J*D26BE>8]>.-T?7M<VSKE3"2\ICL!;C+K.=UH==K+9@7L2#D>)9
M+Y:UZIA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M1G?Z,D
M)C==7B:H6JC2U@M53R4R9DS@G7&S>Q\CA#6U.O\ J3A\&A]VZDWB[$O6;.XI
M6!48QMR/)SVN8N'?R6/-5%1DH*9NPWV7&V]KV-KVYR-O*5GSU=^R/QU[J32V
MV! ;8:4.'H21F6"Q.,E$UD-E46"A*+05/2(1)^Y$IL'3N) -W8^*N%E(^F1)
M[C=R+HH':5?K"@F$6*_6_P##ON1\JA3^SEUTPHG8WH^TK*C"@K1]@/Q#W9\4
M=D?0TUE-6]AU?<T_FGK(M$.%NB_RBP3ZSI5YZ>:@7V&3"*1=0/P%?83_ &JQ
M?I)%LZ#W">%6BO?F3S,B^77LSN%N/_)C!_*>HT.?1U?.1,(I*_97][23#XEH
MI_:(CN<;8I^>^M[ZR_5!71&CO _#>Y1Z2]>?AFZ43"+U1_!V^# Z3?$9&_G#
M_.3=,^%..]\)OL63T?8L/P!XRME.8RJE,(F$3")A$PB8161M^Y5J@=09=]7\
MGDD6ELZ@%?DY6#)1%)O%C5G3^,UK$N7(0O(1TC-I;R.5CG9CVB%O>1<=:E"N
MO+MRS3&.:ZCHA6B<-J(HI8:>IJ6Q2-FO*RDIY:J:SV1NC8=ZA>&;X]NO*6,Z
MT.+Q(]^IJW:2'.:TD$9%[@UN1()S(O;8+GBLK?5;VVA]E;G';J+2F$1QO5C6
M](A)Y&H =#9W3KLD?')S08W &"Y(3LFD#;'%@9UFP*)@)3%G/*?)1R;# *BK
MPB:E# )8IY35NH)HHA('T]8UL;C \R1L8_.0QZ\;G-WR*4>X$;Y)62AUR06C
M5UVN-K.8;]<+$D;+V(!L1QW JFB^P32ZUCHUQ Y;7$A"QFNI[I'Y<XC;QZ^@
M-L#C)""2+1Q%C9T>V7>*QJ3A3 5PZU?!SD>(H<<OAJ@PL0\J_#G4(C>*B&IB
M?+4T^^0B5K6U%&Z-M1$1+'&XAHEBD8\ M?'*P]:\/8R,<FO?K7-(#76=JF[7
MWU3UI(SL01Q$':+$^:)XR'PH7=CX[3?S 7G3^A7!7 ^X6>6]8Y6=E3?#/B"U
MH9E"IE*V]B<>^J[0?)]$?6-'\U'NO=JL)[X2>C/5TPKWV7XL>4%.ZS0:OB81
M,(F$3")A$PB81,(F$6#7?6^>I=2U,E".V][J4/#[E6<1\889.2;,I(4X\Z$&
MCX!!9C&Y0T7$DF.[81*1!@8N+D$;+D@3]NZ8D':&U^T?P_&*RL,^#X?[8340
M$CF$,<R/? ]D<A#I8B'M==\3V.#XY6-D:6N:TKPGDB8RTK]0/R!SN;6)&PY$
M9$$6()!VK Y?Q+O"0)D*[=27Q#N96.K1Z%-A8T8Y*M8Z_E49V+<QB6%64=J,
M$XX+ -"^R;)@&>!XPY]KA"Y6/$78])QS?QHOI@UM2(M'-Y=4A['RLU72-BEU
M-]A8Z6LD&I(67<YX?*-9X9(UKK+PZII#JWJ"0VQ -P"02039@S%\K$#(7!51
MQ?Q(O"DD=FU024[\[61)(:0$CJMB\I>R9Z+96 5A#JH-IDGLVK<04*3231B1
M'Q)!P?./P.CR6R$H/#"WY)1TGY2Z,Z6Q4M6T:/\ 4T4S7NJY8FQ->ZF9.VMW
M@WJ7M9!%+%&]HC8V35AC8Y[VMU3%M12ES?RY<00&@ZQ <6ZE_<B[B"0;DB[B
M;<F[/,'5:F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PBUC6
M[T*M";75-K?KV_JVK]>4W55=[B>9'UC:V+/(E+:MK2O:R:A1-E:W##2/$)/B
M((]Y+QU ,RYV:3J;B]7^R!UVLI#/B(\%_M"FOE8W\-AM)V6];+8/'6DY"09@
MTDQD)/K!' U-2!D>&6KX!*) B@KLDHB'V)S9>*L'R_"2.^GME(MV">VZ_'+S
MG7A':*E6O_7NS=+*5&Z5-4I5^]]J]@8!0$,2B]S2@[2S\]-:#F79@WS)9Z_I
ML!+ IVMZDKZ4&ST7:UZ1<&O7J^5:OPS><J;1DHVXQLM?9SVY>6RRPZZWEM==
M/\V1)@#"OC4>F=R5M88'61<'@4;FM"VM.:=L'89*G8J.[%XIM)8 9*1\\_"
MG+V-N1SXB*%.E'#)N0BWT?3FJ#ZIG@<GDW;T[&S(F0A'_:9QLQ, R+,L*>ZH
M=>>O+9;9H08+.&CG5%R@LW5Y16WX37152WYX43WUX(?^7H^TK+["@K1]@/Q#
MW9\4=D?0TUE-6]AU?<T_FGK(M$.%NB_RBP3ZSI5YZ>:@7V&3"*1=0/P%?83_
M &JQ?I)%LZ#W">%6BO?F3S,B^77LSN%N/_)C!_*>HT.?1U?.1,(I*_97][23
M#XEHI_:(CN<;8I^>^M[ZR_5!71&CO _#>Y1Z2]>?AFZ43"+U1_!V^# Z3?$9
M&_G#_.3=,^%..]\)OL63T?8L/P!XRME.8RJE,(F$3")A$PB81897:ZH,G;]?
M2";]LQ54S"EG#QXSKI2PZ)8B_;.2LF*BAJ2Q.S8K*"[&1.HHX7"!I()<1^0"
MHC*I"WCI(>E*2;EYDN&8=CTF'SFBT;K<1I<0 :*V+#L5F#FP/>TL@J*)\<3X
MV5#=:6)V^QNJ((]]:XPM:VVU&(89#-O=1B='3S0V+H9:NEC>TO:'-+XY7:[2
MYC@6FS3J/NTV=<VCA /I/!-';0=V_B!,/O&@]="0)N[:.<BHU3@8E(R2-,!-
M6@IB]Y@KOF2*L"+XP]+V"[%B(ZPVG.J(9KQQ<)\.TOJ+%VBN*M?OKZE\C,%Q
M</EK7LB8:Z0D.;U0-ZUFM8UE.U[Y7B"\CEXMQ7!&WMB^'6L&@&OH[!@).H/R
M@ZW/.]W$ "^2O-UB$]>8F_-!:O["B[TFC^+0X(Z?$;*K29S$?7%7LE@<+CJ;
M*O1P!#B-1521%%N"Y$.[.$#4I(/9%(2KU^WV3MN-4N/,BCFQ+ ZS":5LTQ:9
M,.KZ2F?5U9WV9^^5FL#/,V)OY-L@8(X&B*)C6.5125N'5#S%28A25<H8'%D-
M5!/(V)A#0=2)Q(8TO +B/=/&LXDA><#XR'PH7=CX[3?S 7G1NA7!7 ^X6>6]
M6BL[*F^&?$%K0S*%3*5M[$X]]5V@^3Z(^L:/YJ/=>[583WPD]&>KIA7OLOQ8
M\H*=UF@U?$PB81,(F$3")A%3LN6=(1@\LQD8J'NTQ;S9"4FV:) 5'U.$MO(6
M?,G)(0V<HL>/*ORFY(M6W.VFO+C?9'C=/?TA ,L8=&^8%XO$QQ:^3/W#7!KR
M"[9DTGDSL5!VPYAN6TY@<^T>-:=1_="XS SHL7860+(,[!I+IW.;S?B&]:I,
M^9#=]E0^"R5>11\B#<2.4-YHOI-XI%@E!NPABJIVU0-6./<0PD':-\T?@E$Q
M^/L=3/:::NQJ"@:\U1.]T%+-41".1D@CB, ,$\TF("1E73DLIG"=KW&C$SSO
M!UA9S(7//6@7>X--P1K'6LX-$=BQPN_K2%FO)[CV)]GZ2AM87H*/#SC A(K-
MK%LK6Q"'-:J5BE@LH[,&DB3$[SK>P91:S.*BX@(%3'<*5B<;L1_M%'.L?(%V
MUBBHM3"Z^>JH'QNC<V.DJB*ELQJQ-3.EA=&7B 4T5&Z9\SWP;XR:6E:)AO@8
M?8O_ "K&MD!O<O9=MM2S@' VUM8O   =8@.RR)$>#V6Q^*;I=\8EO_1J$YLC
M<?[,QON:B\[.J#%?<0_"?XFJ$'F]595>+KO[X"C/CBK+Z:A,HL2[75_<55YB
M13Q^^1_#;Y07L'9QHLM3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(NL-L7A,,7&CC#V/$" Q^Q8GQJ YR1!O';55NV,,&QAD2$N'HQ93
M1ZU0*#GXY5=!--ZR=-ME4%"+7_#_  _=H?7$1A"/9&VBLAK*U!]W5?9I.-4_
MO-XY:BH6P(U/9A)GB%>(-[.*VY'+/F86QG\_2-%B#8TZ<A2@(GZ!^@4;^O-R
M= XEEE2]+1JE*P:5>+?EY8RW+SZ42B03#@4[-SB96M-Y-9-ERJ1HBA8@#P]F
M4XF,E.OQPD*,!,O;/8:*%L13=JS1(3?UXAD/ %:?JR'$ )5V_$ A8X*)9]IU
M]68L2Q;#1S757KOUX<*ZMF3-)%LAPHNJJLIPDEKQNJHHIMY=]]MN2'8WH^TK
M+G"@K1]@/Q#W9\4=D?0TUE-6]AU?<T_FGK(M$.%NB_RBP3ZSI5YZ>:@7V&3"
M*1=0/P%?83_:K%^DD6SH/<)X5:*]^9/,R+Y=>S.X6X_\F,'\IZC0Y]'5\Y$P
MBDK]E?WM),/B6BG]HB.YQMBGY[ZWOK+]4%=$:.\#\-[E'I+UY^&;I1,(O5'\
M';X,#I-\1D;^</\ .3=,^%..]\)OL63T?8L/P!XRME.8RJE,(F$3"*QEL6?*
MZ^G- @!,8 F(Q;-FOZ\E)TA(GX\U&5>*\FLU"+@8^V /F9_@@O#G;0FN0D /
M@0AZ'9LS,J/MN1M?24L-1!B$CY9&2T=*VIBC;&UT<H-3! \22&1KH]43M<T-
MCDUS>[F:O7R/<6NC  (>XM))((ZUSA86(/N<[D6Y[Y4C3EY2N=W1>M1RN."@
M^U5L8(:"E6;.;@G!IG,S=EAW0](18$:C)"2BX\G A3M"U8>@1K:8/)2\ 1P@
MH4A,A\[VK:"&GH:"LAE>_JMU1&]CC \1N@CI7AQ?3RRMC?(:AX-),6U,+8FR
M2MU)XRI62.<^1C@!J!I!&L+AQ>+6< 3;5!UQUKM:PS:5Q^JM[RB[(L3WL8&P
M@=H@6<2?S*J^8S9$6D->[2X!H3:B3B-DQV-N)&FD3:GPS*:Q%N0@\B<Q\KJ"
M+.E![Y)O'%\/AH9FBED=44DAF;#5[[2RQU.\R%CGQ]2RRB*[#&\P3%M1$)&[
MXP!S244A>WKAJO%BYMG MN+@$. )XQK"[200#D5$<\8#X17L/_K53]2-:YVI
MN-_FXT=_]6^N\27/.G7"K%>FB^KZ1:T\V<L26[3P$_?GS+Y/,V^GE79H[V0'
M JA^4=#]7XJMA;FG""?O74>DT:CA>,A\*%W8^.TW\P%Y:-"N"N!]PL\MZV?6
M=E3?#/B"UH9E"IE*V]B<>^J[0?)]$?6-'\U'NO=JL)[X2>C/5TPKWV7XL>4%
M.ZS0:OB81,(F$3")A$PBUC>*CVYL/I[1L,F==QJO)6\F=DMX(;$V6#,2  J#
M>1.4FE_,'AY%&U-W.[D*U2YY=.7339JHX3W:;;[IJI;/W*M#<,TUQRNH,3J,
M0IHJ/#'UT4F'3003;\VKI8 '/GIJENIJ3O-FL:[6#3K6!!Q'3+'JS1_#Z:JH
MHZ:62:L%.]M4R21FHZ":0D"*6%VMK1M%RXBQ(U;V(T,-O&_[+L]@^S2DNI#7
M:.JO%H_LVJZ:(; EB'//+]4/RE:6O(Q5]SSSR\49<H;.>>>>5N=_+F^CN"Z)
MG7OB^E)WT-$E\0H#O@;[D/OA77AO_+K7MQ+7'XR\=R_X3",MG_#5>5]MO^.R
MOS+]Z>.#V:X)L2^M*]2]2P[1- >5UK":ZDF".GI.-$F3[BTO66J>G"ZW&FB"
MNFFO"JODXX])OY8'<$T2#',]MM*-1URYGMAA^JXY7+F^U5B389D'8.1/QEX]
M<'J3"+C('J:KN!R ]7*I_9:O/.U2=+-N?V]K"M[GGR?M>7F,PCG--;C_ &9C
M?<U%YV=;?Q7W$/PG^)JA"YO5657BZ[^^ HSXXJR^FH3*+$NUU?W%5>8D4\?O
MD?PV^4%[!V<:++4PB81,(F$3")A$PBP!LJ9V9&.S\W1J\;;,\/O>L4GYBT**
M,)NUH_FU!QN.OH<P;GB3<!4 PLY%;G")<DZE;.1DD%7L?7/)^K@Q _(::&EE
MPJG-4ZCIXVXI&)IV.@=7]2/CD;,YT;#)6.8'!C6,$)B80V01G6>]].YSA*[5
M#W$Q&S3K;WK BV>3 2+W-[G9?8%:.M5;3?\ 3>7U;9DJ[0U?:'V3[[<#;,L"
M,V/8%D.X##>U>FXXF^.]?Y80?#!QZ*2@%$@PF+6#$7?,'2DLCJM!6I(5S)6E
M95"D;C4-52Q8554O4E 'TM-+34],*B;"2'-;'B,36N='-$^9[YJ>8;^8HJLB
MLGWITC=<PN:XRM=KR6<X.<[5$O&8R2 0;"SAUMRSK&W&;W6$S)#M'PM]+(S(
M8H826E@G4?*2EAECA0-'YK(P,9F3M>VW3ZT&:5A1H:(GH\%/WKN71H=)&D=.
MN5R M=7:Q8HR*.OG;%+',PB%Y=$RF9&R22"*26%HHP*1QIY7/IW24X$,KHC+
M& UX"]XB2QI((.>TN)(#B Z[^NZX6< [-H-CL5*/;6M/FWNQ%:HLH8,'UW2U
M/6A7)AG'YE/SCI2?G[Q G_=1$@Q"./I$X9JU,DI'X=$'3(@0V=<MMI,X=$T4
M1'L*2D%%AM473O=4UU;25+'20T\8%-'021[U,]LK8PX5A$D\S7-;:^]!K"7P
MUW:\C>M :QCFFSG'KC(#<"Q-M3)K<SRYY4W [TG,XZGO[K,R:NZHDT55M1:=
M2&75U+C$4C06GIW,XY)2$@K/[)42ET2-JQ^(;E3D/(V 2?P$VN_C[TC)]A'+
MQ]Z5%!!!B[:&.*IJXIA2"GBBJ86S2R5M/!)$R*J%-+#,P2S:D<S*=K:B,-D:
MV+7U6P;(71%Y+6$:^L2TD ,<X$EFL"TV%RW6):<KFV=^*0.V+**@K>36V'%Q
MVR)'$ IZ7QX..?"&0 L89ID5 >PLB:D;M@_$(N41Y9IN?,I(E6SW1L2>->$5
M]Z"OCIHJRIBHWOEI8YI(X9'N:]TC&.+1)KMCB#FO(+F.WN,EA:2QIN!/&7%C
M2\ .(!< "+$YVL22"-A%SG?-73RD4Z81,(F$3")A$PB81,(F$3")A$PBQ7ZW
M_AWW(^50I_9RZZ843L;T?:5E1A05H^P'XA[L^*.R/H::RFK>PZON:?S3UD6B
M'"W1?Y18)]9TJ\]/-0+[#)A%(NH'X"OL)_M5B_22+9T'N$\*M%>_,GF9%\NO
M9G<+<?\ DQ@_E/4:'/HZOG(F$4E?LK^]I)A\2T4_M$1W.-L4_/?6]]9?J@KH
MC1W@?AO<H])>O/PS=*)A%ZH_@[?!@=)OB,C?SA_G)NF?"G'>^$WV+)Z/L6'X
M \96RG,952F$3")A%AG?5D=,%)U%0MZ7A#8A/:B.-Y8 CSJ^Y!6)./'2HA+9
MD8*Q^-3>,)%7#B/$5$&&\C8DM- )TNR::Z#9$80(09CD.'&II^K**%T\;8JB
M.=E')(8S:1K+U$<CXVDZDGY,LUG-C>;NCC+<KPS<^TUQZB@Q3"-$](L4P^9T
MO4]=A^&5]12RNAE?!+O<T$;HWF.6.2)]B=5[7L-B"%;D)<OAP@#!:0L.QU4K
M'C;^//GQHQV4-2(KJC%"I<W'  XA(+!*.@T+#E3YI\R@0=5A"4UBCWGF/[:K
M[Z\PDTDIY&,C=B.'B.-LC6L8VAB9^68R.61S8XV!\[V1L:ZH>'3D,;^4R"N
MW)]T@$D:!:6W)!N<$Q,["2 +PFP!).J+-SV*Z_7B=]/5Y ?C5 6Y")_-9(W0
M.2/E"Y2EOS\L+CJ"0QCN0/RV6R^7+1^.I/M6PL=N2]I0FQ)SR/:-%"3O9Q,_
M&H\3?'&*RDF,3'F."F%+$QC7.!D>V"E9'&'/=JF234UWD-UW&PM:\6T%TOT<
MI.K\<T7Q["*)TS(.K,2PVMIH'3R->Z.'?ZB-K2]S8WEC-:Y#7$#(J)=XP'PB
MO8?_ %JI^I&M<[JW&_S<:._^K?7>)+DW3KA5BO31?5](M:>;.6)+=IX"?OSY
ME\GF;?3RKLT=[(#@50_*.A^K\56PMS3A!/WKJ/2:-1PO&0^%"[L?':;^8"\M
M&A7!7 ^X6>6];/K.RIOAGQ!:T,RA4RE;>Q./?5=H/D^B/K&C^:CW7NU6$]\)
M/1GJZ85[[+\6/*"G=9H-7Q,(F$3")A$PB81:'_9 /O7:@^/P=]7D_P WY['K
MA5C/R?E^L</6MMT[M-0]\V>BU2B3YUXM(+]:?]/7_6U_GXR#MAZ#XD6[_P!E
MJ?BBZ5_&#;OT8A&<5[C_ &9C?<U%YV==18K[B'X3_$U0ALWJK*KQ==_? 49\
M<59?34)E%B7:ZO[BJO,2*>/WR/X;?*"]@[.-%EJ81,(F$3")A$PB811XI3X_
MT5C,FD<;WZQ2!YO'CI<'N[UM0:CJZV$D'##9SJCS!%.4M5^6_*O"7*BG*?&W
M&G.^_/'G<]&4OL>ZNJI::I&E%,P5%/#.&'"97%@FC;(&EW5XN6ZUKV%[7L%J
MN;=.BAFEB]II';U+)'K=7-&MJ.+;VZE-KVO:YMLN5T7[(:B?Y+4B_6R-_N#G
MO_1TK/[UTW^42_[@O/\ &E%_8LG[^W^46S;H1WW$=Z(Q9$F85N^K-"NC(00Y
M0(REM)?;'@P/?$/6M5T 8/5GHUT8[:;Z;IK^D\_S_/TXUYXYU?N@: 3:!56&
MTTN)QXF<1@GF:Z.E=2[UO$C(]4M=/.7EQ>"""VUK6-UF&C&DK-)(:N5M&ZCZ
MEDCC+73B?7WQKG7!$46K;5M:QO?:K6ENXG@[G93+9N7[4=.G\MG0,=&Y:?6O
M&&>V)L&&<^NA1SE;24:^8B$?\J$0NS;5!4027<D1JC5ZZ<KJVAF#:9QQ0P,P
MG&FPT\CI88QA]1JQR/%GO WG:]O6R7N'M :ZX  OQFHRXN,L)<X $Z[<P-@V
M\1S'(<QFONS[F>#N/ ;15GV=Z3H1Q4.N!<AM;:KCE@_$O).XFI)F30W.;:E.
M#$N>/9*=6(>LN#IM^0(F%7KI\[46@[!=,W2;\["L=,FN) _J*JUFO;$(&N:=
M[ZW4A:V*,-L(XVM8P-#6@!-1@6$D %K6UVVM?6L<\[N))OM)-]JSQIF_Z/[%
MQPC,*%MJO;BBH@VM&BLBK>6!I>&'2!NP'E%PKP@$=O&K<FB.*C'RC)535?1J
M_:+[:<)KI[;6"MP^NPV5L&(4=313/C$K(JJ&2"1T9<Y@D:V1K26%S'M#@+7:
MX7N"O=DC) 71O:\ V):01>P-KCCL0?G5WLHU.F$3")A$PB81,(F$3")A%\7'
M+CANORTU1W=<(J\MM7&^Z;?9QQIMZ'5=1/1531'93S>%=TTU-]=.=MM--]N.
M->2+5, [+]E3$9B%=&)76P^W[*\0*UNI"5EQVNB*41AT1K>K;>NU\;#P0Y-#
M"SXZZC-.E(6"<R"3OV>IZ0C3Y,:11:* '936&WFOMY[<W3L^]9;=5KEE=D4,
M3FMH\CW<MKZSNRM2R\M#8Z7382ESUNONTJ3<2\#$F:\B,(+S)G6Z<EVBHU<T
MZ8E2KD +V?\ +9MZ4H$6/S ^$7]>7F5,]/9>&GA7MI+8^F>2#F.TKQ1DG)HG
M*H,<UU:]?NOK!7U^*S<+'I0)VY<-5>4-"H9ENZ;<HOFVJS)TV<+$/%T?:5F?
MA05H^P'XA[L^*.R/H::RFK>PZON:?S3UD6B'"W1?Y18)]9TJ\]/-0+[#)A%(
MNH'X"OL)_M5B_22+9T'N$\*M%>_,GF9%\NO9G<+<?^3&#^4]1H<^CJ^<B812
M5^RO[VDF'Q+13^T1'<XVQ3\]];WUE^J"NB-'>!^&]RCTEZ\_#-THF$7JC^#M
M\&!TF^(R-_.'^<FZ9\*<=[X3?8LGH^Q8?@#QE;*<QE5*81,(F$4*OQ@OA KJ
M_-M6_5/"LUEI%VXJNBG]&A7TX]CE^:#1?X['O_D.*+67ED6\%N+\#GWZ;_XE
MIU_74-S(]%NV9[FE\J-<W^RF_-E%\IL)]&Q)8X>,!\(KV'_UJI^I&M<^E^XW
M^;C1W_U;Z[Q)?%S3KA5BO31?5](M:>;.6)+=IX"?OSYE\GF;?3RKLT=[(#@5
M0_*.A^K\56PMS3A!/WKJ/2:-1PO&0^%"[L?':;^8"\M&A7!7 ^X6>6];/K.R
MIOAGQ!:T,RA4RE;>Q./?5=H/D^B/K&C^:CW7NU6$]\)/1GJZ85[[+\6/*"G=
M9H-7Q,(F$3")A%:"O[G V3+)_%X['IAHA74A*Q,S*R8M@SBKZ2 W2#0L'#.N
M"RQ5VY9++\^>JX#LVBNB*V[=RMKKISO65%%)30T\LDD-ZF-DS(6O<Z9L4@)8
M][=0,:' 96>X@D @9VD:\.+@ [K207$6:2-H!O<VZ%T-3=D:YN>4S&)0[60\
M$(<FL\5=EA.K(:<$MIO.*V=%PJZ3MTLFU;SBN)G']V9]L"-*+!5'[<4L(<-"
M"_I68;4T44,TQCU9[ !C]9T;S3T]4&/!:T$F"J@DUHS)':0-+P\.:(,D:\D"
M]QRBUP'.9<<VLUPSL<KVL05J<]D ^]=J#X_!WU>3_-V>QZX58S\GY?K'#UKK
M=.[34/?-GHM4HD^=>+2"_6G_ $]?];7^?C(.V'H/B1;O_9:GXHNE?Q@V[]&(
M1G%>X_V9C?<U%YV==18K[B'X3_$U0ALWJK*KQ==_? 49\<59?34)E%B7:ZO[
MBJO,2*>/WR/X;?*"]@[.-%EJ81,(F$3")A$PB81><+:WXT;)_3Z8_2(CGTHP
MGM5AG>^B]&B7*%;V95]TS^=>J!RX*F4H7P _Q.]I_P!*8A]%I#G*WLA^VVB_
M<5=Z33K<NY=V'BW=--YJ1>>%FR5D:813\/8H_O#KV^5Q*?J;I3.>MUOA#0=Y
MH/3J]7["^QW_ !SO(C4H#-6*Y)A$PB81,(F$3")A$PB81?)='1P@LW4Y5U37
M241WV077:KZZ*Z<Z;<HN6RB+ENKQKMSRFNW5271W\BB2FBFNNW!%AX+Z$]:@
M\8D448AK6Y826QQUP.293LKV5D,N"VH,4)[IV#"IQ([;+3& 2LBF9*,I(6A!
MR/N)<*>KA97R:$;>H\%&YYO /N61]:UM"JAA(*NZ]#>T,2CJ;W4<P4(E3+Q1
MR4)/#1DL7.GWQ202*0'SA(D>D<DD!0F?D1XD1-FR3\H_=NUB@3?/U]>960ZW
M_AWW(^50I_9RZZ843L;T?:5E1A05H^P'XA[L^*.R/H::RFK>PZON:?S3UD6B
M'"W1?Y18)]9TJ\]/-0+[#)A%(NH'X"OL)_M5B_22+9T'N$\*M%>_,GF9%\NO
M9G<+<?\ DQ@_E/4:'/HZOG(F$4E?LK^]I)A\2T4_M$1W.-L4_/?6]]9?J@KH
MC1W@?AO<H])>O/PS=*)A%ZH_@[?!@=)OB,C?SA_G)NF?"G'>^$WV+)Z/L6'X
M \96RG,952F$3")A%"K\8+X0*ZOS;5OU3PK-9:1=N*KHI_1H5]./8Y?F@T7^
M.Q[_ .0XHM9>61;P6XOP.??IO_B6G7]=0W,CT6[9GN:7RHUS?[*;\V47RFPG
MT;$ECAXP'PBO8?\ UJI^I&M<^E^XW^;C1W_U;Z[Q)?%S3KA5BO31?5](M:>;
M.6)+=IX"?OSYE\GF;?3RKLT=[(#@50_*.A^K\56PMS3A!/WKJ/2:-1PO&0^%
M"[L?':;^8"\M&A7!7 ^X6>6];/K.RIOAGQ!:T,RA4RE;>Q./?5=H/D^B/K&C
M^:CW7NU6$]\)/1GJZ85[[+\6/*"G=9H-7Q,(F$3")A%B@TZU/F5Y2*^1TLAT
M<EC^,R&&B%(A4HJ/O2$?EDU@,N,+6P6]TC]>UI(+:P!M&X,<60BZ$2'2.5N_
M:DL3,J.D[N<3:Z@CP]T,\D+98YW[]6.D:V6&GJ(&"C9O3121/=4&6HCO,9G1
M0MUV,C /EO1US('-!L6BS #9SFN.N;G6/6V:<M6Y-B2NOZ\]36=!SVQ)VWF2
M9YY8"*Z1CEE%DXT4ESY:72&5ZS>WBR9TNG9EI-$S^T893A(;$M6T39MP>H/E
MF@PT'S8EB[L0IZ: PF-M.06:TN^LA:(8H=XHV;VPTM(3'OII]:6\SC)KZQ<7
M0CAWMSG:URZ][-L7'6)UGFY#G"Y =8=;DM;WL@'WKM0?'X.^KR?YN/V/7"K&
M?D_+]8X>M>;IW::A[YL]%JE$GSKQ:07ZT_Z>O^MK_/QD';#T'Q(MW_LM3\47
M2OXP;=^C$(SBO<?[,QON:B\[.NHL5]Q#\)_B:H0V;U5E5XNN_O@*,^.*LOIJ
M$RBQ+M=7]Q57F)%/'[Y'\-OE!>P=G&BRU,(F$3")A%@MX@EG22J:+)R>#6LR
MK2?,FYXA%&KB8U]&R,H?"0+U_HVCL;GL.D^MM2,8\T'N!-0"2D%6L!PYX!.I
MJ"T<(NT[]H[2Q5E>R*HI'5-.XQMF<(*F5L+7R-:3++3SP]1Q.:7!]8]L_4P&
M^-@D(+3X5#BQA+7!KLRT%S1>PX@YIUR,K,&KK$V+AM5C^Z7:"5P^Q*@&5-:*
M846EI)-[ "C24"9F%38:R:1&KAQ027"BQ.V+!!Q:0RX>OUZB+J,2DLWDJ9?8
M\SD;*###%=@F%13TU8^KI#(\F+J>1[*AT8C?35S@^1\+V-HZ:26.%PQ&82Q,
M,19O;HG5#F><\K@Y@8^P%]8#5N2',R <"7. )!C!:2#M#@ MK.8FJM><+:WX
MT;)_3Z8_2(CGTHPGM5AG>^B]&B7*%;V95]TS^=>J!RX*F4H7P _Q.]I_TIB'
MT6D.<K>R'[;:+]Q5WI-.MR[EW8>+=TTWFI%YX6;)61IA%/P]BC^\.O;Y7$I^
MINE,YZW6^$-!WF@].KU?L+['?\<[R(U* S5BN281,(F$3")A$PB81,(F$3")
MA$PBQ7ZW_AWW(^50I_9RZZ843L;T?:5E1A05H^P'XA[L^*.R/H::RFK>PZON
M:?S3UD6B'"W1?Y18)]9TJ\]/-0+[#)A%(NH'X"OL)_M5B_22+9T'N$\*M%>_
M,GF9%\NO9G<+<?\ DQ@_E/4:'/HZOG(F$4E?LK^]I)A\2T4_M$1W.-L4_/?6
M]]9?J@KHC1W@?AO<H])>O/PS=*)A%ZH_@[?!@=)OB,C?SA_G)NF?"G'>^$WV
M+)Z/L6'X \96RG,952F$3")A%"K\8+X0*ZOS;5OU3PK-9:1=N*KHI_1H5]./
M8Y?F@T7^.Q[_ .0XHM9>61;P6XOP.??IO_B6G7]=0W,CT6[9GN:7RHUS?[*;
M\V47RFPGT;$ECAXP'PBO8?\ UJI^I&M<^E^XW^;C1W_U;Z[Q)?%S3KA5BO31
M?5](M:>;.6)+=IX"?OSYE\GF;?3RKLT=[(#@50_*.A^K\56PMS3A!/WKJ/2:
M-1PO&0^%"[L?':;^8"\M&A7!7 ^X6>6];/K.RIOAGQ!:T,RA4RE;>Q./?5=H
M/D^B/K&C^:CW7NU6$]\)/1GJZ85[[+\6/*"G=9H-7Q,(F$3"+3_XWCERUZ6M
ME6KA=LK]F."Z^D;JJ(J>;R*EG/.OGI[:[>;SSQQSSQY?)SSQQY>/O<9CFE!(
MPP6-O^)B\F1='>Q<8R3=,E#V->!HUBI >T. /5.'"]B"+V)%^<J(5[=&?_%B
M?_GW7_JYKNYY3X2OHIU/3_H(?\)G^E/;HS_XL3_\^Z_]7%SRGPE.IZ?]!#_A
M,_TJ2OXU>VVW0SJQMMSSMMM/J]VVVVYYYVVVYIJ7<\\\\\_?YYYY^_SSS]_G
MG[_.=N^QRX18E\F?_P#=AJ^%>[> )JT   :5X@ !D  _$+ #B 467.PESROU
MI_T]?];7^?C(.V'H/B1;O_9:GXHNE?Q@V[]&(1G%>X_V9C?<U%YV==18K[B'
MX3_$U0ALWJK*KQ==_? 49\<59?34)E%B7:ZO[BJO,2*>/WR/X;?*"]@[.-%E
MJ81,(F$3"*+]-O'6ON,3.6QIK3=0N&L>DYX&V<.%9GPNN@)*NV"*R_"<@T3X
M653;Z[J>CUUT\_;;S===?)QQ@LNE57'+(P4U,0R1[ 3OMR&N(!/7[<EW7AGL
M4]$:[#</K9-)-(V25E#253V,;AFHU]1!'*YK-:C+M5KGD-N2; 7).:IC[OEV
M#_T*TW__ '3;^\62?A;6?JM-X9?]:KOZ).A_]YM)?V<+_DEMT\-3O#.^[<5M
M,_.H?$H@X@4@CH<>A$]S.Z+U$R.(O5U7GMP0?[\*I;L]-$O0;)Z>9OOY^NW/
MDYXR'!,5EQ1E0Z6..,PNC:T1ZUB'AQ-]8G9JY67.^[=N6X3N7U^ TF%8CB.(
MLQ:CK:F9V("F#HG4TT,3&Q=30PC5<)27:P<;@6(%U"YM;\:-D_I],?I$1SZB
M83VJPSO?1>C1+YOUO9E7W3/YUZH'+@J92A? #_$[VG_2F(?1:0YRM[(?MMHO
MW%7>DTZW+N7=AXMW33>:D7GA9LE9&F$4_#V*/[PZ]OE<2GZFZ4SGK=;X0T'>
M:#TZO5^POL=_QSO(C4H#-6*Y)A$PB81,(F$3")A$PB81,(L.^VDOFP\YU4JR
M'3<Y6;7L+V/<U=,I]%V\>5E0.*@.N_8"[^1T9<RH') 0LM+Y#4$?ARA1V$>.
MFH4Z8X!J,)&J'(-2B.,\@O\ 2!]O$OMTZLN?3GK5Q*)P^*6;,8A8_9RM$3C1
MI%0Y^TA-#=B;=IZ$R?T"',2@[>16+%*_ 'G+AMS&(@L8-K/&WM($53X:D-KY
M<@/1< VSY+V6/O7V^+2:37MJHATL[,$]W_9C=ZZ;L95TX36"N?M?Z!:^U)/8
MEVS'H*D.$&J!+T@9<L*]2),D^"?)%,B/8%$@99C9S\IYEDQ]L);?Y"W:C^5W
M2/\ YQL*%ARCZ?N5"6E;]US2LK&APGHSV>2*RR"2^-#%'TSZ4(LDR!V/D!;+
M=XLCW <*I-='+I/9PHDW74T2XWVT15VXXTV\:B-TM//$VP=)#+&TFX&L]CFB
MY ) N<[ FW$5=L!K8<,QW!<2J-=U/A^+8=73MB;K2F&DK(:B41M<6-=(61N#
M&N>QI=8%S0;B*A]RN\23\C^6?KCZK?X_9@7X*XE^DI/\63^"N^_Z56YK^I:6
M?Y7AW^\I]RN\23\C^6?KCZK?X_8_!7$OTE)_BR?P4_I5;FOZEI9_E>'?[RML
M]74?W#AGAI6KU"+=++H4M&;+2U001965T^6AJ6IPN%?L^'Q57M W*H\ZHCE]
M5_0@G'&BFR6NG*FNVVVFU-S.KBT/QO!,1Q0/D@P[$'U4[:("64QN8]H$;970
M-<^[@2'/8+7L2<EQ=[(32?#=U/'<4Q+1MM33T];@U!A\0Q:)E-*)Z4N,A>VF
MEK6B,W&HX/<X\;6K3S]R;\2S\D&3_KFZL?X]YUQ^/[0G]4TA_<:+_<UR3^+/
M'_UC"OWBJ_DD^Y-^)9^2#)_US=6/\>\?C^T)_5-(?W&B_P!S3\6>/_K&%?O%
M5_)+<#<%&]Q)YX/9_H6%Z67.E=!.NP<5;EB%E=/D*_U)#K7$S=PHJ<1[0.3>
MK3D.Q6235UC6ZNS_ )31V1T1VY<Z\_5NEN&5&Z/4Z6LCK!ADM<^H;&Z*(5@C
M=0&F&M$)W1!V^9D"<C4SO?K5M?"<+J*' *3"YGPNJ((!&]T;I'1%V_.DZUSH
MV.(U3:Y8,^*V:BQ_L>GQ>/R46_Z^NMG^,&;$_&OHS^AQ;]UI_P"<3VKJ/Z\/
M[3_X:?L>GQ>/R46_Z^NMG^,&/QKZ,_H<6_=:?^<3VKJ/Z\/[3_X:FR] GG8[
MK!TRZY]?K$Z0]B'TWJ>M1$0DSN*SSI@2CK@HQ5=;K*"'Y'MF'?.F?/"VGHU7
M0MDKMSQMYR&ODXYYT9I#7P8IC>)XC3"1L%95231"5H;(&.M8/:USVAV68#G#
MG5YIXC%#'&YS2YC;&VL1?/9=H/T++_[82V_R%NU'\KND?_.-EF7M8<H^G[E2
M<D[=S6)%8*%/])NU3(E9,L<0B&M]9%TQ=<%9,UADOL!<?NLT[>KHC]=(G!)0
M3]<)*-&.VP[5CJXV(/6+5R2W.,NG[E5GVPEM_D+=J/Y7=(_^<;"6'*/I^Y/M
MA+;_ "%NU'\KND?_ #C82PY1]/W*.WWXZ5=[NSG::Q+IKSII9K&)2MG"D!K:
M4VKU)&G$]X]!X[''W+MF.[(F&B6N[\4YW;<I$%^5&VR*BG"2FVR.F&XM@%;7
M5\]5"^G$<@BU1)(]K^LACC-PV)P'7--LSE;9L79.Y)N^Z$:#:!8-HSC%+I!+
MB.'R8HZ=]!04<]*168K6UL6]R38E32.(AJ(P_6A9:0.:-9H#CAS]RN\23\C^
M6?KCZK?X_9;OP5Q+])2?XLG\%;(_I5;FOZEI9_E>'?[RL_O#;ZG=W^H_8AU:
MMG],;6(1I:NY-%=&\.M'J*5+^V1@C'W;539J4[+ VW#35(6YX65X>\JZ;[)<
M:(J<;;;:7;!<#K,/K>J)W0%F\OCM&][G:SBPC)T;!;K3?.^S):BW:]W#0[=#
MT-9@&!4^.PUK<9H:\OQ*BI*>GWBFAK(Y )(,0JG[X73LU6[UJD!UW"P!M'WW
MZ*=^.S?;*U[PKSIM8[&'S?F#\B&LIMCJ6-/)>YRN(A$G_K[(=V-,,T?/)@7J
MC;T)%SZ1GNW54]$KON@EV)N?[KVBVB^B.$X%B-/C+ZRAZNWYU)24LM.>J<2K
M*N/>WR5T+W6BG8'7C;9X<!< ./SRTET&QC&,;KL1I9\/;!4&GWMLTU0R4;U2
M00.UFLI9&CKXW6L\W;8FQ-AA]]R;\2S\D&3_ *YNK'^/>9E^/[0G]4TA_<:+
M_<U8OQ9X_P#K&%?O%5_)+8SX874OO#TX["R"U+5Z8VL2C92J9'"6R$*M+J*7
M+:ERTFA9ALJJV+=E@+;5CJUCS[59;5[NMHMNVTU;[Z***):VW4MU#1S331VF
MPK"8,5CJ8<7IJYSJZFIX83##2UT#@U\-94.,A?4QD-+ TM#B7 @ Y5H?H=BF
M XI+6ULU"^%]%+3@4\L[Y-\?-3O!(?31-U=6)USK7O;(W)&H[Q ?!C\43M%W
M/[%]@JZZC&&,'M>QB4LC3.5W9U>&R)N,=M62*29=@-O(RQ:O.-V^_.Z38H]2
MXUYUYX7VYYYXXH='=T? ,*P3#<.J8L2-124S893%3P/C+@YQ)8YU4QQ;8C,M
M:>99G48=-+-)(U\6J]UQ=SP;6&T;V?&L//V/3XO'Y*+?]?76S_&#+U^-?1G]
M#BW[K3_SB\?:NH_KP_M/_AK=]X&W0'Q /#@NVY[%OOIQ81D%8-5L(4#1K.VN
MILA)(EVTM%G%%2+<_P!BXFW08\LV2VFJR#MTMRXYTTY;\:;<J:X'I[IEA.DU
M#0T^'QUK)*:J?-(:J&*-I8Z%T8#3'/*2[6(N" +<?$JVBHY*=[W2.C(<S5&J
M7DWN#QL&62DS?;"6W^0MVH_E=TC_ .<;-7JY6'*/I^Y/MA+;_(6[4?RNZ1_\
MXV$L.4?3]RI."=NYK9<,B]@0SI-VJ+1.9!!\BCI/>1=,1^S\05;Z.V+K9B2[
M>M"#3E9!33?EN\:MW"7E\U5+3?CG7@EARCZ?N56?;"6W^0MVH_E=TC_YQL)8
M<H^G[E@)XD07L_VVZ[(U36/22_A\E3L&,RG9Q,+ Z:BA'(T.R.MG2?#H7VM.
M.?6]E"3?E%+EEPEOKJKSNLGSKKQO:,:H9L0HQ3P&,/WYDEY'%K=5H>#FUKC?
MKA;+YUMW<4TYP7<\TR?C^.QUTU$[!ZZ@#,-@BJ*C?ZF:DDC<8YZBE9O8; \.
M=OI<"6V:021H0^Y7>))^1_+/UQ]5O\?LQ/\ !7$OTE)_BR?P5UI_2JW-?U+2
MS_*\._WE/N5WB2?D?RS]<?5;_'['X*XE^DI/\63^"G]*K<U_4M+/\KP[_>5N
M-\1*I^W/:SK%25.5KTINYA*J[D\4,G7,NL?IV+"K- E?'8L\U&NQG:0T[<+[
M$B;=1#1=@TTW::JJ[J)JZZH[]'[DFF&%:#8M5UV,QULL,^#=0,%!%%/()^J:
M.:[FS3TS1'J0/&L'%VL6C5L21\S]TC"JC2V2I?ACX8Q-CE5B+>K'21$03NJR
MQKMZCG E G9K-!+19UGFPOI3^Y-^)9^2#)_US=6/\>\W[^/[0G]4TA_<:+_<
MUJC\6>/_ *QA7[Q5?R2_NOA-^)9QMKSSU!D_DXYXYY_^^7JQ_P!7/Q]Y [OV
MA)!'4FD.8/\ ^QHO]S3\6F/_ *QA7[Q5?R2V0>.EU0[O>)+ ^N\9H+IC:X4A
M5,JGAJ2[V;:/46/-7#23!HX/'ZB%(_V7EJCI?1<2ZY=:.466B:>R.R:BVV^^
MJ?.^@.E&':,U&)2XBRJ>VKAIXXNI8HY2'1/E<[7$DT5A9XM8NN;W X]T5U*^
MI;&(W,!87$ZQ<-H&RS#R*.'^QZ?%X_)1;_KZZV?XP9LS\:^C/Z'%OW6G_G%;
MO:NH_KP_M/\ X:K^I_ 0\6>$6G6LT,=3=E1,0G\-E!1-C>O6A9\H. 2(<5>Z
M,T5KF;HJNMVS175NDJX0346YTUW62UYYWUIZS=1T;GI*J!D.*Z\U-/$S6I:<
M-UI(G,;K$5A(%R+D V'$5,S#)VO:XOAL'-)ZY^P$']&I\OVPEM_D+=J/Y7=(
M_P#G&SGM7VPY1]/W)]L);?Y"W:C^5W2/_G&PEARCZ?N5)J]NYJC.F-;J=)NU
M6LQ)1,M-V8KW1=,>=%8R$,!@),AR0U[>\C4]FY20"6W#-5WH^6X=<KH-U$$'
M"J1+#^L/_P"WW*K/MA+;_(6[4?RNZ1_\XV$L.4?3]R?;"6W^0MVH_E=TC_YQ
ML)8<H^G[E% G?AD^(Q)9Q,I&/Z>S/1@?E<A-L='5P=5$W.C,J7>/FVKA-/L$
MLFFOJBOIPMIHJKIJIQMKJIOKQQMS@$NB^(OEE>U]+9\CW"\LE[.<2+_D3G8Y
MYKZ!85[*'<YHL,PVCFHM*C+24%'32EF&8>YAD@IXXGEA.+M):7,.J2UI(L2
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MU*7$M=<<]U[>JK1KB,DF88S#2=FM(0*7G<:/L]R N1A@$:G4LE$<;*LO5EW
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MY/BCY;%/FSGU7U,(F$3")A$PB81,(F$3"+^;;<:Z[;<_M:\<[<_P<<>7G_\
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M59E9Y,AD7EI /'AKD@U$+EQL--;;%GPS1RR8#'#TJ,C284^JQ*?#FR.+X#5
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MFUA03"+ST+\_'I=/QLV-],#.:>JNR:CX^;SCE]B-$N"NC/R?P;ZNIE:;/!9
MI+_L?G\'.T?Y[J/YA8>9MHA[BO\ A4WBG7$7LONS- ^YM(_.X*H^G;?WUO9O
MY0ET?61)<^H^AW!'1;Y.8']64J^2&.=NL8[Z8AZ7,L>\R-6M26_8[O[?;O\
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MPKO/AOHT"\WW.A%0IA%ZFO@P_!;]*_B>:?U^=SE#3;A7CG=KO-QK)Z/L6'X
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M4L=*# V,/$4TE2"V.3>97Q>.N#)" YP.H'.S?JN:6N :&VU7.+^N)M<!FT7
M-VQPQ><=KXE,H0<MMA!PM2:69.5"$YMMK7<P+64QVA]40X964F.<5^,W#QX!
M.)W.AXV(AI2 D?-9$BFS=>2%-"%&YX@PB:">.C=/)6=2T^K!1NJ864KM^K)G
MU43.J7:\DE/3T[G3/BDBZJ8RXB;JS@:TH<TOU0S6=USPTEPU6-#3UN0#G.L
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MNJ*OW1<W%EN>'L8>SJ<P":6-J&+(LCVC:7MWL@'#CCT@R0*4\7,,^FY_[?\
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ME@O_ ./)]WA[??Z/^NW\D+&_Q7Q^%>)?HJ/_  IOYA/Z)^YS_:^F?^98+_\
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MF,^!9[QXI\=-@?U%#<XQW>N',?>/#_/UJWSN;\'G]\:GS5.O,R6_=5?XS?\
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MADIM[G-75MC#J:5[Y*=YHVTKG1N(+@X2D$RESIX'.<UY)) ?9A+@Z[=5A-G
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M&M82T$-!L<R3FL8?N#?0C_NEW_KGD_\ N9L+\:6Z!_>>O_8I?Y=8!^!NC/\
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M=/P-T9_LBG_;G_C+)&7>&O34[I%?KA+K/[(G*0<1,+!5Z[=7"_U#*1*.Z#M
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M@;)&]LC'!\]VO8X.:X7E(N' $7!&2NQV0\*7KIV\C0"'=DIOV(MF,Q<[M)0
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M32+V53NB(3,(5/;^,=G]2[X> $V;3_5?M:]ZH3[[!X*4RI4ZTDEIM&,XO"N
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MKR7Q&<1J,2G8Y7X[4= 6TEMJX)S%8+S[D>($X,PR!SB>2*#166DH;N\CIJ;
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>J]$+H11GK6CPAK8*.N\EEVS,JBS9(E*?7U]? O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g210084g39a99.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g39a99.jpg
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M 0$! 0$! 0$!_\  $0@!* )+ P$1  (1 0,1 ?_$ !\  0 !!0 # 0$
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MC,VPY-?PI3KQ:E1ZT%[59]9B\/T)9Z\R5J\B55LZC9!CMJ5:LDH8RR).(O+
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MA.F Y$L=(C37]7C6%%NN!!8M6H28X6>.>[')':D61HS(.LLTG)>7 .QD55D
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MBR;K.J7;<DLL\D;23P)6E9*M6'G#'+',BD0PQCDKPQ[2@"7@@BY]+V,HL2(
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M<1R(.VX)VW(.P['Y!F.P_&CQU'<_+\G'\*Y%"Y>?.,68YSN)SNIQZ28L<9N
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M5C&2AC&,8QC&,8R-N@_PB?\ LG?ZX>,9'&,8QC,39OE(D72=SABWUEWH0P#
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M#X@I5IYC##8D@GNZK8+3Q5FDCBU73_)MM"SRP2R5Y&=N$AZ=B(<',7581VM
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M%1R]@/UO5@-?,BD#<KQ!6K05M+<U*NG:K*+GOA1J2O)$D,;PBC.\;V+)K3S
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M?@ZE4:O76"&5;\#RR.JR5EAMB2!3RW=Y&@6!U38;B*61B6'%2 Q ,W)@8V
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MK!C1VV#%6F)4\V)6)N^Q5"%&QV#/LH.V^^YVZN9QN9F,8QC&,8R0*!_&R/\
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M[=_RGFD_PN(UL(I26 CD)3X8",2GK\+M[/H?7;T/R8W'RCOZ=_7*E!\$X6=
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MD'<'*"., J$0*?50J[';TW&VQV_7EN&5+BU7[;XSBM =UFPUYGK@[C(:GAA
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MS[O]BF'NOOP8[Q!]F!JKE_?5P66/>XWOOM8O:O!IHL1(E^PU9E8RV#0"R1,
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M_/OATW\V5-_PW'WD?<^^;KOUI=^UQ]\'Q-^=5_H<'\./IJO/S[X=-_-E3?\
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M_/OATW\V5-_PW'WD?<^^;KOUI=^UQ]\'Q-^=5_H<'\./IJO/S[X=-_-E3?\
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M_/OATW\V5-_PW'WD?<^^;KOUI=^UQ]\'Q-^=5_H<'\./IJO/S[X=-_-E3?\
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M9>9]T.H]1I&:O(9)M0FD22M%)&[:G#6KW%:-E*E)(JD*J-MXR&9"&.XL\O&
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M(WOA[0;'B*\^GU98H; JSV(C,&Z;M#P_%,R@F/F&.SA7"D#==B2(+$ZUT$C
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MS(7AF1HY%#H5=>2,1R1E8;[J0=CDL$TE>:*Q"W&6"1)8VV#<9(V#HW%@5.S
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M!44;Q  ?&S,=E1%!=V(5%9B <34$:2 *BEF,B; #<^C?L'RD]AZG-1ODU/\
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M_&,?"E@^UR_Y^+^OQC'PI8/M<O\ GXOZ_&,?"E@^UR_Y^+^OQC'PI8/M<O\
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M'1'H\)B-.>?6A$-_:>$?3G2Q%7-O3V,JLPE2] U=.(8[2SANG&QX[*K$%B5
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M1]\ 1OMB_P#S#?\ ;QC'P!&^V+_\PW_;QC'P!&^V+_\ ,-_V\8Q\ 1OMB_\
MS#?]O&,? $;[8O\ \PW_ &\8Q\ 1OMB__,-_V\8Q\ 1OMB__ ##?]O&,? $;
M[8O_ ,PW_;QC'P!&^V+_ /,-_P!O&,? $;[8O_S#?]O&,? $;[8O_P PW_;Q
MC'P!&^V+_P#,-_V\8Q\ 1OMB_P#S#?\ ;QC'P!&^V+_\PW_;QC'P!&^V+_\
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M"]R*,TX8K&/8'96X@CC(H"$';;:%P>0^-""=\I#G0OE 8\WO[XYRSZGUVS7
M6 IWV.BTR/'YLWY040%4^B\MMD;QIDU$M9H?B>NZ72=5XMS\D+)8;\3'>[\P
M%SZX0YLY5*_AXKIX81%9(H6DG\RBEK1TJQ)-6MPG4Q,D3:OT(%E,.F11UU?E
M;=9%M"A:Q^,VWW#-[/$G9.JH#(QCV)$7)MMY26V]@$%335I_R]@=>Y;T0JJ[
M'*H=HXVI=0Z*'Y&9W?8P5KM'=Y?,P,VB7'EO,I\R$.T1Y\'[&<%\PIMH54I>
MKO70]9"E"%SKJ4:.U.W57H1S).9JE=[B>7+^1H"U(+,-JTBLY6R]*-[4\/6'
M0D>61%@E#K<T;VB-MG8)[6W-^(XE5)_T0Y"J>/M *#N,]X?9NN6'I_BDOI>[
MJ0Z:,;\GJ_9[7<ZXJG2[[Q^#5N423EU#TR;RKC%CJ%5(]=>Y1#CURVT*(9"F
M8LN# /W*K[ 6\[#?BIQU=6\KT4JM[U2100R"85[K2VUC@>=;=Z*>5:8N,98;
M#)(A#-'!+U((ZH7+P\N18=4$L .2;)NP7@A4%^'9E!!!&[#9CU/SD\R\8QC&
M,YA\#Y-UVV3O(HU4?*;I?+ C_EAY M,4ZLT'@Y\3">CW1]J1*9)7SEMIL;KL
M]U*I3[<DP\PRXM3<1IAC26D]1?N4X5TU)M)JVY!I.GDS2V-0C=@8=P"M>W%$
M H[ A 2!W)/?,9$=C(1,Z#JO[*K&1Z_*R,>_].;!?8!\@_PZNU?FH\5O_P#A
M>:_WPT[YAH_2]6_O^7].3\XD_L0_99K!=@7D_9>MPO'WCWFUUTZ;%_-9?R N
M\KF/C.P!XQ02[&Y$,&Q.#\5A2I?<.@CU;7S^N1YK2:@$6OJ-R0H.Q4:QT3:P
M2:7%3;4;NATXT?DFG0"UJADO6$(#2%7O,!0KM_E$I7\=(/*0'F9I:T3"4N(T
MG<D;&0E8MD4_%N(Q^,8?!&_8>VPVV#3#:)$FBC@_A'X6H&U"_0JRDA;NCSH+
MMR"^.--LL@A)>Z?>-%9NY'0^W](,J,E:16K*6?,7NTNV#IO09LFN"3"S^%$!
M8=]=UPO-7:7C#65A!)J<\00"K 47:M1K1A$GEB14KPB.K642O'T[S[($$&P8
M#NQ]H1*=_;;<[M(QW*@G=FW9CL#O3\H\8/)[BU&$<^H?DYR*$#%*FRY$LCXL
M'B]@L1XO,?*V.W6T_/\ )=XG9KA:S<N<>M%D+/R"9LU.F$)KZWGM[U=;U72K
MUA[-C2KC2/Q 5=6C2.*-%"10PQKI82*&&-5CBB0!(XU55  RJ1R(H59$V&YW
M,1)))W+,>IW9B26)[DDG)&^QMYI?A6<;_1+*_M*9C>:T/YHN_7"?RS+N,WY5
M/W1^TS77R_Y[Y?Q?$ORBDF_)SDA8+'\=>V/EQ4+Q<)B)A,6US2S.3Q\0LOR&
M)H%R9L1+L9@BH:03"=<1)5!EZ:W'<V>BV=&.L:2(]*N)(=3H!';5E=4<VH@K
M,GO<G,*VQ*\UY ;<EWW$4RR]&7>1".E)N.D1N.!W&_4.W].QR!ODJ*'Y6D?D
MY_#V=3O([EM7J\KBE9=!UXQXUD;43$0%;E>RA3;&UWJN-F'V_1OUYJ 8M+OI
MUZ(C?H_?S_%MC2%\2:TL^F6YI1>F$DJ:HL*.W;=EB.GR\ ?]7J/M_K'+*BRF
MM#M(@' ; QDD=S\?4&_[!G0/[&WFE^%9QO\ 1+*_M*9SOFM#^:+OUPG\LS(X
MS?E4_='[3'V-O-+\*SC?Z)97]I3'FM#^:+OUPG\LQQF_*I^Z/VF/L;>:7X5G
M&_T2RO[2F/-:'\T7?KA/Y9CC-^53]T?M,?8V\TOPK.-_HEE?VE,>:T/YHN_7
M"?RS'&;\JG[H_:8^QMYI?A6<;_1+*_M*8\UH?S1=^N$_EF.,WY5/W1^TSCE<
M:5Y,I^7=Y$'?[[S9[HKOR;]JGPKPCQ\GLUZ)54]SL#+U=?HF^V.ORRCI%+LY
M%D3<(K;4=Q,'8)Q3>YB^S@GTK[@;KC3K0K#Q+"K5_?)3(TWD$(D%CR.RH%]G
MI=$DD<NH![.8;++YY/QB\O+G8],[;<SN-N?<GY=^WR9V-^QMYI?A6<;_ $2R
MO[2F<9YK0_FB[]<)_+,S.,WY5/W1^TQ]C;S2_"LXW^B65_:4QYK0_FB[]<)_
M+,<9ORJ?NC]IC[&WFE^%9QO]$LK^TICS6A_-%WZX3^68XS?E4_='[3'V-O-+
M\*SC?Z)97]I3'FM#^:+OUPG\LQQF_*I^Z/VF/L;>:7X5G&_T2RO[2F/-:'\T
M7?KA/Y9CC-^53]T?M,?8V\TOPK.-_HEE?VE,>:T/YHN_7"?RS'&;\JG[H_:8
M^QMYI?A6<;_1+*_M*8\UH?S1=^N$_EF.,WY5/W1^TS3_ .4)Y_Y;0O OS4F6
M;R5Y0?KD3Q2\@I)\$-\8R=>(F0S/*;6X3%P#SGD ;;"S)\-+T6,56&+('O.H
MEJ&S=-;C.;GP[9T=O$&AK%I=N.5M7TT1R-JJR*CFY"$=HQIT9D56V8IS3D!M
MR7?<065E\M8WD0CHR[@1$$C@VXWZAVW';?8[>NQRA^3FH'EK.\!/"Z;5_)3E
M->K<KQ?X?( @2?C(2L9$,(>YU7W!XR<?;[^#;-2X4534>040&%)G.MJDI'Q-
M.>P1=XDLZ.OB'6UETNW)*NJWQ)(FJK$KN+,@9UC.G2&,,VY"<WX@[<CMOE:Z
MR]"':1 .E'L#$20. V!/4&^P[;[#?UV&;G?8V\TOPK.-_HEE?VE,TGFM#^:+
MOUPG\LR;C-^53]T?M,?8V\TOPK.-_HEE?VE,>:T/YHN_7"?RS'&;\JG[H_:8
M^QMYI?A6<;_1+*_M*8\UH?S1=^N$_EF.,WY5/W1^TQ]C;S2_"LXW^B65_:4Q
MYK0_FB[]<)_+,<9ORJ?NC]IC[&WFE^%9QO\ 1+*_M*8\UH?S1=^N$_EF.,WY
M5/W1^TQ]C;S2_"LXW^B65_:4QYK0_FB[]<)_+,<9ORJ?NC]IC[&WFE^%9QO]
M$LK^TICS6A_-%WZX3^68XS?E4_='[3'V-O-+\*SC?Z)97]I3'FM#^:+OUPG\
MLQQF_*I^Z/VF/L;>:7X5G&_T2RO[2F/-:'\T7?KA/Y9CC-^53]T?M,?8V\TO
MPK.-_HEE?VE,>:T/YHN_7"?RS'&;\JG[H_:8^QMYI?A6<;_1+*_M*8\UH?S1
M=^N$_EF.,WY5/W1^TSES\M-1O*05\F'Y7D+YY#<QN-2C5>D*,UH%XYD*66*L
MKZQ06X[4.SO=SM;0E;,Q<:4XZNODM/LL.1--L[D:DL]7X'L:2_BK2%KZ;:@F
M,MCA+)J:SHA%.R3RB%"'GNH*@=1=B0VYVV.+=645I>4BD;+N!&03[:_'U#M^
MPYO]QOG/F0[R'E3L'RDY!$A.<WHSD.(_XJ%)C\6*NL"U1X[TQ/D9%3*=89VA
MIR3J+&T^M.W=,,Z5[-//7;.B"[;#:3<9A:L!F&KJH9A*^Y"^]IX@GN!N=O3<
M^N9"+-Q7\8GP1_\ 2/R#_P#Z9)'V-O-+\*SC?Z)97]I3,7S6A_-%WZX3^69=
MQF_*I^Z/VF/L;>:7X5G&_P!$LK^TICS6A_-%WZX3^68XS?E4_='[3(2[G9/+
MSBM;&2$>27*[QT*ZETU'DO*Z_P"*,UJT=,O,F+(EQ@8QR3Y*;C"1 Z%%EGKG
M;R>D :141I>SG'FX(]2'<ZA'HUZ5Q[UVX*T"=:Y;DU<&*K " 9' TS=W9B(X
M(5_&3S,D48+-VLD,J#_&(S,=D01'=F^0?C.P'JS'LJ@L>PS*0$1?B;2)?9.]
MF-]S\ONTN5NG34404F%/Z#=DQ)TNH>/WC]5R\W>ZMS.L.;.EFME2,:%!@MW7
MM'5C4)&[0:'0RM[[SBEIZ>0T:CU9E\P_):T!95FU'4947\;:E'30\%9F;H4:
M:-^)C:H_%+SD/4E?9?9&W)N_&.,'T4=]MS_K.Y^$<QFA^,/E_"OEN[O9?(_C
MT'KG2QHV 2&R?'LUT(7R6G1--S87%^:VB3VFD.2*0$*J?)%3ZJE7S71;,MVU
MV:&S[( %KDL^JZ,:\.GQ:9=>G5=V1AJ*5FN3M[+7K,*T9P)Y$ 1(^M*E:("*
M)CO(\MJQ3!C(TB<V !'3+! /]!6YKNN_<G8<F[D#L!-7V-O-+\*SC?Z)97]I
M3,+S6A_-%WZX3^69)QF_*I^Z/VF/L;>:7X5G&_T2RO[2F/-:'\T7?KA/Y9CC
M-^53]T?M,?8V\TOPK.-_HEE?VE,>:T/YHN_7"?RS'&;\JG[H_:8^QMYI?A6<
M;_1+*_M*8\UH?S1=^N$_EF.,WY5/W1^TSCG\I'2O)F!YB?)&1;5WWFUC.$_*
M:Y1Z27%^/A"MP:F833Q*GRAH.YVPZNW1'F-H:;%M%*RIE:%/;(NZ7[)/9>&I
M]*;1O&!ATZS%&FDPF='U)96F3KG9$<48Q"0>Y<I+OZ<1ZG"M"3K5-W4GJG;:
M,@ ^SW(YG?\ HW&=C/L;>:7X5G&_T2RO[2F<;YK0_FB[]<)_+,S>,WY5/W1^
MTQ]C;S2_"LXW^B65_:4QYK0_FB[]<)_+,<9ORJ?NC]IC[&WFE^%9QO\ 1+*_
MM*8\UH?S1=^N$_EF.,WY5/W1^TS5KS%Y]Y=Q>-!W3GDSR8O WY#^';"(<'Q?
M)AWT$Y7EYPV,#(*F+\@RB5QA!MX>6G#M14*,0H4@0B<+7.23A[71K.C&ZXCT
MJXC>]NM$LVK*XX#1KYD7C[W+L7C#(K;G@S!^+\>#13+-P'XQ/\9#_P#2/8]:
M/8_XSXCL=OCVV[;[YM+]C;S2_"LXW^B65_:4S5>:T/YHN_7"?RS)>,WY5/W1
M^TQ]C;S2_"LXW^B65_:4QYK0_FB[]<)_+,<9ORJ?NC]IC[&WFE^%9QO]$LK^
MTICS6A_-%WZX3^68XS?E4_='[3-6_+;GWEU&HO,EFO)GDQ:.YY2>)<>(Q"\7
MR8AR,8D^1G-F I-U]?D&2U*B"BCD4A,%Z9CJ+18[HY!$:J3J<QM='LZ,;%KI
MZ5<0C2M8+%M55P4&F6BZ >]R;,Z JK[G@2&XOMQ,,RR\4WD0_CH?_I$=^JNQ
M_P 9\1[[?'Z=O7-I/L;>:7X5G&_T2RO[2F:KS6A_-%WZX3^69-QF_*I^Z/VF
M/L;>:7X5G&_T2RO[2F/-:'\T7?KA/Y9CC-^53]T?M,?8V\TOPK.-_HEE?VE,
M>:T/YHN_7"?RS'&;\JG[H_:8^QMYI?A6<;_1+*_M*8\UH?S1=^N$_EF.,WY5
M/W1^TQ]C;S2_"LXW^B65_:4QYK0_FB[]<)_+,<9ORJ?NC]IG*^&"ZH ^7YX7
M%ZST6K])./?)R="?'%ZKS>1S*#!%;["9;0.D!Y-[OZYTI,QN7)4224AI4S):
MBZ@)W&W(D=6TE23W/;YIUI:L8\35@R36A:9G\DAY!Q7K\1Q(''BW<$\N^PQ=
MF%].3!CY9MB%X]N9[;<F_;OGT%9YWF?C&,8QC&,8QC&,_%)2M*D+2E:%)VE2
M5:TI*DJUZ%)4G?IUM.];WK>MZWK>M^C?[V,9Z8L6-!C1X4*.Q$AQ&&8L2)%9
M;CQHL:.VEIB/'8:2AIAAAI"&F66D);;;2E"$I2G6M5)+$LQ)8DDDDDDD[DDG
MN23W)/<G'IZ9[\IC&,93[AQ%2T3U18^YS4=V&U-VPUN6W$?=9>?BHD[3[9$=
MYZ/'==82O33CK#+BT[6TC::[G;CN>)()7<[$@$ [>FX!(!]0"?EQ_P#?_P!_
ML&5&4QC&,8QFI?B*TZR&[[IUIQK;GEIY%.MZ<0I&UM.7N2IMU'K:UZS:T_OH
M6GTI5K]].]ZS;ZN07T_8@[:1IP.WQ'H#M_3D47_U/^U?_P \VTS49+E@ 56L
M571A-9KP6OZL)\G:C_S*,A#-F[.:<0X7L)?<-EG9$T36TS[\3F;>FR4LL(=>
M4AEI*)))99>'5D>3IQI%'S=FX1(-DC3D3Q1=SQ1=E&YV'<Y0 #?8 ;DD[ #<
MGU)V]2?C/J<!:K6*W*L4ZO5X(#FV\XJS6N6(%PATFR6-8P8%6>.O1&6G"IA0
M@,(%J(SE/RU0!D")MW;$1A"#RRRB-9)))%ACZ4(=V811<WDZ<88D(G.1WX+L
MO)V;;=B2  WV &YW.P]2>VY^4[ #<_$ /09?\CRN,8S6CS2:=D>'7EDPPTX\
M^]XT=W:99:0IQUUUSEMJ0VTTVC2EN..+5I"$(UM2E;TE.M[WK6;30R!K>CDD
M #5-/)).P %N'<DGL /C.13_ .)F_P"RD_\ 0V:\_)#194+Y,OPJB38S\25'
MX55FWXTIER/(9<3N7Z6WF74H<;7K_P":5I2K7_SUFQ\8D-XHUPJ00=0F((((
M([=P1V.1U/\ )H?^H/\ S.='<YK,G&,8QC&,8QC.)=V@3U?[H,XR33"EJ&M_
M)A6Z(LAJ,]N$B6KOUC=3%7+TCV"9&V]Z<TSMS3FT;TO2?5WK>=S R_>[O+R'
M(^*8"%W'(CWOC[[>NWZ]MLPF!\^AV[>6;O\ _K.=M,X;,W&,8QC&,8QC&,8Q
MC-)OE*_^;L\[_P#N>>2?_H]<,WGAC_.3P_\ [:TO_P";!D%K_)K'_83?^VV4
M'R8?_-R>"G_=+X#_ .F-:R[Q3_G+K_\ MC4?_ERY6O\ Y/!_V,7_ *%S>C-#
MDV,8QC&,8QC&,8QC&,8QC&,8QC&<F?ESX4PA\E)Y@PX$23.F/U.AI9BPV'9,
MEY2>P\[6K33#*%NN;2A*EJTA&]Z0E2M_O:WO78> 65?%VC,S!5$MG<L0 -Z-
MH#<G8#<]OZ<Q+W^2S?T+_P"M<Z+\10MOC'(FW$J0M',*"A:%IVE:%IJ@E*DJ
M2K6MI4G>MZ4G>M;UO6];UK><U?[WKNWYW9_]Y\R4^ O_ %5_\ADGYB9=C&,L
M$BJUB79AETE5X+(N 0,8K@>TOC(3M@% +#,#D#P0>86RJ?#%&9U> S"D".^W
M%G20PQ^2TXY"CJ;D$LHB: 2.(7=)7B#L(WDC5UCD9-^+.BRR*C$$J'< @,=Z
M;#??8;@$ [=P#L2-_78D D?'L/DQ-JM8(V(%;R%>"SK55X!P76[)+&0I)P .
MLZA2K'!#%'F5S1D4]L$%^=V(;S+9'0J!J6EW45G2"RRK')"LCK%*T;RQ!V$<
MC1<^DSH#Q<Q]1^!8$KS;CMR.-@2"0"1N =AN =MP#ZC?8;[>NPW],O\ D>5Q
MC&,8QC&,8SB7\J! G2_-CY&>1$A2Y3$'RVN[\YZ/&>>:ALJI89*7I3C:%(CM
M*5K:=./*0C>];UK?ISN/"S*-$\:@L 6T> *"0"Q\P>P!]3^H9@V@>M3[?_6/
M_DN=M,X?,[&,8QC-2?-IEU_B 5#+3CR]>2OA.[M#2%.+TVQYG\">><VE&M[]
M1EEMQUU?H]5MI"W%[TA*MZV^AD"](20![UZX-R=NYT34 !_62 /E)VR*;X _
M[6#_ -Z/-MLU&2XQC&,9J5YDLNO<_P"5)9:<=4CRU\.'EI:0IQ26F?)OESKS
MJM(UO:6VFDJ<=7OT);0E2U;TG6]ZW&BD"S;W('_(^M#OV[G2K8 _I)],AG^"
MG_;0?^ZF;:YI\FQC&,8QC&,8SB5T*!/5_N@3@!),*6H<U\FQ?HKD],9[<)N4
MKM-B<3&7*TC;"'U(WI:65.:<VC>E:3O6];SN:[+][S4%Y#D?$]<A=QR(\A'W
M ]=OU[;9A-_E\9^+RS?^LYVUSALS<8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,IY<2(0
MBR8,^+'FP9K#T69#ELMR8LN+(;4T_&DQWDK9?8?:6IMYEU"VW&U*0M*DJWK=
M02I#*2K*058$@@@[@@CN"#W!'<''KZY^0X<0=$C0!\6-!@PV&HT.%#8:C1(L
M9A&FV8\:.PE#+##+:4H:::0AMM"=)0G2=:UAF9B68EF8DLS$DDGN22>Y)/<D
M]S@ #L!L/D&5.4QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,_/3K6]:WO6M[].]:].O3O6O1Z=ZU_#OT>G7I]'\'IUZ?X<8S]QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC,>M4NT00!"73 8:R69E+&Q82P6.54A$Y:Y;#<E,RPPJY;90Y+,)4F2RI
MJO$=R)#+,1:8Z)"I<>2$1-(HGD>*([\Y(XA,Z]B1QC:6$-NVP.\B[ EN^W$T
M.^QX@$_$"2!_60&(_8<Y\4,IY'S?/V&8Z/SCKE7H)OC??ZL*:AW"EGN"C ],
MO/CHOGED1'#7]TG*O%JE2^G%=FK)SJJ7=0.X!*C%!RP-!M)^#T<Z::OAUDK6
M:<MB.]ITKDPSQZ@SSP:F+,1+UPH@B5:B=.*S-7$D,DQD62Q%&V.ID\QNRN%*
M2 >T#& #%Q.P;?D3S.Y4-LP78A21THSF,R<8QC&,8QC&,UF\OW[7'X'8W:DJ
MW(7JW<?1<G:%\_\ QFSR![LM 9[I(K2ZG_[V-%X_%UWUZ(_5-IM$=QO3]=4@
MRW"5K::,(CJ$8FZ/^)N] 6.GT#=%&R=/$O6_$E#>\N")OQ1])08RPR*;ETSQ
MW^$G+CORX=1>IMMWWZ?+T[_)WVRT>'FBVN>77UG+D]0M]FZ:KC+E]=MC]C5R
MK9EOYGW[:]J7;W*YL]\2[HRS2UI51?AM056ZWL-O+]9X>9@_Q/F/)5?.BN(1
M&+?3]L;5]H1+T^EY@)W\QU>I^-ZF4AWXM\+CS;I\N6_#MM\+VMM]^._^CMMV
MVS;#-1DV,8QC&,8QC&<?9?1:G7^?>:PT]%\B>KC8WE#7F>6@GSODD()''+GP
MOBXV&O=Y!ZA6 %QL=U>%T\A9U@G)%,IL<,837:L_.8JE=G]D*\LMC0FC.FTW
M.E2FW((M,=$Z%^^Q_P 'DY12W6IFHL74 GG9XS)*%,LJX?-0LX/4<"4<1O*-
MRR(![0[A _+?;=5 .P.P&=)/'T<1#<(XP$,7@QTXR"Y90@1KI%AA%AIZ_F0E
M7%BBUT,P#S;1J*4M!&))-SF2R/G!$F:YJ6I;_KK5S.HLKW[LD<"58Y+=B2.K
M&R-'6C>5W2!&C_%E(E81J4]G91Q[9DQ@B- 6+D(H+$$%B !R(/?<^O?O\N2]
MF'E^,8QC&,8QC&,8SGSV#LLJM>6?/JI1^QV8Q.JM>LM^[KP>%]CTH,=Y@CE_
M06Z76:;7=5J/T<]W#H/48]3L-1"";3-E;J=2M[A)D8&+UX;8^BITA+I%F6>E
M"BRR15Z&H-YE'%LVZQGDFDZIJQT:]0S1S2/" )IH0I9UD:/'=]I5"R$[ M)'
MLI'#@VP4;!R[-L0 3V!W ! /O\"^T=*ZZGR;8ZL2N$NRT_O(5H>#L_++AS.)
MSNN7?Q[X9T9OEH/XPHE%)V.'1+5:;>,:,EH;UH,C%A[>69A!;?5DR*>(*-:E
M[UFHL(BFH2%I(K<%HV9(-2OUO-R=&Q86)K$,4+F-&$2/SA0L\,NR!V?J\RVX
MD'8H5XAHXVX#=5Y<22-SW/9CL&&;_P"<]F1C&,8QC&,8QC&,8QC&,8QC&,8Q
MG%[R+,^5">[]N,*H'DR#JY?Q%\P*)SB;S"R5HC1Q#5>+^.Z>6]'%"J9T(Q;V
M^IF3)+I1C1-'/Q_48=9.@JU2:^811K=8F.VTU-)\A07S&ER2QZQHUBRMN*19
MWZB:D;=9WGKI :B1I5CX&RU1IHY)9Y(_,0QG"E,W-SQE ,4RJ5(XC8Q\7V#$
M\R>1WX\]B%4'B3FWW@,_<E\JOD2YK)RI _LMNC@BS<GH\KGQFM2PE3+C)?'E
M]=4[T=KGT-PG+"3(UDF$6H_1Q/06:U/DT]->5K3>(!!YNN8.(#4H3(A%868Y
M5>5&6[Y/:L;#!!(K1JI-9ZQE43=3)J_+BW+<[2-L?:XE=AL4Y[MQ^(@D^T&V
M.VV;QYHLGQC&,8QC&,8QC&,8STR8[4N/(BO>OMF2R['=TT\]'<VT\A3;GLWX
MZVGV%^HK?J/,.MO-J]"VUH6E*M5!(((VW!!&X!&X[]P001^H@@_&,9Q8O-5&
M4_AO=K0L7Y$P?LX=JG<R\;JJUTSRE7]C^+1:Y:^>5SKM[)@+23MU;IQ*PQNC
M=SDS7]Z:-U=[D@D. )=*&TR.]V]>9IK]"(/IK"C16UJ<WE=)WLFQ)#9EI5UD
MB6&69(S6H*H[QRBX[R)5><C"8!4=CU!SDXQ+RE]D*"H=MCR"[\I"?C'#8<^(
MR[>17Q9T2JWFWU.S7.RQ?'L9XC<)%7,?!O8ZR'R_2>W>.?4O**VG!5 6,O>P
MTGC$?D[%G^'71QH1 ?Z]75.PE;*MMV:;T:\L$$T4$1U%M9U!X&:L\<:5J&I5
M-)AC>QR@$BW3<,75#(["E* PX$UDW(8@L>F(8^7M DL\;2DA=B04X<MMB!S&
M3,%Y0#/]C\/[('<Z,0J[O/>R$+5,"7GR*"TF38J>1YLY2'C0"X7)R>S[(E)M
M/S/"N:9$HS'W.:D:*06DI1@O;DCI:S$XK+*+-)8E>OIKSB.9;(G"20P!3NHB
MYM#L$/$CBV7\07A*\N)5RQ#2!=QQX[@GY=]M_7.F.<QF3C&,Y^_*3.=VE^--
MYK_#ZKT\N^5IG2"%LL?&[%6Z_P!'KD.LT$\<JL&L.%[K2SJGK1>H]<'''Z4L
M[:_@V/:!  *Y83829#Z+PR-/&J027YJJ!)ZRPQ78Y9*LIEL1QS-+P@GCVBKF
M5HQ/TX>N8GDDZ4<BMCV>ITF"!SNKDE" PV4E=MV![ML#QW/'< ;D$;RU:;-)
M5FND20DF!(SP0B9/!FW1CQD--E#X[\H47>"DS0=TF/?6Y$GNB3!8:Y*9=5!)
M3HNVI3NAE55ED5'215D=5DC#A)%#$!T$B1N$8 ,H=$< CDBG<"<=P#L1N/0[
M;C]1V)&X_42/D)R^Y'E<8QG+D[T*G4_H_GAJX.>1E^H\&I<ALC=5K3W<Y!4I
M9(A^X!;+4.1D!,@+#!PW3)#G]?+BZ6:!U38>2LS<Y*P#EN.KZN.M-/6\/]'W
MMKV&FN1&:44 B1&."2*:XKAVD(1;$B/.DDPD'" =40QC%Y!7L<C(RA48 <]]
MP6W5-M@.Y4; @$'=NW(YM9X=02PWQOYK#.VHK<"R(MAD329B5=2,H8HA;CY)
MBEQC/1H0Z\V(/SJ+,8Y_7[/:848U9@59''9S2'R"]:U&LLCZG::.%($WC"H@
M@4-QAC4SM'69J\4ED@V9(H6,<4DK1J2%&2P@B)-V+'8DDECMN2>.[>T0N_$%
MNY !.;-9J\EQC&,8REG.,,P9CLI3Z(S460Y(7&U*W)2PAE:G51]0=;F[?2WI
M6VM0];E>TTGW?6W?4RJ@EE VW) &^VVY/;?E[.V_KOV^7MC_ .__ +VSA04*
M]?M7C#Y(2O'4%Y,R:ATVW'S42HHM]TA]RXWRRM\9W'%/##'D#>ZM<(ML[GT2
MH1C5M 4*Q&;+2JC<S.H8Z'V*1.DK[U$I0ZIIHU)]+$U6%$:8PPM0O6Y;V[<D
MTZ"6$PT*TQ2"2Q%'%/- G)VI!5& 2[12F+J[.Q.W)N<:A.VW48$&1EW8*25#
M'MSW.=I^7SBQ+FO/R!X4:!')M*J\HP&LCL!^P"R;X2$Y/@&WA9,T-=*Q92G6
MI[D(N2C+E)=4U-DHWIU7$VU1+5E8WCDC6>94>(,(W02,%:,.B,$8;%0R(=MM
MU![9FIOP7<$'BNX/J#L-P?7N/C[G,ZS'R[&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,9$':.PP>+UZO&Y-.N%](6R]57G==JM&W46SQ2QV^6Y$&
M(3)O5MI%8APV=LNO391&Q0]-,M[TRB0\I#2LRE2:[)(@F@KK#7ELR36.MTTC
MA +=J\-B5F.X"A8FW)[D#<Y8[\ #Q9MV"@+QWW/I\)E'_P#.875O+'BQ\:">
M.V/[&UB-7<OS-VA]%6-#6\'T0)9X=-FU RR-)&@29\BRE @H 3%GBE;MSUBK
M3E2-G&+$%=G3S:1=C>01QBU'' EH6*O*2&2M)$9EFC+I')Q$2N\B/&DL(BEZ
MT<9BDXT$J$#<\26*\6V!# [;'8D>I !!(.XV)!&\IU[JO.[?$3,I]M#VYMVA
M5?J$9JKR='Y<V@7=)Q5,M4"$+U*ES15MW6; U6WXS+NS3X8BP/2^]%>0G$DJ
M683QFA>$BQ+4)E'35;,'3Z\+,^RJ\/5C,H)' .I;8$9<'4^C ^R'[=R5;?BP
M [D'8[;>NW;+3Q;K8CM]!:OX6O6JJ1MV_IM'FUVZQ!$*S"K!R?IEOY1:HQ&,
M!-V(4A'Q-2B[D!48Q*4\-<AO241);C\*/?=IO1L&N\D4QZ-6=9("[1/';JPV
MXBIDCC?_ !4Z!MT&S!@"R@,:(X=>0!'M,NS;;@HS(?0D>JG;OZ;>A[9*V8F7
MXQC&,8QC&,8QC&,8QC&,8QC&,8QC+*[6JX^6:/O@ KQUC2-,FG14%PLSI"%-
M(TT16QN8WI#:E-HTA[7JH4I&O0G>];O$L@0QB1Q&?5 [!#\?==^)[@'T^+*;
M#??8;_+L-_VY=&X[#*Y#C+#+3DMY,B4XVVAM<E]+#$5+\A24Z4\\F+&C1DN.
M;4O3$=AG2O9M-I3:23L"20!L 3OL-R=A\@W).P^,D^I.5SW93&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RBA#1PS4I(V!"'IFS9
M1*8F%%8B:ED9KGM9D^5IAMO4B;+=_P!\E2G?7?D.?Y;KBU?OY<S,VW)F;BH5
M>1)V51LJC<G90.P [ >@QL!Z#;X_Z_ERMRW&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&0KW/
MD<WK]>JHX3;W:.>I71:?TJO'T@HMDCM&J=,>E1(I ++F#FYL"6F0ZT^A$Z*Z
MC>T.(=_R-H7G4+BTY)6>$3QSUIJLD?4:(E)@ 2KJ&*LI ()4CU!&62(7  ;B
M0RL#MOW4[^G;-7;'X PK%)J3\KM_1).H/0T=7Z V2CP'8M^Z&WUFH=::L[04
M,_7ZK7YK+U,%<]B;D5RQ[%\R9:"!5C#^Y]I);2/Q T8F HUARK&G7XE@U>L:
M<]/I&20232*1.UAMI8N=K=W#1\8DB-??;VV(Y<V!_P!)^8?EL-@#V"CL=E[#
MON3*/B]XY3^$0>X/OD6?G?I77^@V"GI4\DW&H7*TGS*^5<_&JU$#Z^&JVT4-
M6D;6M)TW7)%S*UI@G.8@-$'L75=274&H@*>%6G7CFV!0V+?3C%NRP+/^-E*1
MQ/+_ /5$"2E%+%1=%&8^9)[L[$?&%3D2BCL.PW)V^+<@'MODC>/G(CO%*8<J
M1N]-7Y1CI75NEMDT55BIKAD.P])M76+4-]TCF33<B''N%T/[#N*>:>B!5#QT
MG<V1#=(R\;4+B79XYD@-?A5J5>'5,O):=:*I$W(HFS&&"/F-B"_)AQ#!5OC0
MHI!;ENSMOMM\-BY&VY]"QV_5L#N1N9US R_&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,9&G
M2NJ5;FH T2)$1\HX/%+G"J@R2AMV.PS'E*C"AHL8IW<Z0\5([;@1ULQ7M>U6
MK>DK]FM.<7XS\=:'X,TK4KEVY4GU2I0>U1\/QW*RZQJ]B0F&A3HT6D-J:2_<
MX586CAD'-F(#<&&='X<\,:GXCOTZU:O/%2GM+!:U9Z\S:?I\*@26K-JR%$,:
M5:_*>17D0\0!N.0.9/7+A5+A&][JUC"6!A+,9]U0@I"(*C-S&]NQO>VXKSJX
MJWD)7M#<A+:][0XGU?2A6M;S1_$.A>(8?,:'K&FZM$L<,LAT^[6MM"MA"\/F
M$@D=X&D4,5294?=6&VZL!K=1TC5-)DZ6IZ?=H.7D11;K35Q(T+!9.DTJ*LH0
MD M&67NIWV8;V>Z=3YES=^NQ>A]%HU#E6\E\S52-<K8!K#]F+^O&;V,K[)J?
M"<,$-.3(;>X8],B1I<N,C;>E2&M+Z""I:M"4UJUBP(4ZDQ@ADE$2=_;D,:MP
M7L3R;8; G?L<UC.B;<F5>1V7D0-S\@W]3EPN]YJ?-ZS/N-W-Q:]7!KXN)))2
MTONZ5/.EX%?!#(D6(S(FD2QT\4& P@D?&E$BY@C!&#HLF=+CL.6P5YK4JPP1
MM+*P=@B[?!C1I)'))"JD<:/)([$*B*SL0H)%68*"S'8#;N?UG8#]9)(  [DG
M89?G28YB+&FR9L:+$F.P(\5^6\B(V])*R&(@R*C<G;7IE3Y<J-$AQO1I^1*?
M9C--J?<0WN,*Q)4*20&) !) 0%F)VW[*H)8^@ ))V&-QMO\ $=O_ .?3]N5V
M6Y7&,9:2)\&(F@1I4N-&D+44?!UF#.FQXLNP&8H0Q99(H-'><0Z2(1Z[7SIQ
MZ)$2Z^V)#DR"T:BPI#K=ZQR.LC(C,L2"25E4D1H9$B#N0-E4R21QAFV!=T7?
M=@#0D#8$@$G8;GU.Q.P^4[ G8?$"?09=LLRN,8S#R-_IXFZ5OG<\[%9NUN&&
MS5?KB$29!":'KFHOSR6=3&8>:'C83DZ'&]^).PXLB;)9@Q77YCB6-S+7F>"6
MRL9,$+1I)+V"J\N_!!N069N+'BH8A06("C?+2RA@N_M$$@?'L/4_J'ZSL-^W
MKBW]#H'/JI+OE]O%0I-'@;&IG7*VV4-7*K#49)0PPA,JPF)L,1'V5+D8 H;I
MV8C<XC.AP8WM9,EEI:&M8LS"O7@FGG;EQAAB>69N"L[[1HK.>"*SMLOLJK,=
M@"<,RJ.3,JJ-MV8@ ;G8=SV[D@#Y2=LN]>L5?MP,59ZH=#V:MG8,<F$L-?)P
MC(0R-E(T[%("BHYZ3 (09+>].,2XC[S#R-Z6VXI.];RR2*2&1XIHWBEC8K)'
M(C)(C#L5=& 96![$, 1\8RH((!!!!&X(.X(^4$=B,]=GL]?I@ I:+26A@J\%
MC;F%2Y!SV4.!%TM#>WY#FM*]1O2W$)]/HW^^K6LK%%)-(L42&21SQ1%[ECZ[
M#]F"0 22 !ZD^F>]\^#BG!E9DEQL>Q&AADR(!/38[98H(KLD+#/$X ];FI4N
M"&E62OQBDIAI;,%XV+;DK;7.C:<H(Y#&TH1C&C(CR!241Y [1JS;;*SB*0H"
M06".1OQ.S<;@;C<@D#?N0-@2!Z[ D;GXMQ\HR[99E<IH4V&2AQ"(Z7&GCY\9
MB9!G0GVI4.;#E-)>C2HDIA;C$B-(96AYA]E:VG6EI<;6I"M;W5E96964JRDJ
MRL"&5@=BK [$$$$$$;@]C@$$;@[@]P1Z$?+EBJ]QK5TCEYE7*-EX@*S6*G$Y
M3#$MN,S9:D4D [*+:?DL,M37 AN'-#D'X*Y,1@K!GCE/^^09;+,DL,L!194X
M-)%%,H)4DQ3()(G(!)7J1LKJ&V8HRMMQ8$T#!M]COL2I_I4[$?U'L?U[C,FR
M+*Y32YL,>TE^?+BPF%R84)#TN0U&:7,)3&!PZ(EQY:$*DSR$J-!A,:5MV5,D
ML1F$./O-H5559CLJEB S$*"3Q52S-L/B5068^@4$G8 G!('J=O0=_E)V _K/
M8?KRIRF,IILV&-ARR)&7%@#X$9^9.G39#46'"B1FU/294N4^MMB/&CLH6Z^^
M\M#33:%..*2E.]ZJJLS*JJ69B%55!+,Q.P50-R220  -R>PQZ>N5.4QF#SNE
MT 8-Z08(VX% $\?5,3U E-G-18-$^;Z6%Z+.59)3^T,C6X=%L0.TR77EZ:9#
M$XLMQ:4+WZ)UJV&:LBPR,]T*:BJI+6.4\E9>D!N6+6(I(0!W+H5&6\E 8D@!
M/A'?X.RAN_R>R0?Z#F1 38VRA15@#NO/BC4",2'O284X;(<B3&DO,*?'DXT,
MC!>VVO7M8DZ)&EQU^LU(8:=2I&HY$:)WC< .C%6 96 93L=F0LK#?XU)!]02
M,N!W&_R]\N*Y##;S,=Q]E#\C3NV&5N(2\_IG25/;9;VK2W=-)6C;NT)5IO2D
M[5Z-*UZ;=CL3L=AMN=NPW]-S\6_Q8S#R72>=!S1JME[]2Q5AK51?O]C DK2#
M@F0%$C.O,2+J;&29S4T54F'X[[+UCGL,!VG6'FUS$J:7I,RUK+HDJ5YWCEF%
M>.18I&22P0"($<*5>8@@B)27((/'N,M+*"064$+R() (7_6(WW"_K/;/91.B
M4#J5=8MW,[Q4.AU23*G0(]FH]D#6L _.&2G(1*$T8!3)X]<L=,:=B3HR9&WH
MDEMQB0AMU"D:6*UBI*8;5>:M, K&*Q$\,@5AR5BDBJW%@05.VS [@D85E<<D
M96'<;J0PW'J-P2.WQYF.09=C&,L56L]?NU9KESJ9:&>JUN!"+/6C@]S;L U7
MSX^.5#%H+N])V[#(CI<:9&<VE.ULO(5Z->GT9)+%)!++!,C1S0R/%+&PV9)(
MV*.C#XF5@5(^(@Y0$, P.X(!!'H01N"/Z1E]R/*XQC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,9#W4N=%[P3H)"O$A=8+56Q22K]N=%,%#T(2X
M&(P7@X1B0C49>R<Z9!F2$DG'A#:A+#TP65VAJ+OSSQSX0U#Q-=\*V](NT=$O
MZ%J\M^7Q!)0BO:K6H-I]RM)I^F12J(6-VU8JV)EN/)04T(I+%&\5C@/6^&?$
M%31:VNU]0K6M2JZII\=5-)6U)5HS6EN5YTMW7C)D'EH(9X8S65+;"W(D-JJ&
M>3*_C]$F<[IJ*\5V&E&?GD^0*G T-R$FR.D#$R7#,D&I"Y$S15P8[!B3TRYI
M%;3T3;+,^3$;CKS+]SWPO9\(^'5TF][W3ZC[XZK;O:GIU=ZRZS)<U"Q8KZC;
M29Y; O/3DK06A8LW&CD@,<=J:!(FR#Q;KD7B#5S?K><BI^3H5ZM*Y,LQTY:]
M2&*:G7>-8X?*K96>6 Q05PR2AW@CE:09 7E=S3JEM-\VN/"@Y,=V.GP[6#J/
M4HEU !JY415P,4*=::MU2D60:5CW_E%U33 DVRP:\-EWJ#/J(==.F5@M);LX
MWU+2;52%+,-]U:G,T,DU0P2/+,T*6%BFJ3Q,AKVX.O(L32,L#+,_669 8FY.
M57)5HP0X#!7Y !0Q7<,IWY(W$$[>U[(XD$[YJ&6\2/(SIULZBKI(J)$IUD[+
MXWW*'7QO4K;\PS4<F\S6.E66U!6G[N>,194S@"FX*)DIRID9]FA( #JA6PM7
MHJHNY36--JPU!69C/%2U.!I'JP&13<T0U8HG(@C0JNH[MQ'65(B9&FE>:QRA
M,,K,_(>R7B(4,=O8FY$CVB>\?J3MN>P4 +EEUX9>0)>B6N)TQV_],MX[J_!;
MT0%S.M0AM+ZHYS/R0B=%LMJI#S-F:,UFS$^:++AAL2SIHHT>XNMT]EI8JFU>
MR!I/?O3DL0M5%:I U34:ZNM-FGJ"WIAK113[Q%)8DM<'=HNN[;2S;\YYHY*=
M"0JW/DS<XVVYCBW"7FQ'?<$KN "% &R^@!&V'C73.M0NQ^2:;F<LL_G?,;&7
MYGPA9DI8E*-C>CS]>0%U-RT%$MQ3,.F/=!HW"*87:=+?-8WCIR,P5U*+&84?
M4:G/3:EI?1CB6S:B2UJ'!8OQ;55][H(QPW,;3BM8U"="$YO=C)3BD;&6-7YR
M@D\4)2/<GOR_&,3OZ\>2HI[[!#\9.:\4[P^\@ZJ<\962-SZC,K]4Y/XWQ;U)
M ]AFG"H/N=+N)"S^0ULMA+H-H<FV:L]B$/URI$= (MFE$ -?.5EL%7@]@3/5
ML9M9TZ5-5*05%DFMZF:XDI"-'H3P+%IL,*UH@L4M*17F3JF(+))'*9)'BXY&
ML,BF+VFV"1\MG)(D5MY"2Q[AP0#MON 1L V^5*_%WS672R(D=UV4%NU:-7CE
M'*K8YT:Q36&>)TOQ9\H><< Z?>&U-OO%.J&.Q=CI=LZ8XJ*7(RWJ=5SDB86F
M5,;MBGOKH?75VIJ\$L<%NW"*T:DWI]5TJSJ-2N=P$J)3I3PU1R1%$TL85!,_
M*O2GXD!R&!9$;D3^+6*58W;Y7YNK-ZD\03N0,M!'Q$\H"W-A-?I'0^J\UGW6
M^V*D]%AV?JT63.YYP[H%8Y2F]6;ETRJ'+,S\61+)R%I=*<F&OG^(1Z7T6V>W
M /V0N&?O76-*6T\EBM4LK!7BGK&*H0MF]6FN>7BM"9(_Q+0W/QX$9C*U:T($
M@BCD%.C+Q"JSKR8JV[]TC95Y%-BWM!D]GOON[-VW(S8!KDODR7\56AU\DI)=
MVM_7 /4>PT^I](+!!I>F-=8#F;!QRC7MMT6H'"WR */IK#;#M> 6@C'(CS4T
M&)MADK&UQN:6FK%ZZ\:$--ZM.::LCND_DWCCNV*_MB1O.NTYW$DD2E6C61X4
M0R<)3#LW^,+AW56(W7F"8U;<;>P./Q ]P2 212>-OC#?Z1U^N]:Z(S)]X&\R
MZY404*=T:Q7,I2J_;_(.S7[FO.I\R<2D1K%NB\N-#:M(*.**0H$P:@.'*%18
MD05>NU/5:\].6G6(V>U3FD9:T4*3R0Z=%6M6555!BZ]N-Y@@X,ROS=%=W0(H
MF5@[>H5P/:+<5:1F5.Y[\5(&_<=M@2 #F!"?'6^O+[+-M_(^@L1K;:*C:Q=
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MI!HPTT\H:W1I6P[O'42&"-Q; B\P\7-HYH86L/ SO5)@S!"#R//OL%'L.Z$
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M+3N'<0NX>1$D5@0?#2+QT2Y2/=#99Z,N\W:J7?DW1IZI, NG:9TZM7.\5,G
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M &]I@.1[;[!F";[ G< L #W[GOWL9+Q-YA8Q-LK5KD70K4[!VQSO BO@N@]
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MI*];2K:I>IQK'5E2#BZ.LL=>LMD&.9+"+YKH^9,2SQQR]$S&(NH)0X:)')+
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M)^C0R;,">V^F%:TFFV:5JVZQR2Z?2TFM SQN%L3V]&KZ=+%*W$-RTV:I+<K
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>g210084g39b02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g39b02.jpg
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M 0$! 0$! 0$! 0$! 0$! 0$! ?_  !$( 0L"4@,!$0 "$0$#$0'_Q  ?  $
M @(# 0$! 0          ! @#!P4&"0(!"@O_Q !;$   !0, !@4&!P@/!0@#
M 0 " P0%!@ !!P@1$A-4E!15T]35%187(9.5,5.2HZ31TA@U0597=+/7"1D:
M(B,S-%%8<9:7I;76)3)A=;0D-C<X<W>VMR9V> K_Q  = 0$  @,! 0$!
M         0,"! 4&!PD(_\0 7!$  @(! P$$!00,"0D$" 8# 0(  P0%$1(A
M!A-1T10B,9&A!T%AX146&",R4E15DI.4U#-35G&!HK'3U0@7)$)BE=+6\#1T
MEK,)-39S=7:VP24W8[*TM7*"\?_:  P# 0 "$0,1 #\ _OXI$4B*1%(BD12(
MI$4B*1%(BD12(I$4B*1%(BD346D"M6-V!<VN#>K4H%Z#$625J%<B/-2K$2Q+
M#7H],K2*2!EG)U*<XL!Q!Y(P&DF@ 86,(PVO;7S"1B91!((Q[B"#L016Q!!'
M4$'J"/9/1]CZJ[^UO9:FZM+J;NT>B56U6HME=M=FIXJ/796X*NCJ2KHP*LI(
M(()$_@Z^Z.TA?R\9F_O0F_CE?*/3<S\KR?U]O_'/U@^TSL?_ "3[-?[BTO\
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M*%+%3AW)ZT\&4,A,>GG2V928@4W'RX]W<<QMI$43NY0#VI3)CEAQ(&%.Y$&
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M"K\0ZKRE?#](?2,2GG)E.<LUIU*<TPA0G/R9.B3R#R1W+-).*,>PF%&E&!$
MPL80C ,-PBM85KVK3.9F D'*R01T(-]NX/@?6GKU['=C'573LKV8='4,CKH>
ME,K*P!5E88I#*P((()!!!!VF+[H[2%_+QF;^]";^.4]-S/RO)_7V_P#',OM,
M['_R3[-?[BTO]UC[H[2%_+QF;^]";^.4]-S/RO)_7V_\<?:9V/\ Y)]FO]Q:
M7^ZQ]T=I"_EXS-_>A-_'*>FYGY7D_K[?^./M,['_ ,D^S7^XM+_=9<K0OSEF
MQ\D>9"GK,.4G@M#A>ZY$6Z9!EK@!&M],6'D73$H%;N<%.JZ$M6).D%6 =T56
MJ3[>Z4&@'\B^776=8T_Y+^T>7@:KJ6#E56:**LG#SLK&R*Q9KNF5N$NIM2Q.
M=;LC\6')&93NI(/B>VG9+LK2W984]F>S]0N[2656BK1M.K%M8[,=I;179PQA
MS06U56A&W7O*ZWVY(I%P/2SE3\I>0/[92/Q*OSW^WWMU_+3M9_XCUC]\G+^U
M3LM_)K0/]SZ=^[1Z6<J?E+R!_;*1^)4^WWMU_+3M9_XCUC]\C[5.RW\FM _W
M/IW[M'I9RI^4O(']LI'XE3[?>W7\M.UG_B/6/WR/M4[+?R:T#_<^G?NT[Y'5
M^D'*XM+)BQSF?K&6&":0O(@SI]"M&-X5V1IP-C>)TZ6ZC(,$6:X!0E'"0)C2
ME"FQ91H!"]1I&9\K.NZ'KW:'3.U':O)T[LX<!=1([4:H,DMJ.1Z-2N'B'.[_
M #FJ<J^6,5+#B4O7=>$K=6/"U''[ :5JFE:1G:'H-.;K RCA@Z'@FD#$J-UA
MR;QB]UBAU#+0;V07V*]=?)E8"1(0:4<5/?B'];FQO\U[D><*J[O,5+:SA5%E
M&IC%SLC6*&P@E26<4(@\2O<G6,#NQBO?55VK#Y;]"MU6K5<KY2L3[!FH:O>=
M0[178>G"]4>A\K.Q\BW"JKN6RMJK3D=W:'7@[;S#3S\F.J)@O@4=B\C[)\_L
M?4,31Z\G+-3,MBT8MU->2[ULCAT%7-.)Y*!/H=M)DHDNQSUF<AU4.K4THHV>
MNR&5(W UZ;7=U;U"!K$"QBI(>C9' PL98[G'6)&8G(.(*4G$2Q^6E*T%FI?*
M-5G79V#@8VCV97:Y-7R[-1P]0SL2W$PB.=]%N/IF6Z,C&RP5L]-=E5=UE4 ?
M)JSMPPNQSXR8V5E7:@E'9]M/H7#R,3%R*[\D'C5:EV;CJRL."%PMCH[5H_%6
M==)2Y1!UG+.-R53HK8TQUED]N4H>D E8%S.098S8-=$0V]>%6WEW$K3B1*PG
M$@NF.L#1&?\ +*4JL&;\IIKOSK],IL&1VJ*7:EBG(7*T^I^?&S.QFQ,H7XB$
MWTG&R!96IILX[1Q/DX#.AQNQ(>O&JS;$-.A<J\/(%1HRW7CNN-<,B@U7L!58
M+JBCL+$Y374[2;8F%RDSXZ9F9F1F>T\==UCL^2YN$UO2M$G<4R%P2+%Q*U&(
M]$K1G%FJ$Q:<73$9=CMZK3@-V<ZSY:M+TK,UK4\[Y1M.TS3M2JTC/R<_4^T&
M&<+4K\:K,IQ<JC(R:\G':W&OQ[4>VE:CZ1CJ+.=]*O1BI\FF=GXVF86+V.S,
MW,PK-1Q*<7!TG(&3AU7V8]EV/=30]%P2ZJY&2NQK!W-S%.%5C+V]'&M(Q<A9
MG9/EE<8S/30^/!;T#,9YS2A+C1K"2^(G1:0]FE(G%O,DS&$U,*XK"NO $HP8
MBE 2N_CZ/\L&5BZ=GT]O<IM.U+3]3U!-27Y1+7P,5-&LTJK4\;.R:]3>O&S,
M5]:TP/2Q/(Y2BMW:NT5\FW4?D[INS,6SLI0N9A9>%B-A-V/K3+O;44SK,*[%
MI?"1K\?(73<XK:-MO1V+*H>LOKMID6D%(C74J,2;+LJ"RC$!S41A\FC\E2 V
M5AI9YZAL4*2RDQY#>N4ISS;@ <F2*3P7N60:('D<#6?E9U>S.31=;[?ZXNFL
M5S;M%U/M'JE&.O')=;;;<*ZY*Z;:L/*NJML*K93CW6J2E5A7T.7IW8#3UQ6U
M/3.R6EG-4'&KU/"T;!MM8FE36E>376SV)9D45V(G)DLMK0^LZ S3%VDT4-[*
M-69V+,C*<"N2%F*,@ ''TIJ,3B6I>P"'834G,;PB7 .7V3EC1A$J"*Y%KCMM
M/E?+2C:FCY/RHH^BU+?K*/=VL5M)H?'.8EVIJ6!P*GQ <I;,H5(V.#>":@6E
M Q_DU9<)EI[#,NI6-5IS"O0"N?:MPQVKPB%VRK%O(H9*#8PN(J(#D+.D^EG*
MGY2\@?VRD?B5>:^WWMU_+3M9_P"(]8_?)VOM4[+?R:T#_<^G?NT>EG*GY2\@
M?VRD?B5/M][=?RT[6?\ B/6/WR/M4[+?R:T#_<^G?NT>EG*GY2\@?VRD?B5/
MM][=?RT[6?\ B/6/WR/M4[+?R:T#_<^G?NTKYI99KS*SX-1N#1EK)K4O%E>,
M(Q+6V>2I"K$D-B$^/-2W4I74HZZ8TY.G.,(N/=#-(),$&XR@7#^K_P#Z+G-S
M.UFK?+"G:K+RNTR86G=CVPU[09%NLKB-?DZ^+FQ5U%\D8[7"NL6FH(;!6@?<
M*NW\+_Y:V'B:%B?)^=$Q<?1CDY':$9!TJBK3S>*J])-8N.(M)M%9=R@?EPYM
MQVY'?S-^Z4TC/R_9K_O4G7CU?L#]K'9K^3VA_P"Z<#]WG\#?9;5?SGJ'[;D_
MWD?=*:1GY?LU_P!ZDZ\>I]K'9K^3VA_[IP/W>/LMJOYSU#]MR?[R=PQ_EK2N
MR=-HOC^)9US(JD<N>4;(U%K,OS)O0EJ%AE@"5N3BKD!:1M:T!-C5SHY*S"TC
M<WIU*U28 @@P5M+4='[(Z7@Y6HYF@:*F-ATO?<4T;"LL*H-PE528Q>VVQMJZ
MJD!>RQE1068"7XN;K69D4XM&I9YMOL6M V=D*H+';D[FW9$4;L[ML$4%B=@9
MM]]C'[) PC<[#>M*1Y(;,H2C#8U46G.1924MR%#R++'MD:RF%Z7K'$L*+;6M
M[HF2C:G=,G6C:UBL3<X 2\;'RODSR!5M1V4I:W2L76@F7@:;B%-.S&*47VMD
M45UUDV#A94SBVEF3O4065E]^RGM97SW?6; F;=IY:G(R[@V7CC>RI!58S-ZN
M[(X4I8 Q1FX/QZW&U>GK)',UO#-=*1E3(I2JA#T^OS_FM&PQR8HTART^+2%>
MG"L$U2(!)-["8SR/*H!&%W,1@+%<P.SE+\GV-2+?0>RE[/BIG48^/CZ$^1DX
M;NM:Y6-6Q06XQ9OX=6[H@'9R>AII/:6YROI&LUJMS8UEMENH+55D*I8T6L.7
M"[8?P1'/Q4#K.+0O>G\YB9@MKOIA.(I%&S)C'PH5^:58GV($F)23I4S63FF7
M<XV4:N1%&/B+?M@#%B4 E5A*";#NLH^3RH7&VGL96,;)&%D&RO0T%&80Y&)=
MR [K)(K<BA^-I".0FRG;!;.TS]WP?76[VHY%7%M0;O*!Q!NKV)YU LH-B[H.
M2^MU&_/P])^R+SY1&$\3<-+ET#-25I\17BD>56YFDQ;?&E$P4>0WYU<D+(Y&
M7C"8QY2DI' TY>C$G$A+4C5I0':^8_R;:>N4V77V/J]!*+F5C&TFV[%-F4N$
MO?X]-5E]0]*<4.SUA:W#"PJ$<K;0O:K)-(H;7'](#&AN]S5KNXTF\]U:[K6Y
M[D&Q0K$LNW$'DN_QCYRTQ,DLF07=CTCYNW+,9,DMD<JBLGT@)1')D0RPAG&\
MR-<DC3F_DN"HI"26)#:U@ &:\6LTEANN& D4ZC5V,TR_3J;^S.#:FJ7X>-B9
M>+V=Q<G":_.N%&-6^55CM4AL8BSVG:G>X^H"1&*^O9=>595JN2K8=5]UU-VI
MW59 KQT[RUEJ>T,0H]7YMW]0>MTF#)COIEXMGC7C%USYDZ33YU5$MA45Q_FZ
M93=Z3OJA?9L3QI6@8GM2I+D2E<("9,SEE'*U)HRP$ ,$,-KY:73V)U; NU2G
ML_I6-I]*FQLO4-"PL&AJ%K[ULE+,BA5..M?K-<2J*-RQ&QVC+?7L/)3#?4\R
M[)=@@HQ=0R,BP6EN I9:[">]+'B$ +$]!O(SDK_9#6<QL*=U.F<U&O3RDCC,
M6Y'9P0F.TA<&ORX@86P"H10E[RM9?]KI&M+8U<I:_P#:!) TG\-652?)S<+3
M2G8FT44ODW&I="L%./7;W%E]I0$5TI?]Y>U]D6W[VS!^DASVIK*"PZ^ALL6J
ML.=14V6LG>+4G+;E8U?WQ47=BGK %>LUW*<TZ6L'?G"+37+.D7#Y.U"3A=(Y
M*9WDN/OS:)6E(7I0N#0[.J1P1B4H5298GLH3EW.2J"%!=A$G%C%TL70^R&?C
MUY>#I'9O,Q;N1JR<73]+R,>T([5N:[J:7K?C8CHW%CQ=64[,I U;M0UO&M:G
M(S=5HN3;G5=DY=5J<E#+RK=U9=U8,-P-U((Z$&<!]TII&?E^S7_>I.O'JV/M
M8[-?R>T/_=.!^[RK[+:K^<]0_;<G^\C[I32,_+]FO^]2=>/4^UCLU_)[0_\
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M^P7Y@[7_ ++HW^-Q^TDZ1/Y6L$>\<D?JXI]J>H?Q^'^G?_<1]UGV"_,':_\
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M:GJ'\?A_IW_W$?=9]@OS!VO_ &71O\;C]I)TB?RM8(]XY(_5Q3[4]0_C\/\
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MB\C\>G])_P"[C]R9Z<_](K1 _M!F_P#4?3[<]-_)\[]7C_O,?8O(_'I_2?\
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M3?R?._5X_P"\Q]B\C\>G])_[N/W)GIS_ -(K1 _M!F_]1]/MSTW\GSOU>/\
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M[(_LJM1Y_6]$;2;S759?E5)6IOM?#?']'L;(R<=*K=K+ZAWOHS64L+CS4LA
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M\<'ES_JI$F'$I>AHK=-#:UKJ=5]P=Z]9@=?JU:[:O^/PZ_52)#W"7C@\N?\
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MP&Z[*%9U"G8!E;U>O,GEL2./51T"4Z3.0,?-+6BMF*%2F0'Z"CQEHML5-L=
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MG3,7.6G4+[[<PU&E,-QC75\Z42NO*2UCO8YLK1UI+/=RI" UAVM-A[UZR:U
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MUT)5[7M?X;7MT[UVO2)^7*;[ZM:E3?5JO;6A*]5[?!>W_;OP?@_FJ=SXG_\
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MJ"Q'046R8;</1$VS>Y( WO;<@U7N&QXK6O>WPVL(5K7]6N_PTB5,?_OZ]?\
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M9CUD5UBNY\I!9P!5*Z+74L[KG<]G<L:MV;U_63CZH7E[ S#<[J$.VYW)8#H
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M,D&*3B&]>2<M- >L-*.;RS%9Y9!*4LY28!OL(\T"5.G3 ,-N,82""20WL64
M(9)L( )!"C902Q"@DL0!\P)).P^<D^TF-E\3[AYS YMT0>VY<SO+,H=VES2G
MH7)K<[M:]N<$2HL1*E&N1*VTU,K2J"AB*/3J"C"32Q" 8 0;WM>4>VME>MN#
MHP9'1F5E8'<,K*058'J"""#U$$*00=R#T(*C8CP/623RXXJ(.3*4+BH3*"C"
M%"<]0@.(/(.!<LTDXHQ (LTHTL0@&%C"( P"N$5KAO>U0#8""" 00006!!'4
M$$=00>H(]D;+XGW#SF-$EBS:C2-S<V+4#>@3$(D*%$:W)4:)&E* 0E2)$I#>
M60F3)B"P$D$$@ 424 !98 @#:UC-8S,S,&9B69F+%F8G<LQ.Y))))).Y/4QL
MH]A/N'G).VQ<.[<XC[C4>O\ [/QCIXGW#SC;8N'=N<1]QIZ_^S\8Z>)]P\XV
MV+AW;G$?<:>O_L_&.GB?</.-MBX=VYQ'W&GK_P"S\8Z>)]P\XVV+AW;G$?<:
M>O\ [/QCIXGW#SC;8N'=N<1]QIZ_^S\8Z>)]P\XVV+AW;G$?<:>O_L_&.GB?
M</.-MBX=VYQ'W&GK_P"S\8Z>)]P\XVV+AW;G$?<:>O\ [/QCIXGW#SC;8N'=
MN<1]QIZ_^S\8Z>)]P\XVV+AW;G$?<:>O_L_&.GB?</.<Y&A,UWUNW1#G8S?"
MV;F*D@@6ONC/]X(48+WMJU^JPK>O\-0W+8[\=OHWW]LR7;D.I^?YOH/TS9>M
MN^+6^V(["JI;&MN^+6^V(["D1K;OBUOMB.PI$:V[XM;[8CL*1&MN^+6^V(["
MD1K;OBUOMB.PI$:V[XM;[8CL*1&MN^+6^V(["D1K;OBUOMB.PI$:V[XM;[8C
ML*1&MN^+6^V(["D1K;OBUOMB.PI$EIKM^Y7ZBUFKH@-K6<3KV>G(O]W43ZK[
M6SZ[Z[;.NVK7>U[(D36W?%K?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(C6W?%K
M?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(C6W?%K?;$=A2(UMWQ:WVQ'84B-;=\
M6M]L1V%(C6W?%K?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(C6W?%K?;$=A2(UM
MWQ:WVQ'84B3 W0= ._@UFSTQ+K_AB=K:W*O5JON=6K5M:[:M=[ZM5[:KZT2'
MK;OBUOMB.PI$:V[XM;[8CL*1&MN^+6^V(["D1K;OBUOMB.PI$:V[XM;[8CL*
M1&MN^+6^V(["D1K;OBUOMB.PI$:V[XM;[8CL*1&MN^+6^V(["D1K;OBUOMB.
MPI$:V[XM;[8CL*1&MN^+6^V(["D1K;OBUOMB.PI$F'70=$1ZRUFSK4[.HXG7
M_&!U[5]SJOZ_@U6M_P ==(D/6W?%K?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(
MC6W?%K?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(C6W?%K?;$=A2(UMWQ:WVQ'8
M4B-;=\6M]L1V%(C6W?%K?;$=A2(UMWQ:WVQ'84B-;=\6M]L1V%(C6W?%K?;$
M=A2(UMWQ:WVQ'84B;,07(Z"BV0F[/1$VSM#!<6SN0:M=[ M:]]7PWM:UM?P6
MI$J8_P#W]>O^;./_ %AU7K[!_,/[)KSB:F(I$4B*1%(BD12(I$4B*1%(BD12
M)\&:]V/9U[6P+9U?#KV;ZM6KUZ]?P:OPTB>0^(U>E^ECVCO'YJBSBI*PR**2
M*;2!Q*?U#_FB^3\:KY0WLDG&K6(EKT'#"DV28YFK3,G @#C,A01^=%1+NF(6
M ]OG#0S;JMN,VG Y_?U8U2FL5:?Z)EK2UE6RLM?IZBG*Q[*%/"CTFI!P8K-2
MOO=J@W>>H 6)WW?DNX!Z[GN^J,&]K<6/7V<^EROI>N8!3@B!2PYTCK/D*-,P
M7;'^1V),HCDKEN@PXJI*^1<< ;G5TET)9))GNT9(:<=O"A=Z/GUL8&J>W1O"
MN15G"T1!Z.<F@+;9BVV<,K$L86TT=HT6FNX9+(E&195IO?&S*K5?2JGM?&#5
MK5/.X^L%/0,!NK#HS4'<@KN64&S;93^"0 W4GTQT=G2:O,7@KGD3R;>7JO*%
MW,;4TREB3'$%.#F2T*#6B:1N(2-O<E#*6W'O*==&&0D+P8NNVH"6JZ+7Y74$
MQZ\F],7GW *<.;TV$$JAL ?'MOJ9!87%96ZPFL+S8ORFU46/$MMRZ[[ CQVZ
M, 0=MM^@Z[[#:6;KG38BD12(I$I?IKGYXO V1%A2-9#>"RW3SAE2[%3ZQM$W
MVHXY,2B-19*!SDD8=+L<C<E:ESDZR/*G%4<SQ4^).C0H89DYK$'>T :=Z38V
MH6XM9*=U2N978^/]]2P6W-PJN3O*D 6E;54![A>E@MH17U\CO>(%88]=R4(#
M="-AU(.Q/4[;]%XD;,2-;Z5+ODH^;RMHB9\Y;W$K$V#UD&3Q#SZ/5V3O6D>0
M'/RU>@Q4:/(+HU,\4CN+VN4&X_$*6M<>DZ^S&Y,Y;LL=B=O1DQ!CTO<,9E.;
MJ"Y!O]'4;UZ6?L8JMF?Z*CO=;F/4,H=PUM*]XMG (8N+<F Y \*^/$,?;;]\
M)">ML%" \3N QV(]HU'B)RT@$3]BE?/$NDF"3,*['Y@@+$N:GK'KEA=HQA."
M\E+I2@.;_([Q,'B;)7%9%6K)K6;I$F%*L4)7%O\ +0EP1;N<NF-7FIC'2C38
MN2 0=/KR4SWR\<XJTLK<ZZ*Z"BW/B/\ 8L$9I1^ZX[85]X"G/O>0XG_7*FL*
MW+ETV+%MR X[W\#<;R-EM[S$27GZ5(S\Y-<@:H5I,R(L;Z5E!FQ<6D;&V&O&
MB*5CUO?2T>/ SX]]3Q<LQKAR<$P/?3,@,T]3]-./17G"KP2=-H8:<]5F1I-1
M[LXCYF[O?7K9RGJWRO1Q6;B'O)I%0QK,8\=FD.7VL;>P,%M;8\^'L#4\=_5Y
M [#9>O+D&\#Z^UXB;L4B*1%(DQ+_ !#C^9@_S!#2)#I$4B*1%(BD2K6279\;
M-)C1^"WG9</8E[3/VR5(([&LB.F*DI:YJ_\ QYPF+C'6!3"DCP>]IP$I%<O=
M['LJ=*2<WEM"9V<%+MV,1*WTG4^0PA8KXSTM;;BIF$J_WU:%ML&0R"LDLM";
M6$D-S9$"5,=K:_P]MF! #E.HZ%B!QWW]G(]/FVWZZ RE(Y<G4YO<D+CF,U^B
MVG!HOI$#1BMDR-*%_HL;H_HPR67M;DU8[97QZ'CE1$';*;](DQQ*6/O#PM>F
M)?=T5&D-"KIX=5!&GHZX KN[/:NS/F68M2^F/;J]5#H^3976,H7IAU5$%K:Z
MUKL7@ 76IRP[PCGN,BGH@9CP I+#903PXER>FQ.XZ^P]BPI+\M-6<,F&9,8L
MF.K.\RC)J4MS%%,\!C\+:[YQC4+T?69B:E*YXQ-*FV;XMD**7267XUBC&HQ:
MEATG<,RO #G1Z<FZK4,?"?3L3T2S$1ZZ<1N'?Z;WN0_V.MOU-['5*\VE\?-J
M:BFC+OL&8;Z4P*R$16E&<6-R#D%G'X-FR[6!:MNI1@R'DS(!QXGF=R=N";XW
M+(C+FV6H77+;>3*-+Z)P7%\%R)D7*4R,402#Q;(,4R+(AMV2Y-(UJ0B8-RO,
M$^;>@FD,CM!XOBJ4ID05;<F658UM-U#T,F$QIT._(S,C%QL.@#(R+L:[%JYX
ME52L:&&#C-R!L3)NS*2VSLLC8JW+=QRO545F9O54,K'9F/X6[L-NA4(0.F\]
M'Z\K-J*1%(BD12)-!][C_P ]2?H%M(D*D12(I$4B:?SS>_HLDQ8#900I/"WE
M(CH>DS*L>2EWE-(8D%NL ')<K!;[G%A"YF1E6EM9"(\+J>%H&N"+>TW_ +94
M2*2HY%A><!4*\"&V.I X7/8[H+@?6VX#O.)F%GX!]OS>P.3[1_%^O_/M_3TW
ME/'A\SHAP5H:IMB5)LO*H%)RC$LO5FFR&29R8-$S)RN'M<YLY$-HEPWE_0.\
ML<$TE;T*HN0,K4:](4#PE,3E=Q*].;4==;>DX*Y-1Y4*!55IUNLXBWOC<2_$
M5ULE*FIF7NK'%;-6P)H)L%= ]86%3[3U-@I<J&WVWW(+$$>T==MB)7SIVD0J
MBQC6C0Z3-CFR'Y-38:EB!%I3,BR:Y_4,&CVZXY><MQN<ODAE$6AK3(W3(<15
MH,AKDF WA)&IU)5#.VIG9J0I^GQTL7!F;2=GOQ#GTLVCV#'TP6:FF57@VX]=
M5-U[U)C7J^*IU*MK<:H.Y1V->]O'8"WHK=V?OH+6$5%"X8LRJ"64AOO9V8D
M$2S>2W;(\DSXWGQE-G).@"[X ;X&4E8\LQW$YL>:<SY$9=*P61$(T#; C5"K
M%[;O8VNR80(#TD.Q^^X?/6JW4+@KY.(F+5IK"XZ>6[O4FR";,*W-%KX&+9HW
MHK<GR0%S'VM7$.]9&37G!53B+7+&P;=YMO6%'%PFPL87<N@4[H.G,;'U3623
M+':*SH[/6C=@]U>5BQR5KL9Q(\AV<CSE3F]-%VE.%@?'12H&-0H='MB"W.SD
M>>*YQJY8>8;8)@A!MRM91*]5U!*U5%7+N!1  E;\SWM: = E=G-% Z!5 !(&
M\MI)-59)WW4$$^TC;H3])&Q/TS?M<V612(I$4B33_P"1(?ZU7Z0%(D*D12(I
M$4B*1/+;!SOI(MK=I>O+JCRNL?;8\?I#BQ).D^4K)&Z9I9+G5:RQTIOR0E#&
M%4LNWJ((C=U."35&'UK6W,!32A26 A<9#Z_4$TIVT2M&PUK]*KJS&QSAEGH:
MK3ULM+8A[Y:0PR&1=1 SE=K"[MNR5:=9M^_DBS?B2@//HP-FP]<$%MN/6LFL
M@#8#Y^KO]\GL9+V?A%[S5E!CEV#V,QD6-R/2(;4^,(0V89QN6G<\>21PD:S!
MV6)A,RVQR<&,,,C1>6V^>S-8H+>W3R(\I$E]7H=AK&H5Z?AV4:A8+%=M+<YF
M0^?EDIE4K2NH8=%'-4L-]IPFQJ%'=ISK9H/, ]V;'#5C8@6C@HK7JI)[MV;;
M=0H#\F)W.Q$V6)YG:?%C@PIR-),<(4Z0:%W0*C&32!/S(3HW%S*-(7PF\B4(
M3,QD. Y@I>!I&8]R#DX6(>D.32BM'41:I/J!,<YBVDZ2,@:8R,O>:8,$ZKW%
MK5GN@WH)7N @-@3T3T[9';O&*G/=N!&UI7O 1_"<Q5R /7^$WY;G;?EW9Z=!
MT[OHBKLAAF,U8YLLEQY*7"^#WPI+-%#JHD2-P>,A:2C8SCE=GH9CL1D!5AV-
MX;M.$SU<N0A7)42R0EB>%ZL\[7UM<4X^/9CB@$Y^H5DT!!4R)BZ4[]SW?WLX
MRYUN=Z.:]ZBK,*CW:J!E3RY,#OMW=9];<L"6M Y;[GEW83EN=]^I&Y,O?7G)
ML12(I$4B*1-J-WWO0_F:7] "D2LKX:RV>GBQB%T$.SHX6&(#LD  0^EG;5P@
M$S#N$-Q:[A#<8[AMJM<0KVUWN&^PZCV#YCYRCU? ^\>4XO?,75[M[X1^!U/7
MQ'N/G'3P/O'E&^8NKW;WPC\#IU\1[CYQT\#[QY1OF+J]V]\(_ Z=?$>X^<=/
M ^\>4;YBZO=O?"/P.G7Q'N/G'3P/O'E&^8NKW;WPC\#IU\1[CYQT\#[QY1OF
M+J]V]\(_ Z=?$>X^<=/ ^\>4;YBZO=O?"/P.G7Q'N/G'3P/O'E&^8NKW;WPC
M\#IU\1[CYQT\#[QY1OF+J]V]\(_ Z=?$>X^<=/ ^\>4;YBZO=O?"/P.G7Q'N
M/G'3P/O'E&^8NKW;WPC\#IU\1[CYQT\#[QY1OF+J]V]\(_ Z=?$>X^<=/ ^\
M>4;YBZO=O?"/P.G7Q'N/G'3P/O'E&^8NKW;WPC\#IU\1[CYQT\#[QY1OF+J]
MV]\(_ Z=?$>X^<=/ ^\>4;YBZO=O?"/P.G7Q'N/G'3P/O'E.=C1K+=];;%H7
M0 ]^+9$-U2& M?=&?[P LY5Q6U:_58P/K]>OU:KXMOQ/4>[Z?YYDNW(; _TG
MZ/YILK;;N&6\Z1W"JI;&VW<,MYTCN%(C;;N&6\Z1W"D1MMW#+>=([A2(VV[A
MEO.D=PI$P"(91J25HVXX2Q.0H2D*Q'I!*2$RLQ*:K3DGW;KFED*C4*(U02 8
M2SS$B49H1"3E7!.YV*[GB2"5W.Q*@A21["0&8 ^T!CM[3'_7_7N$S[;=PRWG
M2.X5$3 H(95A=B5;<<J)L<G46*4'I#R[*$:@I6D/L UN$&QR5602I3FVMMD*
M"2CBA!,+ *TAF4[J2IV(W!(.S JPW'S,I*D>P@D'H8_Z]WLF?;;N&6\Z1W"H
MB-MNX9;SI'<*1&VW<,MYTCN%(C;;N&6\Z1W"D26F&W[E?J3K+6Z(#:UK"+WO
M;IZ+U6OT&VS?:V;Z[V%;5:X=6N]A!1(FVW<,MYTCN%(C;;N&6\Z1W"D1MMW#
M+>=([A2(VV[AEO.D=PI$;;=PRWG2.X4B-MNX9;SI'<*1, "&4L\]46W'%J50
M20*5 %"0)Z@">QEDX#S@MUC#0D6--L2$P0K%6,,L"P=L6N2S$!2257<@$G8$
M[;D#V#?8;[>W8;^R)GVV[AEO.D=PJ(F TAE/,3''MQQQJ(X2A&::>D,,2*!I
MST@STPQMPA$'#2*E*41I5P#$G4'D7%<HXP(I#, P!(##9@"0& (8!@/: P#;
M'IN ?:!'_P!O9,^VW<,MYTCN%1$;;=PRWG2.X4B-MNX9;SI'<*1&VW<,MYTC
MN%(C;;N&6\Z1W"D28$:#H!W_ &=9L=,2Z[=,)VKBW*S5>PN@ZK!M;7:]MF][
MWO:]KVM:]KHD/;;N&6\Z1W"D1MMW#+>=([A2(VV[AEO.D=PI$;;=PRWG2.X4
MB-MNX9;SI'<*1,!Q+*IN0)0W''B2GA4IKG*$AMTZD #"P*"+C;A7*/"6::6$
MTO9," PP-A6",5KR"1OL2-QL=B1N-P=CXC< ['IN!$S[;=PRWG2.X5$3Y'Y+
M- ,LQ(K,+,"(!A8U:<8!@':X1@&$3?<(@B#>X1!%:]A6O>U[7M>@)!W!V(Z@
MCV@^,3Y) T)B2DZ="I(3D%%DD$$J4I1)))0; **** W! 646 (0%E@"$( AL
M$-K6M:U22222222223N23U))/4DGJ2?;$R;;=PRWG2.X5$1MMW#+>=([A2(V
MV[AEO.D=PI$;;=PRWG2.X4B3#AH.B(]:=9LZU.S:RPFU[?P@=>U?H-[7UW^#
M5:VK\.ND2'MMW#+>=([A2(VV[AEO.D=PI$;;=PRWG2.X4B-MNX9;SI'<*1&V
MW<,MYTCN%(C;;N&6\Z1W"D3 E(9429.B1-QR1&D(*2I$B50D3IDJ9.6$HA.G
M(*;@%$D$E  6446 )9980@ $(0VM:22Q+,2S,268DDDD[DDGJ23U)/4F/9[)
MGVV[AEO.D=PJ(F HAE(-4GDMQQ)RPP!RPXH](6:J.+(*3%FJ3 -UAGF%IB"4
MX!FW&(!!)10;V++ &TEF( ))"@A022%!)) 'L ))) ^<D^TQ_P#?VS/MMW#+
M>=([A41&VW<,MYTCN%(C;;N&6\Z1W"D1MMW#+>=([A2(VV[AEO.D=PI$V8@N
M1T%%LEFV#T1-LV$<"XK!W(-5KWL0&U[VM\-[!M:]_7:UO@I$J8__ ']>O^;.
M/_6'5>OL'\P_LFO.)J8BD12(I$4B*1%(BD12(I$4B*1."E 5PHU(@MG2/*0F
M)W"W]#$,*OIUV]19)T415[&A4=(N7N!%WL.QNS<%["M:]64\>^JY[<.\3GRV
M*\>0Y<M^FVV^^_3:0?8=O;L=IYVP2VE7C9LT;H:$*D:)_CT1>LA2%\)S-D%6
MIDZQT@3=*(K-5STQ9DD$84E18R0JR%BR2XOBB>5J?*IKV2UL3ZQNOJ,G[#9;
MZMD>J&JMOKQ*:C@8JK2$R7INH6NS KN!N%2E4IS+C0"@K+V56)0O>**EZG<*
M6)YL=]U!!W#D="3U*CEMU !$[#&)=IAH7"*/4E _2!L/BV(9)(8DEQBQM9UW
MB?$Y=;<AQ$M>(Q(<F-QQ:'XW>T%E#B@4$/,Q<02AP4Q]X86N.TW4Z&R75T]W
M6XOSJ:KFR[' KQC@OBY!79@PRS?EU-Q1@:Z$-*"VNU[I4V[@MN1QK8J%'M;D
M'7__ %V4CJ#N3N=B -8I9_I?.0!3DF&3,]TCC/D*,L9[Y%I$V+1Q.62W08='
M=^<&:V)HT>Z2^(L[CI!7AH$>&710LO 5C:UQO(HR%JB5[IQM#3_1CD8X6VS%
MNL%=U3KW]%':-*ZUL]-N"47NFE^D;Z@BKZ2':[$!448<K2>7$] RC<'\%FH)
M/5%W90;./J=>.VS=2WICH[.$R=(O!5^0#TZF5J/* G!0G:']AN>F X.93,<M
M:9/%X2])'@QD VC?+*(A&$QSS=>H;&)L:SD20KRNHK0F3>N,"*05X@V56['B
MAL"O3=D5M6+"XJVON(KXA['<,QVJN1X\O;U^8CIUVWW"G?;;?U5Z[[ #82S=
M<Z;$4B*1%(E6]*]8[ML0Q\YQ^^63'AJSK@=V$CQ2SY+?%"N+-F8H*NR7:5MN
M-&QR5.46+Q>1-+N#/(BC6%W"/H9:!R?A,J>W8T94:_)2WT(5OIVI)RS'Q*PM
MSX&2N)W+Y;JJ7',./QLJ(MKVY%DK[PRFXD*I'/<65GU Y.PL7GN$!)7ARW!Z
M'P)VFML_2(YHR;D2[[&,E3=O0:.<.4XUA6+W'(+3*)*_O&9%Z')ED:S&(PS-
M.UM*A#@8Z;.3,F<E+1#5KI<YI=T+@L973;TVH/B8O=VXF.[:ID+EY&8F+935
M4F K8G)<O[PSN&U$8Z.56R]5V=&4.N-C;.X(9AW2E%0L&)-A#_@>ML/O7(@$
MA=^A!V.DX"UYEC,NQ*%Y>](B=.L13X@LGF2UES:VPV2X?CF$I,ARV=-(G(2B
MD1T_?<ED/ TC%D-O79D=W-=C!Q*NZ$M9;NBW\FS!NHS>[KTO'2\YV]"V:>]]
M6;=J%+80HNJ)88]6(4Y68S)@(J9:'@7-;5J'#)N;6*\/6VL"E AY\@=@6+[]
M&',DH>H$ZSE\[+Q96?920'-#9)4,,TEGTI6^'9#;\;&E] A;GH>M\ ;'8XJ!
M7R 1)DL7*2-D01VE+?)T^044R+3.$B-*>;<$81.F4'T!ZFR-)K*UC%?+!YY"
MZV^0Z Y/HQJ:[DU[=RU38K8_):@4A^?WQM[ 0MI._((>BFC@">'(';H!RY<@
MXW;KZ_UXB;L4B*1%(DQ+_$./YF#_ #!#2)#I$4B*1%(BD2FN2D4S;]*7&<EC
M*B=RE"XM42B[U RV3-;;CV,,9*W)RB1Y,\_V.5MF"[O]DKVV)G6&3R*264/)
M$:BY$>/:5:YM5E=[$:AM'RZ;1C4LKW75Y)LT]\JVPKB"K$]&LH?4>ZWK<I?C
M74TUFZTVAPKJ:6#"Y2"Q! !3:S@!Z^[\@17OU&ZLI)XKML2#*DZ3(<UR!TSL
MW8[59-)>V[.CNEL?"#,J'C2QHG0[QJ? &% 5B&XY@U*GB>2-Z>X5+7=.MQ5$
M,@D21XFK1(%J)H9%G:TG['U5Z>^4,0UMIU;;9 PO6N.NY0R;&].VH<5XU5==
M]"%,R_%-5=%E2M98NO=S)L"\]Q8>J\SL.X7B!P'+JS$J3NJON6#= ;*XZ<YF
MS:2V2'Y4UYA58Y>X?%FE4@<F+-)K1%LDK,BI&*Y!22:KY%$Y>0M3R-4Z#G6"
MRF''D(@T6<3)DF,:[QAS;^5E)CV:3BUJ^",JN^YU9;=/#W8BXK6;[T+5?05:
MH(,?4#9DY&1<O<$,+5>Y2PM8[6<2 -B+-E<MM[&+*00=^59"J >0Z@C3D2,G
M[3D*QA)^3#F1VTK<3*,3G3A/F9@*6-KIC?(#;EZ+$1;.CL]S50?',=H93*GZ
M2-SF+&TC<U#8YQ)G:G^.R(U1O7C%?%V(Q!97HV:,T8YP+2K)EXSX-QNT^NO'
M MR7JIKJ9?2Z55TNL>JVI16.8?\ UMC=7PY<Q[486*!9NQXJ"Q8>J>A&Q!GJ
M=7CIN12(I$4B*1)H/O<?^>I/T"VD2%2(I$4B*1-(Z1CJ4S8>EJXR(9#G9M@M
M*=!%<7KLB-4J=716]-Z5ML-UQ5<4[;(TC6FD+YFN8DSFH(B25ZO=BD-K^07+
MH:6ALSJ5%^+C#URUV8N*]*(M;L_J9G^CO:R@K0MA0&]J_OE?\(M=IV0GBS>S
MU4+!CN0/:GK #VL1OTWZ'V2O#J;D&(PC0I943P_Y+DS2WOC8%SG9<I@;IE/+
M45T7\EWBQ,_32])YTL">6.;;(7UQ%+4"MU;'M&T.3A98\I2#C^HGHU^1K]C5
MU8E-C5N4Q^YR$P\*[5\3OCC&ENYM:E'JK7N7"-6UBKQ1CQJ/)5H +.1O^%NI
M=Q2Y7EN-QN02>0Z$ GJ!*EWCNE@E89 RRM%I(WE00Z07HI?&Z3S%T3+\_O3E
MA=TQ?))>* /:]B8,66=SL@&L31*CPX6B\7(EL94%$-YK"W*^T+=%-E5E+:5W
M/_X:<VMZ:$9=-K3/3+IH])K5[,SNQC"QJ1Z?=<:+02XM=:=KMB&[[?[[Q(9C
MO8364+<"0$WY; _>PH( ]@EG<F&Y'E&>T"]A;\THT07? "2 F%),C,.+2(U&
MLS9$;]*KS^;P]#@MC'K%B(OR(HR*D%YUH7''KCC(2]>48K2<C$&+3ISK8^ S
M=WJ39()Q;<LVVX&,VC^C,0V017F-]\&*V]++DKE\4(4W-S:P$=YL35Q'K!-E
M=^^Y@>KU3V<M^6Z<=_FL;HIKG1ST:\&KW92K6J%6,8B:E<'$TY0Y.3+=H36C
MCHZ'J!"4'.CG'[-B]S-4BNI,7*% U&HZX[6Y>LJB:MJ*H%4#+O#*H 1+.9[U
M$ Z!$MYJ@'0*!MTEM._=5[[GU%V)]I&WJD_21L3OUW]O6;_KF2R*1%(BD2:?
M_(D/]:K]("D2%2(I$4B*1%(GEM@^^D@SMNEZ[N"3*"B1J\>2!ZQBFFE\D73L
M\[323.J]DC):6?6,C<BEI:%P@Z9TEN%+DXH<V%!$V!J9T@8\B>)/[#4/L4[:
M)6C8@J7*JKS#0,3=\=J=.6R[?&^_5T<DR"E&>#F)8UUC.W>M73IU]Z._WY[E
M24!Y]&!LV'K]"VQ4;U^H0%  V!/5'MNR2W)'E1@-TRYD2.S+!C 8U'(46=V$
M&-X*@POC=,W*,5SA?,[8:G\FF*9F5FLJ&&10G*#5/)HZ/0I6#R$N3#OK?%9D
M&HI@XMM&HV\PS:=9Z5D-GY9<9E"X_I^-5CFQ>;9%QPWQ\>NON-[%(@AP#W9=
M@U8V_A5XJ*TVX,248ML=@JAPS$\NAFSA'SHC%C@P)FS2%%CY7I!H9(B*&W9J
M,RH1HVE3.-(WQL\IG@%EX@\Z5&O+HFAIBD,^-P]=2B;V?R$26W%Z>V.<Q;"^
MF>DC3&I8\]/&&=5./:U;!!_H)'<BNMLC;T89VS/9WAY'/UBFVUG'O00-K.?=
M!AT_'/K;GC^%PZ ;  ]UT0Q3]),YPQS)3*3"DF&,'.G1)<N<G&0('5UR!I)I
MF<F6*G8]4YCR('#+1A=-.+/*@R0B.1M"I],/<%9JDZC7!BMCX]E IW.?J*<J
M BU-6F-I3.:50!!B^GOGG'[L"O9G%8"J )H+\F#<OX.L^MN2"6MVY$]2_=BO
MEOUZ#?K[;XUYN;,4B*1%(BD3:C=][T/YFE_0 I$Z\LPVP+5BI88YO 3%:D]2
M,(!HM@(SS1&B"#:1B%LV$.]@ZQ7OJM;7>]_768<@ =.G\_G,. \3\/*1O0E'
M>M'KY:'N5.9\!\?.. \3\/*/0E'>M'KY:'N5.9\!\?.. \3\/*/0E'>M'KY:
M'N5.9\!\?.. \3\/*/0E'>M'KY:'N5.9\!\?.. \3\/*/0E'>M'KY:'N5.9\
M!\?.. \3\/*/0E'>M'KY:'N5.9\!\?.. \3\/*/0E'>M'KY:'N5.9\!\?..
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M(/1M=K"V1;-[VM:^R+5KU7IL?;MT/L/CM[8GUO47"'<W;NU(GS<]O#<-A)C
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MM2(Z0FX GU?#_#*NWI$P)7)M7)DZU$0B6(UA!*I(K2K#E"94F4%A-(4)SRE
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M[QH4EPDAI<W7%[*T3-5=MBSY#,3N++.9RC?&)N.:4*V+*R7R&(HVT.[LXJ7
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M/"?/J>VI$>0&GA/GU/;4B/(#3PGSZGMJ1'D!IX3Y]3VU(CR T\)\^I[:D1Y
M:>$^?4]M2)F&QM8B2 72ZP@WNS;?J/5M"M<7KL=KOKO:WPWOJ_!JI$P^0&GA
M/GU/;4B/(#3PGSZGMJ1'D!IX3Y]3VU(CR T\)\^I[:D1Y :>$^?4]M2(\@-/
M"?/J>VI$>0&GA/GU/;4B/(#3PGSZGMJ1'D!IX3Y]3VU(CR T\)\^I[:D1Y :
M>$^?4]M2(\@-/"?/J>VI$>0&GA/GU/;4B/(#3PGSZGMJ1.U)T28M.0 !6H("
<2@!MMF7U!" -@VUW'>]]5K6MKO>][_AO2)__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>g210084g51a11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g51a11.jpg
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M'WZ[;_M(W\;C0^@_ 8V?J?Q./:!]^NV_[2-_&XT/H/P&-GZG\3CV@??KMO\
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M<'MF.%^3!#6779[2\1WCLR'96"41.=",Z)Y*57>CYVPT-[ ^3'FT;H#:.-!
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M=_-A$"&G(ER^3OY,(\N_DY;%%)-+'#$I>661(HT4;9Y)&"(H'S+,0 /J<B2
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M7?QT\@Y%VQ:UC2[HZHED/JZYQ9J?DIO=#M8T*HPY'BNO"-3=:<Z[%=HSL@I
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MC=.WU2P&Z94%2N]1&86Q7CKD&S$NUA:*-K!9A'"&=U4W&1I_S24*61I$FP@
MM,-[73<0.]IKX652)ISA/6+M!3:[C<>G)=>K3EHC4V5[2EIU853%!8,6<,?S
M,L=GW?J2JQ^V"U6DBX]\!HS$ZQRB*/N<RD;LBR/$IC4D!F&>;3VC_)G8L01(
M.CRR^T];I_4S+^89F@ZC'U.M9O\ 2WZG=/3?=HKEZM7MV:53JD\-ZPD<K0P,
M=[K7:"'R#U)]*FV(^LZ\#;J_NY%YKMD!W"L;(%P;'JYW#%S4;,_K=I,#=JV
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M6;_Q@=;_ /4O[)GDO[T?Y-_\TNF_TK7]HQ_=+;N_RZ(_8M:_[FX_P@ORS?\
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M_<W'^$%^6;_Q@=;_ /4O[)C^]'^3?_-+IO\ 2M?VC,-VOY2[[1Z-W995.PC
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M'ZP1Z@Y@']^#_*4?^M?>?V)0O]T>;/\  CV4_D6K_2G_ *W(^^6?^%/]%/\
MZ<?WX/\ *4?^M?>?V)0O]T>/X$>RG\BU?Z4_];CWRS_PI_HI_P#3C^_!_E*/
M_6OO/[$H7^Z/'\"/93^1:O\ 2G_K<>^6?^%/]%/_ *<E47Y7S\I&2\3#3^5E
MXE@(:KH)H\D="^;)%*7#')AE\E2Z[^;GAEECW\G?7?R=_P"'D)?8GV5$<A'1
M:H(1R#RG]0I(_P#"YD7+.Q]J?4?Q5^O_ #<_T3'#DT=LT@AQ7QQ0L38HL.DZ
MCOK".,F7###KY0>^_DQQQZZZ^7OOOY.OZ^^^?EH#8'KZ#YG]^=_9_1^ _=D=
MZ_8_^P?L=1_8>9T/T_B?WXV?T?@/W9B]GVHBI75?[MUEJ];ZM=H44FL]N1Z^
M!T]MU@RFP25M7Z0)AZ:Y:Y#3X@+X/GD$]PR=189=X]_)=#6FL=WL12R]B%[$
MW;#OVX(M=R9];XQIL<G/@;&SF"X76RHV0HV%\L?0#QZGZ9%)]VU5_9R*8HL2
M@VS"^UGTZG"O#QS1^P[*MJ+5\LTR:,7OU.QMU<%F^;/W]/FTBS$](CB)S@F]
M.Q'")WB983V=.7&C[PLSP^ Q/VBP3$>/' [T2-X#@GB"-_%XXC^*0&^7R+#\
M<R"+8H<]G/IL3%7G9E:%19CU/2-?U,.B>L':I2QRE[5]#91&L*XZ&PCCGSGP
MS DRFBCCD@SEJ,$@A6<JPA>22%7Y>#)$L;R)KEO:K+&22-?$-$D'6>8V5\;
M!(T/0D@'T^H/X9.^OV/_ +!^QU']AY7H?I_$_OS.S^C\!^['K]C_ .P?L=1_
M8>-#]/XG]^-G]'X#]V/7['_V#]CJ/[#QH?I_$_OQL_H_ ?NQZ_8_^P?L=1_8
M>-#]/XG]^-G]'X#]V<ECESF91RR?-^?(HKV>?S(XXL/G95]9WW\V.+'"/#'Y
M>_ZL<,,<<>OZL>NNOZN!Z?SG_:<'U_F'^P9BK):N<KCU#@ )JI:A%+6BMD+
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M/Q.;V-/ 0DJRP)J)N%59%/S+ZO-?-=9[."RCM.L[\50+6M"249#LUG*BF+C
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MEH%'H6!,:TJRS2-((IGC/=6Q7K2Q2JO#FG:,>SN.1P3JV-F8$."'77(: UL
M^-,P(]='>_J!FS?.1EF.,9,OO_'H/^AJY_\ 3ROF!Z?SM_M.9/K_ #+_ +!D
M-S.8QQC'&,<8QQC'&,<8QQC.;#_%Z_T_[>^,9D'L=9/U9E]I"_M/(\U^O[#^
M[)<&^G[1^_'L=9/U9E]I"_M/'-?K^P_NQP;Z?M'[\>QUD_5F7VD+^T\<U^O[
M#^['!OI^T?OQ['63]69?:0O[3QS7Z_L/[L<&^G[1^_'L=9/U9E]I"_M/'-?K
M^P_NQP;Z?M'[\>QUD_5F7VD+^T\<U^O[#^['!OI^T?OQ['63]69?:0O[3QS7
MZ_L/[L<&^G[1^_'L=9/U9E]I"_M/'-?K^P_NQP;Z?M'[\>QUD_5F7VD+^T\<
MU^O[#^['!OI^T?OQ['63]69?:0O[3QS7Z_L/[L<&^G[1^_'L=9/U9E]I"_M/
M'-?K^P_NQP;Z?M'[\>QUD_5F7VD+^T\<U^O[#^['!OI^T?OQ['63]69?:0O[
M3QS7Z_L/[L<&^G[1^_'L=9/U9E]I"_M/'-?K^P_NQP;Z?M'[\>QUD_5F7VD+
M^T\<U^O[#^['!OI^T?OQ['63]69?:0O[3QS7Z_L/[L<&^G[1^_'L=9/U9E]I
M"_M/'-?K^P_NQP;Z?M'[\>QUD_5F7VD+^T\<U^O[#^['!OI^T?OSP^_*%^#W
ME-NG?@UPUEJ@RTUN.@UU-FSAL]'6X=,@F#Z8H7T=U9EIG?<41@V7<G0_<.7T
MO76$F66.?6/AO:'I5^[U#OU:YEB[$2<NY"GQ*7V-22*WC8\ZU]#G[;_N?ORJ
M>P/L9[!/T?VE]H8NE]2/7>HW!6>AU6R36GAI)%+W*5&S#IVBD''N<QQ^)0"-
MZ+_WL/SI_P PC'_7?6/^^O.'_!_K'_$S_P!=6_KL^X?X0'Y(?\\H/]4]?_[)
MQ_>P_.G_ #",?]=]8_[Z\?P?ZQ_Q,_\ 75OZ['^$!^2'_/*#_5/7_P#LG'][
M#\Z?\PC'_7?6/^^O'\'^L?\ $S_UU;^NQ_A ?DA_SR@_U3U__LG'][#\Z?\
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M?P3GX0/9,+6'A7\V:C:<UX#,R &4PQ%RW;3CCK'Q&\J' 2Q:V"P9KDT7T"@
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MYWN$D?O]SA+(TLJ>\3\9)797>20<].[NB.[-MF=$9B652,]D;![:[  !TNP
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MDN1L_%I?<RLA>T&8_""#I4$&)XV@&EV"2A'<WO@HTA ].>QI/ ]?GO-@MFW
M]HL\+#EF#IJCM>Y!,[$M*P-0&V&>N^-V][O45#G&QXJIETQ6VJA1YQ,GO8<>
M=C$30$_.Q+Z[[YE2!4?KRN8TDAHGM..,JQ"7JG3J\\B=KF' I3V >WR(B:0K
MY78L=M]CU(:3R#XWJ*1E!WK^.JZW_& S1^<S?Q>GO+!?MU9O>@[+<;'362CL
MK-:MIE5==<K1H)40=4M8$^*%_NKT*BTNQ=%ATI61C!6F+CNKG,1GFX/7D(/H
M .FK>Z.U)^G6:B57BL)#!369H(>I.%FMCK-:NAL3Q::PX+2HG>"F.EVRVO\
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M3E=34$8O3Q"*W*$YL\0EA=M$]SMRANZ'YDIMGWLQ(Q"=IG7[^^VIY*#X )#
M;\;G<R$;LU^#8\K&HK<OBOY)V>)8K(N>#&*V16?Q[0RG=RZOGSN [VJH;0T
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MU"H"M)0Z3-, -?XQ/TNG+88CY.\SO)(/&G9ET-99#]S] >51_P U97"C]04
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MAULJ7 /Q!M\1Y.N(.@6&3]3\H$KU+OQU9=7[7UMUXX#=S[$66D77EE922QT
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M\5NK4>X3;..U#W"1K":NCTNRU^23#K8F-DQ<N5B'*N]-#Q1YNY^8I-1R^_\
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M%>%=CV>>!9M=0I2R0OU.(Q(MP,TW2(([5^-6DJI']E7E1E=G59'Y1IRUS);
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M5>M/3KM7AK@*.X\7V\P5)[%!:%N65 W&PLRJ)EA?212? .<!>)\O"';D6._
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M#O73]A86SJB[=V4E@//GT?==%*#%U:ZM<M)KK.NH+CZV6L5%6AD(:+I\&L3
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MK_PYJ9/'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\
MAQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'
MKM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[
M^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\
M7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQ
MC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM
M3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/
M]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\
MAQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'
MKM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[
M^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\ 7_AQC'KM3[^/]?\ AQC'KM3[^/\
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M!VU4*Q0G88CX@1QVQ.VV!I!R.E(RFZ'LG8JJ\:W7W#?+C8&RZS:?'] ,16[
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M+&.+#KKKYTLLDDT\N7SI9YY)9YLY)I,\\K)99)I&EE=I)'.V=CMF/IY/Z
M/0  #P,P      /0#TR8Y7F<YL/\7K_3_M[XQEF^S2;W3O[03^-QC'LTF]T[
M^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!
M/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-
MQC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q
M[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2
M;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T
M[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M
M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^
M-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8
MQ[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S
M2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]
MT[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._
MM!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03
M^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<
M8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>
MS2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF
M]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=.
M_M!/XW&,>S2;W3O[03^-QC'LTF]T[^T$_C<8Q[-)O=._M!/XW&,>S2;W3O[0
M3^-QC/KJN)^OZNA._M!/XW&,F^,8XQE3[RVTMT5J>Z;9;5NSW *F+ASLJK2Q
MU9=LL))K()2 HKXSIJC4S,SCV T T9[=>-EGG_QA,?7]?>W0IM?MP5$EBA:=
MBHEG+B&,!6=GD,:2.%55))5&/Z,A(XC1G()"C>AK9^0 V0-D^/)&54H\T= M
M%1]CSMDH%6C@HQ:-_,M..PMHE\USWM4 BOI4T#.RS1I:5"P=6STQ*'W6%Z=T
MR<]"+%)YL&V_1.H(RQ]D-*3862,,JF$U[(J,)7D*1#G.R1PZ=NZSQJFW=5,1
M-&1O?CX2#]>2\QH#9.EV6\> "3X!.9XH\E=$OKAG1$NS:VTLT;J"M]C!3%$+
MLK&316FT(:_%88Q>Z[.\RUPG87OM1"UD885**%_(/BL,")(UWZ9?C@]X>K(D
M7 R[;B&$0L)4,AC)[HC]Y=:_,H%,Q,8)8,!D2QEN(8$[ \>FRI<#E]W? %M;
MWQ\^F8^#Y?>-3*,X@+;U7E!74PV_DM,NF<*;NKJZHLO3@D1U.OB4L&:.FN5-
MH?5L PFRHD3$1DW4!"SX2=VMT?J:%5:G*&>=:ZI\)?NO,]= 4#%U22='BCE8
M"*212J.Q&.]'Y/,:"EM^=:"ACYUHD*02!Y .]9G9.\-5C72#77=O$)N\[\ZL
MY5M:"W;,@FRM11WK+IM&K7F1IER];LS7LACQO($C&)NM873,<&+H 2?7%&V8
M#9[+" 1K*)69$5D=[$:<"[+S9FJV0L:<I"()6"\8V(SS7EQW\6]: )(("D[T
M/  =?)T/B'GSGR?O/5*NXG4,^X!BV98YK=;9#2 M_5B^SW#M#[,54VQXKLJV
M+:G4=KJI -9G;1O9 [16C>U^(C]1,86A;:%;"PDQ.DLJGDG-HH>YW95BY=TQ
M(890TH0Q@Q2KRW&X#FFRO(;! /KX+:T"?39V-#>_(\>1E76KS2\=ZJD>6#VS
M.M"VMM:TE=STBIVNW#KV5JN%<I2P*5@G3D*LF&+&V5]I.HC89NLJPU6V41:6
MH:J23]J'HG49I(X^PL3RI+)&)YH82R0PRSNP61P_'C#(@<KP[J/$6#HZK$S1
M@$[Y $ \06\E@H\@:]2#Z^AWZ$;R5CY6^/*B>PCM]IU]3E5HL9G4S2)JO"AZ
MQLM9IC"$-@8NA!;EUZX7.I56W@J"3S*78[(E26R!,R8##25KTGJ+B,I4D?NG
M2!"C,=Q2SJ656+()88)IH6<*)XHI)(2ZH2,F6,$@N!KUWL?,+Z^ATS!3K[I(
M!T<E]:>1VD=Q.2Z]K;82BT/ %[%D8J'':@'#PHW,=<LHT@[9>!)TUI]BF&K]
MW1]==NJ0]- 3VP!,R/"&GA:Z;>I(LEFL\4;,JJY*,I+IW8CM&8<)H@9('^Y/
M&&>%G56(RLB.2%8$C>Q\_!T?7YJ?##U4^#HG*HQ\VM.,-DFZ]K342Q1*XJ=Z
MTM,3090B&*N&SS-6#QA%/HUHKX 9XN8_1.J^8T5MR5K-.I(+9KC(8=O\QW5J
MK9E1H^9F"1%&>0B&J+9)$?(QL8V4E)%5D#([A4=28=]"W$$$#CL[T/B<IXWK
M8V/4;!\ZV1F=%^67CR CK%E8[*7+4=Q&8LJ^P9I[,NB)KRF5-$RNA<9J6"=/
MKT/NR5R2?8KJ)?1<1K%7R_:'L5VKF*H'2.HM)+$M9FDA94D57B;4K\^, *N0
M]ENU*!60M/N*0=O<;@2[L>@W+PVR"0?0:V?384;&V.AY'GR,Q/8WFYXZ:\J6
MQK-/L!8Z)UP3L)(S2K!W,LY5NU@$^(N=:B.A4$A195<NNGK[B[[SD14F?L?.
MU'JXRA/2+:W0^I69JT0KL@LBM(CL4T(;31B"4J7!/=616AC\23C?:5N+:PTT
M:ACR!X\@0-^J@\AX!]-'9]%^>MC,FD\M?'Y<.UDLFRZ[5YZY5\;7:<7,Q8RU
M %"OK;)T)/8I \$!K2L"V^LSV=4N8$M:\(^3G.P5XC,.66L='ZBQ41599>Y+
MVHNV S2,6E6-A'ON*DIAE$3LH20QNJ,Q4@.]%YVX!"\COY#P3Y]"1R&P#L;&
MP-C+!H.Y=<[0-:@49\0Z)1CK"&W6=>LRF$#-JN!:P+B"G:9<+B]$ 9K9W5=Z
MF[?5WM@%"_6K)RH(I-:Q2LU0C3QB,.6"?:1.6",R%PJ.S=LLC!)==N3BQC9@
M"1-75]\3O7KX(^0.O('G1!(]1L;'G+/YJY+'&,<8QQC*MW'M55IFCYW5LH;V
M#LBU:^HR5"BS4PLG5MVA?:UK6F*XS'S-,D70&VJV)X#F31H&&O"S(+SRESBC
M&FVZ51[L_81TCU#9L/))S*)#4KRVIV(C1Y&(AA<JJ(Q9M#P"2(NX1>1!/E5
M&MDNP11Y('EF'J<HI=YBISP]6NOZ)=E#U?8VU6FC&=DR/UF2/1-NI-F774#B
MGNE(&P"K&]C4WFAN(&-BIR>P5V.OE+;0*Q,3QO9T6\W1G5K<?OE4RUJB7UBX
MV@;%.2K!<2:-VK"*,O7L(5BG>*7N!XF59.V)*Q,/A/!@&<QDGC\+AF0J1RV=
M,I&P"-$$$C>IO;_E6FU"O\BW9&O[G>$OC7J^N;(N7L1(AG<GYMUEZLKJO+PK
M(UK2@8FI4JH+[>W.96(6$E?:E0*J UOCT"1"GTE[C=-C%B"!^IVY:L/?[@1>
M#5XDD=HDE<B:>9H45(V*M$[/Q0AAEY0@D/%F$:ACQUL[#$CR0/A503Y\\@!L
M^,[;/RIJBS=F.G):E;I(8MA5_43386$M5CJJC9]LU83N.N5<A8198;J2,QI<
M86/5C7U<M#'8'2Q'B9+*/89T.%Z3,U'WT30[-:2XE;4QF>K#;%*24,(C "L_
M+[)IA)VT:3B T0D&4!^'%OO!"WC0<IS UOE]W7D#6R!]2,;NGE^LK5TM%(2Z
MNO%I(2V:TZO1V: VJ+JE9]WUO03/R,BUC!+(\+M:_%G1%9 .-RFJ$]<%MF$M
M<SFF/QBPGL@Z.\L$4[VZ\0>**U)$1,TT5&7J"]--HCMB%N-APW9$PE,)$H 7
M9&&F 8J$8Z)4'QQ+B,R\?4D?"/O<=;\>N;0TRVH[]3ZI>ZP7Z?6KK6D5MKQW
MS.X_3$=C5BN%)?T????>'I !@\WS.^^^\?G_ #>^^_DYRYH9*\TT$J\98)9(
M9%_R9(G*.O\ ,RD9:"& 8>C $?J(V,R3E69QQC'&,ZQI$HH994 13*<84@B%
M<%D'@8?+#%G)&$)FQ+ 7X%%9X]0#Y''!!XRR8=E%C0=9S894 LH+!02 6;D5
M4$Z+,%5FT/4\59M#PI.A@^A\;_0-;/Z/) _$@?ISS\N7Y1"FZ^K]H87+4.S:
M_9*5LNSZNLM08.-2PRPV&KZ>J6]NPDMMSV3U1;*\L=!NR&"H5!)9"[6_N'3J
MM0*8L:ZZ9A>B@]G)[,D2P7*DD4]6*W%,J7"#'+=FH%GA%4V(HXK->0SS/$(8
MX.$I<]Q$.NUA5#%D<%6*L"4]0@DT#ST25("@$L6V->"1M%;MQY5^[5"@I*2_
MN-FMNL]E;3'2KC$J5K&CUP30%.:F/"T')E$=DL-AV56U*H-\[KJR&*%\>>X'
MP3YP3\J&EW8)K$D\<,4-JK4+L'=>Y:%EPY[2NYBCCJRN[1I(Y)C54//8M+Z8
M* 22K/H:!TO$:\Z&R6 &R!Z[(UE5(/,%$Z3:Z:3ZLV<KFO.][AX\.1YL:.:%
MKV^TBX.J*VFLKQ;="E+1&;8T90B4BF$6=H3UW-ZR4*9E-@A4;4G1I$>RHMU7
M$%"'J*$=]6L5YX8YT$<;0!T=8I%9Q.(D'C@[AXR\!,-+\+CE(T9^[\+*Q7R0
MVB"1XX[.O4 @@9[NK>Q^F&%*BFU/>+NDNEPH5#&L-4;Z[AC M&PKD#3U*^1%
M9;H@L[+%=V?C8WI:5,Q$558-JY(GZ'4L?1J*-!;JSD7(()((;%@Q3)9):*M
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M';EZ'-%+6A:93+:HRW8U$%I5(2B+R1+)-#%'*TJ'M*U=ID6;2L0"&R(G5@Q
M\*X0_$A/E^!) 8E0#Y(;1UO-V.</+L<8QQC'&,UE)\DI5VQ]@ZP9:9VE#9*A
M0S-DUF $C6KC^DRK!VN2F=$5WU;L*:*ME,F_HQ2>#9$]+B)1E2,CB5LJ.TA(
M.H.F!JU>TMVH8IK"UI2PM)[K*T(G(EY5@9%1-AS5$Y$B\45P\325=SXF7@^U
M7D .)Y#97Q\7@D^G+CL?31U\U[RBK=D_N69P:/?<%/E=7 +!4+#.-6XTE4E:
M:BL>YEM?M\G=D]99/C:O5'<6,=85V-8$:'CBV:+8CT\C-)TJ6+\[!IZ_/I$K
M1S1 RF28)<BI/)#]EP[:S31G<KQ.RM\".5<($H/9TK:F&P?&EVAD ;SO94'T
M!&QY/D9T]N^4Z;4@GD*UFH%RO"GQPU76MFW#JDR(9W)_;T2^O&5>6A6-K6TX
MY56J%*'MKDYI8@H)%MF4"K8CF>78<DJ?29+C=-06(('ZG;EJ0=_N!%,9KHDC
MM$DK\9IIS"BK&Q#Q.S\4TV'E""0\681H&/'6SOD2 "0/A5>1)(&B -GQGVR\
MK:DLW,/J*2I6^4?J]575C;8&$M4CJZ39-XUL9M:JU@I8198;H7 SJ@X465A6
M5<U%"_>*D^)LV8]D(KN$Z3,](W.]"#[O-;2MJ8RR5H+*U)I0XB, *2ECVVE6
M0Q1O(5 ,(E=Y>?#BWWE4MXT&9.8!\\O(^876R!OUU\[%\J$%,VBZTO7Z99[Y
M?U.F;_MGO%3(J JN+&F+UC%7K5C8"BY"@[M;0VHC(4,-(UC1(RE+FQ=KQK)6
M,76:W29)ZB7I)X:]=[M>GM^;2\9F97M+&JZ:"$J59BZ&20.D?(QR\#2@.4"L
MS!&?QX&QK2[/\9M[\ Z'DZV-[#5&TI;Q5*Q=:T7T?7+A7DMI0'=8]X=&I; M
M&;*B^L,O^%AT2"7!-UCE_7CUG\G?]?7.;-%)!-+!*O&6&1XI%_R9(V*.O\S*
M1_-E@(8!AZ, 1^HC8S(>5YG'&,<8S5?<'EE3-&["24N_5NQ!I7-:NEHSNZ]I
M1V@2I10M<7G:-C<M::';9=EA54%!KUZHEMTU-Q0]7(RN5G J0A\*1CUJ72)[
M]9YZ\L1=)8(A R6$+O8M5ZD<:SM"*IF:2S'((1/W.PLLI $9!J>58V 8$ AC
MR'$@!59R2 W( !2-\=<BHWYRL;3YY)J11K[<+?H_:=<8ZRP0L[?2&E@TL-:H
MZS:J@1=*LQKL6>U.EMRL-D#7/:XCH568-+@QN]<<((%F0F2=PWVHN@//8KP0
MWZDBVC(D,Z1WC$989A!,LO\ BG.".)F262Q*JPK7D20MRYQI%IPJLS(XXZV"
M8^6BO(:'/XB=$!022P( UHG9BY;;&JFP:EKH6MN+([LVO=I[.D'490^FC5C5
M<M&6,!P 9^H\6=A>V+9%33HE$Q:N(C&9L=(PCQ4YCD<N"F9J\UDRI%'%9J5=
MOOB9;8L,I9AOC%'%5F>1P'(TBA3SV+"^F5=$DJ[^/4*G$'QZDDLH \?/SXT=
M;6/GS0UM-H]WFUMLG%78M:OMQ7(:677T##56MJM=$]$L;ZTQR7GH5^6G<..R
MRE.O2[@1VH4-28))C9JXNL733V?L/-/ +57G':CI0$"RRW+,L#V(HX2*^XPZ
M(%#V1".<B CB)7BJ]X7BK<6T5+L/A^!58*Q/Q:.B=Z7D= _,@&[]M^0*O4%T
MU;4G5/L+@?:=NKE*5NTKFA=RB.[0]'KXGT-.9V]=L"Q ))C!G5T95BJMP:E4
MLBK.Q(R7*G/:[1I].:[#;E2>)#4AEG>.1+'Q1PQF1MS)"]>)I I2!994,TVH
ME')TY6/($905)Y$*""OJ2!]TL&(&P6(!XCSZ ZS74FR1-K4[.TCK)4I(%OV-
M0GB>8G W);:-6["M&M+4-";A +T:!W8:FRF4G]BB]L%,P)_HL'1/46-%RJU2
M;M%@X:&M8C<#CRBMUHK4)*[/%NU,@==MQ<,NSK>21N:[UKRRD>NBC%&\_,;4
MZ.AL?++,YJY+'&,<8QQC*^VGKE3MFBN:"]-8KU;J=).26IS&P/BR1/U=B&Z@
MR,&+'ZQE+4P0S_2#R=]CR2]1]QR=X28;%2R]2PEB-59XPX ?94\XVC.^)4^
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M))/C1HLGP&I+[6>N=1WR_6#8=,UZS<E88VJAZ6,L+96[> /3Z]!9NM;8MJB
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M(+G4TED"-"LZK#5I O&(G=I4D[7<#IO(E.I6=2.$BH%!!8\DC(&]\=EG\'8
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MG[1(IZ_6H.RK-9!4"DSJIAL/'6+RB@5/%(CZ=A%/%K Q,.4U'PG0X7.QH:Q
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MJ-<WPQ7QJ8O&6VR87/9%JHE<3*EVUWXNYZ%6+K341A^K8'52ZJ]$8V6G)B+
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MFL&(UV22:PL=>4.P6'+I&)D\,X($?; + ,W=9900/A8!0H/($*I+#0VPVO\
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M \TD,N&<>>6/<XY'BD26)VCEC=9(Y$8JZ.C!D=&!!5E8!E8$$$ @[&8(!!!
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MC&8P288DP]883=9]88?-FLDBH\:NRI+Q[B!B%?@>2<P/#<6\KO>CY&8T"02
M2/0Z\C?@Z^FQDKR&9QQC(I(C35I2 AKRI>C2*A\!%JE4'  N!&P^7O& 40;"
M.""/KOO++O&/#'K+/++/+Y<LLN^YR222NTDKM)(Y+.[L69B?F6.R3F  !H
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MW)T\]TC;]GS(Z1=+%9K:W%UUU(>PH^!%\I5HJNJ*&5MH'8:%GI[M,FM=?O\
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MDZR\+6.HKT>27NBO:GLE8_?)XZZQ<0H93.9"G,4\I>*?:2,6GDC/$0A@L??
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MT;/D--L5.EI_D"&J@U,7IX/9W?C]?[PY053)9.=NL&[RWFK"V0=V9-CIT/6
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7'&,<8QQC'&,YL/\ %Z_T_P"WOC&?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>g210084g53a66.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g53a66.jpg
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M$0$#$0'_Q  ?  $  @$% 0$!             @,' 00%!@@)"@O_Q !N$
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M[_%1_1T1/$%C[N=_BH_HZ(GB"Q]W._Q4?T=$3Q!8^[G?XJ/Z.B)X@L?=SO\
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M:13T103/X0@&XXY,<..>?W)S$YYX#OZO/=V<\=O?HB*'\&0Q^.>KQV<\<\B
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M[/5...WNYY[> (I"/ "/M (_@#G1%%,_A$R*<<=<A3\<\\=8H&XY[.>.>.>
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M7Z(J&WJ0?QU?SRFB(Y]04^X']8-$5^B+;G]<M_)N/Z4=$6XT18TIW^_&7/\
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MH4J@OKE;R#?\XZT17Z(MNU]2'RSGXRKHBQYF+ZV=N_DY/XZUU+=H\H]:I?\
M-/V>L+)>H52:(FB)HB:(FB)HB:(FB)HB:(FB)HBQGBO]Y+)]\S*G]X-BU)V_
M8WU!0-GVN]94\R_6?RM][:\_V7E-&[1Y1ZT=L/D/J7SK#IG]BB8 0URO76(
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M8MUGAJI761I*P6>>CJ]!1Q5F[<S^8FI!&-C&17#M9NT0,Z>N4$ 6=+H-TA4
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M6$0530W0228XC )X&<2>+QRL-*IR#5L=XY8GCGA'C=HFD#@[I=L9$%TFQ$#
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MO;.&MW::P!F9]TM^'<!O]KD?4[?G/+@T6O=&[8K;&05D@VF-\1Q^$=J:V/\
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M\XI??I\HOJ/_ $KD^O\ R!E)J_\ ZCU+E/V(+I!?M&L_A4Q!_KS3L>O'B?\
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M/N  1'ZM&W0>P/X R]SIOAY'<<MYC<O@TW#5\">5'[2%Z 'I=#%*8NT)\)3
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M^K1MT[3 4QQ#LR]V?0D,/(\!V<<\B "WP\CN.6\QN7P:;AJ^!/*C]I2^=_\
MI=?>A/OAHVZ?K>TWP\CN.6\QN7P:;AJ^!/*9[2B'0!=+F)A(&T)]UBE*80]&
MC;IV%.)P*//HO<=HD-V /(<=H!R'+?#R.XY;S&Y?!IN&KX$\J/VE+YW_ .EU
M]Z$^^&C;I^M[3?#R.XY;S&Y?!IN&KX$\IGM*)>@"Z7,X=8NT-\(=8Q>?1HVZ
M!VD,)#!VY> >PQ1#GN'CD.0X'3?#R.XY;S&Y?!IN"KX$\N/VT-T 72YD*)C;
M0GP%#O'T:-N@\=O'<&7A'3?#R.XY;S&Y?!IN&KX$\J/VE+YW_P"EU]Z$^^&C
M;I^M[3?#R.XY;S&Y?!IN&KX$\IGM*(] %TN8&*0=H;[K' PE#T:-NG:!>.MV
M^B]P''(=XAS[&F^'D=QRWF-R^#3<%7P)Y<?MJ7SO_P!+K[T)]\-&W3];VF^'
MD=QRWF-R^#3<-7P)Y3/:40Z +I<S"<H;0WPB0P%,'HT;=.P1*4X!VY>X'Z$Q
M1Y#D.WCO 0TWP\CN.6\QN7P:;@J^!/+C]M2^=_\ I=?>A/OAHVZ?K>TWP\CN
M.6\QN7P:;AJ^!/*9[2B7H NES.4IR[0GPE.4#%'T:-N@<E, " \#EX!#D!#L
M$ 'VPTWP\CN.6\QN7P:;AJ^!/*C]I#= %TN9  3;0GP )BE#ZM&W0?HCF A0
M[,O#WF, <]P<\B(!R.F^'D=QRWF-R^#3<-7P)Y4?M*7SO_TNOO0GWPT;=/UO
M:;X>1W'+>8W+X--PU? GE,]I1'H NES P$':$^ZQBF, >C1MT[2D$H&'GT7N
M.P3E[!'D>>P!X'AOAY'<<MYC<O@TW#5\">5'[2E\[_\ 2Z^]"??#1MT_6]IO
MAY'<<MYC<O@TW#5\">4SVE$.@"Z7,PG -H3X1(8"F^K1MT[#"4IP#MR]V_0G
M*/(<AV\<\@( WP\CN.6\QN7P:;AJ^!/*C]I:CT '2Z@ B.T)]P <C]6C;IW!
M_P#J]IOAY'<<MYC<O@TW#5\">5'[2T+T /2Z'*4Y=H3X2F*!BCZ-&W0.0,'(
M#P.7@$.0'N$ 'V]-\/([CEO,;E\&FX:O@3RH_:0W0!=+F7J];:$^#K& H?5H
MVZ#R8W<'9EX>.?;'@/X=-\/([CEO,;E\&FX*O@3RX_;4OG?_ *77WH3[X:-N
MGZWM-\/([CEO,;E\&FX:O@3RF>TH_L 72Y]82>E"?=8"@80]&C;I^Y$1 !Y]
M%[CO >SGGL[M-\/([CEO,;E\&FX:O@3RF>TI?.__ $NOO0GWPT;=/UO:;X>1
MW'+>8W+X--PU? GE,]I1+T 72YG 1+M"?" &,41]&C;H'T1#"0P=N7@[C%$.
M>X>.P1#MTWP\CN.6\QN7P:;@J^!/+C]M#] %TN9"F.;:$^ I"B8P^C1MT'@I
M0$1'@,O"(\  ]@ (^T&F^'D=QRWF-R^#3<-7P)Y4?M*7SO\ ]+K[T)]\-&W3
M];VF^'D=QRWF-R^#3<-7P)Y3/:7U:Z%3HK=^^SCI#<29=W(X"<XUQVK7,I5-
M.QK9%Q':2&L$SCJQN8V/^9E)OUEF0%RA&/C@Y-' S2\ )5W"1E$BGXS+W*[)
MZ\Y/R45MN(J:DU5-*(A35D7:1N=GNSYZ>*/5B-6=B<=0*RZ&EGBG#Y(RUN:X
M8ES3K(U# .)[A[B_<1KPY;I4%]<K>0;_ )QUHBOT1;=KZD/EG/QE71%CS,7U
ML[=_)R?QUKJ6[1Y1ZU2_YI^SUA9+U"J31$T1-$31$T1-$31$T1-$31$T1-$6
M,\5_O)9/OF94_O!L6I.W[&^H*!L^UWK*GF7ZS^5OO;7G^R\IHW:/*/6CMA\A
M]2R,GZFG_$+_ %0U"-V#R#U*M;U1KY<WQ9QHI5^B*@OKE;R#?\XZT17Z(J&W
MJ0?QU?SRFB(Y]04^X']8-$5^B+;G]<M_)N/Z4=$6XT18TIW^_&7/_J.L?V"K
M6I.QOD_>5 VN\O[@LEZA2J&OK9OY!'\V71$<>IE\NU^,HZ(KA$ [Q .>[D0#
MG1%C!_U/1HJP!ZIZ%]^Y'M_<>->-NK_!^ZZW\/M^QJ>X?*/4Y1_:'?P/K&'[
MUE#4*50CZHZ\N7XLWT16G_<&_BF_H'1%!#U!'R2?]0NB**_>AY<G]!M$5^B*
M@OKE3R"/YQ?1%?HBH;^IF\NZ^,K:(CKULX\@M^;-HBOT14+>J-?+F^+.-$5^
MB*@OKE;R#?\ ..M$5^B+;M?4A\LY^,JZ(M7/J"GW _K!HBOT1;=3UPW_ (J_
M]">B+<:(MNCZJ[\L3XLAHBW&B*AKZV;^01_-ET1''J9?+M?C*.B*_1%0;URC
MY!Q^<:Z(K]$5"/JCKRY?BS?1%:?]P;^*;^@=$5;?UNAY%+^H71%HOW)>72_I
M'1%?HBH#UR;R"?YQ31%?HBH;^IF\NZ^,K:(CKULX\@M^;-HBOT18ROG^].&/
MODRG]T>4M2-CO)^\*#M;Y?W%9-U"E4%]<K>0;_G'6B*_1%MVOJ0^6<_&5=$6
M/,Q?6SMW\G)_'6NI;M'E'K5+_FG[/6%DO4*I-$31$T1-$31$T1-$31$T1-$3
M1$T18SQ7^\ED^^9E3^\&Q:D[?L;Z@H&S[7>LJ>9?K/Y6^]M>?[+RFC=H\H]:
M.V'R'U+\X(YNS0 B 9>R@  /  %_M8  !W  ?-;L -?B.[JF=4@.=AU0,M_G
M'_\ ==^[Y_/U^F$>1>1QC83DGDR26-))L-KQ)P&L_P!541S=F<1 1R[D\1*/
M)1&_6L1 >!+R'[;=@]41#D.W@1#N$=4[YG5(_O!RW_Q7?OCU7V%9&_1+)GT#
M:OA%KZ-^:?MO90_Y_M?^;:;YG5(_O!RW_P 5W[X].PK(WZ)9,^@;5\(M/1NS
M/R)O1=R?UA  $?'ZU\B "(@ C\UN1 !,80#N 1'CO'3?,ZI']X.6_P#BN_?'
MIV%9&_1+)GT#:OA%KZ-^:?MO90_Y_M?^;:;YG5(_O!RW_P 5W[X].PK(WZ)9
M,^@;5\(M S=F<H<!EW)X!VCP%^M8!R(B(CP$M[(B(C[8B(Z;YG5(_O!RW_Q7
M?OCT["LC?HEDSZ!M7PB#F[,Y@$#9=R>(#W@-^M8@/W0&6XTWS.J1_>#EO_BN
M_?'IV%9&_1+)GT#:OA%KZ-^:?MO90_Y_M?\ FVF^9U2/[P<M_P#%=^^/3L*R
M-^B63/H&U?"+3T;LSB(".7<GB(<@ ^/UKY !XY !^:W(<\!SQW\!SW:;YG5(
M_O!RW_Q7?OCT["LC?HEDSZ!M7PBU]&_-/VWLH?\ /]K_ ,VTWS.J1_>#EO\
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M*N^YNZ/[$1)K^U,NQAQUOP9@2\+3W7)+):E@-3#DEDVYL+LZ9@L5KQT1(!>
M*36&' N&P-Q)&:'+Y'=*9N^W (U+;W:*'N&S76I"0=Y&8O)"M97O4*_79"UH
M[GS@X=Q<^V<+-0<IE7!LHH9'PR95>H"A0$/TW_Z/>6]WL]5VFRSN%QREDMU5
MDBV@.4=94WIU(R=F46G%(;G)4FG$QBA,VAS!)HX\_.S&D?*/])&DM% _(R6Q
M6^WVEM53WIU2+724] V9T;[7HS,*2.$2&,2/#,_.S,YX:<"2?C\EONWPH$!)
M#>5NL13+R)4TMP^74R (B(B($);P*'(B(CP':(B(]NOTC.3]A<<39+03WS;:
M(G[S"OF5E1.0<9I3KX1_U?\ B4PWY[Y0Y$-YVZ\!$>1$-Q67PY'@ Y'_ &P[
M1X  Y'V  .X U'8]8.([/Z,HO<*O3S\-+YQ_2M?3Z;YA[]Y^[#^<5E__ %CI
MV/6#B.S^C*+W":>?AI?./Z5H&_/?*   ;SMV   <  ;BLO@  '< !XX=@!IV
M/6#B.S^C*+W":>?AI?./Z4'?GOE'CG>=NO'@>0YW%9?'@0[A#FX=@A[8=NG8
M]8.([/Z,HO<)IY^&E\X_I6OI]-\WOS]V'\XK+_\ K'3L>L'$=G]&47N$T\_#
M2^<?TK3T^>^7D3>G.W7]80 !'TQ67^1 !$0 1\<.> $1$ [@$1]L=.QZP<1V
M?T91>X33S\-+YQ_2M?3Z;YO?G[L/YQ67_P#6.G8]8.([/Z,HO<)IY^&E\X_I
M6@;\]\H=@;SMUX!R(\!N*R^':(B(CV7#O$1$1'V1$1'M'3L>L'$=G]&47N$T
M\_#2^<?TH._/?*8!*;>=NO$H@(" [BLOB @(<" @-PX$!#L$![!#3L>L'$=G
M]&47N$T\_#2^<?TK7T^F^;WY^[#^<5E__6.G8]8.([/Z,HO<)IY^&E\X_I6@
M[\]\HB CO.W7B)1Y*([BLOB(#P)>0_VP[!ZHB'(=O B'<(Z=CU@XCL_HRB]P
MFGGX:7SC^E:^GTWS>_/W8?SBLO\ ^L=.QZP<1V?T91>X33S\-+YQ_2M/3Y[Y
M>1-Z<[=?UA  $?3%9?Y$ $1 !'QPY$ $QA .X!$>.\=.QZP<1V?T91>X33S\
M-+YQ_2M?3Z;YO?G[L/YQ67_]8Z=CU@XCL_HRB]PFGGX:7SC^E:!OSWRE#@-Y
MVZ\ Y$> W%9? .1$1$> N'>(B(B/LB(B/:.G8]8.([/Z,HO<)IY^&E\X_I0=
M^>^4P"!MYVZ\0'O =Q67Q ?N@-PXT['K!Q'9_1E%[A-//PTOG']*U]/IOF]^
M?NP_G%9?_P!8Z=CU@XCL_HRB]PFGGX:7SC^E:#OSWRB(".\[=>(ASP([BLO\
MASW\#XX<AS[/'?IV/6#B.S^C*+W":>?AI?./Z5KZ?3?-[\_=A_.*R_\ ZQT[
M'K!Q'9_1E%[A-//PTOG']*T#?GOE 1$-YVZ\!,/)A#<5E\!$0   1'QP[1X
M Y'V  .X-.QZP<1V?T91>X33S\-+YQ_2M?3Z;YO?G[L/YQ67_P#6.G8]8.([
M/Z,HO<)IY^&E\X_I6@;\]\I0 I=YVZ\"@   !N*R^   !P   7#@  .P #L
M-.QZP<1V?T91>X33S\-+YQ_2@[\]\HAP.\[=>(<@/ [BLOB')1 Q1[;AW@8
M$![P$ $.T-.QZP<1V?T91>X33S\-+YQ_2M?3Z;YO?G[L/YQ67_\ 6.G8]8.(
M[/Z,HO<)IY^&E\X_I6GI\]\O(&].=NOZP ( /IBLO\@ B B #XX<@ B4HB'<
M(@'/<&G8]8.([/Z,HO<)IY^&E\X_I6OI]-\WOS]V'\XK+_\ K'3L>L'$=G]&
M47N$T\_#2^<?TK0-^>^4!$0WG;KP$P\F$-Q67P$1X O(_P"V':/5  Y'MX
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MB3@,3M/=.&S'R(M3JJJG,JHHHHH<W7.H<YCG.?M'KF.81,8W(B/6$1'M'MU
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M*HH;M'L QQ  X .   UV_9AE1Q[<N</6B%'2C4((^2%%+HE>C/$[@!V0;=!
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M^Q*=&=[Q_;G\',-\EIV894<>W+G+TW)3<!'R0J5>B5Z,\#MP#9!MT #+&*8
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MC];F&]KR6G9AE1Q[<N<O3<E-P$?)"@AT2O1GF01,;9!MS$3))B(CCF&Y$1(
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MX_MS^#F&^2T[,,J./;ESEZ;DIN CY(6_J.P_9KMQRWAK(6"-M>(L47@]RL,
M>TTBHQT',FA9+%&1UW\89ZU(546;M9BT471YZISMTA']P&L6MRAO=RIW4U?=
M*RKIRYKS#/,Y\9>QPS79IU8MQ.![F*J;!#&YKF1L8[6,6C X$'$+Z ZTJO*@
MOKE;R#?\XZT17Z(MNU]2'RSGXRKHBQYF+ZV=N_DY/XZUU+=H\H]:I?\ -/V>
ML+)>H52:(FB)HB:(FB)HB:(FB)HB:(FB)HBQGBO]Y+)]\S*G]X-BU)V_8WU!
M0-GVN]94\R_6?RM][:\_V7E-&[1Y1ZT=L/D/J7P+^>&*NG]+':Q/B*?T'/HN
M1P<]7Z'GCT/>SGCGC7TBW^CK5N:UPRJIL' '_LB7NC'C!>4;Z,0U=99#AJ_T
M]O<U>**L_FABKG,D;TK$^'@U!/QZ+<<//*2B?'UONSU3GGM[N..WD)^3I6?2
MNF]$2_B";Z47$LG/V_"*SYX;JWO5Y_X7([]7NGR=*SZ5TWHB7\03?2BXEDY^
MWX15AYH8JX*G4]*Q/_1IIDX]%N.[/!F5-SSZ'W;SX3CCCLX[QY['R=*SZ5TW
MHB7\03?2BXEDY^WX16?/#=6]ZO/_  N1WZO=/DZ5GTKIO1$OX@F^E%Q+)S]O
MPBK2\T,5=,@%]*Q/CP8X\^BW'!^Z.8_=Z'P]W6X_\M/DZ5GTKIO1$OX@F^E%
MQ+)S]OPBU5\T,590AB>E8GPZP '/HMQP\<" ]WH?![7MZ?)TK/I73>B)?Q!-
M]*+B63G[?A%/YX;JWO5Y_P"%R._5[I\G2L^E=-Z(E_$$WTHN)9.?M^$59O-"
M]7,JFIZ5B?#J%4+QZ+<=V]<2=O/H?=G'4]H>>?8T^3I6?2NF]$2_B";Z47$L
MG/V_"*SYX;JWO5Y_X7([]7NGR=*SZ5TWHB7\03?2BXEDY^WX1=8A>GYK,3/7
M&9-MBG5RVF3BY C<,K1Z9F01U?BX04CJ#03@N*IHX7 ' B0$*J"0E,)!.:?D
MZUFK_K53:AA_V1+WR>,/K3?2BU_Y%DUGQ]O> \4^I=G^>&ZM[U>?^%R._5[J
M/DZ5GTKIO1$OX@F^E%Q+)S]OPBK2\T,5=-)-/TK$^/@TR$Y]%N.#GJ% O/'H
M?#QSQSQR/'MZ?)TK/I73>B)?Q!-]*+B63G[?A$4\T,5=0H%]*Q/APHD?GT6X
MX?4U2*<?6^#OZG'/L<\\#QQI\G2L^E=-Z(E_$$WTHN)9.?M^$7&2GFB^IQ@M
MS+;69TB2ZG@^N;+4>(=?L^AZWB 4.1 1$ XY$ [ '@>,2JZ@$])F&7*JG#9#
MFM=UHE SNZ/^T-HVC':-8[JO0]4V.;/S;++G,&);NYN.&O7_ **.\?(-?="P
M#G/S2A$XMF:)DN*V?2%J1?1%SI2D,]STWK@(&=NZ7/$E$G[?#]D!QP6,,T.T
M,R;C]-*L#HP$%(==7]1*2@FAA?E+'*)X#4-?':G$#,>(RTAUQ&W.!#@?J("W
M5ERR;>!4O;;GTYIG1QEKZD2%VD#W8XB!N;AF$$$''':L2I>:YX\2 *^P)XFI
MV]8B6Z%%8@!R/'"A]O:!AY#@1 4B\#R "(!R.&>HZ['5E"TCZ[40?NZXGUK?
MMN^<,=SX?_E_AH3S7'%$,J;T@T@/A% /QZ9QL''"2:?'U@>WU/GGL[^..SD8
MWGG_ $A;Z*/XBIZ[?F_[7^&ICYKEBA 0](-(=H"'_2<;>R''V@=-YY_TA;Z*
M/XBG7;\W_:_PUHGYKDBB$(3T@T@/4(4O/IG&P<]4 #GCT 1XYX[N1^[IO//^
MD+?11_$4Z[?F_P"U_AK0_FN.*/U/_4&D ZBA3_\ 2<;#SP AQ]8$..>>_M^Y
MIO//^D+?11_$4Z[?F_[7^&I_/<T5[P60_G.-OU Z;SS_ *0M]%'\13KM^;_M
M?X:@'FN.*!4RGI!I#Z),A.KZ9QMV=0RAN>?0!]GK\<<=G'>//8WGG_2%OHH_
MB*==OS?]K_#4_GN:*]X+(?SG&WZ@=-YY_P!(6^BC^(IUV_-_VO\ #5:?FN.*
M3*)?2#2 \J*GY],XV#U14ZG'U@1[NOQS[/'/ <\:;SS_ *0M]%'\13KM^;_M
M?X:*^:XXI1)1/T@T@'A$SDY],XV'CKE$O/'H ASQSSQR'/MZ;SS_ *0M]%'\
M13KM^;_M?X:L^>YHKW@LA_.<;?J!TWGG_2%OHH_B*==OS?\ :_PU6?S7'%',
MD;T@T@'@U!/QZ9QL//*2B?'U@>SU3GGM[N..WD&\\_Z0M]%'\13KM^;_ +7^
M&K/GN:*]X+(?SG&WZ@=-YY_TA;Z*/XBG7;\W_:_PU6'FN.*!4ZGI!I#Z--,G
M'IG&W9X,RIN>?0![>?"<<<=G'>//8WGG_2%OHH_B*==OS?\ :_PU9\]S17O!
M9#^<XV_4#IO//^D+?11_$4Z[?F_[7^&JTO-<<4F3J^D'D!^C5/SZ9QL'JBAU
M../0!'NZW'/L\<]G/&F\\_Z0M]%'\13KM^;_ +7^&M5?-<<4H0Q/2#2 =8 #
MGTSC8>.! >[T 0]KV]-YY_TA;Z*/XBG7;\W_ &O\-3^>YHKW@LA_.<;?J!TW
MGG_2%OHH_B*==OS?]K_#59O-<<491-3T@\@'@P.''IG&W;UP*'?Z /9QU?:'
MGGV--YY_TA;Z*/XBG7;\W_:_PU9\]S17O!9#^<XV_4#IO//^D+?11_$4Z[?F
M_P"U_AJLGFN.*(=8WI!Y ?"G*?CTSC8.KPFFGQSZ /;SU.>>SOX]CG3>>?\
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MAH6@QE[LZ"2IC#H\_/B,M/%)- )6L,\;'/ASP,5S=CV9Y\IV.<@Y-MM;B*]
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M:)'M:6-=(&@/<UI+BUKG8D-+B0"!B<,5QCRTN<6 M87$M:3G$-Q.:"[ 8D#
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M_P#V3&*/_!]D2\Z?*(LGT>NO.:3I3>ON'&E'YJ=%/,^V;$R&..?L6"!0YX"
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M\NBL&2%;:6U;*BLIYW5+X9&F-LH#1&)&D.SP-9+P1AWM:PL7S)ONC$/HMTF
MP'V0+!9#,'\':,.41_%#_P ]:[?>M7%-P\Y3>VND;:96C#2QG7CL=T*)?,G.
MZ QE"ANEP('@S@0?V@R%VB*::G(?M3W<* 'W0'3?>M7%-P\Y3>VJNM4O"Q_K
M="D/F3?=" "/II<"=@"/[P9#]C_\ITWWK5Q3</.4WMIUJEX6/];H6A/,G&Z
MY"'#=+@0 .4I@ 8#(7( 8 '@?VI_ATWWK5Q3</.4WMIUJEX6/];H6A_,G.Z
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M[Y\<>T/_ ,R:=9[MQ7<>95/NDTT7"Q\MO2H-]VNU0$$0'<UM\ 013 0',^.
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M@G-U>6:WD7HK6Z5/26P=MCDVZA]D4M)2-MELN)V(%LI7BX5[=<VL+>!R9%0
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MDYFX2=DSNMHI9+Y# 8B9I:R"GGJ1<!-2EXJ(H'LQHG1B9D(EPAQ=4$EK12.
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M0TQ9XJ/E(TN/3OV3A<2KM298M\C0<<&5*!#  7&Y1,E7840$?/$DS62-U"E
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M^B*@OKE;R#?\XZT17Z(MNU]2'RSGXRKHBU<^H*?<#^L&B*_1%MU/7#?^*O\
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M2$(0!,<YS"( 4I2@)C&$0   1$>-4O<UC7/>YK&,:7/>XAK6M:"7.<XX -:
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MZU?!*,*[PZ;D2>TI^+738?;;Z,OX$]S7ZY]-+D-XIE3SZU?!)A7>'3<B3VE
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M//K5\$IPKO#IN1)[2@G5^FO33(F7+G1F"5,A2 (X3W-<B!0 H<\9G .> [>
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M&7\">YK]<^FER&\4RIY]:O@DPKO#IN1)[2@6K]->45#!ESHS.5#@<W.$]S7
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MH.._OTTN0WBF5//K5\$F%=X=-R)/:6BE7Z:]1,Z9LN=&8!5"&((AA/<UR &
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B1$T1-$31$T1-$31$T1-$31$T1-$31$T1-$31$T1-$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>g210084g55o74.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g55o74.jpg
M_]C_X0S?17AI9@  34T *@    @ #0$   ,    ! S0   $!  ,    ! 4T
M  $"  ,    $    J@$&  ,    !  4   $2  ,    !  $   $5  ,    !
M  0   $:  4    !    L@$;  4    !    N@$H  ,    !  (   $Q  (
M   ?    P@$R  (    4    X0$[  (    /    ]8=I  0    !   !!
M 3P "  (  @ "  MQL   "<0 "W&P   )Q!!9&]B92!0:&]T;W-H;W @,C(N
M-2 H5VEN9&]W<RD ,C R,CHP,3HQ-B Q,CHT.#HT,@!!;6EL82!$92!3:6QV
M80  !)    <    $,#(S,: !  ,    !__\  * "  0    !   ##* #  0
M   !   !/0         & 0,  P    $ !@   1H !0    $   &* 1L !0
M  $   &2 2@  P    $  @   @$ !     $   &: @( !     $   L]
M     $@    !    2     '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2
M     ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1
M# P,# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04
M#@X.#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,_\  $0@ 00"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!
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M:6QV83A"24T$)0      $'TA+B$-X 9W8$X<;X2_LP X0DE-!#H      .4
M   0     0      "W!R:6YT3W5T<'5T    !0    !0<W138F]O; $
M26YT965N=6T     26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O
M;VP     "W!R:6YT97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T
M=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E
M='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#
M35E+ #A"24T$.P     "+0   !     !       2<')I;G1/=71P=71/<'1I
M;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L
M      !#<FY#8F]O;       0VYT0V)O;VP      $QB;'-B;V]L      !.
M9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J
M8P    $       !21T)#     P    !29" @9&]U8D!OX            $=R
M;B!D;W5B0&_@            0FP@(&1O=6) ;^            !"<F1456YT
M1B-2;'0               !";&0@56YT1B-2;'0               !2<VQT
M56YT1B-0>&Q <L            IV96-T;W)$871A8F]O; $     4&=0<V5N
M=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L=
M %1O<"!5;G1&(U)L=                %-C;"!5;G1&(U!R8T!9
M    $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO
M;F<         #&-R;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG
M:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0
M$ $L     0 ! 2P    !  $X0DE-!"8       X             /X   #A"
M24T$#0      !    '@X0DE-!!D       0    >.$))30/S       )
M       ! #A"24TG$       "@ !          (X0DE- _4      $@ +V9F
M  $ ;&9F  8       $ +V9F  $ H9F:  8       $ ,@    $ 6@    8
M      $ -0    $ +0    8       $X0DE- _@      '   /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H     /__________________
M__________\#Z   .$))300(       0     0   D    )      #A"24T$
M'@      !      X0DE-!!H      T$    &              $]   ##
M  8 9P U #4 ;P W #0    !                          $
M     PP   $]                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   $]     %)G:'1L;VYG   ##     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG   !/0    !2
M9VAT;&]N9P   PP    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     0X0DE-! P     "UD    !    H    $$   '@  !YX
M"ST &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $$
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M &\ <P!H &\ <    !0 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '
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M6?KH[J&UCNE6ZMI+;Q[65WB6XM_$'ZL/BQO$S"E'6E*$$H-]Y3W;EV*&:_\
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M5A<5!M#<,&V:NHHZ;-4U3N;:]%O:AGRFR*W=>!TI/BJ?=V-II)J0JTS(%T5
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MD4-17-*]>]K _-GOI]DT>Q)\KL^KQ\.+V1@\EF:_KW9M?N[=.#ZTS5/G.O\
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MLZW]._\ &G^]#K!_LYFQ/^?7?([_ -$3OG_ZA]^_V6'=O_/P.D/_ $;>T_\
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M?^>^Z2_]&UM3_P"JO?O$'\)_9U[Z=_XT_P!Z'7O]G,V)_P ^N^1W_HB=\_\
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MLY6Q/^?8?(S_ -$5OG_ZA]^_V6+=O_/?=)?^C:VI_P#57OWB#^$_LZ]]._\
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M+%N[_GO>DO\ T;>TO_JOW[4/GU[Z5_XT_P!Z'7O]G+V)_P ^P^1O_HB=]?\
MU![]_LL6[O\ GO>DO_1M[2_^J_?M0^?7OI7_ (T_WH=>_P!G+V)_S[#Y&_\
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MKG=G_GMV+_\ 77W[5[H?[XV'_>[O_K7UZG+G\5[^R+_/U[W[Q_'+_E<[L_\
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MLV+_ /7;W[5[G_[XV'_G)=_]:^O4Y=_BO?V1?Y^O>_>/XY_\KO=?_GLV+_\
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M)=_]:^O4Y=_BO?V1?Y^O>_>/XY_\KO=?_GLV+_\ 7;W[5[G_ .^-A_YR7?\
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M\_7O?O'\<_\ E=[K_P#/9L7_ .NWO6KW/_WQL/\ SDN_^M?7J<N?Q7O[(O\
M/U[W[Q_'/_E=[K_\]FQ?_KO[UK]S_P#?&P_\Y+O_ *U];IRY_'>_LB_Z"Z][
M]X_CG_RN]U_^>S8O_P!=O>]?N=_RC[#_ ,Y+O_K7UZG+G\=[^R+_ *"Z][]X
M_CG_ ,KO=?\ Y[-B_P#UV]^U^YW_ "C[#_SDN_\ K7UZG+G\=[^R+_H+KWOW
MC^.?_*[W7_Y[-B__ %V]^U^YW_*/L/\ SDN_^M?7J<N?QWO[(O\ H+KWOWC^
M.?\ RN]U_P#GLV+_ /7;W[7[G_[XV'_G)=_]:^O4Y<_CO?V1?]!=>]^\?QS_
M .5WNO\ \]FQ?_KM[]J]S_\ ?&P_\Y+O_K7UJG+O\5[^R+_/U[W[Q_'/_E<[
MK_\ /9L7_P"NWOVOW/\ ]\;#_P Y+O\ ZU]>IR[_ !7O[(O\_7O?O'\<_P#E
M<[K_ //9L7_Z[>_:_<[_ 'QL/_.2[_ZU]>IR[_%>_LB_S]>]^\?QS_Y7>Z__
M #V;%_\ KM[]K]SO^4?8?^<EW_UKZ]3ES^.]_9%_GZ][]X_CG_RN]U_^>S8O
M_P!=O?M?N=_RC[#_ ,Y+O_K7UZG+G\5[^R+_ #]>]^\?QS_Y7.Z__/9L7_Z[
M>_:_<[_?&P_\Y+O_ *U]>IR[_%>_LB_S]>]^\?QS_P"5SNO_ ,]FQ?\ Z[>_
M:_<[_?&P_P#.2[_ZU]>IR[_%>_LB_P _7O?O'\<_^5SNO_SV;%_^NWOVOW._
MWQL/_.2[_P"M?7J<N_Q7O[(O\_7O?O'\<_\ E<[K_P#/9L7_ .NWOVOW._WQ
ML/\ SDN_^M?7J<N_Q7O[(O\ /U[W[Q_'/_E<[K_\]FQ?_KM[]K]SO]\;#_SD
MN_\ K7UZG+O\5[^R+_/U[W[Q_'/_ )7.Z_\ SV;%_P#KM[]K]SO]\;#_ ,Y+
MO_K7UZG+O\5[^R+_ #]>]^\?QS_Y7.Z__/9L7_Z[>_:_<[_?&P_\Y+O_ *U]
M>IR[_%>_LB_S]>]]>/XZZ[?>]U>+P_\ .LV-K^X\OTM_%]/A\/Y_5J_P]VU^
MYM/[#8=6K^.[I2G_ #3XU_*G5:<O_P =YP](^/\ O7"G7O?_T/G_ /OW7NM_
MCW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?*W^O_MO>Z9IU[KW
MNP/XV]*92JZ6[QW3O+";3VQ@NP.OL?A>L]_=C34.+Q:Y0;SI*.NRF"KZV&:H
M@H(9Z.2CJ*VE5W6K,=*JO)+88Z>ZW.L5ISQ[<;=L]U?75Y8[C)->6MFKN[1"
MV8JDBJ0K/W"18G('AAIB51*D<<K[:+C:>8IYU@1'A6-))2 %=G&14$J* C6!
MDT45)Q$@KJ.IGJZ:GJ(9:B@DCBK($=3+3/+&LT8FCOK3R1,&4D68?3V47M#K
M&OZKSU)M_([HV3NJIJ\3398U>Q<\VX<;2)5/,BT-96&CHA%D8O"3)$%;2&'/
M/N8>4>:[;G#;I]RM=IO[.))FCTW</@NVD EU74]4-<-BI!QT&=SVR3:YTMY;
MF&5B@:L;:P*^1-!0_+J5?_7]H-L7D5QT>8:@K5Q,U9-CH<H:2<8Z;(T\,%34
M4$5<4%,]9!3U,<CQ!BZI(K$ $7$HF@:X:U69#<A Y2HUA22H8K6H4D$ \"01
M6HZ+J&FJG;UP\L1E,(DC,RQB5H@ZF58V8JLACOK",RD VL2#[QT5#69*LI<=
MCJ6IK\A7U,%%0T-%!+55E;654J0TU)24T*O-45-1,X1$12SL0 +GWZ:6*WBE
MGGE5($4LS,0JJH%223@ #))P!UX DT J>NWDCB1Y)72..-6>221@B1HH+,[N
MQ"JJJ+DD\#WCJ*:>DGFI:J&6FJJ::2GJ:>HBDAGIZB%VCF@FBD59(IHI%*LK
M ,K"Q%_=HW25(Y(G#1L 00:@@Y!!X$$9!''K1P:'CUVKJZJZ,K(RAE=2&5E8
M!@RL+J5(/!%Q[PVX]WQZ]>ZY?[[_ 'W]??7O77NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][
M]U[KWOWOW7NO>_>_?/KW7O?_T?G_ /OW7NM_CW[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?AR;>_<>O=>]\B+?
M\;_WQ]^IU[KWOC[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][]
M[]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOP%^/?NO=>]]V_WW^QM[W3
MY]>Z][Z]ZZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[V,/6/:N-ZZH\]2U
M75O7?8%3G6I$BKM]469KY,3#3K.LE/CH\;F<7%%'6-.#*Q!D.A0K+;V"N;.4
MKKF>;;I8>;MTVV*WU$I:/&@D+%2&<O%(25TT4?#DU!Z-]LW2/;DG5]KM[AI*
M9E#$J!7"T9:5KD\?2G7O=R.*S-'N?(_*+:6Z.L=I]X=;_'GXJ[,[HV/\=L%2
MS4&)_P!)*G8^%E["GJMK9&FW-2X+K3$;PJJ_<./QE3&E?MZB$%4RM&]<N)NS
MV<^W;1[?[I8<PWFU;_OW--U97&YSMKD^EU7#"V43H8B]VT"1V\LJ$K=.7C!4
MI#T+^8I5FW"YA:")K>VLHBL:  :J*:G2:G1J.*FB8K6I(5=@1_;YC:%109%]
MN9#-9I-O5NXH?'<8MJ:JK?X7)%4))1S560J(!%1R2JQIYI+I<L59,=%=.?'K
MY T7Q6^079GQDI]BXG=?8_R:Z\[#ZSZVS.ZMH;![^VUT[T!G>VL=OWK:',Y3
M.YW9N2VGG(H\)N">BJJS%/4""1$AF%3![%?.7-?._),ON-R5L'N ;RYMK':K
MFVNKI(9KC;I;[<H[-K>ZT)''.DT9,]LLB)*%UJ2R>&_0<MK>UNA974UGI5GD
M5E4D*X1"VI:DD4- U#3AP-1TF<]FMQ;<EW;MW&;IDR,U'C-K9/'93)PT=9D-
MNU6:W#!AY,=E&@BIZ>NBJX&,],LB)*%U EAI;VP?'[KWK?Y.[1ZQRFX.ILK0
M;*KOD)\K-[0_'KI_<V[\?M[=T?2GQ9Z[W]M_J38U)G\MN:MH=X]EY#%K05F6
MB:IRU4LUHDU)#&JWG7>]]]OMRYAM[3F6-]U39-G@.Y7L4#2P_7[M<V\E[<&)
M(E:&U1S)'"0D*E>XT+L:VT4=XD!:W/AF65M"DT.B-2%6I.210G)/EUFW'DLE
MM2NRT5/F(I*^+;6T* [CS5+1RU-$<]N[)X^IS-?)3PTL;T6+BF,D<3:(4*^H
MV+$J7X]X3J;OGKKK+NE?B[MCHO?NW?YD7Q'ZCP^_^FLSVEM7 Y;9>\\IDJS+
M[#Q%)G=U;B:A[!P4N)@K'S-'7'("%XB\,;A9I$'.MYS)R;ON_P#*9]P[C>-F
MGY#WF]>WODM)I$G@1%2X=HXHM5M('9! \?AZ@U&851;VJP7445Q]&(I1=Q(&
M0L 0>*C)[A2M0:_9U&W--F,!D,SA#NNJS^-J.KMY9J;'9NGQ-9/!7T444<.1
MG>"CIQ)C:@2L@@>,1E@;%A=0@>Z,AT%\=NN^I=WM\8=F]R=I]O=R?*4]@[K[
MFW'V%E\37[#V)WUN#:.%V_A,9@]SX"HI-ZUD$$RUNX9)YITC6()!YC+,QSRI
M!SISSOG,VV?ZX-UM?+FU[7M'TT-C%;(ZW%QMT<TDLC212!H%)'AVP55)U:GT
MZ5#5R;:UCA?Z-9)GDDJ6+4TJY &",G^+^73EA8MQ;ER68HANNNPF*PV$VG_#
MZ3"4V-BF3(U^ IZR:JFEGI:A7H$8C13!0I.J[:;+[(Q\W>H-H=$?*3MOK#8$
M68I=DX7)X#+;7QN?J179?"X7>NS]N[ZH=NUN1\4#923;D.Y10BL,<;5:4XF9
M5,A F#VEYGW/G'V[Y:Y@WIXFW:5)$F:,:4D>">6W:54J= E,7B:*D(6T@D"O
M1;N-O';7L\,0(C!!%>(J :?SITO=AYNLW#M+#9;(&)ZZHAGCJI($\<4TU%65
M- ]0L0+"'[DTOD* D(6TWX]E3]R+TBZ5_OWOW7NO>_>_=>Z][][]U[KWOWOW
M7NO>_>_=>Z][Y 7!)^GOWEU[TZ]?FW^^M[=,C@LUB(,959;$97&4V:HAD<-4
M9#'5=%!E\>9'A%?BYJF*..OHC-&R>6(O'J4B]P?:>"[L[I[B.UNXY)(7T2!&
M#%&I72X!)5J9HU#3K95E"D@@$5'6&.HAF:18I8I3"_CF$<B.T,E@?'*JDF-[
M&]C8V]]8_!YG*P9*KQ>(RF2I,+2BOS%5C\?55M/B:'6(_O<E-312Q4-)Y#I\
MDI5+\7O[]-=VEM);Q7%W''+,VF,,P4NW'2H)!9OD*GK84FI ) XT\NNY)X(F
MB26:*-YW\<*R2(C326OHB5B#(]A]!<^Q"Z^Z'[N[:QN=S/5?3O:79>'VPC2;
MDRNP>O\ =>[\;@%6(5#?QFNP&)KZ;&D4Y\EIF0Z/5].?9'OG.7*'+,]G:\Q\
MT[=M]U<'])+FYA@>3-/TUE=2^<=H.<=.Q6US.':&W=U7B5!('VT'3=D,]@\3
M+!#E,QBL;-56^WBK\A2T<L]VT_LQU$L;2>KC@?7V%TT$M/++!41R03P2O#-#
M-&T4L,L3%)(IHW >.6-U(92+@@W]B-65U5T<,C"H(R"#FH/I3/SZ8.,'CTZ!
ME8*RD,K ,K+RI4\A@1<$$'\>WG([5W-A\=C<OE]NY[%8G,H7P^4R6'R%#CLL
M@77KQM=54\5-7+HYO$S"W/M)!N&WW5Q/:6M_#+=1&CHCJS)FG>H-5_,#JS(Z
M@,R$*>!(X]8$JZ>:1X8)Z>:6(VFCCGC>2+FW[B*Q9#?^H'N1C]E;PR^%R.Y<
M3M3<V4VYA[_Q?<&.P.4K<)BBJB1AD<K34LM#1%4-SY9%L.?=)]UVJUNX-ON=
MSMX[^7X(FD19'_TJ$AF_('JRQ2LK.L;%!Q(!('Y]=25U'#/'335=+%42V\4$
ME1$D\MS8>.%G$C\_T'M,_P"Q]F%/\'3?4KW_ /_2TT<O\1VH-K[0J,9FNQ-Q
M;VWWMKKK,;:QU!U!DJ/KRLS794%#4X7:[]J9;<E%A(ZN)*Y86J/!X7K%:%>5
M+>VA*"6X4%?/TZ5&V(5*:B[ $=N,\!6O6W5@?G8,IO/?M-E]N]4;4ZYZSWAV
MQ@-XYC*]]8BN[6QVW>H:G)T6X-Z)TGA-HY'<4E#/)C&J$ION1.F/D2H8D.JD
M%]K_ ![[9WA- F'VK+]I)FMXX*KRU778^FQ.(JNO<93YK?-5F:QJEEQN*VMB
M:N.HJZJ0" (X",[D*?>-'K,=3J"@\#2A-!GA7Y<?/ATF17>7P51M8%2:'3_O
M7"H\Q6H&>'1CM[_*'I#K_&S5^X-[4IJ5PFQ<[08+'T60KMQ9VF[/RE3A.N:/
M 8>.E%5E<MO7,T<M-0TL?[SR1MK"*K,%!3_&S?M<M)B,=C9:W=DN]=S[9J6@
MRFU)M@T^*VMM/#;NR>X?[_0;BEQ Q^.P^5^[JZA]%##1Z)/.S,8UMK%37A3\
M^GA YP%.JI'E2@%3GY#-> '20K/EWU?BWKL[E<Q%C]E0==;-WE20U.%WM!V?
M59G>N]\_L7"[7'6%1M2'/'*9;/87[&BI(_)DJC(>2(TRHBR/-HOB1W76YS-8
MA,-MZ#';?Q6V-P97>E;O?:5#L"#;6]<K-@=H[DBWC59>/#U>%S^<IWHXI8G<
MQU2-%,L3HZKO6M!Z];%K*21B@I4U%*'@:]-F1^=?QUQNV]N9V;/[LJ,MNO-[
MQVKA.NL?USOK)=I5.\.O,)3[FWUM&;8-%@9\]0[AVMMRJCR%1#/'&LM$Z34[
MS1R1LZ(Q'0G;><[,SG3N/V96GLC;2;AESVV:NMQ..FQ5/M.AJ,IN*LJZ^OKZ
M;$I0XK%TDE2\XJ#"U.GD1F4@GQ=0NHGMZHL,C2&(+^H*XQY<>A*SOR;Z+VWT
M]MWOW*]@XY>I-VR;4@VSN^BQ^<RL.;J]\9.DPFU,?0XK%XNLSLF3S6:KH:..
ME-*)UJG\4B(X*A91_$SO&JSE?A<9MC'9BGQFU:7?=;NK&[KVM-L:'8]5EOX"
MN[6WE+EH< F#I\[_ )%/(TZO!5VA=1(54LR7,42ZG+<"<*Q^$5/ '-. XG@*
MGIJ8- 6#HQ 0M506%%R34 _D.).!4XZ1,/S7^.O]W,3G\EO/(;?K,WOQ^K,=
MLG/[1W7C^R9^REQ/]X$V,G7[8>3=$F?J=ND9&%4IFBDQUZI9#3J\BR\3\1NX
M\BNS*FKQ>)Q%!NW/;,Q%8]=G\.,ILF@W_D:?';4W/OW;PK%S>T]MYHU D@J:
MV&%&4QAM#3P"5TR*"5\Q_JQ\^E MI:1D@ -3S&*\*BN.F/._.WX_XINPZ6@S
M.>S^1V)MGL//4"XW:VX#A>QLGU9BZS);XV9UANI\=_=W?.[MO?9M%4TF/J)W
M5Q(R>1*>I:&36?#[N%=W;VVEA*;;.XYMG;DJ=HTV1QF[=O+0[RW+%'-5P;:V
M0U1D8VW+NFHQD7W#8VE\E53ATCE5)I(HWUXJT4G%?Y?;UXVTFIU%#I-*U&3Z
M#U/RZBXWY[]!2[$ZXWUN&KWAM*#L':-'OJJQ&7V-NM\GU]M">6&AJ=X=CI2X
MF5=G[)I<S*:1,Q6^&AJBDDL+O!%-+&WXCXO=C;L7&S[5Q4T&,AV+M3>6\=P[
MZR.VMC[;VK'N[<N7VGB9*C,9;.B XBNSF,^T@FE$4YJM:/"BIJ+4<Y8RAP!2
M0J*5R  :Y ]?*H^=>D]O'/.9JQT"-2IJ,8H>X#B:C%1\^-'_ '3\R.H.OFJZ
M;>>>BK<SD-_;SV1L3:O6^*W3V3N[>55L?:F(WKGZ:BP&W=OSU2YK%;8RHR%1
M GDA%&8WCFD,@7W V'\9^P]Z=F;XZER$F V'O+K_ &YO'/;AH]\YW%8*F@FV
M?C9:^;%15]36+15$]>R*(IHY'IQ QJ"_A4O[>:154/Q!I_/I]+=W=T-%*@DU
M^74CL[YA]4]=]/=<=YXN+='9O7_:6[M@;7VKD.M=M9K<]744^_LO!C*?.3XR
MBH'R--2XM7<SP2Q1U1J$%*(_N&$?M3[C^)>_:/KC;'9>V%I]P8?(=<9'?NX*
M5LMMZDS%+%@-Y;FVINBHVS@_XL^8W7MO;8PD$U5D*:!HE%0S+JCB=QH2 L5)
MIG_57JS6S^&)%RNFIX>I!IZ@>O2+VA\Z.L<CV[O3IW>9K-J;@Q/;F)ZQVM7)
M@]U5N K9MT=?;-WOLNEWAN0X.+ ;)W?NYMQU$%'BJNH69FI55M,TT<;8:/X<
M=WRM@Y:_#83%X^NS_7^WMS5DV[-L5$_6U7V=EOX5LW_2)BJ;+/D]KOE@&F6.
M>,2)&NF41R>CWLR*/V?M^SKPM9>TD"A(!R,5-!7J3D?Y@'QPITW)!C<_N3,Y
M;&;7[3W5L['0;'WC2T_;M#TU@OXWO\=49NLP<6&WE'@M24[S4TQBDE<-"98O
MW/8-]K];Y;J/?^YNO<WDL'E\AMK*5F.ER6W<M19G%5BTU3-!'40U5#/41QM,
ML6IH7(FA)TR*K CWM6#*&'#IJ6-HG:-B*@^6>C ](=NX/O;J[9_:FW<1N7!8
MK=^&H,M!B-VX/([?S= U91T]5)2U%%DZ:EEE2!Y]"U$:M!4!=<3,A!(=^[=-
M]"O[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>UOUMLFH[([ V9L"ER-
M+B*G>6Y</MN#*5Z2RT>/ES%;%11UE5' #.]/3M+J8*-14<>]$T!/5T0R.J T
M)-.@Y[>[%I.HNK.PNTJ_%5V=H^OMGY_=]5AL9)!%D,K!@<=/D9*"BDJ66GCJ
MJI8-"%SI#$7]BG%\5^Z*[;N6W9AMLP9C!XK$;HW4139S;\6X*O8>SZVJH,YV
M#3;1J<I#N9]F4U31NHKOM3%(58QEU1V6OB)PK_J]/MZ<%O*59U6H%?MH/.G&
MGY= M/\ -;X]8S=F"V/N'>-3@-R9O/;,V2/N]M;HJ=L479N_<?19/;G5E9OJ
MBPU1L^+L&KI*^-VQIK!-$'42!&=%;GF?C=N/#=.=?]N2[@P=0V]L_%C:_8U/
M]PV[-GX#-O)#L/>>>@*BF&W^P*C&Y*/'LCZ]6.?R!1+"7\'&HK3AY]>:!EBC
ME+#N/#S'H3]N:?9UBV_\N=H[A[^[1Z)@VON.E'76V)\MC.QZK[1=C[]W/MR*
M*H[,Z]VS5!S6-NKJZDRV(ERJ21B/1E4\9<PSA%OO_P"&F]>N]S]LX+*[KVOD
ML1UQU_D^R=O;TPAKJ[;'9^V\7N2@VK5G:=68(9H<AC\S624M=3U21S4%932P
M3*&"EM+*"$-#DT^S[>K/:LC2 N***@^1%:8_R^AZ#CJ_^8)UWVMLWHS<N$V3
MO/$YWMSM'"]1;JZ^W&,9C=Y=-;MS>T,GO:A7?-"M5405&,R>WZ".MQM51R2P
M9.@K(:F!BA<(3OVYTFZ/W[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>
M_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[K
MWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>WS;&/ILMN7;V*K#**3)9S$X^J,#!
M)A35E?3T\YA9@RK*(I#I)! /M!NMS+9[7N5W!3QHK>1UJ*C4J%A4>8J,]/VL
M:S7-O$]=#.H-.-"0#3Y]>][-.0_E%_#FFKJJGAR'=QBAF>./7NG;1?0IM=BN
M"L3?WREM_OI>]TMO#(]ML&ME!-+>>E?^<O63<GM!R:LCJ)KZ@/#6G_0/7O<+
M_AI'X>_\K_=G_H3[;_\ K%[=_P"#.][/]\;#_P!D\_\ UMZK_K0\G?QW_P#O
M:?\ 0/7O?O\ AI'X>_\ *_W9_P"A/MO_ .L7OW_!G>]G^^-A_P"R>?\ ZV]>
M_P!:'D[^._\ ][3_ *!Z][\?Y2/P]_&0[L'_ ),^VS_\@O>_^#.][/\ E'V'
M_LGG_P"MO7O]:'D[_?E__O<?_0/7O?0_E(?#[\Y#NP_^3-ML?_(/W[_@SO>S
M_E'V#_G!/_UMZW_K0\G?[\O_ />X_P#H'KWOO_AI'X>_\K_=G_H3[;_^L7OW
M_!G>]G_*/L'_ &3S_P#6[K7^M#R=_OR__P![3_H'KWOW_#2/P]_Y7^[/_0GV
MW_\ 6+W[_@SO>S_E'V#_ +)Y_P#K=U[_ %H>3O\ ?E__ +VG_0/7O?1_E(_#
MX_3(=V#_ ,F;;9_^07OW_!G>]G_*/L'_ #@G_P"MW7O]:'D[_?E__O<?_0/7
MO?O^&D/A]_SL>[/_ $)MM?\ UC]^_P"#/][/^4?8/^<$_P#UMZW_ *T/)W^_
M+_\ WN/_ *!Z][]_PTA\/O\ G8]V?^A-MK_ZQ^_?\&?[V?\ */L'_."?_K;U
M[_6AY._WY?\ ^]Q_] ]>]^_X:0^'W_.Q[L_]";;7_P!8_?O^#/\ >S_E'V#_
M )P3_P#6WKW^M#R=_OR__P![C_Z!Z][]_P -(?#[_G8]V?\ H3;:_P#K'[]_
MP9_O9_RC[!_S@G_ZV]>_UH>3O]^7_P#O<?\ T#U[W[_AI#X??\['NS_T)MM?
M_6/W[_@S_>S_ )1]@_YP3_\ 6WKW^M#R=_OR_P#][C_Z!Z][]_PTA\/O^=CW
M9_Z$VVO_ *Q^_?\ !G^]G_*/L'_."?\ ZV]>_P!:'D[_ 'Y?_P"]Q_\ 0/7O
M?O\ AI#X??\ .Q[L_P#0FVU_]8_?O^#/][/^4?8/^<$__6WKW^M#R=_OR_\
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MMWM6YVD !GEMY$4$T&ID(%3Y9/'I1:R+%=6TKFB+(I/V @GKWO:.R/\ -/\
MA/45]941;VWZT4T[NA;K7+J2C'C4IJ.#Q[Y(6WW0O?F*VAC?8-N#JM,7T?\
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M_ B^_/\ T8=N_P"RZ/\ S=>_UU>2_P#E,N/^<+?Y^O>^O^'2?A3_ ,]KOO\
M]%MEO^O_ +]_P(OOS_T8=N_[+H_\W6Q[J<DTS?7'_.%O\_7O??\ PZ3\*?\
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MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]]W/\ OO\
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MAPJ16"@^ZG^R%6$\0JA2Z_ *D1^GR:=6GB_OWS\^MU-*5QUOT?PG%?Q!LO\
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M-7E\,:LQ5% 3L^2R-32TM#4U];445#Y/LJ.:JGEI*/RMJE^TIY':&G\C<MH
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M???\,Z9_YZ[?W_H'X;_[*/>B9_)%_:?\W7M-E_OZ3_>1_P!!=>UY'_CA2_\
MG1)_UY]^_AG3'_/7;^_] _#?_9/[UJN/]]K^WKVFR_W])_O(_P"@NO:\C_QP
MI?\ SHD_Z\^_?PSIC_GKM_?^@?AO_LG]^U7'^^U_;U[39?[^D_WD?]!=>UY'
M_CA2_P#G1)_UY]]_POI?_GKM_P#_ *!V&_\ LI][U3_[[7]O^QU73:?[]?\
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M:_M_V.O%;/REDK_I1_T%UWKR'_*O2_\ G1)_UY]^_AG3'XW=O_\ V.SL+_\
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MOC_"NFM=O[W[\\?BOJ_N=B+^;RZ=.G^\_P#F_%SJO?5Q;\^_:KC_ 'VO[?\
M8Z]IM/\ ?K_[R/\ /UWKR-K^"DO?Z?<26M;ZW\/UO_A[_]?Y_P#[]U[K?X]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]]W/]?K[]U[KWOKW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U
M[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO
M=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[
MKW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?
MO?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[
MW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=
M>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[K
MW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^
MZ]U[W[W[KW7O?O?NO=>]^]^Z]U[W_]#Y_P#[]U[K?X]^]^Z]U[W[W[KW7O?O
M?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W
M[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>
M]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z
M]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?
MNO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[
MW[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]
M^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7
MO?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]
MU[W[W[KW7O?O?NO=>]^]^Z]U[WRT/I,FAM .DOI.@,1< M]-1'-O?NO=<-:!
MQ&77R%2XC++K*C@L$O<J#Q?Z7]\I(I(6,<L;Q.-)9)4:-P&4.MU8!K,C C^H
M-_?NO=<8I8YT$D,D<T3%P)(I%D0E&,;J'1BI*.I4B_!!_I;WWXG,9D",8U=8
MVD"GQJ[J[(A>VD.ZQL0+W(!L.#[]U[R^779EB$JPF5/,T;RK#K7R-'&R))(L
M=];(CR*";6!8#\^\7]/?NO=9/>01OXS+XW\0<(9=+:!(1J$9<#0&(!-OK;W[
MKW6(RQ"40F1!,T9D6'R+Y3&I"M)X[ZR@9@"PN ?S[\L<CZRB.XC0NY52P1 0
MI=[ A%#, 2;"Y'OW7NNWECC,:R2(AE<11!W5#+(59A&FHC6Y5";"YL+^^'T_
MWW/_ !KW[KW7,?['_??['WU[]U[KOW[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]\EM^?]]^?]MQ[V.'#KW7O]]_ON?<B6DJ:=86J*>:!:F):BG:>&2(
M5%.Y8+- 9$7RPEE(U+=3;Z^Z))'(7\-P=)H:$&A'D?0_(_LZ\00!CK@K*Q(5
M@VDE6TD$*P^H:URK<_3WU#2U-0)GIZ>>=*>(SU#0PO*L$"D S3% PBB#$#4U
MAS[V\D<917959C05(%3Z#U/RZ]0G@.O%E6P9@NLA5#, 68\Z5OR3_A[4>WMB
M;VW;3Y*KVILW=6YZ3#Q>?+U>WMO9?-4^)A"EC-D9\;1U$5%$%YU2E1;\^T%]
MO&S[8\$>X[K;6\DIH@ED2,N?10[ L?DM>KI')("R1LRCT!-/V=1ZFOH:-HTJ
MZVDI7F.F%:FIA@:5B;:8Q(RES_K ^TLPL2I%BOI8%2""#8@@BX(_WOV8U! (
MZIU*!N ?K>W/UO?_ %N/<F:BJZ>&"HGI*F""J!:FGEIYHH:A5M=J>61%28"X
MOI)]T66*1I(TD4R*<@$$C[:<.MT(%2,=<5D1BRJZ,R'U*&4LO/T8 W'^Q]]Q
M8^MGIIZR&CJYJ2F-JBJAIIY*>G/!M-.J-%%P0?41Q[TTT"2)$\JB1N ) )^P
M=>HQ!(&.O&1%949T#-^E2RAV_%PI()_/T]PO=^M=<_?_T?G_ /OW7NM_CW[W
M[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^
M]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O
M?O?NO=>]^]^Z]U[VL^O-EU_8V^MH;!Q5504&3WEN+$[;Q];DY'AQU)5YBMAH
MH*BNEBCEDCI8I)@7(5B%!L/>B: GJZ(7=4!R2!^WH/NU>Q,7U)UIOSM#.T.3
MR6&Z^VGG-W93'X:&.HRU;08''SY&JIL;#/+!%-6RPT[+$K.H9B 2/?2;#W15
M5.\X<5B*S-0[ BK:O=5?BX)*FAQ&,H<HF&DRU9*%'@Q[Y":.-78 $R*/J??J
MC%?/KVAJO1:A>/R\NNY.SME45)UY49O/4&WJGM*;'T&Q\7FJF&CR.>S.2PLV
MX(<'00,S?<Y6/%TTLKQ(20L3'D"_M:[:^/'=F\)ZN#;_ %QN.L_A^.VOELC5
M3P4^,QN.QV]Z.2OV;5Y'+96HHL90Q;KI(F?'>:9#6:2(@S<>]%T RW'_ "=;
M$,IJ1&:8_GP_;Y=!UO'Y6_'78%/0U&ZNV]IT!RF5WIA,514U159G+Y;*]<5\
M>+[ H<5@\'29',9.;9-=,B9;P02"@UAIBBD'VG#U/V2N5Q."DV/N2+-9S/Y_
M:N)Q<V,J(:ZNW)M6:GI]R8.&FE5)/XE@YJN):J)@&A,@U 7]^+"A->'7O"DK
MIT'56E/F./[.E@.\>H'PF<W-'V3M&;;VV]K;7WOG,U!F:2?&XS:.]H*JIVAN
M.HK(7>'^$;D@H9FHY@62<1MI)M[S9SJ+LC;.SL1O_/;/RN*VEG'I%QV6JQ3K
MJ7(PU%3B9JS'K.V3Q=)FJ6EEEH)JJ"&*OBC9Z=I%4D># D '/7C$ZJ'92%/^
M7_5BO4?;7?'4.\=_YWJ[;&_<+FM];<CKI,KA*,U3A&Q%12TF<IZ#*M3)A<U7
M;=K*Z&')T]%45$^,FF2.J2)F52,;_$'LM:CH"09#:DV ^1.'QV0VINBDRDM5
MA]MY2NCK)I=H[Z:*F-1MK=5+0TJ5@II$85%#413PM(A?QU\4=]10K_JKTY]-
M)^CPHXP?(?(^A_XOHOZ_/7IMJ7Y21G&;W@W-\3\_E<3OG9M=A(J'/;LPV/DQ
M]-#OCK19JP4F\-E5>1KGH#60R*:7)4L]-4)%((_*$Z])]J2;-QG8";'S$FTL
MS545+CLG$*:6:H_B-><3C:O^$QU#9B#$Y+*J:6FKI*=*.>IM$DK2>GW;4H\\
M]4$,A42:.T_Y<?S/0Y-\C.D8^P<SU9+V/@(M];?HLA79?$3&LA@I1B,6N<R]
M ,Y)2)M^ISV(P;BMJ\;#5/D*6C_?EA2(%_8K[<^'?=57V!LW8>]]H;@ZYFWI
MF\QMBAKLSA9LA-0[JQ6!JLZNU<MA\;-)D\3N:OB@18:"K6GJW$HD6-D5B*&1
M0"0:TZ<6TE+K&Z%:DBM*Y K2GD>@/W9\_?CI0]6]@]G=<;^VMVQ3=>;=V_O+
M(X[ ;@IL53Y+96<W-1;:;>V#W!EZ>'#YW9V-FJ9'J,I0/5T,;0F)I5D9044?
MC+WY_>2BVC#U7NNMW#D<!#NJCHL91196*?;,U<,8^X!D,;/58Q<-0Y(_;U=2
MTPAH9E9*AHF4@7UH*G4*=4^GGUJ@C.LC_8^RE>)_;T(8^9'Q>.T<AON;NW8V
M.VOBMTU.R*_(9G(2X2:GWE3XYLQ'M5L5F*:BS#;@R6)7[J@I%IS/DJ=EDI5F
M1U8J.D^+'8N9V1O'?VW(Z?)8;KS9^V-V[RBR 7;E=1Q;CR.:QSPX.'+SPINC
M'XIL'-))D*-GI)P"L#2,-/MM)69B'C*G40/.H'GCA7TZK##/(D[M%I5#C(R/
MXOD*U_9\^DSE?FIT_MOL?KKK#<U;4T&X>V=[[PV1L6;%13;GQU16[3Q> R@&
MY:G"4M0VT,KEX]QTR1XVN6.LIV<-4+$AU!.Y+X[=F+)NBKVSM?<.Y=N[3I*.
MJR6<DP57MQV,NVJ+=60IZ+"YV2GR^2J</B:T5%3'2QSR14FFH=4AD1C<.,9X
M]6:WD&H@'2!Q_*OGTI<1\L.G639M!O#>>U=H;JWQ75]%A]N0[DHMV1H(-X9#
M96+JLCN+;D57@L12YW.4!I:26MEIHIJ[721M)/$Z@"#^+?[W_O/^'N_3/1F1
M_B+>^O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]^Z]U[W[W[KW7O?O?NO=>]^]
M^Z]U[W[W[KW7O?O?NO=>]O6V\=!F-Q8'$54DL5-E,UB\=42P!#/'!75T%-+)
M")/094CE)75Q?Z^T.YW3V6V[C>Q*IEA@D< UH2B%@#3-"1FG3]M&LUS;PL2%
M=U!IQH2!U[WL=UW\FOXQTM954T?:G>3I!,\:,U!L4L0IXN!%;4??+^W^_'[K
MS6\4S<H<O@LM::[O_/UD>WLSRPLC+^]KZ@/I%_FZ][A_\,Y?&?\ Y^CWE_Y[
M]B_]>O;O_!P>ZO\ TR7+_P#O=W_GZW_K-<K_ /1UOOV1?YNO>_?\,Y?&;_GZ
M/>7_ )[]B_\ 7KW[_@X/=7_IDN7_ />[O_/U[_6:Y7_Z.M]^R+_-U[W[_AG+
MXS_CM+O'_8T&Q1_UR]Z/WX/=7_IDN7_][N_\_6C[-<K^6ZWW[(O\W7O?1_DY
M?&<?7M+N\?\ 5#L4_P"]1>_#[\'NL?\ G4=@_P![N_\ /U7_ %F>6?\ H[7_
M /O,77O?7_#.GQF_Y^GWA_YP;&_Z]>]_\&_[K?\ 3(<O_P"]W?\ GZ]_K,\L
M_P#1VO\ _>8NO>_?\,Z?&;_GZ?>'_G!L;_KU[]_P;_NM_P!,AR__ +W=_P"?
MKW^LSRS_ -':_P#]YBZ][\/Y.GQF_P"?I]W_ /G#L8?]<O?O^#?]UO\ ID-@
M_P![N_\ /U[_ %F>6?/=K_\ WF+KWOD/Y./QF;_FJG>(_P!:@V(?][B]^_X.
M#W6''E#E_P#WN[_S]>_UFN6/^CK??LBZ][[_ .&;_C/_ ,_5[R_\X-A_]>O?
MO^#A]U?^F0Y>_P![N_\ /U[_ %FN6/\ HZWW[(NO>_?\,W_&?_GZO>7_ )P;
M#_Z]>_?\'#[J_P#3(<O?[W=_Y^O?ZS7+'_1UOOV1=>]^_P"&;_C/_P _5[R_
M\X-A_P#7KW[_ (.'W5_Z9#E[_>[O_/U[_6:Y8_Z.M]^R+KWOW_#-_P 9_P#G
MZO>7_G!L/_KU[]_P</NK_P!,AR]_O=W_ )^O?ZS7+'_1UOOV1=>]^_X9O^,_
M_/U>\O\ S@V'_P!>O?O^#A]U?^F0Y>_WN[_S]>_UFN6/^CK??LBZ][]_PS?\
M9_\ GZO>7_G!L/\ Z]>_?\'#[J_],AR]_O=W_GZ]_K-<L?\ 1UOOV1=>]^_X
M9O\ C/\ \_5[R_\ .#8?_7KW[_@X?=7_ *9#E[_>[O\ S]>_UFN6/^CK??LB
MZ][]_P ,W_&?_GZO>7_G!L/_ *]>_?\ !P^ZO_3(<O?[W=_Y^O?ZS7+'_1UO
MOV1=>]^_X9O^,_\ S]7O+_S@V'_UZ]^_X.'W5_Z9#E[_ 'N[_P _7O\ 6:Y8
M_P"CK??LBZ][]_PS?\9_^?J]Y?\ G!L/_KU[]_P</NK_ -,AR]_O=W_GZ]_K
M-<L?]'6^_9%U[WU_PS?\9_\ GZO>7_G!L/\ Z]>_?\'#[J_],AR__O=W_GZ]
M_K-<L?\ 1UOOV1=>]]'^3A\9P+_Z5.\?_.'8?_$0W][_ .#@]U?^F0Y?_P![
MN_\ /U[_ %FN6?\ HZW_ /O,77O?'_AG/XS_ //U.\/_ #W[%_Z\^_?\&_[K
M?],?R_\ [W=_Y^O?ZS/+7_1VO_\ >8NO>_?\,Y_&?_GZG>'_ )[]B_\ 7GW[
M_@W_ '6_Z8_E_P#WN[_S]>_UF>6O^CM?_P"\Q=>]]C^3G\9R?^9J=X?^>_8O
M_7H<^_#[[_NM_P!,?R__ +W=_P"?KW^LSRR,_O:^I_I8NO>P ^1O\H1=O[)D
MW3\9-V;L["W#M^"KJ]Q]<[SH\/2;DS^+A7SMD.OZG#%:3*Y''0JQGQDH6JGC
M]=.793&TE>V'WU3N6_+L_NSL]EMFVW+*L%[:M*T$+G&B\$G=&CFFFX6L:'MD
MT@Z@'N9/9_Z:Q-WRQ>37-Q&"7AD"AW4?BB*88@<4/<1E:TIU[W2!5TE30U,]
M%6TT]'64DTM-54E5#)3U5+40.8IJ>I@E5)89X95*LC ,K @CWGW%+%<0Q3P2
M*\+J&5E(*L"*@J1@@BA!&".!Z@YU='9)%*NIH0<$$<00<@CKWN-[OU7KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][M
M7H^V^M>K^A^BJ'=&6GS-+E>D=YME>CL-L?9&1VMOK+YO=>^,7B\EO#?DK#<F
M!R?GD@JJF1;U]%%11"DT%D8IRK,SZ>->/IPX#HQ$L:0P@GBA[:"AXC)X@]4C
MUW17;W='R:^2V2V;@:?;]9A/D=L!,+\D<_V1V1B-Z=;8';>R.M\UF,1L'K.%
M?[H;FPPIXJFBI(FTXO(39"<UWD574(_O?']4[UQ?<]*=JT5!V)U1U9\?]W4G
M9U)O9*VIWOE,AM3J;:&Y-NU6W/(,(^&6DS#34:4(-=02T1,[2"2<1V36-.30
MDX^6>M3+$PE 0!T536O'"@_Y_P##T('QER?>'7F8^/M>=ZY')]5=W=T_*+8M
M?TW7==OCZ3KK"XS?'>6^MG[LH]VF)MQ1Y]ZO!+3U\F188[)PY!13)$8:8RKC
MJ*AW*WQ0W?3[IQNR#U75=.;OR.U,QBZ79$_7<&^*7-535DG=^0E?_273=Z05
M,=-3[7@I&1'\U(51Z'[LFC$>)0$ZJC[?R\J=6B!^F?4HT:#3A2OS/'5Z#[.@
MV[ZK]HK\W]A5>RLSV,O=5%\@-B8K>V S5;V-3=LU'6];MZB2AB^..*A7_0_6
M_&RJI)JNJWG4UR2.GV]<'D3)"B4!QT9LC8G9O1O4."SW5^WY,/!\GTVUVSVQ
MB=P+C][[;VGN?^X'\.&3^\J8Z3'XW<%/)6T./FF1J.*>CD<$2M)>[%@[D-^'
M'VYZI"BR01@QK3Q*%JT(!I_(_P"3H5_DIV-V;TW\E.^=S;:[HW3#G*GX8S;O
MZ-Z-SFUFRW7.[=][-_TH#*'"KCZ.6ORN8VO5QX_)92GIY%KYZ:OBC(,"1:7K
M8&RNE^S)\AAJ'$9/:/7G^GU-MX'K*I[*QZ-O*NVUU?OFOVOB\QN+(P)/C]Q]
ME;AH8*"7+PM%CZ+S-#"@:2)AHLZ\#4T_R]>1(I"0N(]= *\<&F?F>/D.D]V=
MV-\A^G:;$9_*[@PV^NU#\79MX[I[CI>GLK*.OL?N[N;K;&;SS6 VEAZAZ;*;
M1Z@VKE*G)08*=9\KD3 L]1(R13(5%O7KK:^Q.M-P;FBZXH>E=^]A_'GN0;ZZ
M[DWG29V/'S;>[UZQQNW#CL!EJFIW#LRJJ,7$P%!5RR5E2L+U4=H) !K42P -
M0&'^ ]6EC5(V;PPCLA)%:\&%,<1C]O25Z[[:WIV;W#M?9LO;F0^0_6/4_P K
M_C]_HV[7AZ\KMM3Y.'='QH[DRV[1EMSX.DHMJ=@TE+FIT)R=###CJ1YDHI?\
MJB)-5A^GUY^A_P ?^16]J.B[J[3\_P#&_P _\B]]>_=>Z[]^]^Z]U[W[W[KW
M7O?O?NO=>]^]^Z]U[W[W[KW7O?(?[[^GO8KFG7NNCQS_ +?_ 'W]![O=^,YH
M?YF'P)W;\'<S38N7YA_"; ;O[W^#^<AQF/I]R=O=+0H^9[T^+%370Q4]7GLQ
MB@#N;:D4AJ*N6>.>DC,<"$'#KW \7[O_ +R[9[NVLD@]K^;9X-OW^,LQBLKX
MGP]OW8*:B-'Q:WA&A%4K*VIV%!%9A=WVZ3;F'^/P O$?-EXM&?GYK^S '0"[
ME$O6?8-)OFG,HV=OB>CP.^:=I)6I\1F_\U@=U1Q%F6"&6_VU6555TE7/J]\/
MDA38O^7E\)^M_@+A!04ORP^9-'L/O3YU9XXFAKMR]5]:9,PY7HSXP054E+/D
ML)F(:&J7<>Z*:!XZC[J>&F<M$Q3WKD*2Y]\?=K?_ 'HO"[>VO*KW&W\O1ZV$
M5Y=)5-PW8BH21"P^FM'8%="NXHP!ZM=TVK;XML6GUT]&F/FJG*Q_(TRW[.N>
MW#+V'O;);_J-;;4V;)7838L!FD2FR>3B!BS6YF0,D4T1=33T[," JEA8B_NS
MGO?LOLGX5=VX_H#97S,HOY6_P5^+.W^M(-B;>ZHV[1;S^2GRNS69V%MW<VX^
M[LAUWBZ=*_LW+]G9_(U>C);KKZ+;>.ITCITB(CE5L>N3M@V#W:Y1FYTW?VI?
MW%]XN8I[HW$EY(UOM>SQQW,L45@MRYTVB6D:I^E9QR74K$N6&I:'-P\NW7'T
MZ;@++;H0ND**R2DJ*OI''4?-J #&>@OP6.Q^\L++GJK9<O:>_-TU.2>OJ<O5
M2T&V-J115M134N%3)2L4Q<&,IHTO'1QO4.26)N;^R4;)[$^$W\P3^9MOSY)8
MGXOU&"Z<Z%^+7:GR.["ZRW!68#%K\INS^A]J5%?2;OWYM'9./QNS.O8^SMP5
M>/J]P83!Z\>_V\X#,:B4M+N\;)[M^R?W?=EY#NO<,3<U;US%9[7;7<:R/^Z+
M3<9@K0V\T[-/<FUB65+:XGI("R8 C4 LBDV_<]UFNELZ010N[+_OPKP) %%U
M$BH&/V]+>LQF]NO>L*+;<VZ%GRV>W3B]O8_(TZ3S?W5Q6>JUC>AQ]96O)69#
M^&0!XZ>:?]P!E_U(]EJJ?YIWRG^=>5I?B+W]4?'N3IGY#=G]7[(P:2=#=;[>
MA^,&-R.^L#CAENALOM_$X;([&%!AI#23-4SUXEHM2N=3,Y'T?W<_;KV=MI/<
M[DN/?/ZU;)M]W<24W&ZE.[.EO(VC<$D=TN-3C6H58Z24(% !TD_?-YN++87)
MB%O(ZK\"CPP2/@I2E!ZUQTI!U5M;8L1W=M\;B7-;=Q>4KIM.=R4XW1+%03/X
M<_#42S1UWDG76H4)9^1^![-+\S_YI'R#^!GRV[+^&?Q+Z]ZGZ.^*'Q5WUE^G
M<;T!NGI?KO>M'W3B-KF+#9W>/?N:W;MNOW/O_,]K&&3(S5*UE-HI*V)8&NHG
M>.O:G[NW)/O-[:;![K>Y>][EN_N5S'9)>MN4-]<P-8/+62.#;HX95AMDLZB(
M(4>LD;:Q0Z%6;AN]QMM[+864<:6<+:=!4$/3BS$BI+?:,'USTEME]6;?WWM+
M';RW9DLQG=U[LH8LU+N&ES60HSAIJHF6GH\!!1U$=+CX,3<1*FAKLA+?4CV)
M'^R(?&/_ (=0_O1_H+K?]#/^R%?\.4_[)MKJ_P"&?W\_T2_WZ_V7;RV_B?\
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M_P _J?\ V&Q-\#_Y"^_?\"[[\_\ 3!C_ +*[3_K;UO\ UR.2?^CW_P!4I/\
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MG^_$WP#_ +"V$^OO8^Z_[\U'_(#_ .SNU_ZV]:/N3R21_P EO_JE+_T#U[V
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M3MZK[)P>VMP4.SN\,YL7'4"215F3I9I&6G3[IYN=6)LOL%RA8+N,'(WOCO\
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M^^K]P?\ HR;3_P!E<_\ VR=>\+8O^4RY_P"<2?\ 6WKWOW\,Z,_Y[#LW_P!
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M%L7_ "F7/_.)/^MO7O?OX9T9_P ]AV;_ .@+MS_[./?OJ_<'_HR;3_V5S_\
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M/?OJ_<'_ *,FT_\ 97/_ -LG7O"V+_E,N?\ G$G_ %MZ][]_#.C/^>P[-_\
M0%VY_P#9Q[]]7[@_]&3:?^RN?_MDZ]X6Q?\ *9<_\XD_ZV]>]^_AG1G_ #V'
M9O\ Z NW/_LX]^^K]P?^C)M/_97/_P!LG7O"V+_E,N?^<2?];>O>_?PSHS_G
ML.S?_0%VY_\ 9Q[]]7[@_P#1DVG_ +*Y_P#MDZ]X6Q?\IES_ ,XD_P"MO7O?
MOX9T9_SV'9O_ * NW/\ [./?OJ_<'_HR;3_V5S_]LG7O"V+_ )3+G_G$G_6W
MKWOW\,Z,_P">P[-_] 7;G_V<>_?5^X/_ $9-I_[*Y_\ MDZ]X6Q?\IES_P X
MD_ZV]>]^_AG1G_/8=F_^@+MS_P"SCW[ZOW!_Z,FT_P#97/\ ]LG7O"V+_E,N
M?^<2?];>O>_?PSHS_GL.S?\ T!=N?_9Q[]]7[@_]&3:?^RN?_MDZ]X6Q?\IE
MS_SB3_K;U[W[^&=&?\]AV;_Z NW/_LX]^^K]P?\ HR;3_P!E<_\ VR=>\+8O
M^4RY_P"<2?\ 6WKWOW\,Z,_Y[#LW_P! 7;G_ -G'OWU?N#_T9-I_[*Y_^V3K
MWA;%_P IES_SB3_K;U[W[^&=&?\ /8=F_P#H"[<_^SCW[ZOW!_Z,FT_]E<__
M &R=>\+8O^4RY_YQ)_UMZ][]_#.C/^>P[-_] 7;G_P!G'OWU?N#_ -&3:?\
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MMZ][]_#.C/\ GL.S?_0%VY_]G'OWU?N#_P!&3:?^RN?_ +9.O>%L7_*9<_\
M.)/^MO7O?OX9T9_SV'9O_H"[<_\ LX]^^K]P?^C)M/\ V5S_ /;)U[PMB_Y3
M+G_G$G_6WKWOW\,Z,_Y[#LW_ - 7;G_V<>_?5^X/_1DVG_LKG_[9.O>%L7_*
M9<_\XD_ZV]>]^_AG1G_/8=F_^@+MS_[./?OJ_<'_ *,FT_\ 97/_ -LG7O"V
M+_E,N?\ G$G_ %MZ][]_#.C/^>P[-_\ 0%VY_P#9Q[]]7[@_]&3:?^RN?_MD
MZ]X6Q?\ *9<_\XD_ZV]>]^_AG1G_ #V'9O\ Z NW/_LX]^^K]P?^C)M/_97/
M_P!LG7O"V+_E,N?^<2?];>O>_?PSHS_GL.S?_0%VY_\ 9Q[]]7[@_P#1DVG_
M +*Y_P#MDZ]X6Q?\IES_ ,XD_P"MO7O?OX9T9_SV'9O_ * NW/\ [./?OJ_<
M'_HR;3_V5S_]LG7O"V+_ )3+G_G$G_6WKWOW\,Z,_P">P[-_] 7;G_V<>_?5
M^X/_ $9-I_[*Y_\ MDZ]X6Q?\IES_P XD_ZV]>]^_AG1G_/8=F_^@+MS_P"S
MCW[ZOW!_Z,FT_P#97/\ ]LG7O"V+_E,N?^<2?];>O>_?PSHS_GL.S?\ T!=N
M?_9Q[]]7[@_]&3:?^RN?_MDZ]X6Q?\IES_SB3_K;U[W[^&=&?\]AV;_Z NW/
M_LX]^^K]P?\ HR;3_P!E<_\ VR=>\+8O^4RY_P"<2?\ 6WKWOW\,Z,_Y[#LW
M_P! 7;G_ -G'OWU?N#_T9-I_[*Y_^V3KWA;%_P IES_SB3_K;U[W[^&=&?\
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MU?N#_P!&3:?^RN?_ +9.O>%L7_*9<_\ .)/^MO7O?OX9T9_SV'9O_H"[<_\
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M,Z,_Y[#LW_T!=N?_ &<>_?5^X/\ T9-I_P"RN?\ [9.O>%L7_*9<_P#.)/\
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MJ$U;-UYF\4D-%#AMJ[A5(Z#+=?M2Q)_!8$C@FQ='&M')':)))'D!%0:?Y_\
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M/'2X/(Y* U:4,]#54KXZ?09O&KZ0NC&Q8,IS6O\ *G5A<(%9&C.@KIXT.&U
M^GRI2G20W5\..Q:S>NW^W-G=O;8PG9>![[K._7I<UUC0[@V/FLEG/CWBNB=P
M[.JJ>3+0;DQ6'JOL9,E3Y*CK8\M3!Q3^5H]1=^R/RQV%NE<)M[=_5FY)]A]:
MY[:6>Z?Q& ['K,7N#&)M' XW;XP^^MQS8NKDW1!N&##4TLM7#%1UV+(DBQTE
M/ XC77A$5HV2#7'KZ=7:YC<T,1TJ1I[O04H3Y_:,CRQTF<3\'.T-E-N+=6P>
MZMH4_9W<&V=\[:[]SVZ>I:#-;6S+[[W/E]TMGNM=I09JBAV95;3J=P5D$%!4
M35^,S2F.?+1552AE:;BOF5MJ;<=!VAO;JNKW%VUB-E]E; QU5BMYU6V]AU&%
M[!7=II<ED]LT>/EK9LIMEMZUJ_;I5+091=+5D3RF5Y/>$?A!&BH^W'7ENUU"
M1XZR@$<:#->(_,_(]-V<_E];O@VEE.F.NN[*#:G1F?[$Z?[2RM#G.O:+>'9M
M-N'JQMB_?8C#[RR.5AH(,-O%>N\<_P!T]"V4PK:TH)XH5ACB27<_R%QF[_CY
MT?U9A*EZK=M+AX:OO7="05E)/O&?9DU;MOI';&5:HDT9,=7;!EFIHIT CE^\
M6^IX=7O:I1V8@T\O\O3<LVJ&*,'NIW'UIA:_8*]+KX]_%7,;!^5'R/[JW'2Q
MT>Q:W/U%#\:MER5..KJ78--V#!C]W_(W>6$2EC5\0W='9U/3UDU-*QE@^P?2
M5CJ-'LF9^I]N])NK!_?K<'_#_#C_ &_OW7NO7M_OO]]S[Z]^Z]U[W[W[KW7O
M?O?NO=>]J':M3MJDW#B:G>.*R>:VS!5(^9Q6&R<.'RE=1A3K@HLG44>0AHYG
M:WK:&0 7XO[T:TP<];72"-0)7I*;VH]X5^U,[1[ S6%V[O.HH'CV_F]PX>HS
M^%QN0+)XZK(X6ER&*GR%.J@@QK41$FWJX]GWWK\6NLMP9?)[;ZKK,AL*'8G5
M&SN\^QM]]O[RI:S#4NR=Y8G:]6^(P^)VUM45U;FL+D=T1Q4\4?DGKUC:RJ?5
M[:5R*%LU-!0=+GMHR2(R1I4,2Q\C3T'S_/JL3KGYI]S;7V_B=W]V8[$]G3]E
M=W[_ /C9U+UGT)U_6X_/U_8G7V=WG01YW<&<WAO9L;C=O;BQ>S)9JJ:7Q4V,
M>5;LR^GV$$WQ+RL6&S1_TD[(I]];>ZWJ.W\MUQDES5#GHNOF3&5.&J*?(+CZ
MG#5&ZLOBLQ35YQ/F62FHI-4DOE5X5L9,BB&E:?G_ ,7TU]*U*ZU\0+JTFO#_
M #D9IT.]-\Z<%+N';J_Z(NQZCK/=?;='T)@NWL0^W<EMB?M59<O19^CJL6V5
MI-PTNRL%F\!5XL9PT[15>1AT10^%XYW4&7^$^XZ#-0;:Q?:?6&?SV+[*V]U=
MV)%19+)4.(Z^S^[:>JJMMU=7G\OCZ#'9C#5HH9Z66> J8,B@IRK:UD/O%'H>
M%1\Z=;:T(8()5+!@#Y4)X9\_\_27V_\ S%]I9/;U5O#,])]S[6VQF>G]T]U=
M3SY##XC)9[M+:NQ:NBHMW4-!MC Y7*97 9_''*4U;!35(85.)D:K#)XWB# _
MQ6BH:_L6KW!VOMK:6RNL:C8-+N'.[JVKOO ;H:L[(ARTF"Q%)UWDL%!GY,[C
M_P"#3OD86=8*>G ECGG5E#>\7"T0DFO"G6OIQ60F4"-2!6AKGRIQ^WR^9Z5,
M7S:FR>+ZFHMJ]'[PWUV)W'3=HUFU-M;(WKUKNC924'4=1@X=RYVO[8Q&Y:K:
M\6VLH-PTR8FH6-ZFKJF,$M-3,K%5)/\ $TT^&H\7E<[B-OYO ;L[-K^PNPYL
MA4938E)U5M3:/5^X]O;IPU+14QR>3?/C?:?8PQQ+4UDM;!$Z0V=EKXGF!B@Q
MYU_U#K?TP%%+ ,":GRH ,C]O21I?G,M7N#(YO";9SFY]N[HV/TYCNJNJ8,72
MX7LS(]W[VWYW3M'=FR=P5V1K?X+AUVNW6<G\3J))GI*"&@J9HY*C5&CM(^(5
M1 :O/Y/N7K"BZSH.M=I]MS;^CEW#6-+L_>>^*[8&&H*+:ZX>++5.^8,[CY!6
M8JZ+3Q*6%0X U;\2M0J&M:?LZU]+Q)F7PPH-<\"2/V_+I]_V?*EJEHMLX?X^
M]S9'N#(=P[WZ*I^L)H-JT"P[^Z^ZWQO:.?RE?O)]P38.CZWJ=M96(T&;"NU5
M,ZH:6-BP7AV1\7<1U9U9NS<^Y^S,6>P=L]IC8]%M;&8^OK\'NK;U9M'";MP6
MY,'G5I8U0YK$YE*N-*@0M'3C1(B2W7WM9"[TIBG'KTEN(HV+R?J!J4\B* @C
M]O7?47S2S_=?=>Q=F[-Z<S:]6;RZ4/9.0WIF,IB\9N39.ZZ#?>X]B;FVCN7;
M3UDK2#;N<V\]#))2&=):H^2*22#U>R>7M_K_ -?\>/\ &QY]N=)>C^V^O^/!
MY))_WP]]:C_Q7_'W[KW7K#_B?J??K_ZWOW7NO6']/Q;_ &'OQ-_]\??NO==^
M_7]^Z]UU8?[[_C?OKW[KW7B+_7W[W[KW7?OWOW7NO>_>_=>Z][][]U[KWOWO
MW7NO>_>_=>Z][][]U[KWOWOW7NO>W_:E92X[=.VLA72F"BH<_AJRLF"-(8:6
MER--/42B-/6YCB0FPY-K#V7;Q!-=;3NEM;IJGDMI%45I5F1@!4\*DC/2BT=8
MKJVD<T19%)/H 03U[WM;Y+^91\(*C(5DT7=60:*2>1XI/]&V\%)1B"#8PDCZ
M?GWQZMONL>_T=K"C\A1^(%S_ (];?Y^LL)?<SD9I'8;TY!/'P9/\%.O>X7_#
MD7PD_P"?U9'_ -%QN_\ ^I_;G_ M^_?_ $P47_9=;?Y^F_\ 7+Y'_P"CRW_.
M&3KWOW_#D7PD_P"?U9'_ -%QN_\ ^I_?O^!;]^_^F"B_[+K;_/U[_7+Y'_Z/
M+?\ .&3KWOW_  Y%\)/^?U9'_P!%QN__ .I_?O\ @6_?O_I@HO\ LNMO\_7O
M]<OD?_H\M_SADZ][]_PY%\)/^?U9'_T7&[__ *G]^_X%OW[_ .F"B_[+K;_/
MU[_7+Y'_ .CRW_.&3KWOW_#D7PD_Y_5D?_1<;O\ _J?W[_@6_?O_ *8*+_LN
MMO\ /U[_ %R^1_\ H\M_SADZ][]_PY%\)/\ G]61_P#1<;O_ /J?W[_@6_?O
M_I@HO^RZV_S]>_UR^1_^CRW_ #ADZ][]_P .1?"3_G]61_\ 1<;O_P#J?W[_
M (%OW[_Z8*+_ ++K;_/U[_7+Y'_Z/+?\X9.O>_?\.1?"3_G]61_]%QN__P"I
M_?O^!;]^_P#I@HO^RZV_S]>_UR^1_P#H\M_SADZ][]_PY%\)/^?U9'_T7&[_
M /ZG]^_X%OW[_P"F"B_[+K;_ #]>_P!<OD?_ */+?\X9.O>_?\.1?"3_ )_5
MD?\ T7&[_P#ZG]^_X%OW[_Z8*+_LNMO\_7O]<OD?_H\M_P X9.O>_?\ #D7P
MD_Y_5D?_ $7&[_\ ZG]^_P"!;]^_^F"B_P"RZV_S]>_UR^1_^CRW_.&3KWOW
M_#D7PD_Y_5D?_1<;O_\ J?W[_@6_?O\ Z8*+_LNMO\_7O]<OD?\ Z/+?\X9.
MO>_?\.1?"3_G]61_]%QN_P#^I_?O^!;]^_\ I@HO^RZV_P _7O\ 7+Y'_P"C
MRW_.&3KWL)>[OYJGQZV-L'(97H_-3]J]HU;&BVMBLMM3,X';&VZPQETW=N5\
MKX6S,&*D :FQ\-ON*D+Y66(,"-N0/N?^Y?,',=M:<_V*[-RB@UW$D=Q%-/.M
M:?30".OA&08>9O@2N@%R*%&^>ZW+UCM[S;%,;O=B:1JT;*B?\,?5\0!^%!Q-
M-1 X^]ZW^_=^[P[/WEN7L+?^?KMT[TWAEJK.[EW%DW22OR^6K7\E36U31I''
MY)&_"JJ@<  "WOJ'R[R]LG*6Q[5RURWML=GL5C"L4$,=0D<:855!)-!\S7S.
M>L;K^_O-TO;K<=PN&EO9G+NYXLQXD_ZJ=>]I#V<](^O>_>_=>Z][][]U[KWO
MWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z]
M[][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7N
MO>S@;5^(&X=R;.P.ZJOL[K#;=1N+KW*=NT>W,QE,N,Q2]7;<RV4Q&Z-S9)J;
M#S4-+7XR;%/-3XQ99*VOI[-"I8JC-&45("GC3\^E2VK,H;Q%!*EJ9X#\N/RZ
M(3O?Y[[5VAOW=&R*#ISN;=U+M/M7"]#5^[<!A<"<!7=T;NP6%SVS-FX<5>?I
M\E68W,09N."JS#018_%U8T3L$U.DQ/B3N:9LAMW$5.W-S9+*;IZMIMD[]HMT
M28[:==L_L3:NY]WTFYJK$UV$_B<.)3!X*2>NFG:";&/22Q-#,S*??O$7&?(_
MRZV+5S55 )JM#Y4()]/V^F>F^7YU[.@7$[LSE)NS9V(PFR^Z:KL;K'([,ARV
M^<;O[J?>VS=AUVSZ+.XW<9PT^:?<NY8J;&P4Z5-/F8ZZ&=:BG1'7WSWM\:<;
M2=4=7YWJG)S=S[NWWO\ [.PL=9L"',Y&&KV_L:@VU(@DV?68>CW#@Z^&IRDL
MQ>1)(YZ22)PRMJ0:$A+.'&D #KSVX$<9C[R2>%?*GEQ_S]<.NOF%F*[O#N?;
M?=^&I_CUL+K/J[IO<<M!VC48#$ST6ZNR,IN^-S#OZ@S^0VIN7&3TN&AI_'"\
M4U+7131E773(SEL/X[]==A[)R&$P]3V'CNU<(-KT6?W1N.@I,-UUC.RMV;VI
M=JXWI-<++2RY^MW#)CYY*M*]:D%I:2HUTJ4\+RCS.Z'--/\ /[?LZ\ENCKI!
M82XJ3PJ2!I_U?/IG[/\ E?VQU/V-B=QY^DZHR_2.Y&WKD=L;+VCDZ_</;&7Z
M?V/UU6;VR_R+DW'!6P;7H-JP96FBH9,8](RB&NI=%9+5SI 7G-='?&MJ#=6Z
ML1N3MK&;*Z2[,7KKMB:NI=OY//;PHZZFW#%MK=6QZ5*;&4NVZC<6Y=NRT510
MUC5IQM)415):H:*6*36MS04&HBH_U?(=6,, #,"P56H>&>-*>AQ^73!MWY(_
M+Y<GLG9&>VGT9ENQ/D9TZ_;71M/CJS=.'VUU_D<;5[5EWCLGLBM:LS-;NVEV
MIM#=L.1I<ECUQPS%;23T@6E2:&:)21?&[H=.TL!L"OB[CASO8^!V9G*#KR*;
M;L6=Z+P^Y,7797=6Y.U]R5F.CHJB#9&-IX<D:!J3'S#%3ZJR6GE4@[#N144H
M//U/RZLMO#X@0Z]3*#3%5^9^P>7IQH>DA4?+OY-R=*[G[0QDWQ^GVSU'N?L+
M;>3[6GIMV3;8^2F>VEF<;A-D[1Z/VE09B7)4U5V-EZJHQ'\36ORM.<W3:*""
MJA<$5[YJCI<9E\MCL?E*?-T&.R=?0T6:I(IH*7+TE)5RT]-DZ6"I5*B&GR$,
M:RHL@#JK , 0?;N#Q'2$X) ./\/5JNW,C79C;V"RN4PU5MS)Y3#8S(Y';U=/
M!55N!KZZA@J:S"UE32L])456+GE:"1XR8W="5XM[:B;^]]:Z>K?[[_6]]>_=
M>Z][][]U[KWOWOW7NO>_>_=>Z][][]U[KWOWOW7NO>Q0Z5[B[ ^/G;?7'=W5
MF;DV[V)U5O#!;XVAEXPSI2YK 5T5=31U<"O&*W&5GB,%73,?'4TLLD3W1V'L
M/<V<K[+SMRSOO*/,=H)]CW*UDMYTX:HY%*FASI=:ZD891PK#('3UO<2VL\-S
M"U)48$'[/\GKTUYK#X_<&)R.$RD(J,?E*2:CJXKV)BF0J6C:Q,<T9LR,.5<
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MD-R86;;K0SX+&U,M%32LL;254R,'0.I?C1U1!24^],)LKN/L'![WK.EH=O\
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M'UO[TVH T6K>G5D"LP#OI7UI7^77"1G5&:./RN/TIK":O\-3<#VO/[J]9_\
M/UI?_0#S'_UQ]MZY?]\_S'3_ (5O_P I/_&3_GZB^>L_Y41_YU1_]&>^_P"Z
MO6?_ #]:7_T \Q_]<O?M<O\ OG^8Z]X5O_RE?\9/7O/6?\J(_P#.J/\ Z,]^
M_NKUG_S]:7_T \Q_]<O?M<O^^?YCKWA6_P#RE?\ &3U[SUG_ "HC_P ZH_\
MHSW[^ZO6?_/UI?\ T \Q_P#7+W[7+_OG^8Z]X5O_ ,I7_&3U[SUG_*B/_.J/
M_HSW[^ZO6?\ S]:7_P! /,?_ %R]^UR_[Y_F.O>%;_\ *5_QD]>\]9_RHC_S
MJC_Z,]^_NKUG_P _6E_] /,?_7+W[7+_ +Y_F.O>%;_\I7_&3U[SUG_*B/\
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M/7O/6?\ *B/_ #JC_P"C/?O[J]9_\_6E_P#0#S'_ -<O?M<O^^?YCKWA6_\
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M_OG^8Z]X5O\ \I7_ !D]>\]9_P J(_\ .J/_ *,]^_NKUG_S]:7_ - /,?\
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M .C/?O[J]9_\_6E_] /,?_7+W[7+_OG^8Z]X5O\ \I7_ !D]>\]9_P J(_\
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M ,ZH_P#HSW[^ZO6?_/UI?_0#S'_UR]^UR_[Y_F.O>%;_ /*5_P 9/7O/6?\
M*B/_ #JC_P"C/?O[J]9_\_6E_P#0#S'_ -<O?M<O^^?YCKWA6_\ RE?\9/7O
M/6?\J(_\ZH_^C/?O[J]9_P#/UI?_ $ \Q_\ 7+W[7+_OG^8Z]X5O_P I7_&3
MU[SUG_*B/_.J/_HSW[^ZO6?_ #]:7_T \Q_]<O?M<O\ OG^8Z]X5O_RE?\9/
M7O/6?\J(_P#.J/\ Z,]^_NKUG_S]:7_T \Q_]<O?M<O^^?YCKWA6_P#RE?\
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MQ_\ 7+W[7+_OG^8Z]X5O_P I7_&3U[SUG_*B/_.J/_HSW[^ZO6?_ #]:7_T
M\Q_]<O?M<O\ OG^8Z]X5O_RE?\9/7O/6?\J(_P#.J/\ Z,]^_NKUG_S]:7_T
M \Q_]<O?M<O^^?YCKWA6_P#RE?\ &3U[SUG_ "HC_P ZH_\ HSW[^ZO6?_/U
MI?\ T \Q_P#7+W[7+_OG^8Z]X5O_ ,I7_&3U[SUG_*B/_.J/_HSW[^ZO6?\
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M7NO>_>_=>Z][][]U[KWOWOW7NO>_>]@5\NO=>]\K?3_>?\/S_O7O=.O=>O\
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MN26J@V_M;?NUL]FIZ.F-;50XO&9BDJZV2"C$D1JI$IXF(B#*7(T@B_NC@E6
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M/M#<_8/3_7_8V'WEN3M*LJ=[4>6VSF=RY2KCAP,F/S,;X/<6)VVB2U*1UC.
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M/]1I\].FNC]N*\:=8?\ 23NG_1IK\]%_?+^^O^C?^,^)?X?_ !#^)?P[^/\
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MCG\6\_G'^>]MCPZ"FK57YUKY_P"KAT]_C&O&CP]/^TI7_/\ G7Y]%TJA\/\
M^X4(A;Y&CNG_ $R9?[YY4W8?ES_I9_T<T/\ >8YJ/<4@/\#/3WVGE#-_=L8+
M[;[8_P"8]HN?_9K/X=N+[;^YW\'_ .<D_O?X+_<?^&?:?W<VC_IC_@WV/^3_
M ,,_N[_#/X=X/V]%_M/5K]V'A]O&N/7AFG5!]31N%.[A3T&KA^70A0?[))_%
M-I_>?Z0/X]K^(/\ "_X__I'_ (U_$/[V;\_V7_\ O!_$/\L_B_\ >K^,_P 6
M^[_<UV^]]/C]EBV'_I _N-W-_=+[3^ZO]T=O_P"DO[C^'_<?W<_O[MG^#_9?
M=_Y5YO[W?8ZOM?W/'JU?MZO=VTU2O&O^3I/'XFB;1\.D:OLJ/\M.CD]F_P"B
MS_23\?/[\_??WV_OWNK_ $/?:_Q3[;^]G^C'>/\ '_XC]C_D/V_]Q?XEH^\_
M:\NG1^[H]F2V5_LQ?^D;+_?CKXT7^@_87^D8=A';Z]4'IO\ NYM?^XPWTRJU
M&M68/X5]D8@<N,IXO"/N+^Z-X>D4K\1I3C7/^KTZ4)]1XA^&F@5K\.F@I7^7
MY]% [%_V4L]3;?\ X8>U!D?]F2[/_P!$9ZJ7=3=XCY ?WMWI_I*/6JLR9!J
M5/\ &_XB)R,$<+YO.?M=/N'\@/\ 9E_X;OC_ $F_W*_NU_ ?CA]__<S^XO\
M=W^Z?]TMV_Z!/[I?W4_R;^$?W5_B&K[?]W]/WG[_ +W'X=%TUKGC7US6OGUJ
M;QZ/XFFE%X4X9TTIY4]/SSTY_%K_ &3[^,]<_P"A[_2-_>_^\WRX_AG^D+_2
M3_>O^_/]^MB_[,Y_?G^^_P#EG\>_OK_"]'W7[-M7\/\ \G]B55GY/#"=QG<"
M=529H5&^SV6M-+MV'LQMG!,7_I,2F?!PSLFTWQ^D1-*K5*Q?<'&*W[H]U.BJ
M4K3_ %4KT[^O26NBN:\*T\_R_GZ= ]1+\,VW'\?AMB3N^+;QI>M1T\U;!NJ?
MIQ=_E\T.GY*Z/<M13H^^8\GY#,D++2/-]L,RR_L'V+W>4GRFE[9W7)M.CZ-Q
M^XG[SZ[;=%'L/);0R^ZZ?-E<5_H@A[1R-3B<'4UFT4KM&B2MI8%;(W_B:+4>
M.]5\.F:\#3C^=.G9OJ/%;1HU:Q733_:U^7^IN@(^-D7PJ@Z-V-%O;(?)7*;3
MC^-/;";*K^SL1OO!;*JMNALW_IYGZ8Q-+G-QT5!OZ3&^37#CJVI=,1_Q9Y&I
M?-8%L/\ [-#_ *,,G]N.G/XO_H<[%^X.8.QO]./^R\_;YK^\@H%RJ_Q7^Y?V
MWW?\,,)_B7V-OM!]EH]V/AZAQX_.E>F%^H\,TT:M)]-6GS_+T^7#HPN?_P!D
MP_TS8@U)^0/\!_V8#J?[9=O+V3_LMG^S6?=[=_NB<J^#;^#?Z0?O?L?XT)U_
MA'\2O]\?XEY/8=9'_9IO[Y]PW_AG]\?XQT5_?W^%_P!U_NOXW_&=M?Z(OX%]
MO^S]W_&/L?)]I_:OY^-?O8\.D=.%#3_+U3_&=<M?CJM?6M>W_)T+6)_V2G_1
M[T%;^,_Z/_[O?)?_ $8_QG^^/V/]V_[N[O\ ].W]Y_N?W_L?X#_$O%]]SIM]
MMSH]OE^WA\R:@T*]%'L019S_ $@KM5\6O2#8@;2R?^E@;Y? QOCDQS8'^)?W
M@-,K.*CR_;@R^+WL:?"%=7Y\:^5.O#Q/JL:-?G2FGAFM/*E:])H#H4_R^Z49
M)_DNO4YEVZ.K'WO'F'^1J9P[YQ'^@X]:Q;DE3*RY5=S?PC^ZHJW2-J3P_=$0
M>?V&F+_TX?Z5/CW_  8;?&[?[O83_0@&.%;%#:_][MX?W>%:V1"P-&,S]_H.
M3 J3#X_)QI][.G2_I7/5%\;Q(---5.WAZG_+7CGH8LS_ ++<.E?E9_> [G.Q
M/[V;D_V8\A=Q+FCO+^X6P?[U''+BF>H60[>_AGD&()I!4>7Q&^OV-=%_LS'^
M@]1CQU#_ !'_ $*9/PMCVVA_LQG^RVZZK^+BH2A7^+?W,_AOF\IJC_%_X-JL
M/L;^Z]FO-:5_*O\ J_GT^OU/@K\-='RUZ//\OYT^71<\D/AY_LR4ARS=^_PC
M_9B,*)URR[]_V4K_ &;GQT']WVI7R3_P+_2!_%?M_"*)?X%_>#1<_P 1X]R]
MQ?[-+_<7<?\ $QU#_I&_T4K_ '\-,VRO]F@_T-?W8H/.-U*%_O!]M_<?P??F
M_P#'?X/;[H>#5[]^G45K2OG6E>M-]1I:NGQ*9X:Z4\_RX^=./4+:?^R6_P"D
MW:1PQ[\_T2?Z;G_T9+6+V'_LF'^S _WRR?VIV6Y;^Z_W?^D?[G^%@K_=K^/W
M^R/W6CV$>V#VL,[\/CNY.NY-M?<2_P"A9-^R)#LPTO\ ?VK\G]_9-MQ3YE<2
M-ZW,OW:F\/#VIM1&SH_6I6OG^S_-TTOB5M=>G3^&O#CYTSQX]#QO,=(-MKY\
M#84G:T6\C2T_^S#R=80O4=@K7?Z+Z P_Z,X=WSTVW7SIZ[TB'[)P14&\=ZH(
M"7_MK^_?^D_L'_2?]U_I$_OAN#^^OWEO/_>3^)U/\6OI_;\?W>KQZ/1X[:?3
M;W=::5T_#3IJ77XDGB?'J-?MZ-+T;_HT_P!#75O^AO[/_11_<+:O^CS[#5]M
M_='^#TG\#MJ_=\WV.CR^3]SRZM?KU>P\]VZ;Z%3W[W[KW7O>2'_/16^OD2W_
M "4/=6^%OLZ<B_M8_P#3#_#U[V+3-)J/[4?U/^[VO_[C\>PJ N.]OV'_ *"Z
MD8F2I[!_O7_0O7O?M4G_ !R3_P Z/_Q;WNB_QM^P_P#075:O_ /]Z/\ T#U[
MW[5)_P <D_\ .C_\6]^HO\;?L/\ T%UZK_P#_>C_ - ]>]^U2?\ ')/_ #H_
M_%O?J+_&W[#_ -!=>J_\ _WH_P#0/7O?M4G_ !R3_P Z/_Q;WZB_QM^P_P#0
M77JO_ /]Z/\ T#U[W[5)_P <D_\ .C_\6]^HO\;?L/\ T%UZK_P#_>C_ - ]
M>]^U2?\ ')/_ #H__%O?J+_&W[#_ -!=>J_\ _WH_P#0/7O?M4G_ !R3_P Z
M/_Q;WZB_QM^P_P#077JO_ /]Z/\ T#U[W[5)_P <D_\ .C_\6]^HO\;?L/\
MT%UZK_P#_>C_ - ]>]^U2?\ ')/_ #H__%O?J+_&W[#_ -!=>J_\ _WH_P#0
M/7O?M4G_ !R3_P Z/_Q;WZB_QM^P_P#077JO_ /]Z/\ T#U[W[5)_P <D_\
M.C_\6]^HO\;?L/\ T%UZK_P#_>C_ - ]>]^U2?\ ')/_ #H__%O?J+_&W[#_
M -!=>J_\ _WH_P#0/7O?M4G_ !R3_P Z/_Q;WZB_QM^P_P#077JO_ /]Z/\
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KY_'G\_\ M-O-Y/\ DBVO_8>Y6[/"_P"%Z?Y4_P W0;[M7]*O\^O>_P#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>g210084g60a22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g210084g60a22.jpg
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M>$$[1W)A<&AI8R!T>7!E.B @(" @(" @("!!<G1W;W)K)B-X03LF(WA!.^*
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M 0$! 0$! 0'_P  1" "X =P# 1$  A$! Q$!_\0 'P !  $$ P$! 0
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M'9-:8%@$PTY<%@4A*TR2M[4&DEC7'I11<N2HU1"H<EC@;;+WM:_+S?6=X02
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MMC&X(*^U"(DYEA2)]QI.F0D$:D/(Y =I()%R+[]OMN?"A8#RD; " =]MQ/\
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M[*.L&"6C2G$.<UK,HQ/H:^RM_4L\IA[XVR)@<B=LCIUC1NK2I5(CM@WON#0
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M-V_(Y/ R:J9[6=[C9(.G.>U,?4<9$-^*U;#"7%Y:2QZ=71:DBD<1.SRWJ/\
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M#/!!1U,LU<7'*ZLII:9DU+" ,KQ *E@GDS'+-FAL'1O4F MIQ.YP!<]H#/\
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M(X?\@N$-NRVJI;#:2-GE)6RX%K:]31&)1^HG&%5L\4^A-=X^U;1,KTR/#:Z
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M85ODQILU)U4Z=K531<)0BHNV .'I<7DI-&,0I:*?"&XTTX0*+$Z.DIFX>P3
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M ,1YK\]^3D^U5ODQW1O^9W5VI&^H\=E'2KZ2@]#'Q%/%M/S.\H^U/)CNC?\
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MZ)D[DB(<"E!25>G)6$!+4%%F!->]K7M:]S6R "1K7$->&D.:'@&S@' . <"
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M*%S:HTM?[+G(]&-S6H3JUZ9LC"!::4$1#B_=\2.6Q!3I5+MX"<A&M&6VDD&
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MUT,D3VR..;)6".1I8T,=$"Q\@?VEXXRPR!V4AY:1:]]D;&.!!%M["0;FX=M
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M)E"Z)TLV&O?+833LC=!"UU/ *6"IG8Z2J(#G7,+P\O8(FN!D<' $%Y>'6$@
MW-)#CVSLQ:+!G)-''VGK?K"&NK=,833[_.9'*%LLG$[7VI+YU);(DZ]I96U9
M,I8]N=(0XE,[')FA&Q-T;C\?;8A$8FQ1J,1!O:(XTMK&V:.(UE'53L=!/61T
M\4388*<4<,$=-$U\CA#$QE?,2P%[I'RR2.FFFDEEF<^5[I'7C:]C2"&EQ.9S
4L[B7$@ N)+!MV6L        O_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
